data_6qwr_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6qwr _Structure_validation_residue.Date_analyzed 2020-03-13 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 34.5 tt0 . . . . . 0 N--CA 1.458 -0.061 0 CA-C-O 120.805 0.336 . . . . 74.24 110.918 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.66 5.48 36.24 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.754 -0.736 . . . . 72.3 112.549 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -68.79 150.27 48.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.772 0.32 . . . . 64.23 110.853 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 13.3 t90 -126.25 121.27 32.2 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.216 -0.447 . . . . 74.53 110.904 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 6.1 p -132.19 122.69 49.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.248 -0.433 . . . . 74.33 111.162 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -87.03 116.65 25.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 72.23 111.102 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -104.7 109.82 21.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 72.5 110.929 -179.815 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 15.0 p90 -107.69 119.88 40.68 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.186 -0.461 . . . . 74.15 110.879 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 2.5 p30 -149.6 161.53 41.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.134 -0.484 . . . . 62.11 110.858 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -86.49 128.47 34.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 73.33 110.879 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 18.1 p -102.11 116.26 32.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.162 -0.472 . . . . 74.22 110.895 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 16.3 mtpp -98.92 106.16 18.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.151 -0.477 . . . . 75.41 110.935 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.3 p -83.36 139.43 17.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 71.31 111.117 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 21.3 t80 -130.82 101.79 5.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.465 . . . . 74.21 110.922 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.1 p -162.26 155.02 2.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.096 -0.502 . . . . 75.41 111.099 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 119.63 72.17 0.36 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.683 -0.77 . . . . 74.34 112.476 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 -89.43 -57.97 2.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.768 0.318 . . . . 63.34 110.863 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -174.48 135.1 0.41 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.165 -0.471 . . . . 75.23 110.898 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 12.7 mt -52.0 165.64 0.2 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 72.53 110.917 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.713 -0.756 . . . . 73.53 112.485 179.913 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.789 0.328 . . . . 61.24 111.069 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -149.45 132.99 16.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 62.13 110.878 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 30.1 m -104.72 154.01 6.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 75.23 111.162 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 10.3 t -151.99 146.1 25.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 72.15 110.862 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -119.43 150.45 21.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.078 -0.51 . . . . 72.25 111.115 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.77 135.2 14.73 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.742 -0.742 . . . . 73.42 112.487 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 60.5 m-20 -87.57 112.95 22.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.359 . . . . 72.52 110.892 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 33.5 t0 -154.38 165.86 35.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.165 -0.47 . . . . 74.35 110.887 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 34.4 p -64.69 148.03 51.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 75.02 111.129 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 8.4 t -158.84 139.92 12.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 75.24 111.13 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -124.81 159.77 30.25 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 75.11 110.898 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 55.8 m -139.08 147.53 42.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.179 -0.464 . . . . 70.43 111.113 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 86.6 m-85 -124.18 132.62 53.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 74.13 110.881 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -134.23 149.3 50.96 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.129 -0.487 . . . . 74.5 110.872 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 10.4 mm -108.28 115.75 49.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.186 -0.461 . . . . 62.11 111.144 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -101.13 125.99 47.8 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.188 -0.46 . . . . 52.34 111.123 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -108.89 117.79 35.12 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.222 -0.444 . . . . 74.13 110.919 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -89.2 105.99 18.15 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.091 -0.504 . . . . 75.25 110.853 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.1 m -103.88 -34.25 3.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 64.33 111.129 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.7 t -135.87 160.12 39.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.224 -0.443 . . . . 75.31 110.884 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 5.7 p -84.56 2.99 38.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.147 -0.478 . . . . 74.42 110.828 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -111.6 -30.84 7.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 73.54 110.876 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 2.6 pp -147.3 165.61 6.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 64.44 111.106 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -154.36 172.84 17.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.472 . . . . 72.41 111.134 179.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.412 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 1.2 p -116.47 147.89 19.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.245 -0.434 . . . . 74.22 111.119 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -142.57 134.66 27.33 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.173 -0.467 . . . . 74.34 110.835 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -119.73 110.96 17.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.454 . . . . 71.23 110.867 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -85.05 131.18 34.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.481 . . . . 75.14 110.859 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 5.6 m -151.34 163.54 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 75.45 111.103 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -171.16 145.57 8.99 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.721 -0.752 . . . . 60.22 112.49 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 7.6 p -117.07 67.44 4.34 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.596 0.712 . . . . 75.53 111.133 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 162.57 41.57 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.686 2.257 . . . . 74.43 112.351 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -84.81 -173.14 4.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 70.23 111.123 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -78.43 131.14 36.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.444 . . . . 73.41 110.866 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -126.26 151.74 47.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.468 . . . . 74.12 111.1 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 15.4 ttpt -114.72 126.32 54.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 75.34 110.892 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 15.7 p90 -126.42 158.84 34.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 75.23 110.89 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 29.6 mt-30 -92.61 157.66 16.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 74.34 110.92 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -176.05 68.76 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.735 -0.745 . . . . 72.23 112.458 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -176.44 -176.59 0.77 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.915 0.388 . . . . 74.54 110.915 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -85.55 -69.41 0.66 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 75.13 110.932 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.4 t -83.31 -34.61 25.66 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.284 -0.416 . . . . 75.11 110.892 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 6.1 mm -64.62 -33.79 65.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.09 -0.504 . . . . 72.42 111.116 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 5.3 t -60.17 -46.79 88.5 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 74.41 110.87 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 22.8 t -56.18 -37.38 69.52 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.124 -0.489 . . . . 74.21 110.839 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.63 -48.64 79.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.112 -0.494 . . . . 74.25 110.904 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 111.73 -13.8 27.18 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.704 -0.76 . . . . 72.42 112.471 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 43.7 mtp180 -118.24 92.74 3.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.887 0.375 . . . . 74.25 110.856 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 90.1 t -113.93 -55.33 4.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 55.35 111.107 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.88 143.81 38.89 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.194 -0.457 . . . . 63.31 110.851 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 11.8 tt0 -147.52 117.87 7.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 71.13 110.891 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 18.8 m -155.75 -176.83 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 73.44 111.14 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -97.29 152.08 19.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 74.31 110.896 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -92.57 135.26 34.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 73.14 110.936 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -128.3 63.29 0.62 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.71 -0.757 . . . . 63.41 112.441 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 112.38 3.06 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.709 2.272 . . . . 74.41 112.362 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -128.36 99.49 5.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 71.04 111.145 179.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 4.9 mt -124.31 144.58 33.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 71.53 111.142 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -147.31 109.73 4.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.177 -0.465 . . . . 75.1 110.878 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 3.6 p -144.5 160.39 41.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.221 -0.445 . . . . 71.01 110.832 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.412 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 4.6 pp -106.19 150.21 26.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.125 -0.489 . . . . 74.41 110.962 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 7.9 pm0 -101.41 141.74 33.84 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.191 -0.459 . . . . 75.52 110.907 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 27.9 p90 -144.45 144.56 31.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 73.42 110.927 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 16.1 m80 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.097 -0.502 . . . . 74.42 110.872 179.962 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 8.7 p90 . . . . . 0 C--O 1.232 0.151 0 CA-C-O 121.642 0.734 . . . . 74.42 110.936 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 176.27 7.0 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.723 2.282 . . . . 75.12 112.354 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 12.7 p90 -115.97 159.47 21.56 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.207 -0.451 . . . . 73.54 110.925 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 60.2 t -123.4 135.33 63.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.126 -0.488 . . . . 73.44 111.107 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -124.08 176.86 16.85 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.72 -0.752 . . . . 73.31 112.491 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.8 p -166.03 152.48 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-O 120.817 0.342 . . . . 70.14 111.167 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 179.12 -153.14 11.9 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.722 -0.752 . . . . 62.45 112.444 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . 0.414 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 13.5 m -106.91 120.45 58.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.826 0.346 . . . . 72.33 111.125 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -114.77 111.01 2.44 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.688 -0.768 . . . . 71.34 112.433 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 8.1 ptp180 -109.31 131.87 54.66 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.805 0.336 . . . . 74.41 110.878 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 3.5 p -117.53 115.92 50.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 75.32 111.107 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 2.6 pp -127.49 170.89 12.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.192 -0.458 . . . . 75.31 110.91 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -140.58 174.69 10.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 73.54 110.914 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -102.8 125.25 49.47 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.131 -0.486 . . . . 64.12 110.923 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -61.15 95.65 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.162 -0.472 . . . . 75.24 110.856 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.1 -78.01 0.57 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.161 -0.472 . . . . 64.05 110.894 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 86.1 m -161.95 83.72 0.58 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 72.15 111.134 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -101.98 170.0 8.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.21 -0.45 . . . . 74.15 110.881 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.29 151.65 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.711 -0.757 . . . . 65.41 112.502 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -79.73 -0.03 32.53 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.827 0.346 . . . . 63.21 111.101 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -86.23 -178.08 6.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 75.12 110.942 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.7 m -65.73 91.64 0.14 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.186 -0.461 . . . . 73.42 110.894 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.2 t 51.87 75.41 0.21 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.108 -0.496 . . . . 70.53 110.872 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -88.92 149.04 23.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.1 -0.5 . . . . 71.21 110.838 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 14.0 t0 -109.96 164.7 12.35 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.127 -0.488 . . . . 74.44 110.902 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 63.8 mt -128.47 125.92 64.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 74.14 111.085 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.04 109.24 9.52 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.172 -0.467 . . . . 71.04 110.913 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -58.68 -173.62 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.207 -0.451 . . . . 72.51 110.857 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 11.2 mmtm -148.55 166.02 29.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.456 . . . . 72.04 110.89 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 42.6 p-90 -157.75 136.32 11.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 74.33 110.921 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.411 ' CB ' ' HD2' ' A' ' 147' ' ' PRO . . . -172.49 166.02 3.52 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.578 0.704 . . . . 63.54 111.129 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' PRO . . . . . 0.414 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 53.5 Cg_endo -69.79 135.35 30.17 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.711 2.274 . . . . 62.42 112.318 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -122.48 165.62 16.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 64.33 111.129 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 23.7 m-85 -122.3 136.32 54.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.214 -0.448 . . . . 74.2 110.89 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 3.7 mm100 -107.16 151.8 24.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.159 -0.473 . . . . 72.4 110.921 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 5.4 p -152.04 117.85 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.207 -0.451 . . . . 74.52 111.181 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . 0.413 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 176.93 -161.63 29.5 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.739 -0.743 . . . . 64.34 112.467 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -136.99 155.9 49.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.769 0.318 . . . . 73.21 110.918 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -139.93 124.16 17.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 75.3 110.872 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 26.3 p90 -144.42 177.45 8.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.461 . . . . 74.25 110.896 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -118.92 100.18 7.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.082 -0.508 . . . . 73.5 110.895 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 18.7 tp -102.03 106.24 17.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.142 -0.481 . . . . 73.0 110.956 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 103.34 -173.76 22.42 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.726 -0.749 . . . . 73.23 112.47 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 9.3 p-10 -101.53 132.26 47.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.861 0.363 . . . . 75.14 110.913 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.6 t 53.01 41.33 32.16 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.139 -0.482 . . . . 74.22 110.921 -179.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 2.3 t90 -171.97 100.49 0.17 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.096 -0.502 . . . . 64.54 110.92 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 13.6 mtm -95.42 173.85 7.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.258 -0.428 . . . . 72.24 110.914 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 2.1 tt -127.69 145.1 51.0 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.271 -0.422 . . . . 74.2 110.911 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 -145.8 138.07 25.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 74.32 110.919 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 13.0 p -153.26 121.75 6.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 64.42 110.89 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' ASP . . . . . 0.413 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 1.3 p30 -154.03 -179.79 8.2 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.166 -0.47 . . . . 63.43 110.856 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 8.2 t -138.48 143.79 31.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 73.2 111.113 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 4.4 ttt180 -113.78 123.34 49.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.158 -0.474 . . . . 74.45 110.856 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 13.2 t80 -121.99 138.97 54.22 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.186 -0.461 . . . . 75.41 110.94 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' ILE . . . . . . . . . . . . . 6.4 tt -177.35 93.91 0.23 Allowed Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.631 0.729 . . . . 73.23 111.171 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.66 134.19 27.59 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.707 2.271 . . . . 72.34 112.379 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -156.89 177.84 11.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.252 -0.431 . . . . 74.53 110.878 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . 0.41 ' HA ' ' HA ' ' A' ' 190' ' ' GLU . 11.3 pttp -128.28 125.32 38.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.126 -0.488 . . . . 74.45 110.859 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -91.94 161.74 14.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 75.55 111.146 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -119.14 165.55 14.05 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.431 . . . . 74.32 110.874 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 21.4 t -146.53 133.13 13.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 72.44 111.171 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 14.0 t -166.53 176.9 6.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 75.2 111.104 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 122.18 141.33 6.0 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.752 -0.737 . . . . 63.22 112.495 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 C--N 1.329 -0.296 0 CA-C-O 120.834 0.35 . . . . 72.51 111.147 -179.841 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.231 0.159 0 CA-C-O 120.82 0.258 . . . . 71.44 112.325 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 85.3 t -109.41 107.69 23.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.274 -0.421 . . . . 62.45 111.115 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 6.7 p -83.69 110.57 18.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.151 -0.477 . . . . 75.05 110.882 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 11.9 p -121.93 171.5 8.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 73.1 111.15 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 29.9 ttpt -153.52 148.08 26.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.208 -0.451 . . . . 65.41 110.922 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 5.9 tp -142.74 124.06 11.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 75.42 111.098 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 190' ' ' GLU . . . . . 0.41 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 19.5 pt-20 -96.94 116.9 30.0 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 75.22 110.863 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 4.1 m -138.36 158.79 31.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 75.13 111.108 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -107.85 89.85 5.79 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.581 0.705 . . . . 75.31 110.875 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 138.46 37.78 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.721 2.281 . . . . 75.11 112.358 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 12.9 m-85 -124.68 116.66 22.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 72.45 110.865 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 45.3 mt -106.44 131.28 56.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.199 -0.455 . . . . 75.22 111.109 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 7.4 tp -117.74 112.33 20.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 74.31 110.889 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -97.87 124.59 42.35 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.145 -0.48 . . . . 72.21 110.855 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -144.64 119.59 9.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.133 -0.485 . . . . 74.15 110.906 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -177.91 -145.83 6.1 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.759 -0.734 . . . . 64.33 112.467 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -127.19 173.8 9.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.803 0.335 . . . . 70.31 111.083 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -140.13 175.82 9.27 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 71.12 110.85 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 16.2 t80 -146.55 115.65 6.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.095 -0.502 . . . . 70.02 110.915 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 15.0 p -77.12 147.66 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.103 -0.499 . . . . 71.01 111.159 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -152.9 143.14 22.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 72.03 110.867 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 12.9 ptmt . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.142 -0.481 . . . . 75.5 110.894 179.977 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 19.1 pt20 . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.87 0.367 . . . . 65.32 110.861 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.41 6.28 38.86 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.781 -0.723 . . . . 73.43 112.543 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -78.43 163.36 25.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.811 0.338 . . . . 72.21 110.878 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 3.7 p-90 -139.96 151.58 45.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.154 -0.475 . . . . 74.51 110.896 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.3 m -144.55 139.36 23.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.226 -0.443 . . . . 74.31 111.107 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -99.14 101.78 13.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.124 -0.489 . . . . 65.54 111.146 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.6 m -97.53 121.46 39.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 75.03 110.829 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 18.8 m-85 -118.64 118.29 31.26 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.134 -0.484 . . . . 74.32 110.888 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -148.01 172.84 13.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.102 -0.499 . . . . 75.11 110.845 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -100.64 124.27 46.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.132 -0.486 . . . . 75.25 110.897 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.5 m -102.28 115.11 29.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.129 -0.487 . . . . 71.0 110.848 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -98.84 113.78 26.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.18 -0.464 . . . . 74.22 110.915 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 32.4 t -92.49 146.62 6.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.242 -0.436 . . . . 74.42 111.124 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -135.21 110.52 9.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 72.22 110.937 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.3 p -166.51 150.34 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.136 -0.484 . . . . 75.23 111.193 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 136.27 76.13 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.721 -0.752 . . . . 71.24 112.474 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -89.51 -65.89 0.97 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.832 0.348 . . . . 73.05 110.836 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.3 mt-10 -162.87 146.89 11.34 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 72.13 110.878 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 2.0 tp -109.81 160.73 16.1 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.195 -0.457 . . . . 71.41 110.933 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.267 0 C-N-CA 120.742 -0.742 . . . . 73.22 112.501 179.916 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.822 0.344 . . . . 73.24 111.091 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -132.38 125.81 31.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 70.34 110.857 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 11.3 p -111.7 137.81 42.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 74.31 111.131 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -147.4 142.05 26.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.084 -0.507 . . . . 43.23 110.895 -179.834 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 39.0 pt -115.72 156.62 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 73.24 111.076 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -84.94 179.02 51.13 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.711 -0.757 . . . . 62.45 112.506 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 79.0 m-20 -133.64 112.95 11.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.836 0.351 . . . . 63.2 110.918 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -145.42 140.58 27.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 75.02 110.831 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 29.8 p -55.68 128.49 35.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 74.35 111.095 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 5.7 t -137.12 150.35 47.93 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.197 -0.456 . . . . 73.4 111.107 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -113.49 152.46 30.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 73.42 110.885 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -136.51 137.29 40.16 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.188 -0.46 . . . . 73.43 111.153 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -103.12 132.14 49.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 71.34 110.891 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -130.96 130.2 43.1 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.123 -0.49 . . . . 74.45 110.856 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.98 115.2 48.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 74.3 111.081 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -101.94 125.61 48.66 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.188 -0.46 . . . . 63.14 111.123 179.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -107.03 117.11 33.21 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.235 -0.439 . . . . 75.04 110.887 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -83.76 95.74 8.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.054 -0.521 . . . . 73.42 110.919 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 9.5 p -92.17 -34.29 6.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 72.43 111.175 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 17.0 m -133.68 160.69 36.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.097 -0.501 . . . . 75.43 110.842 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.6 p -83.48 2.98 34.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.123 -0.489 . . . . 72.41 110.868 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -119.75 -32.27 4.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.13 -0.486 . . . . 75.04 110.93 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 40.5 pt -139.72 153.46 23.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 74.51 111.098 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -146.95 162.92 37.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 65.54 111.088 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.5 m -103.84 151.37 6.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.23 -0.441 . . . . 74.31 111.095 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -141.92 135.75 29.75 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.19 -0.459 . . . . 75.05 110.823 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -122.2 108.18 13.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 71.42 110.88 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -94.77 123.43 38.22 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.118 -0.492 . . . . 75.23 110.833 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.2 p -149.78 154.63 8.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.067 -0.515 . . . . 64.21 111.166 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -162.57 142.23 7.77 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.767 -0.73 . . . . 73.34 112.472 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.9 m -115.17 73.24 3.42 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.617 0.722 . . . . 64.42 111.115 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 161.27 46.56 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.651 2.234 . . . . 74.0 112.357 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -68.71 -169.88 0.19 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.248 -0.433 . . . . 74.42 111.077 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 1.2 tmm_? -78.88 140.67 38.07 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.434 . . . . 73.54 110.85 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -128.2 142.27 51.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.201 -0.454 . . . . 53.34 111.077 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 28.9 ttpt -108.11 135.74 48.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.265 -0.425 . . . . 75.12 110.924 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 6.9 p90 -141.97 157.98 44.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 75.42 110.916 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -96.42 160.78 14.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.151 -0.477 . . . . 72.14 110.896 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -177.87 66.0 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.792 -0.718 . . . . 63.11 112.531 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -173.84 -176.8 1.27 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.931 0.396 . . . . 73.13 110.869 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.88 -68.87 0.7 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 71.23 110.874 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 5.1 m -83.83 -34.55 24.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.208 -0.451 . . . . 74.31 110.897 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.8 mm -64.55 -33.78 65.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.142 -0.481 . . . . 74.51 111.109 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.3 t -63.05 -45.26 93.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.13 -0.486 . . . . 65.34 110.825 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 22.7 t -53.6 -41.72 66.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.124 -0.489 . . . . 72.52 110.88 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -59.5 -44.19 93.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 75.11 110.917 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 110.21 -14.14 30.96 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.762 -0.732 . . . . 70.25 112.505 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 20.2 mtt180 -120.22 93.61 4.11 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.836 0.35 . . . . 75.22 110.813 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.1 t -113.56 -45.82 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 74.13 111.099 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 67.5 m -140.58 144.94 36.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.466 . . . . 72.45 110.834 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -142.01 119.56 11.7 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.103 -0.499 . . . . 73.13 110.909 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.2 p -175.04 157.92 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 72.33 111.151 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -81.17 173.53 12.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.182 -0.463 . . . . 73.22 110.858 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 11.6 m-85 -117.43 130.73 56.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.222 -0.445 . . . . 71.44 110.894 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -117.49 65.81 0.35 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.675 -0.774 . . . . 72.14 112.478 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.75 115.3 4.03 Favored 'Trans proline' 0 N--CA 1.465 -0.187 0 C-N-CA 122.708 2.272 . . . . 72.43 112.384 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -123.03 100.18 6.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.223 -0.444 . . . . 70.24 111.083 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 2.5 tp -122.06 119.83 59.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 74.52 111.137 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -120.65 113.67 20.57 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.199 -0.455 . . . . 71.52 110.897 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' SER . . . . . 0.423 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 4.9 p -142.81 159.48 42.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 64.31 110.858 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -103.94 149.63 24.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.101 -0.5 . . . . 62.13 110.925 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 15.8 mm-40 -101.58 144.95 29.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.468 . . . . 74.53 110.895 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 6.8 t80 -139.94 128.94 23.53 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.185 -0.461 . . . . 74.02 110.933 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 28.1 p80 . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.07 -0.514 . . . . 73.34 110.835 179.946 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 1.4 p90 . . . . . 0 C--O 1.232 0.146 0 CA-C-O 121.68 0.752 . . . . 74.22 110.889 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 177.53 5.5 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.625 2.216 . . . . 72.15 112.315 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -110.97 144.36 40.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.187 -0.461 . . . . 74.11 110.875 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 8.0 p -101.16 130.67 50.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.053 -0.521 . . . . 74.54 111.114 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -129.71 165.33 22.26 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.747 -0.739 . . . . 72.53 112.46 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 13.7 p -161.54 149.7 4.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.881 0.372 . . . . 62.3 111.128 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . 0.423 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -174.41 -155.12 11.68 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.748 -0.739 . . . . 54.24 112.485 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 7.5 p -109.2 124.83 66.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.878 0.37 . . . . 75.11 111.154 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -110.1 114.3 3.81 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.776 -0.726 . . . . 72.05 112.497 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 25.5 ptt180 -115.9 124.56 50.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.823 0.344 . . . . 72.23 110.84 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 26.1 t -104.68 116.34 48.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.274 -0.421 . . . . 74.5 111.151 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.9 mt -130.76 171.24 13.34 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 75.32 110.86 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -160.25 169.53 23.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 75.31 110.895 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -102.93 118.78 37.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 73.03 110.883 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -48.93 108.07 0.17 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.056 -0.52 . . . . 60.45 110.877 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 3.6 mmmp? -111.52 -80.84 0.58 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.479 . . . . 74.32 110.875 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 21.9 m -161.52 81.0 0.59 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 64.42 111.135 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 39.2 m-20 -102.84 166.57 10.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.46 . . . . 71.1 110.899 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.64 155.26 0.11 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.705 -0.759 . . . . 61.55 112.503 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -81.24 3.67 23.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.8 0.333 . . . . 73.41 111.099 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -86.19 -175.33 5.48 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.455 . . . . 72.31 110.911 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 88.6 p -65.59 83.2 0.06 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 65.24 110.87 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 5.4 t 50.31 75.15 0.18 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 61.31 110.869 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -80.04 146.94 31.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 74.43 110.806 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -106.74 161.04 15.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.131 -0.486 . . . . 75.33 110.865 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 57.2 mt -115.73 143.86 24.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.171 -0.468 . . . . 75.43 111.12 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 3.4 mmtp -94.27 104.59 16.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 65.51 110.937 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -58.21 -174.86 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.466 . . . . 73.42 110.866 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -162.28 164.87 27.32 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.233 -0.44 . . . . 75.1 110.906 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 22.6 p-90 -146.6 154.41 41.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.211 -0.45 . . . . 75.42 110.981 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -179.23 164.43 0.97 Allowed Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.579 0.704 . . . . 72.03 111.096 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.82 127.49 14.62 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.577 2.185 . . . . 62.13 112.364 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -120.52 167.94 11.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 73.43 111.132 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -123.04 142.13 51.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 74.42 110.872 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 15.5 tt0 -123.17 151.98 41.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.165 -0.471 . . . . 71.4 110.879 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.1 t -151.08 122.8 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 63.43 111.092 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -174.68 -174.75 41.64 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.73 -0.748 . . . . 74.33 112.461 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -135.58 160.43 38.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.776 0.322 . . . . 75.1 110.988 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.3 tpp85 -122.06 118.54 29.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.241 -0.436 . . . . 65.02 110.873 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -101.35 127.97 47.73 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.204 -0.453 . . . . 73.03 110.897 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -116.73 102.12 9.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.157 -0.474 . . . . 75.2 110.898 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 7.3 tp -97.24 97.01 8.8 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.192 -0.458 . . . . 74.55 110.851 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 51.45 -159.18 2.3 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.608 -0.806 . . . . 70.24 112.516 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 23.2 m-20 -71.71 -29.44 64.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.83 0.348 . . . . 73.5 110.896 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 8.2 p -52.05 172.12 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.155 -0.475 . . . . 71.41 110.909 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 25.4 m0 -49.84 144.2 6.72 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.107 -0.497 . . . . 75.34 110.92 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 2.6 mtt -98.91 173.78 6.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.243 -0.435 . . . . 74.52 110.944 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 8.9 mp -125.68 142.86 51.3 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.268 -0.423 . . . . 73.45 110.876 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -140.15 134.59 31.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 71.35 110.873 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 3.3 t -142.23 122.47 13.87 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.145 -0.479 . . . . 73.43 110.842 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -150.88 165.08 34.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 62.41 110.92 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 1.5 t -133.51 139.76 48.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.212 -0.449 . . . . 54.13 111.192 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 21.9 ttt180 -111.31 131.38 55.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 74.34 110.87 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -134.31 137.0 43.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.23 -0.441 . . . . 74.05 110.924 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' ILE . . . . . 0.515 HG22 ' O ' ' A' ' 170' ' ' ILE . 0.0 OUTLIER -179.34 102.92 0.19 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.606 0.717 . . . . 73.04 111.144 179.898 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 139.22 39.71 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.691 2.261 . . . . 71.4 112.368 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -165.9 177.26 7.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 75.12 110.816 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 8.0 ptmt -128.52 150.61 50.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.053 -0.522 . . . . 71.51 110.873 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 15.3 t -119.43 161.21 20.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.143 -0.48 . . . . 74.15 111.141 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -116.1 172.62 7.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.269 -0.423 . . . . 72.21 110.877 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 14.8 p -164.98 140.06 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 73.52 111.084 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.0 t -165.81 177.67 7.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.177 -0.465 . . . . 74.31 111.114 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -154.83 -139.13 2.73 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.696 -0.764 . . . . 72.33 112.499 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.33 -0.275 0 CA-C-O 120.811 0.338 . . . . 74.14 111.11 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo . . . . . 0 C--O 1.231 0.165 0 CA-C-O 120.799 0.25 . . . . 74.4 112.37 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 85.6 t -96.73 108.35 21.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.248 -0.433 . . . . 73.32 111.146 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 62.0 p -98.12 106.52 18.82 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.188 -0.46 . . . . 72.52 110.889 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 22.2 p -115.74 167.62 10.77 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 72.44 111.122 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.29 159.26 39.86 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.203 -0.453 . . . . 74.51 110.976 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 26.4 mm -142.76 137.67 27.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 73.32 111.07 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -104.78 114.94 29.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 73.32 110.862 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 2.6 t -137.33 163.09 32.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.148 -0.478 . . . . 71.43 111.177 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -107.25 90.0 5.26 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.612 0.72 . . . . 72.22 110.883 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 138.04 36.8 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.693 2.262 . . . . 75.11 112.313 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 10.0 m-85 -120.32 119.67 33.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.195 -0.457 . . . . 75.14 110.897 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 3.6 mp -112.99 132.45 61.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.464 . . . . 71.15 111.101 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 1.4 tt -125.79 112.16 15.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.444 . . . . 74.54 110.895 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 2.6 p -100.39 127.58 46.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.21 -0.45 . . . . 71.43 110.855 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 10.5 tt -147.83 126.05 12.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.154 -0.475 . . . . 74.23 110.963 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -179.42 -142.53 5.02 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.719 -0.753 . . . . 62.12 112.47 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -117.99 174.28 6.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.73 0.3 . . . . 74.05 111.098 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 63.7 p -156.37 163.33 39.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.262 -0.426 . . . . 70.33 110.806 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -136.14 130.05 32.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.047 -0.524 . . . . 70.34 110.925 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 19.7 m -85.18 147.72 5.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.1 -0.5 . . . . 62.15 111.125 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -141.27 105.0 4.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.181 -0.463 . . . . 74.41 110.889 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 37.0 mttm . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.068 -0.515 . . . . 74.34 110.913 179.975 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 . . . . . 0 C--O 1.23 0.06 0 CA-C-O 120.893 0.378 . . . . 75.55 110.942 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 92.18 6.53 64.74 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.756 -0.735 . . . . 73.45 112.464 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -78.93 151.16 31.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.815 0.341 . . . . 74.31 110.883 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -125.36 139.42 53.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 72.14 110.908 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 4.9 m -145.71 134.67 17.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 74.31 111.18 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -97.8 110.91 23.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 72.55 111.095 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.5 t -103.78 117.48 34.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 74.33 110.855 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 30.4 p90 -117.98 124.04 47.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 73.34 110.88 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 4.1 p30 -149.7 171.88 15.98 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.128 -0.487 . . . . 74.32 110.883 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -94.8 122.32 37.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 72.34 110.931 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -93.82 113.53 25.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 53.23 110.845 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 36.7 mttt -93.66 106.97 18.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.197 -0.456 . . . . 72.22 110.877 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.3 p -87.26 130.95 36.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 71.5 111.158 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -121.42 102.69 8.43 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 73.44 110.911 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.9 t -140.16 155.34 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.061 -0.518 . . . . 75.04 111.079 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 130.73 62.16 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.762 -0.732 . . . . 61.3 112.467 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -89.87 -66.15 0.95 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.899 0.38 . . . . 73.11 110.969 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 179.18 130.05 0.08 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.088 -0.505 . . . . 72.12 110.849 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 1.8 tp -51.9 170.12 0.06 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.133 -0.485 . . . . 75.23 110.903 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.276 0 C-N-CA 120.712 -0.756 . . . . 71.3 112.473 179.917 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.758 0.313 . . . . 64.15 111.161 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -121.04 -170.36 2.0 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 75.14 110.807 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 10.4 p -166.08 135.6 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.157 -0.474 . . . . 71.42 111.167 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -175.05 171.53 3.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.469 . . . . 72.42 110.839 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 2.2 pp -102.43 158.22 4.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.09 -0.505 . . . . 73.13 111.106 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -88.72 -81.73 1.29 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.733 -0.746 . . . . 72.12 112.432 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.7 p30 -151.87 93.38 1.84 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.791 0.329 . . . . 72.42 110.867 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -115.49 65.52 0.69 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 73.32 110.851 179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -95.31 103.5 15.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.148 -0.478 . . . . 71.22 111.142 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.2 p -156.75 163.31 39.4 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.251 -0.432 . . . . 70.24 111.142 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 11.8 mt -88.4 163.23 16.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 75.53 110.927 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -131.42 142.57 50.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 74.5 111.103 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -113.88 131.75 56.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.45 . . . . 75.43 110.864 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.403 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.2 OUTLIER -130.78 143.77 50.97 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.089 -0.505 . . . . 73.42 110.788 -179.938 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 12.5 mm -108.09 117.68 54.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 75.23 111.12 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -100.44 132.72 45.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 72.13 111.097 179.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -114.85 116.84 29.22 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.205 -0.452 . . . . 72.44 110.936 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -87.0 101.91 13.9 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 74.53 110.969 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 8.1 p -100.57 -34.57 4.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.121 -0.49 . . . . 74.52 111.084 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 20.3 t -132.46 158.78 41.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 63.42 110.894 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.4 m -84.18 2.82 37.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 74.55 110.771 -179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -112.33 -31.16 6.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 63.41 110.853 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 25.4 pt -148.78 162.24 5.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.24 -0.437 . . . . 73.15 111.148 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -149.57 170.24 19.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 74.45 111.116 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.6 m -112.3 153.57 13.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.203 -0.453 . . . . 74.44 111.203 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -146.15 132.12 19.2 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.191 -0.459 . . . . 73.51 110.841 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 0.403 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 12.0 t80 -115.01 108.82 17.19 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.253 -0.431 . . . . 74.22 110.889 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -86.19 128.49 34.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 64.35 110.945 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 2.7 p -145.32 144.43 21.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.128 -0.487 . . . . 75.21 111.119 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -159.38 133.76 3.48 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.793 -0.718 . . . . 71.22 112.496 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 4.5 p -112.93 75.41 1.96 Allowed Pre-proline 0 C--N 1.33 -0.243 0 CA-C-O 121.659 0.742 . . . . 70.52 111.083 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 162.49 41.87 Favored 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.654 2.236 . . . . 72.23 112.416 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -76.29 -167.93 0.86 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.26 -0.427 . . . . 61.15 111.132 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 35.3 ttp180 -78.02 131.09 37.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.243 -0.435 . . . . 73.42 110.916 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -132.45 151.14 52.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 62.44 111.056 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 22.3 pttm -92.78 135.17 34.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 75.32 110.915 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -116.09 137.23 52.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 72.04 110.891 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 -95.92 151.78 19.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 72.51 110.916 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 174.77 73.6 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.812 -0.709 . . . . 72.33 112.511 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -170.47 -176.44 2.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.912 0.387 . . . . 74.32 110.846 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.19 -70.12 0.62 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 73.24 110.923 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.8 t -85.81 -30.62 22.84 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.212 -0.449 . . . . 74.14 110.788 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 4.4 mm -68.5 -34.66 66.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 75.14 111.156 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.4 t -61.38 -49.66 76.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.465 . . . . 75.24 110.871 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 22.3 t -51.73 -42.46 62.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 64.24 110.851 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -57.66 -45.61 85.3 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.147 -0.479 . . . . 73.31 110.918 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 111.49 -14.82 27.48 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.772 -0.728 . . . . 63.51 112.547 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 9.6 ptt85 -120.46 95.77 4.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.84 0.353 . . . . 74.24 110.94 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 21.9 t -110.5 -46.06 6.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 74.04 111.121 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.6 p -139.63 153.47 47.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.477 . . . . 74.2 110.834 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -135.69 121.96 20.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.142 -0.481 . . . . 73.15 110.896 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.6 p -174.18 161.39 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.199 -0.455 . . . . 74.23 111.118 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -80.13 172.72 13.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.188 -0.46 . . . . 75.14 110.873 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -125.31 130.83 52.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.446 . . . . 72.43 110.919 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -118.68 66.75 0.37 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.708 -0.758 . . . . 75.42 112.441 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 124.99 11.63 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.705 2.27 . . . . 73.24 112.319 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -138.68 106.05 5.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 75.33 111.1 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 16.3 mm -118.56 150.48 20.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.25 -0.432 . . . . 75.31 111.105 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -149.15 109.75 4.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 71.52 110.916 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.0 p -144.37 171.56 14.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 75.0 110.891 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -120.42 153.06 37.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.465 . . . . 72.13 110.888 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 -106.25 139.03 41.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.156 -0.475 . . . . 72.1 110.902 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 30.7 p90 -143.16 148.3 36.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 73.32 110.884 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 25.0 p-80 . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 74.55 110.876 179.933 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 4.1 p90 . . . . . 0 C--O 1.232 0.132 0 CA-C-O 121.625 0.726 . . . . 72.52 110.921 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 177.55 5.48 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.702 2.268 . . . . 65.2 112.345 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -117.35 157.6 25.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 75.03 110.96 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 72.7 t -106.99 128.38 61.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.063 -0.517 . . . . 73.11 111.109 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -119.27 172.88 14.81 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.714 -0.755 . . . . 72.33 112.53 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.3 p -175.56 153.13 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.848 0.356 . . . . 72.53 111.141 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 178.17 -148.65 8.64 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.823 -0.704 . . . . 71.3 112.511 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . 0.465 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 4.9 p -110.39 137.71 41.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.882 0.372 . . . . 65.45 111.145 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -127.36 105.87 0.78 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.712 -0.756 . . . . 72.3 112.408 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 13.0 ptp180 -98.85 130.17 45.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.854 0.359 . . . . 75.44 110.891 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 3.2 m -106.99 109.65 28.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 71.0 111.172 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 1.4 tt -86.47 141.59 29.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 72.33 110.932 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -152.58 129.93 11.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 74.0 110.844 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -101.56 176.48 5.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.097 -0.501 . . . . 72.1 110.948 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -109.19 95.19 5.47 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.218 -0.447 . . . . 73.21 110.85 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.16 -79.61 0.32 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 73.34 110.858 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.7 m -163.22 113.22 1.36 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.254 -0.43 . . . . 73.42 111.135 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . 0.422 ' HB3' ' CB ' ' A' ' 139' ' ' PHE . 10.0 t0 -106.27 117.1 33.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 74.05 110.901 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -78.25 -11.15 85.63 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.759 -0.734 . . . . 73.21 112.49 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -44.95 -30.31 0.99 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.781 0.324 . . . . 74.15 111.076 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 3.4 tp -160.79 -177.49 6.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.227 -0.442 . . . . 75.24 110.916 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 14.9 t -54.28 94.06 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 74.33 110.854 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 68.2 m 49.16 75.49 0.15 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.18 -0.464 . . . . 75.3 110.849 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.422 ' CB ' ' HB3' ' A' ' 133' ' ' ASP . 0.4 OUTLIER -101.58 162.28 13.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 72.32 110.864 -179.958 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -138.53 170.35 16.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.129 -0.487 . . . . 74.45 110.888 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.9 mp -116.7 160.73 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 61.34 111.13 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 3.6 mtmt -122.19 122.36 39.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 74.31 110.899 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -74.31 -172.68 1.49 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.239 -0.437 . . . . 72.04 110.873 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 3.1 mmtm -171.36 -173.46 1.25 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 74.32 110.884 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 52.2 p-90 -154.62 153.23 31.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 75.22 110.955 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -176.44 165.41 1.65 Allowed Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.572 0.701 . . . . 73.41 111.116 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 53.1 Cg_endo -69.77 167.06 25.54 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.635 2.224 . . . . 73.11 112.363 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -160.26 154.97 24.07 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.207 -0.451 . . . . 74.22 111.113 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 11.6 m-85 -104.7 129.32 52.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.234 -0.439 . . . . 71.02 110.872 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 6.2 mm-40 -104.72 156.73 17.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.13 -0.486 . . . . 74.15 110.946 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.3 p -155.79 128.91 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 70.55 111.144 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 166.97 -162.82 36.6 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.749 -0.738 . . . . 72.13 112.517 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 3.3 pp -155.98 170.47 22.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.824 0.345 . . . . 72.04 110.897 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.9 tpp85 -117.68 122.3 43.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 73.13 110.867 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -108.56 153.99 22.59 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.185 -0.461 . . . . 74.5 110.964 -179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 35.7 t0 -121.53 99.26 6.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.482 . . . . 70.01 110.847 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 13.2 mt -97.71 97.53 9.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.28 -0.418 . . . . 74.33 110.936 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 80.65 -147.26 27.91 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.8 -0.714 . . . . 74.12 112.519 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -123.23 -35.49 2.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.866 0.365 . . . . 74.01 110.92 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 1.7 m -51.77 -61.84 2.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 74.5 110.845 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 18.6 p90 -139.58 153.72 47.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.215 -0.448 . . . . 71.23 110.927 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 11.0 mtt -108.34 176.49 5.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 75.52 110.849 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -116.51 146.31 42.69 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 54.52 110.83 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -141.76 134.38 28.39 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.142 -0.481 . . . . 62.45 110.863 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 10.8 t -136.78 124.18 22.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 64.11 110.805 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -144.23 160.72 40.5 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.123 -0.489 . . . . 73.34 110.883 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 58.1 t -150.0 126.73 2.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 64.5 111.156 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -104.58 133.58 49.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.198 -0.456 . . . . 72.51 110.834 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 19.6 t80 -136.74 132.07 34.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 64.53 110.914 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' ILE . . . . . 0.426 HG13 ' HD2' ' A' ' 171' ' ' PRO . 5.0 tp 178.65 132.89 0.23 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.628 0.727 . . . . 74.41 111.144 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . 0.426 ' HD2' HG13 ' A' ' 170' ' ' ILE . 54.6 Cg_endo -69.78 112.77 3.17 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.649 2.233 . . . . 74.53 112.374 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -122.83 151.45 41.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.259 -0.428 . . . . 73.24 110.859 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 20.1 pttt -123.85 134.56 53.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 72.42 110.881 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -101.2 171.21 7.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.228 -0.442 . . . . 65.0 111.133 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -123.51 161.2 25.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.197 -0.456 . . . . 71.44 110.911 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 3.4 t -151.07 143.05 16.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.173 -0.467 . . . . 71.05 111.107 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.4 t -166.98 -178.15 4.09 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.18 -0.464 . . . . 52.13 111.114 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -119.74 -158.38 10.58 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.763 -0.732 . . . . 71.1 112.56 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 6.6 t . . . . . 0 C--N 1.329 -0.313 0 CA-C-O 120.858 0.361 . . . . 73.35 111.152 -179.97 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo . . . . . 0 N--CA 1.466 -0.12 0 CA-C-O 120.853 0.272 . . . . 64.12 112.317 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 45.2 t -139.17 112.4 6.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.151 -0.477 . . . . 72.44 111.083 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.02 104.75 5.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.476 . . . . 61.23 110.849 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 29.4 p -124.14 174.04 7.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 72.2 111.123 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 5.2 ptmt -150.3 145.76 26.36 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.226 -0.443 . . . . 74.45 110.883 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 6.3 pt -127.27 111.24 24.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.273 -0.421 . . . . 70.15 111.149 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -92.0 113.48 25.76 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.186 -0.461 . . . . 65.03 110.913 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 12.1 m -136.77 167.31 24.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 72.13 111.096 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -107.25 88.54 3.98 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.553 0.692 . . . . 73.3 110.86 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 132.5 23.48 Favored 'Trans proline' 0 C--O 1.233 0.242 0 C-N-CA 122.685 2.257 . . . . 74.03 112.363 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -110.05 113.98 27.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.282 -0.417 . . . . 75.23 110.848 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 71.5 mt -105.86 119.94 55.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.158 -0.474 . . . . 74.43 111.159 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 9.7 mp -116.03 108.66 16.5 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.195 -0.457 . . . . 74.23 110.92 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 53.9 p -99.21 114.04 26.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.244 -0.434 . . . . 71.33 110.862 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -134.14 122.2 22.52 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.186 -0.461 . . . . 74.43 110.92 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -175.63 -140.58 3.46 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.774 -0.727 . . . . 64.04 112.497 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -126.65 174.24 8.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.826 0.346 . . . . 64.31 111.078 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 73.7 p -148.11 166.23 28.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.212 -0.449 . . . . 74.32 110.832 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -133.6 136.94 45.19 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.08 -0.509 . . . . 74.42 110.874 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 25.1 m -91.11 149.7 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.095 -0.502 . . . . 73.21 111.137 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -149.84 114.92 5.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 74.12 110.834 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 73.12 110.927 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.817 0.341 . . . . 75.32 110.903 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 99.36 6.08 55.46 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.801 -0.714 . . . . 75.12 112.511 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -77.33 150.9 35.15 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.853 0.359 . . . . 74.53 110.835 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 23.8 m-90 -117.75 138.37 52.08 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.21 -0.45 . . . . 70.35 110.923 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.5 m -141.56 134.7 29.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.25 -0.432 . . . . 73.44 111.108 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -99.66 112.45 24.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.447 . . . . 73.43 111.085 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -99.21 109.37 22.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 71.32 110.81 -179.761 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 12.7 m-85 -107.64 116.51 32.08 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 74.24 110.889 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -154.12 172.66 17.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 53.32 110.967 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -103.57 134.96 46.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.249 -0.432 . . . . 72.15 110.835 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 2.8 m -105.0 107.88 19.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.144 -0.48 . . . . 73.52 110.851 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 31.8 tttp -87.71 109.37 19.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.11 -0.495 . . . . 74.54 110.844 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.7 p -92.65 130.93 41.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 75.44 111.168 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -119.42 100.59 7.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 74.54 110.932 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.4 p -149.34 145.31 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.093 -0.503 . . . . 73.52 111.114 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 148.84 67.32 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.735 -0.745 . . . . 72.24 112.518 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 8.3 tt0 -89.18 -65.84 0.98 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.832 0.349 . . . . 63.24 110.928 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -170.61 169.25 7.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.125 -0.488 . . . . 73.32 110.92 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 11.3 tp -84.59 161.55 20.12 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.167 -0.47 . . . . 75.24 110.905 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.35 0 C-N-CA 120.763 -0.732 . . . . 64.41 112.51 179.856 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.171 0 CA-C-O 120.818 0.342 . . . . 75.43 111.084 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -137.61 134.7 35.84 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.29 -0.414 . . . . 72.04 110.872 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 73.6 t -104.94 142.61 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 73.4 111.149 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 m -155.19 152.9 29.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 73.32 110.882 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 38.3 pt -136.79 157.71 36.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.474 . . . . 74.33 111.138 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -88.78 -90.33 1.15 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.745 -0.741 . . . . 60.24 112.499 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 9.2 m120 57.57 57.27 4.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.795 0.331 . . . . 64.31 110.883 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -55.61 -57.86 10.2 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 74.34 110.915 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -162.85 138.18 6.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 71.35 111.177 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -161.89 146.65 12.89 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.227 -0.442 . . . . 75.0 111.132 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 88.9 mt -90.06 157.65 17.69 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.455 . . . . 74.5 110.828 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.36 144.32 33.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.13 -0.486 . . . . 74.34 111.129 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 15.4 m-85 -102.37 132.53 48.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 74.31 110.935 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -128.43 139.43 52.36 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.145 -0.48 . . . . 74.32 110.923 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.4 mm -110.07 114.92 48.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.196 -0.457 . . . . 74.44 111.123 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -116.15 149.53 38.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.116 -0.493 . . . . 64.55 111.145 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 14.6 m-85 -129.33 137.59 51.08 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.289 -0.414 . . . . 73.34 110.946 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -98.33 102.28 13.98 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.158 -0.474 . . . . 75.21 110.867 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.7 m -99.35 -34.06 4.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.472 . . . . 75.04 111.088 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 58.4 m -135.51 158.77 43.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 74.04 110.917 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 3.9 t -83.99 3.39 34.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 74.52 110.861 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -114.06 -30.56 6.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.149 -0.478 . . . . 64.25 110.849 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -140.89 165.23 20.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 75.43 111.124 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -155.18 168.83 25.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.133 -0.485 . . . . 72.43 111.116 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.413 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 4.2 m -111.66 147.67 15.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 72.15 111.125 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -149.93 128.53 12.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.189 -0.46 . . . . 64.23 110.849 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -121.5 132.91 54.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 72.44 110.882 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 13.1 m-30 -95.02 134.85 37.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.131 -0.486 . . . . 71.21 110.926 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 63.3 t -144.41 136.81 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.107 -0.497 . . . . 73.45 111.086 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -155.29 140.55 7.43 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.743 -0.742 . . . . 64.34 112.439 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.8 t -124.38 66.87 45.5 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.621 0.724 . . . . 71.14 111.083 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 154.91 67.45 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.656 2.237 . . . . 75.11 112.374 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -68.14 -167.63 0.09 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 50.43 111.09 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 9.8 ttm180 -77.46 129.0 35.16 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.203 -0.453 . . . . 73.54 110.859 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -120.72 142.41 49.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.449 . . . . 73.14 111.072 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 21.0 ttpp -91.64 134.99 34.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.165 -0.471 . . . . 73.34 110.9 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -131.98 152.01 51.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.221 -0.445 . . . . 74.2 110.92 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -99.93 156.1 17.33 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 73.23 110.897 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 179.86 68.16 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.737 -0.744 . . . . 73.41 112.487 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -170.53 -176.44 2.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.935 0.398 . . . . 74.41 110.94 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.81 -70.17 0.61 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 74.11 110.847 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.8 t -85.25 -31.24 23.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 73.12 110.828 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 4.8 mm -67.75 -33.59 62.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.198 -0.456 . . . . 74.3 111.146 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 10.0 t -63.66 -48.06 78.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 74.43 110.87 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 27.1 t -51.92 -42.48 62.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.147 -0.479 . . . . 72.31 110.87 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 82.6 mt -57.73 -48.38 79.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.115 -0.493 . . . . 74.15 110.884 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 115.32 -15.21 18.07 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.758 -0.734 . . . . 73.52 112.446 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 14.4 ttp180 -120.31 92.61 3.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.817 0.342 . . . . 72.15 110.885 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 25.3 t -108.15 -52.76 6.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.224 -0.444 . . . . 73.52 111.119 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 60.4 m -140.69 146.06 37.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 70.15 110.846 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -131.01 125.86 34.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 72.41 110.859 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 13.2 p -174.42 156.79 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 73.04 111.167 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -86.39 173.43 9.68 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.187 -0.46 . . . . 70.34 110.83 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -133.48 126.07 30.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 74.12 110.929 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -113.5 72.36 0.23 Allowed Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.717 -0.754 . . . . 72.12 112.458 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 114.21 3.62 Favored 'Trans proline' 0 N--CA 1.465 -0.177 0 C-N-CA 122.754 2.303 . . . . 74.13 112.367 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -129.56 104.87 7.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.219 -0.446 . . . . 72.34 111.129 179.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 1.2 pp -127.89 151.3 34.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 74.11 111.123 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -141.01 111.64 6.95 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.132 -0.485 . . . . 75.45 110.912 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 3.6 p -134.24 -174.15 3.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.23 -0.441 . . . . 75.22 110.837 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.413 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -134.97 147.98 49.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.091 -0.504 . . . . 71.34 110.931 179.994 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -104.31 134.82 46.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 75.12 110.97 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 12.9 p90 -144.71 159.03 43.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.228 -0.442 . . . . 74.34 110.925 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 9.8 t60 . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.111 -0.495 . . . . 73.1 110.855 179.941 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 . . . . . 0 C--O 1.231 0.103 0 CA-C-O 121.701 0.762 . . . . 74.31 110.913 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.81 177.52 5.53 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.725 2.283 . . . . 74.24 112.338 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -116.69 154.54 30.41 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.204 -0.453 . . . . 74.13 110.946 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.4 p -102.57 127.38 56.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.122 -0.49 . . . . 74.21 111.109 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -119.87 167.67 13.56 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.728 -0.749 . . . . 53.23 112.534 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 7.3 p -171.38 154.45 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.826 0.346 . . . . 75.04 111.135 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 178.87 -147.02 7.57 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.695 -0.764 . . . . 73.43 112.452 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . 0.461 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.7 p -112.6 132.43 61.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.852 0.358 . . . . 75.34 111.112 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -123.3 109.6 1.37 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.761 -0.733 . . . . 63.43 112.463 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 10.5 ptm180 -109.41 123.47 49.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.817 0.342 . . . . 61.43 110.892 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . 0.462 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 2.5 p -107.35 119.35 56.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 73.34 111.152 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 2.7 mp -129.46 153.62 47.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.19 -0.459 . . . . 75.12 110.81 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 7.3 p90 -160.21 169.71 22.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.078 -0.51 . . . . 74.13 110.894 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -101.88 117.57 35.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 75.22 110.877 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -53.43 101.38 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.138 -0.483 . . . . 75.15 110.873 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.67 -82.97 0.09 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.234 -0.439 . . . . 74.24 110.865 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.8 m -173.42 128.22 0.43 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 64.32 111.195 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . 0.405 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 5.3 m-20 -114.37 115.3 27.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 73.21 110.878 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -80.82 -2.96 90.47 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.731 -0.747 . . . . 53.42 112.511 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -47.13 -29.73 2.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.824 0.345 . . . . 72.41 111.079 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.8 tp -158.93 -177.94 6.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 63.13 110.921 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -52.19 96.49 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.157 -0.474 . . . . 72.4 110.826 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 93.2 p 46.94 74.13 0.16 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 63.13 110.865 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.405 ' HB3' ' HB2' ' A' ' 133' ' ' ASP . 0.5 OUTLIER -95.76 158.85 15.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.127 -0.488 . . . . 71.14 110.905 -179.928 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -141.36 174.95 10.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 75.41 110.829 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 2.6 mt -131.41 152.68 37.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.155 -0.475 . . . . 74.23 111.118 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 7.1 mmpt? -122.43 122.11 38.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 74.51 110.928 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.462 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 1.9 p-10 -72.08 -166.52 0.24 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 63.25 110.93 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -173.35 177.27 2.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.239 -0.437 . . . . 74.52 110.875 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 30.9 p90 -146.54 153.51 40.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 72.52 110.912 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.457 ' CB ' ' HD2' ' A' ' 147' ' ' PRO . . . 178.98 168.1 0.61 Allowed Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.618 0.723 . . . . 73.41 111.128 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 53.7 Cg_endo -69.79 150.73 68.43 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.68 2.253 . . . . 74.23 112.387 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -148.11 167.31 25.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.217 -0.447 . . . . 54.01 111.087 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 -118.94 166.21 13.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.205 -0.452 . . . . 73.5 110.883 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 1.3 pt20 -157.9 162.48 38.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.167 -0.47 . . . . 73.22 110.973 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 94.1 t -150.61 124.81 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.222 -0.445 . . . . 75.23 111.113 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . 0.418 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . -171.46 -167.16 31.31 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.769 -0.729 . . . . 73.54 112.541 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -145.11 158.54 43.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.834 0.349 . . . . 75.03 110.925 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 3.7 tpp85 -125.33 121.86 35.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 73.54 110.806 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 5.1 m-85 -128.52 173.16 10.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 73.01 110.873 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -121.74 106.83 11.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.1 -0.5 . . . . 73.15 110.883 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -102.94 97.41 7.54 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.194 -0.457 . . . . 75.44 110.948 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 85.75 161.99 35.68 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.677 -0.773 . . . . 65.24 112.537 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -74.26 147.21 42.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.889 0.376 . . . . 72.31 110.889 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 14.2 m 51.9 36.45 18.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.198 -0.455 . . . . 74.22 110.861 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 2.9 t90 -172.69 112.08 0.24 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.153 -0.476 . . . . 74.11 110.933 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 5.3 mtt -110.47 172.74 6.69 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 75.52 110.905 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 41.9 mt -129.49 140.3 51.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.253 -0.43 . . . . 64.51 110.903 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -138.41 136.05 35.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 73.43 110.864 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 24.0 p -143.94 122.27 12.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 74.3 110.84 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' ASP . . . . . 0.418 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.6 OUTLIER -150.77 171.84 16.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.128 -0.487 . . . . 72.44 110.833 179.972 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -141.89 120.12 8.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 73.45 111.101 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 1.9 tmm_? -93.55 135.65 34.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 74.42 110.845 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 21.7 m-85 -134.28 136.27 43.43 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 74.45 110.873 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' ILE . . . . . . . . . . . . . 8.0 tp 178.66 118.89 0.2 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.685 0.755 . . . . 73.54 111.086 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 113.44 3.37 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.633 2.222 . . . . 61.31 112.359 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -117.11 177.34 4.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.216 -0.447 . . . . 74.24 110.846 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 6.8 ptmt -152.32 138.58 18.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.128 -0.487 . . . . 75.33 110.933 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.95 155.1 18.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.258 -0.428 . . . . 75.1 111.15 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -116.19 102.11 9.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 74.31 110.868 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 20.3 m -96.89 146.35 7.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 73.43 111.139 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.6 t -166.7 163.29 16.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 72.12 111.132 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -123.35 162.3 17.3 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.798 -0.715 . . . . 61.12 112.488 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.328 -0.331 0 CA-C-O 120.811 0.339 . . . . 64.32 111.17 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo . . . . . 0 C--O 1.231 0.133 0 CA-C-O 120.794 0.248 . . . . 75.03 112.301 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 87.4 t -95.67 107.17 19.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 70.54 111.16 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 81.0 p -110.02 125.26 52.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 73.24 110.831 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 35.7 p -138.21 159.54 41.77 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.122 -0.49 . . . . 71.23 111.114 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 3.6 pttm -128.87 150.02 50.52 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 74.23 110.94 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 6.3 pt -131.56 108.2 14.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 72.44 111.138 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -98.87 118.34 35.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 72.4 110.86 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 2.4 t -137.66 164.53 28.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 65.51 111.073 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.96 87.73 3.16 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.604 0.716 . . . . 75.24 110.871 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.64 131.71 21.99 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.704 2.269 . . . . 75.24 112.311 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -100.17 107.03 18.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 75.31 110.89 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 3.9 mp -97.99 125.33 51.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.111 -0.495 . . . . 71.12 111.159 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 2.1 mp -119.31 108.12 14.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 73.11 110.977 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.2 120.52 33.57 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 62.21 110.851 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 1.3 tt -144.74 127.41 16.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.116 -0.493 . . . . 65.14 110.823 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 176.18 -146.98 8.35 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.834 -0.698 . . . . 72.24 112.535 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -118.32 174.14 6.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.788 0.327 . . . . 75.34 111.106 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 8.9 p -151.76 171.77 17.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 63.24 110.884 -179.802 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -145.4 148.1 32.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.147 -0.479 . . . . 75.24 110.912 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 14.5 m -111.76 157.4 12.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.49 . . . . 73.01 111.206 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -173.76 155.25 2.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.211 -0.449 . . . . 74.34 110.912 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 18.2 pttp . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.152 -0.476 . . . . 74.34 110.835 -179.982 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.2 mt-30 . . . . . 0 C--O 1.23 0.051 0 CA-C-O 120.862 0.363 . . . . 74.23 110.887 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.61 6.47 46.9 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.731 -0.747 . . . . 73.03 112.521 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.16 150.4 40.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.793 0.33 . . . . 73.51 110.802 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 33.4 m0 -122.24 140.85 52.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.189 -0.459 . . . . 75.1 110.936 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.1 p -148.55 122.58 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.171 -0.468 . . . . 72.21 111.151 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -84.81 114.17 21.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 73.43 111.083 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.7 p -106.06 109.3 21.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.247 -0.433 . . . . 73.13 110.823 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -113.08 123.58 50.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 74.32 110.852 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.87 168.47 25.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 71.24 110.916 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -96.01 127.82 42.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 75.25 110.882 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.1 p -97.45 109.75 22.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.243 -0.435 . . . . 71.41 110.808 -179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 9.2 tmtt? -88.05 106.63 18.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.077 -0.51 . . . . 74.03 110.904 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.1 p -86.29 139.13 17.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.461 . . . . 70.24 111.107 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -135.27 102.46 5.17 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.207 -0.451 . . . . 64.24 110.977 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 8.5 p -168.73 153.99 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.16 -0.473 . . . . 75.14 111.142 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 130.11 71.16 0.12 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.779 -0.724 . . . . 72.31 112.505 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -89.73 -66.07 0.96 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.83 0.347 . . . . 75.42 110.916 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -161.93 154.97 20.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 64.41 110.864 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 9.1 tp -69.74 167.46 17.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.086 -0.506 . . . . 73.52 110.896 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 72.33 112.487 179.894 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.067 0 CA-C-O 120.845 0.355 . . . . 74.11 111.058 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -147.36 140.31 25.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.485 . . . . 74.03 110.875 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 29.7 m -104.96 147.81 10.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.209 -0.45 . . . . 74.21 111.107 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.5 t -139.33 124.12 18.58 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.137 -0.483 . . . . 70.34 110.877 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 5.3 mp -120.76 105.33 16.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.167 -0.469 . . . . 73.14 111.165 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -135.67 109.99 0.79 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.772 -0.727 . . . . 74.31 112.527 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -147.7 152.19 37.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.853 0.359 . . . . 63.34 110.893 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -52.32 148.93 6.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 63.05 110.817 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 43.9 p -76.55 109.41 10.28 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.172 -0.467 . . . . 74.55 111.135 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.8 p -94.61 176.54 6.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 72.1 111.203 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 1.5 pt? -108.71 155.52 20.63 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.202 -0.454 . . . . 72.3 110.921 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -126.02 141.78 51.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.215 -0.448 . . . . 74.4 111.124 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -103.39 131.88 50.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 74.04 110.944 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -131.87 144.39 50.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.129 -0.487 . . . . 64.53 110.914 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.1 mm -115.2 114.2 45.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 54.04 111.118 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -102.87 129.95 49.73 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.15 -0.477 . . . . 72.14 111.06 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 22.7 m-85 -115.62 122.15 44.75 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 75.22 110.962 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -88.96 100.9 13.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 75.31 110.844 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.6 p -96.51 -33.17 4.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.122 -0.49 . . . . 74.12 111.132 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.6 m -132.01 159.17 39.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.15 -0.477 . . . . 71.04 110.828 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -84.03 3.18 35.6 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.105 -0.498 . . . . 62.54 110.788 -179.79 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -116.56 -31.49 5.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 72.13 110.878 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 33.8 pt -144.21 162.19 15.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 70.53 111.142 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -152.7 170.63 19.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 62.51 111.127 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.6 m -115.17 152.56 16.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 72.34 111.158 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -149.96 128.92 12.58 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.185 -0.461 . . . . 74.0 110.82 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -105.99 132.13 52.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.176 -0.466 . . . . 70.43 110.892 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -105.39 121.83 44.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.152 -0.476 . . . . 73.4 110.906 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 5.9 t -145.73 159.24 12.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.129 -0.487 . . . . 74.3 111.08 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -152.64 170.16 31.77 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.65 -0.786 . . . . 72.12 112.425 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.4 t -119.69 64.77 8.88 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.643 0.735 . . . . 75.35 111.148 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 163.36 38.58 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.642 2.228 . . . . 73.32 112.37 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -120.35 -166.96 1.38 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 73.52 111.139 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 33.8 ttp85 -76.86 120.65 22.29 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.266 -0.425 . . . . 74.21 110.821 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -124.26 150.92 44.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.216 -0.447 . . . . 75.11 111.121 179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -101.92 139.66 37.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.188 -0.46 . . . . 73.41 110.864 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -140.87 158.28 44.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 74.35 110.906 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 9.6 mt-30 -99.03 156.83 16.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 71.14 110.889 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -179.67 71.56 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.803 -0.713 . . . . 73.21 112.525 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -178.37 -177.36 0.56 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.893 0.378 . . . . 75.33 110.864 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.02 -68.95 0.7 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 74.12 110.903 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.8 t -83.24 -35.11 25.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.126 -0.488 . . . . 63.51 110.854 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 6.9 mm -63.54 -33.78 63.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.09 -0.505 . . . . 75.34 111.135 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 55.2 p -62.4 -49.24 76.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.235 -0.438 . . . . 62.2 110.911 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.3 t -51.21 -40.26 58.36 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.143 -0.48 . . . . 70.04 110.811 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 13.4 mt -60.73 -46.33 90.81 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.143 -0.48 . . . . 75.14 110.949 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 112.41 -14.43 25.3 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.714 -0.755 . . . . 63.03 112.481 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 27.8 mtp180 -121.1 96.34 5.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.824 0.345 . . . . 72.12 110.862 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 39.6 t -113.8 -44.36 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.461 . . . . 73.22 111.138 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.5 p -142.62 147.75 36.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 73.34 110.874 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -149.39 118.83 6.89 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.172 -0.467 . . . . 62.14 110.843 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 2.9 p -177.76 166.25 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 73.35 111.155 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -90.59 156.58 18.03 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.088 -0.505 . . . . 61.12 110.904 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -113.61 155.03 26.19 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.245 -0.434 . . . . 73.1 110.953 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -122.41 70.11 0.42 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.736 -0.745 . . . . 63.13 112.463 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 112.77 3.17 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.738 2.292 . . . . 72.4 112.328 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -131.97 110.19 10.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.24 -0.437 . . . . 70.32 111.105 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 2.7 mt -129.51 150.01 34.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 75.13 111.103 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 1.2 pp -152.35 115.39 4.65 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.119 -0.491 . . . . 73.53 110.862 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' SER . . . . . 0.424 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 4.3 p -138.78 -176.47 4.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.234 -0.439 . . . . 63.22 110.857 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -130.37 154.97 47.14 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.167 -0.469 . . . . 74.42 110.943 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 45.0 mt-30 -102.65 135.89 43.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 63.14 110.979 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -120.54 118.76 31.05 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.263 -0.426 . . . . 70.44 110.868 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 2.1 t60 . . . . . 0 C--N 1.331 -0.237 0 CA-C-N 116.126 -0.488 . . . . 72.24 110.869 179.913 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.7 t80 . . . . . 0 C--O 1.232 0.151 0 CA-C-O 121.63 0.729 . . . . 74.34 110.921 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 177.64 5.41 Favored 'Trans proline' 0 N--CA 1.465 -0.175 0 C-N-CA 122.713 2.275 . . . . 62.41 112.363 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -112.7 155.25 24.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.245 -0.434 . . . . 75.42 110.941 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.2 p -106.29 124.21 61.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.099 -0.501 . . . . 74.31 111.154 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -116.77 163.37 12.49 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.737 -0.744 . . . . 73.1 112.52 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.1 p -175.73 150.65 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.842 0.353 . . . . 75.51 111.141 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . 0.424 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -176.98 -150.39 8.31 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.757 -0.735 . . . . 63.44 112.508 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . 0.523 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 12.7 p -108.34 130.48 60.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.85 0.357 . . . . 72.11 111.195 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -124.45 109.94 1.33 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.784 -0.722 . . . . 42.43 112.51 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 13.8 ptm180 -104.97 131.81 52.01 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.837 0.351 . . . . 75.34 110.847 -179.802 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . 0.422 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 3.6 p -116.49 119.18 61.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.217 -0.447 . . . . 73.15 111.08 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.7 mp -113.52 172.7 6.81 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.126 -0.488 . . . . 72.02 110.917 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 3.3 p90 -131.2 172.55 12.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.443 . . . . 72.03 110.899 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -111.71 174.69 5.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 62.34 110.918 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -112.68 112.09 23.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.12 -0.491 . . . . 72.13 110.865 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 63.5 mmtt -146.11 -85.8 0.11 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 72.3 110.887 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 7.4 m -163.11 96.22 0.88 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.254 -0.43 . . . . 74.33 111.133 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -112.29 165.83 11.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 74.35 110.884 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 64.22 153.49 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 74.22 112.471 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -82.9 1.8 37.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.838 0.351 . . . . 75.14 111.056 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -87.04 -177.24 5.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.446 . . . . 74.13 110.882 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 6.1 m -64.76 88.1 0.06 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 73.34 110.848 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 9.6 m 53.62 75.28 0.27 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.46 . . . . 74.43 110.793 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -90.49 159.2 16.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.108 -0.496 . . . . 72.43 110.845 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -130.85 172.69 11.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.072 -0.513 . . . . 74.24 110.822 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.4 tt -117.41 171.61 5.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.128 -0.487 . . . . 75.33 111.136 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -119.59 103.98 9.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 73.43 110.896 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.422 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 0.6 OUTLIER -72.74 -171.55 0.86 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.28 -0.418 . . . . 74.33 110.89 179.867 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -172.44 179.28 2.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.221 -0.445 . . . . 73.25 110.929 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 28.7 p-90 -152.08 154.01 35.08 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.232 -0.44 . . . . 74.12 110.878 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.425 ' CB ' ' HD2' ' A' ' 147' ' ' PRO . . . -179.81 166.86 0.82 Allowed Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.594 0.711 . . . . 72.4 111.108 179.874 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' PRO . . . . . 0.523 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 53.9 Cg_endo -69.71 137.16 34.93 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.687 2.258 . . . . 75.22 112.388 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -126.91 160.51 30.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.272 -0.422 . . . . 73.53 111.092 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -103.54 163.94 11.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 75.04 110.917 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 44.4 tt0 -153.07 149.47 28.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.222 -0.445 . . . . 72.32 110.936 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.2 p -146.05 129.85 10.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 74.14 111.113 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . 0.413 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 172.89 -167.58 40.44 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.718 -0.753 . . . . 62.23 112.528 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -148.51 168.42 22.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.803 0.335 . . . . 74.25 110.911 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 7.2 tpp85 -116.76 118.84 33.64 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 73.02 110.895 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -101.68 149.92 23.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.137 -0.483 . . . . 75.44 110.928 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -120.64 98.19 5.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.485 . . . . 74.45 110.923 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 25.0 tp -95.98 98.13 10.15 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 72.55 110.9 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 72.99 -146.38 38.0 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.675 -0.774 . . . . 54.05 112.458 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 35.3 t-20 -120.47 -33.43 3.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.807 0.336 . . . . 75.54 110.847 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 24.3 p -50.74 -65.5 0.55 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.479 . . . . 72.24 110.866 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 52.4 p-90 -141.02 146.18 36.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.144 -0.48 . . . . 72.35 110.938 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 10.8 mmt -101.67 178.69 4.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 60.2 110.898 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 9.2 mt -120.23 149.51 42.15 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.234 -0.439 . . . . 75.34 110.944 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -142.42 133.42 25.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 74.52 110.894 179.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.5 t -137.89 122.39 18.44 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.187 -0.46 . . . . 74.11 110.826 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' ASP . . . . . 0.413 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.5 OUTLIER -154.2 162.73 40.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.146 -0.479 . . . . 65.44 110.859 179.909 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 42.1 t -146.0 125.34 5.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 74.34 111.148 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . 0.42 ' HD3' ' HB ' ' A' ' 195' ' ' ILE . 0.0 OUTLIER -100.92 155.73 17.79 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.259 -0.428 . . . . 73.21 110.871 -179.961 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 26.3 t80 -163.43 143.3 8.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 74.33 110.986 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' ILE . . . . . 0.414 HG13 ' HD2' ' A' ' 171' ' ' PRO . 3.1 tp -179.74 131.51 0.26 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 72.14 111.163 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . 0.414 ' HD2' HG13 ' A' ' 170' ' ' ILE . 53.4 Cg_endo -69.75 116.0 4.35 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.724 2.283 . . . . 72.43 112.272 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -117.47 177.1 4.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 62.14 110.894 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.84 116.93 6.38 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 75.44 110.955 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.2 t -105.92 161.52 14.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.262 -0.426 . . . . 75.2 111.203 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -127.51 176.8 7.2 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.264 -0.425 . . . . 71.14 110.873 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 2.4 p -145.5 141.94 22.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.192 -0.458 . . . . 70.23 111.131 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 2.0 t -166.24 160.17 15.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 74.34 111.139 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -159.3 -157.75 8.73 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.813 -0.708 . . . . 74.44 112.478 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 73.2 p . . . . . 0 C--N 1.329 -0.286 0 CA-C-O 120.774 0.321 . . . . 74.41 111.154 -179.815 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo . . . . . 0 N--CA 1.466 -0.134 0 CA-C-O 120.834 0.264 . . . . 74.34 112.338 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 62.8 t -95.57 105.84 17.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.242 -0.435 . . . . 63.3 111.139 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.72 109.06 20.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.16 -0.473 . . . . 74.22 110.854 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.3 161.03 20.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 73.11 111.161 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 21.9 pttt -136.84 157.28 47.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.435 . . . . 74.22 110.906 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 5.7 tp -154.79 120.7 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.228 -0.442 . . . . 75.41 111.132 179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.38 116.05 31.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.144 -0.48 . . . . 74.34 110.893 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 7.6 p -136.18 155.37 34.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.145 -0.48 . . . . 74.43 111.097 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.04 88.69 3.88 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.683 0.754 . . . . 72.41 110.831 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.87 142.56 47.79 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.659 2.24 . . . . 62.54 112.297 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 5.1 t80 -112.65 123.15 49.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.14 -0.482 . . . . 70.1 110.895 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 195' ' ' ILE . . . . . 0.42 ' HB ' ' HD3' ' A' ' 168' ' ' ARG . 56.7 mt -116.37 125.02 73.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.168 -0.469 . . . . 73.42 111.1 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 7.5 tt -116.39 109.88 17.92 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.122 -0.49 . . . . 74.45 110.982 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.96 119.23 35.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.202 -0.454 . . . . 72.4 110.856 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 55.1 tp -140.07 126.8 20.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.113 -0.494 . . . . 71.51 110.9 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -177.32 -141.27 3.99 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.74 -0.743 . . . . 75.04 112.466 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -129.37 173.42 10.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.781 0.324 . . . . 64.44 111.113 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 99.4 p -146.58 170.26 17.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 53.42 110.803 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 68.6 t80 -139.69 113.01 8.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.099 -0.501 . . . . 74.23 110.938 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 12.6 t -77.33 154.24 5.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.043 -0.526 . . . . 73.52 111.123 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 77.6 t80 -160.32 122.21 3.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.166 -0.47 . . . . 72.42 110.888 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 6.6 ptpp? . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 71.33 110.915 179.984 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.4 pt20 . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.776 0.322 . . . . 71.53 110.913 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.97 5.78 52.94 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.761 -0.733 . . . . 63.14 112.534 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -72.53 150.95 42.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.816 0.341 . . . . 75.45 110.848 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 25.1 t90 -116.32 143.96 44.86 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.206 -0.452 . . . . 70.5 111.001 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.9 t -145.57 123.27 4.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.265 -0.425 . . . . 72.12 111.058 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -82.61 109.19 16.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 74.32 111.108 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -95.07 127.75 41.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.155 -0.475 . . . . 71.15 110.851 -179.772 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 64.4 t80 -138.63 116.18 11.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.102 -0.499 . . . . 73.11 110.945 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -152.62 173.42 15.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.46 . . . . 72.35 110.917 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 14.6 m-85 -102.38 128.41 48.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 73.01 110.856 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 24.6 p -96.72 136.66 36.94 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.194 -0.457 . . . . 45.13 110.857 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.79 106.73 12.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.133 -0.485 . . . . 74.44 110.927 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 27.5 m -78.55 126.68 38.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.435 . . . . 70.41 111.101 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -119.19 106.16 12.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.134 -0.485 . . . . 73.21 110.954 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.9 p -174.07 152.73 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 72.22 111.154 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.72 72.35 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.726 -0.749 . . . . 75.53 112.488 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -89.53 -66.11 0.95 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.813 0.339 . . . . 61.13 110.85 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -171.55 149.07 2.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.127 -0.488 . . . . 73.1 110.882 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.2 tt -103.15 143.67 32.31 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.123 -0.489 . . . . 74.11 110.971 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 C-N-CA 120.767 -0.73 . . . . 61.41 112.463 179.94 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.053 0 CA-C-O 120.778 0.323 . . . . 62.42 111.093 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -143.18 128.44 18.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 71.31 110.874 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 14.4 p -104.77 146.59 11.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 64.12 111.21 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 15.1 t -156.92 137.24 12.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 71.41 110.816 -179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 18.5 tt -112.05 144.69 19.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.133 -0.485 . . . . 74.34 111.115 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -117.45 129.45 8.33 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.699 -0.763 . . . . 74.35 112.505 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.1 t-20 -150.82 128.21 11.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.824 0.345 . . . . 75.02 110.812 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.408 ' O ' ' C ' ' A' ' 53' ' ' THR . 12.8 p-10 -153.79 163.49 39.93 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.107 -0.497 . . . . 72.41 110.897 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' THR . . . . . 0.408 ' C ' ' O ' ' A' ' 52' ' ' ASP . 10.0 t 37.45 43.56 0.42 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 73.02 111.143 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.97 170.5 8.04 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.158 -0.474 . . . . 72.04 111.163 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -156.06 166.15 34.31 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.26 -0.427 . . . . 75.5 110.915 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 43.8 p -140.39 144.66 36.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.198 -0.455 . . . . 74.04 111.144 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -118.94 132.41 56.08 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.434 . . . . 74.53 110.86 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.401 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -131.87 150.51 52.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 74.21 110.832 -179.969 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 20.0 mm -110.47 114.41 46.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.236 -0.438 . . . . 73.23 111.123 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -103.36 123.73 47.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.176 -0.465 . . . . 61.44 111.124 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -112.97 119.51 38.18 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 73.14 110.883 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -80.1 113.73 18.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.084 -0.507 . . . . 65.32 110.863 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 83.3 t -111.27 -32.69 2.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 72.24 111.222 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -124.09 -172.53 2.56 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.104 -0.498 . . . . 75.3 110.85 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 5.0 p -85.82 -36.25 20.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.121 -0.49 . . . . 71.12 110.832 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -126.31 19.36 7.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 74.11 110.932 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 24.8 mt -148.97 135.77 13.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.111 -0.495 . . . . 75.35 111.122 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -153.32 170.13 21.39 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.172 -0.467 . . . . 73.04 111.076 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.3 m -106.34 151.32 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.265 -0.425 . . . . 75.2 111.083 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -143.03 138.32 29.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.129 -0.487 . . . . 74.4 110.839 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 0.401 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 12.0 m-85 -121.59 109.32 14.64 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 73.13 110.92 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -83.83 121.44 27.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.154 -0.475 . . . . 74.05 110.867 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 24.8 t -135.89 146.59 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 75.42 111.1 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -162.31 124.35 1.29 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.678 -0.772 . . . . 64.13 112.497 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 43.7 t -114.91 70.18 2.39 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.638 0.733 . . . . 62.11 111.132 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 162.79 40.72 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 75.24 112.331 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -76.32 -170.52 1.49 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.213 -0.449 . . . . 73.55 111.13 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 19.8 ttp180 -77.48 137.2 38.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 72.4 110.916 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -134.28 150.93 51.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.226 -0.443 . . . . 53.53 111.068 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -100.51 138.31 37.73 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 73.43 110.898 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -128.09 155.31 44.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 72.22 110.894 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.443 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 1.1 pt20 -110.26 153.26 25.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 75.43 110.995 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 179.93 75.22 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.758 -0.734 . . . . 44.54 112.52 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -177.25 -176.89 0.68 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.906 0.384 . . . . 71.55 110.86 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 3.6 mtpm? -85.67 -69.66 0.65 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 74.04 110.868 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.5 t -84.31 -33.41 23.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 72.05 110.928 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 6.1 mm -64.62 -34.33 69.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.124 -0.489 . . . . 75.32 111.113 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 78.6 p -63.7 -50.48 69.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.144 -0.48 . . . . 75.54 110.856 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 44.6 t -51.45 -38.06 51.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.146 -0.479 . . . . 74.31 110.863 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 9.3 tp -64.83 -42.66 94.79 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.172 -0.467 . . . . 71.22 110.931 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 106.14 -14.57 44.1 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.755 -0.736 . . . . 74.23 112.491 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 24.3 ttp180 -114.37 94.33 4.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.834 0.349 . . . . 73.12 110.922 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.443 ' HB ' ' HA ' ' A' ' 82' ' ' GLN . 85.5 t -112.86 -51.83 5.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 75.12 111.106 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 10.9 p -139.12 143.52 38.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.158 -0.474 . . . . 73.12 110.829 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -130.92 118.22 20.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.136 -0.484 . . . . 72.42 110.917 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 9.8 p -176.08 161.26 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.181 -0.463 . . . . 74.21 111.113 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -91.07 174.12 7.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 70.22 110.849 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -119.91 134.53 55.21 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.165 -0.471 . . . . 71.53 110.947 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -121.76 66.61 0.46 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.719 -0.753 . . . . 71.42 112.509 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 117.43 5.08 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.617 2.211 . . . . 74.02 112.321 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -132.37 104.24 6.62 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.157 -0.474 . . . . 75.42 111.087 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 5.0 mp -130.03 150.57 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 73.31 111.094 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -143.75 115.39 8.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 72.42 110.899 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.1 p -142.87 159.65 41.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.232 -0.44 . . . . 72.12 110.887 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -108.12 146.58 32.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.141 -0.481 . . . . 75.12 110.893 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -100.97 137.99 38.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 72.15 110.872 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 28.6 p90 -141.63 156.19 45.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.204 -0.453 . . . . 74.2 110.916 -179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 20.0 m-70 . . . . . 0 C--N 1.33 -0.26 0 CA-C-N 116.115 -0.493 . . . . 71.33 110.835 179.92 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 21.6 p90 . . . . . 0 C--O 1.232 0.161 0 CA-C-O 121.672 0.749 . . . . 75.23 110.919 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 177.74 5.25 Favored 'Trans proline' 0 N--CA 1.465 -0.186 0 C-N-CA 122.69 2.26 . . . . 55.23 112.402 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 1.2 p90 -112.05 162.78 15.02 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.261 -0.427 . . . . 71.42 110.941 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 43.9 t -121.41 136.24 58.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.124 -0.489 . . . . 74.24 111.173 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -128.58 179.09 16.81 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.771 -0.728 . . . . 74.22 112.437 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 7.6 p -163.44 155.79 2.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.89 0.376 . . . . 65.13 111.125 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -179.34 -157.41 19.69 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.73 -0.748 . . . . 61.23 112.509 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . 0.418 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.4 p -107.28 123.71 62.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.812 0.339 . . . . 75.03 111.173 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -115.45 107.66 1.77 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.774 -0.727 . . . . 62.14 112.497 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -106.13 126.82 52.67 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.932 0.396 . . . . 72.42 110.824 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 2.1 p -105.59 108.92 26.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.152 -0.476 . . . . 74.24 111.144 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 3.1 tp -116.58 170.33 8.66 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.259 -0.428 . . . . 75.42 110.993 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -161.7 179.35 8.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.246 -0.433 . . . . 74.24 110.926 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -117.23 115.47 25.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.469 . . . . 74.41 110.882 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -48.05 110.55 0.34 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 65.41 110.799 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 2.8 mmmt -104.09 -89.05 0.41 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 72.42 110.885 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.3 m -175.78 133.94 0.28 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.23 -0.441 . . . . 75.03 111.152 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . 0.418 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 19.3 m-20 -115.9 127.63 55.15 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.166 -0.47 . . . . 73.22 110.937 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -77.12 -11.09 85.88 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.753 -0.737 . . . . 63.01 112.522 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -45.12 -31.09 1.28 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.872 0.368 . . . . 74.33 111.077 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.5 tp -164.6 -177.18 4.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 74.02 110.938 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 16.5 m -51.42 95.24 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 74.12 110.862 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 93.3 p 47.26 72.03 0.28 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.071 -0.513 . . . . 71.11 110.892 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.418 ' HB3' ' HB2' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -88.97 160.26 17.22 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.131 -0.486 . . . . 63.34 110.84 -179.904 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 69.9 m-20 -147.2 -178.61 6.31 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.112 -0.495 . . . . 63.52 110.844 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.405 ' HA ' ' HA ' ' A' ' 176' ' ' VAL . 1.1 pt -141.92 174.39 6.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.128 -0.487 . . . . 74.42 111.139 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 14.7 tptt -123.85 135.58 53.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 74.32 110.877 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -78.5 -173.29 3.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 75.22 110.891 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 1.4 tttp -166.77 177.24 6.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 74.22 110.901 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 64.7 p-90 -156.95 160.3 38.93 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.227 -0.442 . . . . 73.45 110.928 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.427 ' CB ' ' HD2' ' A' ' 147' ' ' PRO . . . 177.44 166.73 0.51 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.622 0.725 . . . . 75.02 111.068 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' PRO . . . . . 0.427 ' HD2' ' CB ' ' A' ' 146' ' ' ALA . 53.4 Cg_endo -69.77 129.64 17.93 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.711 2.274 . . . . 74.32 112.279 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.413 ' HA ' ' HB ' ' A' ' 170' ' ' ILE . . . -122.69 170.17 10.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.217 -0.447 . . . . 73.3 111.113 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 13.2 m-85 -124.18 154.66 39.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.258 -0.428 . . . . 74.45 110.807 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 5.8 tt0 -130.63 151.95 50.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.102 -0.499 . . . . 74.45 110.862 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.4 p -153.1 125.85 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 75.21 111.185 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -179.78 -162.63 29.1 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.776 -0.726 . . . . 74.52 112.451 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -142.6 145.43 33.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.784 0.326 . . . . 71.24 110.857 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 3.9 tpp85 -115.37 119.34 35.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 75.32 110.855 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 63.3 t80 -110.59 150.21 29.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.223 -0.444 . . . . 74.35 110.951 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -121.27 123.52 42.39 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.151 -0.477 . . . . 71.21 110.852 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 1.7 tt -92.29 136.12 33.46 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.157 -0.474 . . . . 75.42 110.898 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -75.41 137.39 21.77 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.782 -0.723 . . . . 72.21 112.52 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 53.02 37.23 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.892 0.377 . . . . 72.43 110.894 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 2.3 m -172.59 173.95 3.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.154 -0.476 . . . . 44.24 110.82 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 7.0 m0 -62.55 158.76 17.27 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.146 -0.479 . . . . 64.22 110.912 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -92.97 171.17 9.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.255 -0.429 . . . . 54.23 110.927 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 80.7 mt -124.3 145.35 49.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 75.22 110.895 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -143.64 134.47 25.28 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.164 -0.471 . . . . 55.24 110.832 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 78.4 p -145.11 121.54 10.99 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.118 -0.492 . . . . 63.41 110.834 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -153.4 174.0 14.92 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.158 -0.474 . . . . 73.12 110.859 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 1.5 t -135.68 151.87 30.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.153 -0.476 . . . . 72.3 111.178 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -117.73 131.49 56.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 75.33 110.901 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 23.4 m-85 -132.07 134.68 45.78 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.144 -0.48 . . . . 75.42 110.966 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' ILE . . . . . 0.413 ' HB ' ' HA ' ' A' ' 148' ' ' ALA . 0.0 OUTLIER -179.13 120.49 0.23 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.618 0.723 . . . . 71.24 111.138 179.93 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.77 108.61 2.12 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.635 2.224 . . . . 74.42 112.333 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -116.48 157.11 25.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 74.52 110.834 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.36 118.98 25.18 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.131 -0.486 . . . . 75.14 110.89 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.9 t -95.08 144.64 25.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.21 -0.45 . . . . 75.22 111.092 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -100.21 150.58 22.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.163 -0.472 . . . . 72.11 110.855 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . 0.405 ' HA ' ' HA ' ' A' ' 141' ' ' ILE . 14.7 p -146.46 127.53 6.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.197 -0.456 . . . . 74.42 111.159 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 15.2 t -167.32 172.16 10.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 73.43 111.073 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -145.48 171.77 26.42 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.688 -0.768 . . . . 72.11 112.493 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.294 0 CA-C-O 120.885 0.374 . . . . 73.54 111.124 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo . . . . . 0 C--O 1.231 0.158 0 CA-C-O 120.767 0.236 . . . . 62.42 112.387 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 49.6 t -96.73 107.99 20.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.265 -0.425 . . . . 72.43 111.14 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 1.7 p -104.16 118.72 37.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 71.52 110.83 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 23.2 p -145.9 176.12 9.92 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.183 -0.462 . . . . 72.34 111.149 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -154.67 166.66 32.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 75.21 110.878 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 47.7 mm -140.23 114.44 6.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 73.12 111.099 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 7.6 tm-20 -103.01 106.74 17.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.136 -0.484 . . . . 65.13 110.93 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 8.7 m -137.03 163.49 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.174 -0.466 . . . . 72.51 111.145 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.3 89.28 4.63 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.61 0.719 . . . . 65.43 110.814 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 137.36 35.11 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.675 2.25 . . . . 75.4 112.385 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -104.26 114.7 29.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.308 -0.405 . . . . 73.11 110.813 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 4.0 mm -101.68 119.2 49.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.109 -0.496 . . . . 74.14 111.116 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 11.9 tp -104.86 109.49 21.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.241 -0.436 . . . . 72.23 110.902 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -102.46 119.58 39.07 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.163 -0.471 . . . . 54.05 110.833 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -139.13 129.65 25.8 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.164 -0.471 . . . . 72.23 110.963 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 179.88 -144.15 5.89 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.766 -0.73 . . . . 65.22 112.454 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -127.1 173.42 9.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.812 0.339 . . . . 65.5 111.087 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 15.2 m -146.96 169.87 18.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.214 -0.448 . . . . 72.33 110.89 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 1.1 t80 -141.49 131.66 24.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.168 -0.469 . . . . 75.14 110.935 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 5.8 t -81.12 158.58 4.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.479 . . . . 75.11 111.089 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -164.6 147.95 8.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.466 . . . . 73.42 110.915 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 35.8 mtpt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 73.34 110.895 -179.964 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 17.5 pt20 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.812 0.339 . . . . 74.45 110.907 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 101.7 7.91 46.97 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.729 -0.748 . . . . 64.13 112.468 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.62 156.23 27.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.81 0.338 . . . . 74.31 110.856 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 41.5 m95 -133.0 143.63 49.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.109 -0.496 . . . . 75.11 110.944 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 m -142.71 137.76 27.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.251 -0.431 . . . . 73.22 111.132 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -96.62 104.91 16.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 75.13 111.087 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.4 m -91.63 130.18 37.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 74.44 110.87 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 13.7 p90 -134.78 116.76 15.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.066 -0.515 . . . . 65.4 110.88 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -150.95 172.32 15.88 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.177 -0.465 . . . . 75.33 110.94 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 12.8 p90 -105.16 131.39 52.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 74.21 110.906 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -96.58 137.3 35.87 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.149 -0.478 . . . . 44.35 110.837 -179.76 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.7 mmtp -116.19 111.64 20.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.128 -0.487 . . . . 72.24 110.878 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 25.4 t -75.11 128.32 36.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.237 -0.438 . . . . 72.43 111.097 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 6.9 m-85 -125.96 106.92 9.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 74.33 110.977 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.7 p -171.59 152.92 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.119 -0.491 . . . . 72.21 111.146 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 169.34 64.74 0.04 OUTLIER Glycine 0 N--CA 1.453 -0.197 0 C-N-CA 120.766 -0.731 . . . . 75.43 112.491 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 13.8 tt0 -89.78 -66.3 0.94 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.76 0.314 . . . . 71.21 110.861 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 71.1 tt0 -175.05 154.88 1.88 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 71.12 110.905 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -110.07 133.91 52.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.484 . . . . 71.14 110.958 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.746 -0.74 . . . . 65.45 112.49 179.909 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.123 0 CA-C-O 120.789 0.328 . . . . 72.13 111.104 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -143.25 130.41 20.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.453 . . . . 73.31 110.846 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.5 p -104.78 138.56 29.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.185 -0.461 . . . . 74.23 111.089 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -142.85 159.16 42.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.117 -0.492 . . . . 75.22 110.835 -179.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -108.47 132.76 55.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.119 -0.491 . . . . 75.41 111.149 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -131.07 51.81 0.85 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.746 -0.74 . . . . 60.25 112.488 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 -102.81 112.6 25.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.834 0.35 . . . . 75.13 110.919 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -55.03 175.18 0.06 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 75.2 110.859 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 7.5 p -53.16 101.82 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.238 -0.437 . . . . 72.43 111.135 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 44.9 p -100.94 176.1 5.39 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 74.12 111.182 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 5.2 mp -129.78 161.51 30.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.269 -0.423 . . . . 73.44 110.924 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.5 143.01 30.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 74.22 111.087 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -123.05 132.41 54.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.248 -0.433 . . . . 75.23 110.862 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 14.5 p-10 -134.75 145.21 48.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 65.22 110.825 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.8 mm -108.95 116.81 52.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 74.42 111.085 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -101.87 125.2 48.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 63.14 111.07 179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 27.1 t80 -110.47 115.59 29.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.22 -0.445 . . . . 74.24 110.91 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -84.14 101.95 12.22 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.092 -0.503 . . . . 73.11 110.89 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.5 p -94.21 -33.15 4.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.151 -0.477 . . . . 75.34 111.041 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.0 m -134.1 164.33 27.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 73.54 110.782 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 7.8 p -86.67 3.14 45.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.083 -0.508 . . . . 71.03 110.885 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -112.43 -32.59 6.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.101 -0.5 . . . . 74.14 110.912 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 21.6 pt -146.44 167.81 6.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.173 -0.467 . . . . 73.42 111.163 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -154.69 169.13 24.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 72.43 111.12 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.409 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 1.4 p -111.62 147.2 15.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.3 -0.409 . . . . 65.22 111.19 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -139.78 127.0 21.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 64.32 110.798 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -108.56 110.43 21.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 71.31 110.874 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -87.03 129.4 34.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.126 -0.488 . . . . 75.23 110.872 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 9.9 m -149.44 163.42 4.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.118 -0.492 . . . . 72.3 111.134 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 175.01 142.57 4.13 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.757 -0.735 . . . . 75.11 112.477 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 3.9 p -118.71 77.78 14.95 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.657 0.741 . . . . 74.43 111.16 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 148.7 65.97 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.63 2.22 . . . . 74.1 112.387 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -67.31 -165.62 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.29 -0.414 . . . . 64.41 111.061 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 43.1 ttp180 -76.66 115.54 16.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 74.3 110.83 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -110.3 149.71 29.79 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.212 -0.449 . . . . 71.34 111.145 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.6 tmmm? -103.27 141.23 36.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 75.34 110.825 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 -139.47 157.33 46.03 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.136 -0.484 . . . . 61.3 110.86 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 9.3 mt-30 -105.96 156.15 18.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.198 -0.455 . . . . 74.0 110.977 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 176.26 73.81 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.712 -0.756 . . . . 74.51 112.512 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -174.37 -177.21 1.21 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.959 0.409 . . . . 74.22 110.857 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 2.3 ptmt -86.76 -69.95 0.64 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.096 -0.502 . . . . 74.52 110.858 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.6 t -84.07 -33.38 24.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.45 . . . . 54.31 110.913 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 4.6 mm -65.39 -34.46 70.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.115 -0.493 . . . . 75.33 111.146 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 63.5 p -61.48 -48.68 80.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.13 -0.486 . . . . 62.42 110.751 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.7 t -52.1 -39.93 60.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 71.21 110.83 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 82.5 mt -60.41 -47.86 84.25 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.163 -0.471 . . . . 74.43 110.941 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 114.93 -14.96 19.22 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.759 -0.734 . . . . 75.04 112.515 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 8.9 mtm180 -121.34 97.15 5.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.899 0.381 . . . . 75.25 110.901 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 17.0 t -112.97 -41.99 4.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.159 -0.473 . . . . 75.31 111.023 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 13.3 p -141.51 154.2 45.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 61.33 110.872 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 82.9 mt-10 -152.56 118.64 5.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.134 -0.485 . . . . 75.42 110.836 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 4.5 p -178.46 164.16 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 72.24 111.165 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -90.84 133.51 35.16 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.466 . . . . 73.51 110.86 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -92.21 146.14 23.95 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 74.33 110.86 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -113.49 70.93 0.23 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.767 -0.73 . . . . 71.1 112.497 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 112.48 3.1 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.714 2.276 . . . . 74.44 112.302 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -136.87 113.76 10.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.239 -0.437 . . . . 63.04 111.171 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 13.5 pt -139.68 153.61 23.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.209 -0.451 . . . . 72.4 111.117 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -142.21 117.05 9.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.204 -0.453 . . . . 75.03 110.898 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.3 p -142.82 161.26 38.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.227 -0.442 . . . . 71.31 110.885 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.409 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 4.5 pp -110.08 146.03 36.09 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.168 -0.469 . . . . 75.22 110.955 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 1.7 pp0? -101.13 144.43 30.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 73.31 110.965 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -152.58 159.78 43.24 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.244 -0.435 . . . . 73.1 110.955 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 7.7 p-80 . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.114 -0.494 . . . . 73.23 110.779 179.961 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 20.8 p90 . . . . . 0 C--O 1.231 0.086 0 CA-C-O 121.624 0.726 . . . . 62.4 110.952 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.67 178.37 4.58 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.72 2.28 . . . . 74.14 112.359 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 1.6 p90 -127.38 159.07 35.56 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.295 -0.411 . . . . 74.23 110.895 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 48.1 t -113.3 136.5 49.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.107 -0.497 . . . . 74.01 111.1 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -127.24 172.46 18.65 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.759 -0.734 . . . . 71.33 112.515 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.2 p -162.46 151.67 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.877 0.37 . . . . 65.34 111.18 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -176.65 -156.23 15.1 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.693 -0.765 . . . . 70.34 112.46 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . 0.455 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 5.8 m -107.82 122.04 61.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.921 0.391 . . . . 61.54 111.083 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -115.9 121.31 5.2 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.699 -0.762 . . . . 71.32 112.523 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -116.51 132.7 56.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.829 0.347 . . . . 73.03 110.862 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 2.8 m -107.66 108.67 25.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 75.02 111.147 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -86.86 166.53 15.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 73.23 110.956 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -149.24 134.51 18.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 74.13 110.902 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 28.3 t80 -100.34 165.13 11.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.147 -0.479 . . . . 73.34 110.909 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -97.49 120.19 37.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 62.4 110.826 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 4.3 tppp? -141.17 -82.18 0.23 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 75.25 110.838 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 31.7 m -162.78 83.92 0.52 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.267 -0.424 . . . . 71.24 111.185 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -104.57 165.11 11.28 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.229 -0.441 . . . . 72.31 110.898 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 62.13 154.85 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.725 -0.75 . . . . 54.43 112.463 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -84.77 1.71 45.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.808 0.337 . . . . 70.0 111.088 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -86.26 -175.75 5.63 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.26 -0.427 . . . . 74.34 110.965 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.4 m -63.55 87.53 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.191 -0.459 . . . . 72.44 110.83 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 38.6 t 51.17 76.63 0.15 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.074 -0.512 . . . . 61.22 110.854 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -86.55 148.87 25.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.163 -0.471 . . . . 73.44 110.806 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 59.4 m-20 -122.03 -178.76 3.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.045 -0.525 . . . . 75.24 110.898 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.406 ' HA ' ' HA ' ' A' ' 176' ' ' VAL . 0.1 OUTLIER -145.2 160.51 13.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.445 . . . . 74.33 111.124 179.988 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 3.4 ttmt -105.27 122.42 45.89 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.21 -0.45 . . . . 73.3 110.918 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -63.59 -173.48 0.07 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.241 -0.436 . . . . 74.11 110.859 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 18.6 tptt -158.45 164.62 36.04 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.191 -0.459 . . . . 74.33 110.913 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 17.6 p90 -155.87 146.48 21.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.167 -0.469 . . . . 75.12 110.889 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.469 ' CB ' ' HD2' ' A' ' 147' ' ' PRO . . . 179.74 168.76 0.68 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.592 0.711 . . . . 62.5 111.138 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' PRO . . . . . 0.469 ' HD2' ' CB ' ' A' ' 146' ' ' ALA . 53.8 Cg_endo -69.75 125.1 11.76 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.703 2.269 . . . . 73.2 112.364 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -117.96 171.08 8.32 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.238 -0.437 . . . . 62.23 111.078 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 16.3 m-85 -123.6 138.55 54.53 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.13 -0.486 . . . . 74.32 110.861 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 40.0 tt0 -119.93 159.49 24.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.138 -0.483 . . . . 74.21 110.862 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -160.7 133.32 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.453 . . . . 71.44 111.154 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . 0.42 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 179.38 -158.67 22.79 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.66 -0.781 . . . . 72.24 112.442 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -146.93 166.38 26.93 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.777 0.322 . . . . 74.13 110.94 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . 0.41 ' HD3' ' N ' ' A' ' 155' ' ' TYR . 5.6 tpp85 -129.56 117.86 21.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.248 -0.433 . . . . 75.22 110.858 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . 0.41 ' N ' ' HD3' ' A' ' 154' ' ' ARG . 3.4 t80 -104.12 144.32 31.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.234 -0.439 . . . . 74.01 110.85 -179.811 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -120.47 98.26 5.96 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.124 -0.489 . . . . 74.05 110.842 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 78.8 mt -69.53 152.77 44.41 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.204 -0.453 . . . . 75.11 110.898 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -52.8 -33.84 43.59 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.733 -0.746 . . . . 72.15 112.495 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -65.78 178.53 1.03 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.86 0.362 . . . . 75.13 110.932 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 1.2 m -66.08 -35.88 81.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.144 -0.48 . . . . 73.34 110.958 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 47.0 p90 -82.76 152.82 25.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.068 -0.515 . . . . 72.32 110.991 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 2.3 mpt? -123.7 177.44 5.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.28 -0.418 . . . . 70.24 110.819 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -118.42 144.56 45.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.464 . . . . 73.3 110.87 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -143.63 137.61 28.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.15 -0.477 . . . . 55.05 110.923 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.0 t -144.06 121.44 11.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 72.54 110.803 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' ASP . . . . . 0.42 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.8 OUTLIER -137.37 159.66 41.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 74.35 110.908 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 50.4 t -132.84 134.44 58.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 72.01 111.15 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 2.1 ttt85 -106.17 137.59 43.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 73.24 110.8 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 23.1 t80 -148.55 132.5 17.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 74.01 110.894 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -178.71 123.63 0.25 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.705 0.764 . . . . 73.23 111.121 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 104.16 1.27 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.669 2.246 . . . . 74.21 112.284 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -117.53 175.03 5.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 73.34 110.935 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.2 132.88 25.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.249 -0.432 . . . . 73.11 110.951 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -111.15 150.85 28.89 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.244 -0.434 . . . . 73.32 111.123 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.44 158.84 16.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.223 -0.444 . . . . 65.42 110.849 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . 0.406 ' HA ' ' HA ' ' A' ' 141' ' ' ILE . 10.3 t -138.61 123.2 21.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.461 . . . . 74.23 111.172 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 15.3 t -166.67 172.57 10.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 74.53 111.149 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 117.72 140.07 6.45 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.755 -0.736 . . . . 62.41 112.443 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 43.5 m . . . . . 0 C--N 1.33 -0.275 0 CA-C-O 120.799 0.333 . . . . 75.41 111.08 -179.839 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo . . . . . 0 C--O 1.231 0.158 0 CA-C-O 120.792 0.247 . . . . 65.13 112.281 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 4.2 t -95.96 159.05 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 74.52 111.186 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 6.2 p -130.43 108.55 10.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.974 0.416 . . . . 74.55 110.906 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 16.8 p -127.36 167.21 16.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.18 -0.464 . . . . 75.23 111.177 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 4.0 tttt -151.92 142.71 22.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 63.11 110.955 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 6.8 tp -137.5 125.68 32.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 73.51 111.092 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -106.55 112.42 25.42 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.137 -0.483 . . . . 71.44 110.876 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 8.2 m -137.83 158.88 33.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.192 -0.458 . . . . 70.23 111.083 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -108.22 88.78 5.11 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.616 0.722 . . . . 54.35 110.813 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 142.16 46.94 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.619 2.213 . . . . 74.4 112.385 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -113.75 112.21 23.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.245 -0.434 . . . . 75.25 110.901 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 4.6 mm -100.45 124.9 54.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 74.52 111.144 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -107.9 109.01 20.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.157 -0.474 . . . . 74.33 110.955 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -97.28 123.8 41.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.212 -0.449 . . . . 72.44 110.856 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 22.8 tp -142.38 127.59 18.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.128 -0.487 . . . . 74.21 110.943 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -179.21 -143.93 5.58 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.751 -0.738 . . . . 64.33 112.509 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -123.93 173.66 8.07 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.815 0.341 . . . . 60.01 111.094 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 19.1 m -154.04 163.55 39.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 63.4 110.825 -179.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -131.47 131.6 43.64 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.217 -0.447 . . . . 74.24 110.897 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 60.5 t -102.22 146.61 10.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.112 -0.494 . . . . 71.25 111.109 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -160.76 157.49 26.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.099 -0.5 . . . . 65.54 110.838 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 3.9 ptmm? . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.128 -0.487 . . . . 74.33 110.863 -179.992 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 7.3 mp0 . . . . . 0 N--CA 1.458 -0.072 0 CA-C-O 120.792 0.329 . . . . 70.21 110.907 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.35 5.84 36.77 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.711 -0.757 . . . . 72.13 112.507 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -66.74 153.3 43.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.337 . . . . 71.01 110.911 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 17.3 t90 -123.74 125.11 44.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.197 -0.456 . . . . 72.34 110.965 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 12.5 m -136.92 135.02 48.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.251 -0.431 . . . . 75.5 111.106 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -93.11 158.01 15.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 65.34 111.135 179.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.0 109.51 5.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.258 -0.428 . . . . 72.21 110.845 -179.745 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -111.37 115.66 29.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 73.24 110.865 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -150.69 173.0 14.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 74.43 110.906 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 28.2 p90 -108.43 132.21 54.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.167 -0.47 . . . . 71.52 110.908 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 25.2 p -104.85 142.45 34.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 73.11 110.841 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 25.4 tptt -121.96 122.95 40.53 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.082 -0.508 . . . . 75.51 110.975 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 20.9 m -89.92 135.29 26.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.281 -0.418 . . . . 62.33 111.154 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -126.68 114.37 17.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.252 -0.431 . . . . 75.01 111.015 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.0 p -174.79 153.55 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 72.51 111.156 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 150.5 67.26 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.775 -0.726 . . . . 63.31 112.517 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -90.16 -66.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.812 0.339 . . . . 73.35 110.958 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 25.0 pt-20 -174.91 170.61 3.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.128 -0.487 . . . . 60.01 110.887 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 36.4 tp -98.27 150.14 21.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.138 -0.483 . . . . 74.12 110.913 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 C-N-CA 120.732 -0.747 . . . . 65.23 112.464 179.931 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.838 0.352 . . . . 75.15 111.087 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -142.36 135.65 28.84 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.241 -0.436 . . . . 61.53 110.833 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.7 p -105.44 142.83 17.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.144 -0.48 . . . . 75.2 111.138 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.0 t -158.14 135.05 9.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 64.14 110.81 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 3.0 pt -89.44 156.38 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 71.21 111.104 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.15 -157.12 9.52 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.738 -0.744 . . . . 71.34 112.463 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -152.05 128.21 10.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.858 0.361 . . . . 74.23 110.847 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -163.64 119.35 1.66 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.147 -0.479 . . . . 73.41 110.92 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 14.9 t -58.7 142.36 50.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 55.11 111.103 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -160.12 164.39 33.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 73.01 111.22 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -109.31 163.0 13.78 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.282 -0.417 . . . . 73.35 110.96 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.4 p -142.55 144.0 32.72 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.239 -0.437 . . . . 75.31 111.19 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -113.84 134.81 54.57 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.261 -0.427 . . . . 74.32 110.924 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.455 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -131.15 142.89 50.29 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.109 -0.496 . . . . 74.34 110.847 -179.949 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -109.3 115.28 49.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 75.54 111.116 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -104.01 134.94 46.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 54.44 111.091 179.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -120.43 123.4 42.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.25 -0.432 . . . . 74.11 110.859 -179.827 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -89.57 101.36 14.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.045 -0.525 . . . . 75.24 110.912 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.5 t -99.48 -38.77 7.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 71.55 111.101 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -125.44 159.01 32.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 64.11 110.829 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 12.2 p -84.35 3.16 37.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.104 -0.498 . . . . 72.44 110.862 -179.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -116.63 -33.13 4.96 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.101 -0.499 . . . . 74.13 110.877 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 1.9 pp -139.31 164.07 25.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 72.12 111.121 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -150.12 167.89 25.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 64.51 111.117 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 13.5 m -113.31 152.98 14.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 60.35 111.203 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -147.91 147.15 29.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 75.44 110.88 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 0.455 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 16.7 m-85 -127.34 110.33 12.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.266 -0.424 . . . . 75.32 110.867 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -87.83 122.85 31.98 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.094 -0.503 . . . . 74.4 110.863 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 25.2 t -145.88 149.11 16.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.136 -0.484 . . . . 73.23 111.094 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -152.97 167.59 31.71 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.744 -0.741 . . . . 71.41 112.511 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.6 m -134.55 67.65 71.76 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.59 0.709 . . . . 73.5 111.104 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 163.65 37.47 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.667 2.244 . . . . 64.01 112.363 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -83.85 -170.91 3.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.192 -0.458 . . . . 73.21 111.129 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 20.5 ttm105 -76.55 135.49 39.26 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 75.15 110.823 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -129.7 144.3 51.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.114 -0.494 . . . . 71.01 111.148 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.83 137.49 42.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 74.51 110.915 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 43.6 p90 -129.78 159.09 37.61 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.435 . . . . 74.52 110.865 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.405 ' HA ' HG22 ' A' ' 93' ' ' VAL . 26.0 mt-30 -98.29 158.08 15.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 74.13 110.878 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -178.0 60.13 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.666 -0.778 . . . . 74.41 112.479 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -167.97 -175.55 2.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.928 0.394 . . . . 72.41 110.85 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.15 -69.27 0.68 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.187 -0.461 . . . . 73.24 110.899 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -84.15 -33.39 24.26 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.203 -0.453 . . . . 73.42 110.817 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.8 mm -64.68 -35.11 73.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 74.43 111.126 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 78.8 p -62.98 -47.89 81.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.472 . . . . 73.12 110.83 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 t -51.29 -37.88 49.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.125 -0.489 . . . . 74.15 110.851 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 9.1 tp -63.34 -39.01 93.36 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.103 -0.499 . . . . 70.43 110.929 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 103.13 -15.41 54.82 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.714 -0.755 . . . . 72.32 112.494 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -120.35 89.43 3.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.873 0.368 . . . . 75.43 110.825 -179.832 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.405 HG22 ' HA ' ' A' ' 82' ' ' GLN . 32.4 t -105.38 -47.4 9.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.207 -0.451 . . . . 73.35 111.157 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 17.9 t -142.22 144.29 33.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.151 -0.477 . . . . 75.11 110.869 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.4 pm0 -133.65 128.56 35.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.09 -0.504 . . . . 72.1 110.865 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.437 ' HA ' ' HB2' ' A' ' 131' ' ' LYS . 10.1 p -175.88 157.02 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.464 . . . . 74.23 111.135 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -81.0 172.52 13.63 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 73.12 110.921 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -132.92 130.72 40.0 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.269 -0.423 . . . . 74.01 110.913 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -113.4 70.98 0.23 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.71 -0.757 . . . . 54.12 112.42 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.66 114.43 3.69 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.694 2.263 . . . . 74.51 112.346 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -133.61 107.45 7.98 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.221 -0.445 . . . . 65.43 111.025 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 8.0 pt -131.55 149.69 33.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.247 -0.433 . . . . 74.44 111.117 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 1.9 pp -138.28 124.15 19.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.127 -0.488 . . . . 74.44 110.945 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.4 p -144.74 165.88 26.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 73.5 110.818 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -113.14 155.0 25.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.138 -0.483 . . . . 72.2 110.904 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 -102.07 132.03 48.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.466 . . . . 71.45 110.844 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 13.0 t80 -120.26 121.91 39.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.24 -0.436 . . . . 72.31 110.902 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.137 -0.483 . . . . 74.5 110.852 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 8.8 p90 . . . . . 0 C--O 1.232 0.143 0 CA-C-O 121.648 0.737 . . . . 74.11 110.873 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 177.75 5.22 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.76 2.307 . . . . 75.41 112.297 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 9.0 m-85 -115.69 159.27 21.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.148 -0.478 . . . . 73.41 110.878 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.8 p -109.69 124.13 66.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.11 -0.495 . . . . 73.21 111.137 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -117.87 163.51 12.83 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.777 -0.725 . . . . 64.31 112.458 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.0 p -163.71 151.35 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.901 0.381 . . . . 74.43 111.164 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -179.26 -151.78 10.03 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.689 -0.767 . . . . 64.02 112.446 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . 0.439 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 32.8 m -110.6 152.27 12.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.896 0.379 . . . . 73.14 111.154 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.03 106.24 0.5 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.691 -0.766 . . . . 74.05 112.447 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 7.2 ptp180 -105.82 128.35 53.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.862 0.363 . . . . 74.53 110.84 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 60.4 t -113.52 114.62 47.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 74.12 111.136 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.1 tt -122.42 152.27 40.4 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 74.4 110.95 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 11.5 p90 -161.58 162.17 30.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.288 -0.415 . . . . 73.3 110.886 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -101.17 116.86 33.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 72.13 110.912 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -50.74 104.56 0.08 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.156 -0.474 . . . . 72.45 110.861 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.437 ' HB2' ' HA ' ' A' ' 96' ' ' VAL . 0.7 OUTLIER -79.49 -79.35 0.14 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 74.11 110.934 179.963 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 32.0 m -167.01 126.44 1.44 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 73.12 111.147 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . 0.458 ' HB3' ' HB3' ' A' ' 139' ' ' PHE . 26.2 t0 -115.18 114.84 25.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.27 -0.423 . . . . 74.4 110.892 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -79.95 -8.1 87.95 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.758 -0.734 . . . . 73.12 112.488 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -46.17 -29.38 1.54 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.831 0.348 . . . . 75.12 111.13 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.6 tp -157.12 -176.83 6.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.222 -0.445 . . . . 73.11 110.869 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 68.4 m -56.63 92.75 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.114 -0.494 . . . . 75.23 110.815 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 58.1 m 50.78 75.08 0.2 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.139 -0.482 . . . . 74.02 110.812 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.458 ' HB3' ' HB3' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -102.54 160.59 14.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 70.45 110.914 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -139.73 172.54 12.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 74.31 110.94 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 5.8 mm -114.26 161.8 12.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.219 -0.446 . . . . 74.43 111.147 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 13.5 mttm -124.11 114.82 20.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.178 -0.464 . . . . 75.35 110.923 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -69.64 -175.33 0.84 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.279 -0.419 . . . . 64.31 110.895 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 6.9 tttp -172.84 -173.64 1.0 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.23 -0.441 . . . . 74.01 110.894 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 59.3 p-90 -148.75 160.23 43.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.187 -0.461 . . . . 73.4 110.966 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . 179.87 163.54 0.84 Allowed Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.593 0.711 . . . . 73.24 111.105 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' PRO . . . . . 0.439 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 54.3 Cg_endo -69.78 169.1 19.74 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.688 2.258 . . . . 75.24 112.306 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.468 ' HA ' HG13 ' A' ' 170' ' ' ILE . . . -167.79 157.07 9.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 63.41 111.094 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 6.2 p90 -115.99 138.42 51.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.449 . . . . 74.34 110.898 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 25.2 tt0 -116.53 158.88 22.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 73.11 110.864 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.3 p -142.79 129.35 17.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.16 -0.473 . . . . 72.51 111.07 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 166.4 -164.42 37.61 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.749 -0.738 . . . . 61.22 112.456 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -161.22 174.01 14.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.709 0.29 . . . . 74.23 110.992 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 7.8 tpp85 -109.45 121.21 44.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.232 -0.44 . . . . 73.23 110.846 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 47.8 t80 -106.98 147.86 29.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 75.55 110.974 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -110.07 112.63 24.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.127 -0.488 . . . . 74.31 110.845 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 23.9 tp -86.15 158.14 19.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.165 -0.47 . . . . 73.33 110.908 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -58.24 -39.57 92.67 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.731 -0.747 . . . . 71.1 112.466 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -64.26 169.35 4.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.832 0.349 . . . . 73.14 110.855 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 72.6 m -54.35 -47.55 72.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 75.33 110.875 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 18.1 p90 -74.23 145.64 43.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.096 -0.502 . . . . 62.22 110.929 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 1.8 mpt? -100.34 178.79 4.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.256 -0.429 . . . . 70.41 110.904 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 4.5 tp -119.55 141.95 48.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 74.42 110.839 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -135.37 136.29 41.35 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.144 -0.48 . . . . 71.42 110.875 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.3 p -133.99 134.03 42.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 75.24 110.912 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -163.81 152.74 13.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 64.21 110.838 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 44.3 t -144.8 119.04 3.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 73.51 111.143 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -93.52 147.08 23.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.196 -0.457 . . . . 74.34 110.868 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' TYR . . . . . 0.411 ' O ' ' HB ' ' A' ' 170' ' ' ILE . 20.1 t80 -152.6 140.03 19.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 74.4 110.943 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' ILE . . . . . 0.468 HG13 ' HA ' ' A' ' 148' ' ' ALA . 0.0 OUTLIER 178.64 132.03 0.22 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.594 0.712 . . . . 74.32 111.196 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . 0.464 ' HD2' HG12 ' A' ' 170' ' ' ILE . 53.8 Cg_endo -69.75 107.97 1.97 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.691 2.261 . . . . 73.11 112.362 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -124.02 152.63 42.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.172 -0.467 . . . . 64.23 110.858 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 10.4 pttm -122.7 132.92 54.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 72.45 110.869 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.6 t -100.16 162.01 13.24 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 72.41 111.131 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -110.63 157.44 19.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 75.24 110.921 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 2.9 t -150.54 136.5 11.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.983 0.42 . . . . 74.34 111.063 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.0 t -166.83 161.83 15.6 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 74.51 111.154 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -123.78 174.56 16.76 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.769 -0.729 . . . . 63.44 112.5 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.32 0 CA-C-O 120.823 0.345 . . . . 73.15 111.107 -179.802 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo . . . . . 0 N--CA 1.465 -0.194 0 CA-C-O 120.829 0.262 . . . . 61.43 112.39 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 84.9 t -98.68 126.22 51.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.291 -0.413 . . . . 74.14 111.129 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 1.3 p -112.46 111.67 22.68 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.155 -0.475 . . . . 73.33 110.831 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 61.9 p -116.44 167.57 10.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.083 -0.508 . . . . 75.44 111.165 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 11.5 ptmt -147.16 160.32 42.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.444 . . . . 75.44 110.837 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 26.7 mt -137.69 109.24 6.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 74.22 111.127 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.52 106.0 18.18 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 73.03 110.871 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 2.3 t -137.01 164.66 29.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.085 -0.507 . . . . 75.22 111.136 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -106.94 89.64 4.6 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-O 121.531 0.681 . . . . 74.45 110.816 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 135.18 29.75 Favored 'Trans proline' 0 C--N 1.34 0.131 0 C-N-CA 122.758 2.306 . . . . 74.22 112.257 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -103.09 118.16 36.18 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.165 -0.47 . . . . 60.43 110.884 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 24.1 mm -109.26 110.37 31.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 53.44 111.196 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -109.15 108.49 19.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 71.45 110.925 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -105.63 133.52 50.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 73.53 110.881 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -153.64 137.74 16.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 74.24 110.916 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 175.48 -140.15 5.07 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.685 -0.769 . . . . 73.33 112.44 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -117.42 173.32 6.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.814 0.34 . . . . 54.14 111.112 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 4.8 p -155.8 166.29 33.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 74.45 110.833 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -132.04 150.7 52.08 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.076 -0.511 . . . . 75.44 110.931 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 5.6 p -113.05 143.62 22.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 74.22 111.148 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 4.6 t80 -141.76 107.86 5.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 71.24 110.889 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 63.5 tttt . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.153 -0.476 . . . . 73.34 110.863 -179.997 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 11.8 mp0 . . . . . 0 N--CA 1.457 -0.079 0 CA-C-O 120.855 0.359 . . . . 74.42 110.901 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 110.6 5.8 27.46 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.734 -0.746 . . . . 72.54 112.481 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -59.69 152.84 21.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.726 0.298 . . . . 74.21 110.922 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 25.0 t90 -121.6 142.36 50.19 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.234 -0.439 . . . . 74.34 110.936 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 39.5 t -146.72 116.75 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 72.53 111.091 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -86.61 105.31 16.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.126 -0.488 . . . . 74.14 111.137 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -101.75 112.77 25.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 64.21 110.847 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -110.16 121.2 44.71 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.123 -0.49 . . . . 65.01 110.998 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -152.12 166.68 30.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.435 . . . . 73.4 110.913 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -100.52 130.59 46.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 74.52 110.894 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -97.17 139.09 33.68 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 74.32 110.882 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 68.8 mttt -111.05 106.97 16.2 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.14 -0.482 . . . . 71.54 110.924 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.4 m -79.13 132.9 31.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 75.42 111.112 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 27.9 t80 -126.97 99.25 5.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 74.34 110.945 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 p -166.12 149.77 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 74.24 111.102 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 132.44 78.71 0.15 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.702 -0.761 . . . . 72.05 112.459 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -89.77 -65.93 0.97 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.735 0.302 . . . . 64.33 110.829 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -171.54 174.28 4.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.196 -0.457 . . . . 72.32 110.846 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 14.9 tp -81.1 155.06 26.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.082 -0.508 . . . . 72.1 110.927 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.75 -0.738 . . . . 74.22 112.494 179.828 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.804 0.335 . . . . 72.23 111.1 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 -153.49 125.85 8.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 73.31 110.921 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 92.0 t -109.45 141.3 25.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 74.32 111.11 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 43.0 t -167.94 159.02 11.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 73.25 110.809 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 45.0 pt -126.08 157.85 35.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.102 -0.499 . . . . 73.22 111.147 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.25 -138.94 0.36 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.742 -0.742 . . . . 73.31 112.45 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -154.22 117.11 4.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.884 0.373 . . . . 72.51 110.802 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -151.94 105.83 3.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.069 -0.514 . . . . 72.21 110.874 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 46.9 p -72.7 117.25 14.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 54.51 111.126 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.1 m -117.74 162.49 17.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 63.42 111.159 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -94.16 162.3 13.92 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.212 -0.449 . . . . 75.34 110.934 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.23 140.21 32.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.239 -0.437 . . . . 74.23 111.14 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -103.45 131.99 50.08 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.216 -0.447 . . . . 73.54 110.831 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 53.3 m-20 -130.13 133.3 46.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 73.43 110.896 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 22.1 mm -109.2 113.53 44.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 74.0 111.139 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -103.74 117.78 35.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 71.22 111.021 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -106.75 114.21 28.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.184 -0.462 . . . . 74.55 110.892 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -81.56 97.19 7.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.089 -0.505 . . . . 74.24 110.88 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.0 m -88.05 -34.15 7.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 73.51 111.129 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 69.2 m -136.23 167.47 21.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 72.0 110.899 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 46.8 t -86.94 2.64 48.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 74.44 110.895 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 65.1 m-20 -113.59 -33.86 5.72 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.096 -0.502 . . . . 75.32 110.912 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 2.2 pp -145.52 169.01 7.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 74.53 111.205 179.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -155.7 173.19 17.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.222 -0.444 . . . . 72.44 111.066 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.41 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 11.6 m -111.55 151.03 13.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 73.32 111.112 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -140.28 133.23 29.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 74.24 110.882 179.881 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -113.54 113.91 25.76 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.198 -0.456 . . . . 73.22 110.842 -179.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -91.64 119.99 32.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 74.53 110.909 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 36.7 t -146.64 149.35 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 63.25 111.144 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -156.51 164.45 32.55 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.697 -0.763 . . . . 70.32 112.473 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 24.6 t -136.55 66.03 56.47 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.614 0.721 . . . . 71.52 111.142 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 162.62 41.36 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.636 2.224 . . . . 71.31 112.353 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -79.28 -168.98 1.68 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.244 -0.435 . . . . 54.02 111.054 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.96 138.52 38.9 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.15 -0.477 . . . . 74.3 110.832 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -128.35 135.65 49.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.445 . . . . 72.35 111.144 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 6.8 ttpm? -107.92 141.63 39.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.223 -0.444 . . . . 75.32 110.857 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -142.07 158.47 43.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.153 -0.476 . . . . 73.35 110.89 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -98.05 158.51 15.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 75.24 110.909 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -177.44 69.59 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.759 -0.734 . . . . 73.53 112.505 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -178.33 -177.14 0.55 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.824 0.345 . . . . 73.21 110.916 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.23 -67.42 0.82 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.163 -0.472 . . . . 74.11 110.915 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.9 t -83.1 -35.62 25.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.447 . . . . 72.03 110.851 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.7 mm -64.62 -33.65 64.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.122 -0.49 . . . . 72.21 111.131 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.7 t -61.85 -47.95 82.72 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.206 -0.452 . . . . 65.24 110.861 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.9 t -53.23 -39.87 64.12 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.153 -0.476 . . . . 73.11 110.844 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -59.83 -42.48 93.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.119 -0.491 . . . . 61.34 110.927 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 104.93 -13.48 49.48 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.704 -0.76 . . . . 64.31 112.506 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 7.2 ptp180 -120.16 96.9 5.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.856 0.36 . . . . 75.15 110.873 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 98.6 t -113.55 -55.41 4.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.234 -0.439 . . . . 73.2 111.175 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 5.8 m -140.51 143.39 35.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 74.34 110.841 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -146.7 126.17 13.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.49 . . . . 72.22 110.862 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 14.2 p -166.1 156.72 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 73.34 111.155 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -72.94 172.97 9.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 75.55 110.835 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 3.5 m-85 -115.74 125.39 52.72 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.106 -0.497 . . . . 70.52 110.889 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -119.46 67.04 0.39 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.664 -0.779 . . . . 71.14 112.464 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 112.01 2.96 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.694 2.263 . . . . 64.1 112.33 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -122.66 95.94 4.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.215 -0.448 . . . . 75.55 111.092 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 5.8 mm -121.7 149.98 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 75.01 111.109 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -150.42 111.1 4.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 75.03 110.913 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.4 p -142.87 167.87 21.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.223 -0.444 . . . . 55.0 110.883 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.41 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -113.58 149.52 34.37 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.144 -0.48 . . . . 74.53 110.92 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -101.9 149.19 24.46 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 70.11 110.922 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -155.5 149.24 25.29 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.177 -0.465 . . . . 74.52 110.958 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 14.6 t-160 . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 73.1 110.891 179.888 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.23 0.058 0 CA-C-O 121.681 0.753 . . . . 74.43 110.905 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -69.67 177.35 5.61 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.695 2.263 . . . . 64.32 112.4 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -110.47 162.84 14.29 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.258 -0.428 . . . . 73.11 110.889 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 92.0 t -128.74 143.81 40.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.065 -0.516 . . . . 72.41 111.14 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -134.96 -175.02 13.65 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.779 -0.724 . . . . 74.33 112.464 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.2 p -169.25 156.1 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.877 0.37 . . . . 74.42 111.129 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 177.78 -152.1 11.48 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.69 -0.767 . . . . 60.12 112.474 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . 0.418 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 34.2 m -107.85 130.35 60.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.897 0.38 . . . . 64.05 111.137 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -125.5 113.31 1.87 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.74 -0.743 . . . . 64.33 112.495 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 14.2 ptt180 -114.58 124.4 51.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.846 0.355 . . . . 74.0 110.925 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 51.5 t -106.09 110.19 30.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 75.43 111.116 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 6.2 mt -126.5 174.5 8.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 64.32 110.83 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -159.02 173.17 16.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.149 -0.478 . . . . 72.23 110.877 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -101.78 119.11 38.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 75.22 110.924 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -46.41 106.18 0.08 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.131 -0.486 . . . . 74.53 110.914 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 31.7 mmtm -105.21 -79.95 0.55 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 64.13 110.882 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.5 m -160.45 85.02 0.71 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.215 -0.448 . . . . 63.41 111.149 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -102.72 166.94 10.21 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.239 -0.437 . . . . 71.23 110.864 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 135' ' ' ALA . . . 83.23 145.49 6.13 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.772 -0.727 . . . . 74.23 112.578 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.411 ' C ' ' O ' ' A' ' 134' ' ' GLY . . . -36.5 -65.32 0.28 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.747 0.308 . . . . 72.45 111.081 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . 0.4 ' O ' ' CB ' ' A' ' 137' ' ' SER . 0.4 OUTLIER -167.38 93.18 0.42 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.24 -0.437 . . . . 74.4 110.911 -179.952 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' SER . . . . . 0.539 ' O ' ' C ' ' A' ' 138' ' ' SER . 1.5 p 167.83 59.82 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.225 -0.443 . . . . 65.4 110.844 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' SER . . . . . 0.539 ' C ' ' O ' ' A' ' 137' ' ' SER . 54.1 m 25.97 74.45 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.47 . . . . 53.45 110.884 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -106.04 143.23 34.46 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.099 -0.5 . . . . 74.42 110.894 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -111.62 173.76 6.19 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.157 -0.474 . . . . 64.11 110.794 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 6.8 tt -128.02 126.47 66.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.133 -0.485 . . . . 71.33 111.132 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 1.3 mtmt -74.58 106.11 6.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 73.55 110.885 179.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -57.4 -176.11 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.175 -0.466 . . . . 64.43 110.856 179.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.92 161.55 37.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 73.4 110.955 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 43.7 p-90 -155.37 135.73 13.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.279 -0.419 . . . . 74.43 110.915 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . 179.94 165.54 0.82 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.568 0.699 . . . . 62.22 111.112 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' PRO . . . . . 0.418 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 52.7 Cg_endo -69.8 142.33 47.48 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.689 2.26 . . . . 74.22 112.266 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -133.73 167.52 20.38 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 62.21 111.126 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 58.8 m-85 -117.76 156.61 28.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.257 -0.429 . . . . 73.32 110.863 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -128.06 149.05 50.56 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.161 -0.472 . . . . 73.34 110.925 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 84.7 t -151.14 123.32 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 71.33 111.125 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . 0.42 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 179.53 -159.04 23.37 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.756 -0.735 . . . . 72.23 112.486 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 20.3 tp -150.78 161.0 43.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.83 0.348 . . . . 74.24 110.939 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.4 tpp85 -117.64 118.71 32.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 73.44 110.887 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -103.91 142.85 33.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 74.55 110.905 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -121.74 97.51 5.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.153 -0.476 . . . . 75.5 110.835 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 6.1 tp -73.24 158.69 34.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 71.3 110.911 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -52.53 -46.24 58.77 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.695 -0.764 . . . . 70.44 112.498 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -58.1 166.51 1.55 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.824 0.345 . . . . 71.34 110.895 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 5.9 m -57.51 -36.73 71.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.141 -0.481 . . . . 74.34 110.871 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 87.5 m95 -79.4 134.7 36.57 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.13 -0.486 . . . . 74.52 110.9 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 32.8 mtt -108.93 176.79 4.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.44 . . . . 75.35 110.82 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -115.92 148.77 39.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 64.42 110.914 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -146.89 133.25 19.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.469 . . . . 74.25 110.929 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 66.0 p -139.98 122.23 15.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 75.01 110.89 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' ASP . . . . . 0.42 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.7 OUTLIER -147.34 155.33 41.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.178 -0.464 . . . . 75.25 110.896 179.921 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 14.6 t -133.18 134.57 57.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 73.14 111.103 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 7.1 tmm_? -107.5 132.16 53.53 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.129 -0.487 . . . . 75.25 110.9 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 38.0 t80 -132.83 139.52 47.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.461 . . . . 72.44 110.852 -179.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' ILE . . . . . . . . . . . . . 1.3 tp -178.1 102.23 0.21 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.622 0.725 . . . . 74.55 111.106 179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 128.26 15.75 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.658 2.239 . . . . 74.4 112.419 179.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -153.17 178.09 10.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 73.32 110.831 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.45 135.45 50.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.15 -0.477 . . . . 72.53 110.886 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -102.62 164.97 11.34 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.224 -0.443 . . . . 74.02 111.186 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -127.24 167.28 16.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 71.43 110.832 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 24.7 t -148.37 139.08 17.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.451 . . . . 73.44 111.165 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.3 t -166.85 155.82 10.52 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 75.34 111.138 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -138.87 -162.04 8.98 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.749 -0.739 . . . . 64.42 112.482 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.9 t . . . . . 0 C--N 1.33 -0.255 0 CA-C-O 120.818 0.342 . . . . 74.25 111.168 -179.901 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo . . . . . 0 C--O 1.231 0.146 0 CA-C-O 120.867 0.278 . . . . 71.12 112.338 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 55.1 t -96.12 107.57 19.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 61.34 111.102 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 9.8 p -99.88 105.39 17.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.125 -0.489 . . . . 73.14 110.918 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 11.8 p -104.62 161.94 13.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.486 . . . . 64.53 111.096 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.46 152.09 31.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 72.44 110.91 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 6.4 tt -152.48 130.35 2.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 74.55 111.089 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -100.7 115.03 29.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.461 . . . . 73.43 110.912 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 1.8 t -137.94 166.61 23.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 65.54 111.086 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -107.03 90.15 5.13 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.572 0.701 . . . . 63.25 110.836 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 117.52 5.13 Favored 'Trans proline' 0 C--O 1.233 0.225 0 C-N-CA 122.617 2.211 . . . . 75.21 112.375 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -100.66 121.82 42.28 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.275 -0.421 . . . . 72.22 110.882 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 13.6 mm -112.33 107.26 22.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.469 . . . . 73.12 111.108 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 2.3 mt -100.4 108.02 19.92 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.108 -0.497 . . . . 75.31 110.938 179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.4 m -100.03 127.53 46.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.44 . . . . 72.05 110.882 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 43.9 tp -146.7 132.23 18.73 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.117 -0.492 . . . . 74.25 110.901 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 177.26 -141.64 5.41 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.773 -0.727 . . . . 73.51 112.506 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -124.49 172.57 9.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.721 0.296 . . . . 74.24 111.179 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 37.1 t -149.56 170.48 18.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.301 -0.409 . . . . 74.15 110.893 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 22.9 t80 -146.5 131.62 18.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.11 -0.495 . . . . 73.24 110.941 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 34.4 m -88.62 160.77 2.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 74.12 111.09 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -169.35 148.96 3.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 70.33 110.885 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.351 0 CA-C-N 116.145 -0.48 . . . . 74.41 110.878 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.7 pt20 . . . . . 0 N--CA 1.458 -0.054 0 CA-C-O 120.906 0.384 . . . . 70.11 110.865 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.83 5.35 29.3 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.678 -0.772 . . . . 72.32 112.493 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.1 145.58 52.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.835 0.35 . . . . 74.3 110.885 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 27.9 m0 -105.66 137.51 43.39 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.183 -0.462 . . . . 74.43 110.934 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.2 t -144.86 112.53 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.188 -0.46 . . . . 52.42 111.066 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.45 106.0 14.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.178 -0.465 . . . . 71.53 111.074 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.2 t -95.89 111.94 23.8 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.463 . . . . 71.52 110.886 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 39.0 t80 -113.14 116.87 30.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 74.24 110.857 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -154.22 168.42 26.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 74.42 110.856 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 20.0 p90 -101.25 133.75 45.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 74.53 110.864 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.5 p -109.29 114.09 27.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.107 -0.497 . . . . 71.53 110.825 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 21.3 mmmt -98.37 106.59 18.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.108 -0.496 . . . . 74.22 110.868 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.2 p -85.07 143.12 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 75.52 111.135 179.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 13.3 m-85 -122.82 116.06 23.04 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.227 -0.442 . . . . 75.31 110.937 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.1 m -148.61 -170.61 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.134 -0.485 . . . . 74.13 111.077 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.66 66.16 0.84 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.712 -0.756 . . . . 75.31 112.495 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 -90.51 -68.19 0.8 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.86 0.362 . . . . 74.35 110.942 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 179.05 121.21 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.125 -0.489 . . . . 73.32 110.897 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.4 mt -83.12 153.05 25.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 75.41 110.953 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 C-N-CA 120.772 -0.728 . . . . 41.14 112.522 179.92 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.753 0.311 . . . . 71.24 111.118 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -144.9 127.56 16.17 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.245 -0.434 . . . . 72.24 110.874 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 22.0 t -105.18 138.85 28.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.166 -0.47 . . . . 74.5 111.151 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.0 m -160.34 151.74 19.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 74.41 110.862 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 16.2 tt -138.11 140.09 41.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.199 -0.455 . . . . 75.14 111.178 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -60.37 -170.04 0.51 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.756 -0.735 . . . . 60.4 112.523 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 -66.46 -58.02 6.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.778 0.323 . . . . 75.32 110.899 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 41.69 40.67 1.5 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 74.12 110.848 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.0 t -68.68 141.3 55.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.177 -0.465 . . . . 64.43 111.168 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.4 t -156.09 174.72 14.96 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.249 -0.432 . . . . 73.43 111.152 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 4.6 pp -90.06 159.18 16.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.208 -0.451 . . . . 75.14 110.908 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -131.16 137.13 48.87 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 74.54 111.092 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -104.24 131.96 51.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 75.34 110.879 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -135.59 139.28 43.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.139 -0.482 . . . . 74.31 110.865 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.84 114.04 45.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.249 -0.432 . . . . 72.43 111.13 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -106.04 127.9 53.49 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.205 -0.452 . . . . 75.54 111.1 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -113.74 125.27 53.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.45 . . . . 73.32 110.963 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -88.66 103.01 15.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.143 -0.481 . . . . 75.33 110.859 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 35.3 m -95.66 -34.4 5.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 74.53 111.136 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -134.25 161.79 33.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.08 -0.509 . . . . 71.15 110.884 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 80.2 p -84.33 3.07 37.4 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 61.34 110.864 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -115.69 -32.47 5.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.468 . . . . 75.02 110.842 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 17.8 pt -142.24 168.69 14.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 75.41 111.153 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -156.78 172.79 18.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.171 -0.468 . . . . 73.31 111.108 179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.418 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 12.0 m -119.04 151.71 21.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 74.13 111.111 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -148.28 144.61 27.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 74.32 110.893 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -127.46 113.68 16.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.202 -0.454 . . . . 75.31 110.91 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -85.74 130.46 34.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.152 -0.476 . . . . 70.15 110.913 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 16.7 t -146.06 154.44 12.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.141 -0.481 . . . . 73.33 111.071 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -156.79 148.25 17.81 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.723 -0.751 . . . . 71.32 112.47 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.3 m -119.77 64.47 8.9 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.573 0.702 . . . . 74.03 111.111 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.72 164.05 35.94 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.663 2.242 . . . . 74.42 112.318 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -90.83 -167.98 1.96 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.18 -0.464 . . . . 73.43 111.134 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 17.1 ttm105 -77.38 136.48 38.43 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.236 -0.438 . . . . 72.32 110.882 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -133.61 151.09 51.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 62.01 111.128 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 39.9 ttmt -116.19 131.25 57.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.228 -0.442 . . . . 75.15 110.838 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -131.26 159.05 38.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 74.33 110.869 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.422 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 15.7 pt20 -94.06 157.27 16.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.116 -0.493 . . . . 75.34 110.92 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -176.05 68.4 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.755 -0.736 . . . . 52.05 112.521 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -175.04 -176.83 1.0 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.912 0.387 . . . . 73.31 110.878 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.7 -69.27 0.67 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.481 . . . . 74.34 110.924 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.9 m -83.67 -34.55 24.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 74.34 110.896 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 6.0 mm -63.73 -33.95 64.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.491 . . . . 73.13 111.131 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 58.2 p -62.32 -44.85 95.55 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.164 -0.471 . . . . 73.42 110.871 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.1 t -57.63 -35.18 70.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.134 -0.484 . . . . 72.43 110.872 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 24.6 mt -65.28 -50.25 66.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.172 -0.467 . . . . 74.15 110.947 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 116.04 -14.35 16.49 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.747 -0.74 . . . . 50.3 112.517 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 23.8 ptt180 -117.72 94.22 4.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.81 0.338 . . . . 75.44 110.861 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.422 ' HB ' ' HA ' ' A' ' 82' ' ' GLN . 64.5 t -114.5 -56.96 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 74.14 111.128 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 69.3 m -138.01 142.62 40.41 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 71.44 110.879 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -146.42 116.47 7.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.134 -0.484 . . . . 71.31 110.901 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 28.8 m -155.78 175.2 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 64.4 111.18 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -83.36 173.77 11.27 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.186 -0.461 . . . . 72.33 110.872 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -120.05 132.87 55.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 70.13 110.849 -179.765 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -132.08 62.06 0.65 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.694 -0.765 . . . . 60.12 112.472 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 113.05 3.24 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.673 2.249 . . . . 73.44 112.394 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -125.7 108.19 11.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 75.3 111.059 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 3.5 mp -129.17 147.92 33.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.28 -0.418 . . . . 73.14 111.104 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -151.97 114.74 4.62 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.155 -0.475 . . . . 75.25 110.939 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 13.0 p -144.79 166.17 25.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 73.42 110.878 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.418 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -111.02 150.47 29.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.144 -0.48 . . . . 75.43 110.956 179.964 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 18.1 mt-30 -101.61 133.55 46.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.464 . . . . 72.31 110.905 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -122.82 119.37 30.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.164 -0.471 . . . . 73.1 110.839 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 2.4 t60 . . . . . 0 C--N 1.33 -0.254 0 CA-C-N 116.092 -0.504 . . . . 64.45 110.838 179.898 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 27.4 t80 . . . . . 0 C--O 1.232 0.147 0 CA-C-O 121.669 0.747 . . . . 74.5 110.924 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 177.57 5.46 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.64 2.226 . . . . 64.34 112.37 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 9.7 m-85 -117.99 147.5 43.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 75.23 110.874 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 23.5 t -104.2 124.2 58.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.088 -0.505 . . . . 72.11 111.109 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -120.04 161.79 14.32 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.795 -0.717 . . . . 42.44 112.534 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.8 p -159.93 147.34 6.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.923 0.392 . . . . 72.04 111.091 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -175.54 -155.9 13.66 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.748 -0.739 . . . . 74.12 112.475 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . 0.455 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.2 p -107.28 133.49 51.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.864 0.364 . . . . 55.43 111.085 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -119.74 110.8 1.89 Allowed Glycine 0 N--CA 1.453 -0.227 0 C-N-CA 120.646 -0.788 . . . . 65.22 112.493 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 11.8 ptm180 -111.78 122.22 47.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.903 0.382 . . . . 70.41 110.912 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 1.4 p -108.12 110.24 31.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.465 . . . . 75.41 111.179 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 17.7 tp -116.84 167.19 11.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.116 -0.493 . . . . 72.44 110.931 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -150.94 178.93 8.68 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 73.43 110.885 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -107.36 144.82 33.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.143 -0.48 . . . . 74.02 110.868 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -81.78 95.41 7.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.458 . . . . 71.31 110.885 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 16.5 tppt? -110.37 -75.9 0.61 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.155 -0.475 . . . . 72.34 110.976 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 88.0 m -160.85 89.64 0.81 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.236 -0.438 . . . . 75.55 111.127 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -102.86 162.72 12.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 75.12 110.863 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 67.4 156.93 0.68 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.774 -0.726 . . . . 71.51 112.473 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -77.54 1.43 19.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.881 0.372 . . . . 62.21 111.12 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -85.89 -178.16 6.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 65.52 110.922 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 16.6 t -67.71 85.72 0.21 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.131 -0.486 . . . . 72.31 110.914 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 3.6 m 50.84 74.84 0.21 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 74.22 110.887 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -84.52 156.08 21.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.118 -0.492 . . . . 74.11 110.914 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -102.7 173.47 6.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.167 -0.469 . . . . 72.41 110.873 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.459 ' HA ' ' HA ' ' A' ' 176' ' ' VAL . 0.6 OUTLIER -153.94 144.11 14.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.258 -0.428 . . . . 63.41 111.126 -179.974 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 19.8 tptt -91.03 118.02 30.05 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 74.33 110.905 179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -58.25 -168.74 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.26 -0.427 . . . . 64.03 110.887 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.59 154.59 49.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 74.32 110.822 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 5.1 t90 -157.32 129.0 6.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 75.02 110.912 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.476 ' CB ' ' HD2' ' A' ' 147' ' ' PRO . . . -173.59 168.96 2.22 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.626 0.727 . . . . 55.43 111.107 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' PRO . . . . . 0.476 ' HD2' ' CB ' ' A' ' 146' ' ' ALA . 53.7 Cg_endo -69.84 132.86 24.08 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.634 2.223 . . . . 70.25 112.346 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -120.29 166.27 13.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 71.14 111.115 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -123.58 137.11 54.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.29 -0.414 . . . . 73.32 110.891 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -114.35 145.55 41.66 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.111 -0.495 . . . . 74.02 110.891 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 58.5 t -143.42 120.49 5.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 72.04 111.086 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . 0.404 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 175.77 -171.98 45.01 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.713 -0.756 . . . . 73.35 112.481 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.5 pt? -131.17 161.19 32.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.847 0.356 . . . . 75.43 110.901 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 2.7 tpp85 -129.71 120.01 24.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 73.44 110.941 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 5.6 t80 -103.77 136.05 44.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.217 -0.447 . . . . 73.22 110.95 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -121.43 105.41 10.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.1 -0.5 . . . . 75.24 110.786 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 7.8 mt -94.74 162.88 13.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 75.34 110.926 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -97.94 36.55 3.9 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.783 -0.723 . . . . 63.54 112.534 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 95.8 m-20 -123.91 35.99 4.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.832 0.349 . . . . 71.32 110.888 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 18.0 p 50.95 38.81 21.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 72.22 110.892 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 8.4 t-105 -165.05 107.13 0.82 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.158 -0.473 . . . . 75.32 110.909 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -99.1 170.54 8.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.205 -0.452 . . . . 75.5 110.885 179.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -129.13 145.21 51.35 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.21 -0.45 . . . . 70.04 110.849 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -144.27 133.42 22.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.131 -0.486 . . . . 74.43 110.865 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 50.7 p -145.89 120.7 9.91 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.188 -0.46 . . . . 72.04 110.891 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' ASP . . . . . 0.404 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.6 OUTLIER -153.3 175.85 12.63 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.089 -0.505 . . . . 75.34 110.897 180.0 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 21.7 t -138.12 133.34 43.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.457 . . . . 65.14 111.105 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 2.1 ttt180 -109.16 125.01 51.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.095 -0.502 . . . . 74.21 110.865 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 13.7 p90 -128.99 146.79 50.88 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.172 -0.467 . . . . 72.44 110.929 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' ILE . . . . . 0.406 ' HA ' ' HD2' ' A' ' 171' ' ' PRO . 5.5 tt -176.8 97.77 0.24 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.557 0.694 . . . . 75.13 111.155 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . 0.406 ' HD2' ' HA ' ' A' ' 170' ' ' ILE . 53.5 Cg_endo -69.82 128.74 16.4 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.691 2.261 . . . . 74.31 112.3 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 11.6 p90 -155.08 178.96 9.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.245 -0.434 . . . . 72.02 110.863 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 13.3 pttp -130.32 140.98 50.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 74.43 110.871 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 9.0 t -104.27 167.81 9.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 75.43 111.189 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -119.38 159.72 23.66 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.27 -0.423 . . . . 73.44 110.849 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . 0.459 ' HA ' ' HA ' ' A' ' 141' ' ' ILE . 13.7 p -144.76 135.74 20.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.122 -0.49 . . . . 73.04 111.088 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.8 t -166.36 159.44 14.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 74.03 111.156 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -146.13 -134.15 2.6 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.773 -0.727 . . . . 55.12 112.491 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 98.7 m . . . . . 0 C--N 1.33 -0.257 0 CA-C-O 120.835 0.35 . . . . 75.34 111.169 -179.888 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo . . . . . 0 C--O 1.231 0.162 0 CA-C-O 120.777 0.24 . . . . 71.15 112.392 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 23.8 t -95.45 106.37 18.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 75.21 111.161 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 83.2 p -110.16 120.22 41.74 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.177 -0.465 . . . . 73.3 110.894 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -140.54 176.37 8.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.125 -0.489 . . . . 72.1 111.082 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.39 162.48 40.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 74.12 110.918 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 4.6 tt -146.04 120.91 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.256 -0.429 . . . . 74.02 111.121 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -96.67 118.16 32.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.157 -0.474 . . . . 71.23 110.871 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 4.4 t -137.52 159.68 34.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 74.13 111.167 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -107.27 90.42 5.68 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.558 0.694 . . . . 74.41 110.869 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 138.09 37.05 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.61 2.207 . . . . 64.55 112.368 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 23.4 m-85 -121.96 109.67 14.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.179 -0.464 . . . . 74.33 110.925 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 8.8 mt -105.25 135.03 45.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 72.51 111.171 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 10.3 tp -120.57 115.43 23.4 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.093 -0.503 . . . . 74.22 110.957 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -99.26 129.25 45.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 72.4 110.907 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 32.8 tp -150.25 129.35 12.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.149 -0.478 . . . . 71.21 110.91 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 177.38 -146.67 7.83 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.801 -0.714 . . . . 62.32 112.536 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -124.0 173.23 8.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.757 0.313 . . . . 65.12 111.101 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -138.35 164.78 28.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.452 . . . . 73.03 110.899 -179.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 34.1 m-85 -133.82 129.95 37.23 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.205 -0.452 . . . . 74.24 110.93 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 28.0 m -77.36 148.28 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 73.44 111.207 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -152.34 105.96 3.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.278 -0.419 . . . . 75.15 110.886 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 14.2 ptmt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.15 -0.477 . . . . 71.13 110.939 179.962 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.821 0.344 . . . . 75.42 110.953 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.73 6.48 76.5 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.758 -0.734 . . . . 70.33 112.487 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -76.89 144.9 38.63 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.837 0.351 . . . . 73.42 110.838 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 13.5 t90 -106.44 150.93 25.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 73.44 110.919 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 22.1 t -145.59 125.82 6.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.242 -0.435 . . . . 74.2 111.131 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -109.76 112.4 24.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 73.44 111.075 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' SER . . . . . 0.445 ' HA ' ' HA ' ' A' ' 201' ' ' SER . 60.2 p -124.42 146.57 48.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 73.23 110.837 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 15.1 p90 -127.19 122.52 34.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.111 -0.495 . . . . 74.33 110.827 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -146.89 158.28 43.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 75.41 110.869 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -93.69 133.57 36.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.143 -0.481 . . . . 72.23 110.886 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -98.89 114.57 27.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.47 . . . . 75.11 110.843 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.1 tppt? -92.68 108.24 19.83 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.041 -0.527 . . . . 72.13 110.874 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.2 p -87.01 140.69 15.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.236 -0.438 . . . . 73.02 111.057 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 41.3 m-85 -134.36 112.85 11.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.111 -0.495 . . . . 73.2 110.959 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 m -72.65 -176.9 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.092 -0.504 . . . . 74.43 111.182 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -93.84 -125.16 4.06 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.748 -0.739 . . . . 54.43 112.465 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -92.37 -66.39 0.93 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.771 0.32 . . . . 62.43 110.861 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.5 mp0 -150.23 -174.21 4.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.155 -0.475 . . . . 63.32 110.877 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.4 pp -86.32 -173.33 4.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 73.34 110.909 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 C-N-CA 120.722 -0.751 . . . . 61.1 112.491 179.895 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.817 0.341 . . . . 65.13 111.139 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -166.33 125.75 1.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 75.43 110.897 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 98.7 t -105.65 131.51 54.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 73.22 111.069 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.5 m -159.4 151.36 20.7 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.138 -0.483 . . . . 75.55 110.803 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 20.0 pt -100.71 157.61 4.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.082 -0.508 . . . . 74.33 111.119 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -72.02 -146.78 0.59 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.737 -0.744 . . . . 72.54 112.508 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -126.1 111.16 14.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.881 0.372 . . . . 75.03 110.88 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -164.01 159.06 20.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.13 -0.487 . . . . 65.24 110.862 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 16.4 p -125.88 123.99 39.88 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 71.43 111.154 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.0 p -137.4 139.33 40.65 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.176 -0.465 . . . . 63.12 111.076 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.5 mt -99.11 153.95 18.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.454 . . . . 74.34 110.921 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.1 p -123.26 161.38 24.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.289 -0.414 . . . . 75.5 111.172 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -105.56 133.36 50.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 73.12 110.861 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -124.04 130.06 51.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 54.34 110.867 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -107.24 114.0 45.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.478 . . . . 72.43 111.101 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -104.13 137.88 41.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.454 . . . . 73.22 111.128 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -123.28 121.98 37.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.279 -0.418 . . . . 73.42 110.893 -179.835 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -89.01 102.26 14.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.111 -0.495 . . . . 71.43 110.892 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.1 m -100.84 -33.4 3.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.105 -0.498 . . . . 72.31 111.125 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.9 t -136.23 158.6 44.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.189 -0.46 . . . . 71.33 110.838 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 47.0 t -83.56 3.21 33.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.102 -0.499 . . . . 75.23 110.848 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 47.6 t30 -115.69 -30.6 6.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 63.32 110.885 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 43.5 pt -138.23 157.48 31.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.132 -0.486 . . . . 75.25 111.127 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -145.33 157.65 44.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.154 -0.475 . . . . 75.22 111.046 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.4 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 1.4 p -106.96 145.93 13.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.15 -0.477 . . . . 75.44 111.145 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -140.54 128.01 21.36 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.209 -0.45 . . . . 73.45 110.897 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 0.425 ' HA ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -108.65 110.43 21.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.259 -0.428 . . . . 74.32 110.919 -179.912 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -87.95 115.42 25.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 74.24 110.907 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 8.9 m -139.59 156.76 26.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 72.24 111.109 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -164.55 142.37 7.72 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.75 -0.738 . . . . 73.04 112.501 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.4 t -118.64 66.21 6.91 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.551 0.691 . . . . 72.23 111.145 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 161.89 44.16 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.758 2.305 . . . . 72.4 112.349 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -78.73 -173.21 3.34 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 74.22 111.092 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 18.1 ttp180 -78.27 132.73 37.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 71.2 110.924 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -131.54 150.8 52.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 60.44 111.074 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 7.3 tttt -109.37 134.08 52.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.3 -0.409 . . . . 70.33 110.911 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -134.51 158.66 43.37 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.247 -0.433 . . . . 73.12 110.902 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -91.32 156.18 17.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.112 -0.495 . . . . 75.42 110.857 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -176.12 65.14 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.803 -0.713 . . . . 75.23 112.513 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -174.29 -174.79 0.91 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.93 0.395 . . . . 74.1 110.882 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -85.5 -70.04 0.62 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.147 -0.478 . . . . 72.25 110.855 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 32.1 t -84.83 -32.18 23.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.26 -0.427 . . . . 73.12 110.808 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.4 mm -66.58 -34.04 67.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.157 -0.474 . . . . 74.2 111.181 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 t -63.11 -41.21 99.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.164 -0.471 . . . . 65.4 110.812 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 61.7 m -60.68 -36.98 80.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 74.03 110.862 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.4 mp -64.14 -50.25 68.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.12 -0.491 . . . . 73.22 110.934 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 116.35 -14.25 15.71 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.754 -0.736 . . . . 63.42 112.482 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 58.4 mtm180 -115.06 89.87 3.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.889 0.376 . . . . 73.44 110.809 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 98.5 t -113.67 -53.25 5.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 75.31 111.137 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 13.3 m -139.28 143.47 37.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 75.35 110.887 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . 0.412 ' O ' ' CG1' ' A' ' 96' ' ' VAL . 1.7 tt0 -145.19 114.3 6.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.465 . . . . 75.13 110.928 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.412 ' CG1' ' O ' ' A' ' 95' ' ' GLU . 11.8 m -160.45 -178.17 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 72.02 111.116 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -98.65 149.13 23.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 54.03 110.831 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -93.16 125.66 37.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 75.44 110.957 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -119.42 63.16 0.46 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.749 -0.739 . . . . 73.31 112.501 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.67 122.53 9.24 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.687 2.258 . . . . 64.42 112.392 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -139.22 97.87 3.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.185 -0.461 . . . . 74.42 111.101 179.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 5.3 mp -129.18 117.56 43.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 72.41 111.157 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.425 HD23 ' HA ' ' A' ' 71' ' ' PHE . 0.9 OUTLIER -113.71 112.98 24.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.228 -0.442 . . . . 74.35 110.948 179.905 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 3.5 p -140.51 165.11 28.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.446 . . . . 73.22 110.822 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.4 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 1.0 OUTLIER -112.76 142.23 45.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.069 -0.514 . . . . 74.11 110.933 179.963 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 16.0 pt20 -101.4 151.5 21.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.166 -0.47 . . . . 75.32 110.92 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 5.1 t80 -149.69 135.8 18.88 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.249 -0.432 . . . . 75.53 110.962 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 10.6 t60 . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 71.54 110.817 179.986 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.0 m-85 . . . . . 0 C--O 1.23 0.053 0 CA-C-O 121.737 0.78 . . . . 74.11 110.903 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.69 176.86 6.15 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.678 2.252 . . . . 74.24 112.353 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -116.47 150.54 37.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.202 -0.454 . . . . 75.11 110.978 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 13.1 p -104.01 133.94 46.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 73.15 111.093 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -132.09 160.2 23.55 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.749 -0.739 . . . . 61.13 112.504 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 7.5 p -156.57 154.73 5.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.874 0.369 . . . . 63.31 111.157 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 178.76 -147.11 7.65 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.777 -0.725 . . . . 65.0 112.489 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 13.8 p -106.57 131.56 56.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.881 0.372 . . . . 74.33 111.093 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -124.29 111.62 1.64 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.749 -0.738 . . . . 74.53 112.508 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 29.0 ptt180 -114.51 130.13 56.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.774 0.321 . . . . 74.54 110.895 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . 0.46 ' O ' ' HB3' ' A' ' 143' ' ' ASP . 3.1 m -111.37 112.66 41.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.237 -0.438 . . . . 75.02 111.091 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 1.3 tp -114.86 171.59 7.56 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.202 -0.454 . . . . 71.4 110.925 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -140.03 178.88 6.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.174 -0.466 . . . . 65.33 110.841 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -117.72 119.4 34.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.144 -0.48 . . . . 73.4 110.906 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -51.89 102.34 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.14 -0.482 . . . . 73.51 110.846 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.86 -80.84 0.55 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 74.41 110.889 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 45.8 m -164.54 89.78 0.53 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 74.32 111.168 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -107.59 172.61 6.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.231 -0.44 . . . . 75.33 110.886 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.53 152.89 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.706 -0.759 . . . . 74.04 112.501 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -79.42 -1.97 39.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.809 0.338 . . . . 72.3 111.04 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -87.2 -177.52 6.01 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.245 -0.434 . . . . 73.53 110.929 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.7 m -66.57 98.12 0.48 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 74.02 110.88 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 89.4 p 46.79 75.17 0.13 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.125 -0.489 . . . . 72.43 110.794 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -89.02 148.26 23.84 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.086 -0.506 . . . . 74.34 110.867 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.18 159.76 15.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.139 -0.482 . . . . 70.54 110.818 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -126.9 118.26 50.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 75.41 111.155 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 1.6 mtpp -69.13 110.84 4.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 72.53 110.843 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.46 ' HB3' ' O ' ' A' ' 126' ' ' VAL . 61.2 m-20 -57.66 -173.44 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 73.4 110.888 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.39 162.53 39.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 71.14 110.906 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 31.1 p-90 -156.47 137.96 14.01 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.217 -0.447 . . . . 73.45 110.896 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.442 ' CB ' ' HD2' ' A' ' 147' ' ' PRO . . . -178.44 167.51 1.01 Allowed Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.603 0.716 . . . . 73.11 111.083 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' PRO . . . . . 0.442 ' HD2' ' CB ' ' A' ' 146' ' ' ALA . 53.5 Cg_endo -69.79 138.62 38.15 Favored 'Trans proline' 0 N--CA 1.465 -0.171 0 C-N-CA 122.712 2.275 . . . . 70.22 112.31 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -132.85 165.16 25.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.181 -0.463 . . . . 74.43 111.117 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -123.27 126.18 46.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.192 -0.458 . . . . 73.23 110.895 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 28.6 tt0 -110.12 155.3 22.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 72.02 110.889 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 4.6 p -144.58 125.73 8.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 71.51 111.138 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . 0.418 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . -176.36 -167.68 35.43 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.728 -0.749 . . . . 75.0 112.474 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 2.1 pp -143.87 161.03 39.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.765 0.317 . . . . 75.31 110.923 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 7.6 tpp85 -117.21 119.49 35.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 73.2 110.852 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -100.13 139.42 35.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.146 -0.479 . . . . 74.52 110.885 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -111.85 92.4 4.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 74.23 110.876 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 3.0 tt -86.27 97.02 10.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 64.43 110.953 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 58.77 -138.35 49.49 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.704 -0.76 . . . . 74.54 112.536 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -119.74 -30.35 4.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.878 0.37 . . . . 73.21 110.886 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -48.86 -66.72 0.35 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 73.33 110.878 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 23.7 p90 -145.73 150.92 37.15 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.151 -0.477 . . . . 73.4 110.904 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 2.4 mpt? -108.63 177.57 4.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 75.54 110.858 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 3.8 tp -126.12 149.15 49.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.232 -0.44 . . . . 75.33 110.916 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 13.8 t-20 -143.9 131.51 21.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 72.54 110.858 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.5 p -141.48 124.41 16.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.179 -0.464 . . . . 75.13 110.871 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 166' ' ' ASP . . . . . 0.418 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 2.3 p30 -156.11 169.69 23.92 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.138 -0.483 . . . . 74.2 110.878 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -142.4 134.04 25.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.182 -0.463 . . . . 75.04 111.119 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.61 142.56 33.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 75.05 110.886 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 4.3 t80 -142.0 137.65 31.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 73.34 110.889 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 170' ' ' ILE . . . . . . . . . . . . . 2.9 tp -177.47 102.25 0.22 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.628 0.728 . . . . 75.54 111.08 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . 0.441 ' HA ' ' HA ' ' A' ' 192' ' ' ASP . 53.9 Cg_endo -69.75 125.27 11.95 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.696 2.264 . . . . 54.24 112.364 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 24.7 p90 -150.93 178.04 9.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 74.45 110.9 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 190' ' ' GLU . 9.7 ptpt -130.85 126.52 36.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 74.2 110.879 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.6 t -93.59 175.26 6.81 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.236 -0.438 . . . . 73.41 111.143 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -126.81 163.71 22.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.254 -0.43 . . . . 74.21 110.844 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 32.7 t -148.84 133.28 9.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.223 -0.444 . . . . 75.13 111.143 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.4 t -165.58 177.69 7.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.216 -0.447 . . . . 75.24 111.173 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 121.68 141.52 6.12 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.72 -0.753 . . . . 61.33 112.485 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.4 m . . . . . 0 C--N 1.329 -0.315 0 CA-C-O 120.737 0.303 . . . . 73.51 111.195 -179.893 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.231 0.17 0 CA-C-O 120.822 0.259 . . . . 72.41 112.35 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 39.6 t -113.38 107.68 23.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.276 -0.42 . . . . 74.14 111.145 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -81.33 106.72 13.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.161 -0.472 . . . . 72.34 110.835 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 21.0 p -121.38 174.7 6.58 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.108 -0.496 . . . . 64.34 111.104 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.55 164.03 35.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.194 -0.457 . . . . 73.52 110.872 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 189' ' ' ILE . . . . . 0.406 ' O ' ' HA ' ' A' ' 173' ' ' LYS . 5.4 mp -144.03 105.8 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 74.24 111.129 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 190' ' ' GLU . . . . . 0.423 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 61.4 tt0 -91.0 102.08 14.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.449 . . . . 73.11 110.869 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 9.3 m -138.68 164.08 26.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.458 . . . . 73.45 111.156 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . 0.441 ' HA ' ' HA ' ' A' ' 171' ' ' PRO . 6.6 p-10 -110.04 88.65 7.18 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.582 0.706 . . . . 75.3 110.867 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 143.28 50.53 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.704 2.269 . . . . 73.21 112.338 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -119.8 123.69 44.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 72.41 110.882 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 18.6 mm -109.03 132.06 58.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.147 -0.479 . . . . 72.32 111.171 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 4.6 tp -120.68 108.25 13.78 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.246 -0.433 . . . . 71.31 110.962 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.41 120.14 35.13 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.239 -0.437 . . . . 63.11 110.919 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -139.4 124.29 18.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.468 . . . . 75.42 110.988 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -176.9 -148.54 7.19 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.737 -0.745 . . . . 64.03 112.494 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -115.82 171.04 8.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.812 0.339 . . . . 73.15 111.108 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 201' ' ' SER . . . . . 0.445 ' HA ' ' HA ' ' A' ' 20' ' ' SER . 0.3 OUTLIER -138.49 156.81 47.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.434 . . . . 65.12 110.806 -179.73 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 8.2 t80 -138.07 135.6 35.99 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.132 -0.485 . . . . 75.13 110.958 -179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 14.9 p -77.36 147.46 7.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.08 -0.509 . . . . 64.02 111.179 179.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -144.57 88.01 1.9 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.16 -0.473 . . . . 75.0 110.872 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 23.1 mtmt . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 75.22 110.902 179.977 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 . . . . . 0 N--CA 1.458 -0.057 0 CA-C-O 120.871 0.367 . . . . 75.33 110.923 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.37 6.22 41.95 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.706 -0.759 . . . . 65.52 112.491 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -61.81 146.12 50.51 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.817 0.341 . . . . 70.1 110.829 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 19.8 t90 -111.47 121.19 44.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.09 -0.504 . . . . 71.3 110.947 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.2 t -123.4 120.17 59.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.242 -0.435 . . . . 65.32 111.121 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -86.8 112.35 21.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 62.22 111.127 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.1 t -109.03 110.0 21.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.236 -0.438 . . . . 72.34 110.874 -179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 43.5 t80 -107.64 120.01 41.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.477 . . . . 70.41 110.919 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.43 ' HA ' ' HA3' ' A' ' 199' ' ' GLY . 7.4 p30 -149.86 174.87 12.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.442 . . . . 73.42 110.91 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 19.1 p90 -110.83 132.9 53.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 73.11 110.861 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 41.9 p -98.18 146.18 25.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 63.21 110.894 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.4 tmtp? -127.25 106.52 9.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 75.21 110.904 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.8 m -77.31 129.7 37.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.245 -0.434 . . . . 73.42 111.128 179.842 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -126.4 107.78 10.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.126 -0.488 . . . . 74.14 110.956 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.8 p -175.71 153.79 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.485 . . . . 73.32 111.079 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.43 71.68 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.778 -0.725 . . . . 70.34 112.54 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -89.14 -65.87 0.98 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.807 0.337 . . . . 72.31 110.895 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -174.99 152.44 1.49 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.106 -0.497 . . . . 71.34 110.855 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -96.11 162.32 13.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.163 -0.471 . . . . 75.43 110.909 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 C-N-CA 120.761 -0.733 . . . . 72.34 112.434 179.99 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.814 0.34 . . . . 74.14 111.084 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 35.8 m-20 -153.64 127.24 8.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.238 -0.437 . . . . 71.03 110.828 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 10.8 p -104.52 137.52 33.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 71.53 111.171 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.0 t -148.45 154.87 40.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.094 -0.503 . . . . 74.1 110.835 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -119.62 154.67 22.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.087 -0.506 . . . . 71.02 111.1 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.39 -124.59 0.56 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.751 -0.738 . . . . 75.21 112.444 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 38.9 m-20 -82.41 -35.61 27.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.87 0.367 . . . . 75.44 110.911 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 41.9 40.03 1.44 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 71.41 110.85 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 1.4 p -108.37 113.09 25.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 70.12 111.158 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.5 t -154.35 173.95 15.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.136 -0.484 . . . . 62.1 111.139 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -92.55 169.11 10.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.248 -0.433 . . . . 74.23 110.924 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 18.6 p -149.36 141.54 24.02 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.172 -0.467 . . . . 75.13 111.113 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -103.27 132.82 49.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 73.12 110.861 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -130.63 130.12 43.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.159 -0.473 . . . . 70.24 110.84 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.08 112.94 42.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.196 -0.456 . . . . 74.31 111.077 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -102.76 121.69 42.97 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.206 -0.452 . . . . 75.53 111.076 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -106.85 122.72 46.97 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 73.12 110.93 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -88.89 107.22 18.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.17 -0.468 . . . . 73.32 110.908 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 63.8 t -103.24 -48.13 10.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.157 -0.474 . . . . 71.44 111.097 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 40.2 t -124.38 165.99 16.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 72.41 110.854 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.1 m -87.43 2.71 49.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.087 -0.506 . . . . 73.31 110.837 -179.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -112.99 -33.68 5.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.084 -0.507 . . . . 74.32 110.936 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 31.4 pt -146.12 160.22 11.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.48 . . . . 74.45 111.081 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -146.57 173.4 12.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 70.34 111.112 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.469 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 14.4 m -115.16 152.13 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.255 -0.429 . . . . 73.14 111.163 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -144.13 144.43 31.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.251 -0.431 . . . . 71.2 110.834 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -120.74 110.14 16.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.157 -0.474 . . . . 73.21 110.914 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -92.6 117.84 30.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 64.5 110.896 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.4 p -150.26 154.61 8.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.161 -0.472 . . . . 65.05 111.117 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -155.56 150.95 22.52 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.691 -0.766 . . . . 73.43 112.452 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 5.8 m -118.2 67.05 6.45 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.587 0.708 . . . . 75.21 111.11 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.69 159.48 53.28 Favored 'Trans proline' 0 N--CA 1.465 -0.16 0 C-N-CA 122.767 2.312 . . . . 70.2 112.35 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -83.39 -167.96 1.91 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.211 -0.45 . . . . 73.24 111.108 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -77.74 127.52 32.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 74.43 110.852 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -123.87 150.62 44.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.245 -0.434 . . . . 74.2 111.166 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 5.4 ttpm? -104.19 144.85 31.04 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.213 -0.449 . . . . 74.14 110.887 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -142.0 155.0 45.43 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.269 -0.423 . . . . 75.24 110.923 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.41 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 0.2 OUTLIER -107.18 151.57 25.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.12 -0.491 . . . . 73.51 110.943 -179.942 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -175.86 75.86 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.707 -0.759 . . . . 62.43 112.41 -179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -178.52 -176.33 0.48 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.94 0.4 . . . . 74.15 110.881 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -85.41 -69.71 0.64 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.192 -0.458 . . . . 74.13 110.88 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 75.3 m -84.58 -34.09 23.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.435 . . . . 71.4 110.886 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.2 mm -64.06 -34.75 70.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 72.33 111.146 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 78.8 p -62.61 -49.09 76.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.471 . . . . 73.0 110.818 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 41.6 t -51.72 -36.89 48.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.102 -0.499 . . . . 74.51 110.786 -179.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -68.55 -46.39 69.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 73.11 110.881 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.67 -12.76 38.9 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.751 -0.738 . . . . 62.31 112.529 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 21.1 mmt85 -108.87 88.69 2.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.827 0.346 . . . . 74.12 110.875 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.41 ' HB ' ' HA ' ' A' ' 82' ' ' GLN . 99.0 t -113.91 -52.87 5.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 74.13 111.044 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 8.5 p -139.85 144.5 37.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 73.32 110.924 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -149.7 119.53 7.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 72.12 110.896 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 3.8 p -177.65 163.84 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.163 -0.471 . . . . 74.42 111.154 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -76.29 163.66 26.81 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.218 -0.447 . . . . 73.11 110.881 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 2.6 m-85 -114.21 139.55 49.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.184 -0.462 . . . . 73.53 110.881 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -117.92 65.94 0.36 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.754 -0.736 . . . . 61.31 112.428 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 115.34 4.05 Favored 'Trans proline' 0 C--N 1.341 0.134 0 C-N-CA 122.682 2.255 . . . . 73.43 112.313 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -139.08 119.88 14.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 73.24 111.103 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.409 ' HA ' ' HA2' ' A' ' 124' ' ' GLY . 0.0 OUTLIER -155.2 136.2 5.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 71.03 111.104 179.913 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -119.69 124.2 45.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.103 -0.499 . . . . 73.12 110.924 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' SER . . . . . 0.412 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 72.3 m -143.69 159.38 42.58 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.177 -0.465 . . . . 62.43 110.874 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.469 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.6 OUTLIER -106.85 152.05 24.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.118 -0.492 . . . . 73.41 110.851 -179.912 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 75.7 mt-30 -101.69 140.36 36.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 74.52 110.857 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -122.65 110.73 15.89 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.12 -0.491 . . . . 74.34 110.953 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.153 -0.476 . . . . 74.43 110.835 179.965 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 . . . . . 0 C--O 1.232 0.176 0 CA-C-O 121.642 0.734 . . . . 74.34 110.981 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 176.96 6.06 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.684 2.256 . . . . 74.03 112.309 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 15.7 p90 -111.08 154.12 24.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.474 . . . . 73.23 110.91 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.3 p -113.75 131.43 65.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 75.14 111.153 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -124.14 168.0 16.36 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.626 -0.797 . . . . 72.31 112.475 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 8.4 p -171.99 153.4 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.886 0.374 . . . . 71.11 111.131 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . 0.412 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -178.26 -152.16 10.04 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.732 -0.747 . . . . 70.3 112.459 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . 0.452 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 12.1 p -107.72 134.57 49.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.786 0.326 . . . . 74.43 111.182 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . 0.409 ' HA2' ' HA ' ' A' ' 102' ' ' ILE . . . -121.87 172.52 15.52 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.709 -0.758 . . . . 72.42 112.553 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 12.3 ptm180 -169.69 130.07 1.02 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.816 0.341 . . . . 72.24 110.904 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 4.0 p -110.18 120.46 61.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.456 . . . . 75.41 111.131 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 5.7 mp -109.42 149.77 29.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 75.24 110.949 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -131.97 152.6 51.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 74.24 110.872 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -102.61 175.09 5.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.087 -0.506 . . . . 64.14 110.851 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.6 p-10 -110.66 95.51 5.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.166 -0.47 . . . . 74.03 110.888 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 9.5 tmtt? -119.35 -68.17 0.93 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 73.32 110.941 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 2.7 m -161.68 63.75 0.25 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.246 -0.434 . . . . 73.42 111.189 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -93.04 163.76 13.53 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.235 -0.439 . . . . 74.14 110.882 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 64.25 150.92 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.699 -0.763 . . . . 73.23 112.448 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -79.66 2.26 23.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.861 0.362 . . . . 75.05 111.115 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -86.09 -176.64 6.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.441 . . . . 74.22 110.916 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 89.0 p -64.93 88.91 0.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 74.43 110.867 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 7.6 m 49.88 76.17 0.15 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.147 -0.479 . . . . 75.31 110.853 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -93.66 159.27 15.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.1 -0.5 . . . . 74.44 110.913 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -117.64 170.6 8.64 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.193 -0.458 . . . . 71.54 110.879 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 30.3 mm -116.09 141.61 32.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 71.42 111.113 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -90.7 106.2 18.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.163 -0.471 . . . . 73.43 110.918 179.854 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -57.23 -176.68 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.225 -0.443 . . . . 73.02 110.868 179.854 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 24.0 tptt -163.73 161.12 23.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.141 -0.481 . . . . 74.11 110.858 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 5.8 p90 -132.77 146.69 52.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 73.32 110.911 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -179.39 162.77 0.96 Allowed Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.527 0.679 . . . . 64.33 111.167 179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' PRO . . . . . 0.452 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 53.6 Cg_endo -69.72 166.43 27.57 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.651 2.234 . . . . 61.05 112.354 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.401 ' HA ' ' HB ' ' A' ' 170' ' ' ILE . . . -153.19 151.47 30.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.261 -0.427 . . . . 71.4 111.11 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 32.0 m-85 -111.81 125.05 53.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 74.32 110.898 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -107.48 158.28 17.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.104 -0.498 . . . . 74.24 110.938 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 15.0 p -161.25 134.79 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.234 -0.439 . . . . 72.2 111.128 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . 0.426 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 179.5 -159.21 23.67 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.71 -0.757 . . . . 51.23 112.506 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.86 148.81 39.39 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.872 0.368 . . . . 72.22 110.85 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 3.8 tpp85 -126.97 122.15 33.71 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.142 -0.481 . . . . 75.33 110.868 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -125.97 164.27 21.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 73.24 111.014 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -122.61 108.74 13.46 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 71.4 110.919 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -50.51 158.79 0.57 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 71.42 110.93 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -50.6 -32.15 23.68 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.775 -0.726 . . . . 63.45 112.482 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -80.76 -168.64 1.84 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.836 0.351 . . . . 74.31 110.901 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 46.9 t -71.04 -35.3 71.91 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.47 . . . . 72.23 110.846 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 3.1 m0 -71.47 153.93 41.87 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.172 -0.467 . . . . 74.5 110.954 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 2.3 mpt? -131.9 173.98 10.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 63.41 110.819 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.506 ' HA ' ' HA ' ' A' ' 200' ' ' ALA . 0.0 OUTLIER -140.84 160.59 39.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 71.43 110.922 179.998 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -163.74 156.62 18.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 75.02 110.908 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 12.2 p -148.25 121.9 9.22 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 73.44 110.829 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 166' ' ' ASP . . . . . 0.426 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 15.6 t70 -130.72 160.84 33.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 73.0 110.883 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 31.8 t -137.04 132.06 46.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.236 -0.438 . . . . 75.41 111.147 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.41 139.31 37.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 75.23 110.868 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 66.5 t80 -143.97 134.21 24.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.146 -0.479 . . . . 71.35 110.897 -179.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 170' ' ' ILE . . . . . 0.401 ' HB ' ' HA ' ' A' ' 148' ' ' ALA . 0.0 OUTLIER 179.83 131.58 0.25 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.601 0.715 . . . . 73.01 111.217 179.904 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . 0.401 ' HD2' HG12 ' A' ' 170' ' ' ILE . 54.3 Cg_endo -69.69 109.27 2.26 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.709 2.273 . . . . 53.42 112.355 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -119.0 176.87 5.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.445 . . . . 72.34 110.865 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.53 147.53 29.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.161 -0.472 . . . . 73.43 110.829 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -132.36 162.83 30.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.489 . . . . 71.53 111.177 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -119.74 170.87 8.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 73.34 110.849 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 21.9 t -148.73 133.19 9.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 75.45 111.119 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 14.8 t -166.55 175.03 8.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 73.15 111.169 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -156.62 -137.08 2.25 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.799 -0.715 . . . . 71.43 112.536 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 98.6 m . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 120.785 0.326 . . . . 75.4 111.156 -179.9 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo . . . . . 0 C--O 1.232 0.182 0 CA-C-O 120.866 0.277 . . . . 73.22 112.336 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 29.7 t -106.62 115.56 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.19 -0.459 . . . . 72.41 111.094 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 19.4 p -110.1 105.84 15.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 72.23 110.814 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 16.2 p -107.74 159.46 16.47 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.115 -0.493 . . . . 65.14 111.138 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 34.8 ttpt -147.17 145.18 29.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 64.31 110.857 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 20.6 pt -146.1 142.05 21.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.127 -0.488 . . . . 62.43 111.1 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -124.14 110.8 15.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 74.23 110.896 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 5.6 t -137.06 157.99 35.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 75.44 111.08 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -108.14 88.39 4.71 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.601 0.715 . . . . 74.1 110.898 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 169.13 19.7 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.716 2.277 . . . . 72.21 112.318 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -126.91 117.2 22.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.465 . . . . 73.12 110.888 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 61.8 mt -103.29 104.27 16.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 75.35 111.187 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 5.5 mt -96.12 108.88 21.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.217 -0.447 . . . . 55.03 110.93 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -108.99 127.7 54.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.244 -0.435 . . . . 73.42 110.848 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 10.4 tt -149.95 132.75 15.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.165 -0.471 . . . . 74.34 110.904 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 199' ' ' GLY . . . . . 0.43 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -177.97 -152.12 9.91 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.776 -0.726 . . . . 72.23 112.468 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 200' ' ' ALA . . . . . 0.506 ' HA ' ' HA ' ' A' ' 163' ' ' LEU . . . -110.09 173.1 6.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.822 0.344 . . . . 65.53 111.034 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 40.6 t -159.98 162.66 34.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 63.54 110.852 -179.739 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -146.55 135.27 22.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.14 -0.482 . . . . 74.3 110.917 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 11.2 p -83.63 152.56 3.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.122 -0.49 . . . . 73.44 111.129 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -151.37 132.08 14.03 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 75.21 110.887 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.125 -0.489 . . . . 75.45 110.885 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 41.6 mt-30 . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.79 0.329 . . . . 73.24 110.945 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.9 9.76 31.78 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.779 -0.724 . . . . 72.11 112.456 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -78.71 169.39 18.31 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.803 0.335 . . . . 73.41 110.874 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 10.1 m-90 -114.9 159.85 20.21 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.215 -0.448 . . . . 75.23 110.937 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.5 m -153.38 126.96 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 73.14 111.152 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -96.4 114.95 26.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.154 -0.475 . . . . 75.5 111.077 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -111.95 113.7 26.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.175 -0.466 . . . . 72.44 110.91 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -106.65 125.66 51.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 74.3 110.873 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -155.55 166.58 33.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.135 -0.484 . . . . 74.33 110.915 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 23.4 p90 -98.86 132.39 44.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.143 -0.48 . . . . 74.44 110.85 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -98.7 122.69 42.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.152 -0.476 . . . . 74.3 110.871 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 29.2 tptt -99.29 106.53 18.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 63.41 110.867 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.4 p -81.2 133.88 28.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.312 -0.404 . . . . 75.33 111.114 179.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -120.5 112.51 19.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.094 -0.503 . . . . 70.41 110.909 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.0 m -153.13 -179.34 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.097 -0.501 . . . . 74.41 111.147 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.63 52.48 0.54 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.682 -0.771 . . . . 71.1 112.477 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 34.0 mt-10 -90.03 -66.75 0.89 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.849 0.357 . . . . 65.4 110.903 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? 177.81 151.94 0.25 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.088 -0.506 . . . . 73.14 110.945 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -109.03 163.73 13.05 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.15 -0.477 . . . . 74.54 110.921 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.26 0 C-N-CA 120.737 -0.744 . . . . 75.52 112.452 179.864 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.733 0.301 . . . . 74.14 111.105 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -159.52 125.15 4.22 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.231 -0.441 . . . . 62.11 110.869 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.402 ' HA ' ' HA2' ' A' ' 83' ' ' GLY . 6.5 p -118.14 148.91 20.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.193 -0.458 . . . . 75.35 111.072 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -173.14 174.47 3.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 72.41 110.878 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 19.3 tt -141.57 154.79 20.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.112 -0.494 . . . . 75.51 111.086 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -124.42 167.54 16.72 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.715 -0.755 . . . . 72.3 112.426 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.9 m-80 -162.66 163.91 26.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.821 0.343 . . . . 71.22 110.904 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -120.36 -68.83 0.88 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 62.43 110.827 179.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 72.3 p -91.93 172.87 8.17 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.216 -0.447 . . . . 74.43 111.144 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 40.3 p -148.38 106.52 3.73 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.226 -0.443 . . . . 73.43 111.122 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.3 pp -160.73 128.74 4.47 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 64.54 110.94 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.54 155.74 45.05 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.274 -0.421 . . . . 75.0 111.182 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -114.95 132.46 56.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 71.54 110.893 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.443 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -129.88 134.83 47.76 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.211 -0.449 . . . . 63.24 110.991 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.0 mm -109.29 115.16 48.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.274 -0.421 . . . . 72.14 111.125 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.445 ' HA ' ' HA ' ' A' ' 70' ' ' ASP . . . -111.31 151.48 28.33 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.178 -0.464 . . . . 62.22 111.084 179.829 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 5.3 m-85 -125.74 132.37 52.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 73.04 110.932 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -98.3 95.22 7.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.081 -0.509 . . . . 73.24 110.893 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.5 t -94.35 -31.74 4.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.151 -0.477 . . . . 75.34 111.089 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 29.7 t -136.15 158.07 45.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 74.23 110.831 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 59.8 p -85.07 3.98 36.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 72.41 110.859 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -114.41 -29.47 6.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 72.41 110.84 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 32.5 pt -142.08 158.0 20.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 73.14 111.113 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -148.91 163.27 37.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 62.12 111.115 179.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.1 m -112.24 152.14 14.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 74.35 111.155 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.445 ' HA ' ' HA ' ' A' ' 60' ' ' ALA . 1.5 p30 -144.58 143.31 30.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 64.25 110.885 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 0.443 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -127.19 108.44 10.89 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 75.3 110.851 -179.907 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -86.33 127.26 34.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.12 -0.491 . . . . 74.21 110.819 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 14.6 p -147.3 147.49 17.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 73.21 111.198 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -161.88 144.18 9.51 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.753 -0.737 . . . . 73.55 112.487 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 44.3 t -119.74 73.18 16.91 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.608 0.718 . . . . 70.41 111.129 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 159.09 54.7 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.669 2.246 . . . . 52.34 112.365 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -74.91 -165.8 0.41 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.251 -0.431 . . . . 72.35 111.181 179.818 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 18.2 ttm105 -77.05 138.22 39.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.283 -0.417 . . . . 71.33 110.833 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -132.77 148.99 52.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.443 . . . . 54.51 111.128 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.6 ttpm? -89.12 123.8 33.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.182 -0.463 . . . . 73.13 110.93 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 59.6 t80 -109.13 138.82 44.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 72.15 110.878 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -109.17 150.91 27.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 74.43 110.917 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.402 ' HA2' ' HA ' ' A' ' 47' ' ' VAL . . . 174.37 84.88 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.696 -0.764 . . . . 74.31 112.447 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -178.07 -175.68 0.5 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.894 0.378 . . . . 75.3 110.976 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 1.4 ptpt -86.54 -70.13 0.63 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.198 -0.455 . . . . 74.22 110.879 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 8.4 t -85.25 -30.52 23.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.225 -0.443 . . . . 75.44 110.869 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 4.8 mm -68.81 -35.21 68.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.123 -0.489 . . . . 73.33 111.114 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.1 t -62.68 -47.38 83.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 72.5 110.861 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.1 t -54.67 -39.85 68.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.149 -0.478 . . . . 71.23 110.837 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 13.9 tp -60.55 -44.23 96.37 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.083 -0.508 . . . . 75.4 110.995 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.24 -14.55 39.86 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.743 -0.741 . . . . 74.55 112.501 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 9.8 mtm180 -120.54 96.74 5.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.897 0.38 . . . . 75.41 110.813 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 99.3 t -107.24 -58.27 3.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 73.05 111.1 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -140.09 148.73 42.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.154 -0.475 . . . . 64.43 110.902 -179.792 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 31.6 mt-10 -126.01 124.59 41.03 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.132 -0.485 . . . . 72.13 110.972 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 14.8 p -176.05 156.76 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 74.21 111.11 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -84.27 173.49 10.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 75.34 110.902 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 14.4 m-85 -130.48 133.17 46.08 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 74.23 110.933 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -114.11 69.63 0.24 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.703 -0.761 . . . . 54.42 112.445 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.82 138.44 37.64 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.694 2.263 . . . . 74.04 112.294 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -155.7 118.08 4.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 60.55 111.115 179.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 30.0 pt -140.15 146.1 25.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 75.42 111.165 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 2.3 pp -132.82 118.99 19.66 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.196 -0.456 . . . . 74.11 110.846 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' SER . . . . . 0.404 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 5.6 p -142.93 163.92 31.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.202 -0.454 . . . . 65.11 110.875 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 1.1 pp -113.87 151.46 32.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 72.43 110.886 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 31.5 mt-30 -106.49 144.05 33.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 73.55 110.907 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 5.4 t80 -136.02 125.41 24.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 65.53 110.968 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 1.9 t60 . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 116.173 -0.467 . . . . 64.31 110.843 179.956 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 6.1 m-85 . . . . . 0 C--O 1.231 0.119 0 CA-C-O 121.689 0.757 . . . . 73.4 110.884 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 178.43 4.57 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.633 2.222 . . . . 73.43 112.349 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 4.0 m-85 -110.24 151.95 26.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.462 . . . . 74.35 110.949 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 8.3 p -101.93 133.01 46.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.109 -0.496 . . . . 75.11 111.101 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -131.92 174.67 20.11 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.796 -0.716 . . . . 71.15 112.568 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.4 p -175.95 153.54 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.865 0.364 . . . . 73.43 111.106 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . 0.404 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -176.01 -158.21 19.09 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.76 -0.734 . . . . 54.2 112.543 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . 0.461 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 21.3 m -107.7 150.66 10.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.869 0.366 . . . . 72.43 111.116 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -130.53 169.07 21.46 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.687 -0.768 . . . . 75.24 112.455 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . 0.414 ' HA ' ' HA ' ' A' ' 145' ' ' TRP . 0.0 OUTLIER -168.55 129.26 1.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.86 0.362 . . . . 71.3 110.923 -179.855 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 3.9 p -118.73 112.04 36.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 73.03 111.152 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 10.0 tt -122.52 151.23 41.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 73.34 110.883 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -160.89 161.94 31.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.187 -0.461 . . . . 72.21 110.833 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 51.5 t80 -101.07 118.59 37.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.49 . . . . 71.53 110.88 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -50.55 102.37 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 65.21 110.845 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -77.52 -80.81 0.1 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.139 -0.482 . . . . 74.35 110.901 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -165.43 112.9 0.96 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.256 -0.429 . . . . 74.34 111.125 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . 0.499 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 1.4 m-20 -103.07 119.36 38.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.144 -0.48 . . . . 71.35 110.923 179.853 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -79.89 -5.82 89.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.806 -0.712 . . . . 62.21 112.445 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -46.81 -28.18 1.46 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.81 0.338 . . . . 73.2 111.113 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -162.86 -178.56 6.2 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.191 -0.458 . . . . 74.2 111.019 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 1.5 m -53.02 93.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.275 -0.42 . . . . 73.1 110.828 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 7.0 m 50.68 71.19 0.44 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.081 -0.509 . . . . 70.22 110.891 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.499 ' HB3' ' HB2' ' A' ' 133' ' ' ASP . 0.5 OUTLIER -92.98 159.88 15.12 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.135 -0.484 . . . . 73.22 110.838 -179.912 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 94.0 m-20 -134.0 167.41 20.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.495 . . . . 75.54 110.891 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 17.6 tt -117.97 149.11 20.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.192 -0.458 . . . . 74.04 111.182 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 16.2 mmtt -113.36 124.54 52.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 74.23 110.931 179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -85.53 -173.32 4.59 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.225 -0.443 . . . . 63.31 110.868 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -171.54 -175.36 1.58 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 72.51 110.904 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' TRP . . . . . 0.414 ' HA ' ' HA ' ' A' ' 125' ' ' ARG . 22.5 p-90 -143.57 160.49 40.54 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.198 -0.456 . . . . 71.33 110.917 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . 178.86 163.15 0.69 Allowed Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.623 0.725 . . . . 74.44 111.086 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 54.3 Cg_endo -69.66 170.61 16.06 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.683 2.255 . . . . 73.3 112.375 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -165.55 153.0 10.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.222 -0.445 . . . . 74.4 111.13 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 12.9 m-85 -96.17 161.3 14.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.242 -0.435 . . . . 73.54 110.819 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 27.7 tp60 -135.0 148.59 50.0 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 62.44 110.949 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 10.2 p -151.54 130.84 3.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.17 -0.468 . . . . 75.33 111.161 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 164.95 -163.21 36.27 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.727 -0.749 . . . . 70.43 112.481 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -148.93 168.26 23.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.788 0.328 . . . . 74.41 110.95 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -133.68 128.51 35.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 73.24 110.88 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -132.66 161.64 33.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.442 . . . . 74.31 110.933 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -121.28 109.58 15.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.147 -0.479 . . . . 73.01 110.904 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 3.6 tp -57.46 160.45 4.12 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.169 -0.469 . . . . 75.12 110.944 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -52.05 -33.24 36.77 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.775 -0.726 . . . . 64.04 112.495 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 4.6 m120 -80.52 173.65 12.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.907 0.384 . . . . 74.14 110.821 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 81.1 p -54.78 -35.74 64.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.113 -0.494 . . . . 75.45 110.815 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 10.3 m0 -69.31 151.68 45.91 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.199 -0.455 . . . . 73.21 110.97 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 38.8 mtt -121.22 174.92 6.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.246 -0.433 . . . . 74.34 110.862 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.417 ' HA ' ' HA ' ' A' ' 200' ' ' ALA . 0.6 OUTLIER -128.65 139.25 52.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.262 -0.427 . . . . 73.5 110.909 179.999 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 12.1 t-20 -139.84 138.33 35.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 71.13 110.984 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.7 p -141.61 121.79 13.85 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.214 -0.448 . . . . 73.24 110.892 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -140.26 167.59 21.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.08 -0.509 . . . . 72.41 110.812 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 46.7 t -150.43 129.05 2.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.157 -0.474 . . . . 61.33 111.115 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . 0.456 ' O ' ' HG3' ' A' ' 168' ' ' ARG . 0.0 OUTLIER -98.59 137.71 36.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 71.32 110.862 -179.972 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 15.9 t80 -138.22 125.37 21.52 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 72.2 110.929 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 170' ' ' ILE . . . . . 0.497 HG13 ' HD2' ' A' ' 171' ' ' PRO . 4.7 tp 178.9 134.69 0.24 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.599 0.714 . . . . 72.34 111.116 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . 0.497 ' HD2' HG13 ' A' ' 170' ' ' ILE . 54.0 Cg_endo -69.85 111.55 2.86 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.609 2.206 . . . . 74.25 112.386 179.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -116.1 159.76 21.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.139 -0.482 . . . . 72.35 110.856 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 5.4 ptpt -140.06 144.79 37.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.146 -0.479 . . . . 74.54 110.926 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 9.4 t -117.79 161.9 18.96 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 73.52 111.137 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 21.6 t70 -118.48 158.54 25.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.14 -0.482 . . . . 71.3 110.844 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 4.5 t -147.94 138.26 16.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 73.33 111.082 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.3 t -166.92 -179.22 4.59 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.131 -0.486 . . . . 71.11 111.116 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -120.55 -161.66 11.53 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.746 -0.74 . . . . 63.02 112.458 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 6.4 t . . . . . 0 C--N 1.331 -0.217 0 CA-C-O 120.84 0.353 . . . . 75.22 111.16 -179.914 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo . . . . . 0 C--O 1.231 0.149 0 CA-C-O 120.839 0.266 . . . . 64.53 112.317 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 26.5 t -103.59 108.17 23.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 72.24 111.111 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -74.13 104.83 5.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.137 -0.483 . . . . 74.14 110.82 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 65.1 p -124.44 168.59 12.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.136 -0.484 . . . . 73.31 111.171 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 3.0 ttpm? -158.97 134.09 8.34 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.207 -0.451 . . . . 75.44 110.944 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -115.75 139.59 41.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.279 -0.419 . . . . 72.52 111.107 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 71.7 tt0 -119.55 114.99 23.1 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.125 -0.489 . . . . 74.22 110.817 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 1.2 p -137.18 171.28 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 70.41 111.111 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -106.93 87.14 2.73 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.594 0.711 . . . . 72.52 110.915 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.65 120.96 7.68 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.742 2.295 . . . . 62.21 112.379 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -102.09 114.0 27.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.258 -0.428 . . . . 74.01 110.887 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 195' ' ' ILE . . . . . 0.405 ' HB ' ' CG ' ' A' ' 168' ' ' ARG . 5.6 mt -103.56 127.3 57.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.162 -0.472 . . . . 74.22 111.133 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 1.1 tt -117.14 107.72 14.82 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.182 -0.463 . . . . 64.34 110.89 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 3.2 m -96.38 123.62 40.09 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.24 -0.436 . . . . 65.42 110.847 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 2.5 tt -144.13 129.21 18.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 73.41 110.86 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 178.94 -146.98 7.53 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.75 -0.738 . . . . 73.21 112.478 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 200' ' ' ALA . . . . . 0.417 ' HA ' ' HA ' ' A' ' 163' ' ' LEU . . . -118.65 174.26 6.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.781 0.324 . . . . 61.35 111.17 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 78.1 p -149.66 175.71 11.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.28 -0.418 . . . . 74.21 110.843 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -157.31 160.9 39.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 73.52 110.895 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 18.2 m -76.76 161.21 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.065 -0.516 . . . . 70.04 111.15 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -155.95 127.59 7.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 74.34 110.865 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 14.3 ttmm . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.119 -0.492 . . . . 73.2 110.924 179.946 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 . . . . . 0 CA--C 1.526 0.04 0 CA-C-O 120.8 0.333 . . . . 75.43 110.881 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.71 11.57 28.33 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 75.22 112.498 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -82.66 160.51 22.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.766 0.317 . . . . 63.25 110.922 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 12.8 m95 -108.76 159.65 16.6 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.257 -0.429 . . . . 74.41 110.936 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -150.5 119.2 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.426 . . . . 74.12 111.139 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -85.0 107.52 17.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.096 -0.502 . . . . 74.14 111.078 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -105.45 112.76 25.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 63.11 110.902 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -111.73 125.79 54.36 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.159 -0.473 . . . . 75.3 110.879 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 4.0 p30 -155.78 172.66 17.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 75.45 110.907 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.8 p90 -100.96 132.21 46.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 71.24 110.867 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -100.68 120.04 39.48 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.151 -0.477 . . . . 70.34 110.88 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 39.1 tttm -93.56 106.82 18.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 72.42 110.849 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 p -84.12 135.8 24.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 72.4 111.106 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -125.84 99.42 5.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.154 -0.475 . . . . 74.34 110.855 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.7 p -147.33 142.26 19.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.155 -0.475 . . . . 75.22 111.152 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 142.08 64.57 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.706 -0.759 . . . . 65.41 112.528 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -89.86 -66.16 0.95 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.766 0.317 . . . . 75.14 110.911 -179.863 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -171.41 134.87 0.9 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.122 -0.49 . . . . 75.42 110.873 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 5.1 tt -104.94 152.69 22.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.186 -0.461 . . . . 71.35 110.992 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.234 0 C-N-CA 120.666 -0.778 . . . . 72.52 112.502 179.946 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.79 0.328 . . . . 74.21 111.062 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 21.8 m-20 -160.48 125.37 3.79 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 65.44 110.922 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 18.5 t -104.4 135.51 41.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.187 -0.46 . . . . 71.51 111.159 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -132.63 137.59 47.06 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 73.13 110.816 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 3.8 tt -101.3 145.03 12.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.094 -0.503 . . . . 74.24 111.094 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -60.24 -168.58 0.38 Allowed Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.746 -0.74 . . . . 75.41 112.462 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -119.05 -37.34 3.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.781 0.324 . . . . 75.34 110.937 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -51.96 150.51 4.21 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.147 -0.479 . . . . 75.15 110.881 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 3.7 p -146.13 178.21 8.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 62.13 111.138 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.6 t -160.14 169.47 23.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.268 -0.424 . . . . 75.14 111.183 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 5.0 mp -91.13 168.38 11.67 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 74.15 110.921 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.1 t -135.94 149.51 48.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.186 -0.461 . . . . 74.24 111.133 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -102.75 133.05 48.43 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.292 -0.413 . . . . 73.35 110.846 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -125.91 138.62 53.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 53.45 110.84 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.53 114.15 45.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 73.45 111.164 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -105.87 121.64 44.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 73.4 111.057 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 7.4 t80 -106.08 117.38 33.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 73.55 110.931 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -92.43 101.83 14.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.124 -0.489 . . . . 74.0 110.892 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 32.5 m -98.39 -31.72 3.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.46 . . . . 70.22 111.156 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 m -125.92 -169.51 2.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.192 -0.458 . . . . 71.0 110.895 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.5 m -84.18 -38.92 20.02 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 74.14 110.893 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -126.09 25.99 6.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.067 -0.515 . . . . 74.4 110.865 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 3.4 mt -145.16 126.94 8.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.22 -0.446 . . . . 70.04 111.136 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -155.05 168.61 26.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.138 -0.483 . . . . 75.12 111.119 179.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.494 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 2.5 m -111.76 152.47 13.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 65.24 111.14 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -131.66 129.41 40.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 63.23 110.821 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -114.38 110.15 19.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 74.3 110.87 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -81.82 113.08 19.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 73.14 110.955 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.8 t -124.04 116.46 47.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.167 -0.47 . . . . 74.43 111.03 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -131.87 152.14 20.03 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.71 -0.757 . . . . 74.23 112.48 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 39.4 t -143.38 69.81 17.69 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.575 0.702 . . . . 71.2 111.144 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.79 140.61 42.98 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.666 2.244 . . . . 74.21 112.373 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.87 -173.66 0.26 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.188 -0.46 . . . . 72.33 111.075 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 8.9 ttm180 -76.43 129.61 36.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 75.13 110.856 -179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -131.03 151.71 51.12 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.227 -0.442 . . . . 70.21 111.085 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.8 tttp -97.59 123.9 41.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.134 -0.485 . . . . 72.02 110.847 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -111.43 151.68 28.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 75.04 110.907 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 18.1 mt-30 -111.71 148.47 33.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 75.31 110.899 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -178.71 81.41 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.789 -0.719 . . . . 74.51 112.479 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -176.52 -175.59 0.67 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.95 0.405 . . . . 73.33 110.868 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.17 -69.72 0.65 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.127 -0.488 . . . . 74.12 110.949 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 16.9 p -85.16 -32.05 22.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.237 -0.438 . . . . 73.52 110.853 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 4.6 mm -67.34 -35.13 72.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.094 -0.503 . . . . 74.35 111.111 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.8 t -62.38 -44.85 95.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.219 -0.446 . . . . 74.14 110.79 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 39.1 t -57.43 -37.31 72.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 72.05 110.904 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 98.5 mt -63.56 -50.3 70.02 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.107 -0.497 . . . . 74.32 110.902 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 114.14 -13.22 21.69 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.721 -0.752 . . . . 75.42 112.475 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.61 96.19 5.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.839 0.352 . . . . 74.14 110.821 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 64.5 t -113.74 -50.84 5.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.253 -0.431 . . . . 72.41 111.108 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 60.5 p -140.11 148.69 42.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 74.25 110.91 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -140.68 118.52 11.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 71.42 110.79 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 1.6 p -179.24 170.31 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.171 -0.468 . . . . 74.53 111.089 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -109.43 160.29 16.32 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.198 -0.455 . . . . 74.21 110.869 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 17.7 m-85 -120.35 145.23 47.35 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.226 -0.443 . . . . 75.11 110.948 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -108.67 87.3 0.48 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.775 -0.726 . . . . 72.12 112.412 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.76 110.43 2.55 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.668 2.245 . . . . 74.41 112.406 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -128.88 95.57 4.12 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.241 -0.436 . . . . 60.52 111.12 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 5.8 mm -116.64 142.22 31.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.229 -0.441 . . . . 74.21 111.138 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -140.13 109.66 6.27 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.188 -0.46 . . . . 75.52 110.934 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.8 p -138.19 -177.6 4.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 73.13 110.854 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.494 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.7 OUTLIER -128.87 141.89 51.14 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 71.23 110.863 -179.946 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 -101.55 132.72 47.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 71.24 110.992 179.853 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 27.5 t80 -137.1 145.61 44.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.237 -0.438 . . . . 75.11 110.937 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 59.0 t-80 . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.152 -0.476 . . . . 64.44 110.917 179.89 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 7.7 p90 . . . . . 0 C--O 1.232 0.137 0 CA-C-O 121.655 0.74 . . . . 72.44 110.985 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 176.95 6.13 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.6 2.2 . . . . 71.54 112.31 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 26.5 m-85 -111.53 144.24 41.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 72.14 110.924 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 13.2 p -100.7 133.26 44.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.237 -0.438 . . . . 73.24 111.102 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.401 ' HA2' ' O ' ' A' ' 105' ' ' LEU . . . -125.92 159.01 20.32 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.738 -0.744 . . . . 74.13 112.489 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.1 p -161.6 149.47 4.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.81 0.338 . . . . 75.14 111.15 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -177.5 -151.3 9.07 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.744 -0.741 . . . . 65.41 112.5 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . 0.497 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.3 p -110.39 126.31 67.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.877 0.37 . . . . 74.4 111.114 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -116.06 119.94 4.72 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.769 -0.729 . . . . 60.05 112.503 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 13.5 ptm180 -120.44 122.88 41.67 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.921 0.391 . . . . 75.11 110.854 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . 0.407 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 3.7 m -118.34 118.6 58.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.202 -0.454 . . . . 73.31 111.117 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -160.02 165.23 32.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.231 -0.441 . . . . 74.14 110.985 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -165.93 -171.12 1.93 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.236 -0.438 . . . . 74.33 110.897 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -94.13 135.12 35.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.174 -0.466 . . . . 75.42 110.926 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -69.63 148.01 49.9 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.138 -0.483 . . . . 72.43 110.843 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -129.55 -69.29 0.69 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 73.05 110.933 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 33.8 m -159.93 75.12 0.6 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.185 -0.461 . . . . 74.15 111.189 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -97.85 175.5 6.13 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.224 -0.444 . . . . 73.21 110.81 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 62.99 149.55 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.735 -0.745 . . . . 71.03 112.479 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -76.51 -1.7 28.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.892 0.377 . . . . 73.21 111.187 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -86.5 -177.09 6.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.135 -0.484 . . . . 74.14 110.906 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -64.06 93.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.198 -0.455 . . . . 62.44 110.847 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 89.0 p 46.06 76.26 0.1 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 71.24 110.88 -179.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -82.96 151.16 26.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 71.42 110.794 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -101.74 165.63 11.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.093 -0.503 . . . . 72.51 110.776 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -127.08 163.0 30.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 73.34 111.168 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -119.21 108.14 14.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 74.45 110.898 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.407 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 1.0 OUTLIER -58.84 -172.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.243 -0.435 . . . . 72.43 110.819 179.967 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 15.9 mmtt -149.47 155.28 40.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.45 . . . . 74.04 110.886 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 45.3 p90 -151.67 136.23 16.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.227 -0.442 . . . . 73.21 110.926 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.545 ' CB ' ' HD2' ' A' ' 147' ' ' PRO . . . -179.28 172.14 0.61 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.583 0.706 . . . . 51.15 111.051 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' PRO . . . . . 0.545 ' HD2' ' CB ' ' A' ' 146' ' ' ALA . 54.3 Cg_endo -69.69 134.09 27.29 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.631 2.221 . . . . 73.43 112.421 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -130.1 166.47 20.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.262 -0.426 . . . . 65.52 111.126 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -121.55 167.39 12.92 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 71.21 110.951 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -165.85 162.3 18.29 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 74.02 110.923 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 10.7 p -153.51 141.32 13.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 73.0 111.147 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -169.4 -171.79 35.41 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.772 -0.728 . . . . 64.24 112.451 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 8.5 tt -149.2 157.08 43.07 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.738 0.304 . . . . 75.11 110.934 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 7.1 tpp85 -108.08 117.43 34.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.224 -0.444 . . . . 74.43 110.836 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 4.5 t80 -105.17 145.38 30.66 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.184 -0.462 . . . . 74.24 110.876 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -115.38 105.77 13.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.091 -0.504 . . . . 55.45 110.897 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 11.9 tp -93.93 164.34 13.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.184 -0.462 . . . . 75.12 110.925 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -76.08 68.38 2.31 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.75 -0.738 . . . . 70.34 112.468 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 64.7 m-80 -151.41 175.25 12.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.804 0.335 . . . . 74.3 110.876 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 6.2 m -56.32 -38.55 71.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.209 -0.45 . . . . 73.42 110.85 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 4.6 p90 -111.8 178.26 4.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.167 -0.47 . . . . 73.22 110.905 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -117.08 170.81 8.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 75.13 110.92 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 5.8 tp -104.09 151.35 23.38 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.246 -0.433 . . . . 71.53 110.886 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 4.0 t-20 -145.07 137.84 26.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.17 -0.468 . . . . 74.35 110.919 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 26.8 p -136.22 122.5 20.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 74.24 110.906 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -140.5 164.62 29.67 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.136 -0.484 . . . . 73.24 110.878 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 94.7 t -150.51 116.61 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.248 -0.433 . . . . 73.4 111.115 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -97.66 146.49 25.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 74.24 110.879 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 62.2 t80 -146.81 143.3 28.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 71.14 110.86 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 170' ' ' ILE . . . . . 0.409 ' O ' HG21 ' A' ' 170' ' ' ILE . 0.0 OUTLIER -179.0 103.14 0.2 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.66 0.743 . . . . 73.32 111.154 179.918 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 127.32 14.48 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.661 2.241 . . . . 72.24 112.439 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -148.64 178.42 8.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.254 -0.43 . . . . 74.01 110.952 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.82 127.74 37.26 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.187 -0.461 . . . . 74.04 110.892 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.8 t -91.88 165.96 12.97 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.291 -0.413 . . . . 70.53 111.123 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -124.58 167.06 15.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 72.23 110.86 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 45.7 t -152.16 139.78 13.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.13 -0.487 . . . . 72.22 111.163 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 14.5 t -167.27 179.35 5.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 72.54 111.149 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 131.63 143.49 5.21 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.747 -0.739 . . . . 63.34 112.45 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 7.1 t . . . . . 0 C--N 1.329 -0.309 0 CA-C-O 120.86 0.362 . . . . 71.45 111.111 -179.912 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo . . . . . 0 C--O 1.231 0.157 0 CA-C-O 120.766 0.236 . . . . 73.12 112.368 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 44.6 t -96.8 107.5 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.227 -0.442 . . . . 71.03 111.092 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 13.3 p -89.36 104.98 17.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 65.43 110.861 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 10.8 p -110.22 166.53 10.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.083 -0.508 . . . . 74.13 111.151 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -152.23 146.6 25.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 74.41 110.922 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 18.2 pt -142.51 130.39 20.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 74.21 111.14 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -99.29 118.23 35.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 74.01 110.837 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 8.5 p -137.79 159.99 33.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 72.11 111.143 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -107.22 90.26 5.46 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.567 0.699 . . . . 74.13 110.927 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 116.31 4.5 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.683 2.255 . . . . 75.44 112.342 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -100.28 119.65 38.72 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.176 -0.466 . . . . 70.2 110.918 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 40.5 mm -108.79 119.48 58.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.123 -0.49 . . . . 64.24 111.094 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 7.3 mp -113.03 107.25 15.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.156 -0.475 . . . . 74.13 110.949 179.863 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -95.31 124.47 39.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.225 -0.443 . . . . 73.3 110.826 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 5.0 mp -146.39 127.92 15.07 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.101 -0.5 . . . . 74.13 110.987 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 177.27 -136.25 3.05 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.655 -0.783 . . . . 64.42 112.442 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -134.06 173.15 11.89 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.85 0.357 . . . . 64.32 111.114 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 2.3 p -144.92 174.83 10.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.434 . . . . 71.53 110.92 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 12.6 t80 -148.63 138.77 22.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.101 -0.499 . . . . 74.23 110.854 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 11.5 p -77.2 151.23 5.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.077 -0.51 . . . . 73.14 111.117 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 -153.13 114.15 4.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.133 -0.485 . . . . 71.14 110.896 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 5.7 ptpt . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 75.41 110.879 179.982 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.892 0.377 . . . . 75.13 110.919 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.94 6.9 68.96 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.72 -0.753 . . . . 60.24 112.421 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -75.54 145.24 41.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.752 0.31 . . . . 74.13 110.884 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -127.22 121.56 31.58 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.234 -0.439 . . . . 74.21 110.958 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.9 p -131.28 123.55 53.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.252 -0.431 . . . . 74.21 111.115 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -84.41 115.18 22.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.117 -0.492 . . . . 73.34 111.097 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -104.62 108.8 20.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 64.3 110.9 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -111.97 125.3 53.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 64.3 110.942 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 5.4 p30 -153.53 174.05 14.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 61.55 110.829 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -98.0 129.45 44.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.113 -0.494 . . . . 74.5 110.814 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -97.22 122.47 40.27 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.148 -0.478 . . . . 72.44 110.836 -179.847 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -102.4 105.76 16.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.089 -0.505 . . . . 73.43 110.902 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.5 m -82.71 131.04 34.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.272 -0.422 . . . . 71.04 111.164 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 10.2 m-85 -123.98 99.35 6.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.177 -0.465 . . . . 73.42 110.901 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 p -158.46 151.26 7.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.216 -0.447 . . . . 75.52 111.164 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.99 72.32 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.707 -0.759 . . . . 74.52 112.419 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.5 tp10 -89.07 -66.47 0.92 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.853 0.358 . . . . 75.12 110.83 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -176.23 172.5 2.31 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 71.21 110.88 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 24.4 tp -104.22 150.77 24.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 74.24 110.884 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.718 -0.753 . . . . 73.13 112.495 179.942 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.821 0.343 . . . . 65.42 111.094 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -137.49 133.96 35.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 71.15 110.833 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.8 m -106.73 151.17 8.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 75.2 111.105 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 14.7 t -156.8 151.28 25.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 75.35 110.818 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 38.4 mm -120.93 116.49 50.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.088 -0.506 . . . . 74.23 111.09 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -51.56 157.9 2.84 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.693 -0.765 . . . . 51.12 112.425 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -51.75 103.28 0.06 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.817 0.341 . . . . 72.33 110.954 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.409 ' O ' ' C ' ' A' ' 53' ' ' THR . 1.1 p-10 -58.48 -56.9 16.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 71.14 110.931 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' THR . . . . . 0.409 ' C ' ' O ' ' A' ' 52' ' ' ASP . 10.2 t 36.73 44.08 0.32 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.115 -0.493 . . . . 74.13 111.186 -179.86 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.6 169.17 8.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.198 -0.455 . . . . 64.32 111.096 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -109.49 150.23 28.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 73.14 110.907 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.5 t -134.47 144.65 48.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.284 -0.416 . . . . 74.55 111.161 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 42.2 m-85 -102.9 132.57 49.02 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.252 -0.431 . . . . 75.45 110.826 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -127.31 146.63 50.38 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.148 -0.478 . . . . 74.21 110.91 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.5 mp -119.28 113.61 41.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.224 -0.444 . . . . 74.5 111.131 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -102.66 117.0 33.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.467 . . . . 75.53 111.09 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 34.7 t80 -108.73 115.76 30.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.156 -0.475 . . . . 74.21 110.96 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -87.23 96.97 10.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.129 -0.487 . . . . 73.55 110.889 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.7 p -86.72 -33.15 6.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.146 -0.479 . . . . 72.42 111.12 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -130.67 164.91 23.98 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.184 -0.462 . . . . 75.15 110.892 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.9 t -87.21 3.24 47.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 74.52 110.92 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 61.6 t30 -110.72 -33.45 6.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.109 -0.496 . . . . 54.43 110.865 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 44.4 pt -150.54 172.02 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 72.35 111.12 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -157.16 172.85 17.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.14 -0.482 . . . . 72.14 111.058 179.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.41 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 10.2 m -112.1 150.97 14.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.223 -0.444 . . . . 74.23 111.129 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -138.11 127.48 24.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 64.24 110.857 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -102.4 147.2 27.01 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.471 . . . . 74.32 110.888 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 30.4 t80 -121.25 112.95 19.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.149 -0.478 . . . . 72.23 110.9 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.5 m -129.47 147.0 33.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 75.24 111.102 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -164.26 128.78 1.87 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.741 -0.742 . . . . 72.14 112.475 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 23.4 t -117.21 68.18 4.89 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.674 0.75 . . . . 75.54 111.155 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 162.67 41.21 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.679 2.253 . . . . 62.35 112.344 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -79.48 -165.67 0.83 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.265 -0.425 . . . . 75.34 111.059 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 55.1 ttp85 -76.88 139.28 40.2 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.148 -0.478 . . . . 75.52 110.916 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -133.83 151.88 51.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 65.42 111.088 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.0 ttpt -104.48 130.7 52.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.16 -0.473 . . . . 73.45 110.863 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -119.26 157.42 28.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 74.43 110.879 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.416 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -110.84 149.53 30.45 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 73.42 110.926 -179.921 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -177.14 75.64 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.783 -0.722 . . . . 73.23 112.493 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.8 tp10 -178.26 -176.37 0.52 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.999 0.428 . . . . 73.15 110.866 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.31 -69.15 0.69 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.174 -0.466 . . . . 74.41 110.92 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.4 t -84.63 -32.88 23.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.254 -0.43 . . . . 75.35 110.855 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.8 mm -65.57 -34.31 69.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 74.54 111.129 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 74.2 p -62.57 -53.81 49.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.475 . . . . 72.21 110.852 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.7 t -51.13 -35.86 37.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.134 -0.485 . . . . 62.21 110.867 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -63.5 -38.26 90.47 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.139 -0.482 . . . . 75.01 110.96 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 100.56 -14.37 59.25 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.776 -0.726 . . . . 61.12 112.505 179.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 19.2 ttt-85 -118.63 95.38 4.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.797 0.332 . . . . 74.33 110.941 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.416 ' HB ' ' HA ' ' A' ' 82' ' ' GLN . 94.0 t -111.66 -53.81 5.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 63.21 111.184 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 11.5 t -140.26 143.05 35.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 65.12 110.821 -179.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -132.27 115.37 15.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 63.42 110.931 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.569 ' HA ' ' HB2' ' A' ' 131' ' ' LYS . 1.4 m -154.47 171.49 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.107 -0.497 . . . . 75.12 111.146 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -86.34 172.1 10.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.202 -0.454 . . . . 64.4 110.895 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -123.25 130.52 52.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.266 -0.424 . . . . 65.41 110.919 -179.856 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -129.12 65.63 0.58 Allowed Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.733 -0.746 . . . . 73.42 112.431 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 112.76 3.16 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.704 2.269 . . . . 70.42 112.381 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -127.43 105.06 8.25 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.167 -0.469 . . . . 73.43 111.054 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.465 ' HA ' ' HA2' ' A' ' 124' ' ' GLY . 4.8 mp -128.23 151.13 34.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 74.45 111.133 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -145.99 115.7 7.26 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 72.11 110.924 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.8 p -139.62 -175.82 4.34 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.216 -0.447 . . . . 72.02 110.832 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.41 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 1.5 pp -134.54 147.86 50.38 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.139 -0.482 . . . . 75.43 110.908 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 1.8 pp0? -104.65 139.0 40.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 73.33 110.915 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 14.2 p90 -143.18 142.74 31.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 74.15 110.956 -179.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 17.5 t-160 . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.143 -0.481 . . . . 71.44 110.876 179.921 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 6.3 m-85 . . . . . 0 C--O 1.231 0.083 0 CA-C-O 121.714 0.769 . . . . 63.52 110.88 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 177.93 5.09 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.67 2.247 . . . . 74.34 112.333 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 11.2 m-85 -115.98 143.99 44.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.242 -0.436 . . . . 75.11 110.876 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 75.7 t -99.35 132.89 43.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.085 -0.507 . . . . 72.33 111.116 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -125.51 169.43 17.46 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.712 -0.756 . . . . 55.24 112.512 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 7.7 p -175.59 152.53 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.915 0.388 . . . . 71.41 111.125 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -179.78 -151.7 10.13 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.834 -0.698 . . . . 71.35 112.555 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . 0.412 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.7 p -111.37 127.25 68.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.827 0.346 . . . . 74.32 111.103 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . 0.465 ' HA2' ' HA ' ' A' ' 102' ' ' ILE . . . -119.77 108.85 1.54 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.79 -0.719 . . . . 71.34 112.513 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 35.7 ptt180 -100.73 123.23 44.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.909 0.385 . . . . 75.43 110.891 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 34.6 t -103.12 110.27 29.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.174 -0.467 . . . . 74.2 111.136 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 2.8 pp -120.3 156.7 30.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.474 . . . . 74.44 110.903 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 9.4 p90 -160.43 166.04 29.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 74.3 110.855 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -102.24 118.03 36.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 74.3 110.899 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -66.11 93.48 0.21 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.129 -0.487 . . . . 60.32 110.89 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.569 ' HB2' ' HA ' ' A' ' 96' ' ' VAL . 0.0 OUTLIER -74.18 -76.39 0.13 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.243 -0.435 . . . . 72.11 110.934 179.984 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 20.2 m -161.97 121.92 2.5 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.214 -0.448 . . . . 74.24 111.055 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . 0.576 ' HB3' ' HB3' ' A' ' 139' ' ' PHE . 27.0 t0 -108.08 114.56 28.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 73.23 110.789 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -75.78 -12.42 83.88 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.691 -0.766 . . . . 73.32 112.469 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -44.37 -29.36 0.67 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.902 0.382 . . . . 64.41 111.083 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -160.29 163.96 32.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.236 -0.438 . . . . 74.14 110.867 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.8 m -42.17 97.86 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.136 -0.484 . . . . 73.1 110.922 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 70.7 m 49.81 65.16 1.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 70.0 110.908 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.576 ' HB3' ' HB3' ' A' ' 133' ' ' ASP . 1.2 t80 -94.5 160.85 14.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 73.42 110.868 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -139.96 167.19 22.69 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.124 -0.489 . . . . 53.34 110.848 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 15.4 mt -117.36 151.79 19.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.471 . . . . 75.41 111.151 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 12.3 tppt? -113.18 122.62 48.05 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 75.45 110.913 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -76.81 -173.74 2.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.129 -0.487 . . . . 73.45 110.853 179.85 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -171.75 179.09 2.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 75.21 110.931 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 52.1 p-90 -140.06 161.37 37.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.216 -0.447 . . . . 74.3 110.881 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -179.8 165.29 0.87 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.59 0.71 . . . . 65.15 111.135 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 54.5 Cg_endo -69.74 161.92 44.08 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.673 2.248 . . . . 74.42 112.402 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -151.3 146.01 25.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 73.51 111.142 179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -103.07 120.24 40.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 52.12 110.896 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 16.7 tt0 -102.94 156.87 17.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 75.03 110.899 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.3 p -164.85 123.67 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.264 -0.426 . . . . 72.05 111.146 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -174.73 -159.54 21.19 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.717 -0.754 . . . . 51.23 112.47 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 19.5 tp -151.8 164.78 36.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.784 0.325 . . . . 75.14 110.876 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.4 tpp85 -115.78 120.43 39.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 75.44 110.931 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -104.68 154.79 19.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 74.43 110.933 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -120.24 104.18 9.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.116 -0.493 . . . . 75.52 110.824 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 23.6 mt -72.57 153.1 41.45 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 75.24 110.905 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -53.0 -33.44 44.24 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.759 -0.734 . . . . 71.12 112.523 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -71.32 176.18 4.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.819 0.342 . . . . 73.41 110.847 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 73.0 m -60.86 -36.53 79.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.127 -0.488 . . . . 73.24 110.884 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 26.6 m0 -80.92 144.17 32.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 74.01 110.945 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 2.4 mpt? -106.77 169.56 8.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 74.52 110.876 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -107.24 148.78 28.5 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 74.41 110.916 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -143.85 133.28 23.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 75.21 110.857 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 42.1 t -135.41 122.53 21.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 70.22 110.858 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -131.47 153.71 49.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.107 -0.497 . . . . 74.34 110.945 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 78.4 t -133.45 121.49 41.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.27 -0.423 . . . . 74.01 111.089 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 3.9 ttm-85 -103.46 132.41 49.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 70.33 110.876 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -143.01 128.18 18.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 75.4 110.942 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 170' ' ' ILE . . . . . 0.43 HG13 ' HD2' ' A' ' 171' ' ' PRO . 3.6 tp 177.91 133.78 0.22 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.576 0.703 . . . . 75.33 111.118 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . 0.43 ' HD2' HG13 ' A' ' 170' ' ' ILE . 53.5 Cg_endo -69.74 111.6 2.85 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.676 2.251 . . . . 51.12 112.366 179.856 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -122.5 153.16 39.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 73.35 110.909 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 14.5 pttm -130.57 153.58 48.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 74.14 110.854 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -123.28 170.74 9.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.126 -0.488 . . . . 73.52 111.094 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -125.03 164.88 19.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 73.04 110.87 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 5.6 p -156.46 142.63 10.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 73.31 111.117 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 10.0 t -166.62 -179.25 4.76 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.215 -0.448 . . . . 62.34 111.12 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -120.49 -161.1 11.36 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.734 -0.746 . . . . 75.31 112.475 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.285 0 CA-C-O 120.786 0.327 . . . . 74.24 111.178 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.231 0.161 0 CA-C-O 120.828 0.262 . . . . 74.24 112.359 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 21.6 t -127.17 107.2 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.222 -0.445 . . . . 75.32 111.179 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 1.2 p -74.93 104.43 5.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.199 -0.455 . . . . 74.4 110.865 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 12.1 p -131.6 172.06 12.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.105 -0.498 . . . . 73.02 111.155 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.84 162.62 39.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.265 -0.425 . . . . 75.4 110.914 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 56.7 mt -137.85 128.33 37.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 74.21 111.153 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -106.57 113.3 26.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.133 -0.485 . . . . 74.01 110.871 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 1.3 t -136.96 169.59 19.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.087 -0.506 . . . . 74.11 111.088 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -107.27 87.14 2.98 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.61 0.719 . . . . 51.43 110.896 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 121.51 8.19 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.631 2.22 . . . . 72.43 112.395 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -103.12 115.89 31.46 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 73.12 110.881 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 9.7 mt -102.9 124.68 57.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 74.32 111.118 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 1.2 tt -112.71 108.54 17.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 74.31 110.897 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.25 115.68 28.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.257 -0.429 . . . . 71.34 110.818 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 5.7 tt -138.21 121.06 16.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.122 -0.49 . . . . 74.13 110.938 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -175.36 -141.44 3.73 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.825 -0.702 . . . . 64.5 112.538 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -128.51 173.82 9.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.781 0.324 . . . . 74.45 111.104 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 26.2 t -146.55 163.51 35.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.458 . . . . 74.22 110.832 -179.749 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -133.9 114.4 13.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.149 -0.478 . . . . 75.31 110.883 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 57.8 t -76.88 145.11 10.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.091 -0.504 . . . . 72.15 111.108 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 -148.08 137.01 21.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.107 -0.497 . . . . 74.35 110.888 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.081 -0.508 . . . . 75.2 110.898 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.4 mp0 . . . . . 0 C--O 1.23 0.061 0 CA-C-O 120.805 0.335 . . . . 74.05 110.904 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.87 6.45 40.17 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.808 -0.711 . . . . 73.23 112.533 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -67.11 145.45 55.29 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.778 0.323 . . . . 74.13 110.857 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -125.43 121.68 34.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.203 -0.453 . . . . 70.22 110.894 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 13.5 m -130.69 134.91 61.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 65.53 111.145 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -94.24 116.81 29.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 63.33 111.162 179.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 p -105.94 108.21 19.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 65.42 110.796 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -112.11 121.22 44.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.146 -0.479 . . . . 71.25 110.89 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -152.15 172.46 16.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 73.35 110.885 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -95.89 131.97 41.68 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 73.22 110.819 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -101.01 109.92 21.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.111 -0.495 . . . . 64.03 110.882 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 29.4 mmtt -93.9 106.33 18.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.485 . . . . 74.35 110.89 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 21.8 t -79.62 121.08 32.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.259 -0.428 . . . . 74.53 111.128 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 10.5 m-85 -105.64 99.67 9.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 75.22 110.948 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 5.5 p -167.69 141.09 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.123 -0.49 . . . . 74.2 111.16 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.75 72.09 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.753 -0.736 . . . . 54.03 112.44 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 16.6 tt0 -89.93 -66.19 0.95 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.809 0.338 . . . . 75.43 110.85 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 179.4 103.44 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 74.32 110.89 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.422 ' CD2' ' C ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -57.15 167.25 0.91 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.092 -0.504 . . . . 75.03 110.901 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 C-N-CA 120.705 -0.759 . . . . 63.03 112.506 179.881 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.755 0.312 . . . . 71.44 111.164 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -150.43 125.25 9.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.276 -0.42 . . . . 72.32 110.873 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 12.5 p -119.13 134.02 64.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.203 -0.453 . . . . 72.41 111.114 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.9 m -153.45 178.51 9.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 65.54 110.849 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 42.6 pt -134.97 145.88 31.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.094 -0.503 . . . . 72.52 111.173 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -62.33 179.13 4.77 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.768 -0.73 . . . . 62.22 112.518 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.7 m-80 -119.96 107.84 13.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.8 0.333 . . . . 71.23 110.896 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -143.92 148.53 35.51 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 71.4 110.898 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.9 p -61.46 134.26 56.69 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.217 -0.447 . . . . 70.44 111.151 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 15.3 t -143.75 169.68 17.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 64.23 111.133 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -155.9 160.44 40.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 71.24 110.931 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 8.8 p -141.12 142.51 34.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.449 . . . . 73.34 111.162 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -102.44 132.2 48.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 73.35 110.899 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.407 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 1.3 m-20 -129.14 149.91 50.75 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.142 -0.481 . . . . 70.33 110.863 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 8.0 mm -122.39 114.36 42.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.443 . . . . 72.03 111.175 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -101.92 130.06 48.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 72.12 111.086 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 14.9 t80 -118.15 118.35 31.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.233 -0.439 . . . . 74.43 110.936 -179.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -90.52 97.01 10.93 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.156 -0.474 . . . . 72.01 110.897 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.0 p -91.16 -34.91 6.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.206 -0.452 . . . . 75.1 111.129 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.2 t -130.02 159.67 35.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 75.25 110.894 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 93.4 p -84.13 2.76 37.96 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 61.33 110.827 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 41.2 m-80 -112.01 -32.5 6.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 73.34 110.876 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 2.3 pp -149.13 164.78 4.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.474 . . . . 74.44 111.142 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -154.68 169.89 22.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 64.42 111.124 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.1 m -110.97 152.93 12.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.445 . . . . 74.14 111.112 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -148.61 124.27 10.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.465 . . . . 54.32 110.875 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 0.407 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 2.4 t80 -102.72 131.06 49.8 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 64.33 110.917 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -111.65 118.64 36.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.108 -0.496 . . . . 72.43 110.829 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.0 p -142.51 151.79 17.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 63.14 111.116 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -160.05 160.7 31.85 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.732 . . . . 74.11 112.491 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 4.0 p -138.29 77.72 35.08 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.691 0.758 . . . . 74.14 111.129 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 152.26 69.32 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.734 2.289 . . . . 73.35 112.346 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -71.17 -168.38 0.29 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 72.01 111.071 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 19.8 ttp-105 -77.58 127.31 32.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 74.43 110.857 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -133.66 140.69 47.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 61.21 111.118 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -89.58 141.73 28.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.443 . . . . 62.41 110.921 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -132.73 147.43 52.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.237 -0.438 . . . . 75.01 110.858 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.417 ' HA ' HG21 ' A' ' 93' ' ' VAL . 0.4 OUTLIER -92.82 155.52 17.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 65.44 110.877 -179.92 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -179.46 72.79 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.759 -0.734 . . . . 61.34 112.517 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -178.9 -174.15 0.34 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.937 0.399 . . . . 72.35 110.846 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 6.0 mtpt -85.82 -70.17 0.61 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.114 -0.494 . . . . 74.52 110.904 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 74.0 m -84.3 -31.1 25.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.259 -0.428 . . . . 72.11 110.899 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 1.2 mt -68.17 -33.73 62.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.122 -0.49 . . . . 74.45 111.119 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.2 t -62.46 -47.26 84.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 74.32 110.842 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 36.9 t -57.69 -35.37 70.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.183 -0.462 . . . . 75.3 110.833 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 4.2 tp -63.64 -48.33 77.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.474 . . . . 74.1 110.988 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 111.37 -13.33 28.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.716 -0.754 . . . . 70.14 112.474 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -117.79 87.47 2.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.906 0.384 . . . . 73.44 110.911 -179.837 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.417 HG21 ' HA ' ' A' ' 82' ' ' GLN . 32.3 t -113.05 -42.05 4.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.195 -0.457 . . . . 75.15 111.14 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 80.4 p -141.0 152.05 44.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.253 -0.43 . . . . 75.31 110.897 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -141.43 116.98 10.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.141 -0.481 . . . . 72.13 110.92 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 2.6 p -178.23 166.42 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 75.13 111.182 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -95.07 156.48 16.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 72.42 110.855 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -93.98 147.63 22.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.165 -0.471 . . . . 74.01 110.99 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -126.39 60.87 0.64 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.773 -0.727 . . . . 70.52 112.501 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 113.86 3.52 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.644 2.229 . . . . 71.14 112.323 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -131.47 108.53 9.65 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.167 -0.469 . . . . 61.21 111.079 179.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 1.2 pp -140.27 153.06 21.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.481 . . . . 73.3 111.085 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -149.62 130.97 14.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.145 -0.48 . . . . 75.13 110.924 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.2 p -151.34 170.45 19.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 74.31 110.87 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -113.46 147.01 38.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 74.34 110.908 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 34.4 mt-30 -101.7 144.78 29.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.181 -0.463 . . . . 73.54 110.98 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 46.7 p90 -153.73 150.4 28.49 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.244 -0.435 . . . . 71.44 110.967 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 2.2 p80 . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.126 -0.488 . . . . 75.1 110.863 179.937 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 8.1 m-85 . . . . . 0 C--O 1.231 0.097 0 CA-C-O 121.683 0.754 . . . . 75.43 110.919 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 177.38 5.61 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.685 2.257 . . . . 74.54 112.38 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -115.32 152.4 32.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.191 -0.459 . . . . 74.43 110.864 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 61.6 t -111.0 141.13 27.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.102 -0.499 . . . . 60.44 111.186 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -133.39 175.69 20.04 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.775 -0.726 . . . . 73.44 112.546 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.5 p -168.16 151.97 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.944 0.402 . . . . 74.0 111.058 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -179.54 -149.68 8.57 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.714 -0.755 . . . . 73.12 112.517 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 11.3 p -108.01 146.07 14.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.829 0.347 . . . . 73.52 111.168 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -140.99 121.03 1.82 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.806 -0.712 . . . . 61.41 112.51 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 3.1 ptm180 -117.48 128.7 55.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.893 0.378 . . . . 74.54 110.874 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 97.8 t -105.94 109.44 27.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.091 -0.504 . . . . 63.44 111.161 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 41.7 mt -118.22 171.99 7.74 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.125 -0.489 . . . . 73.44 110.896 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -148.41 176.39 10.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 74.02 110.949 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -104.57 171.71 7.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 75.21 110.812 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 16.8 t0 -109.72 96.58 6.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.122 -0.49 . . . . 75.44 110.847 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 2.0 mmmp? -118.1 -81.44 0.62 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.466 . . . . 73.02 110.892 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 98.5 m -162.64 85.24 0.55 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.202 -0.454 . . . . 71.12 111.15 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -99.15 161.67 13.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.221 -0.445 . . . . 72.42 110.885 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.46 154.08 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.705 -0.759 . . . . 71.23 112.489 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -82.51 3.24 29.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.833 0.349 . . . . 70.2 111.149 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -86.83 -176.14 5.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 71.23 110.937 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 23.1 t -65.0 87.0 0.06 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 75.35 110.849 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 65.5 m 51.93 75.37 0.22 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 75.05 110.878 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -91.03 157.11 17.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.481 . . . . 74.21 110.883 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -138.12 -173.9 3.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.107 -0.497 . . . . 74.02 110.878 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.437 ' HA ' ' HA ' ' A' ' 176' ' ' VAL . 5.1 pt -141.0 156.98 22.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.205 -0.452 . . . . 70.23 111.147 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 1.8 tttt -96.02 116.39 28.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.159 -0.473 . . . . 72.43 110.941 179.805 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -63.33 -173.76 0.07 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.241 -0.436 . . . . 71.21 110.866 179.887 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -157.18 169.72 24.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.242 -0.435 . . . . 73.33 110.955 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 28.0 p-90 -156.69 146.71 21.06 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.341 -0.39 . . . . 75.5 110.893 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . 179.95 165.06 0.84 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.549 0.69 . . . . 73.15 111.097 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.82 140.41 42.4 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.677 2.252 . . . . 70.35 112.314 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -135.98 177.82 7.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 74.2 111.096 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -126.63 166.54 17.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.18 -0.464 . . . . 74.44 110.872 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 11.3 tt0 -145.32 155.29 43.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 74.31 110.912 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.1 p -154.92 126.87 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.226 -0.443 . . . . 61.35 111.15 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -177.79 -158.69 21.27 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.677 -0.773 . . . . 75.32 112.43 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 46.7 tp -145.17 157.39 44.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.844 0.354 . . . . 75.04 110.867 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 6.2 tpp85 -120.97 117.71 27.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 75.32 110.85 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 3.0 t80 -95.91 132.21 41.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 74.52 110.928 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -119.23 113.34 20.71 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.162 -0.472 . . . . 71.11 110.879 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 38.8 mt -88.44 163.02 16.16 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.209 -0.451 . . . . 73.01 110.861 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -99.44 126.91 9.08 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.758 -0.734 . . . . 71.0 112.482 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 65.3 m-20 58.78 37.84 24.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.873 0.368 . . . . 75.21 110.916 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 3.1 m -167.18 178.03 5.86 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.167 -0.47 . . . . 72.42 110.869 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 5.3 m-90 -64.12 162.09 14.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 74.01 110.936 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 21.5 mtm -106.64 170.56 7.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.231 -0.44 . . . . 74.51 110.918 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 1.2 tt -124.08 148.81 46.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.246 -0.434 . . . . 72.33 110.904 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -143.94 131.79 21.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 73.31 110.887 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 60.5 p -146.56 122.23 10.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.446 . . . . 75.15 110.807 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -157.69 161.22 38.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.053 -0.521 . . . . 74.21 110.89 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 10.9 t -118.58 130.52 73.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 74.5 111.128 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.04 122.17 45.93 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.169 -0.468 . . . . 72.43 110.866 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 15.3 t80 -108.29 115.56 30.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.184 -0.462 . . . . 73.44 110.927 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 170' ' ' ILE . . . . . . . . . . . . . 9.6 tt -134.45 79.35 54.59 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.558 0.694 . . . . 74.11 111.092 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 125.06 11.72 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.587 2.192 . . . . 75.53 112.364 179.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 11.8 p90 -162.14 177.58 9.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 74.32 110.891 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 10.1 pttp -122.83 137.69 54.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.126 -0.488 . . . . 71.35 110.844 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.49 156.1 18.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 73.11 111.146 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -111.81 161.24 16.55 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.259 -0.428 . . . . 71.52 110.915 179.851 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . 0.437 ' HA ' ' HA ' ' A' ' 141' ' ' ILE . 4.7 t -138.31 133.01 42.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.229 -0.441 . . . . 75.51 111.17 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.7 t -166.36 160.48 15.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 74.03 111.134 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -160.38 -133.48 1.5 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.704 -0.76 . . . . 73.44 112.479 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 52.9 m . . . . . 0 C--N 1.329 -0.303 0 CA-C-O 120.817 0.342 . . . . 63.55 111.089 -179.86 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo . . . . . 0 N--CA 1.465 -0.165 0 CA-C-O 120.854 0.273 . . . . 73.44 112.324 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 82.5 t -96.28 107.74 20.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 74.13 111.129 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -108.66 125.46 51.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 64.12 110.882 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 12.8 p -139.66 174.73 10.21 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.099 -0.501 . . . . 71.22 111.128 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 34.4 ttpt -158.95 145.35 16.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 71.53 110.921 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 8.6 tt -143.15 138.31 26.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 72.11 111.147 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -102.17 119.71 39.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.234 -0.439 . . . . 74.1 110.968 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 4.1 t -136.82 158.25 36.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 73.12 111.168 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -107.73 89.95 5.76 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.624 0.725 . . . . 74.11 110.933 179.857 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 121.62 8.3 Favored 'Trans proline' 0 C--O 1.232 0.211 0 C-N-CA 122.697 2.265 . . . . 75.42 112.296 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -99.76 107.43 19.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.268 -0.424 . . . . 74.23 110.889 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 49.1 mm -87.93 119.39 35.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.138 -0.483 . . . . 74.2 111.148 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 5.4 mp -105.98 108.18 19.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.206 -0.452 . . . . 70.32 110.951 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 9.4 m -98.97 112.03 24.26 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.213 -0.448 . . . . 75.13 110.897 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 1.9 tt -136.72 119.88 16.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 70.31 110.899 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -176.16 -145.55 5.61 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.779 -0.724 . . . . 65.51 112.482 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -125.17 173.83 8.49 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.75 0.31 . . . . 74.4 111.186 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.7 t -148.89 169.77 19.8 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.26 -0.427 . . . . 72.22 110.835 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -138.8 146.01 40.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.131 -0.486 . . . . 72.52 110.878 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 15.6 m -97.91 144.81 10.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.124 -0.489 . . . . 60.24 111.158 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -148.28 139.75 23.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.48 . . . . 74.43 110.812 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.09 -0.504 . . . . 72.11 110.892 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 . . . . . 0 N--CA 1.458 -0.054 0 CA-C-O 120.813 0.34 . . . . 71.04 110.964 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 103.28 11.67 33.2 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.675 -0.774 . . . . 75.2 112.514 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -83.28 159.16 21.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.781 0.324 . . . . 70.54 110.887 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 13.3 m95 -107.36 158.34 17.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.247 -0.433 . . . . 73.54 110.902 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -150.71 120.78 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.281 -0.418 . . . . 72.51 111.133 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -87.77 110.08 20.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 74.41 111.117 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 6.5 t -107.61 113.3 26.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.214 -0.448 . . . . 74.43 110.894 -179.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 17.0 p90 -108.41 122.36 46.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 75.54 110.863 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -152.76 167.93 27.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.138 -0.483 . . . . 64.2 110.92 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -102.01 134.89 44.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 73.11 110.929 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -102.69 122.68 44.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 65.32 110.801 -179.763 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 11.3 tptm -96.59 106.61 18.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.054 -0.521 . . . . 75.24 110.83 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 34.3 m -78.86 134.0 28.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.456 . . . . 73.13 111.201 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 17.0 t80 -130.9 99.74 5.01 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.223 -0.444 . . . . 75.42 110.9 -179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.0 p -165.82 152.86 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.118 -0.492 . . . . 75.34 111.127 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 123.59 77.11 0.35 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.739 -0.743 . . . . 71.34 112.48 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 25.6 pt-20 -90.26 -44.11 9.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.837 0.351 . . . . 75.34 110.85 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER 178.58 170.64 0.81 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 74.52 110.866 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 20.8 tp -74.9 161.58 29.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.131 -0.486 . . . . 74.44 110.876 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.709 -0.757 . . . . 51.13 112.496 179.92 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.123 0 CA-C-O 120.807 0.337 . . . . 74.22 111.071 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -161.2 128.61 4.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.225 -0.443 . . . . 73.23 110.861 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 22.3 m -104.36 167.39 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 64.21 111.15 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -164.76 174.41 10.72 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.13 -0.486 . . . . 74.24 110.804 -179.806 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 7.9 tt -134.04 149.24 30.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.089 -0.505 . . . . 72.32 111.08 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -139.3 85.5 0.22 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.709 -0.758 . . . . 74.41 112.468 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -147.77 152.5 37.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.814 0.34 . . . . 72.54 110.925 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 46.2 m-20 -104.0 178.09 4.66 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.156 -0.474 . . . . 71.12 110.818 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 2.3 t -55.73 150.22 13.09 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 73.42 111.124 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -151.58 162.72 40.5 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.208 -0.451 . . . . 75.23 111.112 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 20.3 mt -108.28 153.49 23.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.169 -0.469 . . . . 75.11 110.978 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -135.56 147.89 48.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.26 -0.427 . . . . 74.11 111.062 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -104.22 131.49 51.48 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.18 -0.464 . . . . 73.45 110.835 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 -126.63 138.29 53.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.19 -0.459 . . . . 74.01 110.85 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.08 113.56 44.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.144 -0.48 . . . . 71.31 111.132 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -106.02 120.39 41.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 74.42 111.161 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 8.1 t80 -105.69 118.53 36.83 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.164 -0.471 . . . . 73.4 110.93 -179.8 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -93.76 96.64 9.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.088 -0.505 . . . . 72.22 110.895 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 57.4 t -91.23 -35.17 6.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.144 -0.48 . . . . 73.44 111.133 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.6 m -131.87 163.42 28.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 74.13 110.894 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 33.4 m -87.49 3.45 47.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 62.33 110.865 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 7.1 m120 -107.77 -33.08 7.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.112 -0.495 . . . . 71.1 110.895 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.8 pt -150.36 169.9 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 64.14 111.142 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -157.12 167.32 30.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.45 . . . . 75.44 111.105 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.412 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 2.7 m -110.54 151.57 12.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.183 -0.462 . . . . 74.33 111.077 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -141.69 137.31 31.65 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.173 -0.467 . . . . 72.23 110.866 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -121.02 110.39 16.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.248 -0.433 . . . . 73.13 110.903 -179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 41.0 t80 -87.27 125.95 34.53 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 75.34 110.908 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 40.4 t -146.42 146.78 18.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.234 -0.439 . . . . 74.5 111.16 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -147.97 178.89 25.26 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.673 -0.775 . . . . 60.34 112.458 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.6 t -144.26 66.0 13.81 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.583 0.706 . . . . 75.33 111.111 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 138.14 37.22 Favored 'Trans proline' 0 C--N 1.34 0.132 0 C-N-CA 122.714 2.276 . . . . 73.52 112.359 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -67.47 -166.81 0.05 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.213 -0.448 . . . . 74.02 111.161 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 23.1 ttp180 -75.77 123.75 26.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.242 -0.436 . . . . 65.52 110.881 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -110.66 150.93 28.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 75.23 111.166 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.22 119.51 38.85 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 71.52 110.891 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -114.31 144.84 42.59 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.213 -0.449 . . . . 74.4 110.858 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 28.3 mt-30 -104.26 153.22 21.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.453 . . . . 74.34 110.979 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -178.84 75.9 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.734 -0.746 . . . . 63.35 112.453 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -177.4 -177.46 0.7 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.899 0.381 . . . . 74.32 110.907 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.17 -68.96 0.7 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.152 -0.476 . . . . 73.03 110.917 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.6 m -84.97 -32.74 22.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.236 -0.438 . . . . 73.11 110.829 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.1 mm -66.52 -34.45 70.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.121 -0.491 . . . . 73.34 111.157 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 28.1 t -63.23 -51.28 66.86 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.177 -0.465 . . . . 73.21 110.831 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 58.5 m -51.46 -36.92 46.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.152 -0.476 . . . . 75.42 110.894 -179.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 35.9 mt -64.71 -42.92 94.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.487 . . . . 74.3 110.88 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.34 -13.98 39.71 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.831 -0.699 . . . . 74.21 112.534 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.1 mtp-105 -115.91 90.09 3.25 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.84 0.352 . . . . 74.25 110.825 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 3.9 t -113.79 -43.94 4.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 72.32 111.108 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.3 m -141.18 144.06 34.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 73.1 110.839 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -138.44 118.22 13.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.172 -0.467 . . . . 64.52 110.954 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 5.3 p -178.14 164.41 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.485 . . . . 71.21 111.151 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.417 ' HB2' ' CE2' ' A' ' 128' ' ' PHE . 0.0 OUTLIER -100.21 173.0 6.82 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.208 -0.451 . . . . 73.11 110.923 179.908 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' TYR . . . . . 0.413 ' HA ' ' HB2' ' A' ' 128' ' ' PHE . 62.1 m-85 -133.16 141.3 48.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 74.52 110.873 -179.804 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -108.99 82.07 0.3 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.799 -0.715 . . . . 72.14 112.493 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 112.22 3.01 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.681 2.254 . . . . 74.35 112.374 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -124.89 94.98 4.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.259 -0.428 . . . . 71.21 111.168 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 12.2 mt -112.35 145.73 18.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 74.15 111.098 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -149.2 109.43 4.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 75.54 110.943 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.3 p -140.62 166.21 25.36 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 73.4 110.911 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.412 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -114.76 140.41 48.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.146 -0.479 . . . . 74.23 110.925 -179.99 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 6.9 pt20 -102.62 145.41 29.69 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 73.22 110.864 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 10.5 p90 -140.42 145.31 36.85 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.144 -0.48 . . . . 74.43 110.879 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 58.0 t60 . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.111 -0.495 . . . . 74.5 110.838 179.922 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 6.4 p90 . . . . . 0 C--O 1.232 0.144 0 CA-C-O 121.628 0.727 . . . . 74.54 111.004 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 178.95 4.04 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.669 2.246 . . . . 74.43 112.335 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -108.82 157.2 18.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 72.42 110.878 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 93.4 t -111.4 134.4 53.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.059 -0.519 . . . . 54.33 111.146 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -135.98 168.93 23.81 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.776 -0.726 . . . . 75.04 112.543 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 10.6 p -162.35 152.15 3.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.876 0.37 . . . . 73.22 111.131 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -176.83 -154.32 11.78 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.689 -0.767 . . . . 74.14 112.502 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . 0.482 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 10.2 p -111.13 139.04 36.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.95 0.405 . . . . 74.12 111.086 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -128.72 115.75 2.08 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.777 -0.725 . . . . 63.11 112.546 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 17.3 ptp180 -122.82 116.59 23.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.852 0.358 . . . . 71.11 110.848 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 3.6 p -117.22 114.48 45.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.182 -0.463 . . . . 73.44 111.043 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -150.55 168.15 25.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 62.33 110.924 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.417 ' CE2' ' HB2' ' A' ' 97' ' ' ASP . 1.0 OUTLIER -164.36 -172.45 2.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 74.34 110.899 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -94.44 129.22 41.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 73.33 110.884 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -67.11 124.39 22.94 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.194 -0.457 . . . . 73.22 110.797 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 20.0 mmmt -102.39 -72.48 0.69 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.159 -0.473 . . . . 73.25 110.9 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -151.63 77.13 1.23 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 74.14 111.152 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -94.1 158.68 15.5 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.467 . . . . 71.54 110.905 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.02 159.71 0.19 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.728 -0.749 . . . . 61.1 112.544 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -78.01 4.93 10.96 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.819 0.342 . . . . 75.01 111.14 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -86.27 -176.68 6.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 75.01 110.956 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.6 t -68.33 85.28 0.27 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.194 -0.457 . . . . 71.45 110.889 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 89.5 p 46.22 74.85 0.13 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 71.14 110.953 -179.729 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -86.29 156.5 20.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.149 -0.478 . . . . 74.33 110.837 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -107.62 175.01 5.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.068 -0.515 . . . . 73.24 110.886 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . 0.424 ' HA ' ' HA ' ' A' ' 176' ' ' VAL . 24.7 pt -152.2 135.64 7.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 75.34 111.106 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.54 116.94 13.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.113 -0.494 . . . . 75.51 110.925 179.861 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -63.63 -158.43 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.452 . . . . 71.03 110.801 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 3.0 tttt -128.99 147.3 50.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 74.44 110.888 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 43.2 p90 -158.6 119.01 3.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.156 -0.474 . . . . 70.02 110.897 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.459 ' CB ' ' HD2' ' A' ' 147' ' ' PRO . . . -179.38 168.46 0.8 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.566 0.698 . . . . 74.45 111.112 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 53.4 Cg_endo -69.78 141.01 44.0 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.661 2.24 . . . . 62.11 112.362 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -135.27 168.15 19.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 71.54 111.102 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -116.79 139.78 50.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.243 -0.435 . . . . 74.41 110.837 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 -116.76 145.75 43.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.104 -0.498 . . . . 74.31 110.919 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.59 127.18 8.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.455 . . . . 74.02 111.133 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 176.9 -179.6 47.77 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.724 -0.75 . . . . 55.22 112.531 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -121.98 158.82 28.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.876 0.369 . . . . 73.31 110.842 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -142.79 128.34 19.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.187 -0.461 . . . . 71.23 110.847 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -145.33 179.5 7.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.483 . . . . 75.12 110.974 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -114.16 90.76 3.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.179 -0.464 . . . . 71.02 110.839 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 24.4 tp -58.99 97.2 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 70.12 110.939 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 66.52 -136.38 34.03 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.716 -0.754 . . . . 70.22 112.495 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 52.2 t30 -119.49 -30.89 4.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.795 0.331 . . . . 72.44 110.886 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 35.7 m -49.4 -67.12 0.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.464 . . . . 64.14 110.833 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 5.3 p90 -147.54 161.87 40.22 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.152 -0.476 . . . . 62.44 110.886 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 78.7 mtp -93.28 172.13 8.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 63.21 110.888 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.533 ' C ' ' CD2' ' A' ' 163' ' ' LEU . 0.0 OUTLIER -136.09 152.08 50.49 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.187 -0.46 . . . . 71.32 111.002 179.972 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -155.49 146.68 22.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.265 -0.425 . . . . 53.22 110.854 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 10.2 t -152.59 122.27 6.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.213 -0.448 . . . . 73.35 110.937 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -145.85 177.27 9.05 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.099 -0.501 . . . . 73.34 110.822 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 16.4 t -147.44 141.34 19.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 75.23 111.135 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.97 141.99 40.27 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.127 -0.488 . . . . 74.31 110.814 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 9.5 t80 -139.86 138.88 36.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.11 -0.495 . . . . 74.34 110.916 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 170' ' ' ILE . . . . . . . . . . . . . 1.9 tp -177.87 110.04 0.22 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.613 0.72 . . . . 75.31 111.069 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.85 124.78 11.38 Favored 'Trans proline' 0 N--CA 1.464 -0.217 0 C-N-CA 122.685 2.256 . . . . 64.54 112.353 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -147.04 177.49 9.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 74.03 110.883 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 22.1 pttm -136.73 137.32 39.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 73.24 110.922 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -99.51 169.55 9.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 64.55 111.149 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -129.87 161.98 29.58 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.257 -0.429 . . . . 64.33 110.891 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . 0.424 ' HA ' ' HA ' ' A' ' 141' ' ' ILE . 99.1 t -144.46 127.22 11.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 73.25 111.111 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 5.0 t -163.7 166.04 22.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 72.4 111.182 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -167.7 -150.38 6.5 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.785 -0.721 . . . . 63.52 112.507 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.7 t . . . . . 0 C--N 1.33 -0.249 0 CA-C-O 120.9 0.381 . . . . 73.32 111.081 -179.845 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.232 0.177 0 CA-C-O 120.808 0.253 . . . . 73.13 112.359 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 57.3 t -96.16 105.34 16.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.275 -0.42 . . . . 73.01 111.063 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -104.78 104.88 14.74 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.173 -0.467 . . . . 74.43 110.843 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 6.1 p -122.33 148.57 44.88 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.132 -0.485 . . . . 73.1 111.107 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.02 155.78 47.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.213 -0.449 . . . . 75.41 110.877 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 6.0 pt -144.01 109.91 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.46 . . . . 72.53 111.135 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -90.44 111.51 22.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 71.43 110.921 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 2.7 t -137.79 162.27 32.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 74.34 111.108 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -107.23 88.5 3.94 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.662 0.744 . . . . 62.01 110.871 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 138.45 37.83 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.708 2.272 . . . . 55.45 112.354 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -122.21 126.63 48.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.242 -0.435 . . . . 74.11 110.904 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 21.4 mt -112.44 120.01 61.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.175 -0.466 . . . . 72.42 111.109 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 9.5 tt -104.53 107.93 19.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.446 . . . . 73.32 110.918 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.1 t -96.49 123.4 40.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.128 -0.487 . . . . 62.21 110.878 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 27.2 tp -146.36 127.3 14.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 74.25 110.92 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -179.79 -150.68 9.29 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.711 -0.757 . . . . 43.41 112.496 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 200' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 163' ' ' LEU . . . -117.8 173.01 6.99 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.852 0.358 . . . . 73.34 111.101 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 2.3 p -149.7 169.48 20.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.466 . . . . 75.55 110.88 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 23.2 t80 -148.93 142.36 25.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 72.3 110.926 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 21.5 m -76.95 161.31 4.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.109 -0.496 . . . . 74.13 111.132 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -161.82 116.55 1.95 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 75.03 110.914 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 5.6 ttmm . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.161 -0.472 . . . . 74.15 110.906 -179.987 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 . . . . . 0 C--O 1.23 0.026 0 CA-C-O 120.801 0.334 . . . . 71.41 110.883 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.85 7.91 21.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.734 -0.746 . . . . 72.54 112.513 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -55.15 166.44 0.55 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.8 0.334 . . . . 71.04 110.865 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 10.9 m-90 -109.54 151.33 26.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.131 -0.486 . . . . 74.3 110.883 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -153.24 115.25 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.245 -0.434 . . . . 75.33 111.17 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.04 140.49 32.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.168 -0.469 . . . . 70.2 111.095 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.7 t -136.6 115.09 11.87 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 64.3 110.836 -179.787 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -123.15 117.11 24.62 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.087 -0.506 . . . . 73.3 110.861 -179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -152.79 169.58 22.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.13 -0.486 . . . . 72.25 110.882 -179.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 21.5 p90 -102.85 135.33 44.72 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.15 -0.477 . . . . 73.22 110.813 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 1.3 p -102.3 137.54 40.42 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.063 -0.517 . . . . 63.25 110.873 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.4 ttmt -112.55 108.08 17.04 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.098 -0.501 . . . . 74.21 110.961 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.6 p -76.74 129.65 37.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.186 -0.461 . . . . 71.53 111.145 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -123.39 113.62 19.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 72.14 110.939 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.8 p -176.78 146.11 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.099 -0.5 . . . . 64.11 111.108 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.47 68.94 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.673 -0.775 . . . . 72.12 112.468 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -90.23 -66.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.751 0.31 . . . . 73.31 110.911 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 -175.98 167.78 2.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 73.23 110.931 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 41.4 tp -101.28 156.16 17.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 75.14 110.927 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.398 0 C-N-CA 120.809 -0.71 . . . . 71.04 112.556 179.93 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.82 0.343 . . . . 64.53 111.068 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -146.41 126.06 13.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.225 -0.443 . . . . 64.43 110.793 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 12.0 p -104.79 138.19 30.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 63.15 111.063 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 m -154.74 177.95 10.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.152 -0.476 . . . . 71.04 110.857 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -137.16 154.3 30.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 73.13 111.134 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -111.69 62.7 0.29 Allowed Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.682 -0.771 . . . . 74.15 112.441 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 32.5 m120 -87.88 162.94 16.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.872 0.368 . . . . 70.21 110.81 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -129.13 163.29 25.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.093 -0.503 . . . . 72.13 110.928 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.5 p -69.14 104.58 2.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 74.35 111.11 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -131.16 168.41 17.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.182 -0.463 . . . . 75.13 111.182 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -91.07 168.77 11.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 65.13 110.939 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.98 147.39 38.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.231 -0.441 . . . . 74.13 111.206 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -101.77 151.2 22.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.27 -0.423 . . . . 74.34 110.866 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -149.81 135.48 18.47 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.169 -0.469 . . . . 55.42 110.902 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -107.7 112.47 40.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 72.34 111.088 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -101.42 129.15 47.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 65.0 111.045 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -117.0 128.47 55.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 75.3 110.916 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -98.25 98.41 9.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.489 . . . . 74.51 110.881 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.9 p -95.88 -34.1 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 70.51 111.108 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 25.1 p -139.6 163.16 33.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.48 . . . . 74.13 110.816 -179.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 12.0 p -87.23 3.24 47.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 72.34 110.849 -179.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 20.1 m120 -106.55 -31.18 8.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.135 -0.484 . . . . 73.5 110.911 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.9 pt -150.43 165.48 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.122 -0.49 . . . . 75.44 111.091 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -146.8 166.9 25.28 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.104 -0.498 . . . . 71.21 111.061 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.1 m -114.78 151.41 16.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.161 -0.472 . . . . 75.03 111.086 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -144.62 132.28 21.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.135 -0.484 . . . . 74.02 110.822 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -108.47 118.04 35.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 64.42 110.882 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -88.3 121.39 30.64 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.145 -0.48 . . . . 75.13 110.853 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 42.1 t -146.88 146.86 18.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.191 -0.459 . . . . 74.1 111.094 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -151.33 162.22 29.45 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.79 -0.719 . . . . 71.34 112.465 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.8 p -115.47 70.64 3.17 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.655 0.741 . . . . 75.41 111.173 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 158.96 55.12 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.651 2.234 . . . . 63.15 112.324 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -104.04 -169.81 1.68 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.247 -0.433 . . . . 63.1 111.145 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 50.4 ttp180 -76.35 126.77 31.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.428 . . . . 74.35 110.856 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -121.62 150.3 41.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 74.42 111.141 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 5.5 tttm -84.16 107.81 16.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.252 -0.431 . . . . 73.51 110.966 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 72.0 t80 -84.43 128.29 34.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 75.51 110.85 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.41 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 41.7 mt-30 -103.38 151.61 22.56 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.129 -0.487 . . . . 75.21 110.899 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 172.68 82.45 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.801 -0.714 . . . . 62.14 112.492 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -176.83 -175.08 0.59 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.879 0.371 . . . . 74.24 110.952 -179.903 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.84 -69.5 0.67 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 74.22 110.916 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.6 t -84.96 -31.61 23.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 75.33 110.913 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 1.1 mt -68.19 -34.23 65.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.11 -0.496 . . . . 74.15 111.143 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.6 t -63.3 -51.11 67.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.174 -0.467 . . . . 62.42 110.851 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.8 t -52.01 -38.87 58.32 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.081 -0.508 . . . . 71.21 110.873 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 13.6 mt -64.85 -35.34 80.81 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.14 -0.482 . . . . 74.44 110.909 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.15 -13.39 67.02 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.686 -0.768 . . . . 73.5 112.47 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 10.4 ptp180 -115.0 94.93 4.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.812 0.339 . . . . 75.34 110.837 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.41 ' HB ' ' HA ' ' A' ' 82' ' ' GLN . 99.9 t -111.66 -57.47 3.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.186 -0.461 . . . . 73.32 111.114 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 18.0 p -140.74 159.21 42.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 74.03 110.848 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -128.85 124.62 35.8 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.101 -0.5 . . . . 74.34 110.863 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 10.4 p -175.53 159.58 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.103 -0.499 . . . . 71.51 111.125 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -106.81 173.11 6.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 71.53 110.926 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' TYR . . . . . 0.469 ' HA ' ' HB2' ' A' ' 128' ' ' PHE . 19.3 m-85 -133.61 144.04 49.01 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.255 -0.429 . . . . 72.54 110.94 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -106.91 87.09 0.49 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.781 -0.724 . . . . 74.03 112.46 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 124.72 11.38 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.697 2.264 . . . . 62.3 112.382 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -141.25 94.73 2.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 72.11 111.109 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.35 153.99 19.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.195 -0.457 . . . . 74.41 111.11 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -153.03 108.57 3.28 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.191 -0.459 . . . . 75.23 110.913 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' SER . . . . . 0.401 ' HB3' ' HA3' ' A' ' 122' ' ' GLY . 23.6 p -134.38 166.4 22.92 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 75.24 110.859 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -119.7 150.89 39.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 74.25 110.943 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -102.02 138.26 39.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.216 -0.447 . . . . 73.53 110.88 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 33.2 p90 -149.48 146.99 27.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 75.43 110.918 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 17.6 p80 . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.077 -0.51 . . . . 74.12 110.847 179.94 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 1.3 p90 . . . . . 0 C--O 1.232 0.15 0 CA-C-O 121.653 0.739 . . . . 74.3 110.935 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.77 177.76 5.27 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.664 2.242 . . . . 74.32 112.353 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -117.46 154.34 31.57 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.235 -0.439 . . . . 73.33 110.958 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 25.2 t -102.78 128.16 55.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.111 -0.495 . . . . 75.04 111.095 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -123.17 169.08 15.37 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.774 -0.726 . . . . 62.22 112.525 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 12.9 p -163.77 149.24 3.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.888 0.375 . . . . 75.41 111.131 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . 0.401 ' HA3' ' HB3' ' A' ' 104' ' ' SER . . . -171.47 -149.21 6.44 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.751 -0.738 . . . . 71.43 112.458 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . 0.52 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 14.9 p -129.4 136.14 60.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.829 0.347 . . . . 74.31 111.146 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -122.35 118.29 3.6 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.75 -0.738 . . . . 71.25 112.446 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -121.47 124.72 45.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.827 0.346 . . . . 74.33 110.939 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 27.2 t -118.15 119.79 62.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.255 -0.43 . . . . 74.0 111.107 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.2 pp -150.99 156.57 41.43 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 73.11 110.888 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.469 ' HB2' ' HA ' ' A' ' 98' ' ' TYR . 0.6 OUTLIER -167.42 -173.42 2.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 71.24 110.907 179.949 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -96.89 142.87 28.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 74.53 110.91 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -78.37 114.58 17.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.451 . . . . 73.31 110.875 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.05 -78.11 0.12 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 71.5 110.91 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 3.4 m -170.67 120.3 0.56 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.25 -0.432 . . . . 72.12 111.123 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -105.63 122.98 47.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.48 . . . . 64.15 110.813 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 135' ' ' ALA . . . -80.63 -22.89 61.17 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.699 -0.762 . . . . 72.24 112.464 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.411 ' C ' ' O ' ' A' ' 134' ' ' GLY . . . -36.95 -42.75 0.42 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.872 0.368 . . . . 54.02 111.164 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -142.44 168.49 19.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 71.14 110.896 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 90.1 p -48.27 96.75 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.18 -0.464 . . . . 65.21 110.811 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 4.4 m 49.48 73.79 0.23 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.088 -0.505 . . . . 63.42 110.815 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -100.06 161.63 13.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.074 -0.512 . . . . 74.14 110.934 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -130.03 165.56 21.94 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.185 -0.462 . . . . 74.2 110.916 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 6.4 tt -103.38 155.25 5.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.249 -0.432 . . . . 74.24 111.113 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 7.2 mmtp -123.33 111.96 17.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 74.52 110.858 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -78.95 -159.84 0.2 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.237 -0.438 . . . . 73.15 110.851 179.79 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -171.14 173.53 4.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 73.41 110.945 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 29.1 p90 -154.75 149.19 26.23 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.219 -0.446 . . . . 73.35 110.864 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . 0.475 ' CB ' ' HD2' ' A' ' 147' ' ' PRO . . . 177.97 169.07 0.51 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.562 0.696 . . . . 71.45 111.086 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' PRO . . . . . 0.52 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 53.6 Cg_endo -69.79 144.0 52.49 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.662 2.241 . . . . 75.54 112.344 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -138.84 167.99 20.79 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 75.11 111.144 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -108.71 161.77 14.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.247 -0.433 . . . . 74.25 110.881 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -140.18 157.18 46.01 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.159 -0.473 . . . . 74.04 110.89 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -154.4 131.03 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 74.42 111.092 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 169.77 -167.61 40.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 71.04 112.521 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.7 pp -152.42 169.13 23.32 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.779 0.323 . . . . 73.22 110.979 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 10.1 tpp85 -120.14 125.0 47.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.179 -0.464 . . . . 74.52 110.92 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -123.63 175.09 7.03 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.285 -0.416 . . . . 72.22 110.93 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -122.1 96.66 5.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.1 -0.5 . . . . 73.02 110.891 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 8.8 tt -102.92 140.26 37.42 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.233 -0.439 . . . . 73.52 110.934 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 59.29 171.63 0.43 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.745 -0.741 . . . . 72.33 112.444 179.824 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 45.4 t30 -93.07 158.57 15.71 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.907 0.384 . . . . 75.11 110.804 -179.824 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 58.7 m 51.18 32.24 7.75 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.18 -0.464 . . . . 60.23 110.843 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -174.68 149.7 1.26 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.143 -0.48 . . . . 72.24 110.91 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 11.9 mmt -121.18 172.77 7.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 73.55 110.928 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 5.0 tp -126.11 139.56 53.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.288 -0.415 . . . . 73.13 110.948 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -139.34 139.72 37.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.446 . . . . 75.23 110.927 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 69.2 p -139.8 121.8 15.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 63.32 110.857 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -141.72 164.55 29.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 62.04 110.869 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 40.1 t -150.16 129.86 3.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.147 -0.479 . . . . 74.11 111.104 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.08 144.92 29.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.136 -0.483 . . . . 74.11 110.832 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -146.02 135.16 22.75 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.184 -0.462 . . . . 72.53 110.966 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 170' ' ' ILE . . . . . . . . . . . . . 4.7 tp 179.9 131.85 0.25 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.594 0.711 . . . . 74.02 111.15 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.8 109.74 2.39 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.752 2.301 . . . . 74.35 112.315 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -116.92 178.11 4.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 74.2 110.922 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.01 133.94 18.04 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.178 -0.464 . . . . 75.41 110.84 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 13.2 t -105.64 154.28 20.65 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.166 -0.47 . . . . 75.41 111.077 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -128.53 161.81 28.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.135 -0.484 . . . . 71.12 110.858 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 20.3 t -146.58 132.42 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 71.3 111.175 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.3 t -165.59 160.25 17.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.183 -0.462 . . . . 73.04 111.145 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -136.3 171.37 22.88 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.751 -0.738 . . . . 74.02 112.454 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 2.1 t . . . . . 0 C--N 1.329 -0.31 0 CA-C-O 120.766 0.317 . . . . 75.54 111.173 -179.913 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo . . . . . 0 C--O 1.231 0.165 0 CA-C-O 120.811 0.255 . . . . 72.51 112.353 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 15.0 t -101.32 139.33 22.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.235 -0.439 . . . . 73.22 111.095 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 43.0 p -121.25 105.03 10.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.162 -0.472 . . . . 60.03 110.907 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 22.1 p -105.06 162.07 13.69 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.162 -0.472 . . . . 64.43 111.152 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -159.32 157.38 30.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 74.31 110.884 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 3.5 pt -154.13 130.43 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 64.21 111.139 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -101.62 118.4 36.86 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 63.31 110.881 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 7.1 p -136.25 160.97 38.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.144 -0.48 . . . . 73.41 111.127 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -106.91 87.82 3.19 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.613 0.721 . . . . 71.34 110.85 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.69 158.85 55.6 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.703 2.268 . . . . 70.42 112.33 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -136.94 120.87 17.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.23 -0.441 . . . . 52.22 110.889 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 45.4 mt -105.62 118.5 53.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.445 . . . . 74.13 111.167 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 3.9 mt -106.73 108.33 19.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.156 -0.474 . . . . 72.11 110.924 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 16.6 p -101.03 134.22 44.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 74.54 110.874 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 22.0 tp -156.49 129.7 8.03 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.109 -0.496 . . . . 74.4 110.909 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 179.83 -145.59 6.56 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.74 -0.743 . . . . 63.23 112.501 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -116.73 174.53 6.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.755 0.312 . . . . 71.24 111.084 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 71.8 m -155.67 164.85 38.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 70.42 110.887 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 9.7 t80 -134.34 122.63 22.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.141 -0.481 . . . . 74.34 110.887 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 19.7 m -76.9 127.96 37.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.087 -0.506 . . . . 74.4 111.136 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -112.46 81.35 1.46 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 74.4 110.924 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 55.3 pttt . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.499 . . . . 74.14 110.838 -179.991 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 . . . . . 0 C--O 1.23 0.077 0 CA-C-O 120.839 0.352 . . . . 73.2 110.926 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.85 5.52 35.69 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.781 -0.723 . . . . 65.14 112.423 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -66.8 150.16 49.53 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.778 0.323 . . . . 55.5 110.867 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 25.9 t90 -116.6 144.18 44.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 74.2 110.882 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 12.9 t -141.6 118.83 7.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.268 -0.424 . . . . 72.14 111.13 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -84.76 101.71 12.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.229 -0.441 . . . . 72.45 111.083 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.4 t -97.93 142.09 30.09 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 75.01 110.866 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 73.6 t80 -146.52 118.89 8.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.164 -0.471 . . . . 74.45 110.856 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -149.77 174.72 12.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.132 -0.486 . . . . 55.53 110.927 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 13.3 t80 -106.52 128.76 54.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.471 . . . . 75.32 110.914 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -94.21 147.56 23.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.171 -0.468 . . . . 75.13 110.856 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 20.7 tttt -127.49 111.42 13.78 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.135 -0.484 . . . . 71.32 110.891 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.1 p -75.63 127.09 37.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 72.0 111.153 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 2.6 t80 -119.46 105.15 10.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.144 -0.48 . . . . 73.2 110.915 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.4 t -78.65 157.76 4.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.083 -0.508 . . . . 64.21 111.154 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.5 -112.6 0.13 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.693 -0.765 . . . . 62.31 112.528 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 66.6 mt-10 -89.86 -67.08 0.87 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.854 0.359 . . . . 70.22 110.942 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -177.11 -173.79 0.48 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.127 -0.488 . . . . 73.24 110.88 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 1.9 mt -85.0 -177.78 6.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 74.52 110.911 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 C-N-CA 120.771 -0.728 . . . . 65.02 112.481 179.911 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.058 0 CA-C-O 120.836 0.35 . . . . 72.04 111.057 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -157.9 126.01 5.4 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 72.41 110.875 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.2 p -104.39 140.71 21.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 65.02 111.152 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -140.48 164.83 29.1 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 73.32 110.828 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 23.2 pt -112.25 157.17 13.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.101 -0.5 . . . . 74.13 111.178 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.07 142.52 31.87 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.772 -0.728 . . . . 41.22 112.506 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -93.38 110.86 22.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.805 0.336 . . . . 71.54 110.858 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 19.9 t0 -174.07 148.83 1.39 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.46 . . . . 72.23 110.857 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 2.0 m -70.73 130.54 41.99 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 72.04 111.148 -179.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.97 177.54 7.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.171 -0.468 . . . . 62.24 111.143 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.1 pp -159.97 165.39 32.11 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.219 -0.446 . . . . 73.14 110.942 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -143.3 143.27 31.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 64.54 111.132 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -103.18 133.29 48.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.221 -0.445 . . . . 74.45 110.897 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -121.39 136.44 54.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.12 -0.491 . . . . 63.43 110.844 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 27.5 mm -108.51 113.39 43.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.161 -0.472 . . . . 74.4 111.067 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -102.78 121.19 41.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 72.34 111.1 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -111.3 115.41 29.28 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.187 -0.461 . . . . 65.51 110.968 -179.835 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -82.54 101.9 11.03 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.108 -0.496 . . . . 73.45 110.83 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.0 t -97.1 -35.37 5.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.135 -0.484 . . . . 64.41 111.106 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 27.8 t -134.07 162.09 33.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.487 . . . . 63.01 110.876 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 59.4 p -84.46 2.85 38.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.171 -0.468 . . . . 73.43 110.83 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -115.0 -32.98 5.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.085 -0.507 . . . . 75.54 110.912 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 21.7 pt -142.35 165.04 17.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.164 -0.471 . . . . 73.14 111.156 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -151.55 167.09 29.15 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.222 -0.445 . . . . 63.13 111.118 179.827 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.5 m -108.01 151.07 10.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 74.34 111.179 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -139.15 132.48 30.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 62.41 110.877 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -115.83 110.02 18.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.15 -0.477 . . . . 70.05 110.85 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 30.9 t80 -91.26 115.94 28.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 75.22 110.888 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.3 t -142.23 156.17 19.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 72.01 111.082 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -163.96 148.68 15.11 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.691 -0.766 . . . . 72.14 112.427 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.7 t -119.65 65.35 9.13 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.637 0.732 . . . . 64.21 111.144 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 163.42 38.33 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.688 2.259 . . . . 72.21 112.349 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -89.42 -169.29 2.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 70.34 111.08 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.5 ttp180 -77.42 132.52 38.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.258 -0.428 . . . . 75.14 110.921 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -133.38 152.84 51.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 71.3 111.048 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 14.6 ttmt -82.12 150.33 27.53 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.172 -0.467 . . . . 72.42 110.938 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -138.77 147.69 42.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 75.32 110.896 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 10.6 mt-30 -113.61 153.31 29.07 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.137 -0.483 . . . . 74.34 110.894 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 174.96 80.86 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.758 . . . . 62.24 112.423 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -178.26 -178.37 0.63 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.92 0.391 . . . . 74.24 110.962 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.0 -69.42 0.67 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.213 -0.448 . . . . 71.53 110.877 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 5.3 m -85.22 -32.41 22.64 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.23 -0.441 . . . . 65.45 110.829 -179.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 4.3 mm -66.83 -34.9 72.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 75.21 111.097 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 15.1 t -63.32 -47.84 80.53 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 73.32 110.864 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.2 p -53.14 -38.64 62.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 72.13 110.844 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -63.47 -43.39 97.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.178 -0.464 . . . . 74.15 110.867 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 109.86 -13.55 32.03 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.747 -0.739 . . . . 72.13 112.498 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 41.6 mtt180 -118.81 93.38 4.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.852 0.358 . . . . 73.24 110.916 -179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 4.0 t -113.57 -35.0 2.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 75.4 111.158 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 19.5 m -156.17 161.29 40.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 64.23 110.779 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 44.7 mt-10 -153.86 115.89 4.29 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.118 -0.492 . . . . 72.14 110.875 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 2.1 m -161.68 179.53 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.148 -0.478 . . . . 75.03 111.089 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -98.28 147.92 24.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 74.23 110.854 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 11.6 m-85 -92.34 139.98 30.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.219 -0.446 . . . . 75.33 110.946 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . 0.402 ' N ' ' CD ' ' A' ' 100' ' ' PRO . . . -127.37 55.07 0.76 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.721 -0.752 . . . . 62.5 112.476 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' A' ' 99' ' ' GLY . 53.6 Cg_endo -69.73 111.69 2.87 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.71 2.273 . . . . 75.2 112.402 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -136.07 110.08 8.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.265 -0.425 . . . . 73.01 111.107 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 11.0 pt -140.82 140.59 33.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.213 -0.449 . . . . 74.43 111.17 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -132.49 120.14 21.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 73.53 110.933 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 2.4 p -142.14 162.86 34.41 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 71.41 110.878 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -109.23 144.6 37.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.146 -0.479 . . . . 72.54 110.876 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 3.0 pm0 -105.38 148.99 26.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.109 -0.496 . . . . 71.11 110.87 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 32.2 p90 -149.33 148.44 29.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 72.2 110.913 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 32.3 t60 . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.087 -0.506 . . . . 74.41 110.849 179.959 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 5.4 p90 . . . . . 0 C--O 1.231 0.106 0 CA-C-O 121.654 0.74 . . . . 73.21 110.893 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 179.09 3.93 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.727 2.284 . . . . 74.24 112.35 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -109.87 164.59 12.44 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.22 -0.445 . . . . 74.33 110.974 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.2 p -117.51 139.0 46.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.169 -0.469 . . . . 75.41 111.096 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -139.95 160.5 26.23 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.713 -0.756 . . . . 74.12 112.499 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 4.9 m -152.75 163.88 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.877 0.37 . . . . 75.11 111.18 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 174.98 -145.99 8.19 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.722 -0.751 . . . . 61.42 112.429 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . 0.432 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 11.8 m -105.5 148.89 9.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.853 0.358 . . . . 64.23 111.192 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -144.25 105.95 0.39 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.697 -0.763 . . . . 72.12 112.467 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 15.7 ptm180 -99.78 125.07 45.63 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.899 0.38 . . . . 71.33 110.903 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . 0.4 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 25.2 t -109.51 114.02 45.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.25 -0.432 . . . . 74.34 111.125 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 2.1 pp -124.24 171.12 10.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.465 . . . . 74.2 110.885 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -141.14 178.55 7.31 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.148 -0.478 . . . . 74.1 110.831 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -118.15 119.82 35.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.115 -0.493 . . . . 73.02 110.918 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -60.45 103.61 0.26 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.125 -0.489 . . . . 71.13 110.892 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 7.9 tppt? -123.69 -71.91 0.7 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.449 . . . . 73.3 110.912 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 23.5 m -166.87 92.68 0.44 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.459 . . . . 74.22 111.136 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -107.73 168.98 8.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.464 . . . . 72.02 110.871 179.879 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 79.28 151.68 6.39 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.748 -0.739 . . . . 73.14 112.481 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -39.38 -66.85 0.26 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.831 0.348 . . . . 74.15 111.09 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -166.64 92.33 0.45 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 71.22 110.852 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' SER . . . . . 0.533 ' O ' ' C ' ' A' ' 138' ' ' SER . 0.4 OUTLIER 169.01 60.78 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 45.13 110.878 -179.947 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' SER . . . . . 0.533 ' C ' ' O ' ' A' ' 137' ' ' SER . 8.7 t 27.21 73.93 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.152 -0.476 . . . . 63.25 110.906 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -107.3 159.15 16.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.144 -0.48 . . . . 73.24 110.854 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -145.19 167.12 23.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.088 -0.506 . . . . 65.03 110.943 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 12.5 tt -116.76 132.5 66.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.209 -0.45 . . . . 62.31 111.131 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.72 106.64 12.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 74.01 110.863 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.4 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 0.6 OUTLIER -82.72 -172.43 4.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 62.41 110.879 179.87 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 5.2 tptt -174.95 -169.73 0.42 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 74.32 110.906 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 66.9 p-90 -144.62 161.01 40.22 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.208 -0.451 . . . . 74.22 110.98 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . 178.02 165.29 0.59 Allowed Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.567 0.698 . . . . 70.54 111.14 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' PRO . . . . . 0.432 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 53.6 Cg_endo -69.74 161.88 44.2 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.705 2.27 . . . . 73.23 112.354 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -153.79 160.11 42.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.249 -0.432 . . . . 63.4 111.064 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -118.91 115.23 23.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.223 -0.444 . . . . 65.25 110.903 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 20.6 tt0 -102.86 164.41 11.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.105 -0.498 . . . . 72.14 110.921 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 14.6 p -160.12 137.17 2.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.153 -0.476 . . . . 74.21 111.052 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 177.55 -162.25 30.02 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.767 -0.73 . . . . 72.31 112.528 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -138.69 160.61 39.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.827 0.346 . . . . 73.43 110.888 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 3.4 tpp85 -132.05 119.74 21.43 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 73.35 110.883 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -105.46 140.96 37.78 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.181 -0.463 . . . . 74.43 110.932 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -120.93 117.55 27.63 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.472 . . . . 73.42 110.864 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 3.9 tp -102.3 164.4 11.7 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 75.34 110.887 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -99.51 53.79 0.99 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.739 -0.744 . . . . 65.53 112.486 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -149.87 35.87 0.69 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.362 . . . . 75.32 110.966 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 51.79 35.4 15.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 72.25 110.8 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 51.2 m95 -154.99 101.43 2.26 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.134 -0.484 . . . . 75.22 110.849 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -97.7 168.25 10.45 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.253 -0.43 . . . . 75.35 110.909 179.855 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 4.0 tp -125.26 144.18 50.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.252 -0.431 . . . . 71.44 110.934 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -142.99 139.98 30.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 70.2 110.84 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 52.8 p -150.95 120.94 7.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 71.13 110.87 -179.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -149.08 171.13 16.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.167 -0.47 . . . . 75.31 110.881 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 4.3 t -144.75 135.96 20.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.171 -0.468 . . . . 72.22 111.076 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -102.67 137.34 41.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 74.45 110.872 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 35.1 t80 -141.79 139.2 32.7 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.201 -0.454 . . . . 73.45 110.887 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 170' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER 178.96 125.93 0.21 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.633 0.73 . . . . 74.35 111.096 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 107.25 1.82 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.649 2.233 . . . . 75.02 112.337 179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -126.94 170.0 12.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 74.42 110.894 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.7 141.4 43.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.114 -0.494 . . . . 75.22 110.875 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.32 169.48 12.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 75.42 111.141 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -126.64 170.45 12.08 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 64.2 110.888 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 7.6 p -160.14 137.1 2.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.45 . . . . 73.11 111.213 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.8 t -166.84 175.6 7.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.245 -0.434 . . . . 72.43 111.169 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -156.95 -140.99 3.07 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.8 -0.714 . . . . 63.1 112.495 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.33 -0.244 0 CA-C-O 120.816 0.341 . . . . 74.22 111.073 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo . . . . . 0 C--O 1.231 0.15 0 CA-C-O 120.837 0.265 . . . . 71.23 112.34 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 48.4 t -108.36 108.82 26.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 71.41 111.106 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 85.5 p -99.22 111.3 23.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.075 -0.512 . . . . 65.3 110.827 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 3.1 p -108.53 163.31 13.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 74.1 111.152 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -146.53 148.06 31.78 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.271 -0.422 . . . . 74.51 110.92 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 3.6 pt -142.36 136.35 28.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.285 -0.416 . . . . 72.53 111.165 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -112.17 104.23 12.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.208 -0.451 . . . . 72.31 110.882 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 4.9 p -136.6 163.18 33.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 75.34 111.156 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -106.71 90.68 5.31 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.63 0.729 . . . . 72.45 110.875 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.73 135.99 31.92 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.698 2.265 . . . . 71.4 112.316 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -103.67 124.94 49.77 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.254 -0.43 . . . . 73.43 110.936 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 26.4 mm -107.45 103.19 15.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.159 -0.473 . . . . 75.12 111.186 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 20.7 tp -91.47 110.55 21.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 74.32 110.88 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 20.5 p -110.35 123.58 50.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 75.22 110.864 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -141.4 132.65 26.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 75.13 110.944 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 179.02 -146.43 7.22 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.823 -0.703 . . . . 75.11 112.544 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -125.52 173.37 8.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.796 0.331 . . . . 72.34 111.168 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -147.53 171.1 16.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.425 . . . . 73.25 110.914 -179.77 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 12.6 m-85 -139.33 133.87 31.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.137 -0.483 . . . . 73.21 110.92 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 11.2 p -79.56 147.64 6.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 72.44 111.167 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -146.67 98.07 3.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.212 -0.449 . . . . 63.15 110.865 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 18.1 mtmt . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.095 -0.502 . . . . 74.4 110.809 -179.953 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 . . . . . 0 CA--C 1.524 -0.045 0 CA-C-O 120.879 0.371 . . . . 74.35 110.926 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 103.88 6.21 43.42 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.762 -0.732 . . . . 70.13 112.513 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -66.93 150.46 49.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.809 0.337 . . . . 73.23 110.815 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 4.5 m0 -111.96 142.05 44.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.152 -0.477 . . . . 74.11 110.939 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 43.2 t -145.04 118.95 2.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.263 -0.426 . . . . 73.11 111.041 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.4 119.96 25.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.098 -0.501 . . . . 64.22 111.031 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 22.0 t -106.65 128.6 54.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 72.4 110.807 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 19.2 t80 -138.19 114.55 10.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.095 -0.502 . . . . 74.41 110.829 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -153.5 174.05 14.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 74.42 110.906 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -102.45 129.01 48.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.455 . . . . 74.11 110.915 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.2 p -98.64 148.04 24.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.129 -0.487 . . . . 72.42 110.839 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 39.2 tptt -129.45 106.84 9.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 72.23 110.854 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.2 m -89.68 124.2 42.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.226 -0.443 . . . . 73.53 111.139 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 28.5 t80 -118.93 104.12 10.22 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.166 -0.47 . . . . 75.33 110.933 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.0 p -157.8 150.45 8.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 73.44 111.189 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 144.77 76.8 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.776 -0.726 . . . . 74.23 112.506 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -89.5 -65.63 1.0 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.758 0.313 . . . . 72.31 110.849 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -169.09 124.76 0.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.447 . . . . 72.11 110.902 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -89.2 152.78 21.41 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.164 -0.471 . . . . 73.21 110.86 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.355 0 C-N-CA 120.726 -0.75 . . . . 63.32 112.459 179.88 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.076 0 CA-C-O 120.784 0.326 . . . . 74.12 111.042 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 17.8 t0 -146.18 126.57 14.02 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 64.33 110.866 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.1 p -105.36 140.56 23.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 73.3 111.135 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -158.8 157.85 32.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.45 . . . . 70.12 110.829 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 9.4 tt -132.4 144.04 38.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.102 -0.499 . . . . 74.45 111.084 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -108.19 97.23 1.1 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.782 -0.723 . . . . 72.01 112.517 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -136.7 119.09 15.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.802 0.334 . . . . 74.1 110.895 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 77.1 m-20 -100.81 -56.5 2.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.206 -0.452 . . . . 74.04 110.914 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 5.1 t -60.78 134.06 56.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.137 -0.483 . . . . 74.33 111.127 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.4 p -120.24 121.29 38.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 74.2 111.151 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -159.9 123.41 3.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.247 -0.433 . . . . 73.33 110.946 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.4 m -137.74 130.76 30.29 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 73.13 111.143 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -102.93 132.53 49.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 72.41 110.874 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -131.93 155.95 47.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.119 -0.491 . . . . 63.34 110.872 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 27.4 mm -126.05 115.16 41.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 75.33 111.153 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -99.9 126.05 45.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 73.14 111.11 179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -116.72 118.26 32.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.272 -0.422 . . . . 74.34 110.968 -179.857 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -88.42 101.0 13.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.145 -0.479 . . . . 63.52 110.856 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 9.0 p -98.01 -35.17 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.114 -0.494 . . . . 75.45 111.144 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 m -136.88 161.31 36.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.138 -0.483 . . . . 75.43 110.871 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.8 m -83.74 2.99 35.25 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.171 -0.468 . . . . 72.44 110.827 -179.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -120.16 -33.57 3.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.474 . . . . 74.43 110.831 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 2.5 pp -136.06 148.12 27.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.242 -0.435 . . . . 74.54 111.143 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -143.73 167.78 21.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.249 -0.432 . . . . 74.02 111.143 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.403 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 4.2 m -114.69 151.21 16.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 74.43 111.134 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -143.89 132.45 22.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.167 -0.469 . . . . 45.34 110.885 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -103.88 142.03 35.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 74.33 110.924 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -121.4 118.57 29.75 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.187 -0.46 . . . . 73.24 110.871 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 44.7 t -147.18 145.75 18.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 74.41 111.114 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -132.96 -30.23 0.49 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.754 -0.736 . . . . 63.15 112.514 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 11.0 m 36.6 62.76 2.97 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.623 0.725 . . . . 73.33 111.124 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 163.57 37.78 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.738 2.292 . . . . 72.1 112.306 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -79.64 -169.82 2.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 74.21 111.037 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.7 ttp180 -77.94 126.43 30.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.472 . . . . 72.42 110.912 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -135.77 151.93 50.61 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 75.33 111.089 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 26.3 ttpp -93.15 143.8 25.9 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 74.51 110.844 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 13.8 p90 -139.39 157.73 45.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 75.31 110.917 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.449 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 5.2 pt20 -106.85 157.2 17.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 75.3 110.93 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 178.4 71.05 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.73 -0.748 . . . . 44.42 112.498 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -168.36 -173.48 1.99 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.926 0.393 . . . . 74.33 110.913 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.33 -71.23 0.55 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 65.23 110.932 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 23.1 t -84.89 -30.35 24.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.255 -0.43 . . . . 63.41 110.835 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 4.7 mm -67.99 -34.26 65.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 74.52 111.13 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 4.0 t -63.02 -44.13 96.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.152 -0.476 . . . . 74.4 110.806 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 73.4 m -55.18 -41.6 72.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.134 -0.485 . . . . 72.3 110.85 -179.821 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -58.86 -49.85 76.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.112 -0.495 . . . . 73.4 110.911 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 116.2 -17.12 14.85 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.829 -0.7 . . . . 70.23 112.534 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 6.8 ttp180 -121.27 95.52 4.72 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.856 0.36 . . . . 74.32 110.864 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.449 ' HB ' ' HA ' ' A' ' 82' ' ' GLN . 93.0 t -104.45 -61.09 2.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.136 -0.483 . . . . 72.2 111.073 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.8 p -139.47 149.52 44.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.437 . . . . 74.01 110.921 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -127.74 129.58 47.32 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.146 -0.479 . . . . 70.42 110.906 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.1 p -173.43 163.27 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 75.51 111.126 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 -92.58 152.61 19.51 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.2 -0.454 . . . . 73.04 110.851 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -103.41 148.94 25.29 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.225 -0.443 . . . . 72.22 110.868 -179.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -139.07 62.23 0.56 Allowed Glycine 0 N--CA 1.453 -0.194 0 C-N-CA 120.751 -0.738 . . . . 65.41 112.547 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 118.43 5.68 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.65 2.233 . . . . 71.41 112.325 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -122.38 102.57 8.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.233 -0.44 . . . . 75.33 111.138 179.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 10.8 mm -117.85 147.73 21.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.243 -0.435 . . . . 61.34 111.152 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -151.49 122.46 7.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 73.5 110.924 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.6 p -147.17 173.63 12.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 72.51 110.867 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.403 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.8 OUTLIER -122.03 153.84 38.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.13 -0.486 . . . . 74.35 110.938 179.99 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 19.9 mm-40 -102.1 137.15 40.75 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.137 -0.483 . . . . 71.45 110.897 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -140.91 133.76 29.01 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.184 -0.462 . . . . 73.55 110.933 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 26.9 t60 . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 64.44 110.879 179.85 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.666 0.746 . . . . 74.44 110.9 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 177.52 5.47 Favored 'Trans proline' 0 N--CA 1.465 -0.197 0 C-N-CA 122.71 2.273 . . . . 75.33 112.362 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 14.0 m-85 -117.22 157.78 25.43 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.454 . . . . 72.52 110.932 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 12.5 p -107.24 132.01 55.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.084 -0.507 . . . . 75.1 111.118 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -121.5 161.23 15.65 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.769 -0.729 . . . . 70.23 112.519 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 12.3 p -161.1 150.16 5.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.8 0.333 . . . . 71.22 111.08 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -174.01 -155.37 11.89 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.68 -0.771 . . . . 71.02 112.489 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . 0.44 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 28.9 m -113.75 134.04 57.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.803 0.335 . . . . 74.15 111.168 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -117.27 105.91 1.35 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.734 -0.746 . . . . 64.2 112.531 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 28.5 ptt180 -99.45 112.44 24.64 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.901 0.381 . . . . 74.4 110.866 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 20.0 t -87.24 110.04 20.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.26 -0.427 . . . . 64.12 111.147 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -101.03 135.98 41.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 72.52 110.878 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -135.73 148.26 48.76 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.148 -0.478 . . . . 71.23 110.845 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -100.75 172.75 6.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.101 -0.5 . . . . 70.43 110.859 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -113.53 94.87 5.06 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.178 -0.464 . . . . 75.23 110.9 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 2.6 mmmt -92.62 -86.6 0.24 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.206 -0.452 . . . . 75.43 110.95 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -168.23 111.82 0.61 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.293 -0.412 . . . . 72.34 111.182 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . 0.505 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 49.8 m-20 -101.1 112.76 25.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.429 . . . . 75.34 110.829 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -74.91 -9.87 83.61 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.738 -0.744 . . . . 64.31 112.452 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -45.4 -28.89 0.95 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.721 0.296 . . . . 73.31 111.05 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.2 mt -160.28 179.67 8.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.264 -0.425 . . . . 73.41 110.89 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 9.9 m -53.32 92.36 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.172 -0.467 . . . . 73.22 110.848 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 6.9 m 51.38 73.6 0.3 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.092 -0.503 . . . . 72.41 110.868 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.505 ' HB3' ' HB2' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -94.32 158.55 15.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 74.4 110.892 -179.959 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -135.89 167.64 20.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.461 . . . . 75.21 110.822 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 12.3 tt -112.98 151.04 14.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.12 -0.491 . . . . 75.33 111.13 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 6.0 tppt? -119.51 112.06 18.89 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 73.31 110.896 179.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.41 -173.34 0.29 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.25 -0.432 . . . . 74.02 110.875 179.845 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -170.6 165.2 8.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 75.51 110.882 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 49.2 p90 -132.47 154.48 49.85 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 75.44 110.927 179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -178.5 164.28 1.13 Allowed Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.574 0.702 . . . . 74.31 111.11 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' PRO . . . . . 0.44 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 53.5 Cg_endo -69.71 169.49 18.73 Favored 'Trans proline' 0 N--CA 1.466 -0.144 0 C-N-CA 122.717 2.278 . . . . 72.24 112.376 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -165.37 153.54 11.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.246 -0.434 . . . . 74.11 111.086 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 6.7 p90 -122.03 139.11 54.1 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.218 -0.446 . . . . 75.42 110.857 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -130.75 174.52 9.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.125 -0.489 . . . . 75.41 110.988 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 10.8 p -158.91 147.12 7.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 64.32 111.093 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 170.97 -158.77 30.51 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.777 -0.725 . . . . 61.35 112.58 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.6 pt? -158.22 168.02 28.19 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.768 0.318 . . . . 75.24 110.928 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.6 tpp85 -117.93 120.64 38.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 74.2 110.954 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.8 t80 -115.37 169.64 8.99 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.245 -0.434 . . . . 74.42 110.949 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -121.86 99.66 6.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.147 -0.478 . . . . 71.35 110.924 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 5.9 tt -102.31 103.7 14.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 74.31 110.87 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 94.37 -160.71 23.84 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.792 -0.718 . . . . 65.41 112.51 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 6.3 p30 -118.7 -36.56 3.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.854 0.359 . . . . 65.25 110.928 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 3.7 p -66.39 -56.04 12.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.113 -0.494 . . . . 73.11 110.866 -179.877 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 12.3 p90 -124.91 172.69 9.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.179 -0.464 . . . . 74.53 110.951 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 5.5 ptp -121.84 177.47 5.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.269 -0.423 . . . . 71.14 110.903 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 8.7 tp -111.94 146.2 38.23 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.21 -0.45 . . . . 72.24 110.915 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -144.44 133.51 22.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 64.4 110.9 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 19.6 t -130.89 125.93 34.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.13 -0.487 . . . . 71.12 110.842 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 26.7 m-20 -150.33 142.16 23.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.093 -0.503 . . . . 72.53 110.87 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 40.6 t -139.59 122.62 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 70.42 111.148 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.49 159.99 14.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.236 -0.438 . . . . 74.3 110.804 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 169' ' ' TYR . . . . . 0.406 ' O ' ' HB ' ' A' ' 170' ' ' ILE . 26.3 t80 -164.56 140.99 6.12 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.159 -0.473 . . . . 73.45 110.919 -179.849 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 170' ' ' ILE . . . . . 0.427 HG12 ' O ' ' A' ' 147' ' ' PRO . 5.9 tp 177.86 133.15 0.22 Allowed Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.656 0.741 . . . . 74.54 111.109 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . 0.42 ' HD2' HG13 ' A' ' 170' ' ' ILE . 53.5 Cg_endo -69.69 104.37 1.3 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.716 2.277 . . . . 73.21 112.304 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -121.78 154.25 37.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.257 -0.429 . . . . 74.23 110.858 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 9.6 ptpp? -122.86 146.69 47.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 70.32 110.884 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 11.1 t -116.91 166.0 12.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.211 -0.45 . . . . 72.2 111.185 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -122.8 158.19 30.76 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.26 -0.427 . . . . 71.52 110.858 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 43.9 t -150.26 132.48 5.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 75.45 111.152 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 13.6 t -168.43 176.78 5.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.205 -0.452 . . . . 73.42 111.104 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 131.99 150.39 6.56 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.725 -0.75 . . . . 73.2 112.525 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 6.1 t . . . . . 0 C--N 1.329 -0.284 0 CA-C-O 120.843 0.354 . . . . 74.04 111.161 -179.853 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo . . . . . 0 C--O 1.232 0.185 0 CA-C-O 120.785 0.244 . . . . 73.12 112.344 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 68.0 t -103.61 111.44 33.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 75.35 111.098 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 3.9 p -84.57 135.02 34.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.094 -0.503 . . . . 64.14 110.893 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 40.4 p -145.48 167.75 22.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 63.22 111.097 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -158.99 157.31 31.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.451 . . . . 73.02 110.887 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 36.8 mm -146.66 125.6 4.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.193 -0.458 . . . . 74.5 111.13 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -102.31 114.6 28.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.18 -0.464 . . . . 75.01 110.864 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 2.5 t -136.53 164.32 31.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.126 -0.488 . . . . 73.34 111.1 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -107.23 87.59 3.27 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.651 0.739 . . . . 73.34 110.856 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.93 133.58 25.59 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.722 2.282 . . . . 74.33 112.249 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 23.4 m-85 -100.68 119.33 38.42 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.161 -0.472 . . . . 73.42 110.83 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 53.4 mt -105.57 110.18 30.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.124 -0.489 . . . . 73.55 111.156 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 2.6 tp -110.54 108.84 18.95 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.199 -0.455 . . . . 75.55 110.974 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -110.55 129.27 55.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.231 -0.441 . . . . 74.34 110.901 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 3.1 mp -150.51 134.45 16.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.115 -0.493 . . . . 75.34 110.937 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 178.94 -136.95 3.02 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.686 -0.768 . . . . 54.3 112.467 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -125.02 173.33 8.75 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.835 0.35 . . . . 74.14 111.041 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 29.5 m -149.09 171.0 17.13 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.16 -0.473 . . . . 65.11 110.841 -179.755 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 40.5 t80 -142.24 145.45 34.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.501 . . . . 75.41 110.86 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 33.6 m -93.28 156.83 3.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.04 -0.527 . . . . 72.52 111.108 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -159.72 110.8 1.98 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.127 -0.488 . . . . 75.54 110.911 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 37.1 mtmt . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 74.32 110.914 179.982 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.2 ttm . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.82 0.343 . . . . 75.43 110.901 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 17.7 p30 -86.97 160.46 18.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.236 -0.438 . . . . 71.33 110.912 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -112.45 133.4 54.55 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.149 -0.478 . . . . 71.33 110.89 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 64.3 m-20 -156.91 154.47 29.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 74.5 110.904 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 13.7 m-85 52.32 68.66 2.94 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.677 0.751 . . . . 72.04 110.929 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 166.31 27.99 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.723 2.282 . . . . 73.34 112.359 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.77 154.98 37.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 55.02 111.098 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 23.8 pttm -75.86 151.36 37.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.459 . . . . 73.13 110.896 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 9.9 t -119.96 127.99 53.16 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.424 . . . . 73.15 110.889 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -134.2 103.5 5.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.142 -0.481 . . . . 73.25 111.077 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -125.49 -37.09 0.53 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.737 -0.745 . . . . 70.43 112.523 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.1 p90 -147.44 114.45 6.16 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.897 0.379 . . . . 74.15 110.93 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 18.8 t-20 -141.53 147.89 38.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.096 -0.502 . . . . 75.13 110.897 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 34.5 tt0 -53.72 120.02 5.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.455 . . . . 74.24 110.918 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.66 5.48 36.24 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.754 -0.736 . . . . 72.3 112.549 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -68.79 150.27 48.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.772 0.32 . . . . 64.23 110.853 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 13.3 t90 -126.25 121.27 32.2 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.216 -0.447 . . . . 74.53 110.904 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 6.1 p -132.19 122.69 49.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.248 -0.433 . . . . 74.33 111.162 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -87.03 116.65 25.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 72.23 111.102 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -104.7 109.82 21.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 72.5 110.929 -179.815 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 15.0 p90 -107.69 119.88 40.68 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.186 -0.461 . . . . 74.15 110.879 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 2.5 p30 -149.6 161.53 41.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.134 -0.484 . . . . 62.11 110.858 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -86.49 128.47 34.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 73.33 110.879 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 18.1 p -102.11 116.26 32.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.162 -0.472 . . . . 74.22 110.895 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 16.3 mtpp -98.92 106.16 18.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.151 -0.477 . . . . 75.41 110.935 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.3 p -83.36 139.43 17.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 71.31 111.117 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 21.3 t80 -130.82 101.79 5.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.465 . . . . 74.21 110.922 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.1 p -162.26 155.02 2.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.096 -0.502 . . . . 75.41 111.099 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 119.63 72.17 0.36 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.683 -0.77 . . . . 74.34 112.476 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 -89.43 -57.97 2.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.768 0.318 . . . . 63.34 110.863 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -174.48 135.1 0.41 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.165 -0.471 . . . . 75.23 110.898 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 12.7 mt -52.0 165.64 0.2 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 72.53 110.917 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.33 80.74 0.3 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.713 -0.756 . . . . 73.53 112.485 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 28.4 t0 -79.02 129.37 34.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.879 0.371 . . . . 74.52 110.897 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 18.1 tp -79.9 -56.32 4.34 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 63.33 110.908 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 18.8 t30 -151.31 169.14 22.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 73.42 110.833 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 11.6 p -157.0 142.71 9.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.151 -0.477 . . . . 53.44 111.124 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -53.05 -33.2 44.08 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.704 -0.76 . . . . 71.42 112.511 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -53.08 -34.41 46.76 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.746 -0.74 . . . . 73.25 112.476 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 108.33 -49.36 0.86 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.728 -0.749 . . . . 74.32 112.479 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -65.67 164.26 14.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.78 0.324 . . . . 74.22 111.129 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -130.02 67.98 80.31 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.622 0.725 . . . . 73.41 110.946 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 -177.4 1.84 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.693 2.262 . . . . 73.44 112.36 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -128.0 139.97 52.25 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.223 -0.444 . . . . 71.41 110.884 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -106.4 -179.27 3.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.15 -0.477 . . . . 61.24 111.069 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -149.45 132.99 16.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 62.13 110.878 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 30.1 m -104.72 154.01 6.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 75.23 111.162 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 10.3 t -151.99 146.1 25.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 72.15 110.862 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -119.43 150.45 21.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.078 -0.51 . . . . 72.25 111.115 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.77 135.2 14.73 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.742 -0.742 . . . . 73.42 112.487 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 60.5 m-20 -87.57 112.95 22.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.359 . . . . 72.52 110.892 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 33.5 t0 -154.38 165.86 35.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.165 -0.47 . . . . 74.35 110.887 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 34.4 p -64.69 148.03 51.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 75.02 111.129 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 8.4 t -158.84 139.92 12.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 75.24 111.13 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -124.81 159.77 30.25 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 75.11 110.898 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 55.8 m -139.08 147.53 42.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.179 -0.464 . . . . 70.43 111.113 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 86.6 m-85 -124.18 132.62 53.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 74.13 110.881 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -134.23 149.3 50.96 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.129 -0.487 . . . . 74.5 110.872 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 10.4 mm -108.28 115.75 49.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.186 -0.461 . . . . 62.11 111.144 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -101.13 125.99 47.8 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.188 -0.46 . . . . 52.34 111.123 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -108.89 117.79 35.12 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.222 -0.444 . . . . 74.13 110.919 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -89.2 105.99 18.15 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.091 -0.504 . . . . 75.25 110.853 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.1 m -103.88 -34.25 3.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 64.33 111.129 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.7 t -135.87 160.12 39.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.224 -0.443 . . . . 75.31 110.884 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 5.7 p -84.56 2.99 38.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.147 -0.478 . . . . 74.42 110.828 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -111.6 -30.84 7.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 73.54 110.876 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 2.6 pp -147.3 165.61 6.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 64.44 111.106 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -154.36 172.84 17.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.472 . . . . 72.41 111.134 179.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.412 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 1.2 p -116.47 147.89 19.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.245 -0.434 . . . . 74.22 111.119 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -142.57 134.66 27.33 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.173 -0.467 . . . . 74.34 110.835 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -119.73 110.96 17.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.454 . . . . 71.23 110.867 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -85.05 131.18 34.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.481 . . . . 75.14 110.859 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 5.6 m -151.34 163.54 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 75.45 111.103 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -171.16 145.57 8.99 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.721 -0.752 . . . . 60.22 112.49 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 7.6 p -117.07 67.44 4.34 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.596 0.712 . . . . 75.53 111.133 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 162.57 41.57 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.686 2.257 . . . . 74.43 112.351 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -84.81 -173.14 4.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 70.23 111.123 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -78.43 131.14 36.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.444 . . . . 73.41 110.866 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -126.26 151.74 47.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.468 . . . . 74.12 111.1 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 15.4 ttpt -114.72 126.32 54.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 75.34 110.892 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 15.7 p90 -126.42 158.84 34.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 75.23 110.89 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 29.6 mt-30 -92.61 157.66 16.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 74.34 110.92 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -176.05 68.76 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.735 -0.745 . . . . 72.23 112.458 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -176.44 -176.59 0.77 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.915 0.388 . . . . 74.54 110.915 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -85.55 -69.41 0.66 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 75.13 110.932 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.4 t -83.31 -34.61 25.66 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.284 -0.416 . . . . 75.11 110.892 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 6.1 mm -64.62 -33.79 65.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.09 -0.504 . . . . 72.42 111.116 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 5.3 t -60.17 -46.79 88.5 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 74.41 110.87 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 22.8 t -56.18 -37.38 69.52 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.124 -0.489 . . . . 74.21 110.839 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.63 -48.64 79.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.112 -0.494 . . . . 74.25 110.904 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 111.73 -13.8 27.18 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.704 -0.76 . . . . 72.42 112.471 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 43.7 mtp180 -118.24 92.74 3.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.887 0.375 . . . . 74.25 110.856 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 90.1 t -113.93 -55.33 4.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 55.35 111.107 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.88 143.81 38.89 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.194 -0.457 . . . . 63.31 110.851 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 11.8 tt0 -147.52 117.87 7.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 71.13 110.891 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 18.8 m -155.75 -176.83 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 73.44 111.14 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -97.29 152.08 19.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 74.31 110.896 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -92.57 135.26 34.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 73.14 110.936 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -128.3 63.29 0.62 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.71 -0.757 . . . . 63.41 112.441 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 112.38 3.06 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.709 2.272 . . . . 74.41 112.362 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -128.36 99.49 5.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 71.04 111.145 179.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 4.9 mt -124.31 144.58 33.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 71.53 111.142 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -147.31 109.73 4.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.177 -0.465 . . . . 75.1 110.878 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 3.6 p -144.5 160.39 41.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.221 -0.445 . . . . 71.01 110.832 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.412 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 4.6 pp -106.19 150.21 26.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.125 -0.489 . . . . 74.41 110.962 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 7.9 pm0 -101.41 141.74 33.84 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.191 -0.459 . . . . 75.52 110.907 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 27.9 p90 -144.45 144.56 31.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 73.42 110.927 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 16.1 m80 -79.74 161.05 25.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.097 -0.502 . . . . 74.42 110.872 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 10.6 p90 -154.52 151.15 28.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 74.43 110.923 -179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 13.3 t0 -52.36 144.35 13.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 63.0 110.882 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.9 p -154.37 156.67 37.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.456 . . . . 74.21 110.831 -179.723 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -122.02 -38.85 2.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.142 -0.481 . . . . 72.14 110.901 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 7.7 tt0 -51.84 169.15 0.07 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.129 -0.487 . . . . 74.24 110.876 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 60.0 mtm180 -51.91 -74.08 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 73.34 110.871 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 10.5 mt -64.88 137.25 57.65 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.212 -0.449 . . . . 72.14 110.949 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 8.7 p90 -118.36 68.11 7.32 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-O 121.642 0.734 . . . . 74.42 110.936 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 176.27 7.0 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.723 2.282 . . . . 75.12 112.354 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 12.7 p90 -115.97 159.47 21.56 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.207 -0.451 . . . . 73.54 110.925 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 60.2 t -123.4 135.33 63.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.126 -0.488 . . . . 73.44 111.107 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -124.08 176.86 16.85 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.72 -0.752 . . . . 73.31 112.491 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.8 p -166.03 152.48 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-O 120.817 0.342 . . . . 70.14 111.167 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 179.12 -153.14 11.9 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.722 -0.752 . . . . 62.45 112.444 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . 0.414 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 13.5 m -106.91 120.45 58.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.826 0.346 . . . . 72.33 111.125 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -114.77 111.01 2.44 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.688 -0.768 . . . . 71.34 112.433 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 8.1 ptp180 -109.31 131.87 54.66 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.805 0.336 . . . . 74.41 110.878 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 3.5 p -117.53 115.92 50.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 75.32 111.107 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 2.6 pp -127.49 170.89 12.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.192 -0.458 . . . . 75.31 110.91 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -140.58 174.69 10.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 73.54 110.914 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -102.8 125.25 49.47 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.131 -0.486 . . . . 64.12 110.923 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -61.15 95.65 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.162 -0.472 . . . . 75.24 110.856 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.1 -78.01 0.57 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.161 -0.472 . . . . 64.05 110.894 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 86.1 m -161.95 83.72 0.58 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 72.15 111.134 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -101.98 170.0 8.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.21 -0.45 . . . . 74.15 110.881 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.29 151.65 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.711 -0.757 . . . . 65.41 112.502 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -79.73 -0.03 32.53 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.827 0.346 . . . . 63.21 111.101 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -86.23 -178.08 6.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 75.12 110.942 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.7 m -65.73 91.64 0.14 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.186 -0.461 . . . . 73.42 110.894 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.2 t 51.87 75.41 0.21 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.108 -0.496 . . . . 70.53 110.872 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -88.92 149.04 23.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.1 -0.5 . . . . 71.21 110.838 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 14.0 t0 -109.96 164.7 12.35 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.127 -0.488 . . . . 74.44 110.902 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 63.8 mt -128.47 125.92 64.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 74.14 111.085 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.04 109.24 9.52 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.172 -0.467 . . . . 71.04 110.913 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -58.68 -173.62 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.207 -0.451 . . . . 72.51 110.857 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 11.2 mmtm -148.55 166.02 29.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.456 . . . . 72.04 110.89 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 42.6 p-90 -157.75 136.32 11.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 74.33 110.921 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.411 ' CB ' ' HD2' ' A' ' 147' ' ' PRO . . . -172.49 166.02 3.52 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.578 0.704 . . . . 63.54 111.129 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . 0.414 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 53.5 Cg_endo -69.79 135.35 30.17 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.711 2.274 . . . . 62.42 112.318 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -122.48 165.62 16.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 64.33 111.129 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 23.7 m-85 -122.3 136.32 54.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.214 -0.448 . . . . 74.2 110.89 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 3.7 mm100 -107.16 151.8 24.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.159 -0.473 . . . . 72.4 110.921 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 5.4 p -152.04 117.85 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.207 -0.451 . . . . 74.52 111.181 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . 0.413 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 176.93 -161.63 29.5 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.739 -0.743 . . . . 64.34 112.467 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -136.99 155.9 49.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.769 0.318 . . . . 73.21 110.918 -179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -139.93 124.16 17.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 75.3 110.872 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 26.3 p90 -144.42 177.45 8.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.461 . . . . 74.25 110.896 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -118.92 100.18 7.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.082 -0.508 . . . . 73.5 110.895 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 18.7 tp -102.03 106.24 17.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.142 -0.481 . . . . 73.0 110.956 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 103.34 -173.76 22.42 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.726 -0.749 . . . . 73.23 112.47 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 9.3 p-10 -101.53 132.26 47.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.861 0.363 . . . . 75.14 110.913 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.6 t 53.01 41.33 32.16 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.139 -0.482 . . . . 74.22 110.921 -179.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 2.3 t90 -171.97 100.49 0.17 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.096 -0.502 . . . . 64.54 110.92 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 13.6 mtm -95.42 173.85 7.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.258 -0.428 . . . . 72.24 110.914 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 2.1 tt -127.69 145.1 51.0 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.271 -0.422 . . . . 74.2 110.911 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 -145.8 138.07 25.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 74.32 110.919 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 13.0 p -153.26 121.75 6.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 64.42 110.89 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . 0.413 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 1.3 p30 -154.03 -179.79 8.2 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.166 -0.47 . . . . 63.43 110.856 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 8.2 t -138.48 143.79 31.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 73.2 111.113 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 4.4 ttt180 -113.78 123.34 49.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.158 -0.474 . . . . 74.45 110.856 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 13.2 t80 -121.99 138.97 54.22 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.186 -0.461 . . . . 75.41 110.94 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' ILE . . . . . . . . . . . . . 6.4 tt -177.35 93.91 0.23 Allowed Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.631 0.729 . . . . 73.23 111.171 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.66 134.19 27.59 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.707 2.271 . . . . 72.34 112.379 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -156.89 177.84 11.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.252 -0.431 . . . . 74.53 110.878 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . 0.41 ' HA ' ' HA ' ' A' ' 190' ' ' GLU . 11.3 pttp -128.28 125.32 38.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.126 -0.488 . . . . 74.45 110.859 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -91.94 161.74 14.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 75.55 111.146 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -119.14 165.55 14.05 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.431 . . . . 74.32 110.874 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 21.4 t -146.53 133.13 13.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 72.44 111.171 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 14.0 t -166.53 176.9 6.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 75.2 111.104 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 122.18 141.33 6.0 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.752 -0.737 . . . . 63.22 112.495 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.3 m -173.0 140.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.834 0.35 . . . . 72.51 111.147 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 32.4 tp -102.97 89.23 3.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.214 -0.448 . . . . 74.55 110.946 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 126.1 -87.3 0.35 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.75 -0.738 . . . . 71.41 112.485 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 -170.57 0.4 Allowed 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.704 2.269 . . . . 73.23 112.306 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 29.9 m -83.34 126.84 70.75 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-O 121.605 0.717 . . . . 72.45 111.117 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 165.85 29.59 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.708 2.272 . . . . 71.44 112.325 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 85.3 t -109.41 107.69 23.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.274 -0.421 . . . . 62.45 111.115 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 6.7 p -83.69 110.57 18.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.151 -0.477 . . . . 75.05 110.882 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 11.9 p -121.93 171.5 8.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 73.1 111.15 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 29.9 ttpt -153.52 148.08 26.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.208 -0.451 . . . . 65.41 110.922 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 5.9 tp -142.74 124.06 11.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 75.42 111.098 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 190' ' ' GLU . . . . . 0.41 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 19.5 pt-20 -96.94 116.9 30.0 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 75.22 110.863 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 4.1 m -138.36 158.79 31.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 75.13 111.108 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -107.85 89.85 5.79 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.581 0.705 . . . . 75.31 110.875 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 138.46 37.78 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.721 2.281 . . . . 75.11 112.358 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 12.9 m-85 -124.68 116.66 22.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 72.45 110.865 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 45.3 mt -106.44 131.28 56.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.199 -0.455 . . . . 75.22 111.109 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 7.4 tp -117.74 112.33 20.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 74.31 110.889 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -97.87 124.59 42.35 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.145 -0.48 . . . . 72.21 110.855 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -144.64 119.59 9.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.133 -0.485 . . . . 74.15 110.906 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -177.91 -145.83 6.1 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.759 -0.734 . . . . 64.33 112.467 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -127.19 173.8 9.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.803 0.335 . . . . 70.31 111.083 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -140.13 175.82 9.27 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 71.12 110.85 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 16.2 t80 -146.55 115.65 6.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.095 -0.502 . . . . 70.02 110.915 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 15.0 p -77.12 147.66 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.103 -0.499 . . . . 71.01 111.159 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -152.9 143.14 22.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 72.03 110.867 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 12.9 ptmt -104.83 140.29 38.33 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.142 -0.481 . . . . 75.5 110.894 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -53.05 151.52 4.76 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.24 -0.436 . . . . 73.53 110.917 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -85.03 -43.0 14.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 71.12 111.075 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -54.99 125.53 20.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.239 -0.437 . . . . 74.14 111.108 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -99.91 136.38 39.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.237 -0.438 . . . . 74.33 111.066 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -107.55 155.96 19.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.176 -0.465 . . . . 74.22 110.909 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.236 -0.438 . . . . 74.35 110.895 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.1 mmm . . . . . 0 N--CA 1.458 -0.073 0 CA-C-O 120.804 0.335 . . . . 73.24 110.952 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 56.6 m-20 -106.77 55.84 0.66 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 74.14 110.839 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 22.4 mt-10 -144.94 55.97 1.25 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 64.42 110.869 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -143.31 145.3 32.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.139 -0.482 . . . . 73.23 110.801 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 2.2 p90 -141.58 157.6 65.0 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.655 0.74 . . . . 75.13 110.927 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 140.12 41.74 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.622 2.215 . . . . 62.13 112.384 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -115.49 116.96 29.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.199 -0.455 . . . . 70.55 111.057 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 11.2 ptpt -105.61 155.9 18.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.124 -0.489 . . . . 74.41 110.87 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 11.3 m -155.51 148.15 24.11 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.207 -0.451 . . . . 73.33 110.827 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -147.23 159.71 43.32 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.091 -0.504 . . . . 73.13 111.08 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -51.91 -34.87 38.73 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.748 -0.739 . . . . 34.1 112.48 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.2 p90 -157.96 114.35 2.84 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.824 0.345 . . . . 74.33 110.917 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -122.88 167.24 13.8 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.101 -0.499 . . . . 52.15 110.893 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 19.1 pt20 -69.47 120.17 14.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.238 -0.437 . . . . 65.32 110.861 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.41 6.28 38.86 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.781 -0.723 . . . . 73.43 112.543 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -78.43 163.36 25.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.811 0.338 . . . . 72.21 110.878 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 3.7 p-90 -139.96 151.58 45.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.154 -0.475 . . . . 74.51 110.896 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.3 m -144.55 139.36 23.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.226 -0.443 . . . . 74.31 111.107 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -99.14 101.78 13.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.124 -0.489 . . . . 65.54 111.146 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.6 m -97.53 121.46 39.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 75.03 110.829 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 18.8 m-85 -118.64 118.29 31.26 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.134 -0.484 . . . . 74.32 110.888 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -148.01 172.84 13.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.102 -0.499 . . . . 75.11 110.845 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -100.64 124.27 46.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.132 -0.486 . . . . 75.25 110.897 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.5 m -102.28 115.11 29.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.129 -0.487 . . . . 71.0 110.848 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -98.84 113.78 26.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.18 -0.464 . . . . 74.22 110.915 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 32.4 t -92.49 146.62 6.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.242 -0.436 . . . . 74.42 111.124 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -135.21 110.52 9.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 72.22 110.937 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.3 p -166.51 150.34 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.136 -0.484 . . . . 75.23 111.193 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 136.27 76.13 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.721 -0.752 . . . . 71.24 112.474 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -89.51 -65.89 0.97 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.832 0.348 . . . . 73.05 110.836 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.3 mt-10 -162.87 146.89 11.34 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 72.13 110.878 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 2.0 tp -109.81 160.73 16.1 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.195 -0.457 . . . . 71.41 110.933 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 145.64 -142.41 10.64 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.742 -0.742 . . . . 73.22 112.501 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 18.5 m-20 -136.56 169.55 17.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.921 0.391 . . . . 74.24 110.78 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 12.7 mt -136.73 118.85 15.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 75.54 110.926 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 12.7 m120 -145.23 178.6 7.96 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.206 -0.452 . . . . 74.03 110.911 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 44.2 t -76.05 -62.79 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 75.21 111.115 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -157.5 174.13 34.94 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.776 -0.726 . . . . 72.41 112.421 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 137.96 85.99 0.16 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 74.1 112.461 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 61.18 -161.3 25.58 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.73 -0.748 . . . . 45.01 112.454 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -57.92 140.97 50.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.756 0.312 . . . . 44.42 111.081 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -131.98 68.92 80.75 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.608 0.718 . . . . 75.05 110.922 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 -177.4 1.86 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.642 2.228 . . . . 74.41 112.36 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -139.78 118.85 12.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.197 -0.456 . . . . 73.45 110.941 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -67.81 -178.59 0.98 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.174 -0.466 . . . . 73.24 111.091 179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -132.38 125.81 31.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 70.34 110.857 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 11.3 p -111.7 137.81 42.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 74.31 111.131 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -147.4 142.05 26.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.084 -0.507 . . . . 43.23 110.895 -179.834 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 39.0 pt -115.72 156.62 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 73.24 111.076 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -84.94 179.02 51.13 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.711 -0.757 . . . . 62.45 112.506 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 79.0 m-20 -133.64 112.95 11.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.836 0.351 . . . . 63.2 110.918 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -145.42 140.58 27.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 75.02 110.831 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 29.8 p -55.68 128.49 35.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 74.35 111.095 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 5.7 t -137.12 150.35 47.93 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.197 -0.456 . . . . 73.4 111.107 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -113.49 152.46 30.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 73.42 110.885 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -136.51 137.29 40.16 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.188 -0.46 . . . . 73.43 111.153 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -103.12 132.14 49.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 71.34 110.891 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -130.96 130.2 43.1 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.123 -0.49 . . . . 74.45 110.856 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.98 115.2 48.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 74.3 111.081 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -101.94 125.61 48.66 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.188 -0.46 . . . . 63.14 111.123 179.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -107.03 117.11 33.21 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.235 -0.439 . . . . 75.04 110.887 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -83.76 95.74 8.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.054 -0.521 . . . . 73.42 110.919 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 9.5 p -92.17 -34.29 6.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 72.43 111.175 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 17.0 m -133.68 160.69 36.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.097 -0.501 . . . . 75.43 110.842 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.6 p -83.48 2.98 34.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.123 -0.489 . . . . 72.41 110.868 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -119.75 -32.27 4.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.13 -0.486 . . . . 75.04 110.93 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 40.5 pt -139.72 153.46 23.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 74.51 111.098 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -146.95 162.92 37.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 65.54 111.088 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.5 m -103.84 151.37 6.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.23 -0.441 . . . . 74.31 111.095 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -141.92 135.75 29.75 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.19 -0.459 . . . . 75.05 110.823 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -122.2 108.18 13.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 71.42 110.88 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -94.77 123.43 38.22 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.118 -0.492 . . . . 75.23 110.833 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.2 p -149.78 154.63 8.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.067 -0.515 . . . . 64.21 111.166 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -162.57 142.23 7.77 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.767 -0.73 . . . . 73.34 112.472 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.9 m -115.17 73.24 3.42 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.617 0.722 . . . . 64.42 111.115 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 161.27 46.56 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.651 2.234 . . . . 74.0 112.357 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -68.71 -169.88 0.19 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.248 -0.433 . . . . 74.42 111.077 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 1.2 tmm_? -78.88 140.67 38.07 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.434 . . . . 73.54 110.85 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -128.2 142.27 51.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.201 -0.454 . . . . 53.34 111.077 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 28.9 ttpt -108.11 135.74 48.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.265 -0.425 . . . . 75.12 110.924 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 6.9 p90 -141.97 157.98 44.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 75.42 110.916 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -96.42 160.78 14.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.151 -0.477 . . . . 72.14 110.896 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -177.87 66.0 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.792 -0.718 . . . . 63.11 112.531 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -173.84 -176.8 1.27 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.931 0.396 . . . . 73.13 110.869 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.88 -68.87 0.7 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 71.23 110.874 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 5.1 m -83.83 -34.55 24.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.208 -0.451 . . . . 74.31 110.897 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.8 mm -64.55 -33.78 65.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.142 -0.481 . . . . 74.51 111.109 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.3 t -63.05 -45.26 93.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.13 -0.486 . . . . 65.34 110.825 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 22.7 t -53.6 -41.72 66.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.124 -0.489 . . . . 72.52 110.88 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -59.5 -44.19 93.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 75.11 110.917 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 110.21 -14.14 30.96 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.762 -0.732 . . . . 70.25 112.505 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 20.2 mtt180 -120.22 93.61 4.11 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.836 0.35 . . . . 75.22 110.813 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.1 t -113.56 -45.82 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 74.13 111.099 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 67.5 m -140.58 144.94 36.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.466 . . . . 72.45 110.834 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -142.01 119.56 11.7 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.103 -0.499 . . . . 73.13 110.909 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.2 p -175.04 157.92 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 72.33 111.151 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -81.17 173.53 12.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.182 -0.463 . . . . 73.22 110.858 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 11.6 m-85 -117.43 130.73 56.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.222 -0.445 . . . . 71.44 110.894 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -117.49 65.81 0.35 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.675 -0.774 . . . . 72.14 112.478 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.75 115.3 4.03 Favored 'Trans proline' 0 N--CA 1.465 -0.187 0 C-N-CA 122.708 2.272 . . . . 72.43 112.384 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -123.03 100.18 6.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.223 -0.444 . . . . 70.24 111.083 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 2.5 tp -122.06 119.83 59.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 74.52 111.137 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -120.65 113.67 20.57 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.199 -0.455 . . . . 71.52 110.897 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' SER . . . . . 0.423 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 4.9 p -142.81 159.48 42.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 64.31 110.858 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -103.94 149.63 24.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.101 -0.5 . . . . 62.13 110.925 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 15.8 mm-40 -101.58 144.95 29.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.468 . . . . 74.53 110.895 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 6.8 t80 -139.94 128.94 23.53 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.185 -0.461 . . . . 74.02 110.933 -179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 28.1 p80 -115.86 148.98 39.37 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.07 -0.514 . . . . 73.34 110.835 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -77.29 127.11 32.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.195 -0.457 . . . . 73.2 110.915 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 16.2 p-10 -100.42 53.88 0.88 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 63.03 110.825 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.3 p -114.94 -179.01 3.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.247 -0.433 . . . . 72.42 110.866 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 44.9 t80 -97.96 96.46 8.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 74.25 110.886 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -163.58 177.14 9.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 74.51 110.891 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 4.3 ptp180 -58.56 176.87 0.16 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.114 -0.494 . . . . 72.05 110.942 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -70.78 159.76 33.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.247 -0.433 . . . . 72.11 110.884 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 1.4 p90 -173.69 157.56 2.87 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.68 0.752 . . . . 74.22 110.889 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 177.53 5.5 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.625 2.216 . . . . 72.15 112.315 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -110.97 144.36 40.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.187 -0.461 . . . . 74.11 110.875 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 8.0 p -101.16 130.67 50.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.053 -0.521 . . . . 74.54 111.114 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -129.71 165.33 22.26 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.747 -0.739 . . . . 72.53 112.46 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 13.7 p -161.54 149.7 4.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.881 0.372 . . . . 62.3 111.128 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.423 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -174.41 -155.12 11.68 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.748 -0.739 . . . . 54.24 112.485 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 7.5 p -109.2 124.83 66.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.878 0.37 . . . . 75.11 111.154 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -110.1 114.3 3.81 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.776 -0.726 . . . . 72.05 112.497 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 25.5 ptt180 -115.9 124.56 50.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.823 0.344 . . . . 72.23 110.84 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 26.1 t -104.68 116.34 48.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.274 -0.421 . . . . 74.5 111.151 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.9 mt -130.76 171.24 13.34 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 75.32 110.86 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -160.25 169.53 23.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 75.31 110.895 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -102.93 118.78 37.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 73.03 110.883 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -48.93 108.07 0.17 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.056 -0.52 . . . . 60.45 110.877 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 3.6 mmmp? -111.52 -80.84 0.58 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.479 . . . . 74.32 110.875 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 21.9 m -161.52 81.0 0.59 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 64.42 111.135 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 39.2 m-20 -102.84 166.57 10.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.46 . . . . 71.1 110.899 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.64 155.26 0.11 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.705 -0.759 . . . . 61.55 112.503 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -81.24 3.67 23.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.8 0.333 . . . . 73.41 111.099 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -86.19 -175.33 5.48 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.455 . . . . 72.31 110.911 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 88.6 p -65.59 83.2 0.06 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 65.24 110.87 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 5.4 t 50.31 75.15 0.18 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 61.31 110.869 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -80.04 146.94 31.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 74.43 110.806 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -106.74 161.04 15.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.131 -0.486 . . . . 75.33 110.865 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 57.2 mt -115.73 143.86 24.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.171 -0.468 . . . . 75.43 111.12 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 3.4 mmtp -94.27 104.59 16.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 65.51 110.937 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -58.21 -174.86 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.466 . . . . 73.42 110.866 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -162.28 164.87 27.32 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.233 -0.44 . . . . 75.1 110.906 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 22.6 p-90 -146.6 154.41 41.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.211 -0.45 . . . . 75.42 110.981 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -179.23 164.43 0.97 Allowed Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.579 0.704 . . . . 72.03 111.096 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.82 127.49 14.62 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.577 2.185 . . . . 62.13 112.364 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -120.52 167.94 11.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 73.43 111.132 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -123.04 142.13 51.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 74.42 110.872 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 15.5 tt0 -123.17 151.98 41.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.165 -0.471 . . . . 71.4 110.879 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.1 t -151.08 122.8 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 63.43 111.092 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -174.68 -174.75 41.64 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.73 -0.748 . . . . 74.33 112.461 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -135.58 160.43 38.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.776 0.322 . . . . 75.1 110.988 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.3 tpp85 -122.06 118.54 29.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.241 -0.436 . . . . 65.02 110.873 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -101.35 127.97 47.73 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.204 -0.453 . . . . 73.03 110.897 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -116.73 102.12 9.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.157 -0.474 . . . . 75.2 110.898 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 7.3 tp -97.24 97.01 8.8 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.192 -0.458 . . . . 74.55 110.851 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 51.45 -159.18 2.3 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.608 -0.806 . . . . 70.24 112.516 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 23.2 m-20 -71.71 -29.44 64.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.83 0.348 . . . . 73.5 110.896 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 8.2 p -52.05 172.12 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.155 -0.475 . . . . 71.41 110.909 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 25.4 m0 -49.84 144.2 6.72 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.107 -0.497 . . . . 75.34 110.92 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 2.6 mtt -98.91 173.78 6.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.243 -0.435 . . . . 74.52 110.944 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 8.9 mp -125.68 142.86 51.3 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.268 -0.423 . . . . 73.45 110.876 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -140.15 134.59 31.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 71.35 110.873 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 3.3 t -142.23 122.47 13.87 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.145 -0.479 . . . . 73.43 110.842 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -150.88 165.08 34.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 62.41 110.92 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 1.5 t -133.51 139.76 48.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.212 -0.449 . . . . 54.13 111.192 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 21.9 ttt180 -111.31 131.38 55.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 74.34 110.87 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -134.31 137.0 43.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.23 -0.441 . . . . 74.05 110.924 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' ILE . . . . . 0.515 HG22 ' O ' ' A' ' 170' ' ' ILE . 0.0 OUTLIER -179.34 102.92 0.19 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.606 0.717 . . . . 73.04 111.144 179.898 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 139.22 39.71 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.691 2.261 . . . . 71.4 112.368 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -165.9 177.26 7.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 75.12 110.816 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 8.0 ptmt -128.52 150.61 50.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.053 -0.522 . . . . 71.51 110.873 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 15.3 t -119.43 161.21 20.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.143 -0.48 . . . . 74.15 111.141 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -116.1 172.62 7.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.269 -0.423 . . . . 72.21 110.877 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 14.8 p -164.98 140.06 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 73.52 111.084 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.0 t -165.81 177.67 7.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.177 -0.465 . . . . 74.31 111.114 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -154.83 -139.13 2.73 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.696 -0.764 . . . . 72.33 112.499 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -157.57 104.6 2.0 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.811 0.338 . . . . 74.14 111.11 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -139.52 114.4 9.44 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.245 -0.434 . . . . 65.32 110.955 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 46.11 -105.9 0.11 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.741 -0.742 . . . . 75.31 112.514 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -165.64 0.16 Allowed 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.663 2.242 . . . . 74.31 112.376 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 52.7 t -54.47 132.72 63.04 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-O 121.628 0.728 . . . . 64.55 111.184 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.68 161.17 46.96 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.715 2.277 . . . . 74.4 112.37 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 85.6 t -96.73 108.35 21.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.248 -0.433 . . . . 73.32 111.146 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 62.0 p -98.12 106.52 18.82 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.188 -0.46 . . . . 72.52 110.889 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 22.2 p -115.74 167.62 10.77 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 72.44 111.122 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.29 159.26 39.86 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.203 -0.453 . . . . 74.51 110.976 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 26.4 mm -142.76 137.67 27.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 73.32 111.07 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -104.78 114.94 29.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 73.32 110.862 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 2.6 t -137.33 163.09 32.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.148 -0.478 . . . . 71.43 111.177 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -107.25 90.0 5.26 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.612 0.72 . . . . 72.22 110.883 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 138.04 36.8 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.693 2.262 . . . . 75.11 112.313 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 10.0 m-85 -120.32 119.67 33.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.195 -0.457 . . . . 75.14 110.897 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 3.6 mp -112.99 132.45 61.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.464 . . . . 71.15 111.101 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 1.4 tt -125.79 112.16 15.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.444 . . . . 74.54 110.895 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 2.6 p -100.39 127.58 46.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.21 -0.45 . . . . 71.43 110.855 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 10.5 tt -147.83 126.05 12.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.154 -0.475 . . . . 74.23 110.963 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -179.42 -142.53 5.02 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.719 -0.753 . . . . 62.12 112.47 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -117.99 174.28 6.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.73 0.3 . . . . 74.05 111.098 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 63.7 p -156.37 163.33 39.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.262 -0.426 . . . . 70.33 110.806 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -136.14 130.05 32.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.047 -0.524 . . . . 70.34 110.925 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 19.7 m -85.18 147.72 5.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.1 -0.5 . . . . 62.15 111.125 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -141.27 105.0 4.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.181 -0.463 . . . . 74.41 110.889 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 37.0 mttm -72.61 -65.88 0.73 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.068 -0.515 . . . . 74.34 110.913 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 15.3 tp 58.9 56.29 4.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.192 -0.458 . . . . 65.01 110.912 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -67.98 -48.0 67.02 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.164 -0.471 . . . . 73.43 111.134 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -77.72 151.28 34.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.208 -0.451 . . . . 71.32 111.145 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -65.79 -64.07 0.94 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 75.31 111.045 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 4.3 pp -79.27 166.84 21.7 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.19 -0.459 . . . . 74.22 110.907 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 74.42 110.895 179.946 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.458 -0.046 0 CA-C-O 120.829 0.347 . . . . 75.05 110.861 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 4.6 t-20 -140.27 160.05 40.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.239 -0.437 . . . . 73.11 110.917 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 50.7 mt-10 -146.94 146.56 30.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.189 -0.459 . . . . 72.13 110.892 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 90.5 m-20 -95.17 -61.29 1.5 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.135 -0.484 . . . . 72.15 110.893 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 6.9 t80 58.82 72.05 0.89 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.687 0.756 . . . . 75.21 110.898 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.74 -171.57 0.49 Allowed 'Trans proline' 0 C--N 1.341 0.135 0 C-N-CA 122.662 2.241 . . . . 73.14 112.333 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -124.09 155.8 37.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 62.32 111.079 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.65 107.02 0.63 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.28 -0.418 . . . . 71.32 110.899 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 30.1 m -102.8 -36.3 8.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.236 -0.438 . . . . 75.24 110.84 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.89 134.3 37.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.131 -0.486 . . . . 72.13 111.113 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -174.28 -97.23 0.11 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.803 -0.713 . . . . 70.51 112.55 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -158.9 119.11 3.17 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.82 0.343 . . . . 72.44 110.942 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 11.0 t30 -167.28 164.31 15.37 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.113 -0.494 . . . . 75.43 110.925 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 -56.78 124.16 17.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 75.55 110.942 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 92.18 6.53 64.74 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.756 -0.735 . . . . 73.45 112.464 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -78.93 151.16 31.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.815 0.341 . . . . 74.31 110.883 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -125.36 139.42 53.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 72.14 110.908 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 4.9 m -145.71 134.67 17.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 74.31 111.18 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -97.8 110.91 23.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 72.55 111.095 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.5 t -103.78 117.48 34.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 74.33 110.855 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 30.4 p90 -117.98 124.04 47.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 73.34 110.88 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 4.1 p30 -149.7 171.88 15.98 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.128 -0.487 . . . . 74.32 110.883 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -94.8 122.32 37.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 72.34 110.931 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -93.82 113.53 25.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 53.23 110.845 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 36.7 mttt -93.66 106.97 18.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.197 -0.456 . . . . 72.22 110.877 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.3 p -87.26 130.95 36.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 71.5 111.158 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -121.42 102.69 8.43 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 73.44 110.911 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.9 t -140.16 155.34 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.061 -0.518 . . . . 75.04 111.079 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 130.73 62.16 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.762 -0.732 . . . . 61.3 112.467 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -89.87 -66.15 0.95 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.899 0.38 . . . . 73.11 110.969 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 179.18 130.05 0.08 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.088 -0.505 . . . . 72.12 110.849 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 1.8 tp -51.9 170.12 0.06 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.133 -0.485 . . . . 75.23 110.903 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.45 106.46 1.68 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.712 -0.756 . . . . 71.3 112.473 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -51.54 -58.54 6.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.848 0.356 . . . . 71.22 110.932 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 11.0 tp -173.73 161.68 3.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.177 -0.465 . . . . 75.14 110.937 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 34.5 m-80 -97.57 -56.46 2.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.148 -0.478 . . . . 74.22 110.877 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 28.1 m -70.64 -35.13 59.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 71.3 111.162 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 60.34 -164.8 14.26 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.758 -0.735 . . . . 74.03 112.439 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 138.74 -67.59 0.51 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.663 -0.78 . . . . 72.4 112.419 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -97.27 174.78 30.11 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.731 -0.747 . . . . 74.15 112.501 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -68.78 130.37 42.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.821 0.344 . . . . 51.34 111.053 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.3 tp -148.73 137.45 11.9 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.66 0.743 . . . . 72.32 110.825 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -172.45 0.58 Allowed 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.65 2.233 . . . . 64.41 112.352 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -136.09 142.47 44.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 73.25 110.855 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -117.67 -171.16 2.0 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.482 . . . . 64.15 111.161 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -121.04 -170.36 2.0 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 75.14 110.807 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 10.4 p -166.08 135.6 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.157 -0.474 . . . . 71.42 111.167 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -175.05 171.53 3.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.469 . . . . 72.42 110.839 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 2.2 pp -102.43 158.22 4.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.09 -0.505 . . . . 73.13 111.106 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -88.72 -81.73 1.29 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.733 -0.746 . . . . 72.12 112.432 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.7 p30 -151.87 93.38 1.84 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.791 0.329 . . . . 72.42 110.867 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -115.49 65.52 0.69 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 73.32 110.851 179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -95.31 103.5 15.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.148 -0.478 . . . . 71.22 111.142 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.2 p -156.75 163.31 39.4 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.251 -0.432 . . . . 70.24 111.142 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 11.8 mt -88.4 163.23 16.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 75.53 110.927 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -131.42 142.57 50.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 74.5 111.103 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -113.88 131.75 56.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.45 . . . . 75.43 110.864 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.403 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.2 OUTLIER -130.78 143.77 50.97 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.089 -0.505 . . . . 73.42 110.788 -179.938 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 12.5 mm -108.09 117.68 54.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 75.23 111.12 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -100.44 132.72 45.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 72.13 111.097 179.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -114.85 116.84 29.22 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.205 -0.452 . . . . 72.44 110.936 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -87.0 101.91 13.9 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 74.53 110.969 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 8.1 p -100.57 -34.57 4.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.121 -0.49 . . . . 74.52 111.084 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 20.3 t -132.46 158.78 41.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 63.42 110.894 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.4 m -84.18 2.82 37.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 74.55 110.771 -179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -112.33 -31.16 6.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 63.41 110.853 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 25.4 pt -148.78 162.24 5.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.24 -0.437 . . . . 73.15 111.148 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -149.57 170.24 19.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 74.45 111.116 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.6 m -112.3 153.57 13.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.203 -0.453 . . . . 74.44 111.203 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -146.15 132.12 19.2 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.191 -0.459 . . . . 73.51 110.841 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 0.403 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 12.0 t80 -115.01 108.82 17.19 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.253 -0.431 . . . . 74.22 110.889 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -86.19 128.49 34.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 64.35 110.945 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 2.7 p -145.32 144.43 21.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.128 -0.487 . . . . 75.21 111.119 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -159.38 133.76 3.48 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.793 -0.718 . . . . 71.22 112.496 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 4.5 p -112.93 75.41 1.96 Allowed Pre-proline 0 C--N 1.33 -0.243 0 CA-C-O 121.659 0.742 . . . . 70.52 111.083 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 162.49 41.87 Favored 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.654 2.236 . . . . 72.23 112.416 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -76.29 -167.93 0.86 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.26 -0.427 . . . . 61.15 111.132 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 35.3 ttp180 -78.02 131.09 37.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.243 -0.435 . . . . 73.42 110.916 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -132.45 151.14 52.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 62.44 111.056 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 22.3 pttm -92.78 135.17 34.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 75.32 110.915 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -116.09 137.23 52.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 72.04 110.891 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 -95.92 151.78 19.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 72.51 110.916 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 174.77 73.6 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.812 -0.709 . . . . 72.33 112.511 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -170.47 -176.44 2.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.912 0.387 . . . . 74.32 110.846 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.19 -70.12 0.62 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 73.24 110.923 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.8 t -85.81 -30.62 22.84 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.212 -0.449 . . . . 74.14 110.788 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 4.4 mm -68.5 -34.66 66.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 75.14 111.156 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.4 t -61.38 -49.66 76.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.465 . . . . 75.24 110.871 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 22.3 t -51.73 -42.46 62.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 64.24 110.851 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -57.66 -45.61 85.3 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.147 -0.479 . . . . 73.31 110.918 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 111.49 -14.82 27.48 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.772 -0.728 . . . . 63.51 112.547 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 9.6 ptt85 -120.46 95.77 4.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.84 0.353 . . . . 74.24 110.94 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 21.9 t -110.5 -46.06 6.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 74.04 111.121 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.6 p -139.63 153.47 47.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.477 . . . . 74.2 110.834 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -135.69 121.96 20.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.142 -0.481 . . . . 73.15 110.896 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 7.6 p -174.18 161.39 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.199 -0.455 . . . . 74.23 111.118 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -80.13 172.72 13.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.188 -0.46 . . . . 75.14 110.873 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -125.31 130.83 52.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.446 . . . . 72.43 110.919 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -118.68 66.75 0.37 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.708 -0.758 . . . . 75.42 112.441 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 124.99 11.63 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.705 2.27 . . . . 73.24 112.319 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -138.68 106.05 5.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 75.33 111.1 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 16.3 mm -118.56 150.48 20.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.25 -0.432 . . . . 75.31 111.105 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -149.15 109.75 4.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 71.52 110.916 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.0 p -144.37 171.56 14.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 75.0 110.891 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -120.42 153.06 37.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.465 . . . . 72.13 110.888 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 -106.25 139.03 41.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.156 -0.475 . . . . 72.1 110.902 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 30.7 p90 -143.16 148.3 36.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 73.32 110.884 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 25.0 p-80 -97.5 158.77 15.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 74.55 110.876 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -128.06 125.1 38.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.226 -0.443 . . . . 74.32 110.925 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -52.59 128.64 26.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.099 -0.5 . . . . 70.21 110.913 179.87 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 46.8 m -141.77 172.29 12.89 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 74.44 110.857 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 30.7 t80 -76.57 -38.34 55.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 74.02 110.872 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 61.7 mt-10 -59.63 177.26 0.22 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.138 -0.483 . . . . 75.24 110.954 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 25.9 ttm180 -99.31 -65.55 0.96 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 73.25 110.927 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 26.5 mt -101.49 138.82 37.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 75.23 110.917 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 4.1 p90 -171.49 157.65 4.63 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-O 121.625 0.726 . . . . 72.52 110.921 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 177.55 5.48 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.702 2.268 . . . . 65.2 112.345 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -117.35 157.6 25.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 75.03 110.96 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 72.7 t -106.99 128.38 61.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.063 -0.517 . . . . 73.11 111.109 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -119.27 172.88 14.81 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.714 -0.755 . . . . 72.33 112.53 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.3 p -175.56 153.13 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.848 0.356 . . . . 72.53 111.141 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 178.17 -148.65 8.64 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.823 -0.704 . . . . 71.3 112.511 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . 0.465 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 4.9 p -110.39 137.71 41.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.882 0.372 . . . . 65.45 111.145 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -127.36 105.87 0.78 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.712 -0.756 . . . . 72.3 112.408 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 13.0 ptp180 -98.85 130.17 45.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.854 0.359 . . . . 75.44 110.891 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 3.2 m -106.99 109.65 28.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 71.0 111.172 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 1.4 tt -86.47 141.59 29.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 72.33 110.932 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -152.58 129.93 11.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 74.0 110.844 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -101.56 176.48 5.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.097 -0.501 . . . . 72.1 110.948 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -109.19 95.19 5.47 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.218 -0.447 . . . . 73.21 110.85 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.16 -79.61 0.32 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 73.34 110.858 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.7 m -163.22 113.22 1.36 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.254 -0.43 . . . . 73.42 111.135 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . 0.422 ' HB3' ' CB ' ' A' ' 139' ' ' PHE . 10.0 t0 -106.27 117.1 33.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 74.05 110.901 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -78.25 -11.15 85.63 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.759 -0.734 . . . . 73.21 112.49 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -44.95 -30.31 0.99 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.781 0.324 . . . . 74.15 111.076 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 3.4 tp -160.79 -177.49 6.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.227 -0.442 . . . . 75.24 110.916 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 14.9 t -54.28 94.06 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 74.33 110.854 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 68.2 m 49.16 75.49 0.15 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.18 -0.464 . . . . 75.3 110.849 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.422 ' CB ' ' HB3' ' A' ' 133' ' ' ASP . 0.4 OUTLIER -101.58 162.28 13.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 72.32 110.864 -179.958 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -138.53 170.35 16.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.129 -0.487 . . . . 74.45 110.888 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.9 mp -116.7 160.73 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 61.34 111.13 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 3.6 mtmt -122.19 122.36 39.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 74.31 110.899 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -74.31 -172.68 1.49 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.239 -0.437 . . . . 72.04 110.873 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 3.1 mmtm -171.36 -173.46 1.25 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 74.32 110.884 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 52.2 p-90 -154.62 153.23 31.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 75.22 110.955 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -176.44 165.41 1.65 Allowed Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.572 0.701 . . . . 73.41 111.116 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 53.1 Cg_endo -69.77 167.06 25.54 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.635 2.224 . . . . 73.11 112.363 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -160.26 154.97 24.07 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.207 -0.451 . . . . 74.22 111.113 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 11.6 m-85 -104.7 129.32 52.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.234 -0.439 . . . . 71.02 110.872 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 6.2 mm-40 -104.72 156.73 17.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.13 -0.486 . . . . 74.15 110.946 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.3 p -155.79 128.91 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 70.55 111.144 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 166.97 -162.82 36.6 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.749 -0.738 . . . . 72.13 112.517 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 3.3 pp -155.98 170.47 22.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.824 0.345 . . . . 72.04 110.897 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.9 tpp85 -117.68 122.3 43.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 73.13 110.867 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -108.56 153.99 22.59 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.185 -0.461 . . . . 74.5 110.964 -179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 35.7 t0 -121.53 99.26 6.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.482 . . . . 70.01 110.847 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 13.2 mt -97.71 97.53 9.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.28 -0.418 . . . . 74.33 110.936 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 80.65 -147.26 27.91 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.8 -0.714 . . . . 74.12 112.519 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -123.23 -35.49 2.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.866 0.365 . . . . 74.01 110.92 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 1.7 m -51.77 -61.84 2.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 74.5 110.845 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 18.6 p90 -139.58 153.72 47.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.215 -0.448 . . . . 71.23 110.927 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 11.0 mtt -108.34 176.49 5.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 75.52 110.849 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -116.51 146.31 42.69 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 54.52 110.83 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -141.76 134.38 28.39 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.142 -0.481 . . . . 62.45 110.863 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 10.8 t -136.78 124.18 22.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 64.11 110.805 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -144.23 160.72 40.5 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.123 -0.489 . . . . 73.34 110.883 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 58.1 t -150.0 126.73 2.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 64.5 111.156 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -104.58 133.58 49.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.198 -0.456 . . . . 72.51 110.834 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 19.6 t80 -136.74 132.07 34.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 64.53 110.914 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' ILE . . . . . 0.426 HG13 ' HD2' ' A' ' 171' ' ' PRO . 5.0 tp 178.65 132.89 0.23 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.628 0.727 . . . . 74.41 111.144 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . 0.426 ' HD2' HG13 ' A' ' 170' ' ' ILE . 54.6 Cg_endo -69.78 112.77 3.17 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.649 2.233 . . . . 74.53 112.374 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -122.83 151.45 41.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.259 -0.428 . . . . 73.24 110.859 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 20.1 pttt -123.85 134.56 53.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 72.42 110.881 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -101.2 171.21 7.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.228 -0.442 . . . . 65.0 111.133 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -123.51 161.2 25.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.197 -0.456 . . . . 71.44 110.911 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 3.4 t -151.07 143.05 16.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.173 -0.467 . . . . 71.05 111.107 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.4 t -166.98 -178.15 4.09 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.18 -0.464 . . . . 52.13 111.114 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -119.74 -158.38 10.58 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.763 -0.732 . . . . 71.1 112.56 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 6.6 t -128.63 -172.28 2.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.858 0.361 . . . . 73.35 111.152 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 2.0 mp -65.58 140.19 58.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 75.13 110.945 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 117.81 -82.16 0.33 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.692 -0.766 . . . . 71.51 112.47 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 -161.94 0.08 OUTLIER 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.68 2.253 . . . . 65.03 112.38 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 5.1 m -107.45 86.1 2.57 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.675 0.75 . . . . 73.51 111.173 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.66 151.32 69.59 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.684 2.256 . . . . 64.12 112.317 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 45.2 t -139.17 112.4 6.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.151 -0.477 . . . . 72.44 111.083 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.02 104.75 5.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.476 . . . . 61.23 110.849 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 29.4 p -124.14 174.04 7.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 72.2 111.123 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 5.2 ptmt -150.3 145.76 26.36 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.226 -0.443 . . . . 74.45 110.883 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 6.3 pt -127.27 111.24 24.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.273 -0.421 . . . . 70.15 111.149 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -92.0 113.48 25.76 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.186 -0.461 . . . . 65.03 110.913 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 12.1 m -136.77 167.31 24.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 72.13 111.096 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -107.25 88.54 3.98 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.553 0.692 . . . . 73.3 110.86 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 132.5 23.48 Favored 'Trans proline' 0 C--O 1.233 0.242 0 C-N-CA 122.685 2.257 . . . . 74.03 112.363 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -110.05 113.98 27.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.282 -0.417 . . . . 75.23 110.848 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 71.5 mt -105.86 119.94 55.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.158 -0.474 . . . . 74.43 111.159 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 9.7 mp -116.03 108.66 16.5 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.195 -0.457 . . . . 74.23 110.92 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 53.9 p -99.21 114.04 26.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.244 -0.434 . . . . 71.33 110.862 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -134.14 122.2 22.52 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.186 -0.461 . . . . 74.43 110.92 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -175.63 -140.58 3.46 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.774 -0.727 . . . . 64.04 112.497 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -126.65 174.24 8.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.826 0.346 . . . . 64.31 111.078 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 73.7 p -148.11 166.23 28.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.212 -0.449 . . . . 74.32 110.832 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -133.6 136.94 45.19 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.08 -0.509 . . . . 74.42 110.874 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 25.1 m -91.11 149.7 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.095 -0.502 . . . . 73.21 111.137 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -149.84 114.92 5.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 74.12 110.834 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.33 168.03 6.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 73.12 110.927 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -133.98 111.19 10.21 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.237 -0.438 . . . . 73.5 110.925 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -143.97 159.83 41.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 72.4 111.086 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -116.79 163.74 15.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 72.13 111.085 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -68.61 144.32 54.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.178 -0.464 . . . . 75.31 111.165 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 13.6 tp -87.07 149.27 24.83 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.248 -0.433 . . . . 74.54 110.912 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 42.0 mp0 . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 74.22 110.878 179.952 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.3 mmm . . . . . 0 C--O 1.23 0.05 0 CA-C-O 120.735 0.302 . . . . 75.22 110.833 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 6.2 m-80 55.19 36.22 26.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.266 -0.425 . . . . 75.32 110.876 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -58.85 124.08 18.62 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 74.54 110.865 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 20.0 p-10 -127.11 149.42 49.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.146 -0.479 . . . . 61.14 110.891 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 7.7 m-85 -117.31 160.4 37.77 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-O 121.677 0.751 . . . . 73.43 110.885 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.65 171.41 14.39 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.767 2.312 . . . . 74.52 112.392 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.22 -42.21 3.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.299 -0.41 . . . . 74.44 111.084 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -146.77 141.08 26.35 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.265 -0.425 . . . . 73.2 110.906 179.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 73.3 p -116.36 50.8 1.02 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.2 -0.455 . . . . 72.03 110.872 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.38 -175.15 2.71 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.077 -0.511 . . . . 75.12 111.117 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.99 -64.11 3.08 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.765 -0.731 . . . . 72.13 112.519 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 14.1 p90 -151.89 115.7 4.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.836 0.351 . . . . 75.05 110.99 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 62.4 t30 -151.29 157.35 42.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.109 -0.496 . . . . 74.25 110.871 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -52.29 121.1 6.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 75.32 110.903 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 99.36 6.08 55.46 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.801 -0.714 . . . . 75.12 112.511 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -77.33 150.9 35.15 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.853 0.359 . . . . 74.53 110.835 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 23.8 m-90 -117.75 138.37 52.08 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.21 -0.45 . . . . 70.35 110.923 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.5 m -141.56 134.7 29.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.25 -0.432 . . . . 73.44 111.108 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -99.66 112.45 24.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.447 . . . . 73.43 111.085 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -99.21 109.37 22.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 71.32 110.81 -179.761 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 12.7 m-85 -107.64 116.51 32.08 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 74.24 110.889 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -154.12 172.66 17.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 53.32 110.967 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -103.57 134.96 46.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.249 -0.432 . . . . 72.15 110.835 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 2.8 m -105.0 107.88 19.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.144 -0.48 . . . . 73.52 110.851 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 31.8 tttp -87.71 109.37 19.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.11 -0.495 . . . . 74.54 110.844 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.7 p -92.65 130.93 41.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 75.44 111.168 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -119.42 100.59 7.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 74.54 110.932 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.4 p -149.34 145.31 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.093 -0.503 . . . . 73.52 111.114 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 148.84 67.32 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.735 -0.745 . . . . 72.24 112.518 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 8.3 tt0 -89.18 -65.84 0.98 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.832 0.349 . . . . 63.24 110.928 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -170.61 169.25 7.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.125 -0.488 . . . . 73.32 110.92 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 11.3 tp -84.59 161.55 20.12 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.167 -0.47 . . . . 75.24 110.905 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.11 -33.1 36.91 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.763 -0.732 . . . . 64.41 112.51 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 46.1 m-20 54.19 37.22 26.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.866 0.365 . . . . 73.33 110.859 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 60.4 tp -67.06 127.77 33.85 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.194 -0.457 . . . . 64.53 110.891 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 4.7 p-10 -111.67 103.15 11.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.14 -0.482 . . . . 72.44 110.86 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 11.2 p -75.61 -34.48 29.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.172 -0.467 . . . . 75.03 111.154 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -169.56 114.12 0.54 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.732 -0.747 . . . . 61.53 112.467 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 170.14 -177.28 43.53 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.741 -0.742 . . . . 75.44 112.524 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -103.56 -119.35 4.6 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.723 -0.751 . . . . 72.42 112.49 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -90.85 106.22 18.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.805 0.335 . . . . 71.53 111.143 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -119.18 159.32 45.66 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.582 0.706 . . . . 73.44 110.895 -179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -172.11 0.55 Allowed 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.712 2.275 . . . . 71.34 112.32 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 2.7 p30 -128.06 145.58 50.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.247 -0.433 . . . . 71.12 110.92 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -92.07 167.89 11.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 75.43 111.084 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -137.61 134.7 35.84 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.29 -0.414 . . . . 72.04 110.872 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 73.6 t -104.94 142.61 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 73.4 111.149 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 m -155.19 152.9 29.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 73.32 110.882 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 38.3 pt -136.79 157.71 36.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.474 . . . . 74.33 111.138 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -88.78 -90.33 1.15 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.745 -0.741 . . . . 60.24 112.499 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 9.2 m120 57.57 57.27 4.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.795 0.331 . . . . 64.31 110.883 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -55.61 -57.86 10.2 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 74.34 110.915 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -162.85 138.18 6.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 71.35 111.177 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -161.89 146.65 12.89 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.227 -0.442 . . . . 75.0 111.132 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 88.9 mt -90.06 157.65 17.69 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.455 . . . . 74.5 110.828 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.36 144.32 33.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.13 -0.486 . . . . 74.34 111.129 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 15.4 m-85 -102.37 132.53 48.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 74.31 110.935 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -128.43 139.43 52.36 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.145 -0.48 . . . . 74.32 110.923 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.4 mm -110.07 114.92 48.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.196 -0.457 . . . . 74.44 111.123 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -116.15 149.53 38.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.116 -0.493 . . . . 64.55 111.145 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 14.6 m-85 -129.33 137.59 51.08 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.289 -0.414 . . . . 73.34 110.946 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -98.33 102.28 13.98 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.158 -0.474 . . . . 75.21 110.867 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.7 m -99.35 -34.06 4.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.472 . . . . 75.04 111.088 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 58.4 m -135.51 158.77 43.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 74.04 110.917 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 3.9 t -83.99 3.39 34.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 74.52 110.861 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -114.06 -30.56 6.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.149 -0.478 . . . . 64.25 110.849 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -140.89 165.23 20.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 75.43 111.124 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -155.18 168.83 25.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.133 -0.485 . . . . 72.43 111.116 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.413 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 4.2 m -111.66 147.67 15.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 72.15 111.125 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -149.93 128.53 12.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.189 -0.46 . . . . 64.23 110.849 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -121.5 132.91 54.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 72.44 110.882 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 13.1 m-30 -95.02 134.85 37.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.131 -0.486 . . . . 71.21 110.926 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 63.3 t -144.41 136.81 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.107 -0.497 . . . . 73.45 111.086 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -155.29 140.55 7.43 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.743 -0.742 . . . . 64.34 112.439 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.8 t -124.38 66.87 45.5 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.621 0.724 . . . . 71.14 111.083 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 154.91 67.45 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.656 2.237 . . . . 75.11 112.374 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -68.14 -167.63 0.09 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 50.43 111.09 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 9.8 ttm180 -77.46 129.0 35.16 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.203 -0.453 . . . . 73.54 110.859 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -120.72 142.41 49.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.449 . . . . 73.14 111.072 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 21.0 ttpp -91.64 134.99 34.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.165 -0.471 . . . . 73.34 110.9 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -131.98 152.01 51.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.221 -0.445 . . . . 74.2 110.92 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -99.93 156.1 17.33 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 73.23 110.897 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 179.86 68.16 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.737 -0.744 . . . . 73.41 112.487 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -170.53 -176.44 2.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.935 0.398 . . . . 74.41 110.94 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.81 -70.17 0.61 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 74.11 110.847 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.8 t -85.25 -31.24 23.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 73.12 110.828 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 4.8 mm -67.75 -33.59 62.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.198 -0.456 . . . . 74.3 111.146 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 10.0 t -63.66 -48.06 78.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 74.43 110.87 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 27.1 t -51.92 -42.48 62.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.147 -0.479 . . . . 72.31 110.87 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 82.6 mt -57.73 -48.38 79.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.115 -0.493 . . . . 74.15 110.884 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 115.32 -15.21 18.07 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.758 -0.734 . . . . 73.52 112.446 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 14.4 ttp180 -120.31 92.61 3.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.817 0.342 . . . . 72.15 110.885 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 25.3 t -108.15 -52.76 6.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.224 -0.444 . . . . 73.52 111.119 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 60.4 m -140.69 146.06 37.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 70.15 110.846 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -131.01 125.86 34.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 72.41 110.859 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 13.2 p -174.42 156.79 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 73.04 111.167 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -86.39 173.43 9.68 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.187 -0.46 . . . . 70.34 110.83 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -133.48 126.07 30.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 74.12 110.929 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -113.5 72.36 0.23 Allowed Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.717 -0.754 . . . . 72.12 112.458 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 114.21 3.62 Favored 'Trans proline' 0 N--CA 1.465 -0.177 0 C-N-CA 122.754 2.303 . . . . 74.13 112.367 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -129.56 104.87 7.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.219 -0.446 . . . . 72.34 111.129 179.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 1.2 pp -127.89 151.3 34.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 74.11 111.123 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -141.01 111.64 6.95 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.132 -0.485 . . . . 75.45 110.912 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 3.6 p -134.24 -174.15 3.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.23 -0.441 . . . . 75.22 110.837 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.413 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -134.97 147.98 49.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.091 -0.504 . . . . 71.34 110.931 179.994 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -104.31 134.82 46.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 75.12 110.97 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 12.9 p90 -144.71 159.03 43.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.228 -0.442 . . . . 74.34 110.925 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 9.8 t60 -129.36 149.9 50.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.111 -0.495 . . . . 73.1 110.855 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -90.69 150.01 21.83 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.251 -0.431 . . . . 74.51 110.978 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -55.58 106.86 0.28 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.115 -0.493 . . . . 74.42 110.902 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.0 t -148.43 126.19 11.86 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.275 -0.42 . . . . 64.53 110.86 -179.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 19.3 p90 -121.45 40.96 3.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.115 -0.493 . . . . 73.14 110.871 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 34.1 mt-10 -97.15 -60.73 1.52 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.103 -0.499 . . . . 73.34 110.921 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 46.3 mtt180 -158.74 171.21 20.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.198 -0.455 . . . . 72.33 110.922 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -64.43 132.88 51.31 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.194 -0.457 . . . . 74.33 110.928 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -153.3 160.52 30.84 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.701 0.762 . . . . 74.31 110.913 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.81 177.52 5.53 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.725 2.283 . . . . 74.24 112.338 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -116.69 154.54 30.41 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.204 -0.453 . . . . 74.13 110.946 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 5.4 p -102.57 127.38 56.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.122 -0.49 . . . . 74.21 111.109 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -119.87 167.67 13.56 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.728 -0.749 . . . . 53.23 112.534 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 7.3 p -171.38 154.45 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.826 0.346 . . . . 75.04 111.135 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 178.87 -147.02 7.57 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.695 -0.764 . . . . 73.43 112.452 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . 0.461 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.7 p -112.6 132.43 61.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.852 0.358 . . . . 75.34 111.112 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -123.3 109.6 1.37 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.761 -0.733 . . . . 63.43 112.463 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 10.5 ptm180 -109.41 123.47 49.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.817 0.342 . . . . 61.43 110.892 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . 0.462 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 2.5 p -107.35 119.35 56.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 73.34 111.152 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 2.7 mp -129.46 153.62 47.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.19 -0.459 . . . . 75.12 110.81 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 7.3 p90 -160.21 169.71 22.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.078 -0.51 . . . . 74.13 110.894 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -101.88 117.57 35.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 75.22 110.877 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -53.43 101.38 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.138 -0.483 . . . . 75.15 110.873 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.67 -82.97 0.09 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.234 -0.439 . . . . 74.24 110.865 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.8 m -173.42 128.22 0.43 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 64.32 111.195 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . 0.405 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 5.3 m-20 -114.37 115.3 27.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 73.21 110.878 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -80.82 -2.96 90.47 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.731 -0.747 . . . . 53.42 112.511 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -47.13 -29.73 2.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.824 0.345 . . . . 72.41 111.079 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.8 tp -158.93 -177.94 6.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 63.13 110.921 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -52.19 96.49 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.157 -0.474 . . . . 72.4 110.826 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 93.2 p 46.94 74.13 0.16 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 63.13 110.865 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.405 ' HB3' ' HB2' ' A' ' 133' ' ' ASP . 0.5 OUTLIER -95.76 158.85 15.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.127 -0.488 . . . . 71.14 110.905 -179.928 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -141.36 174.95 10.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 75.41 110.829 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 2.6 mt -131.41 152.68 37.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.155 -0.475 . . . . 74.23 111.118 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 7.1 mmpt? -122.43 122.11 38.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 74.51 110.928 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.462 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 1.9 p-10 -72.08 -166.52 0.24 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 63.25 110.93 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -173.35 177.27 2.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.239 -0.437 . . . . 74.52 110.875 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 30.9 p90 -146.54 153.51 40.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 72.52 110.912 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.457 ' CB ' ' HD2' ' A' ' 147' ' ' PRO . . . 178.98 168.1 0.61 Allowed Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.618 0.723 . . . . 73.41 111.128 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 53.7 Cg_endo -69.79 150.73 68.43 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.68 2.253 . . . . 74.23 112.387 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -148.11 167.31 25.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.217 -0.447 . . . . 54.01 111.087 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 -118.94 166.21 13.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.205 -0.452 . . . . 73.5 110.883 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 1.3 pt20 -157.9 162.48 38.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.167 -0.47 . . . . 73.22 110.973 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 94.1 t -150.61 124.81 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.222 -0.445 . . . . 75.23 111.113 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . 0.418 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . -171.46 -167.16 31.31 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.769 -0.729 . . . . 73.54 112.541 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -145.11 158.54 43.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.834 0.349 . . . . 75.03 110.925 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 3.7 tpp85 -125.33 121.86 35.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 73.54 110.806 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 5.1 m-85 -128.52 173.16 10.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 73.01 110.873 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -121.74 106.83 11.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.1 -0.5 . . . . 73.15 110.883 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -102.94 97.41 7.54 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.194 -0.457 . . . . 75.44 110.948 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 85.75 161.99 35.68 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.677 -0.773 . . . . 65.24 112.537 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -74.26 147.21 42.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.889 0.376 . . . . 72.31 110.889 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 14.2 m 51.9 36.45 18.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.198 -0.455 . . . . 74.22 110.861 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 2.9 t90 -172.69 112.08 0.24 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.153 -0.476 . . . . 74.11 110.933 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 5.3 mtt -110.47 172.74 6.69 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 75.52 110.905 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 41.9 mt -129.49 140.3 51.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.253 -0.43 . . . . 64.51 110.903 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -138.41 136.05 35.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 73.43 110.864 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 24.0 p -143.94 122.27 12.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 74.3 110.84 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . 0.418 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.6 OUTLIER -150.77 171.84 16.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.128 -0.487 . . . . 72.44 110.833 179.972 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -141.89 120.12 8.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 73.45 111.101 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 1.9 tmm_? -93.55 135.65 34.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 74.42 110.845 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 21.7 m-85 -134.28 136.27 43.43 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 74.45 110.873 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' ILE . . . . . . . . . . . . . 8.0 tp 178.66 118.89 0.2 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.685 0.755 . . . . 73.54 111.086 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 113.44 3.37 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.633 2.222 . . . . 61.31 112.359 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -117.11 177.34 4.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.216 -0.447 . . . . 74.24 110.846 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 6.8 ptmt -152.32 138.58 18.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.128 -0.487 . . . . 75.33 110.933 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.95 155.1 18.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.258 -0.428 . . . . 75.1 111.15 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -116.19 102.11 9.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 74.31 110.868 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 20.3 m -96.89 146.35 7.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 73.43 111.139 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.6 t -166.7 163.29 16.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 72.12 111.132 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -123.35 162.3 17.3 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.798 -0.715 . . . . 61.12 112.488 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.2 106.7 16.23 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.811 0.339 . . . . 64.32 111.17 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -140.27 167.21 22.67 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.166 -0.47 . . . . 73.4 110.853 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -50.5 -71.65 0.6 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.753 -0.737 . . . . 72.44 112.484 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.86 -171.91 0.53 Allowed 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.65 2.233 . . . . 73.41 112.322 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.5 p -57.7 111.66 3.75 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.636 0.732 . . . . 74.42 111.114 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 165.98 29.15 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.658 2.238 . . . . 75.03 112.301 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 87.4 t -95.67 107.17 19.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 70.54 111.16 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 81.0 p -110.02 125.26 52.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 73.24 110.831 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 35.7 p -138.21 159.54 41.77 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.122 -0.49 . . . . 71.23 111.114 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 3.6 pttm -128.87 150.02 50.52 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 74.23 110.94 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 6.3 pt -131.56 108.2 14.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 72.44 111.138 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -98.87 118.34 35.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 72.4 110.86 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 2.4 t -137.66 164.53 28.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 65.51 111.073 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.96 87.73 3.16 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.604 0.716 . . . . 75.24 110.871 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.64 131.71 21.99 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.704 2.269 . . . . 75.24 112.311 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -100.17 107.03 18.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 75.31 110.89 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 3.9 mp -97.99 125.33 51.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.111 -0.495 . . . . 71.12 111.159 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 2.1 mp -119.31 108.12 14.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 73.11 110.977 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.2 120.52 33.57 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 62.21 110.851 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 1.3 tt -144.74 127.41 16.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.116 -0.493 . . . . 65.14 110.823 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 176.18 -146.98 8.35 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.834 -0.698 . . . . 72.24 112.535 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -118.32 174.14 6.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.788 0.327 . . . . 75.34 111.106 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 8.9 p -151.76 171.77 17.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 63.24 110.884 -179.802 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -145.4 148.1 32.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.147 -0.479 . . . . 75.24 110.912 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 14.5 m -111.76 157.4 12.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.49 . . . . 73.01 111.206 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -173.76 155.25 2.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.211 -0.449 . . . . 74.34 110.912 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 18.2 pttp -133.5 178.32 7.01 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.152 -0.476 . . . . 74.34 110.835 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -67.83 133.86 49.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 74.03 110.963 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -69.55 142.32 53.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 73.34 111.092 179.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -80.71 106.13 12.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.139 -0.482 . . . . 73.13 111.116 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -93.15 -46.05 7.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.266 -0.425 . . . . 53.42 111.064 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -111.06 113.94 26.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 72.15 110.924 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.186 -0.461 . . . . 72.44 110.889 179.945 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 14.6 mtm . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.796 0.331 . . . . 64.51 110.897 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -121.83 172.89 7.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 65.31 110.903 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -125.66 144.22 50.69 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.087 -0.506 . . . . 65.31 110.931 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -142.05 163.97 31.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 74.02 110.877 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -114.08 160.48 32.26 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.688 0.756 . . . . 73.04 110.921 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 178.66 4.32 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.674 2.25 . . . . 73.3 112.344 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -149.39 143.61 25.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 75.32 111.119 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 76.5 mttt -135.52 146.18 47.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.207 -0.451 . . . . 75.13 110.912 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 2.2 t -60.53 142.26 55.54 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 73.33 110.895 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -84.37 -45.33 12.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 65.24 111.06 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -53.67 -39.52 61.26 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.766 -0.731 . . . . 70.0 112.467 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 10.7 p90 -144.2 112.66 6.51 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.904 0.383 . . . . 73.23 110.921 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 20.1 t30 -131.08 157.03 44.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.465 . . . . 72.12 110.902 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.2 mt-30 -54.52 119.95 5.97 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.224 -0.444 . . . . 74.23 110.887 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.61 6.47 46.9 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.731 -0.747 . . . . 73.03 112.521 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.16 150.4 40.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.793 0.33 . . . . 73.51 110.802 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 33.4 m0 -122.24 140.85 52.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.189 -0.459 . . . . 75.1 110.936 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.1 p -148.55 122.58 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.171 -0.468 . . . . 72.21 111.151 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -84.81 114.17 21.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 73.43 111.083 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.7 p -106.06 109.3 21.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.247 -0.433 . . . . 73.13 110.823 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -113.08 123.58 50.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 74.32 110.852 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.87 168.47 25.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 71.24 110.916 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -96.01 127.82 42.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 75.25 110.882 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.1 p -97.45 109.75 22.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.243 -0.435 . . . . 71.41 110.808 -179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 9.2 tmtt? -88.05 106.63 18.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.077 -0.51 . . . . 74.03 110.904 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.1 p -86.29 139.13 17.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.461 . . . . 70.24 111.107 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -135.27 102.46 5.17 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.207 -0.451 . . . . 64.24 110.977 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 8.5 p -168.73 153.99 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.16 -0.473 . . . . 75.14 111.142 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 130.11 71.16 0.12 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.779 -0.724 . . . . 72.31 112.505 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -89.73 -66.07 0.96 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.83 0.347 . . . . 75.42 110.916 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -161.93 154.97 20.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 64.41 110.864 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 9.1 tp -69.74 167.46 17.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.086 -0.506 . . . . 73.52 110.896 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -85.65 65.36 3.96 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 72.33 112.487 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -85.29 103.97 14.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.834 0.349 . . . . 71.12 110.864 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 30.5 tp -83.24 -35.92 24.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 71.15 110.877 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -51.81 -36.31 47.42 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 75.22 110.938 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 23.2 t -82.71 128.08 39.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 72.1 111.113 179.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -119.98 54.73 0.64 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.662 -0.78 . . . . 73.32 112.489 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 52.95 34.99 47.1 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.782 -0.723 . . . . 71.34 112.484 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -157.16 -103.22 0.2 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.71 -0.757 . . . . 74.43 112.421 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -69.82 166.32 19.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.84 0.352 . . . . 64.13 111.103 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.2 tp 66.4 137.41 0.05 OUTLIER Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.594 0.711 . . . . 74.5 110.869 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 140.87 43.7 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.741 2.294 . . . . 71.33 112.291 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 9.1 t-20 -93.3 150.46 20.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.194 -0.457 . . . . 73.11 110.911 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -93.87 160.55 14.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 74.11 111.058 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -147.36 140.31 25.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.485 . . . . 74.03 110.875 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 29.7 m -104.96 147.81 10.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.209 -0.45 . . . . 74.21 111.107 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.5 t -139.33 124.12 18.58 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.137 -0.483 . . . . 70.34 110.877 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 5.3 mp -120.76 105.33 16.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.167 -0.469 . . . . 73.14 111.165 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -135.67 109.99 0.79 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.772 -0.727 . . . . 74.31 112.527 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -147.7 152.19 37.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.853 0.359 . . . . 63.34 110.893 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -52.32 148.93 6.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 63.05 110.817 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 43.9 p -76.55 109.41 10.28 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.172 -0.467 . . . . 74.55 111.135 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.8 p -94.61 176.54 6.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 72.1 111.203 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 1.5 pt? -108.71 155.52 20.63 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.202 -0.454 . . . . 72.3 110.921 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -126.02 141.78 51.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.215 -0.448 . . . . 74.4 111.124 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -103.39 131.88 50.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 74.04 110.944 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -131.87 144.39 50.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.129 -0.487 . . . . 64.53 110.914 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.1 mm -115.2 114.2 45.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 54.04 111.118 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -102.87 129.95 49.73 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.15 -0.477 . . . . 72.14 111.06 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 22.7 m-85 -115.62 122.15 44.75 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 75.22 110.962 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -88.96 100.9 13.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 75.31 110.844 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.6 p -96.51 -33.17 4.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.122 -0.49 . . . . 74.12 111.132 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.6 m -132.01 159.17 39.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.15 -0.477 . . . . 71.04 110.828 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -84.03 3.18 35.6 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.105 -0.498 . . . . 62.54 110.788 -179.79 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -116.56 -31.49 5.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 72.13 110.878 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 33.8 pt -144.21 162.19 15.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 70.53 111.142 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -152.7 170.63 19.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 62.51 111.127 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.6 m -115.17 152.56 16.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 72.34 111.158 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -149.96 128.92 12.58 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.185 -0.461 . . . . 74.0 110.82 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -105.99 132.13 52.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.176 -0.466 . . . . 70.43 110.892 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -105.39 121.83 44.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.152 -0.476 . . . . 73.4 110.906 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 5.9 t -145.73 159.24 12.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.129 -0.487 . . . . 74.3 111.08 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -152.64 170.16 31.77 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.65 -0.786 . . . . 72.12 112.425 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.4 t -119.69 64.77 8.88 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.643 0.735 . . . . 75.35 111.148 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 163.36 38.58 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.642 2.228 . . . . 73.32 112.37 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -120.35 -166.96 1.38 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 73.52 111.139 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 33.8 ttp85 -76.86 120.65 22.29 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.266 -0.425 . . . . 74.21 110.821 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -124.26 150.92 44.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.216 -0.447 . . . . 75.11 111.121 179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -101.92 139.66 37.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.188 -0.46 . . . . 73.41 110.864 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -140.87 158.28 44.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 74.35 110.906 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 9.6 mt-30 -99.03 156.83 16.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 71.14 110.889 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -179.67 71.56 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.803 -0.713 . . . . 73.21 112.525 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -178.37 -177.36 0.56 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.893 0.378 . . . . 75.33 110.864 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.02 -68.95 0.7 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 74.12 110.903 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.8 t -83.24 -35.11 25.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.126 -0.488 . . . . 63.51 110.854 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 6.9 mm -63.54 -33.78 63.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.09 -0.505 . . . . 75.34 111.135 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 55.2 p -62.4 -49.24 76.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.235 -0.438 . . . . 62.2 110.911 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.3 t -51.21 -40.26 58.36 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.143 -0.48 . . . . 70.04 110.811 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 13.4 mt -60.73 -46.33 90.81 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.143 -0.48 . . . . 75.14 110.949 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 112.41 -14.43 25.3 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.714 -0.755 . . . . 63.03 112.481 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 27.8 mtp180 -121.1 96.34 5.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.824 0.345 . . . . 72.12 110.862 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 39.6 t -113.8 -44.36 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.461 . . . . 73.22 111.138 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.5 p -142.62 147.75 36.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 73.34 110.874 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -149.39 118.83 6.89 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.172 -0.467 . . . . 62.14 110.843 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 2.9 p -177.76 166.25 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 73.35 111.155 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -90.59 156.58 18.03 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.088 -0.505 . . . . 61.12 110.904 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -113.61 155.03 26.19 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.245 -0.434 . . . . 73.1 110.953 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -122.41 70.11 0.42 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.736 -0.745 . . . . 63.13 112.463 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 112.77 3.17 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.738 2.292 . . . . 72.4 112.328 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -131.97 110.19 10.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.24 -0.437 . . . . 70.32 111.105 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 2.7 mt -129.51 150.01 34.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 75.13 111.103 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 1.2 pp -152.35 115.39 4.65 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.119 -0.491 . . . . 73.53 110.862 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' SER . . . . . 0.424 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 4.3 p -138.78 -176.47 4.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.234 -0.439 . . . . 63.22 110.857 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -130.37 154.97 47.14 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.167 -0.469 . . . . 74.42 110.943 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 45.0 mt-30 -102.65 135.89 43.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 63.14 110.979 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -120.54 118.76 31.05 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.263 -0.426 . . . . 70.44 110.868 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -110.9 105.53 14.36 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.126 -0.488 . . . . 72.24 110.869 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -85.22 161.82 19.42 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.201 -0.454 . . . . 74.14 110.938 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -55.02 103.96 0.1 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.107 -0.497 . . . . 75.13 110.844 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 27.2 m -93.9 151.87 19.27 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.182 -0.463 . . . . 71.33 110.883 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -65.25 -179.25 0.57 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.161 -0.472 . . . . 74.41 110.905 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -51.66 -36.04 44.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.171 -0.468 . . . . 74.1 110.899 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 41.6 mtt180 -66.6 -179.97 0.94 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 75.43 110.866 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 13.2 tp -93.47 128.92 39.77 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.216 -0.447 . . . . 73.52 110.974 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.7 t80 -135.24 134.66 21.57 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.63 0.729 . . . . 74.34 110.921 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 177.64 5.41 Favored 'Trans proline' 0 N--CA 1.465 -0.175 0 C-N-CA 122.713 2.275 . . . . 62.41 112.363 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -112.7 155.25 24.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.245 -0.434 . . . . 75.42 110.941 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.2 p -106.29 124.21 61.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.099 -0.501 . . . . 74.31 111.154 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -116.77 163.37 12.49 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.737 -0.744 . . . . 73.1 112.52 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.1 p -175.73 150.65 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.842 0.353 . . . . 75.51 111.141 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.424 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -176.98 -150.39 8.31 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.757 -0.735 . . . . 63.44 112.508 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . 0.523 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 12.7 p -108.34 130.48 60.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.85 0.357 . . . . 72.11 111.195 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -124.45 109.94 1.33 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.784 -0.722 . . . . 42.43 112.51 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 13.8 ptm180 -104.97 131.81 52.01 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.837 0.351 . . . . 75.34 110.847 -179.802 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . 0.422 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 3.6 p -116.49 119.18 61.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.217 -0.447 . . . . 73.15 111.08 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.7 mp -113.52 172.7 6.81 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.126 -0.488 . . . . 72.02 110.917 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 3.3 p90 -131.2 172.55 12.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.443 . . . . 72.03 110.899 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -111.71 174.69 5.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 62.34 110.918 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -112.68 112.09 23.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.12 -0.491 . . . . 72.13 110.865 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 63.5 mmtt -146.11 -85.8 0.11 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 72.3 110.887 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 7.4 m -163.11 96.22 0.88 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.254 -0.43 . . . . 74.33 111.133 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -112.29 165.83 11.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 74.35 110.884 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 64.22 153.49 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 74.22 112.471 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -82.9 1.8 37.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.838 0.351 . . . . 75.14 111.056 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -87.04 -177.24 5.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.446 . . . . 74.13 110.882 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 6.1 m -64.76 88.1 0.06 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 73.34 110.848 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 9.6 m 53.62 75.28 0.27 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.46 . . . . 74.43 110.793 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -90.49 159.2 16.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.108 -0.496 . . . . 72.43 110.845 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -130.85 172.69 11.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.072 -0.513 . . . . 74.24 110.822 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.4 tt -117.41 171.61 5.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.128 -0.487 . . . . 75.33 111.136 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -119.59 103.98 9.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 73.43 110.896 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.422 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 0.6 OUTLIER -72.74 -171.55 0.86 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.28 -0.418 . . . . 74.33 110.89 179.867 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -172.44 179.28 2.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.221 -0.445 . . . . 73.25 110.929 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 28.7 p-90 -152.08 154.01 35.08 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.232 -0.44 . . . . 74.12 110.878 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.425 ' CB ' ' HD2' ' A' ' 147' ' ' PRO . . . -179.81 166.86 0.82 Allowed Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.594 0.711 . . . . 72.4 111.108 179.874 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . 0.523 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 53.9 Cg_endo -69.71 137.16 34.93 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.687 2.258 . . . . 75.22 112.388 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -126.91 160.51 30.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.272 -0.422 . . . . 73.53 111.092 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -103.54 163.94 11.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 75.04 110.917 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 44.4 tt0 -153.07 149.47 28.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.222 -0.445 . . . . 72.32 110.936 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.2 p -146.05 129.85 10.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 74.14 111.113 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . 0.413 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 172.89 -167.58 40.44 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.718 -0.753 . . . . 62.23 112.528 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -148.51 168.42 22.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.803 0.335 . . . . 74.25 110.911 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 7.2 tpp85 -116.76 118.84 33.64 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 73.02 110.895 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -101.68 149.92 23.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.137 -0.483 . . . . 75.44 110.928 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -120.64 98.19 5.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.485 . . . . 74.45 110.923 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 25.0 tp -95.98 98.13 10.15 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 72.55 110.9 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 72.99 -146.38 38.0 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.675 -0.774 . . . . 54.05 112.458 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 35.3 t-20 -120.47 -33.43 3.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.807 0.336 . . . . 75.54 110.847 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 24.3 p -50.74 -65.5 0.55 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.479 . . . . 72.24 110.866 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 52.4 p-90 -141.02 146.18 36.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.144 -0.48 . . . . 72.35 110.938 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 10.8 mmt -101.67 178.69 4.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 60.2 110.898 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 9.2 mt -120.23 149.51 42.15 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.234 -0.439 . . . . 75.34 110.944 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -142.42 133.42 25.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 74.52 110.894 179.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.5 t -137.89 122.39 18.44 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.187 -0.46 . . . . 74.11 110.826 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . 0.413 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.5 OUTLIER -154.2 162.73 40.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.146 -0.479 . . . . 65.44 110.859 179.909 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 42.1 t -146.0 125.34 5.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 74.34 111.148 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . 0.42 ' HD3' ' HB ' ' A' ' 195' ' ' ILE . 0.0 OUTLIER -100.92 155.73 17.79 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.259 -0.428 . . . . 73.21 110.871 -179.961 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 26.3 t80 -163.43 143.3 8.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 74.33 110.986 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' ILE . . . . . 0.414 HG13 ' HD2' ' A' ' 171' ' ' PRO . 3.1 tp -179.74 131.51 0.26 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 72.14 111.163 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . 0.414 ' HD2' HG13 ' A' ' 170' ' ' ILE . 53.4 Cg_endo -69.75 116.0 4.35 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.724 2.283 . . . . 72.43 112.272 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -117.47 177.1 4.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 62.14 110.894 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.84 116.93 6.38 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 75.44 110.955 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.2 t -105.92 161.52 14.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.262 -0.426 . . . . 75.2 111.203 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -127.51 176.8 7.2 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.264 -0.425 . . . . 71.14 110.873 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 2.4 p -145.5 141.94 22.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.192 -0.458 . . . . 70.23 111.131 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 2.0 t -166.24 160.17 15.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 74.34 111.139 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -159.3 -157.75 8.73 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.813 -0.708 . . . . 74.44 112.478 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 73.2 p -127.01 96.39 4.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.774 0.321 . . . . 74.41 111.154 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 9.7 tt -141.33 102.88 4.31 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.253 -0.431 . . . . 72.21 110.95 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 57.68 173.62 0.33 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.822 -0.704 . . . . 72.41 112.449 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.535 ' O ' ' HB ' ' A' ' 183' ' ' VAL . 53.5 Cg_endo -69.71 75.1 1.22 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.698 2.265 . . . . 74.4 112.397 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . 0.535 ' HB ' ' O ' ' A' ' 182' ' ' PRO . 2.4 p 159.57 83.55 0.0 OUTLIER Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 121.635 0.731 . . . . 75.02 111.121 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 142.22 47.63 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.733 2.289 . . . . 74.34 112.338 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 62.8 t -95.57 105.84 17.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.242 -0.435 . . . . 63.3 111.139 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.72 109.06 20.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.16 -0.473 . . . . 74.22 110.854 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -118.3 161.03 20.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 73.11 111.161 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 21.9 pttt -136.84 157.28 47.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.435 . . . . 74.22 110.906 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 5.7 tp -154.79 120.7 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.228 -0.442 . . . . 75.41 111.132 179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.38 116.05 31.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.144 -0.48 . . . . 74.34 110.893 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 7.6 p -136.18 155.37 34.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.145 -0.48 . . . . 74.43 111.097 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.04 88.69 3.88 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.683 0.754 . . . . 72.41 110.831 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.87 142.56 47.79 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.659 2.24 . . . . 62.54 112.297 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 5.1 t80 -112.65 123.15 49.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.14 -0.482 . . . . 70.1 110.895 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 195' ' ' ILE . . . . . 0.42 ' HB ' ' HD3' ' A' ' 168' ' ' ARG . 56.7 mt -116.37 125.02 73.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.168 -0.469 . . . . 73.42 111.1 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 7.5 tt -116.39 109.88 17.92 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.122 -0.49 . . . . 74.45 110.982 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.96 119.23 35.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.202 -0.454 . . . . 72.4 110.856 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 55.1 tp -140.07 126.8 20.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.113 -0.494 . . . . 71.51 110.9 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -177.32 -141.27 3.99 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.74 -0.743 . . . . 75.04 112.466 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -129.37 173.42 10.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.781 0.324 . . . . 64.44 111.113 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 99.4 p -146.58 170.26 17.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 53.42 110.803 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 68.6 t80 -139.69 113.01 8.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.099 -0.501 . . . . 74.23 110.938 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 12.6 t -77.33 154.24 5.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.043 -0.526 . . . . 73.52 111.123 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 77.6 t80 -160.32 122.21 3.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.166 -0.47 . . . . 72.42 110.888 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 6.6 ptpp? -102.89 162.6 12.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 71.33 110.915 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 59.6 mt -97.95 48.14 1.01 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.213 -0.449 . . . . 74.34 110.902 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -132.61 -45.98 0.89 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.252 -0.431 . . . . 63.23 111.101 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -64.8 135.53 55.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.186 -0.461 . . . . 74.22 111.092 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -156.72 169.13 25.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.234 -0.439 . . . . 71.53 111.117 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 7.4 tp 63.06 39.31 10.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 75.24 110.902 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.261 -0.427 . . . . 74.12 110.861 179.935 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 48.4 mtm . . . . . 0 N--CA 1.457 -0.116 0 CA-C-O 120.774 0.321 . . . . 72.54 110.916 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 63.9 m-20 -103.15 52.88 0.77 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 72.32 110.912 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -141.34 55.33 1.53 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.162 -0.472 . . . . 71.44 110.861 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -103.52 135.19 45.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 74.21 110.916 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 38.3 t80 -121.8 136.72 26.38 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.704 0.764 . . . . 75.12 110.973 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 78.6 0.98 Allowed 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.682 2.255 . . . . 73.04 112.361 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -102.39 174.04 6.09 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.241 -0.436 . . . . 75.41 111.114 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 17.5 mtpp 52.92 36.14 20.99 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 72.22 110.819 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 22.2 m -53.59 131.65 39.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.424 . . . . 70.41 110.886 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.52 135.79 33.77 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.172 -0.467 . . . . 74.53 111.114 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -147.41 122.2 1.52 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.721 -0.752 . . . . 65.44 112.493 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -158.46 116.56 2.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.901 0.382 . . . . 65.31 110.915 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 26.1 m120 -152.05 157.76 42.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.131 -0.486 . . . . 74.05 110.822 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.4 pt20 -53.47 127.84 26.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.159 -0.473 . . . . 71.53 110.913 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.97 5.78 52.94 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.761 -0.733 . . . . 63.14 112.534 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -72.53 150.95 42.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.816 0.341 . . . . 75.45 110.848 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 25.1 t90 -116.32 143.96 44.86 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.206 -0.452 . . . . 70.5 111.001 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.9 t -145.57 123.27 4.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.265 -0.425 . . . . 72.12 111.058 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -82.61 109.19 16.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 74.32 111.108 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -95.07 127.75 41.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.155 -0.475 . . . . 71.15 110.851 -179.772 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 64.4 t80 -138.63 116.18 11.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.102 -0.499 . . . . 73.11 110.945 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -152.62 173.42 15.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.46 . . . . 72.35 110.917 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 14.6 m-85 -102.38 128.41 48.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 73.01 110.856 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 24.6 p -96.72 136.66 36.94 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.194 -0.457 . . . . 45.13 110.857 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.79 106.73 12.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.133 -0.485 . . . . 74.44 110.927 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 27.5 m -78.55 126.68 38.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.435 . . . . 70.41 111.101 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -119.19 106.16 12.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.134 -0.485 . . . . 73.21 110.954 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.9 p -174.07 152.73 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 72.22 111.154 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.72 72.35 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.726 -0.749 . . . . 75.53 112.488 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -89.53 -66.11 0.95 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.813 0.339 . . . . 61.13 110.85 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -171.55 149.07 2.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.127 -0.488 . . . . 73.1 110.882 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.2 tt -103.15 143.67 32.31 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.123 -0.489 . . . . 74.11 110.971 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -64.26 106.59 1.48 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.767 -0.73 . . . . 61.41 112.463 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -95.55 -51.39 4.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.764 0.316 . . . . 73.22 110.854 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 17.7 tp -154.32 145.51 22.85 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.212 -0.449 . . . . 75.41 111.009 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 21.2 p-10 -98.14 -39.5 8.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 73.11 110.865 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 16.2 m -142.54 138.44 28.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.199 -0.455 . . . . 64.24 111.127 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 154.84 -136.66 5.27 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.727 -0.749 . . . . 71.14 112.492 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -149.82 -150.66 5.31 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.737 -0.744 . . . . 73.11 112.493 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 108.0 161.21 20.82 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.752 -0.737 . . . . 73.44 112.53 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -78.32 113.16 16.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.813 0.339 . . . . 75.35 111.157 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 16.5 mt 51.84 71.39 1.51 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.622 0.725 . . . . 74.24 110.957 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 81.84 0.79 Allowed 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.649 2.233 . . . . 74.1 112.393 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 10.2 p30 -153.27 127.77 9.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.17 -0.468 . . . . 73.23 110.869 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -100.18 -178.3 3.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.197 -0.456 . . . . 62.42 111.093 179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -143.18 128.44 18.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 71.31 110.874 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 14.4 p -104.77 146.59 11.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 64.12 111.21 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 15.1 t -156.92 137.24 12.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 71.41 110.816 -179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 18.5 tt -112.05 144.69 19.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.133 -0.485 . . . . 74.34 111.115 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -117.45 129.45 8.33 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.699 -0.763 . . . . 74.35 112.505 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.1 t-20 -150.82 128.21 11.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.824 0.345 . . . . 75.02 110.812 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.408 ' O ' ' C ' ' A' ' 53' ' ' THR . 12.8 p-10 -153.79 163.49 39.93 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.107 -0.497 . . . . 72.41 110.897 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' THR . . . . . 0.408 ' C ' ' O ' ' A' ' 52' ' ' ASP . 10.0 t 37.45 43.56 0.42 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 73.02 111.143 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.97 170.5 8.04 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.158 -0.474 . . . . 72.04 111.163 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -156.06 166.15 34.31 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.26 -0.427 . . . . 75.5 110.915 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 43.8 p -140.39 144.66 36.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.198 -0.455 . . . . 74.04 111.144 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -118.94 132.41 56.08 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.434 . . . . 74.53 110.86 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.401 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -131.87 150.51 52.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 74.21 110.832 -179.969 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 20.0 mm -110.47 114.41 46.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.236 -0.438 . . . . 73.23 111.123 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -103.36 123.73 47.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.176 -0.465 . . . . 61.44 111.124 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -112.97 119.51 38.18 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 73.14 110.883 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -80.1 113.73 18.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.084 -0.507 . . . . 65.32 110.863 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 83.3 t -111.27 -32.69 2.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 72.24 111.222 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -124.09 -172.53 2.56 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.104 -0.498 . . . . 75.3 110.85 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 5.0 p -85.82 -36.25 20.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.121 -0.49 . . . . 71.12 110.832 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -126.31 19.36 7.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 74.11 110.932 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 24.8 mt -148.97 135.77 13.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.111 -0.495 . . . . 75.35 111.122 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -153.32 170.13 21.39 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.172 -0.467 . . . . 73.04 111.076 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.3 m -106.34 151.32 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.265 -0.425 . . . . 75.2 111.083 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -143.03 138.32 29.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.129 -0.487 . . . . 74.4 110.839 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 0.401 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 12.0 m-85 -121.59 109.32 14.64 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 73.13 110.92 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -83.83 121.44 27.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.154 -0.475 . . . . 74.05 110.867 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 24.8 t -135.89 146.59 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 75.42 111.1 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -162.31 124.35 1.29 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.678 -0.772 . . . . 64.13 112.497 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 43.7 t -114.91 70.18 2.39 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.638 0.733 . . . . 62.11 111.132 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 162.79 40.72 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 75.24 112.331 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -76.32 -170.52 1.49 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.213 -0.449 . . . . 73.55 111.13 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 19.8 ttp180 -77.48 137.2 38.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 72.4 110.916 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -134.28 150.93 51.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.226 -0.443 . . . . 53.53 111.068 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -100.51 138.31 37.73 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 73.43 110.898 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -128.09 155.31 44.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 72.22 110.894 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.443 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 1.1 pt20 -110.26 153.26 25.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 75.43 110.995 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 179.93 75.22 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.758 -0.734 . . . . 44.54 112.52 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -177.25 -176.89 0.68 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.906 0.384 . . . . 71.55 110.86 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 3.6 mtpm? -85.67 -69.66 0.65 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 74.04 110.868 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.5 t -84.31 -33.41 23.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 72.05 110.928 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 6.1 mm -64.62 -34.33 69.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.124 -0.489 . . . . 75.32 111.113 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 78.6 p -63.7 -50.48 69.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.144 -0.48 . . . . 75.54 110.856 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 44.6 t -51.45 -38.06 51.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.146 -0.479 . . . . 74.31 110.863 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 9.3 tp -64.83 -42.66 94.79 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.172 -0.467 . . . . 71.22 110.931 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 106.14 -14.57 44.1 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.755 -0.736 . . . . 74.23 112.491 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 24.3 ttp180 -114.37 94.33 4.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.834 0.349 . . . . 73.12 110.922 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.443 ' HB ' ' HA ' ' A' ' 82' ' ' GLN . 85.5 t -112.86 -51.83 5.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 75.12 111.106 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 10.9 p -139.12 143.52 38.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.158 -0.474 . . . . 73.12 110.829 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -130.92 118.22 20.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.136 -0.484 . . . . 72.42 110.917 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 9.8 p -176.08 161.26 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.181 -0.463 . . . . 74.21 111.113 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -91.07 174.12 7.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 70.22 110.849 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -119.91 134.53 55.21 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.165 -0.471 . . . . 71.53 110.947 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -121.76 66.61 0.46 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.719 -0.753 . . . . 71.42 112.509 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 117.43 5.08 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.617 2.211 . . . . 74.02 112.321 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -132.37 104.24 6.62 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.157 -0.474 . . . . 75.42 111.087 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 5.0 mp -130.03 150.57 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 73.31 111.094 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -143.75 115.39 8.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 72.42 110.899 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.1 p -142.87 159.65 41.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.232 -0.44 . . . . 72.12 110.887 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -108.12 146.58 32.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.141 -0.481 . . . . 75.12 110.893 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -100.97 137.99 38.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 72.15 110.872 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 28.6 p90 -141.63 156.19 45.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.204 -0.453 . . . . 74.2 110.916 -179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 20.0 m-70 -95.77 130.62 42.64 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.115 -0.493 . . . . 71.33 110.835 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 52.5 t80 -98.5 140.57 32.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 74.43 110.92 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -62.65 125.63 24.61 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.082 -0.508 . . . . 65.13 110.809 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.3 m -150.0 147.39 27.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.47 . . . . 75.33 110.856 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -57.93 -39.42 77.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.136 -0.484 . . . . 74.44 110.914 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 20.9 mm-40 -53.95 172.78 0.07 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.142 -0.481 . . . . 74.43 110.897 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 6.8 tpt85 -117.23 -37.74 3.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.133 -0.485 . . . . 73.13 110.881 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -113.85 110.47 20.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 75.13 110.922 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 21.6 p90 -164.36 155.57 13.58 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.672 0.749 . . . . 75.23 110.919 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 177.74 5.25 Favored 'Trans proline' 0 N--CA 1.465 -0.186 0 C-N-CA 122.69 2.26 . . . . 55.23 112.402 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 1.2 p90 -112.05 162.78 15.02 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.261 -0.427 . . . . 71.42 110.941 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 43.9 t -121.41 136.24 58.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.124 -0.489 . . . . 74.24 111.173 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -128.58 179.09 16.81 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.771 -0.728 . . . . 74.22 112.437 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 7.6 p -163.44 155.79 2.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.89 0.376 . . . . 65.13 111.125 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -179.34 -157.41 19.69 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.73 -0.748 . . . . 61.23 112.509 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . 0.418 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.4 p -107.28 123.71 62.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.812 0.339 . . . . 75.03 111.173 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -115.45 107.66 1.77 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.774 -0.727 . . . . 62.14 112.497 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -106.13 126.82 52.67 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.932 0.396 . . . . 72.42 110.824 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 2.1 p -105.59 108.92 26.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.152 -0.476 . . . . 74.24 111.144 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 3.1 tp -116.58 170.33 8.66 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.259 -0.428 . . . . 75.42 110.993 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -161.7 179.35 8.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.246 -0.433 . . . . 74.24 110.926 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -117.23 115.47 25.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.469 . . . . 74.41 110.882 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -48.05 110.55 0.34 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 65.41 110.799 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 2.8 mmmt -104.09 -89.05 0.41 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 72.42 110.885 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.3 m -175.78 133.94 0.28 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.23 -0.441 . . . . 75.03 111.152 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . 0.418 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 19.3 m-20 -115.9 127.63 55.15 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.166 -0.47 . . . . 73.22 110.937 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -77.12 -11.09 85.88 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.753 -0.737 . . . . 63.01 112.522 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -45.12 -31.09 1.28 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.872 0.368 . . . . 74.33 111.077 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.5 tp -164.6 -177.18 4.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 74.02 110.938 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 16.5 m -51.42 95.24 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 74.12 110.862 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 93.3 p 47.26 72.03 0.28 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.071 -0.513 . . . . 71.11 110.892 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.418 ' HB3' ' HB2' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -88.97 160.26 17.22 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.131 -0.486 . . . . 63.34 110.84 -179.904 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 69.9 m-20 -147.2 -178.61 6.31 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.112 -0.495 . . . . 63.52 110.844 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.405 ' HA ' ' HA ' ' A' ' 176' ' ' VAL . 1.1 pt -141.92 174.39 6.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.128 -0.487 . . . . 74.42 111.139 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 14.7 tptt -123.85 135.58 53.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 74.32 110.877 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -78.5 -173.29 3.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 75.22 110.891 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 1.4 tttp -166.77 177.24 6.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 74.22 110.901 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 64.7 p-90 -156.95 160.3 38.93 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.227 -0.442 . . . . 73.45 110.928 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.427 ' CB ' ' HD2' ' A' ' 147' ' ' PRO . . . 177.44 166.73 0.51 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.622 0.725 . . . . 75.02 111.068 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . 0.427 ' HD2' ' CB ' ' A' ' 146' ' ' ALA . 53.4 Cg_endo -69.77 129.64 17.93 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.711 2.274 . . . . 74.32 112.279 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.413 ' HA ' ' HB ' ' A' ' 170' ' ' ILE . . . -122.69 170.17 10.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.217 -0.447 . . . . 73.3 111.113 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 13.2 m-85 -124.18 154.66 39.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.258 -0.428 . . . . 74.45 110.807 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 5.8 tt0 -130.63 151.95 50.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.102 -0.499 . . . . 74.45 110.862 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.4 p -153.1 125.85 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 75.21 111.185 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -179.78 -162.63 29.1 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.776 -0.726 . . . . 74.52 112.451 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -142.6 145.43 33.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.784 0.326 . . . . 71.24 110.857 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 3.9 tpp85 -115.37 119.34 35.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 75.32 110.855 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 63.3 t80 -110.59 150.21 29.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.223 -0.444 . . . . 74.35 110.951 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -121.27 123.52 42.39 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.151 -0.477 . . . . 71.21 110.852 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 1.7 tt -92.29 136.12 33.46 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.157 -0.474 . . . . 75.42 110.898 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -75.41 137.39 21.77 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.782 -0.723 . . . . 72.21 112.52 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 53.02 37.23 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.892 0.377 . . . . 72.43 110.894 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 2.3 m -172.59 173.95 3.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.154 -0.476 . . . . 44.24 110.82 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 7.0 m0 -62.55 158.76 17.27 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.146 -0.479 . . . . 64.22 110.912 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -92.97 171.17 9.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.255 -0.429 . . . . 54.23 110.927 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 80.7 mt -124.3 145.35 49.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 75.22 110.895 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -143.64 134.47 25.28 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.164 -0.471 . . . . 55.24 110.832 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 78.4 p -145.11 121.54 10.99 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.118 -0.492 . . . . 63.41 110.834 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -153.4 174.0 14.92 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.158 -0.474 . . . . 73.12 110.859 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 1.5 t -135.68 151.87 30.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.153 -0.476 . . . . 72.3 111.178 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -117.73 131.49 56.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 75.33 110.901 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 23.4 m-85 -132.07 134.68 45.78 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.144 -0.48 . . . . 75.42 110.966 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' ILE . . . . . 0.413 ' HB ' ' HA ' ' A' ' 148' ' ' ALA . 0.0 OUTLIER -179.13 120.49 0.23 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.618 0.723 . . . . 71.24 111.138 179.93 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.77 108.61 2.12 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.635 2.224 . . . . 74.42 112.333 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -116.48 157.11 25.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 74.52 110.834 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.36 118.98 25.18 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.131 -0.486 . . . . 75.14 110.89 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.9 t -95.08 144.64 25.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.21 -0.45 . . . . 75.22 111.092 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -100.21 150.58 22.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.163 -0.472 . . . . 72.11 110.855 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . 0.405 ' HA ' ' HA ' ' A' ' 141' ' ' ILE . 14.7 p -146.46 127.53 6.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.197 -0.456 . . . . 74.42 111.159 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 15.2 t -167.32 172.16 10.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 73.43 111.073 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -145.48 171.77 26.42 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.688 -0.768 . . . . 72.11 112.493 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -115.28 113.03 23.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.885 0.374 . . . . 73.54 111.124 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 11.1 tp -140.26 167.16 22.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.157 -0.474 . . . . 72.13 110.905 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -46.47 -68.79 0.98 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 72.54 112.505 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.84 -170.13 0.38 Allowed 'Trans proline' 0 C--O 1.232 0.19 0 C-N-CA 122.681 2.254 . . . . 65.23 112.37 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 4.5 p -66.86 116.12 31.95 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.661 0.743 . . . . 71.23 111.172 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 165.11 32.03 Favored 'Trans proline' 0 C--O 1.231 0.158 0 C-N-CA 122.654 2.236 . . . . 62.42 112.387 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 49.6 t -96.73 107.99 20.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.265 -0.425 . . . . 72.43 111.14 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 1.7 p -104.16 118.72 37.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 71.52 110.83 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 23.2 p -145.9 176.12 9.92 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.183 -0.462 . . . . 72.34 111.149 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -154.67 166.66 32.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 75.21 110.878 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 47.7 mm -140.23 114.44 6.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 73.12 111.099 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 7.6 tm-20 -103.01 106.74 17.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.136 -0.484 . . . . 65.13 110.93 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 8.7 m -137.03 163.49 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.174 -0.466 . . . . 72.51 111.145 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.3 89.28 4.63 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.61 0.719 . . . . 65.43 110.814 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 137.36 35.11 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.675 2.25 . . . . 75.4 112.385 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -104.26 114.7 29.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.308 -0.405 . . . . 73.11 110.813 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 4.0 mm -101.68 119.2 49.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.109 -0.496 . . . . 74.14 111.116 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 11.9 tp -104.86 109.49 21.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.241 -0.436 . . . . 72.23 110.902 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -102.46 119.58 39.07 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.163 -0.471 . . . . 54.05 110.833 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -139.13 129.65 25.8 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.164 -0.471 . . . . 72.23 110.963 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 179.88 -144.15 5.89 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.766 -0.73 . . . . 65.22 112.454 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -127.1 173.42 9.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.812 0.339 . . . . 65.5 111.087 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 15.2 m -146.96 169.87 18.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.214 -0.448 . . . . 72.33 110.89 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 1.1 t80 -141.49 131.66 24.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.168 -0.469 . . . . 75.14 110.935 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 5.8 t -81.12 158.58 4.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.479 . . . . 75.11 111.089 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -164.6 147.95 8.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.466 . . . . 73.42 110.915 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 35.8 mtpt 63.87 60.74 1.01 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 73.34 110.895 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 1.8 pt? -124.35 -178.85 4.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 74.52 110.923 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -88.39 98.97 11.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 74.42 111.081 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -116.85 123.2 46.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.262 -0.426 . . . . 64.14 111.073 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -158.58 157.92 32.92 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 71.51 111.073 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -118.32 160.47 21.58 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.201 -0.454 . . . . 75.33 110.896 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.156 -0.475 . . . . 75.13 110.91 179.879 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.046 0 CA-C-O 120.794 0.331 . . . . 71.45 110.858 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -123.22 115.08 21.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 72.34 110.935 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.1 mp0 -127.03 177.66 6.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.227 -0.442 . . . . 71.31 110.808 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 29.1 m120 -93.8 115.17 27.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.077 -0.51 . . . . 72.11 110.875 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 6.3 t80 -163.02 74.09 1.98 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.659 0.743 . . . . 75.33 110.907 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.83 151.78 68.78 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.72 2.28 . . . . 73.33 112.274 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -158.65 169.59 24.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.238 -0.437 . . . . 60.24 111.074 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.77 175.14 0.06 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.211 -0.45 . . . . 75.42 110.884 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.0 p -103.1 167.46 9.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.229 -0.441 . . . . 75.13 110.831 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -107.83 179.78 4.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.083 -0.508 . . . . 71.03 111.085 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.38 -85.9 1.71 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.698 -0.763 . . . . 70.52 112.513 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 14.1 m-85 -143.81 112.29 6.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.939 0.399 . . . . 74.13 110.894 -179.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -139.01 159.82 41.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.069 -0.514 . . . . 75.43 110.912 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 17.5 pt20 -51.54 120.04 4.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 74.45 110.907 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 101.7 7.91 46.97 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.729 -0.748 . . . . 64.13 112.468 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.62 156.23 27.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.81 0.338 . . . . 74.31 110.856 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 41.5 m95 -133.0 143.63 49.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.109 -0.496 . . . . 75.11 110.944 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 m -142.71 137.76 27.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.251 -0.431 . . . . 73.22 111.132 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -96.62 104.91 16.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 75.13 111.087 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.4 m -91.63 130.18 37.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 74.44 110.87 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 13.7 p90 -134.78 116.76 15.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.066 -0.515 . . . . 65.4 110.88 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -150.95 172.32 15.88 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.177 -0.465 . . . . 75.33 110.94 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 12.8 p90 -105.16 131.39 52.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 74.21 110.906 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -96.58 137.3 35.87 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.149 -0.478 . . . . 44.35 110.837 -179.76 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.7 mmtp -116.19 111.64 20.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.128 -0.487 . . . . 72.24 110.878 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 25.4 t -75.11 128.32 36.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.237 -0.438 . . . . 72.43 111.097 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 6.9 m-85 -125.96 106.92 9.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 74.33 110.977 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.7 p -171.59 152.92 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.119 -0.491 . . . . 72.21 111.146 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 169.34 64.74 0.04 OUTLIER Glycine 0 N--CA 1.453 -0.197 0 C-N-CA 120.766 -0.731 . . . . 75.43 112.491 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 13.8 tt0 -89.78 -66.3 0.94 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.76 0.314 . . . . 71.21 110.861 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 71.1 tt0 -175.05 154.88 1.88 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 71.12 110.905 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -110.07 133.91 52.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.484 . . . . 71.14 110.958 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.44 120.88 23.52 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.746 -0.74 . . . . 65.45 112.49 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -133.42 130.84 39.23 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.838 0.352 . . . . 54.14 110.818 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 5.6 mp -128.55 173.54 10.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.177 -0.465 . . . . 74.24 110.887 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -131.41 148.04 52.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 74.12 110.871 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.6 p -88.78 -34.6 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.469 . . . . 72.31 111.109 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -109.4 151.8 17.19 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.686 -0.769 . . . . 71.03 112.481 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -59.23 126.71 43.2 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.759 -0.734 . . . . 75.05 112.537 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -172.77 -141.24 3.38 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.717 -0.754 . . . . 63.25 112.474 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -84.53 161.47 20.21 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.805 0.336 . . . . 73.23 111.077 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.0 mt -127.45 69.02 74.6 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.636 0.731 . . . . 72.22 110.912 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.77 -170.88 0.42 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.677 2.251 . . . . 74.32 112.314 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -131.62 123.12 27.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 72.31 110.839 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.4 178.75 6.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.174 -0.466 . . . . 72.13 111.104 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -143.25 130.41 20.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.453 . . . . 73.31 110.846 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.5 p -104.78 138.56 29.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.185 -0.461 . . . . 74.23 111.089 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -142.85 159.16 42.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.117 -0.492 . . . . 75.22 110.835 -179.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -108.47 132.76 55.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.119 -0.491 . . . . 75.41 111.149 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -131.07 51.81 0.85 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.746 -0.74 . . . . 60.25 112.488 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 -102.81 112.6 25.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.834 0.35 . . . . 75.13 110.919 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -55.03 175.18 0.06 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 75.2 110.859 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 7.5 p -53.16 101.82 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.238 -0.437 . . . . 72.43 111.135 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 44.9 p -100.94 176.1 5.39 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 74.12 111.182 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 5.2 mp -129.78 161.51 30.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.269 -0.423 . . . . 73.44 110.924 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.5 143.01 30.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 74.22 111.087 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -123.05 132.41 54.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.248 -0.433 . . . . 75.23 110.862 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 14.5 p-10 -134.75 145.21 48.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 65.22 110.825 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.8 mm -108.95 116.81 52.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 74.42 111.085 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -101.87 125.2 48.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 63.14 111.07 179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 27.1 t80 -110.47 115.59 29.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.22 -0.445 . . . . 74.24 110.91 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -84.14 101.95 12.22 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.092 -0.503 . . . . 73.11 110.89 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.5 p -94.21 -33.15 4.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.151 -0.477 . . . . 75.34 111.041 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.0 m -134.1 164.33 27.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 73.54 110.782 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 7.8 p -86.67 3.14 45.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.083 -0.508 . . . . 71.03 110.885 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -112.43 -32.59 6.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.101 -0.5 . . . . 74.14 110.912 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 21.6 pt -146.44 167.81 6.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.173 -0.467 . . . . 73.42 111.163 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -154.69 169.13 24.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 72.43 111.12 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.409 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 1.4 p -111.62 147.2 15.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.3 -0.409 . . . . 65.22 111.19 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -139.78 127.0 21.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 64.32 110.798 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -108.56 110.43 21.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 71.31 110.874 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -87.03 129.4 34.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.126 -0.488 . . . . 75.23 110.872 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 9.9 m -149.44 163.42 4.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.118 -0.492 . . . . 72.3 111.134 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 175.01 142.57 4.13 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.757 -0.735 . . . . 75.11 112.477 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 3.9 p -118.71 77.78 14.95 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.657 0.741 . . . . 74.43 111.16 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 148.7 65.97 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.63 2.22 . . . . 74.1 112.387 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -67.31 -165.62 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.29 -0.414 . . . . 64.41 111.061 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 43.1 ttp180 -76.66 115.54 16.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 74.3 110.83 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -110.3 149.71 29.79 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.212 -0.449 . . . . 71.34 111.145 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.6 tmmm? -103.27 141.23 36.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 75.34 110.825 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 -139.47 157.33 46.03 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.136 -0.484 . . . . 61.3 110.86 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 9.3 mt-30 -105.96 156.15 18.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.198 -0.455 . . . . 74.0 110.977 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 176.26 73.81 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.712 -0.756 . . . . 74.51 112.512 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -174.37 -177.21 1.21 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.959 0.409 . . . . 74.22 110.857 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 2.3 ptmt -86.76 -69.95 0.64 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.096 -0.502 . . . . 74.52 110.858 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.6 t -84.07 -33.38 24.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.45 . . . . 54.31 110.913 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 4.6 mm -65.39 -34.46 70.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.115 -0.493 . . . . 75.33 111.146 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 63.5 p -61.48 -48.68 80.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.13 -0.486 . . . . 62.42 110.751 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.7 t -52.1 -39.93 60.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 71.21 110.83 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 82.5 mt -60.41 -47.86 84.25 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.163 -0.471 . . . . 74.43 110.941 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 114.93 -14.96 19.22 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.759 -0.734 . . . . 75.04 112.515 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 8.9 mtm180 -121.34 97.15 5.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.899 0.381 . . . . 75.25 110.901 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 17.0 t -112.97 -41.99 4.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.159 -0.473 . . . . 75.31 111.023 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 13.3 p -141.51 154.2 45.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 61.33 110.872 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 82.9 mt-10 -152.56 118.64 5.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.134 -0.485 . . . . 75.42 110.836 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 4.5 p -178.46 164.16 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 72.24 111.165 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -90.84 133.51 35.16 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.466 . . . . 73.51 110.86 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -92.21 146.14 23.95 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 74.33 110.86 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -113.49 70.93 0.23 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.767 -0.73 . . . . 71.1 112.497 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 112.48 3.1 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.714 2.276 . . . . 74.44 112.302 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -136.87 113.76 10.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.239 -0.437 . . . . 63.04 111.171 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 13.5 pt -139.68 153.61 23.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.209 -0.451 . . . . 72.4 111.117 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -142.21 117.05 9.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.204 -0.453 . . . . 75.03 110.898 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.3 p -142.82 161.26 38.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.227 -0.442 . . . . 71.31 110.885 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.409 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 4.5 pp -110.08 146.03 36.09 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.168 -0.469 . . . . 75.22 110.955 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 1.7 pp0? -101.13 144.43 30.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 73.31 110.965 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -152.58 159.78 43.24 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.244 -0.435 . . . . 73.1 110.955 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 7.7 p-80 -133.09 147.29 52.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.114 -0.494 . . . . 73.23 110.779 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 6.5 t80 -159.53 167.69 27.97 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.159 -0.473 . . . . 72.54 110.886 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 38.8 t0 58.58 47.41 13.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.105 -0.498 . . . . 62.53 110.946 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 36.0 p -53.91 113.64 1.29 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.171 -0.468 . . . . 74.33 110.856 -179.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 55.4 t80 -112.97 -36.28 5.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.097 -0.501 . . . . 73.4 110.861 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 2.1 tp10 -117.2 155.14 29.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 63.34 110.885 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 55.2 ttp180 -54.3 -45.1 72.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.145 -0.48 . . . . 72.44 110.897 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 13.0 mt -123.66 127.66 48.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.149 -0.478 . . . . 72.41 110.872 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 20.8 p90 -161.2 153.89 17.34 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.624 0.726 . . . . 62.4 110.952 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.67 178.37 4.58 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.72 2.28 . . . . 74.14 112.359 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 1.6 p90 -127.38 159.07 35.56 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.295 -0.411 . . . . 74.23 110.895 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 48.1 t -113.3 136.5 49.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.107 -0.497 . . . . 74.01 111.1 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -127.24 172.46 18.65 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.759 -0.734 . . . . 71.33 112.515 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.2 p -162.46 151.67 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.877 0.37 . . . . 65.34 111.18 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -176.65 -156.23 15.1 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.693 -0.765 . . . . 70.34 112.46 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . 0.455 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 5.8 m -107.82 122.04 61.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.921 0.391 . . . . 61.54 111.083 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -115.9 121.31 5.2 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.699 -0.762 . . . . 71.32 112.523 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -116.51 132.7 56.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.829 0.347 . . . . 73.03 110.862 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 2.8 m -107.66 108.67 25.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 75.02 111.147 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -86.86 166.53 15.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 73.23 110.956 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -149.24 134.51 18.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 74.13 110.902 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 28.3 t80 -100.34 165.13 11.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.147 -0.479 . . . . 73.34 110.909 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -97.49 120.19 37.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 62.4 110.826 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 4.3 tppp? -141.17 -82.18 0.23 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 75.25 110.838 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 31.7 m -162.78 83.92 0.52 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.267 -0.424 . . . . 71.24 111.185 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -104.57 165.11 11.28 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.229 -0.441 . . . . 72.31 110.898 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 62.13 154.85 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.725 -0.75 . . . . 54.43 112.463 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -84.77 1.71 45.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.808 0.337 . . . . 70.0 111.088 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -86.26 -175.75 5.63 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.26 -0.427 . . . . 74.34 110.965 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.4 m -63.55 87.53 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.191 -0.459 . . . . 72.44 110.83 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 38.6 t 51.17 76.63 0.15 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.074 -0.512 . . . . 61.22 110.854 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -86.55 148.87 25.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.163 -0.471 . . . . 73.44 110.806 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 59.4 m-20 -122.03 -178.76 3.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.045 -0.525 . . . . 75.24 110.898 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.406 ' HA ' ' HA ' ' A' ' 176' ' ' VAL . 0.1 OUTLIER -145.2 160.51 13.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.445 . . . . 74.33 111.124 179.988 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 3.4 ttmt -105.27 122.42 45.89 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.21 -0.45 . . . . 73.3 110.918 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -63.59 -173.48 0.07 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.241 -0.436 . . . . 74.11 110.859 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 18.6 tptt -158.45 164.62 36.04 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.191 -0.459 . . . . 74.33 110.913 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 17.6 p90 -155.87 146.48 21.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.167 -0.469 . . . . 75.12 110.889 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.469 ' CB ' ' HD2' ' A' ' 147' ' ' PRO . . . 179.74 168.76 0.68 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.592 0.711 . . . . 62.5 111.138 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . 0.469 ' HD2' ' CB ' ' A' ' 146' ' ' ALA . 53.8 Cg_endo -69.75 125.1 11.76 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.703 2.269 . . . . 73.2 112.364 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -117.96 171.08 8.32 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.238 -0.437 . . . . 62.23 111.078 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 16.3 m-85 -123.6 138.55 54.53 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.13 -0.486 . . . . 74.32 110.861 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 40.0 tt0 -119.93 159.49 24.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.138 -0.483 . . . . 74.21 110.862 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -160.7 133.32 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.453 . . . . 71.44 111.154 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . 0.42 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 179.38 -158.67 22.79 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.66 -0.781 . . . . 72.24 112.442 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -146.93 166.38 26.93 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.777 0.322 . . . . 74.13 110.94 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . 0.41 ' HD3' ' N ' ' A' ' 155' ' ' TYR . 5.6 tpp85 -129.56 117.86 21.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.248 -0.433 . . . . 75.22 110.858 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . 0.41 ' N ' ' HD3' ' A' ' 154' ' ' ARG . 3.4 t80 -104.12 144.32 31.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.234 -0.439 . . . . 74.01 110.85 -179.811 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -120.47 98.26 5.96 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.124 -0.489 . . . . 74.05 110.842 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 78.8 mt -69.53 152.77 44.41 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.204 -0.453 . . . . 75.11 110.898 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -52.8 -33.84 43.59 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.733 -0.746 . . . . 72.15 112.495 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -65.78 178.53 1.03 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.86 0.362 . . . . 75.13 110.932 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 1.2 m -66.08 -35.88 81.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.144 -0.48 . . . . 73.34 110.958 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 47.0 p90 -82.76 152.82 25.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.068 -0.515 . . . . 72.32 110.991 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 2.3 mpt? -123.7 177.44 5.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.28 -0.418 . . . . 70.24 110.819 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -118.42 144.56 45.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.464 . . . . 73.3 110.87 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -143.63 137.61 28.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.15 -0.477 . . . . 55.05 110.923 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.0 t -144.06 121.44 11.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 72.54 110.803 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . 0.42 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.8 OUTLIER -137.37 159.66 41.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 74.35 110.908 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 50.4 t -132.84 134.44 58.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 72.01 111.15 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 2.1 ttt85 -106.17 137.59 43.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 73.24 110.8 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 23.1 t80 -148.55 132.5 17.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 74.01 110.894 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -178.71 123.63 0.25 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.705 0.764 . . . . 73.23 111.121 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 104.16 1.27 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.669 2.246 . . . . 74.21 112.284 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -117.53 175.03 5.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 73.34 110.935 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.2 132.88 25.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.249 -0.432 . . . . 73.11 110.951 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -111.15 150.85 28.89 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.244 -0.434 . . . . 73.32 111.123 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.44 158.84 16.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.223 -0.444 . . . . 65.42 110.849 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . 0.406 ' HA ' ' HA ' ' A' ' 141' ' ' ILE . 10.3 t -138.61 123.2 21.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.461 . . . . 74.23 111.172 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 15.3 t -166.67 172.57 10.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 74.53 111.149 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 117.72 140.07 6.45 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.755 -0.736 . . . . 62.41 112.443 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 43.5 m -167.77 143.24 3.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.799 0.333 . . . . 75.41 111.08 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 7.9 tp -102.84 89.05 3.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.143 -0.481 . . . . 74.33 110.927 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 131.2 -90.7 0.29 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.742 -0.742 . . . . 74.13 112.489 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 -176.92 1.66 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.712 2.275 . . . . 73.02 112.303 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 89.3 t -74.84 120.24 80.62 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-O 121.615 0.722 . . . . 74.12 111.19 179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.79 157.36 60.59 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.71 2.274 . . . . 65.13 112.281 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 4.2 t -95.96 159.05 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 74.52 111.186 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 6.2 p -130.43 108.55 10.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.974 0.416 . . . . 74.55 110.906 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 16.8 p -127.36 167.21 16.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.18 -0.464 . . . . 75.23 111.177 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 4.0 tttt -151.92 142.71 22.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 63.11 110.955 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 6.8 tp -137.5 125.68 32.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 73.51 111.092 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -106.55 112.42 25.42 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.137 -0.483 . . . . 71.44 110.876 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 8.2 m -137.83 158.88 33.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.192 -0.458 . . . . 70.23 111.083 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -108.22 88.78 5.11 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.616 0.722 . . . . 54.35 110.813 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 142.16 46.94 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.619 2.213 . . . . 74.4 112.385 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -113.75 112.21 23.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.245 -0.434 . . . . 75.25 110.901 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 4.6 mm -100.45 124.9 54.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 74.52 111.144 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -107.9 109.01 20.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.157 -0.474 . . . . 74.33 110.955 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -97.28 123.8 41.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.212 -0.449 . . . . 72.44 110.856 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 22.8 tp -142.38 127.59 18.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.128 -0.487 . . . . 74.21 110.943 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -179.21 -143.93 5.58 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.751 -0.738 . . . . 64.33 112.509 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -123.93 173.66 8.07 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.815 0.341 . . . . 60.01 111.094 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 19.1 m -154.04 163.55 39.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 63.4 110.825 -179.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -131.47 131.6 43.64 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.217 -0.447 . . . . 74.24 110.897 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 60.5 t -102.22 146.61 10.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.112 -0.494 . . . . 71.25 111.109 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -160.76 157.49 26.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.099 -0.5 . . . . 65.54 110.838 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 3.9 ptmm? -108.01 -35.88 6.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.128 -0.487 . . . . 74.33 110.863 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 8.0 tp -174.11 164.0 4.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 74.45 110.928 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -65.76 -35.81 81.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.468 . . . . 73.04 111.043 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -128.9 178.25 6.51 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.172 -0.467 . . . . 72.45 111.111 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -87.92 -68.15 0.78 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 65.23 111.138 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 11.9 tp 53.56 37.74 26.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 74.01 110.885 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 72.23 110.911 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 40.8 mtt . . . . . 0 C--O 1.23 0.048 0 CA-C-O 120.807 0.337 . . . . 74.31 110.863 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 17.0 p30 -160.55 154.65 23.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 73.54 110.896 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 24.1 tp10 -142.11 138.08 31.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 75.44 110.852 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 50.9 m-20 -142.77 131.83 23.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.163 -0.471 . . . . 75.33 110.921 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 28.8 t80 -174.55 69.51 0.3 Allowed Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 121.685 0.755 . . . . 72.33 110.911 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 133.35 25.42 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.678 2.252 . . . . 73.33 112.329 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -79.63 165.76 22.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 74.35 111.162 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 4.4 ptpp? -129.09 154.03 47.08 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.262 -0.426 . . . . 72.45 110.932 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 75.8 m -103.21 148.05 26.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.224 -0.444 . . . . 74.32 110.884 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.28 179.38 5.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.122 -0.49 . . . . 70.22 111.091 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.66 37.71 3.35 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.709 -0.758 . . . . 65.13 112.397 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 20.0 m-85 -151.07 115.99 5.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.924 0.393 . . . . 70.42 110.931 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 7.6 m120 -146.87 165.49 29.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 74.33 110.925 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 7.3 mp0 -69.01 120.41 14.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.444 . . . . 70.21 110.907 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.35 5.84 36.77 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.711 -0.757 . . . . 72.13 112.507 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -66.74 153.3 43.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.337 . . . . 71.01 110.911 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 17.3 t90 -123.74 125.11 44.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.197 -0.456 . . . . 72.34 110.965 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 12.5 m -136.92 135.02 48.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.251 -0.431 . . . . 75.5 111.106 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -93.11 158.01 15.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 65.34 111.135 179.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.0 109.51 5.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.258 -0.428 . . . . 72.21 110.845 -179.745 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -111.37 115.66 29.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 73.24 110.865 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -150.69 173.0 14.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 74.43 110.906 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 28.2 p90 -108.43 132.21 54.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.167 -0.47 . . . . 71.52 110.908 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 25.2 p -104.85 142.45 34.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 73.11 110.841 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 25.4 tptt -121.96 122.95 40.53 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.082 -0.508 . . . . 75.51 110.975 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 20.9 m -89.92 135.29 26.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.281 -0.418 . . . . 62.33 111.154 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -126.68 114.37 17.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.252 -0.431 . . . . 75.01 111.015 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.0 p -174.79 153.55 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 72.51 111.156 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 150.5 67.26 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.775 -0.726 . . . . 63.31 112.517 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -90.16 -66.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.812 0.339 . . . . 73.35 110.958 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 25.0 pt-20 -174.91 170.61 3.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.128 -0.487 . . . . 60.01 110.887 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 36.4 tp -98.27 150.14 21.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.138 -0.483 . . . . 74.12 110.913 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -85.58 74.16 2.48 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.732 -0.747 . . . . 65.23 112.464 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -102.37 125.3 49.04 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.879 0.371 . . . . 64.54 110.89 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -151.57 160.33 43.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.163 -0.472 . . . . 74.31 110.911 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -159.59 157.78 30.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 63.11 110.881 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 42.0 t -86.06 -68.96 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.192 -0.458 . . . . 74.32 111.126 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -115.92 119.56 4.6 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.699 -0.762 . . . . 71.11 112.494 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 91.67 153.17 29.39 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.719 -0.753 . . . . 75.14 112.506 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 144.3 176.03 17.96 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.706 -0.759 . . . . 51.15 112.408 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -89.4 149.8 22.81 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.791 0.329 . . . . 74.33 111.143 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.481 ' N ' ' HD2' ' A' ' 43' ' ' PRO . 0.6 OUTLIER -55.07 -60.32 8.44 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.623 0.725 . . . . 74.44 110.877 -179.975 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.481 ' HD2' ' N ' ' A' ' 42' ' ' LEU . 53.1 Cg_endo -69.77 146.65 60.8 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.701 2.267 . . . . 72.41 112.278 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 17.3 p30 -98.09 142.89 29.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.219 -0.446 . . . . 52.44 110.922 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -53.64 164.29 0.56 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 75.15 111.087 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -142.36 135.65 28.84 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.241 -0.436 . . . . 61.53 110.833 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.7 p -105.44 142.83 17.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.144 -0.48 . . . . 75.2 111.138 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.0 t -158.14 135.05 9.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 64.14 110.81 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 3.0 pt -89.44 156.38 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 71.21 111.104 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.15 -157.12 9.52 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.738 -0.744 . . . . 71.34 112.463 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -152.05 128.21 10.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.858 0.361 . . . . 74.23 110.847 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -163.64 119.35 1.66 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.147 -0.479 . . . . 73.41 110.92 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 14.9 t -58.7 142.36 50.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 55.11 111.103 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -160.12 164.39 33.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 73.01 111.22 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -109.31 163.0 13.78 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.282 -0.417 . . . . 73.35 110.96 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.4 p -142.55 144.0 32.72 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.239 -0.437 . . . . 75.31 111.19 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -113.84 134.81 54.57 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.261 -0.427 . . . . 74.32 110.924 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.455 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -131.15 142.89 50.29 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.109 -0.496 . . . . 74.34 110.847 -179.949 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -109.3 115.28 49.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 75.54 111.116 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -104.01 134.94 46.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 54.44 111.091 179.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -120.43 123.4 42.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.25 -0.432 . . . . 74.11 110.859 -179.827 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -89.57 101.36 14.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.045 -0.525 . . . . 75.24 110.912 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.5 t -99.48 -38.77 7.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 71.55 111.101 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -125.44 159.01 32.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 64.11 110.829 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 12.2 p -84.35 3.16 37.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.104 -0.498 . . . . 72.44 110.862 -179.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -116.63 -33.13 4.96 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.101 -0.499 . . . . 74.13 110.877 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 1.9 pp -139.31 164.07 25.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 72.12 111.121 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -150.12 167.89 25.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 64.51 111.117 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 13.5 m -113.31 152.98 14.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 60.35 111.203 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -147.91 147.15 29.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 75.44 110.88 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 0.455 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 16.7 m-85 -127.34 110.33 12.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.266 -0.424 . . . . 75.32 110.867 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -87.83 122.85 31.98 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.094 -0.503 . . . . 74.4 110.863 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 25.2 t -145.88 149.11 16.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.136 -0.484 . . . . 73.23 111.094 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -152.97 167.59 31.71 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.744 -0.741 . . . . 71.41 112.511 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.6 m -134.55 67.65 71.76 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.59 0.709 . . . . 73.5 111.104 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 163.65 37.47 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.667 2.244 . . . . 64.01 112.363 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -83.85 -170.91 3.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.192 -0.458 . . . . 73.21 111.129 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 20.5 ttm105 -76.55 135.49 39.26 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 75.15 110.823 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -129.7 144.3 51.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.114 -0.494 . . . . 71.01 111.148 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.83 137.49 42.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 74.51 110.915 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 43.6 p90 -129.78 159.09 37.61 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.435 . . . . 74.52 110.865 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.405 ' HA ' HG22 ' A' ' 93' ' ' VAL . 26.0 mt-30 -98.29 158.08 15.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 74.13 110.878 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -178.0 60.13 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.666 -0.778 . . . . 74.41 112.479 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -167.97 -175.55 2.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.928 0.394 . . . . 72.41 110.85 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.15 -69.27 0.68 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.187 -0.461 . . . . 73.24 110.899 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -84.15 -33.39 24.26 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.203 -0.453 . . . . 73.42 110.817 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.8 mm -64.68 -35.11 73.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 74.43 111.126 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 78.8 p -62.98 -47.89 81.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.472 . . . . 73.12 110.83 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 t -51.29 -37.88 49.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.125 -0.489 . . . . 74.15 110.851 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 9.1 tp -63.34 -39.01 93.36 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.103 -0.499 . . . . 70.43 110.929 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 103.13 -15.41 54.82 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.714 -0.755 . . . . 72.32 112.494 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -120.35 89.43 3.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.873 0.368 . . . . 75.43 110.825 -179.832 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.405 HG22 ' HA ' ' A' ' 82' ' ' GLN . 32.4 t -105.38 -47.4 9.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.207 -0.451 . . . . 73.35 111.157 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 17.9 t -142.22 144.29 33.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.151 -0.477 . . . . 75.11 110.869 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.4 pm0 -133.65 128.56 35.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.09 -0.504 . . . . 72.1 110.865 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.437 ' HA ' ' HB2' ' A' ' 131' ' ' LYS . 10.1 p -175.88 157.02 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.464 . . . . 74.23 111.135 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -81.0 172.52 13.63 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 73.12 110.921 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -132.92 130.72 40.0 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.269 -0.423 . . . . 74.01 110.913 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -113.4 70.98 0.23 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.71 -0.757 . . . . 54.12 112.42 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.66 114.43 3.69 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.694 2.263 . . . . 74.51 112.346 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -133.61 107.45 7.98 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.221 -0.445 . . . . 65.43 111.025 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 8.0 pt -131.55 149.69 33.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.247 -0.433 . . . . 74.44 111.117 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 1.9 pp -138.28 124.15 19.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.127 -0.488 . . . . 74.44 110.945 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.4 p -144.74 165.88 26.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 73.5 110.818 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -113.14 155.0 25.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.138 -0.483 . . . . 72.2 110.904 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 -102.07 132.03 48.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.466 . . . . 71.45 110.844 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 13.0 t80 -120.26 121.91 39.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.24 -0.436 . . . . 72.31 110.902 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -60.84 126.12 26.23 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.137 -0.483 . . . . 74.5 110.852 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -155.92 108.45 2.63 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.218 -0.446 . . . . 74.22 110.938 -179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -65.45 127.29 31.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.046 -0.525 . . . . 74.23 110.845 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 32.6 p -112.58 -69.66 0.85 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.122 -0.49 . . . . 64.33 110.879 -179.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -109.33 174.44 5.87 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.149 -0.478 . . . . 74.52 110.863 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -76.89 -65.12 0.98 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.134 -0.485 . . . . 75.11 110.918 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 18.8 ttt180 -52.26 -65.71 0.51 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.152 -0.477 . . . . 72.11 110.865 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -99.21 121.52 41.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.442 . . . . 72.51 110.896 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 8.8 p90 -118.73 67.88 7.96 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.648 0.737 . . . . 74.11 110.873 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 177.75 5.22 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.76 2.307 . . . . 75.41 112.297 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 9.0 m-85 -115.69 159.27 21.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.148 -0.478 . . . . 73.41 110.878 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.8 p -109.69 124.13 66.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.11 -0.495 . . . . 73.21 111.137 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -117.87 163.51 12.83 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.777 -0.725 . . . . 64.31 112.458 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.0 p -163.71 151.35 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.901 0.381 . . . . 74.43 111.164 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -179.26 -151.78 10.03 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.689 -0.767 . . . . 64.02 112.446 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . 0.439 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 32.8 m -110.6 152.27 12.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.896 0.379 . . . . 73.14 111.154 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.03 106.24 0.5 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.691 -0.766 . . . . 74.05 112.447 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 7.2 ptp180 -105.82 128.35 53.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.862 0.363 . . . . 74.53 110.84 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 60.4 t -113.52 114.62 47.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 74.12 111.136 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.1 tt -122.42 152.27 40.4 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 74.4 110.95 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 11.5 p90 -161.58 162.17 30.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.288 -0.415 . . . . 73.3 110.886 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -101.17 116.86 33.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 72.13 110.912 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -50.74 104.56 0.08 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.156 -0.474 . . . . 72.45 110.861 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.437 ' HB2' ' HA ' ' A' ' 96' ' ' VAL . 0.7 OUTLIER -79.49 -79.35 0.14 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 74.11 110.934 179.963 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 32.0 m -167.01 126.44 1.44 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 73.12 111.147 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . 0.458 ' HB3' ' HB3' ' A' ' 139' ' ' PHE . 26.2 t0 -115.18 114.84 25.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.27 -0.423 . . . . 74.4 110.892 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -79.95 -8.1 87.95 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.758 -0.734 . . . . 73.12 112.488 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -46.17 -29.38 1.54 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.831 0.348 . . . . 75.12 111.13 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.6 tp -157.12 -176.83 6.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.222 -0.445 . . . . 73.11 110.869 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 68.4 m -56.63 92.75 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.114 -0.494 . . . . 75.23 110.815 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 58.1 m 50.78 75.08 0.2 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.139 -0.482 . . . . 74.02 110.812 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.458 ' HB3' ' HB3' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -102.54 160.59 14.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 70.45 110.914 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -139.73 172.54 12.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 74.31 110.94 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 5.8 mm -114.26 161.8 12.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.219 -0.446 . . . . 74.43 111.147 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 13.5 mttm -124.11 114.82 20.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.178 -0.464 . . . . 75.35 110.923 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -69.64 -175.33 0.84 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.279 -0.419 . . . . 64.31 110.895 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 6.9 tttp -172.84 -173.64 1.0 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.23 -0.441 . . . . 74.01 110.894 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 59.3 p-90 -148.75 160.23 43.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.187 -0.461 . . . . 73.4 110.966 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . 179.87 163.54 0.84 Allowed Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.593 0.711 . . . . 73.24 111.105 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . 0.439 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 54.3 Cg_endo -69.78 169.1 19.74 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.688 2.258 . . . . 75.24 112.306 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.468 ' HA ' HG13 ' A' ' 170' ' ' ILE . . . -167.79 157.07 9.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 63.41 111.094 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 6.2 p90 -115.99 138.42 51.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.449 . . . . 74.34 110.898 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 25.2 tt0 -116.53 158.88 22.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 73.11 110.864 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.3 p -142.79 129.35 17.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.16 -0.473 . . . . 72.51 111.07 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 166.4 -164.42 37.61 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.749 -0.738 . . . . 61.22 112.456 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -161.22 174.01 14.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.709 0.29 . . . . 74.23 110.992 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 7.8 tpp85 -109.45 121.21 44.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.232 -0.44 . . . . 73.23 110.846 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 47.8 t80 -106.98 147.86 29.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 75.55 110.974 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -110.07 112.63 24.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.127 -0.488 . . . . 74.31 110.845 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 23.9 tp -86.15 158.14 19.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.165 -0.47 . . . . 73.33 110.908 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -58.24 -39.57 92.67 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.731 -0.747 . . . . 71.1 112.466 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -64.26 169.35 4.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.832 0.349 . . . . 73.14 110.855 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 72.6 m -54.35 -47.55 72.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 75.33 110.875 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 18.1 p90 -74.23 145.64 43.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.096 -0.502 . . . . 62.22 110.929 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 1.8 mpt? -100.34 178.79 4.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.256 -0.429 . . . . 70.41 110.904 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 4.5 tp -119.55 141.95 48.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 74.42 110.839 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -135.37 136.29 41.35 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.144 -0.48 . . . . 71.42 110.875 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.3 p -133.99 134.03 42.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 75.24 110.912 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -163.81 152.74 13.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 64.21 110.838 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 44.3 t -144.8 119.04 3.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 73.51 111.143 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -93.52 147.08 23.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.196 -0.457 . . . . 74.34 110.868 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' TYR . . . . . 0.411 ' O ' ' HB ' ' A' ' 170' ' ' ILE . 20.1 t80 -152.6 140.03 19.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 74.4 110.943 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' ILE . . . . . 0.468 HG13 ' HA ' ' A' ' 148' ' ' ALA . 0.0 OUTLIER 178.64 132.03 0.22 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.594 0.712 . . . . 74.32 111.196 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . 0.464 ' HD2' HG12 ' A' ' 170' ' ' ILE . 53.8 Cg_endo -69.75 107.97 1.97 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.691 2.261 . . . . 73.11 112.362 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -124.02 152.63 42.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.172 -0.467 . . . . 64.23 110.858 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 10.4 pttm -122.7 132.92 54.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 72.45 110.869 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.6 t -100.16 162.01 13.24 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 72.41 111.131 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -110.63 157.44 19.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 75.24 110.921 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 2.9 t -150.54 136.5 11.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.983 0.42 . . . . 74.34 111.063 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.0 t -166.83 161.83 15.6 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 74.51 111.154 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -123.78 174.56 16.76 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.769 -0.729 . . . . 63.44 112.5 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.8 t -115.52 98.26 6.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.823 0.345 . . . . 73.15 111.107 -179.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 11.2 tp -128.87 165.95 20.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 73.11 110.868 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -51.46 -69.25 1.19 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.708 -0.758 . . . . 61.31 112.531 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 179.78 3.45 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.666 2.244 . . . . 74.1 112.364 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 3.5 p -55.73 111.16 2.81 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.588 0.709 . . . . 74.44 111.196 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 166.19 28.41 Favored 'Trans proline' 0 N--CA 1.465 -0.194 0 C-N-CA 122.757 2.305 . . . . 61.43 112.39 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 84.9 t -98.68 126.22 51.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.291 -0.413 . . . . 74.14 111.129 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 1.3 p -112.46 111.67 22.68 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.155 -0.475 . . . . 73.33 110.831 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 61.9 p -116.44 167.57 10.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.083 -0.508 . . . . 75.44 111.165 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 11.5 ptmt -147.16 160.32 42.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.444 . . . . 75.44 110.837 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 26.7 mt -137.69 109.24 6.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 74.22 111.127 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.52 106.0 18.18 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 73.03 110.871 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 2.3 t -137.01 164.66 29.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.085 -0.507 . . . . 75.22 111.136 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -106.94 89.64 4.6 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-O 121.531 0.681 . . . . 74.45 110.816 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 135.18 29.75 Favored 'Trans proline' 0 C--N 1.34 0.131 0 C-N-CA 122.758 2.306 . . . . 74.22 112.257 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -103.09 118.16 36.18 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.165 -0.47 . . . . 60.43 110.884 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 24.1 mm -109.26 110.37 31.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 53.44 111.196 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -109.15 108.49 19.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 71.45 110.925 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -105.63 133.52 50.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 73.53 110.881 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -153.64 137.74 16.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 74.24 110.916 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 175.48 -140.15 5.07 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.685 -0.769 . . . . 73.33 112.44 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -117.42 173.32 6.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.814 0.34 . . . . 54.14 111.112 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 4.8 p -155.8 166.29 33.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 74.45 110.833 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -132.04 150.7 52.08 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.076 -0.511 . . . . 75.44 110.931 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 5.6 p -113.05 143.62 22.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 74.22 111.148 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 4.6 t80 -141.76 107.86 5.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 71.24 110.889 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 63.5 tttt -93.96 126.14 38.99 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.153 -0.476 . . . . 73.34 110.863 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 9.0 mp -82.36 107.47 15.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.251 -0.431 . . . . 75.45 110.949 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -61.86 -48.62 79.71 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.458 . . . . 75.34 111.106 179.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -128.18 150.65 49.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 70.3 111.122 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -57.74 119.78 7.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.202 -0.454 . . . . 61.42 111.088 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 19.2 tp -67.91 143.39 55.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.207 -0.451 . . . . 74.13 110.972 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.253 -0.43 . . . . 73.43 110.84 -179.98 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.2 mmt . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.788 0.328 . . . . 73.25 110.909 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -120.06 177.84 4.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.264 -0.426 . . . . 72.24 110.868 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -148.51 159.01 44.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 64.44 110.847 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 11.0 m120 -160.6 157.99 28.23 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 65.35 110.916 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -139.5 145.67 44.83 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.654 0.74 . . . . 73.03 110.927 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.83 163.3 38.85 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.708 2.272 . . . . 74.34 112.328 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -149.38 125.25 10.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.238 -0.437 . . . . 74.03 111.149 179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 25.0 mmtt -138.75 175.5 9.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.283 -0.417 . . . . 75.22 110.894 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 74.1 m -127.06 165.44 19.48 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.2 -0.454 . . . . 73.32 110.832 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -164.79 177.24 8.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.108 -0.496 . . . . 75.14 111.102 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.07 -32.95 82.23 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.768 -0.729 . . . . 64.53 112.522 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 9.1 p90 -140.18 110.9 6.81 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.897 0.38 . . . . 75.12 110.938 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -130.2 -177.74 4.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.122 -0.49 . . . . 75.21 110.86 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 11.8 mp0 -57.11 120.74 8.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.133 -0.485 . . . . 74.42 110.901 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 110.6 5.8 27.46 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.734 -0.746 . . . . 72.54 112.481 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -59.69 152.84 21.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.726 0.298 . . . . 74.21 110.922 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 25.0 t90 -121.6 142.36 50.19 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.234 -0.439 . . . . 74.34 110.936 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 39.5 t -146.72 116.75 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 72.53 111.091 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -86.61 105.31 16.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.126 -0.488 . . . . 74.14 111.137 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -101.75 112.77 25.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 64.21 110.847 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -110.16 121.2 44.71 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.123 -0.49 . . . . 65.01 110.998 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -152.12 166.68 30.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.435 . . . . 73.4 110.913 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -100.52 130.59 46.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 74.52 110.894 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -97.17 139.09 33.68 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 74.32 110.882 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 68.8 mttt -111.05 106.97 16.2 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.14 -0.482 . . . . 71.54 110.924 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 23.4 m -79.13 132.9 31.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 75.42 111.112 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 27.9 t80 -126.97 99.25 5.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 74.34 110.945 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 p -166.12 149.77 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 74.24 111.102 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 132.44 78.71 0.15 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.702 -0.761 . . . . 72.05 112.459 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -89.77 -65.93 0.97 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.735 0.302 . . . . 64.33 110.829 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -171.54 174.28 4.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.196 -0.457 . . . . 72.32 110.846 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 14.9 tp -81.1 155.06 26.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.082 -0.508 . . . . 72.1 110.927 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.95 -32.13 41.11 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.75 -0.738 . . . . 74.22 112.494 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 42.02 38.89 1.17 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.797 0.332 . . . . 74.43 110.856 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 4.9 tp -62.46 -37.03 84.35 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.251 -0.432 . . . . 73.42 110.946 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 22.3 m120 -68.73 126.78 30.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.225 -0.443 . . . . 75.15 110.834 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 13.9 p -90.6 144.89 8.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.105 -0.498 . . . . 73.25 111.111 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -132.15 -172.42 13.05 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.723 -0.751 . . . . 73.35 112.482 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -153.7 125.53 1.77 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.694 -0.765 . . . . 75.03 112.494 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.3 -101.43 1.49 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.793 -0.718 . . . . 73.13 112.498 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -77.96 169.72 17.8 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.852 0.358 . . . . 54.21 111.074 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 15.1 mt 59.47 73.29 0.69 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.56 0.695 . . . . 74.22 110.95 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -176.73 1.58 Allowed 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.706 2.271 . . . . 74.23 112.303 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -57.08 168.88 0.61 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.451 . . . . 61.24 110.898 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -90.12 -178.37 5.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 72.23 111.1 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 -153.49 125.85 8.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 73.31 110.921 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 92.0 t -109.45 141.3 25.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 74.32 111.11 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 43.0 t -167.94 159.02 11.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 73.25 110.809 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 45.0 pt -126.08 157.85 35.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.102 -0.499 . . . . 73.22 111.147 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.25 -138.94 0.36 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.742 -0.742 . . . . 73.31 112.45 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -154.22 117.11 4.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.884 0.373 . . . . 72.51 110.802 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -151.94 105.83 3.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.069 -0.514 . . . . 72.21 110.874 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 46.9 p -72.7 117.25 14.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 54.51 111.126 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.1 m -117.74 162.49 17.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 63.42 111.159 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -94.16 162.3 13.92 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.212 -0.449 . . . . 75.34 110.934 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.23 140.21 32.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.239 -0.437 . . . . 74.23 111.14 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -103.45 131.99 50.08 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.216 -0.447 . . . . 73.54 110.831 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 53.3 m-20 -130.13 133.3 46.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 73.43 110.896 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 22.1 mm -109.2 113.53 44.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 74.0 111.139 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -103.74 117.78 35.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 71.22 111.021 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -106.75 114.21 28.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.184 -0.462 . . . . 74.55 110.892 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -81.56 97.19 7.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.089 -0.505 . . . . 74.24 110.88 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.0 m -88.05 -34.15 7.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 73.51 111.129 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 69.2 m -136.23 167.47 21.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 72.0 110.899 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 46.8 t -86.94 2.64 48.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 74.44 110.895 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 65.1 m-20 -113.59 -33.86 5.72 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.096 -0.502 . . . . 75.32 110.912 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 2.2 pp -145.52 169.01 7.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 74.53 111.205 179.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -155.7 173.19 17.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.222 -0.444 . . . . 72.44 111.066 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.41 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 11.6 m -111.55 151.03 13.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 73.32 111.112 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -140.28 133.23 29.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 74.24 110.882 179.881 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -113.54 113.91 25.76 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.198 -0.456 . . . . 73.22 110.842 -179.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -91.64 119.99 32.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 74.53 110.909 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 36.7 t -146.64 149.35 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 63.25 111.144 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -156.51 164.45 32.55 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.697 -0.763 . . . . 70.32 112.473 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 24.6 t -136.55 66.03 56.47 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.614 0.721 . . . . 71.52 111.142 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 162.62 41.36 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.636 2.224 . . . . 71.31 112.353 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -79.28 -168.98 1.68 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.244 -0.435 . . . . 54.02 111.054 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.96 138.52 38.9 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.15 -0.477 . . . . 74.3 110.832 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -128.35 135.65 49.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.445 . . . . 72.35 111.144 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 6.8 ttpm? -107.92 141.63 39.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.223 -0.444 . . . . 75.32 110.857 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -142.07 158.47 43.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.153 -0.476 . . . . 73.35 110.89 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -98.05 158.51 15.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 75.24 110.909 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -177.44 69.59 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.759 -0.734 . . . . 73.53 112.505 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -178.33 -177.14 0.55 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.824 0.345 . . . . 73.21 110.916 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.23 -67.42 0.82 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.163 -0.472 . . . . 74.11 110.915 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.9 t -83.1 -35.62 25.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.447 . . . . 72.03 110.851 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.7 mm -64.62 -33.65 64.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.122 -0.49 . . . . 72.21 111.131 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.7 t -61.85 -47.95 82.72 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.206 -0.452 . . . . 65.24 110.861 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.9 t -53.23 -39.87 64.12 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.153 -0.476 . . . . 73.11 110.844 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -59.83 -42.48 93.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.119 -0.491 . . . . 61.34 110.927 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 104.93 -13.48 49.48 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.704 -0.76 . . . . 64.31 112.506 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 7.2 ptp180 -120.16 96.9 5.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.856 0.36 . . . . 75.15 110.873 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 98.6 t -113.55 -55.41 4.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.234 -0.439 . . . . 73.2 111.175 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 5.8 m -140.51 143.39 35.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 74.34 110.841 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -146.7 126.17 13.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.49 . . . . 72.22 110.862 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 14.2 p -166.1 156.72 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 73.34 111.155 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -72.94 172.97 9.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 75.55 110.835 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 3.5 m-85 -115.74 125.39 52.72 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.106 -0.497 . . . . 70.52 110.889 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -119.46 67.04 0.39 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.664 -0.779 . . . . 71.14 112.464 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 112.01 2.96 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.694 2.263 . . . . 64.1 112.33 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -122.66 95.94 4.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.215 -0.448 . . . . 75.55 111.092 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 5.8 mm -121.7 149.98 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 75.01 111.109 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -150.42 111.1 4.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 75.03 110.913 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.4 p -142.87 167.87 21.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.223 -0.444 . . . . 55.0 110.883 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.41 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -113.58 149.52 34.37 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.144 -0.48 . . . . 74.53 110.92 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -101.9 149.19 24.46 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 70.11 110.922 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -155.5 149.24 25.29 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.177 -0.465 . . . . 74.52 110.958 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 14.6 t-160 -118.46 134.5 55.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 73.1 110.891 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 21.9 t80 -104.85 144.8 31.28 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.231 -0.441 . . . . 75.14 110.923 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -62.55 120.63 11.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.072 -0.513 . . . . 73.34 110.874 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 31.7 p -130.27 175.68 8.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 74.34 110.838 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -78.17 -51.52 10.09 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.141 -0.481 . . . . 70.04 110.83 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -54.54 138.24 41.23 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.466 . . . . 74.11 110.929 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 10.6 mmp_? -72.08 -50.65 26.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 73.11 110.892 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 11.8 mt -97.73 112.96 24.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.464 . . . . 75.05 110.893 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -156.53 139.81 11.05 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.681 0.753 . . . . 74.43 110.905 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -69.67 177.35 5.61 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.695 2.263 . . . . 64.32 112.4 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -110.47 162.84 14.29 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.258 -0.428 . . . . 73.11 110.889 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 92.0 t -128.74 143.81 40.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.065 -0.516 . . . . 72.41 111.14 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -134.96 -175.02 13.65 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.779 -0.724 . . . . 74.33 112.464 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.2 p -169.25 156.1 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.877 0.37 . . . . 74.42 111.129 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 177.78 -152.1 11.48 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.69 -0.767 . . . . 60.12 112.474 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . 0.418 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 34.2 m -107.85 130.35 60.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.897 0.38 . . . . 64.05 111.137 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -125.5 113.31 1.87 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.74 -0.743 . . . . 64.33 112.495 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 14.2 ptt180 -114.58 124.4 51.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.846 0.355 . . . . 74.0 110.925 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 51.5 t -106.09 110.19 30.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 75.43 111.116 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 6.2 mt -126.5 174.5 8.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 64.32 110.83 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -159.02 173.17 16.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.149 -0.478 . . . . 72.23 110.877 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -101.78 119.11 38.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 75.22 110.924 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -46.41 106.18 0.08 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.131 -0.486 . . . . 74.53 110.914 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 31.7 mmtm -105.21 -79.95 0.55 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 64.13 110.882 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.5 m -160.45 85.02 0.71 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.215 -0.448 . . . . 63.41 111.149 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -102.72 166.94 10.21 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.239 -0.437 . . . . 71.23 110.864 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 135' ' ' ALA . . . 83.23 145.49 6.13 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.772 -0.727 . . . . 74.23 112.578 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.411 ' C ' ' O ' ' A' ' 134' ' ' GLY . . . -36.5 -65.32 0.28 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.747 0.308 . . . . 72.45 111.081 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . 0.4 ' O ' ' CB ' ' A' ' 137' ' ' SER . 0.4 OUTLIER -167.38 93.18 0.42 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.24 -0.437 . . . . 74.4 110.911 -179.952 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' SER . . . . . 0.539 ' O ' ' C ' ' A' ' 138' ' ' SER . 1.5 p 167.83 59.82 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.225 -0.443 . . . . 65.4 110.844 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' SER . . . . . 0.539 ' C ' ' O ' ' A' ' 137' ' ' SER . 54.1 m 25.97 74.45 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.47 . . . . 53.45 110.884 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -106.04 143.23 34.46 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.099 -0.5 . . . . 74.42 110.894 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -111.62 173.76 6.19 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.157 -0.474 . . . . 64.11 110.794 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 6.8 tt -128.02 126.47 66.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.133 -0.485 . . . . 71.33 111.132 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 1.3 mtmt -74.58 106.11 6.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 73.55 110.885 179.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -57.4 -176.11 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.175 -0.466 . . . . 64.43 110.856 179.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -139.92 161.55 37.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 73.4 110.955 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 43.7 p-90 -155.37 135.73 13.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.279 -0.419 . . . . 74.43 110.915 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . 179.94 165.54 0.82 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.568 0.699 . . . . 62.22 111.112 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . 0.418 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 52.7 Cg_endo -69.8 142.33 47.48 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.689 2.26 . . . . 74.22 112.266 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -133.73 167.52 20.38 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 62.21 111.126 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 58.8 m-85 -117.76 156.61 28.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.257 -0.429 . . . . 73.32 110.863 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -128.06 149.05 50.56 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.161 -0.472 . . . . 73.34 110.925 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 84.7 t -151.14 123.32 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 71.33 111.125 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . 0.42 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 179.53 -159.04 23.37 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.756 -0.735 . . . . 72.23 112.486 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 20.3 tp -150.78 161.0 43.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.83 0.348 . . . . 74.24 110.939 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.4 tpp85 -117.64 118.71 32.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 73.44 110.887 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -103.91 142.85 33.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 74.55 110.905 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -121.74 97.51 5.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.153 -0.476 . . . . 75.5 110.835 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 6.1 tp -73.24 158.69 34.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 71.3 110.911 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -52.53 -46.24 58.77 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.695 -0.764 . . . . 70.44 112.498 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -58.1 166.51 1.55 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.824 0.345 . . . . 71.34 110.895 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 5.9 m -57.51 -36.73 71.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.141 -0.481 . . . . 74.34 110.871 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 87.5 m95 -79.4 134.7 36.57 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.13 -0.486 . . . . 74.52 110.9 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 32.8 mtt -108.93 176.79 4.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.44 . . . . 75.35 110.82 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -115.92 148.77 39.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 64.42 110.914 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -146.89 133.25 19.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.469 . . . . 74.25 110.929 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 66.0 p -139.98 122.23 15.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 75.01 110.89 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . 0.42 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.7 OUTLIER -147.34 155.33 41.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.178 -0.464 . . . . 75.25 110.896 179.921 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 14.6 t -133.18 134.57 57.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 73.14 111.103 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 7.1 tmm_? -107.5 132.16 53.53 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.129 -0.487 . . . . 75.25 110.9 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 38.0 t80 -132.83 139.52 47.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.461 . . . . 72.44 110.852 -179.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' ILE . . . . . . . . . . . . . 1.3 tp -178.1 102.23 0.21 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.622 0.725 . . . . 74.55 111.106 179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 128.26 15.75 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.658 2.239 . . . . 74.4 112.419 179.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -153.17 178.09 10.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 73.32 110.831 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.45 135.45 50.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.15 -0.477 . . . . 72.53 110.886 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -102.62 164.97 11.34 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.224 -0.443 . . . . 74.02 111.186 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -127.24 167.28 16.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 71.43 110.832 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 24.7 t -148.37 139.08 17.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.451 . . . . 73.44 111.165 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.3 t -166.85 155.82 10.52 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 75.34 111.138 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -138.87 -162.04 8.98 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.749 -0.739 . . . . 64.42 112.482 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.9 t -124.28 107.59 11.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.818 0.342 . . . . 74.25 111.168 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -132.59 166.87 21.12 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.24 -0.436 . . . . 73.15 110.922 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -49.59 -69.65 0.99 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.769 -0.729 . . . . 62.1 112.517 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.75 -171.39 0.47 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.644 2.229 . . . . 74.24 112.401 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 7.4 p -55.97 132.9 73.85 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.662 0.744 . . . . 70.11 111.137 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.75 150.13 67.9 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 122.666 2.244 . . . . 71.12 112.338 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 55.1 t -96.12 107.57 19.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 61.34 111.102 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 9.8 p -99.88 105.39 17.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.125 -0.489 . . . . 73.14 110.918 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 11.8 p -104.62 161.94 13.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.486 . . . . 64.53 111.096 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.46 152.09 31.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 72.44 110.91 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 6.4 tt -152.48 130.35 2.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 74.55 111.089 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -100.7 115.03 29.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.461 . . . . 73.43 110.912 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 1.8 t -137.94 166.61 23.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 65.54 111.086 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -107.03 90.15 5.13 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.572 0.701 . . . . 63.25 110.836 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 117.52 5.13 Favored 'Trans proline' 0 C--O 1.233 0.225 0 C-N-CA 122.617 2.211 . . . . 75.21 112.375 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -100.66 121.82 42.28 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.275 -0.421 . . . . 72.22 110.882 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 13.6 mm -112.33 107.26 22.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.469 . . . . 73.12 111.108 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 2.3 mt -100.4 108.02 19.92 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.108 -0.497 . . . . 75.31 110.938 179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.4 m -100.03 127.53 46.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.44 . . . . 72.05 110.882 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 43.9 tp -146.7 132.23 18.73 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.117 -0.492 . . . . 74.25 110.901 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 177.26 -141.64 5.41 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.773 -0.727 . . . . 73.51 112.506 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -124.49 172.57 9.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.721 0.296 . . . . 74.24 111.179 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 37.1 t -149.56 170.48 18.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.301 -0.409 . . . . 74.15 110.893 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 22.9 t80 -146.5 131.62 18.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.11 -0.495 . . . . 73.24 110.941 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 34.4 m -88.62 160.77 2.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 74.12 111.09 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -169.35 148.96 3.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 70.33 110.885 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.74 176.91 5.0 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.145 -0.48 . . . . 74.41 110.878 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 12.6 tp -90.59 153.42 20.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.434 . . . . 70.15 110.943 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . 61.81 47.85 5.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.251 -0.431 . . . . 74.3 111.096 179.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -128.22 145.92 50.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 72.32 111.107 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -134.59 172.2 13.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.229 -0.441 . . . . 63.41 111.164 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 12.6 mt -88.41 144.73 26.2 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.244 -0.435 . . . . 74.51 110.877 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 . . . . . 0 C--N 1.331 -0.238 0 CA-C-N 116.193 -0.458 . . . . 72.24 110.858 179.942 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 17.2 mtt . . . . . 0 C--O 1.23 0.038 0 CA-C-O 120.822 0.344 . . . . 73.13 110.868 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 44.7 t30 -109.62 59.72 0.6 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.444 . . . . 73.23 110.958 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -121.91 142.19 50.53 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 74.53 110.804 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 40.74 40.98 1.05 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 74.14 110.882 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 20.3 p90 -59.39 153.78 46.88 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.713 0.768 . . . . 73.4 110.878 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 145.53 57.22 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.673 2.249 . . . . 73.43 112.376 179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -140.18 163.02 33.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.286 -0.416 . . . . 75.12 111.105 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 13.2 ttmm -140.63 108.18 5.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 70.13 110.904 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 84.6 p -114.84 50.3 0.98 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.228 -0.442 . . . . 74.2 110.862 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -174.23 157.15 2.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.167 -0.469 . . . . 74.11 111.095 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.06 -93.22 1.85 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.637 -0.792 . . . . 62.21 112.451 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 15.5 p90 -158.64 118.93 3.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.933 0.397 . . . . 74.13 110.891 -179.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -139.21 162.4 35.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.129 -0.487 . . . . 62.14 110.861 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.7 pt20 -53.48 120.2 5.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 70.11 110.865 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.83 5.35 29.3 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.678 -0.772 . . . . 72.32 112.493 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.1 145.58 52.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.835 0.35 . . . . 74.3 110.885 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 27.9 m0 -105.66 137.51 43.39 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.183 -0.462 . . . . 74.43 110.934 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.2 t -144.86 112.53 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.188 -0.46 . . . . 52.42 111.066 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.45 106.0 14.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.178 -0.465 . . . . 71.53 111.074 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.2 t -95.89 111.94 23.8 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.463 . . . . 71.52 110.886 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 39.0 t80 -113.14 116.87 30.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 74.24 110.857 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -154.22 168.42 26.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 74.42 110.856 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 20.0 p90 -101.25 133.75 45.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 74.53 110.864 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.5 p -109.29 114.09 27.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.107 -0.497 . . . . 71.53 110.825 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 21.3 mmmt -98.37 106.59 18.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.108 -0.496 . . . . 74.22 110.868 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.2 p -85.07 143.12 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 75.52 111.135 179.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 13.3 m-85 -122.82 116.06 23.04 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.227 -0.442 . . . . 75.31 110.937 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.1 m -148.61 -170.61 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.134 -0.485 . . . . 74.13 111.077 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.66 66.16 0.84 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.712 -0.756 . . . . 75.31 112.495 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 -90.51 -68.19 0.8 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.86 0.362 . . . . 74.35 110.942 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 179.05 121.21 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.125 -0.489 . . . . 73.32 110.897 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.4 mt -83.12 153.05 25.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 75.41 110.953 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 81.32 -132.98 11.6 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.772 -0.728 . . . . 41.14 112.522 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -136.09 162.59 32.49 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.876 0.369 . . . . 72.2 110.813 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 12.4 tp -80.91 -36.97 30.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.141 -0.481 . . . . 75.33 110.921 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -55.84 146.75 20.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 73.35 110.892 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 26.8 m -139.65 172.86 12.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 73.5 111.162 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -114.37 -131.5 5.2 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.738 -0.744 . . . . 64.53 112.439 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -100.22 -171.39 29.68 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.732 -0.747 . . . . 53.44 112.462 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 52.22 -146.58 14.75 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.752 -0.737 . . . . 63.21 112.415 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -100.36 104.17 15.6 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.803 0.335 . . . . 75.4 111.105 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 70.0 mt -151.37 73.83 8.24 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.621 0.724 . . . . 71.44 110.912 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 -177.39 1.84 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.672 2.248 . . . . 73.24 112.367 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 5.5 p-10 -91.92 140.28 29.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.251 -0.431 . . . . 63.05 110.918 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -65.75 167.89 8.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 71.24 111.118 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -144.9 127.56 16.17 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.245 -0.434 . . . . 72.24 110.874 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 22.0 t -105.18 138.85 28.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.166 -0.47 . . . . 74.5 111.151 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.0 m -160.34 151.74 19.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 74.41 110.862 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 16.2 tt -138.11 140.09 41.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.199 -0.455 . . . . 75.14 111.178 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -60.37 -170.04 0.51 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.756 -0.735 . . . . 60.4 112.523 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 -66.46 -58.02 6.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.778 0.323 . . . . 75.32 110.899 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 41.69 40.67 1.5 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 74.12 110.848 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.0 t -68.68 141.3 55.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.177 -0.465 . . . . 64.43 111.168 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.4 t -156.09 174.72 14.96 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.249 -0.432 . . . . 73.43 111.152 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 4.6 pp -90.06 159.18 16.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.208 -0.451 . . . . 75.14 110.908 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -131.16 137.13 48.87 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 74.54 111.092 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -104.24 131.96 51.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 75.34 110.879 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -135.59 139.28 43.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.139 -0.482 . . . . 74.31 110.865 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.84 114.04 45.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.249 -0.432 . . . . 72.43 111.13 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -106.04 127.9 53.49 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.205 -0.452 . . . . 75.54 111.1 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -113.74 125.27 53.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.45 . . . . 73.32 110.963 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -88.66 103.01 15.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.143 -0.481 . . . . 75.33 110.859 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 35.3 m -95.66 -34.4 5.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 74.53 111.136 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -134.25 161.79 33.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.08 -0.509 . . . . 71.15 110.884 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 80.2 p -84.33 3.07 37.4 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 61.34 110.864 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -115.69 -32.47 5.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.468 . . . . 75.02 110.842 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 17.8 pt -142.24 168.69 14.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 75.41 111.153 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -156.78 172.79 18.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.171 -0.468 . . . . 73.31 111.108 179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.418 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 12.0 m -119.04 151.71 21.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 74.13 111.111 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -148.28 144.61 27.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 74.32 110.893 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -127.46 113.68 16.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.202 -0.454 . . . . 75.31 110.91 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -85.74 130.46 34.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.152 -0.476 . . . . 70.15 110.913 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 16.7 t -146.06 154.44 12.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.141 -0.481 . . . . 73.33 111.071 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -156.79 148.25 17.81 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.723 -0.751 . . . . 71.32 112.47 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.3 m -119.77 64.47 8.9 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.573 0.702 . . . . 74.03 111.111 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.72 164.05 35.94 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.663 2.242 . . . . 74.42 112.318 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -90.83 -167.98 1.96 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.18 -0.464 . . . . 73.43 111.134 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 17.1 ttm105 -77.38 136.48 38.43 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.236 -0.438 . . . . 72.32 110.882 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -133.61 151.09 51.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 62.01 111.128 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 39.9 ttmt -116.19 131.25 57.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.228 -0.442 . . . . 75.15 110.838 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -131.26 159.05 38.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 74.33 110.869 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.422 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 15.7 pt20 -94.06 157.27 16.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.116 -0.493 . . . . 75.34 110.92 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -176.05 68.4 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.755 -0.736 . . . . 52.05 112.521 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -175.04 -176.83 1.0 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.912 0.387 . . . . 73.31 110.878 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.7 -69.27 0.67 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.481 . . . . 74.34 110.924 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.9 m -83.67 -34.55 24.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 74.34 110.896 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 6.0 mm -63.73 -33.95 64.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.491 . . . . 73.13 111.131 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 58.2 p -62.32 -44.85 95.55 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.164 -0.471 . . . . 73.42 110.871 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.1 t -57.63 -35.18 70.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.134 -0.484 . . . . 72.43 110.872 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 24.6 mt -65.28 -50.25 66.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.172 -0.467 . . . . 74.15 110.947 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 116.04 -14.35 16.49 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.747 -0.74 . . . . 50.3 112.517 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 23.8 ptt180 -117.72 94.22 4.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.81 0.338 . . . . 75.44 110.861 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.422 ' HB ' ' HA ' ' A' ' 82' ' ' GLN . 64.5 t -114.5 -56.96 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 74.14 111.128 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 69.3 m -138.01 142.62 40.41 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 71.44 110.879 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -146.42 116.47 7.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.134 -0.484 . . . . 71.31 110.901 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 28.8 m -155.78 175.2 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 64.4 111.18 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -83.36 173.77 11.27 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.186 -0.461 . . . . 72.33 110.872 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -120.05 132.87 55.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 70.13 110.849 -179.765 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -132.08 62.06 0.65 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.694 -0.765 . . . . 60.12 112.472 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 113.05 3.24 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.673 2.249 . . . . 73.44 112.394 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -125.7 108.19 11.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 75.3 111.059 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 3.5 mp -129.17 147.92 33.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.28 -0.418 . . . . 73.14 111.104 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -151.97 114.74 4.62 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.155 -0.475 . . . . 75.25 110.939 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 13.0 p -144.79 166.17 25.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 73.42 110.878 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.418 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -111.02 150.47 29.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.144 -0.48 . . . . 75.43 110.956 179.964 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 18.1 mt-30 -101.61 133.55 46.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.464 . . . . 72.31 110.905 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -122.82 119.37 30.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.164 -0.471 . . . . 73.1 110.839 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 2.4 t60 -78.56 106.72 10.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.092 -0.504 . . . . 64.45 110.838 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 34.0 t80 -79.22 147.43 32.6 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.152 -0.476 . . . . 75.5 110.94 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -74.59 131.59 41.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.086 -0.506 . . . . 63.32 110.912 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 87.9 p -134.58 158.55 43.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.231 -0.441 . . . . 55.13 110.872 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 81.3 t80 -81.47 -46.75 14.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 73.31 110.892 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 33.4 mm-40 -58.01 173.36 0.34 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.086 -0.507 . . . . 73.12 110.956 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 17.9 ptp180 -78.7 -35.93 44.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 74.22 110.794 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -111.41 142.47 43.62 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.231 -0.441 . . . . 72.4 110.953 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 27.4 t80 -166.71 134.63 2.15 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.669 0.747 . . . . 74.5 110.924 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 177.57 5.46 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.64 2.226 . . . . 64.34 112.37 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 9.7 m-85 -117.99 147.5 43.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 75.23 110.874 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 23.5 t -104.2 124.2 58.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.088 -0.505 . . . . 72.11 111.109 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -120.04 161.79 14.32 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.795 -0.717 . . . . 42.44 112.534 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.8 p -159.93 147.34 6.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.923 0.392 . . . . 72.04 111.091 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -175.54 -155.9 13.66 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.748 -0.739 . . . . 74.12 112.475 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . 0.455 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.2 p -107.28 133.49 51.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.864 0.364 . . . . 55.43 111.085 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -119.74 110.8 1.89 Allowed Glycine 0 N--CA 1.453 -0.227 0 C-N-CA 120.646 -0.788 . . . . 65.22 112.493 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 11.8 ptm180 -111.78 122.22 47.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.903 0.382 . . . . 70.41 110.912 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 1.4 p -108.12 110.24 31.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.465 . . . . 75.41 111.179 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 17.7 tp -116.84 167.19 11.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.116 -0.493 . . . . 72.44 110.931 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -150.94 178.93 8.68 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 73.43 110.885 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -107.36 144.82 33.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.143 -0.48 . . . . 74.02 110.868 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -81.78 95.41 7.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.458 . . . . 71.31 110.885 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 16.5 tppt? -110.37 -75.9 0.61 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.155 -0.475 . . . . 72.34 110.976 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 88.0 m -160.85 89.64 0.81 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.236 -0.438 . . . . 75.55 111.127 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -102.86 162.72 12.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 75.12 110.863 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 67.4 156.93 0.68 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.774 -0.726 . . . . 71.51 112.473 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -77.54 1.43 19.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.881 0.372 . . . . 62.21 111.12 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -85.89 -178.16 6.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 65.52 110.922 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 16.6 t -67.71 85.72 0.21 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.131 -0.486 . . . . 72.31 110.914 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 3.6 m 50.84 74.84 0.21 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 74.22 110.887 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -84.52 156.08 21.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.118 -0.492 . . . . 74.11 110.914 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -102.7 173.47 6.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.167 -0.469 . . . . 72.41 110.873 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.459 ' HA ' ' HA ' ' A' ' 176' ' ' VAL . 0.6 OUTLIER -153.94 144.11 14.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.258 -0.428 . . . . 63.41 111.126 -179.974 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 19.8 tptt -91.03 118.02 30.05 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 74.33 110.905 179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -58.25 -168.74 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.26 -0.427 . . . . 64.03 110.887 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.59 154.59 49.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 74.32 110.822 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 5.1 t90 -157.32 129.0 6.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 75.02 110.912 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.476 ' CB ' ' HD2' ' A' ' 147' ' ' PRO . . . -173.59 168.96 2.22 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.626 0.727 . . . . 55.43 111.107 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . 0.476 ' HD2' ' CB ' ' A' ' 146' ' ' ALA . 53.7 Cg_endo -69.84 132.86 24.08 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.634 2.223 . . . . 70.25 112.346 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -120.29 166.27 13.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 71.14 111.115 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -123.58 137.11 54.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.29 -0.414 . . . . 73.32 110.891 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -114.35 145.55 41.66 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.111 -0.495 . . . . 74.02 110.891 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 58.5 t -143.42 120.49 5.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 72.04 111.086 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . 0.404 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 175.77 -171.98 45.01 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.713 -0.756 . . . . 73.35 112.481 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.5 pt? -131.17 161.19 32.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.847 0.356 . . . . 75.43 110.901 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 2.7 tpp85 -129.71 120.01 24.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 73.44 110.941 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 5.6 t80 -103.77 136.05 44.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.217 -0.447 . . . . 73.22 110.95 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -121.43 105.41 10.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.1 -0.5 . . . . 75.24 110.786 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 7.8 mt -94.74 162.88 13.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 75.34 110.926 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -97.94 36.55 3.9 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.783 -0.723 . . . . 63.54 112.534 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 95.8 m-20 -123.91 35.99 4.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.832 0.349 . . . . 71.32 110.888 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 18.0 p 50.95 38.81 21.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 72.22 110.892 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 8.4 t-105 -165.05 107.13 0.82 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.158 -0.473 . . . . 75.32 110.909 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -99.1 170.54 8.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.205 -0.452 . . . . 75.5 110.885 179.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -129.13 145.21 51.35 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.21 -0.45 . . . . 70.04 110.849 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -144.27 133.42 22.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.131 -0.486 . . . . 74.43 110.865 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 50.7 p -145.89 120.7 9.91 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.188 -0.46 . . . . 72.04 110.891 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . 0.404 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.6 OUTLIER -153.3 175.85 12.63 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.089 -0.505 . . . . 75.34 110.897 180.0 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 21.7 t -138.12 133.34 43.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.457 . . . . 65.14 111.105 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 2.1 ttt180 -109.16 125.01 51.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.095 -0.502 . . . . 74.21 110.865 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 13.7 p90 -128.99 146.79 50.88 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.172 -0.467 . . . . 72.44 110.929 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' ILE . . . . . 0.406 ' HA ' ' HD2' ' A' ' 171' ' ' PRO . 5.5 tt -176.8 97.77 0.24 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.557 0.694 . . . . 75.13 111.155 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . 0.406 ' HD2' ' HA ' ' A' ' 170' ' ' ILE . 53.5 Cg_endo -69.82 128.74 16.4 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.691 2.261 . . . . 74.31 112.3 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 11.6 p90 -155.08 178.96 9.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.245 -0.434 . . . . 72.02 110.863 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 13.3 pttp -130.32 140.98 50.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 74.43 110.871 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 9.0 t -104.27 167.81 9.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 75.43 111.189 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -119.38 159.72 23.66 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.27 -0.423 . . . . 73.44 110.849 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . 0.459 ' HA ' ' HA ' ' A' ' 141' ' ' ILE . 13.7 p -144.76 135.74 20.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.122 -0.49 . . . . 73.04 111.088 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.8 t -166.36 159.44 14.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 74.03 111.156 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -146.13 -134.15 2.6 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.773 -0.727 . . . . 55.12 112.491 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 98.7 m -159.9 93.77 1.09 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.835 0.35 . . . . 75.34 111.169 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . 0.403 ' O ' ' HG ' ' A' ' 180' ' ' LEU . 1.6 pt? -142.84 117.14 9.58 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.182 -0.463 . . . . 73.23 110.961 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 55.01 172.16 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.671 -0.776 . . . . 75.14 112.493 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.538 ' O ' ' HB ' ' A' ' 183' ' ' VAL . 54.6 Cg_endo -69.69 71.16 1.5 Allowed 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.699 2.266 . . . . 74.42 112.371 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . 0.538 ' HB ' ' O ' ' A' ' 182' ' ' PRO . 2.5 p 158.13 84.19 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.635 0.731 . . . . 73.13 111.063 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.65 147.84 64.45 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.649 2.233 . . . . 71.15 112.392 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 23.8 t -95.45 106.37 18.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 75.21 111.161 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 83.2 p -110.16 120.22 41.74 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.177 -0.465 . . . . 73.3 110.894 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -140.54 176.37 8.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.125 -0.489 . . . . 72.1 111.082 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.39 162.48 40.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 74.12 110.918 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 4.6 tt -146.04 120.91 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.256 -0.429 . . . . 74.02 111.121 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -96.67 118.16 32.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.157 -0.474 . . . . 71.23 110.871 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 4.4 t -137.52 159.68 34.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 74.13 111.167 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -107.27 90.42 5.68 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.558 0.694 . . . . 74.41 110.869 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 138.09 37.05 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.61 2.207 . . . . 64.55 112.368 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 23.4 m-85 -121.96 109.67 14.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.179 -0.464 . . . . 74.33 110.925 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 8.8 mt -105.25 135.03 45.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 72.51 111.171 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 10.3 tp -120.57 115.43 23.4 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.093 -0.503 . . . . 74.22 110.957 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -99.26 129.25 45.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 72.4 110.907 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 32.8 tp -150.25 129.35 12.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.149 -0.478 . . . . 71.21 110.91 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 177.38 -146.67 7.83 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.801 -0.714 . . . . 62.32 112.536 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -124.0 173.23 8.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.757 0.313 . . . . 65.12 111.101 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -138.35 164.78 28.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.452 . . . . 73.03 110.899 -179.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 34.1 m-85 -133.82 129.95 37.23 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.205 -0.452 . . . . 74.24 110.93 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 28.0 m -77.36 148.28 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 73.44 111.207 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -152.34 105.96 3.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.278 -0.419 . . . . 75.15 110.886 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 14.2 ptmt -102.69 -179.68 4.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.15 -0.477 . . . . 71.13 110.939 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -110.68 159.82 17.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.285 -0.416 . . . . 73.51 110.877 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -62.62 -68.34 0.34 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.46 . . . . 75.41 111.109 179.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -146.21 140.66 26.74 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.201 -0.454 . . . . 61.43 111.098 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -149.38 150.25 32.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.264 -0.425 . . . . 60.11 111.048 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -112.17 147.74 35.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 75.24 110.934 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.204 -0.453 . . . . 75.25 110.855 179.933 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.4 ptt? . . . . . 0 C--O 1.229 0.016 0 CA-C-O 120.81 0.338 . . . . 64.04 110.895 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 9.2 p-10 -166.57 160.18 14.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 74.43 110.897 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 24.6 mp0 -150.25 153.77 36.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 71.34 110.863 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -115.62 104.56 11.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.143 -0.48 . . . . 74.11 110.899 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -116.69 160.5 36.26 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-O 121.716 0.769 . . . . 75.15 110.874 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 175.67 7.79 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.665 2.244 . . . . 75.4 112.37 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -87.25 111.18 20.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.454 . . . . 73.03 111.059 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 16.9 tptt -94.08 -36.57 12.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.25 -0.432 . . . . 75.01 110.89 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 8.4 t 62.84 36.86 12.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.255 -0.429 . . . . 72.31 110.851 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -75.06 -35.25 61.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.148 -0.478 . . . . 71.55 111.109 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -167.38 -145.82 4.65 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.775 -0.726 . . . . 62.42 112.487 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 16.4 p90 -161.67 121.0 2.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.92 0.391 . . . . 75.11 110.93 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -132.02 175.0 9.6 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.096 -0.502 . . . . 71.44 110.921 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.34 134.88 53.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 75.42 110.953 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.73 6.48 76.5 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.758 -0.734 . . . . 70.33 112.487 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -76.89 144.9 38.63 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.837 0.351 . . . . 73.42 110.838 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 13.5 t90 -106.44 150.93 25.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 73.44 110.919 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 22.1 t -145.59 125.82 6.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.242 -0.435 . . . . 74.2 111.131 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -109.76 112.4 24.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 73.44 111.075 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' SER . . . . . 0.445 ' HA ' ' HA ' ' A' ' 201' ' ' SER . 60.2 p -124.42 146.57 48.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 73.23 110.837 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 15.1 p90 -127.19 122.52 34.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.111 -0.495 . . . . 74.33 110.827 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -146.89 158.28 43.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 75.41 110.869 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -93.69 133.57 36.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.143 -0.481 . . . . 72.23 110.886 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -98.89 114.57 27.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.47 . . . . 75.11 110.843 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.1 tppt? -92.68 108.24 19.83 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.041 -0.527 . . . . 72.13 110.874 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.2 p -87.01 140.69 15.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.236 -0.438 . . . . 73.02 111.057 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 41.3 m-85 -134.36 112.85 11.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.111 -0.495 . . . . 73.2 110.959 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 m -72.65 -176.9 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.092 -0.504 . . . . 74.43 111.182 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -93.84 -125.16 4.06 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.748 -0.739 . . . . 54.43 112.465 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -92.37 -66.39 0.93 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.771 0.32 . . . . 62.43 110.861 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.5 mp0 -150.23 -174.21 4.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.155 -0.475 . . . . 63.32 110.877 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.4 pp -86.32 -173.33 4.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 73.34 110.909 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -79.35 65.06 3.69 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.722 -0.751 . . . . 61.1 112.491 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -90.58 51.7 2.05 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.872 0.368 . . . . 74.53 110.866 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 1.1 pp -137.94 47.81 2.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 71.35 110.98 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 38.8 t30 -85.86 129.49 34.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 71.31 110.919 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.3 p -61.34 131.52 26.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.178 -0.465 . . . . 72.42 111.13 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.85 -141.29 9.57 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.717 -0.754 . . . . 73.44 112.44 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -111.0 75.92 0.22 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.69 -0.767 . . . . 60.31 112.49 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -81.03 -150.9 7.55 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.803 -0.713 . . . . 71.15 112.477 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -118.64 168.29 10.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.884 0.373 . . . . 74.3 110.991 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.479 ' N ' ' HD2' ' A' ' 43' ' ' PRO . 0.7 OUTLIER -59.89 -60.54 10.28 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.624 0.726 . . . . 63.24 110.908 -179.967 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.479 ' HD2' ' N ' ' A' ' 42' ' ' LEU . 54.0 Cg_endo -69.71 170.25 16.94 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.737 2.291 . . . . 63.51 112.347 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -119.19 165.11 14.62 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.247 -0.433 . . . . 74.12 110.905 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -73.86 -175.78 2.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 65.13 111.139 179.803 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -166.33 125.75 1.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 75.43 110.897 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 98.7 t -105.65 131.51 54.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 73.22 111.069 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.5 m -159.4 151.36 20.7 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.138 -0.483 . . . . 75.55 110.803 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 20.0 pt -100.71 157.61 4.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.082 -0.508 . . . . 74.33 111.119 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -72.02 -146.78 0.59 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.737 -0.744 . . . . 72.54 112.508 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -126.1 111.16 14.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.881 0.372 . . . . 75.03 110.88 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -164.01 159.06 20.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.13 -0.487 . . . . 65.24 110.862 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 16.4 p -125.88 123.99 39.88 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 71.43 111.154 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.0 p -137.4 139.33 40.65 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.176 -0.465 . . . . 63.12 111.076 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.5 mt -99.11 153.95 18.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.454 . . . . 74.34 110.921 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.1 p -123.26 161.38 24.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.289 -0.414 . . . . 75.5 111.172 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -105.56 133.36 50.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 73.12 110.861 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -124.04 130.06 51.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 54.34 110.867 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -107.24 114.0 45.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.478 . . . . 72.43 111.101 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -104.13 137.88 41.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.454 . . . . 73.22 111.128 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -123.28 121.98 37.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.279 -0.418 . . . . 73.42 110.893 -179.835 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -89.01 102.26 14.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.111 -0.495 . . . . 71.43 110.892 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.1 m -100.84 -33.4 3.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.105 -0.498 . . . . 72.31 111.125 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.9 t -136.23 158.6 44.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.189 -0.46 . . . . 71.33 110.838 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 47.0 t -83.56 3.21 33.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.102 -0.499 . . . . 75.23 110.848 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 47.6 t30 -115.69 -30.6 6.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 63.32 110.885 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 43.5 pt -138.23 157.48 31.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.132 -0.486 . . . . 75.25 111.127 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -145.33 157.65 44.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.154 -0.475 . . . . 75.22 111.046 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.4 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 1.4 p -106.96 145.93 13.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.15 -0.477 . . . . 75.44 111.145 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -140.54 128.01 21.36 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.209 -0.45 . . . . 73.45 110.897 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 0.425 ' HA ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -108.65 110.43 21.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.259 -0.428 . . . . 74.32 110.919 -179.912 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -87.95 115.42 25.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 74.24 110.907 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 8.9 m -139.59 156.76 26.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 72.24 111.109 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -164.55 142.37 7.72 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.75 -0.738 . . . . 73.04 112.501 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.4 t -118.64 66.21 6.91 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.551 0.691 . . . . 72.23 111.145 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 161.89 44.16 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.758 2.305 . . . . 72.4 112.349 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -78.73 -173.21 3.34 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 74.22 111.092 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 18.1 ttp180 -78.27 132.73 37.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 71.2 110.924 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -131.54 150.8 52.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 60.44 111.074 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 7.3 tttt -109.37 134.08 52.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.3 -0.409 . . . . 70.33 110.911 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -134.51 158.66 43.37 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.247 -0.433 . . . . 73.12 110.902 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -91.32 156.18 17.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.112 -0.495 . . . . 75.42 110.857 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -176.12 65.14 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.803 -0.713 . . . . 75.23 112.513 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -174.29 -174.79 0.91 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.93 0.395 . . . . 74.1 110.882 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -85.5 -70.04 0.62 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.147 -0.478 . . . . 72.25 110.855 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 32.1 t -84.83 -32.18 23.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.26 -0.427 . . . . 73.12 110.808 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.4 mm -66.58 -34.04 67.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.157 -0.474 . . . . 74.2 111.181 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 t -63.11 -41.21 99.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.164 -0.471 . . . . 65.4 110.812 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 61.7 m -60.68 -36.98 80.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 74.03 110.862 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.4 mp -64.14 -50.25 68.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.12 -0.491 . . . . 73.22 110.934 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 116.35 -14.25 15.71 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.754 -0.736 . . . . 63.42 112.482 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 58.4 mtm180 -115.06 89.87 3.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.889 0.376 . . . . 73.44 110.809 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 98.5 t -113.67 -53.25 5.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 75.31 111.137 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 13.3 m -139.28 143.47 37.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 75.35 110.887 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . 0.412 ' O ' ' CG1' ' A' ' 96' ' ' VAL . 1.7 tt0 -145.19 114.3 6.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.465 . . . . 75.13 110.928 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.412 ' CG1' ' O ' ' A' ' 95' ' ' GLU . 11.8 m -160.45 -178.17 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 72.02 111.116 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -98.65 149.13 23.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 54.03 110.831 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -93.16 125.66 37.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 75.44 110.957 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -119.42 63.16 0.46 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.749 -0.739 . . . . 73.31 112.501 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.67 122.53 9.24 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.687 2.258 . . . . 64.42 112.392 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -139.22 97.87 3.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.185 -0.461 . . . . 74.42 111.101 179.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 5.3 mp -129.18 117.56 43.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 72.41 111.157 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.425 HD23 ' HA ' ' A' ' 71' ' ' PHE . 0.9 OUTLIER -113.71 112.98 24.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.228 -0.442 . . . . 74.35 110.948 179.905 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 3.5 p -140.51 165.11 28.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.446 . . . . 73.22 110.822 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.4 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 1.0 OUTLIER -112.76 142.23 45.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.069 -0.514 . . . . 74.11 110.933 179.963 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 16.0 pt20 -101.4 151.5 21.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.166 -0.47 . . . . 75.32 110.92 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 5.1 t80 -149.69 135.8 18.88 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.249 -0.432 . . . . 75.53 110.962 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 10.6 t60 -65.69 105.15 1.18 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 71.54 110.817 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 43.8 t80 -110.17 115.7 30.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.173 -0.467 . . . . 71.22 110.874 -179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -163.98 165.9 22.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.082 -0.508 . . . . 74.3 110.851 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 20.9 m -82.87 -46.32 13.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 73.33 110.853 -179.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 3.1 p90 -138.36 156.96 47.12 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 73.31 110.883 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -52.32 108.61 0.31 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 74.34 110.859 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 4.4 tpt180 -160.18 160.67 33.1 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.096 -0.502 . . . . 65.11 110.89 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -70.08 98.85 1.37 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 74.23 110.917 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.0 m-85 -148.41 159.06 39.9 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-O 121.737 0.78 . . . . 74.11 110.903 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.69 176.86 6.15 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.678 2.252 . . . . 74.24 112.353 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -116.47 150.54 37.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.202 -0.454 . . . . 75.11 110.978 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 13.1 p -104.01 133.94 46.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 73.15 111.093 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -132.09 160.2 23.55 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.749 -0.739 . . . . 61.13 112.504 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 7.5 p -156.57 154.73 5.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.874 0.369 . . . . 63.31 111.157 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 178.76 -147.11 7.65 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.777 -0.725 . . . . 65.0 112.489 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 13.8 p -106.57 131.56 56.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.881 0.372 . . . . 74.33 111.093 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -124.29 111.62 1.64 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.749 -0.738 . . . . 74.53 112.508 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 29.0 ptt180 -114.51 130.13 56.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.774 0.321 . . . . 74.54 110.895 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . 0.46 ' O ' ' HB3' ' A' ' 143' ' ' ASP . 3.1 m -111.37 112.66 41.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.237 -0.438 . . . . 75.02 111.091 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 1.3 tp -114.86 171.59 7.56 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.202 -0.454 . . . . 71.4 110.925 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -140.03 178.88 6.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.174 -0.466 . . . . 65.33 110.841 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -117.72 119.4 34.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.144 -0.48 . . . . 73.4 110.906 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -51.89 102.34 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.14 -0.482 . . . . 73.51 110.846 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.86 -80.84 0.55 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 74.41 110.889 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 45.8 m -164.54 89.78 0.53 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 74.32 111.168 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -107.59 172.61 6.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.231 -0.44 . . . . 75.33 110.886 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.53 152.89 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.706 -0.759 . . . . 74.04 112.501 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -79.42 -1.97 39.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.809 0.338 . . . . 72.3 111.04 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -87.2 -177.52 6.01 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.245 -0.434 . . . . 73.53 110.929 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.7 m -66.57 98.12 0.48 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 74.02 110.88 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 89.4 p 46.79 75.17 0.13 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.125 -0.489 . . . . 72.43 110.794 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -89.02 148.26 23.84 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.086 -0.506 . . . . 74.34 110.867 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.18 159.76 15.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.139 -0.482 . . . . 70.54 110.818 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -126.9 118.26 50.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 75.41 111.155 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 1.6 mtpp -69.13 110.84 4.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 72.53 110.843 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.46 ' HB3' ' O ' ' A' ' 126' ' ' VAL . 61.2 m-20 -57.66 -173.44 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 73.4 110.888 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.39 162.53 39.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 71.14 110.906 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 31.1 p-90 -156.47 137.96 14.01 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.217 -0.447 . . . . 73.45 110.896 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.442 ' CB ' ' HD2' ' A' ' 147' ' ' PRO . . . -178.44 167.51 1.01 Allowed Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.603 0.716 . . . . 73.11 111.083 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . 0.442 ' HD2' ' CB ' ' A' ' 146' ' ' ALA . 53.5 Cg_endo -69.79 138.62 38.15 Favored 'Trans proline' 0 N--CA 1.465 -0.171 0 C-N-CA 122.712 2.275 . . . . 70.22 112.31 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -132.85 165.16 25.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.181 -0.463 . . . . 74.43 111.117 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -123.27 126.18 46.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.192 -0.458 . . . . 73.23 110.895 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 28.6 tt0 -110.12 155.3 22.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 72.02 110.889 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 4.6 p -144.58 125.73 8.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 71.51 111.138 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . 0.418 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . -176.36 -167.68 35.43 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.728 -0.749 . . . . 75.0 112.474 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 2.1 pp -143.87 161.03 39.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.765 0.317 . . . . 75.31 110.923 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 7.6 tpp85 -117.21 119.49 35.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 73.2 110.852 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -100.13 139.42 35.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.146 -0.479 . . . . 74.52 110.885 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -111.85 92.4 4.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 74.23 110.876 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 3.0 tt -86.27 97.02 10.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 64.43 110.953 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 58.77 -138.35 49.49 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.704 -0.76 . . . . 74.54 112.536 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -119.74 -30.35 4.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.878 0.37 . . . . 73.21 110.886 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -48.86 -66.72 0.35 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 73.33 110.878 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 23.7 p90 -145.73 150.92 37.15 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.151 -0.477 . . . . 73.4 110.904 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 2.4 mpt? -108.63 177.57 4.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 75.54 110.858 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 3.8 tp -126.12 149.15 49.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.232 -0.44 . . . . 75.33 110.916 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 13.8 t-20 -143.9 131.51 21.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 72.54 110.858 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.5 p -141.48 124.41 16.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.179 -0.464 . . . . 75.13 110.871 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . 0.418 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 2.3 p30 -156.11 169.69 23.92 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.138 -0.483 . . . . 74.2 110.878 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -142.4 134.04 25.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.182 -0.463 . . . . 75.04 111.119 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.61 142.56 33.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 75.05 110.886 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 4.3 t80 -142.0 137.65 31.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 73.34 110.889 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' ILE . . . . . . . . . . . . . 2.9 tp -177.47 102.25 0.22 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.628 0.728 . . . . 75.54 111.08 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . 0.441 ' HA ' ' HA ' ' A' ' 192' ' ' ASP . 53.9 Cg_endo -69.75 125.27 11.95 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.696 2.264 . . . . 54.24 112.364 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 24.7 p90 -150.93 178.04 9.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 74.45 110.9 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 190' ' ' GLU . 9.7 ptpt -130.85 126.52 36.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 74.2 110.879 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.6 t -93.59 175.26 6.81 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.236 -0.438 . . . . 73.41 111.143 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -126.81 163.71 22.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.254 -0.43 . . . . 74.21 110.844 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 32.7 t -148.84 133.28 9.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.223 -0.444 . . . . 75.13 111.143 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.4 t -165.58 177.69 7.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.216 -0.447 . . . . 75.24 111.173 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 121.68 141.52 6.12 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.72 -0.753 . . . . 61.33 112.485 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.4 m -172.55 141.28 1.12 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.737 0.303 . . . . 73.51 111.195 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 29.9 tp -104.87 89.18 3.08 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.287 -0.415 . . . . 74.54 110.988 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 125.2 -85.73 0.36 Allowed Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.746 -0.74 . . . . 74.04 112.458 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 -170.56 0.4 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.681 2.254 . . . . 71.2 112.36 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 26.6 m -84.47 126.4 69.22 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.576 0.703 . . . . 65.22 111.193 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 165.59 30.41 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.688 2.259 . . . . 72.41 112.35 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 39.6 t -113.38 107.68 23.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.276 -0.42 . . . . 74.14 111.145 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -81.33 106.72 13.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.161 -0.472 . . . . 72.34 110.835 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 21.0 p -121.38 174.7 6.58 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.108 -0.496 . . . . 64.34 111.104 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.55 164.03 35.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.194 -0.457 . . . . 73.52 110.872 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 189' ' ' ILE . . . . . 0.406 ' O ' ' HA ' ' A' ' 173' ' ' LYS . 5.4 mp -144.03 105.8 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 74.24 111.129 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 190' ' ' GLU . . . . . 0.423 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 61.4 tt0 -91.0 102.08 14.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.449 . . . . 73.11 110.869 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 9.3 m -138.68 164.08 26.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.458 . . . . 73.45 111.156 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . 0.441 ' HA ' ' HA ' ' A' ' 171' ' ' PRO . 6.6 p-10 -110.04 88.65 7.18 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.582 0.706 . . . . 75.3 110.867 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 143.28 50.53 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.704 2.269 . . . . 73.21 112.338 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -119.8 123.69 44.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 72.41 110.882 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 18.6 mm -109.03 132.06 58.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.147 -0.479 . . . . 72.32 111.171 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 4.6 tp -120.68 108.25 13.78 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.246 -0.433 . . . . 71.31 110.962 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.41 120.14 35.13 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.239 -0.437 . . . . 63.11 110.919 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -139.4 124.29 18.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.468 . . . . 75.42 110.988 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -176.9 -148.54 7.19 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.737 -0.745 . . . . 64.03 112.494 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -115.82 171.04 8.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.812 0.339 . . . . 73.15 111.108 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 201' ' ' SER . . . . . 0.445 ' HA ' ' HA ' ' A' ' 20' ' ' SER . 0.3 OUTLIER -138.49 156.81 47.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.434 . . . . 65.12 110.806 -179.73 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 8.2 t80 -138.07 135.6 35.99 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.132 -0.485 . . . . 75.13 110.958 -179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 14.9 p -77.36 147.46 7.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.08 -0.509 . . . . 64.02 111.179 179.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -144.57 88.01 1.9 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.16 -0.473 . . . . 75.0 110.872 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 23.1 mtmt -70.46 166.84 19.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 75.22 110.902 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 14.5 tp -99.19 -41.21 7.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 60.04 110.872 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -141.95 138.05 31.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.209 -0.451 . . . . 74.23 111.065 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -104.11 -36.26 7.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.23 -0.441 . . . . 75.15 111.122 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -148.63 157.31 43.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.209 -0.45 . . . . 55.01 111.061 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 3.9 tt -151.69 115.46 4.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 75.14 110.922 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 116.127 -0.488 . . . . 71.53 110.898 179.926 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.037 0 CA-C-O 120.81 0.338 . . . . 62.23 110.862 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 20.7 p30 40.47 40.04 0.81 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 71.21 110.917 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -78.03 123.71 27.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 73.52 110.88 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 -134.85 166.35 23.18 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 73.24 110.846 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 8.9 p90 -134.41 157.56 77.14 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.695 0.76 . . . . 74.22 110.868 -179.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 142.62 48.33 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.58 2.186 . . . . 75.21 112.334 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -67.48 113.07 5.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 72.4 111.139 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 21.9 ttpp -77.5 135.03 38.19 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.216 -0.447 . . . . 75.43 110.881 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 4.9 t -138.15 145.73 41.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.262 -0.426 . . . . 61.31 110.891 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.23 -58.18 6.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.066 -0.515 . . . . 72.4 111.195 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.56 -70.68 2.35 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.759 -0.734 . . . . 74.1 112.504 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.2 p90 -156.13 115.62 3.56 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.882 0.372 . . . . 75.52 110.889 -179.799 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 17.2 m120 -128.26 158.13 39.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.459 . . . . 72.51 110.904 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -56.22 121.68 10.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.181 -0.463 . . . . 75.33 110.923 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.37 6.22 41.95 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.706 -0.759 . . . . 65.52 112.491 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -61.81 146.12 50.51 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.817 0.341 . . . . 70.1 110.829 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 19.8 t90 -111.47 121.19 44.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.09 -0.504 . . . . 71.3 110.947 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.2 t -123.4 120.17 59.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.242 -0.435 . . . . 65.32 111.121 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -86.8 112.35 21.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 62.22 111.127 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.1 t -109.03 110.0 21.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.236 -0.438 . . . . 72.34 110.874 -179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 43.5 t80 -107.64 120.01 41.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.477 . . . . 70.41 110.919 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.43 ' HA ' ' HA3' ' A' ' 199' ' ' GLY . 7.4 p30 -149.86 174.87 12.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.442 . . . . 73.42 110.91 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 19.1 p90 -110.83 132.9 53.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 73.11 110.861 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 41.9 p -98.18 146.18 25.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 63.21 110.894 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.4 tmtp? -127.25 106.52 9.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 75.21 110.904 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.8 m -77.31 129.7 37.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.245 -0.434 . . . . 73.42 111.128 179.842 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -126.4 107.78 10.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.126 -0.488 . . . . 74.14 110.956 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.8 p -175.71 153.79 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.485 . . . . 73.32 111.079 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.43 71.68 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.778 -0.725 . . . . 70.34 112.54 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -89.14 -65.87 0.98 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.807 0.337 . . . . 72.31 110.895 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -174.99 152.44 1.49 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.106 -0.497 . . . . 71.34 110.855 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -96.11 162.32 13.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.163 -0.471 . . . . 75.43 110.909 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -53.67 101.9 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.761 -0.733 . . . . 72.34 112.434 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -64.77 -69.84 0.26 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.909 0.385 . . . . 72.22 110.894 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 4.5 tp -81.03 147.56 30.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.138 -0.483 . . . . 70.1 110.982 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 -128.87 149.54 50.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.182 -0.463 . . . . 74.32 110.864 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 30.6 m -51.53 -35.37 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.206 -0.452 . . . . 72.54 111.094 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -136.87 131.56 5.66 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.768 -0.73 . . . . 74.25 112.518 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 126.64 153.86 8.44 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.753 -0.737 . . . . 61.45 112.475 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -87.13 110.9 3.6 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.681 -0.771 . . . . 64.23 112.469 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -118.84 -179.26 3.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.784 0.326 . . . . 74.2 111.089 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.529 ' N ' ' HD2' ' A' ' 43' ' ' PRO . 0.2 OUTLIER 177.47 -57.6 0.0 OUTLIER Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.571 0.701 . . . . 72.34 110.923 179.999 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.529 ' HD2' ' N ' ' A' ' 42' ' ' LEU . 54.1 Cg_endo -69.78 152.21 69.17 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.668 2.245 . . . . 74.33 112.35 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 6.5 m120 -86.5 139.85 30.49 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.2 -0.454 . . . . 74.13 110.938 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.9 169.33 11.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 74.14 111.084 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 35.8 m-20 -153.64 127.24 8.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.238 -0.437 . . . . 71.03 110.828 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 10.8 p -104.52 137.52 33.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 71.53 111.171 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.0 t -148.45 154.87 40.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.094 -0.503 . . . . 74.1 110.835 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -119.62 154.67 22.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.087 -0.506 . . . . 71.02 111.1 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.39 -124.59 0.56 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.751 -0.738 . . . . 75.21 112.444 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 38.9 m-20 -82.41 -35.61 27.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.87 0.367 . . . . 75.44 110.911 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 41.9 40.03 1.44 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 71.41 110.85 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 1.4 p -108.37 113.09 25.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 70.12 111.158 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.5 t -154.35 173.95 15.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.136 -0.484 . . . . 62.1 111.139 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -92.55 169.11 10.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.248 -0.433 . . . . 74.23 110.924 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 18.6 p -149.36 141.54 24.02 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.172 -0.467 . . . . 75.13 111.113 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -103.27 132.82 49.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 73.12 110.861 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -130.63 130.12 43.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.159 -0.473 . . . . 70.24 110.84 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.08 112.94 42.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.196 -0.456 . . . . 74.31 111.077 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -102.76 121.69 42.97 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.206 -0.452 . . . . 75.53 111.076 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -106.85 122.72 46.97 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 73.12 110.93 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -88.89 107.22 18.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.17 -0.468 . . . . 73.32 110.908 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 63.8 t -103.24 -48.13 10.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.157 -0.474 . . . . 71.44 111.097 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 40.2 t -124.38 165.99 16.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 72.41 110.854 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.1 m -87.43 2.71 49.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.087 -0.506 . . . . 73.31 110.837 -179.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -112.99 -33.68 5.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.084 -0.507 . . . . 74.32 110.936 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 31.4 pt -146.12 160.22 11.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.48 . . . . 74.45 111.081 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -146.57 173.4 12.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 70.34 111.112 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.469 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 14.4 m -115.16 152.13 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.255 -0.429 . . . . 73.14 111.163 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -144.13 144.43 31.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.251 -0.431 . . . . 71.2 110.834 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -120.74 110.14 16.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.157 -0.474 . . . . 73.21 110.914 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -92.6 117.84 30.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 64.5 110.896 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.4 p -150.26 154.61 8.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.161 -0.472 . . . . 65.05 111.117 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -155.56 150.95 22.52 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.691 -0.766 . . . . 73.43 112.452 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 5.8 m -118.2 67.05 6.45 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.587 0.708 . . . . 75.21 111.11 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.69 159.48 53.28 Favored 'Trans proline' 0 N--CA 1.465 -0.16 0 C-N-CA 122.767 2.312 . . . . 70.2 112.35 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -83.39 -167.96 1.91 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.211 -0.45 . . . . 73.24 111.108 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -77.74 127.52 32.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 74.43 110.852 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -123.87 150.62 44.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.245 -0.434 . . . . 74.2 111.166 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 5.4 ttpm? -104.19 144.85 31.04 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.213 -0.449 . . . . 74.14 110.887 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -142.0 155.0 45.43 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.269 -0.423 . . . . 75.24 110.923 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.41 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 0.2 OUTLIER -107.18 151.57 25.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.12 -0.491 . . . . 73.51 110.943 -179.942 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -175.86 75.86 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.707 -0.759 . . . . 62.43 112.41 -179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -178.52 -176.33 0.48 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.94 0.4 . . . . 74.15 110.881 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -85.41 -69.71 0.64 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.192 -0.458 . . . . 74.13 110.88 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 75.3 m -84.58 -34.09 23.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.435 . . . . 71.4 110.886 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.2 mm -64.06 -34.75 70.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 72.33 111.146 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 78.8 p -62.61 -49.09 76.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.471 . . . . 73.0 110.818 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 41.6 t -51.72 -36.89 48.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.102 -0.499 . . . . 74.51 110.786 -179.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -68.55 -46.39 69.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 73.11 110.881 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.67 -12.76 38.9 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.751 -0.738 . . . . 62.31 112.529 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 21.1 mmt85 -108.87 88.69 2.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.827 0.346 . . . . 74.12 110.875 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.41 ' HB ' ' HA ' ' A' ' 82' ' ' GLN . 99.0 t -113.91 -52.87 5.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 74.13 111.044 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 8.5 p -139.85 144.5 37.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 73.32 110.924 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -149.7 119.53 7.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 72.12 110.896 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 3.8 p -177.65 163.84 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.163 -0.471 . . . . 74.42 111.154 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -76.29 163.66 26.81 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.218 -0.447 . . . . 73.11 110.881 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 2.6 m-85 -114.21 139.55 49.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.184 -0.462 . . . . 73.53 110.881 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -117.92 65.94 0.36 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.754 -0.736 . . . . 61.31 112.428 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 115.34 4.05 Favored 'Trans proline' 0 C--N 1.341 0.134 0 C-N-CA 122.682 2.255 . . . . 73.43 112.313 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -139.08 119.88 14.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 73.24 111.103 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.409 ' HA ' ' HA2' ' A' ' 124' ' ' GLY . 0.0 OUTLIER -155.2 136.2 5.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 71.03 111.104 179.913 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -119.69 124.2 45.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.103 -0.499 . . . . 73.12 110.924 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' SER . . . . . 0.412 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 72.3 m -143.69 159.38 42.58 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.177 -0.465 . . . . 62.43 110.874 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.469 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.6 OUTLIER -106.85 152.05 24.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.118 -0.492 . . . . 73.41 110.851 -179.912 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 75.7 mt-30 -101.69 140.36 36.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 74.52 110.857 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -122.65 110.73 15.89 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.12 -0.491 . . . . 74.34 110.953 -179.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 -101.36 161.3 13.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.153 -0.476 . . . . 74.43 110.835 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 2.2 t80 -113.78 177.35 4.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.228 -0.442 . . . . 75.34 110.922 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -107.36 126.98 53.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.136 -0.484 . . . . 64.12 110.858 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 179.78 149.8 0.33 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 60.52 110.841 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -95.68 -74.8 0.54 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.479 . . . . 74.42 110.887 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -71.35 143.5 50.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.159 -0.473 . . . . 74.44 110.91 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 23.7 ttt180 53.11 62.02 2.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.159 -0.473 . . . . 74.43 110.856 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 29.2 tp -63.94 94.34 0.1 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 72.12 110.904 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -60.45 160.57 17.58 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.642 0.734 . . . . 74.34 110.981 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 176.96 6.06 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.684 2.256 . . . . 74.03 112.309 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 15.7 p90 -111.08 154.12 24.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.474 . . . . 73.23 110.91 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.3 p -113.75 131.43 65.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 75.14 111.153 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -124.14 168.0 16.36 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.626 -0.797 . . . . 72.31 112.475 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 8.4 p -171.99 153.4 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.886 0.374 . . . . 71.11 111.131 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.412 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -178.26 -152.16 10.04 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.732 -0.747 . . . . 70.3 112.459 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . 0.452 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 12.1 p -107.72 134.57 49.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.786 0.326 . . . . 74.43 111.182 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . 0.409 ' HA2' ' HA ' ' A' ' 102' ' ' ILE . . . -121.87 172.52 15.52 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.709 -0.758 . . . . 72.42 112.553 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 12.3 ptm180 -169.69 130.07 1.02 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.816 0.341 . . . . 72.24 110.904 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 4.0 p -110.18 120.46 61.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.456 . . . . 75.41 111.131 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 5.7 mp -109.42 149.77 29.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 75.24 110.949 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -131.97 152.6 51.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 74.24 110.872 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -102.61 175.09 5.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.087 -0.506 . . . . 64.14 110.851 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.6 p-10 -110.66 95.51 5.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.166 -0.47 . . . . 74.03 110.888 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 9.5 tmtt? -119.35 -68.17 0.93 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 73.32 110.941 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 2.7 m -161.68 63.75 0.25 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.246 -0.434 . . . . 73.42 111.189 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -93.04 163.76 13.53 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.235 -0.439 . . . . 74.14 110.882 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 64.25 150.92 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.699 -0.763 . . . . 73.23 112.448 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -79.66 2.26 23.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.861 0.362 . . . . 75.05 111.115 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -86.09 -176.64 6.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.441 . . . . 74.22 110.916 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 89.0 p -64.93 88.91 0.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 74.43 110.867 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 7.6 m 49.88 76.17 0.15 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.147 -0.479 . . . . 75.31 110.853 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -93.66 159.27 15.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.1 -0.5 . . . . 74.44 110.913 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -117.64 170.6 8.64 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.193 -0.458 . . . . 71.54 110.879 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 30.3 mm -116.09 141.61 32.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 71.42 111.113 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -90.7 106.2 18.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.163 -0.471 . . . . 73.43 110.918 179.854 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -57.23 -176.68 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.225 -0.443 . . . . 73.02 110.868 179.854 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 24.0 tptt -163.73 161.12 23.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.141 -0.481 . . . . 74.11 110.858 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 5.8 p90 -132.77 146.69 52.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 73.32 110.911 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -179.39 162.77 0.96 Allowed Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.527 0.679 . . . . 64.33 111.167 179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . 0.452 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 53.6 Cg_endo -69.72 166.43 27.57 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.651 2.234 . . . . 61.05 112.354 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.401 ' HA ' ' HB ' ' A' ' 170' ' ' ILE . . . -153.19 151.47 30.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.261 -0.427 . . . . 71.4 111.11 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 32.0 m-85 -111.81 125.05 53.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 74.32 110.898 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -107.48 158.28 17.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.104 -0.498 . . . . 74.24 110.938 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 15.0 p -161.25 134.79 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.234 -0.439 . . . . 72.2 111.128 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . 0.426 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 179.5 -159.21 23.67 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.71 -0.757 . . . . 51.23 112.506 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.86 148.81 39.39 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.872 0.368 . . . . 72.22 110.85 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 3.8 tpp85 -126.97 122.15 33.71 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.142 -0.481 . . . . 75.33 110.868 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -125.97 164.27 21.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 73.24 111.014 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -122.61 108.74 13.46 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 71.4 110.919 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -50.51 158.79 0.57 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 71.42 110.93 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -50.6 -32.15 23.68 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.775 -0.726 . . . . 63.45 112.482 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -80.76 -168.64 1.84 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.836 0.351 . . . . 74.31 110.901 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 46.9 t -71.04 -35.3 71.91 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.47 . . . . 72.23 110.846 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 3.1 m0 -71.47 153.93 41.87 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.172 -0.467 . . . . 74.5 110.954 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 2.3 mpt? -131.9 173.98 10.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 63.41 110.819 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.506 ' HA ' ' HA ' ' A' ' 200' ' ' ALA . 0.0 OUTLIER -140.84 160.59 39.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 71.43 110.922 179.998 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -163.74 156.62 18.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 75.02 110.908 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 12.2 p -148.25 121.9 9.22 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 73.44 110.829 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . 0.426 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 15.6 t70 -130.72 160.84 33.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 73.0 110.883 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 31.8 t -137.04 132.06 46.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.236 -0.438 . . . . 75.41 111.147 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.41 139.31 37.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 75.23 110.868 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 66.5 t80 -143.97 134.21 24.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.146 -0.479 . . . . 71.35 110.897 -179.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' ILE . . . . . 0.401 ' HB ' ' HA ' ' A' ' 148' ' ' ALA . 0.0 OUTLIER 179.83 131.58 0.25 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.601 0.715 . . . . 73.01 111.217 179.904 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . 0.401 ' HD2' HG12 ' A' ' 170' ' ' ILE . 54.3 Cg_endo -69.69 109.27 2.26 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.709 2.273 . . . . 53.42 112.355 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -119.0 176.87 5.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.445 . . . . 72.34 110.865 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.53 147.53 29.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.161 -0.472 . . . . 73.43 110.829 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -132.36 162.83 30.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.489 . . . . 71.53 111.177 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -119.74 170.87 8.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 73.34 110.849 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 21.9 t -148.73 133.19 9.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 75.45 111.119 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 14.8 t -166.55 175.03 8.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 73.15 111.169 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -156.62 -137.08 2.25 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.799 -0.715 . . . . 71.43 112.536 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 98.6 m -156.26 113.3 3.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.785 0.326 . . . . 75.4 111.156 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 13.8 tp -139.39 167.86 21.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.197 -0.456 . . . . 72.21 110.907 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -40.82 -71.51 0.31 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.715 -0.755 . . . . 74.42 112.479 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -169.15 0.31 Allowed 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.622 2.214 . . . . 73.23 112.347 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 61.4 t -61.21 132.64 92.58 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.634 0.731 . . . . 74.42 111.103 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 163.14 39.42 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.684 2.256 . . . . 73.22 112.336 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 29.7 t -106.62 115.56 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.19 -0.459 . . . . 72.41 111.094 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 19.4 p -110.1 105.84 15.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 72.23 110.814 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 16.2 p -107.74 159.46 16.47 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.115 -0.493 . . . . 65.14 111.138 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 34.8 ttpt -147.17 145.18 29.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 64.31 110.857 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 20.6 pt -146.1 142.05 21.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.127 -0.488 . . . . 62.43 111.1 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -124.14 110.8 15.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 74.23 110.896 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 5.6 t -137.06 157.99 35.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 75.44 111.08 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -108.14 88.39 4.71 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.601 0.715 . . . . 74.1 110.898 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 169.13 19.7 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.716 2.277 . . . . 72.21 112.318 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -126.91 117.2 22.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.465 . . . . 73.12 110.888 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 61.8 mt -103.29 104.27 16.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 75.35 111.187 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 5.5 mt -96.12 108.88 21.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.217 -0.447 . . . . 55.03 110.93 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -108.99 127.7 54.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.244 -0.435 . . . . 73.42 110.848 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 10.4 tt -149.95 132.75 15.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.165 -0.471 . . . . 74.34 110.904 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 199' ' ' GLY . . . . . 0.43 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -177.97 -152.12 9.91 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.776 -0.726 . . . . 72.23 112.468 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 200' ' ' ALA . . . . . 0.506 ' HA ' ' HA ' ' A' ' 163' ' ' LEU . . . -110.09 173.1 6.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.822 0.344 . . . . 65.53 111.034 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 40.6 t -159.98 162.66 34.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 63.54 110.852 -179.739 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -146.55 135.27 22.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.14 -0.482 . . . . 74.3 110.917 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 11.2 p -83.63 152.56 3.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.122 -0.49 . . . . 73.44 111.129 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -151.37 132.08 14.03 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 75.21 110.887 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.31 161.31 18.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.125 -0.489 . . . . 75.45 110.885 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -118.51 106.42 12.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.258 -0.428 . . . . 65.24 110.895 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -96.08 -36.48 10.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 74.34 111.114 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -59.11 167.81 1.58 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.178 -0.465 . . . . 71.11 111.09 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -77.15 167.88 21.02 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 62.33 111.084 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -143.86 136.55 27.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 75.34 110.897 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 73.2 110.865 179.951 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.6 mpt? . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.789 0.328 . . . . 71.34 110.893 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -147.82 109.74 4.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 74.14 110.912 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.1 mp0 -133.64 177.44 7.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 61.31 110.879 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -85.49 -51.14 6.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.105 -0.498 . . . . 75.11 110.863 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 1.1 t80 58.07 68.49 1.83 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.709 0.766 . . . . 74.51 110.922 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 163.82 36.9 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.683 2.255 . . . . 71.22 112.377 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -140.82 167.02 23.18 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.256 -0.429 . . . . 72.32 111.154 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.24 132.97 10.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 73.45 110.882 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 7.2 p -55.53 -35.32 65.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.261 -0.427 . . . . 74.2 110.793 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -51.37 -52.3 46.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 71.2 111.059 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -52.71 153.45 6.62 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.663 -0.78 . . . . 74.14 112.547 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 21.2 p90 -169.53 127.01 0.92 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.999 0.428 . . . . 75.51 110.939 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 6.2 t30 -169.33 -176.79 2.63 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.474 . . . . 71.33 110.955 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 41.6 mt-30 -51.73 130.9 29.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 73.24 110.945 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.9 9.76 31.78 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.779 -0.724 . . . . 72.11 112.456 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -78.71 169.39 18.31 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.803 0.335 . . . . 73.41 110.874 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 10.1 m-90 -114.9 159.85 20.21 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.215 -0.448 . . . . 75.23 110.937 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.5 m -153.38 126.96 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 73.14 111.152 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -96.4 114.95 26.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.154 -0.475 . . . . 75.5 111.077 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -111.95 113.7 26.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.175 -0.466 . . . . 72.44 110.91 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 48.9 p90 -106.65 125.66 51.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 74.3 110.873 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -155.55 166.58 33.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.135 -0.484 . . . . 74.33 110.915 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 23.4 p90 -98.86 132.39 44.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.143 -0.48 . . . . 74.44 110.85 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -98.7 122.69 42.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.152 -0.476 . . . . 74.3 110.871 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 29.2 tptt -99.29 106.53 18.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 63.41 110.867 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.4 p -81.2 133.88 28.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.312 -0.404 . . . . 75.33 111.114 179.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -120.5 112.51 19.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.094 -0.503 . . . . 70.41 110.909 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.0 m -153.13 -179.34 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.097 -0.501 . . . . 74.41 111.147 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.63 52.48 0.54 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.682 -0.771 . . . . 71.1 112.477 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 34.0 mt-10 -90.03 -66.75 0.89 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.849 0.357 . . . . 65.4 110.903 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? 177.81 151.94 0.25 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.088 -0.506 . . . . 73.14 110.945 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -109.03 163.73 13.05 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.15 -0.477 . . . . 74.54 110.921 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 52.37 -102.47 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.737 -0.744 . . . . 75.52 112.452 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 47.6 t0 53.67 42.77 31.77 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.914 0.388 . . . . 73.52 110.865 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -106.41 128.85 54.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.135 -0.484 . . . . 63.5 110.941 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -166.32 177.23 6.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 63.01 110.856 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 34.8 m -128.79 140.4 49.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.133 -0.485 . . . . 73.21 111.11 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 68.03 153.02 0.4 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.774 -0.727 . . . . 61.14 112.51 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 73.82 -172.87 50.69 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.756 -0.735 . . . . 74.43 112.554 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -83.64 -145.81 6.64 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.754 -0.736 . . . . 72.54 112.447 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -119.4 142.67 47.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.799 0.333 . . . . 55.33 111.103 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -146.19 70.62 13.18 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 121.567 0.699 . . . . 75.2 110.909 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.89 102.8 1.09 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.714 2.276 . . . . 75.22 112.278 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -79.75 -43.3 22.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 72.25 110.941 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -61.87 -179.46 0.2 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 74.14 111.105 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -159.52 125.15 4.22 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.231 -0.441 . . . . 62.11 110.869 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.402 ' HA ' ' HA2' ' A' ' 83' ' ' GLY . 6.5 p -118.14 148.91 20.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.193 -0.458 . . . . 75.35 111.072 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -173.14 174.47 3.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 72.41 110.878 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 19.3 tt -141.57 154.79 20.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.112 -0.494 . . . . 75.51 111.086 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -124.42 167.54 16.72 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.715 -0.755 . . . . 72.3 112.426 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.9 m-80 -162.66 163.91 26.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.821 0.343 . . . . 71.22 110.904 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -120.36 -68.83 0.88 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 62.43 110.827 179.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 72.3 p -91.93 172.87 8.17 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.216 -0.447 . . . . 74.43 111.144 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 40.3 p -148.38 106.52 3.73 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.226 -0.443 . . . . 73.43 111.122 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.3 pp -160.73 128.74 4.47 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 64.54 110.94 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.54 155.74 45.05 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.274 -0.421 . . . . 75.0 111.182 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -114.95 132.46 56.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 71.54 110.893 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.443 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -129.88 134.83 47.76 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.211 -0.449 . . . . 63.24 110.991 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.0 mm -109.29 115.16 48.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.274 -0.421 . . . . 72.14 111.125 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.445 ' HA ' ' HA ' ' A' ' 70' ' ' ASP . . . -111.31 151.48 28.33 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.178 -0.464 . . . . 62.22 111.084 179.829 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 5.3 m-85 -125.74 132.37 52.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 73.04 110.932 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -98.3 95.22 7.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.081 -0.509 . . . . 73.24 110.893 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.5 t -94.35 -31.74 4.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.151 -0.477 . . . . 75.34 111.089 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 29.7 t -136.15 158.07 45.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 74.23 110.831 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 59.8 p -85.07 3.98 36.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 72.41 110.859 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -114.41 -29.47 6.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 72.41 110.84 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 32.5 pt -142.08 158.0 20.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 73.14 111.113 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -148.91 163.27 37.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 62.12 111.115 179.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.1 m -112.24 152.14 14.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 74.35 111.155 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.445 ' HA ' ' HA ' ' A' ' 60' ' ' ALA . 1.5 p30 -144.58 143.31 30.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 64.25 110.885 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 0.443 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -127.19 108.44 10.89 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 75.3 110.851 -179.907 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -86.33 127.26 34.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.12 -0.491 . . . . 74.21 110.819 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 14.6 p -147.3 147.49 17.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 73.21 111.198 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -161.88 144.18 9.51 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.753 -0.737 . . . . 73.55 112.487 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 44.3 t -119.74 73.18 16.91 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.608 0.718 . . . . 70.41 111.129 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 159.09 54.7 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.669 2.246 . . . . 52.34 112.365 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -74.91 -165.8 0.41 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.251 -0.431 . . . . 72.35 111.181 179.818 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 18.2 ttm105 -77.05 138.22 39.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.283 -0.417 . . . . 71.33 110.833 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -132.77 148.99 52.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.443 . . . . 54.51 111.128 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.6 ttpm? -89.12 123.8 33.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.182 -0.463 . . . . 73.13 110.93 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 59.6 t80 -109.13 138.82 44.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 72.15 110.878 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -109.17 150.91 27.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 74.43 110.917 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.402 ' HA2' ' HA ' ' A' ' 47' ' ' VAL . . . 174.37 84.88 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.696 -0.764 . . . . 74.31 112.447 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -178.07 -175.68 0.5 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.894 0.378 . . . . 75.3 110.976 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 1.4 ptpt -86.54 -70.13 0.63 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.198 -0.455 . . . . 74.22 110.879 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 8.4 t -85.25 -30.52 23.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.225 -0.443 . . . . 75.44 110.869 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 4.8 mm -68.81 -35.21 68.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.123 -0.489 . . . . 73.33 111.114 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.1 t -62.68 -47.38 83.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 72.5 110.861 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.1 t -54.67 -39.85 68.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.149 -0.478 . . . . 71.23 110.837 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 13.9 tp -60.55 -44.23 96.37 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.083 -0.508 . . . . 75.4 110.995 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.24 -14.55 39.86 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.743 -0.741 . . . . 74.55 112.501 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 9.8 mtm180 -120.54 96.74 5.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.897 0.38 . . . . 75.41 110.813 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 99.3 t -107.24 -58.27 3.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 73.05 111.1 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -140.09 148.73 42.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.154 -0.475 . . . . 64.43 110.902 -179.792 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 31.6 mt-10 -126.01 124.59 41.03 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.132 -0.485 . . . . 72.13 110.972 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 14.8 p -176.05 156.76 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 74.21 111.11 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -84.27 173.49 10.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 75.34 110.902 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 14.4 m-85 -130.48 133.17 46.08 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 74.23 110.933 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -114.11 69.63 0.24 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.703 -0.761 . . . . 54.42 112.445 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.82 138.44 37.64 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.694 2.263 . . . . 74.04 112.294 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -155.7 118.08 4.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 60.55 111.115 179.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 30.0 pt -140.15 146.1 25.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 75.42 111.165 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 2.3 pp -132.82 118.99 19.66 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.196 -0.456 . . . . 74.11 110.846 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' SER . . . . . 0.404 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 5.6 p -142.93 163.92 31.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.202 -0.454 . . . . 65.11 110.875 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 1.1 pp -113.87 151.46 32.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 72.43 110.886 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 31.5 mt-30 -106.49 144.05 33.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 73.55 110.907 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 5.4 t80 -136.02 125.41 24.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 65.53 110.968 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -86.5 123.14 31.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.173 -0.467 . . . . 64.31 110.843 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 5.9 t80 -91.98 138.82 31.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.142 -0.481 . . . . 73.11 110.95 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -51.6 113.06 0.87 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 73.12 110.846 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 35.0 m -62.35 165.67 5.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.166 -0.47 . . . . 71.34 110.835 -179.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 38.2 m-85 -114.51 -67.13 1.02 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.148 -0.478 . . . . 75.02 110.898 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -102.31 -73.45 0.66 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 73.31 110.854 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 8.2 ttm180 -105.39 179.76 4.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.49 . . . . 74.14 110.903 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 4.0 pp -69.28 146.34 52.35 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 75.51 110.938 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 6.1 m-85 -141.86 160.66 55.02 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-O 121.689 0.757 . . . . 73.4 110.884 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 178.43 4.57 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.633 2.222 . . . . 73.43 112.349 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 4.0 m-85 -110.24 151.95 26.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.462 . . . . 74.35 110.949 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 8.3 p -101.93 133.01 46.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.109 -0.496 . . . . 75.11 111.101 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -131.92 174.67 20.11 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.796 -0.716 . . . . 71.15 112.568 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.4 p -175.95 153.54 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.865 0.364 . . . . 73.43 111.106 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.404 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -176.01 -158.21 19.09 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.76 -0.734 . . . . 54.2 112.543 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . 0.461 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 21.3 m -107.7 150.66 10.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.869 0.366 . . . . 72.43 111.116 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -130.53 169.07 21.46 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.687 -0.768 . . . . 75.24 112.455 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . 0.414 ' HA ' ' HA ' ' A' ' 145' ' ' TRP . 0.0 OUTLIER -168.55 129.26 1.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.86 0.362 . . . . 71.3 110.923 -179.855 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 3.9 p -118.73 112.04 36.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 73.03 111.152 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 10.0 tt -122.52 151.23 41.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 73.34 110.883 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -160.89 161.94 31.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.187 -0.461 . . . . 72.21 110.833 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 51.5 t80 -101.07 118.59 37.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.49 . . . . 71.53 110.88 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -50.55 102.37 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 65.21 110.845 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -77.52 -80.81 0.1 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.139 -0.482 . . . . 74.35 110.901 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -165.43 112.9 0.96 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.256 -0.429 . . . . 74.34 111.125 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . 0.499 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 1.4 m-20 -103.07 119.36 38.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.144 -0.48 . . . . 71.35 110.923 179.853 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -79.89 -5.82 89.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.806 -0.712 . . . . 62.21 112.445 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -46.81 -28.18 1.46 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.81 0.338 . . . . 73.2 111.113 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -162.86 -178.56 6.2 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.191 -0.458 . . . . 74.2 111.019 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 1.5 m -53.02 93.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.275 -0.42 . . . . 73.1 110.828 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 7.0 m 50.68 71.19 0.44 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.081 -0.509 . . . . 70.22 110.891 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.499 ' HB3' ' HB2' ' A' ' 133' ' ' ASP . 0.5 OUTLIER -92.98 159.88 15.12 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.135 -0.484 . . . . 73.22 110.838 -179.912 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 94.0 m-20 -134.0 167.41 20.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.495 . . . . 75.54 110.891 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 17.6 tt -117.97 149.11 20.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.192 -0.458 . . . . 74.04 111.182 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 16.2 mmtt -113.36 124.54 52.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 74.23 110.931 179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -85.53 -173.32 4.59 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.225 -0.443 . . . . 63.31 110.868 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -171.54 -175.36 1.58 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 72.51 110.904 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' TRP . . . . . 0.414 ' HA ' ' HA ' ' A' ' 125' ' ' ARG . 22.5 p-90 -143.57 160.49 40.54 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.198 -0.456 . . . . 71.33 110.917 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . 178.86 163.15 0.69 Allowed Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.623 0.725 . . . . 74.44 111.086 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 54.3 Cg_endo -69.66 170.61 16.06 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.683 2.255 . . . . 73.3 112.375 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -165.55 153.0 10.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.222 -0.445 . . . . 74.4 111.13 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 12.9 m-85 -96.17 161.3 14.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.242 -0.435 . . . . 73.54 110.819 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 27.7 tp60 -135.0 148.59 50.0 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 62.44 110.949 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 10.2 p -151.54 130.84 3.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.17 -0.468 . . . . 75.33 111.161 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 164.95 -163.21 36.27 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.727 -0.749 . . . . 70.43 112.481 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -148.93 168.26 23.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.788 0.328 . . . . 74.41 110.95 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -133.68 128.51 35.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 73.24 110.88 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -132.66 161.64 33.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.442 . . . . 74.31 110.933 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -121.28 109.58 15.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.147 -0.479 . . . . 73.01 110.904 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 3.6 tp -57.46 160.45 4.12 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.169 -0.469 . . . . 75.12 110.944 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -52.05 -33.24 36.77 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.775 -0.726 . . . . 64.04 112.495 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 4.6 m120 -80.52 173.65 12.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.907 0.384 . . . . 74.14 110.821 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 81.1 p -54.78 -35.74 64.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.113 -0.494 . . . . 75.45 110.815 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 10.3 m0 -69.31 151.68 45.91 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.199 -0.455 . . . . 73.21 110.97 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 38.8 mtt -121.22 174.92 6.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.246 -0.433 . . . . 74.34 110.862 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.417 ' HA ' ' HA ' ' A' ' 200' ' ' ALA . 0.6 OUTLIER -128.65 139.25 52.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.262 -0.427 . . . . 73.5 110.909 179.999 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 12.1 t-20 -139.84 138.33 35.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 71.13 110.984 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.7 p -141.61 121.79 13.85 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.214 -0.448 . . . . 73.24 110.892 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -140.26 167.59 21.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.08 -0.509 . . . . 72.41 110.812 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 46.7 t -150.43 129.05 2.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.157 -0.474 . . . . 61.33 111.115 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . 0.456 ' O ' ' HG3' ' A' ' 168' ' ' ARG . 0.0 OUTLIER -98.59 137.71 36.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 71.32 110.862 -179.972 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 15.9 t80 -138.22 125.37 21.52 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 72.2 110.929 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' ILE . . . . . 0.497 HG13 ' HD2' ' A' ' 171' ' ' PRO . 4.7 tp 178.9 134.69 0.24 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.599 0.714 . . . . 72.34 111.116 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . 0.497 ' HD2' HG13 ' A' ' 170' ' ' ILE . 54.0 Cg_endo -69.85 111.55 2.86 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.609 2.206 . . . . 74.25 112.386 179.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -116.1 159.76 21.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.139 -0.482 . . . . 72.35 110.856 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 5.4 ptpt -140.06 144.79 37.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.146 -0.479 . . . . 74.54 110.926 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 9.4 t -117.79 161.9 18.96 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 73.52 111.137 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 21.6 t70 -118.48 158.54 25.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.14 -0.482 . . . . 71.3 110.844 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 4.5 t -147.94 138.26 16.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 73.33 111.082 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.3 t -166.92 -179.22 4.59 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.131 -0.486 . . . . 71.11 111.116 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -120.55 -161.66 11.53 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.746 -0.74 . . . . 63.02 112.458 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 6.4 t -119.9 -171.74 2.2 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.84 0.353 . . . . 75.22 111.16 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 4.9 mp -61.36 147.68 43.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 71.34 110.907 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 116.21 -88.0 0.45 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.716 -0.754 . . . . 73.11 112.441 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.67 -160.22 0.06 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.181 0 C-N-CA 122.772 2.314 . . . . 75.41 112.331 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 16.4 t -105.99 87.76 2.62 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.66 0.743 . . . . 75.22 111.174 179.818 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.87 122.84 9.48 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.671 2.247 . . . . 64.53 112.317 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 26.5 t -103.59 108.17 23.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 72.24 111.111 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -74.13 104.83 5.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.137 -0.483 . . . . 74.14 110.82 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 65.1 p -124.44 168.59 12.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.136 -0.484 . . . . 73.31 111.171 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 3.0 ttpm? -158.97 134.09 8.34 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.207 -0.451 . . . . 75.44 110.944 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -115.75 139.59 41.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.279 -0.419 . . . . 72.52 111.107 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 71.7 tt0 -119.55 114.99 23.1 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.125 -0.489 . . . . 74.22 110.817 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 1.2 p -137.18 171.28 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 70.41 111.111 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -106.93 87.14 2.73 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.594 0.711 . . . . 72.52 110.915 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.65 120.96 7.68 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.742 2.295 . . . . 62.21 112.379 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -102.09 114.0 27.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.258 -0.428 . . . . 74.01 110.887 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 195' ' ' ILE . . . . . 0.405 ' HB ' ' CG ' ' A' ' 168' ' ' ARG . 5.6 mt -103.56 127.3 57.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.162 -0.472 . . . . 74.22 111.133 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 1.1 tt -117.14 107.72 14.82 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.182 -0.463 . . . . 64.34 110.89 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 3.2 m -96.38 123.62 40.09 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.24 -0.436 . . . . 65.42 110.847 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 2.5 tt -144.13 129.21 18.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 73.41 110.86 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 178.94 -146.98 7.53 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.75 -0.738 . . . . 73.21 112.478 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 200' ' ' ALA . . . . . 0.417 ' HA ' ' HA ' ' A' ' 163' ' ' LEU . . . -118.65 174.26 6.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.781 0.324 . . . . 61.35 111.17 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 78.1 p -149.66 175.71 11.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.28 -0.418 . . . . 74.21 110.843 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -157.31 160.9 39.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 73.52 110.895 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 18.2 m -76.76 161.21 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.065 -0.516 . . . . 70.04 111.15 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -155.95 127.59 7.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 74.34 110.865 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 14.3 ttmm 46.77 60.84 3.12 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.119 -0.492 . . . . 73.2 110.924 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -52.33 -54.26 33.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.456 . . . . 72.43 110.957 179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -50.46 113.78 0.97 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.151 -0.477 . . . . 64.24 111.019 179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -139.5 126.51 21.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 73.11 111.104 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . 61.37 38.66 16.03 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.22 -0.445 . . . . 63.41 111.161 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 11.2 tp -134.01 126.14 29.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 75.14 110.912 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 84.0 mt-10 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 75.35 110.871 179.892 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.458 -0.075 0 CA-C-O 120.783 0.325 . . . . 73.5 110.826 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 29.9 m120 -110.36 59.48 0.61 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.23 -0.441 . . . . 73.34 110.879 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 71.9 mm-40 -114.75 153.94 29.42 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.245 -0.434 . . . . 75.21 110.892 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -105.1 168.7 8.89 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.182 -0.463 . . . . 70.15 110.863 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 7.7 m-85 -121.96 160.42 47.25 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.676 0.751 . . . . 73.04 110.881 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 -179.77 3.14 Favored 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.705 2.27 . . . . 75.44 112.353 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.28 159.45 17.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.265 -0.425 . . . . 72.2 111.054 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 2.5 mmpt? -111.75 167.96 9.94 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.214 -0.448 . . . . 73.12 110.92 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 17.6 m -65.29 103.6 0.82 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.192 -0.458 . . . . 74.52 110.852 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -115.52 140.2 49.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.069 -0.514 . . . . 73.43 111.121 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -117.33 46.42 1.15 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.793 -0.717 . . . . 62.14 112.529 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 16.2 p90 -157.21 118.01 3.59 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.864 0.364 . . . . 74.21 110.943 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 43.2 t30 -124.05 153.0 42.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.09 -0.505 . . . . 72.33 110.888 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -53.03 119.25 4.46 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 75.43 110.881 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.71 11.57 28.33 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 75.22 112.498 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -82.66 160.51 22.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.766 0.317 . . . . 63.25 110.922 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 12.8 m95 -108.76 159.65 16.6 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.257 -0.429 . . . . 74.41 110.936 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -150.5 119.2 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.426 . . . . 74.12 111.139 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -85.0 107.52 17.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.096 -0.502 . . . . 74.14 111.078 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -105.45 112.76 25.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 63.11 110.902 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -111.73 125.79 54.36 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.159 -0.473 . . . . 75.3 110.879 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 4.0 p30 -155.78 172.66 17.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 75.45 110.907 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.8 p90 -100.96 132.21 46.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 71.24 110.867 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -100.68 120.04 39.48 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.151 -0.477 . . . . 70.34 110.88 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 39.1 tttm -93.56 106.82 18.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 72.42 110.849 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.3 p -84.12 135.8 24.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 72.4 111.106 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -125.84 99.42 5.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.154 -0.475 . . . . 74.34 110.855 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.7 p -147.33 142.26 19.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.155 -0.475 . . . . 75.22 111.152 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 142.08 64.57 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.706 -0.759 . . . . 65.41 112.528 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -89.86 -66.16 0.95 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.766 0.317 . . . . 75.14 110.911 -179.863 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -171.41 134.87 0.9 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.122 -0.49 . . . . 75.42 110.873 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 5.1 tt -104.94 152.69 22.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.186 -0.461 . . . . 71.35 110.992 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.24 -45.27 2.81 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.666 -0.778 . . . . 72.52 112.502 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -52.01 140.08 21.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.861 0.362 . . . . 70.35 110.827 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER 63.13 53.45 2.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.145 -0.48 . . . . 75.1 110.948 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 16.0 t30 -90.6 -43.28 10.28 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.144 -0.48 . . . . 75.24 110.901 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 13.2 p 39.44 38.69 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.132 -0.485 . . . . 71.31 111.095 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -175.55 112.85 0.42 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.778 -0.725 . . . . 73.24 112.5 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.3 -152.32 43.19 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.756 -0.735 . . . . 74.3 112.481 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -52.42 143.14 22.9 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.767 -0.73 . . . . 71.43 112.497 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -115.14 101.32 8.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.772 0.32 . . . . 62.42 111.141 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -119.51 67.5 10.15 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.613 0.72 . . . . 74.42 110.901 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.78 -23.37 30.8 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.694 2.262 . . . . 74.35 112.352 179.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -85.97 50.61 2.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.224 -0.444 . . . . 74.33 110.874 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -104.15 -170.12 1.73 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 74.21 111.062 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 21.8 m-20 -160.48 125.37 3.79 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 65.44 110.922 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 18.5 t -104.4 135.51 41.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.187 -0.46 . . . . 71.51 111.159 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -132.63 137.59 47.06 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 73.13 110.816 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 3.8 tt -101.3 145.03 12.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.094 -0.503 . . . . 74.24 111.094 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -60.24 -168.58 0.38 Allowed Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.746 -0.74 . . . . 75.41 112.462 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -119.05 -37.34 3.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.781 0.324 . . . . 75.34 110.937 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -51.96 150.51 4.21 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.147 -0.479 . . . . 75.15 110.881 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 3.7 p -146.13 178.21 8.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 62.13 111.138 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.6 t -160.14 169.47 23.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.268 -0.424 . . . . 75.14 111.183 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 5.0 mp -91.13 168.38 11.67 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 74.15 110.921 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 12.1 t -135.94 149.51 48.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.186 -0.461 . . . . 74.24 111.133 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -102.75 133.05 48.43 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.292 -0.413 . . . . 73.35 110.846 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -125.91 138.62 53.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 53.45 110.84 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.53 114.15 45.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 73.45 111.164 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -105.87 121.64 44.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 73.4 111.057 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 7.4 t80 -106.08 117.38 33.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 73.55 110.931 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -92.43 101.83 14.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.124 -0.489 . . . . 74.0 110.892 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 32.5 m -98.39 -31.72 3.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.46 . . . . 70.22 111.156 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.1 m -125.92 -169.51 2.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.192 -0.458 . . . . 71.0 110.895 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.5 m -84.18 -38.92 20.02 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 74.14 110.893 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -126.09 25.99 6.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.067 -0.515 . . . . 74.4 110.865 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 3.4 mt -145.16 126.94 8.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.22 -0.446 . . . . 70.04 111.136 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -155.05 168.61 26.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.138 -0.483 . . . . 75.12 111.119 179.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.494 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 2.5 m -111.76 152.47 13.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 65.24 111.14 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -131.66 129.41 40.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 63.23 110.821 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -114.38 110.15 19.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 74.3 110.87 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -81.82 113.08 19.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 73.14 110.955 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.8 t -124.04 116.46 47.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.167 -0.47 . . . . 74.43 111.03 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -131.87 152.14 20.03 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.71 -0.757 . . . . 74.23 112.48 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 39.4 t -143.38 69.81 17.69 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.575 0.702 . . . . 71.2 111.144 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.79 140.61 42.98 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.666 2.244 . . . . 74.21 112.373 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.87 -173.66 0.26 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.188 -0.46 . . . . 72.33 111.075 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 8.9 ttm180 -76.43 129.61 36.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 75.13 110.856 -179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -131.03 151.71 51.12 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.227 -0.442 . . . . 70.21 111.085 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.8 tttp -97.59 123.9 41.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.134 -0.485 . . . . 72.02 110.847 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -111.43 151.68 28.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 75.04 110.907 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 18.1 mt-30 -111.71 148.47 33.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 75.31 110.899 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -178.71 81.41 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.789 -0.719 . . . . 74.51 112.479 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -176.52 -175.59 0.67 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.95 0.405 . . . . 73.33 110.868 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.17 -69.72 0.65 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.127 -0.488 . . . . 74.12 110.949 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 16.9 p -85.16 -32.05 22.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.237 -0.438 . . . . 73.52 110.853 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 4.6 mm -67.34 -35.13 72.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.094 -0.503 . . . . 74.35 111.111 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.8 t -62.38 -44.85 95.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.219 -0.446 . . . . 74.14 110.79 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 39.1 t -57.43 -37.31 72.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 72.05 110.904 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 98.5 mt -63.56 -50.3 70.02 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.107 -0.497 . . . . 74.32 110.902 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 114.14 -13.22 21.69 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.721 -0.752 . . . . 75.42 112.475 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.61 96.19 5.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.839 0.352 . . . . 74.14 110.821 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 64.5 t -113.74 -50.84 5.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.253 -0.431 . . . . 72.41 111.108 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 60.5 p -140.11 148.69 42.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 74.25 110.91 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -140.68 118.52 11.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 71.42 110.79 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 1.6 p -179.24 170.31 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.171 -0.468 . . . . 74.53 111.089 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -109.43 160.29 16.32 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.198 -0.455 . . . . 74.21 110.869 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 17.7 m-85 -120.35 145.23 47.35 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.226 -0.443 . . . . 75.11 110.948 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -108.67 87.3 0.48 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.775 -0.726 . . . . 72.12 112.412 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.76 110.43 2.55 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.668 2.245 . . . . 74.41 112.406 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -128.88 95.57 4.12 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.241 -0.436 . . . . 60.52 111.12 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 5.8 mm -116.64 142.22 31.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.229 -0.441 . . . . 74.21 111.138 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -140.13 109.66 6.27 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.188 -0.46 . . . . 75.52 110.934 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.8 p -138.19 -177.6 4.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 73.13 110.854 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.494 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.7 OUTLIER -128.87 141.89 51.14 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 71.23 110.863 -179.946 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 -101.55 132.72 47.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 71.24 110.992 179.853 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 27.5 t80 -137.1 145.61 44.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.237 -0.438 . . . . 75.11 110.937 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 59.0 t-80 -71.43 153.64 42.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.152 -0.476 . . . . 64.44 110.917 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 5.2 t80 -149.98 139.74 21.77 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.201 -0.454 . . . . 75.01 110.928 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -57.74 130.03 44.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.056 -0.52 . . . . 75.11 110.87 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.6 t -138.32 161.17 37.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.457 . . . . 65.4 110.834 -179.768 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 28.2 p90 -129.82 39.76 3.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.115 -0.493 . . . . 71.01 110.878 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -117.08 177.67 4.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.209 -0.45 . . . . 74.23 110.851 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 7.8 tpm_? -56.54 -37.79 71.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 74.1 110.855 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 8.1 tp -114.78 153.01 31.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 75.33 110.868 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -120.87 69.61 17.64 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.655 0.74 . . . . 72.44 110.985 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 176.95 6.13 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.6 2.2 . . . . 71.54 112.31 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 26.5 m-85 -111.53 144.24 41.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 72.14 110.924 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 13.2 p -100.7 133.26 44.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.237 -0.438 . . . . 73.24 111.102 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.401 ' HA2' ' O ' ' A' ' 105' ' ' LEU . . . -125.92 159.01 20.32 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.738 -0.744 . . . . 74.13 112.489 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.1 p -161.6 149.47 4.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.81 0.338 . . . . 75.14 111.15 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -177.5 -151.3 9.07 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.744 -0.741 . . . . 65.41 112.5 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . 0.497 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.3 p -110.39 126.31 67.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.877 0.37 . . . . 74.4 111.114 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -116.06 119.94 4.72 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.769 -0.729 . . . . 60.05 112.503 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 13.5 ptm180 -120.44 122.88 41.67 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.921 0.391 . . . . 75.11 110.854 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . 0.407 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 3.7 m -118.34 118.6 58.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.202 -0.454 . . . . 73.31 111.117 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -160.02 165.23 32.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.231 -0.441 . . . . 74.14 110.985 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -165.93 -171.12 1.93 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.236 -0.438 . . . . 74.33 110.897 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -94.13 135.12 35.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.174 -0.466 . . . . 75.42 110.926 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -69.63 148.01 49.9 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.138 -0.483 . . . . 72.43 110.843 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -129.55 -69.29 0.69 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 73.05 110.933 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 33.8 m -159.93 75.12 0.6 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.185 -0.461 . . . . 74.15 111.189 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -97.85 175.5 6.13 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.224 -0.444 . . . . 73.21 110.81 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 62.99 149.55 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.735 -0.745 . . . . 71.03 112.479 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -76.51 -1.7 28.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.892 0.377 . . . . 73.21 111.187 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -86.5 -177.09 6.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.135 -0.484 . . . . 74.14 110.906 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -64.06 93.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.198 -0.455 . . . . 62.44 110.847 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 89.0 p 46.06 76.26 0.1 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 71.24 110.88 -179.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -82.96 151.16 26.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 71.42 110.794 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -101.74 165.63 11.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.093 -0.503 . . . . 72.51 110.776 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -127.08 163.0 30.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 73.34 111.168 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -119.21 108.14 14.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 74.45 110.898 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.407 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 1.0 OUTLIER -58.84 -172.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.243 -0.435 . . . . 72.43 110.819 179.967 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 15.9 mmtt -149.47 155.28 40.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.45 . . . . 74.04 110.886 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 45.3 p90 -151.67 136.23 16.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.227 -0.442 . . . . 73.21 110.926 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.545 ' CB ' ' HD2' ' A' ' 147' ' ' PRO . . . -179.28 172.14 0.61 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.583 0.706 . . . . 51.15 111.051 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . 0.545 ' HD2' ' CB ' ' A' ' 146' ' ' ALA . 54.3 Cg_endo -69.69 134.09 27.29 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.631 2.221 . . . . 73.43 112.421 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -130.1 166.47 20.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.262 -0.426 . . . . 65.52 111.126 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -121.55 167.39 12.92 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 71.21 110.951 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -165.85 162.3 18.29 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 74.02 110.923 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 10.7 p -153.51 141.32 13.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 73.0 111.147 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -169.4 -171.79 35.41 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.772 -0.728 . . . . 64.24 112.451 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 8.5 tt -149.2 157.08 43.07 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.738 0.304 . . . . 75.11 110.934 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 7.1 tpp85 -108.08 117.43 34.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.224 -0.444 . . . . 74.43 110.836 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 4.5 t80 -105.17 145.38 30.66 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.184 -0.462 . . . . 74.24 110.876 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -115.38 105.77 13.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.091 -0.504 . . . . 55.45 110.897 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 11.9 tp -93.93 164.34 13.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.184 -0.462 . . . . 75.12 110.925 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -76.08 68.38 2.31 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.75 -0.738 . . . . 70.34 112.468 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 64.7 m-80 -151.41 175.25 12.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.804 0.335 . . . . 74.3 110.876 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 6.2 m -56.32 -38.55 71.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.209 -0.45 . . . . 73.42 110.85 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 4.6 p90 -111.8 178.26 4.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.167 -0.47 . . . . 73.22 110.905 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -117.08 170.81 8.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 75.13 110.92 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 5.8 tp -104.09 151.35 23.38 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.246 -0.433 . . . . 71.53 110.886 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 4.0 t-20 -145.07 137.84 26.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.17 -0.468 . . . . 74.35 110.919 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 26.8 p -136.22 122.5 20.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 74.24 110.906 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -140.5 164.62 29.67 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.136 -0.484 . . . . 73.24 110.878 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 94.7 t -150.51 116.61 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.248 -0.433 . . . . 73.4 111.115 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -97.66 146.49 25.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 74.24 110.879 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 62.2 t80 -146.81 143.3 28.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 71.14 110.86 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' ILE . . . . . 0.409 ' O ' HG21 ' A' ' 170' ' ' ILE . 0.0 OUTLIER -179.0 103.14 0.2 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.66 0.743 . . . . 73.32 111.154 179.918 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 127.32 14.48 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.661 2.241 . . . . 72.24 112.439 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -148.64 178.42 8.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.254 -0.43 . . . . 74.01 110.952 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.82 127.74 37.26 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.187 -0.461 . . . . 74.04 110.892 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.8 t -91.88 165.96 12.97 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.291 -0.413 . . . . 70.53 111.123 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -124.58 167.06 15.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 72.23 110.86 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 45.7 t -152.16 139.78 13.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.13 -0.487 . . . . 72.22 111.163 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 14.5 t -167.27 179.35 5.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 72.54 111.149 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 131.63 143.49 5.21 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.747 -0.739 . . . . 63.34 112.45 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 7.1 t -173.07 179.09 2.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.86 0.362 . . . . 71.45 111.111 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 9.6 tp -139.29 89.14 2.32 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.184 -0.462 . . . . 74.53 111.015 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 118.03 -82.33 0.33 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.784 -0.722 . . . . 62.14 112.47 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -168.87 0.29 Allowed 'Trans proline' 0 C--N 1.343 0.243 0 C-N-CA 122.644 2.23 . . . . 71.5 112.363 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 7.5 p -82.21 125.63 76.43 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.65 0.738 . . . . 73.2 111.117 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 159.43 53.43 Favored 'Trans proline' 0 C--O 1.231 0.157 0 C-N-CA 122.704 2.269 . . . . 73.12 112.368 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 44.6 t -96.8 107.5 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.227 -0.442 . . . . 71.03 111.092 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 13.3 p -89.36 104.98 17.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 65.43 110.861 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 10.8 p -110.22 166.53 10.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.083 -0.508 . . . . 74.13 111.151 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -152.23 146.6 25.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 74.41 110.922 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 18.2 pt -142.51 130.39 20.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 74.21 111.14 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -99.29 118.23 35.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 74.01 110.837 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 8.5 p -137.79 159.99 33.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 72.11 111.143 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -107.22 90.26 5.46 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.567 0.699 . . . . 74.13 110.927 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 116.31 4.5 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.683 2.255 . . . . 75.44 112.342 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -100.28 119.65 38.72 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.176 -0.466 . . . . 70.2 110.918 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 40.5 mm -108.79 119.48 58.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.123 -0.49 . . . . 64.24 111.094 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 7.3 mp -113.03 107.25 15.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.156 -0.475 . . . . 74.13 110.949 179.863 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -95.31 124.47 39.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.225 -0.443 . . . . 73.3 110.826 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 5.0 mp -146.39 127.92 15.07 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.101 -0.5 . . . . 74.13 110.987 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 177.27 -136.25 3.05 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.655 -0.783 . . . . 64.42 112.442 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -134.06 173.15 11.89 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.85 0.357 . . . . 64.32 111.114 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 2.3 p -144.92 174.83 10.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.434 . . . . 71.53 110.92 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 12.6 t80 -148.63 138.77 22.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.101 -0.499 . . . . 74.23 110.854 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 11.5 p -77.2 151.23 5.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.077 -0.51 . . . . 73.14 111.117 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 -153.13 114.15 4.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.133 -0.485 . . . . 71.14 110.896 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 5.7 ptpt -108.02 -36.54 6.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 75.41 110.879 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 17.1 mt -100.77 151.64 21.44 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.24 -0.436 . . . . 74.52 110.914 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -95.09 117.47 30.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 65.03 111.065 179.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -94.03 -50.44 5.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 75.32 111.154 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -95.43 108.68 20.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 62.51 111.165 179.853 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 23.3 tp -123.29 123.37 40.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 74.21 110.834 -179.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 . . . . . 0 C--N 1.33 -0.239 0 CA-C-N 116.157 -0.474 . . . . 73.35 110.91 179.93 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 81.1 mmm . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.791 0.329 . . . . 74.13 110.916 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -136.29 136.69 39.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.264 -0.426 . . . . 62.51 110.922 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.7 mp0 -141.69 172.61 12.45 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 72.23 110.848 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -108.65 174.26 5.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.12 -0.491 . . . . 71.22 110.864 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -149.63 143.96 17.32 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.714 0.768 . . . . 74.02 110.885 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 -170.67 0.41 Allowed 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.744 2.296 . . . . 74.21 112.342 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -126.21 163.65 22.71 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.258 -0.428 . . . . 60.02 111.084 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 19.9 mmmt -120.32 171.42 8.52 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.205 -0.452 . . . . 75.41 110.962 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 94.9 p -121.49 173.57 7.31 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.262 -0.426 . . . . 75.45 110.828 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -151.78 171.26 17.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 74.45 111.074 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -100.5 33.61 6.22 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.739 -0.743 . . . . 72.11 112.446 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 13.8 p90 -160.33 117.43 2.47 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.906 0.384 . . . . 74.43 110.935 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -162.34 148.96 13.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.476 . . . . 74.4 110.927 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -52.03 127.83 22.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.161 -0.472 . . . . 75.13 110.919 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.94 6.9 68.96 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.72 -0.753 . . . . 60.24 112.421 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -75.54 145.24 41.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.752 0.31 . . . . 74.13 110.884 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -127.22 121.56 31.58 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.234 -0.439 . . . . 74.21 110.958 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.9 p -131.28 123.55 53.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.252 -0.431 . . . . 74.21 111.115 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -84.41 115.18 22.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.117 -0.492 . . . . 73.34 111.097 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -104.62 108.8 20.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 64.3 110.9 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -111.97 125.3 53.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 64.3 110.942 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 5.4 p30 -153.53 174.05 14.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 61.55 110.829 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -98.0 129.45 44.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.113 -0.494 . . . . 74.5 110.814 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -97.22 122.47 40.27 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.148 -0.478 . . . . 72.44 110.836 -179.847 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -102.4 105.76 16.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.089 -0.505 . . . . 73.43 110.902 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.5 m -82.71 131.04 34.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.272 -0.422 . . . . 71.04 111.164 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 10.2 m-85 -123.98 99.35 6.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.177 -0.465 . . . . 73.42 110.901 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 p -158.46 151.26 7.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.216 -0.447 . . . . 75.52 111.164 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.99 72.32 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.707 -0.759 . . . . 74.52 112.419 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.5 tp10 -89.07 -66.47 0.92 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.853 0.358 . . . . 75.12 110.83 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -176.23 172.5 2.31 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 71.21 110.88 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 24.4 tp -104.22 150.77 24.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 74.24 110.884 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.16 105.34 0.19 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.718 -0.753 . . . . 73.13 112.495 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -50.73 -32.77 20.56 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.858 0.361 . . . . 65.11 110.901 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 23.8 tp -50.2 -34.75 23.77 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.114 -0.494 . . . . 71.12 110.9 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 5.5 t30 -51.62 103.78 0.07 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 74.15 110.908 179.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.7 p -58.8 152.23 4.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.441 . . . . 74.42 111.121 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -135.76 -67.39 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.735 -0.745 . . . . 54.34 112.517 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 176.95 120.94 0.65 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.756 -0.735 . . . . 52.34 112.494 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.98 -117.53 8.09 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.74 -0.743 . . . . 61.24 112.47 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -54.62 174.85 0.06 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.803 0.335 . . . . 75.22 111.122 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.6 mt -120.18 67.84 12.9 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.539 0.685 . . . . 75.45 110.89 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.75 -170.66 0.41 Allowed 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.668 2.245 . . . . 74.24 112.337 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -122.79 134.32 54.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 75.12 110.912 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.78 166.32 14.11 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 65.42 111.094 179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -137.49 133.96 35.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 71.15 110.833 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.8 m -106.73 151.17 8.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 75.2 111.105 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 14.7 t -156.8 151.28 25.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 75.35 110.818 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 38.4 mm -120.93 116.49 50.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.088 -0.506 . . . . 74.23 111.09 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -51.56 157.9 2.84 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.693 -0.765 . . . . 51.12 112.425 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -51.75 103.28 0.06 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.817 0.341 . . . . 72.33 110.954 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.409 ' O ' ' C ' ' A' ' 53' ' ' THR . 1.1 p-10 -58.48 -56.9 16.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 71.14 110.931 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' THR . . . . . 0.409 ' C ' ' O ' ' A' ' 52' ' ' ASP . 10.2 t 36.73 44.08 0.32 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.115 -0.493 . . . . 74.13 111.186 -179.86 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.6 169.17 8.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.198 -0.455 . . . . 64.32 111.096 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -109.49 150.23 28.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 73.14 110.907 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.5 t -134.47 144.65 48.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.284 -0.416 . . . . 74.55 111.161 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 42.2 m-85 -102.9 132.57 49.02 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.252 -0.431 . . . . 75.45 110.826 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -127.31 146.63 50.38 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.148 -0.478 . . . . 74.21 110.91 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.5 mp -119.28 113.61 41.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.224 -0.444 . . . . 74.5 111.131 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -102.66 117.0 33.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.467 . . . . 75.53 111.09 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 34.7 t80 -108.73 115.76 30.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.156 -0.475 . . . . 74.21 110.96 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -87.23 96.97 10.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.129 -0.487 . . . . 73.55 110.889 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.7 p -86.72 -33.15 6.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.146 -0.479 . . . . 72.42 111.12 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -130.67 164.91 23.98 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.184 -0.462 . . . . 75.15 110.892 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.9 t -87.21 3.24 47.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 74.52 110.92 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 61.6 t30 -110.72 -33.45 6.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.109 -0.496 . . . . 54.43 110.865 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 44.4 pt -150.54 172.02 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 72.35 111.12 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -157.16 172.85 17.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.14 -0.482 . . . . 72.14 111.058 179.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.41 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 10.2 m -112.1 150.97 14.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.223 -0.444 . . . . 74.23 111.129 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -138.11 127.48 24.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 64.24 110.857 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -102.4 147.2 27.01 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.471 . . . . 74.32 110.888 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 30.4 t80 -121.25 112.95 19.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.149 -0.478 . . . . 72.23 110.9 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.5 m -129.47 147.0 33.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 75.24 111.102 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -164.26 128.78 1.87 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.741 -0.742 . . . . 72.14 112.475 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 23.4 t -117.21 68.18 4.89 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.674 0.75 . . . . 75.54 111.155 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 162.67 41.21 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.679 2.253 . . . . 62.35 112.344 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -79.48 -165.67 0.83 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.265 -0.425 . . . . 75.34 111.059 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 55.1 ttp85 -76.88 139.28 40.2 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.148 -0.478 . . . . 75.52 110.916 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -133.83 151.88 51.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 65.42 111.088 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.0 ttpt -104.48 130.7 52.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.16 -0.473 . . . . 73.45 110.863 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -119.26 157.42 28.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 74.43 110.879 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.416 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -110.84 149.53 30.45 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 73.42 110.926 -179.921 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -177.14 75.64 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.783 -0.722 . . . . 73.23 112.493 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.8 tp10 -178.26 -176.37 0.52 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.999 0.428 . . . . 73.15 110.866 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.31 -69.15 0.69 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.174 -0.466 . . . . 74.41 110.92 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.4 t -84.63 -32.88 23.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.254 -0.43 . . . . 75.35 110.855 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.8 mm -65.57 -34.31 69.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 74.54 111.129 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 74.2 p -62.57 -53.81 49.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.475 . . . . 72.21 110.852 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.7 t -51.13 -35.86 37.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.134 -0.485 . . . . 62.21 110.867 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -63.5 -38.26 90.47 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.139 -0.482 . . . . 75.01 110.96 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 100.56 -14.37 59.25 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.776 -0.726 . . . . 61.12 112.505 179.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 19.2 ttt-85 -118.63 95.38 4.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.797 0.332 . . . . 74.33 110.941 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.416 ' HB ' ' HA ' ' A' ' 82' ' ' GLN . 94.0 t -111.66 -53.81 5.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 63.21 111.184 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 11.5 t -140.26 143.05 35.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 65.12 110.821 -179.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -132.27 115.37 15.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 63.42 110.931 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.569 ' HA ' ' HB2' ' A' ' 131' ' ' LYS . 1.4 m -154.47 171.49 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.107 -0.497 . . . . 75.12 111.146 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -86.34 172.1 10.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.202 -0.454 . . . . 64.4 110.895 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -123.25 130.52 52.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.266 -0.424 . . . . 65.41 110.919 -179.856 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -129.12 65.63 0.58 Allowed Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.733 -0.746 . . . . 73.42 112.431 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 112.76 3.16 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.704 2.269 . . . . 70.42 112.381 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -127.43 105.06 8.25 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.167 -0.469 . . . . 73.43 111.054 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.465 ' HA ' ' HA2' ' A' ' 124' ' ' GLY . 4.8 mp -128.23 151.13 34.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 74.45 111.133 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -145.99 115.7 7.26 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 72.11 110.924 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.8 p -139.62 -175.82 4.34 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.216 -0.447 . . . . 72.02 110.832 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.41 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 1.5 pp -134.54 147.86 50.38 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.139 -0.482 . . . . 75.43 110.908 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 1.8 pp0? -104.65 139.0 40.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 73.33 110.915 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 14.2 p90 -143.18 142.74 31.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 74.15 110.956 -179.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 17.5 t-160 -94.49 138.88 31.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.143 -0.481 . . . . 71.44 110.876 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 4.4 t80 -131.12 107.89 9.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.224 -0.444 . . . . 74.01 110.915 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -173.28 178.07 2.51 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.108 -0.496 . . . . 61.34 110.956 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 57.9 m -110.95 36.22 3.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.274 -0.421 . . . . 73.13 110.819 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 53.57 36.53 23.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.182 -0.463 . . . . 73.54 110.912 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 75.5 mm-40 -84.11 -72.81 0.45 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.151 -0.477 . . . . 74.13 110.877 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 10.9 mmt85 -131.6 171.43 13.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 75.12 110.851 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 10.6 tp -66.61 136.99 56.41 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.193 -0.458 . . . . 75.32 110.934 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 6.3 m-85 -157.32 160.43 30.43 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.714 0.769 . . . . 63.52 110.88 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 177.93 5.09 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.67 2.247 . . . . 74.34 112.333 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 11.2 m-85 -115.98 143.99 44.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.242 -0.436 . . . . 75.11 110.876 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 75.7 t -99.35 132.89 43.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.085 -0.507 . . . . 72.33 111.116 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -125.51 169.43 17.46 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.712 -0.756 . . . . 55.24 112.512 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 7.7 p -175.59 152.53 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.915 0.388 . . . . 71.41 111.125 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -179.78 -151.7 10.13 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.834 -0.698 . . . . 71.35 112.555 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . 0.412 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.7 p -111.37 127.25 68.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.827 0.346 . . . . 74.32 111.103 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . 0.465 ' HA2' ' HA ' ' A' ' 102' ' ' ILE . . . -119.77 108.85 1.54 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.79 -0.719 . . . . 71.34 112.513 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 35.7 ptt180 -100.73 123.23 44.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.909 0.385 . . . . 75.43 110.891 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 34.6 t -103.12 110.27 29.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.174 -0.467 . . . . 74.2 111.136 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 2.8 pp -120.3 156.7 30.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.474 . . . . 74.44 110.903 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 9.4 p90 -160.43 166.04 29.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 74.3 110.855 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -102.24 118.03 36.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 74.3 110.899 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -66.11 93.48 0.21 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.129 -0.487 . . . . 60.32 110.89 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.569 ' HB2' ' HA ' ' A' ' 96' ' ' VAL . 0.0 OUTLIER -74.18 -76.39 0.13 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.243 -0.435 . . . . 72.11 110.934 179.984 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 20.2 m -161.97 121.92 2.5 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.214 -0.448 . . . . 74.24 111.055 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . 0.576 ' HB3' ' HB3' ' A' ' 139' ' ' PHE . 27.0 t0 -108.08 114.56 28.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 73.23 110.789 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -75.78 -12.42 83.88 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.691 -0.766 . . . . 73.32 112.469 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -44.37 -29.36 0.67 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.902 0.382 . . . . 64.41 111.083 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -160.29 163.96 32.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.236 -0.438 . . . . 74.14 110.867 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.8 m -42.17 97.86 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.136 -0.484 . . . . 73.1 110.922 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 70.7 m 49.81 65.16 1.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 70.0 110.908 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.576 ' HB3' ' HB3' ' A' ' 133' ' ' ASP . 1.2 t80 -94.5 160.85 14.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 73.42 110.868 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -139.96 167.19 22.69 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.124 -0.489 . . . . 53.34 110.848 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 15.4 mt -117.36 151.79 19.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.471 . . . . 75.41 111.151 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 12.3 tppt? -113.18 122.62 48.05 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 75.45 110.913 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -76.81 -173.74 2.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.129 -0.487 . . . . 73.45 110.853 179.85 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -171.75 179.09 2.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 75.21 110.931 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 52.1 p-90 -140.06 161.37 37.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.216 -0.447 . . . . 74.3 110.881 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -179.8 165.29 0.87 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.59 0.71 . . . . 65.15 111.135 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 54.5 Cg_endo -69.74 161.92 44.08 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.673 2.248 . . . . 74.42 112.402 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -151.3 146.01 25.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 73.51 111.142 179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -103.07 120.24 40.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 52.12 110.896 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 16.7 tt0 -102.94 156.87 17.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 75.03 110.899 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.3 p -164.85 123.67 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.264 -0.426 . . . . 72.05 111.146 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -174.73 -159.54 21.19 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.717 -0.754 . . . . 51.23 112.47 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 19.5 tp -151.8 164.78 36.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.784 0.325 . . . . 75.14 110.876 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.4 tpp85 -115.78 120.43 39.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 75.44 110.931 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -104.68 154.79 19.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 74.43 110.933 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -120.24 104.18 9.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.116 -0.493 . . . . 75.52 110.824 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 23.6 mt -72.57 153.1 41.45 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 75.24 110.905 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -53.0 -33.44 44.24 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.759 -0.734 . . . . 71.12 112.523 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -71.32 176.18 4.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.819 0.342 . . . . 73.41 110.847 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 73.0 m -60.86 -36.53 79.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.127 -0.488 . . . . 73.24 110.884 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 26.6 m0 -80.92 144.17 32.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 74.01 110.945 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 2.4 mpt? -106.77 169.56 8.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 74.52 110.876 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -107.24 148.78 28.5 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 74.41 110.916 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -143.85 133.28 23.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 75.21 110.857 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 42.1 t -135.41 122.53 21.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 70.22 110.858 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -131.47 153.71 49.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.107 -0.497 . . . . 74.34 110.945 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 78.4 t -133.45 121.49 41.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.27 -0.423 . . . . 74.01 111.089 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 3.9 ttm-85 -103.46 132.41 49.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 70.33 110.876 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -143.01 128.18 18.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 75.4 110.942 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' ILE . . . . . 0.43 HG13 ' HD2' ' A' ' 171' ' ' PRO . 3.6 tp 177.91 133.78 0.22 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.576 0.703 . . . . 75.33 111.118 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . 0.43 ' HD2' HG13 ' A' ' 170' ' ' ILE . 53.5 Cg_endo -69.74 111.6 2.85 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.676 2.251 . . . . 51.12 112.366 179.856 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -122.5 153.16 39.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 73.35 110.909 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 14.5 pttm -130.57 153.58 48.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 74.14 110.854 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -123.28 170.74 9.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.126 -0.488 . . . . 73.52 111.094 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -125.03 164.88 19.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 73.04 110.87 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 5.6 p -156.46 142.63 10.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 73.31 111.117 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 10.0 t -166.62 -179.25 4.76 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.215 -0.448 . . . . 62.34 111.12 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -120.49 -161.1 11.36 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.734 -0.746 . . . . 75.31 112.475 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -124.59 -172.09 2.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.786 0.327 . . . . 74.24 111.178 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 7.8 tp -61.86 146.18 50.5 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.218 -0.447 . . . . 75.44 110.912 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 116.52 -86.78 0.42 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.76 -0.733 . . . . 72.52 112.445 179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.83 -160.83 0.07 OUTLIER 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.648 2.232 . . . . 74.53 112.32 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 19.9 t -106.28 87.66 2.73 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.646 0.736 . . . . 74.44 111.118 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 141.54 45.51 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.674 2.249 . . . . 74.24 112.359 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 21.6 t -127.17 107.2 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.222 -0.445 . . . . 75.32 111.179 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 1.2 p -74.93 104.43 5.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.199 -0.455 . . . . 74.4 110.865 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 12.1 p -131.6 172.06 12.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.105 -0.498 . . . . 73.02 111.155 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.84 162.62 39.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.265 -0.425 . . . . 75.4 110.914 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 56.7 mt -137.85 128.33 37.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 74.21 111.153 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -106.57 113.3 26.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.133 -0.485 . . . . 74.01 110.871 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 1.3 t -136.96 169.59 19.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.087 -0.506 . . . . 74.11 111.088 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -107.27 87.14 2.98 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.61 0.719 . . . . 51.43 110.896 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 121.51 8.19 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.631 2.22 . . . . 72.43 112.395 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -103.12 115.89 31.46 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 73.12 110.881 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 9.7 mt -102.9 124.68 57.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 74.32 111.118 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 1.2 tt -112.71 108.54 17.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 74.31 110.897 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.25 115.68 28.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.257 -0.429 . . . . 71.34 110.818 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 5.7 tt -138.21 121.06 16.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.122 -0.49 . . . . 74.13 110.938 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -175.36 -141.44 3.73 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.825 -0.702 . . . . 64.5 112.538 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -128.51 173.82 9.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.781 0.324 . . . . 74.45 111.104 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 26.2 t -146.55 163.51 35.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.458 . . . . 74.22 110.832 -179.749 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -133.9 114.4 13.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.149 -0.478 . . . . 75.31 110.883 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 57.8 t -76.88 145.11 10.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.091 -0.504 . . . . 72.15 111.108 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 -148.08 137.01 21.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.107 -0.497 . . . . 74.35 110.888 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.43 174.74 10.2 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.081 -0.508 . . . . 75.2 110.898 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 10.3 mp -75.88 -62.02 1.73 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.222 -0.444 . . . . 74.41 110.954 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -55.76 134.22 51.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 60.2 111.145 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -75.37 -60.42 2.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.449 . . . . 52.42 111.088 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . 62.67 40.34 10.33 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.199 -0.455 . . . . 71.41 111.103 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 6.4 mp -97.84 -45.55 6.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 72.22 110.893 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.205 -0.452 . . . . 62.42 110.908 179.865 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 20.5 mtm . . . . . 0 C--O 1.23 0.053 0 CA-C-O 120.774 0.321 . . . . 74.32 110.895 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 12.1 m-80 54.57 39.29 31.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 70.52 110.921 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 64.9 tt0 -77.53 111.93 13.78 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.18 -0.464 . . . . 65.21 110.804 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -101.17 151.54 21.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.163 -0.471 . . . . 73.04 110.866 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 10.0 p90 -51.8 156.98 2.15 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.738 0.78 . . . . 72.34 110.907 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 178.29 4.71 Favored 'Trans proline' 0 N--CA 1.465 -0.2 0 C-N-CA 122.746 2.297 . . . . 70.31 112.351 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -79.22 131.8 36.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.23 -0.441 . . . . 72.42 111.065 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 12.8 ptmm? -97.23 -36.03 10.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 75.05 110.868 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 2.5 t -52.14 -37.62 55.0 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.234 -0.439 . . . . 74.31 110.851 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.24 156.16 2.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.176 -0.465 . . . . 74.41 111.093 179.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -102.6 38.73 3.06 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.731 -0.747 . . . . 73.52 112.512 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 10.5 p90 -163.77 112.13 1.2 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.909 0.385 . . . . 75.25 110.884 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -168.36 169.64 10.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 73.31 110.905 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.4 mp0 -57.86 119.84 7.41 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.142 -0.481 . . . . 74.05 110.904 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.87 6.45 40.17 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.808 -0.711 . . . . 73.23 112.533 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -67.11 145.45 55.29 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.778 0.323 . . . . 74.13 110.857 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -125.43 121.68 34.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.203 -0.453 . . . . 70.22 110.894 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 13.5 m -130.69 134.91 61.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 65.53 111.145 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -94.24 116.81 29.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 63.33 111.162 179.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 p -105.94 108.21 19.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 65.42 110.796 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -112.11 121.22 44.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.146 -0.479 . . . . 71.25 110.89 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -152.15 172.46 16.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 73.35 110.885 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -95.89 131.97 41.68 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 73.22 110.819 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -101.01 109.92 21.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.111 -0.495 . . . . 64.03 110.882 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 29.4 mmtt -93.9 106.33 18.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.485 . . . . 74.35 110.89 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 21.8 t -79.62 121.08 32.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.259 -0.428 . . . . 74.53 111.128 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 10.5 m-85 -105.64 99.67 9.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 75.22 110.948 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 5.5 p -167.69 141.09 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.123 -0.49 . . . . 74.2 111.16 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.75 72.09 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.753 -0.736 . . . . 54.03 112.44 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 16.6 tt0 -89.93 -66.19 0.95 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.809 0.338 . . . . 75.43 110.85 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 179.4 103.44 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 74.32 110.89 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.422 ' CD2' ' C ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -57.15 167.25 0.91 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.092 -0.504 . . . . 75.03 110.901 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -80.68 114.69 3.88 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.705 -0.759 . . . . 63.03 112.506 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -51.48 140.53 17.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.804 0.335 . . . . 75.54 110.868 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -77.11 -33.28 56.92 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.131 -0.486 . . . . 74.15 110.924 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 32.2 t30 -170.5 156.67 5.57 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.223 -0.444 . . . . 73.31 110.896 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.4 p -98.63 138.86 21.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.223 -0.444 . . . . 73.51 111.202 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -105.67 -98.45 2.55 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.759 -0.734 . . . . 75.13 112.496 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -148.87 144.08 11.73 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.757 -0.735 . . . . 60.52 112.519 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 106.15 146.35 13.8 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.763 -0.732 . . . . 62.32 112.568 -179.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -72.2 99.57 2.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.844 0.354 . . . . 74.44 111.111 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.1 mt -145.24 158.83 50.77 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.534 0.683 . . . . 73.23 110.914 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.84 179.57 3.65 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.663 2.242 . . . . 64.41 112.341 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 -56.88 -68.13 0.25 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 73.13 110.909 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -170.96 -172.59 1.16 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.232 -0.44 . . . . 71.44 111.164 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -150.43 125.25 9.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.276 -0.42 . . . . 72.32 110.873 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 12.5 p -119.13 134.02 64.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.203 -0.453 . . . . 72.41 111.114 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.9 m -153.45 178.51 9.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 65.54 110.849 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 42.6 pt -134.97 145.88 31.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.094 -0.503 . . . . 72.52 111.173 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -62.33 179.13 4.77 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.768 -0.73 . . . . 62.22 112.518 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.7 m-80 -119.96 107.84 13.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.8 0.333 . . . . 71.23 110.896 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -143.92 148.53 35.51 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 71.4 110.898 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.9 p -61.46 134.26 56.69 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.217 -0.447 . . . . 70.44 111.151 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 15.3 t -143.75 169.68 17.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 64.23 111.133 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -155.9 160.44 40.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 71.24 110.931 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 8.8 p -141.12 142.51 34.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.449 . . . . 73.34 111.162 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -102.44 132.2 48.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 73.35 110.899 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.407 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 1.3 m-20 -129.14 149.91 50.75 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.142 -0.481 . . . . 70.33 110.863 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 8.0 mm -122.39 114.36 42.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.443 . . . . 72.03 111.175 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -101.92 130.06 48.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 72.12 111.086 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 14.9 t80 -118.15 118.35 31.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.233 -0.439 . . . . 74.43 110.936 -179.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -90.52 97.01 10.93 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.156 -0.474 . . . . 72.01 110.897 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.0 p -91.16 -34.91 6.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.206 -0.452 . . . . 75.1 111.129 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.2 t -130.02 159.67 35.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 75.25 110.894 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 93.4 p -84.13 2.76 37.96 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 61.33 110.827 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 41.2 m-80 -112.01 -32.5 6.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 73.34 110.876 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 2.3 pp -149.13 164.78 4.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.474 . . . . 74.44 111.142 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -154.68 169.89 22.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 64.42 111.124 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.1 m -110.97 152.93 12.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.445 . . . . 74.14 111.112 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -148.61 124.27 10.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.465 . . . . 54.32 110.875 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 0.407 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 2.4 t80 -102.72 131.06 49.8 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 64.33 110.917 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -111.65 118.64 36.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.108 -0.496 . . . . 72.43 110.829 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.0 p -142.51 151.79 17.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 63.14 111.116 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -160.05 160.7 31.85 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.732 . . . . 74.11 112.491 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 4.0 p -138.29 77.72 35.08 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.691 0.758 . . . . 74.14 111.129 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 152.26 69.32 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.734 2.289 . . . . 73.35 112.346 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -71.17 -168.38 0.29 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 72.01 111.071 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 19.8 ttp-105 -77.58 127.31 32.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 74.43 110.857 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -133.66 140.69 47.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 61.21 111.118 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -89.58 141.73 28.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.443 . . . . 62.41 110.921 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -132.73 147.43 52.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.237 -0.438 . . . . 75.01 110.858 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.417 ' HA ' HG21 ' A' ' 93' ' ' VAL . 0.4 OUTLIER -92.82 155.52 17.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 65.44 110.877 -179.92 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -179.46 72.79 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.759 -0.734 . . . . 61.34 112.517 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -178.9 -174.15 0.34 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.937 0.399 . . . . 72.35 110.846 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 6.0 mtpt -85.82 -70.17 0.61 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.114 -0.494 . . . . 74.52 110.904 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 74.0 m -84.3 -31.1 25.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.259 -0.428 . . . . 72.11 110.899 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 1.2 mt -68.17 -33.73 62.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.122 -0.49 . . . . 74.45 111.119 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.2 t -62.46 -47.26 84.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 74.32 110.842 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 36.9 t -57.69 -35.37 70.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.183 -0.462 . . . . 75.3 110.833 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 4.2 tp -63.64 -48.33 77.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.474 . . . . 74.1 110.988 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 111.37 -13.33 28.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.716 -0.754 . . . . 70.14 112.474 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -117.79 87.47 2.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.906 0.384 . . . . 73.44 110.911 -179.837 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.417 HG21 ' HA ' ' A' ' 82' ' ' GLN . 32.3 t -113.05 -42.05 4.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.195 -0.457 . . . . 75.15 111.14 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 80.4 p -141.0 152.05 44.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.253 -0.43 . . . . 75.31 110.897 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -141.43 116.98 10.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.141 -0.481 . . . . 72.13 110.92 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 2.6 p -178.23 166.42 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 75.13 111.182 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -95.07 156.48 16.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 72.42 110.855 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -93.98 147.63 22.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.165 -0.471 . . . . 74.01 110.99 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -126.39 60.87 0.64 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.773 -0.727 . . . . 70.52 112.501 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 113.86 3.52 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.644 2.229 . . . . 71.14 112.323 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -131.47 108.53 9.65 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.167 -0.469 . . . . 61.21 111.079 179.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 1.2 pp -140.27 153.06 21.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.481 . . . . 73.3 111.085 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -149.62 130.97 14.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.145 -0.48 . . . . 75.13 110.924 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.2 p -151.34 170.45 19.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 74.31 110.87 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -113.46 147.01 38.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 74.34 110.908 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 34.4 mt-30 -101.7 144.78 29.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.181 -0.463 . . . . 73.54 110.98 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 46.7 p90 -153.73 150.4 28.49 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.244 -0.435 . . . . 71.44 110.967 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 2.2 p80 -130.7 160.77 33.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.126 -0.488 . . . . 75.1 110.863 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 10.0 t80 -90.38 107.51 19.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.181 -0.463 . . . . 74.31 110.914 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 20.0 t0 -68.65 108.61 3.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.485 . . . . 74.24 110.84 179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 31.2 p -170.1 149.04 3.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 74.31 110.956 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 66.1 m-85 -62.59 105.5 0.65 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.193 -0.458 . . . . 74.4 110.89 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -167.09 161.65 14.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 75.33 110.845 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 21.6 ttt180 -52.16 164.5 0.29 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 74.0 110.876 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 8.6 tp -64.61 123.93 20.57 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.246 -0.434 . . . . 74.23 110.893 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 8.1 m-85 -137.74 160.64 64.06 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.683 0.754 . . . . 75.43 110.919 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 177.38 5.61 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.685 2.257 . . . . 74.54 112.38 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -115.32 152.4 32.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.191 -0.459 . . . . 74.43 110.864 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 61.6 t -111.0 141.13 27.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.102 -0.499 . . . . 60.44 111.186 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -133.39 175.69 20.04 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.775 -0.726 . . . . 73.44 112.546 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.5 p -168.16 151.97 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.944 0.402 . . . . 74.0 111.058 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -179.54 -149.68 8.57 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.714 -0.755 . . . . 73.12 112.517 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 11.3 p -108.01 146.07 14.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.829 0.347 . . . . 73.52 111.168 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -140.99 121.03 1.82 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.806 -0.712 . . . . 61.41 112.51 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 3.1 ptm180 -117.48 128.7 55.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.893 0.378 . . . . 74.54 110.874 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 97.8 t -105.94 109.44 27.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.091 -0.504 . . . . 63.44 111.161 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 41.7 mt -118.22 171.99 7.74 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.125 -0.489 . . . . 73.44 110.896 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -148.41 176.39 10.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 74.02 110.949 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -104.57 171.71 7.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 75.21 110.812 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 16.8 t0 -109.72 96.58 6.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.122 -0.49 . . . . 75.44 110.847 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 2.0 mmmp? -118.1 -81.44 0.62 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.466 . . . . 73.02 110.892 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 98.5 m -162.64 85.24 0.55 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.202 -0.454 . . . . 71.12 111.15 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -99.15 161.67 13.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.221 -0.445 . . . . 72.42 110.885 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.46 154.08 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.705 -0.759 . . . . 71.23 112.489 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -82.51 3.24 29.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.833 0.349 . . . . 70.2 111.149 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -86.83 -176.14 5.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 71.23 110.937 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 23.1 t -65.0 87.0 0.06 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 75.35 110.849 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 65.5 m 51.93 75.37 0.22 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 75.05 110.878 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -91.03 157.11 17.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.481 . . . . 74.21 110.883 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -138.12 -173.9 3.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.107 -0.497 . . . . 74.02 110.878 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.437 ' HA ' ' HA ' ' A' ' 176' ' ' VAL . 5.1 pt -141.0 156.98 22.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.205 -0.452 . . . . 70.23 111.147 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 1.8 tttt -96.02 116.39 28.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.159 -0.473 . . . . 72.43 110.941 179.805 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -63.33 -173.76 0.07 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.241 -0.436 . . . . 71.21 110.866 179.887 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -157.18 169.72 24.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.242 -0.435 . . . . 73.33 110.955 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 28.0 p-90 -156.69 146.71 21.06 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.341 -0.39 . . . . 75.5 110.893 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . 179.95 165.06 0.84 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.549 0.69 . . . . 73.15 111.097 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.82 140.41 42.4 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.677 2.252 . . . . 70.35 112.314 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -135.98 177.82 7.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 74.2 111.096 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -126.63 166.54 17.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.18 -0.464 . . . . 74.44 110.872 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 11.3 tt0 -145.32 155.29 43.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 74.31 110.912 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.1 p -154.92 126.87 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.226 -0.443 . . . . 61.35 111.15 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -177.79 -158.69 21.27 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.677 -0.773 . . . . 75.32 112.43 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 46.7 tp -145.17 157.39 44.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.844 0.354 . . . . 75.04 110.867 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 6.2 tpp85 -120.97 117.71 27.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 75.32 110.85 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 3.0 t80 -95.91 132.21 41.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 74.52 110.928 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -119.23 113.34 20.71 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.162 -0.472 . . . . 71.11 110.879 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 38.8 mt -88.44 163.02 16.16 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.209 -0.451 . . . . 73.01 110.861 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -99.44 126.91 9.08 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.758 -0.734 . . . . 71.0 112.482 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 65.3 m-20 58.78 37.84 24.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.873 0.368 . . . . 75.21 110.916 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 3.1 m -167.18 178.03 5.86 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.167 -0.47 . . . . 72.42 110.869 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 5.3 m-90 -64.12 162.09 14.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 74.01 110.936 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 21.5 mtm -106.64 170.56 7.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.231 -0.44 . . . . 74.51 110.918 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 1.2 tt -124.08 148.81 46.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.246 -0.434 . . . . 72.33 110.904 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -143.94 131.79 21.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 73.31 110.887 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 60.5 p -146.56 122.23 10.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.446 . . . . 75.15 110.807 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -157.69 161.22 38.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.053 -0.521 . . . . 74.21 110.89 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 10.9 t -118.58 130.52 73.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 74.5 111.128 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.04 122.17 45.93 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.169 -0.468 . . . . 72.43 110.866 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 15.3 t80 -108.29 115.56 30.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.184 -0.462 . . . . 73.44 110.927 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' ILE . . . . . . . . . . . . . 9.6 tt -134.45 79.35 54.59 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.558 0.694 . . . . 74.11 111.092 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 125.06 11.72 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.587 2.192 . . . . 75.53 112.364 179.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 11.8 p90 -162.14 177.58 9.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 74.32 110.891 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 10.1 pttp -122.83 137.69 54.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.126 -0.488 . . . . 71.35 110.844 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.49 156.1 18.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 73.11 111.146 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -111.81 161.24 16.55 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.259 -0.428 . . . . 71.52 110.915 179.851 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . 0.437 ' HA ' ' HA ' ' A' ' 141' ' ' ILE . 4.7 t -138.31 133.01 42.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.229 -0.441 . . . . 75.51 111.17 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.7 t -166.36 160.48 15.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 74.03 111.134 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -160.38 -133.48 1.5 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.704 -0.76 . . . . 73.44 112.479 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 52.9 m -153.01 96.65 2.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.817 0.342 . . . . 63.55 111.089 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 3.7 tp -140.03 114.09 8.97 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.2 -0.455 . . . . 74.14 110.878 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 56.84 175.64 0.29 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.738 -0.744 . . . . 64.11 112.437 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.658 ' O ' ' CG2' ' A' ' 183' ' ' VAL . 53.8 Cg_endo -69.72 71.36 1.5 Allowed 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.696 2.264 . . . . 72.05 112.322 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . 0.658 ' CG2' ' O ' ' A' ' 182' ' ' PRO . 1.5 t 153.34 93.95 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.543 0.687 . . . . 74.44 111.044 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 146.0 58.62 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.706 2.27 . . . . 73.44 112.324 179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 82.5 t -96.28 107.74 20.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 74.13 111.129 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -108.66 125.46 51.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 64.12 110.882 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 12.8 p -139.66 174.73 10.21 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.099 -0.501 . . . . 71.22 111.128 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 34.4 ttpt -158.95 145.35 16.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 71.53 110.921 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 8.6 tt -143.15 138.31 26.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 72.11 111.147 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -102.17 119.71 39.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.234 -0.439 . . . . 74.1 110.968 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 4.1 t -136.82 158.25 36.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 73.12 111.168 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -107.73 89.95 5.76 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.624 0.725 . . . . 74.11 110.933 179.857 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 121.62 8.3 Favored 'Trans proline' 0 C--O 1.232 0.211 0 C-N-CA 122.697 2.265 . . . . 75.42 112.296 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -99.76 107.43 19.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.268 -0.424 . . . . 74.23 110.889 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 49.1 mm -87.93 119.39 35.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.138 -0.483 . . . . 74.2 111.148 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 5.4 mp -105.98 108.18 19.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.206 -0.452 . . . . 70.32 110.951 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 9.4 m -98.97 112.03 24.26 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.213 -0.448 . . . . 75.13 110.897 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 1.9 tt -136.72 119.88 16.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 70.31 110.899 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -176.16 -145.55 5.61 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.779 -0.724 . . . . 65.51 112.482 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -125.17 173.83 8.49 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.75 0.31 . . . . 74.4 111.186 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.7 t -148.89 169.77 19.8 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.26 -0.427 . . . . 72.22 110.835 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -138.8 146.01 40.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.131 -0.486 . . . . 72.52 110.878 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 15.6 m -97.91 144.81 10.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.124 -0.489 . . . . 60.24 111.158 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -148.28 139.75 23.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.48 . . . . 74.43 110.812 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -107.93 -35.5 6.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.09 -0.504 . . . . 72.11 110.892 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 10.0 tt -62.45 140.18 58.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.222 -0.444 . . . . 74.33 110.969 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -112.64 -38.68 4.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 72.13 111.095 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -112.95 125.5 54.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.459 . . . . 74.45 111.084 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -109.14 172.22 6.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.262 -0.427 . . . . 74.24 111.17 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -131.04 148.45 52.75 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.279 -0.419 . . . . 74.31 110.957 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 15.9 mm-40 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.266 -0.425 . . . . 70.3 110.855 179.967 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 45.8 mtt . . . . . 0 C--O 1.23 0.058 0 CA-C-O 120.74 0.305 . . . . 71.4 110.891 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -111.05 161.41 15.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.25 -0.432 . . . . 74.41 110.934 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -157.15 143.49 18.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.266 -0.425 . . . . 72.33 110.863 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 59.9 m-20 -148.37 172.85 13.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.489 . . . . 62.23 110.867 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 9.6 p90 -118.48 157.61 49.06 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.722 0.773 . . . . 74.22 110.897 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 179.61 3.57 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.697 2.265 . . . . 54.44 112.363 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -110.16 172.47 6.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.259 -0.428 . . . . 72.41 111.109 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 38.5 mmtm -77.92 146.71 35.38 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.194 -0.457 . . . . 74.24 110.857 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 3.6 m -166.49 157.23 12.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.159 -0.473 . . . . 73.33 110.831 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -79.04 135.72 36.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.109 -0.496 . . . . 62.14 111.09 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -87.75 76.37 2.0 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.831 -0.7 . . . . 73.22 112.532 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -113.46 38.22 2.97 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.886 0.374 . . . . 73.24 110.924 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -143.42 150.06 38.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.117 -0.492 . . . . 73.02 110.912 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -51.99 119.44 4.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 71.04 110.964 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 103.28 11.67 33.2 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.675 -0.774 . . . . 75.2 112.514 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -83.28 159.16 21.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.781 0.324 . . . . 70.54 110.887 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 13.3 m95 -107.36 158.34 17.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.247 -0.433 . . . . 73.54 110.902 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -150.71 120.78 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.281 -0.418 . . . . 72.51 111.133 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -87.77 110.08 20.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 74.41 111.117 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 6.5 t -107.61 113.3 26.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.214 -0.448 . . . . 74.43 110.894 -179.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 17.0 p90 -108.41 122.36 46.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 75.54 110.863 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -152.76 167.93 27.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.138 -0.483 . . . . 64.2 110.92 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -102.01 134.89 44.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 73.11 110.929 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -102.69 122.68 44.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 65.32 110.801 -179.763 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 11.3 tptm -96.59 106.61 18.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.054 -0.521 . . . . 75.24 110.83 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 34.3 m -78.86 134.0 28.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.456 . . . . 73.13 111.201 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 17.0 t80 -130.9 99.74 5.01 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.223 -0.444 . . . . 75.42 110.9 -179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.0 p -165.82 152.86 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.118 -0.492 . . . . 75.34 111.127 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 123.59 77.11 0.35 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.739 -0.743 . . . . 71.34 112.48 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 25.6 pt-20 -90.26 -44.11 9.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.837 0.351 . . . . 75.34 110.85 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER 178.58 170.64 0.81 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 74.52 110.866 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 20.8 tp -74.9 161.58 29.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.131 -0.486 . . . . 74.44 110.876 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.93 39.1 2.88 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.709 -0.757 . . . . 51.13 112.496 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -104.21 155.56 18.63 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.746 0.308 . . . . 73.21 110.953 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.2 mt -130.6 167.53 18.58 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.219 -0.446 . . . . 74.45 110.905 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 17.7 t30 -91.74 172.48 8.45 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 72.14 110.886 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 61.1 t -90.65 -38.65 11.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 74.11 111.173 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -78.04 98.7 1.48 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.768 -0.73 . . . . 61.24 112.522 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 65.27 169.01 2.22 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.752 -0.737 . . . . 52.32 112.471 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -99.21 85.93 0.69 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.705 -0.76 . . . . 50.01 112.522 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -114.5 -179.61 3.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.836 0.351 . . . . 74.54 111.065 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 21.5 mt -53.26 158.84 2.41 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.575 0.702 . . . . 72.41 110.944 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 152.77 69.37 Favored 'Trans proline' 0 C--N 1.34 0.127 0 C-N-CA 122.7 2.267 . . . . 73.42 112.371 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -102.79 -38.06 7.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.443 . . . . 75.42 110.867 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -56.93 179.27 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 74.22 111.071 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -161.2 128.61 4.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.225 -0.443 . . . . 73.23 110.861 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 22.3 m -104.36 167.39 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 64.21 111.15 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -164.76 174.41 10.72 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.13 -0.486 . . . . 74.24 110.804 -179.806 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 7.9 tt -134.04 149.24 30.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.089 -0.505 . . . . 72.32 111.08 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -139.3 85.5 0.22 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.709 -0.758 . . . . 74.41 112.468 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -147.77 152.5 37.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.814 0.34 . . . . 72.54 110.925 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 46.2 m-20 -104.0 178.09 4.66 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.156 -0.474 . . . . 71.12 110.818 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 2.3 t -55.73 150.22 13.09 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 73.42 111.124 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -151.58 162.72 40.5 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.208 -0.451 . . . . 75.23 111.112 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 20.3 mt -108.28 153.49 23.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.169 -0.469 . . . . 75.11 110.978 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -135.56 147.89 48.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.26 -0.427 . . . . 74.11 111.062 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -104.22 131.49 51.48 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.18 -0.464 . . . . 73.45 110.835 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 -126.63 138.29 53.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.19 -0.459 . . . . 74.01 110.85 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.08 113.56 44.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.144 -0.48 . . . . 71.31 111.132 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -106.02 120.39 41.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 74.42 111.161 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 8.1 t80 -105.69 118.53 36.83 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.164 -0.471 . . . . 73.4 110.93 -179.8 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -93.76 96.64 9.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.088 -0.505 . . . . 72.22 110.895 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 57.4 t -91.23 -35.17 6.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.144 -0.48 . . . . 73.44 111.133 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.6 m -131.87 163.42 28.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 74.13 110.894 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 33.4 m -87.49 3.45 47.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 62.33 110.865 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 7.1 m120 -107.77 -33.08 7.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.112 -0.495 . . . . 71.1 110.895 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.8 pt -150.36 169.9 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 64.14 111.142 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -157.12 167.32 30.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.45 . . . . 75.44 111.105 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.412 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 2.7 m -110.54 151.57 12.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.183 -0.462 . . . . 74.33 111.077 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -141.69 137.31 31.65 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.173 -0.467 . . . . 72.23 110.866 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -121.02 110.39 16.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.248 -0.433 . . . . 73.13 110.903 -179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 41.0 t80 -87.27 125.95 34.53 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 75.34 110.908 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 40.4 t -146.42 146.78 18.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.234 -0.439 . . . . 74.5 111.16 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -147.97 178.89 25.26 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.673 -0.775 . . . . 60.34 112.458 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.6 t -144.26 66.0 13.81 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.583 0.706 . . . . 75.33 111.111 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 138.14 37.22 Favored 'Trans proline' 0 C--N 1.34 0.132 0 C-N-CA 122.714 2.276 . . . . 73.52 112.359 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -67.47 -166.81 0.05 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.213 -0.448 . . . . 74.02 111.161 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 23.1 ttp180 -75.77 123.75 26.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.242 -0.436 . . . . 65.52 110.881 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -110.66 150.93 28.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 75.23 111.166 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.22 119.51 38.85 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 71.52 110.891 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -114.31 144.84 42.59 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.213 -0.449 . . . . 74.4 110.858 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 28.3 mt-30 -104.26 153.22 21.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.453 . . . . 74.34 110.979 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -178.84 75.9 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.734 -0.746 . . . . 63.35 112.453 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -177.4 -177.46 0.7 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.899 0.381 . . . . 74.32 110.907 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.17 -68.96 0.7 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.152 -0.476 . . . . 73.03 110.917 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.6 m -84.97 -32.74 22.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.236 -0.438 . . . . 73.11 110.829 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.1 mm -66.52 -34.45 70.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.121 -0.491 . . . . 73.34 111.157 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 28.1 t -63.23 -51.28 66.86 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.177 -0.465 . . . . 73.21 110.831 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 58.5 m -51.46 -36.92 46.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.152 -0.476 . . . . 75.42 110.894 -179.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 35.9 mt -64.71 -42.92 94.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.487 . . . . 74.3 110.88 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.34 -13.98 39.71 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.831 -0.699 . . . . 74.21 112.534 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.1 mtp-105 -115.91 90.09 3.25 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.84 0.352 . . . . 74.25 110.825 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 3.9 t -113.79 -43.94 4.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 72.32 111.108 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.3 m -141.18 144.06 34.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 73.1 110.839 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -138.44 118.22 13.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.172 -0.467 . . . . 64.52 110.954 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 5.3 p -178.14 164.41 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.485 . . . . 71.21 111.151 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.417 ' HB2' ' CE2' ' A' ' 128' ' ' PHE . 0.0 OUTLIER -100.21 173.0 6.82 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.208 -0.451 . . . . 73.11 110.923 179.908 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' TYR . . . . . 0.413 ' HA ' ' HB2' ' A' ' 128' ' ' PHE . 62.1 m-85 -133.16 141.3 48.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 74.52 110.873 -179.804 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -108.99 82.07 0.3 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.799 -0.715 . . . . 72.14 112.493 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 112.22 3.01 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.681 2.254 . . . . 74.35 112.374 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -124.89 94.98 4.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.259 -0.428 . . . . 71.21 111.168 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 12.2 mt -112.35 145.73 18.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 74.15 111.098 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -149.2 109.43 4.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 75.54 110.943 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.3 p -140.62 166.21 25.36 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 73.4 110.911 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.412 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -114.76 140.41 48.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.146 -0.479 . . . . 74.23 110.925 -179.99 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 6.9 pt20 -102.62 145.41 29.69 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 73.22 110.864 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 10.5 p90 -140.42 145.31 36.85 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.144 -0.48 . . . . 74.43 110.879 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 58.0 t60 -100.23 141.09 33.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.111 -0.495 . . . . 74.5 110.838 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.1 t80 -101.13 142.71 32.18 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.461 . . . . 75.32 110.96 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 33.6 t70 -83.56 132.08 34.94 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.14 -0.482 . . . . 73.15 110.906 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.0 m -153.59 -174.35 4.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 55.4 110.807 -179.7 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 15.2 t80 -118.43 -29.9 5.35 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.104 -0.498 . . . . 74.41 110.923 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -57.36 -176.04 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.127 -0.488 . . . . 74.22 110.854 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 55.0 mtm180 -58.05 -174.82 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.115 -0.493 . . . . 73.15 110.935 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 10.8 mp -67.14 165.28 16.27 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 70.12 110.918 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 6.4 p90 -165.85 159.5 13.11 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.628 0.727 . . . . 74.54 111.004 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 178.95 4.04 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.669 2.246 . . . . 74.43 112.335 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -108.82 157.2 18.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 72.42 110.878 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 93.4 t -111.4 134.4 53.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.059 -0.519 . . . . 54.33 111.146 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -135.98 168.93 23.81 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.776 -0.726 . . . . 75.04 112.543 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 10.6 p -162.35 152.15 3.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.876 0.37 . . . . 73.22 111.131 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -176.83 -154.32 11.78 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.689 -0.767 . . . . 74.14 112.502 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . 0.482 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 10.2 p -111.13 139.04 36.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.95 0.405 . . . . 74.12 111.086 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -128.72 115.75 2.08 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.777 -0.725 . . . . 63.11 112.546 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 17.3 ptp180 -122.82 116.59 23.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.852 0.358 . . . . 71.11 110.848 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 3.6 p -117.22 114.48 45.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.182 -0.463 . . . . 73.44 111.043 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -150.55 168.15 25.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 62.33 110.924 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.417 ' CE2' ' HB2' ' A' ' 97' ' ' ASP . 1.0 OUTLIER -164.36 -172.45 2.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 74.34 110.899 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -94.44 129.22 41.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 73.33 110.884 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -67.11 124.39 22.94 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.194 -0.457 . . . . 73.22 110.797 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 20.0 mmmt -102.39 -72.48 0.69 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.159 -0.473 . . . . 73.25 110.9 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -151.63 77.13 1.23 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 74.14 111.152 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -94.1 158.68 15.5 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.467 . . . . 71.54 110.905 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.02 159.71 0.19 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.728 -0.749 . . . . 61.1 112.544 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -78.01 4.93 10.96 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.819 0.342 . . . . 75.01 111.14 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -86.27 -176.68 6.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 75.01 110.956 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.6 t -68.33 85.28 0.27 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.194 -0.457 . . . . 71.45 110.889 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 89.5 p 46.22 74.85 0.13 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 71.14 110.953 -179.729 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -86.29 156.5 20.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.149 -0.478 . . . . 74.33 110.837 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -107.62 175.01 5.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.068 -0.515 . . . . 73.24 110.886 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . 0.424 ' HA ' ' HA ' ' A' ' 176' ' ' VAL . 24.7 pt -152.2 135.64 7.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 75.34 111.106 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.54 116.94 13.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.113 -0.494 . . . . 75.51 110.925 179.861 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -63.63 -158.43 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.452 . . . . 71.03 110.801 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 3.0 tttt -128.99 147.3 50.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 74.44 110.888 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 43.2 p90 -158.6 119.01 3.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.156 -0.474 . . . . 70.02 110.897 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.459 ' CB ' ' HD2' ' A' ' 147' ' ' PRO . . . -179.38 168.46 0.8 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.566 0.698 . . . . 74.45 111.112 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 53.4 Cg_endo -69.78 141.01 44.0 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.661 2.24 . . . . 62.11 112.362 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -135.27 168.15 19.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 71.54 111.102 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -116.79 139.78 50.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.243 -0.435 . . . . 74.41 110.837 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 -116.76 145.75 43.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.104 -0.498 . . . . 74.31 110.919 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.59 127.18 8.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.455 . . . . 74.02 111.133 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 176.9 -179.6 47.77 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.724 -0.75 . . . . 55.22 112.531 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -121.98 158.82 28.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.876 0.369 . . . . 73.31 110.842 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -142.79 128.34 19.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.187 -0.461 . . . . 71.23 110.847 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -145.33 179.5 7.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.483 . . . . 75.12 110.974 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -114.16 90.76 3.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.179 -0.464 . . . . 71.02 110.839 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 24.4 tp -58.99 97.2 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 70.12 110.939 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 66.52 -136.38 34.03 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.716 -0.754 . . . . 70.22 112.495 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 52.2 t30 -119.49 -30.89 4.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.795 0.331 . . . . 72.44 110.886 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 35.7 m -49.4 -67.12 0.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.464 . . . . 64.14 110.833 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 5.3 p90 -147.54 161.87 40.22 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.152 -0.476 . . . . 62.44 110.886 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 78.7 mtp -93.28 172.13 8.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 63.21 110.888 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.533 ' C ' ' CD2' ' A' ' 163' ' ' LEU . 0.0 OUTLIER -136.09 152.08 50.49 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.187 -0.46 . . . . 71.32 111.002 179.972 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -155.49 146.68 22.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.265 -0.425 . . . . 53.22 110.854 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 10.2 t -152.59 122.27 6.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.213 -0.448 . . . . 73.35 110.937 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -145.85 177.27 9.05 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.099 -0.501 . . . . 73.34 110.822 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 16.4 t -147.44 141.34 19.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 75.23 111.135 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.97 141.99 40.27 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.127 -0.488 . . . . 74.31 110.814 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 9.5 t80 -139.86 138.88 36.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.11 -0.495 . . . . 74.34 110.916 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' ILE . . . . . . . . . . . . . 1.9 tp -177.87 110.04 0.22 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.613 0.72 . . . . 75.31 111.069 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.85 124.78 11.38 Favored 'Trans proline' 0 N--CA 1.464 -0.217 0 C-N-CA 122.685 2.256 . . . . 64.54 112.353 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -147.04 177.49 9.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 74.03 110.883 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 22.1 pttm -136.73 137.32 39.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 73.24 110.922 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -99.51 169.55 9.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 64.55 111.149 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -129.87 161.98 29.58 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.257 -0.429 . . . . 64.33 110.891 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . 0.424 ' HA ' ' HA ' ' A' ' 141' ' ' ILE . 99.1 t -144.46 127.22 11.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 73.25 111.111 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 5.0 t -163.7 166.04 22.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 72.4 111.182 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -167.7 -150.38 6.5 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.785 -0.721 . . . . 63.52 112.507 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.7 t -131.75 96.3 3.92 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.9 0.381 . . . . 73.32 111.081 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -141.93 101.84 4.02 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.46 . . . . 65.24 110.904 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 58.22 172.88 0.36 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.772 -0.728 . . . . 70.33 112.513 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.516 ' O ' ' HB ' ' A' ' 183' ' ' VAL . 53.2 Cg_endo -69.76 75.43 1.21 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.698 2.265 . . . . 75.25 112.308 -179.913 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . 0.516 ' HB ' ' O ' ' A' ' 182' ' ' PRO . 2.4 p 160.46 84.0 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.562 0.696 . . . . 60.23 111.149 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 141.73 45.97 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.652 2.235 . . . . 73.13 112.359 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 57.3 t -96.16 105.34 16.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.275 -0.42 . . . . 73.01 111.063 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -104.78 104.88 14.74 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.173 -0.467 . . . . 74.43 110.843 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 6.1 p -122.33 148.57 44.88 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.132 -0.485 . . . . 73.1 111.107 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.02 155.78 47.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.213 -0.449 . . . . 75.41 110.877 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 6.0 pt -144.01 109.91 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.46 . . . . 72.53 111.135 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -90.44 111.51 22.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 71.43 110.921 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 2.7 t -137.79 162.27 32.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 74.34 111.108 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -107.23 88.5 3.94 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.662 0.744 . . . . 62.01 110.871 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 138.45 37.83 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.708 2.272 . . . . 55.45 112.354 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -122.21 126.63 48.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.242 -0.435 . . . . 74.11 110.904 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 21.4 mt -112.44 120.01 61.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.175 -0.466 . . . . 72.42 111.109 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 9.5 tt -104.53 107.93 19.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.446 . . . . 73.32 110.918 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.1 t -96.49 123.4 40.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.128 -0.487 . . . . 62.21 110.878 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 27.2 tp -146.36 127.3 14.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 74.25 110.92 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -179.79 -150.68 9.29 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.711 -0.757 . . . . 43.41 112.496 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 200' ' ' ALA . . . . . 0.448 ' HA ' ' HA ' ' A' ' 163' ' ' LEU . . . -117.8 173.01 6.99 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.852 0.358 . . . . 73.34 111.101 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 2.3 p -149.7 169.48 20.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.466 . . . . 75.55 110.88 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 23.2 t80 -148.93 142.36 25.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 72.3 110.926 -179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 21.5 m -76.95 161.31 4.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.109 -0.496 . . . . 74.13 111.132 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -161.82 116.55 1.95 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 75.03 110.914 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 5.6 ttmm -92.76 147.63 22.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.161 -0.472 . . . . 74.15 110.906 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -143.83 111.94 6.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 73.11 110.882 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -129.4 176.39 8.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.252 -0.431 . . . . 73.24 111.095 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -81.7 -39.26 24.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 65.3 111.15 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -102.5 155.67 18.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 64.41 111.094 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -122.86 154.7 37.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.23 -0.441 . . . . 75.22 110.938 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 . . . . . 0 C--N 1.33 -0.242 0 CA-C-N 116.169 -0.468 . . . . 74.44 110.888 179.975 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.079 0 CA-C-O 120.869 0.366 . . . . 75.21 110.903 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -125.48 149.05 48.6 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.161 -0.472 . . . . 73.01 110.951 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.9 tt0 -129.22 142.53 50.83 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 72.3 110.955 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 20.8 p30 -75.79 175.9 8.28 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.203 -0.453 . . . . 74.4 110.908 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 5.4 p90 -129.1 157.48 75.82 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.627 0.727 . . . . 71.42 110.975 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 89.72 0.52 Allowed 'Trans proline' 0 N--CA 1.466 -0.132 0 C-N-CA 122.718 2.279 . . . . 71.3 112.344 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -80.17 -51.48 8.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.455 . . . . 73.23 111.091 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.72 159.92 2.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.471 . . . . 73.43 110.962 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -130.01 147.34 51.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 63.03 110.847 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.2 177.8 5.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.14 -0.482 . . . . 74.44 111.106 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -119.74 42.16 1.81 Allowed Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.634 -0.794 . . . . 74.54 112.476 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 13.3 m-85 -124.99 85.03 2.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.876 0.37 . . . . 75.02 110.892 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -169.55 -173.37 1.64 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.151 -0.477 . . . . 72.5 110.85 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -45.75 125.5 6.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 71.41 110.883 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.85 7.91 21.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.734 -0.746 . . . . 72.54 112.513 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -55.15 166.44 0.55 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.8 0.334 . . . . 71.04 110.865 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 10.9 m-90 -109.54 151.33 26.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.131 -0.486 . . . . 74.3 110.883 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -153.24 115.25 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.245 -0.434 . . . . 75.33 111.17 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.04 140.49 32.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.168 -0.469 . . . . 70.2 111.095 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.7 t -136.6 115.09 11.87 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 64.3 110.836 -179.787 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -123.15 117.11 24.62 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.087 -0.506 . . . . 73.3 110.861 -179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -152.79 169.58 22.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.13 -0.486 . . . . 72.25 110.882 -179.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 21.5 p90 -102.85 135.33 44.72 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.15 -0.477 . . . . 73.22 110.813 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 1.3 p -102.3 137.54 40.42 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.063 -0.517 . . . . 63.25 110.873 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.4 ttmt -112.55 108.08 17.04 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.098 -0.501 . . . . 74.21 110.961 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.6 p -76.74 129.65 37.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.186 -0.461 . . . . 71.53 111.145 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -123.39 113.62 19.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 72.14 110.939 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.8 p -176.78 146.11 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.099 -0.5 . . . . 64.11 111.108 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.47 68.94 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.673 -0.775 . . . . 72.12 112.468 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -90.23 -66.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.751 0.31 . . . . 73.31 110.911 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 -175.98 167.78 2.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 73.23 110.931 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 41.4 tp -101.28 156.16 17.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 75.14 110.927 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.25 80.7 0.35 Allowed Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.809 -0.71 . . . . 71.04 112.556 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 11.6 t0 -58.89 140.86 54.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.85 0.357 . . . . 71.42 110.876 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 3.4 tt -159.73 122.16 3.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.454 . . . . 72.13 110.932 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.7 p30 -143.87 167.45 22.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.138 -0.483 . . . . 75.11 110.854 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.3 p -59.38 -36.26 63.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.475 . . . . 62.4 111.14 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.12 -156.89 9.08 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.769 -0.729 . . . . 73.1 112.509 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 135.27 -163.08 24.89 Favored Glycine 0 N--CA 1.453 -0.203 0 C-N-CA 120.728 -0.749 . . . . 74.41 112.456 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -91.44 -94.79 1.31 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.742 -0.742 . . . . 61.33 112.458 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -92.98 171.82 8.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.818 0.342 . . . . 71.22 111.136 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.6 tp -135.94 70.24 64.05 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.63 0.729 . . . . 75.41 110.923 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -170.67 0.4 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.702 2.268 . . . . 72.12 112.362 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 75.4 m-20 -109.65 112.93 25.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.211 -0.45 . . . . 72.05 110.877 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -81.13 -176.32 5.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.217 -0.447 . . . . 64.53 111.068 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -146.41 126.06 13.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.225 -0.443 . . . . 64.43 110.793 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 12.0 p -104.79 138.19 30.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 63.15 111.063 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 m -154.74 177.95 10.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.152 -0.476 . . . . 71.04 110.857 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -137.16 154.3 30.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 73.13 111.134 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -111.69 62.7 0.29 Allowed Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.682 -0.771 . . . . 74.15 112.441 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 32.5 m120 -87.88 162.94 16.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.872 0.368 . . . . 70.21 110.81 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -129.13 163.29 25.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.093 -0.503 . . . . 72.13 110.928 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.5 p -69.14 104.58 2.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 74.35 111.11 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -131.16 168.41 17.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.182 -0.463 . . . . 75.13 111.182 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -91.07 168.77 11.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 65.13 110.939 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.98 147.39 38.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.231 -0.441 . . . . 74.13 111.206 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -101.77 151.2 22.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.27 -0.423 . . . . 74.34 110.866 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -149.81 135.48 18.47 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.169 -0.469 . . . . 55.42 110.902 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -107.7 112.47 40.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 72.34 111.088 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -101.42 129.15 47.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 65.0 111.045 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -117.0 128.47 55.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 75.3 110.916 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -98.25 98.41 9.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.489 . . . . 74.51 110.881 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.9 p -95.88 -34.1 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 70.51 111.108 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 25.1 p -139.6 163.16 33.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.48 . . . . 74.13 110.816 -179.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 12.0 p -87.23 3.24 47.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 72.34 110.849 -179.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 20.1 m120 -106.55 -31.18 8.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.135 -0.484 . . . . 73.5 110.911 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.9 pt -150.43 165.48 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.122 -0.49 . . . . 75.44 111.091 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -146.8 166.9 25.28 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.104 -0.498 . . . . 71.21 111.061 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.1 m -114.78 151.41 16.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.161 -0.472 . . . . 75.03 111.086 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -144.62 132.28 21.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.135 -0.484 . . . . 74.02 110.822 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -108.47 118.04 35.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 64.42 110.882 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -88.3 121.39 30.64 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.145 -0.48 . . . . 75.13 110.853 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 42.1 t -146.88 146.86 18.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.191 -0.459 . . . . 74.1 111.094 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -151.33 162.22 29.45 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.79 -0.719 . . . . 71.34 112.465 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.8 p -115.47 70.64 3.17 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.655 0.741 . . . . 75.41 111.173 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 158.96 55.12 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.651 2.234 . . . . 63.15 112.324 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -104.04 -169.81 1.68 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.247 -0.433 . . . . 63.1 111.145 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 50.4 ttp180 -76.35 126.77 31.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.428 . . . . 74.35 110.856 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -121.62 150.3 41.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 74.42 111.141 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 5.5 tttm -84.16 107.81 16.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.252 -0.431 . . . . 73.51 110.966 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 72.0 t80 -84.43 128.29 34.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 75.51 110.85 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.41 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 41.7 mt-30 -103.38 151.61 22.56 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.129 -0.487 . . . . 75.21 110.899 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 172.68 82.45 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.801 -0.714 . . . . 62.14 112.492 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -176.83 -175.08 0.59 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.879 0.371 . . . . 74.24 110.952 -179.903 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.84 -69.5 0.67 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 74.22 110.916 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.6 t -84.96 -31.61 23.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 75.33 110.913 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 1.1 mt -68.19 -34.23 65.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.11 -0.496 . . . . 74.15 111.143 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.6 t -63.3 -51.11 67.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.174 -0.467 . . . . 62.42 110.851 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.8 t -52.01 -38.87 58.32 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.081 -0.508 . . . . 71.21 110.873 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 13.6 mt -64.85 -35.34 80.81 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.14 -0.482 . . . . 74.44 110.909 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.15 -13.39 67.02 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.686 -0.768 . . . . 73.5 112.47 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 10.4 ptp180 -115.0 94.93 4.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.812 0.339 . . . . 75.34 110.837 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.41 ' HB ' ' HA ' ' A' ' 82' ' ' GLN . 99.9 t -111.66 -57.47 3.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.186 -0.461 . . . . 73.32 111.114 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 18.0 p -140.74 159.21 42.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 74.03 110.848 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -128.85 124.62 35.8 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.101 -0.5 . . . . 74.34 110.863 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 10.4 p -175.53 159.58 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.103 -0.499 . . . . 71.51 111.125 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -106.81 173.11 6.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 71.53 110.926 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' TYR . . . . . 0.469 ' HA ' ' HB2' ' A' ' 128' ' ' PHE . 19.3 m-85 -133.61 144.04 49.01 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.255 -0.429 . . . . 72.54 110.94 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -106.91 87.09 0.49 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.781 -0.724 . . . . 74.03 112.46 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 124.72 11.38 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.697 2.264 . . . . 62.3 112.382 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -141.25 94.73 2.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 72.11 111.109 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.35 153.99 19.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.195 -0.457 . . . . 74.41 111.11 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -153.03 108.57 3.28 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.191 -0.459 . . . . 75.23 110.913 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' SER . . . . . 0.401 ' HB3' ' HA3' ' A' ' 122' ' ' GLY . 23.6 p -134.38 166.4 22.92 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 75.24 110.859 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -119.7 150.89 39.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 74.25 110.943 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -102.02 138.26 39.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.216 -0.447 . . . . 73.53 110.88 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 33.2 p90 -149.48 146.99 27.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 75.43 110.918 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 17.6 p80 -148.06 127.48 13.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.077 -0.51 . . . . 74.12 110.847 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 88.2 t80 -100.14 128.45 46.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.194 -0.457 . . . . 74.23 110.917 -179.827 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -51.98 107.81 0.23 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 73.24 110.868 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 24.8 p -113.97 -37.58 4.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.151 -0.477 . . . . 72.34 110.913 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -145.42 170.7 15.85 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.157 -0.474 . . . . 73.05 110.884 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 37.1 tp10 -78.22 -43.48 28.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.142 -0.481 . . . . 73.31 110.893 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 44.5 mtp180 -52.18 160.11 0.82 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.168 -0.469 . . . . 74.52 110.901 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 58.5 tp -76.25 149.93 37.08 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.179 -0.464 . . . . 74.15 110.854 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -164.01 157.45 15.76 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.653 0.739 . . . . 74.3 110.935 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.77 177.76 5.27 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.664 2.242 . . . . 74.32 112.353 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -117.46 154.34 31.57 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.235 -0.439 . . . . 73.33 110.958 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 25.2 t -102.78 128.16 55.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.111 -0.495 . . . . 75.04 111.095 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -123.17 169.08 15.37 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.774 -0.726 . . . . 62.22 112.525 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 12.9 p -163.77 149.24 3.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.888 0.375 . . . . 75.41 111.131 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.401 ' HA3' ' HB3' ' A' ' 104' ' ' SER . . . -171.47 -149.21 6.44 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.751 -0.738 . . . . 71.43 112.458 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . 0.52 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 14.9 p -129.4 136.14 60.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.829 0.347 . . . . 74.31 111.146 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -122.35 118.29 3.6 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.75 -0.738 . . . . 71.25 112.446 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -121.47 124.72 45.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.827 0.346 . . . . 74.33 110.939 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 27.2 t -118.15 119.79 62.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.255 -0.43 . . . . 74.0 111.107 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.2 pp -150.99 156.57 41.43 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 73.11 110.888 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.469 ' HB2' ' HA ' ' A' ' 98' ' ' TYR . 0.6 OUTLIER -167.42 -173.42 2.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 71.24 110.907 179.949 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -96.89 142.87 28.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 74.53 110.91 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -78.37 114.58 17.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.451 . . . . 73.31 110.875 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.05 -78.11 0.12 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 71.5 110.91 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 3.4 m -170.67 120.3 0.56 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.25 -0.432 . . . . 72.12 111.123 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -105.63 122.98 47.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.48 . . . . 64.15 110.813 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 135' ' ' ALA . . . -80.63 -22.89 61.17 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.699 -0.762 . . . . 72.24 112.464 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.411 ' C ' ' O ' ' A' ' 134' ' ' GLY . . . -36.95 -42.75 0.42 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.872 0.368 . . . . 54.02 111.164 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -142.44 168.49 19.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 71.14 110.896 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 90.1 p -48.27 96.75 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.18 -0.464 . . . . 65.21 110.811 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 4.4 m 49.48 73.79 0.23 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.088 -0.505 . . . . 63.42 110.815 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -100.06 161.63 13.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.074 -0.512 . . . . 74.14 110.934 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -130.03 165.56 21.94 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.185 -0.462 . . . . 74.2 110.916 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 6.4 tt -103.38 155.25 5.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.249 -0.432 . . . . 74.24 111.113 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 7.2 mmtp -123.33 111.96 17.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 74.52 110.858 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -78.95 -159.84 0.2 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.237 -0.438 . . . . 73.15 110.851 179.79 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -171.14 173.53 4.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 73.41 110.945 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 29.1 p90 -154.75 149.19 26.23 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.219 -0.446 . . . . 73.35 110.864 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . 0.475 ' CB ' ' HD2' ' A' ' 147' ' ' PRO . . . 177.97 169.07 0.51 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.562 0.696 . . . . 71.45 111.086 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . 0.52 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 53.6 Cg_endo -69.79 144.0 52.49 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.662 2.241 . . . . 75.54 112.344 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -138.84 167.99 20.79 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 75.11 111.144 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -108.71 161.77 14.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.247 -0.433 . . . . 74.25 110.881 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -140.18 157.18 46.01 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.159 -0.473 . . . . 74.04 110.89 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -154.4 131.03 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 74.42 111.092 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 169.77 -167.61 40.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 71.04 112.521 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.7 pp -152.42 169.13 23.32 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.779 0.323 . . . . 73.22 110.979 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 10.1 tpp85 -120.14 125.0 47.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.179 -0.464 . . . . 74.52 110.92 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -123.63 175.09 7.03 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.285 -0.416 . . . . 72.22 110.93 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -122.1 96.66 5.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.1 -0.5 . . . . 73.02 110.891 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 8.8 tt -102.92 140.26 37.42 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.233 -0.439 . . . . 73.52 110.934 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 59.29 171.63 0.43 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.745 -0.741 . . . . 72.33 112.444 179.824 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 45.4 t30 -93.07 158.57 15.71 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.907 0.384 . . . . 75.11 110.804 -179.824 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 58.7 m 51.18 32.24 7.75 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.18 -0.464 . . . . 60.23 110.843 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -174.68 149.7 1.26 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.143 -0.48 . . . . 72.24 110.91 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 11.9 mmt -121.18 172.77 7.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 73.55 110.928 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 5.0 tp -126.11 139.56 53.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.288 -0.415 . . . . 73.13 110.948 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -139.34 139.72 37.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.446 . . . . 75.23 110.927 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 69.2 p -139.8 121.8 15.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 63.32 110.857 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -141.72 164.55 29.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 62.04 110.869 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 40.1 t -150.16 129.86 3.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.147 -0.479 . . . . 74.11 111.104 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.08 144.92 29.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.136 -0.483 . . . . 74.11 110.832 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -146.02 135.16 22.75 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.184 -0.462 . . . . 72.53 110.966 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' ILE . . . . . . . . . . . . . 4.7 tp 179.9 131.85 0.25 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.594 0.711 . . . . 74.02 111.15 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.8 109.74 2.39 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.752 2.301 . . . . 74.35 112.315 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -116.92 178.11 4.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 74.2 110.922 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.01 133.94 18.04 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.178 -0.464 . . . . 75.41 110.84 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 13.2 t -105.64 154.28 20.65 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.166 -0.47 . . . . 75.41 111.077 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -128.53 161.81 28.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.135 -0.484 . . . . 71.12 110.858 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 20.3 t -146.58 132.42 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 71.3 111.175 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.3 t -165.59 160.25 17.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.183 -0.462 . . . . 73.04 111.145 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -136.3 171.37 22.88 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.751 -0.738 . . . . 74.02 112.454 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 2.1 t -110.84 106.07 15.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.766 0.317 . . . . 75.54 111.173 -179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -129.29 167.95 16.94 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.226 -0.443 . . . . 75.03 110.902 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -46.53 -66.81 1.6 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.692 -0.766 . . . . 54.33 112.502 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.68 -167.45 0.22 Allowed 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.68 2.253 . . . . 74.44 112.389 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 4.4 p -73.95 113.89 27.48 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.677 0.751 . . . . 64.24 111.11 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 165.62 30.29 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.691 2.26 . . . . 72.51 112.353 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 15.0 t -101.32 139.33 22.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.235 -0.439 . . . . 73.22 111.095 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 43.0 p -121.25 105.03 10.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.162 -0.472 . . . . 60.03 110.907 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 22.1 p -105.06 162.07 13.69 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.162 -0.472 . . . . 64.43 111.152 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -159.32 157.38 30.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 74.31 110.884 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 3.5 pt -154.13 130.43 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 64.21 111.139 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -101.62 118.4 36.86 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 63.31 110.881 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 7.1 p -136.25 160.97 38.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.144 -0.48 . . . . 73.41 111.127 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -106.91 87.82 3.19 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.613 0.721 . . . . 71.34 110.85 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.69 158.85 55.6 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.703 2.268 . . . . 70.42 112.33 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -136.94 120.87 17.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.23 -0.441 . . . . 52.22 110.889 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 45.4 mt -105.62 118.5 53.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.445 . . . . 74.13 111.167 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 3.9 mt -106.73 108.33 19.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.156 -0.474 . . . . 72.11 110.924 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 16.6 p -101.03 134.22 44.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 74.54 110.874 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 22.0 tp -156.49 129.7 8.03 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.109 -0.496 . . . . 74.4 110.909 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 179.83 -145.59 6.56 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.74 -0.743 . . . . 63.23 112.501 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -116.73 174.53 6.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.755 0.312 . . . . 71.24 111.084 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 71.8 m -155.67 164.85 38.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 70.42 110.887 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 9.7 t80 -134.34 122.63 22.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.141 -0.481 . . . . 74.34 110.887 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 19.7 m -76.9 127.96 37.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.087 -0.506 . . . . 74.4 111.136 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -112.46 81.35 1.46 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 74.4 110.924 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 55.3 pttt -164.12 -166.89 1.21 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.499 . . . . 74.14 110.838 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 1.4 pt? -51.47 170.99 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.221 -0.445 . . . . 73.43 110.928 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -154.05 152.83 30.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.275 -0.42 . . . . 74.34 111.198 179.759 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -77.31 169.9 17.51 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.265 -0.425 . . . . 74.22 111.099 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -155.51 142.01 18.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.182 -0.463 . . . . 64.43 111.072 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -130.38 158.95 38.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 72.32 110.921 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 53.3 mt-10 . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.275 -0.42 . . . . 74.42 110.92 179.875 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.4 mmm . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.817 0.341 . . . . 74.45 110.884 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 49.5 t30 -152.3 146.55 25.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.25 -0.432 . . . . 73.2 110.833 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 18.9 mm-40 -135.45 105.48 6.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.455 . . . . 75.42 110.93 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -104.85 168.25 9.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.131 -0.486 . . . . 64.1 110.892 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -119.6 73.42 16.33 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.685 0.755 . . . . 72.13 110.897 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 90.07 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.673 2.248 . . . . 75.11 112.376 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -101.91 137.94 39.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.255 -0.429 . . . . 70.43 111.174 179.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -71.41 117.64 13.21 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.302 -0.408 . . . . 73.22 110.893 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 7.8 t -98.91 141.43 31.69 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 63.22 110.835 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.16 162.52 13.57 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.095 -0.502 . . . . 73.13 111.093 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -170.13 172.38 43.87 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.756 -0.735 . . . . 71.11 112.489 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 15.1 p90 -159.97 120.64 3.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.877 0.37 . . . . 74.42 110.916 -179.78 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -140.86 162.9 34.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 60.21 110.868 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -52.09 120.36 5.33 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.113 -0.494 . . . . 73.2 110.926 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.85 5.52 35.69 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.781 -0.723 . . . . 65.14 112.423 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -66.8 150.16 49.53 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.778 0.323 . . . . 55.5 110.867 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 25.9 t90 -116.6 144.18 44.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 74.2 110.882 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 12.9 t -141.6 118.83 7.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.268 -0.424 . . . . 72.14 111.13 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -84.76 101.71 12.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.229 -0.441 . . . . 72.45 111.083 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.4 t -97.93 142.09 30.09 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 75.01 110.866 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 73.6 t80 -146.52 118.89 8.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.164 -0.471 . . . . 74.45 110.856 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -149.77 174.72 12.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.132 -0.486 . . . . 55.53 110.927 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 13.3 t80 -106.52 128.76 54.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.471 . . . . 75.32 110.914 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -94.21 147.56 23.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.171 -0.468 . . . . 75.13 110.856 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 20.7 tttt -127.49 111.42 13.78 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.135 -0.484 . . . . 71.32 110.891 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.1 p -75.63 127.09 37.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 72.0 111.153 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 2.6 t80 -119.46 105.15 10.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.144 -0.48 . . . . 73.2 110.915 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.4 t -78.65 157.76 4.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.083 -0.508 . . . . 64.21 111.154 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.5 -112.6 0.13 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.693 -0.765 . . . . 62.31 112.528 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 66.6 mt-10 -89.86 -67.08 0.87 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.854 0.359 . . . . 70.22 110.942 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -177.11 -173.79 0.48 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.127 -0.488 . . . . 73.24 110.88 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 1.9 mt -85.0 -177.78 6.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 74.52 110.911 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.29 75.25 0.42 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.771 -0.728 . . . . 65.02 112.481 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -94.69 152.06 18.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.784 0.326 . . . . 73.42 110.858 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 2.3 tt -155.75 95.04 1.62 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 74.32 110.908 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -74.21 141.53 45.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.121 -0.49 . . . . 75.4 110.901 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 19.8 m -95.68 137.22 24.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.17 -0.468 . . . . 73.13 111.18 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 131.6 -82.53 0.31 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.823 -0.703 . . . . 74.41 112.491 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.19 -179.84 44.14 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.737 -0.745 . . . . 51.24 112.474 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.21 148.25 23.89 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.745 -0.741 . . . . 70.4 112.501 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -55.04 142.08 31.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.848 0.356 . . . . 74.04 111.07 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -148.57 67.9 9.75 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.595 0.712 . . . . 73.4 110.937 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.85 -170.18 0.38 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.663 2.242 . . . . 74.45 112.322 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -67.72 118.17 10.62 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 64.33 110.855 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -62.4 -176.7 0.11 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.089 -0.505 . . . . 72.04 111.057 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -157.9 126.01 5.4 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 72.41 110.875 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.2 p -104.39 140.71 21.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 65.02 111.152 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -140.48 164.83 29.1 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 73.32 110.828 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 23.2 pt -112.25 157.17 13.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.101 -0.5 . . . . 74.13 111.178 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.07 142.52 31.87 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.772 -0.728 . . . . 41.22 112.506 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -93.38 110.86 22.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.805 0.336 . . . . 71.54 110.858 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 19.9 t0 -174.07 148.83 1.39 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.46 . . . . 72.23 110.857 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 2.0 m -70.73 130.54 41.99 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 72.04 111.148 -179.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.97 177.54 7.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.171 -0.468 . . . . 62.24 111.143 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.1 pp -159.97 165.39 32.11 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.219 -0.446 . . . . 73.14 110.942 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -143.3 143.27 31.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 64.54 111.132 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -103.18 133.29 48.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.221 -0.445 . . . . 74.45 110.897 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -121.39 136.44 54.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.12 -0.491 . . . . 63.43 110.844 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 27.5 mm -108.51 113.39 43.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.161 -0.472 . . . . 74.4 111.067 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -102.78 121.19 41.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 72.34 111.1 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -111.3 115.41 29.28 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.187 -0.461 . . . . 65.51 110.968 -179.835 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -82.54 101.9 11.03 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.108 -0.496 . . . . 73.45 110.83 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.0 t -97.1 -35.37 5.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.135 -0.484 . . . . 64.41 111.106 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 27.8 t -134.07 162.09 33.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.487 . . . . 63.01 110.876 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 59.4 p -84.46 2.85 38.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.171 -0.468 . . . . 73.43 110.83 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -115.0 -32.98 5.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.085 -0.507 . . . . 75.54 110.912 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 21.7 pt -142.35 165.04 17.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.164 -0.471 . . . . 73.14 111.156 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -151.55 167.09 29.15 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.222 -0.445 . . . . 63.13 111.118 179.827 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 6.5 m -108.01 151.07 10.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 74.34 111.179 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -139.15 132.48 30.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 62.41 110.877 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -115.83 110.02 18.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.15 -0.477 . . . . 70.05 110.85 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 30.9 t80 -91.26 115.94 28.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 75.22 110.888 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.3 t -142.23 156.17 19.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 72.01 111.082 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -163.96 148.68 15.11 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.691 -0.766 . . . . 72.14 112.427 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.7 t -119.65 65.35 9.13 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.637 0.732 . . . . 64.21 111.144 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 163.42 38.33 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.688 2.259 . . . . 72.21 112.349 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -89.42 -169.29 2.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 70.34 111.08 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.5 ttp180 -77.42 132.52 38.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.258 -0.428 . . . . 75.14 110.921 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -133.38 152.84 51.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 71.3 111.048 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 14.6 ttmt -82.12 150.33 27.53 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.172 -0.467 . . . . 72.42 110.938 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -138.77 147.69 42.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 75.32 110.896 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 10.6 mt-30 -113.61 153.31 29.07 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.137 -0.483 . . . . 74.34 110.894 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 174.96 80.86 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.758 . . . . 62.24 112.423 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -178.26 -178.37 0.63 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.92 0.391 . . . . 74.24 110.962 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.0 -69.42 0.67 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.213 -0.448 . . . . 71.53 110.877 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 5.3 m -85.22 -32.41 22.64 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.23 -0.441 . . . . 65.45 110.829 -179.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 4.3 mm -66.83 -34.9 72.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 75.21 111.097 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 15.1 t -63.32 -47.84 80.53 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 73.32 110.864 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.2 p -53.14 -38.64 62.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 72.13 110.844 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -63.47 -43.39 97.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.178 -0.464 . . . . 74.15 110.867 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 109.86 -13.55 32.03 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.747 -0.739 . . . . 72.13 112.498 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 41.6 mtt180 -118.81 93.38 4.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.852 0.358 . . . . 73.24 110.916 -179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 4.0 t -113.57 -35.0 2.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 75.4 111.158 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 19.5 m -156.17 161.29 40.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 64.23 110.779 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 44.7 mt-10 -153.86 115.89 4.29 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.118 -0.492 . . . . 72.14 110.875 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 2.1 m -161.68 179.53 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.148 -0.478 . . . . 75.03 111.089 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -98.28 147.92 24.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 74.23 110.854 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 11.6 m-85 -92.34 139.98 30.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.219 -0.446 . . . . 75.33 110.946 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.402 ' N ' ' CD ' ' A' ' 100' ' ' PRO . . . -127.37 55.07 0.76 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.721 -0.752 . . . . 62.5 112.476 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' A' ' 99' ' ' GLY . 53.6 Cg_endo -69.73 111.69 2.87 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.71 2.273 . . . . 75.2 112.402 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -136.07 110.08 8.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.265 -0.425 . . . . 73.01 111.107 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 11.0 pt -140.82 140.59 33.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.213 -0.449 . . . . 74.43 111.17 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -132.49 120.14 21.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 73.53 110.933 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 2.4 p -142.14 162.86 34.41 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 71.41 110.878 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -109.23 144.6 37.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.146 -0.479 . . . . 72.54 110.876 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 3.0 pm0 -105.38 148.99 26.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.109 -0.496 . . . . 71.11 110.87 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 32.2 p90 -149.33 148.44 29.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 72.2 110.913 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 32.3 t60 -115.46 152.09 33.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.087 -0.506 . . . . 74.41 110.849 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 17.4 t80 -88.55 110.09 20.6 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 73.31 110.908 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 22.3 m-20 -51.18 109.07 0.3 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.074 -0.512 . . . . 61.25 110.841 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.1 m -170.98 146.86 2.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 73.11 110.884 -179.798 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 15.6 p90 -116.99 49.69 1.15 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 75.12 110.94 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -93.51 -55.19 3.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 73.34 110.925 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 67.7 mtt180 -152.68 -179.7 7.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 75.24 110.922 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 25.9 tp -95.82 117.23 30.16 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.245 -0.434 . . . . 71.55 110.931 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 5.4 p90 -147.58 158.85 42.68 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 121.654 0.74 . . . . 73.21 110.893 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 179.09 3.93 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.727 2.284 . . . . 74.24 112.35 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -109.87 164.59 12.44 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.22 -0.445 . . . . 74.33 110.974 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.2 p -117.51 139.0 46.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.169 -0.469 . . . . 75.41 111.096 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -139.95 160.5 26.23 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.713 -0.756 . . . . 74.12 112.499 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 4.9 m -152.75 163.88 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.877 0.37 . . . . 75.11 111.18 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 174.98 -145.99 8.19 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.722 -0.751 . . . . 61.42 112.429 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . 0.432 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 11.8 m -105.5 148.89 9.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.853 0.358 . . . . 64.23 111.192 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -144.25 105.95 0.39 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.697 -0.763 . . . . 72.12 112.467 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 15.7 ptm180 -99.78 125.07 45.63 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.899 0.38 . . . . 71.33 110.903 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . 0.4 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 25.2 t -109.51 114.02 45.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.25 -0.432 . . . . 74.34 111.125 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 2.1 pp -124.24 171.12 10.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.465 . . . . 74.2 110.885 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -141.14 178.55 7.31 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.148 -0.478 . . . . 74.1 110.831 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -118.15 119.82 35.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.115 -0.493 . . . . 73.02 110.918 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -60.45 103.61 0.26 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.125 -0.489 . . . . 71.13 110.892 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 7.9 tppt? -123.69 -71.91 0.7 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.449 . . . . 73.3 110.912 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 23.5 m -166.87 92.68 0.44 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.459 . . . . 74.22 111.136 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -107.73 168.98 8.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.464 . . . . 72.02 110.871 179.879 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 79.28 151.68 6.39 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.748 -0.739 . . . . 73.14 112.481 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -39.38 -66.85 0.26 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.831 0.348 . . . . 74.15 111.09 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -166.64 92.33 0.45 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 71.22 110.852 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' SER . . . . . 0.533 ' O ' ' C ' ' A' ' 138' ' ' SER . 0.4 OUTLIER 169.01 60.78 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 45.13 110.878 -179.947 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' SER . . . . . 0.533 ' C ' ' O ' ' A' ' 137' ' ' SER . 8.7 t 27.21 73.93 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.152 -0.476 . . . . 63.25 110.906 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -107.3 159.15 16.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.144 -0.48 . . . . 73.24 110.854 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -145.19 167.12 23.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.088 -0.506 . . . . 65.03 110.943 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 12.5 tt -116.76 132.5 66.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.209 -0.45 . . . . 62.31 111.131 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.72 106.64 12.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 74.01 110.863 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.4 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 0.6 OUTLIER -82.72 -172.43 4.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 62.41 110.879 179.87 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 5.2 tptt -174.95 -169.73 0.42 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 74.32 110.906 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 66.9 p-90 -144.62 161.01 40.22 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.208 -0.451 . . . . 74.22 110.98 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . 178.02 165.29 0.59 Allowed Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.567 0.698 . . . . 70.54 111.14 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . 0.432 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 53.6 Cg_endo -69.74 161.88 44.2 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.705 2.27 . . . . 73.23 112.354 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -153.79 160.11 42.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.249 -0.432 . . . . 63.4 111.064 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -118.91 115.23 23.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.223 -0.444 . . . . 65.25 110.903 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 20.6 tt0 -102.86 164.41 11.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.105 -0.498 . . . . 72.14 110.921 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 14.6 p -160.12 137.17 2.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.153 -0.476 . . . . 74.21 111.052 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 177.55 -162.25 30.02 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.767 -0.73 . . . . 72.31 112.528 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -138.69 160.61 39.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.827 0.346 . . . . 73.43 110.888 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 3.4 tpp85 -132.05 119.74 21.43 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 73.35 110.883 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -105.46 140.96 37.78 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.181 -0.463 . . . . 74.43 110.932 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -120.93 117.55 27.63 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.472 . . . . 73.42 110.864 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 3.9 tp -102.3 164.4 11.7 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 75.34 110.887 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -99.51 53.79 0.99 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.739 -0.744 . . . . 65.53 112.486 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -149.87 35.87 0.69 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.362 . . . . 75.32 110.966 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 51.79 35.4 15.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 72.25 110.8 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 51.2 m95 -154.99 101.43 2.26 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.134 -0.484 . . . . 75.22 110.849 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -97.7 168.25 10.45 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.253 -0.43 . . . . 75.35 110.909 179.855 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 4.0 tp -125.26 144.18 50.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.252 -0.431 . . . . 71.44 110.934 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -142.99 139.98 30.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 70.2 110.84 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 52.8 p -150.95 120.94 7.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 71.13 110.87 -179.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -149.08 171.13 16.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.167 -0.47 . . . . 75.31 110.881 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 4.3 t -144.75 135.96 20.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.171 -0.468 . . . . 72.22 111.076 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -102.67 137.34 41.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 74.45 110.872 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 35.1 t80 -141.79 139.2 32.7 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.201 -0.454 . . . . 73.45 110.887 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER 178.96 125.93 0.21 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.633 0.73 . . . . 74.35 111.096 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 107.25 1.82 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.649 2.233 . . . . 75.02 112.337 179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -126.94 170.0 12.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 74.42 110.894 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.7 141.4 43.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.114 -0.494 . . . . 75.22 110.875 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.32 169.48 12.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 75.42 111.141 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -126.64 170.45 12.08 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 64.2 110.888 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 7.6 p -160.14 137.1 2.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.45 . . . . 73.11 111.213 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.8 t -166.84 175.6 7.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.245 -0.434 . . . . 72.43 111.169 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -156.95 -140.99 3.07 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.8 -0.714 . . . . 63.1 112.495 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -157.05 106.17 2.19 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.816 0.341 . . . . 74.22 111.073 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 19.4 tp -139.88 117.78 11.75 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.213 -0.449 . . . . 71.03 110.957 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 46.42 -106.07 0.12 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.827 -0.701 . . . . 75.34 112.442 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 -167.87 0.24 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.694 2.263 . . . . 74.31 112.303 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 59.0 t -54.7 133.18 65.14 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.643 0.735 . . . . 71.32 111.163 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 164.02 36.04 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.686 2.258 . . . . 71.23 112.34 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 48.4 t -108.36 108.82 26.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 71.41 111.106 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 85.5 p -99.22 111.3 23.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.075 -0.512 . . . . 65.3 110.827 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 3.1 p -108.53 163.31 13.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 74.1 111.152 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -146.53 148.06 31.78 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.271 -0.422 . . . . 74.51 110.92 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 3.6 pt -142.36 136.35 28.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.285 -0.416 . . . . 72.53 111.165 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -112.17 104.23 12.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.208 -0.451 . . . . 72.31 110.882 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 4.9 p -136.6 163.18 33.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 75.34 111.156 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -106.71 90.68 5.31 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.63 0.729 . . . . 72.45 110.875 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.73 135.99 31.92 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.698 2.265 . . . . 71.4 112.316 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -103.67 124.94 49.77 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.254 -0.43 . . . . 73.43 110.936 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 26.4 mm -107.45 103.19 15.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.159 -0.473 . . . . 75.12 111.186 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 20.7 tp -91.47 110.55 21.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 74.32 110.88 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 20.5 p -110.35 123.58 50.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 75.22 110.864 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -141.4 132.65 26.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 75.13 110.944 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 179.02 -146.43 7.22 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.823 -0.703 . . . . 75.11 112.544 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -125.52 173.37 8.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.796 0.331 . . . . 72.34 111.168 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -147.53 171.1 16.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.425 . . . . 73.25 110.914 -179.77 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 12.6 m-85 -139.33 133.87 31.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.137 -0.483 . . . . 73.21 110.92 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 11.2 p -79.56 147.64 6.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 72.44 111.167 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -146.67 98.07 3.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.212 -0.449 . . . . 63.15 110.865 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 18.1 mtmt -65.91 173.34 3.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.095 -0.502 . . . . 74.4 110.809 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 11.1 mp -60.7 109.71 1.11 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 74.12 110.877 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -105.6 169.09 8.67 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.192 -0.458 . . . . 65.33 111.127 179.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -123.31 132.18 53.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.283 -0.417 . . . . 62.21 111.108 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -162.07 173.24 14.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 62.02 111.07 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 1.8 pt? -120.21 163.38 17.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 64.22 110.86 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.136 -0.484 . . . . 74.23 110.944 179.923 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.7 tpt . . . . . 0 C--O 1.23 0.044 0 CA-C-O 120.817 0.342 . . . . 73.33 110.904 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 11.4 t-20 -60.77 148.69 38.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.448 . . . . 75.32 110.885 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.9 tm-20 -139.71 107.84 5.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.154 -0.475 . . . . 73.43 110.879 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 8.2 p30 -53.52 147.24 11.29 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.102 -0.499 . . . . 65.44 110.946 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' TYR . . . . . 0.505 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER 175.67 -58.53 0.0 OUTLIER Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.698 0.761 . . . . 74.52 110.964 -179.884 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.505 ' HD2' ' N ' ' A' ' 5' ' ' TYR . 53.8 Cg_endo -69.71 161.24 46.67 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.712 2.275 . . . . 62.25 112.339 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.92 119.47 38.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.261 -0.427 . . . . 75.22 111.203 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 8.4 tptt -110.0 61.85 0.6 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.248 -0.433 . . . . 75.3 110.862 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 60.2 p -170.57 170.66 6.72 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.298 -0.41 . . . . 74.54 110.849 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.32 170.54 9.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.137 -0.483 . . . . 74.2 111.127 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -104.38 43.26 1.7 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.749 -0.739 . . . . 73.2 112.543 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 14.6 p90 -162.38 120.02 2.1 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.894 0.378 . . . . 73.54 110.877 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -166.03 -178.94 4.91 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.11 -0.495 . . . . 75.41 110.877 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -69.4 120.52 15.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.173 -0.467 . . . . 74.35 110.926 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 103.88 6.21 43.42 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.762 -0.732 . . . . 70.13 112.513 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -66.93 150.46 49.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.809 0.337 . . . . 73.23 110.815 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 4.5 m0 -111.96 142.05 44.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.152 -0.477 . . . . 74.11 110.939 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 43.2 t -145.04 118.95 2.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.263 -0.426 . . . . 73.11 111.041 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.4 119.96 25.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.098 -0.501 . . . . 64.22 111.031 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 22.0 t -106.65 128.6 54.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 72.4 110.807 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 19.2 t80 -138.19 114.55 10.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.095 -0.502 . . . . 74.41 110.829 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -153.5 174.05 14.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 74.42 110.906 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -102.45 129.01 48.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.455 . . . . 74.11 110.915 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.2 p -98.64 148.04 24.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.129 -0.487 . . . . 72.42 110.839 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 39.2 tptt -129.45 106.84 9.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 72.23 110.854 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.2 m -89.68 124.2 42.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.226 -0.443 . . . . 73.53 111.139 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 28.5 t80 -118.93 104.12 10.22 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.166 -0.47 . . . . 75.33 110.933 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.0 p -157.8 150.45 8.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 73.44 111.189 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 144.77 76.8 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.776 -0.726 . . . . 74.23 112.506 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -89.5 -65.63 1.0 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.758 0.313 . . . . 72.31 110.849 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -169.09 124.76 0.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.447 . . . . 72.11 110.902 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -89.2 152.78 21.41 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.164 -0.471 . . . . 73.21 110.86 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.45 -119.11 4.92 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.726 -0.75 . . . . 63.32 112.459 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -160.17 157.54 28.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.818 0.342 . . . . 72.51 110.893 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 30.5 tp -81.57 153.2 26.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.218 -0.447 . . . . 72.24 110.926 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 28.9 m120 -75.19 153.48 38.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.217 -0.447 . . . . 71.15 110.926 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 24.0 t -67.55 -41.83 86.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 73.34 111.127 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -179.98 -150.3 9.1 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.72 -0.753 . . . . 73.22 112.517 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.18 -156.56 43.68 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.756 -0.735 . . . . 73.32 112.425 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -52.13 148.27 11.23 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.682 -0.771 . . . . 64.33 112.477 -179.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -91.13 108.88 20.17 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.806 0.336 . . . . 75.44 111.134 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -120.89 159.25 49.74 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.563 0.697 . . . . 75.54 110.885 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.75 97.83 0.66 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.645 2.23 . . . . 75.54 112.373 179.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -52.36 171.5 0.05 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.465 . . . . 70.13 110.866 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -51.55 156.54 1.28 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.479 . . . . 74.12 111.042 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 17.8 t0 -146.18 126.57 14.02 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 64.33 110.866 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.1 p -105.36 140.56 23.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 73.3 111.135 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -158.8 157.85 32.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.45 . . . . 70.12 110.829 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 9.4 tt -132.4 144.04 38.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.102 -0.499 . . . . 74.45 111.084 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -108.19 97.23 1.1 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.782 -0.723 . . . . 72.01 112.517 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -136.7 119.09 15.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.802 0.334 . . . . 74.1 110.895 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 77.1 m-20 -100.81 -56.5 2.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.206 -0.452 . . . . 74.04 110.914 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 5.1 t -60.78 134.06 56.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.137 -0.483 . . . . 74.33 111.127 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.4 p -120.24 121.29 38.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 74.2 111.151 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -159.9 123.41 3.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.247 -0.433 . . . . 73.33 110.946 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 5.4 m -137.74 130.76 30.29 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 73.13 111.143 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -102.93 132.53 49.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 72.41 110.874 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -131.93 155.95 47.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.119 -0.491 . . . . 63.34 110.872 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 27.4 mm -126.05 115.16 41.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 75.33 111.153 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -99.9 126.05 45.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 73.14 111.11 179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -116.72 118.26 32.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.272 -0.422 . . . . 74.34 110.968 -179.857 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -88.42 101.0 13.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.145 -0.479 . . . . 63.52 110.856 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 9.0 p -98.01 -35.17 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.114 -0.494 . . . . 75.45 111.144 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 m -136.88 161.31 36.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.138 -0.483 . . . . 75.43 110.871 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.8 m -83.74 2.99 35.25 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.171 -0.468 . . . . 72.44 110.827 -179.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -120.16 -33.57 3.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.474 . . . . 74.43 110.831 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 2.5 pp -136.06 148.12 27.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.242 -0.435 . . . . 74.54 111.143 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -143.73 167.78 21.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.249 -0.432 . . . . 74.02 111.143 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.403 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 4.2 m -114.69 151.21 16.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 74.43 111.134 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -143.89 132.45 22.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.167 -0.469 . . . . 45.34 110.885 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -103.88 142.03 35.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 74.33 110.924 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -121.4 118.57 29.75 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.187 -0.46 . . . . 73.24 110.871 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 44.7 t -147.18 145.75 18.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 74.41 111.114 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -132.96 -30.23 0.49 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.754 -0.736 . . . . 63.15 112.514 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 11.0 m 36.6 62.76 2.97 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.623 0.725 . . . . 73.33 111.124 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 163.57 37.78 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.738 2.292 . . . . 72.1 112.306 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -79.64 -169.82 2.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 74.21 111.037 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.7 ttp180 -77.94 126.43 30.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.472 . . . . 72.42 110.912 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -135.77 151.93 50.61 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 75.33 111.089 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 26.3 ttpp -93.15 143.8 25.9 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 74.51 110.844 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 13.8 p90 -139.39 157.73 45.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 75.31 110.917 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.449 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 5.2 pt20 -106.85 157.2 17.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 75.3 110.93 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 178.4 71.05 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.73 -0.748 . . . . 44.42 112.498 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -168.36 -173.48 1.99 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.926 0.393 . . . . 74.33 110.913 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.33 -71.23 0.55 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 65.23 110.932 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 23.1 t -84.89 -30.35 24.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.255 -0.43 . . . . 63.41 110.835 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 4.7 mm -67.99 -34.26 65.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 74.52 111.13 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 4.0 t -63.02 -44.13 96.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.152 -0.476 . . . . 74.4 110.806 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 73.4 m -55.18 -41.6 72.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.134 -0.485 . . . . 72.3 110.85 -179.821 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -58.86 -49.85 76.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.112 -0.495 . . . . 73.4 110.911 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 116.2 -17.12 14.85 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.829 -0.7 . . . . 70.23 112.534 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 6.8 ttp180 -121.27 95.52 4.72 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.856 0.36 . . . . 74.32 110.864 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.449 ' HB ' ' HA ' ' A' ' 82' ' ' GLN . 93.0 t -104.45 -61.09 2.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.136 -0.483 . . . . 72.2 111.073 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.8 p -139.47 149.52 44.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.437 . . . . 74.01 110.921 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -127.74 129.58 47.32 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.146 -0.479 . . . . 70.42 110.906 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 6.1 p -173.43 163.27 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 75.51 111.126 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 -92.58 152.61 19.51 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.2 -0.454 . . . . 73.04 110.851 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -103.41 148.94 25.29 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.225 -0.443 . . . . 72.22 110.868 -179.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -139.07 62.23 0.56 Allowed Glycine 0 N--CA 1.453 -0.194 0 C-N-CA 120.751 -0.738 . . . . 65.41 112.547 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 118.43 5.68 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.65 2.233 . . . . 71.41 112.325 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -122.38 102.57 8.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.233 -0.44 . . . . 75.33 111.138 179.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 10.8 mm -117.85 147.73 21.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.243 -0.435 . . . . 61.34 111.152 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -151.49 122.46 7.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 73.5 110.924 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.6 p -147.17 173.63 12.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 72.51 110.867 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.403 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.8 OUTLIER -122.03 153.84 38.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.13 -0.486 . . . . 74.35 110.938 179.99 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 19.9 mm-40 -102.1 137.15 40.75 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.137 -0.483 . . . . 71.45 110.897 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -140.91 133.76 29.01 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.184 -0.462 . . . . 73.55 110.933 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 26.9 t60 -79.17 146.76 32.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 64.44 110.879 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 5.1 m-85 -77.92 140.63 39.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.262 -0.427 . . . . 75.22 110.878 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -100.07 53.12 0.9 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.068 -0.514 . . . . 70.34 110.78 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 87.7 p -137.92 -50.41 0.59 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.218 -0.447 . . . . 75.35 110.869 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -95.78 136.51 36.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.128 -0.487 . . . . 74.31 110.873 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 -96.92 -36.38 10.58 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.135 -0.484 . . . . 64.33 110.912 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 10.1 mpt_? -54.27 173.02 0.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 73.33 110.817 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -68.47 107.86 3.06 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.159 -0.473 . . . . 71.33 110.889 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -141.0 160.64 57.42 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.666 0.746 . . . . 74.44 110.9 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 177.52 5.47 Favored 'Trans proline' 0 N--CA 1.465 -0.197 0 C-N-CA 122.71 2.273 . . . . 75.33 112.362 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 14.0 m-85 -117.22 157.78 25.43 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.454 . . . . 72.52 110.932 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 12.5 p -107.24 132.01 55.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.084 -0.507 . . . . 75.1 111.118 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -121.5 161.23 15.65 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.769 -0.729 . . . . 70.23 112.519 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 12.3 p -161.1 150.16 5.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.8 0.333 . . . . 71.22 111.08 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -174.01 -155.37 11.89 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.68 -0.771 . . . . 71.02 112.489 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . 0.44 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 28.9 m -113.75 134.04 57.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.803 0.335 . . . . 74.15 111.168 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -117.27 105.91 1.35 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.734 -0.746 . . . . 64.2 112.531 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 28.5 ptt180 -99.45 112.44 24.64 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.901 0.381 . . . . 74.4 110.866 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 20.0 t -87.24 110.04 20.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.26 -0.427 . . . . 64.12 111.147 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -101.03 135.98 41.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 72.52 110.878 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -135.73 148.26 48.76 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.148 -0.478 . . . . 71.23 110.845 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -100.75 172.75 6.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.101 -0.5 . . . . 70.43 110.859 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -113.53 94.87 5.06 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.178 -0.464 . . . . 75.23 110.9 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 2.6 mmmt -92.62 -86.6 0.24 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.206 -0.452 . . . . 75.43 110.95 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -168.23 111.82 0.61 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.293 -0.412 . . . . 72.34 111.182 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . 0.505 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 49.8 m-20 -101.1 112.76 25.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.429 . . . . 75.34 110.829 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -74.91 -9.87 83.61 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.738 -0.744 . . . . 64.31 112.452 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -45.4 -28.89 0.95 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.721 0.296 . . . . 73.31 111.05 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.2 mt -160.28 179.67 8.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.264 -0.425 . . . . 73.41 110.89 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 9.9 m -53.32 92.36 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.172 -0.467 . . . . 73.22 110.848 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 6.9 m 51.38 73.6 0.3 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.092 -0.503 . . . . 72.41 110.868 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.505 ' HB3' ' HB2' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -94.32 158.55 15.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 74.4 110.892 -179.959 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -135.89 167.64 20.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.461 . . . . 75.21 110.822 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 12.3 tt -112.98 151.04 14.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.12 -0.491 . . . . 75.33 111.13 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 6.0 tppt? -119.51 112.06 18.89 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 73.31 110.896 179.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.41 -173.34 0.29 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.25 -0.432 . . . . 74.02 110.875 179.845 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -170.6 165.2 8.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 75.51 110.882 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 49.2 p90 -132.47 154.48 49.85 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 75.44 110.927 179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -178.5 164.28 1.13 Allowed Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.574 0.702 . . . . 74.31 111.11 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' PRO . . . . . 0.44 ' HA ' ' HA ' ' A' ' 123' ' ' VAL . 53.5 Cg_endo -69.71 169.49 18.73 Favored 'Trans proline' 0 N--CA 1.466 -0.144 0 C-N-CA 122.717 2.278 . . . . 72.24 112.376 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -165.37 153.54 11.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.246 -0.434 . . . . 74.11 111.086 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 6.7 p90 -122.03 139.11 54.1 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.218 -0.446 . . . . 75.42 110.857 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -130.75 174.52 9.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.125 -0.489 . . . . 75.41 110.988 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 10.8 p -158.91 147.12 7.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 64.32 111.093 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 170.97 -158.77 30.51 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.777 -0.725 . . . . 61.35 112.58 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.6 pt? -158.22 168.02 28.19 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.768 0.318 . . . . 75.24 110.928 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.6 tpp85 -117.93 120.64 38.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 74.2 110.954 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.8 t80 -115.37 169.64 8.99 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.245 -0.434 . . . . 74.42 110.949 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -121.86 99.66 6.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.147 -0.478 . . . . 71.35 110.924 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 5.9 tt -102.31 103.7 14.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 74.31 110.87 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 94.37 -160.71 23.84 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.792 -0.718 . . . . 65.41 112.51 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 6.3 p30 -118.7 -36.56 3.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.854 0.359 . . . . 65.25 110.928 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 3.7 p -66.39 -56.04 12.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.113 -0.494 . . . . 73.11 110.866 -179.877 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 12.3 p90 -124.91 172.69 9.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.179 -0.464 . . . . 74.53 110.951 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 5.5 ptp -121.84 177.47 5.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.269 -0.423 . . . . 71.14 110.903 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 8.7 tp -111.94 146.2 38.23 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.21 -0.45 . . . . 72.24 110.915 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -144.44 133.51 22.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 64.4 110.9 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 19.6 t -130.89 125.93 34.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.13 -0.487 . . . . 71.12 110.842 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 26.7 m-20 -150.33 142.16 23.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.093 -0.503 . . . . 72.53 110.87 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 40.6 t -139.59 122.62 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 70.42 111.148 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.49 159.99 14.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.236 -0.438 . . . . 74.3 110.804 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' TYR . . . . . 0.406 ' O ' ' HB ' ' A' ' 170' ' ' ILE . 26.3 t80 -164.56 140.99 6.12 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.159 -0.473 . . . . 73.45 110.919 -179.849 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' ILE . . . . . 0.427 HG12 ' O ' ' A' ' 147' ' ' PRO . 5.9 tp 177.86 133.15 0.22 Allowed Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.656 0.741 . . . . 74.54 111.109 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . 0.42 ' HD2' HG13 ' A' ' 170' ' ' ILE . 53.5 Cg_endo -69.69 104.37 1.3 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.716 2.277 . . . . 73.21 112.304 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -121.78 154.25 37.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.257 -0.429 . . . . 74.23 110.858 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 9.6 ptpp? -122.86 146.69 47.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 70.32 110.884 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 11.1 t -116.91 166.0 12.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.211 -0.45 . . . . 72.2 111.185 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -122.8 158.19 30.76 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.26 -0.427 . . . . 71.52 110.858 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 43.9 t -150.26 132.48 5.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 75.45 111.152 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 13.6 t -168.43 176.78 5.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.205 -0.452 . . . . 73.42 111.104 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 131.99 150.39 6.56 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.725 -0.75 . . . . 73.2 112.525 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 6.1 t -171.21 177.5 3.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.843 0.354 . . . . 74.04 111.161 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 5.7 tt -138.07 89.56 2.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 74.23 110.894 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 118.21 -81.23 0.32 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.725 -0.75 . . . . 61.2 112.505 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -170.13 0.37 Allowed 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.709 2.273 . . . . 71.5 112.351 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 30.7 m -82.86 124.32 77.07 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.59 0.71 . . . . 73.43 111.138 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 155.42 66.08 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.67 2.246 . . . . 73.12 112.344 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 68.0 t -103.61 111.44 33.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 75.35 111.098 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 3.9 p -84.57 135.02 34.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.094 -0.503 . . . . 64.14 110.893 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 40.4 p -145.48 167.75 22.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 63.22 111.097 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -158.99 157.31 31.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.451 . . . . 73.02 110.887 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 36.8 mm -146.66 125.6 4.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.193 -0.458 . . . . 74.5 111.13 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -102.31 114.6 28.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.18 -0.464 . . . . 75.01 110.864 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 2.5 t -136.53 164.32 31.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.126 -0.488 . . . . 73.34 111.1 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -107.23 87.59 3.27 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.651 0.739 . . . . 73.34 110.856 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.93 133.58 25.59 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.722 2.282 . . . . 74.33 112.249 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 23.4 m-85 -100.68 119.33 38.42 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.161 -0.472 . . . . 73.42 110.83 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 53.4 mt -105.57 110.18 30.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.124 -0.489 . . . . 73.55 111.156 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 2.6 tp -110.54 108.84 18.95 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.199 -0.455 . . . . 75.55 110.974 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -110.55 129.27 55.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.231 -0.441 . . . . 74.34 110.901 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 3.1 mp -150.51 134.45 16.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.115 -0.493 . . . . 75.34 110.937 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 178.94 -136.95 3.02 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.686 -0.768 . . . . 54.3 112.467 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -125.02 173.33 8.75 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.835 0.35 . . . . 74.14 111.041 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 29.5 m -149.09 171.0 17.13 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.16 -0.473 . . . . 65.11 110.841 -179.755 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 40.5 t80 -142.24 145.45 34.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.501 . . . . 75.41 110.86 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 33.6 m -93.28 156.83 3.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.04 -0.527 . . . . 72.52 111.108 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -159.72 110.8 1.98 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.127 -0.488 . . . . 75.54 110.911 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 37.1 mtmt -74.92 173.63 10.38 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 74.32 110.914 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -53.75 -52.16 61.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.27 -0.423 . . . . 73.21 110.931 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . 56.21 36.12 26.9 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 62.31 111.054 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -89.91 112.74 24.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.237 -0.438 . . . . 60.43 111.081 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -144.88 177.0 9.05 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 65.24 111.059 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 8.7 tt -78.15 107.07 10.47 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.234 -0.439 . . . . 75.41 110.913 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.175 -0.466 . . . . 75.52 110.952 179.892 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 34.5 tt0 . . . . . 0 N--CA 1.458 -0.061 0 CA-C-O 120.805 0.336 . . . . 71.23 110.918 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.66 5.48 36.24 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.754 -0.736 . . . . 64.54 112.549 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -68.79 150.27 48.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.772 0.32 . . . . 64.23 110.853 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.568 ' HE1' HG23 ' A' ' 59' ' ' ILE . 13.3 t90 -126.25 121.27 32.2 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.216 -0.447 . . . . 74.53 110.904 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.798 HG13 ' HB3' ' A' ' 60' ' ' ALA . 6.1 p -132.19 122.69 49.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.248 -0.433 . . . . 74.33 111.162 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -87.03 116.65 25.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 72.23 111.102 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -104.7 109.82 21.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 72.5 110.929 -179.815 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 15.0 p90 -107.69 119.88 40.68 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.186 -0.461 . . . . 72.45 110.879 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.41 ' HA ' ' HA3' ' A' ' 199' ' ' GLY . 2.5 p30 -149.6 161.53 41.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.134 -0.484 . . . . 62.11 110.858 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -86.49 128.47 34.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 72.05 110.879 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 18.1 p -102.11 116.26 32.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.162 -0.472 . . . . 74.22 110.895 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 16.3 mtpp -98.92 106.16 18.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.151 -0.477 . . . . 75.41 110.935 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.3 p -83.36 139.43 17.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 71.31 111.117 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 21.3 t80 -130.82 101.79 5.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.465 . . . . 72.01 110.922 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.1 p -162.26 155.02 2.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.096 -0.502 . . . . 75.41 111.099 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 119.63 72.17 0.36 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.683 -0.77 . . . . 71.24 112.476 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 -89.43 -57.97 2.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.768 0.318 . . . . 62.44 110.863 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -174.48 135.1 0.41 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.165 -0.471 . . . . 70.32 110.898 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.659 ' HB2' ' HB3' ' A' ' 45' ' ' ALA . 12.7 mt -52.0 165.64 0.2 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 72.53 110.917 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.713 -0.756 . . . . 73.53 112.485 179.913 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.659 ' HB3' ' HB2' ' A' ' 32' ' ' LEU . . . . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.789 0.328 . . . . 44.33 111.069 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -149.45 132.99 16.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 62.13 110.878 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.619 HG12 ' HA2' ' A' ' 83' ' ' GLY . 30.1 m -104.72 154.01 6.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 73.03 111.162 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 10.3 t -151.99 146.1 25.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 55.44 110.862 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.469 HD13 ' H ' ' A' ' 49' ' ' ILE . 0.2 OUTLIER -119.43 150.45 21.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.078 -0.51 . . . . 72.25 111.115 -180.0 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.77 135.2 14.73 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.742 -0.742 . . . . 73.42 112.487 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 60.5 m-20 -87.57 112.95 22.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.359 . . . . 72.52 110.892 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 33.5 t0 -154.38 165.86 35.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.165 -0.47 . . . . 74.35 110.887 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 34.4 p -64.69 148.03 51.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 75.02 111.129 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 8.4 t -158.84 139.92 12.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 64.51 111.13 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.451 HD12 ' CE1' ' A' ' 57' ' ' PHE . 0.2 OUTLIER -124.81 159.77 30.25 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 74.23 110.898 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 55.8 m -139.08 147.53 42.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.179 -0.464 . . . . 70.43 111.113 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.451 ' CE1' HD12 ' A' ' 55' ' ' LEU . 86.6 m-85 -124.18 132.62 53.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 74.13 110.881 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -134.23 149.3 50.96 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.129 -0.487 . . . . 63.21 110.872 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.568 HG23 ' HE1' ' A' ' 17' ' ' TRP . 10.4 mm -108.28 115.75 49.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.186 -0.461 . . . . 62.11 111.144 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.798 ' HB3' HG13 ' A' ' 18' ' ' VAL . . . -101.13 125.99 47.8 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.188 -0.46 . . . . 41.53 111.123 179.802 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.583 ' HB2' HG13 ' A' ' 69' ' ' VAL . 0.7 OUTLIER -108.89 117.79 35.12 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.222 -0.444 . . . . 74.13 110.919 -179.859 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -89.2 105.99 18.15 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.091 -0.504 . . . . 75.25 110.853 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.1 m -103.88 -34.25 3.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 60.41 111.129 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.7 t -135.87 160.12 39.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.224 -0.443 . . . . 75.31 110.884 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 5.7 p -84.56 2.99 38.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.147 -0.478 . . . . 62.52 110.828 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -111.6 -30.84 7.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 73.43 110.876 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 2.6 pp -147.3 165.61 6.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 62.2 111.106 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -154.36 172.84 17.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.472 . . . . 72.41 111.134 179.823 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.583 HG13 ' HB2' ' A' ' 61' ' ' TYR . 1.2 p -116.47 147.89 19.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.245 -0.434 . . . . 71.11 111.119 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -142.57 134.66 27.33 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.173 -0.467 . . . . 73.04 110.835 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -119.73 110.96 17.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.454 . . . . 71.23 110.867 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -85.05 131.18 34.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.481 . . . . 72.25 110.859 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 5.6 m -151.34 163.54 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 51.15 111.103 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -171.16 145.57 8.99 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.721 -0.752 . . . . 60.22 112.49 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.508 ' O ' HG22 ' A' ' 75' ' ' VAL . 7.6 p -117.07 67.44 4.34 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.596 0.712 . . . . 72.32 111.133 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 162.57 41.57 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.686 2.257 . . . . 63.1 112.351 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -84.81 -173.14 4.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 61.15 111.123 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -78.43 131.14 36.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.444 . . . . 73.41 110.866 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -126.26 151.74 47.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.468 . . . . 62.13 111.1 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 15.4 ttpt -114.72 126.32 54.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 75.34 110.892 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 15.7 p90 -126.42 158.84 34.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 72.21 110.89 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.408 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 29.6 mt-30 -92.61 157.66 16.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 74.34 110.92 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.619 ' HA2' HG12 ' A' ' 47' ' ' VAL . . . -176.05 68.76 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.735 -0.745 . . . . 72.23 112.458 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.517 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.6 tp10 -176.44 -176.59 0.77 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.915 0.388 . . . . 74.54 110.915 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -85.55 -69.41 0.66 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 63.13 110.932 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.4 t -83.31 -34.61 25.66 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.284 -0.416 . . . . 63.24 110.892 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.948 HG21 ' HB2' ' A' ' 135' ' ' ALA . 6.1 mm -64.62 -33.79 65.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.09 -0.504 . . . . 72.42 111.116 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 5.3 t -60.17 -46.79 88.5 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 74.41 110.87 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 22.8 t -56.18 -37.38 69.52 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.124 -0.489 . . . . 74.21 110.839 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.63 -48.64 79.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.112 -0.494 . . . . 70.22 110.904 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 111.73 -13.8 27.18 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.704 -0.76 . . . . 72.42 112.471 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 43.7 mtp180 -118.24 92.74 3.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.887 0.375 . . . . 71.53 110.856 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.893 HG22 HG22 ' A' ' 87' ' ' ILE . 90.1 t -113.93 -55.33 4.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 51.4 111.107 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.88 143.81 38.89 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.194 -0.457 . . . . 63.01 110.851 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 11.8 tt0 -147.52 117.87 7.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 71.13 110.891 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.418 HG12 ' H ' ' A' ' 131' ' ' LYS . 18.8 m -155.75 -176.83 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 73.44 111.14 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -97.29 152.08 19.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 73.42 110.896 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -92.57 135.26 34.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 71.14 110.936 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.56 ' HA3' HD12 ' A' ' 127' ' ' LEU . . . -128.3 63.29 0.62 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.71 -0.757 . . . . 63.41 112.441 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 112.38 3.06 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.709 2.272 . . . . 74.41 112.362 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.762 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -128.36 99.49 5.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 64.22 111.145 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.524 ' C ' HD23 ' A' ' 103' ' ' LEU . 4.9 mt -124.31 144.58 33.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 54.33 111.142 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.563 ' HG ' HG23 ' A' ' 123' ' ' VAL . 0.0 OUTLIER -147.31 109.73 4.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.177 -0.465 . . . . 55.34 110.878 179.968 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 3.6 p -144.5 160.39 41.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.221 -0.445 . . . . 71.01 110.832 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.454 ' O ' HD12 ' A' ' 105' ' ' LEU . 4.6 pp -106.19 150.21 26.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.125 -0.489 . . . . 64.1 110.962 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 7.9 pm0 -101.41 141.74 33.84 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.191 -0.459 . . . . 75.52 110.907 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 27.9 p90 -144.45 144.56 31.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 63.22 110.927 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 16.1 m80 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.097 -0.502 . . . . 74.42 110.872 179.962 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 8.7 p90 . . . . . 0 C--O 1.232 0.151 0 CA-C-O 121.642 0.734 . . . . 62.31 110.936 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 176.27 7.0 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.723 2.282 . . . . 73.33 112.354 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 12.7 p90 -115.97 159.47 21.56 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.207 -0.451 . . . . 73.54 110.925 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 60.2 t -123.4 135.33 63.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.126 -0.488 . . . . 72.14 111.107 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -124.08 176.86 16.85 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.72 -0.752 . . . . 72.21 112.491 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.8 p -166.03 152.48 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-O 120.817 0.342 . . . . 70.14 111.167 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 179.12 -153.14 11.9 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.722 -0.752 . . . . 54.44 112.444 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.563 HG23 ' HG ' ' A' ' 103' ' ' LEU . 13.5 m -106.91 120.45 58.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.826 0.346 . . . . 72.33 111.125 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -114.77 111.01 2.44 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.688 -0.768 . . . . 71.34 112.433 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' ARG . . . . . 0.762 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 8.1 ptp180 -109.31 131.87 54.66 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.805 0.336 . . . . 74.41 110.878 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.423 ' O ' HG13 ' A' ' 126' ' ' VAL . 3.5 p -117.53 115.92 50.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 63.22 111.107 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.56 HD12 ' HA3' ' A' ' 99' ' ' GLY . 2.6 pp -127.49 170.89 12.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.192 -0.458 . . . . 75.31 110.91 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -140.58 174.69 10.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 73.54 110.914 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -102.8 125.25 49.47 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.131 -0.486 . . . . 64.12 110.923 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -61.15 95.65 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.162 -0.472 . . . . 52.23 110.856 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.418 ' H ' HG12 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -115.1 -78.01 0.57 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.161 -0.472 . . . . 64.05 110.894 179.98 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 86.1 m -161.95 83.72 0.58 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 63.32 111.134 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' ASP . . . . . 0.411 ' OD2' HD12 ' A' ' 141' ' ' ILE . 22.8 m-20 -101.98 170.0 8.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.21 -0.45 . . . . 74.15 110.881 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.29 151.65 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.711 -0.757 . . . . 53.11 112.502 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.948 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -79.73 -0.03 32.53 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.827 0.346 . . . . 62.14 111.101 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -86.23 -178.08 6.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 63.23 110.942 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.7 m -65.73 91.64 0.14 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.186 -0.461 . . . . 62.31 110.894 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.2 t 51.87 75.41 0.21 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.108 -0.496 . . . . 63.42 110.872 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.667 ' CE1' HG12 ' A' ' 176' ' ' VAL . 1.1 t80 -88.92 149.04 23.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.1 -0.5 . . . . 71.21 110.838 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 14.0 t0 -109.96 164.7 12.35 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.127 -0.488 . . . . 72.35 110.902 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.411 HD12 ' OD2' ' A' ' 133' ' ' ASP . 63.8 mt -128.47 125.92 64.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 72.21 111.085 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 142' ' ' LYS . . . . . 0.466 ' O ' HG22 ' A' ' 174' ' ' THR . 0.1 OUTLIER -76.04 109.24 9.52 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.172 -0.467 . . . . 71.04 110.913 179.819 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.406 ' HB3' ' HA ' ' A' ' 127' ' ' LEU . 0.8 OUTLIER -58.68 -173.62 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.207 -0.451 . . . . 72.4 110.857 179.877 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 11.2 mmtm -148.55 166.02 29.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.456 . . . . 61.2 110.89 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 42.6 p-90 -157.75 136.32 11.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 74.33 110.921 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.751 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -172.49 166.02 3.52 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.578 0.704 . . . . 61.22 111.129 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 147' ' ' PRO . . . . . 0.751 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.5 Cg_endo -69.79 135.35 30.17 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.711 2.274 . . . . 62.42 112.318 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -122.48 165.62 16.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 64.33 111.129 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 23.7 m-85 -122.3 136.32 54.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.214 -0.448 . . . . 74.2 110.89 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 3.7 mm100 -107.16 151.8 24.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.159 -0.473 . . . . 71.23 110.921 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.429 ' O ' HG13 ' A' ' 151' ' ' VAL . 5.4 p -152.04 117.85 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.207 -0.451 . . . . 74.52 111.181 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' GLY . . . . . 0.43 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 176.93 -161.63 29.5 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.739 -0.743 . . . . 64.34 112.467 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.516 HD23 ' N ' ' A' ' 154' ' ' ARG . 0.6 OUTLIER -136.99 155.9 49.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.769 0.318 . . . . 73.21 110.918 -179.911 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.516 ' N ' HD23 ' A' ' 153' ' ' LEU . 0.4 OUTLIER -139.93 124.16 17.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 71.35 110.872 179.954 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 155' ' ' TYR . . . . . 0.458 ' OH ' HD13 ' A' ' 163' ' ' LEU . 26.3 p90 -144.42 177.45 8.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.461 . . . . 74.25 110.896 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -118.92 100.18 7.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.082 -0.508 . . . . 73.5 110.895 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 18.7 tp -102.03 106.24 17.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.142 -0.481 . . . . 73.0 110.956 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 103.34 -173.76 22.42 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.726 -0.749 . . . . 73.23 112.47 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 9.3 p-10 -101.53 132.26 47.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.861 0.363 . . . . 61.55 110.913 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.6 t 53.01 41.33 32.16 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.139 -0.482 . . . . 74.22 110.921 -179.79 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 2.3 t90 -171.97 100.49 0.17 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.096 -0.502 . . . . 64.54 110.92 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 162' ' ' MET . . . . . 0.545 ' CE ' HG21 ' A' ' 18' ' ' VAL . 13.6 mtm -95.42 173.85 7.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.258 -0.428 . . . . 72.24 110.914 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.458 HD13 ' OH ' ' A' ' 155' ' ' TYR . 2.1 tt -127.69 145.1 51.0 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.271 -0.422 . . . . 74.2 110.911 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 164' ' ' ASN . . . . . 0.452 ' N ' HD23 ' A' ' 163' ' ' LEU . 5.9 t-20 -145.8 138.07 25.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 74.32 110.919 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 13.0 p -153.26 121.75 6.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 64.42 110.89 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 166' ' ' ASP . . . . . 0.43 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 1.3 p30 -154.03 -179.79 8.2 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.166 -0.47 . . . . 63.43 110.856 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.895 HG22 HD12 ' A' ' 196' ' ' LEU . 8.2 t -138.48 143.79 31.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 64.33 111.113 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 168' ' ' ARG . . . . . 0.47 ' NH2' HG21 ' A' ' 170' ' ' ILE . 4.4 ttt180 -113.78 123.34 49.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.158 -0.474 . . . . 74.45 110.856 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 13.2 t80 -121.99 138.97 54.22 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.186 -0.461 . . . . 75.41 110.94 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 170' ' ' ILE . . . . . 0.548 HD11 ' HB3' ' A' ' 146' ' ' ALA . 6.4 tt -177.35 93.91 0.23 Allowed Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.631 0.729 . . . . 73.23 111.171 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.66 134.19 27.59 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.707 2.271 . . . . 63.43 112.379 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -156.89 177.84 11.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.252 -0.431 . . . . 74.51 110.878 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 173' ' ' LYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 190' ' ' GLU . 11.3 pttp -128.28 125.32 38.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.126 -0.488 . . . . 63.4 110.859 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 174' ' ' THR . . . . . 0.466 HG22 ' O ' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -91.94 161.74 14.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 75.55 111.146 179.961 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 175' ' ' ASP . . . . . 0.415 ' HB3' ' HB2' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -119.14 165.55 14.05 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.431 . . . . 61.11 110.874 179.943 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.667 HG12 ' CE1' ' A' ' 139' ' ' PHE . 21.4 t -146.53 133.13 13.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 64.23 111.171 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 14.0 t -166.53 176.9 6.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 75.2 111.104 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 122.18 141.33 6.0 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.752 -0.737 . . . . 63.22 112.495 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 C--N 1.329 -0.296 0 CA-C-O 120.834 0.35 . . . . 62.53 111.147 -179.841 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.231 0.159 0 CA-C-O 120.82 0.258 . . . . 65.42 112.325 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 85.3 t -109.41 107.69 23.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.274 -0.421 . . . . 60.35 111.115 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 6.7 p -83.69 110.57 18.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.151 -0.477 . . . . 75.05 110.882 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 11.9 p -121.93 171.5 8.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 73.1 111.15 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 29.9 ttpt -153.52 148.08 26.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.208 -0.451 . . . . 65.41 110.922 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 5.9 tp -142.74 124.06 11.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 63.4 111.098 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 190' ' ' GLU . . . . . 0.422 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 19.5 pt-20 -96.94 116.9 30.0 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 70.22 110.863 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 4.1 m -138.36 158.79 31.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 72.3 111.108 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.406 ' HA ' ' HD2' ' A' ' 193' ' ' PRO . 1.9 p30 -107.85 89.85 5.79 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.581 0.705 . . . . 73.24 110.875 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 193' ' ' PRO . . . . . 0.406 ' HD2' ' HA ' ' A' ' 192' ' ' ASP . 53.6 Cg_endo -69.79 138.46 37.78 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.721 2.281 . . . . 73.34 112.358 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 12.9 m-85 -124.68 116.66 22.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 72.45 110.865 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 195' ' ' ILE . . . . . 0.412 ' HB ' ' HB3' ' A' ' 168' ' ' ARG . 45.3 mt -106.44 131.28 56.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.199 -0.455 . . . . 64.41 111.109 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 196' ' ' LEU . . . . . 0.895 HD12 HG22 ' A' ' 167' ' ' VAL . 7.4 tp -117.74 112.33 20.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 74.31 110.889 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -97.87 124.59 42.35 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.145 -0.48 . . . . 72.21 110.855 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 198' ' ' LEU . . . . . 0.409 HD22 ' CD2' ' A' ' 196' ' ' LEU . 0.5 OUTLIER -144.64 119.59 9.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.133 -0.485 . . . . 53.41 110.906 -179.993 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 199' ' ' GLY . . . . . 0.41 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -177.91 -145.83 6.1 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.759 -0.734 . . . . 60.4 112.467 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 200' ' ' ALA . . . . . 0.504 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -127.19 173.8 9.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.803 0.335 . . . . 70.31 111.083 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -140.13 175.82 9.27 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 62.42 110.85 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 202' ' ' TYR . . . . . 0.709 ' C ' HG23 ' A' ' 18' ' ' VAL . 16.2 t80 -146.55 115.65 6.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.095 -0.502 . . . . 70.02 110.915 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.428 ' N ' HG23 ' A' ' 18' ' ' VAL . 15.0 p -77.12 147.66 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.103 -0.499 . . . . 71.01 111.159 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -152.9 143.14 22.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 72.03 110.867 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 12.9 ptmt . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.142 -0.481 . . . . 75.5 110.894 179.977 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 19.1 pt20 . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.87 0.367 . . . . 65.32 110.861 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.41 6.28 38.86 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.781 -0.723 . . . . 73.43 112.543 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -78.43 163.36 25.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.811 0.338 . . . . 72.21 110.878 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 3.7 p-90 -139.96 151.58 45.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.154 -0.475 . . . . 71.1 110.896 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.771 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 2.3 m -144.55 139.36 23.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.226 -0.443 . . . . 63.11 111.107 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.414 ' HB1' ' CZ ' ' A' ' 21' ' ' PHE . . . -99.14 101.78 13.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.124 -0.489 . . . . 63.25 111.146 179.794 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.6 m -97.53 121.46 39.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 73.31 110.829 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.414 ' CZ ' ' HB1' ' A' ' 19' ' ' ALA . 18.8 m-85 -118.64 118.29 31.26 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.134 -0.484 . . . . 74.32 110.888 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -148.01 172.84 13.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.102 -0.499 . . . . 75.11 110.845 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -100.64 124.27 46.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.132 -0.486 . . . . 74.31 110.897 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' SER . . . . . 0.506 ' HB2' HG21 ' A' ' 56' ' ' THR . 69.5 m -102.28 115.11 29.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.129 -0.487 . . . . 71.0 110.848 -179.732 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -98.84 113.78 26.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.18 -0.464 . . . . 63.4 110.915 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 32.4 t -92.49 146.62 6.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.242 -0.436 . . . . 73.42 111.124 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -135.21 110.52 9.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 72.22 110.937 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.3 p -166.51 150.34 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.136 -0.484 . . . . 75.23 111.193 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 136.27 76.13 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.721 -0.752 . . . . 71.24 112.474 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -89.51 -65.89 0.97 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.832 0.348 . . . . 73.05 110.836 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.501 ' HA ' HG12 ' A' ' 47' ' ' VAL . 14.3 mt-10 -162.87 146.89 11.34 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 72.13 110.878 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.613 HD12 HG13 ' A' ' 189' ' ' ILE . 2.0 tp -109.81 160.73 16.1 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.195 -0.457 . . . . 54.33 110.933 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.51 ' N ' HD11 ' A' ' 189' ' ' ILE . . . . . . . . 0 N--CA 1.452 -0.267 0 C-N-CA 120.742 -0.742 . . . . 73.22 112.501 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.564 ' HB1' ' HA ' ' A' ' 84' ' ' GLU . . . . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.822 0.344 . . . . 73.24 111.091 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -132.38 125.81 31.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 70.34 110.857 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 82' ' ' GLN . 11.3 p -111.7 137.81 42.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 63.22 111.131 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -147.4 142.05 26.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.084 -0.507 . . . . 43.23 110.895 -179.834 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 39.0 pt -115.72 156.62 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 73.24 111.076 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -84.94 179.02 51.13 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.711 -0.757 . . . . 62.45 112.506 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 79.0 m-20 -133.64 112.95 11.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.836 0.351 . . . . 63.14 110.918 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -145.42 140.58 27.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 75.02 110.831 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 29.8 p -55.68 128.49 35.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 60.22 111.095 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 5.7 t -137.12 150.35 47.93 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.197 -0.456 . . . . 65.12 111.107 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -113.49 152.46 30.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 65.31 110.885 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.506 HG21 ' HB2' ' A' ' 24' ' ' SER . 0.8 OUTLIER -136.51 137.29 40.16 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.188 -0.46 . . . . 52.12 111.153 179.921 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -103.12 132.14 49.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 71.34 110.891 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -130.96 130.2 43.1 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.123 -0.49 . . . . 74.42 110.856 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.98 115.2 48.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 65.02 111.081 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.771 ' HB3' ' CG2' ' A' ' 18' ' ' VAL . . . -101.94 125.61 48.66 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.188 -0.46 . . . . 63.14 111.123 179.78 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -107.03 117.11 33.21 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.235 -0.439 . . . . 75.04 110.887 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -83.76 95.74 8.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.054 -0.521 . . . . 65.5 110.919 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 9.5 p -92.17 -34.29 6.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 72.43 111.175 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 17.0 m -133.68 160.69 36.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.097 -0.501 . . . . 75.43 110.842 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.6 p -83.48 2.98 34.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.123 -0.489 . . . . 70.31 110.868 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -119.75 -32.27 4.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.13 -0.486 . . . . 75.04 110.93 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.437 HG22 ' CD1' ' A' ' 107' ' ' TYR . 40.5 pt -139.72 153.46 23.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 71.01 111.098 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -146.95 162.92 37.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 65.54 111.088 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.5 m -103.84 151.37 6.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.23 -0.441 . . . . 74.31 111.095 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -141.92 135.75 29.75 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.19 -0.459 . . . . 75.05 110.823 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.493 ' CE2' HD13 ' A' ' 103' ' ' LEU . 7.2 m-85 -122.2 108.18 13.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 71.13 110.88 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.832 ' HB2' HG23 ' A' ' 102' ' ' ILE . 18.1 m-85 -94.77 123.43 38.22 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.118 -0.492 . . . . 75.23 110.833 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.2 p -149.78 154.63 8.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.067 -0.515 . . . . 54.14 111.166 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -162.57 142.23 7.77 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.767 -0.73 . . . . 45.02 112.472 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.9 m -115.17 73.24 3.42 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.617 0.722 . . . . 64.42 111.115 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 161.27 46.56 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.651 2.234 . . . . 64.44 112.357 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -68.71 -169.88 0.19 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.248 -0.433 . . . . 74.42 111.077 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 1.2 tmm_? -78.88 140.67 38.07 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.434 . . . . 73.54 110.85 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -128.2 142.27 51.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.201 -0.454 . . . . 53.34 111.077 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 28.9 ttpt -108.11 135.74 48.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.265 -0.425 . . . . 73.35 110.924 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 6.9 p90 -141.97 157.98 44.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 75.42 110.916 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.516 ' O ' HG23 ' A' ' 47' ' ' VAL . 0.5 OUTLIER -96.42 160.78 14.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.151 -0.477 . . . . 72.14 110.896 -179.925 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.518 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -177.87 66.0 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.792 -0.718 . . . . 40.33 112.531 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.564 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.3 tp10 -173.84 -176.8 1.27 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.931 0.396 . . . . 44.31 110.869 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.88 -68.87 0.7 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 71.23 110.874 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 5.1 m -83.83 -34.55 24.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.208 -0.451 . . . . 74.31 110.897 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.752 HG22 HG22 ' A' ' 93' ' ' VAL . 5.8 mm -64.55 -33.78 65.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.142 -0.481 . . . . 74.51 111.109 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.3 t -63.05 -45.26 93.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.13 -0.486 . . . . 50.41 110.825 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 22.7 t -53.6 -41.72 66.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.124 -0.489 . . . . 72.52 110.88 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.405 HD22 ' HA ' ' A' ' 90' ' ' LEU . 0.3 OUTLIER -59.5 -44.19 93.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 73.41 110.917 179.989 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 110.21 -14.14 30.96 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.762 -0.732 . . . . 61.4 112.505 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 20.2 mtt180 -120.22 93.61 4.11 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.836 0.35 . . . . 75.22 110.813 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.752 HG22 HG22 ' A' ' 87' ' ' ILE . 13.1 t -113.56 -45.82 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 72.52 111.099 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 67.5 m -140.58 144.94 36.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.466 . . . . 72.45 110.834 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -142.01 119.56 11.7 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.103 -0.499 . . . . 53.34 110.909 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.471 HG23 ' HB2' ' A' ' 131' ' ' LYS . 7.2 p -175.04 157.92 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 72.33 111.151 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.424 ' N ' HG22 ' A' ' 96' ' ' VAL . 8.2 p-10 -81.17 173.53 12.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.182 -0.463 . . . . 54.34 110.858 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 11.6 m-85 -117.43 130.73 56.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.222 -0.445 . . . . 71.44 110.894 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -117.49 65.81 0.35 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.675 -0.774 . . . . 72.14 112.478 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.75 115.3 4.03 Favored 'Trans proline' 0 N--CA 1.465 -0.187 0 C-N-CA 122.708 2.272 . . . . 72.43 112.384 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.587 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -123.03 100.18 6.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.223 -0.444 . . . . 62.3 111.083 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.832 HG23 ' HB2' ' A' ' 72' ' ' PHE . 2.5 tp -122.06 119.83 59.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 74.52 111.137 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.493 HD13 ' CE2' ' A' ' 71' ' ' PHE . 0.2 OUTLIER -120.65 113.67 20.57 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.199 -0.455 . . . . 71.52 110.897 179.892 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 104' ' ' SER . . . . . 0.439 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 4.9 p -142.81 159.48 42.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 55.05 110.858 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.58 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.6 OUTLIER -103.94 149.63 24.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.101 -0.5 . . . . 54.12 110.925 -179.994 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 15.8 mm-40 -101.58 144.95 29.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.468 . . . . 74.53 110.895 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.437 ' CD1' HG22 ' A' ' 67' ' ' ILE . 6.8 t80 -139.94 128.94 23.53 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.185 -0.461 . . . . 62.24 110.933 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 28.1 p80 . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.07 -0.514 . . . . 72.53 110.835 179.946 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 1.4 p90 . . . . . 0 C--O 1.232 0.146 0 CA-C-O 121.68 0.752 . . . . 74.22 110.889 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 177.53 5.5 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.625 2.216 . . . . 62.34 112.315 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -110.97 144.36 40.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.187 -0.461 . . . . 74.11 110.875 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 8.0 p -101.16 130.67 50.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.053 -0.521 . . . . 74.54 111.114 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -129.71 165.33 22.26 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.747 -0.739 . . . . 72.53 112.46 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 13.7 p -161.54 149.7 4.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.881 0.372 . . . . 51.45 111.128 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' GLY . . . . . 0.439 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -174.41 -155.12 11.68 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.748 -0.739 . . . . 54.24 112.485 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.419 HG13 ' O ' ' A' ' 123' ' ' VAL . 7.5 p -109.2 124.83 66.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.878 0.37 . . . . 75.11 111.154 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -110.1 114.3 3.81 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.776 -0.726 . . . . 72.05 112.497 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' ARG . . . . . 0.587 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 25.5 ptt180 -115.9 124.56 50.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.823 0.344 . . . . 63.25 110.84 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.491 ' O ' HD23 ' A' ' 127' ' ' LEU . 26.1 t -104.68 116.34 48.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.274 -0.421 . . . . 52.15 111.151 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.491 HD23 ' O ' ' A' ' 126' ' ' VAL . 9.9 mt -130.76 171.24 13.34 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 75.32 110.86 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -160.25 169.53 23.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 54.12 110.895 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -102.93 118.78 37.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 62.5 110.883 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -48.93 108.07 0.17 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.056 -0.52 . . . . 50.44 110.877 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.471 ' HB2' HG23 ' A' ' 96' ' ' VAL . 3.6 mmmp? -111.52 -80.84 0.58 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.479 . . . . 74.32 110.875 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 21.9 m -161.52 81.0 0.59 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 64.42 111.135 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 39.2 m-20 -102.84 166.57 10.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.46 . . . . 44.4 110.899 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.64 155.26 0.11 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.705 -0.759 . . . . 61.55 112.503 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.744 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -81.24 3.67 23.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.8 0.333 . . . . 51.13 111.099 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -86.19 -175.33 5.48 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.455 . . . . 62.01 110.911 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 88.6 p -65.59 83.2 0.06 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 61.34 110.87 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 5.4 t 50.31 75.15 0.18 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 61.21 110.869 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -80.04 146.94 31.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 74.43 110.806 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 140' ' ' ASP . . . . . 0.432 ' O ' HG23 ' A' ' 176' ' ' VAL . 2.7 p30 -106.74 161.04 15.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.131 -0.486 . . . . 55.04 110.865 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 57.2 mt -115.73 143.86 24.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.171 -0.468 . . . . 74.2 111.12 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 3.4 mmtp -94.27 104.59 16.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 65.2 110.937 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.471 ' HB2' HD23 ' A' ' 127' ' ' LEU . 0.6 OUTLIER -58.21 -174.86 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.466 . . . . 73.42 110.866 179.897 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -162.28 164.87 27.32 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.233 -0.44 . . . . 75.1 110.906 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 22.6 p-90 -146.6 154.41 41.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.211 -0.45 . . . . 75.42 110.981 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.706 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.23 164.43 0.97 Allowed Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.579 0.704 . . . . 72.03 111.096 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 147' ' ' PRO . . . . . 0.706 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 54.0 Cg_endo -69.82 127.49 14.62 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.577 2.185 . . . . 53.13 112.364 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.616 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -120.52 167.94 11.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 73.43 111.132 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -123.04 142.13 51.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 74.42 110.872 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 15.5 tt0 -123.17 151.98 41.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.165 -0.471 . . . . 71.4 110.879 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.1 t -151.08 122.8 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 52.52 111.092 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 152' ' ' GLY . . . . . 0.41 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . -174.68 -174.75 41.64 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.73 -0.748 . . . . 53.33 112.461 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.4 HD23 ' N ' ' A' ' 153' ' ' LEU . 1.9 pt? -135.58 160.43 38.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.776 0.322 . . . . 75.1 110.988 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.3 tpp85 -122.06 118.54 29.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.241 -0.436 . . . . 64.23 110.873 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -101.35 127.97 47.73 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.204 -0.453 . . . . 73.03 110.897 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -116.73 102.12 9.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.157 -0.474 . . . . 75.2 110.898 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 7.3 tp -97.24 97.01 8.8 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.192 -0.458 . . . . 64.55 110.851 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 51.45 -159.18 2.3 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.608 -0.806 . . . . 70.24 112.516 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 23.2 m-20 -71.71 -29.44 64.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.83 0.348 . . . . 73.5 110.896 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 8.2 p -52.05 172.12 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.155 -0.475 . . . . 71.41 110.909 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 25.4 m0 -49.84 144.2 6.72 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.107 -0.497 . . . . 75.34 110.92 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 162' ' ' MET . . . . . 0.44 ' C ' HD12 ' A' ' 163' ' ' LEU . 2.6 mtt -98.91 173.78 6.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.243 -0.435 . . . . 64.4 110.944 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.44 HD12 ' C ' ' A' ' 162' ' ' MET . 8.9 mp -125.68 142.86 51.3 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.268 -0.423 . . . . 63.33 110.876 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -140.15 134.59 31.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 63.22 110.873 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 3.3 t -142.23 122.47 13.87 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.145 -0.479 . . . . 44.23 110.842 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 166' ' ' ASP . . . . . 0.41 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.4 OUTLIER -150.88 165.08 34.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 53.44 110.92 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.512 HG13 ' HG ' ' A' ' 196' ' ' LEU . 1.5 t -133.51 139.76 48.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.212 -0.449 . . . . 34.05 111.192 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 168' ' ' ARG . . . . . 0.808 ' HD3' HD13 ' A' ' 195' ' ' ILE . 21.9 ttt180 -111.31 131.38 55.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 72.23 110.87 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 169' ' ' TYR . . . . . 0.471 ' OH ' HG11 ' A' ' 167' ' ' VAL . 94.4 m-85 -134.31 137.0 43.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.23 -0.441 . . . . 73.34 110.924 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 170' ' ' ILE . . . . . 0.776 HD13 ' O ' ' A' ' 170' ' ' ILE . 0.0 OUTLIER -179.34 102.92 0.19 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.606 0.717 . . . . 50.42 111.144 179.898 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 139.22 39.71 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.691 2.261 . . . . 71.4 112.368 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 172' ' ' PHE . . . . . 0.688 ' CZ ' ' HB2' ' A' ' 146' ' ' ALA . 0.1 OUTLIER -165.9 177.26 7.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 75.12 110.816 -179.963 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 8.0 ptmt -128.52 150.61 50.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.053 -0.522 . . . . 71.3 110.873 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 15.3 t -119.43 161.21 20.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.143 -0.48 . . . . 74.15 111.141 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -116.1 172.62 7.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.269 -0.423 . . . . 72.21 110.877 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 140' ' ' ASP . 14.8 p -164.98 140.06 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 73.51 111.084 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.0 t -165.81 177.67 7.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.177 -0.465 . . . . 74.31 111.114 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -154.83 -139.13 2.73 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.696 -0.764 . . . . 72.33 112.499 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.33 -0.275 0 CA-C-O 120.811 0.338 . . . . 72.21 111.11 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo . . . . . 0 C--O 1.231 0.165 0 CA-C-O 120.799 0.25 . . . . 74.4 112.37 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.502 HG12 HG23 ' A' ' 187' ' ' THR . 85.6 t -96.73 108.35 21.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.248 -0.433 . . . . 70.41 111.146 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 62.0 p -98.12 106.52 18.82 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.188 -0.46 . . . . 63.2 110.889 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 187' ' ' THR . . . . . 0.502 HG23 HG12 ' A' ' 185' ' ' VAL . 22.2 p -115.74 167.62 10.77 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 72.44 111.122 -179.893 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 188' ' ' LYS . . . . . 0.483 ' O ' HD13 ' A' ' 189' ' ' ILE . 0.0 OUTLIER -155.29 159.26 39.86 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.203 -0.453 . . . . 63.43 110.976 179.898 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 189' ' ' ILE . . . . . 0.613 HG13 HD12 ' A' ' 32' ' ' LEU . 26.4 mm -142.76 137.67 27.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 71.2 111.07 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -104.78 114.94 29.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 50.02 110.862 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 191' ' ' VAL . . . . . 0.406 HG12 ' N ' ' A' ' 192' ' ' ASP . 2.6 t -137.33 163.09 32.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.148 -0.478 . . . . 71.43 111.177 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.416 ' HA ' ' HD2' ' A' ' 193' ' ' PRO . 0.5 OUTLIER -107.25 90.0 5.26 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.612 0.72 . . . . 72.22 110.883 179.919 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 193' ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' ' 192' ' ' ASP . 53.8 Cg_endo -69.78 138.04 36.8 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.693 2.262 . . . . 75.11 112.313 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 10.0 m-85 -120.32 119.67 33.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.195 -0.457 . . . . 72.11 110.897 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 195' ' ' ILE . . . . . 0.808 HD13 ' HD3' ' A' ' 168' ' ' ARG . 3.6 mp -112.99 132.45 61.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.464 . . . . 63.42 111.101 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 196' ' ' LEU . . . . . 0.512 ' HG ' HG13 ' A' ' 167' ' ' VAL . 1.4 tt -125.79 112.16 15.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.444 . . . . 61.0 110.895 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 2.6 p -100.39 127.58 46.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.21 -0.45 . . . . 71.43 110.855 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 198' ' ' LEU . . . . . 0.409 HD23 ' C ' ' A' ' 198' ' ' LEU . 10.5 tt -147.83 126.05 12.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.154 -0.475 . . . . 74.23 110.963 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -179.42 -142.53 5.02 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.719 -0.753 . . . . 62.12 112.47 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 200' ' ' ALA . . . . . 0.415 ' HA ' ' HA ' ' A' ' 163' ' ' LEU . . . -117.99 174.28 6.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.73 0.3 . . . . 32.22 111.098 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 63.7 p -156.37 163.33 39.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.262 -0.426 . . . . 70.33 110.806 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -136.14 130.05 32.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.047 -0.524 . . . . 70.34 110.925 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.409 HG13 ' SD ' ' A' ' 162' ' ' MET . 19.7 m -85.18 147.72 5.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.1 -0.5 . . . . 52.41 111.125 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -141.27 105.0 4.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.181 -0.463 . . . . 74.41 110.889 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 37.0 mttm . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.068 -0.515 . . . . 74.33 110.913 179.975 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 . . . . . 0 C--O 1.23 0.06 0 CA-C-O 120.893 0.378 . . . . 75.14 110.942 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 92.18 6.53 64.74 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.756 -0.735 . . . . 73.45 112.464 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -78.93 151.16 31.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.815 0.341 . . . . 74.31 110.883 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.583 ' CZ2' HG21 ' A' ' 59' ' ' ILE . 0.2 OUTLIER -125.36 139.42 53.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 64.1 110.908 -179.969 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.725 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 4.9 m -145.71 134.67 17.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 55.24 111.18 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -97.8 110.91 23.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 72.23 111.095 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.5 t -103.78 117.48 34.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 74.33 110.855 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 30.4 p90 -117.98 124.04 47.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 73.34 110.88 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.4 ' HB2' ' C ' ' A' ' 198' ' ' LEU . 4.1 p30 -149.7 171.88 15.98 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.128 -0.487 . . . . 74.32 110.883 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -94.8 122.32 37.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 65.5 110.931 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -93.82 113.53 25.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 34.34 110.845 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 36.7 mttt -93.66 106.97 18.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.197 -0.456 . . . . 72.15 110.877 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.512 HG22 HG23 ' A' ' 28' ' ' VAL . 12.3 p -87.26 130.95 36.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 44.33 111.158 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -121.42 102.69 8.43 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 73.4 110.911 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.512 HG23 HG22 ' A' ' 26' ' ' VAL . 7.9 t -140.16 155.34 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.061 -0.518 . . . . 75.04 111.079 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.487 ' HA2' HG13 ' A' ' 47' ' ' VAL . . . 130.73 62.16 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.762 -0.732 . . . . 61.3 112.467 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -89.87 -66.15 0.95 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.899 0.38 . . . . 72.1 110.969 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 179.18 130.05 0.08 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.088 -0.505 . . . . 71.32 110.849 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.739 HD22 ' HB3' ' A' ' 45' ' ' ALA . 1.8 tp -51.9 170.12 0.06 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.133 -0.485 . . . . 75.23 110.903 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.276 0 C-N-CA 120.712 -0.756 . . . . 71.3 112.473 179.917 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.739 ' HB3' HD22 ' A' ' 32' ' ' LEU . . . . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.758 0.313 . . . . 64.15 111.161 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ASP . . . . . 0.579 ' O ' HD13 ' A' ' 32' ' ' LEU . 0.4 OUTLIER -121.04 -170.36 2.0 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 74.31 110.807 179.949 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.487 HG13 ' HA2' ' A' ' 29' ' ' GLY . 10.4 p -166.08 135.6 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.157 -0.474 . . . . 71.41 111.167 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -175.05 171.53 3.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.469 . . . . 71.22 110.839 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 2.2 pp -102.43 158.22 4.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.09 -0.505 . . . . 73.13 111.106 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -88.72 -81.73 1.29 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.733 -0.746 . . . . 72.12 112.432 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.7 p30 -151.87 93.38 1.84 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.791 0.329 . . . . 72.42 110.867 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -115.49 65.52 0.69 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 71.11 110.851 179.883 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' THR . . . . . 0.441 ' O ' HG23 ' A' ' 54' ' ' THR . 0.7 OUTLIER -95.31 103.5 15.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.148 -0.478 . . . . 62.23 111.142 -179.887 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.441 HG23 ' O ' ' A' ' 53' ' ' THR . 2.2 p -156.75 163.31 39.4 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.251 -0.432 . . . . 60.42 111.142 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 11.8 mt -88.4 163.23 16.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 75.53 110.927 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -131.42 142.57 50.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 74.5 111.103 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -113.88 131.75 56.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.45 . . . . 52.02 110.864 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.414 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.2 OUTLIER -130.78 143.77 50.97 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.089 -0.505 . . . . 61.54 110.788 -179.938 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.583 HG21 ' CZ2' ' A' ' 17' ' ' TRP . 12.5 mm -108.09 117.68 54.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 73.44 111.12 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.725 ' HB3' ' CG2' ' A' ' 18' ' ' VAL . . . -100.44 132.72 45.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 53.2 111.097 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.452 ' HB3' HG22 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -114.85 116.84 29.22 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.205 -0.452 . . . . 72.44 110.936 -179.861 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -87.0 101.91 13.9 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 74.53 110.969 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 8.1 p -100.57 -34.57 4.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.121 -0.49 . . . . 65.1 111.084 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 20.3 t -132.46 158.78 41.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 63.42 110.894 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.4 m -84.18 2.82 37.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 74.55 110.771 -179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -112.33 -31.16 6.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 63.41 110.853 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.403 HG22 ' HA ' ' A' ' 107' ' ' TYR . 25.4 pt -148.78 162.24 5.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.24 -0.437 . . . . 73.15 111.148 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -149.57 170.24 19.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 74.12 111.116 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.452 HG22 ' HB3' ' A' ' 61' ' ' TYR . 10.6 m -112.3 153.57 13.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.203 -0.453 . . . . 74.44 111.203 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -146.15 132.12 19.2 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.191 -0.459 . . . . 73.51 110.841 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.414 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 12.0 t80 -115.01 108.82 17.19 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.253 -0.431 . . . . 71.12 110.889 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -86.19 128.49 34.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 64.35 110.945 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 2.7 p -145.32 144.43 21.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.128 -0.487 . . . . 71.11 111.119 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -159.38 133.76 3.48 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.793 -0.718 . . . . 51.32 112.496 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.476 ' O ' HG13 ' A' ' 75' ' ' VAL . 4.5 p -112.93 75.41 1.96 Allowed Pre-proline 0 C--N 1.33 -0.243 0 CA-C-O 121.659 0.742 . . . . 70.52 111.083 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 162.49 41.87 Favored 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.654 2.236 . . . . 63.04 112.416 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -76.29 -167.93 0.86 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.26 -0.427 . . . . 61.15 111.132 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 35.3 ttp180 -78.02 131.09 37.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.243 -0.435 . . . . 73.42 110.916 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -132.45 151.14 52.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 62.44 111.056 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 22.3 pttm -92.78 135.17 34.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 71.25 110.915 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -116.09 137.23 52.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 72.04 110.891 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 -95.92 151.78 19.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 72.51 110.916 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.608 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 174.77 73.6 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.812 -0.709 . . . . 54.34 112.511 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.532 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.3 mm-40 -170.47 -176.44 2.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.912 0.387 . . . . 74.12 110.846 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.19 -70.12 0.62 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 73.24 110.923 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.8 t -85.81 -30.62 22.84 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.212 -0.449 . . . . 74.13 110.788 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.569 HG22 HG22 ' A' ' 93' ' ' VAL . 4.4 mm -68.5 -34.66 66.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 65.55 111.156 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.4 t -61.38 -49.66 76.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.465 . . . . 75.24 110.871 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 22.3 t -51.73 -42.46 62.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 64.24 110.851 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.449 HD22 ' HG2' ' A' ' 92' ' ' ARG . 0.7 OUTLIER -57.66 -45.61 85.3 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.147 -0.479 . . . . 64.11 110.918 179.978 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 111.49 -14.82 27.48 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.772 -0.728 . . . . 63.51 112.547 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.449 ' HG2' HD22 ' A' ' 90' ' ' LEU . 9.6 ptt85 -120.46 95.77 4.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.84 0.353 . . . . 65.04 110.94 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.608 HG21 ' H ' ' A' ' 83' ' ' GLY . 21.9 t -110.5 -46.06 6.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 74.04 111.121 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.409 ' HA ' ' HA ' ' A' ' 133' ' ' ASP . 1.6 p -139.63 153.47 47.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.477 . . . . 74.2 110.834 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -135.69 121.96 20.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.142 -0.481 . . . . 72.22 110.896 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.623 HG21 ' O ' ' A' ' 129' ' ' PHE . 7.6 p -174.18 161.39 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.199 -0.455 . . . . 74.23 111.118 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.43 ' N ' HG22 ' A' ' 96' ' ' VAL . 3.3 p30 -80.13 172.72 13.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.188 -0.46 . . . . 75.14 110.873 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -125.31 130.83 52.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.446 . . . . 63.34 110.919 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -118.68 66.75 0.37 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.708 -0.758 . . . . 75.42 112.441 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 124.99 11.63 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.705 2.27 . . . . 73.24 112.319 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.602 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -138.68 106.05 5.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 75.33 111.1 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.658 ' C ' HD23 ' A' ' 103' ' ' LEU . 16.3 mm -118.56 150.48 20.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.25 -0.432 . . . . 74.03 111.105 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.658 HD23 ' C ' ' A' ' 102' ' ' ILE . 0.0 OUTLIER -149.15 109.75 4.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 71.52 110.916 179.869 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.0 p -144.37 171.56 14.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 75.0 110.891 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -120.42 153.06 37.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.465 . . . . 55.33 110.888 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 -106.25 139.03 41.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.156 -0.475 . . . . 55.31 110.902 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.403 ' HA ' HG22 ' A' ' 67' ' ' ILE . 30.7 p90 -143.16 148.3 36.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 73.04 110.884 -179.822 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 25.0 p-80 . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 73.33 110.876 179.933 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 4.1 p90 . . . . . 0 C--O 1.232 0.132 0 CA-C-O 121.625 0.726 . . . . 72.52 110.921 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 177.55 5.48 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.702 2.268 . . . . 65.2 112.345 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -117.35 157.6 25.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 75.03 110.96 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 72.7 t -106.99 128.38 61.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.063 -0.517 . . . . 73.11 111.109 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -119.27 172.88 14.81 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.714 -0.755 . . . . 72.33 112.53 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.3 p -175.56 153.13 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.848 0.356 . . . . 72.53 111.141 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 178.17 -148.65 8.64 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.823 -0.704 . . . . 60.03 112.511 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.652 HG13 ' HG ' ' A' ' 103' ' ' LEU . 4.9 p -110.39 137.71 41.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.882 0.372 . . . . 64.33 111.145 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' GLY . . . . . 0.424 ' HA3' HD12 ' A' ' 102' ' ' ILE . . . -127.36 105.87 0.78 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.712 -0.756 . . . . 70.52 112.408 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' ARG . . . . . 0.602 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 13.0 ptp180 -98.85 130.17 45.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.854 0.359 . . . . 75.44 110.891 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 3.2 m -106.99 109.65 28.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 71.0 111.172 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 1.4 tt -86.47 141.59 29.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 62.1 110.932 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -152.58 129.93 11.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 74.0 110.844 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.623 ' O ' HG21 ' A' ' 96' ' ' VAL . 0.8 OUTLIER -101.56 176.48 5.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.097 -0.501 . . . . 72.1 110.948 -179.973 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -109.19 95.19 5.47 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.218 -0.447 . . . . 73.21 110.85 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.426 ' HB2' HG23 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -89.16 -79.61 0.32 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 71.31 110.858 179.976 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.7 m -163.22 113.22 1.36 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.254 -0.43 . . . . 73.42 111.135 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' ASP . . . . . 0.43 ' HB3' ' CB ' ' A' ' 139' ' ' PHE . 10.0 t0 -106.27 117.1 33.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 73.13 110.901 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -78.25 -11.15 85.63 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.759 -0.734 . . . . 73.12 112.49 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.455 ' HB2' HG12 ' A' ' 93' ' ' VAL . . . -44.95 -30.31 0.99 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.781 0.324 . . . . 72.21 111.076 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 3.4 tp -160.79 -177.49 6.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.227 -0.442 . . . . 75.24 110.916 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 14.9 t -54.28 94.06 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 74.33 110.854 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 68.2 m 49.16 75.49 0.15 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.18 -0.464 . . . . 75.3 110.849 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.43 ' CB ' ' HB3' ' A' ' 133' ' ' ASP . 0.4 OUTLIER -101.58 162.28 13.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 65.43 110.864 -179.958 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -138.53 170.35 16.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.129 -0.487 . . . . 74.45 110.888 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.425 HG22 ' N ' ' A' ' 142' ' ' LYS . 1.9 mp -116.7 160.73 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 52.34 111.13 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' LYS . . . . . 0.425 ' N ' HG22 ' A' ' 141' ' ' ILE . 3.6 mtmt -122.19 122.36 39.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 74.31 110.899 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -74.31 -172.68 1.49 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.239 -0.437 . . . . 72.04 110.873 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 3.1 mmtm -171.36 -173.46 1.25 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 63.33 110.884 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 52.2 p-90 -154.62 153.23 31.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 72.14 110.955 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.757 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -176.44 165.41 1.65 Allowed Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.572 0.701 . . . . 72.44 111.116 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 147' ' ' PRO . . . . . 0.757 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.1 Cg_endo -69.77 167.06 25.54 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.635 2.224 . . . . 62.33 112.363 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -160.26 154.97 24.07 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.207 -0.451 . . . . 44.34 111.113 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 11.6 m-85 -104.7 129.32 52.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.234 -0.439 . . . . 71.02 110.872 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 6.2 mm-40 -104.72 156.73 17.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.13 -0.486 . . . . 74.15 110.946 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.3 p -155.79 128.91 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 70.55 111.144 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 166.97 -162.82 36.6 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.749 -0.738 . . . . 71.22 112.517 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.424 HD12 ' N ' ' A' ' 154' ' ' ARG . 3.3 pp -155.98 170.47 22.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.824 0.345 . . . . 70.24 110.897 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.424 ' N ' HD12 ' A' ' 153' ' ' LEU . 5.9 tpp85 -117.68 122.3 43.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 71.32 110.867 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -108.56 153.99 22.59 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.185 -0.461 . . . . 71.14 110.964 -179.874 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 35.7 t0 -121.53 99.26 6.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.482 . . . . 60.32 110.847 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 157' ' ' LEU . . . . . 0.448 HD12 HD12 ' A' ' 163' ' ' LEU . 13.2 mt -97.71 97.53 9.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.28 -0.418 . . . . 74.33 110.936 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 80.65 -147.26 27.91 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.8 -0.714 . . . . 74.12 112.519 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -123.23 -35.49 2.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.866 0.365 . . . . 62.53 110.92 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 1.7 m -51.77 -61.84 2.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 74.5 110.845 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 18.6 p90 -139.58 153.72 47.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.215 -0.448 . . . . 71.23 110.927 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 162' ' ' MET . . . . . 0.483 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 11.0 mtt -108.34 176.49 5.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 75.52 110.849 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.448 HD12 HD12 ' A' ' 157' ' ' LEU . 0.9 OUTLIER -116.51 146.31 42.69 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 53.34 110.83 -179.961 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -141.76 134.38 28.39 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.142 -0.481 . . . . 62.43 110.863 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 10.8 t -136.78 124.18 22.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 61.31 110.805 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -144.23 160.72 40.5 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.123 -0.489 . . . . 62.11 110.883 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 58.1 t -150.0 126.73 2.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 64.5 111.156 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 168' ' ' ARG . . . . . 0.564 ' HD2' HD12 ' A' ' 195' ' ' ILE . 0.4 OUTLIER -104.58 133.58 49.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.198 -0.456 . . . . 72.51 110.834 -179.986 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 19.6 t80 -136.74 132.07 34.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 64.53 110.914 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 170' ' ' ILE . . . . . 0.423 HG21 ' O ' ' A' ' 147' ' ' PRO . 5.0 tp 178.65 132.89 0.23 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.628 0.727 . . . . 61.44 111.144 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.78 112.77 3.17 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.649 2.233 . . . . 72.33 112.374 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 172' ' ' PHE . . . . . 0.418 ' HZ ' HG23 ' A' ' 174' ' ' THR . 0.1 OUTLIER -122.83 151.45 41.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.259 -0.428 . . . . 73.24 110.859 -179.953 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 20.1 pttt -123.85 134.56 53.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 71.21 110.881 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 174' ' ' THR . . . . . 0.426 HG22 ' H ' ' A' ' 175' ' ' ASP . 0.2 OUTLIER -101.2 171.21 7.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.228 -0.442 . . . . 64.14 111.133 179.985 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 175' ' ' ASP . . . . . 0.426 ' H ' HG22 ' A' ' 174' ' ' THR . 0.2 OUTLIER -123.51 161.2 25.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.197 -0.456 . . . . 71.22 110.911 179.869 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 3.4 t -151.07 143.05 16.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.173 -0.467 . . . . 62.11 111.107 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.4 t -166.98 -178.15 4.09 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.18 -0.464 . . . . 52.13 111.114 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -119.74 -158.38 10.58 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.763 -0.732 . . . . 71.1 112.56 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 6.6 t . . . . . 0 C--N 1.329 -0.313 0 CA-C-O 120.858 0.361 . . . . 71.33 111.152 -179.97 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo . . . . . 0 N--CA 1.466 -0.12 0 CA-C-O 120.853 0.272 . . . . 64.12 112.317 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 45.2 t -139.17 112.4 6.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.151 -0.477 . . . . 72.44 111.083 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.02 104.75 5.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.476 . . . . 54.4 110.849 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 29.4 p -124.14 174.04 7.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 65.12 111.123 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 5.2 ptmt -150.3 145.76 26.36 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.226 -0.443 . . . . 65.35 110.883 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 189' ' ' ILE . . . . . 0.546 HG21 HD12 ' A' ' 32' ' ' LEU . 6.3 pt -127.27 111.24 24.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.273 -0.421 . . . . 61.25 111.149 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -92.0 113.48 25.76 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.186 -0.461 . . . . 63.12 110.913 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 191' ' ' VAL . . . . . 0.445 HG21 ' CG1' ' A' ' 28' ' ' VAL . 12.1 m -136.77 167.31 24.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 72.13 111.096 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -107.25 88.54 3.98 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.553 0.692 . . . . 73.3 110.86 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 132.5 23.48 Favored 'Trans proline' 0 C--O 1.233 0.242 0 C-N-CA 122.685 2.257 . . . . 74.03 112.363 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -110.05 113.98 27.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.282 -0.417 . . . . 75.23 110.848 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 195' ' ' ILE . . . . . 0.564 HD12 ' HD2' ' A' ' 168' ' ' ARG . 71.5 mt -105.86 119.94 55.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.158 -0.474 . . . . 52.45 111.159 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 9.7 mp -116.03 108.66 16.5 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.195 -0.457 . . . . 62.12 110.92 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 53.9 p -99.21 114.04 26.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.244 -0.434 . . . . 71.33 110.862 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 198' ' ' LEU . . . . . 0.4 ' C ' ' HB2' ' A' ' 22' ' ' ASN . 0.4 OUTLIER -134.14 122.2 22.52 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.186 -0.461 . . . . 74.43 110.92 -179.978 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -175.63 -140.58 3.46 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.774 -0.727 . . . . 64.04 112.497 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 200' ' ' ALA . . . . . 0.483 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -126.65 174.24 8.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.826 0.346 . . . . 45.24 111.078 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 73.7 p -148.11 166.23 28.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.212 -0.449 . . . . 63.44 110.832 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -133.6 136.94 45.19 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.08 -0.509 . . . . 74.42 110.874 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.555 ' HA ' HG12 ' A' ' 18' ' ' VAL . 25.1 m -91.11 149.7 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.095 -0.502 . . . . 73.21 111.137 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -149.84 114.92 5.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 64.43 110.834 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 73.12 110.927 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.817 0.341 . . . . 64.12 110.903 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 99.36 6.08 55.46 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.801 -0.714 . . . . 75.12 112.511 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.455 ' OD2' HG13 ' A' ' 18' ' ' VAL . 0.7 OUTLIER -77.33 150.9 35.15 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.853 0.359 . . . . 72.31 110.835 -179.92 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 23.8 m-90 -117.75 138.37 52.08 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.21 -0.45 . . . . 70.35 110.923 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.629 HG23 ' HB3' ' A' ' 60' ' ' ALA . 11.5 m -141.56 134.7 29.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.25 -0.432 . . . . 73.41 111.108 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.56 ' HB1' ' CZ ' ' A' ' 21' ' ' PHE . . . -99.66 112.45 24.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.447 . . . . 73.03 111.085 179.846 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -99.21 109.37 22.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 71.23 110.81 -179.761 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.56 ' CZ ' ' HB1' ' A' ' 19' ' ' ALA . 12.7 m-85 -107.64 116.51 32.08 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 74.24 110.889 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.415 ' HB2' ' C ' ' A' ' 198' ' ' LEU . 1.7 p30 -154.12 172.66 17.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 53.32 110.967 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -103.57 134.96 46.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.249 -0.432 . . . . 72.15 110.835 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 2.8 m -105.0 107.88 19.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.144 -0.48 . . . . 73.52 110.851 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' LYS . . . . . 0.633 ' O ' HD12 ' A' ' 196' ' ' LEU . 31.8 tttp -87.71 109.37 19.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.11 -0.495 . . . . 74.54 110.844 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.7 p -92.65 130.93 41.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 75.44 111.168 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -119.42 100.59 7.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 74.54 110.932 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.43 HG23 ' CG1' ' A' ' 191' ' ' VAL . 7.4 p -149.34 145.31 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.093 -0.503 . . . . 73.52 111.114 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 148.84 67.32 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.735 -0.745 . . . . 72.24 112.518 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 8.3 tt0 -89.18 -65.84 0.98 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.832 0.349 . . . . 62.31 110.928 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -170.61 169.25 7.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.125 -0.488 . . . . 73.32 110.92 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.718 HD12 HG21 ' A' ' 189' ' ' ILE . 11.3 tp -84.59 161.55 20.12 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.167 -0.47 . . . . 65.42 110.905 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.35 0 C-N-CA 120.763 -0.732 . . . . 64.41 112.51 179.856 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.457 ' HB1' ' HA ' ' A' ' 84' ' ' GLU . . . . . . . . 0 C--O 1.232 0.171 0 CA-C-O 120.818 0.342 . . . . 75.43 111.084 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -137.61 134.7 35.84 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.29 -0.414 . . . . 55.33 110.872 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 73.6 t -104.94 142.61 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 44.54 111.149 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 m -155.19 152.9 29.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 73.32 110.882 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 38.3 pt -136.79 157.71 36.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.474 . . . . 73.5 111.138 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -88.78 -90.33 1.15 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.745 -0.741 . . . . 60.24 112.499 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 9.2 m120 57.57 57.27 4.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.795 0.331 . . . . 64.31 110.883 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.529 ' O ' HG23 ' A' ' 53' ' ' THR . 0.7 OUTLIER -55.61 -57.86 10.2 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 74.34 110.915 179.918 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 53' ' ' THR . . . . . 0.529 HG23 ' O ' ' A' ' 52' ' ' ASP . 0.7 OUTLIER -162.85 138.18 6.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 71.35 111.177 -179.953 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.524 HG23 ' O ' ' A' ' 53' ' ' THR . 0.7 OUTLIER -161.89 146.65 12.89 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.227 -0.442 . . . . 73.23 111.132 -179.942 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 88.9 mt -90.06 157.65 17.69 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.455 . . . . 74.5 110.828 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.36 144.32 33.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.13 -0.486 . . . . 74.34 111.129 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 15.4 m-85 -102.37 132.53 48.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 71.33 110.935 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.495 ' C ' HD13 ' A' ' 59' ' ' ILE . 3.6 m-20 -128.43 139.43 52.36 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.145 -0.48 . . . . 72.24 110.923 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.495 HD13 ' C ' ' A' ' 58' ' ' ASP . 3.4 mm -110.07 114.92 48.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.196 -0.457 . . . . 74.44 111.123 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.629 ' HB3' HG23 ' A' ' 18' ' ' VAL . . . -116.15 149.53 38.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.116 -0.493 . . . . 64.55 111.145 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.485 ' CE2' HG22 ' A' ' 59' ' ' ILE . 14.6 m-85 -129.33 137.59 51.08 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.289 -0.414 . . . . 73.34 110.946 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -98.33 102.28 13.98 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.158 -0.474 . . . . 73.03 110.867 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.7 m -99.35 -34.06 4.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.472 . . . . 75.04 111.088 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 58.4 m -135.51 158.77 43.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 74.04 110.917 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 3.9 t -83.99 3.39 34.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 74.52 110.861 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -114.06 -30.56 6.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.149 -0.478 . . . . 63.31 110.849 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -140.89 165.23 20.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 65.12 111.124 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -155.18 168.83 25.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.133 -0.485 . . . . 65.32 111.116 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.433 HG22 ' HB2' ' A' ' 61' ' ' TYR . 4.2 m -111.66 147.67 15.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 63.1 111.125 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -149.93 128.53 12.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.189 -0.46 . . . . 61.23 110.849 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -121.5 132.91 54.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 71.31 110.882 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.612 ' CD1' HD11 ' A' ' 102' ' ' ILE . 13.1 m-30 -95.02 134.85 37.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.131 -0.486 . . . . 62.32 110.926 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 63.3 t -144.41 136.81 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.107 -0.497 . . . . 64.51 111.086 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -155.29 140.55 7.43 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.743 -0.742 . . . . 63.15 112.439 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.8 t -124.38 66.87 45.5 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.621 0.724 . . . . 71.14 111.083 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 154.91 67.45 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.656 2.237 . . . . 73.3 112.374 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -68.14 -167.63 0.09 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 50.43 111.09 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 9.8 ttm180 -77.46 129.0 35.16 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.203 -0.453 . . . . 73.54 110.859 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ALA . . . . . 0.554 ' HB3' ' CZ ' ' A' ' 81' ' ' PHE . . . -120.72 142.41 49.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.449 . . . . 62.23 111.072 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 21.0 ttpp -91.64 134.99 34.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.165 -0.471 . . . . 72.12 110.9 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' PHE . . . . . 0.554 ' CZ ' ' HB3' ' A' ' 79' ' ' ALA . 22.1 m-85 -131.98 152.01 51.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.221 -0.445 . . . . 70.43 110.92 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -99.93 156.1 17.33 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 73.23 110.897 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.585 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 179.86 68.16 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.737 -0.744 . . . . 55.15 112.487 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.457 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.5 tp10 -170.53 -176.44 2.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.935 0.398 . . . . 74.41 110.94 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.81 -70.17 0.61 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 74.11 110.847 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.8 t -85.25 -31.24 23.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 73.12 110.828 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.616 HG22 HG22 ' A' ' 93' ' ' VAL . 4.8 mm -67.75 -33.59 62.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.198 -0.456 . . . . 73.11 111.146 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 10.0 t -63.66 -48.06 78.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 74.43 110.87 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 27.1 t -51.92 -42.48 62.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.147 -0.479 . . . . 72.31 110.87 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 82.6 mt -57.73 -48.38 79.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.115 -0.493 . . . . 61.41 110.884 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 115.32 -15.21 18.07 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.758 -0.734 . . . . 73.52 112.446 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 14.4 ttp180 -120.31 92.61 3.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.817 0.342 . . . . 63.41 110.885 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.616 HG22 HG22 ' A' ' 87' ' ' ILE . 25.3 t -108.15 -52.76 6.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.224 -0.444 . . . . 73.52 111.119 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 60.4 m -140.69 146.06 37.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 70.13 110.846 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -131.01 125.86 34.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 72.41 110.859 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.452 HG22 ' N ' ' A' ' 97' ' ' ASP . 13.2 p -174.42 156.79 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 63.03 111.167 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.452 ' N ' HG22 ' A' ' 96' ' ' VAL . 2.8 p-10 -86.39 173.43 9.68 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.187 -0.46 . . . . 70.34 110.83 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -133.48 126.07 30.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 64.31 110.929 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -113.5 72.36 0.23 Allowed Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.717 -0.754 . . . . 72.12 112.458 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 114.21 3.62 Favored 'Trans proline' 0 N--CA 1.465 -0.177 0 C-N-CA 122.754 2.303 . . . . 74.13 112.367 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -129.56 104.87 7.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.219 -0.446 . . . . 72.34 111.129 179.858 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.612 HD11 ' CD1' ' A' ' 72' ' ' PHE . 1.2 pp -127.89 151.3 34.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 64.43 111.123 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.439 ' HG ' HG13 ' A' ' 123' ' ' VAL . 0.2 OUTLIER -141.01 111.64 6.95 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.132 -0.485 . . . . 75.31 110.912 179.854 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 104' ' ' SER . . . . . 0.408 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 3.6 p -134.24 -174.15 3.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.23 -0.441 . . . . 75.22 110.837 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.421 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -134.97 147.98 49.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.091 -0.504 . . . . 45.54 110.931 179.994 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -104.31 134.82 46.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 75.12 110.97 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.518 ' CE1' HG13 ' A' ' 119' ' ' VAL . 12.9 p90 -144.71 159.03 43.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.228 -0.442 . . . . 64.22 110.925 -179.83 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 9.8 t60 . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.111 -0.495 . . . . 73.1 110.855 179.941 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 . . . . . 0 C--O 1.231 0.103 0 CA-C-O 121.701 0.762 . . . . 74.31 110.913 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.81 177.52 5.53 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.725 2.283 . . . . 65.51 112.338 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -116.69 154.54 30.41 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.204 -0.453 . . . . 74.13 110.946 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.518 HG13 ' CE1' ' A' ' 107' ' ' TYR . 5.4 p -102.57 127.38 56.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.122 -0.49 . . . . 73.25 111.109 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -119.87 167.67 13.56 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.728 -0.749 . . . . 53.23 112.534 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 7.3 p -171.38 154.45 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.826 0.346 . . . . 51.2 111.135 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' GLY . . . . . 0.408 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . 178.87 -147.02 7.57 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.695 -0.764 . . . . 50.33 112.452 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.462 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.7 p -112.6 132.43 61.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.852 0.358 . . . . 52.51 111.112 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' GLY . . . . . 0.515 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -123.3 109.6 1.37 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.761 -0.733 . . . . 53.54 112.463 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' ARG . . . . . 0.666 ' HE ' HD11 ' A' ' 127' ' ' LEU . 10.5 ptm180 -109.41 123.47 49.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.817 0.342 . . . . 55.13 110.892 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.456 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 2.5 p -107.35 119.35 56.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 73.34 111.152 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.666 HD11 ' HE ' ' A' ' 125' ' ' ARG . 2.7 mp -129.46 153.62 47.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.19 -0.459 . . . . 70.52 110.81 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 7.3 p90 -160.21 169.71 22.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.078 -0.51 . . . . 70.12 110.894 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.406 ' O ' HG23 ' A' ' 96' ' ' VAL . 45.1 m-85 -101.88 117.57 35.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 73.43 110.877 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -53.43 101.38 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.138 -0.483 . . . . 75.15 110.873 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.67 -82.97 0.09 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.234 -0.439 . . . . 61.41 110.865 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.8 m -173.42 128.22 0.43 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 62.21 111.195 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' ASP . . . . . 0.436 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 5.3 m-20 -114.37 115.3 27.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 73.21 110.878 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -80.82 -2.96 90.47 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.731 -0.747 . . . . 41.42 112.511 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.572 ' HB2' HG12 ' A' ' 93' ' ' VAL . . . -47.13 -29.73 2.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.824 0.345 . . . . 72.41 111.079 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.8 tp -158.93 -177.94 6.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 53.22 110.921 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -52.19 96.49 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.157 -0.474 . . . . 72.4 110.826 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 93.2 p 46.94 74.13 0.16 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 63.03 110.865 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.436 ' HB3' ' HB2' ' A' ' 133' ' ' ASP . 0.5 OUTLIER -95.76 158.85 15.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.127 -0.488 . . . . 71.14 110.905 -179.928 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -141.36 174.95 10.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 73.44 110.829 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.815 HG23 HG12 ' A' ' 176' ' ' VAL . 2.6 mt -131.41 152.68 37.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.155 -0.475 . . . . 64.54 111.118 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 142' ' ' LYS . . . . . 0.412 ' O ' HG22 ' A' ' 174' ' ' THR . 7.1 mmpt? -122.43 122.11 38.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 71.2 110.928 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.456 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 1.9 p-10 -72.08 -166.52 0.24 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 63.25 110.93 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -173.35 177.27 2.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.239 -0.437 . . . . 71.23 110.875 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 145' ' ' TRP . . . . . 0.404 ' O ' ' HB2' ' A' ' 146' ' ' ALA . 30.9 p90 -146.54 153.51 40.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 72.52 110.912 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.81 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 178.98 168.1 0.61 Allowed Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.618 0.723 . . . . 73.41 111.128 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 147' ' ' PRO . . . . . 0.81 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.7 Cg_endo -69.79 150.73 68.43 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.68 2.253 . . . . 74.21 112.387 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.541 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -148.11 167.31 25.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.217 -0.447 . . . . 51.12 111.087 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 -118.94 166.21 13.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.205 -0.452 . . . . 73.5 110.883 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 1.3 pt20 -157.9 162.48 38.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.167 -0.47 . . . . 73.22 110.973 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 94.1 t -150.61 124.81 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.222 -0.445 . . . . 75.23 111.113 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 152' ' ' GLY . . . . . 0.438 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . -171.46 -167.16 31.31 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.769 -0.729 . . . . 44.2 112.541 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.471 HD12 ' CD2' ' A' ' 155' ' ' TYR . 1.1 pt? -145.11 158.54 43.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.834 0.349 . . . . 63.22 110.925 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 3.7 tpp85 -125.33 121.86 35.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 62.14 110.806 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 155' ' ' TYR . . . . . 0.471 ' CD2' HD12 ' A' ' 153' ' ' LEU . 5.1 m-85 -128.52 173.16 10.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 73.01 110.873 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -121.74 106.83 11.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.1 -0.5 . . . . 65.24 110.883 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 157' ' ' LEU . . . . . 0.4 HD22 ' HA ' ' A' ' 157' ' ' LEU . 0.3 OUTLIER -102.94 97.41 7.54 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.194 -0.457 . . . . 74.03 110.948 -179.992 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 85.75 161.99 35.68 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.677 -0.773 . . . . 65.24 112.537 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -74.26 147.21 42.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.889 0.376 . . . . 72.31 110.889 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 14.2 m 51.9 36.45 18.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.198 -0.455 . . . . 74.22 110.861 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 2.9 t90 -172.69 112.08 0.24 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.153 -0.476 . . . . 71.32 110.933 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 5.3 mtt -110.47 172.74 6.69 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 75.52 110.905 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.4 ' HA ' ' HA ' ' A' ' 200' ' ' ALA . 41.9 mt -129.49 140.3 51.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.253 -0.43 . . . . 60.43 110.903 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -138.41 136.05 35.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 72.0 110.864 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 24.0 p -143.94 122.27 12.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 74.3 110.84 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 166' ' ' ASP . . . . . 0.438 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.6 OUTLIER -150.77 171.84 16.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.128 -0.487 . . . . 72.44 110.833 179.972 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.497 HG11 ' OH ' ' A' ' 169' ' ' TYR . 0.9 OUTLIER -141.89 120.12 8.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 73.45 111.101 -179.979 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 168' ' ' ARG . . . . . 0.561 ' HD3' HG22 ' A' ' 170' ' ' ILE . 1.9 tmm_? -93.55 135.65 34.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 63.41 110.845 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 169' ' ' TYR . . . . . 0.497 ' OH ' HG11 ' A' ' 167' ' ' VAL . 21.7 m-85 -134.28 136.27 43.43 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 74.45 110.873 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 170' ' ' ILE . . . . . 0.77 HD12 ' HD2' ' A' ' 171' ' ' PRO . 8.0 tp 178.66 118.89 0.2 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.685 0.755 . . . . 73.04 111.086 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 171' ' ' PRO . . . . . 0.77 ' HD2' HD12 ' A' ' 170' ' ' ILE . 53.7 Cg_endo -69.75 113.44 3.37 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.633 2.222 . . . . 61.31 112.359 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -117.11 177.34 4.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.216 -0.447 . . . . 74.24 110.846 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 6.8 ptmt -152.32 138.58 18.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.128 -0.487 . . . . 64.23 110.933 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 174' ' ' THR . . . . . 0.412 HG22 ' O ' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -102.95 155.1 18.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.258 -0.428 . . . . 75.1 111.15 179.963 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -116.19 102.11 9.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 71.04 110.868 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.815 HG12 HG23 ' A' ' 141' ' ' ILE . 20.3 m -96.89 146.35 7.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 71.04 111.139 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.6 t -166.7 163.29 16.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 70.13 111.132 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -123.35 162.3 17.3 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.798 -0.715 . . . . 61.12 112.488 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.328 -0.331 0 CA-C-O 120.811 0.339 . . . . 62.11 111.17 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo . . . . . 0 C--O 1.231 0.133 0 CA-C-O 120.794 0.248 . . . . 75.03 112.301 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 87.4 t -95.67 107.17 19.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 64.54 111.16 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 81.0 p -110.02 125.26 52.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 73.1 110.831 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 35.7 p -138.21 159.54 41.77 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.122 -0.49 . . . . 71.23 111.114 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 3.6 pttm -128.87 150.02 50.52 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 74.04 110.94 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 189' ' ' ILE . . . . . 0.718 HG21 HD12 ' A' ' 32' ' ' LEU . 6.3 pt -131.56 108.2 14.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 72.44 111.138 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -98.87 118.34 35.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 62.42 110.86 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 191' ' ' VAL . . . . . 0.435 HG12 ' H ' ' A' ' 192' ' ' ASP . 2.4 t -137.66 164.53 28.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 65.51 111.073 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.435 ' H ' HG12 ' A' ' 191' ' ' VAL . 0.2 OUTLIER -106.96 87.73 3.16 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.604 0.716 . . . . 75.24 110.871 179.929 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.64 131.71 21.99 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.704 2.269 . . . . 75.24 112.311 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -100.17 107.03 18.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 55.55 110.89 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 195' ' ' ILE . . . . . 0.531 HD13 ' NE ' ' A' ' 168' ' ' ARG . 3.9 mp -97.99 125.33 51.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.111 -0.495 . . . . 62.23 111.159 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 196' ' ' LEU . . . . . 0.633 HD12 ' O ' ' A' ' 25' ' ' LYS . 2.1 mp -119.31 108.12 14.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 61.12 110.977 179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.2 120.52 33.57 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 53.33 110.851 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 198' ' ' LEU . . . . . 0.415 ' C ' ' HB2' ' A' ' 22' ' ' ASN . 1.3 tt -144.74 127.41 16.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.116 -0.493 . . . . 65.14 110.823 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 176.18 -146.98 8.35 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.834 -0.698 . . . . 53.11 112.535 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 200' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' A' ' 163' ' ' LEU . . . -118.32 174.14 6.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.788 0.327 . . . . 75.34 111.106 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 8.9 p -151.76 171.77 17.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 63.24 110.884 -179.802 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -145.4 148.1 32.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.147 -0.479 . . . . 54.33 110.912 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.619 ' HA ' HG12 ' A' ' 18' ' ' VAL . 14.5 m -111.76 157.4 12.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.49 . . . . 73.01 111.206 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -173.76 155.25 2.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.211 -0.449 . . . . 74.34 110.912 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 18.2 pttp . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.152 -0.476 . . . . 74.34 110.835 -179.982 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.2 mt-30 . . . . . 0 C--O 1.23 0.051 0 CA-C-O 120.862 0.363 . . . . 70.24 110.887 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.61 6.47 46.9 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.731 -0.747 . . . . 63.35 112.521 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.16 150.4 40.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.793 0.33 . . . . 70.44 110.802 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 33.4 m0 -122.24 140.85 52.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.189 -0.459 . . . . 73.41 110.936 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.739 HG13 ' HB3' ' A' ' 60' ' ' ALA . 2.1 p -148.55 122.58 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.171 -0.468 . . . . 72.21 111.151 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -84.81 114.17 21.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 64.22 111.083 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.7 p -106.06 109.3 21.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.247 -0.433 . . . . 73.13 110.823 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -113.08 123.58 50.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 74.32 110.852 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.87 168.47 25.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 71.24 110.916 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -96.01 127.82 42.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 75.25 110.882 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.1 p -97.45 109.75 22.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.243 -0.435 . . . . 71.41 110.808 -179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 9.2 tmtt? -88.05 106.63 18.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.077 -0.51 . . . . 74.03 110.904 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.1 p -86.29 139.13 17.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.461 . . . . 63.53 111.107 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -135.27 102.46 5.17 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.207 -0.451 . . . . 63.5 110.977 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.548 ' O ' HD13 ' A' ' 49' ' ' ILE . 8.5 p -168.73 153.99 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.16 -0.473 . . . . 75.14 111.142 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 130.11 71.16 0.12 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.779 -0.724 . . . . 72.31 112.505 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -89.73 -66.07 0.96 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.83 0.347 . . . . 75.42 110.916 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -161.93 154.97 20.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 64.41 110.864 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 9.1 tp -69.74 167.46 17.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.086 -0.506 . . . . 73.52 110.896 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 72.33 112.487 179.894 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.067 0 CA-C-O 120.845 0.355 . . . . 74.11 111.058 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -147.36 140.31 25.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.485 . . . . 74.03 110.875 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 29.7 m -104.96 147.81 10.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.209 -0.45 . . . . 55.01 111.107 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.5 t -139.33 124.12 18.58 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.137 -0.483 . . . . 70.34 110.877 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.548 HD13 ' O ' ' A' ' 28' ' ' VAL . 5.3 mp -120.76 105.33 16.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.167 -0.469 . . . . 73.14 111.165 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -135.67 109.99 0.79 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.772 -0.727 . . . . 74.31 112.527 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -147.7 152.19 37.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.853 0.359 . . . . 63.34 110.893 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -52.32 148.93 6.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 63.05 110.817 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 43.9 p -76.55 109.41 10.28 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.172 -0.467 . . . . 74.55 111.135 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.8 p -94.61 176.54 6.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 64.24 111.203 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 1.5 pt? -108.71 155.52 20.63 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.202 -0.454 . . . . 61.04 110.921 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -126.02 141.78 51.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.215 -0.448 . . . . 74.4 111.124 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -103.39 131.88 50.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 74.04 110.944 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.465 ' C ' HD13 ' A' ' 59' ' ' ILE . 2.8 m-20 -131.87 144.39 50.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.129 -0.487 . . . . 63.04 110.914 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.465 HD13 ' C ' ' A' ' 58' ' ' ASP . 5.1 mm -115.2 114.2 45.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 54.04 111.118 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.739 ' HB3' HG13 ' A' ' 18' ' ' VAL . . . -102.87 129.95 49.73 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.15 -0.477 . . . . 72.14 111.06 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.456 ' HB2' HG22 ' A' ' 69' ' ' VAL . 22.7 m-85 -115.62 122.15 44.75 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 71.33 110.962 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -88.96 100.9 13.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 75.31 110.844 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.6 p -96.51 -33.17 4.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.122 -0.49 . . . . 70.01 111.132 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.6 m -132.01 159.17 39.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.15 -0.477 . . . . 71.04 110.828 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -84.03 3.18 35.6 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.105 -0.498 . . . . 62.54 110.788 -179.79 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -116.56 -31.49 5.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 71.34 110.878 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.432 HD12 ' CE1' ' A' ' 107' ' ' TYR . 33.8 pt -144.21 162.19 15.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 70.53 111.142 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -152.7 170.63 19.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 43.33 111.127 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.456 HG22 ' HB2' ' A' ' 61' ' ' TYR . 4.6 m -115.17 152.56 16.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 63.12 111.158 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.4 ' HA ' ' HA ' ' A' ' 60' ' ' ALA . 0.9 OUTLIER -149.96 128.92 12.58 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.185 -0.461 . . . . 74.0 110.82 179.976 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.405 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 6.7 m-85 -105.99 132.13 52.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.176 -0.466 . . . . 70.43 110.892 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -105.39 121.83 44.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.152 -0.476 . . . . 73.4 110.906 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.415 HG12 ' N ' ' A' ' 74' ' ' GLY . 5.9 t -145.73 159.24 12.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.129 -0.487 . . . . 73.11 111.08 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.415 ' N ' HG12 ' A' ' 73' ' ' VAL . . . -152.64 170.16 31.77 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.65 -0.786 . . . . 72.12 112.425 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.4 t -119.69 64.77 8.88 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.643 0.735 . . . . 74.42 111.148 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 163.36 38.58 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.642 2.228 . . . . 60.34 112.37 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -120.35 -166.96 1.38 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 62.03 111.139 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 33.8 ttp85 -76.86 120.65 22.29 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.266 -0.425 . . . . 61.11 110.821 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ALA . . . . . 0.483 ' HB3' ' HE1' ' A' ' 98' ' ' TYR . . . -124.26 150.92 44.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.216 -0.447 . . . . 75.11 111.121 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -101.92 139.66 37.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.188 -0.46 . . . . 73.41 110.864 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' PHE . . . . . 0.535 ' CE2' HG23 ' A' ' 49' ' ' ILE . 43.7 m-85 -140.87 158.28 44.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 74.35 110.906 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 30.2 mt-30 -99.03 156.83 16.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 71.14 110.889 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.568 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -179.67 71.56 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.803 -0.713 . . . . 63.45 112.525 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -178.37 -177.36 0.56 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.893 0.378 . . . . 61.53 110.864 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.02 -68.95 0.7 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 72.42 110.903 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.8 t -83.24 -35.11 25.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.126 -0.488 . . . . 54.44 110.854 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.916 HG21 ' HB2' ' A' ' 135' ' ' ALA . 6.9 mm -63.54 -33.78 63.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.09 -0.505 . . . . 75.34 111.135 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 55.2 p -62.4 -49.24 76.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.235 -0.438 . . . . 62.2 110.911 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.3 t -51.21 -40.26 58.36 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.143 -0.48 . . . . 64.32 110.811 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 13.4 mt -60.73 -46.33 90.81 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.143 -0.48 . . . . 73.23 110.949 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 112.41 -14.43 25.3 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.714 -0.755 . . . . 34.02 112.481 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 27.8 mtp180 -121.1 96.34 5.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.824 0.345 . . . . 71.44 110.862 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.892 HG22 HG22 ' A' ' 87' ' ' ILE . 39.6 t -113.8 -44.36 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.461 . . . . 45.04 111.138 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.5 p -142.62 147.75 36.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 71.14 110.874 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -149.39 118.83 6.89 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.172 -0.467 . . . . 54.42 110.843 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.648 HG23 ' HB2' ' A' ' 131' ' ' LYS . 2.9 p -177.76 166.25 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 73.35 111.155 179.908 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.477 ' H ' HG22 ' A' ' 96' ' ' VAL . 11.8 t70 -90.59 156.58 18.03 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.088 -0.505 . . . . 54.32 110.904 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' TYR . . . . . 0.483 ' HE1' ' HB3' ' A' ' 79' ' ' ALA . 0.1 OUTLIER -113.61 155.03 26.19 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.245 -0.434 . . . . 71.44 110.953 -179.838 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -122.41 70.11 0.42 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.736 -0.745 . . . . 63.13 112.463 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 112.77 3.17 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.738 2.292 . . . . 63.14 112.328 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.483 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -131.97 110.19 10.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.24 -0.437 . . . . 70.32 111.105 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 2.7 mt -129.51 150.01 34.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 74.25 111.103 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 1.2 pp -152.35 115.39 4.65 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.119 -0.491 . . . . 72.4 110.862 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' SER . . . . . 0.443 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 4.3 p -138.78 -176.47 4.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.234 -0.439 . . . . 55.3 110.857 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.562 HD12 ' CE1' ' A' ' 107' ' ' TYR . 0.1 OUTLIER -130.37 154.97 47.14 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.167 -0.469 . . . . 74.42 110.943 179.994 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 45.0 mt-30 -102.65 135.89 43.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 62.14 110.979 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.562 ' CE1' HD12 ' A' ' 105' ' ' LEU . 2.0 m-85 -120.54 118.76 31.05 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.263 -0.426 . . . . 70.44 110.868 -179.756 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 2.1 t60 . . . . . 0 C--N 1.331 -0.237 0 CA-C-N 116.126 -0.488 . . . . 71.22 110.869 179.913 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.7 t80 . . . . . 0 C--O 1.232 0.151 0 CA-C-O 121.63 0.729 . . . . 72.44 110.921 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 117' ' ' PRO . . . . . 0.742 ' HB3' HD12 ' A' ' 153' ' ' LEU . 53.6 Cg_endo -69.82 177.64 5.41 Favored 'Trans proline' 0 N--CA 1.465 -0.175 0 C-N-CA 122.713 2.275 . . . . 52.43 112.363 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -112.7 155.25 24.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.245 -0.434 . . . . 75.42 110.941 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.2 p -106.29 124.21 61.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.099 -0.501 . . . . 74.31 111.154 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -116.77 163.37 12.49 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.737 -0.744 . . . . 31.03 112.52 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.1 p -175.73 150.65 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.842 0.353 . . . . 55.34 111.141 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' GLY . . . . . 0.443 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -176.98 -150.39 8.31 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.757 -0.735 . . . . 63.44 112.508 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.536 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 12.7 p -108.34 130.48 60.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.85 0.357 . . . . 62.43 111.195 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -124.45 109.94 1.33 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.784 -0.722 . . . . 42.43 112.51 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' ARG . . . . . 0.483 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 13.8 ptm180 -104.97 131.81 52.01 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.837 0.351 . . . . 75.34 110.847 -179.802 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.413 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 3.6 p -116.49 119.18 61.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.217 -0.447 . . . . 73.15 111.08 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.7 mp -113.52 172.7 6.81 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.126 -0.488 . . . . 72.02 110.917 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.475 ' CD2' HG22 ' A' ' 141' ' ' ILE . 3.3 p90 -131.2 172.55 12.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.443 . . . . 72.03 110.899 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.647 ' HB3' HG22 ' A' ' 96' ' ' VAL . 1.5 t80 -111.71 174.69 5.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 62.34 110.918 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -112.68 112.09 23.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.12 -0.491 . . . . 72.13 110.865 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.648 ' HB2' HG23 ' A' ' 96' ' ' VAL . 63.5 mmtt -146.11 -85.8 0.11 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 72.3 110.887 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 7.4 m -163.11 96.22 0.88 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.254 -0.43 . . . . 74.14 111.133 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -112.29 165.83 11.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 70.13 110.884 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 64.22 153.49 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 74.14 112.471 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.916 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -82.9 1.8 37.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.838 0.351 . . . . 72.42 111.056 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.446 HD22 ' N ' ' A' ' 136' ' ' LEU . 2.9 mm? -87.04 -177.24 5.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.446 . . . . 74.13 110.882 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 6.1 m -64.76 88.1 0.06 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 73.34 110.848 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 9.6 m 53.62 75.28 0.27 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.46 . . . . 73.32 110.793 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -90.49 159.2 16.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.108 -0.496 . . . . 72.43 110.845 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -130.85 172.69 11.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.072 -0.513 . . . . 74.24 110.822 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.475 HG22 ' CD2' ' A' ' 128' ' ' PHE . 1.4 tt -117.41 171.61 5.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.128 -0.487 . . . . 52.14 111.136 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -119.59 103.98 9.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 73.43 110.896 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.413 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 0.6 OUTLIER -72.74 -171.55 0.86 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.28 -0.418 . . . . 74.33 110.89 179.867 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -172.44 179.28 2.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.221 -0.445 . . . . 60.25 110.929 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 28.7 p-90 -152.08 154.01 35.08 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.232 -0.44 . . . . 74.12 110.878 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.792 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.81 166.86 0.82 Allowed Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.594 0.711 . . . . 72.4 111.108 179.874 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 147' ' ' PRO . . . . . 0.792 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.9 Cg_endo -69.71 137.16 34.93 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.687 2.258 . . . . 73.24 112.388 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.566 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -126.91 160.51 30.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.272 -0.422 . . . . 73.53 111.092 179.832 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -103.54 163.94 11.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 75.04 110.917 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 44.4 tt0 -153.07 149.47 28.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.222 -0.445 . . . . 55.24 110.936 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.2 p -146.05 129.85 10.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 62.5 111.113 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' GLY . . . . . 0.436 ' C ' HD13 ' A' ' 153' ' ' LEU . . . 172.89 -167.58 40.44 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.718 -0.753 . . . . 44.2 112.528 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.742 HD12 ' HB3' ' A' ' 117' ' ' PRO . 0.0 OUTLIER -148.51 168.42 22.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.803 0.335 . . . . 62.01 110.911 -179.911 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 7.2 tpp85 -116.76 118.84 33.64 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 53.41 110.895 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -101.68 149.92 23.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.137 -0.483 . . . . 75.44 110.928 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -120.64 98.19 5.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.485 . . . . 74.45 110.923 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 25.0 tp -95.98 98.13 10.15 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 72.55 110.9 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 72.99 -146.38 38.0 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.675 -0.774 . . . . 52.24 112.458 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 35.3 t-20 -120.47 -33.43 3.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.807 0.336 . . . . 74.02 110.847 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 24.3 p -50.74 -65.5 0.55 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.479 . . . . 72.14 110.866 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 52.4 p-90 -141.02 146.18 36.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.144 -0.48 . . . . 72.35 110.938 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 162' ' ' MET . . . . . 0.508 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 10.8 mmt -101.67 178.69 4.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 60.2 110.898 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 9.2 mt -120.23 149.51 42.15 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.234 -0.439 . . . . 75.34 110.944 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -142.42 133.42 25.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 72.52 110.894 179.864 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.5 t -137.89 122.39 18.44 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.187 -0.46 . . . . 74.11 110.826 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 166' ' ' ASP . . . . . 0.435 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.5 OUTLIER -154.2 162.73 40.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.146 -0.479 . . . . 61.52 110.859 179.909 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.454 HG13 ' O ' ' A' ' 195' ' ' ILE . 42.1 t -146.0 125.34 5.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 65.14 111.148 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 168' ' ' ARG . . . . . 0.417 ' HD3' ' HB ' ' A' ' 195' ' ' ILE . 0.0 OUTLIER -100.92 155.73 17.79 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.259 -0.428 . . . . 72.14 110.871 -179.961 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 26.3 t80 -163.43 143.3 8.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 74.33 110.986 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 170' ' ' ILE . . . . . 0.566 HG21 ' HB2' ' A' ' 148' ' ' ALA . 3.1 tp -179.74 131.51 0.26 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 71.12 111.163 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 116.0 4.35 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.724 2.283 . . . . 72.43 112.272 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 172' ' ' PHE . . . . . 0.681 ' CZ ' ' HB3' ' A' ' 146' ' ' ALA . 2.1 m-85 -117.47 177.1 4.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 62.14 110.894 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.84 116.93 6.38 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 75.44 110.955 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.2 t -105.92 161.52 14.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.262 -0.426 . . . . 43.24 111.203 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -127.51 176.8 7.2 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.264 -0.425 . . . . 71.14 110.873 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.615 HG12 ' OG1' ' A' ' 187' ' ' THR . 2.4 p -145.5 141.94 22.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.192 -0.458 . . . . 61.43 111.131 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 2.0 t -166.24 160.17 15.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 74.34 111.139 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -159.3 -157.75 8.73 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.813 -0.708 . . . . 74.44 112.478 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 73.2 p . . . . . 0 C--N 1.329 -0.286 0 CA-C-O 120.774 0.321 . . . . 74.41 111.154 -179.815 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo . . . . . 0 N--CA 1.466 -0.134 0 CA-C-O 120.834 0.264 . . . . 72.21 112.338 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 62.8 t -95.57 105.84 17.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.242 -0.435 . . . . 43.54 111.139 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.72 109.06 20.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.16 -0.473 . . . . 74.22 110.854 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 187' ' ' THR . . . . . 0.615 ' OG1' HG12 ' A' ' 176' ' ' VAL . 0.7 OUTLIER -118.3 161.03 20.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 70.3 111.161 -179.976 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 21.9 pttt -136.84 157.28 47.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.435 . . . . 74.22 110.906 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 189' ' ' ILE . . . . . 0.423 ' O ' HG23 ' A' ' 189' ' ' ILE . 5.7 tp -154.79 120.7 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.228 -0.442 . . . . 75.41 111.132 179.795 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.38 116.05 31.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.144 -0.48 . . . . 64.21 110.893 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 7.6 p -136.18 155.37 34.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.145 -0.48 . . . . 74.43 111.097 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.04 88.69 3.88 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.683 0.754 . . . . 72.41 110.831 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.87 142.56 47.79 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.659 2.24 . . . . 52.25 112.297 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 5.1 t80 -112.65 123.15 49.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.14 -0.482 . . . . 70.1 110.895 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 195' ' ' ILE . . . . . 0.454 ' O ' HG13 ' A' ' 167' ' ' VAL . 56.7 mt -116.37 125.02 73.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.168 -0.469 . . . . 73.42 111.1 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 196' ' ' LEU . . . . . 0.524 ' O ' HD23 ' A' ' 196' ' ' LEU . 7.5 tt -116.39 109.88 17.92 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.122 -0.49 . . . . 71.22 110.982 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.96 119.23 35.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.202 -0.454 . . . . 71.45 110.856 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 55.1 tp -140.07 126.8 20.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.113 -0.494 . . . . 71.51 110.9 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -177.32 -141.27 3.99 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.74 -0.743 . . . . 60.22 112.466 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 200' ' ' ALA . . . . . 0.508 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -129.37 173.42 10.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.781 0.324 . . . . 54.34 111.113 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 99.4 p -146.58 170.26 17.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 53.42 110.803 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 202' ' ' TYR . . . . . 0.467 ' C ' HG23 ' A' ' 18' ' ' VAL . 68.6 t80 -139.69 113.01 8.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.099 -0.501 . . . . 74.23 110.938 -179.86 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 12.6 t -77.33 154.24 5.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.043 -0.526 . . . . 73.52 111.123 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 77.6 t80 -160.32 122.21 3.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.166 -0.47 . . . . 63.14 110.888 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 6.6 ptpp? . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 71.33 110.915 179.984 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.4 pt20 . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.776 0.322 . . . . 71.53 110.913 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.97 5.78 52.94 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.761 -0.733 . . . . 54.0 112.534 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -72.53 150.95 42.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.816 0.341 . . . . 73.13 110.848 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.547 ' HE1' HG23 ' A' ' 59' ' ' ILE . 25.1 t90 -116.32 143.96 44.86 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.206 -0.452 . . . . 70.5 111.001 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.9 t -145.57 123.27 4.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.265 -0.425 . . . . 63.1 111.058 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -82.61 109.19 16.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 74.32 111.108 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -95.07 127.75 41.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.155 -0.475 . . . . 71.15 110.851 -179.772 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 64.4 t80 -138.63 116.18 11.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.102 -0.499 . . . . 73.11 110.945 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -152.62 173.42 15.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.46 . . . . 72.35 110.917 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 14.6 m-85 -102.38 128.41 48.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 73.01 110.856 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' SER . . . . . 0.506 ' HB3' HG21 ' A' ' 56' ' ' THR . 24.6 p -96.72 136.66 36.94 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.194 -0.457 . . . . 45.13 110.857 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.79 106.73 12.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.133 -0.485 . . . . 74.44 110.927 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.811 HG12 HD12 ' A' ' 195' ' ' ILE . 27.5 m -78.55 126.68 38.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.435 . . . . 70.41 111.101 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -119.19 106.16 12.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.134 -0.485 . . . . 64.54 110.954 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.9 p -174.07 152.73 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 72.22 111.154 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.72 72.35 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.726 -0.749 . . . . 75.53 112.488 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -89.53 -66.11 0.95 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.813 0.339 . . . . 52.41 110.85 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -171.55 149.07 2.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.127 -0.488 . . . . 72.25 110.882 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.521 HD13 ' HA3' ' A' ' 83' ' ' GLY . 7.2 tt -103.15 143.67 32.31 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.123 -0.489 . . . . 74.11 110.971 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.601 ' H ' HD11 ' A' ' 189' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.348 0 C-N-CA 120.767 -0.73 . . . . 61.41 112.463 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.518 ' HB1' ' CA ' ' A' ' 84' ' ' GLU . . . . . . . . 0 N--CA 1.458 -0.053 0 CA-C-O 120.778 0.323 . . . . 62.42 111.093 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -143.18 128.44 18.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 71.31 110.874 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 14.4 p -104.77 146.59 11.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 44.11 111.21 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 15.1 t -156.92 137.24 12.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 61.41 110.816 -179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 18.5 tt -112.05 144.69 19.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.133 -0.485 . . . . 74.34 111.115 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -117.45 129.45 8.33 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.699 -0.763 . . . . 71.14 112.505 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.1 t-20 -150.82 128.21 11.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.824 0.345 . . . . 61.13 110.812 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.408 ' O ' ' C ' ' A' ' 53' ' ' THR . 12.8 p-10 -153.79 163.49 39.93 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.107 -0.497 . . . . 72.41 110.897 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' THR . . . . . 0.408 ' C ' ' O ' ' A' ' 52' ' ' ASP . 10.0 t 37.45 43.56 0.42 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 71.22 111.143 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.607 ' C ' HD13 ' A' ' 55' ' ' LEU . 0.2 OUTLIER -109.97 170.5 8.04 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.158 -0.474 . . . . 51.02 111.163 -179.998 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.607 HD13 ' C ' ' A' ' 54' ' ' THR . 0.0 OUTLIER -156.06 166.15 34.31 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.26 -0.427 . . . . 75.43 110.915 179.987 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.506 HG21 ' HB3' ' A' ' 24' ' ' SER . 43.8 p -140.39 144.66 36.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.198 -0.455 . . . . 60.22 111.144 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -118.94 132.41 56.08 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.434 . . . . 74.53 110.86 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.41 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -131.87 150.51 52.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 74.21 110.832 -179.969 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.547 HG23 ' HE1' ' A' ' 17' ' ' TRP . 20.0 mm -110.47 114.41 46.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.236 -0.438 . . . . 44.21 111.123 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.438 ' HB2' ' OD2' ' A' ' 70' ' ' ASP . . . -103.36 123.73 47.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.176 -0.465 . . . . 32.45 111.124 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.411 ' O ' ' HB1' ' A' ' 68' ' ' ALA . 0.5 OUTLIER -112.97 119.51 38.18 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 73.14 110.883 -179.81 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -80.1 113.73 18.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.084 -0.507 . . . . 65.32 110.863 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 83.3 t -111.27 -32.69 2.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 70.13 111.222 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -124.09 -172.53 2.56 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.104 -0.498 . . . . 75.3 110.85 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 5.0 p -85.82 -36.25 20.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.121 -0.49 . . . . 71.12 110.832 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -126.31 19.36 7.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 53.24 110.932 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 24.8 mt -148.97 135.77 13.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.111 -0.495 . . . . 75.35 111.122 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.411 ' HB1' ' O ' ' A' ' 61' ' ' TYR . . . -153.32 170.13 21.39 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.172 -0.467 . . . . 71.31 111.076 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.3 m -106.34 151.32 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.265 -0.425 . . . . 55.35 111.083 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.438 ' OD2' ' HB2' ' A' ' 60' ' ' ALA . 0.8 OUTLIER -143.03 138.32 29.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.129 -0.487 . . . . 61.21 110.839 179.883 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.41 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 12.0 m-85 -121.59 109.32 14.64 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 73.13 110.92 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.55 ' CD2' HD13 ' A' ' 102' ' ' ILE . 1.3 t80 -83.83 121.44 27.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.154 -0.475 . . . . 74.05 110.867 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 24.8 t -135.89 146.59 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 75.42 111.1 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -162.31 124.35 1.29 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.678 -0.772 . . . . 62.3 112.497 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 43.7 t -114.91 70.18 2.39 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.638 0.733 . . . . 60.34 111.132 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 162.79 40.72 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 75.24 112.331 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -76.32 -170.52 1.49 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.213 -0.449 . . . . 73.55 111.13 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 19.8 ttp180 -77.48 137.2 38.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 72.4 110.916 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -134.28 150.93 51.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.226 -0.443 . . . . 53.53 111.068 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -100.51 138.31 37.73 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 73.43 110.898 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -128.09 155.31 44.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 72.22 110.894 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.464 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 1.1 pt20 -110.26 153.26 25.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 62.12 110.995 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.612 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 179.93 75.22 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.758 -0.734 . . . . 42.52 112.52 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.518 ' CA ' ' HB1' ' A' ' 45' ' ' ALA . 1.0 OUTLIER -177.25 -176.89 0.68 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.906 0.384 . . . . 71.55 110.86 -179.898 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 3.6 mtpm? -85.67 -69.66 0.65 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 74.04 110.868 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.5 t -84.31 -33.41 23.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 72.05 110.928 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.885 HG22 HG22 ' A' ' 93' ' ' VAL . 6.1 mm -64.62 -34.33 69.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.124 -0.489 . . . . 74.11 111.113 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 78.6 p -63.7 -50.48 69.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.144 -0.48 . . . . 72.43 110.856 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 44.6 t -51.45 -38.06 51.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.146 -0.479 . . . . 62.21 110.863 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 9.3 tp -64.83 -42.66 94.79 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.172 -0.467 . . . . 63.1 110.931 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 106.14 -14.57 44.1 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.755 -0.736 . . . . 74.23 112.491 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 24.3 ttp180 -114.37 94.33 4.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.834 0.349 . . . . 73.12 110.922 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.885 HG22 HG22 ' A' ' 87' ' ' ILE . 85.5 t -112.86 -51.83 5.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 44.13 111.106 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 10.9 p -139.12 143.52 38.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.158 -0.474 . . . . 73.12 110.829 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -130.92 118.22 20.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.136 -0.484 . . . . 64.03 110.917 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.533 HG21 ' CD2' ' A' ' 128' ' ' PHE . 9.8 p -176.08 161.26 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.181 -0.463 . . . . 61.15 111.113 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.435 ' N ' HG22 ' A' ' 96' ' ' VAL . 2.0 p30 -91.07 174.12 7.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 63.33 110.849 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -119.91 134.53 55.21 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.165 -0.471 . . . . 62.33 110.947 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -121.76 66.61 0.46 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.719 -0.753 . . . . 64.22 112.509 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 117.43 5.08 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.617 2.211 . . . . 74.02 112.321 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -132.37 104.24 6.62 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.157 -0.474 . . . . 71.45 111.087 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.602 HG23 ' CA ' ' A' ' 124' ' ' GLY . 5.0 mp -130.03 150.57 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 73.31 111.094 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -143.75 115.39 8.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 72.42 110.899 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.1 p -142.87 159.65 41.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.232 -0.44 . . . . 45.34 110.887 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.622 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.8 OUTLIER -108.12 146.58 32.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.141 -0.481 . . . . 55.54 110.893 -179.963 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -100.97 137.99 38.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 71.04 110.872 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 28.6 p90 -141.63 156.19 45.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.204 -0.453 . . . . 72.53 110.916 -179.84 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 20.0 m-70 . . . . . 0 C--N 1.33 -0.26 0 CA-C-N 116.115 -0.493 . . . . 71.33 110.835 179.92 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 21.6 p90 . . . . . 0 C--O 1.232 0.161 0 CA-C-O 121.672 0.749 . . . . 75.23 110.919 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 117' ' ' PRO . . . . . 0.703 ' HA ' HD23 ' A' ' 153' ' ' LEU . 53.8 Cg_endo -69.73 177.74 5.25 Favored 'Trans proline' 0 N--CA 1.465 -0.186 0 C-N-CA 122.69 2.26 . . . . 53.11 112.402 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 1.2 p90 -112.05 162.78 15.02 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.261 -0.427 . . . . 63.32 110.941 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 43.9 t -121.41 136.24 58.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.124 -0.489 . . . . 74.24 111.173 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -128.58 179.09 16.81 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.771 -0.728 . . . . 74.22 112.437 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.4 HG22 ' N ' ' A' ' 122' ' ' GLY . 7.6 p -163.44 155.79 2.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.89 0.376 . . . . 65.13 111.125 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' GLY . . . . . 0.4 ' N ' HG22 ' A' ' 121' ' ' VAL . . . -179.34 -157.41 19.69 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.73 -0.748 . . . . 33.01 112.509 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.4 p -107.28 123.71 62.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.812 0.339 . . . . 75.03 111.173 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' GLY . . . . . 0.602 ' CA ' HG23 ' A' ' 102' ' ' ILE . . . -115.45 107.66 1.77 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.774 -0.727 . . . . 21.15 112.497 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -106.13 126.82 52.67 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.932 0.396 . . . . 72.42 110.824 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.411 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 2.1 p -105.59 108.92 26.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.152 -0.476 . . . . 71.15 111.144 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 3.1 tp -116.58 170.33 8.66 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.259 -0.428 . . . . 75.42 110.993 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.533 ' CD2' HG21 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -161.7 179.35 8.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.246 -0.433 . . . . 71.4 110.926 179.951 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -117.23 115.47 25.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.469 . . . . 74.41 110.882 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -48.05 110.55 0.34 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 65.41 110.799 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.496 ' HB2' HG23 ' A' ' 96' ' ' VAL . 2.8 mmmt -104.09 -89.05 0.41 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 72.42 110.885 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.3 m -175.78 133.94 0.28 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.23 -0.441 . . . . 74.2 111.152 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' ASP . . . . . 0.462 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 19.3 m-20 -115.9 127.63 55.15 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.166 -0.47 . . . . 73.22 110.937 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -77.12 -11.09 85.88 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.753 -0.737 . . . . 63.01 112.522 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -45.12 -31.09 1.28 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.872 0.368 . . . . 61.11 111.077 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.5 tp -164.6 -177.18 4.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 54.34 110.938 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 16.5 m -51.42 95.24 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 43.15 110.862 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 93.3 p 47.26 72.03 0.28 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.071 -0.513 . . . . 71.11 110.892 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.462 ' HB3' ' HB2' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -88.97 160.26 17.22 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.131 -0.486 . . . . 54.13 110.84 -179.904 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 69.9 m-20 -147.2 -178.61 6.31 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.112 -0.495 . . . . 63.52 110.844 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.647 HG22 ' HA ' ' A' ' 176' ' ' VAL . 1.1 pt -141.92 174.39 6.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.128 -0.487 . . . . 74.42 111.139 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' LYS . . . . . 0.403 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 14.7 tptt -123.85 135.58 53.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 70.34 110.877 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.411 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 2.8 p30 -78.5 -173.29 3.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 72.33 110.891 179.862 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 1.4 tttp -166.77 177.24 6.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 72.5 110.901 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 145' ' ' TRP . . . . . 0.433 ' O ' ' HB2' ' A' ' 146' ' ' ALA . 64.7 p-90 -156.95 160.3 38.93 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.227 -0.442 . . . . 73.45 110.928 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.769 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 177.44 166.73 0.51 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.622 0.725 . . . . 75.02 111.068 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 147' ' ' PRO . . . . . 0.769 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.4 Cg_endo -69.77 129.64 17.93 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.711 2.274 . . . . 74.32 112.279 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.532 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -122.69 170.17 10.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.217 -0.447 . . . . 62.53 111.113 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 13.2 m-85 -124.18 154.66 39.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.258 -0.428 . . . . 74.45 110.807 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 5.8 tt0 -130.63 151.95 50.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.102 -0.499 . . . . 74.45 110.862 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.4 p -153.1 125.85 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 64.24 111.185 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -179.78 -162.63 29.1 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.776 -0.726 . . . . 72.31 112.451 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.764 HD13 ' N ' ' A' ' 154' ' ' ARG . 3.0 tm? -142.6 145.43 33.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.784 0.326 . . . . 64.43 110.857 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.764 ' N ' HD13 ' A' ' 153' ' ' LEU . 3.9 tpp85 -115.37 119.34 35.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 75.32 110.855 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 63.3 t80 -110.59 150.21 29.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.223 -0.444 . . . . 74.35 110.951 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -121.27 123.52 42.39 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.151 -0.477 . . . . 54.34 110.852 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 157' ' ' LEU . . . . . 0.665 HD22 ' HB2' ' A' ' 160' ' ' SER . 1.7 tt -92.29 136.12 33.46 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.157 -0.474 . . . . 75.42 110.898 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 158' ' ' GLY . . . . . 0.577 ' N ' HD23 ' A' ' 157' ' ' LEU . . . -75.41 137.39 21.77 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.782 -0.723 . . . . 72.21 112.52 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 53.02 37.23 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.892 0.377 . . . . 72.43 110.894 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 160' ' ' SER . . . . . 0.665 ' HB2' HD22 ' A' ' 157' ' ' LEU . 2.3 m -172.59 173.95 3.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.154 -0.476 . . . . 44.2 110.82 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 7.0 m0 -62.55 158.76 17.27 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.146 -0.479 . . . . 64.22 110.912 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 162' ' ' MET . . . . . 0.46 ' SD ' HG23 ' A' ' 203' ' ' VAL . 0.3 OUTLIER -92.97 171.17 9.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.255 -0.429 . . . . 54.23 110.927 179.924 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 80.7 mt -124.3 145.35 49.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 75.22 110.895 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -143.64 134.47 25.28 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.164 -0.471 . . . . 55.24 110.832 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 78.4 p -145.11 121.54 10.99 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.118 -0.492 . . . . 63.41 110.834 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -153.4 174.0 14.92 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.158 -0.474 . . . . 73.12 110.859 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.437 HG22 HD12 ' A' ' 196' ' ' LEU . 1.5 t -135.68 151.87 30.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.153 -0.476 . . . . 71.41 111.178 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 168' ' ' ARG . . . . . 0.402 ' HB2' ' HB ' ' A' ' 195' ' ' ILE . 0.1 OUTLIER -117.73 131.49 56.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 75.33 110.901 179.994 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 23.4 m-85 -132.07 134.68 45.78 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.144 -0.48 . . . . 75.42 110.966 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 170' ' ' ILE . . . . . 0.532 HG21 ' HB2' ' A' ' 148' ' ' ALA . 0.0 OUTLIER -179.13 120.49 0.23 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.618 0.723 . . . . 71.24 111.138 179.93 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.77 108.61 2.12 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.635 2.224 . . . . 73.05 112.333 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -116.48 157.11 25.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 74.52 110.834 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.36 118.98 25.18 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.131 -0.486 . . . . 75.14 110.89 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.9 t -95.08 144.64 25.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.21 -0.45 . . . . 73.43 111.092 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 175' ' ' ASP . . . . . 0.403 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.1 OUTLIER -100.21 150.58 22.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.163 -0.472 . . . . 72.11 110.855 179.916 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.647 ' HA ' HG22 ' A' ' 141' ' ' ILE . 14.7 p -146.46 127.53 6.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.197 -0.456 . . . . 74.42 111.159 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 15.2 t -167.32 172.16 10.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 73.43 111.073 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -145.48 171.77 26.42 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.688 -0.768 . . . . 71.52 112.493 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.294 0 CA-C-O 120.885 0.374 . . . . 73.54 111.124 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo . . . . . 0 C--O 1.231 0.158 0 CA-C-O 120.767 0.236 . . . . 62.42 112.387 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 49.6 t -96.73 107.99 20.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.265 -0.425 . . . . 72.12 111.14 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 1.7 p -104.16 118.72 37.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 71.52 110.83 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 23.2 p -145.9 176.12 9.92 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.183 -0.462 . . . . 65.54 111.149 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 188' ' ' LYS . . . . . 0.535 ' O ' HD13 ' A' ' 189' ' ' ILE . 0.2 OUTLIER -154.67 166.66 32.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 75.21 110.878 179.964 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 189' ' ' ILE . . . . . 0.601 HD11 ' H ' ' A' ' 33' ' ' GLY . 47.7 mm -140.23 114.44 6.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 73.11 111.099 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 7.6 tm-20 -103.01 106.74 17.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.136 -0.484 . . . . 65.13 110.93 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 8.7 m -137.03 163.49 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.174 -0.466 . . . . 72.51 111.145 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.3 89.28 4.63 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.61 0.719 . . . . 65.43 110.814 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 137.36 35.11 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.675 2.25 . . . . 63.14 112.385 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -104.26 114.7 29.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.308 -0.405 . . . . 72.51 110.813 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 195' ' ' ILE . . . . . 0.811 HD12 HG12 ' A' ' 26' ' ' VAL . 4.0 mm -101.68 119.2 49.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.109 -0.496 . . . . 74.14 111.116 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 196' ' ' LEU . . . . . 0.437 HD12 HG22 ' A' ' 167' ' ' VAL . 11.9 tp -104.86 109.49 21.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.241 -0.436 . . . . 62.03 110.902 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -102.46 119.58 39.07 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.163 -0.471 . . . . 54.05 110.833 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 198' ' ' LEU . . . . . 0.463 ' H ' HD23 ' A' ' 198' ' ' LEU . 2.0 pt? -139.13 129.65 25.8 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.164 -0.471 . . . . 72.23 110.963 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 179.88 -144.15 5.89 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.766 -0.73 . . . . 65.22 112.454 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 200' ' ' ALA . . . . . 0.427 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -127.1 173.42 9.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.812 0.339 . . . . 65.5 111.087 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 15.2 m -146.96 169.87 18.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.214 -0.448 . . . . 72.33 110.89 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 1.1 t80 -141.49 131.66 24.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.168 -0.469 . . . . 75.14 110.935 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.46 HG23 ' SD ' ' A' ' 162' ' ' MET . 5.8 t -81.12 158.58 4.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.479 . . . . 41.52 111.089 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 204' ' ' PHE . . . . . 0.411 ' N ' HG12 ' A' ' 203' ' ' VAL . 2.1 m-85 -164.6 147.95 8.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.466 . . . . 72.34 110.915 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 35.8 mtpt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 70.34 110.895 -179.964 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 17.5 pt20 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.812 0.339 . . . . 74.45 110.907 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 101.7 7.91 46.97 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.729 -0.748 . . . . 42.51 112.468 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.62 156.23 27.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.81 0.338 . . . . 64.43 110.856 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 41.5 m95 -133.0 143.63 49.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.109 -0.496 . . . . 75.11 110.944 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.757 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 2.6 m -142.71 137.76 27.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.251 -0.431 . . . . 64.14 111.132 179.877 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -96.62 104.91 16.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 73.24 111.087 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.4 m -91.63 130.18 37.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 74.13 110.87 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.704 ' CE2' ' HB3' ' A' ' 200' ' ' ALA . 13.7 p90 -134.78 116.76 15.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.066 -0.515 . . . . 65.4 110.88 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -150.95 172.32 15.88 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.177 -0.465 . . . . 75.33 110.94 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 12.8 p90 -105.16 131.39 52.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 74.21 110.906 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' SER . . . . . 0.412 ' HB2' HG22 ' A' ' 195' ' ' ILE . 0.3 OUTLIER -96.58 137.3 35.87 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.149 -0.478 . . . . 44.14 110.837 -179.76 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.7 mmtp -116.19 111.64 20.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.128 -0.487 . . . . 71.31 110.878 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.512 HG22 HD12 ' A' ' 195' ' ' ILE . 25.4 t -75.11 128.32 36.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.237 -0.438 . . . . 72.32 111.097 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 6.9 m-85 -125.96 106.92 9.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 74.33 110.977 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.7 p -171.59 152.92 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.119 -0.491 . . . . 72.21 111.146 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 169.34 64.74 0.04 OUTLIER Glycine 0 N--CA 1.453 -0.197 0 C-N-CA 120.766 -0.731 . . . . 75.43 112.491 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 13.8 tt0 -89.78 -66.3 0.94 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.76 0.314 . . . . 64.13 110.861 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 71.1 tt0 -175.05 154.88 1.88 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 65.42 110.905 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.593 HD13 ' N ' ' A' ' 33' ' ' GLY . 0.3 OUTLIER -110.07 133.91 52.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.484 . . . . 71.11 110.958 -179.952 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.593 ' N ' HD13 ' A' ' 32' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.746 -0.74 . . . . 42.33 112.49 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.463 ' HB1' ' CA ' ' A' ' 84' ' ' GLU . . . . . . . . 0 N--CA 1.457 -0.123 0 CA-C-O 120.789 0.328 . . . . 72.13 111.104 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -143.25 130.41 20.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.453 . . . . 73.31 110.846 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.5 p -104.78 138.56 29.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.185 -0.461 . . . . 74.23 111.089 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -142.85 159.16 42.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.117 -0.492 . . . . 75.22 110.835 -179.854 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -108.47 132.76 55.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.119 -0.491 . . . . 75.41 111.149 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -131.07 51.81 0.85 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.746 -0.74 . . . . 52.44 112.488 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 -102.81 112.6 25.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.834 0.35 . . . . 75.13 110.919 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.659 ' O ' HG23 ' A' ' 54' ' ' THR . 1.8 t70 -55.03 175.18 0.06 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 75.2 110.859 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 7.5 p -53.16 101.82 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.238 -0.437 . . . . 72.25 111.135 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.659 HG23 ' O ' ' A' ' 52' ' ' ASP . 44.9 p -100.94 176.1 5.39 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 74.12 111.182 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 5.2 mp -129.78 161.51 30.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.269 -0.423 . . . . 63.05 110.924 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.5 143.01 30.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 70.21 111.087 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -123.05 132.41 54.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.248 -0.433 . . . . 75.23 110.862 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.436 ' C ' HD13 ' A' ' 59' ' ' ILE . 14.5 p-10 -134.75 145.21 48.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 65.22 110.825 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.436 HD13 ' C ' ' A' ' 58' ' ' ASP . 5.8 mm -108.95 116.81 52.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 54.25 111.085 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.757 ' HB3' ' CG2' ' A' ' 18' ' ' VAL . . . -101.87 125.2 48.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 63.14 111.07 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.632 ' HB3' HG13 ' A' ' 69' ' ' VAL . 27.1 t80 -110.47 115.59 29.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.22 -0.445 . . . . 62.32 110.91 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -84.14 101.95 12.22 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.092 -0.503 . . . . 72.23 110.89 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.5 p -94.21 -33.15 4.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.151 -0.477 . . . . 75.34 111.041 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.0 m -134.1 164.33 27.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 73.54 110.782 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 7.8 p -86.67 3.14 45.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.083 -0.508 . . . . 54.12 110.885 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -112.43 -32.59 6.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.101 -0.5 . . . . 72.04 110.912 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 21.6 pt -146.44 167.81 6.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.173 -0.467 . . . . 73.42 111.163 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -154.69 169.13 24.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 72.23 111.12 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.632 HG13 ' HB3' ' A' ' 61' ' ' TYR . 1.4 p -111.62 147.2 15.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.3 -0.409 . . . . 65.22 111.19 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -139.78 127.0 21.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 64.32 110.798 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.748 ' CZ ' HD22 ' A' ' 103' ' ' LEU . 0.6 OUTLIER -108.56 110.43 21.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 71.31 110.874 -179.96 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -87.03 129.4 34.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.126 -0.488 . . . . 70.13 110.872 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 9.9 m -149.44 163.42 4.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.118 -0.492 . . . . 65.44 111.134 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 175.01 142.57 4.13 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.757 -0.735 . . . . 62.12 112.477 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.473 ' O ' HG13 ' A' ' 75' ' ' VAL . 3.9 p -118.71 77.78 14.95 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.657 0.741 . . . . 74.43 111.16 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 148.7 65.97 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.63 2.22 . . . . 74.1 112.387 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -67.31 -165.62 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.29 -0.414 . . . . 64.41 111.061 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 43.1 ttp180 -76.66 115.54 16.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 73.21 110.83 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ALA . . . . . 0.467 ' HB3' ' CZ ' ' A' ' 81' ' ' PHE . . . -110.3 149.71 29.79 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.212 -0.449 . . . . 20.44 111.145 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.6 tmmm? -103.27 141.23 36.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 74.32 110.825 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' PHE . . . . . 0.467 ' CZ ' ' HB3' ' A' ' 79' ' ' ALA . 10.3 m-85 -139.47 157.33 46.03 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.136 -0.484 . . . . 61.3 110.86 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 30.2 mt-30 -105.96 156.15 18.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.198 -0.455 . . . . 74.0 110.977 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.59 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 176.26 73.81 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.712 -0.756 . . . . 74.51 112.512 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.463 ' CA ' ' HB1' ' A' ' 45' ' ' ALA . 1.3 tp10 -174.37 -177.21 1.21 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.959 0.409 . . . . 71.41 110.857 -179.831 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 2.3 ptmt -86.76 -69.95 0.64 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.096 -0.502 . . . . 65.25 110.858 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.6 t -84.07 -33.38 24.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.45 . . . . 54.31 110.913 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.841 HG21 ' HB2' ' A' ' 135' ' ' ALA . 4.6 mm -65.39 -34.46 70.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.115 -0.493 . . . . 75.33 111.146 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 63.5 p -61.48 -48.68 80.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.13 -0.486 . . . . 62.42 110.751 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.7 t -52.1 -39.93 60.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 71.21 110.83 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 82.5 mt -60.41 -47.86 84.25 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.163 -0.471 . . . . 74.43 110.941 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 114.93 -14.96 19.22 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.759 -0.734 . . . . 64.02 112.515 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 8.9 mtm180 -121.34 97.15 5.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.899 0.381 . . . . 75.25 110.901 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.628 HG22 HG22 ' A' ' 87' ' ' ILE . 17.0 t -112.97 -41.99 4.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.159 -0.473 . . . . 75.31 111.023 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 13.3 p -141.51 154.2 45.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 61.33 110.872 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 82.9 mt-10 -152.56 118.64 5.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.134 -0.485 . . . . 75.42 110.836 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.734 HG21 ' O ' ' A' ' 129' ' ' PHE . 4.5 p -178.46 164.16 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 72.24 111.165 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.435 ' H ' HG22 ' A' ' 96' ' ' VAL . 4.0 p30 -90.84 133.51 35.16 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.466 . . . . 73.51 110.86 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -92.21 146.14 23.95 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 74.33 110.86 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -113.49 70.93 0.23 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.767 -0.73 . . . . 42.11 112.497 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 112.48 3.1 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.714 2.276 . . . . 74.44 112.302 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -136.87 113.76 10.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.239 -0.437 . . . . 63.04 111.171 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.657 HD13 ' HD2' ' A' ' 168' ' ' ARG . 13.5 pt -139.68 153.61 23.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.209 -0.451 . . . . 72.4 111.117 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.748 HD22 ' CZ ' ' A' ' 71' ' ' PHE . 0.5 OUTLIER -142.21 117.05 9.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.204 -0.453 . . . . 71.21 110.898 179.954 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 104' ' ' SER . . . . . 0.413 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 5.3 p -142.82 161.26 38.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.227 -0.442 . . . . 71.31 110.885 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.461 ' O ' HD12 ' A' ' 105' ' ' LEU . 4.5 pp -110.08 146.03 36.09 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.168 -0.469 . . . . 73.55 110.955 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 1.7 pp0? -101.13 144.43 30.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 65.32 110.965 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -152.58 159.78 43.24 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.244 -0.435 . . . . 63.01 110.955 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 22.1 p80 . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.114 -0.494 . . . . 73.23 110.779 179.961 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 20.8 p90 . . . . . 0 C--O 1.231 0.086 0 CA-C-O 121.624 0.726 . . . . 62.4 110.952 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 117' ' ' PRO . . . . . 0.684 ' HB3' HD12 ' A' ' 153' ' ' LEU . 54.5 Cg_endo -69.67 178.37 4.58 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.72 2.28 . . . . 74.14 112.359 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 1.6 p90 -127.38 159.07 35.56 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.295 -0.411 . . . . 71.23 110.895 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 48.1 t -113.3 136.5 49.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.107 -0.497 . . . . 63.41 111.1 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -127.24 172.46 18.65 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.759 -0.734 . . . . 71.33 112.515 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.2 p -162.46 151.67 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.877 0.37 . . . . 44.21 111.18 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' GLY . . . . . 0.413 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -176.65 -156.23 15.1 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.693 -0.765 . . . . 64.15 112.46 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.471 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 5.8 m -107.82 122.04 61.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.921 0.391 . . . . 60.34 111.083 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' GLY . . . . . 0.539 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -115.9 121.31 5.2 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.699 -0.762 . . . . 50.25 112.523 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -116.51 132.7 56.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.829 0.347 . . . . 73.03 110.862 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.421 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 2.8 m -107.66 108.67 25.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 75.02 111.147 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.523 HD23 ' N ' ' A' ' 128' ' ' PHE . 0.5 OUTLIER -86.86 166.53 15.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 73.23 110.956 179.901 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.523 ' N ' HD23 ' A' ' 127' ' ' LEU . 0.5 OUTLIER -149.24 134.51 18.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 54.3 110.902 179.914 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.734 ' O ' HG21 ' A' ' 96' ' ' VAL . 28.3 t80 -100.34 165.13 11.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.147 -0.479 . . . . 73.34 110.909 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -97.49 120.19 37.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 62.4 110.826 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.69 ' CB ' HG23 ' A' ' 96' ' ' VAL . 4.3 tppp? -141.17 -82.18 0.23 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 71.24 110.838 180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 31.7 m -162.78 83.92 0.52 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.267 -0.424 . . . . 71.24 111.185 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -104.57 165.11 11.28 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.229 -0.441 . . . . 72.31 110.898 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 62.13 154.85 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.725 -0.75 . . . . 54.43 112.463 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.841 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -84.77 1.71 45.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.808 0.337 . . . . 62.1 111.088 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -86.26 -175.75 5.63 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.26 -0.427 . . . . 74.34 110.965 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.4 m -63.55 87.53 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.191 -0.459 . . . . 72.44 110.83 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 38.6 t 51.17 76.63 0.15 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.074 -0.512 . . . . 44.53 110.854 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.715 ' CE1' HG12 ' A' ' 176' ' ' VAL . 1.0 OUTLIER -86.55 148.87 25.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.163 -0.471 . . . . 73.44 110.806 -179.913 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 59.4 m-20 -122.03 -178.76 3.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.045 -0.525 . . . . 75.24 110.898 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.423 ' HA ' ' HA ' ' A' ' 176' ' ' VAL . 0.1 OUTLIER -145.2 160.51 13.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.445 . . . . 63.14 111.124 179.988 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 142' ' ' LYS . . . . . 0.424 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 3.4 ttmt -105.27 122.42 45.89 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.21 -0.45 . . . . 73.3 110.918 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.421 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 0.8 OUTLIER -63.59 -173.48 0.07 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.241 -0.436 . . . . 74.11 110.859 179.84 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 18.6 tptt -158.45 164.62 36.04 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.191 -0.459 . . . . 74.33 110.913 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 17.6 p90 -155.87 146.48 21.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.167 -0.469 . . . . 63.22 110.889 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.833 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 179.74 168.76 0.68 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.592 0.711 . . . . 62.5 111.138 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 147' ' ' PRO . . . . . 0.833 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.8 Cg_endo -69.75 125.1 11.76 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.703 2.269 . . . . 60.21 112.364 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.659 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -117.96 171.08 8.32 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.238 -0.437 . . . . 55.32 111.078 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 16.3 m-85 -123.6 138.55 54.53 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.13 -0.486 . . . . 74.32 110.861 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 40.0 tt0 -119.93 159.49 24.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.138 -0.483 . . . . 74.21 110.862 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -160.7 133.32 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.453 . . . . 71.44 111.154 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 152' ' ' GLY . . . . . 0.443 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 179.38 -158.67 22.79 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.66 -0.781 . . . . 72.24 112.442 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.684 HD12 ' HB3' ' A' ' 117' ' ' PRO . 0.0 OUTLIER -146.93 166.38 26.93 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.777 0.322 . . . . 74.13 110.94 -179.969 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.417 ' HD3' ' N ' ' A' ' 155' ' ' TYR . 5.6 tpp85 -129.56 117.86 21.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.248 -0.433 . . . . 72.0 110.858 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 155' ' ' TYR . . . . . 0.417 ' N ' ' HD3' ' A' ' 154' ' ' ARG . 3.4 t80 -104.12 144.32 31.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.234 -0.439 . . . . 74.01 110.85 -179.811 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -120.47 98.26 5.96 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.124 -0.489 . . . . 74.05 110.842 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 78.8 mt -69.53 152.77 44.41 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.204 -0.453 . . . . 75.11 110.898 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -52.8 -33.84 43.59 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.733 -0.746 . . . . 72.15 112.495 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -65.78 178.53 1.03 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.86 0.362 . . . . 75.13 110.932 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 1.2 m -66.08 -35.88 81.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.144 -0.48 . . . . 73.34 110.958 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 47.0 p90 -82.76 152.82 25.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.068 -0.515 . . . . 70.23 110.991 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 162' ' ' MET . . . . . 0.424 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 2.3 mpt? -123.7 177.44 5.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.28 -0.418 . . . . 63.13 110.819 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.464 HD23 ' N ' ' A' ' 164' ' ' ASN . 1.0 OUTLIER -118.42 144.56 45.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.464 . . . . 71.44 110.87 -179.998 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 164' ' ' ASN . . . . . 0.464 ' N ' HD23 ' A' ' 163' ' ' LEU . 3.1 t-20 -143.63 137.61 28.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.15 -0.477 . . . . 55.05 110.923 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.0 t -144.06 121.44 11.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 72.54 110.803 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 166' ' ' ASP . . . . . 0.443 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.8 OUTLIER -137.37 159.66 41.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 74.35 110.908 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.545 HG13 ' CD1' ' A' ' 196' ' ' LEU . 50.4 t -132.84 134.44 58.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 72.01 111.15 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 168' ' ' ARG . . . . . 0.657 ' HD2' HD13 ' A' ' 102' ' ' ILE . 2.1 ttt85 -106.17 137.59 43.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 61.13 110.8 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 23.1 t80 -148.55 132.5 17.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 74.01 110.894 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 170' ' ' ILE . . . . . 0.659 HG21 ' HB2' ' A' ' 148' ' ' ALA . 0.0 OUTLIER -178.71 123.63 0.25 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.705 0.764 . . . . 63.34 111.121 179.93 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 104.16 1.27 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.669 2.246 . . . . 74.21 112.284 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 172' ' ' PHE . . . . . 0.436 ' HE1' HG23 ' A' ' 174' ' ' THR . 0.3 OUTLIER -117.53 175.03 5.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 73.32 110.935 179.95 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.2 132.88 25.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.249 -0.432 . . . . 70.13 110.951 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 174' ' ' THR . . . . . 0.436 HG23 ' HE1' ' A' ' 172' ' ' PHE . 0.0 OUTLIER -111.15 150.85 28.89 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.244 -0.434 . . . . 73.32 111.123 179.989 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 175' ' ' ASP . . . . . 0.424 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -106.44 158.84 16.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.223 -0.444 . . . . 65.42 110.849 179.922 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.715 HG12 ' CE1' ' A' ' 139' ' ' PHE . 10.3 t -138.61 123.2 21.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.461 . . . . 72.21 111.172 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 15.3 t -166.67 172.57 10.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 74.53 111.149 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 117.72 140.07 6.45 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.755 -0.736 . . . . 62.41 112.443 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 43.5 m . . . . . 0 C--N 1.33 -0.275 0 CA-C-O 120.799 0.333 . . . . 75.41 111.08 -179.839 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo . . . . . 0 C--O 1.231 0.158 0 CA-C-O 120.792 0.247 . . . . 65.13 112.281 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.4 HG12 ' N ' ' A' ' 186' ' ' SER . 4.2 t -95.96 159.05 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 64.42 111.186 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 186' ' ' SER . . . . . 0.4 ' N ' HG12 ' A' ' 185' ' ' VAL . 6.2 p -130.43 108.55 10.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.974 0.416 . . . . 61.45 110.906 -179.845 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 16.8 p -127.36 167.21 16.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.18 -0.464 . . . . 75.23 111.177 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 4.0 tttt -151.92 142.71 22.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 62.24 110.955 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 6.8 tp -137.5 125.68 32.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 73.51 111.092 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -106.55 112.42 25.42 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.137 -0.483 . . . . 43.2 110.876 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 8.2 m -137.83 158.88 33.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.192 -0.458 . . . . 64.21 111.083 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -108.22 88.78 5.11 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.616 0.722 . . . . 53.25 110.813 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 142.16 46.94 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.619 2.213 . . . . 74.4 112.385 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -113.75 112.21 23.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.245 -0.434 . . . . 74.51 110.901 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 195' ' ' ILE . . . . . 0.512 HD12 HG22 ' A' ' 26' ' ' VAL . 4.6 mm -100.45 124.9 54.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 72.31 111.144 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 196' ' ' LEU . . . . . 0.545 ' CD1' HG13 ' A' ' 167' ' ' VAL . 0.8 OUTLIER -107.9 109.01 20.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.157 -0.474 . . . . 70.53 110.955 179.875 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -97.28 123.8 41.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.212 -0.449 . . . . 43.43 110.856 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 22.8 tp -142.38 127.59 18.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.128 -0.487 . . . . 73.23 110.943 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -179.21 -143.93 5.58 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.751 -0.738 . . . . 33.01 112.509 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 200' ' ' ALA . . . . . 0.704 ' HB3' ' CE2' ' A' ' 21' ' ' PHE . . . -123.93 173.66 8.07 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.815 0.341 . . . . 60.01 111.094 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 19.1 m -154.04 163.55 39.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 63.4 110.825 -179.763 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -131.47 131.6 43.64 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.217 -0.447 . . . . 74.24 110.897 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.657 HG13 HG12 ' A' ' 18' ' ' VAL . 60.5 t -102.22 146.61 10.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.112 -0.494 . . . . 62.11 111.109 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -160.76 157.49 26.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.099 -0.5 . . . . 63.2 110.838 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 3.9 ptmm? . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.128 -0.487 . . . . 62.1 110.863 -179.992 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 7.3 mp0 . . . . . 0 N--CA 1.458 -0.072 0 CA-C-O 120.792 0.329 . . . . 70.21 110.907 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.35 5.84 36.77 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.711 -0.757 . . . . 72.13 112.507 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -66.74 153.3 43.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.337 . . . . 71.01 110.911 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 17.3 t90 -123.74 125.11 44.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.197 -0.456 . . . . 72.34 110.965 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.812 HG23 ' HB3' ' A' ' 60' ' ' ALA . 12.5 m -136.92 135.02 48.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.251 -0.431 . . . . 75.5 111.106 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -93.11 158.01 15.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 65.34 111.135 179.818 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.0 109.51 5.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.258 -0.428 . . . . 72.21 110.845 -179.745 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -111.37 115.66 29.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 72.23 110.865 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -150.69 173.0 14.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 74.43 110.906 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 28.2 p90 -108.43 132.21 54.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.167 -0.47 . . . . 71.52 110.908 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 25.2 p -104.85 142.45 34.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 63.31 110.841 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 25.4 tptt -121.96 122.95 40.53 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.082 -0.508 . . . . 75.51 110.975 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.734 HG12 HD12 ' A' ' 195' ' ' ILE . 20.9 m -89.92 135.29 26.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.281 -0.418 . . . . 62.33 111.154 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -126.68 114.37 17.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.252 -0.431 . . . . 75.01 111.015 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.0 p -174.79 153.55 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 60.32 111.156 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 150.5 67.26 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.775 -0.726 . . . . 63.31 112.517 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -90.16 -66.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.812 0.339 . . . . 73.35 110.958 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.661 ' C ' HG12 ' A' ' 47' ' ' VAL . 25.0 pt-20 -174.91 170.61 3.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.128 -0.487 . . . . 53.24 110.887 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.555 HD23 ' CB ' ' A' ' 45' ' ' ALA . 36.4 tp -98.27 150.14 21.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.138 -0.483 . . . . 71.21 110.913 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 C-N-CA 120.732 -0.747 . . . . 65.23 112.464 179.931 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.555 ' CB ' HD23 ' A' ' 32' ' ' LEU . . . . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.838 0.352 . . . . 75.15 111.087 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -142.36 135.65 28.84 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.241 -0.436 . . . . 61.53 110.833 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.661 HG12 ' C ' ' A' ' 31' ' ' GLU . 7.7 p -105.44 142.83 17.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.144 -0.48 . . . . 75.2 111.138 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.0 t -158.14 135.05 9.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 64.14 110.81 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 3.0 pt -89.44 156.38 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 71.21 111.104 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.15 -157.12 9.52 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.738 -0.744 . . . . 62.54 112.463 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -152.05 128.21 10.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.858 0.361 . . . . 74.23 110.847 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -163.64 119.35 1.66 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.147 -0.479 . . . . 65.15 110.92 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' THR . . . . . 0.494 ' O ' HG23 ' A' ' 54' ' ' THR . 14.9 t -58.7 142.36 50.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 51.11 111.103 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.494 HG23 ' O ' ' A' ' 53' ' ' THR . 0.8 OUTLIER -160.12 164.39 33.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 43.45 111.22 179.966 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.458 ' O ' HD12 ' A' ' 55' ' ' LEU . 0.6 OUTLIER -109.31 163.0 13.78 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.282 -0.417 . . . . 54.25 110.96 179.961 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.4 p -142.55 144.0 32.72 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.239 -0.437 . . . . 75.31 111.19 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.423 ' HE2' HD13 ' A' ' 55' ' ' LEU . 48.2 m-85 -113.84 134.81 54.57 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.261 -0.427 . . . . 64.23 110.924 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.463 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -131.15 142.89 50.29 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.109 -0.496 . . . . 74.34 110.847 -179.949 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -109.3 115.28 49.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 75.54 111.116 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.812 ' HB3' HG23 ' A' ' 18' ' ' VAL . . . -104.01 134.94 46.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 54.04 111.091 179.834 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -120.43 123.4 42.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.25 -0.432 . . . . 74.11 110.859 -179.827 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -89.57 101.36 14.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.045 -0.525 . . . . 72.4 110.912 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.5 t -99.48 -38.77 7.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 64.11 111.101 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -125.44 159.01 32.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 64.11 110.829 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 12.2 p -84.35 3.16 37.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.104 -0.498 . . . . 60.34 110.862 -179.817 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -116.63 -33.13 4.96 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.101 -0.499 . . . . 71.2 110.877 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.438 HG21 ' CD1' ' A' ' 107' ' ' TYR . 1.9 pp -139.31 164.07 25.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 72.12 111.121 179.835 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -150.12 167.89 25.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 64.33 111.117 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 13.5 m -113.31 152.98 14.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 60.35 111.203 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -147.91 147.15 29.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 75.44 110.88 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.463 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 16.7 m-85 -127.34 110.33 12.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.266 -0.424 . . . . 72.54 110.867 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -87.83 122.85 31.98 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.094 -0.503 . . . . 74.4 110.863 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 25.2 t -145.88 149.11 16.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.136 -0.484 . . . . 51.15 111.094 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -152.97 167.59 31.71 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.744 -0.741 . . . . 41.24 112.511 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.6 m -134.55 67.65 71.76 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.59 0.709 . . . . 62.34 111.104 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 163.65 37.47 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.667 2.244 . . . . 64.01 112.363 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -83.85 -170.91 3.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.192 -0.458 . . . . 71.3 111.129 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 20.5 ttm105 -76.55 135.49 39.26 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 61.43 110.823 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -129.7 144.3 51.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.114 -0.494 . . . . 62.54 111.148 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.83 137.49 42.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 62.35 110.915 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 43.6 p90 -129.78 159.09 37.61 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.435 . . . . 74.52 110.865 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.411 ' O ' HG23 ' A' ' 47' ' ' VAL . 26.0 mt-30 -98.29 158.08 15.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 74.13 110.878 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.532 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -178.0 60.13 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.666 -0.778 . . . . 74.41 112.479 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.453 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.3 tp10 -167.97 -175.55 2.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.928 0.394 . . . . 63.15 110.85 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.15 -69.27 0.68 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.187 -0.461 . . . . 73.24 110.899 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -84.15 -33.39 24.26 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.203 -0.453 . . . . 64.25 110.817 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.751 HG22 HG22 ' A' ' 93' ' ' VAL . 5.8 mm -64.68 -35.11 73.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 55.25 111.126 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 78.8 p -62.98 -47.89 81.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.472 . . . . 73.12 110.83 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 t -51.29 -37.88 49.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.125 -0.489 . . . . 74.15 110.851 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 9.1 tp -63.34 -39.01 93.36 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.103 -0.499 . . . . 70.43 110.929 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 103.13 -15.41 54.82 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.714 -0.755 . . . . 43.22 112.494 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -120.35 89.43 3.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.873 0.368 . . . . 75.43 110.825 -179.832 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.751 HG22 HG22 ' A' ' 87' ' ' ILE . 32.4 t -105.38 -47.4 9.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.207 -0.451 . . . . 60.23 111.157 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 17.9 t -142.22 144.29 33.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.151 -0.477 . . . . 75.11 110.869 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.4 pm0 -133.65 128.56 35.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.09 -0.504 . . . . 72.1 110.865 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.483 HG22 ' N ' ' A' ' 97' ' ' ASP . 10.1 p -175.88 157.02 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.464 . . . . 71.33 111.135 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.483 ' N ' HG22 ' A' ' 96' ' ' VAL . 1.7 t0 -81.0 172.52 13.63 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 73.12 110.921 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -132.92 130.72 40.0 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.269 -0.423 . . . . 74.01 110.913 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -113.4 70.98 0.23 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.71 -0.757 . . . . 54.12 112.42 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.66 114.43 3.69 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.694 2.263 . . . . 74.51 112.346 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -133.61 107.45 7.98 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.221 -0.445 . . . . 65.43 111.025 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.566 HG22 ' CA ' ' A' ' 124' ' ' GLY . 8.0 pt -131.55 149.69 33.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.247 -0.433 . . . . 55.12 111.117 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.455 ' O ' HD12 ' A' ' 103' ' ' LEU . 1.9 pp -138.28 124.15 19.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.127 -0.488 . . . . 71.23 110.945 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.4 p -144.74 165.88 26.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 73.5 110.818 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.465 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.9 OUTLIER -113.14 155.0 25.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.138 -0.483 . . . . 62.32 110.904 179.982 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 -102.07 132.03 48.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.466 . . . . 62.54 110.844 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.438 ' CD1' HG21 ' A' ' 67' ' ' ILE . 13.0 t80 -120.26 121.91 39.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.24 -0.436 . . . . 72.31 110.902 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.137 -0.483 . . . . 74.5 110.852 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 8.8 p90 . . . . . 0 C--O 1.232 0.143 0 CA-C-O 121.648 0.737 . . . . 62.02 110.873 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 177.75 5.22 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.76 2.307 . . . . 75.41 112.297 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 9.0 m-85 -115.69 159.27 21.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.148 -0.478 . . . . 71.0 110.878 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.8 p -109.69 124.13 66.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.11 -0.495 . . . . 72.11 111.137 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -117.87 163.51 12.83 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.777 -0.725 . . . . 64.31 112.458 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.0 p -163.71 151.35 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.901 0.381 . . . . 74.23 111.164 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -179.26 -151.78 10.03 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.689 -0.767 . . . . 61.51 112.446 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.454 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 32.8 m -110.6 152.27 12.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.896 0.379 . . . . 73.14 111.154 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' GLY . . . . . 0.566 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -139.03 106.24 0.5 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.691 -0.766 . . . . 74.05 112.447 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 7.2 ptp180 -105.82 128.35 53.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.862 0.363 . . . . 74.34 110.84 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 60.4 t -113.52 114.62 47.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 73.14 111.136 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.1 tt -122.42 152.27 40.4 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 72.23 110.95 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 11.5 p90 -161.58 162.17 30.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.288 -0.415 . . . . 73.03 110.886 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -101.17 116.86 33.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 72.13 110.912 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -50.74 104.56 0.08 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.156 -0.474 . . . . 72.45 110.861 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.447 ' HB2' ' HA ' ' A' ' 96' ' ' VAL . 0.7 OUTLIER -79.49 -79.35 0.14 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 62.32 110.934 179.963 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 32.0 m -167.01 126.44 1.44 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 73.12 111.147 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' ASP . . . . . 0.487 ' HB3' ' HB3' ' A' ' 139' ' ' PHE . 26.2 t0 -115.18 114.84 25.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.27 -0.423 . . . . 74.4 110.892 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -79.95 -8.1 87.95 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.758 -0.734 . . . . 73.12 112.488 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.618 ' HB2' HG12 ' A' ' 93' ' ' VAL . . . -46.17 -29.38 1.54 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.831 0.348 . . . . 75.12 111.13 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.419 ' HB3' ' CD1' ' A' ' 139' ' ' PHE . 2.6 tp -157.12 -176.83 6.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.222 -0.445 . . . . 73.11 110.869 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 68.4 m -56.63 92.75 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.114 -0.494 . . . . 75.23 110.815 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 58.1 m 50.78 75.08 0.2 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.139 -0.482 . . . . 63.12 110.812 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.487 ' HB3' ' HB3' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -102.54 160.59 14.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 35.11 110.914 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -139.73 172.54 12.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 74.31 110.94 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.493 HD13 HG13 ' A' ' 176' ' ' VAL . 5.8 mm -114.26 161.8 12.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.219 -0.446 . . . . 74.43 111.147 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 13.5 mttm -124.11 114.82 20.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.178 -0.464 . . . . 60.14 110.923 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -69.64 -175.33 0.84 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.279 -0.419 . . . . 64.31 110.895 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 6.9 tttp -172.84 -173.64 1.0 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.23 -0.441 . . . . 71.51 110.894 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 59.3 p-90 -148.75 160.23 43.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.187 -0.461 . . . . 73.4 110.966 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.691 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 179.87 163.54 0.84 Allowed Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.593 0.711 . . . . 73.24 111.105 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 147' ' ' PRO . . . . . 0.691 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 54.3 Cg_endo -69.78 169.1 19.74 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.688 2.258 . . . . 74.41 112.306 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.626 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -167.79 157.07 9.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 63.41 111.094 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 6.2 p90 -115.99 138.42 51.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.449 . . . . 71.55 110.898 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.406 ' HA ' ' HA ' ' A' ' 168' ' ' ARG . 25.2 tt0 -116.53 158.88 22.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 71.45 110.864 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.3 p -142.79 129.35 17.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.16 -0.473 . . . . 71.45 111.07 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 166.4 -164.42 37.61 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.749 -0.738 . . . . 61.03 112.456 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -161.22 174.01 14.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.709 0.29 . . . . 74.23 110.992 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 7.8 tpp85 -109.45 121.21 44.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.232 -0.44 . . . . 73.23 110.846 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 47.8 t80 -106.98 147.86 29.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 75.55 110.974 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -110.07 112.63 24.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.127 -0.488 . . . . 73.51 110.845 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 23.9 tp -86.15 158.14 19.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.165 -0.47 . . . . 64.34 110.908 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -58.24 -39.57 92.67 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.731 -0.747 . . . . 35.41 112.466 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -64.26 169.35 4.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.832 0.349 . . . . 72.54 110.855 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 72.6 m -54.35 -47.55 72.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 73.14 110.875 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 18.1 p90 -74.23 145.64 43.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.096 -0.502 . . . . 62.22 110.929 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 1.8 mpt? -100.34 178.79 4.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.256 -0.429 . . . . 50.42 110.904 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 4.5 tp -119.55 141.95 48.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 74.42 110.839 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -135.37 136.29 41.35 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.144 -0.48 . . . . 63.0 110.875 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.3 p -133.99 134.03 42.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 75.24 110.912 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -163.81 152.74 13.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 64.21 110.838 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.452 HG13 ' O ' ' A' ' 195' ' ' ILE . 44.3 t -144.8 119.04 3.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 72.44 111.143 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 168' ' ' ARG . . . . . 0.406 ' HA ' ' HA ' ' A' ' 150' ' ' GLN . 0.4 OUTLIER -93.52 147.08 23.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.196 -0.457 . . . . 73.22 110.868 -179.959 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 169' ' ' TYR . . . . . 0.413 ' O ' ' HB ' ' A' ' 170' ' ' ILE . 20.1 t80 -152.6 140.03 19.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 70.14 110.943 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 170' ' ' ILE . . . . . 0.626 HG21 ' HB2' ' A' ' 148' ' ' ALA . 0.0 OUTLIER 178.64 132.03 0.22 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.594 0.712 . . . . 73.43 111.196 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 171' ' ' PRO . . . . . 0.509 ' N ' HD13 ' A' ' 170' ' ' ILE . 53.8 Cg_endo -69.75 107.97 1.97 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.691 2.261 . . . . 61.21 112.362 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -124.02 152.63 42.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.172 -0.467 . . . . 64.23 110.858 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 10.4 pttm -122.7 132.92 54.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 64.41 110.869 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.6 t -100.16 162.01 13.24 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 72.41 111.131 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -110.63 157.44 19.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 61.53 110.921 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.493 HG13 HD13 ' A' ' 141' ' ' ILE . 2.9 t -150.54 136.5 11.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.983 0.42 . . . . 74.11 111.063 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.0 t -166.83 161.83 15.6 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 72.24 111.154 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -123.78 174.56 16.76 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.769 -0.729 . . . . 63.44 112.5 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 179' ' ' THR . . . . . 0.408 ' O ' HG23 ' A' ' 179' ' ' THR . 1.8 t . . . . . 0 C--N 1.329 -0.32 0 CA-C-O 120.823 0.345 . . . . 64.25 111.107 -179.802 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo . . . . . 0 N--CA 1.465 -0.194 0 CA-C-O 120.829 0.262 . . . . 61.34 112.39 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 84.9 t -98.68 126.22 51.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.291 -0.413 . . . . 63.2 111.129 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 1.3 p -112.46 111.67 22.68 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.155 -0.475 . . . . 72.23 110.831 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 61.9 p -116.44 167.57 10.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.083 -0.508 . . . . 75.44 111.165 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 11.5 ptmt -147.16 160.32 42.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.444 . . . . 75.44 110.837 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 189' ' ' ILE . . . . . 0.542 HG22 HG23 ' A' ' 191' ' ' VAL . 26.7 mt -137.69 109.24 6.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 74.22 111.127 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.52 106.0 18.18 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 73.03 110.871 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 191' ' ' VAL . . . . . 0.542 HG23 HG22 ' A' ' 189' ' ' ILE . 2.3 t -137.01 164.66 29.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.085 -0.507 . . . . 75.22 111.136 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.433 ' H ' HG12 ' A' ' 191' ' ' VAL . 0.0 OUTLIER -106.94 89.64 4.6 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-O 121.531 0.681 . . . . 74.45 110.816 -179.998 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 193' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 192' ' ' ASP . 53.8 Cg_endo -69.79 135.18 29.75 Favored 'Trans proline' 0 C--N 1.34 0.131 0 C-N-CA 122.758 2.306 . . . . 63.33 112.257 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -103.09 118.16 36.18 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.165 -0.47 . . . . 55.13 110.884 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 195' ' ' ILE . . . . . 0.734 HD12 HG12 ' A' ' 26' ' ' VAL . 24.1 mm -109.26 110.37 31.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 53.44 111.196 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 196' ' ' LEU . . . . . 0.44 HD12 HD21 ' A' ' 198' ' ' LEU . 0.9 OUTLIER -109.15 108.49 19.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 71.45 110.925 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -105.63 133.52 50.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 70.15 110.881 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 198' ' ' LEU . . . . . 0.44 HD21 HD12 ' A' ' 196' ' ' LEU . 0.1 OUTLIER -153.64 137.74 16.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 72.33 110.916 179.966 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 175.48 -140.15 5.07 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.685 -0.769 . . . . 73.33 112.44 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -117.42 173.32 6.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.814 0.34 . . . . 44.01 111.112 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 4.8 p -155.8 166.29 33.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 74.45 110.833 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -132.04 150.7 52.08 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.076 -0.511 . . . . 73.0 110.931 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.592 HG23 HG12 ' A' ' 18' ' ' VAL . 5.6 p -113.05 143.62 22.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 74.22 111.148 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 4.6 t80 -141.76 107.86 5.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 71.24 110.889 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 63.5 tttt . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.153 -0.476 . . . . 73.34 110.863 -179.997 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 11.8 mp0 . . . . . 0 N--CA 1.457 -0.079 0 CA-C-O 120.855 0.359 . . . . 74.04 110.901 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 110.6 5.8 27.46 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.734 -0.746 . . . . 72.54 112.481 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -59.69 152.84 21.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.726 0.298 . . . . 74.21 110.922 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.579 ' HE1' HG23 ' A' ' 59' ' ' ILE . 25.0 t90 -121.6 142.36 50.19 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.234 -0.439 . . . . 71.34 110.936 -179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.46 HG22 ' HA ' ' A' ' 203' ' ' VAL . 39.5 t -146.72 116.75 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 72.53 111.091 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -86.61 105.31 16.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.126 -0.488 . . . . 74.14 111.137 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -101.75 112.77 25.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 64.21 110.847 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -110.16 121.2 44.71 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.123 -0.49 . . . . 65.01 110.998 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -152.12 166.68 30.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.435 . . . . 73.4 110.913 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -100.52 130.59 46.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 72.33 110.894 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -97.17 139.09 33.68 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 74.32 110.882 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 68.8 mttt -111.05 106.97 16.2 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.14 -0.482 . . . . 70.35 110.924 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.629 HG12 HD12 ' A' ' 195' ' ' ILE . 23.4 m -79.13 132.9 31.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 72.35 111.112 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 27.9 t80 -126.97 99.25 5.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 74.34 110.945 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 p -166.12 149.77 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 63.32 111.102 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 132.44 78.71 0.15 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.702 -0.761 . . . . 72.05 112.459 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -89.77 -65.93 0.97 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.735 0.302 . . . . 64.22 110.829 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.522 ' O ' HD12 ' A' ' 189' ' ' ILE . 1.6 mt-10 -171.54 174.28 4.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.196 -0.457 . . . . 72.32 110.846 -179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.472 ' HB3' ' HB3' ' A' ' 45' ' ' ALA . 14.9 tp -81.1 155.06 26.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.082 -0.508 . . . . 61.32 110.927 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.75 -0.738 . . . . 41.4 112.494 179.828 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.472 ' HB3' ' HB3' ' A' ' 32' ' ' LEU . . . . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.804 0.335 . . . . 72.23 111.1 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 -153.49 125.85 8.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 73.31 110.921 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.471 HG22 ' HA2' ' A' ' 83' ' ' GLY . 92.0 t -109.45 141.3 25.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 74.22 111.11 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 43.0 t -167.94 159.02 11.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 41.14 110.809 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.727 HG22 ' HB3' ' A' ' 81' ' ' PHE . 45.0 pt -126.08 157.85 35.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.102 -0.499 . . . . 73.22 111.147 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.25 -138.94 0.36 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.742 -0.742 . . . . 54.35 112.45 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -154.22 117.11 4.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.884 0.373 . . . . 72.13 110.802 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -151.94 105.83 3.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.069 -0.514 . . . . 72.21 110.874 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 46.9 p -72.7 117.25 14.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 43.14 111.126 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.1 m -117.74 162.49 17.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 62.34 111.159 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -94.16 162.3 13.92 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.212 -0.449 . . . . 74.43 110.934 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.23 140.21 32.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.239 -0.437 . . . . 74.23 111.14 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -103.45 131.99 50.08 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.216 -0.447 . . . . 72.43 110.831 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 53.3 m-20 -130.13 133.3 46.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 73.43 110.896 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.579 HG23 ' HE1' ' A' ' 17' ' ' TRP . 22.1 mm -109.2 113.53 44.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 74.0 111.139 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -103.74 117.78 35.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 62.12 111.021 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -106.75 114.21 28.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.184 -0.462 . . . . 74.55 110.892 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -81.56 97.19 7.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.089 -0.505 . . . . 74.24 110.88 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.0 m -88.05 -34.15 7.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 73.51 111.129 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 69.2 m -136.23 167.47 21.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 72.0 110.899 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 46.8 t -86.94 2.64 48.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 70.53 110.895 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 65.1 m-20 -113.59 -33.86 5.72 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.096 -0.502 . . . . 61.54 110.912 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 2.2 pp -145.52 169.01 7.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 41.22 111.205 179.83 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -155.7 173.19 17.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.222 -0.444 . . . . 72.44 111.066 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.425 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 11.6 m -111.55 151.03 13.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 73.32 111.112 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -140.28 133.23 29.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 62.42 110.882 179.881 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.756 ' CZ ' HD22 ' A' ' 103' ' ' LEU . 0.5 OUTLIER -113.54 113.91 25.76 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.198 -0.456 . . . . 70.13 110.842 -179.852 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -91.64 119.99 32.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 74.53 110.909 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 36.7 t -146.64 149.35 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 63.25 111.144 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -156.51 164.45 32.55 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.697 -0.763 . . . . 70.32 112.473 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 24.6 t -136.55 66.03 56.47 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.614 0.721 . . . . 71.52 111.142 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 162.62 41.36 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.636 2.224 . . . . 71.31 112.353 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -79.28 -168.98 1.68 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.244 -0.435 . . . . 51.11 111.054 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.96 138.52 38.9 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.15 -0.477 . . . . 62.13 110.832 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -128.35 135.65 49.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.445 . . . . 72.11 111.144 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 6.8 ttpm? -107.92 141.63 39.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.223 -0.444 . . . . 75.32 110.857 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' PHE . . . . . 0.727 ' HB3' HG22 ' A' ' 49' ' ' ILE . 13.6 p90 -142.07 158.47 43.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.153 -0.476 . . . . 73.35 110.89 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.419 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 1.2 pm0 -98.05 158.51 15.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 75.24 110.909 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.605 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -177.44 69.59 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.759 -0.734 . . . . 73.53 112.505 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.434 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.9 mm-40 -178.33 -177.14 0.55 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.824 0.345 . . . . 73.21 110.916 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.23 -67.42 0.82 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.163 -0.472 . . . . 72.34 110.915 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.9 t -83.1 -35.62 25.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.447 . . . . 72.03 110.851 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.929 HG22 HG22 ' A' ' 93' ' ' VAL . 5.7 mm -64.62 -33.65 64.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.122 -0.49 . . . . 72.21 111.131 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.7 t -61.85 -47.95 82.72 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.206 -0.452 . . . . 65.24 110.861 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.9 t -53.23 -39.87 64.12 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.153 -0.476 . . . . 43.2 110.844 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -59.83 -42.48 93.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.119 -0.491 . . . . 61.34 110.927 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 104.93 -13.48 49.48 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.704 -0.76 . . . . 64.31 112.506 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 7.2 ptp180 -120.16 96.9 5.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.856 0.36 . . . . 62.11 110.873 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.929 HG22 HG22 ' A' ' 87' ' ' ILE . 98.6 t -113.55 -55.41 4.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.234 -0.439 . . . . 73.02 111.175 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 5.8 m -140.51 143.39 35.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 40.42 110.841 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -146.7 126.17 13.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.49 . . . . 72.22 110.862 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.452 HG22 ' N ' ' A' ' 97' ' ' ASP . 14.2 p -166.1 156.72 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 64.13 111.155 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.452 ' N ' HG22 ' A' ' 96' ' ' VAL . 6.0 p-10 -72.94 172.97 9.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 75.55 110.835 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 3.5 m-85 -115.74 125.39 52.72 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.106 -0.497 . . . . 70.52 110.889 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -119.46 67.04 0.39 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.664 -0.779 . . . . 64.42 112.464 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 112.01 2.96 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.694 2.263 . . . . 62.2 112.33 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.455 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -122.66 95.94 4.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.215 -0.448 . . . . 35.23 111.092 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.669 HG23 ' CA ' ' A' ' 124' ' ' GLY . 5.8 mm -121.7 149.98 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 75.01 111.109 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.756 HD22 ' CZ ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -150.42 111.1 4.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 70.34 110.913 179.936 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.4 p -142.87 167.87 21.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.223 -0.444 . . . . 55.0 110.883 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.425 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -113.58 149.52 34.37 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.144 -0.48 . . . . 74.53 110.92 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -101.9 149.19 24.46 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 70.11 110.922 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -155.5 149.24 25.29 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.177 -0.465 . . . . 74.52 110.958 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 14.6 t-160 . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 73.1 110.891 179.888 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.23 0.058 0 CA-C-O 121.681 0.753 . . . . 74.01 110.905 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' PRO . . . . . 0.559 ' HA ' HD13 ' A' ' 153' ' ' LEU . 55.0 Cg_endo -69.67 177.35 5.61 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.695 2.263 . . . . 64.32 112.4 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -110.47 162.84 14.29 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.258 -0.428 . . . . 73.11 110.889 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 92.0 t -128.74 143.81 40.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.065 -0.516 . . . . 41.15 111.14 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -134.96 -175.02 13.65 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.779 -0.724 . . . . 62.03 112.464 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.2 p -169.25 156.1 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.877 0.37 . . . . 74.42 111.129 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 177.78 -152.1 11.48 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.69 -0.767 . . . . 54.5 112.474 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.5 HG23 ' HG ' ' A' ' 103' ' ' LEU . 34.2 m -107.85 130.35 60.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.897 0.38 . . . . 63.1 111.137 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' GLY . . . . . 0.669 ' CA ' HG23 ' A' ' 102' ' ' ILE . . . -125.5 113.31 1.87 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.74 -0.743 . . . . 64.22 112.495 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 125' ' ' ARG . . . . . 0.455 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 14.2 ptt180 -114.58 124.4 51.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.846 0.355 . . . . 74.0 110.925 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.417 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 51.5 t -106.09 110.19 30.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 52.42 111.116 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.477 HD23 ' HB2' ' A' ' 143' ' ' ASP . 6.2 mt -126.5 174.5 8.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 54.23 110.83 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.517 ' CE2' HG23 ' A' ' 141' ' ' ILE . 0.1 OUTLIER -159.02 173.17 16.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.149 -0.478 . . . . 64.5 110.877 179.921 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.437 ' O ' HG23 ' A' ' 96' ' ' VAL . 5.9 t80 -101.78 119.11 38.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 74.13 110.924 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -46.41 106.18 0.08 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.131 -0.486 . . . . 74.53 110.914 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 31.7 mmtm -105.21 -79.95 0.55 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 63.11 110.882 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.5 m -160.45 85.02 0.71 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.215 -0.448 . . . . 54.55 111.149 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -102.72 166.94 10.21 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.239 -0.437 . . . . 64.32 110.864 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 135' ' ' ALA . . . 83.23 145.49 6.13 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.772 -0.727 . . . . 74.23 112.578 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.507 ' HB2' HG13 ' A' ' 87' ' ' ILE . . . -36.5 -65.32 0.28 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.747 0.308 . . . . 63.5 111.081 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.439 HD23 ' HB1' ' A' ' 135' ' ' ALA . 0.4 OUTLIER -167.38 93.18 0.42 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.24 -0.437 . . . . 64.32 110.911 -179.952 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 137' ' ' SER . . . . . 0.539 ' O ' ' C ' ' A' ' 138' ' ' SER . 1.5 p 167.83 59.82 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.225 -0.443 . . . . 62.21 110.844 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.539 ' C ' ' O ' ' A' ' 137' ' ' SER . 54.1 m 25.97 74.45 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.47 . . . . 53.45 110.884 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -106.04 143.23 34.46 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.099 -0.5 . . . . 74.42 110.894 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -111.62 173.76 6.19 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.157 -0.474 . . . . 64.11 110.794 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.517 HG23 ' CE2' ' A' ' 128' ' ' PHE . 6.8 tt -128.02 126.47 66.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.133 -0.485 . . . . 43.12 111.132 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' LYS . . . . . 0.411 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 1.3 mtmt -74.58 106.11 6.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 72.35 110.885 179.836 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.477 ' HB2' HD23 ' A' ' 127' ' ' LEU . 0.9 OUTLIER -57.4 -176.11 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.175 -0.466 . . . . 64.43 110.856 179.854 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 144' ' ' LYS . . . . . 0.554 ' CE ' HG22 ' A' ' 174' ' ' THR . 0.0 OUTLIER -139.92 161.55 37.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 63.34 110.955 179.952 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 43.7 p-90 -155.37 135.73 13.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.279 -0.419 . . . . 64.32 110.915 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.735 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 179.94 165.54 0.82 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.568 0.699 . . . . 60.31 111.112 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 147' ' ' PRO . . . . . 0.735 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 52.7 Cg_endo -69.8 142.33 47.48 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.689 2.26 . . . . 74.22 112.266 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.563 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -133.73 167.52 20.38 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 62.21 111.126 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 58.8 m-85 -117.76 156.61 28.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.257 -0.429 . . . . 73.32 110.863 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 -128.06 149.05 50.56 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.161 -0.472 . . . . 70.52 110.925 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 84.7 t -151.14 123.32 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 71.33 111.125 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 152' ' ' GLY . . . . . 0.441 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 179.53 -159.04 23.37 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.756 -0.735 . . . . 70.32 112.486 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.559 HD13 ' HA ' ' A' ' 117' ' ' PRO . 20.3 tp -150.78 161.0 43.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.83 0.348 . . . . 52.13 110.939 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.4 tpp85 -117.64 118.71 32.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 60.1 110.887 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -103.91 142.85 33.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 74.55 110.905 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -121.74 97.51 5.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.153 -0.476 . . . . 75.5 110.835 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 6.1 tp -73.24 158.69 34.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 71.04 110.911 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -52.53 -46.24 58.77 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.695 -0.764 . . . . 70.44 112.498 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -58.1 166.51 1.55 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.824 0.345 . . . . 71.34 110.895 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 5.9 m -57.51 -36.73 71.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.141 -0.481 . . . . 61.41 110.871 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 87.5 m95 -79.4 134.7 36.57 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.13 -0.486 . . . . 74.52 110.9 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 162' ' ' MET . . . . . 0.491 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 32.8 mtt -108.93 176.79 4.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.44 . . . . 75.23 110.82 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.416 HD13 ' O ' ' A' ' 199' ' ' GLY . 3.2 mm? -115.92 148.77 39.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 63.23 110.914 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -146.89 133.25 19.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.469 . . . . 74.25 110.929 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 66.0 p -139.98 122.23 15.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 75.01 110.89 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 166' ' ' ASP . . . . . 0.441 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.7 OUTLIER -147.34 155.33 41.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.178 -0.464 . . . . 75.25 110.896 179.921 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.691 HG22 HD23 ' A' ' 196' ' ' LEU . 14.6 t -133.18 134.57 57.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 73.14 111.103 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 7.1 tmm_? -107.5 132.16 53.53 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.129 -0.487 . . . . 74.53 110.9 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 38.0 t80 -132.83 139.52 47.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.461 . . . . 72.32 110.852 -179.802 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 170' ' ' ILE . . . . . 0.563 HG21 ' HB2' ' A' ' 148' ' ' ALA . 1.3 tp -178.1 102.23 0.21 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.622 0.725 . . . . 72.44 111.106 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 128.26 15.75 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.658 2.239 . . . . 72.25 112.419 179.857 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 172' ' ' PHE . . . . . 0.41 ' CE2' ' HB2' ' A' ' 146' ' ' ALA . 1.5 t80 -153.17 178.09 10.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 73.32 110.831 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.45 135.45 50.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.15 -0.477 . . . . 63.13 110.886 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 174' ' ' THR . . . . . 0.554 HG22 ' CE ' ' A' ' 144' ' ' LYS . 1.0 OUTLIER -102.62 164.97 11.34 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.224 -0.443 . . . . 74.02 111.186 179.965 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 175' ' ' ASP . . . . . 0.411 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.3 OUTLIER -127.24 167.28 16.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 64.44 110.832 179.98 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 24.7 t -148.37 139.08 17.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.451 . . . . 71.41 111.165 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.3 t -166.85 155.82 10.52 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 73.24 111.138 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -138.87 -162.04 8.98 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.749 -0.739 . . . . 41.43 112.482 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.9 t . . . . . 0 C--N 1.33 -0.255 0 CA-C-O 120.818 0.342 . . . . 74.25 111.168 -179.901 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo . . . . . 0 C--O 1.231 0.146 0 CA-C-O 120.867 0.278 . . . . 55.21 112.338 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 55.1 t -96.12 107.57 19.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 55.44 111.102 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 9.8 p -99.88 105.39 17.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.125 -0.489 . . . . 72.4 110.918 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 11.8 p -104.62 161.94 13.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.486 . . . . 53.5 111.096 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.46 152.09 31.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 61.43 110.91 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 189' ' ' ILE . . . . . 0.522 HD12 ' O ' ' A' ' 31' ' ' GLU . 6.4 tt -152.48 130.35 2.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 74.55 111.089 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -100.7 115.03 29.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.461 . . . . 73.43 110.912 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 191' ' ' VAL . . . . . 0.463 HG12 ' H ' ' A' ' 192' ' ' ASP . 1.8 t -137.94 166.61 23.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 65.54 111.086 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.463 ' H ' HG12 ' A' ' 191' ' ' VAL . 1.0 OUTLIER -107.03 90.15 5.13 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.572 0.701 . . . . 63.25 110.836 -179.998 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 117.52 5.13 Favored 'Trans proline' 0 C--O 1.233 0.225 0 C-N-CA 122.617 2.211 . . . . 75.21 112.375 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -100.66 121.82 42.28 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.275 -0.421 . . . . 71.34 110.882 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 195' ' ' ILE . . . . . 0.629 HD12 HG12 ' A' ' 26' ' ' VAL . 13.6 mm -112.33 107.26 22.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.469 . . . . 51.12 111.108 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 196' ' ' LEU . . . . . 0.691 HD23 HG22 ' A' ' 167' ' ' VAL . 2.3 mt -100.4 108.02 19.92 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.108 -0.497 . . . . 72.13 110.938 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.4 m -100.03 127.53 46.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.44 . . . . 70.1 110.882 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 43.9 tp -146.7 132.23 18.73 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.117 -0.492 . . . . 65.24 110.901 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 199' ' ' GLY . . . . . 0.416 ' O ' HD13 ' A' ' 163' ' ' LEU . . . 177.26 -141.64 5.41 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.773 -0.727 . . . . 23.4 112.506 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 200' ' ' ALA . . . . . 0.491 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -124.49 172.57 9.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.721 0.296 . . . . 55.14 111.179 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 37.1 t -149.56 170.48 18.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.301 -0.409 . . . . 72.52 110.893 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 202' ' ' TYR . . . . . 0.449 ' O ' HG13 ' A' ' 18' ' ' VAL . 22.9 t80 -146.5 131.62 18.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.11 -0.495 . . . . 73.24 110.941 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.46 ' HA ' HG22 ' A' ' 18' ' ' VAL . 34.4 m -88.62 160.77 2.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 74.12 111.09 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -169.35 148.96 3.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 70.33 110.885 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.351 0 CA-C-N 116.145 -0.48 . . . . 74.41 110.878 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.7 pt20 . . . . . 0 N--CA 1.458 -0.054 0 CA-C-O 120.906 0.384 . . . . 70.11 110.865 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.83 5.35 29.3 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.678 -0.772 . . . . 53.44 112.493 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.1 145.58 52.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.835 0.35 . . . . 74.3 110.885 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 27.9 m0 -105.66 137.51 43.39 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.183 -0.462 . . . . 74.43 110.934 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.503 HG11 HH12 ' A' ' 154' ' ' ARG . 10.2 t -144.86 112.53 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.188 -0.46 . . . . 52.25 111.066 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.45 106.0 14.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.178 -0.465 . . . . 63.11 111.074 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.2 t -95.89 111.94 23.8 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.463 . . . . 71.52 110.886 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.573 ' HE1' HD13 ' A' ' 55' ' ' LEU . 39.0 t80 -113.14 116.87 30.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 74.24 110.857 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -154.22 168.42 26.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 74.42 110.856 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 20.0 p90 -101.25 133.75 45.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 74.53 110.864 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.5 p -109.29 114.09 27.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.107 -0.497 . . . . 71.53 110.825 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 21.3 mmmt -98.37 106.59 18.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.108 -0.496 . . . . 74.22 110.868 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.572 HG23 HG12 ' A' ' 195' ' ' ILE . 12.2 p -85.07 143.12 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 54.5 111.135 179.844 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 13.3 m-85 -122.82 116.06 23.04 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.227 -0.442 . . . . 75.31 110.937 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.1 m -148.61 -170.61 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.134 -0.485 . . . . 73.21 111.077 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.66 66.16 0.84 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.712 -0.756 . . . . 75.31 112.495 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.465 ' HB2' HG13 ' A' ' 191' ' ' VAL . 7.0 tp10 -90.51 -68.19 0.8 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.86 0.362 . . . . 74.35 110.942 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 179.05 121.21 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.125 -0.489 . . . . 73.32 110.897 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.626 HD12 HG22 ' A' ' 47' ' ' VAL . 3.4 mt -83.12 153.05 25.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 63.22 110.953 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 C-N-CA 120.772 -0.728 . . . . 41.14 112.522 179.92 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.4 ' HB1' ' HA ' ' A' ' 84' ' ' GLU . . . . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.753 0.311 . . . . 43.01 111.118 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -144.9 127.56 16.17 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.245 -0.434 . . . . 72.24 110.874 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.626 HG22 HD12 ' A' ' 32' ' ' LEU . 22.0 t -105.18 138.85 28.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.166 -0.47 . . . . 63.53 111.151 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.0 m -160.34 151.74 19.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 65.4 110.862 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 16.2 tt -138.11 140.09 41.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.199 -0.455 . . . . 75.14 111.178 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -60.37 -170.04 0.51 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.756 -0.735 . . . . 60.4 112.523 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 -66.46 -58.02 6.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.778 0.323 . . . . 53.2 110.899 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 41.69 40.67 1.5 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 74.12 110.848 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.0 t -68.68 141.3 55.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.177 -0.465 . . . . 62.03 111.168 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.4 t -156.09 174.72 14.96 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.249 -0.432 . . . . 71.01 111.152 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.573 HD13 ' HE1' ' A' ' 21' ' ' PHE . 4.6 pp -90.06 159.18 16.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.208 -0.451 . . . . 75.14 110.908 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -131.16 137.13 48.87 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 74.54 111.092 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -104.24 131.96 51.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 74.01 110.879 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -135.59 139.28 43.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.139 -0.482 . . . . 74.31 110.865 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.84 114.04 45.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.249 -0.432 . . . . 72.22 111.13 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.64 ' HB2' ' OD2' ' A' ' 70' ' ' ASP . . . -106.04 127.9 53.49 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.205 -0.452 . . . . 45.43 111.1 179.835 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -113.74 125.27 53.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.45 . . . . 73.32 110.963 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -88.66 103.01 15.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.143 -0.481 . . . . 75.33 110.859 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 35.3 m -95.66 -34.4 5.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 74.53 111.136 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -134.25 161.79 33.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.08 -0.509 . . . . 43.02 110.884 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 80.2 p -84.33 3.07 37.4 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 61.34 110.864 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -115.69 -32.47 5.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.468 . . . . 72.45 110.842 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 17.8 pt -142.24 168.69 14.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 75.41 111.153 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -156.78 172.79 18.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.171 -0.468 . . . . 73.31 111.108 179.797 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.456 HG12 ' HB3' ' A' ' 105' ' ' LEU . 12.0 m -119.04 151.71 21.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 73.32 111.111 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.64 ' OD2' ' HB2' ' A' ' 60' ' ' ALA . 10.5 t70 -148.28 144.61 27.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 74.22 110.893 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -127.46 113.68 16.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.202 -0.454 . . . . 72.2 110.91 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -85.74 130.46 34.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.152 -0.476 . . . . 70.15 110.913 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 16.7 t -146.06 154.44 12.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.141 -0.481 . . . . 60.4 111.071 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -156.79 148.25 17.81 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.723 -0.751 . . . . 71.32 112.47 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.3 m -119.77 64.47 8.9 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.573 0.702 . . . . 74.03 111.111 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.72 164.05 35.94 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.663 2.242 . . . . 72.2 112.318 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -90.83 -167.98 1.96 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.18 -0.464 . . . . 51.24 111.134 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 17.1 ttm105 -77.38 136.48 38.43 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.236 -0.438 . . . . 62.15 110.882 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -133.61 151.09 51.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 62.01 111.128 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 39.9 ttmt -116.19 131.25 57.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.228 -0.442 . . . . 71.3 110.838 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -131.26 159.05 38.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 64.21 110.869 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.443 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 3.3 pt20 -94.06 157.27 16.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.116 -0.493 . . . . 74.34 110.92 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.576 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -176.05 68.4 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.755 -0.736 . . . . 51.22 112.521 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.4 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.5 tp10 -175.04 -176.83 1.0 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.912 0.387 . . . . 73.31 110.878 -179.83 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.7 -69.27 0.67 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.481 . . . . 74.34 110.924 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.9 m -83.67 -34.55 24.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 61.43 110.896 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.931 HG21 ' HB2' ' A' ' 135' ' ' ALA . 6.0 mm -63.73 -33.95 64.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.491 . . . . 73.13 111.131 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 58.2 p -62.32 -44.85 95.55 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.164 -0.471 . . . . 71.41 110.871 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.1 t -57.63 -35.18 70.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.134 -0.484 . . . . 63.1 110.872 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.668 HD12 ' HA ' ' A' ' 87' ' ' ILE . 24.6 mt -65.28 -50.25 66.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.172 -0.467 . . . . 65.43 110.947 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 116.04 -14.35 16.49 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.747 -0.74 . . . . 50.3 112.517 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 23.8 ptt180 -117.72 94.22 4.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.81 0.338 . . . . 74.11 110.861 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.898 HG22 HG22 ' A' ' 87' ' ' ILE . 64.5 t -114.5 -56.96 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 63.41 111.128 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 69.3 m -138.01 142.62 40.41 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 71.44 110.879 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -146.42 116.47 7.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.134 -0.484 . . . . 71.31 110.901 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 28.8 m -155.78 175.2 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 62.43 111.18 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -83.36 173.77 11.27 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.186 -0.461 . . . . 72.33 110.872 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -120.05 132.87 55.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 70.13 110.849 -179.765 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -132.08 62.06 0.65 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.694 -0.765 . . . . 31.15 112.472 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 113.05 3.24 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.673 2.249 . . . . 64.0 112.394 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.724 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -125.7 108.19 11.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 73.34 111.059 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 3.5 mp -129.17 147.92 33.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.28 -0.418 . . . . 73.14 111.104 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.412 ' HG ' HG13 ' A' ' 123' ' ' VAL . 0.2 OUTLIER -151.97 114.74 4.62 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.155 -0.475 . . . . 75.25 110.939 179.905 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 13.0 p -144.79 166.17 25.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 73.42 110.878 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.456 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -111.02 150.47 29.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.144 -0.48 . . . . 75.43 110.956 179.964 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 18.1 mt-30 -101.61 133.55 46.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.464 . . . . 72.22 110.905 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -122.82 119.37 30.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.164 -0.471 . . . . 54.21 110.839 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 2.4 t60 . . . . . 0 C--N 1.33 -0.254 0 CA-C-N 116.092 -0.504 . . . . 54.52 110.838 179.898 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 27.4 t80 . . . . . 0 C--O 1.232 0.147 0 CA-C-O 121.669 0.747 . . . . 74.5 110.924 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 177.57 5.46 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.64 2.226 . . . . 64.13 112.37 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 9.7 m-85 -117.99 147.5 43.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 75.23 110.874 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 23.5 t -104.2 124.2 58.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.088 -0.505 . . . . 60.12 111.109 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -120.04 161.79 14.32 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.795 -0.717 . . . . 42.44 112.534 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.8 p -159.93 147.34 6.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.923 0.392 . . . . 65.23 111.091 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -175.54 -155.9 13.66 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.748 -0.739 . . . . 70.32 112.475 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.471 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.2 p -107.28 133.49 51.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.864 0.364 . . . . 51.11 111.085 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -119.74 110.8 1.89 Allowed Glycine 0 N--CA 1.453 -0.227 0 C-N-CA 120.646 -0.788 . . . . 65.22 112.493 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' ARG . . . . . 0.724 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 11.8 ptm180 -111.78 122.22 47.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.903 0.382 . . . . 70.41 110.912 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.566 HG13 ' HD2' ' A' ' 144' ' ' LYS . 1.4 p -108.12 110.24 31.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.465 . . . . 75.41 111.179 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.41 HD12 ' HB3' ' A' ' 143' ' ' ASP . 17.7 tp -116.84 167.19 11.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.116 -0.493 . . . . 71.22 110.931 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -150.94 178.93 8.68 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 73.42 110.885 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -107.36 144.82 33.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.143 -0.48 . . . . 74.02 110.868 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -81.78 95.41 7.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.458 . . . . 51.24 110.885 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 16.5 tppt? -110.37 -75.9 0.61 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.155 -0.475 . . . . 54.41 110.976 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' THR . . . . . 0.484 HG23 ' HA ' ' A' ' 138' ' ' SER . 88.0 m -160.85 89.64 0.81 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.236 -0.438 . . . . 61.02 111.127 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 133' ' ' ASP . . . . . 0.612 ' OD1' HD12 ' A' ' 141' ' ' ILE . 15.8 t70 -102.86 162.72 12.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 75.12 110.863 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 67.4 156.93 0.68 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.774 -0.726 . . . . 71.51 112.473 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.931 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -77.54 1.43 19.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.881 0.372 . . . . 62.21 111.12 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -85.89 -178.16 6.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 64.2 110.922 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 16.6 t -67.71 85.72 0.21 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.131 -0.486 . . . . 72.31 110.914 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.484 ' HA ' HG23 ' A' ' 132' ' ' THR . 3.6 m 50.84 74.84 0.21 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 74.02 110.887 -179.791 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -84.52 156.08 21.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.118 -0.492 . . . . 64.42 110.914 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -102.7 173.47 6.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.167 -0.469 . . . . 72.41 110.873 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.791 HG13 HG23 ' A' ' 176' ' ' VAL . 0.6 OUTLIER -153.94 144.11 14.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.258 -0.428 . . . . 62.11 111.126 -179.974 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 142' ' ' LYS . . . . . 0.439 ' HB2' ' HB3' ' A' ' 175' ' ' ASP . 19.8 tptt -91.03 118.02 30.05 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 73.41 110.905 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.41 ' HB3' HD12 ' A' ' 127' ' ' LEU . 0.8 OUTLIER -58.25 -168.74 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.26 -0.427 . . . . 64.03 110.887 179.823 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 144' ' ' LYS . . . . . 0.566 ' HD2' HG13 ' A' ' 126' ' ' VAL . 0.0 OUTLIER -137.59 154.59 49.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 74.32 110.822 -179.976 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 5.1 t90 -157.32 129.0 6.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 71.1 110.912 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.83 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -173.59 168.96 2.22 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.626 0.727 . . . . 55.43 111.107 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 147' ' ' PRO . . . . . 0.83 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.7 Cg_endo -69.84 132.86 24.08 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.634 2.223 . . . . 31.22 112.346 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -120.29 166.27 13.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 64.43 111.115 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -123.58 137.11 54.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.29 -0.414 . . . . 73.32 110.891 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 -114.35 145.55 41.66 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.111 -0.495 . . . . 74.02 110.891 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 58.5 t -143.42 120.49 5.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 62.44 111.086 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' GLY . . . . . 0.425 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 175.77 -171.98 45.01 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.713 -0.756 . . . . 73.35 112.481 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.5 pt? -131.17 161.19 32.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.847 0.356 . . . . 75.43 110.901 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.503 HH12 HG11 ' A' ' 18' ' ' VAL . 2.7 tpp85 -129.71 120.01 24.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 61.41 110.941 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 5.6 t80 -103.77 136.05 44.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.217 -0.447 . . . . 73.13 110.95 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -121.43 105.41 10.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.1 -0.5 . . . . 75.24 110.786 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 7.8 mt -94.74 162.88 13.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 55.34 110.926 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -97.94 36.55 3.9 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.783 -0.723 . . . . 63.54 112.534 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 95.8 m-20 -123.91 35.99 4.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.832 0.349 . . . . 62.44 110.888 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 18.0 p 50.95 38.81 21.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 72.22 110.892 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 8.4 t-105 -165.05 107.13 0.82 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.158 -0.473 . . . . 61.24 110.909 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 162' ' ' MET . . . . . 0.645 ' SD ' HG13 ' A' ' 203' ' ' VAL . 0.0 OUTLIER -99.1 170.54 8.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.205 -0.452 . . . . 53.12 110.885 179.89 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.573 HD22 ' O ' ' A' ' 162' ' ' MET . 4.5 mm? -129.13 145.21 51.35 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.21 -0.45 . . . . 64.24 110.849 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -144.27 133.42 22.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.131 -0.486 . . . . 51.4 110.865 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 50.7 p -145.89 120.7 9.91 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.188 -0.46 . . . . 64.23 110.891 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 166' ' ' ASP . . . . . 0.425 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.6 OUTLIER -153.3 175.85 12.63 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.089 -0.505 . . . . 75.34 110.897 180.0 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.521 HG22 HD13 ' A' ' 196' ' ' LEU . 21.7 t -138.12 133.34 43.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.457 . . . . 54.41 111.105 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 168' ' ' ARG . . . . . 0.563 HH21 HG21 ' A' ' 170' ' ' ILE . 2.1 ttt180 -109.16 125.01 51.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.095 -0.502 . . . . 65.24 110.865 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 13.7 p90 -128.99 146.79 50.88 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.172 -0.467 . . . . 72.44 110.929 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 170' ' ' ILE . . . . . 0.587 HD11 ' HB3' ' A' ' 146' ' ' ALA . 5.5 tt -176.8 97.77 0.24 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.557 0.694 . . . . 70.12 111.155 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 171' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 170' ' ' ILE . 53.5 Cg_endo -69.82 128.74 16.4 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.691 2.261 . . . . 74.31 112.3 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 11.6 p90 -155.08 178.96 9.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.245 -0.434 . . . . 72.02 110.863 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 13.3 pttp -130.32 140.98 50.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 64.21 110.871 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 174' ' ' THR . . . . . 0.416 HG22 HG23 ' A' ' 189' ' ' ILE . 9.0 t -104.27 167.81 9.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 75.43 111.189 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 175' ' ' ASP . . . . . 0.439 ' HB3' ' HB2' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -119.38 159.72 23.66 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.27 -0.423 . . . . 64.32 110.849 179.908 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.791 HG23 HG13 ' A' ' 141' ' ' ILE . 13.7 p -144.76 135.74 20.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.122 -0.49 . . . . 62.11 111.088 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.8 t -166.36 159.44 14.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 74.03 111.156 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -146.13 -134.15 2.6 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.773 -0.727 . . . . 55.12 112.491 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 98.7 m . . . . . 0 C--N 1.33 -0.257 0 CA-C-O 120.835 0.35 . . . . 52.04 111.169 -179.888 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo . . . . . 0 C--O 1.231 0.162 0 CA-C-O 120.777 0.24 . . . . 53.35 112.392 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 23.8 t -95.45 106.37 18.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 75.21 111.161 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 83.2 p -110.16 120.22 41.74 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.177 -0.465 . . . . 63.44 110.894 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -140.54 176.37 8.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.125 -0.489 . . . . 72.1 111.082 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.39 162.48 40.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 74.12 110.918 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 189' ' ' ILE . . . . . 0.566 HD12 ' HA ' ' A' ' 32' ' ' LEU . 4.6 tt -146.04 120.91 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.256 -0.429 . . . . 74.02 111.121 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -96.67 118.16 32.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.157 -0.474 . . . . 65.43 110.871 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 191' ' ' VAL . . . . . 0.465 HG13 ' HB2' ' A' ' 30' ' ' GLU . 4.4 t -137.52 159.68 34.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 74.01 111.167 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.423 ' N ' HG12 ' A' ' 191' ' ' VAL . 0.4 OUTLIER -107.27 90.42 5.68 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.558 0.694 . . . . 74.41 110.869 179.918 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 138.09 37.05 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.61 2.207 . . . . 61.51 112.368 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 23.4 m-85 -121.96 109.67 14.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.179 -0.464 . . . . 50.22 110.925 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 195' ' ' ILE . . . . . 0.572 HG12 HG23 ' A' ' 26' ' ' VAL . 8.8 mt -105.25 135.03 45.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 53.55 111.171 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 196' ' ' LEU . . . . . 0.521 HD13 HG22 ' A' ' 167' ' ' VAL . 10.3 tp -120.57 115.43 23.4 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.093 -0.503 . . . . 54.43 110.957 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -99.26 129.25 45.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 61.44 110.907 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 32.8 tp -150.25 129.35 12.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.149 -0.478 . . . . 71.21 110.91 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 177.38 -146.67 7.83 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.801 -0.714 . . . . 62.32 112.536 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 200' ' ' ALA . . . . . 0.401 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -124.0 173.23 8.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.757 0.313 . . . . 65.12 111.101 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -138.35 164.78 28.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.452 . . . . 73.03 110.899 -179.798 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 34.1 m-85 -133.82 129.95 37.23 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.205 -0.452 . . . . 74.24 110.93 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.645 HG13 ' SD ' ' A' ' 162' ' ' MET . 28.0 m -77.36 148.28 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 73.44 111.207 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -152.34 105.96 3.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.278 -0.419 . . . . 75.15 110.886 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 14.2 ptmt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.15 -0.477 . . . . 64.55 110.939 179.962 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.821 0.344 . . . . 75.42 110.953 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.73 6.48 76.5 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.758 -0.734 . . . . 52.43 112.487 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -76.89 144.9 38.63 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.837 0.351 . . . . 73.42 110.838 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 13.5 t90 -106.44 150.93 25.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 71.2 110.919 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.581 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 22.1 t -145.59 125.82 6.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.242 -0.435 . . . . 74.2 111.131 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -109.76 112.4 24.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 55.43 111.075 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 201' ' ' SER . 60.2 p -124.42 146.57 48.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 73.22 110.837 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 15.1 p90 -127.19 122.52 34.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.111 -0.495 . . . . 72.11 110.827 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -146.89 158.28 43.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 75.41 110.869 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.803 ' HB3' HD23 ' A' ' 55' ' ' LEU . 29.4 p90 -93.69 133.57 36.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.143 -0.481 . . . . 72.23 110.886 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -98.89 114.57 27.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.47 . . . . 61.52 110.843 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.1 tppt? -92.68 108.24 19.83 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.041 -0.527 . . . . 70.22 110.874 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.455 HG23 ' CD1' ' A' ' 195' ' ' ILE . 14.2 p -87.01 140.69 15.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.236 -0.438 . . . . 72.41 111.057 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 41.3 m-85 -134.36 112.85 11.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.111 -0.495 . . . . 73.2 110.959 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 m -72.65 -176.9 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.092 -0.504 . . . . 74.43 111.182 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -93.84 -125.16 4.06 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.748 -0.739 . . . . 54.43 112.465 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -92.37 -66.39 0.93 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.771 0.32 . . . . 62.43 110.861 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.5 mp0 -150.23 -174.21 4.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.155 -0.475 . . . . 63.32 110.877 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.562 ' HA ' HG23 ' A' ' 189' ' ' ILE . 3.4 pp -86.32 -173.33 4.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 63.5 110.909 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 C-N-CA 120.722 -0.751 . . . . 61.1 112.491 179.895 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.408 ' HB1' HD21 ' A' ' 32' ' ' LEU . . . . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.817 0.341 . . . . 65.13 111.139 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -166.33 125.75 1.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 75.43 110.897 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 98.7 t -105.65 131.51 54.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 73.22 111.069 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.5 m -159.4 151.36 20.7 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.138 -0.483 . . . . 75.55 110.803 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 20.0 pt -100.71 157.61 4.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.082 -0.508 . . . . 74.14 111.119 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -72.02 -146.78 0.59 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.737 -0.744 . . . . 72.54 112.508 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -126.1 111.16 14.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.881 0.372 . . . . 73.32 110.88 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -164.01 159.06 20.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.13 -0.487 . . . . 65.24 110.862 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 16.4 p -125.88 123.99 39.88 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 71.43 111.154 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.0 p -137.4 139.33 40.65 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.176 -0.465 . . . . 60.54 111.076 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.803 HD23 ' HB3' ' A' ' 23' ' ' PHE . 2.5 mt -99.11 153.95 18.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.454 . . . . 72.11 110.921 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.1 p -123.26 161.38 24.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.289 -0.414 . . . . 73.24 111.172 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -105.56 133.36 50.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 73.12 110.861 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -124.04 130.06 51.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 54.34 110.867 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.4 ' O ' HG22 ' A' ' 59' ' ' ILE . 1.6 mp -107.24 114.0 45.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.478 . . . . 72.43 111.101 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.581 ' HB3' ' HB ' ' A' ' 18' ' ' VAL . . . -104.13 137.88 41.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.454 . . . . 72.22 111.128 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.427 ' HB2' HG13 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -123.28 121.98 37.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.279 -0.418 . . . . 73.42 110.893 -179.835 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -89.01 102.26 14.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.111 -0.495 . . . . 65.44 110.892 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.1 m -100.84 -33.4 3.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.105 -0.498 . . . . 72.31 111.125 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.9 t -136.23 158.6 44.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.189 -0.46 . . . . 64.01 110.838 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 47.0 t -83.56 3.21 33.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.102 -0.499 . . . . 75.23 110.848 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 47.6 t30 -115.69 -30.6 6.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 63.32 110.885 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.593 HG22 ' HB2' ' A' ' 107' ' ' TYR . 43.5 pt -138.23 157.48 31.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.132 -0.486 . . . . 75.25 111.127 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -145.33 157.65 44.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.154 -0.475 . . . . 71.13 111.046 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.497 ' CG2' HD21 ' A' ' 103' ' ' LEU . 1.4 p -106.96 145.93 13.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.15 -0.477 . . . . 64.2 111.145 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -140.54 128.01 21.36 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.209 -0.45 . . . . 73.45 110.897 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -108.65 110.43 21.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.259 -0.428 . . . . 74.32 110.919 -179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -87.95 115.42 25.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 74.24 110.907 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 8.9 m -139.59 156.76 26.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 72.24 111.109 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -164.55 142.37 7.72 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.75 -0.738 . . . . 73.04 112.501 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.4 t -118.64 66.21 6.91 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.551 0.691 . . . . 55.2 111.145 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 161.89 44.16 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.758 2.305 . . . . 61.02 112.349 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -78.73 -173.21 3.34 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 31.4 111.092 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 18.1 ttp180 -78.27 132.73 37.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 63.1 110.924 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -131.54 150.8 52.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 60.44 111.074 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 7.3 tttt -109.37 134.08 52.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.3 -0.409 . . . . 65.22 110.911 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -134.51 158.66 43.37 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.247 -0.433 . . . . 63.31 110.902 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -91.32 156.18 17.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.112 -0.495 . . . . 75.32 110.857 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.577 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -176.12 65.14 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.803 -0.713 . . . . 75.23 112.513 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -174.29 -174.79 0.91 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.93 0.395 . . . . 63.33 110.882 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -85.5 -70.04 0.62 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.147 -0.478 . . . . 61.12 110.855 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 32.1 t -84.83 -32.18 23.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.26 -0.427 . . . . 63.44 110.808 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.946 HG21 ' HB2' ' A' ' 135' ' ' ALA . 5.4 mm -66.58 -34.04 67.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.157 -0.474 . . . . 71.44 111.181 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 t -63.11 -41.21 99.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.164 -0.471 . . . . 43.03 110.812 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 61.7 m -60.68 -36.98 80.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 74.03 110.862 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.4 mp -64.14 -50.25 68.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.12 -0.491 . . . . 70.15 110.934 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 116.35 -14.25 15.71 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.754 -0.736 . . . . 63.42 112.482 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 58.4 mtm180 -115.06 89.87 3.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.889 0.376 . . . . 73.44 110.809 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.873 HG22 HG22 ' A' ' 87' ' ' ILE . 98.5 t -113.67 -53.25 5.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 70.14 111.137 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 13.3 m -139.28 143.47 37.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 63.42 110.887 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' GLU . . . . . 0.577 ' O ' HG13 ' A' ' 96' ' ' VAL . 1.7 tt0 -145.19 114.3 6.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.465 . . . . 62.42 110.928 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.577 HG13 ' O ' ' A' ' 95' ' ' GLU . 11.8 m -160.45 -178.17 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 50.22 111.116 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -98.65 149.13 23.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 54.03 110.831 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -93.16 125.66 37.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 75.44 110.957 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -119.42 63.16 0.46 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.749 -0.739 . . . . 62.35 112.501 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.67 122.53 9.24 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.687 2.258 . . . . 64.42 112.392 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.601 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -139.22 97.87 3.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.185 -0.461 . . . . 74.31 111.101 179.838 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 5.3 mp -129.18 117.56 43.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 72.41 111.157 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.662 HD13 ' O ' ' A' ' 103' ' ' LEU . 0.9 OUTLIER -113.71 112.98 24.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.228 -0.442 . . . . 60.32 110.948 179.905 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 104' ' ' SER . . . . . 0.583 ' N ' HD22 ' A' ' 103' ' ' LEU . 3.5 p -140.51 165.11 28.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.446 . . . . 73.22 110.822 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.428 ' H ' HD23 ' A' ' 105' ' ' LEU . 1.0 OUTLIER -112.76 142.23 45.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.069 -0.514 . . . . 74.11 110.933 179.963 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 16.0 pt20 -101.4 151.5 21.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.166 -0.47 . . . . 75.32 110.92 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.593 ' HB2' HG22 ' A' ' 67' ' ' ILE . 5.1 t80 -149.69 135.8 18.88 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.249 -0.432 . . . . 75.53 110.962 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 10.6 t60 . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 71.54 110.817 179.986 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.0 m-85 . . . . . 0 C--O 1.23 0.053 0 CA-C-O 121.737 0.78 . . . . 74.11 110.903 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.69 176.86 6.15 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.678 2.252 . . . . 70.25 112.353 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -116.47 150.54 37.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.202 -0.454 . . . . 74.11 110.978 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 13.1 p -104.01 133.94 46.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 73.15 111.093 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -132.09 160.2 23.55 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.749 -0.739 . . . . 51.21 112.504 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 7.5 p -156.57 154.73 5.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.874 0.369 . . . . 63.31 111.157 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 178.76 -147.11 7.65 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.777 -0.725 . . . . 65.0 112.489 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 13.8 p -106.57 131.56 56.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.881 0.372 . . . . 72.12 111.093 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -124.29 111.62 1.64 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.749 -0.738 . . . . 43.44 112.508 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' ARG . . . . . 0.601 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 29.0 ptt180 -114.51 130.13 56.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.774 0.321 . . . . 72.15 110.895 -179.844 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.461 ' O ' ' HB3' ' A' ' 143' ' ' ASP . 3.1 m -111.37 112.66 41.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.237 -0.438 . . . . 71.04 111.091 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 1.3 tp -114.86 171.59 7.56 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.202 -0.454 . . . . 71.4 110.925 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -140.03 178.88 6.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.174 -0.466 . . . . 65.33 110.841 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -117.72 119.4 34.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.144 -0.48 . . . . 73.4 110.906 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -51.89 102.34 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.14 -0.482 . . . . 73.51 110.846 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.86 -80.84 0.55 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 72.01 110.889 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 45.8 m -164.54 89.78 0.53 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 74.32 111.168 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -107.59 172.61 6.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.231 -0.44 . . . . 75.11 110.886 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.53 152.89 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.706 -0.759 . . . . 74.04 112.501 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.946 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -79.42 -1.97 39.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.809 0.338 . . . . 64.41 111.04 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -87.2 -177.52 6.01 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.245 -0.434 . . . . 62.34 110.929 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.7 m -66.57 98.12 0.48 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 72.25 110.88 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 89.4 p 46.79 75.17 0.13 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.125 -0.489 . . . . 65.22 110.794 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.64 ' CE2' HG12 ' A' ' 176' ' ' VAL . 1.5 t80 -89.02 148.26 23.84 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.086 -0.506 . . . . 72.1 110.867 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.18 159.76 15.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.139 -0.482 . . . . 70.54 110.818 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -126.9 118.26 50.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 73.33 111.155 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 142' ' ' LYS . . . . . 0.43 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 1.6 mtpp -69.13 110.84 4.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 72.53 110.843 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.461 ' HB3' ' O ' ' A' ' 126' ' ' VAL . 61.2 m-20 -57.66 -173.44 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 73.4 110.888 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.39 162.53 39.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 64.52 110.906 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 31.1 p-90 -156.47 137.96 14.01 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.217 -0.447 . . . . 63.31 110.896 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.803 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -178.44 167.51 1.01 Allowed Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.603 0.716 . . . . 73.11 111.083 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 147' ' ' PRO . . . . . 0.803 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.5 Cg_endo -69.79 138.62 38.15 Favored 'Trans proline' 0 N--CA 1.465 -0.171 0 C-N-CA 122.712 2.275 . . . . 70.22 112.31 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.572 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -132.85 165.16 25.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.181 -0.463 . . . . 74.43 111.117 179.856 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -123.27 126.18 46.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.192 -0.458 . . . . 73.23 110.895 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -110.12 155.3 22.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 72.02 110.889 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.575 HG13 HG23 ' A' ' 167' ' ' VAL . 4.6 p -144.58 125.73 8.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 71.51 111.138 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 152' ' ' GLY . . . . . 0.436 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . -176.36 -167.68 35.43 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.728 -0.749 . . . . 75.0 112.474 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 2.1 pp -143.87 161.03 39.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.765 0.317 . . . . 75.31 110.923 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 7.6 tpp85 -117.21 119.49 35.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 64.41 110.852 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -100.13 139.42 35.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.146 -0.479 . . . . 71.41 110.885 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -111.85 92.4 4.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 74.23 110.876 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 3.0 tt -86.27 97.02 10.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 63.52 110.953 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 58.77 -138.35 49.49 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.704 -0.76 . . . . 74.54 112.536 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -119.74 -30.35 4.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.878 0.37 . . . . 71.41 110.886 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -48.86 -66.72 0.35 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 73.33 110.878 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 23.7 p90 -145.73 150.92 37.15 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.151 -0.477 . . . . 71.41 110.904 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 2.4 mpt? -108.63 177.57 4.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 44.55 110.858 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 3.8 tp -126.12 149.15 49.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.232 -0.44 . . . . 75.33 110.916 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 13.8 t-20 -143.9 131.51 21.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 72.54 110.858 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.5 p -141.48 124.41 16.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.179 -0.464 . . . . 52.34 110.871 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 166' ' ' ASP . . . . . 0.436 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 2.3 p30 -156.11 169.69 23.92 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.138 -0.483 . . . . 74.2 110.878 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.575 HG23 HG13 ' A' ' 151' ' ' VAL . 0.1 OUTLIER -142.4 134.04 25.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.182 -0.463 . . . . 75.04 111.119 179.972 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.61 142.56 33.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 72.3 110.886 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 4.3 t80 -142.0 137.65 31.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 73.34 110.889 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 170' ' ' ILE . . . . . 0.572 HG21 ' HB2' ' A' ' 148' ' ' ALA . 2.9 tp -177.47 102.25 0.22 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.628 0.728 . . . . 75.54 111.08 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 171' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 192' ' ' ASP . 53.9 Cg_endo -69.75 125.27 11.95 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.696 2.264 . . . . 42.55 112.364 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 24.7 p90 -150.93 178.04 9.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 74.22 110.9 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 173' ' ' LYS . . . . . 0.433 ' HA ' ' HA ' ' A' ' 190' ' ' GLU . 9.7 ptpt -130.85 126.52 36.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 74.2 110.879 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.6 t -93.59 175.26 6.81 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.236 -0.438 . . . . 73.41 111.143 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 175' ' ' ASP . . . . . 0.43 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.3 OUTLIER -126.81 163.71 22.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.254 -0.43 . . . . 74.21 110.844 179.906 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.64 HG12 ' CE2' ' A' ' 139' ' ' PHE . 32.7 t -148.84 133.28 9.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.223 -0.444 . . . . 74.01 111.143 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.4 t -165.58 177.69 7.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.216 -0.447 . . . . 75.24 111.173 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 121.68 141.52 6.12 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.72 -0.753 . . . . 42.44 112.485 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.4 m . . . . . 0 C--N 1.329 -0.315 0 CA-C-O 120.737 0.303 . . . . 73.51 111.195 -179.893 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.231 0.17 0 CA-C-O 120.822 0.259 . . . . 65.5 112.35 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 39.6 t -113.38 107.68 23.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.276 -0.42 . . . . 74.14 111.145 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -81.33 106.72 13.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.161 -0.472 . . . . 72.34 110.835 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 21.0 p -121.38 174.7 6.58 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.108 -0.496 . . . . 55.43 111.104 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 188' ' ' LYS . . . . . 0.486 ' C ' HD12 ' A' ' 189' ' ' ILE . 0.0 OUTLIER -148.55 164.03 35.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.194 -0.457 . . . . 73.52 110.872 179.925 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 189' ' ' ILE . . . . . 0.562 HG23 ' HA ' ' A' ' 32' ' ' LEU . 5.4 mp -144.03 105.8 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 74.24 111.129 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 190' ' ' GLU . . . . . 0.433 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 61.4 tt0 -91.0 102.08 14.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.449 . . . . 73.11 110.869 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 9.3 m -138.68 164.08 26.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.458 . . . . 61.01 111.156 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 171' ' ' PRO . 6.6 p-10 -110.04 88.65 7.18 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.582 0.706 . . . . 75.3 110.867 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 143.28 50.53 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.704 2.269 . . . . 64.34 112.338 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -119.8 123.69 44.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 62.51 110.882 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 195' ' ' ILE . . . . . 0.455 ' CD1' HG23 ' A' ' 26' ' ' VAL . 18.6 mm -109.03 132.06 58.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.147 -0.479 . . . . 62.31 111.171 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 4.6 tp -120.68 108.25 13.78 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.246 -0.433 . . . . 71.31 110.962 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.41 120.14 35.13 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.239 -0.437 . . . . 60.2 110.919 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -139.4 124.29 18.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.468 . . . . 73.42 110.988 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -176.9 -148.54 7.19 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.737 -0.745 . . . . 45.54 112.494 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -115.82 171.04 8.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.812 0.339 . . . . 40.14 111.108 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 201' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 20' ' ' SER . 0.3 OUTLIER -138.49 156.81 47.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.434 . . . . 65.12 110.806 -179.73 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 8.2 t80 -138.07 135.6 35.99 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.132 -0.485 . . . . 75.13 110.958 -179.901 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 14.9 p -77.36 147.46 7.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.08 -0.509 . . . . 64.02 111.179 179.875 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -144.57 88.01 1.9 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.16 -0.473 . . . . 73.43 110.872 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 23.1 mtmt . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 70.41 110.902 179.977 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 . . . . . 0 N--CA 1.458 -0.057 0 CA-C-O 120.871 0.367 . . . . 75.33 110.923 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.37 6.22 41.95 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.706 -0.759 . . . . 65.52 112.491 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -61.81 146.12 50.51 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.817 0.341 . . . . 64.43 110.829 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 19.8 t90 -111.47 121.19 44.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.09 -0.504 . . . . 71.3 110.947 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.817 HG22 HG23 ' A' ' 203' ' ' VAL . 57.2 t -123.4 120.17 59.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.242 -0.435 . . . . 64.4 111.121 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.623 ' HB3' ' CD1' ' A' ' 202' ' ' TYR . . . -86.8 112.35 21.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 43.41 111.127 179.849 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.1 t -109.03 110.0 21.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.236 -0.438 . . . . 61.35 110.874 -179.792 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.404 ' CZ ' HD12 ' A' ' 55' ' ' LEU . 43.5 t80 -107.64 120.01 41.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.477 . . . . 70.41 110.919 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.445 ' HA ' ' HA3' ' A' ' 199' ' ' GLY . 7.4 p30 -149.86 174.87 12.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.442 . . . . 72.55 110.91 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.648 ' HB3' HD13 ' A' ' 55' ' ' LEU . 19.1 p90 -110.83 132.9 53.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 54.13 110.861 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' SER . . . . . 0.445 ' HB3' HG21 ' A' ' 56' ' ' THR . 41.9 p -98.18 146.18 25.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 63.21 110.894 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.4 tmtp? -127.25 106.52 9.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 61.43 110.904 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.8 m -77.31 129.7 37.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.245 -0.434 . . . . 64.31 111.128 179.842 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -126.4 107.78 10.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.126 -0.488 . . . . 74.14 110.956 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.8 p -175.71 153.79 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.485 . . . . 73.32 111.079 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.43 71.68 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.778 -0.725 . . . . 70.34 112.54 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -89.14 -65.87 0.98 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.807 0.337 . . . . 72.31 110.895 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -174.99 152.44 1.49 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.106 -0.497 . . . . 71.34 110.855 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.618 HD23 ' N ' ' A' ' 33' ' ' GLY . 0.8 OUTLIER -96.11 162.32 13.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.163 -0.471 . . . . 73.22 110.909 -179.99 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.618 ' N ' HD23 ' A' ' 32' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.309 0 C-N-CA 120.761 -0.733 . . . . 72.34 112.434 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.814 0.34 . . . . 61.04 111.084 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 35.8 m-20 -153.64 127.24 8.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.238 -0.437 . . . . 71.03 110.828 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 10.8 p -104.52 137.52 33.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 70.02 111.171 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.0 t -148.45 154.87 40.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.094 -0.503 . . . . 74.1 110.835 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.471 HD13 ' H ' ' A' ' 49' ' ' ILE . 0.2 OUTLIER -119.62 154.67 22.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.087 -0.506 . . . . 70.43 111.1 179.939 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.39 -124.59 0.56 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.751 -0.738 . . . . 75.21 112.444 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 38.9 m-20 -82.41 -35.61 27.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.87 0.367 . . . . 74.32 110.911 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 41.9 40.03 1.44 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 71.41 110.85 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 1.4 p -108.37 113.09 25.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 65.03 111.158 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.5 t -154.35 173.95 15.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.136 -0.484 . . . . 61.24 111.139 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.648 HD13 ' HB3' ' A' ' 23' ' ' PHE . 4.2 mm? -92.55 169.11 10.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.248 -0.433 . . . . 60.22 110.924 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.445 HG21 ' HB3' ' A' ' 24' ' ' SER . 18.6 p -149.36 141.54 24.02 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.172 -0.467 . . . . 75.12 111.113 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -103.27 132.82 49.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 73.12 110.861 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -130.63 130.12 43.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.159 -0.473 . . . . 43.53 110.84 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.41 ' O ' HG22 ' A' ' 59' ' ' ILE . 1.6 mp -108.08 112.94 42.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.196 -0.456 . . . . 74.31 111.077 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -102.76 121.69 42.97 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.206 -0.452 . . . . 75.53 111.076 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -106.85 122.72 46.97 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 73.12 110.93 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -88.89 107.22 18.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.17 -0.468 . . . . 65.14 110.908 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 63.8 t -103.24 -48.13 10.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.157 -0.474 . . . . 70.41 111.097 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 40.2 t -124.38 165.99 16.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 54.22 110.854 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.1 m -87.43 2.71 49.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.087 -0.506 . . . . 73.31 110.837 -179.766 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -112.99 -33.68 5.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.084 -0.507 . . . . 74.32 110.936 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.405 HG22 ' CD1' ' A' ' 107' ' ' TYR . 31.4 pt -146.12 160.22 11.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.48 . . . . 62.4 111.081 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -146.57 173.4 12.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 70.34 111.112 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.483 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 14.4 m -115.16 152.13 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.255 -0.429 . . . . 64.32 111.163 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -144.13 144.43 31.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.251 -0.431 . . . . 53.43 110.834 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.445 ' CZ ' HD22 ' A' ' 103' ' ' LEU . 0.5 OUTLIER -120.74 110.14 16.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.157 -0.474 . . . . 73.11 110.914 -179.949 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.405 ' HB3' HG23 ' A' ' 102' ' ' ILE . 2.5 t80 -92.6 117.84 30.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 53.12 110.896 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.4 p -150.26 154.61 8.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.161 -0.472 . . . . 65.05 111.117 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -155.56 150.95 22.52 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.691 -0.766 . . . . 73.43 112.452 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 5.8 m -118.2 67.05 6.45 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.587 0.708 . . . . 63.14 111.11 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.69 159.48 53.28 Favored 'Trans proline' 0 N--CA 1.465 -0.16 0 C-N-CA 122.767 2.312 . . . . 65.43 112.35 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -83.39 -167.96 1.91 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.211 -0.45 . . . . 51.45 111.108 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -77.74 127.52 32.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 71.52 110.852 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -123.87 150.62 44.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.245 -0.434 . . . . 74.2 111.166 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 5.4 ttpm? -104.19 144.85 31.04 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.213 -0.449 . . . . 74.14 110.887 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -142.0 155.0 45.43 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.269 -0.423 . . . . 72.3 110.923 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.427 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 0.2 OUTLIER -107.18 151.57 25.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.12 -0.491 . . . . 73.51 110.943 -179.942 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.637 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -175.86 75.86 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.707 -0.759 . . . . 62.43 112.41 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -178.52 -176.33 0.48 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.94 0.4 . . . . 64.23 110.881 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -85.41 -69.71 0.64 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.192 -0.458 . . . . 74.13 110.88 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 75.3 m -84.58 -34.09 23.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.435 . . . . 41.4 110.886 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.943 HG21 ' HB2' ' A' ' 135' ' ' ALA . 5.2 mm -64.06 -34.75 70.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 72.2 111.146 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 78.8 p -62.61 -49.09 76.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.471 . . . . 64.03 110.818 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 41.6 t -51.72 -36.89 48.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.102 -0.499 . . . . 61.14 110.786 -179.725 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -68.55 -46.39 69.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 61.24 110.881 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.67 -12.76 38.9 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.751 -0.738 . . . . 44.4 112.529 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 21.1 mmt85 -108.87 88.69 2.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.827 0.346 . . . . 74.12 110.875 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.85 HG22 HG22 ' A' ' 87' ' ' ILE . 99.0 t -113.91 -52.87 5.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 43.22 111.044 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.401 ' HA ' ' HA ' ' A' ' 133' ' ' ASP . 8.5 p -139.85 144.5 37.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 73.32 110.924 -179.828 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -149.7 119.53 7.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 72.12 110.896 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.722 HG23 ' HB2' ' A' ' 131' ' ' LYS . 3.8 p -177.65 163.84 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.163 -0.471 . . . . 72.4 111.154 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -76.29 163.66 26.81 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.218 -0.447 . . . . 73.11 110.881 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 2.6 m-85 -114.21 139.55 49.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.184 -0.462 . . . . 73.53 110.881 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -117.92 65.94 0.36 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.754 -0.736 . . . . 44.24 112.428 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 115.34 4.05 Favored 'Trans proline' 0 C--N 1.341 0.134 0 C-N-CA 122.682 2.255 . . . . 73.43 112.313 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -139.08 119.88 14.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 73.24 111.103 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.406 ' HA ' ' HA2' ' A' ' 124' ' ' GLY . 0.0 OUTLIER -155.2 136.2 5.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 62.45 111.104 179.913 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.445 HD22 ' CZ ' ' A' ' 71' ' ' PHE . 0.3 OUTLIER -119.69 124.2 45.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.103 -0.499 . . . . 72.03 110.924 179.942 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 104' ' ' SER . . . . . 0.425 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 72.3 m -143.69 159.38 42.58 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.177 -0.465 . . . . 53.23 110.874 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.535 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.6 OUTLIER -106.85 152.05 24.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.118 -0.492 . . . . 64.33 110.851 -179.912 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 75.7 mt-30 -101.69 140.36 36.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 74.52 110.857 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.405 ' CD1' HG22 ' A' ' 67' ' ' ILE . 0.3 OUTLIER -122.65 110.73 15.89 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.12 -0.491 . . . . 74.34 110.953 -179.814 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.153 -0.476 . . . . 71.43 110.835 179.965 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 . . . . . 0 C--O 1.232 0.176 0 CA-C-O 121.642 0.734 . . . . 71.43 110.981 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 176.96 6.06 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.684 2.256 . . . . 74.03 112.309 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 15.7 p90 -111.08 154.12 24.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.474 . . . . 72.22 110.91 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.3 p -113.75 131.43 65.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 75.14 111.153 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -124.14 168.0 16.36 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.626 -0.797 . . . . 72.31 112.475 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 8.4 p -171.99 153.4 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.886 0.374 . . . . 71.11 111.131 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' GLY . . . . . 0.425 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -178.26 -152.16 10.04 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.732 -0.747 . . . . 60.21 112.459 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.44 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 12.1 p -107.72 134.57 49.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.786 0.326 . . . . 72.42 111.182 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' GLY . . . . . 0.406 ' HA2' ' HA ' ' A' ' 102' ' ' ILE . . . -121.87 172.52 15.52 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.709 -0.758 . . . . 72.42 112.553 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 12.3 ptm180 -169.69 130.07 1.02 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.816 0.341 . . . . 65.51 110.904 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 4.0 p -110.18 120.46 61.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.456 . . . . 75.41 111.131 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 5.7 mp -109.42 149.77 29.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 74.13 110.949 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.553 ' HE2' HG21 ' A' ' 174' ' ' THR . 20.9 m-85 -131.97 152.6 51.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 74.24 110.872 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.683 ' O ' HG21 ' A' ' 96' ' ' VAL . 1.0 OUTLIER -102.61 175.09 5.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.087 -0.506 . . . . 64.14 110.851 -179.882 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.6 p-10 -110.66 95.51 5.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.166 -0.47 . . . . 72.32 110.888 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.722 ' HB2' HG23 ' A' ' 96' ' ' VAL . 9.5 tmtt? -119.35 -68.17 0.93 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 63.31 110.941 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 2.7 m -161.68 63.75 0.25 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.246 -0.434 . . . . 73.42 111.189 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' ASP . . . . . 0.401 ' HA ' ' HA ' ' A' ' 94' ' ' SER . 4.4 m-20 -93.04 163.76 13.53 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.235 -0.439 . . . . 72.4 110.882 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 64.25 150.92 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.699 -0.763 . . . . 73.23 112.448 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.943 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -79.66 2.26 23.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.861 0.362 . . . . 75.05 111.115 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -86.09 -176.64 6.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.441 . . . . 73.03 110.916 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 89.0 p -64.93 88.91 0.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 54.51 110.867 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 7.6 m 49.88 76.17 0.15 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.147 -0.479 . . . . 70.41 110.853 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -93.66 159.27 15.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.1 -0.5 . . . . 71.22 110.913 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -117.64 170.6 8.64 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.193 -0.458 . . . . 71.54 110.879 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.953 HD13 HG13 ' A' ' 176' ' ' VAL . 30.3 mm -116.09 141.61 32.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 64.3 111.113 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 142' ' ' LYS . . . . . 0.407 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 0.2 OUTLIER -90.7 106.2 18.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.163 -0.471 . . . . 54.5 110.918 179.854 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -57.23 -176.68 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.225 -0.443 . . . . 73.02 110.868 179.854 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 24.0 tptt -163.73 161.12 23.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.141 -0.481 . . . . 71.52 110.858 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 5.8 p90 -132.77 146.69 52.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 73.04 110.911 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.663 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.39 162.77 0.96 Allowed Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.527 0.679 . . . . 64.33 111.167 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 147' ' ' PRO . . . . . 0.663 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.6 Cg_endo -69.72 166.43 27.57 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.651 2.234 . . . . 52.42 112.354 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.419 ' HA ' ' HB ' ' A' ' 170' ' ' ILE . . . -153.19 151.47 30.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.261 -0.427 . . . . 71.4 111.11 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 32.0 m-85 -111.81 125.05 53.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 74.32 110.898 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -107.48 158.28 17.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.104 -0.498 . . . . 74.24 110.938 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 15.0 p -161.25 134.79 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.234 -0.439 . . . . 72.2 111.128 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 152' ' ' GLY . . . . . 0.448 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 179.5 -159.21 23.67 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.71 -0.757 . . . . 51.23 112.506 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.86 148.81 39.39 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.872 0.368 . . . . 72.22 110.85 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 3.8 tpp85 -126.97 122.15 33.71 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.142 -0.481 . . . . 73.03 110.868 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 155' ' ' TYR . . . . . 0.421 ' HB3' HD21 ' A' ' 163' ' ' LEU . 0.8 OUTLIER -125.97 164.27 21.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 65.43 111.014 -179.916 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -122.61 108.74 13.46 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 71.4 110.919 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 157' ' ' LEU . . . . . 0.489 HD23 ' N ' ' A' ' 158' ' ' GLY . 0.4 OUTLIER -50.51 158.79 0.57 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 53.01 110.93 -179.945 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 158' ' ' GLY . . . . . 0.489 ' N ' HD23 ' A' ' 157' ' ' LEU . . . -50.6 -32.15 23.68 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.775 -0.726 . . . . 44.25 112.482 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -80.76 -168.64 1.84 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.836 0.351 . . . . 74.31 110.901 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 46.9 t -71.04 -35.3 71.91 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.47 . . . . 72.23 110.846 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 3.1 m0 -71.47 153.93 41.87 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.172 -0.467 . . . . 74.5 110.954 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 162' ' ' MET . . . . . 0.41 ' C ' HD13 ' A' ' 163' ' ' LEU . 2.3 mpt? -131.9 173.98 10.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 63.34 110.819 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.702 ' N ' HD13 ' A' ' 163' ' ' LEU . 0.0 OUTLIER -140.84 160.59 39.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 71.43 110.922 179.998 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -163.74 156.62 18.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 74.51 110.908 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 12.2 p -148.25 121.9 9.22 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 73.44 110.829 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 166' ' ' ASP . . . . . 0.448 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 15.6 t70 -130.72 160.84 33.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 73.0 110.883 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.513 HG13 ' O ' ' A' ' 195' ' ' ILE . 31.8 t -137.04 132.06 46.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.236 -0.438 . . . . 75.41 111.147 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 168' ' ' ARG . . . . . 0.587 ' HD2' HD12 ' A' ' 195' ' ' ILE . 0.0 OUTLIER -101.41 139.31 37.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 75.23 110.868 -179.96 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 66.5 t80 -143.97 134.21 24.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.146 -0.479 . . . . 71.35 110.897 -179.81 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 170' ' ' ILE . . . . . 0.453 HD13 ' N ' ' A' ' 171' ' ' PRO . 0.0 OUTLIER 179.83 131.58 0.25 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.601 0.715 . . . . 64.41 111.217 179.904 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 171' ' ' PRO . . . . . 0.453 ' N ' HD13 ' A' ' 170' ' ' ILE . 54.3 Cg_endo -69.69 109.27 2.26 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.709 2.273 . . . . 53.42 112.355 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -119.0 176.87 5.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.445 . . . . 72.34 110.865 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.53 147.53 29.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.161 -0.472 . . . . 73.34 110.829 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 174' ' ' THR . . . . . 0.553 HG21 ' HE2' ' A' ' 128' ' ' PHE . 0.6 OUTLIER -132.36 162.83 30.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.489 . . . . 71.53 111.177 179.94 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 175' ' ' ASP . . . . . 0.407 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.1 OUTLIER -119.74 170.87 8.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 73.34 110.849 179.93 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.953 HG13 HD13 ' A' ' 141' ' ' ILE . 21.9 t -148.73 133.19 9.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 75.45 111.119 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 14.8 t -166.55 175.03 8.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 40.53 111.169 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -156.62 -137.08 2.25 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.799 -0.715 . . . . 71.43 112.536 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 98.6 m . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 120.785 0.326 . . . . 74.43 111.156 -179.9 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo . . . . . 0 C--O 1.232 0.182 0 CA-C-O 120.866 0.277 . . . . 73.22 112.336 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 29.7 t -106.62 115.56 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.19 -0.459 . . . . 70.34 111.094 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 19.4 p -110.1 105.84 15.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 60.21 110.814 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 16.2 p -107.74 159.46 16.47 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.115 -0.493 . . . . 65.14 111.138 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 34.8 ttpt -147.17 145.18 29.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 64.31 110.857 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 20.6 pt -146.1 142.05 21.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.127 -0.488 . . . . 62.43 111.1 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -124.14 110.8 15.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 74.23 110.896 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 191' ' ' VAL . . . . . 0.404 HG12 ' N ' ' A' ' 192' ' ' ASP . 5.6 t -137.06 157.99 35.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 75.44 111.08 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.404 ' N ' HG12 ' A' ' 191' ' ' VAL . 2.0 p-10 -108.14 88.39 4.71 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.601 0.715 . . . . 72.44 110.898 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 169.13 19.7 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.716 2.277 . . . . 63.2 112.318 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -126.91 117.2 22.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.465 . . . . 73.12 110.888 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 195' ' ' ILE . . . . . 0.587 HD12 ' HD2' ' A' ' 168' ' ' ARG . 61.8 mt -103.29 104.27 16.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 73.33 111.187 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 196' ' ' LEU . . . . . 0.441 HD23 ' CG1' ' A' ' 167' ' ' VAL . 5.5 mt -96.12 108.88 21.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.217 -0.447 . . . . 54.13 110.93 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -108.99 127.7 54.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.244 -0.435 . . . . 73.42 110.848 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 198' ' ' LEU . . . . . 0.4 ' C ' ' HB2' ' A' ' 22' ' ' ASN . 10.4 tt -149.95 132.75 15.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.165 -0.471 . . . . 72.12 110.904 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 199' ' ' GLY . . . . . 0.445 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -177.97 -152.12 9.91 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.776 -0.726 . . . . 62.41 112.468 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 200' ' ' ALA . . . . . 0.53 ' HA ' ' HA ' ' A' ' 163' ' ' LEU . . . -110.09 173.1 6.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.822 0.344 . . . . 55.41 111.034 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 40.6 t -159.98 162.66 34.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 62.42 110.852 -179.739 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 202' ' ' TYR . . . . . 0.623 ' CD1' ' HB3' ' A' ' 19' ' ' ALA . 0.2 OUTLIER -146.55 135.27 22.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.14 -0.482 . . . . 74.3 110.917 -179.898 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.817 HG23 HG22 ' A' ' 18' ' ' VAL . 11.2 p -83.63 152.56 3.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.122 -0.49 . . . . 73.44 111.129 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -151.37 132.08 14.03 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 75.21 110.887 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.125 -0.489 . . . . 75.45 110.885 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 41.6 mt-30 . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.79 0.329 . . . . 73.24 110.945 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.9 9.76 31.78 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.779 -0.724 . . . . 72.11 112.456 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -78.71 169.39 18.31 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.803 0.335 . . . . 73.41 110.874 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 10.1 m-90 -114.9 159.85 20.21 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.215 -0.448 . . . . 74.11 110.937 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.639 HG23 ' HB3' ' A' ' 60' ' ' ALA . 15.5 m -153.38 126.96 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 41.32 111.152 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -96.4 114.95 26.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.154 -0.475 . . . . 75.5 111.077 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -111.95 113.7 26.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.175 -0.466 . . . . 62.12 110.91 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.773 ' CZ ' ' HB3' ' A' ' 200' ' ' ALA . 48.9 p90 -106.65 125.66 51.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 72.34 110.873 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.405 HD22 ' HE2' ' A' ' 72' ' ' PHE . 0.4 OUTLIER -155.55 166.58 33.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.135 -0.484 . . . . 55.32 110.915 179.992 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 23.4 p90 -98.86 132.39 44.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.143 -0.48 . . . . 74.44 110.85 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -98.7 122.69 42.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.152 -0.476 . . . . 74.3 110.871 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 29.2 tptt -99.29 106.53 18.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 63.41 110.867 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.4 p -81.2 133.88 28.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.312 -0.404 . . . . 75.33 111.114 179.834 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -120.5 112.51 19.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.094 -0.503 . . . . 64.23 110.909 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.484 HG23 HG22 ' A' ' 49' ' ' ILE . 4.0 m -153.13 -179.34 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.097 -0.501 . . . . 64.2 111.147 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.63 52.48 0.54 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.682 -0.771 . . . . 71.1 112.477 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 34.0 mt-10 -90.03 -66.75 0.89 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.849 0.357 . . . . 64.03 110.903 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? 177.81 151.94 0.25 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.088 -0.506 . . . . 73.14 110.945 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.474 HD21 ' HB1' ' A' ' 45' ' ' ALA . 0.9 OUTLIER -109.03 163.73 13.05 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.15 -0.477 . . . . 70.54 110.921 -179.982 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.26 0 C-N-CA 120.737 -0.744 . . . . 75.52 112.452 179.864 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.474 ' HB1' HD21 ' A' ' 32' ' ' LEU . . . . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.733 0.301 . . . . 54.21 111.105 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -159.52 125.15 4.22 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.231 -0.441 . . . . 61.01 110.869 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.423 ' HA ' ' HA2' ' A' ' 83' ' ' GLY . 6.5 p -118.14 148.91 20.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.193 -0.458 . . . . 75.35 111.072 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -173.14 174.47 3.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 72.41 110.878 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.775 HD11 ' CE2' ' A' ' 98' ' ' TYR . 19.3 tt -141.57 154.79 20.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.112 -0.494 . . . . 70.11 111.086 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -124.42 167.54 16.72 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.715 -0.755 . . . . 64.21 112.426 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.9 m-80 -162.66 163.91 26.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.821 0.343 . . . . 71.22 110.904 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -120.36 -68.83 0.88 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 62.43 110.827 179.866 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 72.3 p -91.93 172.87 8.17 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.216 -0.447 . . . . 65.23 111.144 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 40.3 p -148.38 106.52 3.73 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.226 -0.443 . . . . 73.43 111.122 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.406 HD12 ' O ' ' A' ' 55' ' ' LEU . 3.3 pp -160.73 128.74 4.47 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 64.54 110.94 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.459 HG22 ' HA3' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -142.54 155.74 45.05 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.274 -0.421 . . . . 72.35 111.182 179.948 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -114.95 132.46 56.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 70.42 110.893 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.451 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -129.88 134.83 47.76 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.211 -0.449 . . . . 63.24 110.991 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.43 HD13 ' C ' ' A' ' 58' ' ' ASP . 3.0 mm -109.29 115.16 48.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.274 -0.421 . . . . 54.03 111.125 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.639 ' HB3' HG23 ' A' ' 18' ' ' VAL . . . -111.31 151.48 28.33 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.178 -0.464 . . . . 61.1 111.084 179.829 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.457 ' HB2' HG22 ' A' ' 69' ' ' VAL . 5.3 m-85 -125.74 132.37 52.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 73.04 110.932 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -98.3 95.22 7.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.081 -0.509 . . . . 73.24 110.893 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.5 t -94.35 -31.74 4.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.151 -0.477 . . . . 52.24 111.089 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 29.7 t -136.15 158.07 45.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 72.22 110.831 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 59.8 p -85.07 3.98 36.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 72.41 110.859 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -114.41 -29.47 6.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 72.41 110.84 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.424 HG22 ' CD2' ' A' ' 107' ' ' TYR . 32.5 pt -142.08 158.0 20.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 62.32 111.113 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -148.91 163.27 37.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 62.12 111.115 179.839 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.457 HG22 ' HB2' ' A' ' 61' ' ' TYR . 6.1 m -112.24 152.14 14.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 71.02 111.155 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.449 ' HA ' ' HA ' ' A' ' 60' ' ' ALA . 1.5 p30 -144.58 143.31 30.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 64.25 110.885 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.451 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -127.19 108.44 10.89 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 71.33 110.851 -179.907 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.405 ' HE2' HD22 ' A' ' 22' ' ' ASN . 45.8 m-85 -86.33 127.26 34.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.12 -0.491 . . . . 60.15 110.819 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 14.6 p -147.3 147.49 17.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 63.11 111.198 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.459 ' HA3' HG22 ' A' ' 56' ' ' THR . . . -161.88 144.18 9.51 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.753 -0.737 . . . . 73.55 112.487 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 44.3 t -119.74 73.18 16.91 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.608 0.718 . . . . 61.43 111.129 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 159.09 54.7 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.669 2.246 . . . . 44.34 112.365 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -74.91 -165.8 0.41 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.251 -0.431 . . . . 72.35 111.181 179.818 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 18.2 ttm105 -77.05 138.22 39.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.283 -0.417 . . . . 61.54 110.833 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ALA . . . . . 0.668 ' HB3' ' CE2' ' A' ' 98' ' ' TYR . . . -132.77 148.99 52.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.443 . . . . 52.45 111.128 179.836 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.6 ttpm? -89.12 123.8 33.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.182 -0.463 . . . . 72.41 110.93 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 59.6 t80 -109.13 138.82 44.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 62.45 110.878 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.416 ' O ' HG23 ' A' ' 47' ' ' VAL . 7.6 pt20 -109.17 150.91 27.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 74.43 110.917 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.657 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 174.37 84.88 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.696 -0.764 . . . . 74.31 112.447 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -178.07 -175.68 0.5 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.894 0.378 . . . . 52.44 110.976 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 1.4 ptpt -86.54 -70.13 0.63 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.198 -0.455 . . . . 74.22 110.879 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 8.4 t -85.25 -30.52 23.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.225 -0.443 . . . . 73.35 110.869 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.849 HG22 HG22 ' A' ' 93' ' ' VAL . 4.8 mm -68.81 -35.21 68.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.123 -0.489 . . . . 72.12 111.114 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.1 t -62.68 -47.38 83.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 44.42 110.861 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.1 t -54.67 -39.85 68.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.149 -0.478 . . . . 71.23 110.837 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 13.9 tp -60.55 -44.23 96.37 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.083 -0.508 . . . . 75.13 110.995 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.24 -14.55 39.86 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.743 -0.741 . . . . 74.55 112.501 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 9.8 mtm180 -120.54 96.74 5.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.897 0.38 . . . . 71.12 110.813 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.849 HG22 HG22 ' A' ' 87' ' ' ILE . 99.3 t -107.24 -58.27 3.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 64.05 111.1 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.413 ' HA ' ' HA ' ' A' ' 133' ' ' ASP . 0.9 OUTLIER -140.09 148.73 42.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.154 -0.475 . . . . 64.43 110.902 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 31.6 mt-10 -126.01 124.59 41.03 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.132 -0.485 . . . . 71.21 110.972 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.45 HG22 ' N ' ' A' ' 97' ' ' ASP . 14.8 p -176.05 156.76 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 64.45 111.11 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.45 ' N ' HG22 ' A' ' 96' ' ' VAL . 3.9 p30 -84.27 173.49 10.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 75.34 110.902 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' TYR . . . . . 0.775 ' CE2' HD11 ' A' ' 49' ' ' ILE . 14.4 m-85 -130.48 133.17 46.08 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 74.23 110.933 -179.825 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -114.11 69.63 0.24 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.703 -0.761 . . . . 54.42 112.445 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.82 138.44 37.64 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.694 2.263 . . . . 55.12 112.294 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -155.7 118.08 4.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 60.55 111.115 179.86 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.649 HG22 ' CA ' ' A' ' 124' ' ' GLY . 30.0 pt -140.15 146.1 25.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 62.24 111.165 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.42 HD22 ' CE1' ' A' ' 71' ' ' PHE . 2.3 pp -132.82 118.99 19.66 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.196 -0.456 . . . . 74.11 110.846 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' SER . . . . . 0.421 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 5.6 p -142.93 163.92 31.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.202 -0.454 . . . . 65.11 110.875 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.577 ' O ' HD12 ' A' ' 105' ' ' LEU . 1.1 pp -113.87 151.46 32.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 54.52 110.886 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 71.1 mt-30 -106.49 144.05 33.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 73.55 110.907 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.424 ' CD2' HG22 ' A' ' 67' ' ' ILE . 5.4 t80 -136.02 125.41 24.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 65.53 110.968 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 1.9 t60 . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 116.173 -0.467 . . . . 64.31 110.843 179.956 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 6.1 m-85 . . . . . 0 C--O 1.231 0.119 0 CA-C-O 121.689 0.757 . . . . 73.4 110.884 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 178.43 4.57 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.633 2.222 . . . . 73.43 112.349 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 4.0 m-85 -110.24 151.95 26.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.462 . . . . 74.35 110.949 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 8.3 p -101.93 133.01 46.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.109 -0.496 . . . . 75.11 111.101 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -131.92 174.67 20.11 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.796 -0.716 . . . . 71.15 112.568 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.505 HG23 ' HA ' ' A' ' 149' ' ' PHE . 9.4 p -175.95 153.54 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.865 0.364 . . . . 73.43 111.106 -179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 122' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -176.01 -158.21 19.09 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.76 -0.734 . . . . 54.2 112.543 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.45 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 21.3 m -107.7 150.66 10.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.869 0.366 . . . . 72.03 111.116 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' GLY . . . . . 0.649 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -130.53 169.07 21.46 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.687 -0.768 . . . . 75.24 112.455 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 125' ' ' ARG . . . . . 0.432 ' HA ' ' HA ' ' A' ' 145' ' ' TRP . 0.0 OUTLIER -168.55 129.26 1.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.86 0.362 . . . . 71.3 110.923 -179.855 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.468 ' O ' HG13 ' A' ' 126' ' ' VAL . 3.9 p -118.73 112.04 36.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 51.3 111.152 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.457 HD23 ' N ' ' A' ' 128' ' ' PHE . 10.0 tt -122.52 151.23 41.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 73.34 110.883 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.602 ' CE1' HG23 ' A' ' 141' ' ' ILE . 1.3 p90 -160.89 161.94 31.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.187 -0.461 . . . . 72.21 110.833 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 51.5 t80 -101.07 118.59 37.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.49 . . . . 71.53 110.88 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -50.55 102.37 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 65.21 110.845 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -77.52 -80.81 0.1 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.139 -0.482 . . . . 74.35 110.901 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -165.43 112.9 0.96 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.256 -0.429 . . . . 74.34 111.125 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 133' ' ' ASP . . . . . 0.538 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 1.4 m-20 -103.07 119.36 38.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.144 -0.48 . . . . 71.35 110.923 179.853 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -79.89 -5.82 89.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.806 -0.712 . . . . 53.51 112.445 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -46.81 -28.18 1.46 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.81 0.338 . . . . 73.2 111.113 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -162.86 -178.56 6.2 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.191 -0.458 . . . . 71.52 111.019 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 1.5 m -53.02 93.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.275 -0.42 . . . . 73.1 110.828 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 7.0 m 50.68 71.19 0.44 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.081 -0.509 . . . . 70.22 110.891 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.623 ' CE2' HG12 ' A' ' 176' ' ' VAL . 0.5 OUTLIER -92.98 159.88 15.12 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.135 -0.484 . . . . 72.25 110.838 -179.912 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 94.0 m-20 -134.0 167.41 20.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.495 . . . . 75.54 110.891 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.602 HG23 ' CE1' ' A' ' 128' ' ' PHE . 17.6 tt -117.97 149.11 20.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.192 -0.458 . . . . 74.04 111.182 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 16.2 mmtt -113.36 124.54 52.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 73.43 110.931 179.885 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.421 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 0.0 OUTLIER -85.53 -173.32 4.59 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.225 -0.443 . . . . 44.51 110.868 179.915 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -171.54 -175.36 1.58 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 72.51 110.904 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 145' ' ' TRP . . . . . 0.432 ' HA ' ' HA ' ' A' ' 125' ' ' ARG . 22.5 p-90 -143.57 160.49 40.54 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.198 -0.456 . . . . 64.32 110.917 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.679 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 178.86 163.15 0.69 Allowed Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.623 0.725 . . . . 23.01 111.086 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 147' ' ' PRO . . . . . 0.679 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 54.3 Cg_endo -69.66 170.61 16.06 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.683 2.255 . . . . 70.32 112.375 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.45 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -165.55 153.0 10.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.222 -0.445 . . . . 72.12 111.13 179.875 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 149' ' ' PHE . . . . . 0.505 ' HA ' HG23 ' A' ' 121' ' ' VAL . 12.9 m-85 -96.17 161.3 14.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.242 -0.435 . . . . 71.52 110.819 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 27.7 tp60 -135.0 148.59 50.0 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 61.22 110.949 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 10.2 p -151.54 130.84 3.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.17 -0.468 . . . . 74.33 111.161 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' GLY . . . . . 0.405 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 164.95 -163.21 36.27 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.727 -0.749 . . . . 52.15 112.481 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -148.93 168.26 23.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.788 0.328 . . . . 62.31 110.95 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -133.68 128.51 35.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 64.02 110.88 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -132.66 161.64 33.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.442 . . . . 74.31 110.933 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -121.28 109.58 15.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.147 -0.479 . . . . 73.01 110.904 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 3.6 tp -57.46 160.45 4.12 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.169 -0.469 . . . . 62.24 110.944 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -52.05 -33.24 36.77 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.775 -0.726 . . . . 64.04 112.495 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 4.6 m120 -80.52 173.65 12.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.907 0.384 . . . . 74.14 110.821 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 81.1 p -54.78 -35.74 64.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.113 -0.494 . . . . 75.45 110.815 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 10.3 m0 -69.31 151.68 45.91 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.199 -0.455 . . . . 64.34 110.97 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 38.8 mtt -121.22 174.92 6.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.246 -0.433 . . . . 73.11 110.862 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.435 ' HA ' ' HA ' ' A' ' 200' ' ' ALA . 0.6 OUTLIER -128.65 139.25 52.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.262 -0.427 . . . . 72.0 110.909 179.999 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -139.84 138.33 35.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 71.13 110.984 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.7 p -141.61 121.79 13.85 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.214 -0.448 . . . . 73.24 110.892 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 166' ' ' ASP . . . . . 0.405 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 23.3 m-20 -140.26 167.59 21.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.08 -0.509 . . . . 72.41 110.812 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.528 HG13 ' O ' ' A' ' 195' ' ' ILE . 46.7 t -150.43 129.05 2.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.157 -0.474 . . . . 61.33 111.115 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 168' ' ' ARG . . . . . 0.552 ' NH1' HG21 ' A' ' 102' ' ' ILE . 0.0 OUTLIER -98.59 137.71 36.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 71.32 110.862 -179.972 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 15.9 t80 -138.22 125.37 21.52 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 62.2 110.929 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 170' ' ' ILE . . . . . 0.468 HG13 ' HD2' ' A' ' 171' ' ' PRO . 4.7 tp 178.9 134.69 0.24 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.599 0.714 . . . . 72.34 111.116 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 171' ' ' PRO . . . . . 0.468 ' HD2' HG13 ' A' ' 170' ' ' ILE . 54.0 Cg_endo -69.85 111.55 2.86 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.609 2.206 . . . . 64.54 112.386 179.858 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 172' ' ' PHE . . . . . 0.535 ' CE2' ' HB3' ' A' ' 146' ' ' ALA . 5.3 t80 -116.1 159.76 21.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.139 -0.482 . . . . 72.35 110.856 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 5.4 ptpt -140.06 144.79 37.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.146 -0.479 . . . . 73.41 110.926 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 9.4 t -117.79 161.9 18.96 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 73.52 111.137 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 21.6 t70 -118.48 158.54 25.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.14 -0.482 . . . . 71.3 110.844 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.623 HG12 ' CE2' ' A' ' 139' ' ' PHE . 4.5 t -147.94 138.26 16.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 72.54 111.082 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.3 t -166.92 -179.22 4.59 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.131 -0.486 . . . . 71.11 111.116 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -120.55 -161.66 11.53 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.746 -0.74 . . . . 61.35 112.458 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 6.4 t . . . . . 0 C--N 1.331 -0.217 0 CA-C-O 120.84 0.353 . . . . 75.22 111.16 -179.914 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo . . . . . 0 C--O 1.231 0.149 0 CA-C-O 120.839 0.266 . . . . 64.53 112.317 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.418 HG12 HG23 ' A' ' 187' ' ' THR . 26.5 t -103.59 108.17 23.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 71.34 111.111 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -74.13 104.83 5.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.137 -0.483 . . . . 74.14 110.82 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 187' ' ' THR . . . . . 0.418 HG23 HG12 ' A' ' 185' ' ' VAL . 65.1 p -124.44 168.59 12.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.136 -0.484 . . . . 73.31 111.171 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 3.0 ttpm? -158.97 134.09 8.34 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.207 -0.451 . . . . 41.54 110.944 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -115.75 139.59 41.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.279 -0.419 . . . . 72.33 111.107 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 71.7 tt0 -119.55 114.99 23.1 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.125 -0.489 . . . . 74.22 110.817 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 191' ' ' VAL . . . . . 0.539 HG22 ' H ' ' A' ' 192' ' ' ASP . 1.2 p -137.18 171.28 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 70.41 111.111 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.539 ' H ' HG22 ' A' ' 191' ' ' VAL . 4.2 m-20 -106.93 87.14 2.73 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.594 0.711 . . . . 62.11 110.915 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.65 120.96 7.68 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.742 2.295 . . . . 62.21 112.379 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 194' ' ' PHE . . . . . 0.425 ' CE1' HG11 ' A' ' 167' ' ' VAL . 2.1 t80 -102.09 114.0 27.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.258 -0.428 . . . . 72.4 110.887 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 195' ' ' ILE . . . . . 0.55 HD12 ' HG2' ' A' ' 168' ' ' ARG . 5.6 mt -103.56 127.3 57.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.162 -0.472 . . . . 74.22 111.133 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 196' ' ' LEU . . . . . 0.41 ' HG ' HG22 ' A' ' 167' ' ' VAL . 1.1 tt -117.14 107.72 14.82 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.182 -0.463 . . . . 64.34 110.89 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 3.2 m -96.38 123.62 40.09 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.24 -0.436 . . . . 65.42 110.847 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 2.5 tt -144.13 129.21 18.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 62.21 110.86 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 178.94 -146.98 7.53 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.75 -0.738 . . . . 73.21 112.478 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 200' ' ' ALA . . . . . 0.773 ' HB3' ' CZ ' ' A' ' 21' ' ' PHE . . . -118.65 174.26 6.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.781 0.324 . . . . 61.35 111.17 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 78.1 p -149.66 175.71 11.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.28 -0.418 . . . . 74.21 110.843 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -157.31 160.9 39.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 73.52 110.895 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.503 ' HA ' HG12 ' A' ' 18' ' ' VAL . 18.2 m -76.76 161.21 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.065 -0.516 . . . . 65.0 111.15 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -155.95 127.59 7.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 71.11 110.865 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 14.3 ttmm . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.119 -0.492 . . . . 73.2 110.924 179.946 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 . . . . . 0 CA--C 1.526 0.04 0 CA-C-O 120.8 0.333 . . . . 75.43 110.881 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.71 11.57 28.33 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 61.41 112.498 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -82.66 160.51 22.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.766 0.317 . . . . 63.25 110.922 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 12.8 m95 -108.76 159.65 16.6 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.257 -0.429 . . . . 71.43 110.936 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.437 HG13 ' O ' ' A' ' 202' ' ' TYR . 48.1 t -150.5 119.2 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.426 . . . . 45.31 111.139 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -85.0 107.52 17.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.096 -0.502 . . . . 63.13 111.078 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -105.45 112.76 25.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 63.11 110.902 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -111.73 125.79 54.36 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.159 -0.473 . . . . 73.11 110.879 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.43 ' O ' HG22 ' A' ' 56' ' ' THR . 4.0 p30 -155.78 172.66 17.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 71.44 110.907 -179.887 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.8 p90 -100.96 132.21 46.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 71.24 110.867 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' SER . . . . . 0.591 ' OG ' HG23 ' A' ' 195' ' ' ILE . 0.3 OUTLIER -100.68 120.04 39.48 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.151 -0.477 . . . . 65.34 110.88 -179.797 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 39.1 tttm -93.56 106.82 18.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 63.1 110.849 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.614 ' HA ' HD13 ' A' ' 195' ' ' ILE . 11.3 p -84.12 135.8 24.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 72.4 111.106 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -125.84 99.42 5.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.154 -0.475 . . . . 74.34 110.855 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.68 HG23 HG11 ' A' ' 191' ' ' VAL . 2.7 p -147.33 142.26 19.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.155 -0.475 . . . . 71.24 111.152 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 142.08 64.57 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.706 -0.759 . . . . 54.11 112.528 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -89.86 -66.16 0.95 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.766 0.317 . . . . 72.35 110.911 -179.863 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -171.41 134.87 0.9 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.122 -0.49 . . . . 61.14 110.873 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 5.1 tt -104.94 152.69 22.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.186 -0.461 . . . . 71.35 110.992 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.234 0 C-N-CA 120.666 -0.778 . . . . 54.13 112.502 179.946 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.79 0.328 . . . . 74.21 111.062 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 21.8 m-20 -160.48 125.37 3.79 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 54.4 110.922 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.54 HG13 ' O ' ' A' ' 82' ' ' GLN . 18.5 t -104.4 135.51 41.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.187 -0.46 . . . . 65.31 111.159 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -132.63 137.59 47.06 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 73.13 110.816 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 3.8 tt -101.3 145.03 12.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.094 -0.503 . . . . 73.51 111.094 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -60.24 -168.58 0.38 Allowed Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.746 -0.74 . . . . 63.32 112.462 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -119.05 -37.34 3.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.781 0.324 . . . . 73.14 110.937 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -51.96 150.51 4.21 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.147 -0.479 . . . . 75.15 110.881 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 3.7 p -146.13 178.21 8.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 62.13 111.138 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.6 t -160.14 169.47 23.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.268 -0.424 . . . . 75.14 111.183 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 5.0 mp -91.13 168.38 11.67 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 65.22 110.921 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.43 HG22 ' O ' ' A' ' 22' ' ' ASN . 12.1 t -135.94 149.51 48.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.186 -0.461 . . . . 65.41 111.133 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -102.75 133.05 48.43 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.292 -0.413 . . . . 73.35 110.846 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -125.91 138.62 53.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 53.45 110.84 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.53 114.15 45.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 65.42 111.164 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -105.87 121.64 44.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 73.4 111.057 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.785 ' HB3' HG22 ' A' ' 69' ' ' VAL . 7.4 t80 -106.08 117.38 33.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 73.03 110.931 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -92.43 101.83 14.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.124 -0.489 . . . . 60.03 110.892 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.41 HG23 ' OG ' ' A' ' 64' ' ' SER . 32.5 m -98.39 -31.72 3.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.46 . . . . 70.22 111.156 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.41 ' OG ' HG23 ' A' ' 63' ' ' VAL . 1.1 m -125.92 -169.51 2.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.192 -0.458 . . . . 71.0 110.895 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.5 m -84.18 -38.92 20.02 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 74.1 110.893 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -126.09 25.99 6.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.067 -0.515 . . . . 71.3 110.865 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 3.4 mt -145.16 126.94 8.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.22 -0.446 . . . . 70.04 111.136 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.484 ' HB1' ' O ' ' A' ' 61' ' ' TYR . . . -155.05 168.61 26.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.138 -0.483 . . . . 52.34 111.119 179.843 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.785 HG22 ' HB3' ' A' ' 61' ' ' TYR . 2.5 m -111.76 152.47 13.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 61.12 111.14 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -131.66 129.41 40.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 63.23 110.821 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -114.38 110.15 19.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 73.31 110.87 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -81.82 113.08 19.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 73.14 110.955 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.8 t -124.04 116.46 47.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.167 -0.47 . . . . 74.4 111.03 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -131.87 152.14 20.03 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.71 -0.757 . . . . 74.23 112.48 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 39.4 t -143.38 69.81 17.69 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.575 0.702 . . . . 71.2 111.144 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.79 140.61 42.98 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.666 2.244 . . . . 71.22 112.373 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.87 -173.66 0.26 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.188 -0.46 . . . . 72.33 111.075 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 8.9 ttm180 -76.43 129.61 36.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 75.12 110.856 -179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -131.03 151.71 51.12 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.227 -0.442 . . . . 70.21 111.085 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.8 tttp -97.59 123.9 41.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.134 -0.485 . . . . 62.41 110.847 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -111.43 151.68 28.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 71.43 110.907 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.54 ' O ' HG13 ' A' ' 47' ' ' VAL . 18.1 mt-30 -111.71 148.47 33.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 75.31 110.899 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.571 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -178.71 81.41 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.789 -0.719 . . . . 74.51 112.479 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -176.52 -175.59 0.67 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.95 0.405 . . . . 60.2 110.868 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.17 -69.72 0.65 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.127 -0.488 . . . . 65.0 110.949 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 16.9 p -85.16 -32.05 22.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.237 -0.438 . . . . 72.01 110.853 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.951 HG21 ' HB2' ' A' ' 135' ' ' ALA . 4.6 mm -67.34 -35.13 72.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.094 -0.503 . . . . 74.35 111.111 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.8 t -62.38 -44.85 95.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.219 -0.446 . . . . 52.23 110.79 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 39.1 t -57.43 -37.31 72.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 62.1 110.904 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 98.5 mt -63.56 -50.3 70.02 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.107 -0.497 . . . . 52.32 110.902 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 114.14 -13.22 21.69 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.721 -0.752 . . . . 75.42 112.475 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.61 96.19 5.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.839 0.352 . . . . 74.13 110.821 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.887 HG22 HG22 ' A' ' 87' ' ' ILE . 64.5 t -113.74 -50.84 5.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.253 -0.431 . . . . 64.12 111.108 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 60.5 p -140.11 148.69 42.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 64.42 110.91 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -140.68 118.52 11.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 71.42 110.79 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.526 HG22 ' H ' ' A' ' 97' ' ' ASP . 1.6 p -179.24 170.31 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.171 -0.468 . . . . 71.22 111.089 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.526 ' H ' HG22 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -109.43 160.29 16.32 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.198 -0.455 . . . . 74.21 110.869 179.931 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 98' ' ' TYR . . . . . 0.424 ' HA ' ' HB2' ' A' ' 128' ' ' PHE . 17.7 m-85 -120.35 145.23 47.35 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.226 -0.443 . . . . 75.11 110.948 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -108.67 87.3 0.48 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.775 -0.726 . . . . 72.12 112.412 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.656 ' HA ' HG12 ' A' ' 126' ' ' VAL . 54.2 Cg_endo -69.76 110.43 2.55 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.668 2.245 . . . . 74.41 112.406 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.409 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -128.88 95.57 4.12 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.241 -0.436 . . . . 42.13 111.12 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.617 HG23 ' CA ' ' A' ' 124' ' ' GLY . 5.8 mm -116.64 142.22 31.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.229 -0.441 . . . . 62.24 111.138 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.46 ' HG ' HG13 ' A' ' 123' ' ' VAL . 0.3 OUTLIER -140.13 109.66 6.27 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.188 -0.46 . . . . 74.14 110.934 179.959 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 104' ' ' SER . . . . . 0.413 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 4.8 p -138.19 -177.6 4.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 73.13 110.854 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.606 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.7 OUTLIER -128.87 141.89 51.14 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 71.23 110.863 -179.946 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 -101.55 132.72 47.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 65.11 110.992 179.853 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 27.5 t80 -137.1 145.61 44.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.237 -0.438 . . . . 64.21 110.937 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 59.0 t-80 . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.152 -0.476 . . . . 64.44 110.917 179.89 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 7.7 p90 . . . . . 0 C--O 1.232 0.137 0 CA-C-O 121.655 0.74 . . . . 72.44 110.985 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 117' ' ' PRO . . . . . 0.684 ' HA ' HD12 ' A' ' 153' ' ' LEU . 53.8 Cg_endo -69.81 176.95 6.13 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.6 2.2 . . . . 71.54 112.31 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 118' ' ' TYR . . . . . 0.474 ' O ' HG23 ' A' ' 151' ' ' VAL . 26.5 m-85 -111.53 144.24 41.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 71.14 110.924 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 13.2 p -100.7 133.26 44.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.237 -0.438 . . . . 73.24 111.102 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.418 ' HA2' ' O ' ' A' ' 105' ' ' LEU . . . -125.92 159.01 20.32 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.738 -0.744 . . . . 71.34 112.489 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.1 p -161.6 149.47 4.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.81 0.338 . . . . 75.14 111.15 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' GLY . . . . . 0.413 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -177.5 -151.3 9.07 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.744 -0.741 . . . . 53.04 112.5 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.531 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.3 p -110.39 126.31 67.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.877 0.37 . . . . 72.21 111.114 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' GLY . . . . . 0.617 ' CA ' HG23 ' A' ' 102' ' ' ILE . . . -116.06 119.94 4.72 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.769 -0.729 . . . . 60.05 112.503 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' ARG . . . . . 0.409 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 13.5 ptm180 -120.44 122.88 41.67 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.921 0.391 . . . . 74.13 110.854 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.656 HG12 ' HA ' ' A' ' 100' ' ' PRO . 3.7 m -118.34 118.6 58.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.202 -0.454 . . . . 60.11 111.117 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.423 ' HA ' ' HB3' ' A' ' 143' ' ' ASP . 1.2 pt? -160.02 165.23 32.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.231 -0.441 . . . . 72.53 110.985 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.424 ' HB2' ' HA ' ' A' ' 98' ' ' TYR . 1.0 OUTLIER -165.93 -171.12 1.93 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.236 -0.438 . . . . 74.11 110.897 179.925 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -94.13 135.12 35.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.174 -0.466 . . . . 73.3 110.926 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -69.63 148.01 49.9 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.138 -0.483 . . . . 72.43 110.843 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.482 ' CB ' HG23 ' A' ' 96' ' ' VAL . 0.2 OUTLIER -129.55 -69.29 0.69 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 73.05 110.933 179.94 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 33.8 m -159.93 75.12 0.6 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.185 -0.461 . . . . 74.15 111.189 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -97.85 175.5 6.13 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.224 -0.444 . . . . 73.21 110.81 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 62.99 149.55 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.735 -0.745 . . . . 71.03 112.479 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.951 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -76.51 -1.7 28.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.892 0.377 . . . . 43.04 111.187 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -86.5 -177.09 6.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.135 -0.484 . . . . 71.42 110.906 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -64.06 93.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.198 -0.455 . . . . 62.44 110.847 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 89.0 p 46.06 76.26 0.1 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 62.12 110.88 -179.812 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -82.96 151.16 26.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 71.42 110.794 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' ASP . . . . . 0.447 ' O ' HG13 ' A' ' 176' ' ' VAL . 1.6 t70 -101.74 165.63 11.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.093 -0.503 . . . . 72.51 110.776 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -127.08 163.0 30.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 64.25 111.168 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 142' ' ' LYS . . . . . 0.41 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 0.2 OUTLIER -119.21 108.14 14.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 74.45 110.898 179.847 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.428 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 1.0 OUTLIER -58.84 -172.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.243 -0.435 . . . . 44.22 110.819 179.967 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 15.9 mmtt -149.47 155.28 40.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.45 . . . . 55.33 110.886 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 45.3 p90 -151.67 136.23 16.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.227 -0.442 . . . . 63.53 110.926 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.933 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.28 172.14 0.61 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.583 0.706 . . . . 51.15 111.051 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 147' ' ' PRO . . . . . 0.933 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 54.3 Cg_endo -69.69 134.09 27.29 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.631 2.221 . . . . 52.51 112.421 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.468 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -130.1 166.47 20.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.262 -0.426 . . . . 64.2 111.126 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -121.55 167.39 12.92 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 71.21 110.951 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -165.85 162.3 18.29 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 71.41 110.923 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.474 HG23 ' O ' ' A' ' 118' ' ' TYR . 10.7 p -153.51 141.32 13.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 73.0 111.147 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -169.4 -171.79 35.41 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.772 -0.728 . . . . 64.24 112.451 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.684 HD12 ' HA ' ' A' ' 117' ' ' PRO . 8.5 tt -149.2 157.08 43.07 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.738 0.304 . . . . 74.35 110.934 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.438 ' N ' HD23 ' A' ' 153' ' ' LEU . 7.1 tpp85 -108.08 117.43 34.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.224 -0.444 . . . . 74.43 110.836 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 4.5 t80 -105.17 145.38 30.66 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.184 -0.462 . . . . 74.24 110.876 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -115.38 105.77 13.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.091 -0.504 . . . . 55.45 110.897 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 11.9 tp -93.93 164.34 13.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.184 -0.462 . . . . 64.25 110.925 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -76.08 68.38 2.31 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.75 -0.738 . . . . 55.53 112.468 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 64.7 m-80 -151.41 175.25 12.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.804 0.335 . . . . 74.3 110.876 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 6.2 m -56.32 -38.55 71.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.209 -0.45 . . . . 65.32 110.85 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 4.6 p90 -111.8 178.26 4.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.167 -0.47 . . . . 73.22 110.905 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 162' ' ' MET . . . . . 0.46 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 0.0 OUTLIER -117.08 170.81 8.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 53.41 110.92 179.873 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 5.8 tp -104.09 151.35 23.38 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.246 -0.433 . . . . 71.11 110.886 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 4.0 t-20 -145.07 137.84 26.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.17 -0.468 . . . . 74.1 110.919 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 26.8 p -136.22 122.5 20.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 72.54 110.906 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -140.5 164.62 29.67 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.136 -0.484 . . . . 61.22 110.878 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 94.7 t -150.51 116.61 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.248 -0.433 . . . . 73.4 111.115 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -97.66 146.49 25.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 74.24 110.879 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 62.2 t80 -146.81 143.3 28.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 71.14 110.86 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 170' ' ' ILE . . . . . 0.468 HG21 ' HB2' ' A' ' 148' ' ' ALA . 0.0 OUTLIER -179.0 103.14 0.2 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.66 0.743 . . . . 73.32 111.154 179.918 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 127.32 14.48 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.661 2.241 . . . . 72.24 112.439 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -148.64 178.42 8.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.254 -0.43 . . . . 62.04 110.952 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.82 127.74 37.26 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.187 -0.461 . . . . 74.04 110.892 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.8 t -91.88 165.96 12.97 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.291 -0.413 . . . . 63.33 111.123 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 175' ' ' ASP . . . . . 0.41 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -124.58 167.06 15.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 72.23 110.86 179.884 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.447 HG13 ' O ' ' A' ' 140' ' ' ASP . 45.7 t -152.16 139.78 13.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.13 -0.487 . . . . 72.22 111.163 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 14.5 t -167.27 179.35 5.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 63.01 111.149 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 131.63 143.49 5.21 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.747 -0.739 . . . . 63.34 112.45 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 7.1 t . . . . . 0 C--N 1.329 -0.309 0 CA-C-O 120.86 0.362 . . . . 64.21 111.111 -179.912 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo . . . . . 0 C--O 1.231 0.157 0 CA-C-O 120.766 0.236 . . . . 73.11 112.368 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 44.6 t -96.8 107.5 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.227 -0.442 . . . . 71.03 111.092 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 13.3 p -89.36 104.98 17.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 63.51 110.861 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 10.8 p -110.22 166.53 10.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.083 -0.508 . . . . 74.13 111.151 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -152.23 146.6 25.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 73.1 110.922 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 18.2 pt -142.51 130.39 20.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 74.21 111.14 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -99.29 118.23 35.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 74.01 110.837 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 191' ' ' VAL . . . . . 0.68 HG11 HG23 ' A' ' 28' ' ' VAL . 8.5 p -137.79 159.99 33.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 72.11 111.143 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.408 ' N ' HG22 ' A' ' 191' ' ' VAL . 0.2 OUTLIER -107.22 90.26 5.46 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.567 0.699 . . . . 74.13 110.927 179.982 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 116.31 4.5 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.683 2.255 . . . . 75.44 112.342 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -100.28 119.65 38.72 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.176 -0.466 . . . . 70.2 110.918 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 195' ' ' ILE . . . . . 0.614 HD13 ' HA ' ' A' ' 26' ' ' VAL . 40.5 mm -108.79 119.48 58.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.123 -0.49 . . . . 63.44 111.094 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 7.3 mp -113.03 107.25 15.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.156 -0.475 . . . . 74.13 110.949 179.863 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 197' ' ' SER . . . . . 0.603 ' O ' HD12 ' A' ' 198' ' ' LEU . 0.9 OUTLIER -95.31 124.47 39.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.225 -0.443 . . . . 70.13 110.826 -179.907 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 198' ' ' LEU . . . . . 0.603 HD12 ' O ' ' A' ' 197' ' ' SER . 5.0 mp -146.39 127.92 15.07 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.101 -0.5 . . . . 71.43 110.987 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 177.27 -136.25 3.05 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.655 -0.783 . . . . 64.42 112.442 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 200' ' ' ALA . . . . . 0.46 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -134.06 173.15 11.89 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.85 0.357 . . . . 64.32 111.114 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 2.3 p -144.92 174.83 10.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.434 . . . . 71.53 110.92 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 202' ' ' TYR . . . . . 0.437 ' O ' HG13 ' A' ' 18' ' ' VAL . 12.6 t80 -148.63 138.77 22.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.101 -0.499 . . . . 74.23 110.854 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 11.5 p -77.2 151.23 5.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.077 -0.51 . . . . 73.14 111.117 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 -153.13 114.15 4.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.133 -0.485 . . . . 71.14 110.896 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 5.7 ptpt . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 71.21 110.879 179.982 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.892 0.377 . . . . 62.53 110.919 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.94 6.9 68.96 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.72 -0.753 . . . . 60.24 112.421 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -75.54 145.24 41.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.752 0.31 . . . . 74.13 110.884 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -127.22 121.56 31.58 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.234 -0.439 . . . . 73.22 110.958 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.783 HG13 ' HB3' ' A' ' 60' ' ' ALA . 2.9 p -131.28 123.55 53.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.252 -0.431 . . . . 74.21 111.115 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -84.41 115.18 22.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.117 -0.492 . . . . 64.33 111.097 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -104.62 108.8 20.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 62.35 110.9 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -111.97 125.3 53.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 64.3 110.942 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.404 ' HB2' ' C ' ' A' ' 198' ' ' LEU . 5.4 p30 -153.53 174.05 14.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 61.13 110.829 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -98.0 129.45 44.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.113 -0.494 . . . . 74.5 110.814 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -97.22 122.47 40.27 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.148 -0.478 . . . . 72.23 110.836 -179.847 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -102.4 105.76 16.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.089 -0.505 . . . . 73.43 110.902 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.5 m -82.71 131.04 34.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.272 -0.422 . . . . 71.04 111.164 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 10.2 m-85 -123.98 99.35 6.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.177 -0.465 . . . . 71.42 110.901 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 p -158.46 151.26 7.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.216 -0.447 . . . . 51.02 111.164 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.99 72.32 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.707 -0.759 . . . . 64.01 112.419 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.5 tp10 -89.07 -66.47 0.92 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.853 0.358 . . . . 75.12 110.83 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -176.23 172.5 2.31 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 43.05 110.88 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.56 ' HB3' ' HB3' ' A' ' 45' ' ' ALA . 24.4 tp -104.22 150.77 24.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 55.33 110.884 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.718 -0.753 . . . . 42.44 112.495 179.942 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.56 ' HB3' ' HB3' ' A' ' 32' ' ' LEU . . . . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.821 0.343 . . . . 65.42 111.094 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -137.49 133.96 35.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 71.15 110.833 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.404 HG12 ' CA ' ' A' ' 83' ' ' GLY . 21.8 m -106.73 151.17 8.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 73.42 111.105 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 14.7 t -156.8 151.28 25.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 75.35 110.818 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.468 HD12 ' CD1' ' A' ' 81' ' ' PHE . 38.4 mm -120.93 116.49 50.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.088 -0.506 . . . . 74.04 111.09 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -51.56 157.9 2.84 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.693 -0.765 . . . . 40.41 112.425 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -51.75 103.28 0.06 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.817 0.341 . . . . 72.33 110.954 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.409 ' O ' ' C ' ' A' ' 53' ' ' THR . 1.1 p-10 -58.48 -56.9 16.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 71.14 110.931 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' THR . . . . . 0.409 ' C ' ' O ' ' A' ' 52' ' ' ASP . 10.2 t 36.73 44.08 0.32 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.115 -0.493 . . . . 74.13 111.186 -179.86 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.445 HG22 ' H ' ' A' ' 55' ' ' LEU . 0.2 OUTLIER -107.6 169.17 8.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.198 -0.455 . . . . 64.23 111.096 -179.93 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.602 ' O ' HD12 ' A' ' 55' ' ' LEU . 0.9 OUTLIER -109.49 150.23 28.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 73.14 110.907 -179.981 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.5 t -134.47 144.65 48.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.284 -0.416 . . . . 72.21 111.161 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 42.2 m-85 -102.9 132.57 49.02 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.252 -0.431 . . . . 73.53 110.826 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.547 ' C ' HD12 ' A' ' 59' ' ' ILE . 0.3 OUTLIER -127.31 146.63 50.38 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.148 -0.478 . . . . 74.21 110.91 179.96 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.547 HD12 ' C ' ' A' ' 58' ' ' ASP . 1.5 mp -119.28 113.61 41.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.224 -0.444 . . . . 65.31 111.131 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.783 ' HB3' HG13 ' A' ' 18' ' ' VAL . . . -102.66 117.0 33.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.467 . . . . 74.33 111.09 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 34.7 t80 -108.73 115.76 30.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.156 -0.475 . . . . 74.21 110.96 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -87.23 96.97 10.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.129 -0.487 . . . . 73.55 110.889 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.7 p -86.72 -33.15 6.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.146 -0.479 . . . . 72.42 111.12 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -130.67 164.91 23.98 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.184 -0.462 . . . . 62.21 110.892 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.9 t -87.21 3.24 47.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 61.21 110.92 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 61.6 t30 -110.72 -33.45 6.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.109 -0.496 . . . . 52.05 110.865 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.446 HG22 ' HA ' ' A' ' 107' ' ' TYR . 44.4 pt -150.54 172.02 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 72.35 111.12 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -157.16 172.85 17.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.14 -0.482 . . . . 72.14 111.058 179.799 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 10.2 m -112.1 150.97 14.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.223 -0.444 . . . . 72.33 111.129 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -138.11 127.48 24.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 64.24 110.857 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -102.4 147.2 27.01 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.471 . . . . 64.54 110.888 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.4 ' HB3' ' HB ' ' A' ' 102' ' ' ILE . 30.4 t80 -121.25 112.95 19.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.149 -0.478 . . . . 65.54 110.9 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.5 m -129.47 147.0 33.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 73.21 111.102 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -164.26 128.78 1.87 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.741 -0.742 . . . . 64.52 112.475 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 23.4 t -117.21 68.18 4.89 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.674 0.75 . . . . 53.12 111.155 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 162.67 41.21 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.679 2.253 . . . . 62.35 112.344 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -79.48 -165.67 0.83 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.265 -0.425 . . . . 72.5 111.059 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ARG . . . . . 0.404 ' HA ' ' HA ' ' A' ' 97' ' ' ASP . 55.1 ttp85 -76.88 139.28 40.2 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.148 -0.478 . . . . 74.14 110.916 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -133.83 151.88 51.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 52.13 111.088 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.0 ttpt -104.48 130.7 52.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.16 -0.473 . . . . 72.41 110.863 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' PHE . . . . . 0.468 ' CD1' HD12 ' A' ' 49' ' ' ILE . 26.9 m-85 -119.26 157.42 28.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 74.43 110.879 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.433 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -110.84 149.53 30.45 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 73.42 110.926 -179.921 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.644 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -177.14 75.64 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.783 -0.722 . . . . 73.23 112.493 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.532 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.8 tp10 -178.26 -176.37 0.52 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.999 0.428 . . . . 73.15 110.866 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.31 -69.15 0.69 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.174 -0.466 . . . . 65.1 110.92 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.4 t -84.63 -32.88 23.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.254 -0.43 . . . . 73.3 110.855 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.87 HG22 HG22 ' A' ' 93' ' ' VAL . 5.8 mm -65.57 -34.31 69.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 74.54 111.129 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 74.2 p -62.57 -53.81 49.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.475 . . . . 44.23 110.852 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.7 t -51.13 -35.86 37.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.134 -0.485 . . . . 62.21 110.867 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.515 HD13 ' O ' ' A' ' 90' ' ' LEU . 0.3 OUTLIER -63.5 -38.26 90.47 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.139 -0.482 . . . . 62.32 110.96 179.921 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 100.56 -14.37 59.25 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.776 -0.726 . . . . 61.12 112.505 179.882 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 19.2 ttt-85 -118.63 95.38 4.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.797 0.332 . . . . 74.33 110.941 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.87 HG22 HG22 ' A' ' 87' ' ' ILE . 94.0 t -111.66 -53.81 5.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 62.44 111.184 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 11.5 t -140.26 143.05 35.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 65.12 110.821 -179.825 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -132.27 115.37 15.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 63.42 110.931 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.582 ' HA ' ' HB2' ' A' ' 131' ' ' LYS . 1.4 m -154.47 171.49 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.107 -0.497 . . . . 75.12 111.146 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.485 ' O ' HG23 ' A' ' 96' ' ' VAL . 1.1 m-20 -86.34 172.1 10.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.202 -0.454 . . . . 64.4 110.895 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -123.25 130.52 52.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.266 -0.424 . . . . 64.32 110.919 -179.856 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.543 ' HA3' HD12 ' A' ' 127' ' ' LEU . . . -129.12 65.63 0.58 Allowed Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.733 -0.746 . . . . 73.42 112.431 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 112.76 3.16 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.704 2.269 . . . . 62.11 112.381 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -127.43 105.06 8.25 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.167 -0.469 . . . . 73.43 111.054 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.636 HG23 ' CA ' ' A' ' 124' ' ' GLY . 4.8 mp -128.23 151.13 34.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 74.45 111.133 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -145.99 115.7 7.26 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 61.54 110.924 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.8 p -139.62 -175.82 4.34 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.216 -0.447 . . . . 72.02 110.832 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.638 ' O ' HD12 ' A' ' 105' ' ' LEU . 1.5 pp -134.54 147.86 50.38 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.139 -0.482 . . . . 53.32 110.908 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 1.8 pp0? -104.65 139.0 40.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 73.33 110.915 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.446 ' HA ' HG22 ' A' ' 67' ' ' ILE . 14.2 p90 -143.18 142.74 31.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 72.44 110.956 -179.864 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 17.5 t-160 . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.143 -0.481 . . . . 71.44 110.876 179.921 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 6.3 m-85 . . . . . 0 C--O 1.231 0.083 0 CA-C-O 121.714 0.769 . . . . 63.52 110.88 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 117' ' ' PRO . . . . . 0.704 ' HA ' HD13 ' A' ' 153' ' ' LEU . 54.1 Cg_endo -69.77 177.93 5.09 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.67 2.247 . . . . 74.34 112.333 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 11.2 m-85 -115.98 143.99 44.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.242 -0.436 . . . . 71.4 110.876 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.459 HG13 ' HE1' ' A' ' 149' ' ' PHE . 75.7 t -99.35 132.89 43.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.085 -0.507 . . . . 71.24 111.116 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -125.51 169.43 17.46 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.712 -0.756 . . . . 54.55 112.512 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 7.7 p -175.59 152.53 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.915 0.388 . . . . 63.44 111.125 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -179.78 -151.7 10.13 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.834 -0.698 . . . . 71.35 112.555 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.7 p -111.37 127.25 68.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.827 0.346 . . . . 64.11 111.103 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' GLY . . . . . 0.636 ' CA ' HG23 ' A' ' 102' ' ' ILE . . . -119.77 108.85 1.54 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.79 -0.719 . . . . 71.34 112.513 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 35.7 ptt180 -100.73 123.23 44.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.909 0.385 . . . . 71.44 110.891 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 34.6 t -103.12 110.27 29.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.174 -0.467 . . . . 74.2 111.136 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.543 HD12 ' HA3' ' A' ' 99' ' ' GLY . 2.8 pp -120.3 156.7 30.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.474 . . . . 70.23 110.903 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 9.4 p90 -160.43 166.04 29.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 74.3 110.855 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -102.24 118.03 36.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 74.3 110.899 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -66.11 93.48 0.21 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.129 -0.487 . . . . 60.32 110.89 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.582 ' HB2' ' HA ' ' A' ' 96' ' ' VAL . 0.0 OUTLIER -74.18 -76.39 0.13 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.243 -0.435 . . . . 65.43 110.934 179.984 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 20.2 m -161.97 121.92 2.5 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.214 -0.448 . . . . 74.24 111.055 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 133' ' ' ASP . . . . . 0.583 ' HB3' ' HB3' ' A' ' 139' ' ' PHE . 27.0 t0 -108.08 114.56 28.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 43.43 110.789 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -75.78 -12.42 83.88 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.691 -0.766 . . . . 64.23 112.469 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -44.37 -29.36 0.67 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.902 0.382 . . . . 51.11 111.083 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -160.29 163.96 32.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.236 -0.438 . . . . 74.14 110.867 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.8 m -42.17 97.86 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.136 -0.484 . . . . 72.22 110.922 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 70.7 m 49.81 65.16 1.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 70.0 110.908 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.583 ' HB3' ' HB3' ' A' ' 133' ' ' ASP . 1.2 t80 -94.5 160.85 14.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 73.42 110.868 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -139.96 167.19 22.69 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.124 -0.489 . . . . 53.34 110.848 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.474 ' HA ' HG23 ' A' ' 176' ' ' VAL . 15.4 mt -117.36 151.79 19.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.471 . . . . 74.42 111.151 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 12.3 tppt? -113.18 122.62 48.05 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 75.45 110.913 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -76.81 -173.74 2.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.129 -0.487 . . . . 73.45 110.853 179.85 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -171.75 179.09 2.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 75.21 110.931 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 52.1 p-90 -140.06 161.37 37.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.216 -0.447 . . . . 74.3 110.881 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.757 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.8 165.29 0.87 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.59 0.71 . . . . 62.3 111.135 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 147' ' ' PRO . . . . . 0.757 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 54.5 Cg_endo -69.74 161.92 44.08 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.673 2.248 . . . . 74.42 112.402 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.403 ' HA ' ' CB ' ' A' ' 170' ' ' ILE . . . -151.3 146.01 25.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 71.4 111.142 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 149' ' ' PHE . . . . . 0.459 ' HE1' HG13 ' A' ' 119' ' ' VAL . 1.4 t80 -103.07 120.24 40.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 52.12 110.896 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -102.94 156.87 17.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 63.04 110.899 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.443 HG13 ' HB ' ' A' ' 167' ' ' VAL . 7.3 p -164.85 123.67 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.264 -0.426 . . . . 72.0 111.146 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -174.73 -159.54 21.19 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.717 -0.754 . . . . 51.23 112.47 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.704 HD13 ' HA ' ' A' ' 117' ' ' PRO . 19.5 tp -151.8 164.78 36.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.784 0.325 . . . . 71.15 110.876 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.4 tpp85 -115.78 120.43 39.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 75.44 110.931 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -104.68 154.79 19.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 74.43 110.933 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -120.24 104.18 9.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.116 -0.493 . . . . 72.11 110.824 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 157' ' ' LEU . . . . . 0.636 HD11 HD12 ' A' ' 163' ' ' LEU . 23.6 mt -72.57 153.1 41.45 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 71.0 110.905 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -53.0 -33.44 44.24 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.759 -0.734 . . . . 52.44 112.523 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -71.32 176.18 4.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.819 0.342 . . . . 73.41 110.847 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 73.0 m -60.86 -36.53 79.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.127 -0.488 . . . . 73.24 110.884 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 26.6 m0 -80.92 144.17 32.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 74.01 110.945 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 162' ' ' MET . . . . . 0.451 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 2.4 mpt? -106.77 169.56 8.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 74.52 110.876 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.636 HD12 HD11 ' A' ' 157' ' ' LEU . 0.3 OUTLIER -107.24 148.78 28.5 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 53.11 110.916 -179.975 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -143.85 133.28 23.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 75.21 110.857 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 42.1 t -135.41 122.53 21.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 70.22 110.858 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -131.47 153.71 49.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.107 -0.497 . . . . 74.34 110.945 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.621 HG13 ' HE1' ' A' ' 194' ' ' PHE . 78.4 t -133.45 121.49 41.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.27 -0.423 . . . . 60.54 111.089 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 168' ' ' ARG . . . . . 0.798 ' HD2' HD12 ' A' ' 195' ' ' ILE . 3.9 ttm-85 -103.46 132.41 49.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 64.21 110.876 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -143.01 128.18 18.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 75.4 110.942 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 170' ' ' ILE . . . . . 0.459 HG21 ' O ' ' A' ' 147' ' ' PRO . 3.6 tp 177.91 133.78 0.22 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.576 0.703 . . . . 75.33 111.118 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 171' ' ' PRO . . . . . 0.407 ' HD2' HG13 ' A' ' 170' ' ' ILE . 53.5 Cg_endo -69.74 111.6 2.85 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.676 2.251 . . . . 50.45 112.366 179.856 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -122.5 153.16 39.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 73.35 110.909 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 14.5 pttm -130.57 153.58 48.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 61.43 110.854 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -123.28 170.74 9.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.126 -0.488 . . . . 73.52 111.094 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -125.03 164.88 19.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 73.04 110.87 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.48 HG22 ' CE1' ' A' ' 139' ' ' PHE . 5.6 p -156.46 142.63 10.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 73.1 111.117 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 10.0 t -166.62 -179.25 4.76 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.215 -0.448 . . . . 62.34 111.12 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -120.49 -161.1 11.36 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.734 -0.746 . . . . 64.32 112.475 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.285 0 CA-C-O 120.786 0.327 . . . . 71.21 111.178 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.231 0.161 0 CA-C-O 120.828 0.262 . . . . 73.33 112.359 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.444 HG12 ' CG2' ' A' ' 187' ' ' THR . 21.6 t -127.17 107.2 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.222 -0.445 . . . . 71.44 111.179 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 1.2 p -74.93 104.43 5.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.199 -0.455 . . . . 74.4 110.865 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 187' ' ' THR . . . . . 0.444 ' CG2' HG12 ' A' ' 185' ' ' VAL . 12.1 p -131.6 172.06 12.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.105 -0.498 . . . . 65.1 111.155 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.84 162.62 39.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.265 -0.425 . . . . 75.4 110.914 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 189' ' ' ILE . . . . . 0.484 HD11 ' CD1' ' A' ' 32' ' ' LEU . 56.7 mt -137.85 128.33 37.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 74.21 111.153 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -106.57 113.3 26.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.133 -0.485 . . . . 71.33 110.871 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 191' ' ' VAL . . . . . 0.49 HG12 ' H ' ' A' ' 192' ' ' ASP . 1.3 t -136.96 169.59 19.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.087 -0.506 . . . . 62.41 111.088 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.49 ' H ' HG12 ' A' ' 191' ' ' VAL . 20.5 t70 -107.27 87.14 2.98 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.61 0.719 . . . . 51.43 110.896 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 121.51 8.19 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.631 2.22 . . . . 65.41 112.395 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 194' ' ' PHE . . . . . 0.621 ' HE1' HG13 ' A' ' 167' ' ' VAL . 1.7 t80 -103.12 115.89 31.46 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 52.12 110.881 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 195' ' ' ILE . . . . . 0.798 HD12 ' HD2' ' A' ' 168' ' ' ARG . 9.7 mt -102.9 124.68 57.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 61.54 111.118 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 1.2 tt -112.71 108.54 17.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 74.31 110.897 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.25 115.68 28.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.257 -0.429 . . . . 71.34 110.818 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 198' ' ' LEU . . . . . 0.404 ' C ' ' HB2' ' A' ' 22' ' ' ASN . 5.7 tt -138.21 121.06 16.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.122 -0.49 . . . . 74.13 110.938 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -175.36 -141.44 3.73 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.825 -0.702 . . . . 64.5 112.538 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 200' ' ' ALA . . . . . 0.451 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -128.51 173.82 9.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.781 0.324 . . . . 70.03 111.104 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 26.2 t -146.55 163.51 35.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.458 . . . . 74.22 110.832 -179.749 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 202' ' ' TYR . . . . . 0.551 ' C ' HG23 ' A' ' 18' ' ' VAL . 2.1 t80 -133.9 114.4 13.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.149 -0.478 . . . . 75.31 110.883 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 57.8 t -76.88 145.11 10.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.091 -0.504 . . . . 72.15 111.108 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 -148.08 137.01 21.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.107 -0.497 . . . . 72.35 110.888 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.081 -0.508 . . . . 75.2 110.898 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.4 mp0 . . . . . 0 C--O 1.23 0.061 0 CA-C-O 120.805 0.335 . . . . 74.05 110.904 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.87 6.45 40.17 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.808 -0.711 . . . . 52.35 112.533 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -67.11 145.45 55.29 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.778 0.323 . . . . 72.05 110.857 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -125.43 121.68 34.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.203 -0.453 . . . . 52.33 110.894 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.724 HG23 ' HB3' ' A' ' 60' ' ' ALA . 13.5 m -130.69 134.91 61.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 63.23 111.145 179.882 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.56 ' HB1' ' CZ ' ' A' ' 21' ' ' PHE . . . -94.24 116.81 29.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 45.52 111.162 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 p -105.94 108.21 19.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 65.42 110.796 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.56 ' CZ ' ' HB1' ' A' ' 19' ' ' ALA . 16.5 m-85 -112.11 121.22 44.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.146 -0.479 . . . . 71.25 110.89 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -152.15 172.46 16.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 73.35 110.885 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -95.89 131.97 41.68 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 73.22 110.819 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -101.01 109.92 21.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.111 -0.495 . . . . 64.03 110.882 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 29.4 mmtt -93.9 106.33 18.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.485 . . . . 74.35 110.89 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.682 HG22 ' CD1' ' A' ' 195' ' ' ILE . 21.8 t -79.62 121.08 32.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.259 -0.428 . . . . 71.1 111.128 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.512 ' CD1' HD13 ' A' ' 196' ' ' LEU . 10.5 m-85 -105.64 99.67 9.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 75.22 110.948 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.9 HG23 HG11 ' A' ' 191' ' ' VAL . 5.5 p -167.69 141.09 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.123 -0.49 . . . . 74.2 111.16 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.75 72.09 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.753 -0.736 . . . . 54.03 112.44 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 16.6 tt0 -89.93 -66.19 0.95 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.809 0.338 . . . . 72.32 110.85 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 179.4 103.44 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 73.43 110.89 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.688 HD22 ' C ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -57.15 167.25 0.91 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.092 -0.504 . . . . 72.23 110.901 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.549 ' N ' HD22 ' A' ' 32' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.305 0 C-N-CA 120.705 -0.759 . . . . 61.24 112.506 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.4 ' HB1' HD11 ' A' ' 32' ' ' LEU . . . . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.755 0.312 . . . . 71.44 111.164 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -150.43 125.25 9.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.276 -0.42 . . . . 64.15 110.873 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 82' ' ' GLN . 12.5 p -119.13 134.02 64.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.203 -0.453 . . . . 72.41 111.114 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.9 m -153.45 178.51 9.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 54.52 110.849 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.532 HG22 ' CD1' ' A' ' 81' ' ' PHE . 42.6 pt -134.97 145.88 31.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.094 -0.503 . . . . 72.52 111.173 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -62.33 179.13 4.77 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.768 -0.73 . . . . 62.22 112.518 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.7 m-80 -119.96 107.84 13.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.8 0.333 . . . . 54.1 110.896 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -143.92 148.53 35.51 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 71.4 110.898 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.9 p -61.46 134.26 56.69 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.217 -0.447 . . . . 64.02 111.151 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 15.3 t -143.75 169.68 17.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 41.34 111.133 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -155.9 160.44 40.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 71.24 110.931 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.442 HG22 ' HA3' ' A' ' 74' ' ' GLY . 8.8 p -141.12 142.51 34.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.449 . . . . 60.13 111.162 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -102.44 132.2 48.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 73.35 110.899 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.65 ' O ' HD13 ' A' ' 59' ' ' ILE . 1.3 m-20 -129.14 149.91 50.75 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.142 -0.481 . . . . 70.33 110.863 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.65 HD13 ' O ' ' A' ' 58' ' ' ASP . 8.0 mm -122.39 114.36 42.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.443 . . . . 72.03 111.175 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.724 ' HB3' HG23 ' A' ' 18' ' ' VAL . . . -101.92 130.06 48.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 72.12 111.086 179.831 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.501 ' HB3' HG22 ' A' ' 69' ' ' VAL . 14.9 t80 -118.15 118.35 31.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.233 -0.439 . . . . 74.43 110.936 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -90.52 97.01 10.93 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.156 -0.474 . . . . 72.01 110.897 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.0 p -91.16 -34.91 6.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.206 -0.452 . . . . 73.44 111.129 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.2 t -130.02 159.67 35.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 64.33 110.894 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 93.4 p -84.13 2.76 37.96 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 61.13 110.827 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 41.2 m-80 -112.01 -32.5 6.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 73.34 110.876 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.511 HG22 ' CB ' ' A' ' 107' ' ' TYR . 2.3 pp -149.13 164.78 4.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.474 . . . . 74.44 111.142 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -154.68 169.89 22.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 60.04 111.124 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.501 HG22 ' HB3' ' A' ' 61' ' ' TYR . 6.1 m -110.97 152.93 12.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.445 . . . . 74.14 111.112 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -148.61 124.27 10.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.465 . . . . 54.32 110.875 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.658 ' CZ ' HD22 ' A' ' 103' ' ' LEU . 2.4 t80 -102.72 131.06 49.8 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 64.33 110.917 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.553 ' HE2' ' HG ' ' A' ' 197' ' ' SER . 24.2 m-85 -111.65 118.64 36.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.108 -0.496 . . . . 72.43 110.829 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.0 p -142.51 151.79 17.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 42.0 111.116 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.442 ' HA3' HG22 ' A' ' 56' ' ' THR . . . -160.05 160.7 31.85 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.732 . . . . 74.11 112.491 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.477 ' O ' HG13 ' A' ' 75' ' ' VAL . 4.0 p -138.29 77.72 35.08 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.691 0.758 . . . . 72.32 111.129 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 152.26 69.32 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.734 2.289 . . . . 73.35 112.346 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -71.17 -168.38 0.29 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 72.01 111.071 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 19.8 ttp-105 -77.58 127.31 32.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 74.23 110.857 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -133.66 140.69 47.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 44.23 111.118 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -89.58 141.73 28.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.443 . . . . 54.23 110.921 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' PHE . . . . . 0.532 ' CD1' HG22 ' A' ' 49' ' ' ILE . 11.9 m-85 -132.73 147.43 52.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.237 -0.438 . . . . 72.43 110.858 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.583 ' O ' HG23 ' A' ' 47' ' ' VAL . 0.4 OUTLIER -92.82 155.52 17.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 65.41 110.877 -179.92 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.537 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -179.46 72.79 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.759 -0.734 . . . . 61.34 112.517 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -178.9 -174.15 0.34 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.937 0.399 . . . . 70.12 110.846 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 6.0 mtpt -85.82 -70.17 0.61 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.114 -0.494 . . . . 72.33 110.904 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 74.0 m -84.3 -31.1 25.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.259 -0.428 . . . . 72.11 110.899 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.929 HG22 HG22 ' A' ' 93' ' ' VAL . 1.2 mt -68.17 -33.73 62.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.122 -0.49 . . . . 74.45 111.119 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.2 t -62.46 -47.26 84.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 74.32 110.842 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 36.9 t -57.69 -35.37 70.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.183 -0.462 . . . . 75.3 110.833 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.541 HD23 ' HG2' ' A' ' 92' ' ' ARG . 4.2 tp -63.64 -48.33 77.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.474 . . . . 71.31 110.988 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 111.37 -13.33 28.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.716 -0.754 . . . . 64.13 112.474 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.541 ' HG2' HD23 ' A' ' 90' ' ' LEU . 0.0 OUTLIER -117.79 87.47 2.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.906 0.384 . . . . 73.44 110.911 -179.837 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.929 HG22 HG22 ' A' ' 87' ' ' ILE . 32.3 t -113.05 -42.05 4.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.195 -0.457 . . . . 75.15 111.14 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 80.4 p -141.0 152.05 44.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.253 -0.43 . . . . 54.34 110.897 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -141.43 116.98 10.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.141 -0.481 . . . . 72.13 110.92 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.746 HG23 ' HB2' ' A' ' 131' ' ' LYS . 2.6 p -178.23 166.42 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 72.3 111.182 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.473 ' H ' HG22 ' A' ' 96' ' ' VAL . 2.5 p30 -95.07 156.48 16.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 72.42 110.855 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -93.98 147.63 22.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.165 -0.471 . . . . 64.24 110.99 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -126.39 60.87 0.64 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.773 -0.727 . . . . 70.52 112.501 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 113.86 3.52 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.644 2.229 . . . . 53.33 112.323 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.43 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -131.47 108.53 9.65 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.167 -0.469 . . . . 52.42 111.079 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.689 HG22 ' CA ' ' A' ' 124' ' ' GLY . 1.2 pp -140.27 153.06 21.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.481 . . . . 73.3 111.085 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.658 HD22 ' CZ ' ' A' ' 71' ' ' PHE . 0.7 OUTLIER -149.62 130.97 14.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.145 -0.48 . . . . 43.31 110.924 179.913 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.2 p -151.34 170.45 19.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 52.0 110.87 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.593 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.7 OUTLIER -113.46 147.01 38.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 74.21 110.908 179.981 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 34.4 mt-30 -101.7 144.78 29.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.181 -0.463 . . . . 73.54 110.98 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.511 ' CB ' HG22 ' A' ' 67' ' ' ILE . 46.7 p90 -153.73 150.4 28.49 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.244 -0.435 . . . . 63.34 110.967 -179.852 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 2.2 p80 . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.126 -0.488 . . . . 75.1 110.863 179.937 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 8.1 m-85 . . . . . 0 C--O 1.231 0.097 0 CA-C-O 121.683 0.754 . . . . 75.43 110.919 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 117' ' ' PRO . . . . . 0.418 ' HA ' HD13 ' A' ' 153' ' ' LEU . 54.3 Cg_endo -69.72 177.38 5.61 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.685 2.257 . . . . 74.54 112.38 179.884 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 118' ' ' TYR . . . . . 0.433 ' CE1' HD12 ' A' ' 153' ' ' LEU . 3.0 m-85 -115.32 152.4 32.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.191 -0.459 . . . . 74.43 110.864 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 61.6 t -111.0 141.13 27.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.102 -0.499 . . . . 60.44 111.186 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -133.39 175.69 20.04 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.775 -0.726 . . . . 71.15 112.546 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.5 p -168.16 151.97 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.944 0.402 . . . . 61.12 111.058 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -179.54 -149.68 8.57 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.714 -0.755 . . . . 73.12 112.517 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 11.3 p -108.01 146.07 14.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.829 0.347 . . . . 73.24 111.168 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' GLY . . . . . 0.689 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -140.99 121.03 1.82 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.806 -0.712 . . . . 61.41 112.51 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 125' ' ' ARG . . . . . 0.43 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 3.1 ptm180 -117.48 128.7 55.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.893 0.378 . . . . 74.54 110.874 -179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 97.8 t -105.94 109.44 27.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.091 -0.504 . . . . 63.44 111.161 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.445 HD23 ' HB2' ' A' ' 143' ' ' ASP . 41.7 mt -118.22 171.99 7.74 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.125 -0.489 . . . . 71.33 110.896 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -148.41 176.39 10.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 72.52 110.949 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.594 ' O ' HG21 ' A' ' 96' ' ' VAL . 2.5 t80 -104.57 171.71 7.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 73.04 110.812 -179.897 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 16.8 t0 -109.72 96.58 6.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.122 -0.49 . . . . 75.44 110.847 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.746 ' HB2' HG23 ' A' ' 96' ' ' VAL . 2.0 mmmp? -118.1 -81.44 0.62 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.466 . . . . 73.02 110.892 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 98.5 m -162.64 85.24 0.55 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.202 -0.454 . . . . 71.12 111.15 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -99.15 161.67 13.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.221 -0.445 . . . . 72.42 110.885 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.46 154.08 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.705 -0.759 . . . . 71.23 112.489 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.533 ' CB ' HD13 ' A' ' 87' ' ' ILE . . . -82.51 3.24 29.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.833 0.349 . . . . 70.2 111.149 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.457 HD22 ' N ' ' A' ' 136' ' ' LEU . 2.7 mm? -86.83 -176.14 5.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 71.23 110.937 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 23.1 t -65.0 87.0 0.06 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 75.35 110.849 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 65.5 m 51.93 75.37 0.22 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 74.02 110.878 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -91.03 157.11 17.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.481 . . . . 61.41 110.883 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -138.12 -173.9 3.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.107 -0.497 . . . . 71.2 110.878 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.786 HG22 HG13 ' A' ' 176' ' ' VAL . 5.1 pt -141.0 156.98 22.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.205 -0.452 . . . . 70.23 111.147 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 142' ' ' LYS . . . . . 0.433 ' HB2' ' HB3' ' A' ' 175' ' ' ASP . 1.8 tttt -96.02 116.39 28.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.159 -0.473 . . . . 72.43 110.941 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.445 ' HB2' HD23 ' A' ' 127' ' ' LEU . 0.9 OUTLIER -63.33 -173.76 0.07 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.241 -0.436 . . . . 71.21 110.866 179.887 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -157.18 169.72 24.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.242 -0.435 . . . . 73.33 110.955 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 28.0 p-90 -156.69 146.71 21.06 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.341 -0.39 . . . . 75.5 110.893 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.722 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 179.95 165.06 0.84 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.549 0.69 . . . . 72.32 111.097 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 147' ' ' PRO . . . . . 0.722 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.1 Cg_endo -69.82 140.41 42.4 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.677 2.252 . . . . 70.35 112.314 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.651 ' HB1' ' O ' ' A' ' 169' ' ' TYR . . . -135.98 177.82 7.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 74.2 111.096 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -126.63 166.54 17.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.18 -0.464 . . . . 74.44 110.872 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 11.3 tt0 -145.32 155.29 43.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 74.31 110.912 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.1 p -154.92 126.87 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.226 -0.443 . . . . 61.35 111.15 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -177.79 -158.69 21.27 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.677 -0.773 . . . . 53.14 112.43 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.433 HD12 ' CE1' ' A' ' 118' ' ' TYR . 46.7 tp -145.17 157.39 44.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.844 0.354 . . . . 74.42 110.867 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 6.2 tpp85 -120.97 117.71 27.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 72.3 110.85 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 3.0 t80 -95.91 132.21 41.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 74.02 110.928 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -119.23 113.34 20.71 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.162 -0.472 . . . . 71.11 110.879 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 157' ' ' LEU . . . . . 0.46 HD12 ' O ' ' A' ' 161' ' ' TRP . 38.8 mt -88.44 163.02 16.16 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.209 -0.451 . . . . 72.12 110.861 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -99.44 126.91 9.08 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.758 -0.734 . . . . 71.0 112.482 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 65.3 m-20 58.78 37.84 24.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.873 0.368 . . . . 75.21 110.916 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 3.1 m -167.18 178.03 5.86 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.167 -0.47 . . . . 72.42 110.869 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 161' ' ' TRP . . . . . 0.46 ' O ' HD12 ' A' ' 157' ' ' LEU . 5.3 m-90 -64.12 162.09 14.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 71.4 110.936 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 162' ' ' MET . . . . . 0.421 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 21.5 mtm -106.64 170.56 7.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.231 -0.44 . . . . 74.51 110.918 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.509 HD23 ' N ' ' A' ' 164' ' ' ASN . 1.2 tt -124.08 148.81 46.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.246 -0.434 . . . . 71.54 110.904 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 164' ' ' ASN . . . . . 0.509 ' N ' HD23 ' A' ' 163' ' ' LEU . 7.5 t30 -143.94 131.79 21.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 73.31 110.887 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 60.5 p -146.56 122.23 10.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.446 . . . . 75.02 110.807 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -157.69 161.22 38.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.053 -0.521 . . . . 73.43 110.89 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 10.9 t -118.58 130.52 73.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 74.5 111.128 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 168' ' ' ARG . . . . . 0.585 ' CZ ' HD13 ' A' ' 102' ' ' ILE . 0.0 OUTLIER -107.04 122.17 45.93 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.169 -0.468 . . . . 64.4 110.866 -179.958 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 169' ' ' TYR . . . . . 0.651 ' O ' ' HB1' ' A' ' 148' ' ' ALA . 15.3 t80 -108.29 115.56 30.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.184 -0.462 . . . . 73.44 110.927 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 170' ' ' ILE . . . . . 0.563 HG23 ' HG2' ' A' ' 193' ' ' PRO . 9.6 tt -134.45 79.35 54.59 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.558 0.694 . . . . 65.12 111.092 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 171' ' ' PRO . . . . . 0.424 ' HA ' ' HD2' ' A' ' 193' ' ' PRO . 54.0 Cg_endo -69.72 125.06 11.72 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.587 2.192 . . . . 74.24 112.364 179.835 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 11.8 p90 -162.14 177.58 9.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 74.32 110.891 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 10.1 pttp -122.83 137.69 54.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.126 -0.488 . . . . 62.42 110.844 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.49 156.1 18.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 62.43 111.146 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 175' ' ' ASP . . . . . 0.433 ' HB3' ' HB2' ' A' ' 142' ' ' LYS . 0.1 OUTLIER -111.81 161.24 16.55 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.259 -0.428 . . . . 71.52 110.915 179.851 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.786 HG13 HG22 ' A' ' 141' ' ' ILE . 4.7 t -138.31 133.01 42.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.229 -0.441 . . . . 75.51 111.17 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.7 t -166.36 160.48 15.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 74.03 111.134 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -160.38 -133.48 1.5 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.704 -0.76 . . . . 44.34 112.479 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 52.9 m . . . . . 0 C--N 1.329 -0.303 0 CA-C-O 120.817 0.342 . . . . 63.55 111.089 -179.86 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo . . . . . 0 N--CA 1.465 -0.165 0 CA-C-O 120.854 0.273 . . . . 72.13 112.324 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 82.5 t -96.28 107.74 20.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 72.41 111.129 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -108.66 125.46 51.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 63.13 110.882 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 12.8 p -139.66 174.73 10.21 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.099 -0.501 . . . . 64.44 111.128 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 34.4 ttpt -158.95 145.35 16.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 65.34 110.921 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 8.6 tt -143.15 138.31 26.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 64.54 111.147 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -102.17 119.71 39.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.234 -0.439 . . . . 74.1 110.968 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 191' ' ' VAL . . . . . 0.9 HG11 HG23 ' A' ' 28' ' ' VAL . 4.1 t -136.82 158.25 36.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 73.12 111.168 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.4 ' N ' HG12 ' A' ' 191' ' ' VAL . 0.4 OUTLIER -107.73 89.95 5.76 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.624 0.725 . . . . 74.11 110.933 179.857 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 193' ' ' PRO . . . . . 0.563 ' HG2' HG23 ' A' ' 170' ' ' ILE . 53.2 Cg_endo -69.8 121.62 8.3 Favored 'Trans proline' 0 C--O 1.232 0.211 0 C-N-CA 122.697 2.265 . . . . 71.22 112.296 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -99.76 107.43 19.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.268 -0.424 . . . . 74.23 110.889 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 195' ' ' ILE . . . . . 0.682 ' CD1' HG22 ' A' ' 26' ' ' VAL . 49.1 mm -87.93 119.39 35.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.138 -0.483 . . . . 60.44 111.148 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 196' ' ' LEU . . . . . 0.512 HD13 ' CD1' ' A' ' 27' ' ' TYR . 5.4 mp -105.98 108.18 19.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.206 -0.452 . . . . 64.24 110.951 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 197' ' ' SER . . . . . 0.553 ' HG ' ' HE2' ' A' ' 72' ' ' PHE . 9.4 m -98.97 112.03 24.26 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.213 -0.448 . . . . 75.13 110.897 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 1.9 tt -136.72 119.88 16.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 64.44 110.899 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -176.16 -145.55 5.61 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.779 -0.724 . . . . 65.51 112.482 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 200' ' ' ALA . . . . . 0.421 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -125.17 173.83 8.49 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.75 0.31 . . . . 65.2 111.186 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.7 t -148.89 169.77 19.8 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.26 -0.427 . . . . 63.02 110.835 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -138.8 146.01 40.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.131 -0.486 . . . . 72.52 110.878 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.691 ' HA ' HG12 ' A' ' 18' ' ' VAL . 15.6 m -97.91 144.81 10.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.124 -0.489 . . . . 43.52 111.158 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -148.28 139.75 23.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.48 . . . . 74.43 110.812 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.09 -0.504 . . . . 71.44 110.892 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 . . . . . 0 N--CA 1.458 -0.054 0 CA-C-O 120.813 0.34 . . . . 65.42 110.964 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 103.28 11.67 33.2 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.675 -0.774 . . . . 53.34 112.514 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -83.28 159.16 21.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.781 0.324 . . . . 70.54 110.887 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 13.3 m95 -107.36 158.34 17.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.247 -0.433 . . . . 73.54 110.902 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.462 HG13 ' O ' ' A' ' 202' ' ' TYR . 42.9 t -150.71 120.78 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.281 -0.418 . . . . 72.51 111.133 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -87.77 110.08 20.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 63.11 111.117 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 6.5 t -107.61 113.3 26.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.214 -0.448 . . . . 74.43 110.894 -179.822 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.677 ' CE1' ' HB3' ' A' ' 200' ' ' ALA . 17.0 p90 -108.41 122.36 46.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 75.1 110.863 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -152.76 167.93 27.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.138 -0.483 . . . . 54.23 110.92 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -102.01 134.89 44.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 70.01 110.929 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -102.69 122.68 44.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 65.32 110.801 -179.763 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 11.3 tptm -96.59 106.61 18.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.054 -0.521 . . . . 64.11 110.83 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 34.3 m -78.86 134.0 28.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.456 . . . . 70.22 111.201 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 17.0 t80 -130.9 99.74 5.01 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.223 -0.444 . . . . 75.42 110.9 -179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.0 p -165.82 152.86 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.118 -0.492 . . . . 75.34 111.127 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 123.59 77.11 0.35 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.739 -0.743 . . . . 71.34 112.48 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 25.6 pt-20 -90.26 -44.11 9.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.837 0.351 . . . . 75.34 110.85 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.683 ' HA ' HG22 ' A' ' 47' ' ' VAL . 0.9 OUTLIER 178.58 170.64 0.81 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 70.32 110.866 -179.937 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.482 HD23 ' CB ' ' A' ' 45' ' ' ALA . 20.8 tp -74.9 161.58 29.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.131 -0.486 . . . . 64.31 110.876 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.709 -0.757 . . . . 51.13 112.496 179.92 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.482 ' CB ' HD23 ' A' ' 32' ' ' LEU . . . . . . . . 0 N--CA 1.457 -0.123 0 CA-C-O 120.807 0.337 . . . . 74.22 111.071 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -161.2 128.61 4.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.225 -0.443 . . . . 73.23 110.861 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.683 HG22 ' HA ' ' A' ' 31' ' ' GLU . 22.3 m -104.36 167.39 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 45.3 111.15 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -164.76 174.41 10.72 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.13 -0.486 . . . . 74.24 110.804 -179.806 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 7.9 tt -134.04 149.24 30.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.089 -0.505 . . . . 65.11 111.08 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -139.3 85.5 0.22 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.709 -0.758 . . . . 74.41 112.468 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -147.77 152.5 37.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.814 0.34 . . . . 72.54 110.925 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 46.2 m-20 -104.0 178.09 4.66 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.156 -0.474 . . . . 71.12 110.818 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 2.3 t -55.73 150.22 13.09 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 73.42 111.124 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -151.58 162.72 40.5 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.208 -0.451 . . . . 75.23 111.112 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 20.3 mt -108.28 153.49 23.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.169 -0.469 . . . . 75.11 110.978 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.703 HG21 ' CZ ' ' A' ' 72' ' ' PHE . 0.0 OUTLIER -135.56 147.89 48.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.26 -0.427 . . . . 70.05 111.062 -179.995 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -104.22 131.49 51.48 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.18 -0.464 . . . . 73.45 110.835 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 -126.63 138.29 53.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.19 -0.459 . . . . 60.55 110.85 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.404 ' O ' HG22 ' A' ' 59' ' ' ILE . 1.6 mp -108.08 113.56 44.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.144 -0.48 . . . . 65.05 111.132 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -106.02 120.39 41.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 74.42 111.161 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.671 ' HB3' HG22 ' A' ' 69' ' ' VAL . 8.1 t80 -105.69 118.53 36.83 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.164 -0.471 . . . . 73.4 110.93 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -93.76 96.64 9.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.088 -0.505 . . . . 72.22 110.895 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.424 HG22 ' CE1' ' A' ' 61' ' ' TYR . 57.4 t -91.23 -35.17 6.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.144 -0.48 . . . . 73.44 111.133 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.6 m -131.87 163.42 28.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 74.13 110.894 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 33.4 m -87.49 3.45 47.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 62.33 110.865 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 7.1 m120 -107.77 -33.08 7.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.112 -0.495 . . . . 55.23 110.895 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.8 pt -150.36 169.9 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 62.34 111.142 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -157.12 167.32 30.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.45 . . . . 52.43 111.105 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.671 HG22 ' HB3' ' A' ' 61' ' ' TYR . 2.7 m -110.54 151.57 12.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.183 -0.462 . . . . 74.33 111.077 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -141.69 137.31 31.65 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.173 -0.467 . . . . 72.23 110.866 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -121.02 110.39 16.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.248 -0.433 . . . . 73.13 110.903 -179.897 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.703 ' CZ ' HG21 ' A' ' 56' ' ' THR . 41.0 t80 -87.27 125.95 34.53 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 75.34 110.908 -179.883 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 40.4 t -146.42 146.78 18.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.234 -0.439 . . . . 74.5 111.16 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.548 ' HA3' HG22 ' A' ' 56' ' ' THR . . . -147.97 178.89 25.26 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.673 -0.775 . . . . 60.34 112.458 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.6 t -144.26 66.0 13.81 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.583 0.706 . . . . 75.33 111.111 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 138.14 37.22 Favored 'Trans proline' 0 C--N 1.34 0.132 0 C-N-CA 122.714 2.276 . . . . 73.52 112.359 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -67.47 -166.81 0.05 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.213 -0.448 . . . . 35.34 111.161 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 23.1 ttp180 -75.77 123.75 26.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.242 -0.436 . . . . 63.24 110.881 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -110.66 150.93 28.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 71.03 111.166 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.22 119.51 38.85 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 71.52 110.891 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -114.31 144.84 42.59 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.213 -0.449 . . . . 73.24 110.858 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 28.3 mt-30 -104.26 153.22 21.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.453 . . . . 71.12 110.979 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.645 ' HA2' HG12 ' A' ' 47' ' ' VAL . . . -178.84 75.9 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.734 -0.746 . . . . 63.35 112.453 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -177.4 -177.46 0.7 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.899 0.381 . . . . 72.52 110.907 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.17 -68.96 0.7 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.152 -0.476 . . . . 63.24 110.917 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.6 m -84.97 -32.74 22.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.236 -0.438 . . . . 73.11 110.829 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.651 HG22 HG22 ' A' ' 93' ' ' VAL . 5.1 mm -66.52 -34.45 70.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.121 -0.491 . . . . 73.34 111.157 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 28.1 t -63.23 -51.28 66.86 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.177 -0.465 . . . . 73.21 110.831 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 58.5 m -51.46 -36.92 46.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.152 -0.476 . . . . 74.42 110.894 -179.798 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 35.9 mt -64.71 -42.92 94.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.487 . . . . 74.3 110.88 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.34 -13.98 39.71 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.831 -0.699 . . . . 74.21 112.534 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.1 mtp-105 -115.91 90.09 3.25 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.84 0.352 . . . . 74.25 110.825 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.651 HG22 HG22 ' A' ' 87' ' ' ILE . 3.9 t -113.79 -43.94 4.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 71.02 111.108 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.3 m -141.18 144.06 34.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 73.1 110.839 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -138.44 118.22 13.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.172 -0.467 . . . . 63.31 110.954 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.438 HG22 ' N ' ' A' ' 97' ' ' ASP . 5.3 p -178.14 164.41 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.485 . . . . 63.42 111.151 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.438 ' N ' HG22 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -100.21 173.0 6.82 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.208 -0.451 . . . . 62.03 110.923 179.908 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 98' ' ' TYR . . . . . 0.434 ' HA ' ' HB2' ' A' ' 128' ' ' PHE . 62.1 m-85 -133.16 141.3 48.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 74.52 110.873 -179.804 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -108.99 82.07 0.3 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.799 -0.715 . . . . 72.14 112.493 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 112.22 3.01 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.681 2.254 . . . . 74.35 112.374 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -124.89 94.98 4.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.259 -0.428 . . . . 71.21 111.168 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.49 HD12 ' CD1' ' A' ' 72' ' ' PHE . 12.2 mt -112.35 145.73 18.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 74.15 111.098 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -149.2 109.43 4.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 61.12 110.943 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.3 p -140.62 166.21 25.36 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 73.4 110.911 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.429 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -114.76 140.41 48.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.146 -0.479 . . . . 74.23 110.925 -179.99 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 6.9 pt20 -102.62 145.41 29.69 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 64.14 110.864 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 10.5 p90 -140.42 145.31 36.85 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.144 -0.48 . . . . 74.43 110.879 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 58.0 t60 . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.111 -0.495 . . . . 74.5 110.838 179.922 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 116' ' ' TYR . . . . . 0.414 ' HB2' ' HD2' ' A' ' 117' ' ' PRO . 6.4 p90 . . . . . 0 C--O 1.232 0.144 0 CA-C-O 121.628 0.727 . . . . 74.54 111.004 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' PRO . . . . . 0.414 ' HD2' ' HB2' ' A' ' 116' ' ' TYR . 53.4 Cg_endo -69.74 178.95 4.04 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.669 2.246 . . . . 74.43 112.335 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -108.82 157.2 18.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 72.42 110.878 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 93.4 t -111.4 134.4 53.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.059 -0.519 . . . . 54.33 111.146 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -135.98 168.93 23.81 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.776 -0.726 . . . . 75.04 112.543 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 10.6 p -162.35 152.15 3.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.876 0.37 . . . . 73.05 111.131 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -176.83 -154.32 11.78 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.689 -0.767 . . . . 74.14 112.502 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.476 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 10.2 p -111.13 139.04 36.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.95 0.405 . . . . 60.14 111.086 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -128.72 115.75 2.08 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.777 -0.725 . . . . 62.53 112.546 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 17.3 ptp180 -122.82 116.59 23.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.852 0.358 . . . . 71.11 110.848 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.429 ' O ' HG13 ' A' ' 126' ' ' VAL . 3.6 p -117.22 114.48 45.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.182 -0.463 . . . . 52.32 111.043 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.425 HD21 ' HB3' ' A' ' 145' ' ' TRP . 0.0 OUTLIER -150.55 168.15 25.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 62.33 110.924 179.894 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.434 ' HB2' ' HA ' ' A' ' 98' ' ' TYR . 1.0 OUTLIER -164.36 -172.45 2.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 65.23 110.899 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -94.44 129.22 41.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 71.31 110.884 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -67.11 124.39 22.94 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.194 -0.457 . . . . 72.33 110.797 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 20.0 mmmt -102.39 -72.48 0.69 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.159 -0.473 . . . . 73.25 110.9 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -151.63 77.13 1.23 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 74.14 111.152 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -94.1 158.68 15.5 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.467 . . . . 71.54 110.905 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.02 159.71 0.19 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.728 -0.749 . . . . 61.1 112.544 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.599 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -78.01 4.93 10.96 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.819 0.342 . . . . 65.14 111.14 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.46 HD22 ' N ' ' A' ' 136' ' ' LEU . 2.8 mm? -86.27 -176.68 6.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 74.44 110.956 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.6 t -68.33 85.28 0.27 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.194 -0.457 . . . . 71.24 110.889 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 89.5 p 46.22 74.85 0.13 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 71.14 110.953 -179.729 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -86.29 156.5 20.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.149 -0.478 . . . . 74.33 110.837 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -107.62 175.01 5.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.068 -0.515 . . . . 54.24 110.886 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.656 HG22 HG13 ' A' ' 176' ' ' VAL . 24.7 pt -152.2 135.64 7.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 43.11 111.106 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 142' ' ' LYS . . . . . 0.626 ' O ' HG22 ' A' ' 174' ' ' THR . 0.0 OUTLIER -72.54 116.94 13.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.113 -0.494 . . . . 75.51 110.925 179.861 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -63.63 -158.43 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.452 . . . . 71.03 110.801 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 144' ' ' LYS . . . . . 0.625 ' NZ ' HG23 ' A' ' 170' ' ' ILE . 3.0 tttt -128.99 147.3 50.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 74.44 110.888 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 145' ' ' TRP . . . . . 0.425 ' HB3' HD21 ' A' ' 127' ' ' LEU . 43.2 p90 -158.6 119.01 3.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.156 -0.474 . . . . 70.02 110.897 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.834 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.38 168.46 0.8 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.566 0.698 . . . . 63.02 111.112 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 147' ' ' PRO . . . . . 0.834 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.4 Cg_endo -69.78 141.01 44.0 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.661 2.24 . . . . 50.43 112.362 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.6 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -135.27 168.15 19.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 71.01 111.102 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -116.79 139.78 50.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.243 -0.435 . . . . 74.41 110.837 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 -116.76 145.75 43.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.104 -0.498 . . . . 74.31 110.919 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.59 127.18 8.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.455 . . . . 74.02 111.133 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 152' ' ' GLY . . . . . 0.411 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 176.9 -179.6 47.77 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.724 -0.75 . . . . 55.22 112.531 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.494 ' H ' HD23 ' A' ' 153' ' ' LEU . 2.0 pt? -121.98 158.82 28.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.876 0.369 . . . . 73.31 110.842 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -142.79 128.34 19.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.187 -0.461 . . . . 62.23 110.847 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 155' ' ' TYR . . . . . 0.539 ' HB3' HD11 ' A' ' 163' ' ' LEU . 0.8 OUTLIER -145.33 179.5 7.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.483 . . . . 75.12 110.974 -179.901 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -114.16 90.76 3.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.179 -0.464 . . . . 62.54 110.839 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 24.4 tp -58.99 97.2 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 70.12 110.939 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 66.52 -136.38 34.03 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.716 -0.754 . . . . 70.22 112.495 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 52.2 t30 -119.49 -30.89 4.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.795 0.331 . . . . 72.44 110.886 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 35.7 m -49.4 -67.12 0.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.464 . . . . 64.14 110.833 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 5.3 p90 -147.54 161.87 40.22 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.152 -0.476 . . . . 62.44 110.886 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 162' ' ' MET . . . . . 0.556 ' SD ' HG13 ' A' ' 203' ' ' VAL . 78.7 mtp -93.28 172.13 8.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 61.41 110.888 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.822 HD22 ' C ' ' A' ' 163' ' ' LEU . 0.0 OUTLIER -136.09 152.08 50.49 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.187 -0.46 . . . . 64.5 111.002 179.972 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 164' ' ' ASN . . . . . 0.409 ' N ' HD22 ' A' ' 163' ' ' LEU . 4.3 t30 -155.49 146.68 22.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.265 -0.425 . . . . 53.22 110.854 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 10.2 t -152.59 122.27 6.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.213 -0.448 . . . . 73.35 110.937 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 166' ' ' ASP . . . . . 0.411 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.3 OUTLIER -145.85 177.27 9.05 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.099 -0.501 . . . . 73.34 110.822 -179.982 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.451 HG13 ' O ' ' A' ' 195' ' ' ILE . 16.4 t -147.44 141.34 19.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 63.35 111.135 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 168' ' ' ARG . . . . . 0.401 ' HG2' HD12 ' A' ' 195' ' ' ILE . 0.0 OUTLIER -108.97 141.99 40.27 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.127 -0.488 . . . . 74.31 110.814 -179.967 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 9.5 t80 -139.86 138.88 36.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.11 -0.495 . . . . 74.34 110.916 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 170' ' ' ILE . . . . . 0.738 HD12 ' HD2' ' A' ' 171' ' ' PRO . 1.9 tp -177.87 110.04 0.22 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.613 0.72 . . . . 71.52 111.069 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 171' ' ' PRO . . . . . 0.738 ' HD2' HD12 ' A' ' 170' ' ' ILE . 52.9 Cg_endo -69.85 124.78 11.38 Favored 'Trans proline' 0 N--CA 1.464 -0.217 0 C-N-CA 122.685 2.256 . . . . 64.54 112.353 179.888 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 172' ' ' PHE . . . . . 0.516 ' CE2' ' HB2' ' A' ' 146' ' ' ALA . 2.3 t80 -147.04 177.49 9.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 71.23 110.883 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 22.1 pttm -136.73 137.32 39.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 52.01 110.922 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 174' ' ' THR . . . . . 0.626 HG22 ' O ' ' A' ' 142' ' ' LYS . 0.0 OUTLIER -99.51 169.55 9.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 63.24 111.149 -179.974 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 175' ' ' ASP . . . . . 0.423 ' HB3' ' HB2' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -129.87 161.98 29.58 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.257 -0.429 . . . . 64.33 110.891 179.933 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.656 HG13 HG22 ' A' ' 141' ' ' ILE . 99.1 t -144.46 127.22 11.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 73.25 111.111 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 5.0 t -163.7 166.04 22.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 72.4 111.182 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -167.7 -150.38 6.5 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.785 -0.721 . . . . 63.52 112.507 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 179' ' ' THR . . . . . 0.402 ' O ' HG23 ' A' ' 179' ' ' THR . 1.7 t . . . . . 0 C--N 1.33 -0.249 0 CA-C-O 120.9 0.381 . . . . 64.04 111.081 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.232 0.177 0 CA-C-O 120.808 0.253 . . . . 71.43 112.359 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 185' ' ' VAL . . . . . 0.488 HG12 HG23 ' A' ' 187' ' ' THR . 57.3 t -96.16 105.34 16.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.275 -0.42 . . . . 73.01 111.063 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -104.78 104.88 14.74 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.173 -0.467 . . . . 74.43 110.843 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 187' ' ' THR . . . . . 0.488 HG23 HG12 ' A' ' 185' ' ' VAL . 6.1 p -122.33 148.57 44.88 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.132 -0.485 . . . . 73.1 111.107 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.02 155.78 47.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.213 -0.449 . . . . 64.24 110.877 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 6.0 pt -144.01 109.91 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.46 . . . . 72.32 111.135 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -90.44 111.51 22.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 71.43 110.921 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 2.7 t -137.79 162.27 32.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 74.03 111.108 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -107.23 88.5 3.94 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.662 0.744 . . . . 43.25 110.871 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 138.45 37.83 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.708 2.272 . . . . 42.45 112.354 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -122.21 126.63 48.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.242 -0.435 . . . . 62.24 110.904 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 195' ' ' ILE . . . . . 0.451 ' O ' HG13 ' A' ' 167' ' ' VAL . 21.4 mt -112.44 120.01 61.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.175 -0.466 . . . . 72.42 111.109 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 9.5 tt -104.53 107.93 19.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.446 . . . . 64.53 110.918 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.1 t -96.49 123.4 40.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.128 -0.487 . . . . 62.21 110.878 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 27.2 tp -146.36 127.3 14.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 74.25 110.92 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -179.79 -150.68 9.29 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.711 -0.757 . . . . 42.15 112.496 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 200' ' ' ALA . . . . . 0.677 ' HB3' ' CE1' ' A' ' 21' ' ' PHE . . . -117.8 173.01 6.99 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.852 0.358 . . . . 73.34 111.101 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 2.3 p -149.7 169.48 20.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.466 . . . . 75.55 110.88 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 202' ' ' TYR . . . . . 0.462 ' O ' HG13 ' A' ' 18' ' ' VAL . 23.2 t80 -148.93 142.36 25.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 72.15 110.926 -179.868 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.556 HG13 ' SD ' ' A' ' 162' ' ' MET . 21.5 m -76.95 161.31 4.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.109 -0.496 . . . . 65.42 111.132 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -161.82 116.55 1.95 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 75.03 110.914 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 5.6 ttmm . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.161 -0.472 . . . . 64.12 110.906 -179.987 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 . . . . . 0 C--O 1.23 0.026 0 CA-C-O 120.801 0.334 . . . . 71.41 110.883 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.85 7.91 21.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.734 -0.746 . . . . 72.54 112.513 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -55.15 166.44 0.55 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.8 0.334 . . . . 71.04 110.865 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.415 ' HB2' ' HB3' ' A' ' 204' ' ' PHE . 10.9 m-90 -109.54 151.33 26.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.131 -0.486 . . . . 74.3 110.883 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.464 HG12 ' HB3' ' A' ' 60' ' ' ALA . 61.6 t -153.24 115.25 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.245 -0.434 . . . . 75.33 111.17 179.848 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.04 140.49 32.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.168 -0.469 . . . . 62.35 111.095 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.7 t -136.6 115.09 11.87 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 64.3 110.836 -179.787 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.579 ' CE2' ' HB3' ' A' ' 200' ' ' ALA . 1.9 p90 -123.15 117.11 24.62 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.087 -0.506 . . . . 73.3 110.861 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -152.79 169.58 22.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.13 -0.486 . . . . 72.25 110.882 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 21.5 p90 -102.85 135.33 44.72 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.15 -0.477 . . . . 73.22 110.813 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 1.3 p -102.3 137.54 40.42 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.063 -0.517 . . . . 63.25 110.873 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.4 ttmt -112.55 108.08 17.04 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.098 -0.501 . . . . 71.53 110.961 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.6 p -76.74 129.65 37.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.186 -0.461 . . . . 52.14 111.145 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -123.39 113.62 19.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 72.14 110.939 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.56 HG21 HG11 ' A' ' 191' ' ' VAL . 7.8 p -176.78 146.11 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.099 -0.5 . . . . 62.44 111.108 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.47 68.94 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.673 -0.775 . . . . 72.12 112.468 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -90.23 -66.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.751 0.31 . . . . 72.4 110.911 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 -175.98 167.78 2.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 71.34 110.931 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.619 HD12 HG21 ' A' ' 189' ' ' ILE . 41.4 tp -101.28 156.16 17.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 75.14 110.927 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.398 0 C-N-CA 120.809 -0.71 . . . . 71.04 112.556 179.93 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.82 0.343 . . . . 62.43 111.068 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -146.41 126.06 13.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.225 -0.443 . . . . 64.43 110.793 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 82' ' ' GLN . 12.0 p -104.79 138.19 30.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 63.15 111.063 -179.963 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 m -154.74 177.95 10.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.152 -0.476 . . . . 71.04 110.857 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -137.16 154.3 30.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 71.54 111.134 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -111.69 62.7 0.29 Allowed Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.682 -0.771 . . . . 55.53 112.441 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 32.5 m120 -87.88 162.94 16.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.872 0.368 . . . . 61.11 110.81 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -129.13 163.29 25.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.093 -0.503 . . . . 65.23 110.928 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.5 p -69.14 104.58 2.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 74.35 111.11 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -131.16 168.41 17.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.182 -0.463 . . . . 64.11 111.182 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.561 ' H ' HD23 ' A' ' 55' ' ' LEU . 1.0 OUTLIER -91.07 168.77 11.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 65.13 110.939 179.952 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.98 147.39 38.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.231 -0.441 . . . . 73.22 111.206 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -101.77 151.2 22.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.27 -0.423 . . . . 72.44 110.866 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.406 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.9 OUTLIER -149.81 135.48 18.47 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.169 -0.469 . . . . 51.41 110.902 -179.982 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.418 ' O ' HG22 ' A' ' 59' ' ' ILE . 1.6 mp -107.7 112.47 40.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 30.33 111.088 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.464 ' HB3' HG12 ' A' ' 18' ' ' VAL . . . -101.42 129.15 47.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 55.34 111.045 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.512 ' HB3' HG22 ' A' ' 69' ' ' VAL . 0.8 OUTLIER -117.0 128.47 55.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 75.3 110.916 -179.876 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -98.25 98.41 9.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.489 . . . . 74.41 110.881 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.9 p -95.88 -34.1 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 53.53 111.108 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 25.1 p -139.6 163.16 33.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.48 . . . . 52.31 110.816 -179.832 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 12.0 p -87.23 3.24 47.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 72.34 110.849 -179.766 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 20.1 m120 -106.55 -31.18 8.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.135 -0.484 . . . . 73.5 110.911 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.9 pt -150.43 165.48 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.122 -0.49 . . . . 74.35 111.091 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -146.8 166.9 25.28 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.104 -0.498 . . . . 70.04 111.061 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.512 HG22 ' HB3' ' A' ' 61' ' ' TYR . 6.1 m -114.78 151.41 16.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.161 -0.472 . . . . 75.03 111.086 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -144.62 132.28 21.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.135 -0.484 . . . . 72.24 110.822 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.406 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 5.5 m-85 -108.47 118.04 35.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 63.34 110.882 -179.921 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -88.3 121.39 30.64 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.145 -0.48 . . . . 70.1 110.853 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 42.1 t -146.88 146.86 18.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.191 -0.459 . . . . 73.21 111.094 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -151.33 162.22 29.45 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.79 -0.719 . . . . 71.34 112.465 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.495 ' O ' HG13 ' A' ' 75' ' ' VAL . 6.8 p -115.47 70.64 3.17 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.655 0.741 . . . . 75.12 111.173 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 158.96 55.12 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.651 2.234 . . . . 62.03 112.324 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -104.04 -169.81 1.68 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.247 -0.433 . . . . 42.44 111.145 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 50.4 ttp180 -76.35 126.77 31.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.428 . . . . 74.35 110.856 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -121.62 150.3 41.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 61.53 111.141 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 5.5 tttm -84.16 107.81 16.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.252 -0.431 . . . . 65.3 110.966 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 72.0 t80 -84.43 128.29 34.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 75.51 110.85 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.441 ' O ' HG23 ' A' ' 47' ' ' VAL . 41.7 mt-30 -103.38 151.61 22.56 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.129 -0.487 . . . . 73.33 110.899 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.551 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 172.68 82.45 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.801 -0.714 . . . . 62.14 112.492 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -176.83 -175.08 0.59 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.879 0.371 . . . . 63.44 110.952 -179.903 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.84 -69.5 0.67 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 61.13 110.916 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.6 t -84.96 -31.61 23.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 75.33 110.913 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.828 HG22 HG22 ' A' ' 93' ' ' VAL . 1.1 mt -68.19 -34.23 65.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.11 -0.496 . . . . 74.15 111.143 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.6 t -63.3 -51.11 67.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.174 -0.467 . . . . 62.42 110.851 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.8 t -52.01 -38.87 58.32 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.081 -0.508 . . . . 64.03 110.873 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 13.6 mt -64.85 -35.34 80.81 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.14 -0.482 . . . . 74.44 110.909 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.15 -13.39 67.02 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.686 -0.768 . . . . 73.5 112.47 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 10.4 ptp180 -115.0 94.93 4.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.812 0.339 . . . . 71.31 110.837 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.828 HG22 HG22 ' A' ' 87' ' ' ILE . 99.9 t -111.66 -57.47 3.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.186 -0.461 . . . . 73.3 111.114 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 18.0 p -140.74 159.21 42.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 74.03 110.848 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -128.85 124.62 35.8 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.101 -0.5 . . . . 72.41 110.863 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.492 HG11 HG21 ' A' ' 141' ' ' ILE . 10.4 p -175.53 159.58 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.103 -0.499 . . . . 54.03 111.125 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.47 ' N ' HG22 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -106.81 173.11 6.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 64.24 110.926 179.863 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 98' ' ' TYR . . . . . 0.492 ' HA ' ' HB2' ' A' ' 128' ' ' PHE . 19.3 m-85 -133.61 144.04 49.01 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.255 -0.429 . . . . 72.54 110.94 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -106.91 87.09 0.49 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.781 -0.724 . . . . 74.03 112.46 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 124.72 11.38 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.697 2.264 . . . . 54.03 112.382 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.508 ' HB3' ' HG2' ' A' ' 125' ' ' ARG . . . -141.25 94.73 2.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 72.11 111.109 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.404 ' HA ' ' HA2' ' A' ' 124' ' ' GLY . 3.1 mp -117.35 153.99 19.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.195 -0.457 . . . . 74.41 111.11 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -153.03 108.57 3.28 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.191 -0.459 . . . . 75.12 110.913 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 23.6 p -134.38 166.4 22.92 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 75.24 110.859 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.587 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.8 OUTLIER -119.7 150.89 39.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 71.15 110.943 179.988 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -102.02 138.26 39.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.216 -0.447 . . . . 73.53 110.88 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 33.2 p90 -149.48 146.99 27.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 75.43 110.918 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 17.6 p80 . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.077 -0.51 . . . . 74.04 110.847 179.94 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 1.3 p90 . . . . . 0 C--O 1.232 0.15 0 CA-C-O 121.653 0.739 . . . . 53.41 110.935 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.77 177.76 5.27 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.664 2.242 . . . . 74.32 112.353 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -117.46 154.34 31.57 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.235 -0.439 . . . . 64.0 110.958 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 25.2 t -102.78 128.16 55.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.111 -0.495 . . . . 35.54 111.095 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -123.17 169.08 15.37 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.774 -0.726 . . . . 62.22 112.525 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 12.9 p -163.77 149.24 3.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.888 0.375 . . . . 75.41 111.131 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -171.47 -149.21 6.44 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.751 -0.738 . . . . 71.43 112.458 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.573 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 14.9 p -129.4 136.14 60.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.829 0.347 . . . . 74.31 111.146 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 124' ' ' GLY . . . . . 0.404 ' HA2' ' HA ' ' A' ' 102' ' ' ILE . . . -122.35 118.29 3.6 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.75 -0.738 . . . . 71.25 112.446 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 125' ' ' ARG . . . . . 0.508 ' HG2' ' HB3' ' A' ' 101' ' ' ALA . 0.0 OUTLIER -121.47 124.72 45.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.827 0.346 . . . . 74.33 110.939 -179.894 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 27.2 t -118.15 119.79 62.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.255 -0.43 . . . . 74.0 111.107 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.2 pp -150.99 156.57 41.43 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 72.44 110.888 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.492 ' HB2' ' HA ' ' A' ' 98' ' ' TYR . 0.6 OUTLIER -167.42 -173.42 2.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 71.24 110.907 179.949 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -96.89 142.87 28.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 74.53 110.91 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -78.37 114.58 17.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.451 . . . . 73.31 110.875 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.439 ' H ' HG23 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -76.05 -78.11 0.12 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 63.33 110.91 179.981 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 3.4 m -170.67 120.3 0.56 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.25 -0.432 . . . . 71.24 111.123 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' ASP . . . . . 0.406 ' HB2' ' CB ' ' A' ' 139' ' ' PHE . 0.8 OUTLIER -105.63 122.98 47.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.48 . . . . 41.44 110.813 179.953 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 135' ' ' ALA . . . -80.63 -22.89 61.17 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.699 -0.762 . . . . 72.24 112.464 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.637 ' HB2' ' CG1' ' A' ' 93' ' ' VAL . . . -36.95 -42.75 0.42 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.872 0.368 . . . . 54.02 111.164 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.508 HD22 ' O ' ' A' ' 135' ' ' ALA . 0.5 OUTLIER -142.44 168.49 19.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 71.14 110.896 179.976 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 90.1 p -48.27 96.75 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.18 -0.464 . . . . 52.31 110.811 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 4.4 m 49.48 73.79 0.23 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.088 -0.505 . . . . 63.35 110.815 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.406 ' CB ' ' HB2' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -100.06 161.63 13.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.074 -0.512 . . . . 74.14 110.934 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -130.03 165.56 21.94 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.185 -0.462 . . . . 74.2 110.916 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.492 HG21 HG11 ' A' ' 96' ' ' VAL . 6.4 tt -103.38 155.25 5.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.249 -0.432 . . . . 74.24 111.113 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 7.2 mmtp -123.33 111.96 17.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 74.52 110.858 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -78.95 -159.84 0.2 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.237 -0.438 . . . . 73.15 110.851 179.79 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -171.14 173.53 4.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 71.13 110.945 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 145' ' ' TRP . . . . . 0.409 ' O ' ' HB2' ' A' ' 146' ' ' ALA . 29.1 p90 -154.75 149.19 26.23 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.219 -0.446 . . . . 73.35 110.864 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.865 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 177.97 169.07 0.51 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.562 0.696 . . . . 55.33 111.086 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 147' ' ' PRO . . . . . 0.865 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.6 Cg_endo -69.79 144.0 52.49 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.662 2.241 . . . . 75.54 112.344 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.645 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -138.84 167.99 20.79 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 75.11 111.144 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -108.71 161.77 14.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.247 -0.433 . . . . 74.25 110.881 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 3.1 mt-30 -140.18 157.18 46.01 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.159 -0.473 . . . . 63.03 110.89 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -154.4 131.03 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 74.42 111.092 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 152' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 169.77 -167.61 40.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 71.04 112.521 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.54 HD12 ' N ' ' A' ' 154' ' ' ARG . 1.7 pp -152.42 169.13 23.32 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.779 0.323 . . . . 70.54 110.979 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.54 ' N ' HD12 ' A' ' 153' ' ' LEU . 10.1 tpp85 -120.14 125.0 47.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.179 -0.464 . . . . 74.52 110.92 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -123.63 175.09 7.03 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.285 -0.416 . . . . 72.22 110.93 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -122.1 96.66 5.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.1 -0.5 . . . . 73.02 110.891 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 157' ' ' LEU . . . . . 0.409 HD23 ' N ' ' A' ' 158' ' ' GLY . 8.8 tt -102.92 140.26 37.42 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.233 -0.439 . . . . 71.42 110.934 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 158' ' ' GLY . . . . . 0.409 ' N ' HD23 ' A' ' 157' ' ' LEU . . . 59.29 171.63 0.43 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.745 -0.741 . . . . 72.33 112.444 179.824 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 45.4 t30 -93.07 158.57 15.71 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.907 0.384 . . . . 75.11 110.804 -179.824 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 58.7 m 51.18 32.24 7.75 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.18 -0.464 . . . . 60.23 110.843 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -174.68 149.7 1.26 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.143 -0.48 . . . . 72.24 110.91 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 11.9 mmt -121.18 172.77 7.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 73.55 110.928 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 5.0 tp -126.11 139.56 53.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.288 -0.415 . . . . 73.05 110.948 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -139.34 139.72 37.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.446 . . . . 75.23 110.927 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 69.2 p -139.8 121.8 15.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 62.2 110.857 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 166' ' ' ASP . . . . . 0.421 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.5 OUTLIER -141.72 164.55 29.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 62.04 110.869 179.95 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.518 HG13 ' O ' ' A' ' 195' ' ' ILE . 40.1 t -150.16 129.86 3.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.147 -0.479 . . . . 73.1 111.104 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 168' ' ' ARG . . . . . 0.744 ' HG2' HD12 ' A' ' 195' ' ' ILE . 0.0 OUTLIER -101.08 144.92 29.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.136 -0.483 . . . . 74.11 110.832 -179.911 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -146.02 135.16 22.75 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.184 -0.462 . . . . 65.12 110.966 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 170' ' ' ILE . . . . . 0.645 HG21 ' HB2' ' A' ' 148' ' ' ALA . 4.7 tp 179.9 131.85 0.25 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.594 0.711 . . . . 74.02 111.15 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.8 109.74 2.39 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.752 2.301 . . . . 74.35 112.315 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 172' ' ' PHE . . . . . 0.673 ' CZ ' ' HB3' ' A' ' 146' ' ' ALA . 2.0 m-85 -116.92 178.11 4.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 74.2 110.922 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.01 133.94 18.04 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.178 -0.464 . . . . 75.41 110.84 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 174' ' ' THR . . . . . 0.443 HG22 HG13 ' A' ' 189' ' ' ILE . 13.2 t -105.64 154.28 20.65 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.166 -0.47 . . . . 62.31 111.077 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -128.53 161.81 28.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.135 -0.484 . . . . 71.12 110.858 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 20.3 t -146.58 132.42 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 50.41 111.175 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.3 t -165.59 160.25 17.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.183 -0.462 . . . . 64.2 111.145 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -136.3 171.37 22.88 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.751 -0.738 . . . . 63.03 112.454 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 179' ' ' THR . . . . . 0.409 ' O ' HG23 ' A' ' 179' ' ' THR . 2.1 t . . . . . 0 C--N 1.329 -0.31 0 CA-C-O 120.766 0.317 . . . . 71.32 111.173 -179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo . . . . . 0 C--O 1.231 0.165 0 CA-C-O 120.811 0.255 . . . . 61.33 112.353 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 15.0 t -101.32 139.33 22.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.235 -0.439 . . . . 64.12 111.095 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 43.0 p -121.25 105.03 10.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.162 -0.472 . . . . 50.51 110.907 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 22.1 p -105.06 162.07 13.69 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.162 -0.472 . . . . 63.41 111.152 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -159.32 157.38 30.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 72.32 110.884 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 189' ' ' ILE . . . . . 0.619 HG21 HD12 ' A' ' 32' ' ' LEU . 3.5 pt -154.13 130.43 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 51.45 111.139 179.889 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -101.62 118.4 36.86 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 63.31 110.881 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 191' ' ' VAL . . . . . 0.56 HG11 HG21 ' A' ' 28' ' ' VAL . 7.1 p -136.25 160.97 38.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.144 -0.48 . . . . 73.41 111.127 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.415 ' N ' HG22 ' A' ' 191' ' ' VAL . 1.7 p30 -106.91 87.82 3.19 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.613 0.721 . . . . 71.34 110.85 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.69 158.85 55.6 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.703 2.268 . . . . 63.2 112.33 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -136.94 120.87 17.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.23 -0.441 . . . . 52.22 110.889 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 195' ' ' ILE . . . . . 0.744 HD12 ' HG2' ' A' ' 168' ' ' ARG . 45.4 mt -105.62 118.5 53.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.445 . . . . 74.13 111.167 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 3.9 mt -106.73 108.33 19.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.156 -0.474 . . . . 45.42 110.924 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 16.6 p -101.03 134.22 44.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 74.54 110.874 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 22.0 tp -156.49 129.7 8.03 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.109 -0.496 . . . . 73.33 110.909 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 179.83 -145.59 6.56 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.74 -0.743 . . . . 61.22 112.501 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 200' ' ' ALA . . . . . 0.579 ' HB3' ' CE2' ' A' ' 21' ' ' PHE . . . -116.73 174.53 6.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.755 0.312 . . . . 71.24 111.084 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 71.8 m -155.67 164.85 38.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 65.52 110.887 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 9.7 t80 -134.34 122.63 22.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.141 -0.481 . . . . 74.34 110.887 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 19.7 m -76.9 127.96 37.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.087 -0.506 . . . . 71.12 111.136 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 204' ' ' PHE . . . . . 0.415 ' HB3' ' HB2' ' A' ' 17' ' ' TRP . 1.1 m-85 -112.46 81.35 1.46 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 73.12 110.924 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 55.3 pttt . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.499 . . . . 62.3 110.838 -179.991 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 . . . . . 0 C--O 1.23 0.077 0 CA-C-O 120.839 0.352 . . . . 62.13 110.926 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.85 5.52 35.69 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.781 -0.723 . . . . 45.35 112.423 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -66.8 150.16 49.53 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.778 0.323 . . . . 52.13 110.867 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.511 ' HE1' HG23 ' A' ' 59' ' ' ILE . 25.9 t90 -116.6 144.18 44.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 74.2 110.882 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.67 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 12.9 t -141.6 118.83 7.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.268 -0.424 . . . . 72.14 111.13 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -84.76 101.71 12.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.229 -0.441 . . . . 65.23 111.083 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.4 t -97.93 142.09 30.09 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 75.01 110.866 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.549 ' HE2' HD13 ' A' ' 55' ' ' LEU . 73.6 t80 -146.52 118.89 8.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.164 -0.471 . . . . 74.45 110.856 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.412 ' O ' HG23 ' A' ' 56' ' ' THR . 3.9 p30 -149.77 174.72 12.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.132 -0.486 . . . . 51.4 110.927 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 13.3 t80 -106.52 128.76 54.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.471 . . . . 75.32 110.914 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -94.21 147.56 23.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.171 -0.468 . . . . 75.13 110.856 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 20.7 tttt -127.49 111.42 13.78 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.135 -0.484 . . . . 71.32 110.891 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.1 p -75.63 127.09 37.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 65.35 111.153 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 2.6 t80 -119.46 105.15 10.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.144 -0.48 . . . . 70.24 110.915 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.803 HG11 HG11 ' A' ' 47' ' ' VAL . 6.4 t -78.65 157.76 4.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.083 -0.508 . . . . 54.14 111.154 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.505 ' HA3' HG21 ' A' ' 191' ' ' VAL . . . -76.5 -112.6 0.13 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.693 -0.765 . . . . 53.51 112.528 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 66.6 mt-10 -89.86 -67.08 0.87 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.854 0.359 . . . . 64.31 110.942 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.544 ' HA ' HG12 ' A' ' 47' ' ' VAL . 1.7 pm0 -177.11 -173.79 0.48 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.127 -0.488 . . . . 73.11 110.88 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.823 ' HA ' HG21 ' A' ' 189' ' ' ILE . 1.9 mt -85.0 -177.78 6.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 74.52 110.911 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 C-N-CA 120.771 -0.728 . . . . 65.02 112.481 179.911 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.058 0 CA-C-O 120.836 0.35 . . . . 72.04 111.057 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -157.9 126.01 5.4 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 72.41 110.875 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.803 HG11 HG11 ' A' ' 28' ' ' VAL . 7.2 p -104.39 140.71 21.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 65.02 111.152 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -140.48 164.83 29.1 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 65.13 110.828 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.597 HG22 ' CE2' ' A' ' 81' ' ' PHE . 23.2 pt -112.25 157.17 13.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.101 -0.5 . . . . 73.03 111.178 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.07 142.52 31.87 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.772 -0.728 . . . . 34.1 112.506 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -93.38 110.86 22.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.805 0.336 . . . . 51.31 110.858 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 19.9 t0 -174.07 148.83 1.39 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.46 . . . . 72.23 110.857 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 2.0 m -70.73 130.54 41.99 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 72.04 111.148 -179.877 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.97 177.54 7.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.171 -0.468 . . . . 62.24 111.143 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.549 HD13 ' HE2' ' A' ' 21' ' ' PHE . 3.1 pp -159.97 165.39 32.11 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.219 -0.446 . . . . 73.14 110.942 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.491 HG21 ' CE2' ' A' ' 72' ' ' PHE . 0.3 OUTLIER -143.3 143.27 31.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 62.43 111.132 -179.993 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -103.18 133.29 48.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.221 -0.445 . . . . 74.45 110.897 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -121.39 136.44 54.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.12 -0.491 . . . . 63.43 110.844 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.511 HG23 ' HE1' ' A' ' 17' ' ' TRP . 27.5 mm -108.51 113.39 43.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.161 -0.472 . . . . 74.4 111.067 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.67 ' HB3' ' HB ' ' A' ' 18' ' ' VAL . . . -102.78 121.19 41.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 72.34 111.1 179.801 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.435 ' HB3' HG22 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -111.3 115.41 29.28 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.187 -0.461 . . . . 65.51 110.968 -179.835 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -82.54 101.9 11.03 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.108 -0.496 . . . . 71.2 110.83 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.0 t -97.1 -35.37 5.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.135 -0.484 . . . . 64.41 111.106 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 27.8 t -134.07 162.09 33.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.487 . . . . 63.01 110.876 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 59.4 p -84.46 2.85 38.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.171 -0.468 . . . . 64.42 110.83 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -115.0 -32.98 5.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.085 -0.507 . . . . 75.54 110.912 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.425 HG22 ' CB ' ' A' ' 107' ' ' TYR . 21.7 pt -142.35 165.04 17.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.164 -0.471 . . . . 73.14 111.156 179.849 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -151.55 167.09 29.15 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.222 -0.445 . . . . 63.13 111.118 179.827 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.435 HG22 ' HB3' ' A' ' 61' ' ' TYR . 6.5 m -108.01 151.07 10.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 61.23 111.179 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -139.15 132.48 30.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 62.41 110.877 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -115.83 110.02 18.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.15 -0.477 . . . . 70.05 110.85 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.491 ' CE2' HG21 ' A' ' 56' ' ' THR . 30.9 t80 -91.26 115.94 28.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 74.42 110.888 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.404 HG12 ' N ' ' A' ' 74' ' ' GLY . 11.3 t -142.23 156.17 19.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 72.01 111.082 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.404 ' N ' HG12 ' A' ' 73' ' ' VAL . . . -163.96 148.68 15.11 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.691 -0.766 . . . . 53.0 112.427 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.7 t -119.65 65.35 9.13 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.637 0.732 . . . . 44.21 111.144 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 163.42 38.33 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.688 2.259 . . . . 55.54 112.349 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -89.42 -169.29 2.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 70.34 111.08 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.5 ttp180 -77.42 132.52 38.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.258 -0.428 . . . . 74.41 110.921 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ALA . . . . . 0.514 ' HB3' ' CZ ' ' A' ' 98' ' ' TYR . . . -133.38 152.84 51.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 64.14 111.048 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 14.6 ttmt -82.12 150.33 27.53 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.172 -0.467 . . . . 54.21 110.938 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' PHE . . . . . 0.597 ' CE2' HG22 ' A' ' 49' ' ' ILE . 2.5 t80 -138.77 147.69 42.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 74.23 110.896 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.511 ' O ' HG23 ' A' ' 47' ' ' VAL . 32.8 mt-30 -113.61 153.31 29.07 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.137 -0.483 . . . . 74.34 110.894 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.541 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 174.96 80.86 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.758 . . . . 62.24 112.423 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -178.26 -178.37 0.63 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.92 0.391 . . . . 74.24 110.962 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.0 -69.42 0.67 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.213 -0.448 . . . . 54.3 110.877 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 5.3 m -85.22 -32.41 22.64 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.23 -0.441 . . . . 63.34 110.829 -179.848 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.556 HG22 HG22 ' A' ' 93' ' ' VAL . 4.3 mm -66.83 -34.9 72.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 74.33 111.097 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 15.1 t -63.32 -47.84 80.53 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 64.34 110.864 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.2 p -53.14 -38.64 62.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 72.13 110.844 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -63.47 -43.39 97.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.178 -0.464 . . . . 74.15 110.867 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 109.86 -13.55 32.03 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.747 -0.739 . . . . 72.13 112.498 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 41.6 mtt180 -118.81 93.38 4.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.852 0.358 . . . . 73.24 110.916 -179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.556 HG22 HG22 ' A' ' 87' ' ' ILE . 4.0 t -113.57 -35.0 2.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 75.4 111.158 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 19.5 m -156.17 161.29 40.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 62.11 110.779 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' GLU . . . . . 0.629 ' O ' HG13 ' A' ' 96' ' ' VAL . 44.7 mt-10 -153.86 115.89 4.29 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.118 -0.492 . . . . 65.52 110.875 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.629 HG13 ' O ' ' A' ' 95' ' ' GLU . 2.1 m -161.68 179.53 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.148 -0.478 . . . . 75.03 111.089 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -98.28 147.92 24.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 74.23 110.854 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' TYR . . . . . 0.514 ' CZ ' ' HB3' ' A' ' 79' ' ' ALA . 11.6 m-85 -92.34 139.98 30.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.219 -0.446 . . . . 74.43 110.946 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' GLY . . . . . 0.402 ' N ' ' CD ' ' A' ' 100' ' ' PRO . . . -127.37 55.07 0.76 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.721 -0.752 . . . . 51.24 112.476 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' A' ' 99' ' ' GLY . 53.6 Cg_endo -69.73 111.69 2.87 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.71 2.273 . . . . 55.22 112.402 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.453 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -136.07 110.08 8.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.265 -0.425 . . . . 73.01 111.107 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.554 HG22 ' CA ' ' A' ' 124' ' ' GLY . 11.0 pt -140.82 140.59 33.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.213 -0.449 . . . . 74.34 111.17 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.567 ' HG ' HG23 ' A' ' 123' ' ' VAL . 0.1 OUTLIER -132.49 120.14 21.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 73.53 110.933 179.904 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 2.4 p -142.14 162.86 34.41 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 61.33 110.878 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -109.23 144.6 37.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.146 -0.479 . . . . 72.54 110.876 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 3.0 pm0 -105.38 148.99 26.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.109 -0.496 . . . . 71.11 110.87 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.612 ' CE2' HG13 ' A' ' 119' ' ' VAL . 32.2 p90 -149.33 148.44 29.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 72.2 110.913 -179.852 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 32.3 t60 . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.087 -0.506 . . . . 74.41 110.849 179.959 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 5.4 p90 . . . . . 0 C--O 1.231 0.106 0 CA-C-O 121.654 0.74 . . . . 73.21 110.893 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 179.09 3.93 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.727 2.284 . . . . 53.15 112.35 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -109.87 164.59 12.44 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.22 -0.445 . . . . 64.34 110.974 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.612 HG13 ' CE2' ' A' ' 107' ' ' TYR . 6.2 p -117.51 139.0 46.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.169 -0.469 . . . . 73.44 111.096 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -139.95 160.5 26.23 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.713 -0.756 . . . . 74.12 112.499 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 4.9 m -152.75 163.88 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.877 0.37 . . . . 64.0 111.18 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 174.98 -145.99 8.19 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.722 -0.751 . . . . 41.42 112.429 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.567 HG23 ' HG ' ' A' ' 103' ' ' LEU . 11.8 m -105.5 148.89 9.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.853 0.358 . . . . 61.5 111.192 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 124' ' ' GLY . . . . . 0.554 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -144.25 105.95 0.39 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.697 -0.763 . . . . 55.31 112.467 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 125' ' ' ARG . . . . . 0.453 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 15.7 ptm180 -99.78 125.07 45.63 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.899 0.38 . . . . 70.33 110.903 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 25.2 t -109.51 114.02 45.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.25 -0.432 . . . . 64.11 111.125 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.575 HD12 ' N ' ' A' ' 128' ' ' PHE . 2.1 pp -124.24 171.12 10.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.465 . . . . 74.2 110.885 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.575 ' N ' HD12 ' A' ' 127' ' ' LEU . 0.6 OUTLIER -141.14 178.55 7.31 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.148 -0.478 . . . . 53.41 110.831 179.953 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -118.15 119.82 35.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.115 -0.493 . . . . 73.02 110.918 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -60.45 103.61 0.26 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.125 -0.489 . . . . 54.41 110.892 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.519 ' H ' HG12 ' A' ' 96' ' ' VAL . 7.9 tppt? -123.69 -71.91 0.7 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.449 . . . . 71.23 110.912 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 23.5 m -166.87 92.68 0.44 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.459 . . . . 61.32 111.136 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -107.73 168.98 8.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.464 . . . . 53.15 110.871 179.879 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 79.28 151.68 6.39 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.748 -0.739 . . . . 73.14 112.481 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -39.38 -66.85 0.26 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.831 0.348 . . . . 74.15 111.09 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -166.64 92.33 0.45 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 70.44 110.852 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 137' ' ' SER . . . . . 0.533 ' O ' ' C ' ' A' ' 138' ' ' SER . 0.4 OUTLIER 169.01 60.78 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 33.45 110.878 -179.947 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.533 ' C ' ' O ' ' A' ' 137' ' ' SER . 8.7 t 27.21 73.93 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.152 -0.476 . . . . 63.25 110.906 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -107.3 159.15 16.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.144 -0.48 . . . . 73.24 110.854 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -145.19 167.12 23.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.088 -0.506 . . . . 65.03 110.943 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.595 ' HA ' HG23 ' A' ' 176' ' ' VAL . 12.5 tt -116.76 132.5 66.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.209 -0.45 . . . . 62.31 111.131 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 142' ' ' LYS . . . . . 0.733 ' O ' HG22 ' A' ' 174' ' ' THR . 0.0 OUTLIER -80.72 106.64 12.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 74.01 110.863 179.899 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -82.72 -172.43 4.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 62.41 110.879 179.87 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 5.2 tptt -174.95 -169.73 0.42 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 71.14 110.906 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 145' ' ' TRP . . . . . 0.427 ' O ' ' HB2' ' A' ' 146' ' ' ALA . 66.9 p-90 -144.62 161.01 40.22 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.208 -0.451 . . . . 74.22 110.98 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.724 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 178.02 165.29 0.59 Allowed Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.567 0.698 . . . . 53.31 111.14 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 147' ' ' PRO . . . . . 0.724 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.6 Cg_endo -69.74 161.88 44.2 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.705 2.27 . . . . 73.23 112.354 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.644 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -153.79 160.11 42.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.249 -0.432 . . . . 63.4 111.064 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -118.91 115.23 23.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.223 -0.444 . . . . 65.25 110.903 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 20.6 tt0 -102.86 164.41 11.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.105 -0.498 . . . . 72.14 110.921 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 14.6 p -160.12 137.17 2.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.153 -0.476 . . . . 60.21 111.052 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 152' ' ' GLY . . . . . 0.408 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 177.55 -162.25 30.02 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.767 -0.73 . . . . 60.41 112.528 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -138.69 160.61 39.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.827 0.346 . . . . 73.43 110.888 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 3.4 tpp85 -132.05 119.74 21.43 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 73.35 110.883 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -105.46 140.96 37.78 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.181 -0.463 . . . . 74.43 110.932 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -120.93 117.55 27.63 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.472 . . . . 73.42 110.864 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 3.9 tp -102.3 164.4 11.7 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 75.34 110.887 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -99.51 53.79 0.99 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.739 -0.744 . . . . 65.53 112.486 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -149.87 35.87 0.69 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.362 . . . . 75.32 110.966 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 51.79 35.4 15.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 72.25 110.8 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 51.2 m95 -154.99 101.43 2.26 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.134 -0.484 . . . . 73.44 110.849 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 162' ' ' MET . . . . . 0.435 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 0.0 OUTLIER -97.7 168.25 10.45 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.253 -0.43 . . . . 75.35 110.909 179.855 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 4.0 tp -125.26 144.18 50.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.252 -0.431 . . . . 63.21 110.934 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -142.99 139.98 30.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 70.11 110.84 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 52.8 p -150.95 120.94 7.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 71.13 110.87 -179.803 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 166' ' ' ASP . . . . . 0.408 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.6 OUTLIER -149.08 171.13 16.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.167 -0.47 . . . . 55.23 110.881 179.921 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 4.3 t -144.75 135.96 20.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.171 -0.468 . . . . 72.22 111.076 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -102.67 137.34 41.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 74.45 110.872 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 35.1 t80 -141.79 139.2 32.7 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.201 -0.454 . . . . 73.45 110.887 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 170' ' ' ILE . . . . . 0.644 HG21 ' HB2' ' A' ' 148' ' ' ALA . 0.0 OUTLIER 178.96 125.93 0.21 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.633 0.73 . . . . 74.35 111.096 179.885 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 107.25 1.82 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.649 2.233 . . . . 74.33 112.337 179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -126.94 170.0 12.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 65.1 110.894 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.7 141.4 43.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.114 -0.494 . . . . 75.22 110.875 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 174' ' ' THR . . . . . 0.733 HG22 ' O ' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -125.32 169.48 12.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 70.12 111.141 179.958 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -126.64 170.45 12.08 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 52.2 110.888 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 176' ' ' VAL . . . . . 0.595 HG23 ' HA ' ' A' ' 141' ' ' ILE . 7.6 p -160.14 137.1 2.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.45 . . . . 72.12 111.213 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 177' ' ' THR . . . . . 0.558 HG22 ' HD3' ' A' ' 142' ' ' LYS . 12.8 t -166.84 175.6 7.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.245 -0.434 . . . . 72.43 111.169 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -156.95 -140.99 3.07 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.8 -0.714 . . . . 45.3 112.495 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.33 -0.244 0 CA-C-O 120.816 0.341 . . . . 72.33 111.073 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo . . . . . 0 C--O 1.231 0.15 0 CA-C-O 120.837 0.265 . . . . 71.23 112.34 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 48.4 t -108.36 108.82 26.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 71.02 111.106 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 85.5 p -99.22 111.3 23.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.075 -0.512 . . . . 63.43 110.827 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 3.1 p -108.53 163.31 13.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 54.03 111.152 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -146.53 148.06 31.78 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.271 -0.422 . . . . 74.51 110.92 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 189' ' ' ILE . . . . . 0.823 HG21 ' HA ' ' A' ' 32' ' ' LEU . 3.6 pt -142.36 136.35 28.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.285 -0.416 . . . . 51.05 111.165 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -112.17 104.23 12.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.208 -0.451 . . . . 40.33 110.882 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 191' ' ' VAL . . . . . 0.505 HG21 ' HA3' ' A' ' 29' ' ' GLY . 4.9 p -136.6 163.18 33.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 74.15 111.156 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.409 ' N ' HG22 ' A' ' 191' ' ' VAL . 1.4 p-10 -106.71 90.68 5.31 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.63 0.729 . . . . 72.45 110.875 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.73 135.99 31.92 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.698 2.265 . . . . 71.4 112.316 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -103.67 124.94 49.77 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.254 -0.43 . . . . 73.41 110.936 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 26.4 mm -107.45 103.19 15.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.159 -0.473 . . . . 75.12 111.186 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 20.7 tp -91.47 110.55 21.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 74.32 110.88 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 20.5 p -110.35 123.58 50.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 75.22 110.864 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 198' ' ' LEU . . . . . 0.411 HD23 ' N ' ' A' ' 198' ' ' LEU . 1.0 OUTLIER -141.4 132.65 26.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 75.13 110.944 -179.948 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 179.02 -146.43 7.22 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.823 -0.703 . . . . 75.11 112.544 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 200' ' ' ALA . . . . . 0.435 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -125.52 173.37 8.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.796 0.331 . . . . 72.34 111.168 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -147.53 171.1 16.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.425 . . . . 73.25 110.914 -179.77 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 12.6 m-85 -139.33 133.87 31.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.137 -0.483 . . . . 61.51 110.92 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 11.2 p -79.56 147.64 6.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 65.55 111.167 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -146.67 98.07 3.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.212 -0.449 . . . . 63.15 110.865 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 18.1 mtmt . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.095 -0.502 . . . . 65.25 110.809 -179.953 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 . . . . . 0 CA--C 1.524 -0.045 0 CA-C-O 120.879 0.371 . . . . 74.35 110.926 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 103.88 6.21 43.42 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.762 -0.732 . . . . 70.13 112.513 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -66.93 150.46 49.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.809 0.337 . . . . 73.23 110.815 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 4.5 m0 -111.96 142.05 44.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.152 -0.477 . . . . 63.21 110.939 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.632 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 43.2 t -145.04 118.95 2.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.263 -0.426 . . . . 72.41 111.041 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.4 119.96 25.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.098 -0.501 . . . . 64.22 111.031 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 22.0 t -106.65 128.6 54.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 65.45 110.807 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.536 ' CE2' HD21 ' A' ' 55' ' ' LEU . 19.2 t80 -138.19 114.55 10.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.095 -0.502 . . . . 72.3 110.829 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -153.5 174.05 14.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 74.42 110.906 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -102.45 129.01 48.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.455 . . . . 64.52 110.915 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.2 p -98.64 148.04 24.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.129 -0.487 . . . . 53.23 110.839 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 39.2 tptt -129.45 106.84 9.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 61.35 110.854 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.2 m -89.68 124.2 42.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.226 -0.443 . . . . 61.34 111.139 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 28.5 t80 -118.93 104.12 10.22 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.166 -0.47 . . . . 75.33 110.933 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.0 p -157.8 150.45 8.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 50.45 111.189 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 144.77 76.8 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.776 -0.726 . . . . 55.42 112.506 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -89.5 -65.63 1.0 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.758 0.313 . . . . 72.31 110.849 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -169.09 124.76 0.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.447 . . . . 72.11 110.902 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.687 HD13 HG13 ' A' ' 189' ' ' ILE . 0.9 OUTLIER -89.2 152.78 21.41 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.164 -0.471 . . . . 73.21 110.86 -179.95 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.355 0 C-N-CA 120.726 -0.75 . . . . 63.32 112.459 179.88 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.553 ' HB3' ' O ' ' A' ' 32' ' ' LEU . . . . . . . . 0 C--O 1.23 0.076 0 CA-C-O 120.784 0.326 . . . . 41.24 111.042 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 17.8 t0 -146.18 126.57 14.02 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 60.24 110.866 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.633 ' HB ' HD23 ' A' ' 32' ' ' LEU . 7.1 p -105.36 140.56 23.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 62.21 111.135 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -158.8 157.85 32.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.45 . . . . 70.12 110.829 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 9.4 tt -132.4 144.04 38.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.102 -0.499 . . . . 74.45 111.084 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -108.19 97.23 1.1 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.782 -0.723 . . . . 54.22 112.517 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -136.7 119.09 15.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.802 0.334 . . . . 74.1 110.895 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 77.1 m-20 -100.81 -56.5 2.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.206 -0.452 . . . . 74.04 110.914 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 5.1 t -60.78 134.06 56.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.137 -0.483 . . . . 73.21 111.127 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.4 p -120.24 121.29 38.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 74.2 111.151 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.536 HD21 ' CE2' ' A' ' 21' ' ' PHE . 0.3 OUTLIER -159.9 123.41 3.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.247 -0.433 . . . . 73.11 110.946 179.978 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.667 HG21 ' CE1' ' A' ' 72' ' ' PHE . 5.4 m -137.74 130.76 30.29 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 64.11 111.143 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -102.93 132.53 49.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 72.41 110.874 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.577 ' O ' HD13 ' A' ' 59' ' ' ILE . 0.7 OUTLIER -131.93 155.95 47.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.119 -0.491 . . . . 63.34 110.872 179.92 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.577 HD13 ' O ' ' A' ' 58' ' ' ASP . 27.4 mm -126.05 115.16 41.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 75.33 111.153 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.632 ' HB3' ' HB ' ' A' ' 18' ' ' VAL . . . -99.9 126.05 45.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 73.14 111.11 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.555 ' HB3' HG22 ' A' ' 69' ' ' VAL . 0.5 OUTLIER -116.72 118.26 32.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.272 -0.422 . . . . 71.14 110.968 -179.857 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -88.42 101.0 13.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.145 -0.479 . . . . 63.52 110.856 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 9.0 p -98.01 -35.17 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.114 -0.494 . . . . 72.32 111.144 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 m -136.88 161.31 36.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.138 -0.483 . . . . 75.43 110.871 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.8 m -83.74 2.99 35.25 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.171 -0.468 . . . . 72.44 110.827 -179.808 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -120.16 -33.57 3.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.474 . . . . 74.43 110.831 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.572 HG22 ' CD1' ' A' ' 107' ' ' TYR . 2.5 pp -136.06 148.12 27.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.242 -0.435 . . . . 54.11 111.143 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -143.73 167.78 21.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.249 -0.432 . . . . 74.02 111.143 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.555 HG22 ' HB3' ' A' ' 61' ' ' TYR . 4.2 m -114.69 151.21 16.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 64.41 111.134 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -143.89 132.45 22.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.167 -0.469 . . . . 34.12 110.885 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -103.88 142.03 35.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 70.35 110.924 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.667 ' CE1' HG21 ' A' ' 56' ' ' THR . 7.5 t80 -121.4 118.57 29.75 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.187 -0.46 . . . . 73.24 110.871 -179.883 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 44.7 t -147.18 145.75 18.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 71.22 111.114 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -132.96 -30.23 0.49 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.754 -0.736 . . . . 63.15 112.514 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 11.0 m 36.6 62.76 2.97 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.623 0.725 . . . . 71.01 111.124 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 163.57 37.78 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.738 2.292 . . . . 65.15 112.306 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -79.64 -169.82 2.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 74.21 111.037 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.7 ttp180 -77.94 126.43 30.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.472 . . . . 72.42 110.912 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -135.77 151.93 50.61 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 75.33 111.089 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 26.3 ttpp -93.15 143.8 25.9 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 74.51 110.844 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' PHE . . . . . 0.599 ' HE2' HG12 ' A' ' 96' ' ' VAL . 13.8 p90 -139.39 157.73 45.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 75.31 110.917 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.467 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 5.2 pt20 -106.85 157.2 17.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 75.12 110.93 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.661 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 178.4 71.05 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.73 -0.748 . . . . 43.23 112.498 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -168.36 -173.48 1.99 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.926 0.393 . . . . 74.33 110.913 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.33 -71.23 0.55 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 65.23 110.932 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 23.1 t -84.89 -30.35 24.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.255 -0.43 . . . . 55.4 110.835 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.82 HG22 HG22 ' A' ' 93' ' ' VAL . 4.7 mm -67.99 -34.26 65.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 52.42 111.13 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 4.0 t -63.02 -44.13 96.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.152 -0.476 . . . . 74.4 110.806 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 73.4 m -55.18 -41.6 72.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.134 -0.485 . . . . 60.55 110.85 -179.821 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -58.86 -49.85 76.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.112 -0.495 . . . . 73.3 110.911 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 116.2 -17.12 14.85 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.829 -0.7 . . . . 62.31 112.534 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 6.8 ttp180 -121.27 95.52 4.72 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.856 0.36 . . . . 70.42 110.864 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.82 HG22 HG22 ' A' ' 87' ' ' ILE . 93.0 t -104.45 -61.09 2.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.136 -0.483 . . . . 71.5 111.073 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.403 ' HA ' ' HA ' ' A' ' 133' ' ' ASP . 1.8 p -139.47 149.52 44.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.437 . . . . 64.11 110.921 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -127.74 129.58 47.32 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.146 -0.479 . . . . 55.11 110.906 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.61 HG21 ' O ' ' A' ' 129' ' ' PHE . 6.1 p -173.43 163.27 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 75.51 111.126 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.442 ' N ' HG22 ' A' ' 96' ' ' VAL . 10.3 p-10 -92.58 152.61 19.51 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.2 -0.454 . . . . 73.04 110.851 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -103.41 148.94 25.29 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.225 -0.443 . . . . 72.2 110.868 -179.81 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -139.07 62.23 0.56 Allowed Glycine 0 N--CA 1.453 -0.194 0 C-N-CA 120.751 -0.738 . . . . 65.41 112.547 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 118.43 5.68 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.65 2.233 . . . . 71.41 112.325 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.62 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -122.38 102.57 8.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.233 -0.44 . . . . 75.33 111.138 179.841 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.456 HD12 ' HA3' ' A' ' 124' ' ' GLY . 10.8 mm -117.85 147.73 21.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.243 -0.435 . . . . 61.34 111.152 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -151.49 122.46 7.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 65.13 110.924 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' SER . . . . . 0.405 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 8.6 p -147.17 173.63 12.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 72.51 110.867 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.482 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.8 OUTLIER -122.03 153.84 38.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.13 -0.486 . . . . 73.11 110.938 179.99 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 6.5 mm100 -102.1 137.15 40.75 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.137 -0.483 . . . . 71.45 110.897 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' TYR . . . . . 0.572 ' CD1' HG22 ' A' ' 67' ' ' ILE . 10.9 t80 -140.91 133.76 29.01 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.184 -0.462 . . . . 73.55 110.933 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 26.9 t60 . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 64.44 110.879 179.85 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.666 0.746 . . . . 74.44 110.9 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 177.52 5.47 Favored 'Trans proline' 0 N--CA 1.465 -0.197 0 C-N-CA 122.71 2.273 . . . . 75.33 112.362 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 14.0 m-85 -117.22 157.78 25.43 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.454 . . . . 72.52 110.932 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 12.5 p -107.24 132.01 55.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.084 -0.507 . . . . 75.1 111.118 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -121.5 161.23 15.65 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.769 -0.729 . . . . 70.23 112.519 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 12.3 p -161.1 150.16 5.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.8 0.333 . . . . 53.21 111.08 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' GLY . . . . . 0.405 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -174.01 -155.37 11.89 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.68 -0.771 . . . . 70.23 112.489 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.447 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 28.9 m -113.75 134.04 57.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.803 0.335 . . . . 74.15 111.168 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 124' ' ' GLY . . . . . 0.456 ' HA3' HD12 ' A' ' 102' ' ' ILE . . . -117.27 105.91 1.35 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.734 -0.746 . . . . 44.01 112.531 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 125' ' ' ARG . . . . . 0.62 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 28.5 ptt180 -99.45 112.44 24.64 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.901 0.381 . . . . 74.1 110.866 -179.843 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 20.0 t -87.24 110.04 20.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.26 -0.427 . . . . 64.12 111.147 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.521 HD13 ' N ' ' A' ' 128' ' ' PHE . 0.2 OUTLIER -101.03 135.98 41.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 64.1 110.878 179.979 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.521 ' N ' HD13 ' A' ' 127' ' ' LEU . 13.8 m-85 -135.73 148.26 48.76 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.148 -0.478 . . . . 71.23 110.845 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.61 ' O ' HG21 ' A' ' 96' ' ' VAL . 10.2 m-85 -100.75 172.75 6.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.101 -0.5 . . . . 62.04 110.859 -179.896 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -113.53 94.87 5.06 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.178 -0.464 . . . . 61.23 110.9 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.476 ' HB2' HG23 ' A' ' 96' ' ' VAL . 2.6 mmmt -92.62 -86.6 0.24 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.206 -0.452 . . . . 75.43 110.95 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -168.23 111.82 0.61 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.293 -0.412 . . . . 70.31 111.182 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 133' ' ' ASP . . . . . 0.547 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 49.8 m-20 -101.1 112.76 25.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.429 . . . . 75.34 110.829 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -74.91 -9.87 83.61 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.738 -0.744 . . . . 62.31 112.452 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.453 ' HB2' ' CG1' ' A' ' 93' ' ' VAL . . . -45.4 -28.89 0.95 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.721 0.296 . . . . 65.15 111.05 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.2 mt -160.28 179.67 8.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.264 -0.425 . . . . 73.4 110.89 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 9.9 m -53.32 92.36 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.172 -0.467 . . . . 73.22 110.848 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 6.9 m 51.38 73.6 0.3 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.092 -0.503 . . . . 54.2 110.868 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.547 ' HB3' ' HB2' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -94.32 158.55 15.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 74.4 110.892 -179.959 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -135.89 167.64 20.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.461 . . . . 75.21 110.822 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 12.3 tt -112.98 151.04 14.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.12 -0.491 . . . . 75.33 111.13 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 6.0 tppt? -119.51 112.06 18.89 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 54.43 110.896 179.824 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.41 -173.34 0.29 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.25 -0.432 . . . . 74.02 110.875 179.845 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -170.6 165.2 8.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 74.24 110.882 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 49.2 p90 -132.47 154.48 49.85 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 73.41 110.927 179.897 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.726 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -178.5 164.28 1.13 Allowed Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.574 0.702 . . . . 41.1 111.11 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 147' ' ' PRO . . . . . 0.726 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.5 Cg_endo -69.71 169.49 18.73 Favored 'Trans proline' 0 N--CA 1.466 -0.144 0 C-N-CA 122.717 2.278 . . . . 72.24 112.376 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.422 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -165.37 153.54 11.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.246 -0.434 . . . . 34.0 111.086 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 6.7 p90 -122.03 139.11 54.1 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.218 -0.446 . . . . 75.42 110.857 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -130.75 174.52 9.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.125 -0.489 . . . . 75.41 110.988 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 10.8 p -158.91 147.12 7.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 51.33 111.093 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 170.97 -158.77 30.51 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.777 -0.725 . . . . 51.44 112.58 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.6 pt? -158.22 168.02 28.19 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.768 0.318 . . . . 71.2 110.928 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.6 tpp85 -117.93 120.64 38.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 74.2 110.954 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.8 t80 -115.37 169.64 8.99 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.245 -0.434 . . . . 63.31 110.949 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -121.86 99.66 6.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.147 -0.478 . . . . 70.2 110.924 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 5.9 tt -102.31 103.7 14.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 74.31 110.87 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 94.37 -160.71 23.84 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.792 -0.718 . . . . 65.41 112.51 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 6.3 p30 -118.7 -36.56 3.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.854 0.359 . . . . 64.33 110.928 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 3.7 p -66.39 -56.04 12.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.113 -0.494 . . . . 73.11 110.866 -179.877 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 12.3 p90 -124.91 172.69 9.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.179 -0.464 . . . . 72.43 110.951 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 162' ' ' MET . . . . . 0.541 ' CE ' HG13 ' A' ' 203' ' ' VAL . 5.5 ptp -121.84 177.47 5.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.269 -0.423 . . . . 71.14 110.903 179.878 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 8.7 tp -111.94 146.2 38.23 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.21 -0.45 . . . . 63.34 110.915 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -144.44 133.51 22.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 64.4 110.9 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 19.6 t -130.89 125.93 34.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.13 -0.487 . . . . 55.43 110.842 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 26.7 m-20 -150.33 142.16 23.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.093 -0.503 . . . . 72.53 110.87 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.747 ' CG2' HD12 ' A' ' 196' ' ' LEU . 40.6 t -139.59 122.62 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 43.3 111.148 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.49 159.99 14.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.236 -0.438 . . . . 63.23 110.804 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 169' ' ' TYR . . . . . 0.411 ' O ' ' HB ' ' A' ' 170' ' ' ILE . 26.3 t80 -164.56 140.99 6.12 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.159 -0.473 . . . . 73.45 110.919 -179.849 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 170' ' ' ILE . . . . . 0.446 HG12 ' O ' ' A' ' 147' ' ' PRO . 5.9 tp 177.86 133.15 0.22 Allowed Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.656 0.741 . . . . 72.32 111.109 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.69 104.37 1.3 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.716 2.277 . . . . 65.23 112.304 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -121.78 154.25 37.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.257 -0.429 . . . . 74.23 110.858 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 9.6 ptpp? -122.86 146.69 47.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 63.4 110.884 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 11.1 t -116.91 166.0 12.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.211 -0.45 . . . . 54.51 111.185 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -122.8 158.19 30.76 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.26 -0.427 . . . . 52.35 110.858 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 43.9 t -150.26 132.48 5.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 75.45 111.152 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 13.6 t -168.43 176.78 5.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.205 -0.452 . . . . 70.52 111.104 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 131.99 150.39 6.56 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.725 -0.75 . . . . 32.14 112.525 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 6.1 t . . . . . 0 C--N 1.329 -0.284 0 CA-C-O 120.843 0.354 . . . . 74.04 111.161 -179.853 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo . . . . . 0 C--O 1.232 0.185 0 CA-C-O 120.785 0.244 . . . . 73.12 112.344 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 68.0 t -103.61 111.44 33.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 75.35 111.098 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 3.9 p -84.57 135.02 34.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.094 -0.503 . . . . 64.14 110.893 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 40.4 p -145.48 167.75 22.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 63.22 111.097 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -158.99 157.31 31.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.451 . . . . 71.2 110.887 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 189' ' ' ILE . . . . . 0.687 HG13 HD13 ' A' ' 32' ' ' LEU . 36.8 mm -146.66 125.6 4.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.193 -0.458 . . . . 74.5 111.13 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -102.31 114.6 28.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.18 -0.464 . . . . 75.01 110.864 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 191' ' ' VAL . . . . . 0.447 HG23 HG22 ' A' ' 189' ' ' ILE . 2.5 t -136.53 164.32 31.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.126 -0.488 . . . . 54.01 111.1 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 192' ' ' ASP . . . . . 0.434 ' H ' HG12 ' A' ' 191' ' ' VAL . 0.1 OUTLIER -107.23 87.59 3.27 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.651 0.739 . . . . 73.34 110.856 179.89 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.93 133.58 25.59 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.722 2.282 . . . . 74.33 112.249 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 23.4 m-85 -100.68 119.33 38.42 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.161 -0.472 . . . . 72.03 110.83 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 195' ' ' ILE . . . . . 0.484 ' O ' HG13 ' A' ' 167' ' ' VAL . 53.4 mt -105.57 110.18 30.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.124 -0.489 . . . . 71.31 111.156 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 196' ' ' LEU . . . . . 0.747 HD12 ' CG2' ' A' ' 167' ' ' VAL . 2.6 tp -110.54 108.84 18.95 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.199 -0.455 . . . . 74.42 110.974 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 197' ' ' SER . . . . . 0.522 ' O ' HD12 ' A' ' 198' ' ' LEU . 0.4 OUTLIER -110.55 129.27 55.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.231 -0.441 . . . . 73.43 110.901 -179.906 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 198' ' ' LEU . . . . . 0.522 HD12 ' O ' ' A' ' 197' ' ' SER . 3.1 mp -150.51 134.45 16.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.115 -0.493 . . . . 72.33 110.937 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 178.94 -136.95 3.02 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.686 -0.768 . . . . 54.3 112.467 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 200' ' ' ALA . . . . . 0.429 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -125.02 173.33 8.75 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.835 0.35 . . . . 73.13 111.041 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 29.5 m -149.09 171.0 17.13 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.16 -0.473 . . . . 60.51 110.841 -179.755 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 202' ' ' TYR . . . . . 0.449 ' O ' HG13 ' A' ' 18' ' ' VAL . 40.5 t80 -142.24 145.45 34.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.501 . . . . 71.44 110.86 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 203' ' ' VAL . . . . . 0.541 HG13 ' CE ' ' A' ' 162' ' ' MET . 33.6 m -93.28 156.83 3.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.04 -0.527 . . . . 72.52 111.108 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -159.72 110.8 1.98 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.127 -0.488 . . . . 75.54 110.911 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 37.1 mtmt . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 73.13 110.914 179.982 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.2 ttm . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.82 0.343 . . . . 74.31 110.901 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 17.7 p30 -86.97 160.46 18.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.236 -0.438 . . . . 71.33 110.912 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -112.45 133.4 54.55 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.149 -0.478 . . . . 62.13 110.89 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 64.3 m-20 -156.91 154.47 29.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 74.5 110.904 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 13.7 m-85 52.32 68.66 2.94 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.677 0.751 . . . . 72.04 110.929 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 166.31 27.99 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.723 2.282 . . . . 73.34 112.359 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.77 154.98 37.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 55.02 111.098 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 23.8 pttm -75.86 151.36 37.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.459 . . . . 70.13 110.896 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 9.9 t -119.96 127.99 53.16 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.424 . . . . 71.52 110.889 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -134.2 103.5 5.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.142 -0.481 . . . . 73.25 111.077 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -125.49 -37.09 0.53 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.737 -0.745 . . . . 70.43 112.523 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.1 p90 -147.44 114.45 6.16 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.897 0.379 . . . . 73.11 110.93 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 18.8 t-20 -141.53 147.89 38.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.096 -0.502 . . . . 62.13 110.897 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 34.5 tt0 -53.72 120.02 5.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.455 . . . . 71.23 110.918 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.66 5.48 36.24 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.754 -0.736 . . . . 64.54 112.549 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -68.79 150.27 48.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.772 0.32 . . . . 64.23 110.853 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.568 ' HE1' HG23 ' A' ' 59' ' ' ILE . 13.3 t90 -126.25 121.27 32.2 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.216 -0.447 . . . . 74.53 110.904 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.798 HG13 ' HB3' ' A' ' 60' ' ' ALA . 6.1 p -132.19 122.69 49.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.248 -0.433 . . . . 74.33 111.162 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -87.03 116.65 25.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 72.23 111.102 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -104.7 109.82 21.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 72.5 110.929 -179.815 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 15.0 p90 -107.69 119.88 40.68 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.186 -0.461 . . . . 72.45 110.879 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.41 ' HA ' ' HA3' ' A' ' 199' ' ' GLY . 2.5 p30 -149.6 161.53 41.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.134 -0.484 . . . . 62.11 110.858 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -86.49 128.47 34.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 72.05 110.879 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 18.1 p -102.11 116.26 32.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.162 -0.472 . . . . 74.22 110.895 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 16.3 mtpp -98.92 106.16 18.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.151 -0.477 . . . . 75.41 110.935 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.3 p -83.36 139.43 17.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 71.31 111.117 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 21.3 t80 -130.82 101.79 5.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.465 . . . . 72.01 110.922 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.1 p -162.26 155.02 2.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.096 -0.502 . . . . 75.41 111.099 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 119.63 72.17 0.36 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.683 -0.77 . . . . 71.24 112.476 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 -89.43 -57.97 2.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.768 0.318 . . . . 62.44 110.863 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -174.48 135.1 0.41 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.165 -0.471 . . . . 70.32 110.898 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.659 ' HB2' ' HB3' ' A' ' 45' ' ' ALA . 12.7 mt -52.0 165.64 0.2 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 72.53 110.917 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.33 80.74 0.3 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.713 -0.756 . . . . 73.53 112.485 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 28.4 t0 -79.02 129.37 34.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.879 0.371 . . . . 74.52 110.897 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 18.1 tp -79.9 -56.32 4.34 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 63.33 110.908 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 18.8 t30 -151.31 169.14 22.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 64.32 110.833 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.443 HG22 ' H ' ' A' ' 39' ' ' GLY . 11.6 p -157.0 142.71 9.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.151 -0.477 . . . . 53.44 111.124 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -53.05 -33.2 44.08 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.704 -0.76 . . . . 71.42 112.511 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLY . . . . . 0.443 ' H ' HG22 ' A' ' 37' ' ' VAL . . . -53.08 -34.41 46.76 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.746 -0.74 . . . . 61.13 112.476 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 108.33 -49.36 0.86 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.728 -0.749 . . . . 74.32 112.479 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -65.67 164.26 14.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.78 0.324 . . . . 61.13 111.129 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -130.02 67.98 80.31 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.622 0.725 . . . . 73.41 110.946 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 -177.4 1.84 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.693 2.262 . . . . 73.44 112.36 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -128.0 139.97 52.25 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.223 -0.444 . . . . 71.33 110.884 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.659 ' HB3' ' HB2' ' A' ' 32' ' ' LEU . . . -106.4 -179.27 3.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.15 -0.477 . . . . 44.33 111.069 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -149.45 132.99 16.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 62.13 110.878 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.619 HG12 ' HA2' ' A' ' 83' ' ' GLY . 30.1 m -104.72 154.01 6.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 73.03 111.162 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 10.3 t -151.99 146.1 25.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 55.44 110.862 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.469 HD13 ' H ' ' A' ' 49' ' ' ILE . 0.2 OUTLIER -119.43 150.45 21.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.078 -0.51 . . . . 72.25 111.115 -180.0 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.77 135.2 14.73 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.742 -0.742 . . . . 73.42 112.487 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 60.5 m-20 -87.57 112.95 22.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.359 . . . . 72.52 110.892 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 33.5 t0 -154.38 165.86 35.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.165 -0.47 . . . . 74.35 110.887 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 34.4 p -64.69 148.03 51.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 75.02 111.129 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 8.4 t -158.84 139.92 12.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 64.51 111.13 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.451 HD12 ' CE1' ' A' ' 57' ' ' PHE . 0.2 OUTLIER -124.81 159.77 30.25 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 74.23 110.898 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 55.8 m -139.08 147.53 42.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.179 -0.464 . . . . 70.43 111.113 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.451 ' CE1' HD12 ' A' ' 55' ' ' LEU . 86.6 m-85 -124.18 132.62 53.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 74.13 110.881 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -134.23 149.3 50.96 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.129 -0.487 . . . . 63.21 110.872 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.568 HG23 ' HE1' ' A' ' 17' ' ' TRP . 10.4 mm -108.28 115.75 49.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.186 -0.461 . . . . 62.11 111.144 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.798 ' HB3' HG13 ' A' ' 18' ' ' VAL . . . -101.13 125.99 47.8 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.188 -0.46 . . . . 41.53 111.123 179.802 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.583 ' HB2' HG13 ' A' ' 69' ' ' VAL . 0.7 OUTLIER -108.89 117.79 35.12 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.222 -0.444 . . . . 74.13 110.919 -179.859 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -89.2 105.99 18.15 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.091 -0.504 . . . . 75.25 110.853 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.1 m -103.88 -34.25 3.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 60.41 111.129 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.7 t -135.87 160.12 39.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.224 -0.443 . . . . 75.31 110.884 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 5.7 p -84.56 2.99 38.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.147 -0.478 . . . . 62.52 110.828 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -111.6 -30.84 7.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 73.43 110.876 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 2.6 pp -147.3 165.61 6.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 62.2 111.106 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -154.36 172.84 17.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.472 . . . . 72.41 111.134 179.823 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.583 HG13 ' HB2' ' A' ' 61' ' ' TYR . 1.2 p -116.47 147.89 19.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.245 -0.434 . . . . 71.11 111.119 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -142.57 134.66 27.33 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.173 -0.467 . . . . 73.04 110.835 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -119.73 110.96 17.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.454 . . . . 71.23 110.867 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -85.05 131.18 34.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.481 . . . . 72.25 110.859 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 5.6 m -151.34 163.54 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 51.15 111.103 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -171.16 145.57 8.99 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.721 -0.752 . . . . 60.22 112.49 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.508 ' O ' HG22 ' A' ' 75' ' ' VAL . 7.6 p -117.07 67.44 4.34 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.596 0.712 . . . . 72.32 111.133 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 162.57 41.57 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.686 2.257 . . . . 63.1 112.351 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -84.81 -173.14 4.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 61.15 111.123 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -78.43 131.14 36.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.444 . . . . 73.41 110.866 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -126.26 151.74 47.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.468 . . . . 62.13 111.1 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 15.4 ttpt -114.72 126.32 54.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 75.34 110.892 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 15.7 p90 -126.42 158.84 34.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 72.21 110.89 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.408 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 29.6 mt-30 -92.61 157.66 16.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 74.34 110.92 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.619 ' HA2' HG12 ' A' ' 47' ' ' VAL . . . -176.05 68.76 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.735 -0.745 . . . . 72.23 112.458 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.517 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.6 tp10 -176.44 -176.59 0.77 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.915 0.388 . . . . 74.54 110.915 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -85.55 -69.41 0.66 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 63.13 110.932 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.4 t -83.31 -34.61 25.66 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.284 -0.416 . . . . 63.24 110.892 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.948 HG21 ' HB2' ' A' ' 135' ' ' ALA . 6.1 mm -64.62 -33.79 65.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.09 -0.504 . . . . 72.42 111.116 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 5.3 t -60.17 -46.79 88.5 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 74.41 110.87 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 22.8 t -56.18 -37.38 69.52 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.124 -0.489 . . . . 74.21 110.839 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.63 -48.64 79.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.112 -0.494 . . . . 70.22 110.904 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 111.73 -13.8 27.18 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.704 -0.76 . . . . 72.42 112.471 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 43.7 mtp180 -118.24 92.74 3.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.887 0.375 . . . . 71.53 110.856 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.893 HG22 HG22 ' A' ' 87' ' ' ILE . 90.1 t -113.93 -55.33 4.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 51.4 111.107 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.88 143.81 38.89 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.194 -0.457 . . . . 63.01 110.851 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 11.8 tt0 -147.52 117.87 7.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 71.13 110.891 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.418 HG12 ' H ' ' A' ' 131' ' ' LYS . 18.8 m -155.75 -176.83 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 73.44 111.14 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -97.29 152.08 19.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 73.42 110.896 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -92.57 135.26 34.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 71.14 110.936 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.56 ' HA3' HD12 ' A' ' 127' ' ' LEU . . . -128.3 63.29 0.62 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.71 -0.757 . . . . 63.41 112.441 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 112.38 3.06 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.709 2.272 . . . . 74.41 112.362 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.762 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -128.36 99.49 5.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 64.22 111.145 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.524 ' C ' HD23 ' A' ' 103' ' ' LEU . 4.9 mt -124.31 144.58 33.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 54.33 111.142 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.563 ' HG ' HG23 ' A' ' 123' ' ' VAL . 0.0 OUTLIER -147.31 109.73 4.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.177 -0.465 . . . . 55.34 110.878 179.968 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 3.6 p -144.5 160.39 41.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.221 -0.445 . . . . 71.01 110.832 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.454 ' O ' HD12 ' A' ' 105' ' ' LEU . 4.6 pp -106.19 150.21 26.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.125 -0.489 . . . . 64.1 110.962 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 7.9 pm0 -101.41 141.74 33.84 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.191 -0.459 . . . . 75.52 110.907 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 27.9 p90 -144.45 144.56 31.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 63.22 110.927 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 16.1 m80 -79.74 161.05 25.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.097 -0.502 . . . . 74.42 110.872 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.569 ' CE1' HG23 ' A' ' 119' ' ' VAL . 10.6 p90 -154.52 151.15 28.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 74.43 110.923 -179.814 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 13.3 t0 -52.36 144.35 13.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 52.41 110.882 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.9 p -154.37 156.67 37.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.456 . . . . 45.31 110.831 -179.723 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -122.02 -38.85 2.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.142 -0.481 . . . . 63.22 110.901 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 7.7 tt0 -51.84 169.15 0.07 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.129 -0.487 . . . . 74.24 110.876 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 60.0 mtm180 -51.91 -74.08 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 73.34 110.871 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 10.5 mt -64.88 137.25 57.65 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.212 -0.449 . . . . 72.14 110.949 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 8.7 p90 -118.36 68.11 7.32 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-O 121.642 0.734 . . . . 62.31 110.936 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 176.27 7.0 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.723 2.282 . . . . 73.33 112.354 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 12.7 p90 -115.97 159.47 21.56 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.207 -0.451 . . . . 73.54 110.925 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.569 HG23 ' CE1' ' A' ' 109' ' ' TYR . 60.2 t -123.4 135.33 63.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.126 -0.488 . . . . 72.14 111.107 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -124.08 176.86 16.85 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.72 -0.752 . . . . 72.21 112.491 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.8 p -166.03 152.48 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-O 120.817 0.342 . . . . 70.14 111.167 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 179.12 -153.14 11.9 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.722 -0.752 . . . . 54.44 112.444 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.563 HG23 ' HG ' ' A' ' 103' ' ' LEU . 13.5 m -106.91 120.45 58.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.826 0.346 . . . . 72.33 111.125 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -114.77 111.01 2.44 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.688 -0.768 . . . . 71.34 112.433 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' ARG . . . . . 0.762 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 8.1 ptp180 -109.31 131.87 54.66 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.805 0.336 . . . . 74.41 110.878 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.423 ' O ' HG13 ' A' ' 126' ' ' VAL . 3.5 p -117.53 115.92 50.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 63.22 111.107 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.56 HD12 ' HA3' ' A' ' 99' ' ' GLY . 2.6 pp -127.49 170.89 12.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.192 -0.458 . . . . 75.31 110.91 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -140.58 174.69 10.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 73.54 110.914 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -102.8 125.25 49.47 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.131 -0.486 . . . . 64.12 110.923 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -61.15 95.65 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.162 -0.472 . . . . 52.23 110.856 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.418 ' H ' HG12 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -115.1 -78.01 0.57 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.161 -0.472 . . . . 64.05 110.894 179.98 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 86.1 m -161.95 83.72 0.58 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 63.32 111.134 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' ASP . . . . . 0.411 ' OD2' HD12 ' A' ' 141' ' ' ILE . 22.8 m-20 -101.98 170.0 8.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.21 -0.45 . . . . 74.15 110.881 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.29 151.65 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.711 -0.757 . . . . 53.11 112.502 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.948 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -79.73 -0.03 32.53 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.827 0.346 . . . . 62.14 111.101 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -86.23 -178.08 6.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 63.23 110.942 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.7 m -65.73 91.64 0.14 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.186 -0.461 . . . . 62.31 110.894 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.2 t 51.87 75.41 0.21 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.108 -0.496 . . . . 63.42 110.872 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.667 ' CE1' HG12 ' A' ' 176' ' ' VAL . 1.1 t80 -88.92 149.04 23.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.1 -0.5 . . . . 71.21 110.838 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 14.0 t0 -109.96 164.7 12.35 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.127 -0.488 . . . . 72.35 110.902 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.411 HD12 ' OD2' ' A' ' 133' ' ' ASP . 63.8 mt -128.47 125.92 64.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 72.21 111.085 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' LYS . . . . . 0.466 ' O ' HG22 ' A' ' 174' ' ' THR . 0.1 OUTLIER -76.04 109.24 9.52 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.172 -0.467 . . . . 71.04 110.913 179.819 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.406 ' HB3' ' HA ' ' A' ' 127' ' ' LEU . 0.8 OUTLIER -58.68 -173.62 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.207 -0.451 . . . . 72.4 110.857 179.877 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 11.2 mmtm -148.55 166.02 29.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.456 . . . . 61.2 110.89 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 42.6 p-90 -157.75 136.32 11.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 74.33 110.921 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.751 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -172.49 166.02 3.52 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.578 0.704 . . . . 61.22 111.129 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.751 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.5 Cg_endo -69.79 135.35 30.17 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.711 2.274 . . . . 62.42 112.318 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -122.48 165.62 16.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 64.33 111.129 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 23.7 m-85 -122.3 136.32 54.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.214 -0.448 . . . . 74.2 110.89 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 3.7 mm100 -107.16 151.8 24.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.159 -0.473 . . . . 71.23 110.921 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.429 ' O ' HG13 ' A' ' 151' ' ' VAL . 5.4 p -152.04 117.85 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.207 -0.451 . . . . 74.52 111.181 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' GLY . . . . . 0.43 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 176.93 -161.63 29.5 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.739 -0.743 . . . . 64.34 112.467 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.516 HD23 ' N ' ' A' ' 154' ' ' ARG . 0.6 OUTLIER -136.99 155.9 49.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.769 0.318 . . . . 73.21 110.918 -179.911 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.516 ' N ' HD23 ' A' ' 153' ' ' LEU . 0.4 OUTLIER -139.93 124.16 17.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 71.35 110.872 179.954 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 155' ' ' TYR . . . . . 0.458 ' OH ' HD13 ' A' ' 163' ' ' LEU . 26.3 p90 -144.42 177.45 8.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.461 . . . . 74.25 110.896 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -118.92 100.18 7.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.082 -0.508 . . . . 73.5 110.895 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 18.7 tp -102.03 106.24 17.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.142 -0.481 . . . . 73.0 110.956 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 103.34 -173.76 22.42 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.726 -0.749 . . . . 73.23 112.47 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 9.3 p-10 -101.53 132.26 47.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.861 0.363 . . . . 61.55 110.913 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.6 t 53.01 41.33 32.16 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.139 -0.482 . . . . 74.22 110.921 -179.79 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 2.3 t90 -171.97 100.49 0.17 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.096 -0.502 . . . . 64.54 110.92 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.545 ' CE ' HG21 ' A' ' 18' ' ' VAL . 13.6 mtm -95.42 173.85 7.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.258 -0.428 . . . . 72.24 110.914 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.458 HD13 ' OH ' ' A' ' 155' ' ' TYR . 2.1 tt -127.69 145.1 51.0 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.271 -0.422 . . . . 74.2 110.911 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 164' ' ' ASN . . . . . 0.452 ' N ' HD23 ' A' ' 163' ' ' LEU . 5.9 t-20 -145.8 138.07 25.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 74.32 110.919 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 13.0 p -153.26 121.75 6.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 64.42 110.89 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 166' ' ' ASP . . . . . 0.43 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 1.3 p30 -154.03 -179.79 8.2 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.166 -0.47 . . . . 63.43 110.856 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.895 HG22 HD12 ' A' ' 196' ' ' LEU . 8.2 t -138.48 143.79 31.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 64.33 111.113 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 168' ' ' ARG . . . . . 0.47 ' NH2' HG21 ' A' ' 170' ' ' ILE . 4.4 ttt180 -113.78 123.34 49.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.158 -0.474 . . . . 74.45 110.856 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 13.2 t80 -121.99 138.97 54.22 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.186 -0.461 . . . . 75.41 110.94 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 170' ' ' ILE . . . . . 0.548 HD11 ' HB3' ' A' ' 146' ' ' ALA . 6.4 tt -177.35 93.91 0.23 Allowed Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.631 0.729 . . . . 73.23 111.171 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.66 134.19 27.59 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.707 2.271 . . . . 63.43 112.379 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -156.89 177.84 11.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.252 -0.431 . . . . 74.51 110.878 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 173' ' ' LYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 190' ' ' GLU . 11.3 pttp -128.28 125.32 38.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.126 -0.488 . . . . 63.4 110.859 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 174' ' ' THR . . . . . 0.466 HG22 ' O ' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -91.94 161.74 14.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 75.55 111.146 179.961 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 175' ' ' ASP . . . . . 0.415 ' HB3' ' HB2' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -119.14 165.55 14.05 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.431 . . . . 61.11 110.874 179.943 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.667 HG12 ' CE1' ' A' ' 139' ' ' PHE . 21.4 t -146.53 133.13 13.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 64.23 111.171 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 14.0 t -166.53 176.9 6.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 75.2 111.104 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 122.18 141.33 6.0 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.752 -0.737 . . . . 63.22 112.495 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.3 m -173.0 140.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.834 0.35 . . . . 62.53 111.147 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 32.4 tp -102.97 89.23 3.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.214 -0.448 . . . . 61.41 110.946 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 126.1 -87.3 0.35 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.75 -0.738 . . . . 71.41 112.485 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 -170.57 0.4 Allowed 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.704 2.269 . . . . 71.44 112.306 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 29.9 m -83.34 126.84 70.75 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-O 121.605 0.717 . . . . 34.24 111.117 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 165.85 29.59 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.708 2.272 . . . . 65.42 112.325 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 85.3 t -109.41 107.69 23.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.274 -0.421 . . . . 60.35 111.115 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 6.7 p -83.69 110.57 18.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.151 -0.477 . . . . 75.05 110.882 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 11.9 p -121.93 171.5 8.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 73.1 111.15 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 29.9 ttpt -153.52 148.08 26.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.208 -0.451 . . . . 65.41 110.922 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 5.9 tp -142.74 124.06 11.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 63.4 111.098 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 190' ' ' GLU . . . . . 0.422 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 19.5 pt-20 -96.94 116.9 30.0 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 70.22 110.863 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 4.1 m -138.36 158.79 31.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 72.3 111.108 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.406 ' HA ' ' HD2' ' A' ' 193' ' ' PRO . 1.9 p30 -107.85 89.85 5.79 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.581 0.705 . . . . 73.24 110.875 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 193' ' ' PRO . . . . . 0.406 ' HD2' ' HA ' ' A' ' 192' ' ' ASP . 53.6 Cg_endo -69.79 138.46 37.78 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.721 2.281 . . . . 73.34 112.358 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 12.9 m-85 -124.68 116.66 22.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 72.45 110.865 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 195' ' ' ILE . . . . . 0.412 ' HB ' ' HB3' ' A' ' 168' ' ' ARG . 45.3 mt -106.44 131.28 56.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.199 -0.455 . . . . 64.41 111.109 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 196' ' ' LEU . . . . . 0.895 HD12 HG22 ' A' ' 167' ' ' VAL . 7.4 tp -117.74 112.33 20.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 74.31 110.889 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -97.87 124.59 42.35 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.145 -0.48 . . . . 72.21 110.855 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 198' ' ' LEU . . . . . 0.409 HD22 ' CD2' ' A' ' 196' ' ' LEU . 0.5 OUTLIER -144.64 119.59 9.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.133 -0.485 . . . . 53.41 110.906 -179.993 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 199' ' ' GLY . . . . . 0.41 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -177.91 -145.83 6.1 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.759 -0.734 . . . . 60.4 112.467 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 200' ' ' ALA . . . . . 0.504 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -127.19 173.8 9.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.803 0.335 . . . . 70.31 111.083 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -140.13 175.82 9.27 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 62.42 110.85 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 202' ' ' TYR . . . . . 0.709 ' C ' HG23 ' A' ' 18' ' ' VAL . 16.2 t80 -146.55 115.65 6.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.095 -0.502 . . . . 70.02 110.915 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.428 ' N ' HG23 ' A' ' 18' ' ' VAL . 15.0 p -77.12 147.66 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.103 -0.499 . . . . 71.01 111.159 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -152.9 143.14 22.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 72.03 110.867 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 12.9 ptmt -104.83 140.29 38.33 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.142 -0.481 . . . . 75.5 110.894 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -53.05 151.52 4.76 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.24 -0.436 . . . . 64.15 110.917 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -85.03 -43.0 14.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 71.12 111.075 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -54.99 125.53 20.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.239 -0.437 . . . . 72.53 111.108 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -99.91 136.38 39.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.237 -0.438 . . . . 74.33 111.066 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -107.55 155.96 19.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.176 -0.465 . . . . 74.22 110.909 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.236 -0.438 . . . . 74.35 110.895 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.1 mmm . . . . . 0 N--CA 1.458 -0.073 0 CA-C-O 120.804 0.335 . . . . 73.24 110.952 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 56.6 m-20 -106.77 55.84 0.66 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 72.35 110.839 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 22.4 mt-10 -144.94 55.97 1.25 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 63.25 110.869 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -143.31 145.3 32.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.139 -0.482 . . . . 73.23 110.801 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 2.2 p90 -141.58 157.6 65.0 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.655 0.74 . . . . 71.45 110.927 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 140.12 41.74 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.622 2.215 . . . . 42.41 112.384 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -115.49 116.96 29.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.199 -0.455 . . . . 60.33 111.057 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 11.2 ptpt -105.61 155.9 18.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.124 -0.489 . . . . 74.41 110.87 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 11.3 m -155.51 148.15 24.11 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.207 -0.451 . . . . 71.0 110.827 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -147.23 159.71 43.32 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.091 -0.504 . . . . 73.13 111.08 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -51.91 -34.87 38.73 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.748 -0.739 . . . . 31.22 112.48 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.2 p90 -157.96 114.35 2.84 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.824 0.345 . . . . 74.33 110.917 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -122.88 167.24 13.8 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.101 -0.499 . . . . 42.23 110.893 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 19.1 pt20 -69.47 120.17 14.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.238 -0.437 . . . . 65.32 110.861 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.41 6.28 38.86 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.781 -0.723 . . . . 73.43 112.543 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -78.43 163.36 25.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.811 0.338 . . . . 72.21 110.878 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 3.7 p-90 -139.96 151.58 45.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.154 -0.475 . . . . 71.1 110.896 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.771 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 2.3 m -144.55 139.36 23.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.226 -0.443 . . . . 63.11 111.107 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.414 ' HB1' ' CZ ' ' A' ' 21' ' ' PHE . . . -99.14 101.78 13.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.124 -0.489 . . . . 63.25 111.146 179.794 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.6 m -97.53 121.46 39.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 73.31 110.829 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.414 ' CZ ' ' HB1' ' A' ' 19' ' ' ALA . 18.8 m-85 -118.64 118.29 31.26 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.134 -0.484 . . . . 74.32 110.888 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -148.01 172.84 13.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.102 -0.499 . . . . 75.11 110.845 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -100.64 124.27 46.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.132 -0.486 . . . . 74.31 110.897 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' SER . . . . . 0.506 ' HB2' HG21 ' A' ' 56' ' ' THR . 69.5 m -102.28 115.11 29.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.129 -0.487 . . . . 71.0 110.848 -179.732 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -98.84 113.78 26.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.18 -0.464 . . . . 63.4 110.915 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 32.4 t -92.49 146.62 6.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.242 -0.436 . . . . 73.42 111.124 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -135.21 110.52 9.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 72.22 110.937 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.3 p -166.51 150.34 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.136 -0.484 . . . . 75.23 111.193 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 136.27 76.13 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.721 -0.752 . . . . 71.24 112.474 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -89.51 -65.89 0.97 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.832 0.348 . . . . 73.05 110.836 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.501 ' HA ' HG12 ' A' ' 47' ' ' VAL . 14.3 mt-10 -162.87 146.89 11.34 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 72.13 110.878 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.613 HD12 HG13 ' A' ' 189' ' ' ILE . 2.0 tp -109.81 160.73 16.1 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.195 -0.457 . . . . 54.33 110.933 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.51 ' N ' HD11 ' A' ' 189' ' ' ILE . . . 145.64 -142.41 10.64 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.742 -0.742 . . . . 73.22 112.501 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 18.5 m-20 -136.56 169.55 17.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.921 0.391 . . . . 74.24 110.78 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 12.7 mt -136.73 118.85 15.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 61.34 110.926 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 12.7 m120 -145.23 178.6 7.96 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.206 -0.452 . . . . 61.3 110.911 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 44.2 t -76.05 -62.79 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 75.21 111.115 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -157.5 174.13 34.94 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.776 -0.726 . . . . 53.53 112.421 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 137.96 85.99 0.16 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 63.12 112.461 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 61.18 -161.3 25.58 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.73 -0.748 . . . . 45.01 112.454 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -57.92 140.97 50.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.756 0.312 . . . . 41.32 111.081 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -131.98 68.92 80.75 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.608 0.718 . . . . 73.02 110.922 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 -177.4 1.86 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.642 2.228 . . . . 73.32 112.36 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -139.78 118.85 12.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.197 -0.456 . . . . 61.22 110.941 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.564 ' HB1' ' HA ' ' A' ' 84' ' ' GLU . . . -67.81 -178.59 0.98 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.174 -0.466 . . . . 73.24 111.091 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -132.38 125.81 31.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 70.34 110.857 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 82' ' ' GLN . 11.3 p -111.7 137.81 42.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 63.22 111.131 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -147.4 142.05 26.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.084 -0.507 . . . . 43.23 110.895 -179.834 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 39.0 pt -115.72 156.62 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 73.24 111.076 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -84.94 179.02 51.13 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.711 -0.757 . . . . 62.45 112.506 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 79.0 m-20 -133.64 112.95 11.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.836 0.351 . . . . 63.14 110.918 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -145.42 140.58 27.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 75.02 110.831 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 29.8 p -55.68 128.49 35.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 60.22 111.095 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 5.7 t -137.12 150.35 47.93 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.197 -0.456 . . . . 65.12 111.107 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -113.49 152.46 30.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 65.31 110.885 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.506 HG21 ' HB2' ' A' ' 24' ' ' SER . 0.8 OUTLIER -136.51 137.29 40.16 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.188 -0.46 . . . . 52.12 111.153 179.921 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -103.12 132.14 49.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 71.34 110.891 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -130.96 130.2 43.1 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.123 -0.49 . . . . 74.42 110.856 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.98 115.2 48.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 65.02 111.081 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.771 ' HB3' ' CG2' ' A' ' 18' ' ' VAL . . . -101.94 125.61 48.66 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.188 -0.46 . . . . 63.14 111.123 179.78 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -107.03 117.11 33.21 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.235 -0.439 . . . . 75.04 110.887 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -83.76 95.74 8.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.054 -0.521 . . . . 65.5 110.919 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 9.5 p -92.17 -34.29 6.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 72.43 111.175 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 17.0 m -133.68 160.69 36.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.097 -0.501 . . . . 75.43 110.842 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.6 p -83.48 2.98 34.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.123 -0.489 . . . . 70.31 110.868 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -119.75 -32.27 4.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.13 -0.486 . . . . 75.04 110.93 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.437 HG22 ' CD1' ' A' ' 107' ' ' TYR . 40.5 pt -139.72 153.46 23.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 71.01 111.098 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -146.95 162.92 37.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 65.54 111.088 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.5 m -103.84 151.37 6.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.23 -0.441 . . . . 74.31 111.095 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -141.92 135.75 29.75 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.19 -0.459 . . . . 75.05 110.823 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.493 ' CE2' HD13 ' A' ' 103' ' ' LEU . 7.2 m-85 -122.2 108.18 13.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 71.13 110.88 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.832 ' HB2' HG23 ' A' ' 102' ' ' ILE . 18.1 m-85 -94.77 123.43 38.22 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.118 -0.492 . . . . 75.23 110.833 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.2 p -149.78 154.63 8.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.067 -0.515 . . . . 54.14 111.166 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -162.57 142.23 7.77 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.767 -0.73 . . . . 45.02 112.472 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.9 m -115.17 73.24 3.42 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.617 0.722 . . . . 64.42 111.115 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 161.27 46.56 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.651 2.234 . . . . 64.44 112.357 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -68.71 -169.88 0.19 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.248 -0.433 . . . . 74.42 111.077 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 1.2 tmm_? -78.88 140.67 38.07 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.434 . . . . 73.54 110.85 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -128.2 142.27 51.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.201 -0.454 . . . . 53.34 111.077 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 28.9 ttpt -108.11 135.74 48.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.265 -0.425 . . . . 73.35 110.924 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 6.9 p90 -141.97 157.98 44.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 75.42 110.916 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.516 ' O ' HG23 ' A' ' 47' ' ' VAL . 0.5 OUTLIER -96.42 160.78 14.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.151 -0.477 . . . . 72.14 110.896 -179.925 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.518 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -177.87 66.0 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.792 -0.718 . . . . 40.33 112.531 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.564 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.3 tp10 -173.84 -176.8 1.27 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.931 0.396 . . . . 44.31 110.869 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.88 -68.87 0.7 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 71.23 110.874 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 5.1 m -83.83 -34.55 24.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.208 -0.451 . . . . 74.31 110.897 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.752 HG22 HG22 ' A' ' 93' ' ' VAL . 5.8 mm -64.55 -33.78 65.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.142 -0.481 . . . . 74.51 111.109 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.3 t -63.05 -45.26 93.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.13 -0.486 . . . . 50.41 110.825 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 22.7 t -53.6 -41.72 66.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.124 -0.489 . . . . 72.52 110.88 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.405 HD22 ' HA ' ' A' ' 90' ' ' LEU . 0.3 OUTLIER -59.5 -44.19 93.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 73.41 110.917 179.989 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 110.21 -14.14 30.96 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.762 -0.732 . . . . 61.4 112.505 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 20.2 mtt180 -120.22 93.61 4.11 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.836 0.35 . . . . 75.22 110.813 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.752 HG22 HG22 ' A' ' 87' ' ' ILE . 13.1 t -113.56 -45.82 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 72.52 111.099 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 67.5 m -140.58 144.94 36.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.466 . . . . 72.45 110.834 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -142.01 119.56 11.7 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.103 -0.499 . . . . 53.34 110.909 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.471 HG23 ' HB2' ' A' ' 131' ' ' LYS . 7.2 p -175.04 157.92 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 72.33 111.151 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.424 ' N ' HG22 ' A' ' 96' ' ' VAL . 8.2 p-10 -81.17 173.53 12.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.182 -0.463 . . . . 54.34 110.858 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 11.6 m-85 -117.43 130.73 56.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.222 -0.445 . . . . 71.44 110.894 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -117.49 65.81 0.35 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.675 -0.774 . . . . 72.14 112.478 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.75 115.3 4.03 Favored 'Trans proline' 0 N--CA 1.465 -0.187 0 C-N-CA 122.708 2.272 . . . . 72.43 112.384 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.587 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -123.03 100.18 6.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.223 -0.444 . . . . 62.3 111.083 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.832 HG23 ' HB2' ' A' ' 72' ' ' PHE . 2.5 tp -122.06 119.83 59.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 74.52 111.137 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.493 HD13 ' CE2' ' A' ' 71' ' ' PHE . 0.2 OUTLIER -120.65 113.67 20.57 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.199 -0.455 . . . . 71.52 110.897 179.892 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.439 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 4.9 p -142.81 159.48 42.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 55.05 110.858 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.58 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.6 OUTLIER -103.94 149.63 24.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.101 -0.5 . . . . 54.12 110.925 -179.994 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 15.8 mm-40 -101.58 144.95 29.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.468 . . . . 74.53 110.895 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.437 ' CD1' HG22 ' A' ' 67' ' ' ILE . 6.8 t80 -139.94 128.94 23.53 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.185 -0.461 . . . . 62.24 110.933 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 28.1 p80 -115.86 148.98 39.37 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.07 -0.514 . . . . 72.53 110.835 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -77.29 127.11 32.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.195 -0.457 . . . . 73.2 110.915 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 16.2 p-10 -100.42 53.88 0.88 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 63.03 110.825 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.3 p -114.94 -179.01 3.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.247 -0.433 . . . . 72.42 110.866 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 44.9 t80 -97.96 96.46 8.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 74.25 110.886 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -163.58 177.14 9.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 71.21 110.891 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 4.3 ptp180 -58.56 176.87 0.16 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.114 -0.494 . . . . 51.23 110.942 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -70.78 159.76 33.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.247 -0.433 . . . . 71.23 110.884 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 1.4 p90 -173.69 157.56 2.87 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.68 0.752 . . . . 74.22 110.889 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 177.53 5.5 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.625 2.216 . . . . 62.34 112.315 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -110.97 144.36 40.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.187 -0.461 . . . . 74.11 110.875 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 8.0 p -101.16 130.67 50.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.053 -0.521 . . . . 74.54 111.114 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -129.71 165.33 22.26 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.747 -0.739 . . . . 72.53 112.46 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 13.7 p -161.54 149.7 4.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.881 0.372 . . . . 51.45 111.128 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.439 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -174.41 -155.12 11.68 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.748 -0.739 . . . . 54.24 112.485 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.419 HG13 ' O ' ' A' ' 123' ' ' VAL . 7.5 p -109.2 124.83 66.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.878 0.37 . . . . 75.11 111.154 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -110.1 114.3 3.81 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.776 -0.726 . . . . 72.05 112.497 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' ARG . . . . . 0.587 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 25.5 ptt180 -115.9 124.56 50.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.823 0.344 . . . . 63.25 110.84 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.491 ' O ' HD23 ' A' ' 127' ' ' LEU . 26.1 t -104.68 116.34 48.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.274 -0.421 . . . . 52.15 111.151 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.491 HD23 ' O ' ' A' ' 126' ' ' VAL . 9.9 mt -130.76 171.24 13.34 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 75.32 110.86 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -160.25 169.53 23.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 54.12 110.895 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -102.93 118.78 37.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 62.5 110.883 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -48.93 108.07 0.17 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.056 -0.52 . . . . 50.44 110.877 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.471 ' HB2' HG23 ' A' ' 96' ' ' VAL . 3.6 mmmp? -111.52 -80.84 0.58 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.479 . . . . 74.32 110.875 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 21.9 m -161.52 81.0 0.59 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 64.42 111.135 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 39.2 m-20 -102.84 166.57 10.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.46 . . . . 44.4 110.899 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.64 155.26 0.11 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.705 -0.759 . . . . 61.55 112.503 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.744 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -81.24 3.67 23.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.8 0.333 . . . . 51.13 111.099 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -86.19 -175.33 5.48 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.455 . . . . 62.01 110.911 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 88.6 p -65.59 83.2 0.06 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 61.34 110.87 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 5.4 t 50.31 75.15 0.18 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 61.21 110.869 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -80.04 146.94 31.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 74.43 110.806 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 140' ' ' ASP . . . . . 0.432 ' O ' HG23 ' A' ' 176' ' ' VAL . 2.7 p30 -106.74 161.04 15.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.131 -0.486 . . . . 55.04 110.865 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 57.2 mt -115.73 143.86 24.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.171 -0.468 . . . . 74.2 111.12 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 3.4 mmtp -94.27 104.59 16.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 65.2 110.937 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.471 ' HB2' HD23 ' A' ' 127' ' ' LEU . 0.6 OUTLIER -58.21 -174.86 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.466 . . . . 73.42 110.866 179.897 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -162.28 164.87 27.32 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.233 -0.44 . . . . 75.1 110.906 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 22.6 p-90 -146.6 154.41 41.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.211 -0.45 . . . . 75.42 110.981 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.706 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.23 164.43 0.97 Allowed Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.579 0.704 . . . . 72.03 111.096 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.706 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 54.0 Cg_endo -69.82 127.49 14.62 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.577 2.185 . . . . 53.13 112.364 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.616 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -120.52 167.94 11.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 73.43 111.132 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -123.04 142.13 51.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 74.42 110.872 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 15.5 tt0 -123.17 151.98 41.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.165 -0.471 . . . . 71.4 110.879 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.1 t -151.08 122.8 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 52.52 111.092 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' GLY . . . . . 0.41 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . -174.68 -174.75 41.64 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.73 -0.748 . . . . 53.33 112.461 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.4 HD23 ' N ' ' A' ' 153' ' ' LEU . 1.9 pt? -135.58 160.43 38.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.776 0.322 . . . . 75.1 110.988 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.3 tpp85 -122.06 118.54 29.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.241 -0.436 . . . . 64.23 110.873 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -101.35 127.97 47.73 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.204 -0.453 . . . . 73.03 110.897 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -116.73 102.12 9.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.157 -0.474 . . . . 75.2 110.898 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 7.3 tp -97.24 97.01 8.8 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.192 -0.458 . . . . 64.55 110.851 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 51.45 -159.18 2.3 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.608 -0.806 . . . . 70.24 112.516 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 23.2 m-20 -71.71 -29.44 64.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.83 0.348 . . . . 73.5 110.896 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 8.2 p -52.05 172.12 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.155 -0.475 . . . . 71.41 110.909 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 25.4 m0 -49.84 144.2 6.72 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.107 -0.497 . . . . 75.34 110.92 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.44 ' C ' HD12 ' A' ' 163' ' ' LEU . 2.6 mtt -98.91 173.78 6.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.243 -0.435 . . . . 64.4 110.944 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.44 HD12 ' C ' ' A' ' 162' ' ' MET . 8.9 mp -125.68 142.86 51.3 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.268 -0.423 . . . . 63.33 110.876 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -140.15 134.59 31.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 63.22 110.873 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 3.3 t -142.23 122.47 13.87 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.145 -0.479 . . . . 44.23 110.842 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 166' ' ' ASP . . . . . 0.41 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.4 OUTLIER -150.88 165.08 34.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 53.44 110.92 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.512 HG13 ' HG ' ' A' ' 196' ' ' LEU . 1.5 t -133.51 139.76 48.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.212 -0.449 . . . . 34.05 111.192 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 168' ' ' ARG . . . . . 0.808 ' HD3' HD13 ' A' ' 195' ' ' ILE . 21.9 ttt180 -111.31 131.38 55.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 72.23 110.87 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 169' ' ' TYR . . . . . 0.471 ' OH ' HG11 ' A' ' 167' ' ' VAL . 94.4 m-85 -134.31 137.0 43.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.23 -0.441 . . . . 73.34 110.924 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 170' ' ' ILE . . . . . 0.776 HD13 ' O ' ' A' ' 170' ' ' ILE . 0.0 OUTLIER -179.34 102.92 0.19 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.606 0.717 . . . . 50.42 111.144 179.898 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 139.22 39.71 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.691 2.261 . . . . 71.4 112.368 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 172' ' ' PHE . . . . . 0.688 ' CZ ' ' HB2' ' A' ' 146' ' ' ALA . 0.1 OUTLIER -165.9 177.26 7.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 75.12 110.816 -179.963 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 8.0 ptmt -128.52 150.61 50.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.053 -0.522 . . . . 71.3 110.873 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 15.3 t -119.43 161.21 20.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.143 -0.48 . . . . 74.15 111.141 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -116.1 172.62 7.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.269 -0.423 . . . . 72.21 110.877 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 140' ' ' ASP . 14.8 p -164.98 140.06 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 73.51 111.084 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.0 t -165.81 177.67 7.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.177 -0.465 . . . . 74.31 111.114 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -154.83 -139.13 2.73 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.696 -0.764 . . . . 72.33 112.499 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -157.57 104.6 2.0 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.811 0.338 . . . . 72.21 111.11 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -139.52 114.4 9.44 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.245 -0.434 . . . . 64.03 110.955 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 46.11 -105.9 0.11 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.741 -0.742 . . . . 75.31 112.514 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -165.64 0.16 Allowed 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.663 2.242 . . . . 74.31 112.376 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.406 HG13 ' HD2' ' A' ' 184' ' ' PRO . 52.7 t -54.47 132.72 63.04 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-O 121.628 0.728 . . . . 62.54 111.184 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 184' ' ' PRO . . . . . 0.406 ' HD2' HG13 ' A' ' 183' ' ' VAL . 54.0 Cg_endo -69.68 161.17 46.96 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.715 2.277 . . . . 74.4 112.37 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.502 HG12 HG23 ' A' ' 187' ' ' THR . 85.6 t -96.73 108.35 21.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.248 -0.433 . . . . 70.41 111.146 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 62.0 p -98.12 106.52 18.82 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.188 -0.46 . . . . 63.2 110.889 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 187' ' ' THR . . . . . 0.502 HG23 HG12 ' A' ' 185' ' ' VAL . 22.2 p -115.74 167.62 10.77 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 72.44 111.122 -179.893 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 188' ' ' LYS . . . . . 0.483 ' O ' HD13 ' A' ' 189' ' ' ILE . 0.0 OUTLIER -155.29 159.26 39.86 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.203 -0.453 . . . . 63.43 110.976 179.898 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 189' ' ' ILE . . . . . 0.613 HG13 HD12 ' A' ' 32' ' ' LEU . 26.4 mm -142.76 137.67 27.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 71.2 111.07 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -104.78 114.94 29.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 50.02 110.862 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 191' ' ' VAL . . . . . 0.406 HG12 ' N ' ' A' ' 192' ' ' ASP . 2.6 t -137.33 163.09 32.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.148 -0.478 . . . . 71.43 111.177 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.416 ' HA ' ' HD2' ' A' ' 193' ' ' PRO . 0.5 OUTLIER -107.25 90.0 5.26 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.612 0.72 . . . . 72.22 110.883 179.919 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 193' ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' ' 192' ' ' ASP . 53.8 Cg_endo -69.78 138.04 36.8 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.693 2.262 . . . . 75.11 112.313 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 10.0 m-85 -120.32 119.67 33.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.195 -0.457 . . . . 72.11 110.897 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 195' ' ' ILE . . . . . 0.808 HD13 ' HD3' ' A' ' 168' ' ' ARG . 3.6 mp -112.99 132.45 61.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.464 . . . . 63.42 111.101 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 196' ' ' LEU . . . . . 0.512 ' HG ' HG13 ' A' ' 167' ' ' VAL . 1.4 tt -125.79 112.16 15.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.444 . . . . 61.0 110.895 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 2.6 p -100.39 127.58 46.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.21 -0.45 . . . . 71.43 110.855 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 198' ' ' LEU . . . . . 0.409 HD23 ' C ' ' A' ' 198' ' ' LEU . 10.5 tt -147.83 126.05 12.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.154 -0.475 . . . . 74.23 110.963 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -179.42 -142.53 5.02 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.719 -0.753 . . . . 62.12 112.47 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 200' ' ' ALA . . . . . 0.415 ' HA ' ' HA ' ' A' ' 163' ' ' LEU . . . -117.99 174.28 6.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.73 0.3 . . . . 32.22 111.098 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 63.7 p -156.37 163.33 39.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.262 -0.426 . . . . 70.33 110.806 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -136.14 130.05 32.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.047 -0.524 . . . . 70.34 110.925 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.409 HG13 ' SD ' ' A' ' 162' ' ' MET . 19.7 m -85.18 147.72 5.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.1 -0.5 . . . . 52.41 111.125 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -141.27 105.0 4.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.181 -0.463 . . . . 74.41 110.889 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 37.0 mttm -72.61 -65.88 0.73 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.068 -0.515 . . . . 74.33 110.913 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 15.3 tp 58.9 56.29 4.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.192 -0.458 . . . . 63.32 110.912 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -67.98 -48.0 67.02 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.164 -0.471 . . . . 42.33 111.134 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -77.72 151.28 34.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.208 -0.451 . . . . 71.32 111.145 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -65.79 -64.07 0.94 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 75.31 111.045 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 4.3 pp -79.27 166.84 21.7 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.19 -0.459 . . . . 71.21 110.907 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 54.15 110.895 179.946 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.458 -0.046 0 CA-C-O 120.829 0.347 . . . . 75.05 110.861 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 4.6 t-20 -140.27 160.05 40.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.239 -0.437 . . . . 73.11 110.917 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 50.7 mt-10 -146.94 146.56 30.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.189 -0.459 . . . . 71.15 110.892 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 90.5 m-20 -95.17 -61.29 1.5 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.135 -0.484 . . . . 72.15 110.893 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 6.9 t80 58.82 72.05 0.89 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.687 0.756 . . . . 64.51 110.898 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.74 -171.57 0.49 Allowed 'Trans proline' 0 C--N 1.341 0.135 0 C-N-CA 122.662 2.241 . . . . 73.14 112.333 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -124.09 155.8 37.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 43.12 111.079 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.65 107.02 0.63 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.28 -0.418 . . . . 64.45 110.899 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 30.1 m -102.8 -36.3 8.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.236 -0.438 . . . . 75.24 110.84 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.89 134.3 37.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.131 -0.486 . . . . 71.44 111.113 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -174.28 -97.23 0.11 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.803 -0.713 . . . . 70.51 112.55 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -158.9 119.11 3.17 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.82 0.343 . . . . 72.44 110.942 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 11.0 t30 -167.28 164.31 15.37 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.113 -0.494 . . . . 75.43 110.925 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 -56.78 124.16 17.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 75.14 110.942 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 92.18 6.53 64.74 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.756 -0.735 . . . . 73.45 112.464 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -78.93 151.16 31.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.815 0.341 . . . . 74.31 110.883 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.583 ' CZ2' HG21 ' A' ' 59' ' ' ILE . 0.2 OUTLIER -125.36 139.42 53.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 64.1 110.908 -179.969 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.725 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 4.9 m -145.71 134.67 17.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 55.24 111.18 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -97.8 110.91 23.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 72.23 111.095 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.5 t -103.78 117.48 34.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 74.33 110.855 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 30.4 p90 -117.98 124.04 47.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 73.34 110.88 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.4 ' HB2' ' C ' ' A' ' 198' ' ' LEU . 4.1 p30 -149.7 171.88 15.98 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.128 -0.487 . . . . 74.32 110.883 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -94.8 122.32 37.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 65.5 110.931 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -93.82 113.53 25.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 34.34 110.845 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 36.7 mttt -93.66 106.97 18.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.197 -0.456 . . . . 72.15 110.877 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.512 HG22 HG23 ' A' ' 28' ' ' VAL . 12.3 p -87.26 130.95 36.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 44.33 111.158 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -121.42 102.69 8.43 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 73.4 110.911 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.512 HG23 HG22 ' A' ' 26' ' ' VAL . 7.9 t -140.16 155.34 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.061 -0.518 . . . . 75.04 111.079 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.487 ' HA2' HG13 ' A' ' 47' ' ' VAL . . . 130.73 62.16 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.762 -0.732 . . . . 61.3 112.467 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -89.87 -66.15 0.95 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.899 0.38 . . . . 72.1 110.969 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 179.18 130.05 0.08 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.088 -0.505 . . . . 71.32 110.849 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.739 HD22 ' HB3' ' A' ' 45' ' ' ALA . 1.8 tp -51.9 170.12 0.06 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.133 -0.485 . . . . 75.23 110.903 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.45 106.46 1.68 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.712 -0.756 . . . . 71.3 112.473 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -51.54 -58.54 6.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.848 0.356 . . . . 71.22 110.932 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 11.0 tp -173.73 161.68 3.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.177 -0.465 . . . . 71.5 110.937 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 34.5 m-80 -97.57 -56.46 2.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.148 -0.478 . . . . 74.22 110.877 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 28.1 m -70.64 -35.13 59.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 71.3 111.162 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 60.34 -164.8 14.26 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.758 -0.735 . . . . 74.03 112.439 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 138.74 -67.59 0.51 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.663 -0.78 . . . . 40.53 112.419 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -97.27 174.78 30.11 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.731 -0.747 . . . . 72.22 112.501 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -68.78 130.37 42.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.821 0.344 . . . . 51.34 111.053 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.401 HD12 ' HA ' ' A' ' 42' ' ' LEU . 8.3 tp -148.73 137.45 11.9 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.66 0.743 . . . . 72.32 110.825 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -172.45 0.58 Allowed 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.65 2.233 . . . . 61.41 112.352 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -136.09 142.47 44.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 72.22 110.855 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.739 ' HB3' HD22 ' A' ' 32' ' ' LEU . . . -117.67 -171.16 2.0 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.482 . . . . 64.15 111.161 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ASP . . . . . 0.579 ' O ' HD13 ' A' ' 32' ' ' LEU . 0.4 OUTLIER -121.04 -170.36 2.0 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 74.31 110.807 179.949 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.487 HG13 ' HA2' ' A' ' 29' ' ' GLY . 10.4 p -166.08 135.6 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.157 -0.474 . . . . 71.41 111.167 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -175.05 171.53 3.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.469 . . . . 71.22 110.839 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 2.2 pp -102.43 158.22 4.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.09 -0.505 . . . . 73.13 111.106 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -88.72 -81.73 1.29 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.733 -0.746 . . . . 72.12 112.432 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.7 p30 -151.87 93.38 1.84 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.791 0.329 . . . . 72.42 110.867 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -115.49 65.52 0.69 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 71.11 110.851 179.883 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' THR . . . . . 0.441 ' O ' HG23 ' A' ' 54' ' ' THR . 0.7 OUTLIER -95.31 103.5 15.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.148 -0.478 . . . . 62.23 111.142 -179.887 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.441 HG23 ' O ' ' A' ' 53' ' ' THR . 2.2 p -156.75 163.31 39.4 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.251 -0.432 . . . . 60.42 111.142 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 11.8 mt -88.4 163.23 16.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 75.53 110.927 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -131.42 142.57 50.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 74.5 111.103 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -113.88 131.75 56.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.45 . . . . 52.02 110.864 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.414 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.2 OUTLIER -130.78 143.77 50.97 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.089 -0.505 . . . . 61.54 110.788 -179.938 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.583 HG21 ' CZ2' ' A' ' 17' ' ' TRP . 12.5 mm -108.09 117.68 54.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 73.44 111.12 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.725 ' HB3' ' CG2' ' A' ' 18' ' ' VAL . . . -100.44 132.72 45.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 53.2 111.097 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.452 ' HB3' HG22 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -114.85 116.84 29.22 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.205 -0.452 . . . . 72.44 110.936 -179.861 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -87.0 101.91 13.9 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 74.53 110.969 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 8.1 p -100.57 -34.57 4.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.121 -0.49 . . . . 65.1 111.084 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 20.3 t -132.46 158.78 41.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 63.42 110.894 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.4 m -84.18 2.82 37.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 74.55 110.771 -179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -112.33 -31.16 6.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 63.41 110.853 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.403 HG22 ' HA ' ' A' ' 107' ' ' TYR . 25.4 pt -148.78 162.24 5.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.24 -0.437 . . . . 73.15 111.148 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -149.57 170.24 19.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 74.12 111.116 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.452 HG22 ' HB3' ' A' ' 61' ' ' TYR . 10.6 m -112.3 153.57 13.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.203 -0.453 . . . . 74.44 111.203 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -146.15 132.12 19.2 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.191 -0.459 . . . . 73.51 110.841 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.414 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 12.0 t80 -115.01 108.82 17.19 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.253 -0.431 . . . . 71.12 110.889 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -86.19 128.49 34.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 64.35 110.945 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 2.7 p -145.32 144.43 21.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.128 -0.487 . . . . 71.11 111.119 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -159.38 133.76 3.48 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.793 -0.718 . . . . 51.32 112.496 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.476 ' O ' HG13 ' A' ' 75' ' ' VAL . 4.5 p -112.93 75.41 1.96 Allowed Pre-proline 0 C--N 1.33 -0.243 0 CA-C-O 121.659 0.742 . . . . 70.52 111.083 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 162.49 41.87 Favored 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.654 2.236 . . . . 63.04 112.416 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -76.29 -167.93 0.86 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.26 -0.427 . . . . 61.15 111.132 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 35.3 ttp180 -78.02 131.09 37.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.243 -0.435 . . . . 73.42 110.916 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -132.45 151.14 52.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 62.44 111.056 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 22.3 pttm -92.78 135.17 34.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 71.25 110.915 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -116.09 137.23 52.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 72.04 110.891 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 -95.92 151.78 19.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 72.51 110.916 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.608 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 174.77 73.6 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.812 -0.709 . . . . 54.34 112.511 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.532 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.3 mm-40 -170.47 -176.44 2.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.912 0.387 . . . . 74.12 110.846 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.19 -70.12 0.62 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 73.24 110.923 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.8 t -85.81 -30.62 22.84 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.212 -0.449 . . . . 74.13 110.788 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.569 HG22 HG22 ' A' ' 93' ' ' VAL . 4.4 mm -68.5 -34.66 66.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 65.55 111.156 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.4 t -61.38 -49.66 76.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.465 . . . . 75.24 110.871 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 22.3 t -51.73 -42.46 62.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 64.24 110.851 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.449 HD22 ' HG2' ' A' ' 92' ' ' ARG . 0.7 OUTLIER -57.66 -45.61 85.3 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.147 -0.479 . . . . 64.11 110.918 179.978 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 111.49 -14.82 27.48 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.772 -0.728 . . . . 63.51 112.547 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.449 ' HG2' HD22 ' A' ' 90' ' ' LEU . 9.6 ptt85 -120.46 95.77 4.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.84 0.353 . . . . 65.04 110.94 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.608 HG21 ' H ' ' A' ' 83' ' ' GLY . 21.9 t -110.5 -46.06 6.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 74.04 111.121 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.409 ' HA ' ' HA ' ' A' ' 133' ' ' ASP . 1.6 p -139.63 153.47 47.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.477 . . . . 74.2 110.834 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -135.69 121.96 20.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.142 -0.481 . . . . 72.22 110.896 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.623 HG21 ' O ' ' A' ' 129' ' ' PHE . 7.6 p -174.18 161.39 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.199 -0.455 . . . . 74.23 111.118 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.43 ' N ' HG22 ' A' ' 96' ' ' VAL . 3.3 p30 -80.13 172.72 13.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.188 -0.46 . . . . 75.14 110.873 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -125.31 130.83 52.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.446 . . . . 63.34 110.919 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -118.68 66.75 0.37 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.708 -0.758 . . . . 75.42 112.441 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 124.99 11.63 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.705 2.27 . . . . 73.24 112.319 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.602 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -138.68 106.05 5.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 75.33 111.1 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.658 ' C ' HD23 ' A' ' 103' ' ' LEU . 16.3 mm -118.56 150.48 20.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.25 -0.432 . . . . 74.03 111.105 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.658 HD23 ' C ' ' A' ' 102' ' ' ILE . 0.0 OUTLIER -149.15 109.75 4.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 71.52 110.916 179.869 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.0 p -144.37 171.56 14.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 75.0 110.891 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -120.42 153.06 37.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.465 . . . . 55.33 110.888 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 -106.25 139.03 41.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.156 -0.475 . . . . 55.31 110.902 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.403 ' HA ' HG22 ' A' ' 67' ' ' ILE . 30.7 p90 -143.16 148.3 36.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 73.04 110.884 -179.822 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 25.0 p-80 -97.5 158.77 15.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 73.33 110.876 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -128.06 125.1 38.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.226 -0.443 . . . . 74.25 110.925 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -52.59 128.64 26.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.099 -0.5 . . . . 70.21 110.913 179.87 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 46.8 m -141.77 172.29 12.89 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 71.02 110.857 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 30.7 t80 -76.57 -38.34 55.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 54.21 110.872 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 61.7 mt-10 -59.63 177.26 0.22 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.138 -0.483 . . . . 75.24 110.954 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 25.9 ttm180 -99.31 -65.55 0.96 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 72.31 110.927 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 26.5 mt -101.49 138.82 37.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 52.23 110.917 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 4.1 p90 -171.49 157.65 4.63 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-O 121.625 0.726 . . . . 72.52 110.921 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 177.55 5.48 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.702 2.268 . . . . 65.2 112.345 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -117.35 157.6 25.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 75.03 110.96 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 72.7 t -106.99 128.38 61.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.063 -0.517 . . . . 73.11 111.109 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -119.27 172.88 14.81 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.714 -0.755 . . . . 72.33 112.53 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.3 p -175.56 153.13 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.848 0.356 . . . . 72.53 111.141 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 178.17 -148.65 8.64 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.823 -0.704 . . . . 60.03 112.511 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.652 HG13 ' HG ' ' A' ' 103' ' ' LEU . 4.9 p -110.39 137.71 41.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.882 0.372 . . . . 64.33 111.145 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' GLY . . . . . 0.424 ' HA3' HD12 ' A' ' 102' ' ' ILE . . . -127.36 105.87 0.78 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.712 -0.756 . . . . 70.52 112.408 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' ARG . . . . . 0.602 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 13.0 ptp180 -98.85 130.17 45.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.854 0.359 . . . . 75.44 110.891 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 3.2 m -106.99 109.65 28.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 71.0 111.172 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 1.4 tt -86.47 141.59 29.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 62.1 110.932 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -152.58 129.93 11.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 74.0 110.844 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.623 ' O ' HG21 ' A' ' 96' ' ' VAL . 0.8 OUTLIER -101.56 176.48 5.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.097 -0.501 . . . . 72.1 110.948 -179.973 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -109.19 95.19 5.47 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.218 -0.447 . . . . 73.21 110.85 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.426 ' HB2' HG23 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -89.16 -79.61 0.32 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 71.31 110.858 179.976 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.7 m -163.22 113.22 1.36 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.254 -0.43 . . . . 73.42 111.135 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' ASP . . . . . 0.43 ' HB3' ' CB ' ' A' ' 139' ' ' PHE . 10.0 t0 -106.27 117.1 33.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 73.13 110.901 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -78.25 -11.15 85.63 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.759 -0.734 . . . . 73.12 112.49 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.455 ' HB2' HG12 ' A' ' 93' ' ' VAL . . . -44.95 -30.31 0.99 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.781 0.324 . . . . 72.21 111.076 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 3.4 tp -160.79 -177.49 6.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.227 -0.442 . . . . 75.24 110.916 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 14.9 t -54.28 94.06 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 74.33 110.854 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 68.2 m 49.16 75.49 0.15 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.18 -0.464 . . . . 75.3 110.849 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.43 ' CB ' ' HB3' ' A' ' 133' ' ' ASP . 0.4 OUTLIER -101.58 162.28 13.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 65.43 110.864 -179.958 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -138.53 170.35 16.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.129 -0.487 . . . . 74.45 110.888 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.425 HG22 ' N ' ' A' ' 142' ' ' LYS . 1.9 mp -116.7 160.73 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 52.34 111.13 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' LYS . . . . . 0.425 ' N ' HG22 ' A' ' 141' ' ' ILE . 3.6 mtmt -122.19 122.36 39.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 74.31 110.899 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -74.31 -172.68 1.49 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.239 -0.437 . . . . 72.04 110.873 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 3.1 mmtm -171.36 -173.46 1.25 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 63.33 110.884 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 52.2 p-90 -154.62 153.23 31.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 72.14 110.955 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.757 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -176.44 165.41 1.65 Allowed Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.572 0.701 . . . . 72.44 111.116 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.757 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.1 Cg_endo -69.77 167.06 25.54 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.635 2.224 . . . . 62.33 112.363 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -160.26 154.97 24.07 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.207 -0.451 . . . . 44.34 111.113 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 11.6 m-85 -104.7 129.32 52.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.234 -0.439 . . . . 71.02 110.872 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 6.2 mm-40 -104.72 156.73 17.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.13 -0.486 . . . . 74.15 110.946 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.3 p -155.79 128.91 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 70.55 111.144 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 166.97 -162.82 36.6 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.749 -0.738 . . . . 71.22 112.517 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.424 HD12 ' N ' ' A' ' 154' ' ' ARG . 3.3 pp -155.98 170.47 22.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.824 0.345 . . . . 70.24 110.897 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.424 ' N ' HD12 ' A' ' 153' ' ' LEU . 5.9 tpp85 -117.68 122.3 43.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 71.32 110.867 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -108.56 153.99 22.59 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.185 -0.461 . . . . 71.14 110.964 -179.874 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 35.7 t0 -121.53 99.26 6.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.482 . . . . 60.32 110.847 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 157' ' ' LEU . . . . . 0.448 HD12 HD12 ' A' ' 163' ' ' LEU . 13.2 mt -97.71 97.53 9.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.28 -0.418 . . . . 74.33 110.936 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 80.65 -147.26 27.91 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.8 -0.714 . . . . 74.12 112.519 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -123.23 -35.49 2.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.866 0.365 . . . . 62.53 110.92 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 1.7 m -51.77 -61.84 2.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 74.5 110.845 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 18.6 p90 -139.58 153.72 47.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.215 -0.448 . . . . 71.23 110.927 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.483 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 11.0 mtt -108.34 176.49 5.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 75.52 110.849 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.448 HD12 HD12 ' A' ' 157' ' ' LEU . 0.9 OUTLIER -116.51 146.31 42.69 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 53.34 110.83 -179.961 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -141.76 134.38 28.39 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.142 -0.481 . . . . 62.43 110.863 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 10.8 t -136.78 124.18 22.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 61.31 110.805 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -144.23 160.72 40.5 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.123 -0.489 . . . . 62.11 110.883 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 58.1 t -150.0 126.73 2.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 64.5 111.156 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 168' ' ' ARG . . . . . 0.564 ' HD2' HD12 ' A' ' 195' ' ' ILE . 0.4 OUTLIER -104.58 133.58 49.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.198 -0.456 . . . . 72.51 110.834 -179.986 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 19.6 t80 -136.74 132.07 34.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 64.53 110.914 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 170' ' ' ILE . . . . . 0.423 HG21 ' O ' ' A' ' 147' ' ' PRO . 5.0 tp 178.65 132.89 0.23 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.628 0.727 . . . . 61.44 111.144 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.78 112.77 3.17 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.649 2.233 . . . . 72.33 112.374 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 172' ' ' PHE . . . . . 0.418 ' HZ ' HG23 ' A' ' 174' ' ' THR . 0.1 OUTLIER -122.83 151.45 41.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.259 -0.428 . . . . 73.24 110.859 -179.953 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 20.1 pttt -123.85 134.56 53.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 71.21 110.881 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 174' ' ' THR . . . . . 0.426 HG22 ' H ' ' A' ' 175' ' ' ASP . 0.2 OUTLIER -101.2 171.21 7.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.228 -0.442 . . . . 64.14 111.133 179.985 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 175' ' ' ASP . . . . . 0.426 ' H ' HG22 ' A' ' 174' ' ' THR . 0.2 OUTLIER -123.51 161.2 25.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.197 -0.456 . . . . 71.22 110.911 179.869 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 3.4 t -151.07 143.05 16.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.173 -0.467 . . . . 62.11 111.107 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.4 t -166.98 -178.15 4.09 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.18 -0.464 . . . . 52.13 111.114 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -119.74 -158.38 10.58 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.763 -0.732 . . . . 71.1 112.56 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 6.6 t -128.63 -172.28 2.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.858 0.361 . . . . 71.33 111.152 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 2.0 mp -65.58 140.19 58.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 75.13 110.945 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 117.81 -82.16 0.33 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.692 -0.766 . . . . 71.51 112.47 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 -161.94 0.08 OUTLIER 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.68 2.253 . . . . 65.03 112.38 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 5.1 m -107.45 86.1 2.57 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.675 0.75 . . . . 53.34 111.173 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.66 151.32 69.59 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.684 2.256 . . . . 64.12 112.317 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 45.2 t -139.17 112.4 6.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.151 -0.477 . . . . 72.44 111.083 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.02 104.75 5.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.476 . . . . 54.4 110.849 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 29.4 p -124.14 174.04 7.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 65.12 111.123 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 5.2 ptmt -150.3 145.76 26.36 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.226 -0.443 . . . . 65.35 110.883 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 189' ' ' ILE . . . . . 0.546 HG21 HD12 ' A' ' 32' ' ' LEU . 6.3 pt -127.27 111.24 24.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.273 -0.421 . . . . 61.25 111.149 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -92.0 113.48 25.76 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.186 -0.461 . . . . 63.12 110.913 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 191' ' ' VAL . . . . . 0.445 HG21 ' CG1' ' A' ' 28' ' ' VAL . 12.1 m -136.77 167.31 24.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 72.13 111.096 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -107.25 88.54 3.98 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.553 0.692 . . . . 73.3 110.86 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 132.5 23.48 Favored 'Trans proline' 0 C--O 1.233 0.242 0 C-N-CA 122.685 2.257 . . . . 74.03 112.363 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -110.05 113.98 27.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.282 -0.417 . . . . 75.23 110.848 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 195' ' ' ILE . . . . . 0.564 HD12 ' HD2' ' A' ' 168' ' ' ARG . 71.5 mt -105.86 119.94 55.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.158 -0.474 . . . . 52.45 111.159 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 9.7 mp -116.03 108.66 16.5 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.195 -0.457 . . . . 62.12 110.92 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 53.9 p -99.21 114.04 26.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.244 -0.434 . . . . 71.33 110.862 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 198' ' ' LEU . . . . . 0.4 ' C ' ' HB2' ' A' ' 22' ' ' ASN . 0.4 OUTLIER -134.14 122.2 22.52 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.186 -0.461 . . . . 74.43 110.92 -179.978 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -175.63 -140.58 3.46 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.774 -0.727 . . . . 64.04 112.497 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 200' ' ' ALA . . . . . 0.483 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -126.65 174.24 8.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.826 0.346 . . . . 45.24 111.078 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 73.7 p -148.11 166.23 28.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.212 -0.449 . . . . 63.44 110.832 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -133.6 136.94 45.19 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.08 -0.509 . . . . 74.42 110.874 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.555 ' HA ' HG12 ' A' ' 18' ' ' VAL . 25.1 m -91.11 149.7 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.095 -0.502 . . . . 73.21 111.137 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -149.84 114.92 5.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 64.43 110.834 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.33 168.03 6.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 73.12 110.927 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -133.98 111.19 10.21 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.237 -0.438 . . . . 73.42 110.925 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -143.97 159.83 41.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 61.21 111.086 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -116.79 163.74 15.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 72.13 111.085 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -68.61 144.32 54.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.178 -0.464 . . . . 75.31 111.165 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 13.6 tp -87.07 149.27 24.83 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.248 -0.433 . . . . 74.54 110.912 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 42.0 mp0 . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 74.22 110.878 179.952 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.3 mmm . . . . . 0 C--O 1.23 0.05 0 CA-C-O 120.735 0.302 . . . . 75.22 110.833 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 9.8 m120 55.19 36.22 26.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.266 -0.425 . . . . 75.32 110.876 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -58.85 124.08 18.62 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 74.54 110.865 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 20.0 p-10 -127.11 149.42 49.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.146 -0.479 . . . . 61.13 110.891 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 7.7 m-85 -117.31 160.4 37.77 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-O 121.677 0.751 . . . . 73.43 110.885 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.65 171.41 14.39 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.767 2.312 . . . . 74.52 112.392 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.22 -42.21 3.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.299 -0.41 . . . . 74.44 111.084 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -146.77 141.08 26.35 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.265 -0.425 . . . . 65.13 110.906 179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 73.3 p -116.36 50.8 1.02 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.2 -0.455 . . . . 72.03 110.872 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.38 -175.15 2.71 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.077 -0.511 . . . . 71.22 111.117 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.99 -64.11 3.08 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.765 -0.731 . . . . 72.13 112.519 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 14.1 p90 -151.89 115.7 4.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.836 0.351 . . . . 75.05 110.99 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 62.4 t30 -151.29 157.35 42.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.109 -0.496 . . . . 71.41 110.871 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -52.29 121.1 6.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 64.12 110.903 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 99.36 6.08 55.46 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.801 -0.714 . . . . 75.12 112.511 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.455 ' OD2' HG13 ' A' ' 18' ' ' VAL . 0.7 OUTLIER -77.33 150.9 35.15 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.853 0.359 . . . . 72.31 110.835 -179.92 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 23.8 m-90 -117.75 138.37 52.08 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.21 -0.45 . . . . 70.35 110.923 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.629 HG23 ' HB3' ' A' ' 60' ' ' ALA . 11.5 m -141.56 134.7 29.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.25 -0.432 . . . . 73.41 111.108 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.56 ' HB1' ' CZ ' ' A' ' 21' ' ' PHE . . . -99.66 112.45 24.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.447 . . . . 73.03 111.085 179.846 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -99.21 109.37 22.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 71.23 110.81 -179.761 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.56 ' CZ ' ' HB1' ' A' ' 19' ' ' ALA . 12.7 m-85 -107.64 116.51 32.08 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 74.24 110.889 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.415 ' HB2' ' C ' ' A' ' 198' ' ' LEU . 1.7 p30 -154.12 172.66 17.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 53.32 110.967 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -103.57 134.96 46.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.249 -0.432 . . . . 72.15 110.835 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 2.8 m -105.0 107.88 19.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.144 -0.48 . . . . 73.52 110.851 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.633 ' O ' HD12 ' A' ' 196' ' ' LEU . 31.8 tttp -87.71 109.37 19.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.11 -0.495 . . . . 74.54 110.844 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.7 p -92.65 130.93 41.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 75.44 111.168 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -119.42 100.59 7.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 74.54 110.932 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.43 HG23 ' CG1' ' A' ' 191' ' ' VAL . 7.4 p -149.34 145.31 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.093 -0.503 . . . . 73.52 111.114 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 148.84 67.32 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.735 -0.745 . . . . 72.24 112.518 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 8.3 tt0 -89.18 -65.84 0.98 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.832 0.349 . . . . 62.31 110.928 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -170.61 169.25 7.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.125 -0.488 . . . . 73.32 110.92 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.718 HD12 HG21 ' A' ' 189' ' ' ILE . 11.3 tp -84.59 161.55 20.12 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.167 -0.47 . . . . 65.42 110.905 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.11 -33.1 36.91 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.763 -0.732 . . . . 64.41 112.51 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 46.1 m-20 54.19 37.22 26.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.866 0.365 . . . . 73.33 110.859 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 60.4 tp -67.06 127.77 33.85 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.194 -0.457 . . . . 61.32 110.891 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 4.7 p-10 -111.67 103.15 11.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.14 -0.482 . . . . 72.44 110.86 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 11.2 p -75.61 -34.48 29.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.172 -0.467 . . . . 75.03 111.154 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -169.56 114.12 0.54 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.732 -0.747 . . . . 61.53 112.467 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 170.14 -177.28 43.53 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.741 -0.742 . . . . 75.44 112.524 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -103.56 -119.35 4.6 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.723 -0.751 . . . . 52.32 112.49 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.473 ' C ' HD22 ' A' ' 42' ' ' LEU . . . -90.85 106.22 18.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.805 0.335 . . . . 71.53 111.143 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.473 HD22 ' C ' ' A' ' 41' ' ' ALA . 4.6 mm? -119.18 159.32 45.66 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.582 0.706 . . . . 62.45 110.895 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -172.11 0.55 Allowed 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.712 2.275 . . . . 71.34 112.32 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 2.7 p30 -128.06 145.58 50.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.247 -0.433 . . . . 71.12 110.92 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.457 ' HB1' ' HA ' ' A' ' 84' ' ' GLU . . . -92.07 167.89 11.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 75.43 111.084 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -137.61 134.7 35.84 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.29 -0.414 . . . . 55.33 110.872 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 73.6 t -104.94 142.61 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 44.54 111.149 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 m -155.19 152.9 29.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 73.32 110.882 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 38.3 pt -136.79 157.71 36.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.474 . . . . 73.5 111.138 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -88.78 -90.33 1.15 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.745 -0.741 . . . . 60.24 112.499 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 9.2 m120 57.57 57.27 4.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.795 0.331 . . . . 64.31 110.883 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.529 ' O ' HG23 ' A' ' 53' ' ' THR . 0.7 OUTLIER -55.61 -57.86 10.2 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 74.34 110.915 179.918 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 53' ' ' THR . . . . . 0.529 HG23 ' O ' ' A' ' 52' ' ' ASP . 0.7 OUTLIER -162.85 138.18 6.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 71.35 111.177 -179.953 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.524 HG23 ' O ' ' A' ' 53' ' ' THR . 0.7 OUTLIER -161.89 146.65 12.89 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.227 -0.442 . . . . 73.23 111.132 -179.942 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 88.9 mt -90.06 157.65 17.69 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.455 . . . . 74.5 110.828 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.36 144.32 33.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.13 -0.486 . . . . 74.34 111.129 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 15.4 m-85 -102.37 132.53 48.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 71.33 110.935 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.495 ' C ' HD13 ' A' ' 59' ' ' ILE . 3.6 m-20 -128.43 139.43 52.36 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.145 -0.48 . . . . 72.24 110.923 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.495 HD13 ' C ' ' A' ' 58' ' ' ASP . 3.4 mm -110.07 114.92 48.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.196 -0.457 . . . . 74.44 111.123 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.629 ' HB3' HG23 ' A' ' 18' ' ' VAL . . . -116.15 149.53 38.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.116 -0.493 . . . . 64.55 111.145 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.485 ' CE2' HG22 ' A' ' 59' ' ' ILE . 14.6 m-85 -129.33 137.59 51.08 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.289 -0.414 . . . . 73.34 110.946 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -98.33 102.28 13.98 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.158 -0.474 . . . . 73.03 110.867 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.7 m -99.35 -34.06 4.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.472 . . . . 75.04 111.088 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 58.4 m -135.51 158.77 43.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 74.04 110.917 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 3.9 t -83.99 3.39 34.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 74.52 110.861 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -114.06 -30.56 6.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.149 -0.478 . . . . 63.31 110.849 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -140.89 165.23 20.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 65.12 111.124 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -155.18 168.83 25.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.133 -0.485 . . . . 65.32 111.116 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.433 HG22 ' HB2' ' A' ' 61' ' ' TYR . 4.2 m -111.66 147.67 15.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 63.1 111.125 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -149.93 128.53 12.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.189 -0.46 . . . . 61.23 110.849 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -121.5 132.91 54.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 71.31 110.882 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.612 ' CD1' HD11 ' A' ' 102' ' ' ILE . 13.1 m-30 -95.02 134.85 37.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.131 -0.486 . . . . 62.32 110.926 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 63.3 t -144.41 136.81 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.107 -0.497 . . . . 64.51 111.086 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -155.29 140.55 7.43 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.743 -0.742 . . . . 63.15 112.439 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.8 t -124.38 66.87 45.5 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.621 0.724 . . . . 71.14 111.083 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 154.91 67.45 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.656 2.237 . . . . 73.3 112.374 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -68.14 -167.63 0.09 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 50.43 111.09 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 9.8 ttm180 -77.46 129.0 35.16 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.203 -0.453 . . . . 73.54 110.859 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ALA . . . . . 0.554 ' HB3' ' CZ ' ' A' ' 81' ' ' PHE . . . -120.72 142.41 49.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.449 . . . . 62.23 111.072 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 21.0 ttpp -91.64 134.99 34.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.165 -0.471 . . . . 72.12 110.9 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' PHE . . . . . 0.554 ' CZ ' ' HB3' ' A' ' 79' ' ' ALA . 22.1 m-85 -131.98 152.01 51.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.221 -0.445 . . . . 70.43 110.92 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -99.93 156.1 17.33 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 73.23 110.897 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.585 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 179.86 68.16 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.737 -0.744 . . . . 55.15 112.487 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.457 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.5 tp10 -170.53 -176.44 2.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.935 0.398 . . . . 74.41 110.94 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.81 -70.17 0.61 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 74.11 110.847 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.8 t -85.25 -31.24 23.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 73.12 110.828 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.616 HG22 HG22 ' A' ' 93' ' ' VAL . 4.8 mm -67.75 -33.59 62.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.198 -0.456 . . . . 73.11 111.146 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 10.0 t -63.66 -48.06 78.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 74.43 110.87 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 27.1 t -51.92 -42.48 62.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.147 -0.479 . . . . 72.31 110.87 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 82.6 mt -57.73 -48.38 79.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.115 -0.493 . . . . 61.41 110.884 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 115.32 -15.21 18.07 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.758 -0.734 . . . . 73.52 112.446 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 14.4 ttp180 -120.31 92.61 3.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.817 0.342 . . . . 63.41 110.885 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.616 HG22 HG22 ' A' ' 87' ' ' ILE . 25.3 t -108.15 -52.76 6.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.224 -0.444 . . . . 73.52 111.119 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 60.4 m -140.69 146.06 37.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 70.13 110.846 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -131.01 125.86 34.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 72.41 110.859 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.452 HG22 ' N ' ' A' ' 97' ' ' ASP . 13.2 p -174.42 156.79 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 63.03 111.167 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.452 ' N ' HG22 ' A' ' 96' ' ' VAL . 2.8 p-10 -86.39 173.43 9.68 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.187 -0.46 . . . . 70.34 110.83 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -133.48 126.07 30.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 64.31 110.929 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -113.5 72.36 0.23 Allowed Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.717 -0.754 . . . . 72.12 112.458 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 114.21 3.62 Favored 'Trans proline' 0 N--CA 1.465 -0.177 0 C-N-CA 122.754 2.303 . . . . 74.13 112.367 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -129.56 104.87 7.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.219 -0.446 . . . . 72.34 111.129 179.858 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.612 HD11 ' CD1' ' A' ' 72' ' ' PHE . 1.2 pp -127.89 151.3 34.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 64.43 111.123 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.439 ' HG ' HG13 ' A' ' 123' ' ' VAL . 0.2 OUTLIER -141.01 111.64 6.95 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.132 -0.485 . . . . 75.31 110.912 179.854 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.408 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 3.6 p -134.24 -174.15 3.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.23 -0.441 . . . . 75.22 110.837 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.421 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -134.97 147.98 49.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.091 -0.504 . . . . 45.54 110.931 179.994 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -104.31 134.82 46.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 75.12 110.97 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.518 ' CE1' HG13 ' A' ' 119' ' ' VAL . 12.9 p90 -144.71 159.03 43.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.228 -0.442 . . . . 64.22 110.925 -179.83 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 9.8 t60 -129.36 149.9 50.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.111 -0.495 . . . . 73.1 110.855 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -90.69 150.01 21.83 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.251 -0.431 . . . . 74.51 110.978 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -55.58 106.86 0.28 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.115 -0.493 . . . . 72.22 110.902 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.0 t -148.43 126.19 11.86 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.275 -0.42 . . . . 63.41 110.86 -179.772 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 19.3 p90 -121.45 40.96 3.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.115 -0.493 . . . . 73.14 110.871 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 34.1 mt-10 -97.15 -60.73 1.52 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.103 -0.499 . . . . 64.02 110.921 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 46.3 mtt180 -158.74 171.21 20.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.198 -0.455 . . . . 64.45 110.922 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -64.43 132.88 51.31 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.194 -0.457 . . . . 74.11 110.928 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -153.3 160.52 30.84 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.701 0.762 . . . . 74.31 110.913 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.81 177.52 5.53 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.725 2.283 . . . . 65.51 112.338 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -116.69 154.54 30.41 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.204 -0.453 . . . . 74.13 110.946 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.518 HG13 ' CE1' ' A' ' 107' ' ' TYR . 5.4 p -102.57 127.38 56.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.122 -0.49 . . . . 73.25 111.109 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -119.87 167.67 13.56 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.728 -0.749 . . . . 53.23 112.534 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 7.3 p -171.38 154.45 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.826 0.346 . . . . 51.2 111.135 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.408 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . 178.87 -147.02 7.57 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.695 -0.764 . . . . 50.33 112.452 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.462 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.7 p -112.6 132.43 61.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.852 0.358 . . . . 52.51 111.112 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' GLY . . . . . 0.515 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -123.3 109.6 1.37 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.761 -0.733 . . . . 53.54 112.463 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' ARG . . . . . 0.666 ' HE ' HD11 ' A' ' 127' ' ' LEU . 10.5 ptm180 -109.41 123.47 49.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.817 0.342 . . . . 55.13 110.892 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.456 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 2.5 p -107.35 119.35 56.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 73.34 111.152 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.666 HD11 ' HE ' ' A' ' 125' ' ' ARG . 2.7 mp -129.46 153.62 47.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.19 -0.459 . . . . 70.52 110.81 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 7.3 p90 -160.21 169.71 22.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.078 -0.51 . . . . 70.12 110.894 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.406 ' O ' HG23 ' A' ' 96' ' ' VAL . 45.1 m-85 -101.88 117.57 35.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 73.43 110.877 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -53.43 101.38 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.138 -0.483 . . . . 75.15 110.873 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.67 -82.97 0.09 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.234 -0.439 . . . . 61.41 110.865 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.8 m -173.42 128.22 0.43 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 62.21 111.195 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' ASP . . . . . 0.436 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 5.3 m-20 -114.37 115.3 27.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 73.21 110.878 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -80.82 -2.96 90.47 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.731 -0.747 . . . . 41.42 112.511 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.572 ' HB2' HG12 ' A' ' 93' ' ' VAL . . . -47.13 -29.73 2.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.824 0.345 . . . . 72.41 111.079 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.8 tp -158.93 -177.94 6.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 53.22 110.921 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -52.19 96.49 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.157 -0.474 . . . . 72.4 110.826 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 93.2 p 46.94 74.13 0.16 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 63.03 110.865 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.436 ' HB3' ' HB2' ' A' ' 133' ' ' ASP . 0.5 OUTLIER -95.76 158.85 15.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.127 -0.488 . . . . 71.14 110.905 -179.928 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -141.36 174.95 10.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 73.44 110.829 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.815 HG23 HG12 ' A' ' 176' ' ' VAL . 2.6 mt -131.41 152.68 37.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.155 -0.475 . . . . 64.54 111.118 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' LYS . . . . . 0.412 ' O ' HG22 ' A' ' 174' ' ' THR . 7.1 mmpt? -122.43 122.11 38.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 71.2 110.928 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.456 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 1.9 p-10 -72.08 -166.52 0.24 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 63.25 110.93 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -173.35 177.27 2.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.239 -0.437 . . . . 71.23 110.875 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' TRP . . . . . 0.404 ' O ' ' HB2' ' A' ' 146' ' ' ALA . 30.9 p90 -146.54 153.51 40.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 72.52 110.912 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.81 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 178.98 168.1 0.61 Allowed Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.618 0.723 . . . . 73.41 111.128 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.81 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.7 Cg_endo -69.79 150.73 68.43 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.68 2.253 . . . . 74.21 112.387 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.541 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -148.11 167.31 25.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.217 -0.447 . . . . 51.12 111.087 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 -118.94 166.21 13.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.205 -0.452 . . . . 73.5 110.883 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 1.3 pt20 -157.9 162.48 38.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.167 -0.47 . . . . 73.22 110.973 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 94.1 t -150.61 124.81 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.222 -0.445 . . . . 75.23 111.113 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' GLY . . . . . 0.438 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . -171.46 -167.16 31.31 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.769 -0.729 . . . . 44.2 112.541 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.471 HD12 ' CD2' ' A' ' 155' ' ' TYR . 1.1 pt? -145.11 158.54 43.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.834 0.349 . . . . 63.22 110.925 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 3.7 tpp85 -125.33 121.86 35.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 62.14 110.806 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' TYR . . . . . 0.471 ' CD2' HD12 ' A' ' 153' ' ' LEU . 5.1 m-85 -128.52 173.16 10.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 73.01 110.873 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -121.74 106.83 11.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.1 -0.5 . . . . 65.24 110.883 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 157' ' ' LEU . . . . . 0.4 HD22 ' HA ' ' A' ' 157' ' ' LEU . 0.3 OUTLIER -102.94 97.41 7.54 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.194 -0.457 . . . . 74.03 110.948 -179.992 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 85.75 161.99 35.68 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.677 -0.773 . . . . 65.24 112.537 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -74.26 147.21 42.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.889 0.376 . . . . 72.31 110.889 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 14.2 m 51.9 36.45 18.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.198 -0.455 . . . . 74.22 110.861 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 2.9 t90 -172.69 112.08 0.24 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.153 -0.476 . . . . 71.32 110.933 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 5.3 mtt -110.47 172.74 6.69 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 75.52 110.905 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.4 ' HA ' ' HA ' ' A' ' 200' ' ' ALA . 41.9 mt -129.49 140.3 51.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.253 -0.43 . . . . 60.43 110.903 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -138.41 136.05 35.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 72.0 110.864 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 24.0 p -143.94 122.27 12.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 74.3 110.84 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 166' ' ' ASP . . . . . 0.438 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.6 OUTLIER -150.77 171.84 16.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.128 -0.487 . . . . 72.44 110.833 179.972 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.497 HG11 ' OH ' ' A' ' 169' ' ' TYR . 0.9 OUTLIER -141.89 120.12 8.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 73.45 111.101 -179.979 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 168' ' ' ARG . . . . . 0.561 ' HD3' HG22 ' A' ' 170' ' ' ILE . 1.9 tmm_? -93.55 135.65 34.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 63.41 110.845 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 169' ' ' TYR . . . . . 0.497 ' OH ' HG11 ' A' ' 167' ' ' VAL . 21.7 m-85 -134.28 136.27 43.43 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 74.45 110.873 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 170' ' ' ILE . . . . . 0.77 HD12 ' HD2' ' A' ' 171' ' ' PRO . 8.0 tp 178.66 118.89 0.2 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.685 0.755 . . . . 73.04 111.086 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 171' ' ' PRO . . . . . 0.77 ' HD2' HD12 ' A' ' 170' ' ' ILE . 53.7 Cg_endo -69.75 113.44 3.37 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.633 2.222 . . . . 61.31 112.359 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -117.11 177.34 4.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.216 -0.447 . . . . 74.24 110.846 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 6.8 ptmt -152.32 138.58 18.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.128 -0.487 . . . . 64.23 110.933 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 174' ' ' THR . . . . . 0.412 HG22 ' O ' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -102.95 155.1 18.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.258 -0.428 . . . . 75.1 111.15 179.963 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -116.19 102.11 9.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 71.04 110.868 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.815 HG12 HG23 ' A' ' 141' ' ' ILE . 20.3 m -96.89 146.35 7.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 71.04 111.139 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.6 t -166.7 163.29 16.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 70.13 111.132 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -123.35 162.3 17.3 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.798 -0.715 . . . . 61.12 112.488 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.2 106.7 16.23 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.811 0.339 . . . . 62.11 111.17 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.418 HD23 ' HD2' ' A' ' 182' ' ' PRO . 0.1 OUTLIER -140.27 167.21 22.67 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.166 -0.47 . . . . 73.4 110.853 -179.959 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -50.5 -71.65 0.6 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.753 -0.737 . . . . 54.22 112.484 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.418 ' HD2' HD23 ' A' ' 180' ' ' LEU . 53.5 Cg_endo -69.86 -171.91 0.53 Allowed 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.65 2.233 . . . . 73.33 112.322 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.44 HG13 ' O ' ' A' ' 183' ' ' VAL . 3.5 p -57.7 111.66 3.75 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.636 0.732 . . . . 74.42 111.114 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 165.98 29.15 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.658 2.238 . . . . 75.03 112.301 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 87.4 t -95.67 107.17 19.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 64.54 111.16 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 81.0 p -110.02 125.26 52.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 73.1 110.831 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 35.7 p -138.21 159.54 41.77 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.122 -0.49 . . . . 71.23 111.114 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 3.6 pttm -128.87 150.02 50.52 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 74.04 110.94 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 189' ' ' ILE . . . . . 0.718 HG21 HD12 ' A' ' 32' ' ' LEU . 6.3 pt -131.56 108.2 14.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 72.44 111.138 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -98.87 118.34 35.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 62.42 110.86 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 191' ' ' VAL . . . . . 0.435 HG12 ' H ' ' A' ' 192' ' ' ASP . 2.4 t -137.66 164.53 28.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 65.51 111.073 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.435 ' H ' HG12 ' A' ' 191' ' ' VAL . 0.2 OUTLIER -106.96 87.73 3.16 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.604 0.716 . . . . 75.24 110.871 179.929 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.64 131.71 21.99 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.704 2.269 . . . . 75.24 112.311 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -100.17 107.03 18.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 55.55 110.89 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 195' ' ' ILE . . . . . 0.531 HD13 ' NE ' ' A' ' 168' ' ' ARG . 3.9 mp -97.99 125.33 51.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.111 -0.495 . . . . 62.23 111.159 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 196' ' ' LEU . . . . . 0.633 HD12 ' O ' ' A' ' 25' ' ' LYS . 2.1 mp -119.31 108.12 14.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 61.12 110.977 179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.2 120.52 33.57 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 53.33 110.851 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 198' ' ' LEU . . . . . 0.415 ' C ' ' HB2' ' A' ' 22' ' ' ASN . 1.3 tt -144.74 127.41 16.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.116 -0.493 . . . . 65.14 110.823 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 176.18 -146.98 8.35 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.834 -0.698 . . . . 53.11 112.535 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 200' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' A' ' 163' ' ' LEU . . . -118.32 174.14 6.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.788 0.327 . . . . 75.34 111.106 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 8.9 p -151.76 171.77 17.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 63.24 110.884 -179.802 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -145.4 148.1 32.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.147 -0.479 . . . . 54.33 110.912 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.619 ' HA ' HG12 ' A' ' 18' ' ' VAL . 14.5 m -111.76 157.4 12.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.49 . . . . 73.01 111.206 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -173.76 155.25 2.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.211 -0.449 . . . . 74.34 110.912 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 18.2 pttp -133.5 178.32 7.01 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.152 -0.476 . . . . 74.34 110.835 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -67.83 133.86 49.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 72.11 110.963 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -69.55 142.32 53.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 73.34 111.092 179.833 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -80.71 106.13 12.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.139 -0.482 . . . . 73.13 111.116 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -93.15 -46.05 7.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.266 -0.425 . . . . 22.43 111.064 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -111.06 113.94 26.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 72.15 110.924 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.186 -0.461 . . . . 72.44 110.889 179.945 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 14.6 mtm . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.796 0.331 . . . . 64.51 110.897 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -121.83 172.89 7.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 61.32 110.903 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -125.66 144.22 50.69 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.087 -0.506 . . . . 65.31 110.931 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -142.05 163.97 31.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 62.04 110.877 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -114.08 160.48 32.26 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.688 0.756 . . . . 72.1 110.921 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 178.66 4.32 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.674 2.25 . . . . 71.2 112.344 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -149.39 143.61 25.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 75.32 111.119 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 76.5 mttt -135.52 146.18 47.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.207 -0.451 . . . . 64.31 110.912 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 2.2 t -60.53 142.26 55.54 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 73.33 110.895 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -84.37 -45.33 12.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 63.12 111.06 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -53.67 -39.52 61.26 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.766 -0.731 . . . . 70.0 112.467 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 10.7 p90 -144.2 112.66 6.51 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.904 0.383 . . . . 73.23 110.921 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 20.1 t30 -131.08 157.03 44.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.465 . . . . 72.12 110.902 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.2 mt-30 -54.52 119.95 5.97 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.224 -0.444 . . . . 70.24 110.887 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.61 6.47 46.9 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.731 -0.747 . . . . 63.35 112.521 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.16 150.4 40.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.793 0.33 . . . . 70.44 110.802 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.428 ' CZ3' HD21 ' A' ' 206' ' ' LEU . 33.4 m0 -122.24 140.85 52.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.189 -0.459 . . . . 73.41 110.936 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.739 HG13 ' HB3' ' A' ' 60' ' ' ALA . 2.1 p -148.55 122.58 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.171 -0.468 . . . . 72.21 111.151 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -84.81 114.17 21.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 64.22 111.083 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.7 p -106.06 109.3 21.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.247 -0.433 . . . . 73.13 110.823 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -113.08 123.58 50.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 74.32 110.852 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.87 168.47 25.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 71.24 110.916 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -96.01 127.82 42.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 75.25 110.882 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.1 p -97.45 109.75 22.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.243 -0.435 . . . . 71.41 110.808 -179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 9.2 tmtt? -88.05 106.63 18.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.077 -0.51 . . . . 74.03 110.904 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.1 p -86.29 139.13 17.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.461 . . . . 63.53 111.107 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -135.27 102.46 5.17 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.207 -0.451 . . . . 63.5 110.977 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.548 ' O ' HD13 ' A' ' 49' ' ' ILE . 8.5 p -168.73 153.99 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.16 -0.473 . . . . 75.14 111.142 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 130.11 71.16 0.12 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.779 -0.724 . . . . 72.31 112.505 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -89.73 -66.07 0.96 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.83 0.347 . . . . 75.42 110.916 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -161.93 154.97 20.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 64.41 110.864 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 9.1 tp -69.74 167.46 17.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.086 -0.506 . . . . 73.52 110.896 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -85.65 65.36 3.96 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 72.33 112.487 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -85.29 103.97 14.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.834 0.349 . . . . 71.12 110.864 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 30.5 tp -83.24 -35.92 24.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 53.35 110.877 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -51.81 -36.31 47.42 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 75.22 110.938 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 23.2 t -82.71 128.08 39.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 72.1 111.113 179.902 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -119.98 54.73 0.64 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.662 -0.78 . . . . 61.44 112.489 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 52.95 34.99 47.1 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.782 -0.723 . . . . 61.04 112.484 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -157.16 -103.22 0.2 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.71 -0.757 . . . . 74.43 112.421 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -69.82 166.32 19.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.84 0.352 . . . . 45.11 111.103 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.2 tp 66.4 137.41 0.05 OUTLIER Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.594 0.711 . . . . 73.13 110.869 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 140.87 43.7 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.741 2.294 . . . . 54.12 112.291 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 9.1 t-20 -93.3 150.46 20.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.194 -0.457 . . . . 71.13 110.911 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -93.87 160.55 14.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 74.11 111.058 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -147.36 140.31 25.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.485 . . . . 74.03 110.875 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 29.7 m -104.96 147.81 10.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.209 -0.45 . . . . 55.01 111.107 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.5 t -139.33 124.12 18.58 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.137 -0.483 . . . . 70.34 110.877 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.548 HD13 ' O ' ' A' ' 28' ' ' VAL . 5.3 mp -120.76 105.33 16.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.167 -0.469 . . . . 73.14 111.165 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -135.67 109.99 0.79 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.772 -0.727 . . . . 74.31 112.527 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -147.7 152.19 37.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.853 0.359 . . . . 63.34 110.893 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -52.32 148.93 6.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 63.05 110.817 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 43.9 p -76.55 109.41 10.28 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.172 -0.467 . . . . 74.55 111.135 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.8 p -94.61 176.54 6.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 64.24 111.203 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 1.5 pt? -108.71 155.52 20.63 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.202 -0.454 . . . . 61.04 110.921 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -126.02 141.78 51.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.215 -0.448 . . . . 74.4 111.124 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -103.39 131.88 50.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 74.04 110.944 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.465 ' C ' HD13 ' A' ' 59' ' ' ILE . 2.8 m-20 -131.87 144.39 50.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.129 -0.487 . . . . 63.04 110.914 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.465 HD13 ' C ' ' A' ' 58' ' ' ASP . 5.1 mm -115.2 114.2 45.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 54.04 111.118 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.739 ' HB3' HG13 ' A' ' 18' ' ' VAL . . . -102.87 129.95 49.73 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.15 -0.477 . . . . 72.14 111.06 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.456 ' HB2' HG22 ' A' ' 69' ' ' VAL . 22.7 m-85 -115.62 122.15 44.75 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 71.33 110.962 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -88.96 100.9 13.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 75.31 110.844 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.6 p -96.51 -33.17 4.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.122 -0.49 . . . . 70.01 111.132 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.6 m -132.01 159.17 39.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.15 -0.477 . . . . 71.04 110.828 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -84.03 3.18 35.6 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.105 -0.498 . . . . 62.54 110.788 -179.79 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -116.56 -31.49 5.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 71.34 110.878 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.432 HD12 ' CE1' ' A' ' 107' ' ' TYR . 33.8 pt -144.21 162.19 15.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 70.53 111.142 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -152.7 170.63 19.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 43.33 111.127 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.456 HG22 ' HB2' ' A' ' 61' ' ' TYR . 4.6 m -115.17 152.56 16.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 63.12 111.158 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.4 ' HA ' ' HA ' ' A' ' 60' ' ' ALA . 0.9 OUTLIER -149.96 128.92 12.58 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.185 -0.461 . . . . 74.0 110.82 179.976 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.405 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 6.7 m-85 -105.99 132.13 52.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.176 -0.466 . . . . 70.43 110.892 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -105.39 121.83 44.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.152 -0.476 . . . . 73.4 110.906 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.415 HG12 ' N ' ' A' ' 74' ' ' GLY . 5.9 t -145.73 159.24 12.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.129 -0.487 . . . . 73.11 111.08 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.415 ' N ' HG12 ' A' ' 73' ' ' VAL . . . -152.64 170.16 31.77 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.65 -0.786 . . . . 72.12 112.425 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.4 t -119.69 64.77 8.88 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.643 0.735 . . . . 74.42 111.148 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 163.36 38.58 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.642 2.228 . . . . 60.34 112.37 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -120.35 -166.96 1.38 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 62.03 111.139 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 33.8 ttp85 -76.86 120.65 22.29 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.266 -0.425 . . . . 61.11 110.821 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ALA . . . . . 0.483 ' HB3' ' HE1' ' A' ' 98' ' ' TYR . . . -124.26 150.92 44.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.216 -0.447 . . . . 75.11 111.121 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -101.92 139.66 37.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.188 -0.46 . . . . 73.41 110.864 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' PHE . . . . . 0.535 ' CE2' HG23 ' A' ' 49' ' ' ILE . 43.7 m-85 -140.87 158.28 44.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 74.35 110.906 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 30.2 mt-30 -99.03 156.83 16.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 71.14 110.889 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.568 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -179.67 71.56 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.803 -0.713 . . . . 63.45 112.525 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -178.37 -177.36 0.56 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.893 0.378 . . . . 61.53 110.864 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.02 -68.95 0.7 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 72.42 110.903 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.8 t -83.24 -35.11 25.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.126 -0.488 . . . . 54.44 110.854 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.916 HG21 ' HB2' ' A' ' 135' ' ' ALA . 6.9 mm -63.54 -33.78 63.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.09 -0.505 . . . . 75.34 111.135 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 55.2 p -62.4 -49.24 76.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.235 -0.438 . . . . 62.2 110.911 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.3 t -51.21 -40.26 58.36 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.143 -0.48 . . . . 64.32 110.811 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 13.4 mt -60.73 -46.33 90.81 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.143 -0.48 . . . . 73.23 110.949 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 112.41 -14.43 25.3 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.714 -0.755 . . . . 34.02 112.481 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 27.8 mtp180 -121.1 96.34 5.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.824 0.345 . . . . 71.44 110.862 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.892 HG22 HG22 ' A' ' 87' ' ' ILE . 39.6 t -113.8 -44.36 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.461 . . . . 45.04 111.138 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.5 p -142.62 147.75 36.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 71.14 110.874 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -149.39 118.83 6.89 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.172 -0.467 . . . . 54.42 110.843 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.648 HG23 ' HB2' ' A' ' 131' ' ' LYS . 2.9 p -177.76 166.25 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 73.35 111.155 179.908 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.477 ' H ' HG22 ' A' ' 96' ' ' VAL . 11.8 t70 -90.59 156.58 18.03 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.088 -0.505 . . . . 54.32 110.904 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' TYR . . . . . 0.483 ' HE1' ' HB3' ' A' ' 79' ' ' ALA . 0.1 OUTLIER -113.61 155.03 26.19 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.245 -0.434 . . . . 71.44 110.953 -179.838 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -122.41 70.11 0.42 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.736 -0.745 . . . . 63.13 112.463 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 112.77 3.17 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.738 2.292 . . . . 63.14 112.328 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.483 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -131.97 110.19 10.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.24 -0.437 . . . . 70.32 111.105 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 2.7 mt -129.51 150.01 34.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 74.25 111.103 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 1.2 pp -152.35 115.39 4.65 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.119 -0.491 . . . . 72.4 110.862 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.443 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 4.3 p -138.78 -176.47 4.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.234 -0.439 . . . . 55.3 110.857 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.562 HD12 ' CE1' ' A' ' 107' ' ' TYR . 0.1 OUTLIER -130.37 154.97 47.14 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.167 -0.469 . . . . 74.42 110.943 179.994 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 45.0 mt-30 -102.65 135.89 43.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 62.14 110.979 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.562 ' CE1' HD12 ' A' ' 105' ' ' LEU . 2.0 m-85 -120.54 118.76 31.05 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.263 -0.426 . . . . 70.44 110.868 -179.756 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -110.9 105.53 14.36 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.126 -0.488 . . . . 71.22 110.869 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -85.22 161.82 19.42 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.201 -0.454 . . . . 72.02 110.938 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -55.02 103.96 0.1 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.107 -0.497 . . . . 73.32 110.844 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 27.2 m -93.9 151.87 19.27 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.182 -0.463 . . . . 70.5 110.883 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -65.25 -179.25 0.57 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.161 -0.472 . . . . 71.13 110.905 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -51.66 -36.04 44.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.171 -0.468 . . . . 74.1 110.899 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 41.6 mtt180 -66.6 -179.97 0.94 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 75.43 110.866 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 13.2 tp -93.47 128.92 39.77 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.216 -0.447 . . . . 73.52 110.974 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.7 t80 -135.24 134.66 21.57 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.63 0.729 . . . . 72.44 110.921 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' PRO . . . . . 0.742 ' HB3' HD12 ' A' ' 153' ' ' LEU . 53.6 Cg_endo -69.82 177.64 5.41 Favored 'Trans proline' 0 N--CA 1.465 -0.175 0 C-N-CA 122.713 2.275 . . . . 52.43 112.363 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -112.7 155.25 24.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.245 -0.434 . . . . 75.42 110.941 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.2 p -106.29 124.21 61.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.099 -0.501 . . . . 74.31 111.154 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -116.77 163.37 12.49 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.737 -0.744 . . . . 31.03 112.52 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.1 p -175.73 150.65 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.842 0.353 . . . . 55.34 111.141 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.443 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -176.98 -150.39 8.31 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.757 -0.735 . . . . 63.44 112.508 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.536 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 12.7 p -108.34 130.48 60.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.85 0.357 . . . . 62.43 111.195 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -124.45 109.94 1.33 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.784 -0.722 . . . . 42.43 112.51 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' ARG . . . . . 0.483 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 13.8 ptm180 -104.97 131.81 52.01 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.837 0.351 . . . . 75.34 110.847 -179.802 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.413 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 3.6 p -116.49 119.18 61.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.217 -0.447 . . . . 73.15 111.08 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.7 mp -113.52 172.7 6.81 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.126 -0.488 . . . . 72.02 110.917 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.475 ' CD2' HG22 ' A' ' 141' ' ' ILE . 3.3 p90 -131.2 172.55 12.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.443 . . . . 72.03 110.899 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.647 ' HB3' HG22 ' A' ' 96' ' ' VAL . 1.5 t80 -111.71 174.69 5.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 62.34 110.918 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -112.68 112.09 23.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.12 -0.491 . . . . 72.13 110.865 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.648 ' HB2' HG23 ' A' ' 96' ' ' VAL . 63.5 mmtt -146.11 -85.8 0.11 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 72.3 110.887 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 7.4 m -163.11 96.22 0.88 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.254 -0.43 . . . . 74.14 111.133 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -112.29 165.83 11.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 70.13 110.884 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 64.22 153.49 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 74.14 112.471 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.916 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -82.9 1.8 37.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.838 0.351 . . . . 72.42 111.056 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.462 HD12 HD13 ' A' ' 180' ' ' LEU . 2.9 mm? -87.04 -177.24 5.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.446 . . . . 74.13 110.882 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 6.1 m -64.76 88.1 0.06 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 73.34 110.848 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 9.6 m 53.62 75.28 0.27 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.46 . . . . 73.32 110.793 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -90.49 159.2 16.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.108 -0.496 . . . . 72.43 110.845 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -130.85 172.69 11.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.072 -0.513 . . . . 74.24 110.822 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.475 HG22 ' CD2' ' A' ' 128' ' ' PHE . 1.4 tt -117.41 171.61 5.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.128 -0.487 . . . . 52.14 111.136 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -119.59 103.98 9.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 73.43 110.896 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.413 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 0.6 OUTLIER -72.74 -171.55 0.86 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.28 -0.418 . . . . 74.33 110.89 179.867 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -172.44 179.28 2.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.221 -0.445 . . . . 60.25 110.929 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 28.7 p-90 -152.08 154.01 35.08 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.232 -0.44 . . . . 74.12 110.878 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.792 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.81 166.86 0.82 Allowed Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.594 0.711 . . . . 72.4 111.108 179.874 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.792 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.9 Cg_endo -69.71 137.16 34.93 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.687 2.258 . . . . 73.24 112.388 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.566 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -126.91 160.51 30.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.272 -0.422 . . . . 73.53 111.092 179.832 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -103.54 163.94 11.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 75.04 110.917 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 44.4 tt0 -153.07 149.47 28.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.222 -0.445 . . . . 55.24 110.936 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.2 p -146.05 129.85 10.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 62.5 111.113 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' GLY . . . . . 0.436 ' C ' HD13 ' A' ' 153' ' ' LEU . . . 172.89 -167.58 40.44 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.718 -0.753 . . . . 44.2 112.528 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.742 HD12 ' HB3' ' A' ' 117' ' ' PRO . 0.0 OUTLIER -148.51 168.42 22.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.803 0.335 . . . . 62.01 110.911 -179.911 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 7.2 tpp85 -116.76 118.84 33.64 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 53.41 110.895 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -101.68 149.92 23.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.137 -0.483 . . . . 75.44 110.928 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -120.64 98.19 5.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.485 . . . . 74.45 110.923 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 25.0 tp -95.98 98.13 10.15 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 72.55 110.9 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 72.99 -146.38 38.0 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.675 -0.774 . . . . 52.24 112.458 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 35.3 t-20 -120.47 -33.43 3.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.807 0.336 . . . . 74.02 110.847 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 24.3 p -50.74 -65.5 0.55 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.479 . . . . 72.14 110.866 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 52.4 p-90 -141.02 146.18 36.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.144 -0.48 . . . . 72.35 110.938 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.508 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 10.8 mmt -101.67 178.69 4.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 60.2 110.898 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 9.2 mt -120.23 149.51 42.15 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.234 -0.439 . . . . 75.34 110.944 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -142.42 133.42 25.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 72.52 110.894 179.864 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.5 t -137.89 122.39 18.44 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.187 -0.46 . . . . 74.11 110.826 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 166' ' ' ASP . . . . . 0.435 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.5 OUTLIER -154.2 162.73 40.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.146 -0.479 . . . . 61.52 110.859 179.909 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.454 HG13 ' O ' ' A' ' 195' ' ' ILE . 42.1 t -146.0 125.34 5.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 65.14 111.148 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 168' ' ' ARG . . . . . 0.417 ' HD3' ' HB ' ' A' ' 195' ' ' ILE . 0.0 OUTLIER -100.92 155.73 17.79 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.259 -0.428 . . . . 72.14 110.871 -179.961 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 26.3 t80 -163.43 143.3 8.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 74.33 110.986 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 170' ' ' ILE . . . . . 0.566 HG21 ' HB2' ' A' ' 148' ' ' ALA . 3.1 tp -179.74 131.51 0.26 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 71.12 111.163 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 116.0 4.35 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.724 2.283 . . . . 72.43 112.272 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 172' ' ' PHE . . . . . 0.681 ' CZ ' ' HB3' ' A' ' 146' ' ' ALA . 2.1 m-85 -117.47 177.1 4.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 62.14 110.894 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.84 116.93 6.38 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 75.44 110.955 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.2 t -105.92 161.52 14.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.262 -0.426 . . . . 43.24 111.203 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -127.51 176.8 7.2 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.264 -0.425 . . . . 71.14 110.873 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.615 HG12 ' OG1' ' A' ' 187' ' ' THR . 2.4 p -145.5 141.94 22.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.192 -0.458 . . . . 61.43 111.131 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 2.0 t -166.24 160.17 15.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 74.34 111.139 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -159.3 -157.75 8.73 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.813 -0.708 . . . . 74.44 112.478 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 73.2 p -127.01 96.39 4.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.774 0.321 . . . . 74.41 111.154 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.462 HD13 HD12 ' A' ' 136' ' ' LEU . 9.7 tt -141.33 102.88 4.31 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.253 -0.431 . . . . 64.11 110.95 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 57.68 173.62 0.33 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.822 -0.704 . . . . 63.34 112.449 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.535 ' O ' ' HB ' ' A' ' 183' ' ' VAL . 53.5 Cg_endo -69.71 75.1 1.22 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.698 2.265 . . . . 74.4 112.397 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.535 ' HB ' ' O ' ' A' ' 182' ' ' PRO . 2.4 p 159.57 83.55 0.0 OUTLIER Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 121.635 0.731 . . . . 75.02 111.121 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 142.22 47.63 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.733 2.289 . . . . 72.21 112.338 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 62.8 t -95.57 105.84 17.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.242 -0.435 . . . . 43.54 111.139 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.72 109.06 20.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.16 -0.473 . . . . 74.22 110.854 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 187' ' ' THR . . . . . 0.615 ' OG1' HG12 ' A' ' 176' ' ' VAL . 0.7 OUTLIER -118.3 161.03 20.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 70.3 111.161 -179.976 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 21.9 pttt -136.84 157.28 47.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.435 . . . . 74.22 110.906 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 189' ' ' ILE . . . . . 0.423 ' O ' HG23 ' A' ' 189' ' ' ILE . 5.7 tp -154.79 120.7 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.228 -0.442 . . . . 75.41 111.132 179.795 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.38 116.05 31.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.144 -0.48 . . . . 64.21 110.893 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 7.6 p -136.18 155.37 34.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.145 -0.48 . . . . 74.43 111.097 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.04 88.69 3.88 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.683 0.754 . . . . 72.41 110.831 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.87 142.56 47.79 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.659 2.24 . . . . 52.25 112.297 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 5.1 t80 -112.65 123.15 49.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.14 -0.482 . . . . 70.1 110.895 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 195' ' ' ILE . . . . . 0.454 ' O ' HG13 ' A' ' 167' ' ' VAL . 56.7 mt -116.37 125.02 73.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.168 -0.469 . . . . 73.42 111.1 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 196' ' ' LEU . . . . . 0.524 ' O ' HD23 ' A' ' 196' ' ' LEU . 7.5 tt -116.39 109.88 17.92 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.122 -0.49 . . . . 71.22 110.982 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.96 119.23 35.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.202 -0.454 . . . . 71.45 110.856 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 55.1 tp -140.07 126.8 20.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.113 -0.494 . . . . 71.51 110.9 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -177.32 -141.27 3.99 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.74 -0.743 . . . . 60.22 112.466 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 200' ' ' ALA . . . . . 0.508 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -129.37 173.42 10.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.781 0.324 . . . . 54.34 111.113 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 99.4 p -146.58 170.26 17.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 53.42 110.803 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 202' ' ' TYR . . . . . 0.467 ' C ' HG23 ' A' ' 18' ' ' VAL . 68.6 t80 -139.69 113.01 8.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.099 -0.501 . . . . 74.23 110.938 -179.86 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 12.6 t -77.33 154.24 5.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.043 -0.526 . . . . 73.52 111.123 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 77.6 t80 -160.32 122.21 3.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.166 -0.47 . . . . 63.14 110.888 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 6.6 ptpp? -102.89 162.6 12.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 71.33 110.915 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 206' ' ' LEU . . . . . 0.428 HD21 ' CZ3' ' A' ' 17' ' ' TRP . 59.6 mt -97.95 48.14 1.01 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.213 -0.449 . . . . 74.34 110.902 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -132.61 -45.98 0.89 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.252 -0.431 . . . . 62.13 111.101 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -64.8 135.53 55.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.186 -0.461 . . . . 74.22 111.092 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -156.72 169.13 25.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.234 -0.439 . . . . 65.13 111.117 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 7.4 tp 63.06 39.31 10.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 65.13 110.902 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.261 -0.427 . . . . 74.12 110.861 179.935 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 48.4 mtm . . . . . 0 N--CA 1.457 -0.116 0 CA-C-O 120.774 0.321 . . . . 72.54 110.916 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 63.9 m-20 -103.15 52.88 0.77 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 72.32 110.912 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -141.34 55.33 1.53 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.162 -0.472 . . . . 71.44 110.861 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -103.52 135.19 45.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 74.21 110.916 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 38.3 t80 -121.8 136.72 26.38 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.704 0.764 . . . . 73.12 110.973 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 78.6 0.98 Allowed 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.682 2.255 . . . . 73.04 112.361 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -102.39 174.04 6.09 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.241 -0.436 . . . . 62.44 111.114 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 17.5 mtpp 52.92 36.14 20.99 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 72.05 110.819 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 22.2 m -53.59 131.65 39.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.424 . . . . 63.41 110.886 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.52 135.79 33.77 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.172 -0.467 . . . . 74.53 111.114 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.525 ' CA ' HD12 ' A' ' 206' ' ' LEU . . . -147.41 122.2 1.52 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.721 -0.752 . . . . 62.31 112.493 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -158.46 116.56 2.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.901 0.382 . . . . 65.31 110.915 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 26.1 m120 -152.05 157.76 42.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.131 -0.486 . . . . 73.45 110.822 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.4 pt20 -53.47 127.84 26.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.159 -0.473 . . . . 71.53 110.913 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.97 5.78 52.94 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.761 -0.733 . . . . 54.0 112.534 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -72.53 150.95 42.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.816 0.341 . . . . 73.13 110.848 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.547 ' HE1' HG23 ' A' ' 59' ' ' ILE . 25.1 t90 -116.32 143.96 44.86 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.206 -0.452 . . . . 70.5 111.001 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.9 t -145.57 123.27 4.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.265 -0.425 . . . . 63.1 111.058 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -82.61 109.19 16.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 74.32 111.108 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -95.07 127.75 41.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.155 -0.475 . . . . 71.15 110.851 -179.772 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 64.4 t80 -138.63 116.18 11.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.102 -0.499 . . . . 73.11 110.945 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -152.62 173.42 15.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.46 . . . . 72.35 110.917 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 14.6 m-85 -102.38 128.41 48.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 73.01 110.856 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' SER . . . . . 0.506 ' HB3' HG21 ' A' ' 56' ' ' THR . 24.6 p -96.72 136.66 36.94 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.194 -0.457 . . . . 45.13 110.857 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.79 106.73 12.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.133 -0.485 . . . . 74.44 110.927 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.811 HG12 HD12 ' A' ' 195' ' ' ILE . 27.5 m -78.55 126.68 38.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.435 . . . . 70.41 111.101 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -119.19 106.16 12.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.134 -0.485 . . . . 64.54 110.954 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.9 p -174.07 152.73 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 72.22 111.154 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.72 72.35 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.726 -0.749 . . . . 75.53 112.488 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -89.53 -66.11 0.95 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.813 0.339 . . . . 52.41 110.85 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -171.55 149.07 2.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.127 -0.488 . . . . 72.25 110.882 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.521 HD13 ' HA3' ' A' ' 83' ' ' GLY . 7.2 tt -103.15 143.67 32.31 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.123 -0.489 . . . . 74.11 110.971 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.601 ' H ' HD11 ' A' ' 189' ' ' ILE . . . -64.26 106.59 1.48 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.767 -0.73 . . . . 61.41 112.463 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -95.55 -51.39 4.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.764 0.316 . . . . 73.22 110.854 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.487 HD21 ' HA3' ' A' ' 38' ' ' GLY . 17.7 tp -154.32 145.51 22.85 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.212 -0.449 . . . . 74.3 111.009 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 21.2 p-10 -98.14 -39.5 8.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 73.11 110.865 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 16.2 m -142.54 138.44 28.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.199 -0.455 . . . . 62.25 111.127 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.487 ' HA3' HD21 ' A' ' 35' ' ' LEU . . . 154.84 -136.66 5.27 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.727 -0.749 . . . . 71.14 112.492 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -149.82 -150.66 5.31 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.737 -0.744 . . . . 73.11 112.493 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 108.0 161.21 20.82 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.752 -0.737 . . . . 71.11 112.53 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -78.32 113.16 16.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.813 0.339 . . . . 60.5 111.157 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 16.5 mt 51.84 71.39 1.51 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.622 0.725 . . . . 74.24 110.957 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 81.84 0.79 Allowed 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.649 2.233 . . . . 72.12 112.393 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 10.2 p30 -153.27 127.77 9.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.17 -0.468 . . . . 64.55 110.869 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.518 ' HB1' ' CA ' ' A' ' 84' ' ' GLU . . . -100.18 -178.3 3.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.197 -0.456 . . . . 62.42 111.093 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -143.18 128.44 18.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 71.31 110.874 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 14.4 p -104.77 146.59 11.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 44.11 111.21 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 15.1 t -156.92 137.24 12.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 61.41 110.816 -179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 18.5 tt -112.05 144.69 19.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.133 -0.485 . . . . 74.34 111.115 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -117.45 129.45 8.33 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.699 -0.763 . . . . 71.14 112.505 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.1 t-20 -150.82 128.21 11.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.824 0.345 . . . . 61.13 110.812 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.408 ' O ' ' C ' ' A' ' 53' ' ' THR . 12.8 p-10 -153.79 163.49 39.93 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.107 -0.497 . . . . 72.41 110.897 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' THR . . . . . 0.408 ' C ' ' O ' ' A' ' 52' ' ' ASP . 10.0 t 37.45 43.56 0.42 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 71.22 111.143 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.607 ' C ' HD13 ' A' ' 55' ' ' LEU . 0.2 OUTLIER -109.97 170.5 8.04 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.158 -0.474 . . . . 51.02 111.163 -179.998 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.607 HD13 ' C ' ' A' ' 54' ' ' THR . 0.0 OUTLIER -156.06 166.15 34.31 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.26 -0.427 . . . . 75.43 110.915 179.987 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.506 HG21 ' HB3' ' A' ' 24' ' ' SER . 43.8 p -140.39 144.66 36.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.198 -0.455 . . . . 60.22 111.144 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -118.94 132.41 56.08 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.434 . . . . 74.53 110.86 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.41 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -131.87 150.51 52.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 74.21 110.832 -179.969 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.547 HG23 ' HE1' ' A' ' 17' ' ' TRP . 20.0 mm -110.47 114.41 46.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.236 -0.438 . . . . 44.21 111.123 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.438 ' HB2' ' OD2' ' A' ' 70' ' ' ASP . . . -103.36 123.73 47.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.176 -0.465 . . . . 32.45 111.124 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.411 ' O ' ' HB1' ' A' ' 68' ' ' ALA . 0.5 OUTLIER -112.97 119.51 38.18 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 73.14 110.883 -179.81 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -80.1 113.73 18.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.084 -0.507 . . . . 65.32 110.863 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 83.3 t -111.27 -32.69 2.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 70.13 111.222 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -124.09 -172.53 2.56 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.104 -0.498 . . . . 75.3 110.85 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 5.0 p -85.82 -36.25 20.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.121 -0.49 . . . . 71.12 110.832 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -126.31 19.36 7.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 53.24 110.932 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 24.8 mt -148.97 135.77 13.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.111 -0.495 . . . . 75.35 111.122 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.411 ' HB1' ' O ' ' A' ' 61' ' ' TYR . . . -153.32 170.13 21.39 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.172 -0.467 . . . . 71.31 111.076 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.3 m -106.34 151.32 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.265 -0.425 . . . . 55.35 111.083 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.438 ' OD2' ' HB2' ' A' ' 60' ' ' ALA . 0.8 OUTLIER -143.03 138.32 29.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.129 -0.487 . . . . 61.21 110.839 179.883 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.41 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 12.0 m-85 -121.59 109.32 14.64 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 73.13 110.92 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.55 ' CD2' HD13 ' A' ' 102' ' ' ILE . 1.3 t80 -83.83 121.44 27.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.154 -0.475 . . . . 74.05 110.867 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 24.8 t -135.89 146.59 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 75.42 111.1 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -162.31 124.35 1.29 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.678 -0.772 . . . . 62.3 112.497 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 43.7 t -114.91 70.18 2.39 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.638 0.733 . . . . 60.34 111.132 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 162.79 40.72 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 75.24 112.331 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -76.32 -170.52 1.49 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.213 -0.449 . . . . 73.55 111.13 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 19.8 ttp180 -77.48 137.2 38.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 72.4 110.916 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -134.28 150.93 51.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.226 -0.443 . . . . 53.53 111.068 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -100.51 138.31 37.73 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 73.43 110.898 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -128.09 155.31 44.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 72.22 110.894 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.464 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 1.1 pt20 -110.26 153.26 25.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 62.12 110.995 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.612 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 179.93 75.22 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.758 -0.734 . . . . 42.52 112.52 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.518 ' CA ' ' HB1' ' A' ' 45' ' ' ALA . 1.0 OUTLIER -177.25 -176.89 0.68 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.906 0.384 . . . . 71.55 110.86 -179.898 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 3.6 mtpm? -85.67 -69.66 0.65 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 74.04 110.868 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.5 t -84.31 -33.41 23.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 72.05 110.928 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.885 HG22 HG22 ' A' ' 93' ' ' VAL . 6.1 mm -64.62 -34.33 69.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.124 -0.489 . . . . 74.11 111.113 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 78.6 p -63.7 -50.48 69.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.144 -0.48 . . . . 72.43 110.856 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 44.6 t -51.45 -38.06 51.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.146 -0.479 . . . . 62.21 110.863 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 9.3 tp -64.83 -42.66 94.79 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.172 -0.467 . . . . 63.1 110.931 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 106.14 -14.57 44.1 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.755 -0.736 . . . . 74.23 112.491 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 24.3 ttp180 -114.37 94.33 4.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.834 0.349 . . . . 73.12 110.922 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.885 HG22 HG22 ' A' ' 87' ' ' ILE . 85.5 t -112.86 -51.83 5.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 44.13 111.106 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 10.9 p -139.12 143.52 38.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.158 -0.474 . . . . 73.12 110.829 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -130.92 118.22 20.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.136 -0.484 . . . . 64.03 110.917 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.533 HG21 ' CD2' ' A' ' 128' ' ' PHE . 9.8 p -176.08 161.26 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.181 -0.463 . . . . 61.15 111.113 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.435 ' N ' HG22 ' A' ' 96' ' ' VAL . 2.0 p30 -91.07 174.12 7.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 63.33 110.849 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -119.91 134.53 55.21 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.165 -0.471 . . . . 62.33 110.947 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -121.76 66.61 0.46 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.719 -0.753 . . . . 64.22 112.509 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 117.43 5.08 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.617 2.211 . . . . 74.02 112.321 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -132.37 104.24 6.62 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.157 -0.474 . . . . 71.45 111.087 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.602 HG23 ' CA ' ' A' ' 124' ' ' GLY . 5.0 mp -130.03 150.57 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 73.31 111.094 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -143.75 115.39 8.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 72.42 110.899 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.1 p -142.87 159.65 41.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.232 -0.44 . . . . 45.34 110.887 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.622 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.8 OUTLIER -108.12 146.58 32.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.141 -0.481 . . . . 55.54 110.893 -179.963 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -100.97 137.99 38.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 71.04 110.872 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 28.6 p90 -141.63 156.19 45.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.204 -0.453 . . . . 72.53 110.916 -179.84 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 20.0 m-70 -95.77 130.62 42.64 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.115 -0.493 . . . . 71.33 110.835 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 52.5 t80 -98.5 140.57 32.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 74.43 110.92 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -62.65 125.63 24.61 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.082 -0.508 . . . . 64.51 110.809 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.3 m -150.0 147.39 27.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.47 . . . . 74.31 110.856 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -57.93 -39.42 77.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.136 -0.484 . . . . 74.44 110.914 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 20.9 mm-40 -53.95 172.78 0.07 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.142 -0.481 . . . . 74.43 110.897 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 6.8 tpt85 -117.23 -37.74 3.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.133 -0.485 . . . . 73.13 110.881 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -113.85 110.47 20.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 75.13 110.922 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 21.6 p90 -164.36 155.57 13.58 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.672 0.749 . . . . 75.23 110.919 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' PRO . . . . . 0.703 ' HA ' HD23 ' A' ' 153' ' ' LEU . 53.8 Cg_endo -69.73 177.74 5.25 Favored 'Trans proline' 0 N--CA 1.465 -0.186 0 C-N-CA 122.69 2.26 . . . . 53.11 112.402 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 1.2 p90 -112.05 162.78 15.02 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.261 -0.427 . . . . 63.32 110.941 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 43.9 t -121.41 136.24 58.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.124 -0.489 . . . . 74.24 111.173 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -128.58 179.09 16.81 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.771 -0.728 . . . . 74.22 112.437 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.4 HG22 ' N ' ' A' ' 122' ' ' GLY . 7.6 p -163.44 155.79 2.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.89 0.376 . . . . 65.13 111.125 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.4 ' N ' HG22 ' A' ' 121' ' ' VAL . . . -179.34 -157.41 19.69 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.73 -0.748 . . . . 33.01 112.509 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.4 p -107.28 123.71 62.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.812 0.339 . . . . 75.03 111.173 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' GLY . . . . . 0.602 ' CA ' HG23 ' A' ' 102' ' ' ILE . . . -115.45 107.66 1.77 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.774 -0.727 . . . . 21.15 112.497 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -106.13 126.82 52.67 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.932 0.396 . . . . 72.42 110.824 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.411 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 2.1 p -105.59 108.92 26.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.152 -0.476 . . . . 71.15 111.144 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 3.1 tp -116.58 170.33 8.66 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.259 -0.428 . . . . 75.42 110.993 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.533 ' CD2' HG21 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -161.7 179.35 8.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.246 -0.433 . . . . 71.4 110.926 179.951 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -117.23 115.47 25.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.469 . . . . 74.41 110.882 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -48.05 110.55 0.34 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 65.41 110.799 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.496 ' HB2' HG23 ' A' ' 96' ' ' VAL . 2.8 mmmt -104.09 -89.05 0.41 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 72.42 110.885 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.3 m -175.78 133.94 0.28 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.23 -0.441 . . . . 74.2 111.152 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' ASP . . . . . 0.462 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 19.3 m-20 -115.9 127.63 55.15 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.166 -0.47 . . . . 73.22 110.937 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -77.12 -11.09 85.88 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.753 -0.737 . . . . 63.01 112.522 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -45.12 -31.09 1.28 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.872 0.368 . . . . 61.11 111.077 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.5 tp -164.6 -177.18 4.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 54.34 110.938 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.538 ' HB2' HD13 ' A' ' 180' ' ' LEU . 16.5 m -51.42 95.24 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 43.15 110.862 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 93.3 p 47.26 72.03 0.28 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.071 -0.513 . . . . 71.11 110.892 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.462 ' HB3' ' HB2' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -88.97 160.26 17.22 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.131 -0.486 . . . . 54.13 110.84 -179.904 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 69.9 m-20 -147.2 -178.61 6.31 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.112 -0.495 . . . . 63.52 110.844 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.647 HG22 ' HA ' ' A' ' 176' ' ' VAL . 1.1 pt -141.92 174.39 6.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.128 -0.487 . . . . 74.42 111.139 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' LYS . . . . . 0.403 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 14.7 tptt -123.85 135.58 53.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 70.34 110.877 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.411 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 2.8 p30 -78.5 -173.29 3.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 72.33 110.891 179.862 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 1.4 tttp -166.77 177.24 6.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 72.5 110.901 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' TRP . . . . . 0.433 ' O ' ' HB2' ' A' ' 146' ' ' ALA . 64.7 p-90 -156.95 160.3 38.93 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.227 -0.442 . . . . 73.45 110.928 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.769 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 177.44 166.73 0.51 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.622 0.725 . . . . 75.02 111.068 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.769 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.4 Cg_endo -69.77 129.64 17.93 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.711 2.274 . . . . 74.32 112.279 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.532 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -122.69 170.17 10.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.217 -0.447 . . . . 62.53 111.113 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 13.2 m-85 -124.18 154.66 39.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.258 -0.428 . . . . 74.45 110.807 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 5.8 tt0 -130.63 151.95 50.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.102 -0.499 . . . . 74.45 110.862 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.4 p -153.1 125.85 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 64.24 111.185 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -179.78 -162.63 29.1 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.776 -0.726 . . . . 72.31 112.451 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.764 HD13 ' N ' ' A' ' 154' ' ' ARG . 3.0 tm? -142.6 145.43 33.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.784 0.326 . . . . 64.43 110.857 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.764 ' N ' HD13 ' A' ' 153' ' ' LEU . 3.9 tpp85 -115.37 119.34 35.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 75.32 110.855 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 63.3 t80 -110.59 150.21 29.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.223 -0.444 . . . . 74.35 110.951 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -121.27 123.52 42.39 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.151 -0.477 . . . . 54.34 110.852 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 157' ' ' LEU . . . . . 0.665 HD22 ' HB2' ' A' ' 160' ' ' SER . 1.7 tt -92.29 136.12 33.46 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.157 -0.474 . . . . 75.42 110.898 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 158' ' ' GLY . . . . . 0.577 ' N ' HD23 ' A' ' 157' ' ' LEU . . . -75.41 137.39 21.77 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.782 -0.723 . . . . 72.21 112.52 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 53.02 37.23 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.892 0.377 . . . . 72.43 110.894 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 160' ' ' SER . . . . . 0.665 ' HB2' HD22 ' A' ' 157' ' ' LEU . 2.3 m -172.59 173.95 3.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.154 -0.476 . . . . 44.2 110.82 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 7.0 m0 -62.55 158.76 17.27 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.146 -0.479 . . . . 64.22 110.912 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.46 ' SD ' HG23 ' A' ' 203' ' ' VAL . 0.3 OUTLIER -92.97 171.17 9.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.255 -0.429 . . . . 54.23 110.927 179.924 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 80.7 mt -124.3 145.35 49.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 75.22 110.895 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -143.64 134.47 25.28 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.164 -0.471 . . . . 55.24 110.832 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 78.4 p -145.11 121.54 10.99 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.118 -0.492 . . . . 63.41 110.834 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -153.4 174.0 14.92 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.158 -0.474 . . . . 73.12 110.859 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.437 HG22 HD12 ' A' ' 196' ' ' LEU . 1.5 t -135.68 151.87 30.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.153 -0.476 . . . . 71.41 111.178 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 168' ' ' ARG . . . . . 0.402 ' HB2' ' HB ' ' A' ' 195' ' ' ILE . 0.1 OUTLIER -117.73 131.49 56.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 75.33 110.901 179.994 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 23.4 m-85 -132.07 134.68 45.78 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.144 -0.48 . . . . 75.42 110.966 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 170' ' ' ILE . . . . . 0.532 HG21 ' HB2' ' A' ' 148' ' ' ALA . 0.0 OUTLIER -179.13 120.49 0.23 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.618 0.723 . . . . 71.24 111.138 179.93 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.77 108.61 2.12 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.635 2.224 . . . . 73.05 112.333 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -116.48 157.11 25.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 74.52 110.834 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.36 118.98 25.18 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.131 -0.486 . . . . 75.14 110.89 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.9 t -95.08 144.64 25.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.21 -0.45 . . . . 73.43 111.092 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 175' ' ' ASP . . . . . 0.403 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.1 OUTLIER -100.21 150.58 22.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.163 -0.472 . . . . 72.11 110.855 179.916 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.647 ' HA ' HG22 ' A' ' 141' ' ' ILE . 14.7 p -146.46 127.53 6.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.197 -0.456 . . . . 74.42 111.159 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 15.2 t -167.32 172.16 10.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 73.43 111.073 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -145.48 171.77 26.42 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.688 -0.768 . . . . 71.52 112.493 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -115.28 113.03 23.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.885 0.374 . . . . 73.54 111.124 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.538 HD13 ' HB2' ' A' ' 137' ' ' SER . 11.1 tp -140.26 167.16 22.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.157 -0.474 . . . . 71.11 110.905 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -46.47 -68.79 0.98 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 72.54 112.505 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.84 -170.13 0.38 Allowed 'Trans proline' 0 C--O 1.232 0.19 0 C-N-CA 122.681 2.254 . . . . 61.41 112.37 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.416 HG13 ' O ' ' A' ' 183' ' ' VAL . 4.5 p -66.86 116.12 31.95 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.661 0.743 . . . . 63.13 111.172 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 165.11 32.03 Favored 'Trans proline' 0 C--O 1.231 0.158 0 C-N-CA 122.654 2.236 . . . . 62.42 112.387 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 49.6 t -96.73 107.99 20.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.265 -0.425 . . . . 72.12 111.14 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 1.7 p -104.16 118.72 37.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 71.52 110.83 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 23.2 p -145.9 176.12 9.92 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.183 -0.462 . . . . 65.54 111.149 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 188' ' ' LYS . . . . . 0.535 ' O ' HD13 ' A' ' 189' ' ' ILE . 0.2 OUTLIER -154.67 166.66 32.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 75.21 110.878 179.964 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 189' ' ' ILE . . . . . 0.601 HD11 ' H ' ' A' ' 33' ' ' GLY . 47.7 mm -140.23 114.44 6.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 73.11 111.099 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 7.6 tm-20 -103.01 106.74 17.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.136 -0.484 . . . . 65.13 110.93 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 8.7 m -137.03 163.49 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.174 -0.466 . . . . 72.51 111.145 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.3 89.28 4.63 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.61 0.719 . . . . 65.43 110.814 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 137.36 35.11 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.675 2.25 . . . . 63.14 112.385 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -104.26 114.7 29.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.308 -0.405 . . . . 72.51 110.813 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 195' ' ' ILE . . . . . 0.811 HD12 HG12 ' A' ' 26' ' ' VAL . 4.0 mm -101.68 119.2 49.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.109 -0.496 . . . . 74.14 111.116 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 196' ' ' LEU . . . . . 0.437 HD12 HG22 ' A' ' 167' ' ' VAL . 11.9 tp -104.86 109.49 21.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.241 -0.436 . . . . 62.03 110.902 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -102.46 119.58 39.07 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.163 -0.471 . . . . 54.05 110.833 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 198' ' ' LEU . . . . . 0.463 ' H ' HD23 ' A' ' 198' ' ' LEU . 2.0 pt? -139.13 129.65 25.8 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.164 -0.471 . . . . 72.23 110.963 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 179.88 -144.15 5.89 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.766 -0.73 . . . . 65.22 112.454 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 200' ' ' ALA . . . . . 0.427 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -127.1 173.42 9.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.812 0.339 . . . . 65.5 111.087 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 15.2 m -146.96 169.87 18.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.214 -0.448 . . . . 72.33 110.89 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 1.1 t80 -141.49 131.66 24.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.168 -0.469 . . . . 75.14 110.935 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.46 HG23 ' SD ' ' A' ' 162' ' ' MET . 5.8 t -81.12 158.58 4.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.479 . . . . 41.52 111.089 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 204' ' ' PHE . . . . . 0.411 ' N ' HG12 ' A' ' 203' ' ' VAL . 2.1 m-85 -164.6 147.95 8.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.466 . . . . 72.34 110.915 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 35.8 mtpt 63.87 60.74 1.01 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 70.34 110.895 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 206' ' ' LEU . . . . . 0.525 HD12 ' CA ' ' A' ' 11' ' ' GLY . 1.8 pt? -124.35 -178.85 4.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 74.52 110.923 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -88.39 98.97 11.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 61.15 111.081 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -116.85 123.2 46.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.262 -0.426 . . . . 64.14 111.073 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -158.58 157.92 32.92 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 71.51 111.073 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 210' ' ' LEU . . . . . 0.53 ' H ' HD23 ' A' ' 210' ' ' LEU . 1.7 pt? -118.32 160.47 21.58 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.201 -0.454 . . . . 65.55 110.896 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.156 -0.475 . . . . 75.13 110.91 179.879 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.046 0 CA-C-O 120.794 0.331 . . . . 45.5 110.858 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -123.22 115.08 21.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 64.24 110.935 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.1 mp0 -127.03 177.66 6.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.227 -0.442 . . . . 71.31 110.808 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 29.1 m120 -93.8 115.17 27.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.077 -0.51 . . . . 72.11 110.875 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.685 ' O ' ' HB3' ' A' ' 209' ' ' ALA . 6.3 t80 -163.02 74.09 1.98 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.659 0.743 . . . . 74.11 110.907 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.83 151.78 68.78 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.72 2.28 . . . . 51.45 112.274 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.406 ' HB3' ' HB1' ' A' ' 209' ' ' ALA . . . -158.65 169.59 24.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.238 -0.437 . . . . 34.14 111.074 179.892 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.77 175.14 0.06 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.211 -0.45 . . . . 75.23 110.884 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.0 p -103.1 167.46 9.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.229 -0.441 . . . . 43.54 110.831 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -107.83 179.78 4.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.083 -0.508 . . . . 40.41 111.085 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.38 -85.9 1.71 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.698 -0.763 . . . . 70.52 112.513 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 14.1 m-85 -143.81 112.29 6.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.939 0.399 . . . . 74.13 110.894 -179.828 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -139.01 159.82 41.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.069 -0.514 . . . . 64.44 110.912 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 17.5 pt20 -51.54 120.04 4.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 74.45 110.907 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 101.7 7.91 46.97 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.729 -0.748 . . . . 42.51 112.468 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.62 156.23 27.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.81 0.338 . . . . 64.43 110.856 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 41.5 m95 -133.0 143.63 49.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.109 -0.496 . . . . 75.11 110.944 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.757 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 2.6 m -142.71 137.76 27.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.251 -0.431 . . . . 64.14 111.132 179.877 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -96.62 104.91 16.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 73.24 111.087 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.4 m -91.63 130.18 37.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 74.13 110.87 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.704 ' CE2' ' HB3' ' A' ' 200' ' ' ALA . 13.7 p90 -134.78 116.76 15.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.066 -0.515 . . . . 65.4 110.88 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -150.95 172.32 15.88 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.177 -0.465 . . . . 75.33 110.94 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 12.8 p90 -105.16 131.39 52.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 74.21 110.906 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' SER . . . . . 0.412 ' HB2' HG22 ' A' ' 195' ' ' ILE . 0.3 OUTLIER -96.58 137.3 35.87 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.149 -0.478 . . . . 44.14 110.837 -179.76 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.7 mmtp -116.19 111.64 20.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.128 -0.487 . . . . 71.31 110.878 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.512 HG22 HD12 ' A' ' 195' ' ' ILE . 25.4 t -75.11 128.32 36.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.237 -0.438 . . . . 72.32 111.097 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 6.9 m-85 -125.96 106.92 9.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 74.33 110.977 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.7 p -171.59 152.92 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.119 -0.491 . . . . 72.21 111.146 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 169.34 64.74 0.04 OUTLIER Glycine 0 N--CA 1.453 -0.197 0 C-N-CA 120.766 -0.731 . . . . 75.43 112.491 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 13.8 tt0 -89.78 -66.3 0.94 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.76 0.314 . . . . 64.13 110.861 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 71.1 tt0 -175.05 154.88 1.88 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 65.42 110.905 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.593 HD13 ' N ' ' A' ' 33' ' ' GLY . 0.3 OUTLIER -110.07 133.91 52.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.484 . . . . 71.11 110.958 -179.952 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.593 ' N ' HD13 ' A' ' 32' ' ' LEU . . . -62.44 120.88 23.52 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.746 -0.74 . . . . 42.33 112.49 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -133.42 130.84 39.23 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.838 0.352 . . . . 54.14 110.818 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 5.6 mp -128.55 173.54 10.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.177 -0.465 . . . . 74.24 110.887 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -131.41 148.04 52.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 74.12 110.871 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.6 p -88.78 -34.6 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.469 . . . . 72.31 111.109 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -109.4 151.8 17.19 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.686 -0.769 . . . . 71.03 112.481 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -59.23 126.71 43.2 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.759 -0.734 . . . . 75.05 112.537 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -172.77 -141.24 3.38 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.717 -0.754 . . . . 52.34 112.474 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -84.53 161.47 20.21 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.805 0.336 . . . . 60.44 111.077 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.0 mt -127.45 69.02 74.6 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.636 0.731 . . . . 72.22 110.912 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.77 -170.88 0.42 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.677 2.251 . . . . 74.32 112.314 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -131.62 123.12 27.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 44.1 110.839 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.463 ' HB1' ' CA ' ' A' ' 84' ' ' GLU . . . -76.4 178.75 6.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.174 -0.466 . . . . 72.13 111.104 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -143.25 130.41 20.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.453 . . . . 73.31 110.846 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.5 p -104.78 138.56 29.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.185 -0.461 . . . . 74.23 111.089 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -142.85 159.16 42.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.117 -0.492 . . . . 75.22 110.835 -179.854 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -108.47 132.76 55.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.119 -0.491 . . . . 75.41 111.149 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -131.07 51.81 0.85 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.746 -0.74 . . . . 52.44 112.488 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 -102.81 112.6 25.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.834 0.35 . . . . 75.13 110.919 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.659 ' O ' HG23 ' A' ' 54' ' ' THR . 1.8 t70 -55.03 175.18 0.06 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 75.2 110.859 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 7.5 p -53.16 101.82 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.238 -0.437 . . . . 72.25 111.135 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.659 HG23 ' O ' ' A' ' 52' ' ' ASP . 44.9 p -100.94 176.1 5.39 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 74.12 111.182 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 5.2 mp -129.78 161.51 30.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.269 -0.423 . . . . 63.05 110.924 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.5 143.01 30.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 70.21 111.087 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -123.05 132.41 54.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.248 -0.433 . . . . 75.23 110.862 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.436 ' C ' HD13 ' A' ' 59' ' ' ILE . 14.5 p-10 -134.75 145.21 48.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 65.22 110.825 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.436 HD13 ' C ' ' A' ' 58' ' ' ASP . 5.8 mm -108.95 116.81 52.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 54.25 111.085 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.757 ' HB3' ' CG2' ' A' ' 18' ' ' VAL . . . -101.87 125.2 48.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 63.14 111.07 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.632 ' HB3' HG13 ' A' ' 69' ' ' VAL . 27.1 t80 -110.47 115.59 29.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.22 -0.445 . . . . 62.32 110.91 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -84.14 101.95 12.22 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.092 -0.503 . . . . 72.23 110.89 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.5 p -94.21 -33.15 4.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.151 -0.477 . . . . 75.34 111.041 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.0 m -134.1 164.33 27.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 73.54 110.782 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 7.8 p -86.67 3.14 45.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.083 -0.508 . . . . 54.12 110.885 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -112.43 -32.59 6.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.101 -0.5 . . . . 72.04 110.912 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 21.6 pt -146.44 167.81 6.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.173 -0.467 . . . . 73.42 111.163 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -154.69 169.13 24.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 72.23 111.12 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.632 HG13 ' HB3' ' A' ' 61' ' ' TYR . 1.4 p -111.62 147.2 15.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.3 -0.409 . . . . 65.22 111.19 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -139.78 127.0 21.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 64.32 110.798 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.748 ' CZ ' HD22 ' A' ' 103' ' ' LEU . 0.6 OUTLIER -108.56 110.43 21.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 71.31 110.874 -179.96 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -87.03 129.4 34.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.126 -0.488 . . . . 70.13 110.872 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 9.9 m -149.44 163.42 4.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.118 -0.492 . . . . 65.44 111.134 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 175.01 142.57 4.13 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.757 -0.735 . . . . 62.12 112.477 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.473 ' O ' HG13 ' A' ' 75' ' ' VAL . 3.9 p -118.71 77.78 14.95 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.657 0.741 . . . . 74.43 111.16 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 148.7 65.97 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.63 2.22 . . . . 74.1 112.387 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -67.31 -165.62 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.29 -0.414 . . . . 64.41 111.061 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 43.1 ttp180 -76.66 115.54 16.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 73.21 110.83 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ALA . . . . . 0.467 ' HB3' ' CZ ' ' A' ' 81' ' ' PHE . . . -110.3 149.71 29.79 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.212 -0.449 . . . . 20.44 111.145 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.6 tmmm? -103.27 141.23 36.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 74.32 110.825 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' PHE . . . . . 0.467 ' CZ ' ' HB3' ' A' ' 79' ' ' ALA . 10.3 m-85 -139.47 157.33 46.03 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.136 -0.484 . . . . 61.3 110.86 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 30.2 mt-30 -105.96 156.15 18.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.198 -0.455 . . . . 74.0 110.977 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.59 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 176.26 73.81 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.712 -0.756 . . . . 74.51 112.512 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.463 ' CA ' ' HB1' ' A' ' 45' ' ' ALA . 1.3 tp10 -174.37 -177.21 1.21 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.959 0.409 . . . . 71.41 110.857 -179.831 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 2.3 ptmt -86.76 -69.95 0.64 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.096 -0.502 . . . . 65.25 110.858 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.6 t -84.07 -33.38 24.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.45 . . . . 54.31 110.913 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.841 HG21 ' HB2' ' A' ' 135' ' ' ALA . 4.6 mm -65.39 -34.46 70.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.115 -0.493 . . . . 75.33 111.146 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 63.5 p -61.48 -48.68 80.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.13 -0.486 . . . . 62.42 110.751 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.7 t -52.1 -39.93 60.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 71.21 110.83 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 82.5 mt -60.41 -47.86 84.25 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.163 -0.471 . . . . 74.43 110.941 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 114.93 -14.96 19.22 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.759 -0.734 . . . . 64.02 112.515 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 8.9 mtm180 -121.34 97.15 5.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.899 0.381 . . . . 75.25 110.901 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.628 HG22 HG22 ' A' ' 87' ' ' ILE . 17.0 t -112.97 -41.99 4.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.159 -0.473 . . . . 75.31 111.023 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 13.3 p -141.51 154.2 45.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 61.33 110.872 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 82.9 mt-10 -152.56 118.64 5.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.134 -0.485 . . . . 75.42 110.836 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.734 HG21 ' O ' ' A' ' 129' ' ' PHE . 4.5 p -178.46 164.16 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 72.24 111.165 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.435 ' H ' HG22 ' A' ' 96' ' ' VAL . 4.0 p30 -90.84 133.51 35.16 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.466 . . . . 73.51 110.86 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -92.21 146.14 23.95 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 74.33 110.86 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -113.49 70.93 0.23 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.767 -0.73 . . . . 42.11 112.497 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 112.48 3.1 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.714 2.276 . . . . 74.44 112.302 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -136.87 113.76 10.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.239 -0.437 . . . . 63.04 111.171 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.657 HD13 ' HD2' ' A' ' 168' ' ' ARG . 13.5 pt -139.68 153.61 23.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.209 -0.451 . . . . 72.4 111.117 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.748 HD22 ' CZ ' ' A' ' 71' ' ' PHE . 0.5 OUTLIER -142.21 117.05 9.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.204 -0.453 . . . . 71.21 110.898 179.954 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.413 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 5.3 p -142.82 161.26 38.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.227 -0.442 . . . . 71.31 110.885 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.461 ' O ' HD12 ' A' ' 105' ' ' LEU . 4.5 pp -110.08 146.03 36.09 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.168 -0.469 . . . . 73.55 110.955 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 1.7 pp0? -101.13 144.43 30.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 65.32 110.965 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -152.58 159.78 43.24 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.244 -0.435 . . . . 63.01 110.955 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 22.1 p80 -133.09 147.29 52.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.114 -0.494 . . . . 73.23 110.779 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 6.5 t80 -159.53 167.69 27.97 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.159 -0.473 . . . . 72.54 110.886 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 38.8 t0 58.58 47.41 13.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.105 -0.498 . . . . 62.53 110.946 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 36.0 p -53.91 113.64 1.29 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.171 -0.468 . . . . 74.33 110.856 -179.76 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 55.4 t80 -112.97 -36.28 5.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.097 -0.501 . . . . 73.4 110.861 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 2.1 tp10 -117.2 155.14 29.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 61.55 110.885 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 55.2 ttp180 -54.3 -45.1 72.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.145 -0.48 . . . . 72.44 110.897 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 13.0 mt -123.66 127.66 48.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.149 -0.478 . . . . 72.41 110.872 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 20.8 p90 -161.2 153.89 17.34 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.624 0.726 . . . . 62.4 110.952 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' PRO . . . . . 0.684 ' HB3' HD12 ' A' ' 153' ' ' LEU . 54.5 Cg_endo -69.67 178.37 4.58 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.72 2.28 . . . . 74.14 112.359 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 1.6 p90 -127.38 159.07 35.56 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.295 -0.411 . . . . 71.23 110.895 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 48.1 t -113.3 136.5 49.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.107 -0.497 . . . . 63.41 111.1 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -127.24 172.46 18.65 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.759 -0.734 . . . . 71.33 112.515 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.2 p -162.46 151.67 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.877 0.37 . . . . 44.21 111.18 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.413 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -176.65 -156.23 15.1 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.693 -0.765 . . . . 64.15 112.46 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.471 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 5.8 m -107.82 122.04 61.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.921 0.391 . . . . 60.34 111.083 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' GLY . . . . . 0.539 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -115.9 121.31 5.2 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.699 -0.762 . . . . 50.25 112.523 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -116.51 132.7 56.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.829 0.347 . . . . 73.03 110.862 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.421 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 2.8 m -107.66 108.67 25.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 75.02 111.147 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.523 HD23 ' N ' ' A' ' 128' ' ' PHE . 0.5 OUTLIER -86.86 166.53 15.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 73.23 110.956 179.901 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.523 ' N ' HD23 ' A' ' 127' ' ' LEU . 0.5 OUTLIER -149.24 134.51 18.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 54.3 110.902 179.914 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.734 ' O ' HG21 ' A' ' 96' ' ' VAL . 28.3 t80 -100.34 165.13 11.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.147 -0.479 . . . . 73.34 110.909 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -97.49 120.19 37.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 62.4 110.826 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.69 ' CB ' HG23 ' A' ' 96' ' ' VAL . 4.3 tppp? -141.17 -82.18 0.23 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 71.24 110.838 180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 31.7 m -162.78 83.92 0.52 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.267 -0.424 . . . . 71.24 111.185 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -104.57 165.11 11.28 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.229 -0.441 . . . . 72.31 110.898 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 62.13 154.85 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.725 -0.75 . . . . 54.43 112.463 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.841 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -84.77 1.71 45.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.808 0.337 . . . . 62.1 111.088 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -86.26 -175.75 5.63 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.26 -0.427 . . . . 74.34 110.965 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.4 m -63.55 87.53 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.191 -0.459 . . . . 72.44 110.83 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 38.6 t 51.17 76.63 0.15 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.074 -0.512 . . . . 44.53 110.854 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.715 ' CE1' HG12 ' A' ' 176' ' ' VAL . 1.0 OUTLIER -86.55 148.87 25.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.163 -0.471 . . . . 73.44 110.806 -179.913 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 59.4 m-20 -122.03 -178.76 3.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.045 -0.525 . . . . 75.24 110.898 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.423 ' HA ' ' HA ' ' A' ' 176' ' ' VAL . 0.1 OUTLIER -145.2 160.51 13.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.445 . . . . 63.14 111.124 179.988 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 142' ' ' LYS . . . . . 0.424 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 3.4 ttmt -105.27 122.42 45.89 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.21 -0.45 . . . . 73.3 110.918 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.421 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 0.8 OUTLIER -63.59 -173.48 0.07 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.241 -0.436 . . . . 74.11 110.859 179.84 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 18.6 tptt -158.45 164.62 36.04 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.191 -0.459 . . . . 74.33 110.913 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 17.6 p90 -155.87 146.48 21.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.167 -0.469 . . . . 63.22 110.889 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.833 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 179.74 168.76 0.68 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.592 0.711 . . . . 62.5 111.138 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.833 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.8 Cg_endo -69.75 125.1 11.76 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.703 2.269 . . . . 60.21 112.364 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.659 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -117.96 171.08 8.32 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.238 -0.437 . . . . 55.32 111.078 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 16.3 m-85 -123.6 138.55 54.53 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.13 -0.486 . . . . 74.32 110.861 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 40.0 tt0 -119.93 159.49 24.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.138 -0.483 . . . . 74.21 110.862 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -160.7 133.32 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.453 . . . . 71.44 111.154 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 152' ' ' GLY . . . . . 0.443 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 179.38 -158.67 22.79 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.66 -0.781 . . . . 72.24 112.442 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.684 HD12 ' HB3' ' A' ' 117' ' ' PRO . 0.0 OUTLIER -146.93 166.38 26.93 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.777 0.322 . . . . 74.13 110.94 -179.969 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.417 ' HD3' ' N ' ' A' ' 155' ' ' TYR . 5.6 tpp85 -129.56 117.86 21.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.248 -0.433 . . . . 72.0 110.858 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 155' ' ' TYR . . . . . 0.417 ' N ' ' HD3' ' A' ' 154' ' ' ARG . 3.4 t80 -104.12 144.32 31.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.234 -0.439 . . . . 74.01 110.85 -179.811 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -120.47 98.26 5.96 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.124 -0.489 . . . . 74.05 110.842 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 78.8 mt -69.53 152.77 44.41 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.204 -0.453 . . . . 75.11 110.898 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -52.8 -33.84 43.59 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.733 -0.746 . . . . 72.15 112.495 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -65.78 178.53 1.03 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.86 0.362 . . . . 75.13 110.932 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 1.2 m -66.08 -35.88 81.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.144 -0.48 . . . . 73.34 110.958 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 47.0 p90 -82.76 152.82 25.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.068 -0.515 . . . . 70.23 110.991 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.424 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 2.3 mpt? -123.7 177.44 5.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.28 -0.418 . . . . 63.13 110.819 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.464 HD23 ' N ' ' A' ' 164' ' ' ASN . 1.0 OUTLIER -118.42 144.56 45.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.464 . . . . 71.44 110.87 -179.998 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 164' ' ' ASN . . . . . 0.464 ' N ' HD23 ' A' ' 163' ' ' LEU . 3.1 t-20 -143.63 137.61 28.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.15 -0.477 . . . . 55.05 110.923 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.0 t -144.06 121.44 11.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 72.54 110.803 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 166' ' ' ASP . . . . . 0.443 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.8 OUTLIER -137.37 159.66 41.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 74.35 110.908 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.545 HG13 ' CD1' ' A' ' 196' ' ' LEU . 50.4 t -132.84 134.44 58.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 72.01 111.15 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 168' ' ' ARG . . . . . 0.657 ' HD2' HD13 ' A' ' 102' ' ' ILE . 2.1 ttt85 -106.17 137.59 43.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 61.13 110.8 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 23.1 t80 -148.55 132.5 17.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 74.01 110.894 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 170' ' ' ILE . . . . . 0.659 HG21 ' HB2' ' A' ' 148' ' ' ALA . 0.0 OUTLIER -178.71 123.63 0.25 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.705 0.764 . . . . 63.34 111.121 179.93 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 104.16 1.27 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.669 2.246 . . . . 74.21 112.284 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 172' ' ' PHE . . . . . 0.436 ' HE1' HG23 ' A' ' 174' ' ' THR . 0.3 OUTLIER -117.53 175.03 5.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 73.32 110.935 179.95 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.2 132.88 25.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.249 -0.432 . . . . 70.13 110.951 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 174' ' ' THR . . . . . 0.436 HG23 ' HE1' ' A' ' 172' ' ' PHE . 0.0 OUTLIER -111.15 150.85 28.89 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.244 -0.434 . . . . 73.32 111.123 179.989 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 175' ' ' ASP . . . . . 0.424 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -106.44 158.84 16.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.223 -0.444 . . . . 65.42 110.849 179.922 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.715 HG12 ' CE1' ' A' ' 139' ' ' PHE . 10.3 t -138.61 123.2 21.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.461 . . . . 72.21 111.172 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 15.3 t -166.67 172.57 10.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 74.53 111.149 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 117.72 140.07 6.45 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.755 -0.736 . . . . 62.41 112.443 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 179' ' ' THR . . . . . 0.509 HG21 ' HG2' ' A' ' 182' ' ' PRO . 43.5 m -167.77 143.24 3.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.799 0.333 . . . . 75.41 111.08 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 7.9 tp -102.84 89.05 3.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.143 -0.481 . . . . 64.33 110.927 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 131.2 -90.7 0.29 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.742 -0.742 . . . . 74.13 112.489 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.509 ' HG2' HG21 ' A' ' 179' ' ' THR . 53.6 Cg_endo -69.8 -176.92 1.66 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.712 2.275 . . . . 62.41 112.303 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 89.3 t -74.84 120.24 80.62 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-O 121.615 0.722 . . . . 64.52 111.19 179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.79 157.36 60.59 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.71 2.274 . . . . 65.13 112.281 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.4 HG12 ' N ' ' A' ' 186' ' ' SER . 4.2 t -95.96 159.05 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 64.42 111.186 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 186' ' ' SER . . . . . 0.4 ' N ' HG12 ' A' ' 185' ' ' VAL . 6.2 p -130.43 108.55 10.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.974 0.416 . . . . 61.45 110.906 -179.845 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 16.8 p -127.36 167.21 16.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.18 -0.464 . . . . 75.23 111.177 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 4.0 tttt -151.92 142.71 22.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 62.24 110.955 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 6.8 tp -137.5 125.68 32.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 73.51 111.092 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -106.55 112.42 25.42 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.137 -0.483 . . . . 43.2 110.876 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 8.2 m -137.83 158.88 33.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.192 -0.458 . . . . 64.21 111.083 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -108.22 88.78 5.11 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.616 0.722 . . . . 53.25 110.813 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 142.16 46.94 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.619 2.213 . . . . 74.4 112.385 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -113.75 112.21 23.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.245 -0.434 . . . . 74.51 110.901 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 195' ' ' ILE . . . . . 0.512 HD12 HG22 ' A' ' 26' ' ' VAL . 4.6 mm -100.45 124.9 54.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 72.31 111.144 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 196' ' ' LEU . . . . . 0.545 ' CD1' HG13 ' A' ' 167' ' ' VAL . 0.8 OUTLIER -107.9 109.01 20.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.157 -0.474 . . . . 70.53 110.955 179.875 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -97.28 123.8 41.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.212 -0.449 . . . . 43.43 110.856 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 22.8 tp -142.38 127.59 18.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.128 -0.487 . . . . 73.23 110.943 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -179.21 -143.93 5.58 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.751 -0.738 . . . . 33.01 112.509 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 200' ' ' ALA . . . . . 0.704 ' HB3' ' CE2' ' A' ' 21' ' ' PHE . . . -123.93 173.66 8.07 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.815 0.341 . . . . 60.01 111.094 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 19.1 m -154.04 163.55 39.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 63.4 110.825 -179.763 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -131.47 131.6 43.64 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.217 -0.447 . . . . 74.24 110.897 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.657 HG13 HG12 ' A' ' 18' ' ' VAL . 60.5 t -102.22 146.61 10.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.112 -0.494 . . . . 62.11 111.109 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -160.76 157.49 26.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.099 -0.5 . . . . 63.2 110.838 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 3.9 ptmm? -108.01 -35.88 6.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.128 -0.487 . . . . 62.1 110.863 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 8.0 tp -174.11 164.0 4.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 72.54 110.928 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -65.76 -35.81 81.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.468 . . . . 73.04 111.043 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -128.9 178.25 6.51 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.172 -0.467 . . . . 72.45 111.111 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 209' ' ' ALA . . . . . 0.685 ' HB3' ' O ' ' A' ' 5' ' ' TYR . . . -87.92 -68.15 0.78 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 63.43 111.138 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 11.9 tp 53.56 37.74 26.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 74.01 110.885 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 61.41 110.911 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 40.8 mtt . . . . . 0 C--O 1.23 0.048 0 CA-C-O 120.807 0.337 . . . . 74.31 110.863 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 17.0 p30 -160.55 154.65 23.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 73.54 110.896 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 24.1 tp10 -142.11 138.08 31.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 73.23 110.852 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 50.9 m-20 -142.77 131.83 23.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.163 -0.471 . . . . 75.33 110.921 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 28.8 t80 -174.55 69.51 0.3 Allowed Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 121.685 0.755 . . . . 52.32 110.911 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 133.35 25.42 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.678 2.252 . . . . 73.33 112.329 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -79.63 165.76 22.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 74.35 111.162 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 4.4 ptpp? -129.09 154.03 47.08 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.262 -0.426 . . . . 72.45 110.932 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 75.8 m -103.21 148.05 26.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.224 -0.444 . . . . 62.43 110.884 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.28 179.38 5.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.122 -0.49 . . . . 61.31 111.091 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.66 37.71 3.35 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.709 -0.758 . . . . 65.13 112.397 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 20.0 m-85 -151.07 115.99 5.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.924 0.393 . . . . 64.43 110.931 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 7.6 m120 -146.87 165.49 29.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 74.33 110.925 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 7.3 mp0 -69.01 120.41 14.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.444 . . . . 70.21 110.907 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.35 5.84 36.77 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.711 -0.757 . . . . 72.13 112.507 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -66.74 153.3 43.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.337 . . . . 71.01 110.911 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 17.3 t90 -123.74 125.11 44.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.197 -0.456 . . . . 72.34 110.965 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.812 HG23 ' HB3' ' A' ' 60' ' ' ALA . 12.5 m -136.92 135.02 48.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.251 -0.431 . . . . 75.5 111.106 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -93.11 158.01 15.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 65.34 111.135 179.818 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.0 109.51 5.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.258 -0.428 . . . . 72.21 110.845 -179.745 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -111.37 115.66 29.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 72.23 110.865 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -150.69 173.0 14.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 74.43 110.906 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 28.2 p90 -108.43 132.21 54.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.167 -0.47 . . . . 71.52 110.908 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 25.2 p -104.85 142.45 34.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 63.31 110.841 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 25.4 tptt -121.96 122.95 40.53 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.082 -0.508 . . . . 75.51 110.975 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.734 HG12 HD12 ' A' ' 195' ' ' ILE . 20.9 m -89.92 135.29 26.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.281 -0.418 . . . . 62.33 111.154 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -126.68 114.37 17.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.252 -0.431 . . . . 75.01 111.015 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.0 p -174.79 153.55 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 60.32 111.156 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 150.5 67.26 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.775 -0.726 . . . . 63.31 112.517 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -90.16 -66.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.812 0.339 . . . . 73.35 110.958 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.661 ' C ' HG12 ' A' ' 47' ' ' VAL . 25.0 pt-20 -174.91 170.61 3.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.128 -0.487 . . . . 53.24 110.887 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.555 HD23 ' CB ' ' A' ' 45' ' ' ALA . 36.4 tp -98.27 150.14 21.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.138 -0.483 . . . . 71.21 110.913 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -85.58 74.16 2.48 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.732 -0.747 . . . . 65.23 112.464 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -102.37 125.3 49.04 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.879 0.371 . . . . 63.23 110.89 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -151.57 160.33 43.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.163 -0.472 . . . . 61.22 110.911 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -159.59 157.78 30.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 62.22 110.881 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 42.0 t -86.06 -68.96 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.192 -0.458 . . . . 64.12 111.126 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -115.92 119.56 4.6 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.699 -0.762 . . . . 60.14 112.494 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 91.67 153.17 29.39 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.719 -0.753 . . . . 75.14 112.506 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 144.3 176.03 17.96 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.706 -0.759 . . . . 51.15 112.408 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -89.4 149.8 22.81 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.791 0.329 . . . . 73.15 111.143 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.492 ' N ' ' HD2' ' A' ' 43' ' ' PRO . 0.6 OUTLIER -55.07 -60.32 8.44 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.623 0.725 . . . . 74.44 110.877 -179.975 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.492 ' HD2' ' N ' ' A' ' 42' ' ' LEU . 53.1 Cg_endo -69.77 146.65 60.8 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.701 2.267 . . . . 72.41 112.278 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 17.3 p30 -98.09 142.89 29.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.219 -0.446 . . . . 52.44 110.922 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.555 ' CB ' HD23 ' A' ' 32' ' ' LEU . . . -53.64 164.29 0.56 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 75.15 111.087 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -142.36 135.65 28.84 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.241 -0.436 . . . . 61.53 110.833 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.661 HG12 ' C ' ' A' ' 31' ' ' GLU . 7.7 p -105.44 142.83 17.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.144 -0.48 . . . . 75.2 111.138 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.0 t -158.14 135.05 9.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 64.14 110.81 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 3.0 pt -89.44 156.38 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 71.21 111.104 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.15 -157.12 9.52 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.738 -0.744 . . . . 62.54 112.463 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -152.05 128.21 10.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.858 0.361 . . . . 74.23 110.847 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -163.64 119.35 1.66 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.147 -0.479 . . . . 65.15 110.92 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' THR . . . . . 0.494 ' O ' HG23 ' A' ' 54' ' ' THR . 14.9 t -58.7 142.36 50.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 51.11 111.103 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.494 HG23 ' O ' ' A' ' 53' ' ' THR . 0.8 OUTLIER -160.12 164.39 33.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 43.45 111.22 179.966 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.458 ' O ' HD12 ' A' ' 55' ' ' LEU . 0.6 OUTLIER -109.31 163.0 13.78 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.282 -0.417 . . . . 54.25 110.96 179.961 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.4 p -142.55 144.0 32.72 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.239 -0.437 . . . . 75.31 111.19 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.423 ' HE2' HD13 ' A' ' 55' ' ' LEU . 48.2 m-85 -113.84 134.81 54.57 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.261 -0.427 . . . . 64.23 110.924 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.463 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -131.15 142.89 50.29 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.109 -0.496 . . . . 74.34 110.847 -179.949 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -109.3 115.28 49.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 75.54 111.116 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.812 ' HB3' HG23 ' A' ' 18' ' ' VAL . . . -104.01 134.94 46.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 54.04 111.091 179.834 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -120.43 123.4 42.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.25 -0.432 . . . . 74.11 110.859 -179.827 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -89.57 101.36 14.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.045 -0.525 . . . . 72.4 110.912 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.5 t -99.48 -38.77 7.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 64.11 111.101 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -125.44 159.01 32.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 64.11 110.829 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 12.2 p -84.35 3.16 37.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.104 -0.498 . . . . 60.34 110.862 -179.817 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -116.63 -33.13 4.96 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.101 -0.499 . . . . 71.2 110.877 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.438 HG21 ' CD1' ' A' ' 107' ' ' TYR . 1.9 pp -139.31 164.07 25.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 72.12 111.121 179.835 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -150.12 167.89 25.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 64.33 111.117 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 13.5 m -113.31 152.98 14.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 60.35 111.203 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -147.91 147.15 29.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 75.44 110.88 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.463 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 16.7 m-85 -127.34 110.33 12.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.266 -0.424 . . . . 72.54 110.867 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -87.83 122.85 31.98 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.094 -0.503 . . . . 74.4 110.863 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 25.2 t -145.88 149.11 16.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.136 -0.484 . . . . 51.15 111.094 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -152.97 167.59 31.71 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.744 -0.741 . . . . 41.24 112.511 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.6 m -134.55 67.65 71.76 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.59 0.709 . . . . 62.34 111.104 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 163.65 37.47 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.667 2.244 . . . . 64.01 112.363 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -83.85 -170.91 3.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.192 -0.458 . . . . 71.3 111.129 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 20.5 ttm105 -76.55 135.49 39.26 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 61.43 110.823 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -129.7 144.3 51.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.114 -0.494 . . . . 62.54 111.148 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.83 137.49 42.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 62.35 110.915 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 43.6 p90 -129.78 159.09 37.61 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.435 . . . . 74.52 110.865 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.411 ' O ' HG23 ' A' ' 47' ' ' VAL . 26.0 mt-30 -98.29 158.08 15.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 74.13 110.878 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.532 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -178.0 60.13 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.666 -0.778 . . . . 74.41 112.479 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.453 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.3 tp10 -167.97 -175.55 2.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.928 0.394 . . . . 63.15 110.85 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.15 -69.27 0.68 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.187 -0.461 . . . . 73.24 110.899 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -84.15 -33.39 24.26 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.203 -0.453 . . . . 64.25 110.817 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.751 HG22 HG22 ' A' ' 93' ' ' VAL . 5.8 mm -64.68 -35.11 73.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 55.25 111.126 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 78.8 p -62.98 -47.89 81.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.472 . . . . 73.12 110.83 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 t -51.29 -37.88 49.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.125 -0.489 . . . . 74.15 110.851 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 9.1 tp -63.34 -39.01 93.36 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.103 -0.499 . . . . 70.43 110.929 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 103.13 -15.41 54.82 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.714 -0.755 . . . . 43.22 112.494 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -120.35 89.43 3.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.873 0.368 . . . . 75.43 110.825 -179.832 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.751 HG22 HG22 ' A' ' 87' ' ' ILE . 32.4 t -105.38 -47.4 9.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.207 -0.451 . . . . 60.23 111.157 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 17.9 t -142.22 144.29 33.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.151 -0.477 . . . . 75.11 110.869 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.4 pm0 -133.65 128.56 35.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.09 -0.504 . . . . 72.1 110.865 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.483 HG22 ' N ' ' A' ' 97' ' ' ASP . 10.1 p -175.88 157.02 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.464 . . . . 71.33 111.135 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.483 ' N ' HG22 ' A' ' 96' ' ' VAL . 1.7 t0 -81.0 172.52 13.63 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 73.12 110.921 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -132.92 130.72 40.0 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.269 -0.423 . . . . 74.01 110.913 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -113.4 70.98 0.23 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.71 -0.757 . . . . 54.12 112.42 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.66 114.43 3.69 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.694 2.263 . . . . 74.51 112.346 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -133.61 107.45 7.98 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.221 -0.445 . . . . 65.43 111.025 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.566 HG22 ' CA ' ' A' ' 124' ' ' GLY . 8.0 pt -131.55 149.69 33.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.247 -0.433 . . . . 55.12 111.117 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.455 ' O ' HD12 ' A' ' 103' ' ' LEU . 1.9 pp -138.28 124.15 19.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.127 -0.488 . . . . 71.23 110.945 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.4 p -144.74 165.88 26.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 73.5 110.818 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.465 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.9 OUTLIER -113.14 155.0 25.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.138 -0.483 . . . . 62.32 110.904 179.982 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 -102.07 132.03 48.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.466 . . . . 62.54 110.844 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.438 ' CD1' HG21 ' A' ' 67' ' ' ILE . 13.0 t80 -120.26 121.91 39.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.24 -0.436 . . . . 72.31 110.902 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -60.84 126.12 26.23 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.137 -0.483 . . . . 74.5 110.852 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -155.92 108.45 2.63 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.218 -0.446 . . . . 74.22 110.938 -179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -65.45 127.29 31.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.046 -0.525 . . . . 64.44 110.845 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 32.6 p -112.58 -69.66 0.85 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.122 -0.49 . . . . 64.33 110.879 -179.795 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -109.33 174.44 5.87 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.149 -0.478 . . . . 74.52 110.863 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -76.89 -65.12 0.98 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.134 -0.485 . . . . 75.11 110.918 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 18.8 ttt180 -52.26 -65.71 0.51 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.152 -0.477 . . . . 72.11 110.865 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -99.21 121.52 41.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.442 . . . . 72.51 110.896 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 8.8 p90 -118.73 67.88 7.96 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.648 0.737 . . . . 62.02 110.873 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 177.75 5.22 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.76 2.307 . . . . 75.41 112.297 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 9.0 m-85 -115.69 159.27 21.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.148 -0.478 . . . . 71.0 110.878 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.8 p -109.69 124.13 66.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.11 -0.495 . . . . 72.11 111.137 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -117.87 163.51 12.83 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.777 -0.725 . . . . 64.31 112.458 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.0 p -163.71 151.35 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.901 0.381 . . . . 74.23 111.164 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -179.26 -151.78 10.03 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.689 -0.767 . . . . 61.51 112.446 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.454 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 32.8 m -110.6 152.27 12.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.896 0.379 . . . . 73.14 111.154 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' GLY . . . . . 0.566 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -139.03 106.24 0.5 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.691 -0.766 . . . . 74.05 112.447 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 7.2 ptp180 -105.82 128.35 53.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.862 0.363 . . . . 74.34 110.84 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 60.4 t -113.52 114.62 47.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 73.14 111.136 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.1 tt -122.42 152.27 40.4 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 72.23 110.95 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 11.5 p90 -161.58 162.17 30.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.288 -0.415 . . . . 73.03 110.886 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -101.17 116.86 33.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 72.13 110.912 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -50.74 104.56 0.08 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.156 -0.474 . . . . 72.45 110.861 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.447 ' HB2' ' HA ' ' A' ' 96' ' ' VAL . 0.7 OUTLIER -79.49 -79.35 0.14 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 62.32 110.934 179.963 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 32.0 m -167.01 126.44 1.44 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 73.12 111.147 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' ASP . . . . . 0.487 ' HB3' ' HB3' ' A' ' 139' ' ' PHE . 26.2 t0 -115.18 114.84 25.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.27 -0.423 . . . . 74.4 110.892 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -79.95 -8.1 87.95 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.758 -0.734 . . . . 73.12 112.488 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.618 ' HB2' HG12 ' A' ' 93' ' ' VAL . . . -46.17 -29.38 1.54 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.831 0.348 . . . . 75.12 111.13 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.419 ' HB3' ' CD1' ' A' ' 139' ' ' PHE . 2.6 tp -157.12 -176.83 6.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.222 -0.445 . . . . 73.11 110.869 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 68.4 m -56.63 92.75 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.114 -0.494 . . . . 75.23 110.815 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 58.1 m 50.78 75.08 0.2 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.139 -0.482 . . . . 63.12 110.812 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.487 ' HB3' ' HB3' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -102.54 160.59 14.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 35.11 110.914 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -139.73 172.54 12.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 74.31 110.94 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.493 HD13 HG13 ' A' ' 176' ' ' VAL . 5.8 mm -114.26 161.8 12.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.219 -0.446 . . . . 74.43 111.147 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 13.5 mttm -124.11 114.82 20.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.178 -0.464 . . . . 60.14 110.923 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -69.64 -175.33 0.84 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.279 -0.419 . . . . 64.31 110.895 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 6.9 tttp -172.84 -173.64 1.0 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.23 -0.441 . . . . 71.51 110.894 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 59.3 p-90 -148.75 160.23 43.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.187 -0.461 . . . . 73.4 110.966 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.691 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 179.87 163.54 0.84 Allowed Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.593 0.711 . . . . 73.24 111.105 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.691 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 54.3 Cg_endo -69.78 169.1 19.74 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.688 2.258 . . . . 74.41 112.306 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.626 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -167.79 157.07 9.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 63.41 111.094 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 6.2 p90 -115.99 138.42 51.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.449 . . . . 71.55 110.898 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.406 ' HA ' ' HA ' ' A' ' 168' ' ' ARG . 25.2 tt0 -116.53 158.88 22.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 71.45 110.864 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.3 p -142.79 129.35 17.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.16 -0.473 . . . . 71.45 111.07 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 166.4 -164.42 37.61 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.749 -0.738 . . . . 61.03 112.456 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -161.22 174.01 14.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.709 0.29 . . . . 74.23 110.992 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 7.8 tpp85 -109.45 121.21 44.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.232 -0.44 . . . . 73.23 110.846 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 47.8 t80 -106.98 147.86 29.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 75.55 110.974 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -110.07 112.63 24.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.127 -0.488 . . . . 73.51 110.845 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 23.9 tp -86.15 158.14 19.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.165 -0.47 . . . . 64.34 110.908 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -58.24 -39.57 92.67 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.731 -0.747 . . . . 35.41 112.466 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -64.26 169.35 4.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.832 0.349 . . . . 72.54 110.855 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 72.6 m -54.35 -47.55 72.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 73.14 110.875 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 18.1 p90 -74.23 145.64 43.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.096 -0.502 . . . . 62.22 110.929 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 1.8 mpt? -100.34 178.79 4.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.256 -0.429 . . . . 50.42 110.904 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 4.5 tp -119.55 141.95 48.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 74.42 110.839 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -135.37 136.29 41.35 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.144 -0.48 . . . . 63.0 110.875 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.3 p -133.99 134.03 42.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 75.24 110.912 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -163.81 152.74 13.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 64.21 110.838 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.452 HG13 ' O ' ' A' ' 195' ' ' ILE . 44.3 t -144.8 119.04 3.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 72.44 111.143 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 168' ' ' ARG . . . . . 0.406 ' HA ' ' HA ' ' A' ' 150' ' ' GLN . 0.4 OUTLIER -93.52 147.08 23.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.196 -0.457 . . . . 73.22 110.868 -179.959 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 169' ' ' TYR . . . . . 0.413 ' O ' ' HB ' ' A' ' 170' ' ' ILE . 20.1 t80 -152.6 140.03 19.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 70.14 110.943 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 170' ' ' ILE . . . . . 0.626 HG21 ' HB2' ' A' ' 148' ' ' ALA . 0.0 OUTLIER 178.64 132.03 0.22 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.594 0.712 . . . . 73.43 111.196 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 171' ' ' PRO . . . . . 0.509 ' N ' HD13 ' A' ' 170' ' ' ILE . 53.8 Cg_endo -69.75 107.97 1.97 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.691 2.261 . . . . 61.21 112.362 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -124.02 152.63 42.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.172 -0.467 . . . . 64.23 110.858 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 10.4 pttm -122.7 132.92 54.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 64.41 110.869 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.6 t -100.16 162.01 13.24 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 72.41 111.131 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -110.63 157.44 19.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 61.53 110.921 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.493 HG13 HD13 ' A' ' 141' ' ' ILE . 2.9 t -150.54 136.5 11.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.983 0.42 . . . . 74.11 111.063 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.0 t -166.83 161.83 15.6 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 72.24 111.154 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -123.78 174.56 16.76 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.769 -0.729 . . . . 63.44 112.5 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 179' ' ' THR . . . . . 0.408 ' O ' HG23 ' A' ' 179' ' ' THR . 1.8 t -115.52 98.26 6.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.823 0.345 . . . . 64.25 111.107 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 11.2 tp -128.87 165.95 20.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 61.35 110.868 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -51.46 -69.25 1.19 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.708 -0.758 . . . . 61.22 112.531 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 179.78 3.45 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.666 2.244 . . . . 54.31 112.364 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.445 HG13 ' O ' ' A' ' 183' ' ' VAL . 3.5 p -55.73 111.16 2.81 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.588 0.709 . . . . 74.44 111.196 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 184' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 183' ' ' VAL . 53.9 Cg_endo -69.74 166.19 28.41 Favored 'Trans proline' 0 N--CA 1.465 -0.194 0 C-N-CA 122.757 2.305 . . . . 61.34 112.39 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 84.9 t -98.68 126.22 51.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.291 -0.413 . . . . 63.2 111.129 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 1.3 p -112.46 111.67 22.68 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.155 -0.475 . . . . 72.23 110.831 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 61.9 p -116.44 167.57 10.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.083 -0.508 . . . . 75.44 111.165 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 11.5 ptmt -147.16 160.32 42.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.444 . . . . 75.44 110.837 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 189' ' ' ILE . . . . . 0.542 HG22 HG23 ' A' ' 191' ' ' VAL . 26.7 mt -137.69 109.24 6.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 74.22 111.127 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.52 106.0 18.18 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 73.03 110.871 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 191' ' ' VAL . . . . . 0.542 HG23 HG22 ' A' ' 189' ' ' ILE . 2.3 t -137.01 164.66 29.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.085 -0.507 . . . . 75.22 111.136 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.433 ' H ' HG12 ' A' ' 191' ' ' VAL . 0.0 OUTLIER -106.94 89.64 4.6 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-O 121.531 0.681 . . . . 74.45 110.816 -179.998 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 193' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 192' ' ' ASP . 53.8 Cg_endo -69.79 135.18 29.75 Favored 'Trans proline' 0 C--N 1.34 0.131 0 C-N-CA 122.758 2.306 . . . . 63.33 112.257 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -103.09 118.16 36.18 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.165 -0.47 . . . . 55.13 110.884 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 195' ' ' ILE . . . . . 0.734 HD12 HG12 ' A' ' 26' ' ' VAL . 24.1 mm -109.26 110.37 31.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 53.44 111.196 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 196' ' ' LEU . . . . . 0.44 HD12 HD21 ' A' ' 198' ' ' LEU . 0.9 OUTLIER -109.15 108.49 19.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 71.45 110.925 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -105.63 133.52 50.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 70.15 110.881 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 198' ' ' LEU . . . . . 0.44 HD21 HD12 ' A' ' 196' ' ' LEU . 0.1 OUTLIER -153.64 137.74 16.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 72.33 110.916 179.966 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 175.48 -140.15 5.07 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.685 -0.769 . . . . 73.33 112.44 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -117.42 173.32 6.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.814 0.34 . . . . 44.01 111.112 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 4.8 p -155.8 166.29 33.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 74.45 110.833 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -132.04 150.7 52.08 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.076 -0.511 . . . . 73.0 110.931 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.592 HG23 HG12 ' A' ' 18' ' ' VAL . 5.6 p -113.05 143.62 22.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 74.22 111.148 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 4.6 t80 -141.76 107.86 5.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 71.24 110.889 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 63.5 tttt -93.96 126.14 38.99 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.153 -0.476 . . . . 73.34 110.863 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 9.0 mp -82.36 107.47 15.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.251 -0.431 . . . . 75.45 110.949 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -61.86 -48.62 79.71 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.458 . . . . 73.31 111.106 179.79 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -128.18 150.65 49.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 70.3 111.122 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -57.74 119.78 7.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.202 -0.454 . . . . 61.42 111.088 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 19.2 tp -67.91 143.39 55.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.207 -0.451 . . . . 74.13 110.972 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.253 -0.43 . . . . 51.33 110.84 -179.98 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.2 mmt . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.788 0.328 . . . . 55.24 110.909 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -120.06 177.84 4.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.264 -0.426 . . . . 65.44 110.868 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -148.51 159.01 44.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 63.15 110.847 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 11.0 m120 -160.6 157.99 28.23 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 63.1 110.916 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -139.5 145.67 44.83 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.654 0.74 . . . . 73.03 110.927 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.83 163.3 38.85 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.708 2.272 . . . . 74.34 112.328 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -149.38 125.25 10.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.238 -0.437 . . . . 74.03 111.149 179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 25.0 mmtt -138.75 175.5 9.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.283 -0.417 . . . . 73.33 110.894 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 74.1 m -127.06 165.44 19.48 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.2 -0.454 . . . . 73.32 110.832 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -164.79 177.24 8.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.108 -0.496 . . . . 75.14 111.102 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.07 -32.95 82.23 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.768 -0.729 . . . . 64.53 112.522 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 9.1 p90 -140.18 110.9 6.81 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.897 0.38 . . . . 73.21 110.938 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -130.2 -177.74 4.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.122 -0.49 . . . . 75.21 110.86 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 11.8 mp0 -57.11 120.74 8.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.133 -0.485 . . . . 74.04 110.901 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 110.6 5.8 27.46 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.734 -0.746 . . . . 72.54 112.481 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -59.69 152.84 21.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.726 0.298 . . . . 74.21 110.922 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.579 ' HE1' HG23 ' A' ' 59' ' ' ILE . 25.0 t90 -121.6 142.36 50.19 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.234 -0.439 . . . . 71.34 110.936 -179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.46 HG22 ' HA ' ' A' ' 203' ' ' VAL . 39.5 t -146.72 116.75 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 72.53 111.091 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -86.61 105.31 16.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.126 -0.488 . . . . 74.14 111.137 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -101.75 112.77 25.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 64.21 110.847 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -110.16 121.2 44.71 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.123 -0.49 . . . . 65.01 110.998 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -152.12 166.68 30.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.435 . . . . 73.4 110.913 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -100.52 130.59 46.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 72.33 110.894 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -97.17 139.09 33.68 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 74.32 110.882 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 68.8 mttt -111.05 106.97 16.2 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.14 -0.482 . . . . 70.35 110.924 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.629 HG12 HD12 ' A' ' 195' ' ' ILE . 23.4 m -79.13 132.9 31.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 72.35 111.112 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 27.9 t80 -126.97 99.25 5.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 74.34 110.945 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 p -166.12 149.77 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 63.32 111.102 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 132.44 78.71 0.15 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.702 -0.761 . . . . 72.05 112.459 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -89.77 -65.93 0.97 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.735 0.302 . . . . 64.22 110.829 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.522 ' O ' HD12 ' A' ' 189' ' ' ILE . 1.6 mt-10 -171.54 174.28 4.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.196 -0.457 . . . . 72.32 110.846 -179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.472 ' HB3' ' HB3' ' A' ' 45' ' ' ALA . 14.9 tp -81.1 155.06 26.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.082 -0.508 . . . . 61.32 110.927 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.95 -32.13 41.11 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.75 -0.738 . . . . 41.4 112.494 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 42.02 38.89 1.17 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.797 0.332 . . . . 74.43 110.856 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 4.9 tp -62.46 -37.03 84.35 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.251 -0.432 . . . . 73.42 110.946 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 22.3 m120 -68.73 126.78 30.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.225 -0.443 . . . . 71.31 110.834 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 13.9 p -90.6 144.89 8.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.105 -0.498 . . . . 73.25 111.111 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -132.15 -172.42 13.05 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.723 -0.751 . . . . 73.35 112.482 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -153.7 125.53 1.77 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.694 -0.765 . . . . 71.54 112.494 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.3 -101.43 1.49 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.793 -0.718 . . . . 64.42 112.498 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -77.96 169.72 17.8 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.852 0.358 . . . . 45.01 111.074 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 15.1 mt 59.47 73.29 0.69 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.56 0.695 . . . . 71.33 110.95 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -176.73 1.58 Allowed 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.706 2.271 . . . . 62.3 112.303 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -57.08 168.88 0.61 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.451 . . . . 61.24 110.898 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.472 ' HB3' ' HB3' ' A' ' 32' ' ' LEU . . . -90.12 -178.37 5.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 72.23 111.1 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 -153.49 125.85 8.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 73.31 110.921 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.471 HG22 ' HA2' ' A' ' 83' ' ' GLY . 92.0 t -109.45 141.3 25.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 74.22 111.11 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 43.0 t -167.94 159.02 11.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 41.14 110.809 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.727 HG22 ' HB3' ' A' ' 81' ' ' PHE . 45.0 pt -126.08 157.85 35.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.102 -0.499 . . . . 73.22 111.147 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.25 -138.94 0.36 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.742 -0.742 . . . . 54.35 112.45 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -154.22 117.11 4.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.884 0.373 . . . . 72.13 110.802 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -151.94 105.83 3.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.069 -0.514 . . . . 72.21 110.874 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 46.9 p -72.7 117.25 14.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 43.14 111.126 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.1 m -117.74 162.49 17.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 62.34 111.159 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -94.16 162.3 13.92 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.212 -0.449 . . . . 74.43 110.934 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.23 140.21 32.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.239 -0.437 . . . . 74.23 111.14 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -103.45 131.99 50.08 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.216 -0.447 . . . . 72.43 110.831 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 53.3 m-20 -130.13 133.3 46.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 73.43 110.896 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.579 HG23 ' HE1' ' A' ' 17' ' ' TRP . 22.1 mm -109.2 113.53 44.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 74.0 111.139 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -103.74 117.78 35.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 62.12 111.021 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -106.75 114.21 28.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.184 -0.462 . . . . 74.55 110.892 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -81.56 97.19 7.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.089 -0.505 . . . . 74.24 110.88 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.0 m -88.05 -34.15 7.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 73.51 111.129 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 69.2 m -136.23 167.47 21.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 72.0 110.899 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 46.8 t -86.94 2.64 48.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 70.53 110.895 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 65.1 m-20 -113.59 -33.86 5.72 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.096 -0.502 . . . . 61.54 110.912 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 2.2 pp -145.52 169.01 7.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 41.22 111.205 179.83 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -155.7 173.19 17.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.222 -0.444 . . . . 72.44 111.066 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.425 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 11.6 m -111.55 151.03 13.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 73.32 111.112 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -140.28 133.23 29.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 62.42 110.882 179.881 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.756 ' CZ ' HD22 ' A' ' 103' ' ' LEU . 0.5 OUTLIER -113.54 113.91 25.76 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.198 -0.456 . . . . 70.13 110.842 -179.852 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -91.64 119.99 32.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 74.53 110.909 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 36.7 t -146.64 149.35 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 63.25 111.144 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -156.51 164.45 32.55 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.697 -0.763 . . . . 70.32 112.473 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 24.6 t -136.55 66.03 56.47 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.614 0.721 . . . . 71.52 111.142 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 162.62 41.36 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.636 2.224 . . . . 71.31 112.353 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -79.28 -168.98 1.68 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.244 -0.435 . . . . 51.11 111.054 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.96 138.52 38.9 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.15 -0.477 . . . . 62.13 110.832 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -128.35 135.65 49.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.445 . . . . 72.11 111.144 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 6.8 ttpm? -107.92 141.63 39.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.223 -0.444 . . . . 75.32 110.857 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' PHE . . . . . 0.727 ' HB3' HG22 ' A' ' 49' ' ' ILE . 13.6 p90 -142.07 158.47 43.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.153 -0.476 . . . . 73.35 110.89 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.419 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 1.2 pm0 -98.05 158.51 15.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 75.24 110.909 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.605 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -177.44 69.59 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.759 -0.734 . . . . 73.53 112.505 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.434 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.9 mm-40 -178.33 -177.14 0.55 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.824 0.345 . . . . 73.21 110.916 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.23 -67.42 0.82 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.163 -0.472 . . . . 72.34 110.915 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.9 t -83.1 -35.62 25.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.447 . . . . 72.03 110.851 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.929 HG22 HG22 ' A' ' 93' ' ' VAL . 5.7 mm -64.62 -33.65 64.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.122 -0.49 . . . . 72.21 111.131 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.7 t -61.85 -47.95 82.72 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.206 -0.452 . . . . 65.24 110.861 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.9 t -53.23 -39.87 64.12 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.153 -0.476 . . . . 43.2 110.844 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -59.83 -42.48 93.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.119 -0.491 . . . . 61.34 110.927 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 104.93 -13.48 49.48 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.704 -0.76 . . . . 64.31 112.506 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 7.2 ptp180 -120.16 96.9 5.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.856 0.36 . . . . 62.11 110.873 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.929 HG22 HG22 ' A' ' 87' ' ' ILE . 98.6 t -113.55 -55.41 4.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.234 -0.439 . . . . 73.02 111.175 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 5.8 m -140.51 143.39 35.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 40.42 110.841 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -146.7 126.17 13.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.49 . . . . 72.22 110.862 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.452 HG22 ' N ' ' A' ' 97' ' ' ASP . 14.2 p -166.1 156.72 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 64.13 111.155 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.452 ' N ' HG22 ' A' ' 96' ' ' VAL . 6.0 p-10 -72.94 172.97 9.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 75.55 110.835 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 3.5 m-85 -115.74 125.39 52.72 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.106 -0.497 . . . . 70.52 110.889 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -119.46 67.04 0.39 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.664 -0.779 . . . . 64.42 112.464 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 112.01 2.96 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.694 2.263 . . . . 62.2 112.33 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.455 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -122.66 95.94 4.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.215 -0.448 . . . . 35.23 111.092 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.669 HG23 ' CA ' ' A' ' 124' ' ' GLY . 5.8 mm -121.7 149.98 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 75.01 111.109 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.756 HD22 ' CZ ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -150.42 111.1 4.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 70.34 110.913 179.936 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.4 p -142.87 167.87 21.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.223 -0.444 . . . . 55.0 110.883 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.425 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -113.58 149.52 34.37 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.144 -0.48 . . . . 74.53 110.92 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -101.9 149.19 24.46 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 70.11 110.922 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -155.5 149.24 25.29 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.177 -0.465 . . . . 74.52 110.958 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 14.6 t-160 -118.46 134.5 55.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 73.1 110.891 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 21.9 t80 -104.85 144.8 31.28 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.231 -0.441 . . . . 75.14 110.923 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -62.55 120.63 11.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.072 -0.513 . . . . 73.34 110.874 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 31.7 p -130.27 175.68 8.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 61.12 110.838 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -78.17 -51.52 10.09 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.141 -0.481 . . . . 70.04 110.83 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -54.54 138.24 41.23 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.466 . . . . 74.11 110.929 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 10.6 mmp_? -72.08 -50.65 26.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 73.11 110.892 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 11.8 mt -97.73 112.96 24.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.464 . . . . 72.3 110.893 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -156.53 139.81 11.05 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.681 0.753 . . . . 74.01 110.905 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' PRO . . . . . 0.559 ' HA ' HD13 ' A' ' 153' ' ' LEU . 55.0 Cg_endo -69.67 177.35 5.61 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.695 2.263 . . . . 64.32 112.4 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -110.47 162.84 14.29 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.258 -0.428 . . . . 73.11 110.889 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 92.0 t -128.74 143.81 40.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.065 -0.516 . . . . 41.15 111.14 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -134.96 -175.02 13.65 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.779 -0.724 . . . . 62.03 112.464 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.2 p -169.25 156.1 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.877 0.37 . . . . 74.42 111.129 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 177.78 -152.1 11.48 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.69 -0.767 . . . . 54.5 112.474 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.5 HG23 ' HG ' ' A' ' 103' ' ' LEU . 34.2 m -107.85 130.35 60.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.897 0.38 . . . . 63.1 111.137 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' GLY . . . . . 0.669 ' CA ' HG23 ' A' ' 102' ' ' ILE . . . -125.5 113.31 1.87 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.74 -0.743 . . . . 64.22 112.495 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 125' ' ' ARG . . . . . 0.455 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 14.2 ptt180 -114.58 124.4 51.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.846 0.355 . . . . 74.0 110.925 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.417 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 51.5 t -106.09 110.19 30.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 52.42 111.116 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.477 HD23 ' HB2' ' A' ' 143' ' ' ASP . 6.2 mt -126.5 174.5 8.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 54.23 110.83 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.517 ' CE2' HG23 ' A' ' 141' ' ' ILE . 0.1 OUTLIER -159.02 173.17 16.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.149 -0.478 . . . . 64.5 110.877 179.921 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.437 ' O ' HG23 ' A' ' 96' ' ' VAL . 5.9 t80 -101.78 119.11 38.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 74.13 110.924 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -46.41 106.18 0.08 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.131 -0.486 . . . . 74.53 110.914 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 31.7 mmtm -105.21 -79.95 0.55 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 63.11 110.882 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.5 m -160.45 85.02 0.71 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.215 -0.448 . . . . 54.55 111.149 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -102.72 166.94 10.21 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.239 -0.437 . . . . 64.32 110.864 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 135' ' ' ALA . . . 83.23 145.49 6.13 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.772 -0.727 . . . . 74.23 112.578 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.507 ' HB2' HG13 ' A' ' 87' ' ' ILE . . . -36.5 -65.32 0.28 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.747 0.308 . . . . 63.5 111.081 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.439 HD23 ' HB1' ' A' ' 135' ' ' ALA . 0.4 OUTLIER -167.38 93.18 0.42 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.24 -0.437 . . . . 64.32 110.911 -179.952 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.655 ' HB2' HD21 ' A' ' 180' ' ' LEU . 1.5 p 167.83 59.82 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.225 -0.443 . . . . 62.21 110.844 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.539 ' C ' ' O ' ' A' ' 137' ' ' SER . 54.1 m 25.97 74.45 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.47 . . . . 53.45 110.884 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -106.04 143.23 34.46 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.099 -0.5 . . . . 74.42 110.894 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -111.62 173.76 6.19 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.157 -0.474 . . . . 64.11 110.794 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.517 HG23 ' CE2' ' A' ' 128' ' ' PHE . 6.8 tt -128.02 126.47 66.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.133 -0.485 . . . . 43.12 111.132 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' LYS . . . . . 0.411 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 1.3 mtmt -74.58 106.11 6.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 72.35 110.885 179.836 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.477 ' HB2' HD23 ' A' ' 127' ' ' LEU . 0.9 OUTLIER -57.4 -176.11 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.175 -0.466 . . . . 64.43 110.856 179.854 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 144' ' ' LYS . . . . . 0.554 ' CE ' HG22 ' A' ' 174' ' ' THR . 0.0 OUTLIER -139.92 161.55 37.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 63.34 110.955 179.952 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 43.7 p-90 -155.37 135.73 13.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.279 -0.419 . . . . 64.32 110.915 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.735 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 179.94 165.54 0.82 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.568 0.699 . . . . 60.31 111.112 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.735 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 52.7 Cg_endo -69.8 142.33 47.48 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.689 2.26 . . . . 74.22 112.266 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.563 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -133.73 167.52 20.38 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 62.21 111.126 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 58.8 m-85 -117.76 156.61 28.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.257 -0.429 . . . . 73.32 110.863 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 -128.06 149.05 50.56 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.161 -0.472 . . . . 70.52 110.925 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 84.7 t -151.14 123.32 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 71.33 111.125 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 152' ' ' GLY . . . . . 0.441 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 179.53 -159.04 23.37 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.756 -0.735 . . . . 70.32 112.486 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.559 HD13 ' HA ' ' A' ' 117' ' ' PRO . 20.3 tp -150.78 161.0 43.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.83 0.348 . . . . 52.13 110.939 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.4 tpp85 -117.64 118.71 32.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 60.1 110.887 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -103.91 142.85 33.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 74.55 110.905 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -121.74 97.51 5.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.153 -0.476 . . . . 75.5 110.835 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 6.1 tp -73.24 158.69 34.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 71.04 110.911 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -52.53 -46.24 58.77 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.695 -0.764 . . . . 70.44 112.498 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -58.1 166.51 1.55 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.824 0.345 . . . . 71.34 110.895 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 5.9 m -57.51 -36.73 71.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.141 -0.481 . . . . 61.41 110.871 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 87.5 m95 -79.4 134.7 36.57 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.13 -0.486 . . . . 74.52 110.9 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.491 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 32.8 mtt -108.93 176.79 4.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.44 . . . . 75.23 110.82 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.416 HD13 ' O ' ' A' ' 199' ' ' GLY . 3.2 mm? -115.92 148.77 39.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 63.23 110.914 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -146.89 133.25 19.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.469 . . . . 74.25 110.929 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 66.0 p -139.98 122.23 15.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 75.01 110.89 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 166' ' ' ASP . . . . . 0.441 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.7 OUTLIER -147.34 155.33 41.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.178 -0.464 . . . . 75.25 110.896 179.921 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.691 HG22 HD23 ' A' ' 196' ' ' LEU . 14.6 t -133.18 134.57 57.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 73.14 111.103 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 7.1 tmm_? -107.5 132.16 53.53 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.129 -0.487 . . . . 74.53 110.9 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 38.0 t80 -132.83 139.52 47.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.461 . . . . 72.32 110.852 -179.802 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 170' ' ' ILE . . . . . 0.563 HG21 ' HB2' ' A' ' 148' ' ' ALA . 1.3 tp -178.1 102.23 0.21 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.622 0.725 . . . . 72.44 111.106 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 128.26 15.75 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.658 2.239 . . . . 72.25 112.419 179.857 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 172' ' ' PHE . . . . . 0.41 ' CE2' ' HB2' ' A' ' 146' ' ' ALA . 1.5 t80 -153.17 178.09 10.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 73.32 110.831 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.45 135.45 50.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.15 -0.477 . . . . 63.13 110.886 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 174' ' ' THR . . . . . 0.554 HG22 ' CE ' ' A' ' 144' ' ' LYS . 1.0 OUTLIER -102.62 164.97 11.34 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.224 -0.443 . . . . 74.02 111.186 179.965 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 175' ' ' ASP . . . . . 0.411 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.3 OUTLIER -127.24 167.28 16.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 64.44 110.832 179.98 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 24.7 t -148.37 139.08 17.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.451 . . . . 71.41 111.165 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.3 t -166.85 155.82 10.52 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 73.24 111.138 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -138.87 -162.04 8.98 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.749 -0.739 . . . . 41.43 112.482 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 179' ' ' THR . . . . . 0.642 ' O ' HD22 ' A' ' 180' ' ' LEU . 1.9 t -124.28 107.59 11.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.818 0.342 . . . . 74.25 111.168 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.655 HD21 ' HB2' ' A' ' 137' ' ' SER . 4.3 mm? -132.59 166.87 21.12 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.24 -0.436 . . . . 71.12 110.922 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -49.59 -69.65 0.99 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.769 -0.729 . . . . 60.13 112.517 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.75 -171.39 0.47 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.644 2.229 . . . . 72.52 112.401 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.405 HG23 ' HD2' ' A' ' 184' ' ' PRO . 7.4 p -55.97 132.9 73.85 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.662 0.744 . . . . 41.41 111.137 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 184' ' ' PRO . . . . . 0.405 ' HD2' HG23 ' A' ' 183' ' ' VAL . 54.6 Cg_endo -69.75 150.13 67.9 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 122.666 2.244 . . . . 55.21 112.338 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 55.1 t -96.12 107.57 19.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 55.44 111.102 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 9.8 p -99.88 105.39 17.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.125 -0.489 . . . . 72.4 110.918 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 11.8 p -104.62 161.94 13.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.486 . . . . 53.5 111.096 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.46 152.09 31.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 61.43 110.91 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 189' ' ' ILE . . . . . 0.522 HD12 ' O ' ' A' ' 31' ' ' GLU . 6.4 tt -152.48 130.35 2.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 74.55 111.089 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -100.7 115.03 29.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.461 . . . . 73.43 110.912 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 191' ' ' VAL . . . . . 0.463 HG12 ' H ' ' A' ' 192' ' ' ASP . 1.8 t -137.94 166.61 23.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 65.54 111.086 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.463 ' H ' HG12 ' A' ' 191' ' ' VAL . 1.0 OUTLIER -107.03 90.15 5.13 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.572 0.701 . . . . 63.25 110.836 -179.998 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 117.52 5.13 Favored 'Trans proline' 0 C--O 1.233 0.225 0 C-N-CA 122.617 2.211 . . . . 75.21 112.375 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -100.66 121.82 42.28 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.275 -0.421 . . . . 71.34 110.882 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 195' ' ' ILE . . . . . 0.629 HD12 HG12 ' A' ' 26' ' ' VAL . 13.6 mm -112.33 107.26 22.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.469 . . . . 51.12 111.108 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 196' ' ' LEU . . . . . 0.691 HD23 HG22 ' A' ' 167' ' ' VAL . 2.3 mt -100.4 108.02 19.92 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.108 -0.497 . . . . 72.13 110.938 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.4 m -100.03 127.53 46.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.44 . . . . 70.1 110.882 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 43.9 tp -146.7 132.23 18.73 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.117 -0.492 . . . . 65.24 110.901 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 199' ' ' GLY . . . . . 0.416 ' O ' HD13 ' A' ' 163' ' ' LEU . . . 177.26 -141.64 5.41 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.773 -0.727 . . . . 23.4 112.506 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 200' ' ' ALA . . . . . 0.491 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -124.49 172.57 9.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.721 0.296 . . . . 55.14 111.179 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 37.1 t -149.56 170.48 18.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.301 -0.409 . . . . 72.52 110.893 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 202' ' ' TYR . . . . . 0.449 ' O ' HG13 ' A' ' 18' ' ' VAL . 22.9 t80 -146.5 131.62 18.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.11 -0.495 . . . . 73.24 110.941 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.46 ' HA ' HG22 ' A' ' 18' ' ' VAL . 34.4 m -88.62 160.77 2.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 74.12 111.09 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -169.35 148.96 3.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 70.33 110.885 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.74 176.91 5.0 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.145 -0.48 . . . . 74.41 110.878 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 12.6 tp -90.59 153.42 20.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.434 . . . . 70.15 110.943 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . 61.81 47.85 5.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.251 -0.431 . . . . 63.31 111.096 179.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -128.22 145.92 50.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 55.01 111.107 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -134.59 172.2 13.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.229 -0.441 . . . . 63.41 111.164 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 12.6 mt -88.41 144.73 26.2 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.244 -0.435 . . . . 74.51 110.877 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 . . . . . 0 C--N 1.331 -0.238 0 CA-C-N 116.193 -0.458 . . . . 72.24 110.858 179.942 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 17.2 mtt . . . . . 0 C--O 1.23 0.038 0 CA-C-O 120.822 0.344 . . . . 73.13 110.868 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 44.7 t30 -109.62 59.72 0.6 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.444 . . . . 73.23 110.958 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -121.91 142.19 50.53 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 73.13 110.804 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 40.74 40.98 1.05 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 74.14 110.882 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 20.3 p90 -59.39 153.78 46.88 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.713 0.768 . . . . 72.12 110.878 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 145.53 57.22 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.673 2.249 . . . . 73.43 112.376 179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -140.18 163.02 33.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.286 -0.416 . . . . 52.11 111.105 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 13.2 ttmm -140.63 108.18 5.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 64.32 110.904 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 84.6 p -114.84 50.3 0.98 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.228 -0.442 . . . . 52.31 110.862 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -174.23 157.15 2.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.167 -0.469 . . . . 72.13 111.095 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.06 -93.22 1.85 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.637 -0.792 . . . . 51.53 112.451 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 15.5 p90 -158.64 118.93 3.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.933 0.397 . . . . 65.41 110.891 -179.782 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -139.21 162.4 35.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.129 -0.487 . . . . 62.14 110.861 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.7 pt20 -53.48 120.2 5.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 70.11 110.865 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.83 5.35 29.3 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.678 -0.772 . . . . 53.44 112.493 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.1 145.58 52.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.835 0.35 . . . . 74.3 110.885 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 27.9 m0 -105.66 137.51 43.39 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.183 -0.462 . . . . 74.43 110.934 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.503 HG11 HH12 ' A' ' 154' ' ' ARG . 10.2 t -144.86 112.53 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.188 -0.46 . . . . 52.25 111.066 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.45 106.0 14.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.178 -0.465 . . . . 63.11 111.074 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.2 t -95.89 111.94 23.8 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.463 . . . . 71.52 110.886 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.573 ' HE1' HD13 ' A' ' 55' ' ' LEU . 39.0 t80 -113.14 116.87 30.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 74.24 110.857 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -154.22 168.42 26.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 74.42 110.856 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 20.0 p90 -101.25 133.75 45.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 74.53 110.864 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.5 p -109.29 114.09 27.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.107 -0.497 . . . . 71.53 110.825 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 21.3 mmmt -98.37 106.59 18.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.108 -0.496 . . . . 74.22 110.868 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.572 HG23 HG12 ' A' ' 195' ' ' ILE . 12.2 p -85.07 143.12 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 54.5 111.135 179.844 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 13.3 m-85 -122.82 116.06 23.04 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.227 -0.442 . . . . 75.31 110.937 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.1 m -148.61 -170.61 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.134 -0.485 . . . . 73.21 111.077 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.66 66.16 0.84 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.712 -0.756 . . . . 75.31 112.495 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.465 ' HB2' HG13 ' A' ' 191' ' ' VAL . 7.0 tp10 -90.51 -68.19 0.8 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.86 0.362 . . . . 74.35 110.942 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 179.05 121.21 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.125 -0.489 . . . . 73.32 110.897 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.626 HD12 HG22 ' A' ' 47' ' ' VAL . 3.4 mt -83.12 153.05 25.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 63.22 110.953 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 81.32 -132.98 11.6 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.772 -0.728 . . . . 41.14 112.522 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -136.09 162.59 32.49 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.876 0.369 . . . . 64.43 110.813 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 12.4 tp -80.91 -36.97 30.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.141 -0.481 . . . . 75.33 110.921 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -55.84 146.75 20.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 73.35 110.892 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 26.8 m -139.65 172.86 12.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 72.31 111.162 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -114.37 -131.5 5.2 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.738 -0.744 . . . . 64.53 112.439 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -100.22 -171.39 29.68 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.732 -0.747 . . . . 51.31 112.462 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 52.22 -146.58 14.75 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.752 -0.737 . . . . 63.21 112.415 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -100.36 104.17 15.6 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.803 0.335 . . . . 61.35 111.105 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 70.0 mt -151.37 73.83 8.24 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.621 0.724 . . . . 71.44 110.912 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 -177.39 1.84 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.672 2.248 . . . . 55.32 112.367 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 5.5 p-10 -91.92 140.28 29.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.251 -0.431 . . . . 61.23 110.918 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.4 ' HB1' ' HA ' ' A' ' 84' ' ' GLU . . . -65.75 167.89 8.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 43.01 111.118 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -144.9 127.56 16.17 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.245 -0.434 . . . . 72.24 110.874 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.626 HG22 HD12 ' A' ' 32' ' ' LEU . 22.0 t -105.18 138.85 28.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.166 -0.47 . . . . 63.53 111.151 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.0 m -160.34 151.74 19.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 65.4 110.862 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 16.2 tt -138.11 140.09 41.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.199 -0.455 . . . . 75.14 111.178 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -60.37 -170.04 0.51 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.756 -0.735 . . . . 60.4 112.523 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 -66.46 -58.02 6.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.778 0.323 . . . . 53.2 110.899 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 41.69 40.67 1.5 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 74.12 110.848 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.0 t -68.68 141.3 55.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.177 -0.465 . . . . 62.03 111.168 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.4 t -156.09 174.72 14.96 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.249 -0.432 . . . . 71.01 111.152 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.573 HD13 ' HE1' ' A' ' 21' ' ' PHE . 4.6 pp -90.06 159.18 16.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.208 -0.451 . . . . 75.14 110.908 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -131.16 137.13 48.87 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 74.54 111.092 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -104.24 131.96 51.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 74.01 110.879 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -135.59 139.28 43.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.139 -0.482 . . . . 74.31 110.865 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.84 114.04 45.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.249 -0.432 . . . . 72.22 111.13 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.64 ' HB2' ' OD2' ' A' ' 70' ' ' ASP . . . -106.04 127.9 53.49 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.205 -0.452 . . . . 45.43 111.1 179.835 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -113.74 125.27 53.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.45 . . . . 73.32 110.963 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -88.66 103.01 15.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.143 -0.481 . . . . 75.33 110.859 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 35.3 m -95.66 -34.4 5.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 74.53 111.136 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -134.25 161.79 33.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.08 -0.509 . . . . 43.02 110.884 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 80.2 p -84.33 3.07 37.4 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 61.34 110.864 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -115.69 -32.47 5.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.468 . . . . 72.45 110.842 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 17.8 pt -142.24 168.69 14.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 75.41 111.153 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -156.78 172.79 18.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.171 -0.468 . . . . 73.31 111.108 179.797 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.456 HG12 ' HB3' ' A' ' 105' ' ' LEU . 12.0 m -119.04 151.71 21.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 73.32 111.111 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.64 ' OD2' ' HB2' ' A' ' 60' ' ' ALA . 10.5 t70 -148.28 144.61 27.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 74.22 110.893 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -127.46 113.68 16.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.202 -0.454 . . . . 72.2 110.91 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -85.74 130.46 34.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.152 -0.476 . . . . 70.15 110.913 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 16.7 t -146.06 154.44 12.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.141 -0.481 . . . . 60.4 111.071 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -156.79 148.25 17.81 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.723 -0.751 . . . . 71.32 112.47 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.3 m -119.77 64.47 8.9 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.573 0.702 . . . . 74.03 111.111 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.72 164.05 35.94 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.663 2.242 . . . . 72.2 112.318 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -90.83 -167.98 1.96 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.18 -0.464 . . . . 51.24 111.134 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 17.1 ttm105 -77.38 136.48 38.43 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.236 -0.438 . . . . 62.15 110.882 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -133.61 151.09 51.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 62.01 111.128 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 39.9 ttmt -116.19 131.25 57.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.228 -0.442 . . . . 71.3 110.838 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -131.26 159.05 38.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 64.21 110.869 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.443 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 3.3 pt20 -94.06 157.27 16.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.116 -0.493 . . . . 74.34 110.92 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.576 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -176.05 68.4 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.755 -0.736 . . . . 51.22 112.521 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.4 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.5 tp10 -175.04 -176.83 1.0 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.912 0.387 . . . . 73.31 110.878 -179.83 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.7 -69.27 0.67 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.481 . . . . 74.34 110.924 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.9 m -83.67 -34.55 24.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 61.43 110.896 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.931 HG21 ' HB2' ' A' ' 135' ' ' ALA . 6.0 mm -63.73 -33.95 64.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.491 . . . . 73.13 111.131 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 58.2 p -62.32 -44.85 95.55 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.164 -0.471 . . . . 71.41 110.871 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.1 t -57.63 -35.18 70.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.134 -0.484 . . . . 63.1 110.872 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.668 HD12 ' HA ' ' A' ' 87' ' ' ILE . 24.6 mt -65.28 -50.25 66.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.172 -0.467 . . . . 65.43 110.947 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 116.04 -14.35 16.49 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.747 -0.74 . . . . 50.3 112.517 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 23.8 ptt180 -117.72 94.22 4.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.81 0.338 . . . . 74.11 110.861 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.898 HG22 HG22 ' A' ' 87' ' ' ILE . 64.5 t -114.5 -56.96 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 63.41 111.128 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 69.3 m -138.01 142.62 40.41 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 71.44 110.879 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -146.42 116.47 7.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.134 -0.484 . . . . 71.31 110.901 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 28.8 m -155.78 175.2 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 62.43 111.18 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -83.36 173.77 11.27 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.186 -0.461 . . . . 72.33 110.872 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -120.05 132.87 55.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 70.13 110.849 -179.765 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -132.08 62.06 0.65 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.694 -0.765 . . . . 31.15 112.472 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 113.05 3.24 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.673 2.249 . . . . 64.0 112.394 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.724 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -125.7 108.19 11.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 73.34 111.059 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 3.5 mp -129.17 147.92 33.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.28 -0.418 . . . . 73.14 111.104 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.412 ' HG ' HG13 ' A' ' 123' ' ' VAL . 0.2 OUTLIER -151.97 114.74 4.62 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.155 -0.475 . . . . 75.25 110.939 179.905 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 13.0 p -144.79 166.17 25.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 73.42 110.878 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.456 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -111.02 150.47 29.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.144 -0.48 . . . . 75.43 110.956 179.964 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 18.1 mt-30 -101.61 133.55 46.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.464 . . . . 72.22 110.905 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -122.82 119.37 30.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.164 -0.471 . . . . 54.21 110.839 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 2.4 t60 -78.56 106.72 10.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.092 -0.504 . . . . 54.52 110.838 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 34.0 t80 -79.22 147.43 32.6 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.152 -0.476 . . . . 73.24 110.94 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -74.59 131.59 41.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.086 -0.506 . . . . 63.32 110.912 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 87.9 p -134.58 158.55 43.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.231 -0.441 . . . . 55.13 110.872 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 81.3 t80 -81.47 -46.75 14.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 72.45 110.892 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 33.4 mm-40 -58.01 173.36 0.34 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.086 -0.507 . . . . 72.11 110.956 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.62 ' HG2' HD23 ' A' ' 115' ' ' LEU . 17.9 ptp180 -78.7 -35.93 44.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 73.41 110.794 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.62 HD23 ' HG2' ' A' ' 114' ' ' ARG . 1.2 pt? -111.41 142.47 43.62 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.231 -0.441 . . . . 72.4 110.953 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 27.4 t80 -166.71 134.63 2.15 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.669 0.747 . . . . 74.5 110.924 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 177.57 5.46 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.64 2.226 . . . . 64.13 112.37 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 9.7 m-85 -117.99 147.5 43.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 75.23 110.874 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 23.5 t -104.2 124.2 58.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.088 -0.505 . . . . 60.12 111.109 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -120.04 161.79 14.32 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.795 -0.717 . . . . 42.44 112.534 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.8 p -159.93 147.34 6.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.923 0.392 . . . . 65.23 111.091 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -175.54 -155.9 13.66 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.748 -0.739 . . . . 70.32 112.475 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.471 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.2 p -107.28 133.49 51.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.864 0.364 . . . . 51.11 111.085 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -119.74 110.8 1.89 Allowed Glycine 0 N--CA 1.453 -0.227 0 C-N-CA 120.646 -0.788 . . . . 65.22 112.493 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' ARG . . . . . 0.724 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 11.8 ptm180 -111.78 122.22 47.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.903 0.382 . . . . 70.41 110.912 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.566 HG13 ' HD2' ' A' ' 144' ' ' LYS . 1.4 p -108.12 110.24 31.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.465 . . . . 75.41 111.179 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.41 HD12 ' HB3' ' A' ' 143' ' ' ASP . 17.7 tp -116.84 167.19 11.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.116 -0.493 . . . . 71.22 110.931 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -150.94 178.93 8.68 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 73.42 110.885 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -107.36 144.82 33.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.143 -0.48 . . . . 74.02 110.868 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -81.78 95.41 7.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.458 . . . . 51.24 110.885 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 16.5 tppt? -110.37 -75.9 0.61 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.155 -0.475 . . . . 54.41 110.976 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' THR . . . . . 0.484 HG23 ' HA ' ' A' ' 138' ' ' SER . 88.0 m -160.85 89.64 0.81 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.236 -0.438 . . . . 61.02 111.127 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' ASP . . . . . 0.612 ' OD1' HD12 ' A' ' 141' ' ' ILE . 15.8 t70 -102.86 162.72 12.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 75.12 110.863 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 67.4 156.93 0.68 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.774 -0.726 . . . . 71.51 112.473 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.931 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -77.54 1.43 19.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.881 0.372 . . . . 62.21 111.12 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -85.89 -178.16 6.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 64.2 110.922 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 16.6 t -67.71 85.72 0.21 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.131 -0.486 . . . . 72.31 110.914 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.484 ' HA ' HG23 ' A' ' 132' ' ' THR . 3.6 m 50.84 74.84 0.21 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 74.02 110.887 -179.791 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -84.52 156.08 21.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.118 -0.492 . . . . 64.42 110.914 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -102.7 173.47 6.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.167 -0.469 . . . . 72.41 110.873 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.791 HG13 HG23 ' A' ' 176' ' ' VAL . 0.6 OUTLIER -153.94 144.11 14.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.258 -0.428 . . . . 62.11 111.126 -179.974 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 142' ' ' LYS . . . . . 0.439 ' HB2' ' HB3' ' A' ' 175' ' ' ASP . 19.8 tptt -91.03 118.02 30.05 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 73.41 110.905 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.41 ' HB3' HD12 ' A' ' 127' ' ' LEU . 0.8 OUTLIER -58.25 -168.74 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.26 -0.427 . . . . 64.03 110.887 179.823 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 144' ' ' LYS . . . . . 0.566 ' HD2' HG13 ' A' ' 126' ' ' VAL . 0.0 OUTLIER -137.59 154.59 49.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 74.32 110.822 -179.976 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 5.1 t90 -157.32 129.0 6.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 71.1 110.912 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.83 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -173.59 168.96 2.22 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.626 0.727 . . . . 55.43 111.107 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.83 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.7 Cg_endo -69.84 132.86 24.08 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.634 2.223 . . . . 31.22 112.346 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -120.29 166.27 13.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 64.43 111.115 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -123.58 137.11 54.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.29 -0.414 . . . . 73.32 110.891 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 -114.35 145.55 41.66 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.111 -0.495 . . . . 74.02 110.891 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 58.5 t -143.42 120.49 5.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 62.44 111.086 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' GLY . . . . . 0.425 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 175.77 -171.98 45.01 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.713 -0.756 . . . . 73.35 112.481 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.5 pt? -131.17 161.19 32.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.847 0.356 . . . . 75.43 110.901 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.503 HH12 HG11 ' A' ' 18' ' ' VAL . 2.7 tpp85 -129.71 120.01 24.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 61.41 110.941 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 5.6 t80 -103.77 136.05 44.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.217 -0.447 . . . . 73.13 110.95 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -121.43 105.41 10.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.1 -0.5 . . . . 75.24 110.786 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 7.8 mt -94.74 162.88 13.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 55.34 110.926 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -97.94 36.55 3.9 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.783 -0.723 . . . . 63.54 112.534 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 95.8 m-20 -123.91 35.99 4.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.832 0.349 . . . . 62.44 110.888 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 18.0 p 50.95 38.81 21.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 72.22 110.892 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 8.4 t-105 -165.05 107.13 0.82 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.158 -0.473 . . . . 61.24 110.909 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.645 ' SD ' HG13 ' A' ' 203' ' ' VAL . 0.0 OUTLIER -99.1 170.54 8.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.205 -0.452 . . . . 53.12 110.885 179.89 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.573 HD22 ' O ' ' A' ' 162' ' ' MET . 4.5 mm? -129.13 145.21 51.35 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.21 -0.45 . . . . 64.24 110.849 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -144.27 133.42 22.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.131 -0.486 . . . . 51.4 110.865 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 50.7 p -145.89 120.7 9.91 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.188 -0.46 . . . . 64.23 110.891 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 166' ' ' ASP . . . . . 0.425 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.6 OUTLIER -153.3 175.85 12.63 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.089 -0.505 . . . . 75.34 110.897 180.0 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.521 HG22 HD13 ' A' ' 196' ' ' LEU . 21.7 t -138.12 133.34 43.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.457 . . . . 54.41 111.105 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 168' ' ' ARG . . . . . 0.563 HH21 HG21 ' A' ' 170' ' ' ILE . 2.1 ttt180 -109.16 125.01 51.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.095 -0.502 . . . . 65.24 110.865 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 13.7 p90 -128.99 146.79 50.88 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.172 -0.467 . . . . 72.44 110.929 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 170' ' ' ILE . . . . . 0.587 HD11 ' HB3' ' A' ' 146' ' ' ALA . 5.5 tt -176.8 97.77 0.24 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.557 0.694 . . . . 70.12 111.155 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 171' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 170' ' ' ILE . 53.5 Cg_endo -69.82 128.74 16.4 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.691 2.261 . . . . 74.31 112.3 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 11.6 p90 -155.08 178.96 9.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.245 -0.434 . . . . 72.02 110.863 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 13.3 pttp -130.32 140.98 50.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 64.21 110.871 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' THR . . . . . 0.416 HG22 HG23 ' A' ' 189' ' ' ILE . 9.0 t -104.27 167.81 9.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 75.43 111.189 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 175' ' ' ASP . . . . . 0.439 ' HB3' ' HB2' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -119.38 159.72 23.66 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.27 -0.423 . . . . 64.32 110.849 179.908 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.791 HG23 HG13 ' A' ' 141' ' ' ILE . 13.7 p -144.76 135.74 20.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.122 -0.49 . . . . 62.11 111.088 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.8 t -166.36 159.44 14.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 74.03 111.156 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -146.13 -134.15 2.6 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.773 -0.727 . . . . 55.12 112.491 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 98.7 m -159.9 93.77 1.09 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.835 0.35 . . . . 52.04 111.169 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.525 ' H ' HD23 ' A' ' 180' ' ' LEU . 1.6 pt? -142.84 117.14 9.58 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.182 -0.463 . . . . 52.32 110.961 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 55.01 172.16 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.671 -0.776 . . . . 75.14 112.493 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.54 ' O ' ' HB ' ' A' ' 183' ' ' VAL . 54.6 Cg_endo -69.69 71.16 1.5 Allowed 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.699 2.266 . . . . 74.42 112.371 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.54 ' HB ' ' O ' ' A' ' 182' ' ' PRO . 2.5 p 158.13 84.19 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.635 0.731 . . . . 73.13 111.063 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.65 147.84 64.45 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.649 2.233 . . . . 53.35 112.392 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 23.8 t -95.45 106.37 18.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 75.21 111.161 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 83.2 p -110.16 120.22 41.74 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.177 -0.465 . . . . 63.44 110.894 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -140.54 176.37 8.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.125 -0.489 . . . . 72.1 111.082 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.39 162.48 40.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 74.12 110.918 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 189' ' ' ILE . . . . . 0.566 HD12 ' HA ' ' A' ' 32' ' ' LEU . 4.6 tt -146.04 120.91 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.256 -0.429 . . . . 74.02 111.121 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -96.67 118.16 32.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.157 -0.474 . . . . 65.43 110.871 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 191' ' ' VAL . . . . . 0.465 HG13 ' HB2' ' A' ' 30' ' ' GLU . 4.4 t -137.52 159.68 34.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 74.01 111.167 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.423 ' N ' HG12 ' A' ' 191' ' ' VAL . 0.4 OUTLIER -107.27 90.42 5.68 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.558 0.694 . . . . 74.41 110.869 179.918 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 138.09 37.05 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.61 2.207 . . . . 61.51 112.368 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 23.4 m-85 -121.96 109.67 14.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.179 -0.464 . . . . 50.22 110.925 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 195' ' ' ILE . . . . . 0.572 HG12 HG23 ' A' ' 26' ' ' VAL . 8.8 mt -105.25 135.03 45.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 53.55 111.171 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 196' ' ' LEU . . . . . 0.521 HD13 HG22 ' A' ' 167' ' ' VAL . 10.3 tp -120.57 115.43 23.4 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.093 -0.503 . . . . 54.43 110.957 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -99.26 129.25 45.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 61.44 110.907 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 32.8 tp -150.25 129.35 12.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.149 -0.478 . . . . 71.21 110.91 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 177.38 -146.67 7.83 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.801 -0.714 . . . . 62.32 112.536 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 200' ' ' ALA . . . . . 0.401 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -124.0 173.23 8.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.757 0.313 . . . . 65.12 111.101 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -138.35 164.78 28.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.452 . . . . 73.03 110.899 -179.798 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 34.1 m-85 -133.82 129.95 37.23 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.205 -0.452 . . . . 74.24 110.93 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.645 HG13 ' SD ' ' A' ' 162' ' ' MET . 28.0 m -77.36 148.28 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 73.44 111.207 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -152.34 105.96 3.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.278 -0.419 . . . . 75.15 110.886 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 14.2 ptmt -102.69 -179.68 4.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.15 -0.477 . . . . 64.55 110.939 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 206' ' ' LEU . . . . . 0.472 HD12 ' O ' ' A' ' 206' ' ' LEU . 0.8 OUTLIER -110.68 159.82 17.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.285 -0.416 . . . . 73.51 110.877 179.993 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -62.62 -68.34 0.34 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.46 . . . . 62.43 111.109 179.79 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -146.21 140.66 26.74 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.201 -0.454 . . . . 44.42 111.098 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -149.38 150.25 32.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.264 -0.425 . . . . 60.11 111.048 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 210' ' ' LEU . . . . . 0.527 ' H ' HD23 ' A' ' 210' ' ' LEU . 1.2 pt? -112.17 147.74 35.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 61.03 110.934 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.204 -0.453 . . . . 63.11 110.855 179.933 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.4 ptt? . . . . . 0 C--O 1.229 0.016 0 CA-C-O 120.81 0.338 . . . . 63.24 110.895 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 9.2 p-10 -166.57 160.18 14.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 74.43 110.897 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 24.6 mp0 -150.25 153.77 36.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 44.35 110.863 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -115.62 104.56 11.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.143 -0.48 . . . . 74.11 110.899 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -116.69 160.5 36.26 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-O 121.716 0.769 . . . . 75.15 110.874 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 175.67 7.79 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.665 2.244 . . . . 75.4 112.37 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -87.25 111.18 20.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.454 . . . . 60.51 111.059 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 16.9 tptt -94.08 -36.57 12.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.25 -0.432 . . . . 75.01 110.89 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.63 ' CB ' HG11 ' A' ' 203' ' ' VAL . 8.4 t 62.84 36.86 12.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.255 -0.429 . . . . 72.31 110.851 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -75.06 -35.25 61.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.148 -0.478 . . . . 71.55 111.109 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -167.38 -145.82 4.65 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.775 -0.726 . . . . 54.34 112.487 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 16.4 p90 -161.67 121.0 2.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.92 0.391 . . . . 75.11 110.93 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -132.02 175.0 9.6 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.096 -0.502 . . . . 71.4 110.921 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.34 134.88 53.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 75.42 110.953 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.73 6.48 76.5 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.758 -0.734 . . . . 52.43 112.487 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -76.89 144.9 38.63 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.837 0.351 . . . . 73.42 110.838 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 13.5 t90 -106.44 150.93 25.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 71.2 110.919 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.581 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 22.1 t -145.59 125.82 6.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.242 -0.435 . . . . 74.2 111.131 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -109.76 112.4 24.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 55.43 111.075 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 201' ' ' SER . 60.2 p -124.42 146.57 48.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 73.22 110.837 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 15.1 p90 -127.19 122.52 34.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.111 -0.495 . . . . 72.11 110.827 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -146.89 158.28 43.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 75.41 110.869 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.803 ' HB3' HD23 ' A' ' 55' ' ' LEU . 29.4 p90 -93.69 133.57 36.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.143 -0.481 . . . . 72.23 110.886 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -98.89 114.57 27.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.47 . . . . 61.52 110.843 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.1 tppt? -92.68 108.24 19.83 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.041 -0.527 . . . . 70.22 110.874 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.455 HG23 ' CD1' ' A' ' 195' ' ' ILE . 14.2 p -87.01 140.69 15.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.236 -0.438 . . . . 72.41 111.057 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 41.3 m-85 -134.36 112.85 11.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.111 -0.495 . . . . 73.2 110.959 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 m -72.65 -176.9 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.092 -0.504 . . . . 74.43 111.182 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -93.84 -125.16 4.06 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.748 -0.739 . . . . 54.43 112.465 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -92.37 -66.39 0.93 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.771 0.32 . . . . 62.43 110.861 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.5 mp0 -150.23 -174.21 4.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.155 -0.475 . . . . 63.32 110.877 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.562 ' HA ' HG23 ' A' ' 189' ' ' ILE . 3.4 pp -86.32 -173.33 4.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 63.5 110.909 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -79.35 65.06 3.69 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.722 -0.751 . . . . 61.1 112.491 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -90.58 51.7 2.05 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.872 0.368 . . . . 63.23 110.866 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.487 ' O ' HD12 ' A' ' 35' ' ' LEU . 1.1 pp -137.94 47.81 2.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 63.44 110.98 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 38.8 t30 -85.86 129.49 34.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 55.31 110.919 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.3 p -61.34 131.52 26.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.178 -0.465 . . . . 72.42 111.13 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.85 -141.29 9.57 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.717 -0.754 . . . . 73.44 112.44 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -111.0 75.92 0.22 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.69 -0.767 . . . . 51.34 112.49 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -81.03 -150.9 7.55 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.803 -0.713 . . . . 71.15 112.477 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -118.64 168.29 10.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.884 0.373 . . . . 73.53 110.991 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.492 ' N ' ' HD2' ' A' ' 43' ' ' PRO . 0.7 OUTLIER -59.89 -60.54 10.28 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.624 0.726 . . . . 61.23 110.908 -179.967 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.492 ' HD2' ' N ' ' A' ' 42' ' ' LEU . 54.0 Cg_endo -69.71 170.25 16.94 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.737 2.291 . . . . 63.51 112.347 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -119.19 165.11 14.62 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.247 -0.433 . . . . 65.04 110.905 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.408 ' HB1' HD21 ' A' ' 32' ' ' LEU . . . -73.86 -175.78 2.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 65.13 111.139 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -166.33 125.75 1.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 75.43 110.897 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 98.7 t -105.65 131.51 54.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 73.22 111.069 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.5 m -159.4 151.36 20.7 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.138 -0.483 . . . . 75.55 110.803 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 20.0 pt -100.71 157.61 4.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.082 -0.508 . . . . 74.14 111.119 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -72.02 -146.78 0.59 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.737 -0.744 . . . . 72.54 112.508 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -126.1 111.16 14.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.881 0.372 . . . . 73.32 110.88 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -164.01 159.06 20.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.13 -0.487 . . . . 65.24 110.862 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 16.4 p -125.88 123.99 39.88 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 71.43 111.154 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.0 p -137.4 139.33 40.65 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.176 -0.465 . . . . 60.54 111.076 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.803 HD23 ' HB3' ' A' ' 23' ' ' PHE . 2.5 mt -99.11 153.95 18.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.454 . . . . 72.11 110.921 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.1 p -123.26 161.38 24.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.289 -0.414 . . . . 73.24 111.172 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -105.56 133.36 50.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 73.12 110.861 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -124.04 130.06 51.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 54.34 110.867 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.4 ' O ' HG22 ' A' ' 59' ' ' ILE . 1.6 mp -107.24 114.0 45.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.478 . . . . 72.43 111.101 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.581 ' HB3' ' HB ' ' A' ' 18' ' ' VAL . . . -104.13 137.88 41.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.454 . . . . 72.22 111.128 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.427 ' HB2' HG13 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -123.28 121.98 37.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.279 -0.418 . . . . 73.42 110.893 -179.835 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -89.01 102.26 14.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.111 -0.495 . . . . 65.44 110.892 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.1 m -100.84 -33.4 3.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.105 -0.498 . . . . 72.31 111.125 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.9 t -136.23 158.6 44.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.189 -0.46 . . . . 64.01 110.838 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 47.0 t -83.56 3.21 33.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.102 -0.499 . . . . 75.23 110.848 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 47.6 t30 -115.69 -30.6 6.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 63.32 110.885 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.593 HG22 ' HB2' ' A' ' 107' ' ' TYR . 43.5 pt -138.23 157.48 31.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.132 -0.486 . . . . 75.25 111.127 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -145.33 157.65 44.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.154 -0.475 . . . . 71.13 111.046 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.497 ' CG2' HD21 ' A' ' 103' ' ' LEU . 1.4 p -106.96 145.93 13.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.15 -0.477 . . . . 64.2 111.145 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -140.54 128.01 21.36 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.209 -0.45 . . . . 73.45 110.897 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -108.65 110.43 21.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.259 -0.428 . . . . 74.32 110.919 -179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -87.95 115.42 25.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 74.24 110.907 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 8.9 m -139.59 156.76 26.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 72.24 111.109 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -164.55 142.37 7.72 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.75 -0.738 . . . . 73.04 112.501 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.4 t -118.64 66.21 6.91 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.551 0.691 . . . . 55.2 111.145 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 161.89 44.16 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.758 2.305 . . . . 61.02 112.349 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -78.73 -173.21 3.34 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 31.4 111.092 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 18.1 ttp180 -78.27 132.73 37.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 63.1 110.924 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -131.54 150.8 52.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 60.44 111.074 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 7.3 tttt -109.37 134.08 52.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.3 -0.409 . . . . 65.22 110.911 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -134.51 158.66 43.37 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.247 -0.433 . . . . 63.31 110.902 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -91.32 156.18 17.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.112 -0.495 . . . . 75.32 110.857 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.577 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -176.12 65.14 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.803 -0.713 . . . . 75.23 112.513 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -174.29 -174.79 0.91 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.93 0.395 . . . . 63.33 110.882 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -85.5 -70.04 0.62 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.147 -0.478 . . . . 61.12 110.855 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 32.1 t -84.83 -32.18 23.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.26 -0.427 . . . . 63.44 110.808 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.946 HG21 ' HB2' ' A' ' 135' ' ' ALA . 5.4 mm -66.58 -34.04 67.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.157 -0.474 . . . . 71.44 111.181 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 t -63.11 -41.21 99.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.164 -0.471 . . . . 43.03 110.812 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 61.7 m -60.68 -36.98 80.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 74.03 110.862 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.4 mp -64.14 -50.25 68.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.12 -0.491 . . . . 70.15 110.934 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 116.35 -14.25 15.71 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.754 -0.736 . . . . 63.42 112.482 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 58.4 mtm180 -115.06 89.87 3.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.889 0.376 . . . . 73.44 110.809 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.873 HG22 HG22 ' A' ' 87' ' ' ILE . 98.5 t -113.67 -53.25 5.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 70.14 111.137 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 13.3 m -139.28 143.47 37.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 63.42 110.887 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' GLU . . . . . 0.577 ' O ' HG13 ' A' ' 96' ' ' VAL . 1.7 tt0 -145.19 114.3 6.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.465 . . . . 62.42 110.928 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.577 HG13 ' O ' ' A' ' 95' ' ' GLU . 11.8 m -160.45 -178.17 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 50.22 111.116 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -98.65 149.13 23.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 54.03 110.831 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -93.16 125.66 37.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 75.44 110.957 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -119.42 63.16 0.46 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.749 -0.739 . . . . 62.35 112.501 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.67 122.53 9.24 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.687 2.258 . . . . 64.42 112.392 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.601 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -139.22 97.87 3.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.185 -0.461 . . . . 74.31 111.101 179.838 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 5.3 mp -129.18 117.56 43.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 72.41 111.157 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.662 HD13 ' O ' ' A' ' 103' ' ' LEU . 0.9 OUTLIER -113.71 112.98 24.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.228 -0.442 . . . . 60.32 110.948 179.905 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.583 ' N ' HD22 ' A' ' 103' ' ' LEU . 3.5 p -140.51 165.11 28.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.446 . . . . 73.22 110.822 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.428 ' H ' HD23 ' A' ' 105' ' ' LEU . 1.0 OUTLIER -112.76 142.23 45.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.069 -0.514 . . . . 74.11 110.933 179.963 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 16.0 pt20 -101.4 151.5 21.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.166 -0.47 . . . . 75.32 110.92 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.593 ' HB2' HG22 ' A' ' 67' ' ' ILE . 5.1 t80 -149.69 135.8 18.88 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.249 -0.432 . . . . 75.53 110.962 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 10.6 t60 -65.69 105.15 1.18 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 71.54 110.817 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.42 ' HB2' HG12 ' A' ' 119' ' ' VAL . 43.8 t80 -110.17 115.7 30.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.173 -0.467 . . . . 71.22 110.874 -179.823 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -163.98 165.9 22.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.082 -0.508 . . . . 54.52 110.851 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 20.9 m -82.87 -46.32 13.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 65.11 110.853 -179.749 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 3.1 p90 -138.36 156.96 47.12 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 73.31 110.883 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -52.32 108.61 0.31 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 54.11 110.859 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 4.4 tpt180 -160.18 160.67 33.1 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.096 -0.502 . . . . 62.12 110.89 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -70.08 98.85 1.37 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 74.23 110.917 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.0 m-85 -148.41 159.06 39.9 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-O 121.737 0.78 . . . . 74.11 110.903 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.69 176.86 6.15 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.678 2.252 . . . . 70.25 112.353 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -116.47 150.54 37.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.202 -0.454 . . . . 74.11 110.978 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.42 HG12 ' HB2' ' A' ' 109' ' ' TYR . 13.1 p -104.01 133.94 46.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 73.15 111.093 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -132.09 160.2 23.55 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.749 -0.739 . . . . 51.21 112.504 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 7.5 p -156.57 154.73 5.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.874 0.369 . . . . 63.31 111.157 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 178.76 -147.11 7.65 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.777 -0.725 . . . . 65.0 112.489 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 13.8 p -106.57 131.56 56.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.881 0.372 . . . . 72.12 111.093 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -124.29 111.62 1.64 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.749 -0.738 . . . . 43.44 112.508 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' ARG . . . . . 0.601 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 29.0 ptt180 -114.51 130.13 56.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.774 0.321 . . . . 72.15 110.895 -179.844 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.461 ' O ' ' HB3' ' A' ' 143' ' ' ASP . 3.1 m -111.37 112.66 41.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.237 -0.438 . . . . 71.04 111.091 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 1.3 tp -114.86 171.59 7.56 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.202 -0.454 . . . . 71.4 110.925 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -140.03 178.88 6.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.174 -0.466 . . . . 65.33 110.841 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -117.72 119.4 34.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.144 -0.48 . . . . 73.4 110.906 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -51.89 102.34 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.14 -0.482 . . . . 73.51 110.846 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.86 -80.84 0.55 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 72.01 110.889 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 45.8 m -164.54 89.78 0.53 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 74.32 111.168 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -107.59 172.61 6.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.231 -0.44 . . . . 75.11 110.886 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.53 152.89 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.706 -0.759 . . . . 74.04 112.501 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.946 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -79.42 -1.97 39.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.809 0.338 . . . . 64.41 111.04 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -87.2 -177.52 6.01 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.245 -0.434 . . . . 62.34 110.929 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.7 m -66.57 98.12 0.48 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 72.25 110.88 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 89.4 p 46.79 75.17 0.13 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.125 -0.489 . . . . 65.22 110.794 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.64 ' CE2' HG12 ' A' ' 176' ' ' VAL . 1.5 t80 -89.02 148.26 23.84 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.086 -0.506 . . . . 72.1 110.867 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.18 159.76 15.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.139 -0.482 . . . . 70.54 110.818 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -126.9 118.26 50.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 73.33 111.155 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 142' ' ' LYS . . . . . 0.43 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 1.6 mtpp -69.13 110.84 4.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 72.53 110.843 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.461 ' HB3' ' O ' ' A' ' 126' ' ' VAL . 61.2 m-20 -57.66 -173.44 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 73.4 110.888 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.39 162.53 39.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 64.52 110.906 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 31.1 p-90 -156.47 137.96 14.01 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.217 -0.447 . . . . 63.31 110.896 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.803 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -178.44 167.51 1.01 Allowed Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.603 0.716 . . . . 73.11 111.083 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.803 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.5 Cg_endo -69.79 138.62 38.15 Favored 'Trans proline' 0 N--CA 1.465 -0.171 0 C-N-CA 122.712 2.275 . . . . 70.22 112.31 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.572 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -132.85 165.16 25.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.181 -0.463 . . . . 74.43 111.117 179.856 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -123.27 126.18 46.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.192 -0.458 . . . . 73.23 110.895 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -110.12 155.3 22.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 72.02 110.889 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.575 HG13 HG23 ' A' ' 167' ' ' VAL . 4.6 p -144.58 125.73 8.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 71.51 111.138 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 152' ' ' GLY . . . . . 0.436 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . -176.36 -167.68 35.43 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.728 -0.749 . . . . 75.0 112.474 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 2.1 pp -143.87 161.03 39.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.765 0.317 . . . . 75.31 110.923 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 7.6 tpp85 -117.21 119.49 35.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 64.41 110.852 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -100.13 139.42 35.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.146 -0.479 . . . . 71.41 110.885 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -111.85 92.4 4.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 74.23 110.876 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 3.0 tt -86.27 97.02 10.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 63.52 110.953 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 58.77 -138.35 49.49 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.704 -0.76 . . . . 74.54 112.536 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -119.74 -30.35 4.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.878 0.37 . . . . 71.41 110.886 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -48.86 -66.72 0.35 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 73.33 110.878 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 23.7 p90 -145.73 150.92 37.15 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.151 -0.477 . . . . 71.41 110.904 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 2.4 mpt? -108.63 177.57 4.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 44.55 110.858 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 3.8 tp -126.12 149.15 49.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.232 -0.44 . . . . 75.33 110.916 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 13.8 t-20 -143.9 131.51 21.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 72.54 110.858 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.5 p -141.48 124.41 16.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.179 -0.464 . . . . 52.34 110.871 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 166' ' ' ASP . . . . . 0.436 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 2.3 p30 -156.11 169.69 23.92 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.138 -0.483 . . . . 74.2 110.878 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.575 HG23 HG13 ' A' ' 151' ' ' VAL . 0.1 OUTLIER -142.4 134.04 25.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.182 -0.463 . . . . 75.04 111.119 179.972 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.61 142.56 33.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 72.3 110.886 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 4.3 t80 -142.0 137.65 31.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 73.34 110.889 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 170' ' ' ILE . . . . . 0.572 HG21 ' HB2' ' A' ' 148' ' ' ALA . 2.9 tp -177.47 102.25 0.22 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.628 0.728 . . . . 75.54 111.08 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 171' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 192' ' ' ASP . 53.9 Cg_endo -69.75 125.27 11.95 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.696 2.264 . . . . 42.55 112.364 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 24.7 p90 -150.93 178.04 9.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 74.22 110.9 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 173' ' ' LYS . . . . . 0.433 ' HA ' ' HA ' ' A' ' 190' ' ' GLU . 9.7 ptpt -130.85 126.52 36.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 74.2 110.879 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.6 t -93.59 175.26 6.81 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.236 -0.438 . . . . 73.41 111.143 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 175' ' ' ASP . . . . . 0.43 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.3 OUTLIER -126.81 163.71 22.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.254 -0.43 . . . . 74.21 110.844 179.906 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.64 HG12 ' CE2' ' A' ' 139' ' ' PHE . 32.7 t -148.84 133.28 9.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.223 -0.444 . . . . 74.01 111.143 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.4 t -165.58 177.69 7.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.216 -0.447 . . . . 75.24 111.173 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 121.68 141.52 6.12 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.72 -0.753 . . . . 42.44 112.485 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.4 m -172.55 141.28 1.12 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.737 0.303 . . . . 73.51 111.195 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 29.9 tp -104.87 89.18 3.08 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.287 -0.415 . . . . 72.25 110.988 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 125.2 -85.73 0.36 Allowed Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.746 -0.74 . . . . 43.11 112.458 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 -170.56 0.4 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.681 2.254 . . . . 71.2 112.36 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 26.6 m -84.47 126.4 69.22 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.576 0.703 . . . . 62.32 111.193 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 165.59 30.41 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.688 2.259 . . . . 65.5 112.35 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 39.6 t -113.38 107.68 23.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.276 -0.42 . . . . 74.14 111.145 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -81.33 106.72 13.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.161 -0.472 . . . . 72.34 110.835 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 21.0 p -121.38 174.7 6.58 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.108 -0.496 . . . . 55.43 111.104 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 188' ' ' LYS . . . . . 0.486 ' C ' HD12 ' A' ' 189' ' ' ILE . 0.0 OUTLIER -148.55 164.03 35.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.194 -0.457 . . . . 73.52 110.872 179.925 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 189' ' ' ILE . . . . . 0.562 HG23 ' HA ' ' A' ' 32' ' ' LEU . 5.4 mp -144.03 105.8 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 74.24 111.129 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 190' ' ' GLU . . . . . 0.433 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 61.4 tt0 -91.0 102.08 14.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.449 . . . . 73.11 110.869 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 9.3 m -138.68 164.08 26.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.458 . . . . 61.01 111.156 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 171' ' ' PRO . 6.6 p-10 -110.04 88.65 7.18 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.582 0.706 . . . . 75.3 110.867 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 143.28 50.53 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.704 2.269 . . . . 64.34 112.338 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -119.8 123.69 44.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 62.51 110.882 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 195' ' ' ILE . . . . . 0.455 ' CD1' HG23 ' A' ' 26' ' ' VAL . 18.6 mm -109.03 132.06 58.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.147 -0.479 . . . . 62.31 111.171 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 4.6 tp -120.68 108.25 13.78 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.246 -0.433 . . . . 71.31 110.962 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.41 120.14 35.13 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.239 -0.437 . . . . 60.2 110.919 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -139.4 124.29 18.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.468 . . . . 73.42 110.988 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -176.9 -148.54 7.19 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.737 -0.745 . . . . 45.54 112.494 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -115.82 171.04 8.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.812 0.339 . . . . 40.14 111.108 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 201' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 20' ' ' SER . 0.3 OUTLIER -138.49 156.81 47.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.434 . . . . 65.12 110.806 -179.73 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 8.2 t80 -138.07 135.6 35.99 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.132 -0.485 . . . . 75.13 110.958 -179.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.63 HG11 ' CB ' ' A' ' 9' ' ' SER . 14.9 p -77.36 147.46 7.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.08 -0.509 . . . . 64.02 111.179 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -144.57 88.01 1.9 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.16 -0.473 . . . . 73.43 110.872 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 23.1 mtmt -70.46 166.84 19.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 70.41 110.902 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 14.5 tp -99.19 -41.21 7.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 60.04 110.872 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -141.95 138.05 31.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.209 -0.451 . . . . 72.25 111.065 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -104.11 -36.26 7.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.23 -0.441 . . . . 63.45 111.122 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -148.63 157.31 43.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.209 -0.45 . . . . 43.12 111.061 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 3.9 tt -151.69 115.46 4.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 75.14 110.922 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 116.127 -0.488 . . . . 65.14 110.898 179.926 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.037 0 CA-C-O 120.81 0.338 . . . . 61.12 110.862 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 20.7 p30 40.47 40.04 0.81 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 70.22 110.917 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -78.03 123.71 27.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 73.52 110.88 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 -134.85 166.35 23.18 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 71.21 110.846 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 8.9 p90 -134.41 157.56 77.14 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.695 0.76 . . . . 74.22 110.868 -179.849 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 142.62 48.33 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.58 2.186 . . . . 63.22 112.334 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -67.48 113.07 5.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 72.4 111.139 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 21.9 ttpp -77.5 135.03 38.19 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.216 -0.447 . . . . 74.14 110.881 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 4.9 t -138.15 145.73 41.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.262 -0.426 . . . . 61.31 110.891 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.612 ' HB1' ' OD1' ' A' ' 13' ' ' ASN . . . -65.23 -58.18 6.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.066 -0.515 . . . . 72.4 111.195 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.56 -70.68 2.35 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.759 -0.734 . . . . 74.1 112.504 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.2 p90 -156.13 115.62 3.56 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.882 0.372 . . . . 74.23 110.889 -179.799 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ASN . . . . . 0.612 ' OD1' ' HB1' ' A' ' 10' ' ' ALA . 17.2 m120 -128.26 158.13 39.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.459 . . . . 71.53 110.904 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -56.22 121.68 10.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.181 -0.463 . . . . 75.33 110.923 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.37 6.22 41.95 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.706 -0.759 . . . . 65.52 112.491 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -61.81 146.12 50.51 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.817 0.341 . . . . 64.43 110.829 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 19.8 t90 -111.47 121.19 44.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.09 -0.504 . . . . 71.3 110.947 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.817 HG22 HG23 ' A' ' 203' ' ' VAL . 57.2 t -123.4 120.17 59.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.242 -0.435 . . . . 64.4 111.121 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.623 ' HB3' ' CD1' ' A' ' 202' ' ' TYR . . . -86.8 112.35 21.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 43.41 111.127 179.849 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.1 t -109.03 110.0 21.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.236 -0.438 . . . . 61.35 110.874 -179.792 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.404 ' CZ ' HD12 ' A' ' 55' ' ' LEU . 43.5 t80 -107.64 120.01 41.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.477 . . . . 70.41 110.919 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.445 ' HA ' ' HA3' ' A' ' 199' ' ' GLY . 7.4 p30 -149.86 174.87 12.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.442 . . . . 72.55 110.91 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.648 ' HB3' HD13 ' A' ' 55' ' ' LEU . 19.1 p90 -110.83 132.9 53.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 54.13 110.861 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' SER . . . . . 0.445 ' HB3' HG21 ' A' ' 56' ' ' THR . 41.9 p -98.18 146.18 25.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 63.21 110.894 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.4 tmtp? -127.25 106.52 9.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 61.43 110.904 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.8 m -77.31 129.7 37.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.245 -0.434 . . . . 64.31 111.128 179.842 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -126.4 107.78 10.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.126 -0.488 . . . . 74.14 110.956 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.8 p -175.71 153.79 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.485 . . . . 73.32 111.079 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.43 71.68 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.778 -0.725 . . . . 70.34 112.54 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -89.14 -65.87 0.98 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.807 0.337 . . . . 72.31 110.895 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -174.99 152.44 1.49 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.106 -0.497 . . . . 71.34 110.855 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.618 HD23 ' N ' ' A' ' 33' ' ' GLY . 0.8 OUTLIER -96.11 162.32 13.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.163 -0.471 . . . . 73.22 110.909 -179.99 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.618 ' N ' HD23 ' A' ' 32' ' ' LEU . . . -53.67 101.9 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.761 -0.733 . . . . 72.34 112.434 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -64.77 -69.84 0.26 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.909 0.385 . . . . 70.55 110.894 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 4.5 tp -81.03 147.56 30.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.138 -0.483 . . . . 70.1 110.982 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 -128.87 149.54 50.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.182 -0.463 . . . . 65.33 110.864 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 30.6 m -51.53 -35.37 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.206 -0.452 . . . . 61.53 111.094 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -136.87 131.56 5.66 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.768 -0.73 . . . . 52.23 112.518 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 126.64 153.86 8.44 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.753 -0.737 . . . . 61.45 112.475 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -87.13 110.9 3.6 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.681 -0.771 . . . . 64.23 112.469 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -118.84 -179.26 3.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.784 0.326 . . . . 70.41 111.089 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.542 ' N ' ' HD2' ' A' ' 43' ' ' PRO . 0.2 OUTLIER 177.47 -57.6 0.0 OUTLIER Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.571 0.701 . . . . 72.34 110.923 179.999 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.542 ' HD2' ' N ' ' A' ' 42' ' ' LEU . 54.1 Cg_endo -69.78 152.21 69.17 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.668 2.245 . . . . 70.14 112.35 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 6.5 m120 -86.5 139.85 30.49 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.2 -0.454 . . . . 74.13 110.938 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.9 169.33 11.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 61.04 111.084 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 35.8 m-20 -153.64 127.24 8.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.238 -0.437 . . . . 71.03 110.828 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 10.8 p -104.52 137.52 33.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 70.02 111.171 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.0 t -148.45 154.87 40.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.094 -0.503 . . . . 74.1 110.835 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.471 HD13 ' H ' ' A' ' 49' ' ' ILE . 0.2 OUTLIER -119.62 154.67 22.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.087 -0.506 . . . . 70.43 111.1 179.939 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.39 -124.59 0.56 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.751 -0.738 . . . . 75.21 112.444 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 38.9 m-20 -82.41 -35.61 27.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.87 0.367 . . . . 74.32 110.911 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 41.9 40.03 1.44 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 71.41 110.85 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 1.4 p -108.37 113.09 25.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 65.03 111.158 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.5 t -154.35 173.95 15.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.136 -0.484 . . . . 61.24 111.139 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.648 HD13 ' HB3' ' A' ' 23' ' ' PHE . 4.2 mm? -92.55 169.11 10.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.248 -0.433 . . . . 60.22 110.924 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.445 HG21 ' HB3' ' A' ' 24' ' ' SER . 18.6 p -149.36 141.54 24.02 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.172 -0.467 . . . . 75.12 111.113 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -103.27 132.82 49.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 73.12 110.861 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -130.63 130.12 43.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.159 -0.473 . . . . 43.53 110.84 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.41 ' O ' HG22 ' A' ' 59' ' ' ILE . 1.6 mp -108.08 112.94 42.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.196 -0.456 . . . . 74.31 111.077 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -102.76 121.69 42.97 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.206 -0.452 . . . . 75.53 111.076 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -106.85 122.72 46.97 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 73.12 110.93 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -88.89 107.22 18.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.17 -0.468 . . . . 65.14 110.908 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 63.8 t -103.24 -48.13 10.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.157 -0.474 . . . . 70.41 111.097 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 40.2 t -124.38 165.99 16.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 54.22 110.854 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.1 m -87.43 2.71 49.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.087 -0.506 . . . . 73.31 110.837 -179.766 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -112.99 -33.68 5.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.084 -0.507 . . . . 74.32 110.936 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.405 HG22 ' CD1' ' A' ' 107' ' ' TYR . 31.4 pt -146.12 160.22 11.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.48 . . . . 62.4 111.081 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -146.57 173.4 12.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 70.34 111.112 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.483 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 14.4 m -115.16 152.13 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.255 -0.429 . . . . 64.32 111.163 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -144.13 144.43 31.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.251 -0.431 . . . . 53.43 110.834 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.445 ' CZ ' HD22 ' A' ' 103' ' ' LEU . 0.5 OUTLIER -120.74 110.14 16.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.157 -0.474 . . . . 73.11 110.914 -179.949 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.405 ' HB3' HG23 ' A' ' 102' ' ' ILE . 2.5 t80 -92.6 117.84 30.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 53.12 110.896 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.4 p -150.26 154.61 8.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.161 -0.472 . . . . 65.05 111.117 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -155.56 150.95 22.52 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.691 -0.766 . . . . 73.43 112.452 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 5.8 m -118.2 67.05 6.45 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.587 0.708 . . . . 63.14 111.11 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.69 159.48 53.28 Favored 'Trans proline' 0 N--CA 1.465 -0.16 0 C-N-CA 122.767 2.312 . . . . 65.43 112.35 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -83.39 -167.96 1.91 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.211 -0.45 . . . . 51.45 111.108 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -77.74 127.52 32.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 71.52 110.852 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -123.87 150.62 44.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.245 -0.434 . . . . 74.2 111.166 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 5.4 ttpm? -104.19 144.85 31.04 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.213 -0.449 . . . . 74.14 110.887 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -142.0 155.0 45.43 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.269 -0.423 . . . . 72.3 110.923 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.427 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 0.2 OUTLIER -107.18 151.57 25.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.12 -0.491 . . . . 73.51 110.943 -179.942 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.637 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -175.86 75.86 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.707 -0.759 . . . . 62.43 112.41 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -178.52 -176.33 0.48 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.94 0.4 . . . . 64.23 110.881 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -85.41 -69.71 0.64 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.192 -0.458 . . . . 74.13 110.88 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 75.3 m -84.58 -34.09 23.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.435 . . . . 41.4 110.886 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.943 HG21 ' HB2' ' A' ' 135' ' ' ALA . 5.2 mm -64.06 -34.75 70.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 72.2 111.146 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 78.8 p -62.61 -49.09 76.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.471 . . . . 64.03 110.818 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 41.6 t -51.72 -36.89 48.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.102 -0.499 . . . . 61.14 110.786 -179.725 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -68.55 -46.39 69.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 61.24 110.881 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.67 -12.76 38.9 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.751 -0.738 . . . . 44.4 112.529 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 21.1 mmt85 -108.87 88.69 2.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.827 0.346 . . . . 74.12 110.875 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.85 HG22 HG22 ' A' ' 87' ' ' ILE . 99.0 t -113.91 -52.87 5.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 43.22 111.044 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.401 ' HA ' ' HA ' ' A' ' 133' ' ' ASP . 8.5 p -139.85 144.5 37.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 73.32 110.924 -179.828 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -149.7 119.53 7.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 72.12 110.896 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.722 HG23 ' HB2' ' A' ' 131' ' ' LYS . 3.8 p -177.65 163.84 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.163 -0.471 . . . . 72.4 111.154 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -76.29 163.66 26.81 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.218 -0.447 . . . . 73.11 110.881 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 2.6 m-85 -114.21 139.55 49.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.184 -0.462 . . . . 73.53 110.881 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -117.92 65.94 0.36 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.754 -0.736 . . . . 44.24 112.428 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 115.34 4.05 Favored 'Trans proline' 0 C--N 1.341 0.134 0 C-N-CA 122.682 2.255 . . . . 73.43 112.313 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -139.08 119.88 14.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 73.24 111.103 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.406 ' HA ' ' HA2' ' A' ' 124' ' ' GLY . 0.0 OUTLIER -155.2 136.2 5.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 62.45 111.104 179.913 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.445 HD22 ' CZ ' ' A' ' 71' ' ' PHE . 0.3 OUTLIER -119.69 124.2 45.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.103 -0.499 . . . . 72.03 110.924 179.942 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.425 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 72.3 m -143.69 159.38 42.58 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.177 -0.465 . . . . 53.23 110.874 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.535 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.6 OUTLIER -106.85 152.05 24.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.118 -0.492 . . . . 64.33 110.851 -179.912 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 75.7 mt-30 -101.69 140.36 36.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 74.52 110.857 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.405 ' CD1' HG22 ' A' ' 67' ' ' ILE . 0.3 OUTLIER -122.65 110.73 15.89 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.12 -0.491 . . . . 74.34 110.953 -179.814 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 -101.36 161.3 13.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.153 -0.476 . . . . 71.43 110.835 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 2.2 t80 -113.78 177.35 4.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.228 -0.442 . . . . 74.55 110.922 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -107.36 126.98 53.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.136 -0.484 . . . . 64.12 110.858 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 179.78 149.8 0.33 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 54.52 110.841 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -95.68 -74.8 0.54 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.479 . . . . 74.24 110.887 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -71.35 143.5 50.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.159 -0.473 . . . . 74.44 110.91 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 23.7 ttt180 53.11 62.02 2.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.159 -0.473 . . . . 65.32 110.856 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 29.2 tp -63.94 94.34 0.1 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 72.12 110.904 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -60.45 160.57 17.58 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.642 0.734 . . . . 71.43 110.981 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 176.96 6.06 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.684 2.256 . . . . 74.03 112.309 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 15.7 p90 -111.08 154.12 24.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.474 . . . . 72.22 110.91 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.3 p -113.75 131.43 65.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 75.14 111.153 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -124.14 168.0 16.36 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.626 -0.797 . . . . 72.31 112.475 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 8.4 p -171.99 153.4 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.886 0.374 . . . . 71.11 111.131 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.425 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -178.26 -152.16 10.04 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.732 -0.747 . . . . 60.21 112.459 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.44 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 12.1 p -107.72 134.57 49.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.786 0.326 . . . . 72.42 111.182 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' GLY . . . . . 0.406 ' HA2' ' HA ' ' A' ' 102' ' ' ILE . . . -121.87 172.52 15.52 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.709 -0.758 . . . . 72.42 112.553 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 12.3 ptm180 -169.69 130.07 1.02 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.816 0.341 . . . . 65.51 110.904 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 4.0 p -110.18 120.46 61.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.456 . . . . 75.41 111.131 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 5.7 mp -109.42 149.77 29.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 74.13 110.949 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.553 ' HE2' HG21 ' A' ' 174' ' ' THR . 20.9 m-85 -131.97 152.6 51.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 74.24 110.872 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.683 ' O ' HG21 ' A' ' 96' ' ' VAL . 1.0 OUTLIER -102.61 175.09 5.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.087 -0.506 . . . . 64.14 110.851 -179.882 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.6 p-10 -110.66 95.51 5.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.166 -0.47 . . . . 72.32 110.888 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.722 ' HB2' HG23 ' A' ' 96' ' ' VAL . 9.5 tmtt? -119.35 -68.17 0.93 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 63.31 110.941 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 2.7 m -161.68 63.75 0.25 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.246 -0.434 . . . . 73.42 111.189 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' ASP . . . . . 0.401 ' HA ' ' HA ' ' A' ' 94' ' ' SER . 4.4 m-20 -93.04 163.76 13.53 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.235 -0.439 . . . . 72.4 110.882 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 64.25 150.92 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.699 -0.763 . . . . 73.23 112.448 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.943 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -79.66 2.26 23.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.861 0.362 . . . . 75.05 111.115 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.606 HD12 HD22 ' A' ' 180' ' ' LEU . 1.4 mm? -86.09 -176.64 6.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.441 . . . . 73.03 110.916 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.699 ' OG ' HD13 ' A' ' 180' ' ' LEU . 89.0 p -64.93 88.91 0.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 54.51 110.867 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 7.6 m 49.88 76.17 0.15 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.147 -0.479 . . . . 70.41 110.853 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -93.66 159.27 15.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.1 -0.5 . . . . 71.22 110.913 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -117.64 170.6 8.64 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.193 -0.458 . . . . 71.54 110.879 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.953 HD13 HG13 ' A' ' 176' ' ' VAL . 30.3 mm -116.09 141.61 32.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 64.3 111.113 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' LYS . . . . . 0.407 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 0.2 OUTLIER -90.7 106.2 18.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.163 -0.471 . . . . 54.5 110.918 179.854 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -57.23 -176.68 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.225 -0.443 . . . . 73.02 110.868 179.854 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 24.0 tptt -163.73 161.12 23.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.141 -0.481 . . . . 71.52 110.858 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 5.8 p90 -132.77 146.69 52.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 73.04 110.911 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.663 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.39 162.77 0.96 Allowed Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.527 0.679 . . . . 64.33 111.167 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.663 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.6 Cg_endo -69.72 166.43 27.57 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.651 2.234 . . . . 52.42 112.354 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.419 ' HA ' ' HB ' ' A' ' 170' ' ' ILE . . . -153.19 151.47 30.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.261 -0.427 . . . . 71.4 111.11 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 32.0 m-85 -111.81 125.05 53.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 74.32 110.898 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -107.48 158.28 17.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.104 -0.498 . . . . 74.24 110.938 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 15.0 p -161.25 134.79 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.234 -0.439 . . . . 72.2 111.128 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 152' ' ' GLY . . . . . 0.448 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 179.5 -159.21 23.67 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.71 -0.757 . . . . 51.23 112.506 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.86 148.81 39.39 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.872 0.368 . . . . 72.22 110.85 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 3.8 tpp85 -126.97 122.15 33.71 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.142 -0.481 . . . . 73.03 110.868 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 155' ' ' TYR . . . . . 0.421 ' HB3' HD21 ' A' ' 163' ' ' LEU . 0.8 OUTLIER -125.97 164.27 21.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 65.43 111.014 -179.916 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -122.61 108.74 13.46 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 71.4 110.919 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 157' ' ' LEU . . . . . 0.489 HD23 ' N ' ' A' ' 158' ' ' GLY . 0.4 OUTLIER -50.51 158.79 0.57 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 53.01 110.93 -179.945 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 158' ' ' GLY . . . . . 0.489 ' N ' HD23 ' A' ' 157' ' ' LEU . . . -50.6 -32.15 23.68 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.775 -0.726 . . . . 44.25 112.482 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -80.76 -168.64 1.84 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.836 0.351 . . . . 74.31 110.901 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 46.9 t -71.04 -35.3 71.91 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.47 . . . . 72.23 110.846 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 3.1 m0 -71.47 153.93 41.87 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.172 -0.467 . . . . 74.5 110.954 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.41 ' C ' HD13 ' A' ' 163' ' ' LEU . 2.3 mpt? -131.9 173.98 10.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 63.34 110.819 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.702 ' N ' HD13 ' A' ' 163' ' ' LEU . 0.0 OUTLIER -140.84 160.59 39.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 71.43 110.922 179.998 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -163.74 156.62 18.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 74.51 110.908 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 12.2 p -148.25 121.9 9.22 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 73.44 110.829 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 166' ' ' ASP . . . . . 0.448 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 15.6 t70 -130.72 160.84 33.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 73.0 110.883 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.513 HG13 ' O ' ' A' ' 195' ' ' ILE . 31.8 t -137.04 132.06 46.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.236 -0.438 . . . . 75.41 111.147 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 168' ' ' ARG . . . . . 0.587 ' HD2' HD12 ' A' ' 195' ' ' ILE . 0.0 OUTLIER -101.41 139.31 37.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 75.23 110.868 -179.96 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 66.5 t80 -143.97 134.21 24.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.146 -0.479 . . . . 71.35 110.897 -179.81 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 170' ' ' ILE . . . . . 0.453 HD13 ' N ' ' A' ' 171' ' ' PRO . 0.0 OUTLIER 179.83 131.58 0.25 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.601 0.715 . . . . 64.41 111.217 179.904 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 171' ' ' PRO . . . . . 0.453 ' N ' HD13 ' A' ' 170' ' ' ILE . 54.3 Cg_endo -69.69 109.27 2.26 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.709 2.273 . . . . 53.42 112.355 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -119.0 176.87 5.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.445 . . . . 72.34 110.865 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.53 147.53 29.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.161 -0.472 . . . . 73.34 110.829 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 174' ' ' THR . . . . . 0.553 HG21 ' HE2' ' A' ' 128' ' ' PHE . 0.6 OUTLIER -132.36 162.83 30.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.489 . . . . 71.53 111.177 179.94 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 175' ' ' ASP . . . . . 0.407 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.1 OUTLIER -119.74 170.87 8.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 73.34 110.849 179.93 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.953 HG13 HD13 ' A' ' 141' ' ' ILE . 21.9 t -148.73 133.19 9.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 75.45 111.119 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 14.8 t -166.55 175.03 8.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 40.53 111.169 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -156.62 -137.08 2.25 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.799 -0.715 . . . . 71.43 112.536 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 98.6 m -156.26 113.3 3.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.785 0.326 . . . . 74.43 111.156 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.699 HD13 ' OG ' ' A' ' 137' ' ' SER . 13.8 tp -139.39 167.86 21.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.197 -0.456 . . . . 62.32 110.907 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -40.82 -71.51 0.31 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.715 -0.755 . . . . 43.45 112.479 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -169.15 0.31 Allowed 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.622 2.214 . . . . 73.23 112.347 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.404 HG13 ' HD2' ' A' ' 184' ' ' PRO . 61.4 t -61.21 132.64 92.58 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.634 0.731 . . . . 74.42 111.103 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 184' ' ' PRO . . . . . 0.404 ' HD2' HG13 ' A' ' 183' ' ' VAL . 53.7 Cg_endo -69.79 163.14 39.42 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.684 2.256 . . . . 73.22 112.336 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 29.7 t -106.62 115.56 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.19 -0.459 . . . . 70.34 111.094 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 19.4 p -110.1 105.84 15.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 60.21 110.814 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 16.2 p -107.74 159.46 16.47 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.115 -0.493 . . . . 65.14 111.138 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 34.8 ttpt -147.17 145.18 29.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 64.31 110.857 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 20.6 pt -146.1 142.05 21.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.127 -0.488 . . . . 62.43 111.1 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -124.14 110.8 15.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 74.23 110.896 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 191' ' ' VAL . . . . . 0.404 HG12 ' N ' ' A' ' 192' ' ' ASP . 5.6 t -137.06 157.99 35.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 75.44 111.08 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.404 ' N ' HG12 ' A' ' 191' ' ' VAL . 2.0 p-10 -108.14 88.39 4.71 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.601 0.715 . . . . 72.44 110.898 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 169.13 19.7 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.716 2.277 . . . . 63.2 112.318 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -126.91 117.2 22.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.465 . . . . 73.12 110.888 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 195' ' ' ILE . . . . . 0.587 HD12 ' HD2' ' A' ' 168' ' ' ARG . 61.8 mt -103.29 104.27 16.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 73.33 111.187 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 196' ' ' LEU . . . . . 0.441 HD23 ' CG1' ' A' ' 167' ' ' VAL . 5.5 mt -96.12 108.88 21.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.217 -0.447 . . . . 54.13 110.93 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -108.99 127.7 54.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.244 -0.435 . . . . 73.42 110.848 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 198' ' ' LEU . . . . . 0.4 ' C ' ' HB2' ' A' ' 22' ' ' ASN . 10.4 tt -149.95 132.75 15.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.165 -0.471 . . . . 72.12 110.904 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 199' ' ' GLY . . . . . 0.445 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -177.97 -152.12 9.91 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.776 -0.726 . . . . 62.41 112.468 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 200' ' ' ALA . . . . . 0.53 ' HA ' ' HA ' ' A' ' 163' ' ' LEU . . . -110.09 173.1 6.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.822 0.344 . . . . 55.41 111.034 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 40.6 t -159.98 162.66 34.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 62.42 110.852 -179.739 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 202' ' ' TYR . . . . . 0.623 ' CD1' ' HB3' ' A' ' 19' ' ' ALA . 0.2 OUTLIER -146.55 135.27 22.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.14 -0.482 . . . . 74.3 110.917 -179.898 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.817 HG23 HG22 ' A' ' 18' ' ' VAL . 11.2 p -83.63 152.56 3.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.122 -0.49 . . . . 73.44 111.129 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -151.37 132.08 14.03 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 75.21 110.887 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.31 161.31 18.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.125 -0.489 . . . . 75.45 110.885 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -118.51 106.42 12.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.258 -0.428 . . . . 55.4 110.895 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -96.08 -36.48 10.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 74.34 111.114 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -59.11 167.81 1.58 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.178 -0.465 . . . . 62.53 111.09 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -77.15 167.88 21.02 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 62.33 111.084 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -143.86 136.55 27.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 73.05 110.897 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 73.2 110.865 179.951 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.6 mpt? . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.789 0.328 . . . . 63.14 110.893 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -147.82 109.74 4.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 72.41 110.912 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.1 mp0 -133.64 177.44 7.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 61.31 110.879 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -85.49 -51.14 6.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.105 -0.498 . . . . 72.34 110.863 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 1.1 t80 58.07 68.49 1.83 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.709 0.766 . . . . 74.01 110.922 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 163.82 36.9 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.683 2.255 . . . . 65.33 112.377 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -140.82 167.02 23.18 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.256 -0.429 . . . . 72.32 111.154 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' LYS . . . . . 0.622 ' O ' ' HB2' ' A' ' 207' ' ' ALA . 0.0 OUTLIER -156.24 132.97 10.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 71.11 110.882 -179.984 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 7.2 p -55.53 -35.32 65.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.261 -0.427 . . . . 74.2 110.793 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -51.37 -52.3 46.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 40.23 111.059 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -52.71 153.45 6.62 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.663 -0.78 . . . . 74.14 112.547 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 21.2 p90 -169.53 127.01 0.92 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.999 0.428 . . . . 75.51 110.939 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 6.2 t30 -169.33 -176.79 2.63 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.474 . . . . 71.33 110.955 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 41.6 mt-30 -51.73 130.9 29.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 73.24 110.945 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.9 9.76 31.78 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.779 -0.724 . . . . 72.11 112.456 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -78.71 169.39 18.31 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.803 0.335 . . . . 73.41 110.874 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 10.1 m-90 -114.9 159.85 20.21 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.215 -0.448 . . . . 74.11 110.937 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.639 HG23 ' HB3' ' A' ' 60' ' ' ALA . 15.5 m -153.38 126.96 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 41.32 111.152 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -96.4 114.95 26.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.154 -0.475 . . . . 75.5 111.077 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -111.95 113.7 26.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.175 -0.466 . . . . 62.12 110.91 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.773 ' CZ ' ' HB3' ' A' ' 200' ' ' ALA . 48.9 p90 -106.65 125.66 51.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 72.34 110.873 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.405 HD22 ' HE2' ' A' ' 72' ' ' PHE . 0.4 OUTLIER -155.55 166.58 33.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.135 -0.484 . . . . 55.32 110.915 179.992 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 23.4 p90 -98.86 132.39 44.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.143 -0.48 . . . . 74.44 110.85 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -98.7 122.69 42.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.152 -0.476 . . . . 74.3 110.871 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 29.2 tptt -99.29 106.53 18.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 63.41 110.867 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.4 p -81.2 133.88 28.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.312 -0.404 . . . . 75.33 111.114 179.834 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -120.5 112.51 19.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.094 -0.503 . . . . 64.23 110.909 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.484 HG23 HG22 ' A' ' 49' ' ' ILE . 4.0 m -153.13 -179.34 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.097 -0.501 . . . . 64.2 111.147 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.63 52.48 0.54 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.682 -0.771 . . . . 71.1 112.477 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 34.0 mt-10 -90.03 -66.75 0.89 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.849 0.357 . . . . 64.03 110.903 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? 177.81 151.94 0.25 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.088 -0.506 . . . . 73.14 110.945 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.474 HD21 ' HB1' ' A' ' 45' ' ' ALA . 0.9 OUTLIER -109.03 163.73 13.05 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.15 -0.477 . . . . 70.54 110.921 -179.982 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 52.37 -102.47 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.737 -0.744 . . . . 75.52 112.452 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 47.6 t0 53.67 42.77 31.77 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.914 0.388 . . . . 73.52 110.865 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.559 HD13 ' N ' ' A' ' 36' ' ' ASN . 0.4 OUTLIER -106.41 128.85 54.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.135 -0.484 . . . . 54.35 110.941 -179.979 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.559 ' N ' HD13 ' A' ' 35' ' ' LEU . 3.2 p-10 -166.32 177.23 6.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 52.0 110.856 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 34.8 m -128.79 140.4 49.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.133 -0.485 . . . . 73.21 111.11 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 68.03 153.02 0.4 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.774 -0.727 . . . . 61.14 112.51 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 73.82 -172.87 50.69 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.756 -0.735 . . . . 74.43 112.554 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -83.64 -145.81 6.64 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.754 -0.736 . . . . 72.54 112.447 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -119.4 142.67 47.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.799 0.333 . . . . 42.12 111.103 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -146.19 70.62 13.18 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 121.567 0.699 . . . . 75.2 110.909 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.89 102.8 1.09 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.714 2.276 . . . . 75.22 112.278 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -79.75 -43.3 22.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 55.44 110.941 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.474 ' HB1' HD21 ' A' ' 32' ' ' LEU . . . -61.87 -179.46 0.2 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 54.21 111.105 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -159.52 125.15 4.22 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.231 -0.441 . . . . 61.01 110.869 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.423 ' HA ' ' HA2' ' A' ' 83' ' ' GLY . 6.5 p -118.14 148.91 20.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.193 -0.458 . . . . 75.35 111.072 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -173.14 174.47 3.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 72.41 110.878 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.775 HD11 ' CE2' ' A' ' 98' ' ' TYR . 19.3 tt -141.57 154.79 20.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.112 -0.494 . . . . 70.11 111.086 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -124.42 167.54 16.72 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.715 -0.755 . . . . 64.21 112.426 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.9 m-80 -162.66 163.91 26.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.821 0.343 . . . . 71.22 110.904 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -120.36 -68.83 0.88 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 62.43 110.827 179.866 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 72.3 p -91.93 172.87 8.17 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.216 -0.447 . . . . 65.23 111.144 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 40.3 p -148.38 106.52 3.73 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.226 -0.443 . . . . 73.43 111.122 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.406 HD12 ' O ' ' A' ' 55' ' ' LEU . 3.3 pp -160.73 128.74 4.47 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 64.54 110.94 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.459 HG22 ' HA3' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -142.54 155.74 45.05 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.274 -0.421 . . . . 72.35 111.182 179.948 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -114.95 132.46 56.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 70.42 110.893 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.451 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -129.88 134.83 47.76 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.211 -0.449 . . . . 63.24 110.991 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.43 HD13 ' C ' ' A' ' 58' ' ' ASP . 3.0 mm -109.29 115.16 48.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.274 -0.421 . . . . 54.03 111.125 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.639 ' HB3' HG23 ' A' ' 18' ' ' VAL . . . -111.31 151.48 28.33 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.178 -0.464 . . . . 61.1 111.084 179.829 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.457 ' HB2' HG22 ' A' ' 69' ' ' VAL . 5.3 m-85 -125.74 132.37 52.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 73.04 110.932 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -98.3 95.22 7.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.081 -0.509 . . . . 73.24 110.893 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.5 t -94.35 -31.74 4.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.151 -0.477 . . . . 52.24 111.089 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 29.7 t -136.15 158.07 45.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 72.22 110.831 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 59.8 p -85.07 3.98 36.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 72.41 110.859 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -114.41 -29.47 6.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 72.41 110.84 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.424 HG22 ' CD2' ' A' ' 107' ' ' TYR . 32.5 pt -142.08 158.0 20.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 62.32 111.113 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -148.91 163.27 37.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 62.12 111.115 179.839 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.457 HG22 ' HB2' ' A' ' 61' ' ' TYR . 6.1 m -112.24 152.14 14.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 71.02 111.155 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.449 ' HA ' ' HA ' ' A' ' 60' ' ' ALA . 1.5 p30 -144.58 143.31 30.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 64.25 110.885 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.451 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -127.19 108.44 10.89 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 71.33 110.851 -179.907 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.405 ' HE2' HD22 ' A' ' 22' ' ' ASN . 45.8 m-85 -86.33 127.26 34.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.12 -0.491 . . . . 60.15 110.819 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 14.6 p -147.3 147.49 17.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 63.11 111.198 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.459 ' HA3' HG22 ' A' ' 56' ' ' THR . . . -161.88 144.18 9.51 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.753 -0.737 . . . . 73.55 112.487 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 44.3 t -119.74 73.18 16.91 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.608 0.718 . . . . 61.43 111.129 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 159.09 54.7 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.669 2.246 . . . . 44.34 112.365 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -74.91 -165.8 0.41 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.251 -0.431 . . . . 72.35 111.181 179.818 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 18.2 ttm105 -77.05 138.22 39.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.283 -0.417 . . . . 61.54 110.833 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ALA . . . . . 0.668 ' HB3' ' CE2' ' A' ' 98' ' ' TYR . . . -132.77 148.99 52.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.443 . . . . 52.45 111.128 179.836 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.6 ttpm? -89.12 123.8 33.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.182 -0.463 . . . . 72.41 110.93 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 59.6 t80 -109.13 138.82 44.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 62.45 110.878 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.416 ' O ' HG23 ' A' ' 47' ' ' VAL . 7.6 pt20 -109.17 150.91 27.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 74.43 110.917 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.657 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 174.37 84.88 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.696 -0.764 . . . . 74.31 112.447 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -178.07 -175.68 0.5 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.894 0.378 . . . . 52.44 110.976 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 1.4 ptpt -86.54 -70.13 0.63 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.198 -0.455 . . . . 74.22 110.879 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 8.4 t -85.25 -30.52 23.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.225 -0.443 . . . . 73.35 110.869 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.849 HG22 HG22 ' A' ' 93' ' ' VAL . 4.8 mm -68.81 -35.21 68.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.123 -0.489 . . . . 72.12 111.114 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.1 t -62.68 -47.38 83.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 44.42 110.861 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.1 t -54.67 -39.85 68.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.149 -0.478 . . . . 71.23 110.837 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 13.9 tp -60.55 -44.23 96.37 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.083 -0.508 . . . . 75.13 110.995 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.24 -14.55 39.86 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.743 -0.741 . . . . 74.55 112.501 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 9.8 mtm180 -120.54 96.74 5.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.897 0.38 . . . . 71.12 110.813 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.849 HG22 HG22 ' A' ' 87' ' ' ILE . 99.3 t -107.24 -58.27 3.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 64.05 111.1 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.413 ' HA ' ' HA ' ' A' ' 133' ' ' ASP . 0.9 OUTLIER -140.09 148.73 42.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.154 -0.475 . . . . 64.43 110.902 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 31.6 mt-10 -126.01 124.59 41.03 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.132 -0.485 . . . . 71.21 110.972 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.45 HG22 ' N ' ' A' ' 97' ' ' ASP . 14.8 p -176.05 156.76 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 64.45 111.11 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.45 ' N ' HG22 ' A' ' 96' ' ' VAL . 3.9 p30 -84.27 173.49 10.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 75.34 110.902 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' TYR . . . . . 0.775 ' CE2' HD11 ' A' ' 49' ' ' ILE . 14.4 m-85 -130.48 133.17 46.08 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 74.23 110.933 -179.825 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -114.11 69.63 0.24 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.703 -0.761 . . . . 54.42 112.445 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.82 138.44 37.64 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.694 2.263 . . . . 55.12 112.294 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -155.7 118.08 4.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 60.55 111.115 179.86 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.649 HG22 ' CA ' ' A' ' 124' ' ' GLY . 30.0 pt -140.15 146.1 25.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 62.24 111.165 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.42 HD22 ' CE1' ' A' ' 71' ' ' PHE . 2.3 pp -132.82 118.99 19.66 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.196 -0.456 . . . . 74.11 110.846 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.421 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 5.6 p -142.93 163.92 31.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.202 -0.454 . . . . 65.11 110.875 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.577 ' O ' HD12 ' A' ' 105' ' ' LEU . 1.1 pp -113.87 151.46 32.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 54.52 110.886 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 71.1 mt-30 -106.49 144.05 33.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 73.55 110.907 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.424 ' CD2' HG22 ' A' ' 67' ' ' ILE . 5.4 t80 -136.02 125.41 24.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 65.53 110.968 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -86.5 123.14 31.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.173 -0.467 . . . . 64.31 110.843 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 5.9 t80 -91.98 138.82 31.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.142 -0.481 . . . . 73.11 110.95 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -51.6 113.06 0.87 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 73.12 110.846 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 35.0 m -62.35 165.67 5.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.166 -0.47 . . . . 71.34 110.835 -179.735 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 38.2 m-85 -114.51 -67.13 1.02 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.148 -0.478 . . . . 75.02 110.898 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -102.31 -73.45 0.66 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 71.23 110.854 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 8.2 ttm180 -105.39 179.76 4.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.49 . . . . 72.41 110.903 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 4.0 pp -69.28 146.34 52.35 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 74.01 110.938 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 6.1 m-85 -141.86 160.66 55.02 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-O 121.689 0.757 . . . . 73.4 110.884 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 178.43 4.57 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.633 2.222 . . . . 73.43 112.349 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 4.0 m-85 -110.24 151.95 26.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.462 . . . . 74.35 110.949 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 8.3 p -101.93 133.01 46.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.109 -0.496 . . . . 75.11 111.101 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -131.92 174.67 20.11 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.796 -0.716 . . . . 71.15 112.568 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.505 HG23 ' HA ' ' A' ' 149' ' ' PHE . 9.4 p -175.95 153.54 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.865 0.364 . . . . 73.43 111.106 -179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -176.01 -158.21 19.09 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.76 -0.734 . . . . 54.2 112.543 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.45 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 21.3 m -107.7 150.66 10.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.869 0.366 . . . . 72.03 111.116 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' GLY . . . . . 0.649 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -130.53 169.07 21.46 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.687 -0.768 . . . . 75.24 112.455 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 125' ' ' ARG . . . . . 0.432 ' HA ' ' HA ' ' A' ' 145' ' ' TRP . 0.0 OUTLIER -168.55 129.26 1.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.86 0.362 . . . . 71.3 110.923 -179.855 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.468 ' O ' HG13 ' A' ' 126' ' ' VAL . 3.9 p -118.73 112.04 36.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 51.3 111.152 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.457 HD23 ' N ' ' A' ' 128' ' ' PHE . 10.0 tt -122.52 151.23 41.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 73.34 110.883 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.602 ' CE1' HG23 ' A' ' 141' ' ' ILE . 1.3 p90 -160.89 161.94 31.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.187 -0.461 . . . . 72.21 110.833 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 51.5 t80 -101.07 118.59 37.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.49 . . . . 71.53 110.88 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -50.55 102.37 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 65.21 110.845 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -77.52 -80.81 0.1 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.139 -0.482 . . . . 74.35 110.901 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -165.43 112.9 0.96 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.256 -0.429 . . . . 74.34 111.125 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 133' ' ' ASP . . . . . 0.538 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 1.4 m-20 -103.07 119.36 38.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.144 -0.48 . . . . 71.35 110.923 179.853 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -79.89 -5.82 89.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.806 -0.712 . . . . 53.51 112.445 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -46.81 -28.18 1.46 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.81 0.338 . . . . 73.2 111.113 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -162.86 -178.56 6.2 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.191 -0.458 . . . . 71.52 111.019 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 1.5 m -53.02 93.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.275 -0.42 . . . . 73.1 110.828 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 7.0 m 50.68 71.19 0.44 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.081 -0.509 . . . . 70.22 110.891 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.623 ' CE2' HG12 ' A' ' 176' ' ' VAL . 0.5 OUTLIER -92.98 159.88 15.12 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.135 -0.484 . . . . 72.25 110.838 -179.912 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 94.0 m-20 -134.0 167.41 20.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.495 . . . . 75.54 110.891 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.602 HG23 ' CE1' ' A' ' 128' ' ' PHE . 17.6 tt -117.97 149.11 20.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.192 -0.458 . . . . 74.04 111.182 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 16.2 mmtt -113.36 124.54 52.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 73.43 110.931 179.885 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.421 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 0.0 OUTLIER -85.53 -173.32 4.59 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.225 -0.443 . . . . 44.51 110.868 179.915 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -171.54 -175.36 1.58 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 72.51 110.904 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 145' ' ' TRP . . . . . 0.432 ' HA ' ' HA ' ' A' ' 125' ' ' ARG . 22.5 p-90 -143.57 160.49 40.54 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.198 -0.456 . . . . 64.32 110.917 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.679 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 178.86 163.15 0.69 Allowed Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.623 0.725 . . . . 23.01 111.086 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.679 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 54.3 Cg_endo -69.66 170.61 16.06 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.683 2.255 . . . . 70.32 112.375 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.45 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -165.55 153.0 10.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.222 -0.445 . . . . 72.12 111.13 179.875 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 149' ' ' PHE . . . . . 0.505 ' HA ' HG23 ' A' ' 121' ' ' VAL . 12.9 m-85 -96.17 161.3 14.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.242 -0.435 . . . . 71.52 110.819 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 27.7 tp60 -135.0 148.59 50.0 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 61.22 110.949 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 10.2 p -151.54 130.84 3.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.17 -0.468 . . . . 74.33 111.161 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' GLY . . . . . 0.405 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 164.95 -163.21 36.27 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.727 -0.749 . . . . 52.15 112.481 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -148.93 168.26 23.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.788 0.328 . . . . 62.31 110.95 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -133.68 128.51 35.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 64.02 110.88 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -132.66 161.64 33.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.442 . . . . 74.31 110.933 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -121.28 109.58 15.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.147 -0.479 . . . . 73.01 110.904 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 3.6 tp -57.46 160.45 4.12 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.169 -0.469 . . . . 62.24 110.944 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -52.05 -33.24 36.77 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.775 -0.726 . . . . 64.04 112.495 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 4.6 m120 -80.52 173.65 12.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.907 0.384 . . . . 74.14 110.821 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 81.1 p -54.78 -35.74 64.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.113 -0.494 . . . . 75.45 110.815 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 10.3 m0 -69.31 151.68 45.91 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.199 -0.455 . . . . 64.34 110.97 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 38.8 mtt -121.22 174.92 6.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.246 -0.433 . . . . 73.11 110.862 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.435 ' HA ' ' HA ' ' A' ' 200' ' ' ALA . 0.6 OUTLIER -128.65 139.25 52.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.262 -0.427 . . . . 72.0 110.909 179.999 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -139.84 138.33 35.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 71.13 110.984 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.7 p -141.61 121.79 13.85 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.214 -0.448 . . . . 73.24 110.892 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 166' ' ' ASP . . . . . 0.405 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 23.3 m-20 -140.26 167.59 21.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.08 -0.509 . . . . 72.41 110.812 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.528 HG13 ' O ' ' A' ' 195' ' ' ILE . 46.7 t -150.43 129.05 2.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.157 -0.474 . . . . 61.33 111.115 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 168' ' ' ARG . . . . . 0.552 ' NH1' HG21 ' A' ' 102' ' ' ILE . 0.0 OUTLIER -98.59 137.71 36.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 71.32 110.862 -179.972 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 15.9 t80 -138.22 125.37 21.52 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 62.2 110.929 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 170' ' ' ILE . . . . . 0.468 HG13 ' HD2' ' A' ' 171' ' ' PRO . 4.7 tp 178.9 134.69 0.24 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.599 0.714 . . . . 72.34 111.116 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 171' ' ' PRO . . . . . 0.468 ' HD2' HG13 ' A' ' 170' ' ' ILE . 54.0 Cg_endo -69.85 111.55 2.86 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.609 2.206 . . . . 64.54 112.386 179.858 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 172' ' ' PHE . . . . . 0.535 ' CE2' ' HB3' ' A' ' 146' ' ' ALA . 5.3 t80 -116.1 159.76 21.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.139 -0.482 . . . . 72.35 110.856 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 5.4 ptpt -140.06 144.79 37.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.146 -0.479 . . . . 73.41 110.926 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 9.4 t -117.79 161.9 18.96 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 73.52 111.137 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 21.6 t70 -118.48 158.54 25.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.14 -0.482 . . . . 71.3 110.844 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.623 HG12 ' CE2' ' A' ' 139' ' ' PHE . 4.5 t -147.94 138.26 16.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 72.54 111.082 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.3 t -166.92 -179.22 4.59 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.131 -0.486 . . . . 71.11 111.116 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -120.55 -161.66 11.53 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.746 -0.74 . . . . 61.35 112.458 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 6.4 t -119.9 -171.74 2.2 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.84 0.353 . . . . 75.22 111.16 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 4.9 mp -61.36 147.68 43.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 71.34 110.907 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 116.21 -88.0 0.45 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.716 -0.754 . . . . 73.11 112.441 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.403 ' O ' ' HD3' ' A' ' 184' ' ' PRO . 53.9 Cg_endo -69.67 -160.22 0.06 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.181 0 C-N-CA 122.772 2.314 . . . . 72.34 112.331 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 16.4 t -105.99 87.76 2.62 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.66 0.743 . . . . 54.23 111.174 179.818 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 184' ' ' PRO . . . . . 0.403 ' HD3' ' O ' ' A' ' 182' ' ' PRO . 53.1 Cg_endo -69.87 122.84 9.48 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.671 2.247 . . . . 64.53 112.317 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.418 HG12 HG23 ' A' ' 187' ' ' THR . 26.5 t -103.59 108.17 23.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 71.34 111.111 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -74.13 104.83 5.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.137 -0.483 . . . . 74.14 110.82 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 187' ' ' THR . . . . . 0.418 HG23 HG12 ' A' ' 185' ' ' VAL . 65.1 p -124.44 168.59 12.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.136 -0.484 . . . . 73.31 111.171 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 3.0 ttpm? -158.97 134.09 8.34 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.207 -0.451 . . . . 41.54 110.944 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -115.75 139.59 41.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.279 -0.419 . . . . 72.33 111.107 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 71.7 tt0 -119.55 114.99 23.1 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.125 -0.489 . . . . 74.22 110.817 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 191' ' ' VAL . . . . . 0.539 HG22 ' H ' ' A' ' 192' ' ' ASP . 1.2 p -137.18 171.28 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 70.41 111.111 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.539 ' H ' HG22 ' A' ' 191' ' ' VAL . 4.2 m-20 -106.93 87.14 2.73 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.594 0.711 . . . . 62.11 110.915 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.65 120.96 7.68 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.742 2.295 . . . . 62.21 112.379 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 194' ' ' PHE . . . . . 0.425 ' CE1' HG11 ' A' ' 167' ' ' VAL . 2.1 t80 -102.09 114.0 27.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.258 -0.428 . . . . 72.4 110.887 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 195' ' ' ILE . . . . . 0.55 HD12 ' HG2' ' A' ' 168' ' ' ARG . 5.6 mt -103.56 127.3 57.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.162 -0.472 . . . . 74.22 111.133 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 196' ' ' LEU . . . . . 0.41 ' HG ' HG22 ' A' ' 167' ' ' VAL . 1.1 tt -117.14 107.72 14.82 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.182 -0.463 . . . . 64.34 110.89 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 3.2 m -96.38 123.62 40.09 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.24 -0.436 . . . . 65.42 110.847 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 2.5 tt -144.13 129.21 18.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 62.21 110.86 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 178.94 -146.98 7.53 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.75 -0.738 . . . . 73.21 112.478 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 200' ' ' ALA . . . . . 0.773 ' HB3' ' CZ ' ' A' ' 21' ' ' PHE . . . -118.65 174.26 6.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.781 0.324 . . . . 61.35 111.17 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 78.1 p -149.66 175.71 11.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.28 -0.418 . . . . 74.21 110.843 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -157.31 160.9 39.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 73.52 110.895 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.503 ' HA ' HG12 ' A' ' 18' ' ' VAL . 18.2 m -76.76 161.21 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.065 -0.516 . . . . 65.0 111.15 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -155.95 127.59 7.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 71.11 110.865 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 14.3 ttmm 46.77 60.84 3.12 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.119 -0.492 . . . . 73.2 110.924 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 206' ' ' LEU . . . . . 0.472 HD21 ' HB ' ' A' ' 203' ' ' VAL . 4.0 mm? -52.33 -54.26 33.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.456 . . . . 72.43 110.957 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 207' ' ' ALA . . . . . 0.622 ' HB2' ' O ' ' A' ' 8' ' ' LYS . . . -50.46 113.78 0.97 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.151 -0.477 . . . . 64.24 111.019 179.822 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -139.5 126.51 21.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 72.11 111.104 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . 61.37 38.66 16.03 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.22 -0.445 . . . . 63.41 111.161 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 11.2 tp -134.01 126.14 29.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 73.34 110.912 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 84.0 mt-10 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 62.33 110.871 179.892 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.458 -0.075 0 CA-C-O 120.783 0.325 . . . . 61.31 110.826 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 29.9 m120 -110.36 59.48 0.61 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.23 -0.441 . . . . 73.34 110.879 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 71.9 mm-40 -114.75 153.94 29.42 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.245 -0.434 . . . . 73.42 110.892 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -105.1 168.7 8.89 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.182 -0.463 . . . . 70.15 110.863 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 7.7 m-85 -121.96 160.42 47.25 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.676 0.751 . . . . 73.04 110.881 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 -179.77 3.14 Favored 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.705 2.27 . . . . 75.44 112.353 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.28 159.45 17.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.265 -0.425 . . . . 72.2 111.054 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 2.5 mmpt? -111.75 167.96 9.94 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.214 -0.448 . . . . 70.34 110.92 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 17.6 m -65.29 103.6 0.82 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.192 -0.458 . . . . 74.52 110.852 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -115.52 140.2 49.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.069 -0.514 . . . . 52.13 111.121 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -117.33 46.42 1.15 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.793 -0.717 . . . . 51.34 112.529 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 16.2 p90 -157.21 118.01 3.59 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.864 0.364 . . . . 74.21 110.943 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 43.2 t30 -124.05 153.0 42.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.09 -0.505 . . . . 61.24 110.888 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -53.03 119.25 4.46 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 75.43 110.881 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.71 11.57 28.33 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 61.41 112.498 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -82.66 160.51 22.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.766 0.317 . . . . 63.25 110.922 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 12.8 m95 -108.76 159.65 16.6 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.257 -0.429 . . . . 71.43 110.936 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.437 HG13 ' O ' ' A' ' 202' ' ' TYR . 48.1 t -150.5 119.2 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.426 . . . . 45.31 111.139 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -85.0 107.52 17.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.096 -0.502 . . . . 63.13 111.078 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -105.45 112.76 25.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 63.11 110.902 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -111.73 125.79 54.36 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.159 -0.473 . . . . 73.11 110.879 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.43 ' O ' HG22 ' A' ' 56' ' ' THR . 4.0 p30 -155.78 172.66 17.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 71.44 110.907 -179.887 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.8 p90 -100.96 132.21 46.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 71.24 110.867 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' SER . . . . . 0.591 ' OG ' HG23 ' A' ' 195' ' ' ILE . 0.3 OUTLIER -100.68 120.04 39.48 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.151 -0.477 . . . . 65.34 110.88 -179.797 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 39.1 tttm -93.56 106.82 18.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 63.1 110.849 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.614 ' HA ' HD13 ' A' ' 195' ' ' ILE . 11.3 p -84.12 135.8 24.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 72.4 111.106 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -125.84 99.42 5.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.154 -0.475 . . . . 74.34 110.855 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.68 HG23 HG11 ' A' ' 191' ' ' VAL . 2.7 p -147.33 142.26 19.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.155 -0.475 . . . . 71.24 111.152 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 142.08 64.57 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.706 -0.759 . . . . 54.11 112.528 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -89.86 -66.16 0.95 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.766 0.317 . . . . 72.35 110.911 -179.863 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -171.41 134.87 0.9 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.122 -0.49 . . . . 61.14 110.873 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 5.1 tt -104.94 152.69 22.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.186 -0.461 . . . . 71.35 110.992 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.24 -45.27 2.81 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.666 -0.778 . . . . 54.13 112.502 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -52.01 140.08 21.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.861 0.362 . . . . 70.35 110.827 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.547 HD13 ' OE1' ' A' ' 190' ' ' GLU . 0.9 OUTLIER 63.13 53.45 2.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.145 -0.48 . . . . 75.1 110.948 -179.944 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 16.0 t30 -90.6 -43.28 10.28 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.144 -0.48 . . . . 74.23 110.901 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.604 ' O ' HG22 ' A' ' 37' ' ' VAL . 13.2 p 39.44 38.69 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.132 -0.485 . . . . 70.33 111.095 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -175.55 112.85 0.42 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.778 -0.725 . . . . 73.24 112.5 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.3 -152.32 43.19 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.756 -0.735 . . . . 74.3 112.481 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -52.42 143.14 22.9 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.767 -0.73 . . . . 65.42 112.497 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -115.14 101.32 8.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.772 0.32 . . . . 62.42 111.141 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.626 HD22 ' OE2' ' A' ' 84' ' ' GLU . 0.4 OUTLIER -119.51 67.5 10.15 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.613 0.72 . . . . 73.33 110.901 -179.946 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.78 -23.37 30.8 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.694 2.262 . . . . 74.35 112.352 179.843 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -85.97 50.61 2.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.224 -0.444 . . . . 74.33 110.874 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -104.15 -170.12 1.73 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 74.21 111.062 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 21.8 m-20 -160.48 125.37 3.79 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 54.4 110.922 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.54 HG13 ' O ' ' A' ' 82' ' ' GLN . 18.5 t -104.4 135.51 41.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.187 -0.46 . . . . 65.31 111.159 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -132.63 137.59 47.06 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 73.13 110.816 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 3.8 tt -101.3 145.03 12.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.094 -0.503 . . . . 73.51 111.094 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -60.24 -168.58 0.38 Allowed Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.746 -0.74 . . . . 63.32 112.462 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -119.05 -37.34 3.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.781 0.324 . . . . 73.14 110.937 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -51.96 150.51 4.21 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.147 -0.479 . . . . 75.15 110.881 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 3.7 p -146.13 178.21 8.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 62.13 111.138 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.6 t -160.14 169.47 23.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.268 -0.424 . . . . 75.14 111.183 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 5.0 mp -91.13 168.38 11.67 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 65.22 110.921 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.43 HG22 ' O ' ' A' ' 22' ' ' ASN . 12.1 t -135.94 149.51 48.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.186 -0.461 . . . . 65.41 111.133 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -102.75 133.05 48.43 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.292 -0.413 . . . . 73.35 110.846 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -125.91 138.62 53.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 53.45 110.84 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.53 114.15 45.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 65.42 111.164 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -105.87 121.64 44.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 73.4 111.057 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.785 ' HB3' HG22 ' A' ' 69' ' ' VAL . 7.4 t80 -106.08 117.38 33.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 73.03 110.931 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -92.43 101.83 14.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.124 -0.489 . . . . 60.03 110.892 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.41 HG23 ' OG ' ' A' ' 64' ' ' SER . 32.5 m -98.39 -31.72 3.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.46 . . . . 70.22 111.156 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.41 ' OG ' HG23 ' A' ' 63' ' ' VAL . 1.1 m -125.92 -169.51 2.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.192 -0.458 . . . . 71.0 110.895 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.5 m -84.18 -38.92 20.02 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 74.1 110.893 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -126.09 25.99 6.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.067 -0.515 . . . . 71.3 110.865 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 3.4 mt -145.16 126.94 8.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.22 -0.446 . . . . 70.04 111.136 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.484 ' HB1' ' O ' ' A' ' 61' ' ' TYR . . . -155.05 168.61 26.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.138 -0.483 . . . . 52.34 111.119 179.843 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.785 HG22 ' HB3' ' A' ' 61' ' ' TYR . 2.5 m -111.76 152.47 13.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 61.12 111.14 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -131.66 129.41 40.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 63.23 110.821 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -114.38 110.15 19.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 73.31 110.87 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -81.82 113.08 19.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 73.14 110.955 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.8 t -124.04 116.46 47.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.167 -0.47 . . . . 74.4 111.03 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -131.87 152.14 20.03 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.71 -0.757 . . . . 74.23 112.48 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 39.4 t -143.38 69.81 17.69 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.575 0.702 . . . . 71.2 111.144 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.79 140.61 42.98 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.666 2.244 . . . . 71.22 112.373 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.87 -173.66 0.26 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.188 -0.46 . . . . 72.33 111.075 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 8.9 ttm180 -76.43 129.61 36.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 75.12 110.856 -179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -131.03 151.71 51.12 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.227 -0.442 . . . . 70.21 111.085 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.8 tttp -97.59 123.9 41.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.134 -0.485 . . . . 62.41 110.847 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -111.43 151.68 28.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 71.43 110.907 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.54 ' O ' HG13 ' A' ' 47' ' ' VAL . 18.1 mt-30 -111.71 148.47 33.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 75.31 110.899 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.571 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -178.71 81.41 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.789 -0.719 . . . . 74.51 112.479 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.626 ' OE2' HD22 ' A' ' 42' ' ' LEU . 1.4 mm-40 -176.52 -175.59 0.67 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.95 0.405 . . . . 60.2 110.868 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.17 -69.72 0.65 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.127 -0.488 . . . . 65.0 110.949 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 16.9 p -85.16 -32.05 22.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.237 -0.438 . . . . 72.01 110.853 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.951 HG21 ' HB2' ' A' ' 135' ' ' ALA . 4.6 mm -67.34 -35.13 72.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.094 -0.503 . . . . 74.35 111.111 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.8 t -62.38 -44.85 95.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.219 -0.446 . . . . 52.23 110.79 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 39.1 t -57.43 -37.31 72.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 62.1 110.904 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 98.5 mt -63.56 -50.3 70.02 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.107 -0.497 . . . . 52.32 110.902 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 114.14 -13.22 21.69 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.721 -0.752 . . . . 75.42 112.475 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.61 96.19 5.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.839 0.352 . . . . 74.13 110.821 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.887 HG22 HG22 ' A' ' 87' ' ' ILE . 64.5 t -113.74 -50.84 5.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.253 -0.431 . . . . 64.12 111.108 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 60.5 p -140.11 148.69 42.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 64.42 110.91 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -140.68 118.52 11.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 71.42 110.79 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.526 HG22 ' H ' ' A' ' 97' ' ' ASP . 1.6 p -179.24 170.31 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.171 -0.468 . . . . 71.22 111.089 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.526 ' H ' HG22 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -109.43 160.29 16.32 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.198 -0.455 . . . . 74.21 110.869 179.931 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 98' ' ' TYR . . . . . 0.424 ' HA ' ' HB2' ' A' ' 128' ' ' PHE . 17.7 m-85 -120.35 145.23 47.35 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.226 -0.443 . . . . 75.11 110.948 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -108.67 87.3 0.48 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.775 -0.726 . . . . 72.12 112.412 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.656 ' HA ' HG12 ' A' ' 126' ' ' VAL . 54.2 Cg_endo -69.76 110.43 2.55 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.668 2.245 . . . . 74.41 112.406 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.409 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -128.88 95.57 4.12 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.241 -0.436 . . . . 42.13 111.12 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.617 HG23 ' CA ' ' A' ' 124' ' ' GLY . 5.8 mm -116.64 142.22 31.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.229 -0.441 . . . . 62.24 111.138 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.46 ' HG ' HG13 ' A' ' 123' ' ' VAL . 0.3 OUTLIER -140.13 109.66 6.27 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.188 -0.46 . . . . 74.14 110.934 179.959 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.413 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 4.8 p -138.19 -177.6 4.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 73.13 110.854 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.606 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.7 OUTLIER -128.87 141.89 51.14 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 71.23 110.863 -179.946 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 -101.55 132.72 47.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 65.11 110.992 179.853 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 27.5 t80 -137.1 145.61 44.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.237 -0.438 . . . . 64.21 110.937 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 59.0 t-80 -71.43 153.64 42.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.152 -0.476 . . . . 64.44 110.917 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 5.2 t80 -149.98 139.74 21.77 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.201 -0.454 . . . . 75.01 110.928 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -57.74 130.03 44.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.056 -0.52 . . . . 75.11 110.87 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.6 t -138.32 161.17 37.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.457 . . . . 63.22 110.834 -179.768 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 28.2 p90 -129.82 39.76 3.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.115 -0.493 . . . . 70.33 110.878 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -117.08 177.67 4.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.209 -0.45 . . . . 44.12 110.851 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 7.8 tpm_? -56.54 -37.79 71.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 64.54 110.855 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 8.1 tp -114.78 153.01 31.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 74.24 110.868 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -120.87 69.61 17.64 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.655 0.74 . . . . 72.44 110.985 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' PRO . . . . . 0.684 ' HA ' HD12 ' A' ' 153' ' ' LEU . 53.8 Cg_endo -69.81 176.95 6.13 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.6 2.2 . . . . 71.54 112.31 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.474 ' O ' HG23 ' A' ' 151' ' ' VAL . 26.5 m-85 -111.53 144.24 41.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 71.14 110.924 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 13.2 p -100.7 133.26 44.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.237 -0.438 . . . . 73.24 111.102 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.418 ' HA2' ' O ' ' A' ' 105' ' ' LEU . . . -125.92 159.01 20.32 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.738 -0.744 . . . . 71.34 112.489 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.1 p -161.6 149.47 4.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.81 0.338 . . . . 75.14 111.15 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.413 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -177.5 -151.3 9.07 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.744 -0.741 . . . . 53.04 112.5 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.531 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.3 p -110.39 126.31 67.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.877 0.37 . . . . 72.21 111.114 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' GLY . . . . . 0.617 ' CA ' HG23 ' A' ' 102' ' ' ILE . . . -116.06 119.94 4.72 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.769 -0.729 . . . . 60.05 112.503 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' ARG . . . . . 0.409 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 13.5 ptm180 -120.44 122.88 41.67 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.921 0.391 . . . . 74.13 110.854 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.656 HG12 ' HA ' ' A' ' 100' ' ' PRO . 3.7 m -118.34 118.6 58.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.202 -0.454 . . . . 60.11 111.117 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.423 ' HA ' ' HB3' ' A' ' 143' ' ' ASP . 1.2 pt? -160.02 165.23 32.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.231 -0.441 . . . . 72.53 110.985 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.424 ' HB2' ' HA ' ' A' ' 98' ' ' TYR . 1.0 OUTLIER -165.93 -171.12 1.93 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.236 -0.438 . . . . 74.11 110.897 179.925 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -94.13 135.12 35.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.174 -0.466 . . . . 73.3 110.926 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -69.63 148.01 49.9 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.138 -0.483 . . . . 72.43 110.843 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.482 ' CB ' HG23 ' A' ' 96' ' ' VAL . 0.2 OUTLIER -129.55 -69.29 0.69 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 73.05 110.933 179.94 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 33.8 m -159.93 75.12 0.6 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.185 -0.461 . . . . 74.15 111.189 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -97.85 175.5 6.13 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.224 -0.444 . . . . 73.21 110.81 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 62.99 149.55 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.735 -0.745 . . . . 71.03 112.479 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.951 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -76.51 -1.7 28.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.892 0.377 . . . . 43.04 111.187 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -86.5 -177.09 6.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.135 -0.484 . . . . 71.42 110.906 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -64.06 93.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.198 -0.455 . . . . 62.44 110.847 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 89.0 p 46.06 76.26 0.1 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 62.12 110.88 -179.812 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -82.96 151.16 26.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 71.42 110.794 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' ASP . . . . . 0.447 ' O ' HG13 ' A' ' 176' ' ' VAL . 1.6 t70 -101.74 165.63 11.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.093 -0.503 . . . . 72.51 110.776 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -127.08 163.0 30.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 64.25 111.168 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 142' ' ' LYS . . . . . 0.41 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 0.2 OUTLIER -119.21 108.14 14.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 74.45 110.898 179.847 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.428 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 1.0 OUTLIER -58.84 -172.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.243 -0.435 . . . . 44.22 110.819 179.967 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 15.9 mmtt -149.47 155.28 40.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.45 . . . . 55.33 110.886 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 45.3 p90 -151.67 136.23 16.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.227 -0.442 . . . . 63.53 110.926 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.933 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.28 172.14 0.61 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.583 0.706 . . . . 51.15 111.051 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.933 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 54.3 Cg_endo -69.69 134.09 27.29 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.631 2.221 . . . . 52.51 112.421 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.468 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -130.1 166.47 20.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.262 -0.426 . . . . 64.2 111.126 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -121.55 167.39 12.92 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 71.21 110.951 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -165.85 162.3 18.29 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 71.41 110.923 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.474 HG23 ' O ' ' A' ' 118' ' ' TYR . 10.7 p -153.51 141.32 13.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 73.0 111.147 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -169.4 -171.79 35.41 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.772 -0.728 . . . . 64.24 112.451 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.684 HD12 ' HA ' ' A' ' 117' ' ' PRO . 8.5 tt -149.2 157.08 43.07 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.738 0.304 . . . . 74.35 110.934 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.438 ' N ' HD23 ' A' ' 153' ' ' LEU . 7.1 tpp85 -108.08 117.43 34.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.224 -0.444 . . . . 74.43 110.836 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 4.5 t80 -105.17 145.38 30.66 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.184 -0.462 . . . . 74.24 110.876 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -115.38 105.77 13.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.091 -0.504 . . . . 55.45 110.897 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 11.9 tp -93.93 164.34 13.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.184 -0.462 . . . . 64.25 110.925 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -76.08 68.38 2.31 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.75 -0.738 . . . . 55.53 112.468 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 64.7 m-80 -151.41 175.25 12.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.804 0.335 . . . . 74.3 110.876 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 6.2 m -56.32 -38.55 71.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.209 -0.45 . . . . 65.32 110.85 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 4.6 p90 -111.8 178.26 4.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.167 -0.47 . . . . 73.22 110.905 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.46 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 0.0 OUTLIER -117.08 170.81 8.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 53.41 110.92 179.873 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 5.8 tp -104.09 151.35 23.38 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.246 -0.433 . . . . 71.11 110.886 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 4.0 t-20 -145.07 137.84 26.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.17 -0.468 . . . . 74.1 110.919 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 26.8 p -136.22 122.5 20.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 72.54 110.906 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -140.5 164.62 29.67 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.136 -0.484 . . . . 61.22 110.878 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 94.7 t -150.51 116.61 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.248 -0.433 . . . . 73.4 111.115 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -97.66 146.49 25.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 74.24 110.879 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 62.2 t80 -146.81 143.3 28.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 71.14 110.86 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 170' ' ' ILE . . . . . 0.468 HG21 ' HB2' ' A' ' 148' ' ' ALA . 0.0 OUTLIER -179.0 103.14 0.2 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.66 0.743 . . . . 73.32 111.154 179.918 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 127.32 14.48 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.661 2.241 . . . . 72.24 112.439 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -148.64 178.42 8.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.254 -0.43 . . . . 62.04 110.952 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.82 127.74 37.26 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.187 -0.461 . . . . 74.04 110.892 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.8 t -91.88 165.96 12.97 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.291 -0.413 . . . . 63.33 111.123 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 175' ' ' ASP . . . . . 0.41 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -124.58 167.06 15.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 72.23 110.86 179.884 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.447 HG13 ' O ' ' A' ' 140' ' ' ASP . 45.7 t -152.16 139.78 13.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.13 -0.487 . . . . 72.22 111.163 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 14.5 t -167.27 179.35 5.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 63.01 111.149 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 131.63 143.49 5.21 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.747 -0.739 . . . . 63.34 112.45 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 7.1 t -173.07 179.09 2.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.86 0.362 . . . . 64.21 111.111 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 9.6 tp -139.29 89.14 2.32 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.184 -0.462 . . . . 74.53 111.015 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 118.03 -82.33 0.33 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.784 -0.722 . . . . 62.14 112.47 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -168.87 0.29 Allowed 'Trans proline' 0 C--N 1.343 0.243 0 C-N-CA 122.644 2.23 . . . . 53.25 112.363 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 7.5 p -82.21 125.63 76.43 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.65 0.738 . . . . 72.54 111.117 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 159.43 53.43 Favored 'Trans proline' 0 C--O 1.231 0.157 0 C-N-CA 122.704 2.269 . . . . 73.11 112.368 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 44.6 t -96.8 107.5 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.227 -0.442 . . . . 71.03 111.092 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 13.3 p -89.36 104.98 17.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 63.51 110.861 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 10.8 p -110.22 166.53 10.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.083 -0.508 . . . . 74.13 111.151 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -152.23 146.6 25.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 73.1 110.922 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 18.2 pt -142.51 130.39 20.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 74.21 111.14 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 190' ' ' GLU . . . . . 0.547 ' OE1' HD13 ' A' ' 35' ' ' LEU . 10.3 pt-20 -99.29 118.23 35.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 74.01 110.837 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 191' ' ' VAL . . . . . 0.68 HG11 HG23 ' A' ' 28' ' ' VAL . 8.5 p -137.79 159.99 33.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 72.11 111.143 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.408 ' N ' HG22 ' A' ' 191' ' ' VAL . 0.2 OUTLIER -107.22 90.26 5.46 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.567 0.699 . . . . 74.13 110.927 179.982 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 116.31 4.5 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.683 2.255 . . . . 75.44 112.342 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -100.28 119.65 38.72 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.176 -0.466 . . . . 70.2 110.918 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 195' ' ' ILE . . . . . 0.614 HD13 ' HA ' ' A' ' 26' ' ' VAL . 40.5 mm -108.79 119.48 58.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.123 -0.49 . . . . 63.44 111.094 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 7.3 mp -113.03 107.25 15.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.156 -0.475 . . . . 74.13 110.949 179.863 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 197' ' ' SER . . . . . 0.603 ' O ' HD12 ' A' ' 198' ' ' LEU . 0.9 OUTLIER -95.31 124.47 39.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.225 -0.443 . . . . 70.13 110.826 -179.907 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 198' ' ' LEU . . . . . 0.603 HD12 ' O ' ' A' ' 197' ' ' SER . 5.0 mp -146.39 127.92 15.07 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.101 -0.5 . . . . 71.43 110.987 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 177.27 -136.25 3.05 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.655 -0.783 . . . . 64.42 112.442 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 200' ' ' ALA . . . . . 0.46 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -134.06 173.15 11.89 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.85 0.357 . . . . 64.32 111.114 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 2.3 p -144.92 174.83 10.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.434 . . . . 71.53 110.92 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 202' ' ' TYR . . . . . 0.437 ' O ' HG13 ' A' ' 18' ' ' VAL . 12.6 t80 -148.63 138.77 22.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.101 -0.499 . . . . 74.23 110.854 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 11.5 p -77.2 151.23 5.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.077 -0.51 . . . . 73.14 111.117 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 -153.13 114.15 4.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.133 -0.485 . . . . 71.14 110.896 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 5.7 ptpt -108.02 -36.54 6.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 71.21 110.879 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 17.1 mt -100.77 151.64 21.44 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.24 -0.436 . . . . 74.52 110.914 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -95.09 117.47 30.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 65.03 111.065 179.84 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -94.03 -50.44 5.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 75.32 111.154 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -95.43 108.68 20.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 61.33 111.165 179.853 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 23.3 tp -123.29 123.37 40.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 60.43 110.834 -179.867 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 . . . . . 0 C--N 1.33 -0.239 0 CA-C-N 116.157 -0.474 . . . . 73.35 110.91 179.93 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 81.1 mmm . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.791 0.329 . . . . 74.13 110.916 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -136.29 136.69 39.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.264 -0.426 . . . . 61.04 110.922 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.7 mp0 -141.69 172.61 12.45 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 63.5 110.848 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -108.65 174.26 5.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.12 -0.491 . . . . 55.11 110.864 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -149.63 143.96 17.32 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.714 0.768 . . . . 71.21 110.885 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 -170.67 0.41 Allowed 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.744 2.296 . . . . 74.21 112.342 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -126.21 163.65 22.71 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.258 -0.428 . . . . 60.02 111.084 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 19.9 mmmt -120.32 171.42 8.52 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.205 -0.452 . . . . 75.24 110.962 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 94.9 p -121.49 173.57 7.31 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.262 -0.426 . . . . 53.54 110.828 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -151.78 171.26 17.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 74.45 111.074 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -100.5 33.61 6.22 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.739 -0.743 . . . . 72.11 112.446 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 13.8 p90 -160.33 117.43 2.47 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.906 0.384 . . . . 73.44 110.935 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -162.34 148.96 13.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.476 . . . . 74.4 110.927 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -52.03 127.83 22.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.161 -0.472 . . . . 62.53 110.919 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.94 6.9 68.96 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.72 -0.753 . . . . 60.24 112.421 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -75.54 145.24 41.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.752 0.31 . . . . 74.13 110.884 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -127.22 121.56 31.58 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.234 -0.439 . . . . 73.22 110.958 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.783 HG13 ' HB3' ' A' ' 60' ' ' ALA . 2.9 p -131.28 123.55 53.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.252 -0.431 . . . . 74.21 111.115 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -84.41 115.18 22.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.117 -0.492 . . . . 64.33 111.097 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -104.62 108.8 20.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 62.35 110.9 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -111.97 125.3 53.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 64.3 110.942 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.404 ' HB2' ' C ' ' A' ' 198' ' ' LEU . 5.4 p30 -153.53 174.05 14.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 61.13 110.829 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -98.0 129.45 44.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.113 -0.494 . . . . 74.5 110.814 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -97.22 122.47 40.27 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.148 -0.478 . . . . 72.23 110.836 -179.847 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -102.4 105.76 16.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.089 -0.505 . . . . 73.43 110.902 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.5 m -82.71 131.04 34.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.272 -0.422 . . . . 71.04 111.164 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 10.2 m-85 -123.98 99.35 6.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.177 -0.465 . . . . 71.42 110.901 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 p -158.46 151.26 7.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.216 -0.447 . . . . 51.02 111.164 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.99 72.32 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.707 -0.759 . . . . 64.01 112.419 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.5 tp10 -89.07 -66.47 0.92 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.853 0.358 . . . . 75.12 110.83 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -176.23 172.5 2.31 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 43.05 110.88 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.56 ' HB3' ' HB3' ' A' ' 45' ' ' ALA . 24.4 tp -104.22 150.77 24.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 55.33 110.884 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.16 105.34 0.19 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.718 -0.753 . . . . 42.44 112.495 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -50.73 -32.77 20.56 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.858 0.361 . . . . 54.42 110.901 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 23.8 tp -50.2 -34.75 23.77 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.114 -0.494 . . . . 71.12 110.9 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 5.5 t30 -51.62 103.78 0.07 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 50.02 110.908 179.882 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.7 p -58.8 152.23 4.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.441 . . . . 74.42 111.121 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -135.76 -67.39 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.735 -0.745 . . . . 51.41 112.517 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 176.95 120.94 0.65 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.756 -0.735 . . . . 52.34 112.494 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.98 -117.53 8.09 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.74 -0.743 . . . . 61.24 112.47 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -54.62 174.85 0.06 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.803 0.335 . . . . 75.22 111.122 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.6 mt -120.18 67.84 12.9 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.539 0.685 . . . . 75.45 110.89 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.75 -170.66 0.41 Allowed 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.668 2.245 . . . . 65.21 112.337 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -122.79 134.32 54.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 75.12 110.912 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.56 ' HB3' ' HB3' ' A' ' 32' ' ' LEU . . . -88.78 166.32 14.11 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 65.42 111.094 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -137.49 133.96 35.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 71.15 110.833 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.404 HG12 ' CA ' ' A' ' 83' ' ' GLY . 21.8 m -106.73 151.17 8.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 73.42 111.105 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 14.7 t -156.8 151.28 25.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 75.35 110.818 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.468 HD12 ' CD1' ' A' ' 81' ' ' PHE . 38.4 mm -120.93 116.49 50.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.088 -0.506 . . . . 74.04 111.09 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -51.56 157.9 2.84 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.693 -0.765 . . . . 40.41 112.425 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -51.75 103.28 0.06 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.817 0.341 . . . . 72.33 110.954 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.409 ' O ' ' C ' ' A' ' 53' ' ' THR . 1.1 p-10 -58.48 -56.9 16.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 71.14 110.931 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' THR . . . . . 0.409 ' C ' ' O ' ' A' ' 52' ' ' ASP . 10.2 t 36.73 44.08 0.32 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.115 -0.493 . . . . 74.13 111.186 -179.86 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.445 HG22 ' H ' ' A' ' 55' ' ' LEU . 0.2 OUTLIER -107.6 169.17 8.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.198 -0.455 . . . . 64.23 111.096 -179.93 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.602 ' O ' HD12 ' A' ' 55' ' ' LEU . 0.9 OUTLIER -109.49 150.23 28.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 73.14 110.907 -179.981 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.5 t -134.47 144.65 48.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.284 -0.416 . . . . 72.21 111.161 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 42.2 m-85 -102.9 132.57 49.02 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.252 -0.431 . . . . 73.53 110.826 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.547 ' C ' HD12 ' A' ' 59' ' ' ILE . 0.3 OUTLIER -127.31 146.63 50.38 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.148 -0.478 . . . . 74.21 110.91 179.96 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.547 HD12 ' C ' ' A' ' 58' ' ' ASP . 1.5 mp -119.28 113.61 41.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.224 -0.444 . . . . 65.31 111.131 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.783 ' HB3' HG13 ' A' ' 18' ' ' VAL . . . -102.66 117.0 33.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.467 . . . . 74.33 111.09 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 34.7 t80 -108.73 115.76 30.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.156 -0.475 . . . . 74.21 110.96 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -87.23 96.97 10.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.129 -0.487 . . . . 73.55 110.889 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.7 p -86.72 -33.15 6.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.146 -0.479 . . . . 72.42 111.12 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -130.67 164.91 23.98 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.184 -0.462 . . . . 62.21 110.892 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.9 t -87.21 3.24 47.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 61.21 110.92 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 61.6 t30 -110.72 -33.45 6.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.109 -0.496 . . . . 52.05 110.865 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.446 HG22 ' HA ' ' A' ' 107' ' ' TYR . 44.4 pt -150.54 172.02 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 72.35 111.12 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -157.16 172.85 17.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.14 -0.482 . . . . 72.14 111.058 179.799 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 10.2 m -112.1 150.97 14.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.223 -0.444 . . . . 72.33 111.129 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -138.11 127.48 24.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 64.24 110.857 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -102.4 147.2 27.01 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.471 . . . . 64.54 110.888 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.4 ' HB3' ' HB ' ' A' ' 102' ' ' ILE . 30.4 t80 -121.25 112.95 19.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.149 -0.478 . . . . 65.54 110.9 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.5 m -129.47 147.0 33.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 73.21 111.102 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -164.26 128.78 1.87 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.741 -0.742 . . . . 64.52 112.475 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 23.4 t -117.21 68.18 4.89 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.674 0.75 . . . . 53.12 111.155 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 162.67 41.21 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.679 2.253 . . . . 62.35 112.344 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -79.48 -165.67 0.83 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.265 -0.425 . . . . 72.5 111.059 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ARG . . . . . 0.404 ' HA ' ' HA ' ' A' ' 97' ' ' ASP . 55.1 ttp85 -76.88 139.28 40.2 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.148 -0.478 . . . . 74.14 110.916 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -133.83 151.88 51.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 52.13 111.088 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.0 ttpt -104.48 130.7 52.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.16 -0.473 . . . . 72.41 110.863 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' PHE . . . . . 0.468 ' CD1' HD12 ' A' ' 49' ' ' ILE . 26.9 m-85 -119.26 157.42 28.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 74.43 110.879 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.433 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -110.84 149.53 30.45 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 73.42 110.926 -179.921 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.644 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -177.14 75.64 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.783 -0.722 . . . . 73.23 112.493 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.532 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.8 tp10 -178.26 -176.37 0.52 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.999 0.428 . . . . 73.15 110.866 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.31 -69.15 0.69 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.174 -0.466 . . . . 65.1 110.92 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.4 t -84.63 -32.88 23.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.254 -0.43 . . . . 73.3 110.855 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.87 HG22 HG22 ' A' ' 93' ' ' VAL . 5.8 mm -65.57 -34.31 69.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 74.54 111.129 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 74.2 p -62.57 -53.81 49.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.475 . . . . 44.23 110.852 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.7 t -51.13 -35.86 37.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.134 -0.485 . . . . 62.21 110.867 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.515 HD13 ' O ' ' A' ' 90' ' ' LEU . 0.3 OUTLIER -63.5 -38.26 90.47 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.139 -0.482 . . . . 62.32 110.96 179.921 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 100.56 -14.37 59.25 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.776 -0.726 . . . . 61.12 112.505 179.882 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 19.2 ttt-85 -118.63 95.38 4.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.797 0.332 . . . . 74.33 110.941 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.87 HG22 HG22 ' A' ' 87' ' ' ILE . 94.0 t -111.66 -53.81 5.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 62.44 111.184 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 11.5 t -140.26 143.05 35.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 65.12 110.821 -179.825 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -132.27 115.37 15.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 63.42 110.931 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.582 ' HA ' ' HB2' ' A' ' 131' ' ' LYS . 1.4 m -154.47 171.49 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.107 -0.497 . . . . 75.12 111.146 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.485 ' O ' HG23 ' A' ' 96' ' ' VAL . 1.1 m-20 -86.34 172.1 10.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.202 -0.454 . . . . 64.4 110.895 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -123.25 130.52 52.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.266 -0.424 . . . . 64.32 110.919 -179.856 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.543 ' HA3' HD12 ' A' ' 127' ' ' LEU . . . -129.12 65.63 0.58 Allowed Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.733 -0.746 . . . . 73.42 112.431 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 112.76 3.16 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.704 2.269 . . . . 62.11 112.381 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -127.43 105.06 8.25 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.167 -0.469 . . . . 73.43 111.054 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.636 HG23 ' CA ' ' A' ' 124' ' ' GLY . 4.8 mp -128.23 151.13 34.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 74.45 111.133 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -145.99 115.7 7.26 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 61.54 110.924 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.8 p -139.62 -175.82 4.34 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.216 -0.447 . . . . 72.02 110.832 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.638 ' O ' HD12 ' A' ' 105' ' ' LEU . 1.5 pp -134.54 147.86 50.38 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.139 -0.482 . . . . 53.32 110.908 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 1.8 pp0? -104.65 139.0 40.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 73.33 110.915 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.446 ' HA ' HG22 ' A' ' 67' ' ' ILE . 14.2 p90 -143.18 142.74 31.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 72.44 110.956 -179.864 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 17.5 t-160 -94.49 138.88 31.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.143 -0.481 . . . . 71.44 110.876 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 4.4 t80 -131.12 107.89 9.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.224 -0.444 . . . . 73.51 110.915 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -173.28 178.07 2.51 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.108 -0.496 . . . . 23.41 110.956 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 57.9 m -110.95 36.22 3.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.274 -0.421 . . . . 53.34 110.819 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 53.57 36.53 23.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.182 -0.463 . . . . 73.54 110.912 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 75.5 mm-40 -84.11 -72.81 0.45 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.151 -0.477 . . . . 74.13 110.877 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 10.9 mmt85 -131.6 171.43 13.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 75.12 110.851 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 10.6 tp -66.61 136.99 56.41 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.193 -0.458 . . . . 70.41 110.934 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 6.3 m-85 -157.32 160.43 30.43 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.714 0.769 . . . . 63.52 110.88 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' PRO . . . . . 0.704 ' HA ' HD13 ' A' ' 153' ' ' LEU . 54.1 Cg_endo -69.77 177.93 5.09 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.67 2.247 . . . . 74.34 112.333 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 11.2 m-85 -115.98 143.99 44.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.242 -0.436 . . . . 71.4 110.876 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.459 HG13 ' HE1' ' A' ' 149' ' ' PHE . 75.7 t -99.35 132.89 43.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.085 -0.507 . . . . 71.24 111.116 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -125.51 169.43 17.46 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.712 -0.756 . . . . 54.55 112.512 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 7.7 p -175.59 152.53 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.915 0.388 . . . . 63.44 111.125 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -179.78 -151.7 10.13 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.834 -0.698 . . . . 71.35 112.555 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.7 p -111.37 127.25 68.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.827 0.346 . . . . 64.11 111.103 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' GLY . . . . . 0.636 ' CA ' HG23 ' A' ' 102' ' ' ILE . . . -119.77 108.85 1.54 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.79 -0.719 . . . . 71.34 112.513 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 35.7 ptt180 -100.73 123.23 44.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.909 0.385 . . . . 71.44 110.891 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 34.6 t -103.12 110.27 29.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.174 -0.467 . . . . 74.2 111.136 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.543 HD12 ' HA3' ' A' ' 99' ' ' GLY . 2.8 pp -120.3 156.7 30.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.474 . . . . 70.23 110.903 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 9.4 p90 -160.43 166.04 29.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 74.3 110.855 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -102.24 118.03 36.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 74.3 110.899 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -66.11 93.48 0.21 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.129 -0.487 . . . . 60.32 110.89 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.582 ' HB2' ' HA ' ' A' ' 96' ' ' VAL . 0.0 OUTLIER -74.18 -76.39 0.13 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.243 -0.435 . . . . 65.43 110.934 179.984 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 20.2 m -161.97 121.92 2.5 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.214 -0.448 . . . . 74.24 111.055 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 133' ' ' ASP . . . . . 0.583 ' HB3' ' HB3' ' A' ' 139' ' ' PHE . 27.0 t0 -108.08 114.56 28.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 43.43 110.789 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -75.78 -12.42 83.88 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.691 -0.766 . . . . 64.23 112.469 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -44.37 -29.36 0.67 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.902 0.382 . . . . 51.11 111.083 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -160.29 163.96 32.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.236 -0.438 . . . . 74.14 110.867 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.8 m -42.17 97.86 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.136 -0.484 . . . . 72.22 110.922 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 70.7 m 49.81 65.16 1.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 70.0 110.908 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.583 ' HB3' ' HB3' ' A' ' 133' ' ' ASP . 1.2 t80 -94.5 160.85 14.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 73.42 110.868 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -139.96 167.19 22.69 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.124 -0.489 . . . . 53.34 110.848 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.474 ' HA ' HG23 ' A' ' 176' ' ' VAL . 15.4 mt -117.36 151.79 19.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.471 . . . . 74.42 111.151 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 12.3 tppt? -113.18 122.62 48.05 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 75.45 110.913 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -76.81 -173.74 2.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.129 -0.487 . . . . 73.45 110.853 179.85 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -171.75 179.09 2.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 75.21 110.931 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 52.1 p-90 -140.06 161.37 37.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.216 -0.447 . . . . 74.3 110.881 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.757 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.8 165.29 0.87 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.59 0.71 . . . . 62.3 111.135 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.757 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 54.5 Cg_endo -69.74 161.92 44.08 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.673 2.248 . . . . 74.42 112.402 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.403 ' HA ' ' CB ' ' A' ' 170' ' ' ILE . . . -151.3 146.01 25.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 71.4 111.142 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 149' ' ' PHE . . . . . 0.459 ' HE1' HG13 ' A' ' 119' ' ' VAL . 1.4 t80 -103.07 120.24 40.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 52.12 110.896 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -102.94 156.87 17.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 63.04 110.899 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.443 HG13 ' HB ' ' A' ' 167' ' ' VAL . 7.3 p -164.85 123.67 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.264 -0.426 . . . . 72.0 111.146 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -174.73 -159.54 21.19 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.717 -0.754 . . . . 51.23 112.47 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.704 HD13 ' HA ' ' A' ' 117' ' ' PRO . 19.5 tp -151.8 164.78 36.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.784 0.325 . . . . 71.15 110.876 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.4 tpp85 -115.78 120.43 39.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 75.44 110.931 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -104.68 154.79 19.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 74.43 110.933 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -120.24 104.18 9.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.116 -0.493 . . . . 72.11 110.824 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 157' ' ' LEU . . . . . 0.636 HD11 HD12 ' A' ' 163' ' ' LEU . 23.6 mt -72.57 153.1 41.45 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 71.0 110.905 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -53.0 -33.44 44.24 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.759 -0.734 . . . . 52.44 112.523 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -71.32 176.18 4.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.819 0.342 . . . . 73.41 110.847 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 73.0 m -60.86 -36.53 79.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.127 -0.488 . . . . 73.24 110.884 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 26.6 m0 -80.92 144.17 32.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 74.01 110.945 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.451 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 2.4 mpt? -106.77 169.56 8.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 74.52 110.876 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.636 HD12 HD11 ' A' ' 157' ' ' LEU . 0.3 OUTLIER -107.24 148.78 28.5 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 53.11 110.916 -179.975 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -143.85 133.28 23.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 75.21 110.857 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 42.1 t -135.41 122.53 21.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 70.22 110.858 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -131.47 153.71 49.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.107 -0.497 . . . . 74.34 110.945 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.621 HG13 ' HE1' ' A' ' 194' ' ' PHE . 78.4 t -133.45 121.49 41.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.27 -0.423 . . . . 60.54 111.089 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 168' ' ' ARG . . . . . 0.798 ' HD2' HD12 ' A' ' 195' ' ' ILE . 3.9 ttm-85 -103.46 132.41 49.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 64.21 110.876 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -143.01 128.18 18.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 75.4 110.942 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 170' ' ' ILE . . . . . 0.459 HG21 ' O ' ' A' ' 147' ' ' PRO . 3.6 tp 177.91 133.78 0.22 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.576 0.703 . . . . 75.33 111.118 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 171' ' ' PRO . . . . . 0.407 ' HD2' HG13 ' A' ' 170' ' ' ILE . 53.5 Cg_endo -69.74 111.6 2.85 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.676 2.251 . . . . 50.45 112.366 179.856 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -122.5 153.16 39.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 73.35 110.909 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 14.5 pttm -130.57 153.58 48.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 61.43 110.854 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -123.28 170.74 9.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.126 -0.488 . . . . 73.52 111.094 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -125.03 164.88 19.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 73.04 110.87 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.48 HG22 ' CE1' ' A' ' 139' ' ' PHE . 5.6 p -156.46 142.63 10.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 73.1 111.117 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 10.0 t -166.62 -179.25 4.76 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.215 -0.448 . . . . 62.34 111.12 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -120.49 -161.1 11.36 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.734 -0.746 . . . . 64.32 112.475 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -124.59 -172.09 2.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.786 0.327 . . . . 71.21 111.178 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 7.8 tp -61.86 146.18 50.5 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.218 -0.447 . . . . 75.44 110.912 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 116.52 -86.78 0.42 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.76 -0.733 . . . . 72.52 112.445 179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.83 -160.83 0.07 OUTLIER 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.648 2.232 . . . . 74.53 112.32 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 19.9 t -106.28 87.66 2.73 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.646 0.736 . . . . 74.44 111.118 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 141.54 45.51 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.674 2.249 . . . . 73.33 112.359 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.444 HG12 ' CG2' ' A' ' 187' ' ' THR . 21.6 t -127.17 107.2 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.222 -0.445 . . . . 71.44 111.179 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 1.2 p -74.93 104.43 5.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.199 -0.455 . . . . 74.4 110.865 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 187' ' ' THR . . . . . 0.444 ' CG2' HG12 ' A' ' 185' ' ' VAL . 12.1 p -131.6 172.06 12.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.105 -0.498 . . . . 65.1 111.155 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.84 162.62 39.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.265 -0.425 . . . . 75.4 110.914 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 189' ' ' ILE . . . . . 0.484 HD11 ' CD1' ' A' ' 32' ' ' LEU . 56.7 mt -137.85 128.33 37.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 74.21 111.153 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -106.57 113.3 26.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.133 -0.485 . . . . 71.33 110.871 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 191' ' ' VAL . . . . . 0.49 HG12 ' H ' ' A' ' 192' ' ' ASP . 1.3 t -136.96 169.59 19.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.087 -0.506 . . . . 62.41 111.088 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.49 ' H ' HG12 ' A' ' 191' ' ' VAL . 20.5 t70 -107.27 87.14 2.98 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.61 0.719 . . . . 51.43 110.896 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 121.51 8.19 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.631 2.22 . . . . 65.41 112.395 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 194' ' ' PHE . . . . . 0.621 ' HE1' HG13 ' A' ' 167' ' ' VAL . 1.7 t80 -103.12 115.89 31.46 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 52.12 110.881 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 195' ' ' ILE . . . . . 0.798 HD12 ' HD2' ' A' ' 168' ' ' ARG . 9.7 mt -102.9 124.68 57.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 61.54 111.118 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 1.2 tt -112.71 108.54 17.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 74.31 110.897 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.25 115.68 28.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.257 -0.429 . . . . 71.34 110.818 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 198' ' ' LEU . . . . . 0.404 ' C ' ' HB2' ' A' ' 22' ' ' ASN . 5.7 tt -138.21 121.06 16.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.122 -0.49 . . . . 74.13 110.938 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -175.36 -141.44 3.73 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.825 -0.702 . . . . 64.5 112.538 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 200' ' ' ALA . . . . . 0.451 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -128.51 173.82 9.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.781 0.324 . . . . 70.03 111.104 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 26.2 t -146.55 163.51 35.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.458 . . . . 74.22 110.832 -179.749 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 202' ' ' TYR . . . . . 0.551 ' C ' HG23 ' A' ' 18' ' ' VAL . 2.1 t80 -133.9 114.4 13.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.149 -0.478 . . . . 75.31 110.883 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 57.8 t -76.88 145.11 10.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.091 -0.504 . . . . 72.15 111.108 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 -148.08 137.01 21.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.107 -0.497 . . . . 72.35 110.888 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.43 174.74 10.2 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.081 -0.508 . . . . 75.2 110.898 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 10.3 mp -75.88 -62.02 1.73 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.222 -0.444 . . . . 74.41 110.954 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -55.76 134.22 51.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 60.2 111.145 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 208' ' ' ALA . . . . . 0.563 ' HB1' HD13 ' A' ' 210' ' ' LEU . . . -75.37 -60.42 2.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.449 . . . . 52.03 111.088 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . 62.67 40.34 10.33 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.199 -0.455 . . . . 60.45 111.103 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 210' ' ' LEU . . . . . 0.563 HD13 ' HB1' ' A' ' 208' ' ' ALA . 6.4 mp -97.84 -45.55 6.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 53.41 110.893 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.205 -0.452 . . . . 62.42 110.908 179.865 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 20.5 mtm . . . . . 0 C--O 1.23 0.053 0 CA-C-O 120.774 0.321 . . . . 73.44 110.895 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 12.1 m-80 54.57 39.29 31.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 70.52 110.921 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 64.9 tt0 -77.53 111.93 13.78 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.18 -0.464 . . . . 65.21 110.804 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -101.17 151.54 21.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.163 -0.471 . . . . 73.04 110.866 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 10.0 p90 -51.8 156.98 2.15 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.738 0.78 . . . . 63.02 110.907 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 178.29 4.71 Favored 'Trans proline' 0 N--CA 1.465 -0.2 0 C-N-CA 122.746 2.297 . . . . 70.31 112.351 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -79.22 131.8 36.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.23 -0.441 . . . . 53.01 111.065 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 12.8 ptmm? -97.23 -36.03 10.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 73.42 110.868 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 2.5 t -52.14 -37.62 55.0 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.234 -0.439 . . . . 74.31 110.851 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.24 156.16 2.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.176 -0.465 . . . . 74.41 111.093 179.892 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -102.6 38.73 3.06 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.731 -0.747 . . . . 73.52 112.512 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 10.5 p90 -163.77 112.13 1.2 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.909 0.385 . . . . 70.02 110.884 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -168.36 169.64 10.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 73.31 110.905 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.4 mp0 -57.86 119.84 7.41 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.142 -0.481 . . . . 74.05 110.904 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.87 6.45 40.17 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.808 -0.711 . . . . 52.35 112.533 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -67.11 145.45 55.29 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.778 0.323 . . . . 72.05 110.857 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -125.43 121.68 34.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.203 -0.453 . . . . 52.33 110.894 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.724 HG23 ' HB3' ' A' ' 60' ' ' ALA . 13.5 m -130.69 134.91 61.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 63.23 111.145 179.882 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.56 ' HB1' ' CZ ' ' A' ' 21' ' ' PHE . . . -94.24 116.81 29.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 45.52 111.162 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 p -105.94 108.21 19.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 65.42 110.796 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.56 ' CZ ' ' HB1' ' A' ' 19' ' ' ALA . 16.5 m-85 -112.11 121.22 44.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.146 -0.479 . . . . 71.25 110.89 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -152.15 172.46 16.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 73.35 110.885 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -95.89 131.97 41.68 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 73.22 110.819 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -101.01 109.92 21.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.111 -0.495 . . . . 64.03 110.882 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 29.4 mmtt -93.9 106.33 18.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.485 . . . . 74.35 110.89 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.682 HG22 ' CD1' ' A' ' 195' ' ' ILE . 21.8 t -79.62 121.08 32.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.259 -0.428 . . . . 71.1 111.128 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.512 ' CD1' HD13 ' A' ' 196' ' ' LEU . 10.5 m-85 -105.64 99.67 9.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 75.22 110.948 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.9 HG23 HG11 ' A' ' 191' ' ' VAL . 5.5 p -167.69 141.09 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.123 -0.49 . . . . 74.2 111.16 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.75 72.09 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.753 -0.736 . . . . 54.03 112.44 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 16.6 tt0 -89.93 -66.19 0.95 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.809 0.338 . . . . 72.32 110.85 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 179.4 103.44 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 73.43 110.89 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.688 HD22 ' C ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -57.15 167.25 0.91 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.092 -0.504 . . . . 72.23 110.901 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.549 ' N ' HD22 ' A' ' 32' ' ' LEU . . . -80.68 114.69 3.88 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.705 -0.759 . . . . 61.24 112.506 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -51.48 140.53 17.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.804 0.335 . . . . 75.2 110.868 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.615 ' HB2' HG11 ' A' ' 185' ' ' VAL . 2.2 pt? -77.11 -33.28 56.92 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.131 -0.486 . . . . 74.15 110.924 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 32.2 t30 -170.5 156.67 5.57 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.223 -0.444 . . . . 73.31 110.896 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.4 p -98.63 138.86 21.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.223 -0.444 . . . . 31.22 111.202 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -105.67 -98.45 2.55 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.759 -0.734 . . . . 43.32 112.496 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -148.87 144.08 11.73 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.757 -0.735 . . . . 60.52 112.519 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 106.15 146.35 13.8 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.763 -0.732 . . . . 23.41 112.568 -179.843 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -72.2 99.57 2.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.844 0.354 . . . . 74.44 111.111 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.1 mt -145.24 158.83 50.77 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.534 0.683 . . . . 73.23 110.914 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.84 179.57 3.65 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.663 2.242 . . . . 53.13 112.341 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 -56.88 -68.13 0.25 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 64.33 110.909 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.4 ' HB1' HD11 ' A' ' 32' ' ' LEU . . . -170.96 -172.59 1.16 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.232 -0.44 . . . . 71.44 111.164 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -150.43 125.25 9.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.276 -0.42 . . . . 64.15 110.873 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 82' ' ' GLN . 12.5 p -119.13 134.02 64.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.203 -0.453 . . . . 72.41 111.114 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.9 m -153.45 178.51 9.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 54.52 110.849 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.532 HG22 ' CD1' ' A' ' 81' ' ' PHE . 42.6 pt -134.97 145.88 31.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.094 -0.503 . . . . 72.52 111.173 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -62.33 179.13 4.77 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.768 -0.73 . . . . 62.22 112.518 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.7 m-80 -119.96 107.84 13.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.8 0.333 . . . . 54.1 110.896 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -143.92 148.53 35.51 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 71.4 110.898 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.9 p -61.46 134.26 56.69 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.217 -0.447 . . . . 64.02 111.151 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 15.3 t -143.75 169.68 17.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 41.34 111.133 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -155.9 160.44 40.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 71.24 110.931 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.442 HG22 ' HA3' ' A' ' 74' ' ' GLY . 8.8 p -141.12 142.51 34.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.449 . . . . 60.13 111.162 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -102.44 132.2 48.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 73.35 110.899 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.65 ' O ' HD13 ' A' ' 59' ' ' ILE . 1.3 m-20 -129.14 149.91 50.75 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.142 -0.481 . . . . 70.33 110.863 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.65 HD13 ' O ' ' A' ' 58' ' ' ASP . 8.0 mm -122.39 114.36 42.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.443 . . . . 72.03 111.175 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.724 ' HB3' HG23 ' A' ' 18' ' ' VAL . . . -101.92 130.06 48.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 72.12 111.086 179.831 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.501 ' HB3' HG22 ' A' ' 69' ' ' VAL . 14.9 t80 -118.15 118.35 31.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.233 -0.439 . . . . 74.43 110.936 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -90.52 97.01 10.93 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.156 -0.474 . . . . 72.01 110.897 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.0 p -91.16 -34.91 6.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.206 -0.452 . . . . 73.44 111.129 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.2 t -130.02 159.67 35.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 64.33 110.894 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 93.4 p -84.13 2.76 37.96 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 61.13 110.827 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 41.2 m-80 -112.01 -32.5 6.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 73.34 110.876 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.511 HG22 ' CB ' ' A' ' 107' ' ' TYR . 2.3 pp -149.13 164.78 4.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.474 . . . . 74.44 111.142 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -154.68 169.89 22.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 60.04 111.124 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.501 HG22 ' HB3' ' A' ' 61' ' ' TYR . 6.1 m -110.97 152.93 12.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.445 . . . . 74.14 111.112 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -148.61 124.27 10.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.465 . . . . 54.32 110.875 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.658 ' CZ ' HD22 ' A' ' 103' ' ' LEU . 2.4 t80 -102.72 131.06 49.8 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 64.33 110.917 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.553 ' HE2' ' HG ' ' A' ' 197' ' ' SER . 24.2 m-85 -111.65 118.64 36.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.108 -0.496 . . . . 72.43 110.829 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.0 p -142.51 151.79 17.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 42.0 111.116 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.442 ' HA3' HG22 ' A' ' 56' ' ' THR . . . -160.05 160.7 31.85 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.732 . . . . 74.11 112.491 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.477 ' O ' HG13 ' A' ' 75' ' ' VAL . 4.0 p -138.29 77.72 35.08 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.691 0.758 . . . . 72.32 111.129 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 152.26 69.32 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.734 2.289 . . . . 73.35 112.346 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -71.17 -168.38 0.29 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 72.01 111.071 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 19.8 ttp-105 -77.58 127.31 32.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 74.23 110.857 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -133.66 140.69 47.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 44.23 111.118 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -89.58 141.73 28.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.443 . . . . 54.23 110.921 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' PHE . . . . . 0.532 ' CD1' HG22 ' A' ' 49' ' ' ILE . 11.9 m-85 -132.73 147.43 52.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.237 -0.438 . . . . 72.43 110.858 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.583 ' O ' HG23 ' A' ' 47' ' ' VAL . 0.4 OUTLIER -92.82 155.52 17.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 65.41 110.877 -179.92 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.537 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -179.46 72.79 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.759 -0.734 . . . . 61.34 112.517 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -178.9 -174.15 0.34 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.937 0.399 . . . . 70.12 110.846 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 6.0 mtpt -85.82 -70.17 0.61 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.114 -0.494 . . . . 72.33 110.904 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 74.0 m -84.3 -31.1 25.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.259 -0.428 . . . . 72.11 110.899 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.929 HG22 HG22 ' A' ' 93' ' ' VAL . 1.2 mt -68.17 -33.73 62.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.122 -0.49 . . . . 74.45 111.119 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.2 t -62.46 -47.26 84.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 74.32 110.842 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 36.9 t -57.69 -35.37 70.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.183 -0.462 . . . . 75.3 110.833 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.541 HD23 ' HG2' ' A' ' 92' ' ' ARG . 4.2 tp -63.64 -48.33 77.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.474 . . . . 71.31 110.988 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 111.37 -13.33 28.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.716 -0.754 . . . . 64.13 112.474 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.541 ' HG2' HD23 ' A' ' 90' ' ' LEU . 0.0 OUTLIER -117.79 87.47 2.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.906 0.384 . . . . 73.44 110.911 -179.837 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.929 HG22 HG22 ' A' ' 87' ' ' ILE . 32.3 t -113.05 -42.05 4.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.195 -0.457 . . . . 75.15 111.14 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 80.4 p -141.0 152.05 44.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.253 -0.43 . . . . 54.34 110.897 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -141.43 116.98 10.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.141 -0.481 . . . . 72.13 110.92 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.746 HG23 ' HB2' ' A' ' 131' ' ' LYS . 2.6 p -178.23 166.42 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 72.3 111.182 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.473 ' H ' HG22 ' A' ' 96' ' ' VAL . 2.5 p30 -95.07 156.48 16.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 72.42 110.855 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -93.98 147.63 22.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.165 -0.471 . . . . 64.24 110.99 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -126.39 60.87 0.64 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.773 -0.727 . . . . 70.52 112.501 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 113.86 3.52 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.644 2.229 . . . . 53.33 112.323 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.43 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -131.47 108.53 9.65 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.167 -0.469 . . . . 52.42 111.079 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.689 HG22 ' CA ' ' A' ' 124' ' ' GLY . 1.2 pp -140.27 153.06 21.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.481 . . . . 73.3 111.085 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.658 HD22 ' CZ ' ' A' ' 71' ' ' PHE . 0.7 OUTLIER -149.62 130.97 14.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.145 -0.48 . . . . 43.31 110.924 179.913 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.2 p -151.34 170.45 19.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 52.0 110.87 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.593 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.7 OUTLIER -113.46 147.01 38.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 74.21 110.908 179.981 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 34.4 mt-30 -101.7 144.78 29.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.181 -0.463 . . . . 73.54 110.98 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.511 ' CB ' HG22 ' A' ' 67' ' ' ILE . 46.7 p90 -153.73 150.4 28.49 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.244 -0.435 . . . . 63.34 110.967 -179.852 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 2.2 p80 -130.7 160.77 33.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.126 -0.488 . . . . 75.1 110.863 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 10.0 t80 -90.38 107.51 19.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.181 -0.463 . . . . 74.31 110.914 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 20.0 t0 -68.65 108.61 3.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.485 . . . . 73.02 110.84 179.897 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 31.2 p -170.1 149.04 3.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 62.42 110.956 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 66.1 m-85 -62.59 105.5 0.65 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.193 -0.458 . . . . 74.4 110.89 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -167.09 161.65 14.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 75.33 110.845 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 21.6 ttt180 -52.16 164.5 0.29 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 74.0 110.876 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 8.6 tp -64.61 123.93 20.57 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.246 -0.434 . . . . 74.23 110.893 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 8.1 m-85 -137.74 160.64 64.06 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.683 0.754 . . . . 75.43 110.919 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' PRO . . . . . 0.418 ' HA ' HD13 ' A' ' 153' ' ' LEU . 54.3 Cg_endo -69.72 177.38 5.61 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.685 2.257 . . . . 74.54 112.38 179.884 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.433 ' CE1' HD12 ' A' ' 153' ' ' LEU . 3.0 m-85 -115.32 152.4 32.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.191 -0.459 . . . . 74.43 110.864 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 61.6 t -111.0 141.13 27.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.102 -0.499 . . . . 60.44 111.186 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -133.39 175.69 20.04 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.775 -0.726 . . . . 71.15 112.546 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.5 p -168.16 151.97 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.944 0.402 . . . . 61.12 111.058 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -179.54 -149.68 8.57 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.714 -0.755 . . . . 73.12 112.517 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 11.3 p -108.01 146.07 14.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.829 0.347 . . . . 73.24 111.168 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' GLY . . . . . 0.689 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -140.99 121.03 1.82 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.806 -0.712 . . . . 61.41 112.51 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 125' ' ' ARG . . . . . 0.43 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 3.1 ptm180 -117.48 128.7 55.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.893 0.378 . . . . 74.54 110.874 -179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 97.8 t -105.94 109.44 27.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.091 -0.504 . . . . 63.44 111.161 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.445 HD23 ' HB2' ' A' ' 143' ' ' ASP . 41.7 mt -118.22 171.99 7.74 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.125 -0.489 . . . . 71.33 110.896 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -148.41 176.39 10.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 72.52 110.949 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.594 ' O ' HG21 ' A' ' 96' ' ' VAL . 2.5 t80 -104.57 171.71 7.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 73.04 110.812 -179.897 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 16.8 t0 -109.72 96.58 6.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.122 -0.49 . . . . 75.44 110.847 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.746 ' HB2' HG23 ' A' ' 96' ' ' VAL . 2.0 mmmp? -118.1 -81.44 0.62 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.466 . . . . 73.02 110.892 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 98.5 m -162.64 85.24 0.55 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.202 -0.454 . . . . 71.12 111.15 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -99.15 161.67 13.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.221 -0.445 . . . . 72.42 110.885 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.46 154.08 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.705 -0.759 . . . . 71.23 112.489 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.533 ' CB ' HD13 ' A' ' 87' ' ' ILE . . . -82.51 3.24 29.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.833 0.349 . . . . 70.2 111.149 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.746 HD12 HD22 ' A' ' 180' ' ' LEU . 2.7 mm? -86.83 -176.14 5.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 71.23 110.937 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 23.1 t -65.0 87.0 0.06 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 75.35 110.849 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 65.5 m 51.93 75.37 0.22 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 74.02 110.878 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -91.03 157.11 17.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.481 . . . . 61.41 110.883 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -138.12 -173.9 3.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.107 -0.497 . . . . 71.2 110.878 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.786 HG22 HG13 ' A' ' 176' ' ' VAL . 5.1 pt -141.0 156.98 22.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.205 -0.452 . . . . 70.23 111.147 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 142' ' ' LYS . . . . . 0.433 ' HB2' ' HB3' ' A' ' 175' ' ' ASP . 1.8 tttt -96.02 116.39 28.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.159 -0.473 . . . . 72.43 110.941 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.445 ' HB2' HD23 ' A' ' 127' ' ' LEU . 0.9 OUTLIER -63.33 -173.76 0.07 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.241 -0.436 . . . . 71.21 110.866 179.887 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -157.18 169.72 24.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.242 -0.435 . . . . 73.33 110.955 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 28.0 p-90 -156.69 146.71 21.06 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.341 -0.39 . . . . 75.5 110.893 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.722 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 179.95 165.06 0.84 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.549 0.69 . . . . 72.32 111.097 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.722 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.1 Cg_endo -69.82 140.41 42.4 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.677 2.252 . . . . 70.35 112.314 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.651 ' HB1' ' O ' ' A' ' 169' ' ' TYR . . . -135.98 177.82 7.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 74.2 111.096 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -126.63 166.54 17.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.18 -0.464 . . . . 74.44 110.872 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 11.3 tt0 -145.32 155.29 43.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 74.31 110.912 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.1 p -154.92 126.87 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.226 -0.443 . . . . 61.35 111.15 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -177.79 -158.69 21.27 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.677 -0.773 . . . . 53.14 112.43 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.433 HD12 ' CE1' ' A' ' 118' ' ' TYR . 46.7 tp -145.17 157.39 44.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.844 0.354 . . . . 74.42 110.867 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 6.2 tpp85 -120.97 117.71 27.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 72.3 110.85 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 3.0 t80 -95.91 132.21 41.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 74.02 110.928 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -119.23 113.34 20.71 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.162 -0.472 . . . . 71.11 110.879 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 157' ' ' LEU . . . . . 0.46 HD12 ' O ' ' A' ' 161' ' ' TRP . 38.8 mt -88.44 163.02 16.16 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.209 -0.451 . . . . 72.12 110.861 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -99.44 126.91 9.08 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.758 -0.734 . . . . 71.0 112.482 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 65.3 m-20 58.78 37.84 24.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.873 0.368 . . . . 75.21 110.916 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 3.1 m -167.18 178.03 5.86 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.167 -0.47 . . . . 72.42 110.869 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 161' ' ' TRP . . . . . 0.46 ' O ' HD12 ' A' ' 157' ' ' LEU . 5.3 m-90 -64.12 162.09 14.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 71.4 110.936 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.421 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 21.5 mtm -106.64 170.56 7.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.231 -0.44 . . . . 74.51 110.918 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.509 HD23 ' N ' ' A' ' 164' ' ' ASN . 1.2 tt -124.08 148.81 46.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.246 -0.434 . . . . 71.54 110.904 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 164' ' ' ASN . . . . . 0.509 ' N ' HD23 ' A' ' 163' ' ' LEU . 7.5 t30 -143.94 131.79 21.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 73.31 110.887 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 60.5 p -146.56 122.23 10.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.446 . . . . 75.02 110.807 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -157.69 161.22 38.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.053 -0.521 . . . . 73.43 110.89 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 10.9 t -118.58 130.52 73.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 74.5 111.128 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 168' ' ' ARG . . . . . 0.585 ' CZ ' HD13 ' A' ' 102' ' ' ILE . 0.0 OUTLIER -107.04 122.17 45.93 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.169 -0.468 . . . . 64.4 110.866 -179.958 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 169' ' ' TYR . . . . . 0.651 ' O ' ' HB1' ' A' ' 148' ' ' ALA . 15.3 t80 -108.29 115.56 30.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.184 -0.462 . . . . 73.44 110.927 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 170' ' ' ILE . . . . . 0.563 HG23 ' HG2' ' A' ' 193' ' ' PRO . 9.6 tt -134.45 79.35 54.59 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.558 0.694 . . . . 65.12 111.092 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 171' ' ' PRO . . . . . 0.424 ' HA ' ' HD2' ' A' ' 193' ' ' PRO . 54.0 Cg_endo -69.72 125.06 11.72 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.587 2.192 . . . . 74.24 112.364 179.835 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 11.8 p90 -162.14 177.58 9.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 74.32 110.891 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 10.1 pttp -122.83 137.69 54.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.126 -0.488 . . . . 62.42 110.844 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.49 156.1 18.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 62.43 111.146 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 175' ' ' ASP . . . . . 0.433 ' HB3' ' HB2' ' A' ' 142' ' ' LYS . 0.1 OUTLIER -111.81 161.24 16.55 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.259 -0.428 . . . . 71.52 110.915 179.851 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.786 HG13 HG22 ' A' ' 141' ' ' ILE . 4.7 t -138.31 133.01 42.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.229 -0.441 . . . . 75.51 111.17 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.7 t -166.36 160.48 15.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 74.03 111.134 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -160.38 -133.48 1.5 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.704 -0.76 . . . . 44.34 112.479 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 52.9 m -153.01 96.65 2.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.817 0.342 . . . . 63.55 111.089 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.746 HD22 HD12 ' A' ' 136' ' ' LEU . 3.7 tp -140.03 114.09 8.97 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.2 -0.455 . . . . 60.24 110.878 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 56.84 175.64 0.29 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.738 -0.744 . . . . 64.11 112.437 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.881 ' O ' HG23 ' A' ' 183' ' ' VAL . 53.8 Cg_endo -69.72 71.36 1.5 Allowed 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.696 2.264 . . . . 61.04 112.322 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.881 HG23 ' O ' ' A' ' 182' ' ' PRO . 1.5 t 153.34 93.95 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.543 0.687 . . . . 72.51 111.044 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 146.0 58.62 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.706 2.27 . . . . 72.13 112.324 179.9 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.615 HG11 ' HB2' ' A' ' 35' ' ' LEU . 82.5 t -96.28 107.74 20.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 72.41 111.129 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -108.66 125.46 51.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 63.13 110.882 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 12.8 p -139.66 174.73 10.21 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.099 -0.501 . . . . 64.44 111.128 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 34.4 ttpt -158.95 145.35 16.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 65.34 110.921 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 8.6 tt -143.15 138.31 26.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 64.54 111.147 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -102.17 119.71 39.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.234 -0.439 . . . . 74.1 110.968 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 191' ' ' VAL . . . . . 0.9 HG11 HG23 ' A' ' 28' ' ' VAL . 4.1 t -136.82 158.25 36.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 73.12 111.168 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.4 ' N ' HG12 ' A' ' 191' ' ' VAL . 0.4 OUTLIER -107.73 89.95 5.76 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.624 0.725 . . . . 74.11 110.933 179.857 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 193' ' ' PRO . . . . . 0.563 ' HG2' HG23 ' A' ' 170' ' ' ILE . 53.2 Cg_endo -69.8 121.62 8.3 Favored 'Trans proline' 0 C--O 1.232 0.211 0 C-N-CA 122.697 2.265 . . . . 71.22 112.296 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -99.76 107.43 19.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.268 -0.424 . . . . 74.23 110.889 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 195' ' ' ILE . . . . . 0.682 ' CD1' HG22 ' A' ' 26' ' ' VAL . 49.1 mm -87.93 119.39 35.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.138 -0.483 . . . . 60.44 111.148 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 196' ' ' LEU . . . . . 0.512 HD13 ' CD1' ' A' ' 27' ' ' TYR . 5.4 mp -105.98 108.18 19.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.206 -0.452 . . . . 64.24 110.951 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 197' ' ' SER . . . . . 0.553 ' HG ' ' HE2' ' A' ' 72' ' ' PHE . 9.4 m -98.97 112.03 24.26 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.213 -0.448 . . . . 75.13 110.897 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 1.9 tt -136.72 119.88 16.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 64.44 110.899 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -176.16 -145.55 5.61 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.779 -0.724 . . . . 65.51 112.482 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 200' ' ' ALA . . . . . 0.421 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -125.17 173.83 8.49 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.75 0.31 . . . . 65.2 111.186 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.7 t -148.89 169.77 19.8 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.26 -0.427 . . . . 63.02 110.835 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -138.8 146.01 40.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.131 -0.486 . . . . 72.52 110.878 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.691 ' HA ' HG12 ' A' ' 18' ' ' VAL . 15.6 m -97.91 144.81 10.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.124 -0.489 . . . . 43.52 111.158 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -148.28 139.75 23.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.48 . . . . 74.43 110.812 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -107.93 -35.5 6.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.09 -0.504 . . . . 71.44 110.892 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 206' ' ' LEU . . . . . 0.458 HD21 ' C ' ' A' ' 208' ' ' ALA . 10.0 tt -62.45 140.18 58.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.222 -0.444 . . . . 74.33 110.969 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -112.64 -38.68 4.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 71.43 111.095 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 208' ' ' ALA . . . . . 0.458 ' C ' HD21 ' A' ' 206' ' ' LEU . . . -112.95 125.5 54.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.459 . . . . 72.02 111.084 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -109.14 172.22 6.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.262 -0.427 . . . . 70.5 111.17 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -131.04 148.45 52.75 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.279 -0.419 . . . . 44.44 110.957 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 15.9 mm-40 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.266 -0.425 . . . . 70.3 110.855 179.967 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 45.8 mtt . . . . . 0 C--O 1.23 0.058 0 CA-C-O 120.74 0.305 . . . . 65.41 110.891 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -111.05 161.41 15.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.25 -0.432 . . . . 74.41 110.934 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -157.15 143.49 18.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.266 -0.425 . . . . 64.44 110.863 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 59.9 m-20 -148.37 172.85 13.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.489 . . . . 62.23 110.867 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 9.6 p90 -118.48 157.61 49.06 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.722 0.773 . . . . 74.22 110.897 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 179.61 3.57 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.697 2.265 . . . . 54.44 112.363 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -110.16 172.47 6.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.259 -0.428 . . . . 72.41 111.109 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 38.5 mmtm -77.92 146.71 35.38 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.194 -0.457 . . . . 73.41 110.857 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 3.6 m -166.49 157.23 12.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.159 -0.473 . . . . 73.33 110.831 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -79.04 135.72 36.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.109 -0.496 . . . . 61.4 111.09 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -87.75 76.37 2.0 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.831 -0.7 . . . . 73.22 112.532 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -113.46 38.22 2.97 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.886 0.374 . . . . 73.24 110.924 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -143.42 150.06 38.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.117 -0.492 . . . . 63.33 110.912 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -51.99 119.44 4.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 65.42 110.964 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 103.28 11.67 33.2 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.675 -0.774 . . . . 53.34 112.514 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -83.28 159.16 21.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.781 0.324 . . . . 70.54 110.887 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 13.3 m95 -107.36 158.34 17.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.247 -0.433 . . . . 73.54 110.902 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.462 HG13 ' O ' ' A' ' 202' ' ' TYR . 42.9 t -150.71 120.78 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.281 -0.418 . . . . 72.51 111.133 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -87.77 110.08 20.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 63.11 111.117 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 6.5 t -107.61 113.3 26.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.214 -0.448 . . . . 74.43 110.894 -179.822 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.677 ' CE1' ' HB3' ' A' ' 200' ' ' ALA . 17.0 p90 -108.41 122.36 46.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 75.1 110.863 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -152.76 167.93 27.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.138 -0.483 . . . . 54.23 110.92 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -102.01 134.89 44.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 70.01 110.929 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -102.69 122.68 44.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 65.32 110.801 -179.763 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 11.3 tptm -96.59 106.61 18.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.054 -0.521 . . . . 64.11 110.83 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 34.3 m -78.86 134.0 28.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.456 . . . . 70.22 111.201 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 17.0 t80 -130.9 99.74 5.01 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.223 -0.444 . . . . 75.42 110.9 -179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.0 p -165.82 152.86 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.118 -0.492 . . . . 75.34 111.127 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 123.59 77.11 0.35 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.739 -0.743 . . . . 71.34 112.48 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 25.6 pt-20 -90.26 -44.11 9.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.837 0.351 . . . . 75.34 110.85 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.683 ' HA ' HG22 ' A' ' 47' ' ' VAL . 0.9 OUTLIER 178.58 170.64 0.81 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 70.32 110.866 -179.937 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.482 HD23 ' CB ' ' A' ' 45' ' ' ALA . 20.8 tp -74.9 161.58 29.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.131 -0.486 . . . . 64.31 110.876 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.93 39.1 2.88 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.709 -0.757 . . . . 51.13 112.496 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ASP . . . . . 0.72 ' O ' HD23 ' A' ' 35' ' ' LEU . 3.7 t70 -104.21 155.56 18.63 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.746 0.308 . . . . 72.21 110.953 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.72 HD23 ' O ' ' A' ' 34' ' ' ASP . 9.2 mt -130.6 167.53 18.58 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.219 -0.446 . . . . 70.32 110.905 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 17.7 t30 -91.74 172.48 8.45 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 71.14 110.886 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 61.1 t -90.65 -38.65 11.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 62.43 111.173 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -78.04 98.7 1.48 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.768 -0.73 . . . . 52.5 112.522 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 65.27 169.01 2.22 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.752 -0.737 . . . . 42.02 112.471 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -99.21 85.93 0.69 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.705 -0.76 . . . . 50.01 112.522 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -114.5 -179.61 3.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.836 0.351 . . . . 73.41 111.065 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 21.5 mt -53.26 158.84 2.41 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.575 0.702 . . . . 72.41 110.944 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 152.77 69.37 Favored 'Trans proline' 0 C--N 1.34 0.127 0 C-N-CA 122.7 2.267 . . . . 73.42 112.371 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -102.79 -38.06 7.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.443 . . . . 75.42 110.867 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.482 ' CB ' HD23 ' A' ' 32' ' ' LEU . . . -56.93 179.27 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 74.22 111.071 179.885 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -161.2 128.61 4.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.225 -0.443 . . . . 73.23 110.861 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.683 HG22 ' HA ' ' A' ' 31' ' ' GLU . 22.3 m -104.36 167.39 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 45.3 111.15 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -164.76 174.41 10.72 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.13 -0.486 . . . . 74.24 110.804 -179.806 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 7.9 tt -134.04 149.24 30.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.089 -0.505 . . . . 65.11 111.08 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -139.3 85.5 0.22 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.709 -0.758 . . . . 74.41 112.468 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -147.77 152.5 37.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.814 0.34 . . . . 72.54 110.925 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 46.2 m-20 -104.0 178.09 4.66 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.156 -0.474 . . . . 71.12 110.818 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 2.3 t -55.73 150.22 13.09 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 73.42 111.124 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -151.58 162.72 40.5 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.208 -0.451 . . . . 75.23 111.112 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 20.3 mt -108.28 153.49 23.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.169 -0.469 . . . . 75.11 110.978 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.703 HG21 ' CZ ' ' A' ' 72' ' ' PHE . 0.0 OUTLIER -135.56 147.89 48.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.26 -0.427 . . . . 70.05 111.062 -179.995 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -104.22 131.49 51.48 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.18 -0.464 . . . . 73.45 110.835 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 -126.63 138.29 53.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.19 -0.459 . . . . 60.55 110.85 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.404 ' O ' HG22 ' A' ' 59' ' ' ILE . 1.6 mp -108.08 113.56 44.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.144 -0.48 . . . . 65.05 111.132 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -106.02 120.39 41.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 74.42 111.161 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.671 ' HB3' HG22 ' A' ' 69' ' ' VAL . 8.1 t80 -105.69 118.53 36.83 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.164 -0.471 . . . . 73.4 110.93 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -93.76 96.64 9.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.088 -0.505 . . . . 72.22 110.895 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.424 HG22 ' CE1' ' A' ' 61' ' ' TYR . 57.4 t -91.23 -35.17 6.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.144 -0.48 . . . . 73.44 111.133 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.6 m -131.87 163.42 28.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 74.13 110.894 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 33.4 m -87.49 3.45 47.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 62.33 110.865 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 7.1 m120 -107.77 -33.08 7.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.112 -0.495 . . . . 55.23 110.895 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.8 pt -150.36 169.9 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 62.34 111.142 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -157.12 167.32 30.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.45 . . . . 52.43 111.105 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.671 HG22 ' HB3' ' A' ' 61' ' ' TYR . 2.7 m -110.54 151.57 12.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.183 -0.462 . . . . 74.33 111.077 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -141.69 137.31 31.65 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.173 -0.467 . . . . 72.23 110.866 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -121.02 110.39 16.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.248 -0.433 . . . . 73.13 110.903 -179.897 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.703 ' CZ ' HG21 ' A' ' 56' ' ' THR . 41.0 t80 -87.27 125.95 34.53 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 75.34 110.908 -179.883 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 40.4 t -146.42 146.78 18.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.234 -0.439 . . . . 74.5 111.16 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.548 ' HA3' HG22 ' A' ' 56' ' ' THR . . . -147.97 178.89 25.26 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.673 -0.775 . . . . 60.34 112.458 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.6 t -144.26 66.0 13.81 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.583 0.706 . . . . 75.33 111.111 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 138.14 37.22 Favored 'Trans proline' 0 C--N 1.34 0.132 0 C-N-CA 122.714 2.276 . . . . 73.52 112.359 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -67.47 -166.81 0.05 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.213 -0.448 . . . . 35.34 111.161 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 23.1 ttp180 -75.77 123.75 26.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.242 -0.436 . . . . 63.24 110.881 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -110.66 150.93 28.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 71.03 111.166 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.22 119.51 38.85 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 71.52 110.891 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -114.31 144.84 42.59 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.213 -0.449 . . . . 73.24 110.858 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 28.3 mt-30 -104.26 153.22 21.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.453 . . . . 71.12 110.979 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.645 ' HA2' HG12 ' A' ' 47' ' ' VAL . . . -178.84 75.9 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.734 -0.746 . . . . 63.35 112.453 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -177.4 -177.46 0.7 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.899 0.381 . . . . 72.52 110.907 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.17 -68.96 0.7 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.152 -0.476 . . . . 63.24 110.917 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.6 m -84.97 -32.74 22.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.236 -0.438 . . . . 73.11 110.829 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.651 HG22 HG22 ' A' ' 93' ' ' VAL . 5.1 mm -66.52 -34.45 70.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.121 -0.491 . . . . 73.34 111.157 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 28.1 t -63.23 -51.28 66.86 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.177 -0.465 . . . . 73.21 110.831 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 58.5 m -51.46 -36.92 46.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.152 -0.476 . . . . 74.42 110.894 -179.798 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 35.9 mt -64.71 -42.92 94.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.487 . . . . 74.3 110.88 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.34 -13.98 39.71 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.831 -0.699 . . . . 74.21 112.534 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.1 mtp-105 -115.91 90.09 3.25 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.84 0.352 . . . . 74.25 110.825 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.651 HG22 HG22 ' A' ' 87' ' ' ILE . 3.9 t -113.79 -43.94 4.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 71.02 111.108 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.3 m -141.18 144.06 34.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 73.1 110.839 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -138.44 118.22 13.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.172 -0.467 . . . . 63.31 110.954 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.438 HG22 ' N ' ' A' ' 97' ' ' ASP . 5.3 p -178.14 164.41 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.485 . . . . 63.42 111.151 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.438 ' N ' HG22 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -100.21 173.0 6.82 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.208 -0.451 . . . . 62.03 110.923 179.908 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 98' ' ' TYR . . . . . 0.434 ' HA ' ' HB2' ' A' ' 128' ' ' PHE . 62.1 m-85 -133.16 141.3 48.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 74.52 110.873 -179.804 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -108.99 82.07 0.3 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.799 -0.715 . . . . 72.14 112.493 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 112.22 3.01 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.681 2.254 . . . . 74.35 112.374 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -124.89 94.98 4.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.259 -0.428 . . . . 71.21 111.168 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.49 HD12 ' CD1' ' A' ' 72' ' ' PHE . 12.2 mt -112.35 145.73 18.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 74.15 111.098 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -149.2 109.43 4.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 61.12 110.943 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.3 p -140.62 166.21 25.36 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 73.4 110.911 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.429 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -114.76 140.41 48.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.146 -0.479 . . . . 74.23 110.925 -179.99 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 6.9 pt20 -102.62 145.41 29.69 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 64.14 110.864 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 10.5 p90 -140.42 145.31 36.85 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.144 -0.48 . . . . 74.43 110.879 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 58.0 t60 -100.23 141.09 33.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.111 -0.495 . . . . 74.5 110.838 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.1 t80 -101.13 142.71 32.18 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.461 . . . . 74.15 110.96 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 33.6 t70 -83.56 132.08 34.94 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.14 -0.482 . . . . 73.15 110.906 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.0 m -153.59 -174.35 4.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 55.4 110.807 -179.7 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 15.2 t80 -118.43 -29.9 5.35 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.104 -0.498 . . . . 65.52 110.923 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -57.36 -176.04 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.127 -0.488 . . . . 73.01 110.854 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 55.0 mtm180 -58.05 -174.82 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.115 -0.493 . . . . 70.32 110.935 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 10.8 mp -67.14 165.28 16.27 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 70.12 110.918 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' TYR . . . . . 0.414 ' HB2' ' HD2' ' A' ' 117' ' ' PRO . 6.4 p90 -165.85 159.5 13.11 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.628 0.727 . . . . 74.54 111.004 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' PRO . . . . . 0.414 ' HD2' ' HB2' ' A' ' 116' ' ' TYR . 53.4 Cg_endo -69.74 178.95 4.04 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.669 2.246 . . . . 74.43 112.335 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -108.82 157.2 18.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 72.42 110.878 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 93.4 t -111.4 134.4 53.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.059 -0.519 . . . . 54.33 111.146 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -135.98 168.93 23.81 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.776 -0.726 . . . . 75.04 112.543 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 10.6 p -162.35 152.15 3.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.876 0.37 . . . . 73.05 111.131 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -176.83 -154.32 11.78 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.689 -0.767 . . . . 74.14 112.502 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.476 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 10.2 p -111.13 139.04 36.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.95 0.405 . . . . 60.14 111.086 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -128.72 115.75 2.08 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.777 -0.725 . . . . 62.53 112.546 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 17.3 ptp180 -122.82 116.59 23.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.852 0.358 . . . . 71.11 110.848 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.429 ' O ' HG13 ' A' ' 126' ' ' VAL . 3.6 p -117.22 114.48 45.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.182 -0.463 . . . . 52.32 111.043 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.425 HD21 ' HB3' ' A' ' 145' ' ' TRP . 0.0 OUTLIER -150.55 168.15 25.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 62.33 110.924 179.894 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.434 ' HB2' ' HA ' ' A' ' 98' ' ' TYR . 1.0 OUTLIER -164.36 -172.45 2.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 65.23 110.899 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -94.44 129.22 41.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 71.31 110.884 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -67.11 124.39 22.94 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.194 -0.457 . . . . 72.33 110.797 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 20.0 mmmt -102.39 -72.48 0.69 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.159 -0.473 . . . . 73.25 110.9 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -151.63 77.13 1.23 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 74.14 111.152 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -94.1 158.68 15.5 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.467 . . . . 71.54 110.905 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.02 159.71 0.19 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.728 -0.749 . . . . 61.1 112.544 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.599 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -78.01 4.93 10.96 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.819 0.342 . . . . 65.14 111.14 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.639 HD12 HD22 ' A' ' 180' ' ' LEU . 2.8 mm? -86.27 -176.68 6.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 74.44 110.956 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.6 t -68.33 85.28 0.27 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.194 -0.457 . . . . 71.24 110.889 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 89.5 p 46.22 74.85 0.13 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 71.14 110.953 -179.729 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -86.29 156.5 20.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.149 -0.478 . . . . 74.33 110.837 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -107.62 175.01 5.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.068 -0.515 . . . . 54.24 110.886 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.656 HG22 HG13 ' A' ' 176' ' ' VAL . 24.7 pt -152.2 135.64 7.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 43.11 111.106 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 142' ' ' LYS . . . . . 0.626 ' O ' HG22 ' A' ' 174' ' ' THR . 0.0 OUTLIER -72.54 116.94 13.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.113 -0.494 . . . . 75.51 110.925 179.861 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -63.63 -158.43 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.452 . . . . 71.03 110.801 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 144' ' ' LYS . . . . . 0.625 ' NZ ' HG23 ' A' ' 170' ' ' ILE . 3.0 tttt -128.99 147.3 50.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 74.44 110.888 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 145' ' ' TRP . . . . . 0.425 ' HB3' HD21 ' A' ' 127' ' ' LEU . 43.2 p90 -158.6 119.01 3.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.156 -0.474 . . . . 70.02 110.897 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.834 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.38 168.46 0.8 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.566 0.698 . . . . 63.02 111.112 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.834 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.4 Cg_endo -69.78 141.01 44.0 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.661 2.24 . . . . 50.43 112.362 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.6 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -135.27 168.15 19.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 71.01 111.102 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -116.79 139.78 50.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.243 -0.435 . . . . 74.41 110.837 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 -116.76 145.75 43.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.104 -0.498 . . . . 74.31 110.919 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.59 127.18 8.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.455 . . . . 74.02 111.133 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 152' ' ' GLY . . . . . 0.411 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 176.9 -179.6 47.77 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.724 -0.75 . . . . 55.22 112.531 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.494 ' H ' HD23 ' A' ' 153' ' ' LEU . 2.0 pt? -121.98 158.82 28.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.876 0.369 . . . . 73.31 110.842 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -142.79 128.34 19.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.187 -0.461 . . . . 62.23 110.847 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 155' ' ' TYR . . . . . 0.539 ' HB3' HD11 ' A' ' 163' ' ' LEU . 0.8 OUTLIER -145.33 179.5 7.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.483 . . . . 75.12 110.974 -179.901 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -114.16 90.76 3.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.179 -0.464 . . . . 62.54 110.839 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 24.4 tp -58.99 97.2 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 70.12 110.939 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 66.52 -136.38 34.03 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.716 -0.754 . . . . 70.22 112.495 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 52.2 t30 -119.49 -30.89 4.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.795 0.331 . . . . 72.44 110.886 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 35.7 m -49.4 -67.12 0.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.464 . . . . 64.14 110.833 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 5.3 p90 -147.54 161.87 40.22 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.152 -0.476 . . . . 62.44 110.886 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.556 ' SD ' HG13 ' A' ' 203' ' ' VAL . 78.7 mtp -93.28 172.13 8.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 61.41 110.888 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.822 HD22 ' C ' ' A' ' 163' ' ' LEU . 0.0 OUTLIER -136.09 152.08 50.49 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.187 -0.46 . . . . 64.5 111.002 179.972 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 164' ' ' ASN . . . . . 0.409 ' N ' HD22 ' A' ' 163' ' ' LEU . 4.3 t30 -155.49 146.68 22.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.265 -0.425 . . . . 53.22 110.854 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 10.2 t -152.59 122.27 6.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.213 -0.448 . . . . 73.35 110.937 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 166' ' ' ASP . . . . . 0.411 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.3 OUTLIER -145.85 177.27 9.05 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.099 -0.501 . . . . 73.34 110.822 -179.982 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.451 HG13 ' O ' ' A' ' 195' ' ' ILE . 16.4 t -147.44 141.34 19.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 63.35 111.135 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 168' ' ' ARG . . . . . 0.401 ' HG2' HD12 ' A' ' 195' ' ' ILE . 0.0 OUTLIER -108.97 141.99 40.27 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.127 -0.488 . . . . 74.31 110.814 -179.967 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 9.5 t80 -139.86 138.88 36.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.11 -0.495 . . . . 74.34 110.916 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 170' ' ' ILE . . . . . 0.738 HD12 ' HD2' ' A' ' 171' ' ' PRO . 1.9 tp -177.87 110.04 0.22 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.613 0.72 . . . . 71.52 111.069 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 171' ' ' PRO . . . . . 0.738 ' HD2' HD12 ' A' ' 170' ' ' ILE . 52.9 Cg_endo -69.85 124.78 11.38 Favored 'Trans proline' 0 N--CA 1.464 -0.217 0 C-N-CA 122.685 2.256 . . . . 64.54 112.353 179.888 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 172' ' ' PHE . . . . . 0.516 ' CE2' ' HB2' ' A' ' 146' ' ' ALA . 2.3 t80 -147.04 177.49 9.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 71.23 110.883 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 22.1 pttm -136.73 137.32 39.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 52.01 110.922 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 174' ' ' THR . . . . . 0.626 HG22 ' O ' ' A' ' 142' ' ' LYS . 0.0 OUTLIER -99.51 169.55 9.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 63.24 111.149 -179.974 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 175' ' ' ASP . . . . . 0.423 ' HB3' ' HB2' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -129.87 161.98 29.58 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.257 -0.429 . . . . 64.33 110.891 179.933 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.656 HG13 HG22 ' A' ' 141' ' ' ILE . 99.1 t -144.46 127.22 11.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 73.25 111.111 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 5.0 t -163.7 166.04 22.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 72.4 111.182 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -167.7 -150.38 6.5 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.785 -0.721 . . . . 63.52 112.507 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 179' ' ' THR . . . . . 0.402 ' O ' HG23 ' A' ' 179' ' ' THR . 1.7 t -131.75 96.3 3.92 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.9 0.381 . . . . 64.04 111.081 -179.845 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.639 HD22 HD12 ' A' ' 136' ' ' LEU . 0.5 OUTLIER -141.93 101.84 4.02 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.46 . . . . 41.23 110.904 179.961 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 58.22 172.88 0.36 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.772 -0.728 . . . . 70.33 112.513 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.518 ' O ' ' HB ' ' A' ' 183' ' ' VAL . 53.2 Cg_endo -69.76 75.43 1.21 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.698 2.265 . . . . 75.25 112.308 -179.913 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.518 ' HB ' ' O ' ' A' ' 182' ' ' PRO . 2.4 p 160.46 84.0 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.562 0.696 . . . . 51.23 111.149 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 141.73 45.97 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.652 2.235 . . . . 71.43 112.359 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 185' ' ' VAL . . . . . 0.488 HG12 HG23 ' A' ' 187' ' ' THR . 57.3 t -96.16 105.34 16.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.275 -0.42 . . . . 73.01 111.063 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -104.78 104.88 14.74 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.173 -0.467 . . . . 74.43 110.843 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 187' ' ' THR . . . . . 0.488 HG23 HG12 ' A' ' 185' ' ' VAL . 6.1 p -122.33 148.57 44.88 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.132 -0.485 . . . . 73.1 111.107 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.02 155.78 47.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.213 -0.449 . . . . 64.24 110.877 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 6.0 pt -144.01 109.91 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.46 . . . . 72.32 111.135 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -90.44 111.51 22.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 71.43 110.921 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 2.7 t -137.79 162.27 32.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 74.03 111.108 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -107.23 88.5 3.94 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.662 0.744 . . . . 43.25 110.871 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 138.45 37.83 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.708 2.272 . . . . 42.45 112.354 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -122.21 126.63 48.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.242 -0.435 . . . . 62.24 110.904 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 195' ' ' ILE . . . . . 0.451 ' O ' HG13 ' A' ' 167' ' ' VAL . 21.4 mt -112.44 120.01 61.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.175 -0.466 . . . . 72.42 111.109 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 9.5 tt -104.53 107.93 19.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.446 . . . . 64.53 110.918 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.1 t -96.49 123.4 40.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.128 -0.487 . . . . 62.21 110.878 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 27.2 tp -146.36 127.3 14.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 74.25 110.92 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -179.79 -150.68 9.29 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.711 -0.757 . . . . 42.15 112.496 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 200' ' ' ALA . . . . . 0.677 ' HB3' ' CE1' ' A' ' 21' ' ' PHE . . . -117.8 173.01 6.99 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.852 0.358 . . . . 73.34 111.101 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 2.3 p -149.7 169.48 20.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.466 . . . . 75.55 110.88 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 202' ' ' TYR . . . . . 0.462 ' O ' HG13 ' A' ' 18' ' ' VAL . 23.2 t80 -148.93 142.36 25.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 72.15 110.926 -179.868 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.556 HG13 ' SD ' ' A' ' 162' ' ' MET . 21.5 m -76.95 161.31 4.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.109 -0.496 . . . . 65.42 111.132 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -161.82 116.55 1.95 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 75.03 110.914 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 5.6 ttmm -92.76 147.63 22.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.161 -0.472 . . . . 64.12 110.906 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -143.83 111.94 6.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 73.11 110.882 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -129.4 176.39 8.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.252 -0.431 . . . . 73.24 111.095 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -81.7 -39.26 24.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 52.34 111.15 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -102.5 155.67 18.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 64.41 111.094 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -122.86 154.7 37.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.23 -0.441 . . . . 62.13 110.938 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 . . . . . 0 C--N 1.33 -0.242 0 CA-C-N 116.169 -0.468 . . . . 72.32 110.888 179.975 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.079 0 CA-C-O 120.869 0.366 . . . . 62.54 110.903 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -125.48 149.05 48.6 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.161 -0.472 . . . . 72.32 110.951 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.9 tt0 -129.22 142.53 50.83 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 63.3 110.955 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 20.8 p30 -75.79 175.9 8.28 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.203 -0.453 . . . . 74.4 110.908 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 5.4 p90 -129.1 157.48 75.82 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.627 0.727 . . . . 71.42 110.975 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 89.72 0.52 Allowed 'Trans proline' 0 N--CA 1.466 -0.132 0 C-N-CA 122.718 2.279 . . . . 64.21 112.344 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -80.17 -51.48 8.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.455 . . . . 73.23 111.091 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.72 159.92 2.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.471 . . . . 73.43 110.962 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -130.01 147.34 51.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 63.03 110.847 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.2 177.8 5.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.14 -0.482 . . . . 74.44 111.106 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -119.74 42.16 1.81 Allowed Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.634 -0.794 . . . . 74.54 112.476 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 13.3 m-85 -124.99 85.03 2.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.876 0.37 . . . . 75.02 110.892 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -169.55 -173.37 1.64 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.151 -0.477 . . . . 72.5 110.85 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -45.75 125.5 6.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 71.41 110.883 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.85 7.91 21.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.734 -0.746 . . . . 72.54 112.513 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -55.15 166.44 0.55 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.8 0.334 . . . . 71.04 110.865 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.415 ' HB2' ' HB3' ' A' ' 204' ' ' PHE . 10.9 m-90 -109.54 151.33 26.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.131 -0.486 . . . . 74.3 110.883 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.464 HG12 ' HB3' ' A' ' 60' ' ' ALA . 61.6 t -153.24 115.25 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.245 -0.434 . . . . 75.33 111.17 179.848 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.04 140.49 32.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.168 -0.469 . . . . 62.35 111.095 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.7 t -136.6 115.09 11.87 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 64.3 110.836 -179.787 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.579 ' CE2' ' HB3' ' A' ' 200' ' ' ALA . 1.9 p90 -123.15 117.11 24.62 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.087 -0.506 . . . . 73.3 110.861 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -152.79 169.58 22.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.13 -0.486 . . . . 72.25 110.882 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 21.5 p90 -102.85 135.33 44.72 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.15 -0.477 . . . . 73.22 110.813 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 1.3 p -102.3 137.54 40.42 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.063 -0.517 . . . . 63.25 110.873 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.4 ttmt -112.55 108.08 17.04 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.098 -0.501 . . . . 71.53 110.961 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.6 p -76.74 129.65 37.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.186 -0.461 . . . . 52.14 111.145 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -123.39 113.62 19.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 72.14 110.939 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.56 HG21 HG11 ' A' ' 191' ' ' VAL . 7.8 p -176.78 146.11 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.099 -0.5 . . . . 62.44 111.108 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.47 68.94 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.673 -0.775 . . . . 72.12 112.468 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -90.23 -66.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.751 0.31 . . . . 72.4 110.911 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 -175.98 167.78 2.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 71.34 110.931 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.619 HD12 HG21 ' A' ' 189' ' ' ILE . 41.4 tp -101.28 156.16 17.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 75.14 110.927 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.25 80.7 0.35 Allowed Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.809 -0.71 . . . . 71.04 112.556 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 11.6 t0 -58.89 140.86 54.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.85 0.357 . . . . 54.45 110.876 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.418 HD23 ' N ' ' A' ' 36' ' ' ASN . 3.4 tt -159.73 122.16 3.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.454 . . . . 70.55 110.932 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.418 ' N ' HD23 ' A' ' 35' ' ' LEU . 2.7 p30 -143.87 167.45 22.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.138 -0.483 . . . . 75.11 110.854 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.3 p -59.38 -36.26 63.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.475 . . . . 62.4 111.14 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.12 -156.89 9.08 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.769 -0.729 . . . . 64.44 112.509 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 135.27 -163.08 24.89 Favored Glycine 0 N--CA 1.453 -0.203 0 C-N-CA 120.728 -0.749 . . . . 74.41 112.456 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -91.44 -94.79 1.31 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.742 -0.742 . . . . 61.33 112.458 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -92.98 171.82 8.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.818 0.342 . . . . 50.42 111.136 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.6 tp -135.94 70.24 64.05 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.63 0.729 . . . . 75.24 110.923 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -170.67 0.4 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.702 2.268 . . . . 64.1 112.362 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 75.4 m-20 -109.65 112.93 25.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.211 -0.45 . . . . 72.05 110.877 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -81.13 -176.32 5.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.217 -0.447 . . . . 62.43 111.068 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -146.41 126.06 13.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.225 -0.443 . . . . 64.43 110.793 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 82' ' ' GLN . 12.0 p -104.79 138.19 30.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 63.15 111.063 -179.963 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 m -154.74 177.95 10.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.152 -0.476 . . . . 71.04 110.857 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -137.16 154.3 30.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 71.54 111.134 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -111.69 62.7 0.29 Allowed Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.682 -0.771 . . . . 55.53 112.441 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 32.5 m120 -87.88 162.94 16.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.872 0.368 . . . . 61.11 110.81 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -129.13 163.29 25.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.093 -0.503 . . . . 65.23 110.928 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.5 p -69.14 104.58 2.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 74.35 111.11 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -131.16 168.41 17.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.182 -0.463 . . . . 64.11 111.182 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.561 ' H ' HD23 ' A' ' 55' ' ' LEU . 1.0 OUTLIER -91.07 168.77 11.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 65.13 110.939 179.952 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.98 147.39 38.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.231 -0.441 . . . . 73.22 111.206 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -101.77 151.2 22.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.27 -0.423 . . . . 72.44 110.866 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.406 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.9 OUTLIER -149.81 135.48 18.47 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.169 -0.469 . . . . 51.41 110.902 -179.982 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.418 ' O ' HG22 ' A' ' 59' ' ' ILE . 1.6 mp -107.7 112.47 40.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 30.33 111.088 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.464 ' HB3' HG12 ' A' ' 18' ' ' VAL . . . -101.42 129.15 47.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 55.34 111.045 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.512 ' HB3' HG22 ' A' ' 69' ' ' VAL . 0.8 OUTLIER -117.0 128.47 55.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 75.3 110.916 -179.876 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -98.25 98.41 9.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.489 . . . . 74.41 110.881 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.9 p -95.88 -34.1 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 53.53 111.108 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 25.1 p -139.6 163.16 33.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.48 . . . . 52.31 110.816 -179.832 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 12.0 p -87.23 3.24 47.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 72.34 110.849 -179.766 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 20.1 m120 -106.55 -31.18 8.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.135 -0.484 . . . . 73.5 110.911 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.9 pt -150.43 165.48 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.122 -0.49 . . . . 74.35 111.091 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -146.8 166.9 25.28 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.104 -0.498 . . . . 70.04 111.061 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.512 HG22 ' HB3' ' A' ' 61' ' ' TYR . 6.1 m -114.78 151.41 16.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.161 -0.472 . . . . 75.03 111.086 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -144.62 132.28 21.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.135 -0.484 . . . . 72.24 110.822 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.406 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 5.5 m-85 -108.47 118.04 35.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 63.34 110.882 -179.921 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -88.3 121.39 30.64 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.145 -0.48 . . . . 70.1 110.853 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 42.1 t -146.88 146.86 18.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.191 -0.459 . . . . 73.21 111.094 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -151.33 162.22 29.45 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.79 -0.719 . . . . 71.34 112.465 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.495 ' O ' HG13 ' A' ' 75' ' ' VAL . 6.8 p -115.47 70.64 3.17 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.655 0.741 . . . . 75.12 111.173 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 158.96 55.12 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.651 2.234 . . . . 62.03 112.324 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -104.04 -169.81 1.68 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.247 -0.433 . . . . 42.44 111.145 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 50.4 ttp180 -76.35 126.77 31.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.428 . . . . 74.35 110.856 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -121.62 150.3 41.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 61.53 111.141 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 5.5 tttm -84.16 107.81 16.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.252 -0.431 . . . . 65.3 110.966 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 72.0 t80 -84.43 128.29 34.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 75.51 110.85 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.441 ' O ' HG23 ' A' ' 47' ' ' VAL . 41.7 mt-30 -103.38 151.61 22.56 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.129 -0.487 . . . . 73.33 110.899 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.551 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 172.68 82.45 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.801 -0.714 . . . . 62.14 112.492 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -176.83 -175.08 0.59 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.879 0.371 . . . . 63.44 110.952 -179.903 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.84 -69.5 0.67 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 61.13 110.916 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.6 t -84.96 -31.61 23.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 75.33 110.913 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.828 HG22 HG22 ' A' ' 93' ' ' VAL . 1.1 mt -68.19 -34.23 65.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.11 -0.496 . . . . 74.15 111.143 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.6 t -63.3 -51.11 67.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.174 -0.467 . . . . 62.42 110.851 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.8 t -52.01 -38.87 58.32 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.081 -0.508 . . . . 64.03 110.873 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 13.6 mt -64.85 -35.34 80.81 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.14 -0.482 . . . . 74.44 110.909 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.15 -13.39 67.02 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.686 -0.768 . . . . 73.5 112.47 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 10.4 ptp180 -115.0 94.93 4.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.812 0.339 . . . . 71.31 110.837 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.828 HG22 HG22 ' A' ' 87' ' ' ILE . 99.9 t -111.66 -57.47 3.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.186 -0.461 . . . . 73.3 111.114 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 18.0 p -140.74 159.21 42.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 74.03 110.848 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -128.85 124.62 35.8 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.101 -0.5 . . . . 72.41 110.863 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.492 HG11 HG21 ' A' ' 141' ' ' ILE . 10.4 p -175.53 159.58 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.103 -0.499 . . . . 54.03 111.125 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.47 ' N ' HG22 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -106.81 173.11 6.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 64.24 110.926 179.863 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 98' ' ' TYR . . . . . 0.492 ' HA ' ' HB2' ' A' ' 128' ' ' PHE . 19.3 m-85 -133.61 144.04 49.01 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.255 -0.429 . . . . 72.54 110.94 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -106.91 87.09 0.49 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.781 -0.724 . . . . 74.03 112.46 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 124.72 11.38 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.697 2.264 . . . . 54.03 112.382 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.508 ' HB3' ' HG2' ' A' ' 125' ' ' ARG . . . -141.25 94.73 2.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 72.11 111.109 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.404 ' HA ' ' HA2' ' A' ' 124' ' ' GLY . 3.1 mp -117.35 153.99 19.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.195 -0.457 . . . . 74.41 111.11 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -153.03 108.57 3.28 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.191 -0.459 . . . . 75.12 110.913 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 23.6 p -134.38 166.4 22.92 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 75.24 110.859 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.587 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.8 OUTLIER -119.7 150.89 39.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 71.15 110.943 179.988 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -102.02 138.26 39.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.216 -0.447 . . . . 73.53 110.88 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 33.2 p90 -149.48 146.99 27.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 75.43 110.918 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 17.6 p80 -148.06 127.48 13.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.077 -0.51 . . . . 74.04 110.847 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 88.2 t80 -100.14 128.45 46.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.194 -0.457 . . . . 74.23 110.917 -179.827 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -51.98 107.81 0.23 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 73.24 110.868 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 24.8 p -113.97 -37.58 4.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.151 -0.477 . . . . 72.34 110.913 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -145.42 170.7 15.85 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.157 -0.474 . . . . 73.05 110.884 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 37.1 tp10 -78.22 -43.48 28.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.142 -0.481 . . . . 64.4 110.893 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 44.5 mtp180 -52.18 160.11 0.82 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.168 -0.469 . . . . 70.54 110.901 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 58.5 tp -76.25 149.93 37.08 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.179 -0.464 . . . . 73.3 110.854 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -164.01 157.45 15.76 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.653 0.739 . . . . 53.41 110.935 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.77 177.76 5.27 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.664 2.242 . . . . 74.32 112.353 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -117.46 154.34 31.57 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.235 -0.439 . . . . 64.0 110.958 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 25.2 t -102.78 128.16 55.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.111 -0.495 . . . . 35.54 111.095 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -123.17 169.08 15.37 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.774 -0.726 . . . . 62.22 112.525 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 12.9 p -163.77 149.24 3.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.888 0.375 . . . . 75.41 111.131 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -171.47 -149.21 6.44 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.751 -0.738 . . . . 71.43 112.458 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.573 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 14.9 p -129.4 136.14 60.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.829 0.347 . . . . 74.31 111.146 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 124' ' ' GLY . . . . . 0.404 ' HA2' ' HA ' ' A' ' 102' ' ' ILE . . . -122.35 118.29 3.6 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.75 -0.738 . . . . 71.25 112.446 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 125' ' ' ARG . . . . . 0.508 ' HG2' ' HB3' ' A' ' 101' ' ' ALA . 0.0 OUTLIER -121.47 124.72 45.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.827 0.346 . . . . 74.33 110.939 -179.894 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 27.2 t -118.15 119.79 62.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.255 -0.43 . . . . 74.0 111.107 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.2 pp -150.99 156.57 41.43 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 72.44 110.888 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.492 ' HB2' ' HA ' ' A' ' 98' ' ' TYR . 0.6 OUTLIER -167.42 -173.42 2.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 71.24 110.907 179.949 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -96.89 142.87 28.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 74.53 110.91 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -78.37 114.58 17.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.451 . . . . 73.31 110.875 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.439 ' H ' HG23 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -76.05 -78.11 0.12 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 63.33 110.91 179.981 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 3.4 m -170.67 120.3 0.56 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.25 -0.432 . . . . 71.24 111.123 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' ASP . . . . . 0.406 ' HB2' ' CB ' ' A' ' 139' ' ' PHE . 0.8 OUTLIER -105.63 122.98 47.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.48 . . . . 41.44 110.813 179.953 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 135' ' ' ALA . . . -80.63 -22.89 61.17 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.699 -0.762 . . . . 72.24 112.464 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.637 ' HB2' ' CG1' ' A' ' 93' ' ' VAL . . . -36.95 -42.75 0.42 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.872 0.368 . . . . 54.02 111.164 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.508 HD22 ' O ' ' A' ' 135' ' ' ALA . 0.5 OUTLIER -142.44 168.49 19.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 71.14 110.896 179.976 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 90.1 p -48.27 96.75 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.18 -0.464 . . . . 52.31 110.811 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 4.4 m 49.48 73.79 0.23 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.088 -0.505 . . . . 63.35 110.815 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.406 ' CB ' ' HB2' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -100.06 161.63 13.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.074 -0.512 . . . . 74.14 110.934 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -130.03 165.56 21.94 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.185 -0.462 . . . . 74.2 110.916 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.492 HG21 HG11 ' A' ' 96' ' ' VAL . 6.4 tt -103.38 155.25 5.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.249 -0.432 . . . . 74.24 111.113 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 7.2 mmtp -123.33 111.96 17.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 74.52 110.858 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -78.95 -159.84 0.2 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.237 -0.438 . . . . 73.15 110.851 179.79 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -171.14 173.53 4.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 71.13 110.945 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 145' ' ' TRP . . . . . 0.409 ' O ' ' HB2' ' A' ' 146' ' ' ALA . 29.1 p90 -154.75 149.19 26.23 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.219 -0.446 . . . . 73.35 110.864 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.865 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 177.97 169.07 0.51 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.562 0.696 . . . . 55.33 111.086 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.865 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.6 Cg_endo -69.79 144.0 52.49 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.662 2.241 . . . . 75.54 112.344 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.645 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -138.84 167.99 20.79 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 75.11 111.144 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -108.71 161.77 14.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.247 -0.433 . . . . 74.25 110.881 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 3.1 mt-30 -140.18 157.18 46.01 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.159 -0.473 . . . . 63.03 110.89 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -154.4 131.03 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 74.42 111.092 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 152' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 169.77 -167.61 40.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 71.04 112.521 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.54 HD12 ' N ' ' A' ' 154' ' ' ARG . 1.7 pp -152.42 169.13 23.32 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.779 0.323 . . . . 70.54 110.979 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.54 ' N ' HD12 ' A' ' 153' ' ' LEU . 10.1 tpp85 -120.14 125.0 47.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.179 -0.464 . . . . 74.52 110.92 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -123.63 175.09 7.03 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.285 -0.416 . . . . 72.22 110.93 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -122.1 96.66 5.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.1 -0.5 . . . . 73.02 110.891 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 157' ' ' LEU . . . . . 0.409 HD23 ' N ' ' A' ' 158' ' ' GLY . 8.8 tt -102.92 140.26 37.42 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.233 -0.439 . . . . 71.42 110.934 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 158' ' ' GLY . . . . . 0.409 ' N ' HD23 ' A' ' 157' ' ' LEU . . . 59.29 171.63 0.43 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.745 -0.741 . . . . 72.33 112.444 179.824 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 45.4 t30 -93.07 158.57 15.71 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.907 0.384 . . . . 75.11 110.804 -179.824 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 58.7 m 51.18 32.24 7.75 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.18 -0.464 . . . . 60.23 110.843 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -174.68 149.7 1.26 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.143 -0.48 . . . . 72.24 110.91 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 11.9 mmt -121.18 172.77 7.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 73.55 110.928 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 5.0 tp -126.11 139.56 53.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.288 -0.415 . . . . 73.05 110.948 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -139.34 139.72 37.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.446 . . . . 75.23 110.927 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 69.2 p -139.8 121.8 15.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 62.2 110.857 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 166' ' ' ASP . . . . . 0.421 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.5 OUTLIER -141.72 164.55 29.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 62.04 110.869 179.95 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.518 HG13 ' O ' ' A' ' 195' ' ' ILE . 40.1 t -150.16 129.86 3.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.147 -0.479 . . . . 73.1 111.104 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 168' ' ' ARG . . . . . 0.744 ' HG2' HD12 ' A' ' 195' ' ' ILE . 0.0 OUTLIER -101.08 144.92 29.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.136 -0.483 . . . . 74.11 110.832 -179.911 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -146.02 135.16 22.75 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.184 -0.462 . . . . 65.12 110.966 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 170' ' ' ILE . . . . . 0.645 HG21 ' HB2' ' A' ' 148' ' ' ALA . 4.7 tp 179.9 131.85 0.25 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.594 0.711 . . . . 74.02 111.15 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.8 109.74 2.39 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.752 2.301 . . . . 74.35 112.315 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 172' ' ' PHE . . . . . 0.673 ' CZ ' ' HB3' ' A' ' 146' ' ' ALA . 2.0 m-85 -116.92 178.11 4.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 74.2 110.922 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.01 133.94 18.04 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.178 -0.464 . . . . 75.41 110.84 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 174' ' ' THR . . . . . 0.443 HG22 HG13 ' A' ' 189' ' ' ILE . 13.2 t -105.64 154.28 20.65 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.166 -0.47 . . . . 62.31 111.077 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -128.53 161.81 28.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.135 -0.484 . . . . 71.12 110.858 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 20.3 t -146.58 132.42 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 50.41 111.175 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.3 t -165.59 160.25 17.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.183 -0.462 . . . . 64.2 111.145 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -136.3 171.37 22.88 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.751 -0.738 . . . . 63.03 112.454 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 179' ' ' THR . . . . . 0.409 ' O ' HG23 ' A' ' 179' ' ' THR . 2.1 t -110.84 106.07 15.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.766 0.317 . . . . 71.32 111.173 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.68 HD11 ' CA ' ' A' ' 184' ' ' PRO . 0.4 OUTLIER -129.29 167.95 16.94 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.226 -0.443 . . . . 75.03 110.902 179.908 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -46.53 -66.81 1.6 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.692 -0.766 . . . . 42.54 112.502 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.68 -167.45 0.22 Allowed 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.68 2.253 . . . . 74.44 112.389 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.449 HG13 ' O ' ' A' ' 183' ' ' VAL . 4.4 p -73.95 113.89 27.48 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.677 0.751 . . . . 63.25 111.11 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 184' ' ' PRO . . . . . 0.68 ' CA ' HD11 ' A' ' 180' ' ' LEU . 54.1 Cg_endo -69.71 165.62 30.29 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.691 2.26 . . . . 61.33 112.353 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 15.0 t -101.32 139.33 22.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.235 -0.439 . . . . 64.12 111.095 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 43.0 p -121.25 105.03 10.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.162 -0.472 . . . . 50.51 110.907 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 22.1 p -105.06 162.07 13.69 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.162 -0.472 . . . . 63.41 111.152 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -159.32 157.38 30.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 72.32 110.884 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 189' ' ' ILE . . . . . 0.619 HG21 HD12 ' A' ' 32' ' ' LEU . 3.5 pt -154.13 130.43 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 51.45 111.139 179.889 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -101.62 118.4 36.86 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 63.31 110.881 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 191' ' ' VAL . . . . . 0.56 HG11 HG21 ' A' ' 28' ' ' VAL . 7.1 p -136.25 160.97 38.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.144 -0.48 . . . . 73.41 111.127 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.415 ' N ' HG22 ' A' ' 191' ' ' VAL . 1.7 p30 -106.91 87.82 3.19 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.613 0.721 . . . . 71.34 110.85 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.69 158.85 55.6 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.703 2.268 . . . . 63.2 112.33 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -136.94 120.87 17.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.23 -0.441 . . . . 52.22 110.889 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 195' ' ' ILE . . . . . 0.744 HD12 ' HG2' ' A' ' 168' ' ' ARG . 45.4 mt -105.62 118.5 53.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.445 . . . . 74.13 111.167 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 3.9 mt -106.73 108.33 19.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.156 -0.474 . . . . 45.42 110.924 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 16.6 p -101.03 134.22 44.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 74.54 110.874 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 22.0 tp -156.49 129.7 8.03 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.109 -0.496 . . . . 73.33 110.909 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 179.83 -145.59 6.56 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.74 -0.743 . . . . 61.22 112.501 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 200' ' ' ALA . . . . . 0.579 ' HB3' ' CE2' ' A' ' 21' ' ' PHE . . . -116.73 174.53 6.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.755 0.312 . . . . 71.24 111.084 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 71.8 m -155.67 164.85 38.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 65.52 110.887 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 9.7 t80 -134.34 122.63 22.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.141 -0.481 . . . . 74.34 110.887 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 19.7 m -76.9 127.96 37.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.087 -0.506 . . . . 71.12 111.136 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 204' ' ' PHE . . . . . 0.415 ' HB3' ' HB2' ' A' ' 17' ' ' TRP . 1.1 m-85 -112.46 81.35 1.46 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 73.12 110.924 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 205' ' ' LYS . . . . . 0.545 ' HG3' HD23 ' A' ' 206' ' ' LEU . 55.3 pttt -164.12 -166.89 1.21 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.499 . . . . 62.3 110.838 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 206' ' ' LEU . . . . . 0.545 HD23 ' HG3' ' A' ' 205' ' ' LYS . 1.4 pt? -51.47 170.99 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.221 -0.445 . . . . 71.44 110.928 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -154.05 152.83 30.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.275 -0.42 . . . . 53.34 111.198 179.759 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -77.31 169.9 17.51 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.265 -0.425 . . . . 73.02 111.099 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -155.51 142.01 18.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.182 -0.463 . . . . 53.41 111.072 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 210' ' ' LEU . . . . . 0.473 ' O ' HD12 ' A' ' 210' ' ' LEU . 0.7 OUTLIER -130.38 158.95 38.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 70.14 110.921 -179.913 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 53.3 mt-10 . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.275 -0.42 . . . . 74.42 110.92 179.875 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.4 mmm . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.817 0.341 . . . . 72.21 110.884 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 49.5 t30 -152.3 146.55 25.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.25 -0.432 . . . . 73.2 110.833 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 18.9 mm-40 -135.45 105.48 6.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.455 . . . . 75.42 110.93 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -104.85 168.25 9.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.131 -0.486 . . . . 64.1 110.892 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -119.6 73.42 16.33 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.685 0.755 . . . . 60.45 110.897 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 90.07 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.673 2.248 . . . . 71.21 112.376 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -101.91 137.94 39.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.255 -0.429 . . . . 70.43 111.174 179.86 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -71.41 117.64 13.21 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.302 -0.408 . . . . 73.22 110.893 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 7.8 t -98.91 141.43 31.69 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 62.24 110.835 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.16 162.52 13.57 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.095 -0.502 . . . . 73.13 111.093 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -170.13 172.38 43.87 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.756 -0.735 . . . . 71.11 112.489 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 15.1 p90 -159.97 120.64 3.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.877 0.37 . . . . 74.42 110.916 -179.78 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -140.86 162.9 34.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 60.21 110.868 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -52.09 120.36 5.33 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.113 -0.494 . . . . 62.13 110.926 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.85 5.52 35.69 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.781 -0.723 . . . . 45.35 112.423 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -66.8 150.16 49.53 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.778 0.323 . . . . 52.13 110.867 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.511 ' HE1' HG23 ' A' ' 59' ' ' ILE . 25.9 t90 -116.6 144.18 44.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 74.2 110.882 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.67 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 12.9 t -141.6 118.83 7.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.268 -0.424 . . . . 72.14 111.13 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -84.76 101.71 12.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.229 -0.441 . . . . 65.23 111.083 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.4 t -97.93 142.09 30.09 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 75.01 110.866 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.549 ' HE2' HD13 ' A' ' 55' ' ' LEU . 73.6 t80 -146.52 118.89 8.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.164 -0.471 . . . . 74.45 110.856 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.412 ' O ' HG23 ' A' ' 56' ' ' THR . 3.9 p30 -149.77 174.72 12.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.132 -0.486 . . . . 51.4 110.927 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 13.3 t80 -106.52 128.76 54.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.471 . . . . 75.32 110.914 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -94.21 147.56 23.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.171 -0.468 . . . . 75.13 110.856 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 20.7 tttt -127.49 111.42 13.78 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.135 -0.484 . . . . 71.32 110.891 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.1 p -75.63 127.09 37.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 65.35 111.153 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 2.6 t80 -119.46 105.15 10.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.144 -0.48 . . . . 70.24 110.915 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.803 HG11 HG11 ' A' ' 47' ' ' VAL . 6.4 t -78.65 157.76 4.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.083 -0.508 . . . . 54.14 111.154 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.505 ' HA3' HG21 ' A' ' 191' ' ' VAL . . . -76.5 -112.6 0.13 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.693 -0.765 . . . . 53.51 112.528 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 66.6 mt-10 -89.86 -67.08 0.87 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.854 0.359 . . . . 64.31 110.942 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.544 ' HA ' HG12 ' A' ' 47' ' ' VAL . 1.7 pm0 -177.11 -173.79 0.48 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.127 -0.488 . . . . 73.11 110.88 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.823 ' HA ' HG21 ' A' ' 189' ' ' ILE . 1.9 mt -85.0 -177.78 6.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 74.52 110.911 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.29 75.25 0.42 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.771 -0.728 . . . . 65.02 112.481 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -94.69 152.06 18.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.784 0.326 . . . . 73.42 110.858 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 2.3 tt -155.75 95.04 1.62 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 63.32 110.908 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -74.21 141.53 45.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.121 -0.49 . . . . 75.4 110.901 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 19.8 m -95.68 137.22 24.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.17 -0.468 . . . . 71.25 111.18 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 131.6 -82.53 0.31 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.823 -0.703 . . . . 74.41 112.491 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.19 -179.84 44.14 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.737 -0.745 . . . . 43.14 112.474 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.21 148.25 23.89 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.745 -0.741 . . . . 70.4 112.501 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -55.04 142.08 31.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.848 0.356 . . . . 44.23 111.07 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -148.57 67.9 9.75 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.595 0.712 . . . . 73.2 110.937 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.85 -170.18 0.38 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.663 2.242 . . . . 74.45 112.322 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -67.72 118.17 10.62 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 64.33 110.855 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -62.4 -176.7 0.11 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.089 -0.505 . . . . 72.04 111.057 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -157.9 126.01 5.4 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 72.41 110.875 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.803 HG11 HG11 ' A' ' 28' ' ' VAL . 7.2 p -104.39 140.71 21.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 65.02 111.152 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -140.48 164.83 29.1 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 65.13 110.828 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.597 HG22 ' CE2' ' A' ' 81' ' ' PHE . 23.2 pt -112.25 157.17 13.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.101 -0.5 . . . . 73.03 111.178 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.07 142.52 31.87 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.772 -0.728 . . . . 34.1 112.506 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -93.38 110.86 22.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.805 0.336 . . . . 51.31 110.858 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 19.9 t0 -174.07 148.83 1.39 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.46 . . . . 72.23 110.857 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 2.0 m -70.73 130.54 41.99 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 72.04 111.148 -179.877 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.97 177.54 7.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.171 -0.468 . . . . 62.24 111.143 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.549 HD13 ' HE2' ' A' ' 21' ' ' PHE . 3.1 pp -159.97 165.39 32.11 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.219 -0.446 . . . . 73.14 110.942 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.491 HG21 ' CE2' ' A' ' 72' ' ' PHE . 0.3 OUTLIER -143.3 143.27 31.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 62.43 111.132 -179.993 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -103.18 133.29 48.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.221 -0.445 . . . . 74.45 110.897 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -121.39 136.44 54.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.12 -0.491 . . . . 63.43 110.844 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.511 HG23 ' HE1' ' A' ' 17' ' ' TRP . 27.5 mm -108.51 113.39 43.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.161 -0.472 . . . . 74.4 111.067 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.67 ' HB3' ' HB ' ' A' ' 18' ' ' VAL . . . -102.78 121.19 41.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 72.34 111.1 179.801 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.435 ' HB3' HG22 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -111.3 115.41 29.28 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.187 -0.461 . . . . 65.51 110.968 -179.835 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -82.54 101.9 11.03 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.108 -0.496 . . . . 71.2 110.83 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.0 t -97.1 -35.37 5.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.135 -0.484 . . . . 64.41 111.106 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 27.8 t -134.07 162.09 33.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.487 . . . . 63.01 110.876 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 59.4 p -84.46 2.85 38.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.171 -0.468 . . . . 64.42 110.83 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -115.0 -32.98 5.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.085 -0.507 . . . . 75.54 110.912 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.425 HG22 ' CB ' ' A' ' 107' ' ' TYR . 21.7 pt -142.35 165.04 17.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.164 -0.471 . . . . 73.14 111.156 179.849 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -151.55 167.09 29.15 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.222 -0.445 . . . . 63.13 111.118 179.827 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.435 HG22 ' HB3' ' A' ' 61' ' ' TYR . 6.5 m -108.01 151.07 10.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 61.23 111.179 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -139.15 132.48 30.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 62.41 110.877 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -115.83 110.02 18.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.15 -0.477 . . . . 70.05 110.85 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.491 ' CE2' HG21 ' A' ' 56' ' ' THR . 30.9 t80 -91.26 115.94 28.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 74.42 110.888 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.404 HG12 ' N ' ' A' ' 74' ' ' GLY . 11.3 t -142.23 156.17 19.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 72.01 111.082 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.404 ' N ' HG12 ' A' ' 73' ' ' VAL . . . -163.96 148.68 15.11 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.691 -0.766 . . . . 53.0 112.427 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.7 t -119.65 65.35 9.13 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.637 0.732 . . . . 44.21 111.144 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 163.42 38.33 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.688 2.259 . . . . 55.54 112.349 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -89.42 -169.29 2.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 70.34 111.08 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.5 ttp180 -77.42 132.52 38.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.258 -0.428 . . . . 74.41 110.921 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ALA . . . . . 0.514 ' HB3' ' CZ ' ' A' ' 98' ' ' TYR . . . -133.38 152.84 51.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 64.14 111.048 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 14.6 ttmt -82.12 150.33 27.53 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.172 -0.467 . . . . 54.21 110.938 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' PHE . . . . . 0.597 ' CE2' HG22 ' A' ' 49' ' ' ILE . 2.5 t80 -138.77 147.69 42.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 74.23 110.896 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.511 ' O ' HG23 ' A' ' 47' ' ' VAL . 32.8 mt-30 -113.61 153.31 29.07 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.137 -0.483 . . . . 74.34 110.894 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.541 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 174.96 80.86 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.758 . . . . 62.24 112.423 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -178.26 -178.37 0.63 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.92 0.391 . . . . 74.24 110.962 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.0 -69.42 0.67 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.213 -0.448 . . . . 54.3 110.877 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 5.3 m -85.22 -32.41 22.64 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.23 -0.441 . . . . 63.34 110.829 -179.848 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.556 HG22 HG22 ' A' ' 93' ' ' VAL . 4.3 mm -66.83 -34.9 72.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 74.33 111.097 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 15.1 t -63.32 -47.84 80.53 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 64.34 110.864 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.2 p -53.14 -38.64 62.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 72.13 110.844 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -63.47 -43.39 97.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.178 -0.464 . . . . 74.15 110.867 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 109.86 -13.55 32.03 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.747 -0.739 . . . . 72.13 112.498 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 41.6 mtt180 -118.81 93.38 4.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.852 0.358 . . . . 73.24 110.916 -179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.556 HG22 HG22 ' A' ' 87' ' ' ILE . 4.0 t -113.57 -35.0 2.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 75.4 111.158 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 19.5 m -156.17 161.29 40.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 62.11 110.779 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' GLU . . . . . 0.629 ' O ' HG13 ' A' ' 96' ' ' VAL . 44.7 mt-10 -153.86 115.89 4.29 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.118 -0.492 . . . . 65.52 110.875 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.629 HG13 ' O ' ' A' ' 95' ' ' GLU . 2.1 m -161.68 179.53 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.148 -0.478 . . . . 75.03 111.089 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -98.28 147.92 24.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 74.23 110.854 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' TYR . . . . . 0.514 ' CZ ' ' HB3' ' A' ' 79' ' ' ALA . 11.6 m-85 -92.34 139.98 30.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.219 -0.446 . . . . 74.43 110.946 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.402 ' N ' ' CD ' ' A' ' 100' ' ' PRO . . . -127.37 55.07 0.76 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.721 -0.752 . . . . 51.24 112.476 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' A' ' 99' ' ' GLY . 53.6 Cg_endo -69.73 111.69 2.87 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.71 2.273 . . . . 55.22 112.402 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.453 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -136.07 110.08 8.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.265 -0.425 . . . . 73.01 111.107 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.554 HG22 ' CA ' ' A' ' 124' ' ' GLY . 11.0 pt -140.82 140.59 33.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.213 -0.449 . . . . 74.34 111.17 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.567 ' HG ' HG23 ' A' ' 123' ' ' VAL . 0.1 OUTLIER -132.49 120.14 21.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 73.53 110.933 179.904 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 2.4 p -142.14 162.86 34.41 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 61.33 110.878 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -109.23 144.6 37.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.146 -0.479 . . . . 72.54 110.876 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 3.0 pm0 -105.38 148.99 26.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.109 -0.496 . . . . 71.11 110.87 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.612 ' CE2' HG13 ' A' ' 119' ' ' VAL . 32.2 p90 -149.33 148.44 29.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 72.2 110.913 -179.852 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 62.2 t-80 -115.46 152.09 33.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.087 -0.506 . . . . 74.41 110.849 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 17.4 t80 -88.55 110.09 20.6 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 73.31 110.908 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 22.3 m-20 -51.18 109.07 0.3 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.074 -0.512 . . . . 61.25 110.841 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.1 m -170.98 146.86 2.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 73.11 110.884 -179.798 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 15.6 p90 -116.99 49.69 1.15 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 71.22 110.94 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -93.51 -55.19 3.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 73.34 110.925 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 67.7 mtt180 -152.68 -179.7 7.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 64.32 110.922 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 25.9 tp -95.82 117.23 30.16 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.245 -0.434 . . . . 71.04 110.931 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 5.4 p90 -147.58 158.85 42.68 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 121.654 0.74 . . . . 73.21 110.893 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 179.09 3.93 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.727 2.284 . . . . 53.15 112.35 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -109.87 164.59 12.44 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.22 -0.445 . . . . 64.34 110.974 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.612 HG13 ' CE2' ' A' ' 107' ' ' TYR . 6.2 p -117.51 139.0 46.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.169 -0.469 . . . . 73.44 111.096 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -139.95 160.5 26.23 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.713 -0.756 . . . . 74.12 112.499 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 4.9 m -152.75 163.88 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.877 0.37 . . . . 64.0 111.18 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 174.98 -145.99 8.19 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.722 -0.751 . . . . 41.42 112.429 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.567 HG23 ' HG ' ' A' ' 103' ' ' LEU . 11.8 m -105.5 148.89 9.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.853 0.358 . . . . 61.5 111.192 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 124' ' ' GLY . . . . . 0.554 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -144.25 105.95 0.39 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.697 -0.763 . . . . 55.31 112.467 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 125' ' ' ARG . . . . . 0.453 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 15.7 ptm180 -99.78 125.07 45.63 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.899 0.38 . . . . 70.33 110.903 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 25.2 t -109.51 114.02 45.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.25 -0.432 . . . . 64.11 111.125 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.575 HD12 ' N ' ' A' ' 128' ' ' PHE . 2.1 pp -124.24 171.12 10.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.465 . . . . 74.2 110.885 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.575 ' N ' HD12 ' A' ' 127' ' ' LEU . 0.6 OUTLIER -141.14 178.55 7.31 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.148 -0.478 . . . . 53.41 110.831 179.953 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -118.15 119.82 35.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.115 -0.493 . . . . 73.02 110.918 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -60.45 103.61 0.26 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.125 -0.489 . . . . 54.41 110.892 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.519 ' H ' HG12 ' A' ' 96' ' ' VAL . 7.9 tppt? -123.69 -71.91 0.7 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.449 . . . . 71.23 110.912 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 23.5 m -166.87 92.68 0.44 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.459 . . . . 61.32 111.136 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -107.73 168.98 8.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.464 . . . . 53.15 110.871 179.879 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 79.28 151.68 6.39 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.748 -0.739 . . . . 73.14 112.481 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -39.38 -66.85 0.26 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.831 0.348 . . . . 74.15 111.09 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -166.64 92.33 0.45 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 70.44 110.852 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.645 ' OG ' HD13 ' A' ' 180' ' ' LEU . 0.4 OUTLIER 169.01 60.78 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 33.45 110.878 -179.947 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.533 ' C ' ' O ' ' A' ' 137' ' ' SER . 8.7 t 27.21 73.93 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.152 -0.476 . . . . 63.25 110.906 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -107.3 159.15 16.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.144 -0.48 . . . . 73.24 110.854 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -145.19 167.12 23.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.088 -0.506 . . . . 65.03 110.943 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.595 ' HA ' HG23 ' A' ' 176' ' ' VAL . 12.5 tt -116.76 132.5 66.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.209 -0.45 . . . . 62.31 111.131 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' LYS . . . . . 0.733 ' O ' HG22 ' A' ' 174' ' ' THR . 0.0 OUTLIER -80.72 106.64 12.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 74.01 110.863 179.899 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -82.72 -172.43 4.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 62.41 110.879 179.87 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 5.2 tptt -174.95 -169.73 0.42 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 71.14 110.906 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 145' ' ' TRP . . . . . 0.427 ' O ' ' HB2' ' A' ' 146' ' ' ALA . 66.9 p-90 -144.62 161.01 40.22 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.208 -0.451 . . . . 74.22 110.98 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.724 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 178.02 165.29 0.59 Allowed Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.567 0.698 . . . . 53.31 111.14 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.724 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.6 Cg_endo -69.74 161.88 44.2 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.705 2.27 . . . . 73.23 112.354 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.644 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -153.79 160.11 42.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.249 -0.432 . . . . 63.4 111.064 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -118.91 115.23 23.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.223 -0.444 . . . . 65.25 110.903 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 20.6 tt0 -102.86 164.41 11.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.105 -0.498 . . . . 72.14 110.921 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 14.6 p -160.12 137.17 2.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.153 -0.476 . . . . 60.21 111.052 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 152' ' ' GLY . . . . . 0.408 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 177.55 -162.25 30.02 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.767 -0.73 . . . . 60.41 112.528 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -138.69 160.61 39.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.827 0.346 . . . . 73.43 110.888 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 3.4 tpp85 -132.05 119.74 21.43 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 73.35 110.883 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -105.46 140.96 37.78 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.181 -0.463 . . . . 74.43 110.932 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -120.93 117.55 27.63 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.472 . . . . 73.42 110.864 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 3.9 tp -102.3 164.4 11.7 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 75.34 110.887 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -99.51 53.79 0.99 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.739 -0.744 . . . . 65.53 112.486 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -149.87 35.87 0.69 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.362 . . . . 75.32 110.966 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 51.79 35.4 15.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 72.25 110.8 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 51.2 m95 -154.99 101.43 2.26 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.134 -0.484 . . . . 73.44 110.849 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.435 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 0.0 OUTLIER -97.7 168.25 10.45 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.253 -0.43 . . . . 75.35 110.909 179.855 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 4.0 tp -125.26 144.18 50.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.252 -0.431 . . . . 63.21 110.934 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -142.99 139.98 30.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 70.11 110.84 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 52.8 p -150.95 120.94 7.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 71.13 110.87 -179.803 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 166' ' ' ASP . . . . . 0.408 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.6 OUTLIER -149.08 171.13 16.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.167 -0.47 . . . . 55.23 110.881 179.921 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 4.3 t -144.75 135.96 20.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.171 -0.468 . . . . 72.22 111.076 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -102.67 137.34 41.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 74.45 110.872 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 35.1 t80 -141.79 139.2 32.7 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.201 -0.454 . . . . 73.45 110.887 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 170' ' ' ILE . . . . . 0.644 HG21 ' HB2' ' A' ' 148' ' ' ALA . 0.0 OUTLIER 178.96 125.93 0.21 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.633 0.73 . . . . 74.35 111.096 179.885 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 107.25 1.82 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.649 2.233 . . . . 74.33 112.337 179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -126.94 170.0 12.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 65.1 110.894 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.7 141.4 43.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.114 -0.494 . . . . 75.22 110.875 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 174' ' ' THR . . . . . 0.733 HG22 ' O ' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -125.32 169.48 12.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 70.12 111.141 179.958 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -126.64 170.45 12.08 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 52.2 110.888 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 176' ' ' VAL . . . . . 0.595 HG23 ' HA ' ' A' ' 141' ' ' ILE . 7.6 p -160.14 137.1 2.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.45 . . . . 72.12 111.213 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 177' ' ' THR . . . . . 0.558 HG22 ' HD3' ' A' ' 142' ' ' LYS . 12.8 t -166.84 175.6 7.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.245 -0.434 . . . . 72.43 111.169 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -156.95 -140.99 3.07 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.8 -0.714 . . . . 45.3 112.495 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -157.05 106.17 2.19 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.816 0.341 . . . . 72.33 111.073 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 180' ' ' LEU . . . . . 0.645 HD13 ' OG ' ' A' ' 137' ' ' SER . 19.4 tp -139.88 117.78 11.75 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.213 -0.449 . . . . 70.01 110.957 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 46.42 -106.07 0.12 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.827 -0.701 . . . . 75.34 112.442 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 -167.87 0.24 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.694 2.263 . . . . 74.31 112.303 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.408 HG13 ' HD2' ' A' ' 184' ' ' PRO . 59.0 t -54.7 133.18 65.14 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.643 0.735 . . . . 71.32 111.163 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 184' ' ' PRO . . . . . 0.408 ' HD2' HG13 ' A' ' 183' ' ' VAL . 54.0 Cg_endo -69.71 164.02 36.04 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.686 2.258 . . . . 71.23 112.34 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 48.4 t -108.36 108.82 26.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 71.02 111.106 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 85.5 p -99.22 111.3 23.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.075 -0.512 . . . . 63.43 110.827 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 3.1 p -108.53 163.31 13.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 54.03 111.152 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -146.53 148.06 31.78 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.271 -0.422 . . . . 74.51 110.92 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 189' ' ' ILE . . . . . 0.823 HG21 ' HA ' ' A' ' 32' ' ' LEU . 3.6 pt -142.36 136.35 28.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.285 -0.416 . . . . 51.05 111.165 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -112.17 104.23 12.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.208 -0.451 . . . . 40.33 110.882 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 191' ' ' VAL . . . . . 0.505 HG21 ' HA3' ' A' ' 29' ' ' GLY . 4.9 p -136.6 163.18 33.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 74.15 111.156 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.409 ' N ' HG22 ' A' ' 191' ' ' VAL . 1.4 p-10 -106.71 90.68 5.31 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.63 0.729 . . . . 72.45 110.875 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.73 135.99 31.92 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.698 2.265 . . . . 71.4 112.316 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -103.67 124.94 49.77 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.254 -0.43 . . . . 73.41 110.936 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 26.4 mm -107.45 103.19 15.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.159 -0.473 . . . . 75.12 111.186 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 20.7 tp -91.47 110.55 21.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 74.32 110.88 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 20.5 p -110.35 123.58 50.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 75.22 110.864 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 198' ' ' LEU . . . . . 0.411 HD23 ' N ' ' A' ' 198' ' ' LEU . 1.0 OUTLIER -141.4 132.65 26.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 75.13 110.944 -179.948 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 179.02 -146.43 7.22 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.823 -0.703 . . . . 75.11 112.544 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 200' ' ' ALA . . . . . 0.435 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -125.52 173.37 8.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.796 0.331 . . . . 72.34 111.168 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -147.53 171.1 16.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.425 . . . . 73.25 110.914 -179.77 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 12.6 m-85 -139.33 133.87 31.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.137 -0.483 . . . . 61.51 110.92 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 11.2 p -79.56 147.64 6.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 65.55 111.167 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -146.67 98.07 3.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.212 -0.449 . . . . 63.15 110.865 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 18.1 mtmt -65.91 173.34 3.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.095 -0.502 . . . . 65.25 110.809 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 11.1 mp -60.7 109.71 1.11 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 72.02 110.877 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -105.6 169.09 8.67 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.192 -0.458 . . . . 65.33 111.127 179.785 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -123.31 132.18 53.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.283 -0.417 . . . . 62.21 111.108 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -162.07 173.24 14.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 62.02 111.07 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 210' ' ' LEU . . . . . 0.534 ' H ' HD23 ' A' ' 210' ' ' LEU . 1.8 pt? -120.21 163.38 17.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 60.05 110.86 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.136 -0.484 . . . . 64.52 110.944 179.923 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.7 tpt . . . . . 0 C--O 1.23 0.044 0 CA-C-O 120.817 0.342 . . . . 63.02 110.904 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 11.4 t-20 -60.77 148.69 38.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.448 . . . . 74.33 110.885 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.9 tm-20 -139.71 107.84 5.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.154 -0.475 . . . . 73.03 110.879 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 8.2 p30 -53.52 147.24 11.29 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.102 -0.499 . . . . 63.31 110.946 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' TYR . . . . . 0.519 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER 175.67 -58.53 0.0 OUTLIER Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.698 0.761 . . . . 74.52 110.964 -179.884 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.519 ' HD2' ' N ' ' A' ' 5' ' ' TYR . 53.8 Cg_endo -69.71 161.24 46.67 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.712 2.275 . . . . 62.25 112.339 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.92 119.47 38.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.261 -0.427 . . . . 65.11 111.203 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 8.4 tptt -110.0 61.85 0.6 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.248 -0.433 . . . . 75.3 110.862 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 60.2 p -170.57 170.66 6.72 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.298 -0.41 . . . . 44.41 110.849 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.713 ' HB1' ' CE2' ' A' ' 12' ' ' TYR . . . -91.32 170.54 9.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.137 -0.483 . . . . 50.44 111.127 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -104.38 43.26 1.7 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.749 -0.739 . . . . 73.2 112.543 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.713 ' CE2' ' HB1' ' A' ' 10' ' ' ALA . 14.6 p90 -162.38 120.02 2.1 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.894 0.378 . . . . 63.42 110.877 -179.743 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -166.03 -178.94 4.91 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.11 -0.495 . . . . 63.44 110.877 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -69.4 120.52 15.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.173 -0.467 . . . . 74.35 110.926 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 103.88 6.21 43.42 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.762 -0.732 . . . . 70.13 112.513 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -66.93 150.46 49.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.809 0.337 . . . . 73.23 110.815 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.588 ' CZ2' HD13 ' A' ' 206' ' ' LEU . 4.5 m0 -111.96 142.05 44.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.152 -0.477 . . . . 63.21 110.939 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.632 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 43.2 t -145.04 118.95 2.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.263 -0.426 . . . . 72.41 111.041 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.4 119.96 25.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.098 -0.501 . . . . 64.22 111.031 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 22.0 t -106.65 128.6 54.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 65.45 110.807 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.536 ' CE2' HD21 ' A' ' 55' ' ' LEU . 19.2 t80 -138.19 114.55 10.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.095 -0.502 . . . . 72.3 110.829 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -153.5 174.05 14.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 74.42 110.906 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -102.45 129.01 48.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.455 . . . . 64.52 110.915 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.2 p -98.64 148.04 24.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.129 -0.487 . . . . 53.23 110.839 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 39.2 tptt -129.45 106.84 9.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 61.35 110.854 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.2 m -89.68 124.2 42.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.226 -0.443 . . . . 61.34 111.139 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 28.5 t80 -118.93 104.12 10.22 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.166 -0.47 . . . . 75.33 110.933 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.0 p -157.8 150.45 8.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 50.45 111.189 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 144.77 76.8 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.776 -0.726 . . . . 55.42 112.506 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -89.5 -65.63 1.0 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.758 0.313 . . . . 72.31 110.849 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -169.09 124.76 0.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.447 . . . . 72.11 110.902 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.687 HD13 HG13 ' A' ' 189' ' ' ILE . 0.9 OUTLIER -89.2 152.78 21.41 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.164 -0.471 . . . . 73.21 110.86 -179.95 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.45 -119.11 4.92 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.726 -0.75 . . . . 63.32 112.459 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -160.17 157.54 28.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.818 0.342 . . . . 72.44 110.893 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 30.5 tp -81.57 153.2 26.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.218 -0.447 . . . . 63.51 110.926 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 28.9 m120 -75.19 153.48 38.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.217 -0.447 . . . . 71.15 110.926 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 24.0 t -67.55 -41.83 86.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 51.34 111.127 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -179.98 -150.3 9.1 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.72 -0.753 . . . . 73.22 112.517 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.18 -156.56 43.68 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.756 -0.735 . . . . 25.44 112.425 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -52.13 148.27 11.23 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.682 -0.771 . . . . 64.33 112.477 -179.871 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.504 ' C ' HD22 ' A' ' 42' ' ' LEU . . . -91.13 108.88 20.17 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.806 0.336 . . . . 63.41 111.134 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.504 HD22 ' C ' ' A' ' 41' ' ' ALA . 4.5 mm? -120.89 159.25 49.74 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.563 0.697 . . . . 75.54 110.885 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.75 97.83 0.66 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.645 2.23 . . . . 73.42 112.373 179.84 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -52.36 171.5 0.05 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.465 . . . . 70.13 110.866 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.553 ' HB3' ' O ' ' A' ' 32' ' ' LEU . . . -51.55 156.54 1.28 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.479 . . . . 41.24 111.042 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 17.8 t0 -146.18 126.57 14.02 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 60.24 110.866 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.633 ' HB ' HD23 ' A' ' 32' ' ' LEU . 7.1 p -105.36 140.56 23.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 62.21 111.135 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -158.8 157.85 32.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.45 . . . . 70.12 110.829 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 9.4 tt -132.4 144.04 38.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.102 -0.499 . . . . 74.45 111.084 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -108.19 97.23 1.1 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.782 -0.723 . . . . 54.22 112.517 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -136.7 119.09 15.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.802 0.334 . . . . 74.1 110.895 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 77.1 m-20 -100.81 -56.5 2.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.206 -0.452 . . . . 74.04 110.914 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 5.1 t -60.78 134.06 56.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.137 -0.483 . . . . 73.21 111.127 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.4 p -120.24 121.29 38.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 74.2 111.151 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.536 HD21 ' CE2' ' A' ' 21' ' ' PHE . 0.3 OUTLIER -159.9 123.41 3.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.247 -0.433 . . . . 73.11 110.946 179.978 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.667 HG21 ' CE1' ' A' ' 72' ' ' PHE . 5.4 m -137.74 130.76 30.29 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 64.11 111.143 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -102.93 132.53 49.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 72.41 110.874 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.577 ' O ' HD13 ' A' ' 59' ' ' ILE . 0.7 OUTLIER -131.93 155.95 47.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.119 -0.491 . . . . 63.34 110.872 179.92 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.577 HD13 ' O ' ' A' ' 58' ' ' ASP . 27.4 mm -126.05 115.16 41.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 75.33 111.153 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.632 ' HB3' ' HB ' ' A' ' 18' ' ' VAL . . . -99.9 126.05 45.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 73.14 111.11 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.555 ' HB3' HG22 ' A' ' 69' ' ' VAL . 0.5 OUTLIER -116.72 118.26 32.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.272 -0.422 . . . . 71.14 110.968 -179.857 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -88.42 101.0 13.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.145 -0.479 . . . . 63.52 110.856 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 9.0 p -98.01 -35.17 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.114 -0.494 . . . . 72.32 111.144 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 m -136.88 161.31 36.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.138 -0.483 . . . . 75.43 110.871 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.8 m -83.74 2.99 35.25 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.171 -0.468 . . . . 72.44 110.827 -179.808 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -120.16 -33.57 3.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.474 . . . . 74.43 110.831 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.572 HG22 ' CD1' ' A' ' 107' ' ' TYR . 2.5 pp -136.06 148.12 27.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.242 -0.435 . . . . 54.11 111.143 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -143.73 167.78 21.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.249 -0.432 . . . . 74.02 111.143 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.555 HG22 ' HB3' ' A' ' 61' ' ' TYR . 4.2 m -114.69 151.21 16.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 64.41 111.134 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -143.89 132.45 22.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.167 -0.469 . . . . 34.12 110.885 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -103.88 142.03 35.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 70.35 110.924 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.667 ' CE1' HG21 ' A' ' 56' ' ' THR . 7.5 t80 -121.4 118.57 29.75 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.187 -0.46 . . . . 73.24 110.871 -179.883 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 44.7 t -147.18 145.75 18.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 71.22 111.114 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -132.96 -30.23 0.49 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.754 -0.736 . . . . 63.15 112.514 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 11.0 m 36.6 62.76 2.97 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.623 0.725 . . . . 71.01 111.124 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 163.57 37.78 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.738 2.292 . . . . 65.15 112.306 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -79.64 -169.82 2.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 74.21 111.037 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.7 ttp180 -77.94 126.43 30.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.472 . . . . 72.42 110.912 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -135.77 151.93 50.61 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 75.33 111.089 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 26.3 ttpp -93.15 143.8 25.9 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 74.51 110.844 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' PHE . . . . . 0.599 ' HE2' HG12 ' A' ' 96' ' ' VAL . 13.8 p90 -139.39 157.73 45.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 75.31 110.917 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.467 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 5.2 pt20 -106.85 157.2 17.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 75.12 110.93 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.661 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 178.4 71.05 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.73 -0.748 . . . . 43.23 112.498 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -168.36 -173.48 1.99 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.926 0.393 . . . . 74.33 110.913 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.33 -71.23 0.55 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 65.23 110.932 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 23.1 t -84.89 -30.35 24.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.255 -0.43 . . . . 55.4 110.835 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.82 HG22 HG22 ' A' ' 93' ' ' VAL . 4.7 mm -67.99 -34.26 65.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 52.42 111.13 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 4.0 t -63.02 -44.13 96.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.152 -0.476 . . . . 74.4 110.806 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 73.4 m -55.18 -41.6 72.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.134 -0.485 . . . . 60.55 110.85 -179.821 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -58.86 -49.85 76.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.112 -0.495 . . . . 73.3 110.911 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 116.2 -17.12 14.85 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.829 -0.7 . . . . 62.31 112.534 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 6.8 ttp180 -121.27 95.52 4.72 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.856 0.36 . . . . 70.42 110.864 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.82 HG22 HG22 ' A' ' 87' ' ' ILE . 93.0 t -104.45 -61.09 2.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.136 -0.483 . . . . 71.5 111.073 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.403 ' HA ' ' HA ' ' A' ' 133' ' ' ASP . 1.8 p -139.47 149.52 44.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.437 . . . . 64.11 110.921 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -127.74 129.58 47.32 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.146 -0.479 . . . . 55.11 110.906 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.61 HG21 ' O ' ' A' ' 129' ' ' PHE . 6.1 p -173.43 163.27 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 75.51 111.126 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.442 ' N ' HG22 ' A' ' 96' ' ' VAL . 10.3 p-10 -92.58 152.61 19.51 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.2 -0.454 . . . . 73.04 110.851 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -103.41 148.94 25.29 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.225 -0.443 . . . . 72.2 110.868 -179.81 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -139.07 62.23 0.56 Allowed Glycine 0 N--CA 1.453 -0.194 0 C-N-CA 120.751 -0.738 . . . . 65.41 112.547 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 118.43 5.68 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.65 2.233 . . . . 71.41 112.325 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.62 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -122.38 102.57 8.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.233 -0.44 . . . . 75.33 111.138 179.841 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.456 HD12 ' HA3' ' A' ' 124' ' ' GLY . 10.8 mm -117.85 147.73 21.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.243 -0.435 . . . . 61.34 111.152 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -151.49 122.46 7.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 65.13 110.924 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.405 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 8.6 p -147.17 173.63 12.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 72.51 110.867 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.482 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.8 OUTLIER -122.03 153.84 38.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.13 -0.486 . . . . 73.11 110.938 179.99 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 6.5 mm100 -102.1 137.15 40.75 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.137 -0.483 . . . . 71.45 110.897 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' TYR . . . . . 0.572 ' CD1' HG22 ' A' ' 67' ' ' ILE . 10.9 t80 -140.91 133.76 29.01 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.184 -0.462 . . . . 73.55 110.933 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 26.9 t60 -79.17 146.76 32.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 64.44 110.879 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 5.1 m-85 -77.92 140.63 39.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.262 -0.427 . . . . 74.04 110.878 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -100.07 53.12 0.9 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.068 -0.514 . . . . 70.34 110.78 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 87.7 p -137.92 -50.41 0.59 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.218 -0.447 . . . . 75.35 110.869 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -95.78 136.51 36.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.128 -0.487 . . . . 74.31 110.873 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 -96.92 -36.38 10.58 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.135 -0.484 . . . . 64.33 110.912 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 10.1 mpt_? -54.27 173.02 0.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 73.33 110.817 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -68.47 107.86 3.06 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.159 -0.473 . . . . 71.33 110.889 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -141.0 160.64 57.42 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.666 0.746 . . . . 74.44 110.9 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 177.52 5.47 Favored 'Trans proline' 0 N--CA 1.465 -0.197 0 C-N-CA 122.71 2.273 . . . . 75.33 112.362 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 14.0 m-85 -117.22 157.78 25.43 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.454 . . . . 72.52 110.932 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 12.5 p -107.24 132.01 55.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.084 -0.507 . . . . 75.1 111.118 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -121.5 161.23 15.65 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.769 -0.729 . . . . 70.23 112.519 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 12.3 p -161.1 150.16 5.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.8 0.333 . . . . 53.21 111.08 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.405 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -174.01 -155.37 11.89 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.68 -0.771 . . . . 70.23 112.489 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.447 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 28.9 m -113.75 134.04 57.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.803 0.335 . . . . 74.15 111.168 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 124' ' ' GLY . . . . . 0.456 ' HA3' HD12 ' A' ' 102' ' ' ILE . . . -117.27 105.91 1.35 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.734 -0.746 . . . . 44.01 112.531 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 125' ' ' ARG . . . . . 0.62 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 28.5 ptt180 -99.45 112.44 24.64 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.901 0.381 . . . . 74.1 110.866 -179.843 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 20.0 t -87.24 110.04 20.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.26 -0.427 . . . . 64.12 111.147 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.521 HD13 ' N ' ' A' ' 128' ' ' PHE . 0.2 OUTLIER -101.03 135.98 41.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 64.1 110.878 179.979 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.521 ' N ' HD13 ' A' ' 127' ' ' LEU . 13.8 m-85 -135.73 148.26 48.76 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.148 -0.478 . . . . 71.23 110.845 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.61 ' O ' HG21 ' A' ' 96' ' ' VAL . 10.2 m-85 -100.75 172.75 6.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.101 -0.5 . . . . 62.04 110.859 -179.896 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -113.53 94.87 5.06 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.178 -0.464 . . . . 61.23 110.9 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.476 ' HB2' HG23 ' A' ' 96' ' ' VAL . 2.6 mmmt -92.62 -86.6 0.24 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.206 -0.452 . . . . 75.43 110.95 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -168.23 111.82 0.61 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.293 -0.412 . . . . 70.31 111.182 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 133' ' ' ASP . . . . . 0.547 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 49.8 m-20 -101.1 112.76 25.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.429 . . . . 75.34 110.829 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -74.91 -9.87 83.61 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.738 -0.744 . . . . 62.31 112.452 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.453 ' HB2' ' CG1' ' A' ' 93' ' ' VAL . . . -45.4 -28.89 0.95 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.721 0.296 . . . . 65.15 111.05 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.2 mt -160.28 179.67 8.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.264 -0.425 . . . . 73.4 110.89 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 9.9 m -53.32 92.36 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.172 -0.467 . . . . 73.22 110.848 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 6.9 m 51.38 73.6 0.3 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.092 -0.503 . . . . 54.2 110.868 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.547 ' HB3' ' HB2' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -94.32 158.55 15.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 74.4 110.892 -179.959 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -135.89 167.64 20.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.461 . . . . 75.21 110.822 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 12.3 tt -112.98 151.04 14.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.12 -0.491 . . . . 75.33 111.13 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 6.0 tppt? -119.51 112.06 18.89 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 54.43 110.896 179.824 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.41 -173.34 0.29 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.25 -0.432 . . . . 74.02 110.875 179.845 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -170.6 165.2 8.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 74.24 110.882 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 49.2 p90 -132.47 154.48 49.85 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 73.41 110.927 179.897 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.726 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -178.5 164.28 1.13 Allowed Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.574 0.702 . . . . 41.1 111.11 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 147' ' ' PRO . . . . . 0.726 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.5 Cg_endo -69.71 169.49 18.73 Favored 'Trans proline' 0 N--CA 1.466 -0.144 0 C-N-CA 122.717 2.278 . . . . 72.24 112.376 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.422 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -165.37 153.54 11.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.246 -0.434 . . . . 34.0 111.086 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 6.7 p90 -122.03 139.11 54.1 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.218 -0.446 . . . . 75.42 110.857 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -130.75 174.52 9.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.125 -0.489 . . . . 75.41 110.988 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 10.8 p -158.91 147.12 7.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 51.33 111.093 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 170.97 -158.77 30.51 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.777 -0.725 . . . . 51.44 112.58 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.6 pt? -158.22 168.02 28.19 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.768 0.318 . . . . 71.2 110.928 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.6 tpp85 -117.93 120.64 38.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 74.2 110.954 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.8 t80 -115.37 169.64 8.99 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.245 -0.434 . . . . 63.31 110.949 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -121.86 99.66 6.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.147 -0.478 . . . . 70.2 110.924 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 5.9 tt -102.31 103.7 14.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 74.31 110.87 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 94.37 -160.71 23.84 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.792 -0.718 . . . . 65.41 112.51 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 6.3 p30 -118.7 -36.56 3.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.854 0.359 . . . . 64.33 110.928 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 3.7 p -66.39 -56.04 12.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.113 -0.494 . . . . 73.11 110.866 -179.877 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 12.3 p90 -124.91 172.69 9.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.179 -0.464 . . . . 72.43 110.951 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.541 ' CE ' HG13 ' A' ' 203' ' ' VAL . 5.5 ptp -121.84 177.47 5.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.269 -0.423 . . . . 71.14 110.903 179.878 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 8.7 tp -111.94 146.2 38.23 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.21 -0.45 . . . . 63.34 110.915 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -144.44 133.51 22.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 64.4 110.9 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 19.6 t -130.89 125.93 34.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.13 -0.487 . . . . 55.43 110.842 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 26.7 m-20 -150.33 142.16 23.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.093 -0.503 . . . . 72.53 110.87 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.747 ' CG2' HD12 ' A' ' 196' ' ' LEU . 40.6 t -139.59 122.62 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 43.3 111.148 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.49 159.99 14.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.236 -0.438 . . . . 63.23 110.804 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 169' ' ' TYR . . . . . 0.411 ' O ' ' HB ' ' A' ' 170' ' ' ILE . 26.3 t80 -164.56 140.99 6.12 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.159 -0.473 . . . . 73.45 110.919 -179.849 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 170' ' ' ILE . . . . . 0.446 HG12 ' O ' ' A' ' 147' ' ' PRO . 5.9 tp 177.86 133.15 0.22 Allowed Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.656 0.741 . . . . 72.32 111.109 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.69 104.37 1.3 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.716 2.277 . . . . 65.23 112.304 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -121.78 154.25 37.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.257 -0.429 . . . . 74.23 110.858 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 9.6 ptpp? -122.86 146.69 47.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 63.4 110.884 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 11.1 t -116.91 166.0 12.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.211 -0.45 . . . . 54.51 111.185 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -122.8 158.19 30.76 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.26 -0.427 . . . . 52.35 110.858 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 43.9 t -150.26 132.48 5.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 75.45 111.152 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 13.6 t -168.43 176.78 5.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.205 -0.452 . . . . 70.52 111.104 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 131.99 150.39 6.56 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.725 -0.75 . . . . 32.14 112.525 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 6.1 t -171.21 177.5 3.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.843 0.354 . . . . 74.04 111.161 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 5.7 tt -138.07 89.56 2.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 65.13 110.894 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 118.21 -81.23 0.32 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.725 -0.75 . . . . 61.2 112.505 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -170.13 0.37 Allowed 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.709 2.273 . . . . 71.5 112.351 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 30.7 m -82.86 124.32 77.07 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.59 0.71 . . . . 63.15 111.138 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 155.42 66.08 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.67 2.246 . . . . 73.12 112.344 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 68.0 t -103.61 111.44 33.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 75.35 111.098 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 3.9 p -84.57 135.02 34.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.094 -0.503 . . . . 64.14 110.893 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 40.4 p -145.48 167.75 22.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 63.22 111.097 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -158.99 157.31 31.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.451 . . . . 71.2 110.887 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 189' ' ' ILE . . . . . 0.687 HG13 HD13 ' A' ' 32' ' ' LEU . 36.8 mm -146.66 125.6 4.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.193 -0.458 . . . . 74.5 111.13 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -102.31 114.6 28.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.18 -0.464 . . . . 75.01 110.864 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 191' ' ' VAL . . . . . 0.447 HG23 HG22 ' A' ' 189' ' ' ILE . 2.5 t -136.53 164.32 31.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.126 -0.488 . . . . 54.01 111.1 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 192' ' ' ASP . . . . . 0.434 ' H ' HG12 ' A' ' 191' ' ' VAL . 0.1 OUTLIER -107.23 87.59 3.27 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.651 0.739 . . . . 73.34 110.856 179.89 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.93 133.58 25.59 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.722 2.282 . . . . 74.33 112.249 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 23.4 m-85 -100.68 119.33 38.42 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.161 -0.472 . . . . 72.03 110.83 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 195' ' ' ILE . . . . . 0.484 ' O ' HG13 ' A' ' 167' ' ' VAL . 53.4 mt -105.57 110.18 30.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.124 -0.489 . . . . 71.31 111.156 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 196' ' ' LEU . . . . . 0.747 HD12 ' CG2' ' A' ' 167' ' ' VAL . 2.6 tp -110.54 108.84 18.95 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.199 -0.455 . . . . 74.42 110.974 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 197' ' ' SER . . . . . 0.522 ' O ' HD12 ' A' ' 198' ' ' LEU . 0.4 OUTLIER -110.55 129.27 55.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.231 -0.441 . . . . 73.43 110.901 -179.906 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 198' ' ' LEU . . . . . 0.522 HD12 ' O ' ' A' ' 197' ' ' SER . 3.1 mp -150.51 134.45 16.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.115 -0.493 . . . . 72.33 110.937 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 178.94 -136.95 3.02 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.686 -0.768 . . . . 54.3 112.467 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 200' ' ' ALA . . . . . 0.429 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -125.02 173.33 8.75 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.835 0.35 . . . . 73.13 111.041 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 29.5 m -149.09 171.0 17.13 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.16 -0.473 . . . . 60.51 110.841 -179.755 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 202' ' ' TYR . . . . . 0.449 ' O ' HG13 ' A' ' 18' ' ' VAL . 40.5 t80 -142.24 145.45 34.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.501 . . . . 71.44 110.86 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 203' ' ' VAL . . . . . 0.541 HG13 ' CE ' ' A' ' 162' ' ' MET . 33.6 m -93.28 156.83 3.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.04 -0.527 . . . . 72.52 111.108 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -159.72 110.8 1.98 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.127 -0.488 . . . . 75.54 110.911 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 37.1 mtmt -74.92 173.63 10.38 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 73.13 110.914 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 206' ' ' LEU . . . . . 0.588 HD13 ' CZ2' ' A' ' 17' ' ' TRP . 4.5 mm? -53.75 -52.16 61.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.27 -0.423 . . . . 64.42 110.931 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . 56.21 36.12 26.9 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 62.31 111.054 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -89.91 112.74 24.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.237 -0.438 . . . . 53.45 111.081 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -144.88 177.0 9.05 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 63.35 111.059 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 8.7 tt -78.15 107.07 10.47 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.234 -0.439 . . . . 75.41 110.913 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.175 -0.466 . . . . 61.33 110.952 179.892 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 34.5 tt0 . . . . . 0 N--CA 1.458 -0.061 0 CA-C-O 120.805 0.336 . . . . 71.23 110.918 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.66 5.48 36.24 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.754 -0.736 . . . . 64.54 112.549 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -68.79 150.27 48.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.772 0.32 . . . . 64.23 110.853 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.568 ' HE1' HG23 ' A' ' 59' ' ' ILE . 13.3 t90 -126.25 121.27 32.2 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.216 -0.447 . . . . 74.53 110.904 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.798 HG13 ' HB3' ' A' ' 60' ' ' ALA . 6.1 p -132.19 122.69 49.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.248 -0.433 . . . . 74.33 111.162 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -87.03 116.65 25.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 72.23 111.102 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -104.7 109.82 21.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 72.5 110.929 -179.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 15.0 p90 -107.69 119.88 40.68 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.186 -0.461 . . . . 72.45 110.879 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.41 ' HA ' ' HA3' ' A' ' 199' ' ' GLY . 2.5 p30 -149.6 161.53 41.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.134 -0.484 . . . . 62.11 110.858 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -86.49 128.47 34.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 72.05 110.879 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 18.1 p -102.11 116.26 32.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.162 -0.472 . . . . 74.22 110.895 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 16.3 mtpp -98.92 106.16 18.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.151 -0.477 . . . . 75.41 110.935 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.3 p -83.36 139.43 17.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 71.31 111.117 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 21.3 t80 -130.82 101.79 5.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.465 . . . . 72.01 110.922 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.1 p -162.26 155.02 2.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.096 -0.502 . . . . 75.41 111.099 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 119.63 72.17 0.36 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.683 -0.77 . . . . 71.24 112.476 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 -89.43 -57.97 2.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.768 0.318 . . . . 62.44 110.863 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -174.48 135.1 0.41 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.165 -0.471 . . . . 70.32 110.898 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.659 ' HB2' ' HB3' ' A' ' 45' ' ' ALA . 12.7 mt -52.0 165.64 0.2 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 72.53 110.917 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.713 -0.756 . . . . 73.53 112.485 179.913 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.659 ' HB3' ' HB2' ' A' ' 32' ' ' LEU . . . . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.789 0.328 . . . . 44.33 111.069 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -149.45 132.99 16.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 62.13 110.878 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.619 HG12 ' HA2' ' A' ' 83' ' ' GLY . 30.1 m -104.72 154.01 6.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 73.03 111.162 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 10.3 t -151.99 146.1 25.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 55.44 110.862 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.469 HD13 ' H ' ' A' ' 49' ' ' ILE . 0.2 OUTLIER -119.43 150.45 21.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.078 -0.51 . . . . 72.25 111.115 -180.0 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.77 135.2 14.73 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.742 -0.742 . . . . 73.42 112.487 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 60.5 m-20 -87.57 112.95 22.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.359 . . . . 72.52 110.892 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 33.5 t0 -154.38 165.86 35.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.165 -0.47 . . . . 74.35 110.887 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 34.4 p -64.69 148.03 51.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 75.02 111.129 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 8.4 t -158.84 139.92 12.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 64.51 111.13 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.451 HD12 ' CE1' ' A' ' 57' ' ' PHE . 0.2 OUTLIER -124.81 159.77 30.25 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 74.23 110.898 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 55.8 m -139.08 147.53 42.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.179 -0.464 . . . . 70.43 111.113 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.451 ' CE1' HD12 ' A' ' 55' ' ' LEU . 86.6 m-85 -124.18 132.62 53.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 74.13 110.881 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -134.23 149.3 50.96 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.129 -0.487 . . . . 63.21 110.872 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.568 HG23 ' HE1' ' A' ' 17' ' ' TRP . 10.4 mm -108.28 115.75 49.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.186 -0.461 . . . . 62.11 111.144 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.798 ' HB3' HG13 ' A' ' 18' ' ' VAL . . . -101.13 125.99 47.8 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.188 -0.46 . . . . 41.53 111.123 179.802 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.583 ' HB2' HG13 ' A' ' 69' ' ' VAL . 0.7 OUTLIER -108.89 117.79 35.12 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.222 -0.444 . . . . 74.13 110.919 -179.859 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -89.2 105.99 18.15 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.091 -0.504 . . . . 75.25 110.853 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.1 m -103.88 -34.25 3.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 60.41 111.129 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.7 t -135.87 160.12 39.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.224 -0.443 . . . . 75.31 110.884 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 5.7 p -84.56 2.99 38.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.147 -0.478 . . . . 62.52 110.828 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -111.6 -30.84 7.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 73.43 110.876 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 2.6 pp -147.3 165.61 6.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 62.2 111.106 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -154.36 172.84 17.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.472 . . . . 72.41 111.134 179.823 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.583 HG13 ' HB2' ' A' ' 61' ' ' TYR . 1.2 p -116.47 147.89 19.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.245 -0.434 . . . . 71.11 111.119 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -142.57 134.66 27.33 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.173 -0.467 . . . . 73.04 110.835 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -119.73 110.96 17.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.454 . . . . 71.23 110.867 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -85.05 131.18 34.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.481 . . . . 72.25 110.859 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 5.6 m -151.34 163.54 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 51.15 111.103 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -171.16 145.57 8.99 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.721 -0.752 . . . . 60.22 112.49 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.508 ' O ' HG22 ' A' ' 75' ' ' VAL . 7.6 p -117.07 67.44 4.34 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.596 0.712 . . . . 72.32 111.133 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 162.57 41.57 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.686 2.257 . . . . 63.1 112.351 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -84.81 -173.14 4.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 61.15 111.123 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -78.43 131.14 36.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.444 . . . . 73.41 110.866 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -126.26 151.74 47.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.468 . . . . 62.13 111.1 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 15.4 ttpt -114.72 126.32 54.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 75.34 110.892 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 15.7 p90 -126.42 158.84 34.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 72.21 110.89 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.408 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 29.6 mt-30 -92.61 157.66 16.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 74.34 110.92 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.619 ' HA2' HG12 ' A' ' 47' ' ' VAL . . . -176.05 68.76 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.735 -0.745 . . . . 72.23 112.458 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.517 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.6 tp10 -176.44 -176.59 0.77 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.915 0.388 . . . . 74.54 110.915 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -85.55 -69.41 0.66 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 63.13 110.932 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.4 t -83.31 -34.61 25.66 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.284 -0.416 . . . . 63.24 110.892 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.948 HG21 ' HB2' ' A' ' 135' ' ' ALA . 6.1 mm -64.62 -33.79 65.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.09 -0.504 . . . . 72.42 111.116 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 5.3 t -60.17 -46.79 88.5 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 74.41 110.87 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 22.8 t -56.18 -37.38 69.52 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.124 -0.489 . . . . 74.21 110.839 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.63 -48.64 79.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.112 -0.494 . . . . 70.22 110.904 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 111.73 -13.8 27.18 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.704 -0.76 . . . . 72.42 112.471 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 43.7 mtp180 -118.24 92.74 3.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.887 0.375 . . . . 71.53 110.856 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.893 HG22 HG22 ' A' ' 87' ' ' ILE . 90.1 t -113.93 -55.33 4.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 51.4 111.107 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.88 143.81 38.89 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.194 -0.457 . . . . 63.01 110.851 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 11.8 tt0 -147.52 117.87 7.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 71.13 110.891 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.418 HG12 ' H ' ' A' ' 131' ' ' LYS . 18.8 m -155.75 -176.83 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 73.44 111.14 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -97.29 152.08 19.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 73.42 110.896 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -92.57 135.26 34.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 71.14 110.936 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.56 ' HA3' HD12 ' A' ' 127' ' ' LEU . . . -128.3 63.29 0.62 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.71 -0.757 . . . . 63.41 112.441 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 112.38 3.06 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.709 2.272 . . . . 74.41 112.362 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.762 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -128.36 99.49 5.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 64.22 111.145 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.524 ' C ' HD23 ' A' ' 103' ' ' LEU . 4.9 mt -124.31 144.58 33.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 54.33 111.142 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.563 ' HG ' HG23 ' A' ' 123' ' ' VAL . 0.0 OUTLIER -147.31 109.73 4.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.177 -0.465 . . . . 55.34 110.878 179.968 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 3.6 p -144.5 160.39 41.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.221 -0.445 . . . . 71.01 110.832 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.454 ' O ' HD12 ' A' ' 105' ' ' LEU . 4.6 pp -106.19 150.21 26.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.125 -0.489 . . . . 64.1 110.962 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 7.9 pm0 -101.41 141.74 33.84 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.191 -0.459 . . . . 75.52 110.907 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 27.9 p90 -144.45 144.56 31.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 63.22 110.927 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 16.1 m80 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.097 -0.502 . . . . 74.42 110.872 179.962 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 8.7 p90 . . . . . 0 C--O 1.232 0.151 0 CA-C-O 121.642 0.734 . . . . 62.31 110.936 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 176.27 7.0 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.723 2.282 . . . . 73.33 112.354 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 12.7 p90 -115.97 159.47 21.56 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.207 -0.451 . . . . 73.54 110.925 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 60.2 t -123.4 135.33 63.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.126 -0.488 . . . . 72.14 111.107 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -124.08 176.86 16.85 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.72 -0.752 . . . . 72.21 112.491 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.8 p -166.03 152.48 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-O 120.817 0.342 . . . . 70.14 111.167 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 179.12 -153.14 11.9 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.722 -0.752 . . . . 54.44 112.444 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.563 HG23 ' HG ' ' A' ' 103' ' ' LEU . 13.5 m -106.91 120.45 58.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.826 0.346 . . . . 72.33 111.125 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -114.77 111.01 2.44 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.688 -0.768 . . . . 71.34 112.433 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . 0.762 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 8.1 ptp180 -109.31 131.87 54.66 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.805 0.336 . . . . 74.41 110.878 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.423 ' O ' HG13 ' A' ' 126' ' ' VAL . 3.5 p -117.53 115.92 50.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 63.22 111.107 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.56 HD12 ' HA3' ' A' ' 99' ' ' GLY . 2.6 pp -127.49 170.89 12.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.192 -0.458 . . . . 75.31 110.91 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -140.58 174.69 10.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 73.54 110.914 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -102.8 125.25 49.47 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.131 -0.486 . . . . 64.12 110.923 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -61.15 95.65 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.162 -0.472 . . . . 52.23 110.856 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.418 ' H ' HG12 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -115.1 -78.01 0.57 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.161 -0.472 . . . . 64.05 110.894 179.98 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 86.1 m -161.95 83.72 0.58 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 63.32 111.134 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . 0.411 ' OD2' HD12 ' A' ' 141' ' ' ILE . 22.8 m-20 -101.98 170.0 8.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.21 -0.45 . . . . 74.15 110.881 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.29 151.65 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.711 -0.757 . . . . 53.11 112.502 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.948 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -79.73 -0.03 32.53 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.827 0.346 . . . . 62.14 111.101 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -86.23 -178.08 6.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 63.23 110.942 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.7 m -65.73 91.64 0.14 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.186 -0.461 . . . . 62.31 110.894 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.2 t 51.87 75.41 0.21 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.108 -0.496 . . . . 63.42 110.872 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.667 ' CE1' HG12 ' A' ' 176' ' ' VAL . 1.1 t80 -88.92 149.04 23.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.1 -0.5 . . . . 71.21 110.838 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 14.0 t0 -109.96 164.7 12.35 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.127 -0.488 . . . . 72.35 110.902 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.411 HD12 ' OD2' ' A' ' 133' ' ' ASP . 63.8 mt -128.47 125.92 64.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 72.21 111.085 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . 0.466 ' O ' HG22 ' A' ' 174' ' ' THR . 0.1 OUTLIER -76.04 109.24 9.52 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.172 -0.467 . . . . 71.04 110.913 179.819 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.406 ' HB3' ' HA ' ' A' ' 127' ' ' LEU . 0.8 OUTLIER -58.68 -173.62 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.207 -0.451 . . . . 72.4 110.857 179.877 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 11.2 mmtm -148.55 166.02 29.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.456 . . . . 61.2 110.89 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 42.6 p-90 -157.75 136.32 11.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 74.33 110.921 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.751 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -172.49 166.02 3.52 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.578 0.704 . . . . 61.22 111.129 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' PRO . . . . . 0.751 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.5 Cg_endo -69.79 135.35 30.17 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.711 2.274 . . . . 62.42 112.318 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -122.48 165.62 16.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 64.33 111.129 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 23.7 m-85 -122.3 136.32 54.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.214 -0.448 . . . . 74.2 110.89 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 3.7 mm100 -107.16 151.8 24.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.159 -0.473 . . . . 71.23 110.921 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.429 ' O ' HG13 ' A' ' 151' ' ' VAL . 5.4 p -152.04 117.85 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.207 -0.451 . . . . 74.52 111.181 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . 0.43 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 176.93 -161.63 29.5 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.739 -0.743 . . . . 64.34 112.467 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.516 HD23 ' N ' ' A' ' 154' ' ' ARG . 0.6 OUTLIER -136.99 155.9 49.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.769 0.318 . . . . 73.21 110.918 -179.911 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.516 ' N ' HD23 ' A' ' 153' ' ' LEU . 0.4 OUTLIER -139.93 124.16 17.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 71.35 110.872 179.954 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . 0.458 ' OH ' HD13 ' A' ' 163' ' ' LEU . 26.3 p90 -144.42 177.45 8.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.461 . . . . 74.25 110.896 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -118.92 100.18 7.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.082 -0.508 . . . . 73.5 110.895 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 18.7 tp -102.03 106.24 17.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.142 -0.481 . . . . 73.0 110.956 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 103.34 -173.76 22.42 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.726 -0.749 . . . . 73.23 112.47 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 9.3 p-10 -101.53 132.26 47.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.861 0.363 . . . . 61.55 110.913 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.6 t 53.01 41.33 32.16 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.139 -0.482 . . . . 74.22 110.921 -179.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 2.3 t90 -171.97 100.49 0.17 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.096 -0.502 . . . . 64.54 110.92 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' MET . . . . . 0.545 ' CE ' HG21 ' A' ' 18' ' ' VAL . 13.6 mtm -95.42 173.85 7.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.258 -0.428 . . . . 72.24 110.914 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.458 HD13 ' OH ' ' A' ' 155' ' ' TYR . 2.1 tt -127.69 145.1 51.0 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.271 -0.422 . . . . 74.2 110.911 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . 0.452 ' N ' HD23 ' A' ' 163' ' ' LEU . 5.9 t-20 -145.8 138.07 25.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 74.32 110.919 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 13.0 p -153.26 121.75 6.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 64.42 110.89 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' ASP . . . . . 0.43 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 1.3 p30 -154.03 -179.79 8.2 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.166 -0.47 . . . . 63.43 110.856 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.895 HG22 HD12 ' A' ' 196' ' ' LEU . 8.2 t -138.48 143.79 31.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 64.33 111.113 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . 0.47 ' NH2' HG21 ' A' ' 170' ' ' ILE . 4.4 ttt180 -113.78 123.34 49.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.158 -0.474 . . . . 74.45 110.856 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 13.2 t80 -121.99 138.97 54.22 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.186 -0.461 . . . . 75.41 110.94 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' ILE . . . . . 0.548 HD11 ' HB3' ' A' ' 146' ' ' ALA . 6.4 tt -177.35 93.91 0.23 Allowed Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.631 0.729 . . . . 73.23 111.171 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.66 134.19 27.59 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.707 2.271 . . . . 63.43 112.379 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -156.89 177.84 11.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.252 -0.431 . . . . 74.51 110.878 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 190' ' ' GLU . 11.3 pttp -128.28 125.32 38.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.126 -0.488 . . . . 63.4 110.859 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 174' ' ' THR . . . . . 0.466 HG22 ' O ' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -91.94 161.74 14.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 75.55 111.146 179.961 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . 0.415 ' HB3' ' HB2' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -119.14 165.55 14.05 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.431 . . . . 61.11 110.874 179.943 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.667 HG12 ' CE1' ' A' ' 139' ' ' PHE . 21.4 t -146.53 133.13 13.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 64.23 111.171 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 14.0 t -166.53 176.9 6.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 75.2 111.104 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 122.18 141.33 6.0 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.752 -0.737 . . . . 63.22 112.495 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 C--N 1.329 -0.296 0 CA-C-O 120.834 0.35 . . . . 62.53 111.147 -179.841 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.231 0.159 0 CA-C-O 120.82 0.258 . . . . 65.42 112.325 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 85.3 t -109.41 107.69 23.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.274 -0.421 . . . . 60.35 111.115 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 6.7 p -83.69 110.57 18.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.151 -0.477 . . . . 75.05 110.882 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 11.9 p -121.93 171.5 8.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 73.1 111.15 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 29.9 ttpt -153.52 148.08 26.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.208 -0.451 . . . . 65.41 110.922 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 5.9 tp -142.74 124.06 11.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 63.4 111.098 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 190' ' ' GLU . . . . . 0.422 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 19.5 pt-20 -96.94 116.9 30.0 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 70.22 110.863 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 4.1 m -138.36 158.79 31.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 72.3 111.108 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.406 ' HA ' ' HD2' ' A' ' 193' ' ' PRO . 1.9 p30 -107.85 89.85 5.79 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.581 0.705 . . . . 73.24 110.875 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . 0.406 ' HD2' ' HA ' ' A' ' 192' ' ' ASP . 53.6 Cg_endo -69.79 138.46 37.78 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.721 2.281 . . . . 73.34 112.358 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 12.9 m-85 -124.68 116.66 22.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 72.45 110.865 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 195' ' ' ILE . . . . . 0.412 ' HB ' ' HB3' ' A' ' 168' ' ' ARG . 45.3 mt -106.44 131.28 56.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.199 -0.455 . . . . 64.41 111.109 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . 0.895 HD12 HG22 ' A' ' 167' ' ' VAL . 7.4 tp -117.74 112.33 20.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 74.31 110.889 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -97.87 124.59 42.35 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.145 -0.48 . . . . 72.21 110.855 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 198' ' ' LEU . . . . . 0.409 HD22 ' CD2' ' A' ' 196' ' ' LEU . 0.5 OUTLIER -144.64 119.59 9.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.133 -0.485 . . . . 53.41 110.906 -179.993 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 199' ' ' GLY . . . . . 0.41 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -177.91 -145.83 6.1 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.759 -0.734 . . . . 60.4 112.467 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 200' ' ' ALA . . . . . 0.504 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -127.19 173.8 9.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.803 0.335 . . . . 70.31 111.083 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -140.13 175.82 9.27 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 62.42 110.85 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 202' ' ' TYR . . . . . 0.709 ' C ' HG23 ' A' ' 18' ' ' VAL . 16.2 t80 -146.55 115.65 6.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.095 -0.502 . . . . 70.02 110.915 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.428 ' N ' HG23 ' A' ' 18' ' ' VAL . 15.0 p -77.12 147.66 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.103 -0.499 . . . . 71.01 111.159 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -152.9 143.14 22.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 72.03 110.867 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 12.9 ptmt . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.142 -0.481 . . . . 75.5 110.894 179.977 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 19.1 pt20 . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.87 0.367 . . . . 65.32 110.861 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.41 6.28 38.86 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.781 -0.723 . . . . 73.43 112.543 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -78.43 163.36 25.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.811 0.338 . . . . 72.21 110.878 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 3.7 p-90 -139.96 151.58 45.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.154 -0.475 . . . . 71.1 110.896 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.771 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 2.3 m -144.55 139.36 23.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.226 -0.443 . . . . 63.11 111.107 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.414 ' HB1' ' CZ ' ' A' ' 21' ' ' PHE . . . -99.14 101.78 13.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.124 -0.489 . . . . 63.25 111.146 179.794 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.6 m -97.53 121.46 39.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 73.31 110.829 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.414 ' CZ ' ' HB1' ' A' ' 19' ' ' ALA . 18.8 m-85 -118.64 118.29 31.26 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.134 -0.484 . . . . 74.32 110.888 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -148.01 172.84 13.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.102 -0.499 . . . . 75.11 110.845 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -100.64 124.27 46.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.132 -0.486 . . . . 74.31 110.897 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . 0.506 ' HB2' HG21 ' A' ' 56' ' ' THR . 69.5 m -102.28 115.11 29.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.129 -0.487 . . . . 71.0 110.848 -179.732 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -98.84 113.78 26.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.18 -0.464 . . . . 63.4 110.915 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 32.4 t -92.49 146.62 6.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.242 -0.436 . . . . 73.42 111.124 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -135.21 110.52 9.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 72.22 110.937 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.3 p -166.51 150.34 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.136 -0.484 . . . . 75.23 111.193 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 136.27 76.13 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.721 -0.752 . . . . 71.24 112.474 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -89.51 -65.89 0.97 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.832 0.348 . . . . 73.05 110.836 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.501 ' HA ' HG12 ' A' ' 47' ' ' VAL . 14.3 mt-10 -162.87 146.89 11.34 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 72.13 110.878 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.613 HD12 HG13 ' A' ' 189' ' ' ILE . 2.0 tp -109.81 160.73 16.1 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.195 -0.457 . . . . 54.33 110.933 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.51 ' N ' HD11 ' A' ' 189' ' ' ILE . . . . . . . . 0 N--CA 1.452 -0.267 0 C-N-CA 120.742 -0.742 . . . . 73.22 112.501 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.564 ' HB1' ' HA ' ' A' ' 84' ' ' GLU . . . . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.822 0.344 . . . . 73.24 111.091 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -132.38 125.81 31.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 70.34 110.857 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 82' ' ' GLN . 11.3 p -111.7 137.81 42.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 63.22 111.131 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -147.4 142.05 26.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.084 -0.507 . . . . 43.23 110.895 -179.834 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 39.0 pt -115.72 156.62 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 73.24 111.076 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -84.94 179.02 51.13 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.711 -0.757 . . . . 62.45 112.506 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 79.0 m-20 -133.64 112.95 11.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.836 0.351 . . . . 63.14 110.918 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -145.42 140.58 27.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 75.02 110.831 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 29.8 p -55.68 128.49 35.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 60.22 111.095 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 5.7 t -137.12 150.35 47.93 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.197 -0.456 . . . . 65.12 111.107 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -113.49 152.46 30.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 65.31 110.885 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.506 HG21 ' HB2' ' A' ' 24' ' ' SER . 0.8 OUTLIER -136.51 137.29 40.16 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.188 -0.46 . . . . 52.12 111.153 179.921 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -103.12 132.14 49.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 71.34 110.891 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -130.96 130.2 43.1 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.123 -0.49 . . . . 74.42 110.856 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.98 115.2 48.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 65.02 111.081 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.771 ' HB3' ' CG2' ' A' ' 18' ' ' VAL . . . -101.94 125.61 48.66 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.188 -0.46 . . . . 63.14 111.123 179.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -107.03 117.11 33.21 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.235 -0.439 . . . . 75.04 110.887 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -83.76 95.74 8.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.054 -0.521 . . . . 65.5 110.919 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 9.5 p -92.17 -34.29 6.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 72.43 111.175 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 17.0 m -133.68 160.69 36.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.097 -0.501 . . . . 75.43 110.842 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.6 p -83.48 2.98 34.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.123 -0.489 . . . . 70.31 110.868 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -119.75 -32.27 4.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.13 -0.486 . . . . 75.04 110.93 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.437 HG22 ' CD1' ' A' ' 107' ' ' TYR . 40.5 pt -139.72 153.46 23.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 71.01 111.098 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -146.95 162.92 37.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 65.54 111.088 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.5 m -103.84 151.37 6.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.23 -0.441 . . . . 74.31 111.095 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -141.92 135.75 29.75 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.19 -0.459 . . . . 75.05 110.823 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.493 ' CE2' HD13 ' A' ' 103' ' ' LEU . 7.2 m-85 -122.2 108.18 13.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 71.13 110.88 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.832 ' HB2' HG23 ' A' ' 102' ' ' ILE . 18.1 m-85 -94.77 123.43 38.22 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.118 -0.492 . . . . 75.23 110.833 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.2 p -149.78 154.63 8.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.067 -0.515 . . . . 54.14 111.166 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -162.57 142.23 7.77 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.767 -0.73 . . . . 45.02 112.472 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.9 m -115.17 73.24 3.42 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.617 0.722 . . . . 64.42 111.115 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 161.27 46.56 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.651 2.234 . . . . 64.44 112.357 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -68.71 -169.88 0.19 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.248 -0.433 . . . . 74.42 111.077 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 1.2 tmm_? -78.88 140.67 38.07 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.434 . . . . 73.54 110.85 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -128.2 142.27 51.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.201 -0.454 . . . . 53.34 111.077 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 28.9 ttpt -108.11 135.74 48.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.265 -0.425 . . . . 73.35 110.924 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 6.9 p90 -141.97 157.98 44.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 75.42 110.916 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.516 ' O ' HG23 ' A' ' 47' ' ' VAL . 0.5 OUTLIER -96.42 160.78 14.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.151 -0.477 . . . . 72.14 110.896 -179.925 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.518 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -177.87 66.0 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.792 -0.718 . . . . 40.33 112.531 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.564 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.3 tp10 -173.84 -176.8 1.27 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.931 0.396 . . . . 44.31 110.869 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.88 -68.87 0.7 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 71.23 110.874 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 5.1 m -83.83 -34.55 24.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.208 -0.451 . . . . 74.31 110.897 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.752 HG22 HG22 ' A' ' 93' ' ' VAL . 5.8 mm -64.55 -33.78 65.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.142 -0.481 . . . . 74.51 111.109 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.3 t -63.05 -45.26 93.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.13 -0.486 . . . . 50.41 110.825 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 22.7 t -53.6 -41.72 66.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.124 -0.489 . . . . 72.52 110.88 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.405 HD22 ' HA ' ' A' ' 90' ' ' LEU . 0.3 OUTLIER -59.5 -44.19 93.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 73.41 110.917 179.989 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 110.21 -14.14 30.96 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.762 -0.732 . . . . 61.4 112.505 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 20.2 mtt180 -120.22 93.61 4.11 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.836 0.35 . . . . 75.22 110.813 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.752 HG22 HG22 ' A' ' 87' ' ' ILE . 13.1 t -113.56 -45.82 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 72.52 111.099 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 67.5 m -140.58 144.94 36.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.466 . . . . 72.45 110.834 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -142.01 119.56 11.7 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.103 -0.499 . . . . 53.34 110.909 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.471 HG23 ' HB2' ' A' ' 131' ' ' LYS . 7.2 p -175.04 157.92 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 72.33 111.151 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.424 ' N ' HG22 ' A' ' 96' ' ' VAL . 8.2 p-10 -81.17 173.53 12.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.182 -0.463 . . . . 54.34 110.858 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 11.6 m-85 -117.43 130.73 56.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.222 -0.445 . . . . 71.44 110.894 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -117.49 65.81 0.35 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.675 -0.774 . . . . 72.14 112.478 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.75 115.3 4.03 Favored 'Trans proline' 0 N--CA 1.465 -0.187 0 C-N-CA 122.708 2.272 . . . . 72.43 112.384 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.587 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -123.03 100.18 6.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.223 -0.444 . . . . 62.3 111.083 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.832 HG23 ' HB2' ' A' ' 72' ' ' PHE . 2.5 tp -122.06 119.83 59.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 74.52 111.137 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.493 HD13 ' CE2' ' A' ' 71' ' ' PHE . 0.2 OUTLIER -120.65 113.67 20.57 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.199 -0.455 . . . . 71.52 110.897 179.892 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . 0.439 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 4.9 p -142.81 159.48 42.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 55.05 110.858 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.58 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.6 OUTLIER -103.94 149.63 24.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.101 -0.5 . . . . 54.12 110.925 -179.994 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 15.8 mm-40 -101.58 144.95 29.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.468 . . . . 74.53 110.895 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.437 ' CD1' HG22 ' A' ' 67' ' ' ILE . 6.8 t80 -139.94 128.94 23.53 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.185 -0.461 . . . . 62.24 110.933 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 28.1 p80 . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.07 -0.514 . . . . 72.53 110.835 179.946 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 1.4 p90 . . . . . 0 C--O 1.232 0.146 0 CA-C-O 121.68 0.752 . . . . 74.22 110.889 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 177.53 5.5 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.625 2.216 . . . . 62.34 112.315 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -110.97 144.36 40.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.187 -0.461 . . . . 74.11 110.875 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 8.0 p -101.16 130.67 50.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.053 -0.521 . . . . 74.54 111.114 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -129.71 165.33 22.26 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.747 -0.739 . . . . 72.53 112.46 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 13.7 p -161.54 149.7 4.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.881 0.372 . . . . 51.45 111.128 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . 0.439 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -174.41 -155.12 11.68 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.748 -0.739 . . . . 54.24 112.485 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.419 HG13 ' O ' ' A' ' 123' ' ' VAL . 7.5 p -109.2 124.83 66.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.878 0.37 . . . . 75.11 111.154 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -110.1 114.3 3.81 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.776 -0.726 . . . . 72.05 112.497 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . 0.587 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 25.5 ptt180 -115.9 124.56 50.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.823 0.344 . . . . 63.25 110.84 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.491 ' O ' HD23 ' A' ' 127' ' ' LEU . 26.1 t -104.68 116.34 48.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.274 -0.421 . . . . 52.15 111.151 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.491 HD23 ' O ' ' A' ' 126' ' ' VAL . 9.9 mt -130.76 171.24 13.34 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 75.32 110.86 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -160.25 169.53 23.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 54.12 110.895 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -102.93 118.78 37.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 62.5 110.883 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -48.93 108.07 0.17 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.056 -0.52 . . . . 50.44 110.877 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.471 ' HB2' HG23 ' A' ' 96' ' ' VAL . 3.6 mmmp? -111.52 -80.84 0.58 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.479 . . . . 74.32 110.875 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 21.9 m -161.52 81.0 0.59 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 64.42 111.135 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 39.2 m-20 -102.84 166.57 10.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.46 . . . . 44.4 110.899 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.64 155.26 0.11 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.705 -0.759 . . . . 61.55 112.503 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.744 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -81.24 3.67 23.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.8 0.333 . . . . 51.13 111.099 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -86.19 -175.33 5.48 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.455 . . . . 62.01 110.911 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 88.6 p -65.59 83.2 0.06 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 61.34 110.87 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 5.4 t 50.31 75.15 0.18 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 61.21 110.869 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -80.04 146.94 31.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 74.43 110.806 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . 0.432 ' O ' HG23 ' A' ' 176' ' ' VAL . 2.7 p30 -106.74 161.04 15.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.131 -0.486 . . . . 55.04 110.865 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 57.2 mt -115.73 143.86 24.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.171 -0.468 . . . . 74.2 111.12 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 3.4 mmtp -94.27 104.59 16.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 65.2 110.937 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.471 ' HB2' HD23 ' A' ' 127' ' ' LEU . 0.6 OUTLIER -58.21 -174.86 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.466 . . . . 73.42 110.866 179.897 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -162.28 164.87 27.32 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.233 -0.44 . . . . 75.1 110.906 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 22.6 p-90 -146.6 154.41 41.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.211 -0.45 . . . . 75.42 110.981 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.706 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.23 164.43 0.97 Allowed Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.579 0.704 . . . . 72.03 111.096 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' PRO . . . . . 0.706 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 54.0 Cg_endo -69.82 127.49 14.62 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.577 2.185 . . . . 53.13 112.364 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.616 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -120.52 167.94 11.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 73.43 111.132 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -123.04 142.13 51.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 74.42 110.872 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 15.5 tt0 -123.17 151.98 41.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.165 -0.471 . . . . 71.4 110.879 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.1 t -151.08 122.8 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 52.52 111.092 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . 0.41 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . -174.68 -174.75 41.64 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.73 -0.748 . . . . 53.33 112.461 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.4 HD23 ' N ' ' A' ' 153' ' ' LEU . 1.9 pt? -135.58 160.43 38.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.776 0.322 . . . . 75.1 110.988 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.3 tpp85 -122.06 118.54 29.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.241 -0.436 . . . . 64.23 110.873 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -101.35 127.97 47.73 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.204 -0.453 . . . . 73.03 110.897 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -116.73 102.12 9.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.157 -0.474 . . . . 75.2 110.898 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 7.3 tp -97.24 97.01 8.8 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.192 -0.458 . . . . 64.55 110.851 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 51.45 -159.18 2.3 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.608 -0.806 . . . . 70.24 112.516 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 23.2 m-20 -71.71 -29.44 64.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.83 0.348 . . . . 73.5 110.896 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 8.2 p -52.05 172.12 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.155 -0.475 . . . . 71.41 110.909 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 25.4 m0 -49.84 144.2 6.72 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.107 -0.497 . . . . 75.34 110.92 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' MET . . . . . 0.44 ' C ' HD12 ' A' ' 163' ' ' LEU . 2.6 mtt -98.91 173.78 6.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.243 -0.435 . . . . 64.4 110.944 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.44 HD12 ' C ' ' A' ' 162' ' ' MET . 8.9 mp -125.68 142.86 51.3 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.268 -0.423 . . . . 63.33 110.876 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -140.15 134.59 31.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 63.22 110.873 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 3.3 t -142.23 122.47 13.87 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.145 -0.479 . . . . 44.23 110.842 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' ASP . . . . . 0.41 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.4 OUTLIER -150.88 165.08 34.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 53.44 110.92 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.512 HG13 ' HG ' ' A' ' 196' ' ' LEU . 1.5 t -133.51 139.76 48.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.212 -0.449 . . . . 34.05 111.192 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . 0.808 ' HD3' HD13 ' A' ' 195' ' ' ILE . 21.9 ttt180 -111.31 131.38 55.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 72.23 110.87 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' TYR . . . . . 0.471 ' OH ' HG11 ' A' ' 167' ' ' VAL . 94.4 m-85 -134.31 137.0 43.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.23 -0.441 . . . . 73.34 110.924 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' ILE . . . . . 0.776 HD13 ' O ' ' A' ' 170' ' ' ILE . 0.0 OUTLIER -179.34 102.92 0.19 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.606 0.717 . . . . 50.42 111.144 179.898 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 139.22 39.71 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.691 2.261 . . . . 71.4 112.368 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . 0.688 ' CZ ' ' HB2' ' A' ' 146' ' ' ALA . 0.1 OUTLIER -165.9 177.26 7.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 75.12 110.816 -179.963 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 8.0 ptmt -128.52 150.61 50.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.053 -0.522 . . . . 71.3 110.873 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 15.3 t -119.43 161.21 20.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.143 -0.48 . . . . 74.15 111.141 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -116.1 172.62 7.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.269 -0.423 . . . . 72.21 110.877 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 140' ' ' ASP . 14.8 p -164.98 140.06 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 73.51 111.084 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.0 t -165.81 177.67 7.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.177 -0.465 . . . . 74.31 111.114 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -154.83 -139.13 2.73 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.696 -0.764 . . . . 72.33 112.499 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.33 -0.275 0 CA-C-O 120.811 0.338 . . . . 72.21 111.11 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo . . . . . 0 C--O 1.231 0.165 0 CA-C-O 120.799 0.25 . . . . 74.4 112.37 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.502 HG12 HG23 ' A' ' 187' ' ' THR . 85.6 t -96.73 108.35 21.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.248 -0.433 . . . . 70.41 111.146 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 62.0 p -98.12 106.52 18.82 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.188 -0.46 . . . . 63.2 110.889 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . 0.502 HG23 HG12 ' A' ' 185' ' ' VAL . 22.2 p -115.74 167.62 10.77 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 72.44 111.122 -179.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 188' ' ' LYS . . . . . 0.483 ' O ' HD13 ' A' ' 189' ' ' ILE . 0.0 OUTLIER -155.29 159.26 39.86 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.203 -0.453 . . . . 63.43 110.976 179.898 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 189' ' ' ILE . . . . . 0.613 HG13 HD12 ' A' ' 32' ' ' LEU . 26.4 mm -142.76 137.67 27.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 71.2 111.07 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -104.78 114.94 29.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 50.02 110.862 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 191' ' ' VAL . . . . . 0.406 HG12 ' N ' ' A' ' 192' ' ' ASP . 2.6 t -137.33 163.09 32.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.148 -0.478 . . . . 71.43 111.177 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.416 ' HA ' ' HD2' ' A' ' 193' ' ' PRO . 0.5 OUTLIER -107.25 90.0 5.26 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.612 0.72 . . . . 72.22 110.883 179.919 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' ' 192' ' ' ASP . 53.8 Cg_endo -69.78 138.04 36.8 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.693 2.262 . . . . 75.11 112.313 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 10.0 m-85 -120.32 119.67 33.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.195 -0.457 . . . . 72.11 110.897 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 195' ' ' ILE . . . . . 0.808 HD13 ' HD3' ' A' ' 168' ' ' ARG . 3.6 mp -112.99 132.45 61.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.464 . . . . 63.42 111.101 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . 0.512 ' HG ' HG13 ' A' ' 167' ' ' VAL . 1.4 tt -125.79 112.16 15.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.444 . . . . 61.0 110.895 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 2.6 p -100.39 127.58 46.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.21 -0.45 . . . . 71.43 110.855 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 198' ' ' LEU . . . . . 0.409 HD23 ' C ' ' A' ' 198' ' ' LEU . 10.5 tt -147.83 126.05 12.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.154 -0.475 . . . . 74.23 110.963 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -179.42 -142.53 5.02 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.719 -0.753 . . . . 62.12 112.47 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 200' ' ' ALA . . . . . 0.415 ' HA ' ' HA ' ' A' ' 163' ' ' LEU . . . -117.99 174.28 6.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.73 0.3 . . . . 32.22 111.098 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 63.7 p -156.37 163.33 39.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.262 -0.426 . . . . 70.33 110.806 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -136.14 130.05 32.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.047 -0.524 . . . . 70.34 110.925 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.409 HG13 ' SD ' ' A' ' 162' ' ' MET . 19.7 m -85.18 147.72 5.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.1 -0.5 . . . . 52.41 111.125 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -141.27 105.0 4.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.181 -0.463 . . . . 74.41 110.889 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 37.0 mttm . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.068 -0.515 . . . . 74.33 110.913 179.975 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 . . . . . 0 C--O 1.23 0.06 0 CA-C-O 120.893 0.378 . . . . 75.14 110.942 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 92.18 6.53 64.74 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.756 -0.735 . . . . 73.45 112.464 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -78.93 151.16 31.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.815 0.341 . . . . 74.31 110.883 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.583 ' CZ2' HG21 ' A' ' 59' ' ' ILE . 0.2 OUTLIER -125.36 139.42 53.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 64.1 110.908 -179.969 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.725 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 4.9 m -145.71 134.67 17.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 55.24 111.18 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -97.8 110.91 23.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 72.23 111.095 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.5 t -103.78 117.48 34.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 74.33 110.855 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 30.4 p90 -117.98 124.04 47.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 73.34 110.88 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.4 ' HB2' ' C ' ' A' ' 198' ' ' LEU . 4.1 p30 -149.7 171.88 15.98 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.128 -0.487 . . . . 74.32 110.883 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -94.8 122.32 37.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 65.5 110.931 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -93.82 113.53 25.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 34.34 110.845 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 36.7 mttt -93.66 106.97 18.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.197 -0.456 . . . . 72.15 110.877 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.512 HG22 HG23 ' A' ' 28' ' ' VAL . 12.3 p -87.26 130.95 36.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 44.33 111.158 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -121.42 102.69 8.43 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 73.4 110.911 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.512 HG23 HG22 ' A' ' 26' ' ' VAL . 7.9 t -140.16 155.34 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.061 -0.518 . . . . 75.04 111.079 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.487 ' HA2' HG13 ' A' ' 47' ' ' VAL . . . 130.73 62.16 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.762 -0.732 . . . . 61.3 112.467 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -89.87 -66.15 0.95 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.899 0.38 . . . . 72.1 110.969 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 179.18 130.05 0.08 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.088 -0.505 . . . . 71.32 110.849 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.739 HD22 ' HB3' ' A' ' 45' ' ' ALA . 1.8 tp -51.9 170.12 0.06 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.133 -0.485 . . . . 75.23 110.903 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.276 0 C-N-CA 120.712 -0.756 . . . . 71.3 112.473 179.917 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.739 ' HB3' HD22 ' A' ' 32' ' ' LEU . . . . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.758 0.313 . . . . 64.15 111.161 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . 0.579 ' O ' HD13 ' A' ' 32' ' ' LEU . 0.4 OUTLIER -121.04 -170.36 2.0 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 74.31 110.807 179.949 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.487 HG13 ' HA2' ' A' ' 29' ' ' GLY . 10.4 p -166.08 135.6 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.157 -0.474 . . . . 71.41 111.167 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -175.05 171.53 3.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.469 . . . . 71.22 110.839 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 2.2 pp -102.43 158.22 4.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.09 -0.505 . . . . 73.13 111.106 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -88.72 -81.73 1.29 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.733 -0.746 . . . . 72.12 112.432 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.7 p30 -151.87 93.38 1.84 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.791 0.329 . . . . 72.42 110.867 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -115.49 65.52 0.69 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 71.11 110.851 179.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . 0.441 ' O ' HG23 ' A' ' 54' ' ' THR . 0.7 OUTLIER -95.31 103.5 15.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.148 -0.478 . . . . 62.23 111.142 -179.887 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.441 HG23 ' O ' ' A' ' 53' ' ' THR . 2.2 p -156.75 163.31 39.4 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.251 -0.432 . . . . 60.42 111.142 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 11.8 mt -88.4 163.23 16.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 75.53 110.927 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -131.42 142.57 50.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 74.5 111.103 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -113.88 131.75 56.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.45 . . . . 52.02 110.864 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.414 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.2 OUTLIER -130.78 143.77 50.97 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.089 -0.505 . . . . 61.54 110.788 -179.938 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.583 HG21 ' CZ2' ' A' ' 17' ' ' TRP . 12.5 mm -108.09 117.68 54.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 73.44 111.12 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.725 ' HB3' ' CG2' ' A' ' 18' ' ' VAL . . . -100.44 132.72 45.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 53.2 111.097 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.452 ' HB3' HG22 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -114.85 116.84 29.22 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.205 -0.452 . . . . 72.44 110.936 -179.861 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -87.0 101.91 13.9 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 74.53 110.969 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 8.1 p -100.57 -34.57 4.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.121 -0.49 . . . . 65.1 111.084 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 20.3 t -132.46 158.78 41.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 63.42 110.894 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.4 m -84.18 2.82 37.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 74.55 110.771 -179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -112.33 -31.16 6.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 63.41 110.853 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.403 HG22 ' HA ' ' A' ' 107' ' ' TYR . 25.4 pt -148.78 162.24 5.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.24 -0.437 . . . . 73.15 111.148 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -149.57 170.24 19.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 74.12 111.116 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.452 HG22 ' HB3' ' A' ' 61' ' ' TYR . 10.6 m -112.3 153.57 13.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.203 -0.453 . . . . 74.44 111.203 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -146.15 132.12 19.2 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.191 -0.459 . . . . 73.51 110.841 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.414 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 12.0 t80 -115.01 108.82 17.19 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.253 -0.431 . . . . 71.12 110.889 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -86.19 128.49 34.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 64.35 110.945 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 2.7 p -145.32 144.43 21.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.128 -0.487 . . . . 71.11 111.119 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -159.38 133.76 3.48 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.793 -0.718 . . . . 51.32 112.496 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.476 ' O ' HG13 ' A' ' 75' ' ' VAL . 4.5 p -112.93 75.41 1.96 Allowed Pre-proline 0 C--N 1.33 -0.243 0 CA-C-O 121.659 0.742 . . . . 70.52 111.083 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 162.49 41.87 Favored 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.654 2.236 . . . . 63.04 112.416 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -76.29 -167.93 0.86 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.26 -0.427 . . . . 61.15 111.132 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 35.3 ttp180 -78.02 131.09 37.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.243 -0.435 . . . . 73.42 110.916 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -132.45 151.14 52.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 62.44 111.056 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 22.3 pttm -92.78 135.17 34.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 71.25 110.915 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -116.09 137.23 52.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 72.04 110.891 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 -95.92 151.78 19.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 72.51 110.916 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.608 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 174.77 73.6 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.812 -0.709 . . . . 54.34 112.511 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.532 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.3 mm-40 -170.47 -176.44 2.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.912 0.387 . . . . 74.12 110.846 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.19 -70.12 0.62 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 73.24 110.923 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.8 t -85.81 -30.62 22.84 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.212 -0.449 . . . . 74.13 110.788 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.569 HG22 HG22 ' A' ' 93' ' ' VAL . 4.4 mm -68.5 -34.66 66.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 65.55 111.156 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.4 t -61.38 -49.66 76.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.465 . . . . 75.24 110.871 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 22.3 t -51.73 -42.46 62.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 64.24 110.851 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.449 HD22 ' HG2' ' A' ' 92' ' ' ARG . 0.7 OUTLIER -57.66 -45.61 85.3 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.147 -0.479 . . . . 64.11 110.918 179.978 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 111.49 -14.82 27.48 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.772 -0.728 . . . . 63.51 112.547 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.449 ' HG2' HD22 ' A' ' 90' ' ' LEU . 9.6 ptt85 -120.46 95.77 4.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.84 0.353 . . . . 65.04 110.94 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.608 HG21 ' H ' ' A' ' 83' ' ' GLY . 21.9 t -110.5 -46.06 6.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 74.04 111.121 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.409 ' HA ' ' HA ' ' A' ' 133' ' ' ASP . 1.6 p -139.63 153.47 47.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.477 . . . . 74.2 110.834 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -135.69 121.96 20.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.142 -0.481 . . . . 72.22 110.896 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.623 HG21 ' O ' ' A' ' 129' ' ' PHE . 7.6 p -174.18 161.39 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.199 -0.455 . . . . 74.23 111.118 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.43 ' N ' HG22 ' A' ' 96' ' ' VAL . 3.3 p30 -80.13 172.72 13.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.188 -0.46 . . . . 75.14 110.873 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -125.31 130.83 52.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.446 . . . . 63.34 110.919 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -118.68 66.75 0.37 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.708 -0.758 . . . . 75.42 112.441 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 124.99 11.63 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.705 2.27 . . . . 73.24 112.319 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.602 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -138.68 106.05 5.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 75.33 111.1 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.658 ' C ' HD23 ' A' ' 103' ' ' LEU . 16.3 mm -118.56 150.48 20.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.25 -0.432 . . . . 74.03 111.105 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.658 HD23 ' C ' ' A' ' 102' ' ' ILE . 0.0 OUTLIER -149.15 109.75 4.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 71.52 110.916 179.869 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.0 p -144.37 171.56 14.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 75.0 110.891 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -120.42 153.06 37.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.465 . . . . 55.33 110.888 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 -106.25 139.03 41.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.156 -0.475 . . . . 55.31 110.902 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.403 ' HA ' HG22 ' A' ' 67' ' ' ILE . 30.7 p90 -143.16 148.3 36.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 73.04 110.884 -179.822 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 25.0 p-80 . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 73.33 110.876 179.933 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 4.1 p90 . . . . . 0 C--O 1.232 0.132 0 CA-C-O 121.625 0.726 . . . . 72.52 110.921 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 177.55 5.48 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.702 2.268 . . . . 65.2 112.345 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -117.35 157.6 25.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 75.03 110.96 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 72.7 t -106.99 128.38 61.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.063 -0.517 . . . . 73.11 111.109 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -119.27 172.88 14.81 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.714 -0.755 . . . . 72.33 112.53 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.3 p -175.56 153.13 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.848 0.356 . . . . 72.53 111.141 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 178.17 -148.65 8.64 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.823 -0.704 . . . . 60.03 112.511 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.652 HG13 ' HG ' ' A' ' 103' ' ' LEU . 4.9 p -110.39 137.71 41.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.882 0.372 . . . . 64.33 111.145 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . 0.424 ' HA3' HD12 ' A' ' 102' ' ' ILE . . . -127.36 105.87 0.78 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.712 -0.756 . . . . 70.52 112.408 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . 0.602 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 13.0 ptp180 -98.85 130.17 45.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.854 0.359 . . . . 75.44 110.891 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 3.2 m -106.99 109.65 28.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 71.0 111.172 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 1.4 tt -86.47 141.59 29.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 62.1 110.932 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -152.58 129.93 11.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 74.0 110.844 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.623 ' O ' HG21 ' A' ' 96' ' ' VAL . 0.8 OUTLIER -101.56 176.48 5.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.097 -0.501 . . . . 72.1 110.948 -179.973 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -109.19 95.19 5.47 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.218 -0.447 . . . . 73.21 110.85 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.426 ' HB2' HG23 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -89.16 -79.61 0.32 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 71.31 110.858 179.976 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.7 m -163.22 113.22 1.36 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.254 -0.43 . . . . 73.42 111.135 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . 0.43 ' HB3' ' CB ' ' A' ' 139' ' ' PHE . 10.0 t0 -106.27 117.1 33.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 73.13 110.901 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -78.25 -11.15 85.63 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.759 -0.734 . . . . 73.12 112.49 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.455 ' HB2' HG12 ' A' ' 93' ' ' VAL . . . -44.95 -30.31 0.99 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.781 0.324 . . . . 72.21 111.076 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 3.4 tp -160.79 -177.49 6.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.227 -0.442 . . . . 75.24 110.916 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 14.9 t -54.28 94.06 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 74.33 110.854 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 68.2 m 49.16 75.49 0.15 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.18 -0.464 . . . . 75.3 110.849 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.43 ' CB ' ' HB3' ' A' ' 133' ' ' ASP . 0.4 OUTLIER -101.58 162.28 13.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 65.43 110.864 -179.958 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -138.53 170.35 16.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.129 -0.487 . . . . 74.45 110.888 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.425 HG22 ' N ' ' A' ' 142' ' ' LYS . 1.9 mp -116.7 160.73 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 52.34 111.13 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . 0.425 ' N ' HG22 ' A' ' 141' ' ' ILE . 3.6 mtmt -122.19 122.36 39.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 74.31 110.899 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -74.31 -172.68 1.49 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.239 -0.437 . . . . 72.04 110.873 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 3.1 mmtm -171.36 -173.46 1.25 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 63.33 110.884 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 52.2 p-90 -154.62 153.23 31.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 72.14 110.955 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.757 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -176.44 165.41 1.65 Allowed Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.572 0.701 . . . . 72.44 111.116 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' PRO . . . . . 0.757 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.1 Cg_endo -69.77 167.06 25.54 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.635 2.224 . . . . 62.33 112.363 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -160.26 154.97 24.07 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.207 -0.451 . . . . 44.34 111.113 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 11.6 m-85 -104.7 129.32 52.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.234 -0.439 . . . . 71.02 110.872 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 6.2 mm-40 -104.72 156.73 17.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.13 -0.486 . . . . 74.15 110.946 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.3 p -155.79 128.91 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 70.55 111.144 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 166.97 -162.82 36.6 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.749 -0.738 . . . . 71.22 112.517 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.424 HD12 ' N ' ' A' ' 154' ' ' ARG . 3.3 pp -155.98 170.47 22.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.824 0.345 . . . . 70.24 110.897 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.424 ' N ' HD12 ' A' ' 153' ' ' LEU . 5.9 tpp85 -117.68 122.3 43.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 71.32 110.867 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -108.56 153.99 22.59 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.185 -0.461 . . . . 71.14 110.964 -179.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 35.7 t0 -121.53 99.26 6.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.482 . . . . 60.32 110.847 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' LEU . . . . . 0.448 HD12 HD12 ' A' ' 163' ' ' LEU . 13.2 mt -97.71 97.53 9.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.28 -0.418 . . . . 74.33 110.936 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 80.65 -147.26 27.91 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.8 -0.714 . . . . 74.12 112.519 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -123.23 -35.49 2.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.866 0.365 . . . . 62.53 110.92 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 1.7 m -51.77 -61.84 2.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 74.5 110.845 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 18.6 p90 -139.58 153.72 47.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.215 -0.448 . . . . 71.23 110.927 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' MET . . . . . 0.483 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 11.0 mtt -108.34 176.49 5.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 75.52 110.849 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.448 HD12 HD12 ' A' ' 157' ' ' LEU . 0.9 OUTLIER -116.51 146.31 42.69 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 53.34 110.83 -179.961 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -141.76 134.38 28.39 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.142 -0.481 . . . . 62.43 110.863 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 10.8 t -136.78 124.18 22.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 61.31 110.805 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -144.23 160.72 40.5 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.123 -0.489 . . . . 62.11 110.883 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 58.1 t -150.0 126.73 2.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 64.5 111.156 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . 0.564 ' HD2' HD12 ' A' ' 195' ' ' ILE . 0.4 OUTLIER -104.58 133.58 49.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.198 -0.456 . . . . 72.51 110.834 -179.986 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 19.6 t80 -136.74 132.07 34.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 64.53 110.914 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' ILE . . . . . 0.423 HG21 ' O ' ' A' ' 147' ' ' PRO . 5.0 tp 178.65 132.89 0.23 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.628 0.727 . . . . 61.44 111.144 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.78 112.77 3.17 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.649 2.233 . . . . 72.33 112.374 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . 0.418 ' HZ ' HG23 ' A' ' 174' ' ' THR . 0.1 OUTLIER -122.83 151.45 41.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.259 -0.428 . . . . 73.24 110.859 -179.953 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 20.1 pttt -123.85 134.56 53.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 71.21 110.881 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 174' ' ' THR . . . . . 0.426 HG22 ' H ' ' A' ' 175' ' ' ASP . 0.2 OUTLIER -101.2 171.21 7.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.228 -0.442 . . . . 64.14 111.133 179.985 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . 0.426 ' H ' HG22 ' A' ' 174' ' ' THR . 0.2 OUTLIER -123.51 161.2 25.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.197 -0.456 . . . . 71.22 110.911 179.869 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 3.4 t -151.07 143.05 16.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.173 -0.467 . . . . 62.11 111.107 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.4 t -166.98 -178.15 4.09 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.18 -0.464 . . . . 52.13 111.114 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -119.74 -158.38 10.58 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.763 -0.732 . . . . 71.1 112.56 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 6.6 t . . . . . 0 C--N 1.329 -0.313 0 CA-C-O 120.858 0.361 . . . . 71.33 111.152 -179.97 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo . . . . . 0 N--CA 1.466 -0.12 0 CA-C-O 120.853 0.272 . . . . 64.12 112.317 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 45.2 t -139.17 112.4 6.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.151 -0.477 . . . . 72.44 111.083 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.02 104.75 5.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.476 . . . . 54.4 110.849 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 29.4 p -124.14 174.04 7.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 65.12 111.123 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 5.2 ptmt -150.3 145.76 26.36 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.226 -0.443 . . . . 65.35 110.883 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 189' ' ' ILE . . . . . 0.546 HG21 HD12 ' A' ' 32' ' ' LEU . 6.3 pt -127.27 111.24 24.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.273 -0.421 . . . . 61.25 111.149 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -92.0 113.48 25.76 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.186 -0.461 . . . . 63.12 110.913 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 191' ' ' VAL . . . . . 0.445 HG21 ' CG1' ' A' ' 28' ' ' VAL . 12.1 m -136.77 167.31 24.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 72.13 111.096 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -107.25 88.54 3.98 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.553 0.692 . . . . 73.3 110.86 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 132.5 23.48 Favored 'Trans proline' 0 C--O 1.233 0.242 0 C-N-CA 122.685 2.257 . . . . 74.03 112.363 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -110.05 113.98 27.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.282 -0.417 . . . . 75.23 110.848 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 195' ' ' ILE . . . . . 0.564 HD12 ' HD2' ' A' ' 168' ' ' ARG . 71.5 mt -105.86 119.94 55.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.158 -0.474 . . . . 52.45 111.159 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 9.7 mp -116.03 108.66 16.5 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.195 -0.457 . . . . 62.12 110.92 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 53.9 p -99.21 114.04 26.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.244 -0.434 . . . . 71.33 110.862 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 198' ' ' LEU . . . . . 0.4 ' C ' ' HB2' ' A' ' 22' ' ' ASN . 0.4 OUTLIER -134.14 122.2 22.52 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.186 -0.461 . . . . 74.43 110.92 -179.978 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -175.63 -140.58 3.46 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.774 -0.727 . . . . 64.04 112.497 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 200' ' ' ALA . . . . . 0.483 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -126.65 174.24 8.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.826 0.346 . . . . 45.24 111.078 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 73.7 p -148.11 166.23 28.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.212 -0.449 . . . . 63.44 110.832 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -133.6 136.94 45.19 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.08 -0.509 . . . . 74.42 110.874 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.555 ' HA ' HG12 ' A' ' 18' ' ' VAL . 25.1 m -91.11 149.7 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.095 -0.502 . . . . 73.21 111.137 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -149.84 114.92 5.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 64.43 110.834 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 73.12 110.927 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.817 0.341 . . . . 64.12 110.903 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 99.36 6.08 55.46 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.801 -0.714 . . . . 75.12 112.511 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.455 ' OD2' HG13 ' A' ' 18' ' ' VAL . 0.7 OUTLIER -77.33 150.9 35.15 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.853 0.359 . . . . 72.31 110.835 -179.92 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 23.8 m-90 -117.75 138.37 52.08 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.21 -0.45 . . . . 70.35 110.923 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.629 HG23 ' HB3' ' A' ' 60' ' ' ALA . 11.5 m -141.56 134.7 29.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.25 -0.432 . . . . 73.41 111.108 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.56 ' HB1' ' CZ ' ' A' ' 21' ' ' PHE . . . -99.66 112.45 24.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.447 . . . . 73.03 111.085 179.846 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -99.21 109.37 22.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 71.23 110.81 -179.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.56 ' CZ ' ' HB1' ' A' ' 19' ' ' ALA . 12.7 m-85 -107.64 116.51 32.08 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 74.24 110.889 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.415 ' HB2' ' C ' ' A' ' 198' ' ' LEU . 1.4 p-10 -154.12 172.66 17.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 53.32 110.967 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -103.57 134.96 46.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.249 -0.432 . . . . 72.15 110.835 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 2.8 m -105.0 107.88 19.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.144 -0.48 . . . . 73.52 110.851 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . 0.633 ' O ' HD12 ' A' ' 196' ' ' LEU . 31.8 tttp -87.71 109.37 19.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.11 -0.495 . . . . 74.54 110.844 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.7 p -92.65 130.93 41.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 75.44 111.168 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -119.42 100.59 7.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 74.54 110.932 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.43 HG23 ' CG1' ' A' ' 191' ' ' VAL . 7.4 p -149.34 145.31 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.093 -0.503 . . . . 73.52 111.114 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 148.84 67.32 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.735 -0.745 . . . . 72.24 112.518 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 8.3 tt0 -89.18 -65.84 0.98 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.832 0.349 . . . . 62.31 110.928 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -170.61 169.25 7.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.125 -0.488 . . . . 73.32 110.92 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.718 HD12 HG21 ' A' ' 189' ' ' ILE . 11.3 tp -84.59 161.55 20.12 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.167 -0.47 . . . . 65.42 110.905 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.35 0 C-N-CA 120.763 -0.732 . . . . 64.41 112.51 179.856 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.457 ' HB1' ' HA ' ' A' ' 84' ' ' GLU . . . . . . . . 0 C--O 1.232 0.171 0 CA-C-O 120.818 0.342 . . . . 75.43 111.084 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -137.61 134.7 35.84 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.29 -0.414 . . . . 55.33 110.872 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 73.6 t -104.94 142.61 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 44.54 111.149 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 m -155.19 152.9 29.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 73.32 110.882 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 38.3 pt -136.79 157.71 36.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.474 . . . . 73.5 111.138 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -88.78 -90.33 1.15 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.745 -0.741 . . . . 60.24 112.499 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 9.2 m120 57.57 57.27 4.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.795 0.331 . . . . 64.31 110.883 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.529 ' O ' HG23 ' A' ' 53' ' ' THR . 0.7 OUTLIER -55.61 -57.86 10.2 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 74.34 110.915 179.918 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . 0.529 HG23 ' O ' ' A' ' 52' ' ' ASP . 0.7 OUTLIER -162.85 138.18 6.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 71.35 111.177 -179.953 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.524 HG23 ' O ' ' A' ' 53' ' ' THR . 0.7 OUTLIER -161.89 146.65 12.89 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.227 -0.442 . . . . 73.23 111.132 -179.942 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 88.9 mt -90.06 157.65 17.69 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.455 . . . . 74.5 110.828 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.36 144.32 33.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.13 -0.486 . . . . 74.34 111.129 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 15.4 m-85 -102.37 132.53 48.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 71.33 110.935 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.495 ' C ' HD13 ' A' ' 59' ' ' ILE . 3.6 m-20 -128.43 139.43 52.36 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.145 -0.48 . . . . 72.24 110.923 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.495 HD13 ' C ' ' A' ' 58' ' ' ASP . 3.4 mm -110.07 114.92 48.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.196 -0.457 . . . . 74.44 111.123 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.629 ' HB3' HG23 ' A' ' 18' ' ' VAL . . . -116.15 149.53 38.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.116 -0.493 . . . . 64.55 111.145 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.485 ' CE2' HG22 ' A' ' 59' ' ' ILE . 14.6 m-85 -129.33 137.59 51.08 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.289 -0.414 . . . . 73.34 110.946 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -98.33 102.28 13.98 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.158 -0.474 . . . . 73.03 110.867 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.7 m -99.35 -34.06 4.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.472 . . . . 75.04 111.088 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 58.4 m -135.51 158.77 43.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 74.04 110.917 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 3.9 t -83.99 3.39 34.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 74.52 110.861 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -114.06 -30.56 6.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.149 -0.478 . . . . 63.31 110.849 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -140.89 165.23 20.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 65.12 111.124 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -155.18 168.83 25.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.133 -0.485 . . . . 65.32 111.116 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.433 HG22 ' HB2' ' A' ' 61' ' ' TYR . 4.2 m -111.66 147.67 15.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 63.1 111.125 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -149.93 128.53 12.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.189 -0.46 . . . . 61.23 110.849 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -121.5 132.91 54.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 71.31 110.882 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.612 ' CD1' HD11 ' A' ' 102' ' ' ILE . 13.1 m-30 -95.02 134.85 37.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.131 -0.486 . . . . 62.32 110.926 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 63.3 t -144.41 136.81 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.107 -0.497 . . . . 64.51 111.086 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -155.29 140.55 7.43 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.743 -0.742 . . . . 63.15 112.439 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.8 t -124.38 66.87 45.5 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.621 0.724 . . . . 71.14 111.083 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 154.91 67.45 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.656 2.237 . . . . 73.3 112.374 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -68.14 -167.63 0.09 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 50.43 111.09 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 9.8 ttm180 -77.46 129.0 35.16 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.203 -0.453 . . . . 73.54 110.859 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . 0.554 ' HB3' ' CZ ' ' A' ' 81' ' ' PHE . . . -120.72 142.41 49.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.449 . . . . 62.23 111.072 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 21.0 ttpp -91.64 134.99 34.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.165 -0.471 . . . . 72.12 110.9 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . 0.554 ' CZ ' ' HB3' ' A' ' 79' ' ' ALA . 22.1 m-85 -131.98 152.01 51.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.221 -0.445 . . . . 70.43 110.92 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -99.93 156.1 17.33 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 73.23 110.897 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.585 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 179.86 68.16 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.737 -0.744 . . . . 55.15 112.487 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.457 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.5 tp10 -170.53 -176.44 2.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.935 0.398 . . . . 74.41 110.94 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.81 -70.17 0.61 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 74.11 110.847 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.8 t -85.25 -31.24 23.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 73.12 110.828 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.616 HG22 HG22 ' A' ' 93' ' ' VAL . 4.8 mm -67.75 -33.59 62.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.198 -0.456 . . . . 73.11 111.146 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 10.0 t -63.66 -48.06 78.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 74.43 110.87 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 27.1 t -51.92 -42.48 62.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.147 -0.479 . . . . 72.31 110.87 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 82.6 mt -57.73 -48.38 79.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.115 -0.493 . . . . 61.41 110.884 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 115.32 -15.21 18.07 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.758 -0.734 . . . . 73.52 112.446 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 14.4 ttp180 -120.31 92.61 3.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.817 0.342 . . . . 63.41 110.885 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.616 HG22 HG22 ' A' ' 87' ' ' ILE . 25.3 t -108.15 -52.76 6.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.224 -0.444 . . . . 73.52 111.119 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 60.4 m -140.69 146.06 37.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 70.13 110.846 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -131.01 125.86 34.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 72.41 110.859 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.452 HG22 ' N ' ' A' ' 97' ' ' ASP . 13.2 p -174.42 156.79 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 63.03 111.167 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.452 ' N ' HG22 ' A' ' 96' ' ' VAL . 2.8 p-10 -86.39 173.43 9.68 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.187 -0.46 . . . . 70.34 110.83 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -133.48 126.07 30.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 64.31 110.929 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -113.5 72.36 0.23 Allowed Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.717 -0.754 . . . . 72.12 112.458 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 114.21 3.62 Favored 'Trans proline' 0 N--CA 1.465 -0.177 0 C-N-CA 122.754 2.303 . . . . 74.13 112.367 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -129.56 104.87 7.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.219 -0.446 . . . . 72.34 111.129 179.858 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.612 HD11 ' CD1' ' A' ' 72' ' ' PHE . 1.2 pp -127.89 151.3 34.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 64.43 111.123 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.439 ' HG ' HG13 ' A' ' 123' ' ' VAL . 0.2 OUTLIER -141.01 111.64 6.95 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.132 -0.485 . . . . 75.31 110.912 179.854 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . 0.408 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 3.6 p -134.24 -174.15 3.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.23 -0.441 . . . . 75.22 110.837 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.421 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -134.97 147.98 49.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.091 -0.504 . . . . 45.54 110.931 179.994 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -104.31 134.82 46.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 75.12 110.97 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.518 ' CE1' HG13 ' A' ' 119' ' ' VAL . 12.9 p90 -144.71 159.03 43.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.228 -0.442 . . . . 64.22 110.925 -179.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 9.8 t60 . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.111 -0.495 . . . . 73.1 110.855 179.941 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 . . . . . 0 C--O 1.231 0.103 0 CA-C-O 121.701 0.762 . . . . 74.31 110.913 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.81 177.52 5.53 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.725 2.283 . . . . 65.51 112.338 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -116.69 154.54 30.41 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.204 -0.453 . . . . 74.13 110.946 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.518 HG13 ' CE1' ' A' ' 107' ' ' TYR . 5.4 p -102.57 127.38 56.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.122 -0.49 . . . . 73.25 111.109 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -119.87 167.67 13.56 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.728 -0.749 . . . . 53.23 112.534 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 7.3 p -171.38 154.45 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.826 0.346 . . . . 51.2 111.135 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . 0.408 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . 178.87 -147.02 7.57 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.695 -0.764 . . . . 50.33 112.452 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.462 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.7 p -112.6 132.43 61.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.852 0.358 . . . . 52.51 111.112 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . 0.515 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -123.3 109.6 1.37 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.761 -0.733 . . . . 53.54 112.463 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . 0.666 ' HE ' HD11 ' A' ' 127' ' ' LEU . 10.5 ptm180 -109.41 123.47 49.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.817 0.342 . . . . 55.13 110.892 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.456 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 2.5 p -107.35 119.35 56.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 73.34 111.152 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.666 HD11 ' HE ' ' A' ' 125' ' ' ARG . 2.7 mp -129.46 153.62 47.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.19 -0.459 . . . . 70.52 110.81 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 7.3 p90 -160.21 169.71 22.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.078 -0.51 . . . . 70.12 110.894 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.406 ' O ' HG23 ' A' ' 96' ' ' VAL . 45.1 m-85 -101.88 117.57 35.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 73.43 110.877 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -53.43 101.38 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.138 -0.483 . . . . 75.15 110.873 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.67 -82.97 0.09 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.234 -0.439 . . . . 61.41 110.865 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.8 m -173.42 128.22 0.43 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 62.21 111.195 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . 0.436 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 5.3 m-20 -114.37 115.3 27.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 73.21 110.878 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -80.82 -2.96 90.47 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.731 -0.747 . . . . 41.42 112.511 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.572 ' HB2' HG12 ' A' ' 93' ' ' VAL . . . -47.13 -29.73 2.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.824 0.345 . . . . 72.41 111.079 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.8 tp -158.93 -177.94 6.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 53.22 110.921 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -52.19 96.49 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.157 -0.474 . . . . 72.4 110.826 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 93.2 p 46.94 74.13 0.16 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 63.03 110.865 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.436 ' HB3' ' HB2' ' A' ' 133' ' ' ASP . 0.5 OUTLIER -95.76 158.85 15.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.127 -0.488 . . . . 71.14 110.905 -179.928 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -141.36 174.95 10.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 73.44 110.829 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.815 HG23 HG12 ' A' ' 176' ' ' VAL . 2.6 mt -131.41 152.68 37.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.155 -0.475 . . . . 64.54 111.118 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . 0.412 ' O ' HG22 ' A' ' 174' ' ' THR . 7.1 mmpt? -122.43 122.11 38.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 71.2 110.928 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.456 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 1.9 p-10 -72.08 -166.52 0.24 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 63.25 110.93 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -173.35 177.27 2.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.239 -0.437 . . . . 71.23 110.875 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' TRP . . . . . 0.404 ' O ' ' HB2' ' A' ' 146' ' ' ALA . 30.9 p90 -146.54 153.51 40.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 72.52 110.912 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.81 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 178.98 168.1 0.61 Allowed Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.618 0.723 . . . . 73.41 111.128 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' PRO . . . . . 0.81 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.7 Cg_endo -69.79 150.73 68.43 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.68 2.253 . . . . 74.21 112.387 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.541 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -148.11 167.31 25.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.217 -0.447 . . . . 51.12 111.087 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 -118.94 166.21 13.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.205 -0.452 . . . . 73.5 110.883 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 1.3 pt20 -157.9 162.48 38.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.167 -0.47 . . . . 73.22 110.973 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 94.1 t -150.61 124.81 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.222 -0.445 . . . . 75.23 111.113 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . 0.438 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . -171.46 -167.16 31.31 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.769 -0.729 . . . . 44.2 112.541 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.471 HD12 ' CD2' ' A' ' 155' ' ' TYR . 1.1 pt? -145.11 158.54 43.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.834 0.349 . . . . 63.22 110.925 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 3.7 tpp85 -125.33 121.86 35.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 62.14 110.806 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . 0.471 ' CD2' HD12 ' A' ' 153' ' ' LEU . 5.1 m-85 -128.52 173.16 10.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 73.01 110.873 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -121.74 106.83 11.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.1 -0.5 . . . . 65.24 110.883 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' LEU . . . . . 0.4 HD22 ' HA ' ' A' ' 157' ' ' LEU . 0.3 OUTLIER -102.94 97.41 7.54 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.194 -0.457 . . . . 74.03 110.948 -179.992 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 85.75 161.99 35.68 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.677 -0.773 . . . . 65.24 112.537 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -74.26 147.21 42.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.889 0.376 . . . . 72.31 110.889 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 14.2 m 51.9 36.45 18.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.198 -0.455 . . . . 74.22 110.861 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 2.9 t90 -172.69 112.08 0.24 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.153 -0.476 . . . . 71.32 110.933 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 5.3 mtt -110.47 172.74 6.69 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 75.52 110.905 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.4 ' HA ' ' HA ' ' A' ' 200' ' ' ALA . 41.9 mt -129.49 140.3 51.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.253 -0.43 . . . . 60.43 110.903 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -138.41 136.05 35.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 72.0 110.864 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 24.0 p -143.94 122.27 12.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 74.3 110.84 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' ASP . . . . . 0.438 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.6 OUTLIER -150.77 171.84 16.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.128 -0.487 . . . . 72.44 110.833 179.972 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.497 HG11 ' OH ' ' A' ' 169' ' ' TYR . 0.9 OUTLIER -141.89 120.12 8.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 73.45 111.101 -179.979 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . 0.561 ' HD3' HG22 ' A' ' 170' ' ' ILE . 1.9 tmm_? -93.55 135.65 34.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 63.41 110.845 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' TYR . . . . . 0.497 ' OH ' HG11 ' A' ' 167' ' ' VAL . 21.7 m-85 -134.28 136.27 43.43 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 74.45 110.873 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' ILE . . . . . 0.77 HD12 ' HD2' ' A' ' 171' ' ' PRO . 8.0 tp 178.66 118.89 0.2 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.685 0.755 . . . . 73.04 111.086 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . 0.77 ' HD2' HD12 ' A' ' 170' ' ' ILE . 53.7 Cg_endo -69.75 113.44 3.37 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.633 2.222 . . . . 61.31 112.359 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -117.11 177.34 4.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.216 -0.447 . . . . 74.24 110.846 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 6.8 ptmt -152.32 138.58 18.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.128 -0.487 . . . . 64.23 110.933 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 174' ' ' THR . . . . . 0.412 HG22 ' O ' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -102.95 155.1 18.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.258 -0.428 . . . . 75.1 111.15 179.963 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -116.19 102.11 9.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 71.04 110.868 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.815 HG12 HG23 ' A' ' 141' ' ' ILE . 20.3 m -96.89 146.35 7.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 71.04 111.139 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.6 t -166.7 163.29 16.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 70.13 111.132 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -123.35 162.3 17.3 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.798 -0.715 . . . . 61.12 112.488 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.328 -0.331 0 CA-C-O 120.811 0.339 . . . . 62.11 111.17 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo . . . . . 0 C--O 1.231 0.133 0 CA-C-O 120.794 0.248 . . . . 75.03 112.301 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 87.4 t -95.67 107.17 19.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 64.54 111.16 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 81.0 p -110.02 125.26 52.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 73.1 110.831 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 35.7 p -138.21 159.54 41.77 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.122 -0.49 . . . . 71.23 111.114 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 3.6 pttm -128.87 150.02 50.52 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 74.04 110.94 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 189' ' ' ILE . . . . . 0.718 HG21 HD12 ' A' ' 32' ' ' LEU . 6.3 pt -131.56 108.2 14.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 72.44 111.138 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -98.87 118.34 35.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 62.42 110.86 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 191' ' ' VAL . . . . . 0.435 HG12 ' H ' ' A' ' 192' ' ' ASP . 2.4 t -137.66 164.53 28.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 65.51 111.073 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.435 ' H ' HG12 ' A' ' 191' ' ' VAL . 0.2 OUTLIER -106.96 87.73 3.16 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.604 0.716 . . . . 75.24 110.871 179.929 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.64 131.71 21.99 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.704 2.269 . . . . 75.24 112.311 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -100.17 107.03 18.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 55.55 110.89 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 195' ' ' ILE . . . . . 0.531 HD13 ' NE ' ' A' ' 168' ' ' ARG . 3.9 mp -97.99 125.33 51.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.111 -0.495 . . . . 62.23 111.159 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . 0.633 HD12 ' O ' ' A' ' 25' ' ' LYS . 2.1 mp -119.31 108.12 14.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 61.12 110.977 179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.2 120.52 33.57 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 53.33 110.851 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 198' ' ' LEU . . . . . 0.415 ' C ' ' HB2' ' A' ' 22' ' ' ASN . 1.3 tt -144.74 127.41 16.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.116 -0.493 . . . . 65.14 110.823 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 176.18 -146.98 8.35 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.834 -0.698 . . . . 53.11 112.535 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 200' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' A' ' 163' ' ' LEU . . . -118.32 174.14 6.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.788 0.327 . . . . 75.34 111.106 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 8.9 p -151.76 171.77 17.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 63.24 110.884 -179.802 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -145.4 148.1 32.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.147 -0.479 . . . . 54.33 110.912 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.619 ' HA ' HG12 ' A' ' 18' ' ' VAL . 14.5 m -111.76 157.4 12.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.49 . . . . 73.01 111.206 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -173.76 155.25 2.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.211 -0.449 . . . . 74.34 110.912 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 18.2 pttp . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.152 -0.476 . . . . 74.34 110.835 -179.982 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.2 mt-30 . . . . . 0 C--O 1.23 0.051 0 CA-C-O 120.862 0.363 . . . . 70.24 110.887 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.61 6.47 46.9 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.731 -0.747 . . . . 63.35 112.521 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.16 150.4 40.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.793 0.33 . . . . 70.44 110.802 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 33.4 m0 -122.24 140.85 52.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.189 -0.459 . . . . 73.41 110.936 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.739 HG13 ' HB3' ' A' ' 60' ' ' ALA . 2.1 p -148.55 122.58 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.171 -0.468 . . . . 72.21 111.151 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -84.81 114.17 21.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 64.22 111.083 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.7 p -106.06 109.3 21.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.247 -0.433 . . . . 73.13 110.823 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -113.08 123.58 50.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 74.32 110.852 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.87 168.47 25.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 71.24 110.916 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -96.01 127.82 42.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 75.25 110.882 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.1 p -97.45 109.75 22.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.243 -0.435 . . . . 71.41 110.808 -179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 9.2 tmtt? -88.05 106.63 18.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.077 -0.51 . . . . 74.03 110.904 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.1 p -86.29 139.13 17.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.461 . . . . 63.53 111.107 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -135.27 102.46 5.17 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.207 -0.451 . . . . 63.5 110.977 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.548 ' O ' HD13 ' A' ' 49' ' ' ILE . 8.5 p -168.73 153.99 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.16 -0.473 . . . . 75.14 111.142 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 130.11 71.16 0.12 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.779 -0.724 . . . . 72.31 112.505 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -89.73 -66.07 0.96 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.83 0.347 . . . . 75.42 110.916 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -161.93 154.97 20.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 64.41 110.864 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 9.1 tp -69.74 167.46 17.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.086 -0.506 . . . . 73.52 110.896 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 72.33 112.487 179.894 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.067 0 CA-C-O 120.845 0.355 . . . . 74.11 111.058 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -147.36 140.31 25.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.485 . . . . 74.03 110.875 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 29.7 m -104.96 147.81 10.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.209 -0.45 . . . . 55.01 111.107 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.5 t -139.33 124.12 18.58 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.137 -0.483 . . . . 70.34 110.877 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.548 HD13 ' O ' ' A' ' 28' ' ' VAL . 5.3 mp -120.76 105.33 16.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.167 -0.469 . . . . 73.14 111.165 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -135.67 109.99 0.79 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.772 -0.727 . . . . 74.31 112.527 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -147.7 152.19 37.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.853 0.359 . . . . 63.34 110.893 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -52.32 148.93 6.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 63.05 110.817 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 43.9 p -76.55 109.41 10.28 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.172 -0.467 . . . . 74.55 111.135 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.8 p -94.61 176.54 6.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 64.24 111.203 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 1.5 pt? -108.71 155.52 20.63 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.202 -0.454 . . . . 61.04 110.921 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -126.02 141.78 51.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.215 -0.448 . . . . 74.4 111.124 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -103.39 131.88 50.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 74.04 110.944 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.465 ' C ' HD13 ' A' ' 59' ' ' ILE . 2.8 m-20 -131.87 144.39 50.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.129 -0.487 . . . . 63.04 110.914 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.465 HD13 ' C ' ' A' ' 58' ' ' ASP . 5.1 mm -115.2 114.2 45.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 54.04 111.118 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.739 ' HB3' HG13 ' A' ' 18' ' ' VAL . . . -102.87 129.95 49.73 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.15 -0.477 . . . . 72.14 111.06 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.456 ' HB2' HG22 ' A' ' 69' ' ' VAL . 22.7 m-85 -115.62 122.15 44.75 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 71.33 110.962 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -88.96 100.9 13.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 75.31 110.844 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.6 p -96.51 -33.17 4.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.122 -0.49 . . . . 70.01 111.132 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.6 m -132.01 159.17 39.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.15 -0.477 . . . . 71.04 110.828 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -84.03 3.18 35.6 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.105 -0.498 . . . . 62.54 110.788 -179.79 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -116.56 -31.49 5.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 71.34 110.878 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.432 HD12 ' CE1' ' A' ' 107' ' ' TYR . 33.8 pt -144.21 162.19 15.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 70.53 111.142 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -152.7 170.63 19.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 43.33 111.127 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.456 HG22 ' HB2' ' A' ' 61' ' ' TYR . 4.6 m -115.17 152.56 16.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 63.12 111.158 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.4 ' HA ' ' HA ' ' A' ' 60' ' ' ALA . 0.9 OUTLIER -149.96 128.92 12.58 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.185 -0.461 . . . . 74.0 110.82 179.976 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.405 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 6.7 m-85 -105.99 132.13 52.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.176 -0.466 . . . . 70.43 110.892 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -105.39 121.83 44.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.152 -0.476 . . . . 73.4 110.906 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.415 HG12 ' N ' ' A' ' 74' ' ' GLY . 5.9 t -145.73 159.24 12.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.129 -0.487 . . . . 73.11 111.08 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.415 ' N ' HG12 ' A' ' 73' ' ' VAL . . . -152.64 170.16 31.77 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.65 -0.786 . . . . 72.12 112.425 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.4 t -119.69 64.77 8.88 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.643 0.735 . . . . 74.42 111.148 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 163.36 38.58 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.642 2.228 . . . . 60.34 112.37 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -120.35 -166.96 1.38 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 62.03 111.139 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 33.8 ttp85 -76.86 120.65 22.29 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.266 -0.425 . . . . 61.11 110.821 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . 0.483 ' HB3' ' HE1' ' A' ' 98' ' ' TYR . . . -124.26 150.92 44.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.216 -0.447 . . . . 75.11 111.121 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -101.92 139.66 37.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.188 -0.46 . . . . 73.41 110.864 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . 0.535 ' CE2' HG23 ' A' ' 49' ' ' ILE . 43.7 m-85 -140.87 158.28 44.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 74.35 110.906 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 9.6 mt-30 -99.03 156.83 16.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 71.14 110.889 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.568 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -179.67 71.56 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.803 -0.713 . . . . 63.45 112.525 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -178.37 -177.36 0.56 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.893 0.378 . . . . 61.53 110.864 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.02 -68.95 0.7 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 72.42 110.903 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.8 t -83.24 -35.11 25.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.126 -0.488 . . . . 54.44 110.854 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.916 HG21 ' HB2' ' A' ' 135' ' ' ALA . 6.9 mm -63.54 -33.78 63.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.09 -0.505 . . . . 75.34 111.135 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 55.2 p -62.4 -49.24 76.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.235 -0.438 . . . . 62.2 110.911 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.3 t -51.21 -40.26 58.36 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.143 -0.48 . . . . 64.32 110.811 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 13.4 mt -60.73 -46.33 90.81 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.143 -0.48 . . . . 73.23 110.949 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 112.41 -14.43 25.3 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.714 -0.755 . . . . 34.02 112.481 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 27.8 mtp180 -121.1 96.34 5.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.824 0.345 . . . . 71.44 110.862 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.892 HG22 HG22 ' A' ' 87' ' ' ILE . 39.6 t -113.8 -44.36 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.461 . . . . 45.04 111.138 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.5 p -142.62 147.75 36.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 71.14 110.874 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -149.39 118.83 6.89 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.172 -0.467 . . . . 54.42 110.843 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.648 HG23 ' HB2' ' A' ' 131' ' ' LYS . 2.9 p -177.76 166.25 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 73.35 111.155 179.908 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.477 ' H ' HG22 ' A' ' 96' ' ' VAL . 11.8 t70 -90.59 156.58 18.03 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.088 -0.505 . . . . 54.32 110.904 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' TYR . . . . . 0.483 ' HE1' ' HB3' ' A' ' 79' ' ' ALA . 0.1 OUTLIER -113.61 155.03 26.19 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.245 -0.434 . . . . 71.44 110.953 -179.838 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -122.41 70.11 0.42 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.736 -0.745 . . . . 63.13 112.463 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 112.77 3.17 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.738 2.292 . . . . 63.14 112.328 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.483 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -131.97 110.19 10.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.24 -0.437 . . . . 70.32 111.105 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 2.7 mt -129.51 150.01 34.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 74.25 111.103 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 1.2 pp -152.35 115.39 4.65 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.119 -0.491 . . . . 72.4 110.862 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . 0.443 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 4.3 p -138.78 -176.47 4.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.234 -0.439 . . . . 55.3 110.857 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.562 HD12 ' CE1' ' A' ' 107' ' ' TYR . 0.1 OUTLIER -130.37 154.97 47.14 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.167 -0.469 . . . . 74.42 110.943 179.994 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 45.0 mt-30 -102.65 135.89 43.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 62.14 110.979 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.562 ' CE1' HD12 ' A' ' 105' ' ' LEU . 2.0 m-85 -120.54 118.76 31.05 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.263 -0.426 . . . . 70.44 110.868 -179.756 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 2.1 t60 . . . . . 0 C--N 1.331 -0.237 0 CA-C-N 116.126 -0.488 . . . . 71.22 110.869 179.913 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.7 t80 . . . . . 0 C--O 1.232 0.151 0 CA-C-O 121.63 0.729 . . . . 72.44 110.921 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . 0.742 ' HB3' HD12 ' A' ' 153' ' ' LEU . 53.6 Cg_endo -69.82 177.64 5.41 Favored 'Trans proline' 0 N--CA 1.465 -0.175 0 C-N-CA 122.713 2.275 . . . . 52.43 112.363 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -112.7 155.25 24.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.245 -0.434 . . . . 75.42 110.941 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.2 p -106.29 124.21 61.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.099 -0.501 . . . . 74.31 111.154 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -116.77 163.37 12.49 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.737 -0.744 . . . . 31.03 112.52 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.1 p -175.73 150.65 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.842 0.353 . . . . 55.34 111.141 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . 0.443 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -176.98 -150.39 8.31 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.757 -0.735 . . . . 63.44 112.508 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.536 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 12.7 p -108.34 130.48 60.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.85 0.357 . . . . 62.43 111.195 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -124.45 109.94 1.33 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.784 -0.722 . . . . 42.43 112.51 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . 0.483 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 13.8 ptm180 -104.97 131.81 52.01 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.837 0.351 . . . . 75.34 110.847 -179.802 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.413 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 3.6 p -116.49 119.18 61.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.217 -0.447 . . . . 73.15 111.08 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.7 mp -113.52 172.7 6.81 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.126 -0.488 . . . . 72.02 110.917 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.475 ' CD2' HG22 ' A' ' 141' ' ' ILE . 3.3 p90 -131.2 172.55 12.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.443 . . . . 72.03 110.899 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.647 ' HB3' HG22 ' A' ' 96' ' ' VAL . 1.5 t80 -111.71 174.69 5.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 62.34 110.918 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -112.68 112.09 23.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.12 -0.491 . . . . 72.13 110.865 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.648 ' HB2' HG23 ' A' ' 96' ' ' VAL . 63.5 mmtt -146.11 -85.8 0.11 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 72.3 110.887 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 7.4 m -163.11 96.22 0.88 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.254 -0.43 . . . . 74.14 111.133 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -112.29 165.83 11.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 70.13 110.884 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 64.22 153.49 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 74.14 112.471 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.916 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -82.9 1.8 37.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.838 0.351 . . . . 72.42 111.056 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.446 HD22 ' N ' ' A' ' 136' ' ' LEU . 2.9 mm? -87.04 -177.24 5.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.446 . . . . 74.13 110.882 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 6.1 m -64.76 88.1 0.06 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 73.34 110.848 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 9.6 m 53.62 75.28 0.27 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.46 . . . . 73.32 110.793 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -90.49 159.2 16.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.108 -0.496 . . . . 72.43 110.845 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -130.85 172.69 11.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.072 -0.513 . . . . 74.24 110.822 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.475 HG22 ' CD2' ' A' ' 128' ' ' PHE . 1.4 tt -117.41 171.61 5.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.128 -0.487 . . . . 52.14 111.136 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -119.59 103.98 9.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 73.43 110.896 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.413 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 0.6 OUTLIER -72.74 -171.55 0.86 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.28 -0.418 . . . . 74.33 110.89 179.867 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -172.44 179.28 2.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.221 -0.445 . . . . 60.25 110.929 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 28.7 p-90 -152.08 154.01 35.08 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.232 -0.44 . . . . 74.12 110.878 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.792 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.81 166.86 0.82 Allowed Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.594 0.711 . . . . 72.4 111.108 179.874 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' PRO . . . . . 0.792 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.9 Cg_endo -69.71 137.16 34.93 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.687 2.258 . . . . 73.24 112.388 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.566 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -126.91 160.51 30.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.272 -0.422 . . . . 73.53 111.092 179.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -103.54 163.94 11.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 75.04 110.917 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 44.4 tt0 -153.07 149.47 28.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.222 -0.445 . . . . 55.24 110.936 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.2 p -146.05 129.85 10.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 62.5 111.113 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . 0.436 ' C ' HD13 ' A' ' 153' ' ' LEU . . . 172.89 -167.58 40.44 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.718 -0.753 . . . . 44.2 112.528 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.742 HD12 ' HB3' ' A' ' 117' ' ' PRO . 0.0 OUTLIER -148.51 168.42 22.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.803 0.335 . . . . 62.01 110.911 -179.911 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 7.2 tpp85 -116.76 118.84 33.64 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 53.41 110.895 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -101.68 149.92 23.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.137 -0.483 . . . . 75.44 110.928 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -120.64 98.19 5.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.485 . . . . 74.45 110.923 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 25.0 tp -95.98 98.13 10.15 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 72.55 110.9 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 72.99 -146.38 38.0 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.675 -0.774 . . . . 52.24 112.458 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 35.3 t-20 -120.47 -33.43 3.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.807 0.336 . . . . 74.02 110.847 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 24.3 p -50.74 -65.5 0.55 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.479 . . . . 72.14 110.866 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 52.4 p-90 -141.02 146.18 36.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.144 -0.48 . . . . 72.35 110.938 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' MET . . . . . 0.508 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 10.8 mmt -101.67 178.69 4.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 60.2 110.898 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 9.2 mt -120.23 149.51 42.15 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.234 -0.439 . . . . 75.34 110.944 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -142.42 133.42 25.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 72.52 110.894 179.864 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.5 t -137.89 122.39 18.44 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.187 -0.46 . . . . 74.11 110.826 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' ASP . . . . . 0.435 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.5 OUTLIER -154.2 162.73 40.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.146 -0.479 . . . . 61.52 110.859 179.909 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.454 HG13 ' O ' ' A' ' 195' ' ' ILE . 42.1 t -146.0 125.34 5.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 65.14 111.148 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . 0.417 ' HD3' ' HB ' ' A' ' 195' ' ' ILE . 0.0 OUTLIER -100.92 155.73 17.79 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.259 -0.428 . . . . 72.14 110.871 -179.961 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 26.3 t80 -163.43 143.3 8.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 74.33 110.986 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' ILE . . . . . 0.566 HG21 ' HB2' ' A' ' 148' ' ' ALA . 3.1 tp -179.74 131.51 0.26 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 71.12 111.163 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 116.0 4.35 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.724 2.283 . . . . 72.43 112.272 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . 0.681 ' CZ ' ' HB3' ' A' ' 146' ' ' ALA . 2.1 m-85 -117.47 177.1 4.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 62.14 110.894 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.84 116.93 6.38 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 75.44 110.955 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.2 t -105.92 161.52 14.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.262 -0.426 . . . . 43.24 111.203 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -127.51 176.8 7.2 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.264 -0.425 . . . . 71.14 110.873 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.615 HG12 ' OG1' ' A' ' 187' ' ' THR . 2.4 p -145.5 141.94 22.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.192 -0.458 . . . . 61.43 111.131 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 2.0 t -166.24 160.17 15.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 74.34 111.139 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -159.3 -157.75 8.73 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.813 -0.708 . . . . 74.44 112.478 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 73.2 p . . . . . 0 C--N 1.329 -0.286 0 CA-C-O 120.774 0.321 . . . . 74.41 111.154 -179.815 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo . . . . . 0 N--CA 1.466 -0.134 0 CA-C-O 120.834 0.264 . . . . 72.21 112.338 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 62.8 t -95.57 105.84 17.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.242 -0.435 . . . . 43.54 111.139 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.72 109.06 20.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.16 -0.473 . . . . 74.22 110.854 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . 0.615 ' OG1' HG12 ' A' ' 176' ' ' VAL . 0.7 OUTLIER -118.3 161.03 20.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 70.3 111.161 -179.976 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 21.9 pttt -136.84 157.28 47.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.435 . . . . 74.22 110.906 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 189' ' ' ILE . . . . . 0.423 ' O ' HG23 ' A' ' 189' ' ' ILE . 5.7 tp -154.79 120.7 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.228 -0.442 . . . . 75.41 111.132 179.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.38 116.05 31.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.144 -0.48 . . . . 64.21 110.893 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 7.6 p -136.18 155.37 34.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.145 -0.48 . . . . 74.43 111.097 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.04 88.69 3.88 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.683 0.754 . . . . 72.41 110.831 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.87 142.56 47.79 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.659 2.24 . . . . 52.25 112.297 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 5.1 t80 -112.65 123.15 49.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.14 -0.482 . . . . 70.1 110.895 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 195' ' ' ILE . . . . . 0.454 ' O ' HG13 ' A' ' 167' ' ' VAL . 56.7 mt -116.37 125.02 73.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.168 -0.469 . . . . 73.42 111.1 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . 0.524 ' O ' HD23 ' A' ' 196' ' ' LEU . 7.5 tt -116.39 109.88 17.92 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.122 -0.49 . . . . 71.22 110.982 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.96 119.23 35.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.202 -0.454 . . . . 71.45 110.856 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 55.1 tp -140.07 126.8 20.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.113 -0.494 . . . . 71.51 110.9 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -177.32 -141.27 3.99 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.74 -0.743 . . . . 60.22 112.466 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 200' ' ' ALA . . . . . 0.508 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -129.37 173.42 10.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.781 0.324 . . . . 54.34 111.113 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 99.4 p -146.58 170.26 17.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 53.42 110.803 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 202' ' ' TYR . . . . . 0.467 ' C ' HG23 ' A' ' 18' ' ' VAL . 68.6 t80 -139.69 113.01 8.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.099 -0.501 . . . . 74.23 110.938 -179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 12.6 t -77.33 154.24 5.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.043 -0.526 . . . . 73.52 111.123 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 77.6 t80 -160.32 122.21 3.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.166 -0.47 . . . . 63.14 110.888 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 6.6 ptpp? . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 71.33 110.915 179.984 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.4 pt20 . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.776 0.322 . . . . 71.53 110.913 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.97 5.78 52.94 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.761 -0.733 . . . . 54.0 112.534 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -72.53 150.95 42.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.816 0.341 . . . . 73.13 110.848 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.547 ' HE1' HG23 ' A' ' 59' ' ' ILE . 25.1 t90 -116.32 143.96 44.86 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.206 -0.452 . . . . 70.5 111.001 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.9 t -145.57 123.27 4.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.265 -0.425 . . . . 63.1 111.058 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -82.61 109.19 16.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 74.32 111.108 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -95.07 127.75 41.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.155 -0.475 . . . . 71.15 110.851 -179.772 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 64.4 t80 -138.63 116.18 11.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.102 -0.499 . . . . 73.11 110.945 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -152.62 173.42 15.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.46 . . . . 72.35 110.917 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 14.6 m-85 -102.38 128.41 48.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 73.01 110.856 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . 0.506 ' HB3' HG21 ' A' ' 56' ' ' THR . 24.6 p -96.72 136.66 36.94 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.194 -0.457 . . . . 45.13 110.857 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.79 106.73 12.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.133 -0.485 . . . . 74.44 110.927 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.811 HG12 HD12 ' A' ' 195' ' ' ILE . 27.5 m -78.55 126.68 38.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.435 . . . . 70.41 111.101 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -119.19 106.16 12.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.134 -0.485 . . . . 64.54 110.954 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.9 p -174.07 152.73 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 72.22 111.154 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.72 72.35 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.726 -0.749 . . . . 75.53 112.488 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -89.53 -66.11 0.95 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.813 0.339 . . . . 52.41 110.85 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -171.55 149.07 2.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.127 -0.488 . . . . 72.25 110.882 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.521 HD13 ' HA3' ' A' ' 83' ' ' GLY . 7.2 tt -103.15 143.67 32.31 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.123 -0.489 . . . . 74.11 110.971 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.601 ' H ' HD11 ' A' ' 189' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.348 0 C-N-CA 120.767 -0.73 . . . . 61.41 112.463 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.518 ' HB1' ' CA ' ' A' ' 84' ' ' GLU . . . . . . . . 0 N--CA 1.458 -0.053 0 CA-C-O 120.778 0.323 . . . . 62.42 111.093 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -143.18 128.44 18.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 71.31 110.874 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 14.4 p -104.77 146.59 11.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 44.11 111.21 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 15.1 t -156.92 137.24 12.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 61.41 110.816 -179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 18.5 tt -112.05 144.69 19.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.133 -0.485 . . . . 74.34 111.115 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -117.45 129.45 8.33 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.699 -0.763 . . . . 71.14 112.505 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.1 t-20 -150.82 128.21 11.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.824 0.345 . . . . 61.13 110.812 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.408 ' O ' ' C ' ' A' ' 53' ' ' THR . 12.8 p-10 -153.79 163.49 39.93 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.107 -0.497 . . . . 72.41 110.897 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . 0.408 ' C ' ' O ' ' A' ' 52' ' ' ASP . 10.0 t 37.45 43.56 0.42 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 71.22 111.143 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.607 ' C ' HD13 ' A' ' 55' ' ' LEU . 0.2 OUTLIER -109.97 170.5 8.04 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.158 -0.474 . . . . 51.02 111.163 -179.998 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.607 HD13 ' C ' ' A' ' 54' ' ' THR . 0.0 OUTLIER -156.06 166.15 34.31 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.26 -0.427 . . . . 75.43 110.915 179.987 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.506 HG21 ' HB3' ' A' ' 24' ' ' SER . 43.8 p -140.39 144.66 36.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.198 -0.455 . . . . 60.22 111.144 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -118.94 132.41 56.08 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.434 . . . . 74.53 110.86 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.41 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -131.87 150.51 52.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 74.21 110.832 -179.969 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.547 HG23 ' HE1' ' A' ' 17' ' ' TRP . 20.0 mm -110.47 114.41 46.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.236 -0.438 . . . . 44.21 111.123 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.438 ' HB2' ' OD2' ' A' ' 70' ' ' ASP . . . -103.36 123.73 47.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.176 -0.465 . . . . 32.45 111.124 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.411 ' O ' ' HB1' ' A' ' 68' ' ' ALA . 0.5 OUTLIER -112.97 119.51 38.18 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 73.14 110.883 -179.81 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -80.1 113.73 18.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.084 -0.507 . . . . 65.32 110.863 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 83.3 t -111.27 -32.69 2.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 70.13 111.222 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -124.09 -172.53 2.56 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.104 -0.498 . . . . 75.3 110.85 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 5.0 p -85.82 -36.25 20.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.121 -0.49 . . . . 71.12 110.832 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -126.31 19.36 7.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 53.24 110.932 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 24.8 mt -148.97 135.77 13.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.111 -0.495 . . . . 75.35 111.122 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.411 ' HB1' ' O ' ' A' ' 61' ' ' TYR . . . -153.32 170.13 21.39 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.172 -0.467 . . . . 71.31 111.076 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.3 m -106.34 151.32 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.265 -0.425 . . . . 55.35 111.083 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.438 ' OD2' ' HB2' ' A' ' 60' ' ' ALA . 0.8 OUTLIER -143.03 138.32 29.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.129 -0.487 . . . . 61.21 110.839 179.883 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.41 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 12.0 m-85 -121.59 109.32 14.64 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 73.13 110.92 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.55 ' CD2' HD13 ' A' ' 102' ' ' ILE . 1.3 t80 -83.83 121.44 27.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.154 -0.475 . . . . 74.05 110.867 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 24.8 t -135.89 146.59 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 75.42 111.1 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -162.31 124.35 1.29 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.678 -0.772 . . . . 62.3 112.497 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 43.7 t -114.91 70.18 2.39 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.638 0.733 . . . . 60.34 111.132 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 162.79 40.72 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 75.24 112.331 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -76.32 -170.52 1.49 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.213 -0.449 . . . . 73.55 111.13 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 19.8 ttp180 -77.48 137.2 38.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 72.4 110.916 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -134.28 150.93 51.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.226 -0.443 . . . . 53.53 111.068 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -100.51 138.31 37.73 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 73.43 110.898 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -128.09 155.31 44.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 72.22 110.894 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.464 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 1.1 pt20 -110.26 153.26 25.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 62.12 110.995 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.612 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 179.93 75.22 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.758 -0.734 . . . . 42.52 112.52 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.518 ' CA ' ' HB1' ' A' ' 45' ' ' ALA . 1.0 OUTLIER -177.25 -176.89 0.68 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.906 0.384 . . . . 71.55 110.86 -179.898 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 3.6 mtpm? -85.67 -69.66 0.65 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 74.04 110.868 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.5 t -84.31 -33.41 23.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 72.05 110.928 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.885 HG22 HG22 ' A' ' 93' ' ' VAL . 6.1 mm -64.62 -34.33 69.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.124 -0.489 . . . . 74.11 111.113 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 78.6 p -63.7 -50.48 69.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.144 -0.48 . . . . 72.43 110.856 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 44.6 t -51.45 -38.06 51.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.146 -0.479 . . . . 62.21 110.863 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 9.3 tp -64.83 -42.66 94.79 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.172 -0.467 . . . . 63.1 110.931 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 106.14 -14.57 44.1 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.755 -0.736 . . . . 74.23 112.491 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 24.3 ttp180 -114.37 94.33 4.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.834 0.349 . . . . 73.12 110.922 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.885 HG22 HG22 ' A' ' 87' ' ' ILE . 85.5 t -112.86 -51.83 5.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 44.13 111.106 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 10.9 p -139.12 143.52 38.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.158 -0.474 . . . . 73.12 110.829 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -130.92 118.22 20.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.136 -0.484 . . . . 64.03 110.917 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.533 HG21 ' CD2' ' A' ' 128' ' ' PHE . 9.8 p -176.08 161.26 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.181 -0.463 . . . . 61.15 111.113 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.435 ' N ' HG22 ' A' ' 96' ' ' VAL . 2.0 p30 -91.07 174.12 7.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 63.33 110.849 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -119.91 134.53 55.21 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.165 -0.471 . . . . 62.33 110.947 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -121.76 66.61 0.46 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.719 -0.753 . . . . 64.22 112.509 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 117.43 5.08 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.617 2.211 . . . . 74.02 112.321 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -132.37 104.24 6.62 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.157 -0.474 . . . . 71.45 111.087 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.602 HG23 ' CA ' ' A' ' 124' ' ' GLY . 5.0 mp -130.03 150.57 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 73.31 111.094 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -143.75 115.39 8.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 72.42 110.899 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.1 p -142.87 159.65 41.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.232 -0.44 . . . . 45.34 110.887 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.622 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.8 OUTLIER -108.12 146.58 32.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.141 -0.481 . . . . 55.54 110.893 -179.963 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -100.97 137.99 38.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 71.04 110.872 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 28.6 p90 -141.63 156.19 45.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.204 -0.453 . . . . 72.53 110.916 -179.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 20.0 m-70 . . . . . 0 C--N 1.33 -0.26 0 CA-C-N 116.115 -0.493 . . . . 71.33 110.835 179.92 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 21.6 p90 . . . . . 0 C--O 1.232 0.161 0 CA-C-O 121.672 0.749 . . . . 75.23 110.919 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . 0.703 ' HA ' HD23 ' A' ' 153' ' ' LEU . 53.8 Cg_endo -69.73 177.74 5.25 Favored 'Trans proline' 0 N--CA 1.465 -0.186 0 C-N-CA 122.69 2.26 . . . . 53.11 112.402 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 1.2 p90 -112.05 162.78 15.02 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.261 -0.427 . . . . 63.32 110.941 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 43.9 t -121.41 136.24 58.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.124 -0.489 . . . . 74.24 111.173 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -128.58 179.09 16.81 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.771 -0.728 . . . . 74.22 112.437 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.4 HG22 ' N ' ' A' ' 122' ' ' GLY . 7.6 p -163.44 155.79 2.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.89 0.376 . . . . 65.13 111.125 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . 0.4 ' N ' HG22 ' A' ' 121' ' ' VAL . . . -179.34 -157.41 19.69 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.73 -0.748 . . . . 33.01 112.509 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.4 p -107.28 123.71 62.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.812 0.339 . . . . 75.03 111.173 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . 0.602 ' CA ' HG23 ' A' ' 102' ' ' ILE . . . -115.45 107.66 1.77 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.774 -0.727 . . . . 21.15 112.497 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -106.13 126.82 52.67 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.932 0.396 . . . . 72.42 110.824 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.411 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 2.1 p -105.59 108.92 26.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.152 -0.476 . . . . 71.15 111.144 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 3.1 tp -116.58 170.33 8.66 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.259 -0.428 . . . . 75.42 110.993 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.533 ' CD2' HG21 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -161.7 179.35 8.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.246 -0.433 . . . . 71.4 110.926 179.951 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -117.23 115.47 25.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.469 . . . . 74.41 110.882 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -48.05 110.55 0.34 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 65.41 110.799 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.496 ' HB2' HG23 ' A' ' 96' ' ' VAL . 2.8 mmmt -104.09 -89.05 0.41 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 72.42 110.885 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.3 m -175.78 133.94 0.28 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.23 -0.441 . . . . 74.2 111.152 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . 0.462 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 19.3 m-20 -115.9 127.63 55.15 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.166 -0.47 . . . . 73.22 110.937 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -77.12 -11.09 85.88 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.753 -0.737 . . . . 63.01 112.522 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -45.12 -31.09 1.28 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.872 0.368 . . . . 61.11 111.077 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.5 tp -164.6 -177.18 4.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 54.34 110.938 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 16.5 m -51.42 95.24 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 43.15 110.862 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 93.3 p 47.26 72.03 0.28 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.071 -0.513 . . . . 71.11 110.892 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.462 ' HB3' ' HB2' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -88.97 160.26 17.22 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.131 -0.486 . . . . 54.13 110.84 -179.904 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 69.9 m-20 -147.2 -178.61 6.31 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.112 -0.495 . . . . 63.52 110.844 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.647 HG22 ' HA ' ' A' ' 176' ' ' VAL . 1.1 pt -141.92 174.39 6.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.128 -0.487 . . . . 74.42 111.139 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . 0.403 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 14.7 tptt -123.85 135.58 53.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 70.34 110.877 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.411 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 2.8 p30 -78.5 -173.29 3.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 72.33 110.891 179.862 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 1.4 tttp -166.77 177.24 6.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 72.5 110.901 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' TRP . . . . . 0.433 ' O ' ' HB2' ' A' ' 146' ' ' ALA . 64.7 p-90 -156.95 160.3 38.93 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.227 -0.442 . . . . 73.45 110.928 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.769 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 177.44 166.73 0.51 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.622 0.725 . . . . 75.02 111.068 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' PRO . . . . . 0.769 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.4 Cg_endo -69.77 129.64 17.93 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.711 2.274 . . . . 74.32 112.279 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.532 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -122.69 170.17 10.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.217 -0.447 . . . . 62.53 111.113 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 13.2 m-85 -124.18 154.66 39.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.258 -0.428 . . . . 74.45 110.807 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 5.8 tt0 -130.63 151.95 50.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.102 -0.499 . . . . 74.45 110.862 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.4 p -153.1 125.85 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 64.24 111.185 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -179.78 -162.63 29.1 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.776 -0.726 . . . . 72.31 112.451 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.764 HD13 ' N ' ' A' ' 154' ' ' ARG . 3.0 tm? -142.6 145.43 33.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.784 0.326 . . . . 64.43 110.857 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.764 ' N ' HD13 ' A' ' 153' ' ' LEU . 3.9 tpp85 -115.37 119.34 35.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 75.32 110.855 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 63.3 t80 -110.59 150.21 29.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.223 -0.444 . . . . 74.35 110.951 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -121.27 123.52 42.39 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.151 -0.477 . . . . 54.34 110.852 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' LEU . . . . . 0.665 HD22 ' HB2' ' A' ' 160' ' ' SER . 1.7 tt -92.29 136.12 33.46 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.157 -0.474 . . . . 75.42 110.898 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . 0.577 ' N ' HD23 ' A' ' 157' ' ' LEU . . . -75.41 137.39 21.77 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.782 -0.723 . . . . 72.21 112.52 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 53.02 37.23 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.892 0.377 . . . . 72.43 110.894 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . 0.665 ' HB2' HD22 ' A' ' 157' ' ' LEU . 2.3 m -172.59 173.95 3.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.154 -0.476 . . . . 44.2 110.82 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 7.0 m0 -62.55 158.76 17.27 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.146 -0.479 . . . . 64.22 110.912 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' MET . . . . . 0.46 ' SD ' HG23 ' A' ' 203' ' ' VAL . 0.3 OUTLIER -92.97 171.17 9.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.255 -0.429 . . . . 54.23 110.927 179.924 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 80.7 mt -124.3 145.35 49.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 75.22 110.895 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -143.64 134.47 25.28 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.164 -0.471 . . . . 55.24 110.832 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 78.4 p -145.11 121.54 10.99 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.118 -0.492 . . . . 63.41 110.834 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -153.4 174.0 14.92 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.158 -0.474 . . . . 73.12 110.859 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.437 HG22 HD12 ' A' ' 196' ' ' LEU . 1.5 t -135.68 151.87 30.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.153 -0.476 . . . . 71.41 111.178 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . 0.402 ' HB2' ' HB ' ' A' ' 195' ' ' ILE . 0.1 OUTLIER -117.73 131.49 56.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 75.33 110.901 179.994 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 23.4 m-85 -132.07 134.68 45.78 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.144 -0.48 . . . . 75.42 110.966 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' ILE . . . . . 0.532 HG21 ' HB2' ' A' ' 148' ' ' ALA . 0.0 OUTLIER -179.13 120.49 0.23 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.618 0.723 . . . . 71.24 111.138 179.93 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.77 108.61 2.12 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.635 2.224 . . . . 73.05 112.333 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -116.48 157.11 25.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 74.52 110.834 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.36 118.98 25.18 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.131 -0.486 . . . . 75.14 110.89 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.9 t -95.08 144.64 25.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.21 -0.45 . . . . 73.43 111.092 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . 0.403 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.1 OUTLIER -100.21 150.58 22.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.163 -0.472 . . . . 72.11 110.855 179.916 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.647 ' HA ' HG22 ' A' ' 141' ' ' ILE . 14.7 p -146.46 127.53 6.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.197 -0.456 . . . . 74.42 111.159 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 15.2 t -167.32 172.16 10.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 73.43 111.073 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -145.48 171.77 26.42 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.688 -0.768 . . . . 71.52 112.493 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.294 0 CA-C-O 120.885 0.374 . . . . 73.54 111.124 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo . . . . . 0 C--O 1.231 0.158 0 CA-C-O 120.767 0.236 . . . . 62.42 112.387 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 49.6 t -96.73 107.99 20.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.265 -0.425 . . . . 72.12 111.14 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 1.7 p -104.16 118.72 37.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 71.52 110.83 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 23.2 p -145.9 176.12 9.92 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.183 -0.462 . . . . 65.54 111.149 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 188' ' ' LYS . . . . . 0.535 ' O ' HD13 ' A' ' 189' ' ' ILE . 0.2 OUTLIER -154.67 166.66 32.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 75.21 110.878 179.964 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 189' ' ' ILE . . . . . 0.601 HD11 ' H ' ' A' ' 33' ' ' GLY . 47.7 mm -140.23 114.44 6.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 73.11 111.099 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 7.6 tm-20 -103.01 106.74 17.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.136 -0.484 . . . . 65.13 110.93 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 8.7 m -137.03 163.49 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.174 -0.466 . . . . 72.51 111.145 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.3 89.28 4.63 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.61 0.719 . . . . 65.43 110.814 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 137.36 35.11 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.675 2.25 . . . . 63.14 112.385 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -104.26 114.7 29.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.308 -0.405 . . . . 72.51 110.813 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 195' ' ' ILE . . . . . 0.811 HD12 HG12 ' A' ' 26' ' ' VAL . 4.0 mm -101.68 119.2 49.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.109 -0.496 . . . . 74.14 111.116 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . 0.437 HD12 HG22 ' A' ' 167' ' ' VAL . 11.9 tp -104.86 109.49 21.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.241 -0.436 . . . . 62.03 110.902 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -102.46 119.58 39.07 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.163 -0.471 . . . . 54.05 110.833 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 198' ' ' LEU . . . . . 0.463 ' H ' HD23 ' A' ' 198' ' ' LEU . 2.0 pt? -139.13 129.65 25.8 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.164 -0.471 . . . . 72.23 110.963 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 179.88 -144.15 5.89 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.766 -0.73 . . . . 65.22 112.454 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 200' ' ' ALA . . . . . 0.427 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -127.1 173.42 9.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.812 0.339 . . . . 65.5 111.087 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 15.2 m -146.96 169.87 18.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.214 -0.448 . . . . 72.33 110.89 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 1.1 t80 -141.49 131.66 24.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.168 -0.469 . . . . 75.14 110.935 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.46 HG23 ' SD ' ' A' ' 162' ' ' MET . 5.8 t -81.12 158.58 4.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.479 . . . . 41.52 111.089 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 204' ' ' PHE . . . . . 0.411 ' N ' HG12 ' A' ' 203' ' ' VAL . 2.1 m-85 -164.6 147.95 8.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.466 . . . . 72.34 110.915 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 35.8 mtpt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 70.34 110.895 -179.964 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 17.5 pt20 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.812 0.339 . . . . 74.45 110.907 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 101.7 7.91 46.97 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.729 -0.748 . . . . 42.51 112.468 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.62 156.23 27.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.81 0.338 . . . . 64.43 110.856 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 41.5 m95 -133.0 143.63 49.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.109 -0.496 . . . . 75.11 110.944 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.757 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 2.6 m -142.71 137.76 27.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.251 -0.431 . . . . 64.14 111.132 179.877 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -96.62 104.91 16.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 73.24 111.087 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.4 m -91.63 130.18 37.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 74.13 110.87 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.704 ' CE2' ' HB3' ' A' ' 200' ' ' ALA . 13.7 p90 -134.78 116.76 15.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.066 -0.515 . . . . 65.4 110.88 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -150.95 172.32 15.88 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.177 -0.465 . . . . 75.33 110.94 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 12.8 p90 -105.16 131.39 52.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 74.21 110.906 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . 0.412 ' HB2' HG22 ' A' ' 195' ' ' ILE . 0.3 OUTLIER -96.58 137.3 35.87 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.149 -0.478 . . . . 44.14 110.837 -179.76 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.7 mmtp -116.19 111.64 20.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.128 -0.487 . . . . 71.31 110.878 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.512 HG22 HD12 ' A' ' 195' ' ' ILE . 25.4 t -75.11 128.32 36.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.237 -0.438 . . . . 72.32 111.097 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 6.9 m-85 -125.96 106.92 9.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 74.33 110.977 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.7 p -171.59 152.92 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.119 -0.491 . . . . 72.21 111.146 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 169.34 64.74 0.04 OUTLIER Glycine 0 N--CA 1.453 -0.197 0 C-N-CA 120.766 -0.731 . . . . 75.43 112.491 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 13.8 tt0 -89.78 -66.3 0.94 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.76 0.314 . . . . 64.13 110.861 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 71.1 tt0 -175.05 154.88 1.88 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 65.42 110.905 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.593 HD13 ' N ' ' A' ' 33' ' ' GLY . 0.3 OUTLIER -110.07 133.91 52.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.484 . . . . 71.11 110.958 -179.952 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.593 ' N ' HD13 ' A' ' 32' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.746 -0.74 . . . . 42.33 112.49 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.463 ' HB1' ' CA ' ' A' ' 84' ' ' GLU . . . . . . . . 0 N--CA 1.457 -0.123 0 CA-C-O 120.789 0.328 . . . . 72.13 111.104 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -143.25 130.41 20.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.453 . . . . 73.31 110.846 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.5 p -104.78 138.56 29.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.185 -0.461 . . . . 74.23 111.089 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -142.85 159.16 42.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.117 -0.492 . . . . 75.22 110.835 -179.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -108.47 132.76 55.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.119 -0.491 . . . . 75.41 111.149 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -131.07 51.81 0.85 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.746 -0.74 . . . . 52.44 112.488 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 -102.81 112.6 25.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.834 0.35 . . . . 75.13 110.919 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.659 ' O ' HG23 ' A' ' 54' ' ' THR . 1.8 t70 -55.03 175.18 0.06 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 75.2 110.859 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 7.5 p -53.16 101.82 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.238 -0.437 . . . . 72.25 111.135 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.659 HG23 ' O ' ' A' ' 52' ' ' ASP . 44.9 p -100.94 176.1 5.39 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 74.12 111.182 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 5.2 mp -129.78 161.51 30.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.269 -0.423 . . . . 63.05 110.924 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.5 143.01 30.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 70.21 111.087 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -123.05 132.41 54.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.248 -0.433 . . . . 75.23 110.862 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.436 ' C ' HD13 ' A' ' 59' ' ' ILE . 14.5 p-10 -134.75 145.21 48.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 65.22 110.825 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.436 HD13 ' C ' ' A' ' 58' ' ' ASP . 5.8 mm -108.95 116.81 52.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 54.25 111.085 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.757 ' HB3' ' CG2' ' A' ' 18' ' ' VAL . . . -101.87 125.2 48.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 63.14 111.07 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.632 ' HB3' HG13 ' A' ' 69' ' ' VAL . 27.1 t80 -110.47 115.59 29.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.22 -0.445 . . . . 62.32 110.91 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -84.14 101.95 12.22 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.092 -0.503 . . . . 72.23 110.89 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.5 p -94.21 -33.15 4.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.151 -0.477 . . . . 75.34 111.041 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.0 m -134.1 164.33 27.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 73.54 110.782 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 7.8 p -86.67 3.14 45.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.083 -0.508 . . . . 54.12 110.885 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -112.43 -32.59 6.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.101 -0.5 . . . . 72.04 110.912 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 21.6 pt -146.44 167.81 6.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.173 -0.467 . . . . 73.42 111.163 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -154.69 169.13 24.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 72.23 111.12 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.632 HG13 ' HB3' ' A' ' 61' ' ' TYR . 1.4 p -111.62 147.2 15.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.3 -0.409 . . . . 65.22 111.19 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -139.78 127.0 21.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 64.32 110.798 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.748 ' CZ ' HD22 ' A' ' 103' ' ' LEU . 0.6 OUTLIER -108.56 110.43 21.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 71.31 110.874 -179.96 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -87.03 129.4 34.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.126 -0.488 . . . . 70.13 110.872 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 9.9 m -149.44 163.42 4.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.118 -0.492 . . . . 65.44 111.134 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 175.01 142.57 4.13 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.757 -0.735 . . . . 62.12 112.477 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.473 ' O ' HG13 ' A' ' 75' ' ' VAL . 3.9 p -118.71 77.78 14.95 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.657 0.741 . . . . 74.43 111.16 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 148.7 65.97 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.63 2.22 . . . . 74.1 112.387 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -67.31 -165.62 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.29 -0.414 . . . . 64.41 111.061 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 43.1 ttp180 -76.66 115.54 16.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 73.21 110.83 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . 0.467 ' HB3' ' CZ ' ' A' ' 81' ' ' PHE . . . -110.3 149.71 29.79 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.212 -0.449 . . . . 20.44 111.145 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.6 tmmm? -103.27 141.23 36.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 74.32 110.825 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . 0.467 ' CZ ' ' HB3' ' A' ' 79' ' ' ALA . 10.3 m-85 -139.47 157.33 46.03 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.136 -0.484 . . . . 61.3 110.86 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 9.3 mt-30 -105.96 156.15 18.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.198 -0.455 . . . . 74.0 110.977 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.59 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 176.26 73.81 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.712 -0.756 . . . . 74.51 112.512 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.463 ' CA ' ' HB1' ' A' ' 45' ' ' ALA . 1.3 tp10 -174.37 -177.21 1.21 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.959 0.409 . . . . 71.41 110.857 -179.831 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 2.3 ptmt -86.76 -69.95 0.64 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.096 -0.502 . . . . 65.25 110.858 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.6 t -84.07 -33.38 24.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.45 . . . . 54.31 110.913 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.841 HG21 ' HB2' ' A' ' 135' ' ' ALA . 4.6 mm -65.39 -34.46 70.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.115 -0.493 . . . . 75.33 111.146 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 63.5 p -61.48 -48.68 80.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.13 -0.486 . . . . 62.42 110.751 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.7 t -52.1 -39.93 60.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 71.21 110.83 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 82.5 mt -60.41 -47.86 84.25 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.163 -0.471 . . . . 74.43 110.941 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 114.93 -14.96 19.22 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.759 -0.734 . . . . 64.02 112.515 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 8.9 mtm180 -121.34 97.15 5.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.899 0.381 . . . . 75.25 110.901 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.628 HG22 HG22 ' A' ' 87' ' ' ILE . 17.0 t -112.97 -41.99 4.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.159 -0.473 . . . . 75.31 111.023 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 13.3 p -141.51 154.2 45.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 61.33 110.872 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 82.9 mt-10 -152.56 118.64 5.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.134 -0.485 . . . . 75.42 110.836 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.734 HG21 ' O ' ' A' ' 129' ' ' PHE . 4.5 p -178.46 164.16 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 72.24 111.165 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.435 ' H ' HG22 ' A' ' 96' ' ' VAL . 4.0 p30 -90.84 133.51 35.16 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.466 . . . . 73.51 110.86 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -92.21 146.14 23.95 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 74.33 110.86 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -113.49 70.93 0.23 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.767 -0.73 . . . . 42.11 112.497 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 112.48 3.1 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.714 2.276 . . . . 74.44 112.302 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -136.87 113.76 10.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.239 -0.437 . . . . 63.04 111.171 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.657 HD13 ' HD2' ' A' ' 168' ' ' ARG . 13.5 pt -139.68 153.61 23.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.209 -0.451 . . . . 72.4 111.117 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.748 HD22 ' CZ ' ' A' ' 71' ' ' PHE . 0.5 OUTLIER -142.21 117.05 9.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.204 -0.453 . . . . 71.21 110.898 179.954 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . 0.413 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 5.3 p -142.82 161.26 38.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.227 -0.442 . . . . 71.31 110.885 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.461 ' O ' HD12 ' A' ' 105' ' ' LEU . 4.5 pp -110.08 146.03 36.09 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.168 -0.469 . . . . 73.55 110.955 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 1.7 pp0? -101.13 144.43 30.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 65.32 110.965 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -152.58 159.78 43.24 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.244 -0.435 . . . . 63.01 110.955 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 7.7 p-80 . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.114 -0.494 . . . . 73.23 110.779 179.961 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 20.8 p90 . . . . . 0 C--O 1.231 0.086 0 CA-C-O 121.624 0.726 . . . . 62.4 110.952 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . 0.684 ' HB3' HD12 ' A' ' 153' ' ' LEU . 54.5 Cg_endo -69.67 178.37 4.58 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.72 2.28 . . . . 74.14 112.359 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 1.6 p90 -127.38 159.07 35.56 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.295 -0.411 . . . . 71.23 110.895 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 48.1 t -113.3 136.5 49.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.107 -0.497 . . . . 63.41 111.1 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -127.24 172.46 18.65 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.759 -0.734 . . . . 71.33 112.515 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.2 p -162.46 151.67 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.877 0.37 . . . . 44.21 111.18 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . 0.413 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -176.65 -156.23 15.1 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.693 -0.765 . . . . 64.15 112.46 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.471 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 5.8 m -107.82 122.04 61.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.921 0.391 . . . . 60.34 111.083 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . 0.539 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -115.9 121.31 5.2 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.699 -0.762 . . . . 50.25 112.523 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -116.51 132.7 56.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.829 0.347 . . . . 73.03 110.862 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.421 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 2.8 m -107.66 108.67 25.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 75.02 111.147 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.523 HD23 ' N ' ' A' ' 128' ' ' PHE . 0.5 OUTLIER -86.86 166.53 15.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 73.23 110.956 179.901 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.523 ' N ' HD23 ' A' ' 127' ' ' LEU . 0.5 OUTLIER -149.24 134.51 18.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 54.3 110.902 179.914 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.734 ' O ' HG21 ' A' ' 96' ' ' VAL . 28.3 t80 -100.34 165.13 11.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.147 -0.479 . . . . 73.34 110.909 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -97.49 120.19 37.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 62.4 110.826 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.69 ' CB ' HG23 ' A' ' 96' ' ' VAL . 4.3 tppp? -141.17 -82.18 0.23 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 71.24 110.838 180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 31.7 m -162.78 83.92 0.52 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.267 -0.424 . . . . 71.24 111.185 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -104.57 165.11 11.28 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.229 -0.441 . . . . 72.31 110.898 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 62.13 154.85 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.725 -0.75 . . . . 54.43 112.463 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.841 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -84.77 1.71 45.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.808 0.337 . . . . 62.1 111.088 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -86.26 -175.75 5.63 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.26 -0.427 . . . . 74.34 110.965 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.4 m -63.55 87.53 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.191 -0.459 . . . . 72.44 110.83 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 38.6 t 51.17 76.63 0.15 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.074 -0.512 . . . . 44.53 110.854 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.715 ' CE1' HG12 ' A' ' 176' ' ' VAL . 1.0 OUTLIER -86.55 148.87 25.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.163 -0.471 . . . . 73.44 110.806 -179.913 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 59.4 m-20 -122.03 -178.76 3.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.045 -0.525 . . . . 75.24 110.898 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.423 ' HA ' ' HA ' ' A' ' 176' ' ' VAL . 0.1 OUTLIER -145.2 160.51 13.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.445 . . . . 63.14 111.124 179.988 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . 0.424 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 3.4 ttmt -105.27 122.42 45.89 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.21 -0.45 . . . . 73.3 110.918 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.421 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 0.8 OUTLIER -63.59 -173.48 0.07 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.241 -0.436 . . . . 74.11 110.859 179.84 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 18.6 tptt -158.45 164.62 36.04 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.191 -0.459 . . . . 74.33 110.913 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 17.6 p90 -155.87 146.48 21.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.167 -0.469 . . . . 63.22 110.889 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.833 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 179.74 168.76 0.68 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.592 0.711 . . . . 62.5 111.138 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' PRO . . . . . 0.833 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.8 Cg_endo -69.75 125.1 11.76 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.703 2.269 . . . . 60.21 112.364 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.659 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -117.96 171.08 8.32 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.238 -0.437 . . . . 55.32 111.078 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 16.3 m-85 -123.6 138.55 54.53 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.13 -0.486 . . . . 74.32 110.861 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 40.0 tt0 -119.93 159.49 24.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.138 -0.483 . . . . 74.21 110.862 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -160.7 133.32 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.453 . . . . 71.44 111.154 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . 0.443 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 179.38 -158.67 22.79 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.66 -0.781 . . . . 72.24 112.442 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.684 HD12 ' HB3' ' A' ' 117' ' ' PRO . 0.0 OUTLIER -146.93 166.38 26.93 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.777 0.322 . . . . 74.13 110.94 -179.969 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.417 ' HD3' ' N ' ' A' ' 155' ' ' TYR . 5.6 tpp85 -129.56 117.86 21.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.248 -0.433 . . . . 72.0 110.858 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . 0.417 ' N ' ' HD3' ' A' ' 154' ' ' ARG . 3.4 t80 -104.12 144.32 31.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.234 -0.439 . . . . 74.01 110.85 -179.811 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -120.47 98.26 5.96 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.124 -0.489 . . . . 74.05 110.842 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 78.8 mt -69.53 152.77 44.41 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.204 -0.453 . . . . 75.11 110.898 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -52.8 -33.84 43.59 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.733 -0.746 . . . . 72.15 112.495 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -65.78 178.53 1.03 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.86 0.362 . . . . 75.13 110.932 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 1.2 m -66.08 -35.88 81.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.144 -0.48 . . . . 73.34 110.958 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 47.0 p90 -82.76 152.82 25.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.068 -0.515 . . . . 70.23 110.991 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' MET . . . . . 0.424 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 2.3 mpt? -123.7 177.44 5.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.28 -0.418 . . . . 63.13 110.819 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.464 HD23 ' N ' ' A' ' 164' ' ' ASN . 1.0 OUTLIER -118.42 144.56 45.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.464 . . . . 71.44 110.87 -179.998 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . 0.464 ' N ' HD23 ' A' ' 163' ' ' LEU . 3.1 t-20 -143.63 137.61 28.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.15 -0.477 . . . . 55.05 110.923 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.0 t -144.06 121.44 11.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 72.54 110.803 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' ASP . . . . . 0.443 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.8 OUTLIER -137.37 159.66 41.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 74.35 110.908 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.545 HG13 ' CD1' ' A' ' 196' ' ' LEU . 50.4 t -132.84 134.44 58.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 72.01 111.15 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . 0.657 ' HD2' HD13 ' A' ' 102' ' ' ILE . 2.1 ttt85 -106.17 137.59 43.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 61.13 110.8 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 23.1 t80 -148.55 132.5 17.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 74.01 110.894 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' ILE . . . . . 0.659 HG21 ' HB2' ' A' ' 148' ' ' ALA . 0.0 OUTLIER -178.71 123.63 0.25 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.705 0.764 . . . . 63.34 111.121 179.93 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 104.16 1.27 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.669 2.246 . . . . 74.21 112.284 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . 0.436 ' HE1' HG23 ' A' ' 174' ' ' THR . 0.3 OUTLIER -117.53 175.03 5.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 73.32 110.935 179.95 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.2 132.88 25.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.249 -0.432 . . . . 70.13 110.951 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 174' ' ' THR . . . . . 0.436 HG23 ' HE1' ' A' ' 172' ' ' PHE . 0.0 OUTLIER -111.15 150.85 28.89 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.244 -0.434 . . . . 73.32 111.123 179.989 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . 0.424 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -106.44 158.84 16.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.223 -0.444 . . . . 65.42 110.849 179.922 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.715 HG12 ' CE1' ' A' ' 139' ' ' PHE . 10.3 t -138.61 123.2 21.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.461 . . . . 72.21 111.172 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 15.3 t -166.67 172.57 10.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 74.53 111.149 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 117.72 140.07 6.45 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.755 -0.736 . . . . 62.41 112.443 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 43.5 m . . . . . 0 C--N 1.33 -0.275 0 CA-C-O 120.799 0.333 . . . . 75.41 111.08 -179.839 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo . . . . . 0 C--O 1.231 0.158 0 CA-C-O 120.792 0.247 . . . . 65.13 112.281 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.4 HG12 ' N ' ' A' ' 186' ' ' SER . 4.2 t -95.96 159.05 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 64.42 111.186 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 186' ' ' SER . . . . . 0.4 ' N ' HG12 ' A' ' 185' ' ' VAL . 6.2 p -130.43 108.55 10.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.974 0.416 . . . . 61.45 110.906 -179.845 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 16.8 p -127.36 167.21 16.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.18 -0.464 . . . . 75.23 111.177 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 4.0 tttt -151.92 142.71 22.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 62.24 110.955 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 6.8 tp -137.5 125.68 32.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 73.51 111.092 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -106.55 112.42 25.42 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.137 -0.483 . . . . 43.2 110.876 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 8.2 m -137.83 158.88 33.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.192 -0.458 . . . . 64.21 111.083 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -108.22 88.78 5.11 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.616 0.722 . . . . 53.25 110.813 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 142.16 46.94 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.619 2.213 . . . . 74.4 112.385 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -113.75 112.21 23.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.245 -0.434 . . . . 74.51 110.901 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 195' ' ' ILE . . . . . 0.512 HD12 HG22 ' A' ' 26' ' ' VAL . 4.6 mm -100.45 124.9 54.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 72.31 111.144 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . 0.545 ' CD1' HG13 ' A' ' 167' ' ' VAL . 0.8 OUTLIER -107.9 109.01 20.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.157 -0.474 . . . . 70.53 110.955 179.875 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -97.28 123.8 41.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.212 -0.449 . . . . 43.43 110.856 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 22.8 tp -142.38 127.59 18.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.128 -0.487 . . . . 73.23 110.943 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -179.21 -143.93 5.58 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.751 -0.738 . . . . 33.01 112.509 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 200' ' ' ALA . . . . . 0.704 ' HB3' ' CE2' ' A' ' 21' ' ' PHE . . . -123.93 173.66 8.07 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.815 0.341 . . . . 60.01 111.094 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 19.1 m -154.04 163.55 39.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 63.4 110.825 -179.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -131.47 131.6 43.64 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.217 -0.447 . . . . 74.24 110.897 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.657 HG13 HG12 ' A' ' 18' ' ' VAL . 60.5 t -102.22 146.61 10.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.112 -0.494 . . . . 62.11 111.109 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -160.76 157.49 26.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.099 -0.5 . . . . 63.2 110.838 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 3.9 ptmm? . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.128 -0.487 . . . . 62.1 110.863 -179.992 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 7.3 mp0 . . . . . 0 N--CA 1.458 -0.072 0 CA-C-O 120.792 0.329 . . . . 70.21 110.907 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.35 5.84 36.77 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.711 -0.757 . . . . 72.13 112.507 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -66.74 153.3 43.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.337 . . . . 71.01 110.911 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 17.3 t90 -123.74 125.11 44.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.197 -0.456 . . . . 72.34 110.965 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.812 HG23 ' HB3' ' A' ' 60' ' ' ALA . 12.5 m -136.92 135.02 48.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.251 -0.431 . . . . 75.5 111.106 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -93.11 158.01 15.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 65.34 111.135 179.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.0 109.51 5.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.258 -0.428 . . . . 72.21 110.845 -179.745 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -111.37 115.66 29.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 72.23 110.865 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -150.69 173.0 14.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 74.43 110.906 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 28.2 p90 -108.43 132.21 54.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.167 -0.47 . . . . 71.52 110.908 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 25.2 p -104.85 142.45 34.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 63.31 110.841 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 25.4 tptt -121.96 122.95 40.53 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.082 -0.508 . . . . 75.51 110.975 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.734 HG12 HD12 ' A' ' 195' ' ' ILE . 20.9 m -89.92 135.29 26.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.281 -0.418 . . . . 62.33 111.154 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -126.68 114.37 17.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.252 -0.431 . . . . 75.01 111.015 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.0 p -174.79 153.55 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 60.32 111.156 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 150.5 67.26 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.775 -0.726 . . . . 63.31 112.517 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -90.16 -66.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.812 0.339 . . . . 73.35 110.958 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.661 ' C ' HG12 ' A' ' 47' ' ' VAL . 25.0 pt-20 -174.91 170.61 3.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.128 -0.487 . . . . 53.24 110.887 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.555 HD23 ' CB ' ' A' ' 45' ' ' ALA . 36.4 tp -98.27 150.14 21.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.138 -0.483 . . . . 71.21 110.913 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 C-N-CA 120.732 -0.747 . . . . 65.23 112.464 179.931 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.555 ' CB ' HD23 ' A' ' 32' ' ' LEU . . . . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.838 0.352 . . . . 75.15 111.087 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -142.36 135.65 28.84 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.241 -0.436 . . . . 61.53 110.833 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.661 HG12 ' C ' ' A' ' 31' ' ' GLU . 7.7 p -105.44 142.83 17.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.144 -0.48 . . . . 75.2 111.138 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.0 t -158.14 135.05 9.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 64.14 110.81 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 3.0 pt -89.44 156.38 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 71.21 111.104 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.15 -157.12 9.52 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.738 -0.744 . . . . 62.54 112.463 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -152.05 128.21 10.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.858 0.361 . . . . 74.23 110.847 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -163.64 119.35 1.66 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.147 -0.479 . . . . 65.15 110.92 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . 0.494 ' O ' HG23 ' A' ' 54' ' ' THR . 14.9 t -58.7 142.36 50.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 51.11 111.103 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.494 HG23 ' O ' ' A' ' 53' ' ' THR . 0.8 OUTLIER -160.12 164.39 33.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 43.45 111.22 179.966 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.458 ' O ' HD12 ' A' ' 55' ' ' LEU . 0.6 OUTLIER -109.31 163.0 13.78 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.282 -0.417 . . . . 54.25 110.96 179.961 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.4 p -142.55 144.0 32.72 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.239 -0.437 . . . . 75.31 111.19 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.423 ' HE2' HD13 ' A' ' 55' ' ' LEU . 48.2 m-85 -113.84 134.81 54.57 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.261 -0.427 . . . . 64.23 110.924 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.463 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -131.15 142.89 50.29 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.109 -0.496 . . . . 74.34 110.847 -179.949 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -109.3 115.28 49.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 75.54 111.116 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.812 ' HB3' HG23 ' A' ' 18' ' ' VAL . . . -104.01 134.94 46.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 54.04 111.091 179.834 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -120.43 123.4 42.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.25 -0.432 . . . . 74.11 110.859 -179.827 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -89.57 101.36 14.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.045 -0.525 . . . . 72.4 110.912 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.5 t -99.48 -38.77 7.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 64.11 111.101 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -125.44 159.01 32.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 64.11 110.829 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 12.2 p -84.35 3.16 37.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.104 -0.498 . . . . 60.34 110.862 -179.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -116.63 -33.13 4.96 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.101 -0.499 . . . . 71.2 110.877 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.438 HG21 ' CD1' ' A' ' 107' ' ' TYR . 1.9 pp -139.31 164.07 25.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 72.12 111.121 179.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -150.12 167.89 25.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 64.33 111.117 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 13.5 m -113.31 152.98 14.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 60.35 111.203 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -147.91 147.15 29.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 75.44 110.88 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.463 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 16.7 m-85 -127.34 110.33 12.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.266 -0.424 . . . . 72.54 110.867 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -87.83 122.85 31.98 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.094 -0.503 . . . . 74.4 110.863 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 25.2 t -145.88 149.11 16.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.136 -0.484 . . . . 51.15 111.094 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -152.97 167.59 31.71 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.744 -0.741 . . . . 41.24 112.511 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.6 m -134.55 67.65 71.76 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.59 0.709 . . . . 62.34 111.104 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 163.65 37.47 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.667 2.244 . . . . 64.01 112.363 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -83.85 -170.91 3.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.192 -0.458 . . . . 71.3 111.129 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 20.5 ttm105 -76.55 135.49 39.26 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 61.43 110.823 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -129.7 144.3 51.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.114 -0.494 . . . . 62.54 111.148 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.83 137.49 42.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 62.35 110.915 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 43.6 p90 -129.78 159.09 37.61 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.435 . . . . 74.52 110.865 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.411 ' O ' HG23 ' A' ' 47' ' ' VAL . 26.0 mt-30 -98.29 158.08 15.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 74.13 110.878 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.532 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -178.0 60.13 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.666 -0.778 . . . . 74.41 112.479 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.453 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.3 tp10 -167.97 -175.55 2.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.928 0.394 . . . . 63.15 110.85 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.15 -69.27 0.68 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.187 -0.461 . . . . 73.24 110.899 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -84.15 -33.39 24.26 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.203 -0.453 . . . . 64.25 110.817 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.751 HG22 HG22 ' A' ' 93' ' ' VAL . 5.8 mm -64.68 -35.11 73.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 55.25 111.126 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 78.8 p -62.98 -47.89 81.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.472 . . . . 73.12 110.83 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 t -51.29 -37.88 49.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.125 -0.489 . . . . 74.15 110.851 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 9.1 tp -63.34 -39.01 93.36 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.103 -0.499 . . . . 70.43 110.929 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 103.13 -15.41 54.82 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.714 -0.755 . . . . 43.22 112.494 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -120.35 89.43 3.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.873 0.368 . . . . 75.43 110.825 -179.832 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.751 HG22 HG22 ' A' ' 87' ' ' ILE . 32.4 t -105.38 -47.4 9.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.207 -0.451 . . . . 60.23 111.157 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 17.9 t -142.22 144.29 33.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.151 -0.477 . . . . 75.11 110.869 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.4 pm0 -133.65 128.56 35.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.09 -0.504 . . . . 72.1 110.865 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.483 HG22 ' N ' ' A' ' 97' ' ' ASP . 10.1 p -175.88 157.02 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.464 . . . . 71.33 111.135 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.483 ' N ' HG22 ' A' ' 96' ' ' VAL . 1.7 t0 -81.0 172.52 13.63 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 73.12 110.921 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -132.92 130.72 40.0 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.269 -0.423 . . . . 74.01 110.913 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -113.4 70.98 0.23 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.71 -0.757 . . . . 54.12 112.42 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.66 114.43 3.69 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.694 2.263 . . . . 74.51 112.346 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -133.61 107.45 7.98 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.221 -0.445 . . . . 65.43 111.025 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.566 HG22 ' CA ' ' A' ' 124' ' ' GLY . 8.0 pt -131.55 149.69 33.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.247 -0.433 . . . . 55.12 111.117 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.455 ' O ' HD12 ' A' ' 103' ' ' LEU . 1.9 pp -138.28 124.15 19.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.127 -0.488 . . . . 71.23 110.945 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.4 p -144.74 165.88 26.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 73.5 110.818 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.465 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.9 OUTLIER -113.14 155.0 25.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.138 -0.483 . . . . 62.32 110.904 179.982 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 -102.07 132.03 48.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.466 . . . . 62.54 110.844 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.438 ' CD1' HG21 ' A' ' 67' ' ' ILE . 13.0 t80 -120.26 121.91 39.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.24 -0.436 . . . . 72.31 110.902 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.137 -0.483 . . . . 74.5 110.852 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 8.8 p90 . . . . . 0 C--O 1.232 0.143 0 CA-C-O 121.648 0.737 . . . . 62.02 110.873 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 177.75 5.22 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.76 2.307 . . . . 75.41 112.297 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 9.0 m-85 -115.69 159.27 21.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.148 -0.478 . . . . 71.0 110.878 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.8 p -109.69 124.13 66.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.11 -0.495 . . . . 72.11 111.137 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -117.87 163.51 12.83 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.777 -0.725 . . . . 64.31 112.458 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.0 p -163.71 151.35 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.901 0.381 . . . . 74.23 111.164 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -179.26 -151.78 10.03 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.689 -0.767 . . . . 61.51 112.446 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.454 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 32.8 m -110.6 152.27 12.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.896 0.379 . . . . 73.14 111.154 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . 0.566 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -139.03 106.24 0.5 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.691 -0.766 . . . . 74.05 112.447 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 7.2 ptp180 -105.82 128.35 53.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.862 0.363 . . . . 74.34 110.84 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 60.4 t -113.52 114.62 47.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 73.14 111.136 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.1 tt -122.42 152.27 40.4 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 72.23 110.95 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 11.5 p90 -161.58 162.17 30.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.288 -0.415 . . . . 73.03 110.886 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -101.17 116.86 33.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 72.13 110.912 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -50.74 104.56 0.08 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.156 -0.474 . . . . 72.45 110.861 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.447 ' HB2' ' HA ' ' A' ' 96' ' ' VAL . 0.7 OUTLIER -79.49 -79.35 0.14 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 62.32 110.934 179.963 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 32.0 m -167.01 126.44 1.44 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 73.12 111.147 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . 0.487 ' HB3' ' HB3' ' A' ' 139' ' ' PHE . 26.2 t0 -115.18 114.84 25.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.27 -0.423 . . . . 74.4 110.892 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -79.95 -8.1 87.95 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.758 -0.734 . . . . 73.12 112.488 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.618 ' HB2' HG12 ' A' ' 93' ' ' VAL . . . -46.17 -29.38 1.54 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.831 0.348 . . . . 75.12 111.13 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.419 ' HB3' ' CD1' ' A' ' 139' ' ' PHE . 2.6 tp -157.12 -176.83 6.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.222 -0.445 . . . . 73.11 110.869 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 68.4 m -56.63 92.75 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.114 -0.494 . . . . 75.23 110.815 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 58.1 m 50.78 75.08 0.2 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.139 -0.482 . . . . 63.12 110.812 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.487 ' HB3' ' HB3' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -102.54 160.59 14.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 35.11 110.914 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -139.73 172.54 12.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 74.31 110.94 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.493 HD13 HG13 ' A' ' 176' ' ' VAL . 5.8 mm -114.26 161.8 12.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.219 -0.446 . . . . 74.43 111.147 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 13.5 mttm -124.11 114.82 20.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.178 -0.464 . . . . 60.14 110.923 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -69.64 -175.33 0.84 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.279 -0.419 . . . . 64.31 110.895 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 6.9 tttp -172.84 -173.64 1.0 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.23 -0.441 . . . . 71.51 110.894 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 59.3 p-90 -148.75 160.23 43.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.187 -0.461 . . . . 73.4 110.966 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.691 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 179.87 163.54 0.84 Allowed Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.593 0.711 . . . . 73.24 111.105 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' PRO . . . . . 0.691 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 54.3 Cg_endo -69.78 169.1 19.74 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.688 2.258 . . . . 74.41 112.306 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.626 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -167.79 157.07 9.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 63.41 111.094 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 6.2 p90 -115.99 138.42 51.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.449 . . . . 71.55 110.898 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.406 ' HA ' ' HA ' ' A' ' 168' ' ' ARG . 25.2 tt0 -116.53 158.88 22.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 71.45 110.864 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.3 p -142.79 129.35 17.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.16 -0.473 . . . . 71.45 111.07 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 166.4 -164.42 37.61 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.749 -0.738 . . . . 61.03 112.456 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -161.22 174.01 14.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.709 0.29 . . . . 74.23 110.992 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 7.8 tpp85 -109.45 121.21 44.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.232 -0.44 . . . . 73.23 110.846 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 47.8 t80 -106.98 147.86 29.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 75.55 110.974 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -110.07 112.63 24.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.127 -0.488 . . . . 73.51 110.845 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 23.9 tp -86.15 158.14 19.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.165 -0.47 . . . . 64.34 110.908 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -58.24 -39.57 92.67 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.731 -0.747 . . . . 35.41 112.466 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -64.26 169.35 4.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.832 0.349 . . . . 72.54 110.855 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 72.6 m -54.35 -47.55 72.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 73.14 110.875 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 18.1 p90 -74.23 145.64 43.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.096 -0.502 . . . . 62.22 110.929 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 1.8 mpt? -100.34 178.79 4.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.256 -0.429 . . . . 50.42 110.904 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 4.5 tp -119.55 141.95 48.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 74.42 110.839 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -135.37 136.29 41.35 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.144 -0.48 . . . . 63.0 110.875 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.3 p -133.99 134.03 42.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 75.24 110.912 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -163.81 152.74 13.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 64.21 110.838 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.452 HG13 ' O ' ' A' ' 195' ' ' ILE . 44.3 t -144.8 119.04 3.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 72.44 111.143 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . 0.406 ' HA ' ' HA ' ' A' ' 150' ' ' GLN . 0.4 OUTLIER -93.52 147.08 23.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.196 -0.457 . . . . 73.22 110.868 -179.959 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' TYR . . . . . 0.413 ' O ' ' HB ' ' A' ' 170' ' ' ILE . 20.1 t80 -152.6 140.03 19.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 70.14 110.943 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' ILE . . . . . 0.626 HG21 ' HB2' ' A' ' 148' ' ' ALA . 0.0 OUTLIER 178.64 132.03 0.22 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.594 0.712 . . . . 73.43 111.196 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . 0.509 ' N ' HD13 ' A' ' 170' ' ' ILE . 53.8 Cg_endo -69.75 107.97 1.97 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.691 2.261 . . . . 61.21 112.362 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -124.02 152.63 42.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.172 -0.467 . . . . 64.23 110.858 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 10.4 pttm -122.7 132.92 54.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 64.41 110.869 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.6 t -100.16 162.01 13.24 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 72.41 111.131 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -110.63 157.44 19.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 61.53 110.921 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.493 HG13 HD13 ' A' ' 141' ' ' ILE . 2.9 t -150.54 136.5 11.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.983 0.42 . . . . 74.11 111.063 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.0 t -166.83 161.83 15.6 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 72.24 111.154 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -123.78 174.56 16.76 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.769 -0.729 . . . . 63.44 112.5 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . 0.408 ' O ' HG23 ' A' ' 179' ' ' THR . 1.8 t . . . . . 0 C--N 1.329 -0.32 0 CA-C-O 120.823 0.345 . . . . 64.25 111.107 -179.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo . . . . . 0 N--CA 1.465 -0.194 0 CA-C-O 120.829 0.262 . . . . 61.34 112.39 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 84.9 t -98.68 126.22 51.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.291 -0.413 . . . . 63.2 111.129 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 1.3 p -112.46 111.67 22.68 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.155 -0.475 . . . . 72.23 110.831 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 61.9 p -116.44 167.57 10.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.083 -0.508 . . . . 75.44 111.165 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 11.5 ptmt -147.16 160.32 42.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.444 . . . . 75.44 110.837 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 189' ' ' ILE . . . . . 0.542 HG22 HG23 ' A' ' 191' ' ' VAL . 26.7 mt -137.69 109.24 6.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 74.22 111.127 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.52 106.0 18.18 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 73.03 110.871 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 191' ' ' VAL . . . . . 0.542 HG23 HG22 ' A' ' 189' ' ' ILE . 2.3 t -137.01 164.66 29.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.085 -0.507 . . . . 75.22 111.136 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.433 ' H ' HG12 ' A' ' 191' ' ' VAL . 0.0 OUTLIER -106.94 89.64 4.6 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-O 121.531 0.681 . . . . 74.45 110.816 -179.998 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 192' ' ' ASP . 53.8 Cg_endo -69.79 135.18 29.75 Favored 'Trans proline' 0 C--N 1.34 0.131 0 C-N-CA 122.758 2.306 . . . . 63.33 112.257 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -103.09 118.16 36.18 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.165 -0.47 . . . . 55.13 110.884 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 195' ' ' ILE . . . . . 0.734 HD12 HG12 ' A' ' 26' ' ' VAL . 24.1 mm -109.26 110.37 31.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 53.44 111.196 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . 0.44 HD12 HD21 ' A' ' 198' ' ' LEU . 0.9 OUTLIER -109.15 108.49 19.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 71.45 110.925 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -105.63 133.52 50.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 70.15 110.881 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 198' ' ' LEU . . . . . 0.44 HD21 HD12 ' A' ' 196' ' ' LEU . 0.1 OUTLIER -153.64 137.74 16.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 72.33 110.916 179.966 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 175.48 -140.15 5.07 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.685 -0.769 . . . . 73.33 112.44 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -117.42 173.32 6.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.814 0.34 . . . . 44.01 111.112 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 4.8 p -155.8 166.29 33.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 74.45 110.833 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -132.04 150.7 52.08 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.076 -0.511 . . . . 73.0 110.931 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.592 HG23 HG12 ' A' ' 18' ' ' VAL . 5.6 p -113.05 143.62 22.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 74.22 111.148 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 4.6 t80 -141.76 107.86 5.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 71.24 110.889 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 63.5 tttt . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.153 -0.476 . . . . 73.34 110.863 -179.997 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 11.8 mp0 . . . . . 0 N--CA 1.457 -0.079 0 CA-C-O 120.855 0.359 . . . . 74.04 110.901 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 110.6 5.8 27.46 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.734 -0.746 . . . . 72.54 112.481 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -59.69 152.84 21.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.726 0.298 . . . . 74.21 110.922 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.579 ' HE1' HG23 ' A' ' 59' ' ' ILE . 25.0 t90 -121.6 142.36 50.19 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.234 -0.439 . . . . 71.34 110.936 -179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.46 HG22 ' HA ' ' A' ' 203' ' ' VAL . 39.5 t -146.72 116.75 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 72.53 111.091 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -86.61 105.31 16.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.126 -0.488 . . . . 74.14 111.137 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -101.75 112.77 25.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 64.21 110.847 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -110.16 121.2 44.71 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.123 -0.49 . . . . 65.01 110.998 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -152.12 166.68 30.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.435 . . . . 73.4 110.913 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -100.52 130.59 46.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 72.33 110.894 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -97.17 139.09 33.68 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 74.32 110.882 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 68.8 mttt -111.05 106.97 16.2 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.14 -0.482 . . . . 70.35 110.924 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.629 HG12 HD12 ' A' ' 195' ' ' ILE . 23.4 m -79.13 132.9 31.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 72.35 111.112 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 27.9 t80 -126.97 99.25 5.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 74.34 110.945 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 p -166.12 149.77 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 63.32 111.102 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 132.44 78.71 0.15 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.702 -0.761 . . . . 72.05 112.459 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -89.77 -65.93 0.97 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.735 0.302 . . . . 64.22 110.829 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.522 ' O ' HD12 ' A' ' 189' ' ' ILE . 1.6 mt-10 -171.54 174.28 4.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.196 -0.457 . . . . 72.32 110.846 -179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.472 ' HB3' ' HB3' ' A' ' 45' ' ' ALA . 14.9 tp -81.1 155.06 26.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.082 -0.508 . . . . 61.32 110.927 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.75 -0.738 . . . . 41.4 112.494 179.828 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.472 ' HB3' ' HB3' ' A' ' 32' ' ' LEU . . . . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.804 0.335 . . . . 72.23 111.1 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 -153.49 125.85 8.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 73.31 110.921 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.471 HG22 ' HA2' ' A' ' 83' ' ' GLY . 92.0 t -109.45 141.3 25.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 74.22 111.11 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 43.0 t -167.94 159.02 11.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 41.14 110.809 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.727 HG22 ' HB3' ' A' ' 81' ' ' PHE . 45.0 pt -126.08 157.85 35.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.102 -0.499 . . . . 73.22 111.147 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.25 -138.94 0.36 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.742 -0.742 . . . . 54.35 112.45 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -154.22 117.11 4.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.884 0.373 . . . . 72.13 110.802 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -151.94 105.83 3.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.069 -0.514 . . . . 72.21 110.874 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 46.9 p -72.7 117.25 14.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 43.14 111.126 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.1 m -117.74 162.49 17.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 62.34 111.159 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -94.16 162.3 13.92 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.212 -0.449 . . . . 74.43 110.934 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.23 140.21 32.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.239 -0.437 . . . . 74.23 111.14 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -103.45 131.99 50.08 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.216 -0.447 . . . . 72.43 110.831 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 53.3 m-20 -130.13 133.3 46.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 73.43 110.896 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.579 HG23 ' HE1' ' A' ' 17' ' ' TRP . 22.1 mm -109.2 113.53 44.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 74.0 111.139 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -103.74 117.78 35.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 62.12 111.021 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -106.75 114.21 28.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.184 -0.462 . . . . 74.55 110.892 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -81.56 97.19 7.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.089 -0.505 . . . . 74.24 110.88 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.0 m -88.05 -34.15 7.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 73.51 111.129 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 69.2 m -136.23 167.47 21.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 72.0 110.899 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 46.8 t -86.94 2.64 48.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 70.53 110.895 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 65.1 m-20 -113.59 -33.86 5.72 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.096 -0.502 . . . . 61.54 110.912 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 2.2 pp -145.52 169.01 7.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 41.22 111.205 179.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -155.7 173.19 17.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.222 -0.444 . . . . 72.44 111.066 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.425 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 11.6 m -111.55 151.03 13.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 73.32 111.112 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -140.28 133.23 29.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 62.42 110.882 179.881 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.756 ' CZ ' HD22 ' A' ' 103' ' ' LEU . 0.5 OUTLIER -113.54 113.91 25.76 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.198 -0.456 . . . . 70.13 110.842 -179.852 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -91.64 119.99 32.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 74.53 110.909 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 36.7 t -146.64 149.35 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 63.25 111.144 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -156.51 164.45 32.55 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.697 -0.763 . . . . 70.32 112.473 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 24.6 t -136.55 66.03 56.47 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.614 0.721 . . . . 71.52 111.142 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 162.62 41.36 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.636 2.224 . . . . 71.31 112.353 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -79.28 -168.98 1.68 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.244 -0.435 . . . . 51.11 111.054 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.96 138.52 38.9 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.15 -0.477 . . . . 62.13 110.832 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -128.35 135.65 49.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.445 . . . . 72.11 111.144 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 6.8 ttpm? -107.92 141.63 39.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.223 -0.444 . . . . 75.32 110.857 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . 0.727 ' HB3' HG22 ' A' ' 49' ' ' ILE . 13.6 p90 -142.07 158.47 43.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.153 -0.476 . . . . 73.35 110.89 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.419 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 1.2 pm0 -98.05 158.51 15.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 75.24 110.909 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.605 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -177.44 69.59 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.759 -0.734 . . . . 73.53 112.505 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.434 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.9 mm-40 -178.33 -177.14 0.55 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.824 0.345 . . . . 73.21 110.916 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.23 -67.42 0.82 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.163 -0.472 . . . . 72.34 110.915 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.9 t -83.1 -35.62 25.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.447 . . . . 72.03 110.851 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.929 HG22 HG22 ' A' ' 93' ' ' VAL . 5.7 mm -64.62 -33.65 64.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.122 -0.49 . . . . 72.21 111.131 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.7 t -61.85 -47.95 82.72 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.206 -0.452 . . . . 65.24 110.861 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.9 t -53.23 -39.87 64.12 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.153 -0.476 . . . . 43.2 110.844 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -59.83 -42.48 93.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.119 -0.491 . . . . 61.34 110.927 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 104.93 -13.48 49.48 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.704 -0.76 . . . . 64.31 112.506 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 7.2 ptp180 -120.16 96.9 5.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.856 0.36 . . . . 62.11 110.873 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.929 HG22 HG22 ' A' ' 87' ' ' ILE . 98.6 t -113.55 -55.41 4.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.234 -0.439 . . . . 73.02 111.175 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 5.8 m -140.51 143.39 35.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 40.42 110.841 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -146.7 126.17 13.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.49 . . . . 72.22 110.862 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.452 HG22 ' N ' ' A' ' 97' ' ' ASP . 14.2 p -166.1 156.72 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 64.13 111.155 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.452 ' N ' HG22 ' A' ' 96' ' ' VAL . 6.0 p-10 -72.94 172.97 9.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 75.55 110.835 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 3.5 m-85 -115.74 125.39 52.72 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.106 -0.497 . . . . 70.52 110.889 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -119.46 67.04 0.39 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.664 -0.779 . . . . 64.42 112.464 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 112.01 2.96 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.694 2.263 . . . . 62.2 112.33 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.455 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -122.66 95.94 4.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.215 -0.448 . . . . 35.23 111.092 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.669 HG23 ' CA ' ' A' ' 124' ' ' GLY . 5.8 mm -121.7 149.98 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 75.01 111.109 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.756 HD22 ' CZ ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -150.42 111.1 4.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 70.34 110.913 179.936 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.4 p -142.87 167.87 21.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.223 -0.444 . . . . 55.0 110.883 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.425 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -113.58 149.52 34.37 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.144 -0.48 . . . . 74.53 110.92 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -101.9 149.19 24.46 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 70.11 110.922 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -155.5 149.24 25.29 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.177 -0.465 . . . . 74.52 110.958 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 14.6 t-160 . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 73.1 110.891 179.888 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.23 0.058 0 CA-C-O 121.681 0.753 . . . . 74.01 110.905 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . 0.559 ' HA ' HD13 ' A' ' 153' ' ' LEU . 55.0 Cg_endo -69.67 177.35 5.61 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.695 2.263 . . . . 64.32 112.4 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -110.47 162.84 14.29 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.258 -0.428 . . . . 73.11 110.889 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 92.0 t -128.74 143.81 40.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.065 -0.516 . . . . 41.15 111.14 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -134.96 -175.02 13.65 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.779 -0.724 . . . . 62.03 112.464 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.2 p -169.25 156.1 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.877 0.37 . . . . 74.42 111.129 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 177.78 -152.1 11.48 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.69 -0.767 . . . . 54.5 112.474 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.5 HG23 ' HG ' ' A' ' 103' ' ' LEU . 34.2 m -107.85 130.35 60.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.897 0.38 . . . . 63.1 111.137 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . 0.669 ' CA ' HG23 ' A' ' 102' ' ' ILE . . . -125.5 113.31 1.87 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.74 -0.743 . . . . 64.22 112.495 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . 0.455 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 14.2 ptt180 -114.58 124.4 51.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.846 0.355 . . . . 74.0 110.925 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.417 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 51.5 t -106.09 110.19 30.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 52.42 111.116 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.477 HD23 ' HB2' ' A' ' 143' ' ' ASP . 6.2 mt -126.5 174.5 8.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 54.23 110.83 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.517 ' CE2' HG23 ' A' ' 141' ' ' ILE . 0.1 OUTLIER -159.02 173.17 16.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.149 -0.478 . . . . 64.5 110.877 179.921 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.437 ' O ' HG23 ' A' ' 96' ' ' VAL . 5.9 t80 -101.78 119.11 38.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 74.13 110.924 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -46.41 106.18 0.08 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.131 -0.486 . . . . 74.53 110.914 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 31.7 mmtm -105.21 -79.95 0.55 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 63.11 110.882 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.5 m -160.45 85.02 0.71 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.215 -0.448 . . . . 54.55 111.149 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -102.72 166.94 10.21 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.239 -0.437 . . . . 64.32 110.864 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 135' ' ' ALA . . . 83.23 145.49 6.13 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.772 -0.727 . . . . 74.23 112.578 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.507 ' HB2' HG13 ' A' ' 87' ' ' ILE . . . -36.5 -65.32 0.28 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.747 0.308 . . . . 63.5 111.081 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.439 HD23 ' HB1' ' A' ' 135' ' ' ALA . 0.4 OUTLIER -167.38 93.18 0.42 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.24 -0.437 . . . . 64.32 110.911 -179.952 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . 0.539 ' O ' ' C ' ' A' ' 138' ' ' SER . 1.5 p 167.83 59.82 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.225 -0.443 . . . . 62.21 110.844 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.539 ' C ' ' O ' ' A' ' 137' ' ' SER . 54.1 m 25.97 74.45 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.47 . . . . 53.45 110.884 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -106.04 143.23 34.46 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.099 -0.5 . . . . 74.42 110.894 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -111.62 173.76 6.19 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.157 -0.474 . . . . 64.11 110.794 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.517 HG23 ' CE2' ' A' ' 128' ' ' PHE . 6.8 tt -128.02 126.47 66.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.133 -0.485 . . . . 43.12 111.132 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . 0.411 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 1.3 mtmt -74.58 106.11 6.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 72.35 110.885 179.836 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.477 ' HB2' HD23 ' A' ' 127' ' ' LEU . 0.9 OUTLIER -57.4 -176.11 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.175 -0.466 . . . . 64.43 110.856 179.854 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . 0.554 ' CE ' HG22 ' A' ' 174' ' ' THR . 0.0 OUTLIER -139.92 161.55 37.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 63.34 110.955 179.952 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 43.7 p-90 -155.37 135.73 13.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.279 -0.419 . . . . 64.32 110.915 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.735 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 179.94 165.54 0.82 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.568 0.699 . . . . 60.31 111.112 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' PRO . . . . . 0.735 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 52.7 Cg_endo -69.8 142.33 47.48 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.689 2.26 . . . . 74.22 112.266 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.563 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -133.73 167.52 20.38 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 62.21 111.126 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 58.8 m-85 -117.76 156.61 28.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.257 -0.429 . . . . 73.32 110.863 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -128.06 149.05 50.56 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.161 -0.472 . . . . 70.52 110.925 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 84.7 t -151.14 123.32 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 71.33 111.125 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . 0.441 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 179.53 -159.04 23.37 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.756 -0.735 . . . . 70.32 112.486 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.559 HD13 ' HA ' ' A' ' 117' ' ' PRO . 20.3 tp -150.78 161.0 43.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.83 0.348 . . . . 52.13 110.939 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.4 tpp85 -117.64 118.71 32.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 60.1 110.887 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -103.91 142.85 33.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 74.55 110.905 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -121.74 97.51 5.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.153 -0.476 . . . . 75.5 110.835 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 6.1 tp -73.24 158.69 34.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 71.04 110.911 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -52.53 -46.24 58.77 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.695 -0.764 . . . . 70.44 112.498 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -58.1 166.51 1.55 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.824 0.345 . . . . 71.34 110.895 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 5.9 m -57.51 -36.73 71.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.141 -0.481 . . . . 61.41 110.871 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 87.5 m95 -79.4 134.7 36.57 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.13 -0.486 . . . . 74.52 110.9 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' MET . . . . . 0.491 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 32.8 mtt -108.93 176.79 4.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.44 . . . . 75.23 110.82 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.416 HD13 ' O ' ' A' ' 199' ' ' GLY . 3.2 mm? -115.92 148.77 39.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 63.23 110.914 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -146.89 133.25 19.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.469 . . . . 74.25 110.929 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 66.0 p -139.98 122.23 15.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 75.01 110.89 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' ASP . . . . . 0.441 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.7 OUTLIER -147.34 155.33 41.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.178 -0.464 . . . . 75.25 110.896 179.921 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.691 HG22 HD23 ' A' ' 196' ' ' LEU . 14.6 t -133.18 134.57 57.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 73.14 111.103 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 7.1 tmm_? -107.5 132.16 53.53 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.129 -0.487 . . . . 74.53 110.9 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 38.0 t80 -132.83 139.52 47.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.461 . . . . 72.32 110.852 -179.802 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' ILE . . . . . 0.563 HG21 ' HB2' ' A' ' 148' ' ' ALA . 1.3 tp -178.1 102.23 0.21 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.622 0.725 . . . . 72.44 111.106 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 128.26 15.75 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.658 2.239 . . . . 72.25 112.419 179.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . 0.41 ' CE2' ' HB2' ' A' ' 146' ' ' ALA . 1.5 t80 -153.17 178.09 10.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 73.32 110.831 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.45 135.45 50.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.15 -0.477 . . . . 63.13 110.886 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 174' ' ' THR . . . . . 0.554 HG22 ' CE ' ' A' ' 144' ' ' LYS . 1.0 OUTLIER -102.62 164.97 11.34 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.224 -0.443 . . . . 74.02 111.186 179.965 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . 0.411 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.3 OUTLIER -127.24 167.28 16.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 64.44 110.832 179.98 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 24.7 t -148.37 139.08 17.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.451 . . . . 71.41 111.165 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.3 t -166.85 155.82 10.52 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 73.24 111.138 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -138.87 -162.04 8.98 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.749 -0.739 . . . . 41.43 112.482 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.9 t . . . . . 0 C--N 1.33 -0.255 0 CA-C-O 120.818 0.342 . . . . 74.25 111.168 -179.901 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo . . . . . 0 C--O 1.231 0.146 0 CA-C-O 120.867 0.278 . . . . 55.21 112.338 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 55.1 t -96.12 107.57 19.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 55.44 111.102 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 9.8 p -99.88 105.39 17.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.125 -0.489 . . . . 72.4 110.918 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 11.8 p -104.62 161.94 13.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.486 . . . . 53.5 111.096 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.46 152.09 31.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 61.43 110.91 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 189' ' ' ILE . . . . . 0.522 HD12 ' O ' ' A' ' 31' ' ' GLU . 6.4 tt -152.48 130.35 2.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 74.55 111.089 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -100.7 115.03 29.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.461 . . . . 73.43 110.912 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 191' ' ' VAL . . . . . 0.463 HG12 ' H ' ' A' ' 192' ' ' ASP . 1.8 t -137.94 166.61 23.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 65.54 111.086 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.463 ' H ' HG12 ' A' ' 191' ' ' VAL . 1.0 OUTLIER -107.03 90.15 5.13 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.572 0.701 . . . . 63.25 110.836 -179.998 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 117.52 5.13 Favored 'Trans proline' 0 C--O 1.233 0.225 0 C-N-CA 122.617 2.211 . . . . 75.21 112.375 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -100.66 121.82 42.28 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.275 -0.421 . . . . 71.34 110.882 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 195' ' ' ILE . . . . . 0.629 HD12 HG12 ' A' ' 26' ' ' VAL . 13.6 mm -112.33 107.26 22.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.469 . . . . 51.12 111.108 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . 0.691 HD23 HG22 ' A' ' 167' ' ' VAL . 2.3 mt -100.4 108.02 19.92 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.108 -0.497 . . . . 72.13 110.938 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.4 m -100.03 127.53 46.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.44 . . . . 70.1 110.882 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 43.9 tp -146.7 132.23 18.73 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.117 -0.492 . . . . 65.24 110.901 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 199' ' ' GLY . . . . . 0.416 ' O ' HD13 ' A' ' 163' ' ' LEU . . . 177.26 -141.64 5.41 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.773 -0.727 . . . . 23.4 112.506 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 200' ' ' ALA . . . . . 0.491 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -124.49 172.57 9.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.721 0.296 . . . . 55.14 111.179 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 37.1 t -149.56 170.48 18.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.301 -0.409 . . . . 72.52 110.893 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 202' ' ' TYR . . . . . 0.449 ' O ' HG13 ' A' ' 18' ' ' VAL . 22.9 t80 -146.5 131.62 18.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.11 -0.495 . . . . 73.24 110.941 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.46 ' HA ' HG22 ' A' ' 18' ' ' VAL . 34.4 m -88.62 160.77 2.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 74.12 111.09 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -169.35 148.96 3.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 70.33 110.885 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.351 0 CA-C-N 116.145 -0.48 . . . . 74.41 110.878 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.7 pt20 . . . . . 0 N--CA 1.458 -0.054 0 CA-C-O 120.906 0.384 . . . . 70.11 110.865 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.83 5.35 29.3 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.678 -0.772 . . . . 53.44 112.493 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.1 145.58 52.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.835 0.35 . . . . 74.3 110.885 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 27.9 m0 -105.66 137.51 43.39 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.183 -0.462 . . . . 74.43 110.934 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.503 HG11 HH12 ' A' ' 154' ' ' ARG . 10.2 t -144.86 112.53 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.188 -0.46 . . . . 52.25 111.066 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.45 106.0 14.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.178 -0.465 . . . . 63.11 111.074 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.2 t -95.89 111.94 23.8 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.463 . . . . 71.52 110.886 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.573 ' HE1' HD13 ' A' ' 55' ' ' LEU . 39.0 t80 -113.14 116.87 30.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 74.24 110.857 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -154.22 168.42 26.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 74.42 110.856 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 20.0 p90 -101.25 133.75 45.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 74.53 110.864 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.5 p -109.29 114.09 27.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.107 -0.497 . . . . 71.53 110.825 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 21.3 mmmt -98.37 106.59 18.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.108 -0.496 . . . . 74.22 110.868 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.572 HG23 HG12 ' A' ' 195' ' ' ILE . 12.2 p -85.07 143.12 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 54.5 111.135 179.844 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 13.3 m-85 -122.82 116.06 23.04 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.227 -0.442 . . . . 75.31 110.937 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.1 m -148.61 -170.61 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.134 -0.485 . . . . 73.21 111.077 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.66 66.16 0.84 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.712 -0.756 . . . . 75.31 112.495 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.465 ' HB2' HG13 ' A' ' 191' ' ' VAL . 7.0 tp10 -90.51 -68.19 0.8 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.86 0.362 . . . . 74.35 110.942 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 179.05 121.21 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.125 -0.489 . . . . 73.32 110.897 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.626 HD12 HG22 ' A' ' 47' ' ' VAL . 3.4 mt -83.12 153.05 25.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 63.22 110.953 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 C-N-CA 120.772 -0.728 . . . . 41.14 112.522 179.92 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.4 ' HB1' ' HA ' ' A' ' 84' ' ' GLU . . . . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.753 0.311 . . . . 43.01 111.118 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -144.9 127.56 16.17 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.245 -0.434 . . . . 72.24 110.874 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.626 HG22 HD12 ' A' ' 32' ' ' LEU . 22.0 t -105.18 138.85 28.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.166 -0.47 . . . . 63.53 111.151 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.0 m -160.34 151.74 19.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 65.4 110.862 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 16.2 tt -138.11 140.09 41.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.199 -0.455 . . . . 75.14 111.178 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -60.37 -170.04 0.51 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.756 -0.735 . . . . 60.4 112.523 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 -66.46 -58.02 6.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.778 0.323 . . . . 53.2 110.899 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 41.69 40.67 1.5 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 74.12 110.848 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.0 t -68.68 141.3 55.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.177 -0.465 . . . . 62.03 111.168 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.4 t -156.09 174.72 14.96 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.249 -0.432 . . . . 71.01 111.152 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.573 HD13 ' HE1' ' A' ' 21' ' ' PHE . 4.6 pp -90.06 159.18 16.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.208 -0.451 . . . . 75.14 110.908 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -131.16 137.13 48.87 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 74.54 111.092 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -104.24 131.96 51.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 74.01 110.879 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -135.59 139.28 43.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.139 -0.482 . . . . 74.31 110.865 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.84 114.04 45.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.249 -0.432 . . . . 72.22 111.13 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.64 ' HB2' ' OD2' ' A' ' 70' ' ' ASP . . . -106.04 127.9 53.49 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.205 -0.452 . . . . 45.43 111.1 179.835 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -113.74 125.27 53.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.45 . . . . 73.32 110.963 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -88.66 103.01 15.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.143 -0.481 . . . . 75.33 110.859 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 35.3 m -95.66 -34.4 5.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 74.53 111.136 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -134.25 161.79 33.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.08 -0.509 . . . . 43.02 110.884 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 80.2 p -84.33 3.07 37.4 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 61.34 110.864 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -115.69 -32.47 5.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.468 . . . . 72.45 110.842 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 17.8 pt -142.24 168.69 14.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 75.41 111.153 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -156.78 172.79 18.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.171 -0.468 . . . . 73.31 111.108 179.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.456 HG12 ' HB3' ' A' ' 105' ' ' LEU . 12.0 m -119.04 151.71 21.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 73.32 111.111 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.64 ' OD2' ' HB2' ' A' ' 60' ' ' ALA . 10.5 t70 -148.28 144.61 27.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 74.22 110.893 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -127.46 113.68 16.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.202 -0.454 . . . . 72.2 110.91 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -85.74 130.46 34.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.152 -0.476 . . . . 70.15 110.913 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 16.7 t -146.06 154.44 12.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.141 -0.481 . . . . 60.4 111.071 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -156.79 148.25 17.81 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.723 -0.751 . . . . 71.32 112.47 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.3 m -119.77 64.47 8.9 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.573 0.702 . . . . 74.03 111.111 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.72 164.05 35.94 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.663 2.242 . . . . 72.2 112.318 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -90.83 -167.98 1.96 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.18 -0.464 . . . . 51.24 111.134 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 17.1 ttm105 -77.38 136.48 38.43 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.236 -0.438 . . . . 62.15 110.882 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -133.61 151.09 51.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 62.01 111.128 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 39.9 ttmt -116.19 131.25 57.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.228 -0.442 . . . . 71.3 110.838 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -131.26 159.05 38.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 64.21 110.869 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.443 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 15.7 pt20 -94.06 157.27 16.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.116 -0.493 . . . . 74.34 110.92 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.576 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -176.05 68.4 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.755 -0.736 . . . . 51.22 112.521 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.4 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.5 tp10 -175.04 -176.83 1.0 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.912 0.387 . . . . 73.31 110.878 -179.83 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.7 -69.27 0.67 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.481 . . . . 74.34 110.924 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.9 m -83.67 -34.55 24.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 61.43 110.896 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.931 HG21 ' HB2' ' A' ' 135' ' ' ALA . 6.0 mm -63.73 -33.95 64.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.491 . . . . 73.13 111.131 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 58.2 p -62.32 -44.85 95.55 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.164 -0.471 . . . . 71.41 110.871 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.1 t -57.63 -35.18 70.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.134 -0.484 . . . . 63.1 110.872 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.668 HD12 ' HA ' ' A' ' 87' ' ' ILE . 24.6 mt -65.28 -50.25 66.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.172 -0.467 . . . . 65.43 110.947 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 116.04 -14.35 16.49 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.747 -0.74 . . . . 50.3 112.517 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 23.8 ptt180 -117.72 94.22 4.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.81 0.338 . . . . 74.11 110.861 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.898 HG22 HG22 ' A' ' 87' ' ' ILE . 64.5 t -114.5 -56.96 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 63.41 111.128 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 69.3 m -138.01 142.62 40.41 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 71.44 110.879 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -146.42 116.47 7.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.134 -0.484 . . . . 71.31 110.901 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 28.8 m -155.78 175.2 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 62.43 111.18 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -83.36 173.77 11.27 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.186 -0.461 . . . . 72.33 110.872 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -120.05 132.87 55.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 70.13 110.849 -179.765 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -132.08 62.06 0.65 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.694 -0.765 . . . . 31.15 112.472 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 113.05 3.24 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.673 2.249 . . . . 64.0 112.394 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.724 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -125.7 108.19 11.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 73.34 111.059 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 3.5 mp -129.17 147.92 33.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.28 -0.418 . . . . 73.14 111.104 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.412 ' HG ' HG13 ' A' ' 123' ' ' VAL . 0.2 OUTLIER -151.97 114.74 4.62 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.155 -0.475 . . . . 75.25 110.939 179.905 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 13.0 p -144.79 166.17 25.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 73.42 110.878 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.456 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -111.02 150.47 29.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.144 -0.48 . . . . 75.43 110.956 179.964 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 18.1 mt-30 -101.61 133.55 46.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.464 . . . . 72.22 110.905 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -122.82 119.37 30.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.164 -0.471 . . . . 54.21 110.839 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 2.4 t60 . . . . . 0 C--N 1.33 -0.254 0 CA-C-N 116.092 -0.504 . . . . 54.52 110.838 179.898 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 27.4 t80 . . . . . 0 C--O 1.232 0.147 0 CA-C-O 121.669 0.747 . . . . 74.5 110.924 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 177.57 5.46 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.64 2.226 . . . . 64.13 112.37 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 9.7 m-85 -117.99 147.5 43.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 75.23 110.874 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 23.5 t -104.2 124.2 58.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.088 -0.505 . . . . 60.12 111.109 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -120.04 161.79 14.32 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.795 -0.717 . . . . 42.44 112.534 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.8 p -159.93 147.34 6.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.923 0.392 . . . . 65.23 111.091 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -175.54 -155.9 13.66 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.748 -0.739 . . . . 70.32 112.475 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.471 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.2 p -107.28 133.49 51.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.864 0.364 . . . . 51.11 111.085 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -119.74 110.8 1.89 Allowed Glycine 0 N--CA 1.453 -0.227 0 C-N-CA 120.646 -0.788 . . . . 65.22 112.493 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . 0.724 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 11.8 ptm180 -111.78 122.22 47.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.903 0.382 . . . . 70.41 110.912 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.566 HG13 ' HD2' ' A' ' 144' ' ' LYS . 1.4 p -108.12 110.24 31.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.465 . . . . 75.41 111.179 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.41 HD12 ' HB3' ' A' ' 143' ' ' ASP . 17.7 tp -116.84 167.19 11.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.116 -0.493 . . . . 71.22 110.931 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -150.94 178.93 8.68 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 73.42 110.885 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -107.36 144.82 33.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.143 -0.48 . . . . 74.02 110.868 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -81.78 95.41 7.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.458 . . . . 51.24 110.885 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 16.5 tppt? -110.37 -75.9 0.61 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.155 -0.475 . . . . 54.41 110.976 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . 0.484 HG23 ' HA ' ' A' ' 138' ' ' SER . 88.0 m -160.85 89.64 0.81 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.236 -0.438 . . . . 61.02 111.127 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . 0.612 ' OD1' HD12 ' A' ' 141' ' ' ILE . 15.8 t70 -102.86 162.72 12.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 75.12 110.863 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 67.4 156.93 0.68 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.774 -0.726 . . . . 71.51 112.473 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.931 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -77.54 1.43 19.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.881 0.372 . . . . 62.21 111.12 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -85.89 -178.16 6.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 64.2 110.922 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 16.6 t -67.71 85.72 0.21 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.131 -0.486 . . . . 72.31 110.914 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.484 ' HA ' HG23 ' A' ' 132' ' ' THR . 3.6 m 50.84 74.84 0.21 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 74.02 110.887 -179.791 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -84.52 156.08 21.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.118 -0.492 . . . . 64.42 110.914 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -102.7 173.47 6.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.167 -0.469 . . . . 72.41 110.873 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.791 HG13 HG23 ' A' ' 176' ' ' VAL . 0.6 OUTLIER -153.94 144.11 14.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.258 -0.428 . . . . 62.11 111.126 -179.974 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . 0.439 ' HB2' ' HB3' ' A' ' 175' ' ' ASP . 19.8 tptt -91.03 118.02 30.05 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 73.41 110.905 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.41 ' HB3' HD12 ' A' ' 127' ' ' LEU . 0.8 OUTLIER -58.25 -168.74 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.26 -0.427 . . . . 64.03 110.887 179.823 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . 0.566 ' HD2' HG13 ' A' ' 126' ' ' VAL . 0.0 OUTLIER -137.59 154.59 49.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 74.32 110.822 -179.976 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 5.1 t90 -157.32 129.0 6.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 71.1 110.912 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.83 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -173.59 168.96 2.22 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.626 0.727 . . . . 55.43 111.107 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' PRO . . . . . 0.83 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.7 Cg_endo -69.84 132.86 24.08 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.634 2.223 . . . . 31.22 112.346 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -120.29 166.27 13.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 64.43 111.115 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -123.58 137.11 54.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.29 -0.414 . . . . 73.32 110.891 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -114.35 145.55 41.66 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.111 -0.495 . . . . 74.02 110.891 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 58.5 t -143.42 120.49 5.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 62.44 111.086 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . 0.425 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 175.77 -171.98 45.01 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.713 -0.756 . . . . 73.35 112.481 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.5 pt? -131.17 161.19 32.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.847 0.356 . . . . 75.43 110.901 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.503 HH12 HG11 ' A' ' 18' ' ' VAL . 2.7 tpp85 -129.71 120.01 24.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 61.41 110.941 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 5.6 t80 -103.77 136.05 44.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.217 -0.447 . . . . 73.13 110.95 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -121.43 105.41 10.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.1 -0.5 . . . . 75.24 110.786 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 7.8 mt -94.74 162.88 13.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 55.34 110.926 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -97.94 36.55 3.9 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.783 -0.723 . . . . 63.54 112.534 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 95.8 m-20 -123.91 35.99 4.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.832 0.349 . . . . 62.44 110.888 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 18.0 p 50.95 38.81 21.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 72.22 110.892 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 8.4 t-105 -165.05 107.13 0.82 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.158 -0.473 . . . . 61.24 110.909 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' MET . . . . . 0.645 ' SD ' HG13 ' A' ' 203' ' ' VAL . 0.0 OUTLIER -99.1 170.54 8.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.205 -0.452 . . . . 53.12 110.885 179.89 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.573 HD22 ' O ' ' A' ' 162' ' ' MET . 4.5 mm? -129.13 145.21 51.35 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.21 -0.45 . . . . 64.24 110.849 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -144.27 133.42 22.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.131 -0.486 . . . . 51.4 110.865 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 50.7 p -145.89 120.7 9.91 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.188 -0.46 . . . . 64.23 110.891 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' ASP . . . . . 0.425 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.6 OUTLIER -153.3 175.85 12.63 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.089 -0.505 . . . . 75.34 110.897 180.0 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.521 HG22 HD13 ' A' ' 196' ' ' LEU . 21.7 t -138.12 133.34 43.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.457 . . . . 54.41 111.105 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . 0.563 HH21 HG21 ' A' ' 170' ' ' ILE . 2.1 ttt180 -109.16 125.01 51.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.095 -0.502 . . . . 65.24 110.865 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 13.7 p90 -128.99 146.79 50.88 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.172 -0.467 . . . . 72.44 110.929 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' ILE . . . . . 0.587 HD11 ' HB3' ' A' ' 146' ' ' ALA . 5.5 tt -176.8 97.77 0.24 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.557 0.694 . . . . 70.12 111.155 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 170' ' ' ILE . 53.5 Cg_endo -69.82 128.74 16.4 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.691 2.261 . . . . 74.31 112.3 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 11.6 p90 -155.08 178.96 9.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.245 -0.434 . . . . 72.02 110.863 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 13.3 pttp -130.32 140.98 50.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 64.21 110.871 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 174' ' ' THR . . . . . 0.416 HG22 HG23 ' A' ' 189' ' ' ILE . 9.0 t -104.27 167.81 9.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 75.43 111.189 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . 0.439 ' HB3' ' HB2' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -119.38 159.72 23.66 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.27 -0.423 . . . . 64.32 110.849 179.908 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.791 HG23 HG13 ' A' ' 141' ' ' ILE . 13.7 p -144.76 135.74 20.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.122 -0.49 . . . . 62.11 111.088 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.8 t -166.36 159.44 14.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 74.03 111.156 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -146.13 -134.15 2.6 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.773 -0.727 . . . . 55.12 112.491 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 98.7 m . . . . . 0 C--N 1.33 -0.257 0 CA-C-O 120.835 0.35 . . . . 52.04 111.169 -179.888 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo . . . . . 0 C--O 1.231 0.162 0 CA-C-O 120.777 0.24 . . . . 53.35 112.392 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 23.8 t -95.45 106.37 18.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 75.21 111.161 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 83.2 p -110.16 120.22 41.74 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.177 -0.465 . . . . 63.44 110.894 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -140.54 176.37 8.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.125 -0.489 . . . . 72.1 111.082 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.39 162.48 40.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 74.12 110.918 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 189' ' ' ILE . . . . . 0.566 HD12 ' HA ' ' A' ' 32' ' ' LEU . 4.6 tt -146.04 120.91 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.256 -0.429 . . . . 74.02 111.121 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -96.67 118.16 32.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.157 -0.474 . . . . 65.43 110.871 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 191' ' ' VAL . . . . . 0.465 HG13 ' HB2' ' A' ' 30' ' ' GLU . 4.4 t -137.52 159.68 34.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 74.01 111.167 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.423 ' N ' HG12 ' A' ' 191' ' ' VAL . 0.4 OUTLIER -107.27 90.42 5.68 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.558 0.694 . . . . 74.41 110.869 179.918 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 138.09 37.05 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.61 2.207 . . . . 61.51 112.368 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 23.4 m-85 -121.96 109.67 14.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.179 -0.464 . . . . 50.22 110.925 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 195' ' ' ILE . . . . . 0.572 HG12 HG23 ' A' ' 26' ' ' VAL . 8.8 mt -105.25 135.03 45.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 53.55 111.171 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . 0.521 HD13 HG22 ' A' ' 167' ' ' VAL . 10.3 tp -120.57 115.43 23.4 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.093 -0.503 . . . . 54.43 110.957 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -99.26 129.25 45.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 61.44 110.907 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 32.8 tp -150.25 129.35 12.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.149 -0.478 . . . . 71.21 110.91 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 177.38 -146.67 7.83 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.801 -0.714 . . . . 62.32 112.536 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 200' ' ' ALA . . . . . 0.401 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -124.0 173.23 8.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.757 0.313 . . . . 65.12 111.101 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -138.35 164.78 28.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.452 . . . . 73.03 110.899 -179.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 34.1 m-85 -133.82 129.95 37.23 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.205 -0.452 . . . . 74.24 110.93 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.645 HG13 ' SD ' ' A' ' 162' ' ' MET . 28.0 m -77.36 148.28 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 73.44 111.207 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -152.34 105.96 3.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.278 -0.419 . . . . 75.15 110.886 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 14.2 ptmt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.15 -0.477 . . . . 64.55 110.939 179.962 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.821 0.344 . . . . 75.42 110.953 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.73 6.48 76.5 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.758 -0.734 . . . . 52.43 112.487 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -76.89 144.9 38.63 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.837 0.351 . . . . 73.42 110.838 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 13.5 t90 -106.44 150.93 25.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 71.2 110.919 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.581 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 22.1 t -145.59 125.82 6.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.242 -0.435 . . . . 74.2 111.131 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -109.76 112.4 24.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 55.43 111.075 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 201' ' ' SER . 60.2 p -124.42 146.57 48.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 73.22 110.837 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 15.1 p90 -127.19 122.52 34.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.111 -0.495 . . . . 72.11 110.827 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -146.89 158.28 43.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 75.41 110.869 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.803 ' HB3' HD23 ' A' ' 55' ' ' LEU . 29.4 p90 -93.69 133.57 36.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.143 -0.481 . . . . 72.23 110.886 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -98.89 114.57 27.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.47 . . . . 61.52 110.843 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.1 tppt? -92.68 108.24 19.83 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.041 -0.527 . . . . 70.22 110.874 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.455 HG23 ' CD1' ' A' ' 195' ' ' ILE . 14.2 p -87.01 140.69 15.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.236 -0.438 . . . . 72.41 111.057 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 41.3 m-85 -134.36 112.85 11.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.111 -0.495 . . . . 73.2 110.959 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 m -72.65 -176.9 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.092 -0.504 . . . . 74.43 111.182 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -93.84 -125.16 4.06 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.748 -0.739 . . . . 54.43 112.465 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -92.37 -66.39 0.93 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.771 0.32 . . . . 62.43 110.861 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.5 mp0 -150.23 -174.21 4.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.155 -0.475 . . . . 63.32 110.877 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.562 ' HA ' HG23 ' A' ' 189' ' ' ILE . 3.4 pp -86.32 -173.33 4.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 63.5 110.909 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 C-N-CA 120.722 -0.751 . . . . 61.1 112.491 179.895 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.408 ' HB1' HD21 ' A' ' 32' ' ' LEU . . . . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.817 0.341 . . . . 65.13 111.139 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -166.33 125.75 1.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 75.43 110.897 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 98.7 t -105.65 131.51 54.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 73.22 111.069 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.5 m -159.4 151.36 20.7 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.138 -0.483 . . . . 75.55 110.803 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 20.0 pt -100.71 157.61 4.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.082 -0.508 . . . . 74.14 111.119 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -72.02 -146.78 0.59 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.737 -0.744 . . . . 72.54 112.508 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -126.1 111.16 14.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.881 0.372 . . . . 73.32 110.88 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -164.01 159.06 20.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.13 -0.487 . . . . 65.24 110.862 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 16.4 p -125.88 123.99 39.88 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 71.43 111.154 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.0 p -137.4 139.33 40.65 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.176 -0.465 . . . . 60.54 111.076 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.803 HD23 ' HB3' ' A' ' 23' ' ' PHE . 2.5 mt -99.11 153.95 18.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.454 . . . . 72.11 110.921 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.1 p -123.26 161.38 24.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.289 -0.414 . . . . 73.24 111.172 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -105.56 133.36 50.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 73.12 110.861 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -124.04 130.06 51.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 54.34 110.867 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.4 ' O ' HG22 ' A' ' 59' ' ' ILE . 1.6 mp -107.24 114.0 45.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.478 . . . . 72.43 111.101 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.581 ' HB3' ' HB ' ' A' ' 18' ' ' VAL . . . -104.13 137.88 41.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.454 . . . . 72.22 111.128 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.427 ' HB2' HG13 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -123.28 121.98 37.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.279 -0.418 . . . . 73.42 110.893 -179.835 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -89.01 102.26 14.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.111 -0.495 . . . . 65.44 110.892 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.1 m -100.84 -33.4 3.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.105 -0.498 . . . . 72.31 111.125 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.9 t -136.23 158.6 44.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.189 -0.46 . . . . 64.01 110.838 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 47.0 t -83.56 3.21 33.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.102 -0.499 . . . . 75.23 110.848 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 47.6 t30 -115.69 -30.6 6.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 63.32 110.885 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.593 HG22 ' HB2' ' A' ' 107' ' ' TYR . 43.5 pt -138.23 157.48 31.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.132 -0.486 . . . . 75.25 111.127 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -145.33 157.65 44.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.154 -0.475 . . . . 71.13 111.046 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.497 ' CG2' HD21 ' A' ' 103' ' ' LEU . 1.4 p -106.96 145.93 13.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.15 -0.477 . . . . 64.2 111.145 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -140.54 128.01 21.36 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.209 -0.45 . . . . 73.45 110.897 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -108.65 110.43 21.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.259 -0.428 . . . . 74.32 110.919 -179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -87.95 115.42 25.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 74.24 110.907 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 8.9 m -139.59 156.76 26.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 72.24 111.109 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -164.55 142.37 7.72 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.75 -0.738 . . . . 73.04 112.501 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.4 t -118.64 66.21 6.91 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.551 0.691 . . . . 55.2 111.145 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 161.89 44.16 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.758 2.305 . . . . 61.02 112.349 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -78.73 -173.21 3.34 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 31.4 111.092 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 18.1 ttp180 -78.27 132.73 37.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 63.1 110.924 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -131.54 150.8 52.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 60.44 111.074 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 7.3 tttt -109.37 134.08 52.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.3 -0.409 . . . . 65.22 110.911 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -134.51 158.66 43.37 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.247 -0.433 . . . . 63.31 110.902 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -91.32 156.18 17.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.112 -0.495 . . . . 75.32 110.857 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.577 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -176.12 65.14 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.803 -0.713 . . . . 75.23 112.513 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -174.29 -174.79 0.91 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.93 0.395 . . . . 63.33 110.882 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -85.5 -70.04 0.62 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.147 -0.478 . . . . 61.12 110.855 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 32.1 t -84.83 -32.18 23.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.26 -0.427 . . . . 63.44 110.808 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.946 HG21 ' HB2' ' A' ' 135' ' ' ALA . 5.4 mm -66.58 -34.04 67.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.157 -0.474 . . . . 71.44 111.181 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 t -63.11 -41.21 99.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.164 -0.471 . . . . 43.03 110.812 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 61.7 m -60.68 -36.98 80.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 74.03 110.862 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.4 mp -64.14 -50.25 68.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.12 -0.491 . . . . 70.15 110.934 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 116.35 -14.25 15.71 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.754 -0.736 . . . . 63.42 112.482 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 58.4 mtm180 -115.06 89.87 3.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.889 0.376 . . . . 73.44 110.809 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.873 HG22 HG22 ' A' ' 87' ' ' ILE . 98.5 t -113.67 -53.25 5.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 70.14 111.137 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 13.3 m -139.28 143.47 37.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 63.42 110.887 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . 0.577 ' O ' HG13 ' A' ' 96' ' ' VAL . 1.7 tt0 -145.19 114.3 6.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.465 . . . . 62.42 110.928 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.577 HG13 ' O ' ' A' ' 95' ' ' GLU . 11.8 m -160.45 -178.17 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 50.22 111.116 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -98.65 149.13 23.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 54.03 110.831 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -93.16 125.66 37.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 75.44 110.957 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -119.42 63.16 0.46 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.749 -0.739 . . . . 62.35 112.501 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.67 122.53 9.24 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.687 2.258 . . . . 64.42 112.392 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.601 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -139.22 97.87 3.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.185 -0.461 . . . . 74.31 111.101 179.838 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 5.3 mp -129.18 117.56 43.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 72.41 111.157 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.662 HD13 ' O ' ' A' ' 103' ' ' LEU . 0.9 OUTLIER -113.71 112.98 24.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.228 -0.442 . . . . 60.32 110.948 179.905 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . 0.583 ' N ' HD22 ' A' ' 103' ' ' LEU . 3.5 p -140.51 165.11 28.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.446 . . . . 73.22 110.822 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.428 ' H ' HD23 ' A' ' 105' ' ' LEU . 1.0 OUTLIER -112.76 142.23 45.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.069 -0.514 . . . . 74.11 110.933 179.963 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 16.0 pt20 -101.4 151.5 21.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.166 -0.47 . . . . 75.32 110.92 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.593 ' HB2' HG22 ' A' ' 67' ' ' ILE . 5.1 t80 -149.69 135.8 18.88 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.249 -0.432 . . . . 75.53 110.962 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 10.6 t60 . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 71.54 110.817 179.986 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.0 m-85 . . . . . 0 C--O 1.23 0.053 0 CA-C-O 121.737 0.78 . . . . 74.11 110.903 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.69 176.86 6.15 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.678 2.252 . . . . 70.25 112.353 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -116.47 150.54 37.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.202 -0.454 . . . . 74.11 110.978 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 13.1 p -104.01 133.94 46.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 73.15 111.093 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -132.09 160.2 23.55 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.749 -0.739 . . . . 51.21 112.504 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 7.5 p -156.57 154.73 5.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.874 0.369 . . . . 63.31 111.157 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 178.76 -147.11 7.65 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.777 -0.725 . . . . 65.0 112.489 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 13.8 p -106.57 131.56 56.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.881 0.372 . . . . 72.12 111.093 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -124.29 111.62 1.64 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.749 -0.738 . . . . 43.44 112.508 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . 0.601 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 29.0 ptt180 -114.51 130.13 56.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.774 0.321 . . . . 72.15 110.895 -179.844 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.461 ' O ' ' HB3' ' A' ' 143' ' ' ASP . 3.1 m -111.37 112.66 41.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.237 -0.438 . . . . 71.04 111.091 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 1.3 tp -114.86 171.59 7.56 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.202 -0.454 . . . . 71.4 110.925 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -140.03 178.88 6.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.174 -0.466 . . . . 65.33 110.841 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -117.72 119.4 34.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.144 -0.48 . . . . 73.4 110.906 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -51.89 102.34 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.14 -0.482 . . . . 73.51 110.846 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.86 -80.84 0.55 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 72.01 110.889 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 45.8 m -164.54 89.78 0.53 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 74.32 111.168 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -107.59 172.61 6.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.231 -0.44 . . . . 75.11 110.886 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.53 152.89 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.706 -0.759 . . . . 74.04 112.501 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.946 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -79.42 -1.97 39.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.809 0.338 . . . . 64.41 111.04 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -87.2 -177.52 6.01 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.245 -0.434 . . . . 62.34 110.929 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.7 m -66.57 98.12 0.48 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 72.25 110.88 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 89.4 p 46.79 75.17 0.13 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.125 -0.489 . . . . 65.22 110.794 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.64 ' CE2' HG12 ' A' ' 176' ' ' VAL . 1.5 t80 -89.02 148.26 23.84 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.086 -0.506 . . . . 72.1 110.867 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.18 159.76 15.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.139 -0.482 . . . . 70.54 110.818 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -126.9 118.26 50.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 73.33 111.155 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . 0.43 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 1.6 mtpp -69.13 110.84 4.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 72.53 110.843 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.461 ' HB3' ' O ' ' A' ' 126' ' ' VAL . 61.2 m-20 -57.66 -173.44 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 73.4 110.888 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.39 162.53 39.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 64.52 110.906 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 31.1 p-90 -156.47 137.96 14.01 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.217 -0.447 . . . . 63.31 110.896 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.803 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -178.44 167.51 1.01 Allowed Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.603 0.716 . . . . 73.11 111.083 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' PRO . . . . . 0.803 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.5 Cg_endo -69.79 138.62 38.15 Favored 'Trans proline' 0 N--CA 1.465 -0.171 0 C-N-CA 122.712 2.275 . . . . 70.22 112.31 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.572 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -132.85 165.16 25.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.181 -0.463 . . . . 74.43 111.117 179.856 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -123.27 126.18 46.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.192 -0.458 . . . . 73.23 110.895 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 28.6 tt0 -110.12 155.3 22.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 72.02 110.889 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.575 HG13 HG23 ' A' ' 167' ' ' VAL . 4.6 p -144.58 125.73 8.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 71.51 111.138 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . 0.436 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . -176.36 -167.68 35.43 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.728 -0.749 . . . . 75.0 112.474 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 2.1 pp -143.87 161.03 39.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.765 0.317 . . . . 75.31 110.923 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 7.6 tpp85 -117.21 119.49 35.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 64.41 110.852 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -100.13 139.42 35.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.146 -0.479 . . . . 71.41 110.885 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -111.85 92.4 4.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 74.23 110.876 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 3.0 tt -86.27 97.02 10.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 63.52 110.953 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 58.77 -138.35 49.49 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.704 -0.76 . . . . 74.54 112.536 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -119.74 -30.35 4.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.878 0.37 . . . . 71.41 110.886 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -48.86 -66.72 0.35 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 73.33 110.878 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 23.7 p90 -145.73 150.92 37.15 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.151 -0.477 . . . . 71.41 110.904 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 2.4 mpt? -108.63 177.57 4.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 44.55 110.858 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 3.8 tp -126.12 149.15 49.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.232 -0.44 . . . . 75.33 110.916 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 13.8 t-20 -143.9 131.51 21.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 72.54 110.858 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.5 p -141.48 124.41 16.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.179 -0.464 . . . . 52.34 110.871 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 166' ' ' ASP . . . . . 0.436 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 2.3 p30 -156.11 169.69 23.92 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.138 -0.483 . . . . 74.2 110.878 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.575 HG23 HG13 ' A' ' 151' ' ' VAL . 0.1 OUTLIER -142.4 134.04 25.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.182 -0.463 . . . . 75.04 111.119 179.972 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.61 142.56 33.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 72.3 110.886 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 4.3 t80 -142.0 137.65 31.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 73.34 110.889 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 170' ' ' ILE . . . . . 0.572 HG21 ' HB2' ' A' ' 148' ' ' ALA . 2.9 tp -177.47 102.25 0.22 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.628 0.728 . . . . 75.54 111.08 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 192' ' ' ASP . 53.9 Cg_endo -69.75 125.27 11.95 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.696 2.264 . . . . 42.55 112.364 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 24.7 p90 -150.93 178.04 9.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 74.22 110.9 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . 0.433 ' HA ' ' HA ' ' A' ' 190' ' ' GLU . 9.7 ptpt -130.85 126.52 36.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 74.2 110.879 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.6 t -93.59 175.26 6.81 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.236 -0.438 . . . . 73.41 111.143 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . 0.43 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.3 OUTLIER -126.81 163.71 22.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.254 -0.43 . . . . 74.21 110.844 179.906 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.64 HG12 ' CE2' ' A' ' 139' ' ' PHE . 32.7 t -148.84 133.28 9.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.223 -0.444 . . . . 74.01 111.143 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.4 t -165.58 177.69 7.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.216 -0.447 . . . . 75.24 111.173 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 121.68 141.52 6.12 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.72 -0.753 . . . . 42.44 112.485 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.4 m . . . . . 0 C--N 1.329 -0.315 0 CA-C-O 120.737 0.303 . . . . 73.51 111.195 -179.893 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.231 0.17 0 CA-C-O 120.822 0.259 . . . . 65.5 112.35 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 39.6 t -113.38 107.68 23.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.276 -0.42 . . . . 74.14 111.145 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -81.33 106.72 13.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.161 -0.472 . . . . 72.34 110.835 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 21.0 p -121.38 174.7 6.58 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.108 -0.496 . . . . 55.43 111.104 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 188' ' ' LYS . . . . . 0.486 ' C ' HD12 ' A' ' 189' ' ' ILE . 0.0 OUTLIER -148.55 164.03 35.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.194 -0.457 . . . . 73.52 110.872 179.925 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 189' ' ' ILE . . . . . 0.562 HG23 ' HA ' ' A' ' 32' ' ' LEU . 5.4 mp -144.03 105.8 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 74.24 111.129 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 190' ' ' GLU . . . . . 0.433 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 61.4 tt0 -91.0 102.08 14.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.449 . . . . 73.11 110.869 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 9.3 m -138.68 164.08 26.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.458 . . . . 61.01 111.156 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 171' ' ' PRO . 6.6 p-10 -110.04 88.65 7.18 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.582 0.706 . . . . 75.3 110.867 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 143.28 50.53 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.704 2.269 . . . . 64.34 112.338 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -119.8 123.69 44.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 62.51 110.882 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 195' ' ' ILE . . . . . 0.455 ' CD1' HG23 ' A' ' 26' ' ' VAL . 18.6 mm -109.03 132.06 58.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.147 -0.479 . . . . 62.31 111.171 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 4.6 tp -120.68 108.25 13.78 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.246 -0.433 . . . . 71.31 110.962 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.41 120.14 35.13 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.239 -0.437 . . . . 60.2 110.919 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -139.4 124.29 18.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.468 . . . . 73.42 110.988 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -176.9 -148.54 7.19 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.737 -0.745 . . . . 45.54 112.494 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -115.82 171.04 8.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.812 0.339 . . . . 40.14 111.108 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 20' ' ' SER . 0.3 OUTLIER -138.49 156.81 47.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.434 . . . . 65.12 110.806 -179.73 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 8.2 t80 -138.07 135.6 35.99 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.132 -0.485 . . . . 75.13 110.958 -179.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 14.9 p -77.36 147.46 7.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.08 -0.509 . . . . 64.02 111.179 179.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -144.57 88.01 1.9 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.16 -0.473 . . . . 73.43 110.872 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 23.1 mtmt . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 70.41 110.902 179.977 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 . . . . . 0 N--CA 1.458 -0.057 0 CA-C-O 120.871 0.367 . . . . 75.33 110.923 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.37 6.22 41.95 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.706 -0.759 . . . . 65.52 112.491 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -61.81 146.12 50.51 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.817 0.341 . . . . 64.43 110.829 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 19.8 t90 -111.47 121.19 44.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.09 -0.504 . . . . 71.3 110.947 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.817 HG22 HG23 ' A' ' 203' ' ' VAL . 57.2 t -123.4 120.17 59.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.242 -0.435 . . . . 64.4 111.121 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.623 ' HB3' ' CD1' ' A' ' 202' ' ' TYR . . . -86.8 112.35 21.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 43.41 111.127 179.849 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.1 t -109.03 110.0 21.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.236 -0.438 . . . . 61.35 110.874 -179.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.404 ' CZ ' HD12 ' A' ' 55' ' ' LEU . 43.5 t80 -107.64 120.01 41.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.477 . . . . 70.41 110.919 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.445 ' HA ' ' HA3' ' A' ' 199' ' ' GLY . 7.4 p30 -149.86 174.87 12.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.442 . . . . 72.55 110.91 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.648 ' HB3' HD13 ' A' ' 55' ' ' LEU . 19.1 p90 -110.83 132.9 53.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 54.13 110.861 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . 0.445 ' HB3' HG21 ' A' ' 56' ' ' THR . 41.9 p -98.18 146.18 25.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 63.21 110.894 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.4 tmtp? -127.25 106.52 9.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 61.43 110.904 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.8 m -77.31 129.7 37.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.245 -0.434 . . . . 64.31 111.128 179.842 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -126.4 107.78 10.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.126 -0.488 . . . . 74.14 110.956 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.8 p -175.71 153.79 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.485 . . . . 73.32 111.079 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.43 71.68 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.778 -0.725 . . . . 70.34 112.54 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -89.14 -65.87 0.98 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.807 0.337 . . . . 72.31 110.895 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -174.99 152.44 1.49 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.106 -0.497 . . . . 71.34 110.855 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.618 HD23 ' N ' ' A' ' 33' ' ' GLY . 0.8 OUTLIER -96.11 162.32 13.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.163 -0.471 . . . . 73.22 110.909 -179.99 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.618 ' N ' HD23 ' A' ' 32' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.309 0 C-N-CA 120.761 -0.733 . . . . 72.34 112.434 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.814 0.34 . . . . 61.04 111.084 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 35.8 m-20 -153.64 127.24 8.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.238 -0.437 . . . . 71.03 110.828 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 10.8 p -104.52 137.52 33.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 70.02 111.171 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.0 t -148.45 154.87 40.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.094 -0.503 . . . . 74.1 110.835 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.471 HD13 ' H ' ' A' ' 49' ' ' ILE . 0.2 OUTLIER -119.62 154.67 22.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.087 -0.506 . . . . 70.43 111.1 179.939 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.39 -124.59 0.56 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.751 -0.738 . . . . 75.21 112.444 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 38.9 m-20 -82.41 -35.61 27.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.87 0.367 . . . . 74.32 110.911 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 41.9 40.03 1.44 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 71.41 110.85 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 1.4 p -108.37 113.09 25.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 65.03 111.158 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.5 t -154.35 173.95 15.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.136 -0.484 . . . . 61.24 111.139 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.648 HD13 ' HB3' ' A' ' 23' ' ' PHE . 4.2 mm? -92.55 169.11 10.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.248 -0.433 . . . . 60.22 110.924 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.445 HG21 ' HB3' ' A' ' 24' ' ' SER . 18.6 p -149.36 141.54 24.02 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.172 -0.467 . . . . 75.12 111.113 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -103.27 132.82 49.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 73.12 110.861 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -130.63 130.12 43.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.159 -0.473 . . . . 43.53 110.84 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.41 ' O ' HG22 ' A' ' 59' ' ' ILE . 1.6 mp -108.08 112.94 42.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.196 -0.456 . . . . 74.31 111.077 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -102.76 121.69 42.97 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.206 -0.452 . . . . 75.53 111.076 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -106.85 122.72 46.97 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 73.12 110.93 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -88.89 107.22 18.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.17 -0.468 . . . . 65.14 110.908 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 63.8 t -103.24 -48.13 10.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.157 -0.474 . . . . 70.41 111.097 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 40.2 t -124.38 165.99 16.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 54.22 110.854 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.1 m -87.43 2.71 49.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.087 -0.506 . . . . 73.31 110.837 -179.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -112.99 -33.68 5.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.084 -0.507 . . . . 74.32 110.936 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.405 HG22 ' CD1' ' A' ' 107' ' ' TYR . 31.4 pt -146.12 160.22 11.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.48 . . . . 62.4 111.081 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -146.57 173.4 12.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 70.34 111.112 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.483 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 14.4 m -115.16 152.13 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.255 -0.429 . . . . 64.32 111.163 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -144.13 144.43 31.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.251 -0.431 . . . . 53.43 110.834 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.445 ' CZ ' HD22 ' A' ' 103' ' ' LEU . 0.5 OUTLIER -120.74 110.14 16.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.157 -0.474 . . . . 73.11 110.914 -179.949 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.405 ' HB3' HG23 ' A' ' 102' ' ' ILE . 2.5 t80 -92.6 117.84 30.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 53.12 110.896 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.4 p -150.26 154.61 8.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.161 -0.472 . . . . 65.05 111.117 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -155.56 150.95 22.52 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.691 -0.766 . . . . 73.43 112.452 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 5.8 m -118.2 67.05 6.45 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.587 0.708 . . . . 63.14 111.11 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.69 159.48 53.28 Favored 'Trans proline' 0 N--CA 1.465 -0.16 0 C-N-CA 122.767 2.312 . . . . 65.43 112.35 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -83.39 -167.96 1.91 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.211 -0.45 . . . . 51.45 111.108 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -77.74 127.52 32.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 71.52 110.852 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -123.87 150.62 44.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.245 -0.434 . . . . 74.2 111.166 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 5.4 ttpm? -104.19 144.85 31.04 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.213 -0.449 . . . . 74.14 110.887 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -142.0 155.0 45.43 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.269 -0.423 . . . . 72.3 110.923 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.427 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 0.2 OUTLIER -107.18 151.57 25.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.12 -0.491 . . . . 73.51 110.943 -179.942 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.637 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -175.86 75.86 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.707 -0.759 . . . . 62.43 112.41 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -178.52 -176.33 0.48 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.94 0.4 . . . . 64.23 110.881 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -85.41 -69.71 0.64 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.192 -0.458 . . . . 74.13 110.88 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 75.3 m -84.58 -34.09 23.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.435 . . . . 41.4 110.886 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.943 HG21 ' HB2' ' A' ' 135' ' ' ALA . 5.2 mm -64.06 -34.75 70.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 72.2 111.146 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 78.8 p -62.61 -49.09 76.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.471 . . . . 64.03 110.818 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 41.6 t -51.72 -36.89 48.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.102 -0.499 . . . . 61.14 110.786 -179.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -68.55 -46.39 69.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 61.24 110.881 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.67 -12.76 38.9 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.751 -0.738 . . . . 44.4 112.529 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 21.1 mmt85 -108.87 88.69 2.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.827 0.346 . . . . 74.12 110.875 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.85 HG22 HG22 ' A' ' 87' ' ' ILE . 99.0 t -113.91 -52.87 5.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 43.22 111.044 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.401 ' HA ' ' HA ' ' A' ' 133' ' ' ASP . 8.5 p -139.85 144.5 37.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 73.32 110.924 -179.828 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -149.7 119.53 7.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 72.12 110.896 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.722 HG23 ' HB2' ' A' ' 131' ' ' LYS . 3.8 p -177.65 163.84 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.163 -0.471 . . . . 72.4 111.154 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -76.29 163.66 26.81 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.218 -0.447 . . . . 73.11 110.881 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 2.6 m-85 -114.21 139.55 49.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.184 -0.462 . . . . 73.53 110.881 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -117.92 65.94 0.36 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.754 -0.736 . . . . 44.24 112.428 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 115.34 4.05 Favored 'Trans proline' 0 C--N 1.341 0.134 0 C-N-CA 122.682 2.255 . . . . 73.43 112.313 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -139.08 119.88 14.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 73.24 111.103 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.406 ' HA ' ' HA2' ' A' ' 124' ' ' GLY . 0.0 OUTLIER -155.2 136.2 5.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 62.45 111.104 179.913 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.445 HD22 ' CZ ' ' A' ' 71' ' ' PHE . 0.3 OUTLIER -119.69 124.2 45.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.103 -0.499 . . . . 72.03 110.924 179.942 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . 0.425 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 72.3 m -143.69 159.38 42.58 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.177 -0.465 . . . . 53.23 110.874 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.535 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.6 OUTLIER -106.85 152.05 24.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.118 -0.492 . . . . 64.33 110.851 -179.912 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 75.7 mt-30 -101.69 140.36 36.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 74.52 110.857 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.405 ' CD1' HG22 ' A' ' 67' ' ' ILE . 0.3 OUTLIER -122.65 110.73 15.89 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.12 -0.491 . . . . 74.34 110.953 -179.814 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.153 -0.476 . . . . 71.43 110.835 179.965 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 . . . . . 0 C--O 1.232 0.176 0 CA-C-O 121.642 0.734 . . . . 71.43 110.981 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 176.96 6.06 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.684 2.256 . . . . 74.03 112.309 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 15.7 p90 -111.08 154.12 24.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.474 . . . . 72.22 110.91 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.3 p -113.75 131.43 65.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 75.14 111.153 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -124.14 168.0 16.36 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.626 -0.797 . . . . 72.31 112.475 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 8.4 p -171.99 153.4 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.886 0.374 . . . . 71.11 111.131 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . 0.425 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -178.26 -152.16 10.04 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.732 -0.747 . . . . 60.21 112.459 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.44 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 12.1 p -107.72 134.57 49.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.786 0.326 . . . . 72.42 111.182 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . 0.406 ' HA2' ' HA ' ' A' ' 102' ' ' ILE . . . -121.87 172.52 15.52 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.709 -0.758 . . . . 72.42 112.553 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 12.3 ptm180 -169.69 130.07 1.02 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.816 0.341 . . . . 65.51 110.904 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 4.0 p -110.18 120.46 61.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.456 . . . . 75.41 111.131 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 5.7 mp -109.42 149.77 29.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 74.13 110.949 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.553 ' HE2' HG21 ' A' ' 174' ' ' THR . 20.9 m-85 -131.97 152.6 51.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 74.24 110.872 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.683 ' O ' HG21 ' A' ' 96' ' ' VAL . 1.0 OUTLIER -102.61 175.09 5.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.087 -0.506 . . . . 64.14 110.851 -179.882 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.6 p-10 -110.66 95.51 5.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.166 -0.47 . . . . 72.32 110.888 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.722 ' HB2' HG23 ' A' ' 96' ' ' VAL . 9.5 tmtt? -119.35 -68.17 0.93 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 63.31 110.941 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 2.7 m -161.68 63.75 0.25 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.246 -0.434 . . . . 73.42 111.189 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . 0.401 ' HA ' ' HA ' ' A' ' 94' ' ' SER . 4.4 m-20 -93.04 163.76 13.53 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.235 -0.439 . . . . 72.4 110.882 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 64.25 150.92 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.699 -0.763 . . . . 73.23 112.448 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.943 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -79.66 2.26 23.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.861 0.362 . . . . 75.05 111.115 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -86.09 -176.64 6.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.441 . . . . 73.03 110.916 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 89.0 p -64.93 88.91 0.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 54.51 110.867 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 7.6 m 49.88 76.17 0.15 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.147 -0.479 . . . . 70.41 110.853 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -93.66 159.27 15.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.1 -0.5 . . . . 71.22 110.913 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -117.64 170.6 8.64 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.193 -0.458 . . . . 71.54 110.879 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.953 HD13 HG13 ' A' ' 176' ' ' VAL . 30.3 mm -116.09 141.61 32.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 64.3 111.113 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . 0.407 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 0.2 OUTLIER -90.7 106.2 18.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.163 -0.471 . . . . 54.5 110.918 179.854 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -57.23 -176.68 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.225 -0.443 . . . . 73.02 110.868 179.854 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 24.0 tptt -163.73 161.12 23.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.141 -0.481 . . . . 71.52 110.858 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 5.8 p90 -132.77 146.69 52.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 73.04 110.911 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.663 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.39 162.77 0.96 Allowed Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.527 0.679 . . . . 64.33 111.167 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' PRO . . . . . 0.663 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.6 Cg_endo -69.72 166.43 27.57 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.651 2.234 . . . . 52.42 112.354 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.419 ' HA ' ' HB ' ' A' ' 170' ' ' ILE . . . -153.19 151.47 30.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.261 -0.427 . . . . 71.4 111.11 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 32.0 m-85 -111.81 125.05 53.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 74.32 110.898 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -107.48 158.28 17.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.104 -0.498 . . . . 74.24 110.938 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 15.0 p -161.25 134.79 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.234 -0.439 . . . . 72.2 111.128 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . 0.448 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 179.5 -159.21 23.67 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.71 -0.757 . . . . 51.23 112.506 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.86 148.81 39.39 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.872 0.368 . . . . 72.22 110.85 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 3.8 tpp85 -126.97 122.15 33.71 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.142 -0.481 . . . . 73.03 110.868 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . 0.421 ' HB3' HD21 ' A' ' 163' ' ' LEU . 0.8 OUTLIER -125.97 164.27 21.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 65.43 111.014 -179.916 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -122.61 108.74 13.46 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 71.4 110.919 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' LEU . . . . . 0.489 HD23 ' N ' ' A' ' 158' ' ' GLY . 0.4 OUTLIER -50.51 158.79 0.57 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 53.01 110.93 -179.945 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . 0.489 ' N ' HD23 ' A' ' 157' ' ' LEU . . . -50.6 -32.15 23.68 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.775 -0.726 . . . . 44.25 112.482 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -80.76 -168.64 1.84 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.836 0.351 . . . . 74.31 110.901 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 46.9 t -71.04 -35.3 71.91 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.47 . . . . 72.23 110.846 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 3.1 m0 -71.47 153.93 41.87 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.172 -0.467 . . . . 74.5 110.954 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' MET . . . . . 0.41 ' C ' HD13 ' A' ' 163' ' ' LEU . 2.3 mpt? -131.9 173.98 10.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 63.34 110.819 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.702 ' N ' HD13 ' A' ' 163' ' ' LEU . 0.0 OUTLIER -140.84 160.59 39.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 71.43 110.922 179.998 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -163.74 156.62 18.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 74.51 110.908 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 12.2 p -148.25 121.9 9.22 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 73.44 110.829 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 166' ' ' ASP . . . . . 0.448 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 15.6 t70 -130.72 160.84 33.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 73.0 110.883 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.513 HG13 ' O ' ' A' ' 195' ' ' ILE . 31.8 t -137.04 132.06 46.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.236 -0.438 . . . . 75.41 111.147 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . 0.587 ' HD2' HD12 ' A' ' 195' ' ' ILE . 0.0 OUTLIER -101.41 139.31 37.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 75.23 110.868 -179.96 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 66.5 t80 -143.97 134.21 24.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.146 -0.479 . . . . 71.35 110.897 -179.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 170' ' ' ILE . . . . . 0.453 HD13 ' N ' ' A' ' 171' ' ' PRO . 0.0 OUTLIER 179.83 131.58 0.25 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.601 0.715 . . . . 64.41 111.217 179.904 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . 0.453 ' N ' HD13 ' A' ' 170' ' ' ILE . 54.3 Cg_endo -69.69 109.27 2.26 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.709 2.273 . . . . 53.42 112.355 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -119.0 176.87 5.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.445 . . . . 72.34 110.865 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.53 147.53 29.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.161 -0.472 . . . . 73.34 110.829 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 174' ' ' THR . . . . . 0.553 HG21 ' HE2' ' A' ' 128' ' ' PHE . 0.6 OUTLIER -132.36 162.83 30.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.489 . . . . 71.53 111.177 179.94 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . 0.407 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.1 OUTLIER -119.74 170.87 8.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 73.34 110.849 179.93 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.953 HG13 HD13 ' A' ' 141' ' ' ILE . 21.9 t -148.73 133.19 9.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 75.45 111.119 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 14.8 t -166.55 175.03 8.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 40.53 111.169 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -156.62 -137.08 2.25 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.799 -0.715 . . . . 71.43 112.536 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 98.6 m . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 120.785 0.326 . . . . 74.43 111.156 -179.9 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo . . . . . 0 C--O 1.232 0.182 0 CA-C-O 120.866 0.277 . . . . 73.22 112.336 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 29.7 t -106.62 115.56 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.19 -0.459 . . . . 70.34 111.094 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 19.4 p -110.1 105.84 15.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 60.21 110.814 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 16.2 p -107.74 159.46 16.47 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.115 -0.493 . . . . 65.14 111.138 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 34.8 ttpt -147.17 145.18 29.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 64.31 110.857 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 20.6 pt -146.1 142.05 21.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.127 -0.488 . . . . 62.43 111.1 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -124.14 110.8 15.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 74.23 110.896 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 191' ' ' VAL . . . . . 0.404 HG12 ' N ' ' A' ' 192' ' ' ASP . 5.6 t -137.06 157.99 35.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 75.44 111.08 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.404 ' N ' HG12 ' A' ' 191' ' ' VAL . 2.0 p-10 -108.14 88.39 4.71 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.601 0.715 . . . . 72.44 110.898 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 169.13 19.7 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.716 2.277 . . . . 63.2 112.318 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -126.91 117.2 22.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.465 . . . . 73.12 110.888 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 195' ' ' ILE . . . . . 0.587 HD12 ' HD2' ' A' ' 168' ' ' ARG . 61.8 mt -103.29 104.27 16.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 73.33 111.187 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . 0.441 HD23 ' CG1' ' A' ' 167' ' ' VAL . 5.5 mt -96.12 108.88 21.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.217 -0.447 . . . . 54.13 110.93 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -108.99 127.7 54.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.244 -0.435 . . . . 73.42 110.848 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 198' ' ' LEU . . . . . 0.4 ' C ' ' HB2' ' A' ' 22' ' ' ASN . 10.4 tt -149.95 132.75 15.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.165 -0.471 . . . . 72.12 110.904 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 199' ' ' GLY . . . . . 0.445 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -177.97 -152.12 9.91 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.776 -0.726 . . . . 62.41 112.468 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 200' ' ' ALA . . . . . 0.53 ' HA ' ' HA ' ' A' ' 163' ' ' LEU . . . -110.09 173.1 6.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.822 0.344 . . . . 55.41 111.034 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 40.6 t -159.98 162.66 34.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 62.42 110.852 -179.739 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 202' ' ' TYR . . . . . 0.623 ' CD1' ' HB3' ' A' ' 19' ' ' ALA . 0.2 OUTLIER -146.55 135.27 22.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.14 -0.482 . . . . 74.3 110.917 -179.898 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.817 HG23 HG22 ' A' ' 18' ' ' VAL . 11.2 p -83.63 152.56 3.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.122 -0.49 . . . . 73.44 111.129 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -151.37 132.08 14.03 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 75.21 110.887 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.125 -0.489 . . . . 75.45 110.885 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 41.6 mt-30 . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.79 0.329 . . . . 73.24 110.945 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.9 9.76 31.78 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.779 -0.724 . . . . 72.11 112.456 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -78.71 169.39 18.31 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.803 0.335 . . . . 73.41 110.874 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 10.1 m-90 -114.9 159.85 20.21 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.215 -0.448 . . . . 74.11 110.937 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.639 HG23 ' HB3' ' A' ' 60' ' ' ALA . 15.5 m -153.38 126.96 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 41.32 111.152 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -96.4 114.95 26.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.154 -0.475 . . . . 75.5 111.077 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -111.95 113.7 26.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.175 -0.466 . . . . 62.12 110.91 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.773 ' CZ ' ' HB3' ' A' ' 200' ' ' ALA . 48.9 p90 -106.65 125.66 51.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 72.34 110.873 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -155.55 166.58 33.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.135 -0.484 . . . . 55.32 110.915 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 23.4 p90 -98.86 132.39 44.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.143 -0.48 . . . . 74.44 110.85 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -98.7 122.69 42.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.152 -0.476 . . . . 74.3 110.871 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 29.2 tptt -99.29 106.53 18.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 63.41 110.867 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.4 p -81.2 133.88 28.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.312 -0.404 . . . . 75.33 111.114 179.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -120.5 112.51 19.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.094 -0.503 . . . . 64.23 110.909 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.484 HG23 HG22 ' A' ' 49' ' ' ILE . 4.0 m -153.13 -179.34 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.097 -0.501 . . . . 64.2 111.147 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.63 52.48 0.54 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.682 -0.771 . . . . 71.1 112.477 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 34.0 mt-10 -90.03 -66.75 0.89 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.849 0.357 . . . . 64.03 110.903 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? 177.81 151.94 0.25 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.088 -0.506 . . . . 73.14 110.945 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.474 HD21 ' HB1' ' A' ' 45' ' ' ALA . 0.9 OUTLIER -109.03 163.73 13.05 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.15 -0.477 . . . . 70.54 110.921 -179.982 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.26 0 C-N-CA 120.737 -0.744 . . . . 75.52 112.452 179.864 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.474 ' HB1' HD21 ' A' ' 32' ' ' LEU . . . . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.733 0.301 . . . . 54.21 111.105 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -159.52 125.15 4.22 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.231 -0.441 . . . . 61.01 110.869 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.423 ' HA ' ' HA2' ' A' ' 83' ' ' GLY . 6.5 p -118.14 148.91 20.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.193 -0.458 . . . . 75.35 111.072 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -173.14 174.47 3.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 72.41 110.878 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.775 HD11 ' CE2' ' A' ' 98' ' ' TYR . 19.3 tt -141.57 154.79 20.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.112 -0.494 . . . . 70.11 111.086 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -124.42 167.54 16.72 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.715 -0.755 . . . . 64.21 112.426 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.9 m-80 -162.66 163.91 26.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.821 0.343 . . . . 71.22 110.904 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -120.36 -68.83 0.88 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 62.43 110.827 179.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 72.3 p -91.93 172.87 8.17 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.216 -0.447 . . . . 65.23 111.144 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 40.3 p -148.38 106.52 3.73 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.226 -0.443 . . . . 73.43 111.122 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.406 HD12 ' O ' ' A' ' 55' ' ' LEU . 3.3 pp -160.73 128.74 4.47 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 64.54 110.94 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.459 HG22 ' HA3' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -142.54 155.74 45.05 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.274 -0.421 . . . . 72.35 111.182 179.948 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -114.95 132.46 56.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 70.42 110.893 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.451 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -129.88 134.83 47.76 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.211 -0.449 . . . . 63.24 110.991 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.43 HD13 ' C ' ' A' ' 58' ' ' ASP . 3.0 mm -109.29 115.16 48.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.274 -0.421 . . . . 54.03 111.125 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.639 ' HB3' HG23 ' A' ' 18' ' ' VAL . . . -111.31 151.48 28.33 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.178 -0.464 . . . . 61.1 111.084 179.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.457 ' HB2' HG22 ' A' ' 69' ' ' VAL . 5.3 m-85 -125.74 132.37 52.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 73.04 110.932 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -98.3 95.22 7.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.081 -0.509 . . . . 73.24 110.893 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.5 t -94.35 -31.74 4.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.151 -0.477 . . . . 52.24 111.089 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 29.7 t -136.15 158.07 45.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 72.22 110.831 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 59.8 p -85.07 3.98 36.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 72.41 110.859 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -114.41 -29.47 6.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 72.41 110.84 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.424 HG22 ' CD2' ' A' ' 107' ' ' TYR . 32.5 pt -142.08 158.0 20.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 62.32 111.113 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -148.91 163.27 37.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 62.12 111.115 179.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.457 HG22 ' HB2' ' A' ' 61' ' ' TYR . 6.1 m -112.24 152.14 14.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 71.02 111.155 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.449 ' HA ' ' HA ' ' A' ' 60' ' ' ALA . 1.5 p30 -144.58 143.31 30.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 64.25 110.885 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.451 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -127.19 108.44 10.89 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 71.33 110.851 -179.907 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -86.33 127.26 34.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.12 -0.491 . . . . 60.15 110.819 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 14.6 p -147.3 147.49 17.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 63.11 111.198 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.459 ' HA3' HG22 ' A' ' 56' ' ' THR . . . -161.88 144.18 9.51 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.753 -0.737 . . . . 73.55 112.487 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 44.3 t -119.74 73.18 16.91 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.608 0.718 . . . . 61.43 111.129 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 159.09 54.7 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.669 2.246 . . . . 44.34 112.365 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -74.91 -165.8 0.41 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.251 -0.431 . . . . 72.35 111.181 179.818 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 18.2 ttm105 -77.05 138.22 39.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.283 -0.417 . . . . 61.54 110.833 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . 0.668 ' HB3' ' CE2' ' A' ' 98' ' ' TYR . . . -132.77 148.99 52.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.443 . . . . 52.45 111.128 179.836 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.6 ttpm? -89.12 123.8 33.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.182 -0.463 . . . . 72.41 110.93 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 59.6 t80 -109.13 138.82 44.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 62.45 110.878 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.416 ' O ' HG23 ' A' ' 47' ' ' VAL . 7.6 pt20 -109.17 150.91 27.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 74.43 110.917 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.657 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 174.37 84.88 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.696 -0.764 . . . . 74.31 112.447 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -178.07 -175.68 0.5 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.894 0.378 . . . . 52.44 110.976 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 1.4 ptpt -86.54 -70.13 0.63 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.198 -0.455 . . . . 74.22 110.879 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 8.4 t -85.25 -30.52 23.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.225 -0.443 . . . . 73.35 110.869 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.849 HG22 HG22 ' A' ' 93' ' ' VAL . 4.8 mm -68.81 -35.21 68.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.123 -0.489 . . . . 72.12 111.114 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.1 t -62.68 -47.38 83.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 44.42 110.861 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.1 t -54.67 -39.85 68.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.149 -0.478 . . . . 71.23 110.837 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 13.9 tp -60.55 -44.23 96.37 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.083 -0.508 . . . . 75.13 110.995 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.24 -14.55 39.86 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.743 -0.741 . . . . 74.55 112.501 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 9.8 mtm180 -120.54 96.74 5.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.897 0.38 . . . . 71.12 110.813 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.849 HG22 HG22 ' A' ' 87' ' ' ILE . 99.3 t -107.24 -58.27 3.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 64.05 111.1 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.413 ' HA ' ' HA ' ' A' ' 133' ' ' ASP . 0.9 OUTLIER -140.09 148.73 42.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.154 -0.475 . . . . 64.43 110.902 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 31.6 mt-10 -126.01 124.59 41.03 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.132 -0.485 . . . . 71.21 110.972 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.45 HG22 ' N ' ' A' ' 97' ' ' ASP . 14.8 p -176.05 156.76 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 64.45 111.11 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.45 ' N ' HG22 ' A' ' 96' ' ' VAL . 3.9 p30 -84.27 173.49 10.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 75.34 110.902 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' TYR . . . . . 0.775 ' CE2' HD11 ' A' ' 49' ' ' ILE . 14.4 m-85 -130.48 133.17 46.08 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 74.23 110.933 -179.825 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -114.11 69.63 0.24 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.703 -0.761 . . . . 54.42 112.445 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.82 138.44 37.64 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.694 2.263 . . . . 55.12 112.294 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -155.7 118.08 4.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 60.55 111.115 179.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.649 HG22 ' CA ' ' A' ' 124' ' ' GLY . 30.0 pt -140.15 146.1 25.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 62.24 111.165 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.42 HD22 ' CE1' ' A' ' 71' ' ' PHE . 2.3 pp -132.82 118.99 19.66 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.196 -0.456 . . . . 74.11 110.846 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . 0.421 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 5.6 p -142.93 163.92 31.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.202 -0.454 . . . . 65.11 110.875 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.577 ' O ' HD12 ' A' ' 105' ' ' LEU . 1.1 pp -113.87 151.46 32.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 54.52 110.886 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 31.5 mt-30 -106.49 144.05 33.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 73.55 110.907 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.424 ' CD2' HG22 ' A' ' 67' ' ' ILE . 5.4 t80 -136.02 125.41 24.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 65.53 110.968 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 1.9 t60 . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 116.173 -0.467 . . . . 64.31 110.843 179.956 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 6.1 m-85 . . . . . 0 C--O 1.231 0.119 0 CA-C-O 121.689 0.757 . . . . 73.4 110.884 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 178.43 4.57 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.633 2.222 . . . . 73.43 112.349 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 4.0 m-85 -110.24 151.95 26.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.462 . . . . 74.35 110.949 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 8.3 p -101.93 133.01 46.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.109 -0.496 . . . . 75.11 111.101 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -131.92 174.67 20.11 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.796 -0.716 . . . . 71.15 112.568 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.505 HG23 ' HA ' ' A' ' 149' ' ' PHE . 9.4 p -175.95 153.54 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.865 0.364 . . . . 73.43 111.106 -179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -176.01 -158.21 19.09 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.76 -0.734 . . . . 54.2 112.543 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.45 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 21.3 m -107.7 150.66 10.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.869 0.366 . . . . 72.03 111.116 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . 0.649 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -130.53 169.07 21.46 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.687 -0.768 . . . . 75.24 112.455 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . 0.432 ' HA ' ' HA ' ' A' ' 145' ' ' TRP . 0.0 OUTLIER -168.55 129.26 1.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.86 0.362 . . . . 71.3 110.923 -179.855 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.468 ' O ' HG13 ' A' ' 126' ' ' VAL . 3.9 p -118.73 112.04 36.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 51.3 111.152 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.457 HD23 ' N ' ' A' ' 128' ' ' PHE . 10.0 tt -122.52 151.23 41.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 73.34 110.883 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.602 ' CE1' HG23 ' A' ' 141' ' ' ILE . 1.3 p90 -160.89 161.94 31.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.187 -0.461 . . . . 72.21 110.833 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 51.5 t80 -101.07 118.59 37.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.49 . . . . 71.53 110.88 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -50.55 102.37 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 65.21 110.845 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -77.52 -80.81 0.1 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.139 -0.482 . . . . 74.35 110.901 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -165.43 112.9 0.96 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.256 -0.429 . . . . 74.34 111.125 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . 0.538 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 1.4 m-20 -103.07 119.36 38.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.144 -0.48 . . . . 71.35 110.923 179.853 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -79.89 -5.82 89.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.806 -0.712 . . . . 53.51 112.445 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -46.81 -28.18 1.46 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.81 0.338 . . . . 73.2 111.113 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -162.86 -178.56 6.2 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.191 -0.458 . . . . 71.52 111.019 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 1.5 m -53.02 93.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.275 -0.42 . . . . 73.1 110.828 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 7.0 m 50.68 71.19 0.44 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.081 -0.509 . . . . 70.22 110.891 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.623 ' CE2' HG12 ' A' ' 176' ' ' VAL . 0.5 OUTLIER -92.98 159.88 15.12 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.135 -0.484 . . . . 72.25 110.838 -179.912 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 94.0 m-20 -134.0 167.41 20.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.495 . . . . 75.54 110.891 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.602 HG23 ' CE1' ' A' ' 128' ' ' PHE . 17.6 tt -117.97 149.11 20.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.192 -0.458 . . . . 74.04 111.182 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 16.2 mmtt -113.36 124.54 52.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 73.43 110.931 179.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.421 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 0.0 OUTLIER -85.53 -173.32 4.59 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.225 -0.443 . . . . 44.51 110.868 179.915 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -171.54 -175.36 1.58 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 72.51 110.904 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' TRP . . . . . 0.432 ' HA ' ' HA ' ' A' ' 125' ' ' ARG . 22.5 p-90 -143.57 160.49 40.54 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.198 -0.456 . . . . 64.32 110.917 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.679 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 178.86 163.15 0.69 Allowed Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.623 0.725 . . . . 23.01 111.086 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' PRO . . . . . 0.679 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 54.3 Cg_endo -69.66 170.61 16.06 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.683 2.255 . . . . 70.32 112.375 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.45 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -165.55 153.0 10.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.222 -0.445 . . . . 72.12 111.13 179.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . 0.505 ' HA ' HG23 ' A' ' 121' ' ' VAL . 12.9 m-85 -96.17 161.3 14.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.242 -0.435 . . . . 71.52 110.819 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 27.7 tp60 -135.0 148.59 50.0 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 61.22 110.949 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 10.2 p -151.54 130.84 3.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.17 -0.468 . . . . 74.33 111.161 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . 0.405 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 164.95 -163.21 36.27 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.727 -0.749 . . . . 52.15 112.481 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -148.93 168.26 23.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.788 0.328 . . . . 62.31 110.95 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -133.68 128.51 35.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 64.02 110.88 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -132.66 161.64 33.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.442 . . . . 74.31 110.933 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -121.28 109.58 15.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.147 -0.479 . . . . 73.01 110.904 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 3.6 tp -57.46 160.45 4.12 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.169 -0.469 . . . . 62.24 110.944 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -52.05 -33.24 36.77 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.775 -0.726 . . . . 64.04 112.495 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 4.6 m120 -80.52 173.65 12.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.907 0.384 . . . . 74.14 110.821 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 81.1 p -54.78 -35.74 64.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.113 -0.494 . . . . 75.45 110.815 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 10.3 m0 -69.31 151.68 45.91 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.199 -0.455 . . . . 64.34 110.97 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 38.8 mtt -121.22 174.92 6.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.246 -0.433 . . . . 73.11 110.862 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.435 ' HA ' ' HA ' ' A' ' 200' ' ' ALA . 0.6 OUTLIER -128.65 139.25 52.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.262 -0.427 . . . . 72.0 110.909 179.999 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 12.1 t-20 -139.84 138.33 35.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 71.13 110.984 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.7 p -141.61 121.79 13.85 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.214 -0.448 . . . . 73.24 110.892 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 166' ' ' ASP . . . . . 0.405 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 23.3 m-20 -140.26 167.59 21.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.08 -0.509 . . . . 72.41 110.812 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.528 HG13 ' O ' ' A' ' 195' ' ' ILE . 46.7 t -150.43 129.05 2.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.157 -0.474 . . . . 61.33 111.115 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . 0.552 ' NH1' HG21 ' A' ' 102' ' ' ILE . 0.0 OUTLIER -98.59 137.71 36.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 71.32 110.862 -179.972 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 15.9 t80 -138.22 125.37 21.52 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 62.2 110.929 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 170' ' ' ILE . . . . . 0.468 HG13 ' HD2' ' A' ' 171' ' ' PRO . 4.7 tp 178.9 134.69 0.24 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.599 0.714 . . . . 72.34 111.116 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . 0.468 ' HD2' HG13 ' A' ' 170' ' ' ILE . 54.0 Cg_endo -69.85 111.55 2.86 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.609 2.206 . . . . 64.54 112.386 179.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . 0.535 ' CE2' ' HB3' ' A' ' 146' ' ' ALA . 5.3 t80 -116.1 159.76 21.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.139 -0.482 . . . . 72.35 110.856 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 5.4 ptpt -140.06 144.79 37.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.146 -0.479 . . . . 73.41 110.926 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 9.4 t -117.79 161.9 18.96 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 73.52 111.137 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 21.6 t70 -118.48 158.54 25.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.14 -0.482 . . . . 71.3 110.844 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.623 HG12 ' CE2' ' A' ' 139' ' ' PHE . 4.5 t -147.94 138.26 16.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 72.54 111.082 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.3 t -166.92 -179.22 4.59 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.131 -0.486 . . . . 71.11 111.116 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -120.55 -161.66 11.53 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.746 -0.74 . . . . 61.35 112.458 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 6.4 t . . . . . 0 C--N 1.331 -0.217 0 CA-C-O 120.84 0.353 . . . . 75.22 111.16 -179.914 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo . . . . . 0 C--O 1.231 0.149 0 CA-C-O 120.839 0.266 . . . . 64.53 112.317 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.418 HG12 HG23 ' A' ' 187' ' ' THR . 26.5 t -103.59 108.17 23.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 71.34 111.111 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -74.13 104.83 5.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.137 -0.483 . . . . 74.14 110.82 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . 0.418 HG23 HG12 ' A' ' 185' ' ' VAL . 65.1 p -124.44 168.59 12.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.136 -0.484 . . . . 73.31 111.171 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 3.0 ttpm? -158.97 134.09 8.34 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.207 -0.451 . . . . 41.54 110.944 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -115.75 139.59 41.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.279 -0.419 . . . . 72.33 111.107 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 71.7 tt0 -119.55 114.99 23.1 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.125 -0.489 . . . . 74.22 110.817 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 191' ' ' VAL . . . . . 0.539 HG22 ' H ' ' A' ' 192' ' ' ASP . 1.2 p -137.18 171.28 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 70.41 111.111 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.539 ' H ' HG22 ' A' ' 191' ' ' VAL . 4.2 m-20 -106.93 87.14 2.73 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.594 0.711 . . . . 62.11 110.915 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.65 120.96 7.68 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.742 2.295 . . . . 62.21 112.379 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 194' ' ' PHE . . . . . 0.425 ' CE1' HG11 ' A' ' 167' ' ' VAL . 2.1 t80 -102.09 114.0 27.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.258 -0.428 . . . . 72.4 110.887 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 195' ' ' ILE . . . . . 0.55 HD12 ' HG2' ' A' ' 168' ' ' ARG . 5.6 mt -103.56 127.3 57.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.162 -0.472 . . . . 74.22 111.133 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . 0.41 ' HG ' HG22 ' A' ' 167' ' ' VAL . 1.1 tt -117.14 107.72 14.82 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.182 -0.463 . . . . 64.34 110.89 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 3.2 m -96.38 123.62 40.09 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.24 -0.436 . . . . 65.42 110.847 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 2.5 tt -144.13 129.21 18.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 62.21 110.86 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 178.94 -146.98 7.53 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.75 -0.738 . . . . 73.21 112.478 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 200' ' ' ALA . . . . . 0.773 ' HB3' ' CZ ' ' A' ' 21' ' ' PHE . . . -118.65 174.26 6.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.781 0.324 . . . . 61.35 111.17 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 78.1 p -149.66 175.71 11.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.28 -0.418 . . . . 74.21 110.843 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -157.31 160.9 39.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 73.52 110.895 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.503 ' HA ' HG12 ' A' ' 18' ' ' VAL . 18.2 m -76.76 161.21 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.065 -0.516 . . . . 65.0 111.15 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -155.95 127.59 7.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 71.11 110.865 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 14.3 ttmm . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.119 -0.492 . . . . 73.2 110.924 179.946 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 . . . . . 0 CA--C 1.526 0.04 0 CA-C-O 120.8 0.333 . . . . 75.43 110.881 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.71 11.57 28.33 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 61.41 112.498 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -82.66 160.51 22.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.766 0.317 . . . . 63.25 110.922 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 12.8 m95 -108.76 159.65 16.6 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.257 -0.429 . . . . 71.43 110.936 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.437 HG13 ' O ' ' A' ' 202' ' ' TYR . 48.1 t -150.5 119.2 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.426 . . . . 45.31 111.139 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -85.0 107.52 17.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.096 -0.502 . . . . 63.13 111.078 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -105.45 112.76 25.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 63.11 110.902 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -111.73 125.79 54.36 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.159 -0.473 . . . . 73.11 110.879 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.43 ' O ' HG22 ' A' ' 56' ' ' THR . 4.0 p30 -155.78 172.66 17.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 71.44 110.907 -179.887 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.8 p90 -100.96 132.21 46.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 71.24 110.867 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . 0.591 ' OG ' HG23 ' A' ' 195' ' ' ILE . 0.3 OUTLIER -100.68 120.04 39.48 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.151 -0.477 . . . . 65.34 110.88 -179.797 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 39.1 tttm -93.56 106.82 18.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 63.1 110.849 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.614 ' HA ' HD13 ' A' ' 195' ' ' ILE . 11.3 p -84.12 135.8 24.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 72.4 111.106 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -125.84 99.42 5.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.154 -0.475 . . . . 74.34 110.855 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.68 HG23 HG11 ' A' ' 191' ' ' VAL . 2.7 p -147.33 142.26 19.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.155 -0.475 . . . . 71.24 111.152 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 142.08 64.57 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.706 -0.759 . . . . 54.11 112.528 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -89.86 -66.16 0.95 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.766 0.317 . . . . 72.35 110.911 -179.863 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -171.41 134.87 0.9 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.122 -0.49 . . . . 61.14 110.873 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 5.1 tt -104.94 152.69 22.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.186 -0.461 . . . . 71.35 110.992 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.234 0 C-N-CA 120.666 -0.778 . . . . 54.13 112.502 179.946 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.79 0.328 . . . . 74.21 111.062 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 21.8 m-20 -160.48 125.37 3.79 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 54.4 110.922 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.54 HG13 ' O ' ' A' ' 82' ' ' GLN . 18.5 t -104.4 135.51 41.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.187 -0.46 . . . . 65.31 111.159 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -132.63 137.59 47.06 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 73.13 110.816 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 3.8 tt -101.3 145.03 12.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.094 -0.503 . . . . 73.51 111.094 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -60.24 -168.58 0.38 Allowed Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.746 -0.74 . . . . 63.32 112.462 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -119.05 -37.34 3.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.781 0.324 . . . . 73.14 110.937 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -51.96 150.51 4.21 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.147 -0.479 . . . . 75.15 110.881 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 3.7 p -146.13 178.21 8.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 62.13 111.138 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.6 t -160.14 169.47 23.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.268 -0.424 . . . . 75.14 111.183 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 5.0 mp -91.13 168.38 11.67 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 65.22 110.921 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.43 HG22 ' O ' ' A' ' 22' ' ' ASN . 12.1 t -135.94 149.51 48.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.186 -0.461 . . . . 65.41 111.133 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -102.75 133.05 48.43 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.292 -0.413 . . . . 73.35 110.846 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -125.91 138.62 53.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 53.45 110.84 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.53 114.15 45.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 65.42 111.164 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -105.87 121.64 44.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 73.4 111.057 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.785 ' HB3' HG22 ' A' ' 69' ' ' VAL . 7.4 t80 -106.08 117.38 33.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 73.03 110.931 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -92.43 101.83 14.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.124 -0.489 . . . . 60.03 110.892 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.41 HG23 ' OG ' ' A' ' 64' ' ' SER . 32.5 m -98.39 -31.72 3.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.46 . . . . 70.22 111.156 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.41 ' OG ' HG23 ' A' ' 63' ' ' VAL . 1.1 m -125.92 -169.51 2.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.192 -0.458 . . . . 71.0 110.895 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.5 m -84.18 -38.92 20.02 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 74.1 110.893 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -126.09 25.99 6.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.067 -0.515 . . . . 71.3 110.865 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 3.4 mt -145.16 126.94 8.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.22 -0.446 . . . . 70.04 111.136 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.484 ' HB1' ' O ' ' A' ' 61' ' ' TYR . . . -155.05 168.61 26.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.138 -0.483 . . . . 52.34 111.119 179.843 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.785 HG22 ' HB3' ' A' ' 61' ' ' TYR . 2.5 m -111.76 152.47 13.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 61.12 111.14 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -131.66 129.41 40.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 63.23 110.821 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -114.38 110.15 19.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 73.31 110.87 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -81.82 113.08 19.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 73.14 110.955 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.8 t -124.04 116.46 47.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.167 -0.47 . . . . 74.4 111.03 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -131.87 152.14 20.03 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.71 -0.757 . . . . 74.23 112.48 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 39.4 t -143.38 69.81 17.69 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.575 0.702 . . . . 71.2 111.144 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.79 140.61 42.98 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.666 2.244 . . . . 71.22 112.373 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.87 -173.66 0.26 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.188 -0.46 . . . . 72.33 111.075 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 8.9 ttm180 -76.43 129.61 36.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 75.12 110.856 -179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -131.03 151.71 51.12 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.227 -0.442 . . . . 70.21 111.085 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.8 tttp -97.59 123.9 41.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.134 -0.485 . . . . 62.41 110.847 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -111.43 151.68 28.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 71.43 110.907 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.54 ' O ' HG13 ' A' ' 47' ' ' VAL . 18.1 mt-30 -111.71 148.47 33.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 75.31 110.899 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.571 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -178.71 81.41 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.789 -0.719 . . . . 74.51 112.479 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -176.52 -175.59 0.67 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.95 0.405 . . . . 60.2 110.868 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.17 -69.72 0.65 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.127 -0.488 . . . . 65.0 110.949 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 16.9 p -85.16 -32.05 22.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.237 -0.438 . . . . 72.01 110.853 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.951 HG21 ' HB2' ' A' ' 135' ' ' ALA . 4.6 mm -67.34 -35.13 72.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.094 -0.503 . . . . 74.35 111.111 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.8 t -62.38 -44.85 95.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.219 -0.446 . . . . 52.23 110.79 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 39.1 t -57.43 -37.31 72.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 62.1 110.904 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 98.5 mt -63.56 -50.3 70.02 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.107 -0.497 . . . . 52.32 110.902 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 114.14 -13.22 21.69 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.721 -0.752 . . . . 75.42 112.475 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.61 96.19 5.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.839 0.352 . . . . 74.13 110.821 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.887 HG22 HG22 ' A' ' 87' ' ' ILE . 64.5 t -113.74 -50.84 5.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.253 -0.431 . . . . 64.12 111.108 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 60.5 p -140.11 148.69 42.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 64.42 110.91 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -140.68 118.52 11.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 71.42 110.79 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.526 HG22 ' H ' ' A' ' 97' ' ' ASP . 1.6 p -179.24 170.31 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.171 -0.468 . . . . 71.22 111.089 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.526 ' H ' HG22 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -109.43 160.29 16.32 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.198 -0.455 . . . . 74.21 110.869 179.931 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' TYR . . . . . 0.424 ' HA ' ' HB2' ' A' ' 128' ' ' PHE . 17.7 m-85 -120.35 145.23 47.35 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.226 -0.443 . . . . 75.11 110.948 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -108.67 87.3 0.48 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.775 -0.726 . . . . 72.12 112.412 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.656 ' HA ' HG12 ' A' ' 126' ' ' VAL . 54.2 Cg_endo -69.76 110.43 2.55 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.668 2.245 . . . . 74.41 112.406 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.409 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -128.88 95.57 4.12 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.241 -0.436 . . . . 42.13 111.12 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.617 HG23 ' CA ' ' A' ' 124' ' ' GLY . 5.8 mm -116.64 142.22 31.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.229 -0.441 . . . . 62.24 111.138 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.46 ' HG ' HG13 ' A' ' 123' ' ' VAL . 0.3 OUTLIER -140.13 109.66 6.27 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.188 -0.46 . . . . 74.14 110.934 179.959 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . 0.413 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 4.8 p -138.19 -177.6 4.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 73.13 110.854 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.606 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.7 OUTLIER -128.87 141.89 51.14 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 71.23 110.863 -179.946 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 -101.55 132.72 47.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 65.11 110.992 179.853 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 27.5 t80 -137.1 145.61 44.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.237 -0.438 . . . . 64.21 110.937 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 59.0 t-80 . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.152 -0.476 . . . . 64.44 110.917 179.89 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 7.7 p90 . . . . . 0 C--O 1.232 0.137 0 CA-C-O 121.655 0.74 . . . . 72.44 110.985 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . 0.684 ' HA ' HD12 ' A' ' 153' ' ' LEU . 53.8 Cg_endo -69.81 176.95 6.13 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.6 2.2 . . . . 71.54 112.31 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . 0.474 ' O ' HG23 ' A' ' 151' ' ' VAL . 26.5 m-85 -111.53 144.24 41.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 71.14 110.924 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 13.2 p -100.7 133.26 44.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.237 -0.438 . . . . 73.24 111.102 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.418 ' HA2' ' O ' ' A' ' 105' ' ' LEU . . . -125.92 159.01 20.32 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.738 -0.744 . . . . 71.34 112.489 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.1 p -161.6 149.47 4.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.81 0.338 . . . . 75.14 111.15 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . 0.413 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -177.5 -151.3 9.07 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.744 -0.741 . . . . 53.04 112.5 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.531 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.3 p -110.39 126.31 67.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.877 0.37 . . . . 72.21 111.114 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . 0.617 ' CA ' HG23 ' A' ' 102' ' ' ILE . . . -116.06 119.94 4.72 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.769 -0.729 . . . . 60.05 112.503 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . 0.409 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 13.5 ptm180 -120.44 122.88 41.67 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.921 0.391 . . . . 74.13 110.854 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.656 HG12 ' HA ' ' A' ' 100' ' ' PRO . 3.7 m -118.34 118.6 58.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.202 -0.454 . . . . 60.11 111.117 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.423 ' HA ' ' HB3' ' A' ' 143' ' ' ASP . 1.2 pt? -160.02 165.23 32.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.231 -0.441 . . . . 72.53 110.985 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.424 ' HB2' ' HA ' ' A' ' 98' ' ' TYR . 1.0 OUTLIER -165.93 -171.12 1.93 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.236 -0.438 . . . . 74.11 110.897 179.925 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -94.13 135.12 35.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.174 -0.466 . . . . 73.3 110.926 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -69.63 148.01 49.9 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.138 -0.483 . . . . 72.43 110.843 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.482 ' CB ' HG23 ' A' ' 96' ' ' VAL . 0.2 OUTLIER -129.55 -69.29 0.69 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 73.05 110.933 179.94 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 33.8 m -159.93 75.12 0.6 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.185 -0.461 . . . . 74.15 111.189 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -97.85 175.5 6.13 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.224 -0.444 . . . . 73.21 110.81 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 62.99 149.55 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.735 -0.745 . . . . 71.03 112.479 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.951 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -76.51 -1.7 28.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.892 0.377 . . . . 43.04 111.187 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -86.5 -177.09 6.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.135 -0.484 . . . . 71.42 110.906 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -64.06 93.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.198 -0.455 . . . . 62.44 110.847 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 89.0 p 46.06 76.26 0.1 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 62.12 110.88 -179.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -82.96 151.16 26.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 71.42 110.794 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . 0.447 ' O ' HG13 ' A' ' 176' ' ' VAL . 1.6 t70 -101.74 165.63 11.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.093 -0.503 . . . . 72.51 110.776 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -127.08 163.0 30.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 64.25 111.168 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . 0.41 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 0.2 OUTLIER -119.21 108.14 14.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 74.45 110.898 179.847 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.428 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 1.0 OUTLIER -58.84 -172.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.243 -0.435 . . . . 44.22 110.819 179.967 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 15.9 mmtt -149.47 155.28 40.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.45 . . . . 55.33 110.886 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 45.3 p90 -151.67 136.23 16.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.227 -0.442 . . . . 63.53 110.926 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.933 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.28 172.14 0.61 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.583 0.706 . . . . 51.15 111.051 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' PRO . . . . . 0.933 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 54.3 Cg_endo -69.69 134.09 27.29 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.631 2.221 . . . . 52.51 112.421 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.468 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -130.1 166.47 20.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.262 -0.426 . . . . 64.2 111.126 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -121.55 167.39 12.92 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 71.21 110.951 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -165.85 162.3 18.29 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 71.41 110.923 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.474 HG23 ' O ' ' A' ' 118' ' ' TYR . 10.7 p -153.51 141.32 13.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 73.0 111.147 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -169.4 -171.79 35.41 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.772 -0.728 . . . . 64.24 112.451 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.684 HD12 ' HA ' ' A' ' 117' ' ' PRO . 8.5 tt -149.2 157.08 43.07 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.738 0.304 . . . . 74.35 110.934 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.438 ' N ' HD23 ' A' ' 153' ' ' LEU . 7.1 tpp85 -108.08 117.43 34.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.224 -0.444 . . . . 74.43 110.836 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 4.5 t80 -105.17 145.38 30.66 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.184 -0.462 . . . . 74.24 110.876 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -115.38 105.77 13.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.091 -0.504 . . . . 55.45 110.897 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 11.9 tp -93.93 164.34 13.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.184 -0.462 . . . . 64.25 110.925 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -76.08 68.38 2.31 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.75 -0.738 . . . . 55.53 112.468 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 64.7 m-80 -151.41 175.25 12.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.804 0.335 . . . . 74.3 110.876 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 6.2 m -56.32 -38.55 71.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.209 -0.45 . . . . 65.32 110.85 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 4.6 p90 -111.8 178.26 4.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.167 -0.47 . . . . 73.22 110.905 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' MET . . . . . 0.46 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 0.0 OUTLIER -117.08 170.81 8.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 53.41 110.92 179.873 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 5.8 tp -104.09 151.35 23.38 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.246 -0.433 . . . . 71.11 110.886 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 4.0 t-20 -145.07 137.84 26.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.17 -0.468 . . . . 74.1 110.919 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 26.8 p -136.22 122.5 20.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 72.54 110.906 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -140.5 164.62 29.67 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.136 -0.484 . . . . 61.22 110.878 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 94.7 t -150.51 116.61 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.248 -0.433 . . . . 73.4 111.115 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -97.66 146.49 25.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 74.24 110.879 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 62.2 t80 -146.81 143.3 28.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 71.14 110.86 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 170' ' ' ILE . . . . . 0.468 HG21 ' HB2' ' A' ' 148' ' ' ALA . 0.0 OUTLIER -179.0 103.14 0.2 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.66 0.743 . . . . 73.32 111.154 179.918 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 127.32 14.48 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.661 2.241 . . . . 72.24 112.439 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -148.64 178.42 8.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.254 -0.43 . . . . 62.04 110.952 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.82 127.74 37.26 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.187 -0.461 . . . . 74.04 110.892 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.8 t -91.88 165.96 12.97 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.291 -0.413 . . . . 63.33 111.123 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . 0.41 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -124.58 167.06 15.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 72.23 110.86 179.884 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.447 HG13 ' O ' ' A' ' 140' ' ' ASP . 45.7 t -152.16 139.78 13.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.13 -0.487 . . . . 72.22 111.163 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 14.5 t -167.27 179.35 5.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 63.01 111.149 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 131.63 143.49 5.21 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.747 -0.739 . . . . 63.34 112.45 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 7.1 t . . . . . 0 C--N 1.329 -0.309 0 CA-C-O 120.86 0.362 . . . . 64.21 111.111 -179.912 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo . . . . . 0 C--O 1.231 0.157 0 CA-C-O 120.766 0.236 . . . . 73.11 112.368 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 44.6 t -96.8 107.5 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.227 -0.442 . . . . 71.03 111.092 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 13.3 p -89.36 104.98 17.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 63.51 110.861 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 10.8 p -110.22 166.53 10.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.083 -0.508 . . . . 74.13 111.151 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -152.23 146.6 25.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 73.1 110.922 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 18.2 pt -142.51 130.39 20.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 74.21 111.14 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -99.29 118.23 35.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 74.01 110.837 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 191' ' ' VAL . . . . . 0.68 HG11 HG23 ' A' ' 28' ' ' VAL . 8.5 p -137.79 159.99 33.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 72.11 111.143 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.408 ' N ' HG22 ' A' ' 191' ' ' VAL . 0.2 OUTLIER -107.22 90.26 5.46 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.567 0.699 . . . . 74.13 110.927 179.982 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 116.31 4.5 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.683 2.255 . . . . 75.44 112.342 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -100.28 119.65 38.72 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.176 -0.466 . . . . 70.2 110.918 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 195' ' ' ILE . . . . . 0.614 HD13 ' HA ' ' A' ' 26' ' ' VAL . 40.5 mm -108.79 119.48 58.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.123 -0.49 . . . . 63.44 111.094 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 7.3 mp -113.03 107.25 15.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.156 -0.475 . . . . 74.13 110.949 179.863 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 197' ' ' SER . . . . . 0.603 ' O ' HD12 ' A' ' 198' ' ' LEU . 0.9 OUTLIER -95.31 124.47 39.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.225 -0.443 . . . . 70.13 110.826 -179.907 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 198' ' ' LEU . . . . . 0.603 HD12 ' O ' ' A' ' 197' ' ' SER . 5.0 mp -146.39 127.92 15.07 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.101 -0.5 . . . . 71.43 110.987 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 177.27 -136.25 3.05 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.655 -0.783 . . . . 64.42 112.442 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 200' ' ' ALA . . . . . 0.46 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -134.06 173.15 11.89 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.85 0.357 . . . . 64.32 111.114 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 2.3 p -144.92 174.83 10.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.434 . . . . 71.53 110.92 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 202' ' ' TYR . . . . . 0.437 ' O ' HG13 ' A' ' 18' ' ' VAL . 12.6 t80 -148.63 138.77 22.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.101 -0.499 . . . . 74.23 110.854 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 11.5 p -77.2 151.23 5.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.077 -0.51 . . . . 73.14 111.117 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 -153.13 114.15 4.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.133 -0.485 . . . . 71.14 110.896 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 5.7 ptpt . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 71.21 110.879 179.982 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.892 0.377 . . . . 62.53 110.919 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.94 6.9 68.96 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.72 -0.753 . . . . 60.24 112.421 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -75.54 145.24 41.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.752 0.31 . . . . 74.13 110.884 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -127.22 121.56 31.58 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.234 -0.439 . . . . 73.22 110.958 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.783 HG13 ' HB3' ' A' ' 60' ' ' ALA . 2.9 p -131.28 123.55 53.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.252 -0.431 . . . . 74.21 111.115 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -84.41 115.18 22.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.117 -0.492 . . . . 64.33 111.097 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -104.62 108.8 20.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 62.35 110.9 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -111.97 125.3 53.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 64.3 110.942 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.404 ' HB2' ' C ' ' A' ' 198' ' ' LEU . 5.4 p30 -153.53 174.05 14.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 61.13 110.829 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -98.0 129.45 44.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.113 -0.494 . . . . 74.5 110.814 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -97.22 122.47 40.27 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.148 -0.478 . . . . 72.23 110.836 -179.847 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -102.4 105.76 16.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.089 -0.505 . . . . 73.43 110.902 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.5 m -82.71 131.04 34.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.272 -0.422 . . . . 71.04 111.164 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 10.2 m-85 -123.98 99.35 6.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.177 -0.465 . . . . 71.42 110.901 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 p -158.46 151.26 7.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.216 -0.447 . . . . 51.02 111.164 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.99 72.32 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.707 -0.759 . . . . 64.01 112.419 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.5 tp10 -89.07 -66.47 0.92 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.853 0.358 . . . . 75.12 110.83 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -176.23 172.5 2.31 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 43.05 110.88 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.56 ' HB3' ' HB3' ' A' ' 45' ' ' ALA . 24.4 tp -104.22 150.77 24.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 55.33 110.884 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.718 -0.753 . . . . 42.44 112.495 179.942 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.56 ' HB3' ' HB3' ' A' ' 32' ' ' LEU . . . . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.821 0.343 . . . . 65.42 111.094 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -137.49 133.96 35.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 71.15 110.833 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.404 HG12 ' CA ' ' A' ' 83' ' ' GLY . 21.8 m -106.73 151.17 8.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 73.42 111.105 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 14.7 t -156.8 151.28 25.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 75.35 110.818 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.468 HD12 ' CD1' ' A' ' 81' ' ' PHE . 38.4 mm -120.93 116.49 50.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.088 -0.506 . . . . 74.04 111.09 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -51.56 157.9 2.84 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.693 -0.765 . . . . 40.41 112.425 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -51.75 103.28 0.06 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.817 0.341 . . . . 72.33 110.954 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.409 ' O ' ' C ' ' A' ' 53' ' ' THR . 1.1 p-10 -58.48 -56.9 16.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 71.14 110.931 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . 0.409 ' C ' ' O ' ' A' ' 52' ' ' ASP . 10.2 t 36.73 44.08 0.32 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.115 -0.493 . . . . 74.13 111.186 -179.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.445 HG22 ' H ' ' A' ' 55' ' ' LEU . 0.2 OUTLIER -107.6 169.17 8.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.198 -0.455 . . . . 64.23 111.096 -179.93 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.602 ' O ' HD12 ' A' ' 55' ' ' LEU . 0.9 OUTLIER -109.49 150.23 28.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 73.14 110.907 -179.981 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.5 t -134.47 144.65 48.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.284 -0.416 . . . . 72.21 111.161 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 42.2 m-85 -102.9 132.57 49.02 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.252 -0.431 . . . . 73.53 110.826 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.547 ' C ' HD12 ' A' ' 59' ' ' ILE . 0.3 OUTLIER -127.31 146.63 50.38 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.148 -0.478 . . . . 74.21 110.91 179.96 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.547 HD12 ' C ' ' A' ' 58' ' ' ASP . 1.5 mp -119.28 113.61 41.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.224 -0.444 . . . . 65.31 111.131 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.783 ' HB3' HG13 ' A' ' 18' ' ' VAL . . . -102.66 117.0 33.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.467 . . . . 74.33 111.09 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 34.7 t80 -108.73 115.76 30.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.156 -0.475 . . . . 74.21 110.96 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -87.23 96.97 10.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.129 -0.487 . . . . 73.55 110.889 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.7 p -86.72 -33.15 6.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.146 -0.479 . . . . 72.42 111.12 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -130.67 164.91 23.98 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.184 -0.462 . . . . 62.21 110.892 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.9 t -87.21 3.24 47.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 61.21 110.92 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 61.6 t30 -110.72 -33.45 6.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.109 -0.496 . . . . 52.05 110.865 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.446 HG22 ' HA ' ' A' ' 107' ' ' TYR . 44.4 pt -150.54 172.02 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 72.35 111.12 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -157.16 172.85 17.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.14 -0.482 . . . . 72.14 111.058 179.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 10.2 m -112.1 150.97 14.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.223 -0.444 . . . . 72.33 111.129 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -138.11 127.48 24.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 64.24 110.857 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -102.4 147.2 27.01 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.471 . . . . 64.54 110.888 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.4 ' HB3' ' HB ' ' A' ' 102' ' ' ILE . 30.4 t80 -121.25 112.95 19.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.149 -0.478 . . . . 65.54 110.9 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.5 m -129.47 147.0 33.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 73.21 111.102 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -164.26 128.78 1.87 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.741 -0.742 . . . . 64.52 112.475 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 23.4 t -117.21 68.18 4.89 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.674 0.75 . . . . 53.12 111.155 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 162.67 41.21 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.679 2.253 . . . . 62.35 112.344 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -79.48 -165.67 0.83 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.265 -0.425 . . . . 72.5 111.059 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . 0.404 ' HA ' ' HA ' ' A' ' 97' ' ' ASP . 55.1 ttp85 -76.88 139.28 40.2 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.148 -0.478 . . . . 74.14 110.916 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -133.83 151.88 51.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 52.13 111.088 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.0 ttpt -104.48 130.7 52.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.16 -0.473 . . . . 72.41 110.863 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . 0.468 ' CD1' HD12 ' A' ' 49' ' ' ILE . 26.9 m-85 -119.26 157.42 28.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 74.43 110.879 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.433 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -110.84 149.53 30.45 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 73.42 110.926 -179.921 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.644 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -177.14 75.64 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.783 -0.722 . . . . 73.23 112.493 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.532 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.8 tp10 -178.26 -176.37 0.52 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.999 0.428 . . . . 73.15 110.866 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.31 -69.15 0.69 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.174 -0.466 . . . . 65.1 110.92 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.4 t -84.63 -32.88 23.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.254 -0.43 . . . . 73.3 110.855 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.87 HG22 HG22 ' A' ' 93' ' ' VAL . 5.8 mm -65.57 -34.31 69.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 74.54 111.129 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 74.2 p -62.57 -53.81 49.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.475 . . . . 44.23 110.852 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.7 t -51.13 -35.86 37.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.134 -0.485 . . . . 62.21 110.867 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.515 HD13 ' O ' ' A' ' 90' ' ' LEU . 0.3 OUTLIER -63.5 -38.26 90.47 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.139 -0.482 . . . . 62.32 110.96 179.921 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 100.56 -14.37 59.25 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.776 -0.726 . . . . 61.12 112.505 179.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 19.2 ttt-85 -118.63 95.38 4.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.797 0.332 . . . . 74.33 110.941 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.87 HG22 HG22 ' A' ' 87' ' ' ILE . 94.0 t -111.66 -53.81 5.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 62.44 111.184 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 11.5 t -140.26 143.05 35.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 65.12 110.821 -179.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -132.27 115.37 15.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 63.42 110.931 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.582 ' HA ' ' HB2' ' A' ' 131' ' ' LYS . 1.4 m -154.47 171.49 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.107 -0.497 . . . . 75.12 111.146 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.485 ' O ' HG23 ' A' ' 96' ' ' VAL . 1.1 m-20 -86.34 172.1 10.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.202 -0.454 . . . . 64.4 110.895 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -123.25 130.52 52.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.266 -0.424 . . . . 64.32 110.919 -179.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.543 ' HA3' HD12 ' A' ' 127' ' ' LEU . . . -129.12 65.63 0.58 Allowed Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.733 -0.746 . . . . 73.42 112.431 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 112.76 3.16 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.704 2.269 . . . . 62.11 112.381 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -127.43 105.06 8.25 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.167 -0.469 . . . . 73.43 111.054 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.636 HG23 ' CA ' ' A' ' 124' ' ' GLY . 4.8 mp -128.23 151.13 34.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 74.45 111.133 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -145.99 115.7 7.26 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 61.54 110.924 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.8 p -139.62 -175.82 4.34 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.216 -0.447 . . . . 72.02 110.832 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.638 ' O ' HD12 ' A' ' 105' ' ' LEU . 1.5 pp -134.54 147.86 50.38 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.139 -0.482 . . . . 53.32 110.908 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 1.8 pp0? -104.65 139.0 40.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 73.33 110.915 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.446 ' HA ' HG22 ' A' ' 67' ' ' ILE . 14.2 p90 -143.18 142.74 31.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 72.44 110.956 -179.864 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 17.5 t-160 . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.143 -0.481 . . . . 71.44 110.876 179.921 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 6.3 m-85 . . . . . 0 C--O 1.231 0.083 0 CA-C-O 121.714 0.769 . . . . 63.52 110.88 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . 0.704 ' HA ' HD13 ' A' ' 153' ' ' LEU . 54.1 Cg_endo -69.77 177.93 5.09 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.67 2.247 . . . . 74.34 112.333 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 11.2 m-85 -115.98 143.99 44.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.242 -0.436 . . . . 71.4 110.876 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.459 HG13 ' HE1' ' A' ' 149' ' ' PHE . 75.7 t -99.35 132.89 43.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.085 -0.507 . . . . 71.24 111.116 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -125.51 169.43 17.46 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.712 -0.756 . . . . 54.55 112.512 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 7.7 p -175.59 152.53 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.915 0.388 . . . . 63.44 111.125 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -179.78 -151.7 10.13 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.834 -0.698 . . . . 71.35 112.555 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.7 p -111.37 127.25 68.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.827 0.346 . . . . 64.11 111.103 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . 0.636 ' CA ' HG23 ' A' ' 102' ' ' ILE . . . -119.77 108.85 1.54 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.79 -0.719 . . . . 71.34 112.513 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 35.7 ptt180 -100.73 123.23 44.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.909 0.385 . . . . 71.44 110.891 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 34.6 t -103.12 110.27 29.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.174 -0.467 . . . . 74.2 111.136 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.543 HD12 ' HA3' ' A' ' 99' ' ' GLY . 2.8 pp -120.3 156.7 30.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.474 . . . . 70.23 110.903 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 9.4 p90 -160.43 166.04 29.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 74.3 110.855 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -102.24 118.03 36.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 74.3 110.899 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -66.11 93.48 0.21 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.129 -0.487 . . . . 60.32 110.89 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.582 ' HB2' ' HA ' ' A' ' 96' ' ' VAL . 0.0 OUTLIER -74.18 -76.39 0.13 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.243 -0.435 . . . . 65.43 110.934 179.984 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 20.2 m -161.97 121.92 2.5 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.214 -0.448 . . . . 74.24 111.055 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . 0.583 ' HB3' ' HB3' ' A' ' 139' ' ' PHE . 27.0 t0 -108.08 114.56 28.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 43.43 110.789 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -75.78 -12.42 83.88 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.691 -0.766 . . . . 64.23 112.469 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -44.37 -29.36 0.67 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.902 0.382 . . . . 51.11 111.083 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -160.29 163.96 32.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.236 -0.438 . . . . 74.14 110.867 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.8 m -42.17 97.86 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.136 -0.484 . . . . 72.22 110.922 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 70.7 m 49.81 65.16 1.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 70.0 110.908 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.583 ' HB3' ' HB3' ' A' ' 133' ' ' ASP . 1.2 t80 -94.5 160.85 14.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 73.42 110.868 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -139.96 167.19 22.69 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.124 -0.489 . . . . 53.34 110.848 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.474 ' HA ' HG23 ' A' ' 176' ' ' VAL . 15.4 mt -117.36 151.79 19.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.471 . . . . 74.42 111.151 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 12.3 tppt? -113.18 122.62 48.05 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 75.45 110.913 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -76.81 -173.74 2.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.129 -0.487 . . . . 73.45 110.853 179.85 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -171.75 179.09 2.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 75.21 110.931 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 52.1 p-90 -140.06 161.37 37.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.216 -0.447 . . . . 74.3 110.881 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.757 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.8 165.29 0.87 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.59 0.71 . . . . 62.3 111.135 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' PRO . . . . . 0.757 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 54.5 Cg_endo -69.74 161.92 44.08 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.673 2.248 . . . . 74.42 112.402 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.403 ' HA ' ' CB ' ' A' ' 170' ' ' ILE . . . -151.3 146.01 25.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 71.4 111.142 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . 0.459 ' HE1' HG13 ' A' ' 119' ' ' VAL . 1.4 t80 -103.07 120.24 40.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 52.12 110.896 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 16.7 tt0 -102.94 156.87 17.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 63.04 110.899 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.443 HG13 ' HB ' ' A' ' 167' ' ' VAL . 7.3 p -164.85 123.67 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.264 -0.426 . . . . 72.0 111.146 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -174.73 -159.54 21.19 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.717 -0.754 . . . . 51.23 112.47 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.704 HD13 ' HA ' ' A' ' 117' ' ' PRO . 19.5 tp -151.8 164.78 36.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.784 0.325 . . . . 71.15 110.876 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.4 tpp85 -115.78 120.43 39.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 75.44 110.931 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -104.68 154.79 19.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 74.43 110.933 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -120.24 104.18 9.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.116 -0.493 . . . . 72.11 110.824 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' LEU . . . . . 0.636 HD11 HD12 ' A' ' 163' ' ' LEU . 23.6 mt -72.57 153.1 41.45 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 71.0 110.905 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -53.0 -33.44 44.24 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.759 -0.734 . . . . 52.44 112.523 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -71.32 176.18 4.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.819 0.342 . . . . 73.41 110.847 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 73.0 m -60.86 -36.53 79.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.127 -0.488 . . . . 73.24 110.884 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 26.6 m0 -80.92 144.17 32.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 74.01 110.945 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' MET . . . . . 0.451 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 2.4 mpt? -106.77 169.56 8.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 74.52 110.876 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.636 HD12 HD11 ' A' ' 157' ' ' LEU . 0.3 OUTLIER -107.24 148.78 28.5 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 53.11 110.916 -179.975 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -143.85 133.28 23.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 75.21 110.857 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 42.1 t -135.41 122.53 21.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 70.22 110.858 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -131.47 153.71 49.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.107 -0.497 . . . . 74.34 110.945 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.621 HG13 ' HE1' ' A' ' 194' ' ' PHE . 78.4 t -133.45 121.49 41.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.27 -0.423 . . . . 60.54 111.089 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . 0.798 ' HD2' HD12 ' A' ' 195' ' ' ILE . 3.9 ttm-85 -103.46 132.41 49.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 64.21 110.876 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -143.01 128.18 18.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 75.4 110.942 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 170' ' ' ILE . . . . . 0.459 HG21 ' O ' ' A' ' 147' ' ' PRO . 3.6 tp 177.91 133.78 0.22 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.576 0.703 . . . . 75.33 111.118 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . 0.407 ' HD2' HG13 ' A' ' 170' ' ' ILE . 53.5 Cg_endo -69.74 111.6 2.85 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.676 2.251 . . . . 50.45 112.366 179.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -122.5 153.16 39.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 73.35 110.909 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 14.5 pttm -130.57 153.58 48.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 61.43 110.854 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -123.28 170.74 9.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.126 -0.488 . . . . 73.52 111.094 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -125.03 164.88 19.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 73.04 110.87 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.48 HG22 ' CE1' ' A' ' 139' ' ' PHE . 5.6 p -156.46 142.63 10.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 73.1 111.117 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 10.0 t -166.62 -179.25 4.76 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.215 -0.448 . . . . 62.34 111.12 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -120.49 -161.1 11.36 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.734 -0.746 . . . . 64.32 112.475 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.285 0 CA-C-O 120.786 0.327 . . . . 71.21 111.178 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.231 0.161 0 CA-C-O 120.828 0.262 . . . . 73.33 112.359 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.444 HG12 ' CG2' ' A' ' 187' ' ' THR . 21.6 t -127.17 107.2 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.222 -0.445 . . . . 71.44 111.179 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 1.2 p -74.93 104.43 5.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.199 -0.455 . . . . 74.4 110.865 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . 0.444 ' CG2' HG12 ' A' ' 185' ' ' VAL . 12.1 p -131.6 172.06 12.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.105 -0.498 . . . . 65.1 111.155 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.84 162.62 39.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.265 -0.425 . . . . 75.4 110.914 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 189' ' ' ILE . . . . . 0.484 HD11 ' CD1' ' A' ' 32' ' ' LEU . 56.7 mt -137.85 128.33 37.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 74.21 111.153 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -106.57 113.3 26.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.133 -0.485 . . . . 71.33 110.871 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 191' ' ' VAL . . . . . 0.49 HG12 ' H ' ' A' ' 192' ' ' ASP . 1.3 t -136.96 169.59 19.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.087 -0.506 . . . . 62.41 111.088 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.49 ' H ' HG12 ' A' ' 191' ' ' VAL . 20.5 t70 -107.27 87.14 2.98 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.61 0.719 . . . . 51.43 110.896 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 121.51 8.19 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.631 2.22 . . . . 65.41 112.395 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 194' ' ' PHE . . . . . 0.621 ' HE1' HG13 ' A' ' 167' ' ' VAL . 1.7 t80 -103.12 115.89 31.46 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 52.12 110.881 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 195' ' ' ILE . . . . . 0.798 HD12 ' HD2' ' A' ' 168' ' ' ARG . 9.7 mt -102.9 124.68 57.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 61.54 111.118 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 1.2 tt -112.71 108.54 17.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 74.31 110.897 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.25 115.68 28.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.257 -0.429 . . . . 71.34 110.818 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 198' ' ' LEU . . . . . 0.404 ' C ' ' HB2' ' A' ' 22' ' ' ASN . 5.7 tt -138.21 121.06 16.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.122 -0.49 . . . . 74.13 110.938 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -175.36 -141.44 3.73 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.825 -0.702 . . . . 64.5 112.538 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 200' ' ' ALA . . . . . 0.451 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -128.51 173.82 9.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.781 0.324 . . . . 70.03 111.104 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 26.2 t -146.55 163.51 35.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.458 . . . . 74.22 110.832 -179.749 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 202' ' ' TYR . . . . . 0.551 ' C ' HG23 ' A' ' 18' ' ' VAL . 2.1 t80 -133.9 114.4 13.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.149 -0.478 . . . . 75.31 110.883 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 57.8 t -76.88 145.11 10.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.091 -0.504 . . . . 72.15 111.108 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 -148.08 137.01 21.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.107 -0.497 . . . . 72.35 110.888 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.081 -0.508 . . . . 75.2 110.898 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.4 mp0 . . . . . 0 C--O 1.23 0.061 0 CA-C-O 120.805 0.335 . . . . 74.05 110.904 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.87 6.45 40.17 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.808 -0.711 . . . . 52.35 112.533 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -67.11 145.45 55.29 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.778 0.323 . . . . 72.05 110.857 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -125.43 121.68 34.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.203 -0.453 . . . . 52.33 110.894 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.724 HG23 ' HB3' ' A' ' 60' ' ' ALA . 13.5 m -130.69 134.91 61.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 63.23 111.145 179.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.56 ' HB1' ' CZ ' ' A' ' 21' ' ' PHE . . . -94.24 116.81 29.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 45.52 111.162 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 p -105.94 108.21 19.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 65.42 110.796 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.56 ' CZ ' ' HB1' ' A' ' 19' ' ' ALA . 16.5 m-85 -112.11 121.22 44.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.146 -0.479 . . . . 71.25 110.89 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -152.15 172.46 16.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 73.35 110.885 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -95.89 131.97 41.68 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 73.22 110.819 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -101.01 109.92 21.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.111 -0.495 . . . . 64.03 110.882 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 29.4 mmtt -93.9 106.33 18.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.485 . . . . 74.35 110.89 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.682 HG22 ' CD1' ' A' ' 195' ' ' ILE . 21.8 t -79.62 121.08 32.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.259 -0.428 . . . . 71.1 111.128 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.512 ' CD1' HD13 ' A' ' 196' ' ' LEU . 10.5 m-85 -105.64 99.67 9.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 75.22 110.948 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.9 HG23 HG11 ' A' ' 191' ' ' VAL . 5.5 p -167.69 141.09 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.123 -0.49 . . . . 74.2 111.16 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.75 72.09 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.753 -0.736 . . . . 54.03 112.44 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 16.6 tt0 -89.93 -66.19 0.95 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.809 0.338 . . . . 72.32 110.85 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 179.4 103.44 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 73.43 110.89 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.688 HD22 ' C ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -57.15 167.25 0.91 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.092 -0.504 . . . . 72.23 110.901 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.549 ' N ' HD22 ' A' ' 32' ' ' LEU . . . . . . . . 0 N--CA 1.451 -0.305 0 C-N-CA 120.705 -0.759 . . . . 61.24 112.506 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.4 ' HB1' HD11 ' A' ' 32' ' ' LEU . . . . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.755 0.312 . . . . 71.44 111.164 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -150.43 125.25 9.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.276 -0.42 . . . . 64.15 110.873 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 82' ' ' GLN . 12.5 p -119.13 134.02 64.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.203 -0.453 . . . . 72.41 111.114 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.9 m -153.45 178.51 9.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 54.52 110.849 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.532 HG22 ' CD1' ' A' ' 81' ' ' PHE . 42.6 pt -134.97 145.88 31.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.094 -0.503 . . . . 72.52 111.173 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -62.33 179.13 4.77 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.768 -0.73 . . . . 62.22 112.518 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.7 m-80 -119.96 107.84 13.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.8 0.333 . . . . 54.1 110.896 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -143.92 148.53 35.51 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 71.4 110.898 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.9 p -61.46 134.26 56.69 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.217 -0.447 . . . . 64.02 111.151 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 15.3 t -143.75 169.68 17.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 41.34 111.133 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -155.9 160.44 40.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 71.24 110.931 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.442 HG22 ' HA3' ' A' ' 74' ' ' GLY . 8.8 p -141.12 142.51 34.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.449 . . . . 60.13 111.162 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -102.44 132.2 48.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 73.35 110.899 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.65 ' O ' HD13 ' A' ' 59' ' ' ILE . 1.3 m-20 -129.14 149.91 50.75 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.142 -0.481 . . . . 70.33 110.863 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.65 HD13 ' O ' ' A' ' 58' ' ' ASP . 8.0 mm -122.39 114.36 42.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.443 . . . . 72.03 111.175 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.724 ' HB3' HG23 ' A' ' 18' ' ' VAL . . . -101.92 130.06 48.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 72.12 111.086 179.831 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.501 ' HB3' HG22 ' A' ' 69' ' ' VAL . 14.9 t80 -118.15 118.35 31.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.233 -0.439 . . . . 74.43 110.936 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -90.52 97.01 10.93 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.156 -0.474 . . . . 72.01 110.897 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.0 p -91.16 -34.91 6.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.206 -0.452 . . . . 73.44 111.129 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.2 t -130.02 159.67 35.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 64.33 110.894 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 93.4 p -84.13 2.76 37.96 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 61.13 110.827 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 41.2 m-80 -112.01 -32.5 6.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 73.34 110.876 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.511 HG22 ' CB ' ' A' ' 107' ' ' TYR . 2.3 pp -149.13 164.78 4.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.474 . . . . 74.44 111.142 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -154.68 169.89 22.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 60.04 111.124 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.501 HG22 ' HB3' ' A' ' 61' ' ' TYR . 6.1 m -110.97 152.93 12.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.445 . . . . 74.14 111.112 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -148.61 124.27 10.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.465 . . . . 54.32 110.875 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.658 ' CZ ' HD22 ' A' ' 103' ' ' LEU . 2.4 t80 -102.72 131.06 49.8 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 64.33 110.917 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.553 ' HE2' ' HG ' ' A' ' 197' ' ' SER . 24.2 m-85 -111.65 118.64 36.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.108 -0.496 . . . . 72.43 110.829 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.0 p -142.51 151.79 17.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 42.0 111.116 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.442 ' HA3' HG22 ' A' ' 56' ' ' THR . . . -160.05 160.7 31.85 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.732 . . . . 74.11 112.491 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.477 ' O ' HG13 ' A' ' 75' ' ' VAL . 4.0 p -138.29 77.72 35.08 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.691 0.758 . . . . 72.32 111.129 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 152.26 69.32 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.734 2.289 . . . . 73.35 112.346 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -71.17 -168.38 0.29 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 72.01 111.071 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 19.8 ttp-105 -77.58 127.31 32.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 74.23 110.857 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -133.66 140.69 47.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 44.23 111.118 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -89.58 141.73 28.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.443 . . . . 54.23 110.921 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . 0.532 ' CD1' HG22 ' A' ' 49' ' ' ILE . 11.9 m-85 -132.73 147.43 52.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.237 -0.438 . . . . 72.43 110.858 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.583 ' O ' HG23 ' A' ' 47' ' ' VAL . 0.4 OUTLIER -92.82 155.52 17.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 65.41 110.877 -179.92 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.537 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -179.46 72.79 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.759 -0.734 . . . . 61.34 112.517 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -178.9 -174.15 0.34 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.937 0.399 . . . . 70.12 110.846 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 6.0 mtpt -85.82 -70.17 0.61 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.114 -0.494 . . . . 72.33 110.904 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 74.0 m -84.3 -31.1 25.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.259 -0.428 . . . . 72.11 110.899 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.929 HG22 HG22 ' A' ' 93' ' ' VAL . 1.2 mt -68.17 -33.73 62.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.122 -0.49 . . . . 74.45 111.119 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.2 t -62.46 -47.26 84.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 74.32 110.842 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 36.9 t -57.69 -35.37 70.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.183 -0.462 . . . . 75.3 110.833 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.541 HD23 ' HG2' ' A' ' 92' ' ' ARG . 4.2 tp -63.64 -48.33 77.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.474 . . . . 71.31 110.988 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 111.37 -13.33 28.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.716 -0.754 . . . . 64.13 112.474 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.541 ' HG2' HD23 ' A' ' 90' ' ' LEU . 0.0 OUTLIER -117.79 87.47 2.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.906 0.384 . . . . 73.44 110.911 -179.837 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.929 HG22 HG22 ' A' ' 87' ' ' ILE . 32.3 t -113.05 -42.05 4.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.195 -0.457 . . . . 75.15 111.14 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 80.4 p -141.0 152.05 44.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.253 -0.43 . . . . 54.34 110.897 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -141.43 116.98 10.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.141 -0.481 . . . . 72.13 110.92 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.746 HG23 ' HB2' ' A' ' 131' ' ' LYS . 2.6 p -178.23 166.42 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 72.3 111.182 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.473 ' H ' HG22 ' A' ' 96' ' ' VAL . 2.5 p30 -95.07 156.48 16.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 72.42 110.855 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -93.98 147.63 22.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.165 -0.471 . . . . 64.24 110.99 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -126.39 60.87 0.64 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.773 -0.727 . . . . 70.52 112.501 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 113.86 3.52 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.644 2.229 . . . . 53.33 112.323 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.43 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -131.47 108.53 9.65 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.167 -0.469 . . . . 52.42 111.079 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.689 HG22 ' CA ' ' A' ' 124' ' ' GLY . 1.2 pp -140.27 153.06 21.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.481 . . . . 73.3 111.085 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.658 HD22 ' CZ ' ' A' ' 71' ' ' PHE . 0.7 OUTLIER -149.62 130.97 14.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.145 -0.48 . . . . 43.31 110.924 179.913 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.2 p -151.34 170.45 19.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 52.0 110.87 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.593 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.7 OUTLIER -113.46 147.01 38.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 74.21 110.908 179.981 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 34.4 mt-30 -101.7 144.78 29.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.181 -0.463 . . . . 73.54 110.98 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.511 ' CB ' HG22 ' A' ' 67' ' ' ILE . 46.7 p90 -153.73 150.4 28.49 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.244 -0.435 . . . . 63.34 110.967 -179.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 2.2 p80 . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.126 -0.488 . . . . 75.1 110.863 179.937 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 8.1 m-85 . . . . . 0 C--O 1.231 0.097 0 CA-C-O 121.683 0.754 . . . . 75.43 110.919 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . 0.418 ' HA ' HD13 ' A' ' 153' ' ' LEU . 54.3 Cg_endo -69.72 177.38 5.61 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.685 2.257 . . . . 74.54 112.38 179.884 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . 0.433 ' CE1' HD12 ' A' ' 153' ' ' LEU . 3.0 m-85 -115.32 152.4 32.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.191 -0.459 . . . . 74.43 110.864 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 61.6 t -111.0 141.13 27.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.102 -0.499 . . . . 60.44 111.186 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -133.39 175.69 20.04 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.775 -0.726 . . . . 71.15 112.546 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.5 p -168.16 151.97 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.944 0.402 . . . . 61.12 111.058 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -179.54 -149.68 8.57 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.714 -0.755 . . . . 73.12 112.517 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 11.3 p -108.01 146.07 14.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.829 0.347 . . . . 73.24 111.168 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . 0.689 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -140.99 121.03 1.82 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.806 -0.712 . . . . 61.41 112.51 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . 0.43 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 3.1 ptm180 -117.48 128.7 55.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.893 0.378 . . . . 74.54 110.874 -179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 97.8 t -105.94 109.44 27.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.091 -0.504 . . . . 63.44 111.161 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.445 HD23 ' HB2' ' A' ' 143' ' ' ASP . 41.7 mt -118.22 171.99 7.74 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.125 -0.489 . . . . 71.33 110.896 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -148.41 176.39 10.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 72.52 110.949 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.594 ' O ' HG21 ' A' ' 96' ' ' VAL . 2.5 t80 -104.57 171.71 7.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 73.04 110.812 -179.897 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 16.8 t0 -109.72 96.58 6.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.122 -0.49 . . . . 75.44 110.847 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.746 ' HB2' HG23 ' A' ' 96' ' ' VAL . 2.0 mmmp? -118.1 -81.44 0.62 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.466 . . . . 73.02 110.892 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 98.5 m -162.64 85.24 0.55 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.202 -0.454 . . . . 71.12 111.15 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -99.15 161.67 13.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.221 -0.445 . . . . 72.42 110.885 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.46 154.08 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.705 -0.759 . . . . 71.23 112.489 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.533 ' CB ' HD13 ' A' ' 87' ' ' ILE . . . -82.51 3.24 29.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.833 0.349 . . . . 70.2 111.149 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.457 HD22 ' N ' ' A' ' 136' ' ' LEU . 2.7 mm? -86.83 -176.14 5.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 71.23 110.937 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 23.1 t -65.0 87.0 0.06 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 75.35 110.849 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 65.5 m 51.93 75.37 0.22 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 74.02 110.878 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -91.03 157.11 17.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.481 . . . . 61.41 110.883 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -138.12 -173.9 3.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.107 -0.497 . . . . 71.2 110.878 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.786 HG22 HG13 ' A' ' 176' ' ' VAL . 5.1 pt -141.0 156.98 22.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.205 -0.452 . . . . 70.23 111.147 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . 0.433 ' HB2' ' HB3' ' A' ' 175' ' ' ASP . 1.8 tttt -96.02 116.39 28.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.159 -0.473 . . . . 72.43 110.941 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.445 ' HB2' HD23 ' A' ' 127' ' ' LEU . 0.9 OUTLIER -63.33 -173.76 0.07 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.241 -0.436 . . . . 71.21 110.866 179.887 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -157.18 169.72 24.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.242 -0.435 . . . . 73.33 110.955 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 28.0 p-90 -156.69 146.71 21.06 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.341 -0.39 . . . . 75.5 110.893 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.722 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 179.95 165.06 0.84 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.549 0.69 . . . . 72.32 111.097 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' PRO . . . . . 0.722 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.1 Cg_endo -69.82 140.41 42.4 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.677 2.252 . . . . 70.35 112.314 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.651 ' HB1' ' O ' ' A' ' 169' ' ' TYR . . . -135.98 177.82 7.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 74.2 111.096 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -126.63 166.54 17.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.18 -0.464 . . . . 74.44 110.872 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 11.3 tt0 -145.32 155.29 43.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 74.31 110.912 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.1 p -154.92 126.87 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.226 -0.443 . . . . 61.35 111.15 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -177.79 -158.69 21.27 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.677 -0.773 . . . . 53.14 112.43 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.433 HD12 ' CE1' ' A' ' 118' ' ' TYR . 46.7 tp -145.17 157.39 44.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.844 0.354 . . . . 74.42 110.867 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 6.2 tpp85 -120.97 117.71 27.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 72.3 110.85 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 3.0 t80 -95.91 132.21 41.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 74.02 110.928 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -119.23 113.34 20.71 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.162 -0.472 . . . . 71.11 110.879 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' LEU . . . . . 0.46 HD12 ' O ' ' A' ' 161' ' ' TRP . 38.8 mt -88.44 163.02 16.16 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.209 -0.451 . . . . 72.12 110.861 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -99.44 126.91 9.08 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.758 -0.734 . . . . 71.0 112.482 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 65.3 m-20 58.78 37.84 24.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.873 0.368 . . . . 75.21 110.916 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 3.1 m -167.18 178.03 5.86 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.167 -0.47 . . . . 72.42 110.869 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' TRP . . . . . 0.46 ' O ' HD12 ' A' ' 157' ' ' LEU . 5.3 m-90 -64.12 162.09 14.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 71.4 110.936 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' MET . . . . . 0.421 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 21.5 mtm -106.64 170.56 7.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.231 -0.44 . . . . 74.51 110.918 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.509 HD23 ' N ' ' A' ' 164' ' ' ASN . 1.2 tt -124.08 148.81 46.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.246 -0.434 . . . . 71.54 110.904 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . 0.509 ' N ' HD23 ' A' ' 163' ' ' LEU . 4.8 t-20 -143.94 131.79 21.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 73.31 110.887 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 60.5 p -146.56 122.23 10.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.446 . . . . 75.02 110.807 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -157.69 161.22 38.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.053 -0.521 . . . . 73.43 110.89 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 10.9 t -118.58 130.52 73.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 74.5 111.128 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . 0.585 ' CZ ' HD13 ' A' ' 102' ' ' ILE . 0.0 OUTLIER -107.04 122.17 45.93 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.169 -0.468 . . . . 64.4 110.866 -179.958 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 169' ' ' TYR . . . . . 0.651 ' O ' ' HB1' ' A' ' 148' ' ' ALA . 15.3 t80 -108.29 115.56 30.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.184 -0.462 . . . . 73.44 110.927 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 170' ' ' ILE . . . . . 0.563 HG23 ' HG2' ' A' ' 193' ' ' PRO . 9.6 tt -134.45 79.35 54.59 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.558 0.694 . . . . 65.12 111.092 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . 0.424 ' HA ' ' HD2' ' A' ' 193' ' ' PRO . 54.0 Cg_endo -69.72 125.06 11.72 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.587 2.192 . . . . 74.24 112.364 179.835 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 11.8 p90 -162.14 177.58 9.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 74.32 110.891 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 10.1 pttp -122.83 137.69 54.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.126 -0.488 . . . . 62.42 110.844 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.49 156.1 18.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 62.43 111.146 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . 0.433 ' HB3' ' HB2' ' A' ' 142' ' ' LYS . 0.1 OUTLIER -111.81 161.24 16.55 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.259 -0.428 . . . . 71.52 110.915 179.851 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.786 HG13 HG22 ' A' ' 141' ' ' ILE . 4.7 t -138.31 133.01 42.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.229 -0.441 . . . . 75.51 111.17 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.7 t -166.36 160.48 15.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 74.03 111.134 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -160.38 -133.48 1.5 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.704 -0.76 . . . . 44.34 112.479 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 52.9 m . . . . . 0 C--N 1.329 -0.303 0 CA-C-O 120.817 0.342 . . . . 63.55 111.089 -179.86 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo . . . . . 0 N--CA 1.465 -0.165 0 CA-C-O 120.854 0.273 . . . . 72.13 112.324 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 82.5 t -96.28 107.74 20.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 72.41 111.129 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -108.66 125.46 51.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 63.13 110.882 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 12.8 p -139.66 174.73 10.21 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.099 -0.501 . . . . 64.44 111.128 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 34.4 ttpt -158.95 145.35 16.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 65.34 110.921 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 8.6 tt -143.15 138.31 26.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 64.54 111.147 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -102.17 119.71 39.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.234 -0.439 . . . . 74.1 110.968 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 191' ' ' VAL . . . . . 0.9 HG11 HG23 ' A' ' 28' ' ' VAL . 4.1 t -136.82 158.25 36.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 73.12 111.168 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.4 ' N ' HG12 ' A' ' 191' ' ' VAL . 0.4 OUTLIER -107.73 89.95 5.76 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.624 0.725 . . . . 74.11 110.933 179.857 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . 0.563 ' HG2' HG23 ' A' ' 170' ' ' ILE . 53.2 Cg_endo -69.8 121.62 8.3 Favored 'Trans proline' 0 C--O 1.232 0.211 0 C-N-CA 122.697 2.265 . . . . 71.22 112.296 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -99.76 107.43 19.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.268 -0.424 . . . . 74.23 110.889 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 195' ' ' ILE . . . . . 0.682 ' CD1' HG22 ' A' ' 26' ' ' VAL . 49.1 mm -87.93 119.39 35.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.138 -0.483 . . . . 60.44 111.148 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . 0.512 HD13 ' CD1' ' A' ' 27' ' ' TYR . 5.4 mp -105.98 108.18 19.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.206 -0.452 . . . . 64.24 110.951 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 197' ' ' SER . . . . . 0.553 ' HG ' ' HE2' ' A' ' 72' ' ' PHE . 9.4 m -98.97 112.03 24.26 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.213 -0.448 . . . . 75.13 110.897 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 1.9 tt -136.72 119.88 16.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 64.44 110.899 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -176.16 -145.55 5.61 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.779 -0.724 . . . . 65.51 112.482 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 200' ' ' ALA . . . . . 0.421 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -125.17 173.83 8.49 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.75 0.31 . . . . 65.2 111.186 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.7 t -148.89 169.77 19.8 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.26 -0.427 . . . . 63.02 110.835 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -138.8 146.01 40.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.131 -0.486 . . . . 72.52 110.878 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.691 ' HA ' HG12 ' A' ' 18' ' ' VAL . 15.6 m -97.91 144.81 10.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.124 -0.489 . . . . 43.52 111.158 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -148.28 139.75 23.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.48 . . . . 74.43 110.812 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.09 -0.504 . . . . 71.44 110.892 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 . . . . . 0 N--CA 1.458 -0.054 0 CA-C-O 120.813 0.34 . . . . 65.42 110.964 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 103.28 11.67 33.2 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.675 -0.774 . . . . 53.34 112.514 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -83.28 159.16 21.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.781 0.324 . . . . 70.54 110.887 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 13.3 m95 -107.36 158.34 17.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.247 -0.433 . . . . 73.54 110.902 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.462 HG13 ' O ' ' A' ' 202' ' ' TYR . 42.9 t -150.71 120.78 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.281 -0.418 . . . . 72.51 111.133 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -87.77 110.08 20.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 63.11 111.117 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 6.5 t -107.61 113.3 26.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.214 -0.448 . . . . 74.43 110.894 -179.822 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.677 ' CE1' ' HB3' ' A' ' 200' ' ' ALA . 17.0 p90 -108.41 122.36 46.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 75.1 110.863 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -152.76 167.93 27.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.138 -0.483 . . . . 54.23 110.92 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -102.01 134.89 44.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 70.01 110.929 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -102.69 122.68 44.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 65.32 110.801 -179.763 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 11.3 tptm -96.59 106.61 18.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.054 -0.521 . . . . 64.11 110.83 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 34.3 m -78.86 134.0 28.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.456 . . . . 70.22 111.201 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 17.0 t80 -130.9 99.74 5.01 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.223 -0.444 . . . . 75.42 110.9 -179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.0 p -165.82 152.86 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.118 -0.492 . . . . 75.34 111.127 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 123.59 77.11 0.35 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.739 -0.743 . . . . 71.34 112.48 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 25.6 pt-20 -90.26 -44.11 9.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.837 0.351 . . . . 75.34 110.85 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.683 ' HA ' HG22 ' A' ' 47' ' ' VAL . 0.9 OUTLIER 178.58 170.64 0.81 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 70.32 110.866 -179.937 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.482 HD23 ' CB ' ' A' ' 45' ' ' ALA . 20.8 tp -74.9 161.58 29.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.131 -0.486 . . . . 64.31 110.876 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.709 -0.757 . . . . 51.13 112.496 179.92 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.482 ' CB ' HD23 ' A' ' 32' ' ' LEU . . . . . . . . 0 N--CA 1.457 -0.123 0 CA-C-O 120.807 0.337 . . . . 74.22 111.071 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -161.2 128.61 4.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.225 -0.443 . . . . 73.23 110.861 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.683 HG22 ' HA ' ' A' ' 31' ' ' GLU . 22.3 m -104.36 167.39 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 45.3 111.15 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -164.76 174.41 10.72 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.13 -0.486 . . . . 74.24 110.804 -179.806 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 7.9 tt -134.04 149.24 30.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.089 -0.505 . . . . 65.11 111.08 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -139.3 85.5 0.22 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.709 -0.758 . . . . 74.41 112.468 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -147.77 152.5 37.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.814 0.34 . . . . 72.54 110.925 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 46.2 m-20 -104.0 178.09 4.66 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.156 -0.474 . . . . 71.12 110.818 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 2.3 t -55.73 150.22 13.09 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 73.42 111.124 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -151.58 162.72 40.5 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.208 -0.451 . . . . 75.23 111.112 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 20.3 mt -108.28 153.49 23.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.169 -0.469 . . . . 75.11 110.978 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.703 HG21 ' CZ ' ' A' ' 72' ' ' PHE . 0.0 OUTLIER -135.56 147.89 48.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.26 -0.427 . . . . 70.05 111.062 -179.995 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -104.22 131.49 51.48 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.18 -0.464 . . . . 73.45 110.835 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 -126.63 138.29 53.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.19 -0.459 . . . . 60.55 110.85 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.404 ' O ' HG22 ' A' ' 59' ' ' ILE . 1.6 mp -108.08 113.56 44.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.144 -0.48 . . . . 65.05 111.132 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -106.02 120.39 41.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 74.42 111.161 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.671 ' HB3' HG22 ' A' ' 69' ' ' VAL . 8.1 t80 -105.69 118.53 36.83 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.164 -0.471 . . . . 73.4 110.93 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -93.76 96.64 9.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.088 -0.505 . . . . 72.22 110.895 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.424 HG22 ' CE1' ' A' ' 61' ' ' TYR . 57.4 t -91.23 -35.17 6.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.144 -0.48 . . . . 73.44 111.133 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.6 m -131.87 163.42 28.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 74.13 110.894 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 33.4 m -87.49 3.45 47.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 62.33 110.865 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 7.1 m120 -107.77 -33.08 7.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.112 -0.495 . . . . 55.23 110.895 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.8 pt -150.36 169.9 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 62.34 111.142 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -157.12 167.32 30.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.45 . . . . 52.43 111.105 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.671 HG22 ' HB3' ' A' ' 61' ' ' TYR . 2.7 m -110.54 151.57 12.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.183 -0.462 . . . . 74.33 111.077 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -141.69 137.31 31.65 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.173 -0.467 . . . . 72.23 110.866 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -121.02 110.39 16.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.248 -0.433 . . . . 73.13 110.903 -179.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.703 ' CZ ' HG21 ' A' ' 56' ' ' THR . 41.0 t80 -87.27 125.95 34.53 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 75.34 110.908 -179.883 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 40.4 t -146.42 146.78 18.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.234 -0.439 . . . . 74.5 111.16 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.548 ' HA3' HG22 ' A' ' 56' ' ' THR . . . -147.97 178.89 25.26 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.673 -0.775 . . . . 60.34 112.458 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.6 t -144.26 66.0 13.81 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.583 0.706 . . . . 75.33 111.111 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 138.14 37.22 Favored 'Trans proline' 0 C--N 1.34 0.132 0 C-N-CA 122.714 2.276 . . . . 73.52 112.359 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -67.47 -166.81 0.05 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.213 -0.448 . . . . 35.34 111.161 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 23.1 ttp180 -75.77 123.75 26.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.242 -0.436 . . . . 63.24 110.881 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -110.66 150.93 28.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 71.03 111.166 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.22 119.51 38.85 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 71.52 110.891 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -114.31 144.84 42.59 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.213 -0.449 . . . . 73.24 110.858 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 28.3 mt-30 -104.26 153.22 21.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.453 . . . . 71.12 110.979 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.645 ' HA2' HG12 ' A' ' 47' ' ' VAL . . . -178.84 75.9 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.734 -0.746 . . . . 63.35 112.453 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -177.4 -177.46 0.7 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.899 0.381 . . . . 72.52 110.907 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.17 -68.96 0.7 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.152 -0.476 . . . . 63.24 110.917 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.6 m -84.97 -32.74 22.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.236 -0.438 . . . . 73.11 110.829 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.651 HG22 HG22 ' A' ' 93' ' ' VAL . 5.1 mm -66.52 -34.45 70.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.121 -0.491 . . . . 73.34 111.157 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 28.1 t -63.23 -51.28 66.86 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.177 -0.465 . . . . 73.21 110.831 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 58.5 m -51.46 -36.92 46.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.152 -0.476 . . . . 74.42 110.894 -179.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 35.9 mt -64.71 -42.92 94.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.487 . . . . 74.3 110.88 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.34 -13.98 39.71 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.831 -0.699 . . . . 74.21 112.534 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.1 mtp-105 -115.91 90.09 3.25 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.84 0.352 . . . . 74.25 110.825 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.651 HG22 HG22 ' A' ' 87' ' ' ILE . 3.9 t -113.79 -43.94 4.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 71.02 111.108 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.3 m -141.18 144.06 34.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 73.1 110.839 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -138.44 118.22 13.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.172 -0.467 . . . . 63.31 110.954 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.438 HG22 ' N ' ' A' ' 97' ' ' ASP . 5.3 p -178.14 164.41 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.485 . . . . 63.42 111.151 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.438 ' N ' HG22 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -100.21 173.0 6.82 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.208 -0.451 . . . . 62.03 110.923 179.908 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' TYR . . . . . 0.434 ' HA ' ' HB2' ' A' ' 128' ' ' PHE . 62.1 m-85 -133.16 141.3 48.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 74.52 110.873 -179.804 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -108.99 82.07 0.3 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.799 -0.715 . . . . 72.14 112.493 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 112.22 3.01 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.681 2.254 . . . . 74.35 112.374 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -124.89 94.98 4.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.259 -0.428 . . . . 71.21 111.168 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.49 HD12 ' CD1' ' A' ' 72' ' ' PHE . 12.2 mt -112.35 145.73 18.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 74.15 111.098 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -149.2 109.43 4.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 61.12 110.943 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.3 p -140.62 166.21 25.36 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 73.4 110.911 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.429 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -114.76 140.41 48.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.146 -0.479 . . . . 74.23 110.925 -179.99 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 6.9 pt20 -102.62 145.41 29.69 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 64.14 110.864 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 10.5 p90 -140.42 145.31 36.85 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.144 -0.48 . . . . 74.43 110.879 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 58.0 t60 . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.111 -0.495 . . . . 74.5 110.838 179.922 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . 0.414 ' HB2' ' HD2' ' A' ' 117' ' ' PRO . 6.4 p90 . . . . . 0 C--O 1.232 0.144 0 CA-C-O 121.628 0.727 . . . . 74.54 111.004 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . 0.414 ' HD2' ' HB2' ' A' ' 116' ' ' TYR . 53.4 Cg_endo -69.74 178.95 4.04 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.669 2.246 . . . . 74.43 112.335 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -108.82 157.2 18.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 72.42 110.878 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 93.4 t -111.4 134.4 53.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.059 -0.519 . . . . 54.33 111.146 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -135.98 168.93 23.81 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.776 -0.726 . . . . 75.04 112.543 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 10.6 p -162.35 152.15 3.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.876 0.37 . . . . 73.05 111.131 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -176.83 -154.32 11.78 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.689 -0.767 . . . . 74.14 112.502 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.476 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 10.2 p -111.13 139.04 36.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.95 0.405 . . . . 60.14 111.086 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -128.72 115.75 2.08 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.777 -0.725 . . . . 62.53 112.546 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 17.3 ptp180 -122.82 116.59 23.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.852 0.358 . . . . 71.11 110.848 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.429 ' O ' HG13 ' A' ' 126' ' ' VAL . 3.6 p -117.22 114.48 45.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.182 -0.463 . . . . 52.32 111.043 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.425 HD21 ' HB3' ' A' ' 145' ' ' TRP . 0.0 OUTLIER -150.55 168.15 25.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 62.33 110.924 179.894 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.434 ' HB2' ' HA ' ' A' ' 98' ' ' TYR . 1.0 OUTLIER -164.36 -172.45 2.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 65.23 110.899 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -94.44 129.22 41.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 71.31 110.884 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -67.11 124.39 22.94 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.194 -0.457 . . . . 72.33 110.797 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 20.0 mmmt -102.39 -72.48 0.69 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.159 -0.473 . . . . 73.25 110.9 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -151.63 77.13 1.23 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 74.14 111.152 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -94.1 158.68 15.5 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.467 . . . . 71.54 110.905 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.02 159.71 0.19 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.728 -0.749 . . . . 61.1 112.544 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.599 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -78.01 4.93 10.96 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.819 0.342 . . . . 65.14 111.14 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.46 HD22 ' N ' ' A' ' 136' ' ' LEU . 2.8 mm? -86.27 -176.68 6.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 74.44 110.956 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.6 t -68.33 85.28 0.27 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.194 -0.457 . . . . 71.24 110.889 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 89.5 p 46.22 74.85 0.13 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 71.14 110.953 -179.729 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -86.29 156.5 20.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.149 -0.478 . . . . 74.33 110.837 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -107.62 175.01 5.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.068 -0.515 . . . . 54.24 110.886 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.656 HG22 HG13 ' A' ' 176' ' ' VAL . 24.7 pt -152.2 135.64 7.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 43.11 111.106 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . 0.626 ' O ' HG22 ' A' ' 174' ' ' THR . 0.0 OUTLIER -72.54 116.94 13.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.113 -0.494 . . . . 75.51 110.925 179.861 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -63.63 -158.43 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.452 . . . . 71.03 110.801 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . 0.625 ' NZ ' HG23 ' A' ' 170' ' ' ILE . 3.0 tttt -128.99 147.3 50.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 74.44 110.888 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' TRP . . . . . 0.425 ' HB3' HD21 ' A' ' 127' ' ' LEU . 43.2 p90 -158.6 119.01 3.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.156 -0.474 . . . . 70.02 110.897 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.834 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.38 168.46 0.8 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.566 0.698 . . . . 63.02 111.112 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' PRO . . . . . 0.834 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.4 Cg_endo -69.78 141.01 44.0 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.661 2.24 . . . . 50.43 112.362 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.6 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -135.27 168.15 19.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 71.01 111.102 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -116.79 139.78 50.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.243 -0.435 . . . . 74.41 110.837 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 -116.76 145.75 43.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.104 -0.498 . . . . 74.31 110.919 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.59 127.18 8.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.455 . . . . 74.02 111.133 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . 0.411 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 176.9 -179.6 47.77 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.724 -0.75 . . . . 55.22 112.531 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.494 ' H ' HD23 ' A' ' 153' ' ' LEU . 2.0 pt? -121.98 158.82 28.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.876 0.369 . . . . 73.31 110.842 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -142.79 128.34 19.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.187 -0.461 . . . . 62.23 110.847 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . 0.539 ' HB3' HD11 ' A' ' 163' ' ' LEU . 0.8 OUTLIER -145.33 179.5 7.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.483 . . . . 75.12 110.974 -179.901 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -114.16 90.76 3.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.179 -0.464 . . . . 62.54 110.839 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 24.4 tp -58.99 97.2 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 70.12 110.939 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 66.52 -136.38 34.03 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.716 -0.754 . . . . 70.22 112.495 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 52.2 t30 -119.49 -30.89 4.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.795 0.331 . . . . 72.44 110.886 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 35.7 m -49.4 -67.12 0.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.464 . . . . 64.14 110.833 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 5.3 p90 -147.54 161.87 40.22 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.152 -0.476 . . . . 62.44 110.886 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' MET . . . . . 0.556 ' SD ' HG13 ' A' ' 203' ' ' VAL . 78.7 mtp -93.28 172.13 8.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 61.41 110.888 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.822 HD22 ' C ' ' A' ' 163' ' ' LEU . 0.0 OUTLIER -136.09 152.08 50.49 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.187 -0.46 . . . . 64.5 111.002 179.972 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . 0.409 ' N ' HD22 ' A' ' 163' ' ' LEU . 6.1 t-20 -155.49 146.68 22.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.265 -0.425 . . . . 53.22 110.854 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 10.2 t -152.59 122.27 6.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.213 -0.448 . . . . 73.35 110.937 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 166' ' ' ASP . . . . . 0.411 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.3 OUTLIER -145.85 177.27 9.05 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.099 -0.501 . . . . 73.34 110.822 -179.982 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.451 HG13 ' O ' ' A' ' 195' ' ' ILE . 16.4 t -147.44 141.34 19.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 63.35 111.135 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . 0.401 ' HG2' HD12 ' A' ' 195' ' ' ILE . 0.0 OUTLIER -108.97 141.99 40.27 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.127 -0.488 . . . . 74.31 110.814 -179.967 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 9.5 t80 -139.86 138.88 36.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.11 -0.495 . . . . 74.34 110.916 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 170' ' ' ILE . . . . . 0.738 HD12 ' HD2' ' A' ' 171' ' ' PRO . 1.9 tp -177.87 110.04 0.22 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.613 0.72 . . . . 71.52 111.069 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . 0.738 ' HD2' HD12 ' A' ' 170' ' ' ILE . 52.9 Cg_endo -69.85 124.78 11.38 Favored 'Trans proline' 0 N--CA 1.464 -0.217 0 C-N-CA 122.685 2.256 . . . . 64.54 112.353 179.888 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . 0.516 ' CE2' ' HB2' ' A' ' 146' ' ' ALA . 2.3 t80 -147.04 177.49 9.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 71.23 110.883 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 22.1 pttm -136.73 137.32 39.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 52.01 110.922 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 174' ' ' THR . . . . . 0.626 HG22 ' O ' ' A' ' 142' ' ' LYS . 0.0 OUTLIER -99.51 169.55 9.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 63.24 111.149 -179.974 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . 0.423 ' HB3' ' HB2' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -129.87 161.98 29.58 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.257 -0.429 . . . . 64.33 110.891 179.933 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.656 HG13 HG22 ' A' ' 141' ' ' ILE . 99.1 t -144.46 127.22 11.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 73.25 111.111 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 5.0 t -163.7 166.04 22.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 72.4 111.182 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -167.7 -150.38 6.5 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.785 -0.721 . . . . 63.52 112.507 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . 0.402 ' O ' HG23 ' A' ' 179' ' ' THR . 1.7 t . . . . . 0 C--N 1.33 -0.249 0 CA-C-O 120.9 0.381 . . . . 64.04 111.081 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.232 0.177 0 CA-C-O 120.808 0.253 . . . . 71.43 112.359 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . 0.488 HG12 HG23 ' A' ' 187' ' ' THR . 57.3 t -96.16 105.34 16.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.275 -0.42 . . . . 73.01 111.063 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -104.78 104.88 14.74 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.173 -0.467 . . . . 74.43 110.843 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . 0.488 HG23 HG12 ' A' ' 185' ' ' VAL . 6.1 p -122.33 148.57 44.88 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.132 -0.485 . . . . 73.1 111.107 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.02 155.78 47.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.213 -0.449 . . . . 64.24 110.877 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 6.0 pt -144.01 109.91 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.46 . . . . 72.32 111.135 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -90.44 111.51 22.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 71.43 110.921 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 2.7 t -137.79 162.27 32.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 74.03 111.108 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -107.23 88.5 3.94 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.662 0.744 . . . . 43.25 110.871 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 138.45 37.83 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.708 2.272 . . . . 42.45 112.354 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -122.21 126.63 48.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.242 -0.435 . . . . 62.24 110.904 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 195' ' ' ILE . . . . . 0.451 ' O ' HG13 ' A' ' 167' ' ' VAL . 21.4 mt -112.44 120.01 61.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.175 -0.466 . . . . 72.42 111.109 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 9.5 tt -104.53 107.93 19.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.446 . . . . 64.53 110.918 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.1 t -96.49 123.4 40.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.128 -0.487 . . . . 62.21 110.878 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 27.2 tp -146.36 127.3 14.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 74.25 110.92 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -179.79 -150.68 9.29 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.711 -0.757 . . . . 42.15 112.496 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 200' ' ' ALA . . . . . 0.677 ' HB3' ' CE1' ' A' ' 21' ' ' PHE . . . -117.8 173.01 6.99 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.852 0.358 . . . . 73.34 111.101 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 2.3 p -149.7 169.48 20.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.466 . . . . 75.55 110.88 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 202' ' ' TYR . . . . . 0.462 ' O ' HG13 ' A' ' 18' ' ' VAL . 23.2 t80 -148.93 142.36 25.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 72.15 110.926 -179.868 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.556 HG13 ' SD ' ' A' ' 162' ' ' MET . 21.5 m -76.95 161.31 4.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.109 -0.496 . . . . 65.42 111.132 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -161.82 116.55 1.95 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 75.03 110.914 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 5.6 ttmm . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.161 -0.472 . . . . 64.12 110.906 -179.987 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 . . . . . 0 C--O 1.23 0.026 0 CA-C-O 120.801 0.334 . . . . 71.41 110.883 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.85 7.91 21.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.734 -0.746 . . . . 72.54 112.513 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -55.15 166.44 0.55 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.8 0.334 . . . . 71.04 110.865 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.415 ' HB2' ' HB3' ' A' ' 204' ' ' PHE . 10.9 m-90 -109.54 151.33 26.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.131 -0.486 . . . . 74.3 110.883 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.464 HG12 ' HB3' ' A' ' 60' ' ' ALA . 61.6 t -153.24 115.25 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.245 -0.434 . . . . 75.33 111.17 179.848 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.04 140.49 32.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.168 -0.469 . . . . 62.35 111.095 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.7 t -136.6 115.09 11.87 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 64.3 110.836 -179.787 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.579 ' CE2' ' HB3' ' A' ' 200' ' ' ALA . 1.9 p90 -123.15 117.11 24.62 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.087 -0.506 . . . . 73.3 110.861 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -152.79 169.58 22.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.13 -0.486 . . . . 72.25 110.882 -179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 21.5 p90 -102.85 135.33 44.72 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.15 -0.477 . . . . 73.22 110.813 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 1.3 p -102.3 137.54 40.42 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.063 -0.517 . . . . 63.25 110.873 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.4 ttmt -112.55 108.08 17.04 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.098 -0.501 . . . . 71.53 110.961 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.6 p -76.74 129.65 37.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.186 -0.461 . . . . 52.14 111.145 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -123.39 113.62 19.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 72.14 110.939 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.56 HG21 HG11 ' A' ' 191' ' ' VAL . 7.8 p -176.78 146.11 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.099 -0.5 . . . . 62.44 111.108 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.47 68.94 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.673 -0.775 . . . . 72.12 112.468 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -90.23 -66.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.751 0.31 . . . . 72.4 110.911 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 -175.98 167.78 2.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 71.34 110.931 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.619 HD12 HG21 ' A' ' 189' ' ' ILE . 41.4 tp -101.28 156.16 17.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 75.14 110.927 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.398 0 C-N-CA 120.809 -0.71 . . . . 71.04 112.556 179.93 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.82 0.343 . . . . 62.43 111.068 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -146.41 126.06 13.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.225 -0.443 . . . . 64.43 110.793 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 82' ' ' GLN . 12.0 p -104.79 138.19 30.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 63.15 111.063 -179.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 m -154.74 177.95 10.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.152 -0.476 . . . . 71.04 110.857 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -137.16 154.3 30.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 71.54 111.134 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -111.69 62.7 0.29 Allowed Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.682 -0.771 . . . . 55.53 112.441 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 32.5 m120 -87.88 162.94 16.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.872 0.368 . . . . 61.11 110.81 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -129.13 163.29 25.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.093 -0.503 . . . . 65.23 110.928 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.5 p -69.14 104.58 2.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 74.35 111.11 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -131.16 168.41 17.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.182 -0.463 . . . . 64.11 111.182 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.561 ' H ' HD23 ' A' ' 55' ' ' LEU . 1.0 OUTLIER -91.07 168.77 11.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 65.13 110.939 179.952 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.98 147.39 38.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.231 -0.441 . . . . 73.22 111.206 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -101.77 151.2 22.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.27 -0.423 . . . . 72.44 110.866 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.406 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.9 OUTLIER -149.81 135.48 18.47 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.169 -0.469 . . . . 51.41 110.902 -179.982 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.418 ' O ' HG22 ' A' ' 59' ' ' ILE . 1.6 mp -107.7 112.47 40.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 30.33 111.088 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.464 ' HB3' HG12 ' A' ' 18' ' ' VAL . . . -101.42 129.15 47.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 55.34 111.045 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.512 ' HB3' HG22 ' A' ' 69' ' ' VAL . 0.8 OUTLIER -117.0 128.47 55.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 75.3 110.916 -179.876 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -98.25 98.41 9.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.489 . . . . 74.41 110.881 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.9 p -95.88 -34.1 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 53.53 111.108 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 25.1 p -139.6 163.16 33.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.48 . . . . 52.31 110.816 -179.832 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 12.0 p -87.23 3.24 47.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 72.34 110.849 -179.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 20.1 m120 -106.55 -31.18 8.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.135 -0.484 . . . . 73.5 110.911 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.9 pt -150.43 165.48 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.122 -0.49 . . . . 74.35 111.091 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -146.8 166.9 25.28 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.104 -0.498 . . . . 70.04 111.061 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.512 HG22 ' HB3' ' A' ' 61' ' ' TYR . 6.1 m -114.78 151.41 16.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.161 -0.472 . . . . 75.03 111.086 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -144.62 132.28 21.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.135 -0.484 . . . . 72.24 110.822 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.406 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 5.5 m-85 -108.47 118.04 35.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 63.34 110.882 -179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -88.3 121.39 30.64 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.145 -0.48 . . . . 70.1 110.853 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 42.1 t -146.88 146.86 18.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.191 -0.459 . . . . 73.21 111.094 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -151.33 162.22 29.45 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.79 -0.719 . . . . 71.34 112.465 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.495 ' O ' HG13 ' A' ' 75' ' ' VAL . 6.8 p -115.47 70.64 3.17 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.655 0.741 . . . . 75.12 111.173 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 158.96 55.12 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.651 2.234 . . . . 62.03 112.324 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -104.04 -169.81 1.68 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.247 -0.433 . . . . 42.44 111.145 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 50.4 ttp180 -76.35 126.77 31.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.428 . . . . 74.35 110.856 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -121.62 150.3 41.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 61.53 111.141 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 5.5 tttm -84.16 107.81 16.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.252 -0.431 . . . . 65.3 110.966 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 72.0 t80 -84.43 128.29 34.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 75.51 110.85 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.441 ' O ' HG23 ' A' ' 47' ' ' VAL . 41.7 mt-30 -103.38 151.61 22.56 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.129 -0.487 . . . . 73.33 110.899 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.551 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 172.68 82.45 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.801 -0.714 . . . . 62.14 112.492 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -176.83 -175.08 0.59 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.879 0.371 . . . . 63.44 110.952 -179.903 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.84 -69.5 0.67 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 61.13 110.916 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.6 t -84.96 -31.61 23.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 75.33 110.913 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.828 HG22 HG22 ' A' ' 93' ' ' VAL . 1.1 mt -68.19 -34.23 65.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.11 -0.496 . . . . 74.15 111.143 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.6 t -63.3 -51.11 67.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.174 -0.467 . . . . 62.42 110.851 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.8 t -52.01 -38.87 58.32 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.081 -0.508 . . . . 64.03 110.873 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 13.6 mt -64.85 -35.34 80.81 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.14 -0.482 . . . . 74.44 110.909 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.15 -13.39 67.02 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.686 -0.768 . . . . 73.5 112.47 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 10.4 ptp180 -115.0 94.93 4.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.812 0.339 . . . . 71.31 110.837 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.828 HG22 HG22 ' A' ' 87' ' ' ILE . 99.9 t -111.66 -57.47 3.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.186 -0.461 . . . . 73.3 111.114 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 18.0 p -140.74 159.21 42.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 74.03 110.848 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -128.85 124.62 35.8 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.101 -0.5 . . . . 72.41 110.863 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.492 HG11 HG21 ' A' ' 141' ' ' ILE . 10.4 p -175.53 159.58 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.103 -0.499 . . . . 54.03 111.125 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.47 ' N ' HG22 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -106.81 173.11 6.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 64.24 110.926 179.863 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' TYR . . . . . 0.492 ' HA ' ' HB2' ' A' ' 128' ' ' PHE . 19.3 m-85 -133.61 144.04 49.01 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.255 -0.429 . . . . 72.54 110.94 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -106.91 87.09 0.49 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.781 -0.724 . . . . 74.03 112.46 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 124.72 11.38 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.697 2.264 . . . . 54.03 112.382 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.508 ' HB3' ' HG2' ' A' ' 125' ' ' ARG . . . -141.25 94.73 2.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 72.11 111.109 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.404 ' HA ' ' HA2' ' A' ' 124' ' ' GLY . 3.1 mp -117.35 153.99 19.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.195 -0.457 . . . . 74.41 111.11 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -153.03 108.57 3.28 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.191 -0.459 . . . . 75.12 110.913 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 23.6 p -134.38 166.4 22.92 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 75.24 110.859 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.587 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.8 OUTLIER -119.7 150.89 39.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 71.15 110.943 179.988 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -102.02 138.26 39.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.216 -0.447 . . . . 73.53 110.88 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 33.2 p90 -149.48 146.99 27.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 75.43 110.918 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 17.6 p80 . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.077 -0.51 . . . . 74.04 110.847 179.94 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 1.3 p90 . . . . . 0 C--O 1.232 0.15 0 CA-C-O 121.653 0.739 . . . . 53.41 110.935 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.77 177.76 5.27 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.664 2.242 . . . . 74.32 112.353 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -117.46 154.34 31.57 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.235 -0.439 . . . . 64.0 110.958 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 25.2 t -102.78 128.16 55.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.111 -0.495 . . . . 35.54 111.095 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -123.17 169.08 15.37 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.774 -0.726 . . . . 62.22 112.525 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 12.9 p -163.77 149.24 3.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.888 0.375 . . . . 75.41 111.131 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -171.47 -149.21 6.44 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.751 -0.738 . . . . 71.43 112.458 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.573 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 14.9 p -129.4 136.14 60.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.829 0.347 . . . . 74.31 111.146 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . 0.404 ' HA2' ' HA ' ' A' ' 102' ' ' ILE . . . -122.35 118.29 3.6 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.75 -0.738 . . . . 71.25 112.446 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . 0.508 ' HG2' ' HB3' ' A' ' 101' ' ' ALA . 0.0 OUTLIER -121.47 124.72 45.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.827 0.346 . . . . 74.33 110.939 -179.894 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 27.2 t -118.15 119.79 62.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.255 -0.43 . . . . 74.0 111.107 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.2 pp -150.99 156.57 41.43 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 72.44 110.888 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.492 ' HB2' ' HA ' ' A' ' 98' ' ' TYR . 0.6 OUTLIER -167.42 -173.42 2.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 71.24 110.907 179.949 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -96.89 142.87 28.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 74.53 110.91 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -78.37 114.58 17.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.451 . . . . 73.31 110.875 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.439 ' H ' HG23 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -76.05 -78.11 0.12 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 63.33 110.91 179.981 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 3.4 m -170.67 120.3 0.56 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.25 -0.432 . . . . 71.24 111.123 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . 0.406 ' HB2' ' CB ' ' A' ' 139' ' ' PHE . 0.8 OUTLIER -105.63 122.98 47.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.48 . . . . 41.44 110.813 179.953 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 135' ' ' ALA . . . -80.63 -22.89 61.17 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.699 -0.762 . . . . 72.24 112.464 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.637 ' HB2' ' CG1' ' A' ' 93' ' ' VAL . . . -36.95 -42.75 0.42 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.872 0.368 . . . . 54.02 111.164 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.508 HD22 ' O ' ' A' ' 135' ' ' ALA . 0.5 OUTLIER -142.44 168.49 19.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 71.14 110.896 179.976 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 90.1 p -48.27 96.75 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.18 -0.464 . . . . 52.31 110.811 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 4.4 m 49.48 73.79 0.23 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.088 -0.505 . . . . 63.35 110.815 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.406 ' CB ' ' HB2' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -100.06 161.63 13.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.074 -0.512 . . . . 74.14 110.934 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -130.03 165.56 21.94 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.185 -0.462 . . . . 74.2 110.916 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.492 HG21 HG11 ' A' ' 96' ' ' VAL . 6.4 tt -103.38 155.25 5.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.249 -0.432 . . . . 74.24 111.113 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 7.2 mmtp -123.33 111.96 17.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 74.52 110.858 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -78.95 -159.84 0.2 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.237 -0.438 . . . . 73.15 110.851 179.79 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -171.14 173.53 4.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 71.13 110.945 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' TRP . . . . . 0.409 ' O ' ' HB2' ' A' ' 146' ' ' ALA . 29.1 p90 -154.75 149.19 26.23 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.219 -0.446 . . . . 73.35 110.864 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.865 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 177.97 169.07 0.51 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.562 0.696 . . . . 55.33 111.086 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' PRO . . . . . 0.865 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.6 Cg_endo -69.79 144.0 52.49 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.662 2.241 . . . . 75.54 112.344 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.645 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -138.84 167.99 20.79 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 75.11 111.144 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -108.71 161.77 14.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.247 -0.433 . . . . 74.25 110.881 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -140.18 157.18 46.01 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.159 -0.473 . . . . 63.03 110.89 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -154.4 131.03 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 74.42 111.092 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 169.77 -167.61 40.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 71.04 112.521 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.54 HD12 ' N ' ' A' ' 154' ' ' ARG . 1.7 pp -152.42 169.13 23.32 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.779 0.323 . . . . 70.54 110.979 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.54 ' N ' HD12 ' A' ' 153' ' ' LEU . 10.1 tpp85 -120.14 125.0 47.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.179 -0.464 . . . . 74.52 110.92 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -123.63 175.09 7.03 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.285 -0.416 . . . . 72.22 110.93 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -122.1 96.66 5.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.1 -0.5 . . . . 73.02 110.891 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' LEU . . . . . 0.409 HD23 ' N ' ' A' ' 158' ' ' GLY . 8.8 tt -102.92 140.26 37.42 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.233 -0.439 . . . . 71.42 110.934 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . 0.409 ' N ' HD23 ' A' ' 157' ' ' LEU . . . 59.29 171.63 0.43 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.745 -0.741 . . . . 72.33 112.444 179.824 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 45.4 t30 -93.07 158.57 15.71 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.907 0.384 . . . . 75.11 110.804 -179.824 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 58.7 m 51.18 32.24 7.75 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.18 -0.464 . . . . 60.23 110.843 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -174.68 149.7 1.26 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.143 -0.48 . . . . 72.24 110.91 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 11.9 mmt -121.18 172.77 7.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 73.55 110.928 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 5.0 tp -126.11 139.56 53.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.288 -0.415 . . . . 73.05 110.948 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -139.34 139.72 37.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.446 . . . . 75.23 110.927 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 69.2 p -139.8 121.8 15.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 62.2 110.857 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 166' ' ' ASP . . . . . 0.421 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.5 OUTLIER -141.72 164.55 29.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 62.04 110.869 179.95 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.518 HG13 ' O ' ' A' ' 195' ' ' ILE . 40.1 t -150.16 129.86 3.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.147 -0.479 . . . . 73.1 111.104 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . 0.744 ' HG2' HD12 ' A' ' 195' ' ' ILE . 0.0 OUTLIER -101.08 144.92 29.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.136 -0.483 . . . . 74.11 110.832 -179.911 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -146.02 135.16 22.75 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.184 -0.462 . . . . 65.12 110.966 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 170' ' ' ILE . . . . . 0.645 HG21 ' HB2' ' A' ' 148' ' ' ALA . 4.7 tp 179.9 131.85 0.25 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.594 0.711 . . . . 74.02 111.15 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.8 109.74 2.39 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.752 2.301 . . . . 74.35 112.315 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . 0.673 ' CZ ' ' HB3' ' A' ' 146' ' ' ALA . 2.0 m-85 -116.92 178.11 4.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 74.2 110.922 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.01 133.94 18.04 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.178 -0.464 . . . . 75.41 110.84 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 174' ' ' THR . . . . . 0.443 HG22 HG13 ' A' ' 189' ' ' ILE . 13.2 t -105.64 154.28 20.65 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.166 -0.47 . . . . 62.31 111.077 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -128.53 161.81 28.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.135 -0.484 . . . . 71.12 110.858 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 20.3 t -146.58 132.42 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 50.41 111.175 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.3 t -165.59 160.25 17.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.183 -0.462 . . . . 64.2 111.145 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -136.3 171.37 22.88 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.751 -0.738 . . . . 63.03 112.454 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . 0.409 ' O ' HG23 ' A' ' 179' ' ' THR . 2.1 t . . . . . 0 C--N 1.329 -0.31 0 CA-C-O 120.766 0.317 . . . . 71.32 111.173 -179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo . . . . . 0 C--O 1.231 0.165 0 CA-C-O 120.811 0.255 . . . . 61.33 112.353 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 15.0 t -101.32 139.33 22.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.235 -0.439 . . . . 64.12 111.095 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 43.0 p -121.25 105.03 10.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.162 -0.472 . . . . 50.51 110.907 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 22.1 p -105.06 162.07 13.69 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.162 -0.472 . . . . 63.41 111.152 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -159.32 157.38 30.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 72.32 110.884 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 189' ' ' ILE . . . . . 0.619 HG21 HD12 ' A' ' 32' ' ' LEU . 3.5 pt -154.13 130.43 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 51.45 111.139 179.889 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -101.62 118.4 36.86 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 63.31 110.881 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 191' ' ' VAL . . . . . 0.56 HG11 HG21 ' A' ' 28' ' ' VAL . 7.1 p -136.25 160.97 38.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.144 -0.48 . . . . 73.41 111.127 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.415 ' N ' HG22 ' A' ' 191' ' ' VAL . 1.7 p30 -106.91 87.82 3.19 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.613 0.721 . . . . 71.34 110.85 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.69 158.85 55.6 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.703 2.268 . . . . 63.2 112.33 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -136.94 120.87 17.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.23 -0.441 . . . . 52.22 110.889 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 195' ' ' ILE . . . . . 0.744 HD12 ' HG2' ' A' ' 168' ' ' ARG . 45.4 mt -105.62 118.5 53.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.445 . . . . 74.13 111.167 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 3.9 mt -106.73 108.33 19.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.156 -0.474 . . . . 45.42 110.924 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 16.6 p -101.03 134.22 44.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 74.54 110.874 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 22.0 tp -156.49 129.7 8.03 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.109 -0.496 . . . . 73.33 110.909 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 179.83 -145.59 6.56 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.74 -0.743 . . . . 61.22 112.501 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 200' ' ' ALA . . . . . 0.579 ' HB3' ' CE2' ' A' ' 21' ' ' PHE . . . -116.73 174.53 6.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.755 0.312 . . . . 71.24 111.084 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 71.8 m -155.67 164.85 38.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 65.52 110.887 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 9.7 t80 -134.34 122.63 22.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.141 -0.481 . . . . 74.34 110.887 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 19.7 m -76.9 127.96 37.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.087 -0.506 . . . . 71.12 111.136 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 204' ' ' PHE . . . . . 0.415 ' HB3' ' HB2' ' A' ' 17' ' ' TRP . 1.1 m-85 -112.46 81.35 1.46 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 73.12 110.924 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 55.3 pttt . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.499 . . . . 62.3 110.838 -179.991 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 . . . . . 0 C--O 1.23 0.077 0 CA-C-O 120.839 0.352 . . . . 62.13 110.926 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.85 5.52 35.69 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.781 -0.723 . . . . 45.35 112.423 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -66.8 150.16 49.53 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.778 0.323 . . . . 52.13 110.867 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.511 ' HE1' HG23 ' A' ' 59' ' ' ILE . 25.9 t90 -116.6 144.18 44.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 74.2 110.882 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.67 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 12.9 t -141.6 118.83 7.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.268 -0.424 . . . . 72.14 111.13 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -84.76 101.71 12.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.229 -0.441 . . . . 65.23 111.083 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.4 t -97.93 142.09 30.09 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 75.01 110.866 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.549 ' HE2' HD13 ' A' ' 55' ' ' LEU . 73.6 t80 -146.52 118.89 8.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.164 -0.471 . . . . 74.45 110.856 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.412 ' O ' HG23 ' A' ' 56' ' ' THR . 3.9 p30 -149.77 174.72 12.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.132 -0.486 . . . . 51.4 110.927 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 13.3 t80 -106.52 128.76 54.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.471 . . . . 75.32 110.914 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -94.21 147.56 23.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.171 -0.468 . . . . 75.13 110.856 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 20.7 tttt -127.49 111.42 13.78 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.135 -0.484 . . . . 71.32 110.891 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.1 p -75.63 127.09 37.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 65.35 111.153 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 2.6 t80 -119.46 105.15 10.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.144 -0.48 . . . . 70.24 110.915 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.803 HG11 HG11 ' A' ' 47' ' ' VAL . 6.4 t -78.65 157.76 4.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.083 -0.508 . . . . 54.14 111.154 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.505 ' HA3' HG21 ' A' ' 191' ' ' VAL . . . -76.5 -112.6 0.13 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.693 -0.765 . . . . 53.51 112.528 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 66.6 mt-10 -89.86 -67.08 0.87 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.854 0.359 . . . . 64.31 110.942 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.544 ' HA ' HG12 ' A' ' 47' ' ' VAL . 1.7 pm0 -177.11 -173.79 0.48 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.127 -0.488 . . . . 73.11 110.88 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.823 ' HA ' HG21 ' A' ' 189' ' ' ILE . 1.9 mt -85.0 -177.78 6.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 74.52 110.911 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 C-N-CA 120.771 -0.728 . . . . 65.02 112.481 179.911 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.058 0 CA-C-O 120.836 0.35 . . . . 72.04 111.057 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -157.9 126.01 5.4 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 72.41 110.875 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.803 HG11 HG11 ' A' ' 28' ' ' VAL . 7.2 p -104.39 140.71 21.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 65.02 111.152 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -140.48 164.83 29.1 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 65.13 110.828 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.597 HG22 ' CE2' ' A' ' 81' ' ' PHE . 23.2 pt -112.25 157.17 13.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.101 -0.5 . . . . 73.03 111.178 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.07 142.52 31.87 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.772 -0.728 . . . . 34.1 112.506 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -93.38 110.86 22.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.805 0.336 . . . . 51.31 110.858 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 19.9 t0 -174.07 148.83 1.39 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.46 . . . . 72.23 110.857 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 2.0 m -70.73 130.54 41.99 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 72.04 111.148 -179.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.97 177.54 7.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.171 -0.468 . . . . 62.24 111.143 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.549 HD13 ' HE2' ' A' ' 21' ' ' PHE . 3.1 pp -159.97 165.39 32.11 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.219 -0.446 . . . . 73.14 110.942 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.491 HG21 ' CE2' ' A' ' 72' ' ' PHE . 0.3 OUTLIER -143.3 143.27 31.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 62.43 111.132 -179.993 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -103.18 133.29 48.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.221 -0.445 . . . . 74.45 110.897 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -121.39 136.44 54.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.12 -0.491 . . . . 63.43 110.844 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.511 HG23 ' HE1' ' A' ' 17' ' ' TRP . 27.5 mm -108.51 113.39 43.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.161 -0.472 . . . . 74.4 111.067 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.67 ' HB3' ' HB ' ' A' ' 18' ' ' VAL . . . -102.78 121.19 41.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 72.34 111.1 179.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.435 ' HB3' HG22 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -111.3 115.41 29.28 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.187 -0.461 . . . . 65.51 110.968 -179.835 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -82.54 101.9 11.03 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.108 -0.496 . . . . 71.2 110.83 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.0 t -97.1 -35.37 5.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.135 -0.484 . . . . 64.41 111.106 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 27.8 t -134.07 162.09 33.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.487 . . . . 63.01 110.876 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 59.4 p -84.46 2.85 38.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.171 -0.468 . . . . 64.42 110.83 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -115.0 -32.98 5.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.085 -0.507 . . . . 75.54 110.912 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.425 HG22 ' CB ' ' A' ' 107' ' ' TYR . 21.7 pt -142.35 165.04 17.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.164 -0.471 . . . . 73.14 111.156 179.849 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -151.55 167.09 29.15 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.222 -0.445 . . . . 63.13 111.118 179.827 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.435 HG22 ' HB3' ' A' ' 61' ' ' TYR . 6.5 m -108.01 151.07 10.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 61.23 111.179 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -139.15 132.48 30.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 62.41 110.877 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -115.83 110.02 18.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.15 -0.477 . . . . 70.05 110.85 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.491 ' CE2' HG21 ' A' ' 56' ' ' THR . 30.9 t80 -91.26 115.94 28.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 74.42 110.888 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.404 HG12 ' N ' ' A' ' 74' ' ' GLY . 11.3 t -142.23 156.17 19.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 72.01 111.082 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.404 ' N ' HG12 ' A' ' 73' ' ' VAL . . . -163.96 148.68 15.11 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.691 -0.766 . . . . 53.0 112.427 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.7 t -119.65 65.35 9.13 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.637 0.732 . . . . 44.21 111.144 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 163.42 38.33 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.688 2.259 . . . . 55.54 112.349 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -89.42 -169.29 2.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 70.34 111.08 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.5 ttp180 -77.42 132.52 38.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.258 -0.428 . . . . 74.41 110.921 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . 0.514 ' HB3' ' CZ ' ' A' ' 98' ' ' TYR . . . -133.38 152.84 51.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 64.14 111.048 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 14.6 ttmt -82.12 150.33 27.53 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.172 -0.467 . . . . 54.21 110.938 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . 0.597 ' CE2' HG22 ' A' ' 49' ' ' ILE . 2.5 t80 -138.77 147.69 42.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 74.23 110.896 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.511 ' O ' HG23 ' A' ' 47' ' ' VAL . 10.6 mt-30 -113.61 153.31 29.07 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.137 -0.483 . . . . 74.34 110.894 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.541 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 174.96 80.86 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.758 . . . . 62.24 112.423 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -178.26 -178.37 0.63 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.92 0.391 . . . . 74.24 110.962 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.0 -69.42 0.67 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.213 -0.448 . . . . 54.3 110.877 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 5.3 m -85.22 -32.41 22.64 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.23 -0.441 . . . . 63.34 110.829 -179.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.556 HG22 HG22 ' A' ' 93' ' ' VAL . 4.3 mm -66.83 -34.9 72.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 74.33 111.097 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 15.1 t -63.32 -47.84 80.53 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 64.34 110.864 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.2 p -53.14 -38.64 62.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 72.13 110.844 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -63.47 -43.39 97.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.178 -0.464 . . . . 74.15 110.867 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 109.86 -13.55 32.03 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.747 -0.739 . . . . 72.13 112.498 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 41.6 mtt180 -118.81 93.38 4.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.852 0.358 . . . . 73.24 110.916 -179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.556 HG22 HG22 ' A' ' 87' ' ' ILE . 4.0 t -113.57 -35.0 2.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 75.4 111.158 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 19.5 m -156.17 161.29 40.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 62.11 110.779 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . 0.629 ' O ' HG13 ' A' ' 96' ' ' VAL . 44.7 mt-10 -153.86 115.89 4.29 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.118 -0.492 . . . . 65.52 110.875 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.629 HG13 ' O ' ' A' ' 95' ' ' GLU . 2.1 m -161.68 179.53 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.148 -0.478 . . . . 75.03 111.089 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -98.28 147.92 24.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 74.23 110.854 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' TYR . . . . . 0.514 ' CZ ' ' HB3' ' A' ' 79' ' ' ALA . 11.6 m-85 -92.34 139.98 30.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.219 -0.446 . . . . 74.43 110.946 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . 0.402 ' N ' ' CD ' ' A' ' 100' ' ' PRO . . . -127.37 55.07 0.76 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.721 -0.752 . . . . 51.24 112.476 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' A' ' 99' ' ' GLY . 53.6 Cg_endo -69.73 111.69 2.87 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.71 2.273 . . . . 55.22 112.402 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.453 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -136.07 110.08 8.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.265 -0.425 . . . . 73.01 111.107 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.554 HG22 ' CA ' ' A' ' 124' ' ' GLY . 11.0 pt -140.82 140.59 33.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.213 -0.449 . . . . 74.34 111.17 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.567 ' HG ' HG23 ' A' ' 123' ' ' VAL . 0.1 OUTLIER -132.49 120.14 21.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 73.53 110.933 179.904 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 2.4 p -142.14 162.86 34.41 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 61.33 110.878 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -109.23 144.6 37.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.146 -0.479 . . . . 72.54 110.876 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 3.0 pm0 -105.38 148.99 26.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.109 -0.496 . . . . 71.11 110.87 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.612 ' CE2' HG13 ' A' ' 119' ' ' VAL . 32.2 p90 -149.33 148.44 29.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 72.2 110.913 -179.852 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 32.3 t60 . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.087 -0.506 . . . . 74.41 110.849 179.959 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 5.4 p90 . . . . . 0 C--O 1.231 0.106 0 CA-C-O 121.654 0.74 . . . . 73.21 110.893 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 179.09 3.93 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.727 2.284 . . . . 53.15 112.35 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -109.87 164.59 12.44 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.22 -0.445 . . . . 64.34 110.974 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.612 HG13 ' CE2' ' A' ' 107' ' ' TYR . 6.2 p -117.51 139.0 46.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.169 -0.469 . . . . 73.44 111.096 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -139.95 160.5 26.23 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.713 -0.756 . . . . 74.12 112.499 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 4.9 m -152.75 163.88 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.877 0.37 . . . . 64.0 111.18 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 174.98 -145.99 8.19 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.722 -0.751 . . . . 41.42 112.429 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.567 HG23 ' HG ' ' A' ' 103' ' ' LEU . 11.8 m -105.5 148.89 9.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.853 0.358 . . . . 61.5 111.192 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . 0.554 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -144.25 105.95 0.39 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.697 -0.763 . . . . 55.31 112.467 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . 0.453 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 15.7 ptm180 -99.78 125.07 45.63 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.899 0.38 . . . . 70.33 110.903 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 25.2 t -109.51 114.02 45.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.25 -0.432 . . . . 64.11 111.125 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.575 HD12 ' N ' ' A' ' 128' ' ' PHE . 2.1 pp -124.24 171.12 10.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.465 . . . . 74.2 110.885 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.575 ' N ' HD12 ' A' ' 127' ' ' LEU . 0.6 OUTLIER -141.14 178.55 7.31 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.148 -0.478 . . . . 53.41 110.831 179.953 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -118.15 119.82 35.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.115 -0.493 . . . . 73.02 110.918 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -60.45 103.61 0.26 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.125 -0.489 . . . . 54.41 110.892 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.519 ' H ' HG12 ' A' ' 96' ' ' VAL . 7.9 tppt? -123.69 -71.91 0.7 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.449 . . . . 71.23 110.912 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 23.5 m -166.87 92.68 0.44 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.459 . . . . 61.32 111.136 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -107.73 168.98 8.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.464 . . . . 53.15 110.871 179.879 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 79.28 151.68 6.39 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.748 -0.739 . . . . 73.14 112.481 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -39.38 -66.85 0.26 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.831 0.348 . . . . 74.15 111.09 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -166.64 92.33 0.45 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 70.44 110.852 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . 0.533 ' O ' ' C ' ' A' ' 138' ' ' SER . 0.4 OUTLIER 169.01 60.78 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 33.45 110.878 -179.947 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.533 ' C ' ' O ' ' A' ' 137' ' ' SER . 8.7 t 27.21 73.93 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.152 -0.476 . . . . 63.25 110.906 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -107.3 159.15 16.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.144 -0.48 . . . . 73.24 110.854 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -145.19 167.12 23.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.088 -0.506 . . . . 65.03 110.943 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.595 ' HA ' HG23 ' A' ' 176' ' ' VAL . 12.5 tt -116.76 132.5 66.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.209 -0.45 . . . . 62.31 111.131 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . 0.733 ' O ' HG22 ' A' ' 174' ' ' THR . 0.0 OUTLIER -80.72 106.64 12.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 74.01 110.863 179.899 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -82.72 -172.43 4.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 62.41 110.879 179.87 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 5.2 tptt -174.95 -169.73 0.42 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 71.14 110.906 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' TRP . . . . . 0.427 ' O ' ' HB2' ' A' ' 146' ' ' ALA . 66.9 p-90 -144.62 161.01 40.22 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.208 -0.451 . . . . 74.22 110.98 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.724 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 178.02 165.29 0.59 Allowed Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.567 0.698 . . . . 53.31 111.14 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' PRO . . . . . 0.724 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.6 Cg_endo -69.74 161.88 44.2 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.705 2.27 . . . . 73.23 112.354 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.644 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -153.79 160.11 42.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.249 -0.432 . . . . 63.4 111.064 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -118.91 115.23 23.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.223 -0.444 . . . . 65.25 110.903 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 20.6 tt0 -102.86 164.41 11.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.105 -0.498 . . . . 72.14 110.921 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 14.6 p -160.12 137.17 2.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.153 -0.476 . . . . 60.21 111.052 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . 0.408 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 177.55 -162.25 30.02 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.767 -0.73 . . . . 60.41 112.528 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -138.69 160.61 39.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.827 0.346 . . . . 73.43 110.888 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 3.4 tpp85 -132.05 119.74 21.43 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 73.35 110.883 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -105.46 140.96 37.78 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.181 -0.463 . . . . 74.43 110.932 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -120.93 117.55 27.63 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.472 . . . . 73.42 110.864 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 3.9 tp -102.3 164.4 11.7 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 75.34 110.887 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -99.51 53.79 0.99 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.739 -0.744 . . . . 65.53 112.486 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -149.87 35.87 0.69 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.362 . . . . 75.32 110.966 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 51.79 35.4 15.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 72.25 110.8 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 51.2 m95 -154.99 101.43 2.26 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.134 -0.484 . . . . 73.44 110.849 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' MET . . . . . 0.435 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 0.0 OUTLIER -97.7 168.25 10.45 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.253 -0.43 . . . . 75.35 110.909 179.855 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 4.0 tp -125.26 144.18 50.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.252 -0.431 . . . . 63.21 110.934 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -142.99 139.98 30.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 70.11 110.84 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 52.8 p -150.95 120.94 7.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 71.13 110.87 -179.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 166' ' ' ASP . . . . . 0.408 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.6 OUTLIER -149.08 171.13 16.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.167 -0.47 . . . . 55.23 110.881 179.921 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 4.3 t -144.75 135.96 20.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.171 -0.468 . . . . 72.22 111.076 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -102.67 137.34 41.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 74.45 110.872 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 35.1 t80 -141.79 139.2 32.7 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.201 -0.454 . . . . 73.45 110.887 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 170' ' ' ILE . . . . . 0.644 HG21 ' HB2' ' A' ' 148' ' ' ALA . 0.0 OUTLIER 178.96 125.93 0.21 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.633 0.73 . . . . 74.35 111.096 179.885 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 107.25 1.82 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.649 2.233 . . . . 74.33 112.337 179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -126.94 170.0 12.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 65.1 110.894 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.7 141.4 43.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.114 -0.494 . . . . 75.22 110.875 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 174' ' ' THR . . . . . 0.733 HG22 ' O ' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -125.32 169.48 12.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 70.12 111.141 179.958 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -126.64 170.45 12.08 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 52.2 110.888 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . 0.595 HG23 ' HA ' ' A' ' 141' ' ' ILE . 7.6 p -160.14 137.1 2.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.45 . . . . 72.12 111.213 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . 0.558 HG22 ' HD3' ' A' ' 142' ' ' LYS . 12.8 t -166.84 175.6 7.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.245 -0.434 . . . . 72.43 111.169 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -156.95 -140.99 3.07 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.8 -0.714 . . . . 45.3 112.495 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.33 -0.244 0 CA-C-O 120.816 0.341 . . . . 72.33 111.073 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo . . . . . 0 C--O 1.231 0.15 0 CA-C-O 120.837 0.265 . . . . 71.23 112.34 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 48.4 t -108.36 108.82 26.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 71.02 111.106 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 85.5 p -99.22 111.3 23.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.075 -0.512 . . . . 63.43 110.827 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 3.1 p -108.53 163.31 13.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 54.03 111.152 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -146.53 148.06 31.78 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.271 -0.422 . . . . 74.51 110.92 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 189' ' ' ILE . . . . . 0.823 HG21 ' HA ' ' A' ' 32' ' ' LEU . 3.6 pt -142.36 136.35 28.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.285 -0.416 . . . . 51.05 111.165 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -112.17 104.23 12.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.208 -0.451 . . . . 40.33 110.882 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 191' ' ' VAL . . . . . 0.505 HG21 ' HA3' ' A' ' 29' ' ' GLY . 4.9 p -136.6 163.18 33.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 74.15 111.156 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.409 ' N ' HG22 ' A' ' 191' ' ' VAL . 1.4 p-10 -106.71 90.68 5.31 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.63 0.729 . . . . 72.45 110.875 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.73 135.99 31.92 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.698 2.265 . . . . 71.4 112.316 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -103.67 124.94 49.77 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.254 -0.43 . . . . 73.41 110.936 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 26.4 mm -107.45 103.19 15.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.159 -0.473 . . . . 75.12 111.186 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 20.7 tp -91.47 110.55 21.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 74.32 110.88 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 20.5 p -110.35 123.58 50.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 75.22 110.864 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 198' ' ' LEU . . . . . 0.411 HD23 ' N ' ' A' ' 198' ' ' LEU . 1.0 OUTLIER -141.4 132.65 26.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 75.13 110.944 -179.948 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 179.02 -146.43 7.22 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.823 -0.703 . . . . 75.11 112.544 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 200' ' ' ALA . . . . . 0.435 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -125.52 173.37 8.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.796 0.331 . . . . 72.34 111.168 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -147.53 171.1 16.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.425 . . . . 73.25 110.914 -179.77 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 12.6 m-85 -139.33 133.87 31.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.137 -0.483 . . . . 61.51 110.92 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 11.2 p -79.56 147.64 6.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 65.55 111.167 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -146.67 98.07 3.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.212 -0.449 . . . . 63.15 110.865 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 18.1 mtmt . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.095 -0.502 . . . . 65.25 110.809 -179.953 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 . . . . . 0 CA--C 1.524 -0.045 0 CA-C-O 120.879 0.371 . . . . 74.35 110.926 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 103.88 6.21 43.42 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.762 -0.732 . . . . 70.13 112.513 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -66.93 150.46 49.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.809 0.337 . . . . 73.23 110.815 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 4.5 m0 -111.96 142.05 44.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.152 -0.477 . . . . 63.21 110.939 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.632 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 43.2 t -145.04 118.95 2.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.263 -0.426 . . . . 72.41 111.041 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.4 119.96 25.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.098 -0.501 . . . . 64.22 111.031 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 22.0 t -106.65 128.6 54.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 65.45 110.807 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.536 ' CE2' HD21 ' A' ' 55' ' ' LEU . 19.2 t80 -138.19 114.55 10.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.095 -0.502 . . . . 72.3 110.829 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -153.5 174.05 14.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 74.42 110.906 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -102.45 129.01 48.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.455 . . . . 64.52 110.915 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.2 p -98.64 148.04 24.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.129 -0.487 . . . . 53.23 110.839 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 39.2 tptt -129.45 106.84 9.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 61.35 110.854 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.2 m -89.68 124.2 42.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.226 -0.443 . . . . 61.34 111.139 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 28.5 t80 -118.93 104.12 10.22 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.166 -0.47 . . . . 75.33 110.933 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.0 p -157.8 150.45 8.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 50.45 111.189 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 144.77 76.8 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.776 -0.726 . . . . 55.42 112.506 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -89.5 -65.63 1.0 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.758 0.313 . . . . 72.31 110.849 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -169.09 124.76 0.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.447 . . . . 72.11 110.902 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.687 HD13 HG13 ' A' ' 189' ' ' ILE . 0.9 OUTLIER -89.2 152.78 21.41 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.164 -0.471 . . . . 73.21 110.86 -179.95 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.355 0 C-N-CA 120.726 -0.75 . . . . 63.32 112.459 179.88 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.553 ' HB3' ' O ' ' A' ' 32' ' ' LEU . . . . . . . . 0 C--O 1.23 0.076 0 CA-C-O 120.784 0.326 . . . . 41.24 111.042 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 17.8 t0 -146.18 126.57 14.02 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 60.24 110.866 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.633 ' HB ' HD23 ' A' ' 32' ' ' LEU . 7.1 p -105.36 140.56 23.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 62.21 111.135 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -158.8 157.85 32.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.45 . . . . 70.12 110.829 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 9.4 tt -132.4 144.04 38.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.102 -0.499 . . . . 74.45 111.084 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -108.19 97.23 1.1 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.782 -0.723 . . . . 54.22 112.517 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -136.7 119.09 15.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.802 0.334 . . . . 74.1 110.895 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 77.1 m-20 -100.81 -56.5 2.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.206 -0.452 . . . . 74.04 110.914 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 5.1 t -60.78 134.06 56.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.137 -0.483 . . . . 73.21 111.127 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.4 p -120.24 121.29 38.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 74.2 111.151 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.536 HD21 ' CE2' ' A' ' 21' ' ' PHE . 0.3 OUTLIER -159.9 123.41 3.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.247 -0.433 . . . . 73.11 110.946 179.978 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.667 HG21 ' CE1' ' A' ' 72' ' ' PHE . 5.4 m -137.74 130.76 30.29 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 64.11 111.143 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -102.93 132.53 49.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 72.41 110.874 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.577 ' O ' HD13 ' A' ' 59' ' ' ILE . 0.7 OUTLIER -131.93 155.95 47.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.119 -0.491 . . . . 63.34 110.872 179.92 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.577 HD13 ' O ' ' A' ' 58' ' ' ASP . 27.4 mm -126.05 115.16 41.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 75.33 111.153 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.632 ' HB3' ' HB ' ' A' ' 18' ' ' VAL . . . -99.9 126.05 45.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 73.14 111.11 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.555 ' HB3' HG22 ' A' ' 69' ' ' VAL . 0.5 OUTLIER -116.72 118.26 32.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.272 -0.422 . . . . 71.14 110.968 -179.857 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -88.42 101.0 13.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.145 -0.479 . . . . 63.52 110.856 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 9.0 p -98.01 -35.17 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.114 -0.494 . . . . 72.32 111.144 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 m -136.88 161.31 36.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.138 -0.483 . . . . 75.43 110.871 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.8 m -83.74 2.99 35.25 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.171 -0.468 . . . . 72.44 110.827 -179.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -120.16 -33.57 3.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.474 . . . . 74.43 110.831 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.572 HG22 ' CD1' ' A' ' 107' ' ' TYR . 2.5 pp -136.06 148.12 27.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.242 -0.435 . . . . 54.11 111.143 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -143.73 167.78 21.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.249 -0.432 . . . . 74.02 111.143 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.555 HG22 ' HB3' ' A' ' 61' ' ' TYR . 4.2 m -114.69 151.21 16.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 64.41 111.134 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -143.89 132.45 22.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.167 -0.469 . . . . 34.12 110.885 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -103.88 142.03 35.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 70.35 110.924 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.667 ' CE1' HG21 ' A' ' 56' ' ' THR . 7.5 t80 -121.4 118.57 29.75 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.187 -0.46 . . . . 73.24 110.871 -179.883 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 44.7 t -147.18 145.75 18.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 71.22 111.114 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -132.96 -30.23 0.49 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.754 -0.736 . . . . 63.15 112.514 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 11.0 m 36.6 62.76 2.97 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.623 0.725 . . . . 71.01 111.124 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 163.57 37.78 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.738 2.292 . . . . 65.15 112.306 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -79.64 -169.82 2.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 74.21 111.037 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.7 ttp180 -77.94 126.43 30.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.472 . . . . 72.42 110.912 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -135.77 151.93 50.61 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 75.33 111.089 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 26.3 ttpp -93.15 143.8 25.9 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 74.51 110.844 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . 0.599 ' HE2' HG12 ' A' ' 96' ' ' VAL . 13.8 p90 -139.39 157.73 45.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 75.31 110.917 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.467 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 5.2 pt20 -106.85 157.2 17.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 75.12 110.93 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.661 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 178.4 71.05 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.73 -0.748 . . . . 43.23 112.498 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -168.36 -173.48 1.99 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.926 0.393 . . . . 74.33 110.913 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.33 -71.23 0.55 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 65.23 110.932 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 23.1 t -84.89 -30.35 24.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.255 -0.43 . . . . 55.4 110.835 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.82 HG22 HG22 ' A' ' 93' ' ' VAL . 4.7 mm -67.99 -34.26 65.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 52.42 111.13 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 4.0 t -63.02 -44.13 96.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.152 -0.476 . . . . 74.4 110.806 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 73.4 m -55.18 -41.6 72.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.134 -0.485 . . . . 60.55 110.85 -179.821 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -58.86 -49.85 76.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.112 -0.495 . . . . 73.3 110.911 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 116.2 -17.12 14.85 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.829 -0.7 . . . . 62.31 112.534 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 6.8 ttp180 -121.27 95.52 4.72 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.856 0.36 . . . . 70.42 110.864 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.82 HG22 HG22 ' A' ' 87' ' ' ILE . 93.0 t -104.45 -61.09 2.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.136 -0.483 . . . . 71.5 111.073 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.403 ' HA ' ' HA ' ' A' ' 133' ' ' ASP . 1.8 p -139.47 149.52 44.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.437 . . . . 64.11 110.921 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -127.74 129.58 47.32 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.146 -0.479 . . . . 55.11 110.906 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.61 HG21 ' O ' ' A' ' 129' ' ' PHE . 6.1 p -173.43 163.27 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 75.51 111.126 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.442 ' N ' HG22 ' A' ' 96' ' ' VAL . 10.3 p-10 -92.58 152.61 19.51 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.2 -0.454 . . . . 73.04 110.851 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -103.41 148.94 25.29 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.225 -0.443 . . . . 72.2 110.868 -179.81 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -139.07 62.23 0.56 Allowed Glycine 0 N--CA 1.453 -0.194 0 C-N-CA 120.751 -0.738 . . . . 65.41 112.547 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 118.43 5.68 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.65 2.233 . . . . 71.41 112.325 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.62 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -122.38 102.57 8.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.233 -0.44 . . . . 75.33 111.138 179.841 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.456 HD12 ' HA3' ' A' ' 124' ' ' GLY . 10.8 mm -117.85 147.73 21.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.243 -0.435 . . . . 61.34 111.152 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -151.49 122.46 7.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 65.13 110.924 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . 0.405 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 8.6 p -147.17 173.63 12.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 72.51 110.867 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.482 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.8 OUTLIER -122.03 153.84 38.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.13 -0.486 . . . . 73.11 110.938 179.99 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 19.9 mm-40 -102.1 137.15 40.75 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.137 -0.483 . . . . 71.45 110.897 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' TYR . . . . . 0.572 ' CD1' HG22 ' A' ' 67' ' ' ILE . 10.9 t80 -140.91 133.76 29.01 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.184 -0.462 . . . . 73.55 110.933 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 26.9 t60 . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 64.44 110.879 179.85 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.666 0.746 . . . . 74.44 110.9 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 177.52 5.47 Favored 'Trans proline' 0 N--CA 1.465 -0.197 0 C-N-CA 122.71 2.273 . . . . 75.33 112.362 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 14.0 m-85 -117.22 157.78 25.43 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.454 . . . . 72.52 110.932 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 12.5 p -107.24 132.01 55.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.084 -0.507 . . . . 75.1 111.118 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -121.5 161.23 15.65 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.769 -0.729 . . . . 70.23 112.519 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 12.3 p -161.1 150.16 5.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.8 0.333 . . . . 53.21 111.08 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . 0.405 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -174.01 -155.37 11.89 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.68 -0.771 . . . . 70.23 112.489 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.447 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 28.9 m -113.75 134.04 57.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.803 0.335 . . . . 74.15 111.168 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . 0.456 ' HA3' HD12 ' A' ' 102' ' ' ILE . . . -117.27 105.91 1.35 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.734 -0.746 . . . . 44.01 112.531 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . 0.62 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 28.5 ptt180 -99.45 112.44 24.64 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.901 0.381 . . . . 74.1 110.866 -179.843 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 20.0 t -87.24 110.04 20.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.26 -0.427 . . . . 64.12 111.147 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.521 HD13 ' N ' ' A' ' 128' ' ' PHE . 0.2 OUTLIER -101.03 135.98 41.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 64.1 110.878 179.979 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.521 ' N ' HD13 ' A' ' 127' ' ' LEU . 13.8 m-85 -135.73 148.26 48.76 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.148 -0.478 . . . . 71.23 110.845 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.61 ' O ' HG21 ' A' ' 96' ' ' VAL . 10.2 m-85 -100.75 172.75 6.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.101 -0.5 . . . . 62.04 110.859 -179.896 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -113.53 94.87 5.06 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.178 -0.464 . . . . 61.23 110.9 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.476 ' HB2' HG23 ' A' ' 96' ' ' VAL . 2.6 mmmt -92.62 -86.6 0.24 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.206 -0.452 . . . . 75.43 110.95 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -168.23 111.82 0.61 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.293 -0.412 . . . . 70.31 111.182 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . 0.547 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 49.8 m-20 -101.1 112.76 25.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.429 . . . . 75.34 110.829 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -74.91 -9.87 83.61 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.738 -0.744 . . . . 62.31 112.452 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.453 ' HB2' ' CG1' ' A' ' 93' ' ' VAL . . . -45.4 -28.89 0.95 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.721 0.296 . . . . 65.15 111.05 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.2 mt -160.28 179.67 8.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.264 -0.425 . . . . 73.4 110.89 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 9.9 m -53.32 92.36 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.172 -0.467 . . . . 73.22 110.848 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 6.9 m 51.38 73.6 0.3 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.092 -0.503 . . . . 54.2 110.868 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.547 ' HB3' ' HB2' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -94.32 158.55 15.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 74.4 110.892 -179.959 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -135.89 167.64 20.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.461 . . . . 75.21 110.822 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 12.3 tt -112.98 151.04 14.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.12 -0.491 . . . . 75.33 111.13 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 6.0 tppt? -119.51 112.06 18.89 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 54.43 110.896 179.824 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.41 -173.34 0.29 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.25 -0.432 . . . . 74.02 110.875 179.845 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -170.6 165.2 8.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 74.24 110.882 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 49.2 p90 -132.47 154.48 49.85 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 73.41 110.927 179.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.726 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -178.5 164.28 1.13 Allowed Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.574 0.702 . . . . 41.1 111.11 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' PRO . . . . . 0.726 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.5 Cg_endo -69.71 169.49 18.73 Favored 'Trans proline' 0 N--CA 1.466 -0.144 0 C-N-CA 122.717 2.278 . . . . 72.24 112.376 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.422 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -165.37 153.54 11.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.246 -0.434 . . . . 34.0 111.086 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 6.7 p90 -122.03 139.11 54.1 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.218 -0.446 . . . . 75.42 110.857 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -130.75 174.52 9.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.125 -0.489 . . . . 75.41 110.988 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 10.8 p -158.91 147.12 7.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 51.33 111.093 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 170.97 -158.77 30.51 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.777 -0.725 . . . . 51.44 112.58 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.6 pt? -158.22 168.02 28.19 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.768 0.318 . . . . 71.2 110.928 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.6 tpp85 -117.93 120.64 38.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 74.2 110.954 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.8 t80 -115.37 169.64 8.99 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.245 -0.434 . . . . 63.31 110.949 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -121.86 99.66 6.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.147 -0.478 . . . . 70.2 110.924 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 5.9 tt -102.31 103.7 14.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 74.31 110.87 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 94.37 -160.71 23.84 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.792 -0.718 . . . . 65.41 112.51 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 6.3 p30 -118.7 -36.56 3.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.854 0.359 . . . . 64.33 110.928 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 3.7 p -66.39 -56.04 12.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.113 -0.494 . . . . 73.11 110.866 -179.877 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 12.3 p90 -124.91 172.69 9.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.179 -0.464 . . . . 72.43 110.951 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' MET . . . . . 0.541 ' CE ' HG13 ' A' ' 203' ' ' VAL . 5.5 ptp -121.84 177.47 5.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.269 -0.423 . . . . 71.14 110.903 179.878 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 8.7 tp -111.94 146.2 38.23 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.21 -0.45 . . . . 63.34 110.915 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -144.44 133.51 22.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 64.4 110.9 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 19.6 t -130.89 125.93 34.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.13 -0.487 . . . . 55.43 110.842 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 26.7 m-20 -150.33 142.16 23.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.093 -0.503 . . . . 72.53 110.87 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.747 ' CG2' HD12 ' A' ' 196' ' ' LEU . 40.6 t -139.59 122.62 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 43.3 111.148 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.49 159.99 14.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.236 -0.438 . . . . 63.23 110.804 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 169' ' ' TYR . . . . . 0.411 ' O ' ' HB ' ' A' ' 170' ' ' ILE . 26.3 t80 -164.56 140.99 6.12 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.159 -0.473 . . . . 73.45 110.919 -179.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 170' ' ' ILE . . . . . 0.446 HG12 ' O ' ' A' ' 147' ' ' PRO . 5.9 tp 177.86 133.15 0.22 Allowed Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.656 0.741 . . . . 72.32 111.109 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.69 104.37 1.3 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.716 2.277 . . . . 65.23 112.304 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -121.78 154.25 37.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.257 -0.429 . . . . 74.23 110.858 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 9.6 ptpp? -122.86 146.69 47.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 63.4 110.884 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 11.1 t -116.91 166.0 12.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.211 -0.45 . . . . 54.51 111.185 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -122.8 158.19 30.76 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.26 -0.427 . . . . 52.35 110.858 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 43.9 t -150.26 132.48 5.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 75.45 111.152 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 13.6 t -168.43 176.78 5.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.205 -0.452 . . . . 70.52 111.104 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 131.99 150.39 6.56 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.725 -0.75 . . . . 32.14 112.525 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 6.1 t . . . . . 0 C--N 1.329 -0.284 0 CA-C-O 120.843 0.354 . . . . 74.04 111.161 -179.853 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo . . . . . 0 C--O 1.232 0.185 0 CA-C-O 120.785 0.244 . . . . 73.12 112.344 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 68.0 t -103.61 111.44 33.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 75.35 111.098 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 3.9 p -84.57 135.02 34.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.094 -0.503 . . . . 64.14 110.893 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 40.4 p -145.48 167.75 22.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 63.22 111.097 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -158.99 157.31 31.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.451 . . . . 71.2 110.887 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 189' ' ' ILE . . . . . 0.687 HG13 HD13 ' A' ' 32' ' ' LEU . 36.8 mm -146.66 125.6 4.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.193 -0.458 . . . . 74.5 111.13 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -102.31 114.6 28.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.18 -0.464 . . . . 75.01 110.864 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 191' ' ' VAL . . . . . 0.447 HG23 HG22 ' A' ' 189' ' ' ILE . 2.5 t -136.53 164.32 31.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.126 -0.488 . . . . 54.01 111.1 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 192' ' ' ASP . . . . . 0.434 ' H ' HG12 ' A' ' 191' ' ' VAL . 0.1 OUTLIER -107.23 87.59 3.27 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.651 0.739 . . . . 73.34 110.856 179.89 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.93 133.58 25.59 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.722 2.282 . . . . 74.33 112.249 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 23.4 m-85 -100.68 119.33 38.42 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.161 -0.472 . . . . 72.03 110.83 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 195' ' ' ILE . . . . . 0.484 ' O ' HG13 ' A' ' 167' ' ' VAL . 53.4 mt -105.57 110.18 30.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.124 -0.489 . . . . 71.31 111.156 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 196' ' ' LEU . . . . . 0.747 HD12 ' CG2' ' A' ' 167' ' ' VAL . 2.6 tp -110.54 108.84 18.95 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.199 -0.455 . . . . 74.42 110.974 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 197' ' ' SER . . . . . 0.522 ' O ' HD12 ' A' ' 198' ' ' LEU . 0.4 OUTLIER -110.55 129.27 55.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.231 -0.441 . . . . 73.43 110.901 -179.906 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 198' ' ' LEU . . . . . 0.522 HD12 ' O ' ' A' ' 197' ' ' SER . 3.1 mp -150.51 134.45 16.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.115 -0.493 . . . . 72.33 110.937 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 178.94 -136.95 3.02 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.686 -0.768 . . . . 54.3 112.467 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 200' ' ' ALA . . . . . 0.429 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -125.02 173.33 8.75 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.835 0.35 . . . . 73.13 111.041 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 29.5 m -149.09 171.0 17.13 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.16 -0.473 . . . . 60.51 110.841 -179.755 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 202' ' ' TYR . . . . . 0.449 ' O ' HG13 ' A' ' 18' ' ' VAL . 40.5 t80 -142.24 145.45 34.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.501 . . . . 71.44 110.86 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 203' ' ' VAL . . . . . 0.541 HG13 ' CE ' ' A' ' 162' ' ' MET . 33.6 m -93.28 156.83 3.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.04 -0.527 . . . . 72.52 111.108 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -159.72 110.8 1.98 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.127 -0.488 . . . . 75.54 110.911 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 37.1 mtmt . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 73.13 110.914 179.982 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.2 ttm . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.82 0.343 . . . . 74.31 110.901 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 17.7 p30 -86.97 160.46 18.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.236 -0.438 . . . . 71.33 110.912 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -112.45 133.4 54.55 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.149 -0.478 . . . . 62.13 110.89 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 64.3 m-20 -156.91 154.47 29.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 74.5 110.904 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 13.7 m-85 52.32 68.66 2.94 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.677 0.751 . . . . 72.04 110.929 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 166.31 27.99 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.723 2.282 . . . . 73.34 112.359 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -65.77 154.98 37.55 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 55.02 111.098 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 23.8 pttm -75.86 151.36 37.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.459 . . . . 70.13 110.896 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 9.9 t -119.96 127.99 53.16 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.424 . . . . 71.52 110.889 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -134.2 103.5 5.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.142 -0.481 . . . . 73.25 111.077 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -125.49 -37.09 0.53 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.737 -0.745 . . . . 70.43 112.523 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.1 p90 -147.44 114.45 6.16 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.897 0.379 . . . . 73.11 110.93 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 18.8 t-20 -141.53 147.89 38.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.096 -0.502 . . . . 62.13 110.897 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 34.5 tt0 -53.72 120.02 5.7 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.455 . . . . 71.23 110.918 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.66 5.48 36.24 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.754 -0.736 . . . . 64.54 112.549 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -68.79 150.27 48.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.772 0.32 . . . . 64.23 110.853 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.568 ' HE1' HG23 ' A' ' 59' ' ' ILE . 13.3 t90 -126.25 121.27 32.2 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.216 -0.447 . . . . 74.53 110.904 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.798 HG13 ' HB3' ' A' ' 60' ' ' ALA . 6.1 p -132.19 122.69 49.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.248 -0.433 . . . . 74.33 111.162 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -87.03 116.65 25.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 72.23 111.102 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -104.7 109.82 21.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 72.5 110.929 -179.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 15.0 p90 -107.69 119.88 40.68 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.186 -0.461 . . . . 72.45 110.879 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.41 ' HA ' ' HA3' ' A' ' 199' ' ' GLY . 2.5 p30 -149.6 161.53 41.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.134 -0.484 . . . . 62.11 110.858 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 8.3 m-85 -86.49 128.47 34.97 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.156 -0.475 . . . . 72.05 110.879 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 18.1 p -102.11 116.26 32.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.162 -0.472 . . . . 74.22 110.895 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 16.3 mtpp -98.92 106.16 18.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.151 -0.477 . . . . 75.41 110.935 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.3 p -83.36 139.43 17.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 71.31 111.117 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 21.3 t80 -130.82 101.79 5.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.465 . . . . 72.01 110.922 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.1 p -162.26 155.02 2.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.096 -0.502 . . . . 75.41 111.099 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 119.63 72.17 0.36 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.683 -0.77 . . . . 71.24 112.476 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 -89.43 -57.97 2.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.768 0.318 . . . . 62.44 110.863 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -174.48 135.1 0.41 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.165 -0.471 . . . . 70.32 110.898 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.659 ' HB2' ' HB3' ' A' ' 45' ' ' ALA . 12.7 mt -52.0 165.64 0.2 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 72.53 110.917 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.33 80.74 0.3 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.713 -0.756 . . . . 73.53 112.485 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 28.4 t0 -79.02 129.37 34.38 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.879 0.371 . . . . 74.52 110.897 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 18.1 tp -79.9 -56.32 4.34 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.191 -0.459 . . . . 63.33 110.908 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 18.8 t30 -151.31 169.14 22.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 64.32 110.833 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.443 HG22 ' H ' ' A' ' 39' ' ' GLY . 11.6 p -157.0 142.71 9.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.151 -0.477 . . . . 53.44 111.124 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -53.05 -33.2 44.08 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.704 -0.76 . . . . 71.42 112.511 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . 0.443 ' H ' HG22 ' A' ' 37' ' ' VAL . . . -53.08 -34.41 46.76 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.746 -0.74 . . . . 61.13 112.476 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 108.33 -49.36 0.86 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.728 -0.749 . . . . 74.32 112.479 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -65.67 164.26 14.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.78 0.324 . . . . 61.13 111.129 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -130.02 67.98 80.31 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.622 0.725 . . . . 73.41 110.946 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 -177.4 1.84 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.693 2.262 . . . . 73.44 112.36 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -128.0 139.97 52.25 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.223 -0.444 . . . . 71.33 110.884 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.659 ' HB3' ' HB2' ' A' ' 32' ' ' LEU . . . -106.4 -179.27 3.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.15 -0.477 . . . . 44.33 111.069 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -149.45 132.99 16.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 62.13 110.878 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.619 HG12 ' HA2' ' A' ' 83' ' ' GLY . 30.1 m -104.72 154.01 6.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 73.03 111.162 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 10.3 t -151.99 146.1 25.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 55.44 110.862 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.469 HD13 ' H ' ' A' ' 49' ' ' ILE . 0.2 OUTLIER -119.43 150.45 21.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.078 -0.51 . . . . 72.25 111.115 -180.0 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.77 135.2 14.73 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.742 -0.742 . . . . 73.42 112.487 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 60.5 m-20 -87.57 112.95 22.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.855 0.359 . . . . 72.52 110.892 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 33.5 t0 -154.38 165.86 35.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.165 -0.47 . . . . 74.35 110.887 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 34.4 p -64.69 148.03 51.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 75.02 111.129 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 8.4 t -158.84 139.92 12.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 64.51 111.13 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.451 HD12 ' CE1' ' A' ' 57' ' ' PHE . 0.2 OUTLIER -124.81 159.77 30.25 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 74.23 110.898 179.977 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 55.8 m -139.08 147.53 42.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.179 -0.464 . . . . 70.43 111.113 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.451 ' CE1' HD12 ' A' ' 55' ' ' LEU . 86.6 m-85 -124.18 132.62 53.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.233 -0.439 . . . . 74.13 110.881 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -134.23 149.3 50.96 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.129 -0.487 . . . . 63.21 110.872 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.568 HG23 ' HE1' ' A' ' 17' ' ' TRP . 10.4 mm -108.28 115.75 49.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.186 -0.461 . . . . 62.11 111.144 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.798 ' HB3' HG13 ' A' ' 18' ' ' VAL . . . -101.13 125.99 47.8 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.188 -0.46 . . . . 41.53 111.123 179.802 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.583 ' HB2' HG13 ' A' ' 69' ' ' VAL . 0.7 OUTLIER -108.89 117.79 35.12 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.222 -0.444 . . . . 74.13 110.919 -179.859 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -89.2 105.99 18.15 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.091 -0.504 . . . . 75.25 110.853 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.1 m -103.88 -34.25 3.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 60.41 111.129 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.7 t -135.87 160.12 39.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.224 -0.443 . . . . 75.31 110.884 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 5.7 p -84.56 2.99 38.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.147 -0.478 . . . . 62.52 110.828 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -111.6 -30.84 7.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 73.43 110.876 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 2.6 pp -147.3 165.61 6.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 62.2 111.106 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -154.36 172.84 17.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.472 . . . . 72.41 111.134 179.823 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.583 HG13 ' HB2' ' A' ' 61' ' ' TYR . 1.2 p -116.47 147.89 19.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.245 -0.434 . . . . 71.11 111.119 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -142.57 134.66 27.33 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.173 -0.467 . . . . 73.04 110.835 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -119.73 110.96 17.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.454 . . . . 71.23 110.867 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 14.4 m-85 -85.05 131.18 34.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.481 . . . . 72.25 110.859 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 5.6 m -151.34 163.54 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 51.15 111.103 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -171.16 145.57 8.99 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.721 -0.752 . . . . 60.22 112.49 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.508 ' O ' HG22 ' A' ' 75' ' ' VAL . 7.6 p -117.07 67.44 4.34 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.596 0.712 . . . . 72.32 111.133 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 162.57 41.57 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.686 2.257 . . . . 63.1 112.351 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -84.81 -173.14 4.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 61.15 111.123 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -78.43 131.14 36.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.444 . . . . 73.41 110.866 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -126.26 151.74 47.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.468 . . . . 62.13 111.1 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 15.4 ttpt -114.72 126.32 54.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 75.34 110.892 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 15.7 p90 -126.42 158.84 34.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 72.21 110.89 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.408 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 29.6 mt-30 -92.61 157.66 16.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 74.34 110.92 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.619 ' HA2' HG12 ' A' ' 47' ' ' VAL . . . -176.05 68.76 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.735 -0.745 . . . . 72.23 112.458 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.517 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.6 tp10 -176.44 -176.59 0.77 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.915 0.388 . . . . 74.54 110.915 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -85.55 -69.41 0.66 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 63.13 110.932 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.4 t -83.31 -34.61 25.66 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.284 -0.416 . . . . 63.24 110.892 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.948 HG21 ' HB2' ' A' ' 135' ' ' ALA . 6.1 mm -64.62 -33.79 65.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.09 -0.504 . . . . 72.42 111.116 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 5.3 t -60.17 -46.79 88.5 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 74.41 110.87 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 22.8 t -56.18 -37.38 69.52 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.124 -0.489 . . . . 74.21 110.839 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.63 -48.64 79.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.112 -0.494 . . . . 70.22 110.904 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 111.73 -13.8 27.18 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.704 -0.76 . . . . 72.42 112.471 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 43.7 mtp180 -118.24 92.74 3.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.887 0.375 . . . . 71.53 110.856 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.893 HG22 HG22 ' A' ' 87' ' ' ILE . 90.1 t -113.93 -55.33 4.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 51.4 111.107 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.88 143.81 38.89 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.194 -0.457 . . . . 63.01 110.851 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 11.8 tt0 -147.52 117.87 7.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 71.13 110.891 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.418 HG12 ' H ' ' A' ' 131' ' ' LYS . 18.8 m -155.75 -176.83 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.177 -0.465 . . . . 73.44 111.14 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -97.29 152.08 19.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 73.42 110.896 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -92.57 135.26 34.23 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 71.14 110.936 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.56 ' HA3' HD12 ' A' ' 127' ' ' LEU . . . -128.3 63.29 0.62 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.71 -0.757 . . . . 63.41 112.441 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 112.38 3.06 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.709 2.272 . . . . 74.41 112.362 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.762 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -128.36 99.49 5.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 64.22 111.145 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.524 ' C ' HD23 ' A' ' 103' ' ' LEU . 4.9 mt -124.31 144.58 33.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.216 -0.447 . . . . 54.33 111.142 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.563 ' HG ' HG23 ' A' ' 123' ' ' VAL . 0.0 OUTLIER -147.31 109.73 4.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.177 -0.465 . . . . 55.34 110.878 179.968 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 3.6 p -144.5 160.39 41.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.221 -0.445 . . . . 71.01 110.832 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.454 ' O ' HD12 ' A' ' 105' ' ' LEU . 4.6 pp -106.19 150.21 26.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.125 -0.489 . . . . 64.1 110.962 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 7.9 pm0 -101.41 141.74 33.84 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.191 -0.459 . . . . 75.52 110.907 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 27.9 p90 -144.45 144.56 31.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 63.22 110.927 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 16.1 m80 -79.74 161.05 25.98 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.097 -0.502 . . . . 74.42 110.872 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.569 ' CE1' HG23 ' A' ' 119' ' ' VAL . 10.6 p90 -154.52 151.15 28.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 74.43 110.923 -179.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 13.3 t0 -52.36 144.35 13.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 52.41 110.882 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.9 p -154.37 156.67 37.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.456 . . . . 45.31 110.831 -179.723 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -122.02 -38.85 2.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.142 -0.481 . . . . 63.22 110.901 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 7.7 tt0 -51.84 169.15 0.07 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.129 -0.487 . . . . 74.24 110.876 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 60.0 mtm180 -51.91 -74.08 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 73.34 110.871 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 10.5 mt -64.88 137.25 57.65 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.212 -0.449 . . . . 72.14 110.949 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 8.7 p90 -118.36 68.11 7.32 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-O 121.642 0.734 . . . . 62.31 110.936 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 176.27 7.0 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.723 2.282 . . . . 73.33 112.354 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 12.7 p90 -115.97 159.47 21.56 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.207 -0.451 . . . . 73.54 110.925 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.569 HG23 ' CE1' ' A' ' 109' ' ' TYR . 60.2 t -123.4 135.33 63.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.126 -0.488 . . . . 72.14 111.107 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -124.08 176.86 16.85 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.72 -0.752 . . . . 72.21 112.491 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.8 p -166.03 152.48 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-O 120.817 0.342 . . . . 70.14 111.167 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 179.12 -153.14 11.9 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.722 -0.752 . . . . 54.44 112.444 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.563 HG23 ' HG ' ' A' ' 103' ' ' LEU . 13.5 m -106.91 120.45 58.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.826 0.346 . . . . 72.33 111.125 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -114.77 111.01 2.44 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.688 -0.768 . . . . 71.34 112.433 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . 0.762 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 8.1 ptp180 -109.31 131.87 54.66 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.805 0.336 . . . . 74.41 110.878 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.423 ' O ' HG13 ' A' ' 126' ' ' VAL . 3.5 p -117.53 115.92 50.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 63.22 111.107 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.56 HD12 ' HA3' ' A' ' 99' ' ' GLY . 2.6 pp -127.49 170.89 12.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.192 -0.458 . . . . 75.31 110.91 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -140.58 174.69 10.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 73.54 110.914 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -102.8 125.25 49.47 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.131 -0.486 . . . . 64.12 110.923 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -61.15 95.65 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.162 -0.472 . . . . 52.23 110.856 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.418 ' H ' HG12 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -115.1 -78.01 0.57 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.161 -0.472 . . . . 64.05 110.894 179.98 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 86.1 m -161.95 83.72 0.58 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 63.32 111.134 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . 0.411 ' OD2' HD12 ' A' ' 141' ' ' ILE . 22.8 m-20 -101.98 170.0 8.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.21 -0.45 . . . . 74.15 110.881 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.29 151.65 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.711 -0.757 . . . . 53.11 112.502 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.948 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -79.73 -0.03 32.53 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.827 0.346 . . . . 62.14 111.101 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -86.23 -178.08 6.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 63.23 110.942 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.7 m -65.73 91.64 0.14 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.186 -0.461 . . . . 62.31 110.894 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.2 t 51.87 75.41 0.21 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.108 -0.496 . . . . 63.42 110.872 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.667 ' CE1' HG12 ' A' ' 176' ' ' VAL . 1.1 t80 -88.92 149.04 23.51 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.1 -0.5 . . . . 71.21 110.838 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 14.0 t0 -109.96 164.7 12.35 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.127 -0.488 . . . . 72.35 110.902 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.411 HD12 ' OD2' ' A' ' 133' ' ' ASP . 63.8 mt -128.47 125.92 64.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 72.21 111.085 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . 0.466 ' O ' HG22 ' A' ' 174' ' ' THR . 0.1 OUTLIER -76.04 109.24 9.52 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.172 -0.467 . . . . 71.04 110.913 179.819 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.406 ' HB3' ' HA ' ' A' ' 127' ' ' LEU . 0.8 OUTLIER -58.68 -173.62 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.207 -0.451 . . . . 72.4 110.857 179.877 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 11.2 mmtm -148.55 166.02 29.5 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.456 . . . . 61.2 110.89 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 42.6 p-90 -157.75 136.32 11.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 74.33 110.921 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.751 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -172.49 166.02 3.52 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.578 0.704 . . . . 61.22 111.129 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.751 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.5 Cg_endo -69.79 135.35 30.17 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.711 2.274 . . . . 62.42 112.318 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -122.48 165.62 16.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 64.33 111.129 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 23.7 m-85 -122.3 136.32 54.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.214 -0.448 . . . . 74.2 110.89 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 3.7 mm100 -107.16 151.8 24.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.159 -0.473 . . . . 71.23 110.921 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.429 ' O ' HG13 ' A' ' 151' ' ' VAL . 5.4 p -152.04 117.85 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.207 -0.451 . . . . 74.52 111.181 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . 0.43 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 176.93 -161.63 29.5 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.739 -0.743 . . . . 64.34 112.467 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.516 HD23 ' N ' ' A' ' 154' ' ' ARG . 0.6 OUTLIER -136.99 155.9 49.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.769 0.318 . . . . 73.21 110.918 -179.911 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.516 ' N ' HD23 ' A' ' 153' ' ' LEU . 0.4 OUTLIER -139.93 124.16 17.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 71.35 110.872 179.954 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . 0.458 ' OH ' HD13 ' A' ' 163' ' ' LEU . 26.3 p90 -144.42 177.45 8.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.461 . . . . 74.25 110.896 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -118.92 100.18 7.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.082 -0.508 . . . . 73.5 110.895 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 18.7 tp -102.03 106.24 17.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.142 -0.481 . . . . 73.0 110.956 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 103.34 -173.76 22.42 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.726 -0.749 . . . . 73.23 112.47 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 9.3 p-10 -101.53 132.26 47.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.861 0.363 . . . . 61.55 110.913 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 22.6 t 53.01 41.33 32.16 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.139 -0.482 . . . . 74.22 110.921 -179.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 2.3 t90 -171.97 100.49 0.17 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.096 -0.502 . . . . 64.54 110.92 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.545 ' CE ' HG21 ' A' ' 18' ' ' VAL . 13.6 mtm -95.42 173.85 7.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.258 -0.428 . . . . 72.24 110.914 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.458 HD13 ' OH ' ' A' ' 155' ' ' TYR . 2.1 tt -127.69 145.1 51.0 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.271 -0.422 . . . . 74.2 110.911 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . 0.452 ' N ' HD23 ' A' ' 163' ' ' LEU . 5.9 t-20 -145.8 138.07 25.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 74.32 110.919 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 13.0 p -153.26 121.75 6.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 64.42 110.89 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . 0.43 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 1.3 p30 -154.03 -179.79 8.2 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.166 -0.47 . . . . 63.43 110.856 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.895 HG22 HD12 ' A' ' 196' ' ' LEU . 8.2 t -138.48 143.79 31.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 64.33 111.113 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . 0.47 ' NH2' HG21 ' A' ' 170' ' ' ILE . 4.4 ttt180 -113.78 123.34 49.61 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.158 -0.474 . . . . 74.45 110.856 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 13.2 t80 -121.99 138.97 54.22 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.186 -0.461 . . . . 75.41 110.94 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' ILE . . . . . 0.548 HD11 ' HB3' ' A' ' 146' ' ' ALA . 6.4 tt -177.35 93.91 0.23 Allowed Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.631 0.729 . . . . 73.23 111.171 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.66 134.19 27.59 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.707 2.271 . . . . 63.43 112.379 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -156.89 177.84 11.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.252 -0.431 . . . . 74.51 110.878 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 190' ' ' GLU . 11.3 pttp -128.28 125.32 38.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.126 -0.488 . . . . 63.4 110.859 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . 0.466 HG22 ' O ' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -91.94 161.74 14.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.23 -0.441 . . . . 75.55 111.146 179.961 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . 0.415 ' HB3' ' HB2' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -119.14 165.55 14.05 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.431 . . . . 61.11 110.874 179.943 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.667 HG12 ' CE1' ' A' ' 139' ' ' PHE . 21.4 t -146.53 133.13 13.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 64.23 111.171 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 14.0 t -166.53 176.9 6.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 75.2 111.104 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 122.18 141.33 6.0 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.752 -0.737 . . . . 63.22 112.495 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.3 m -173.0 140.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.834 0.35 . . . . 62.53 111.147 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 32.4 tp -102.97 89.23 3.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.214 -0.448 . . . . 61.41 110.946 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 126.1 -87.3 0.35 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.75 -0.738 . . . . 71.41 112.485 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 -170.57 0.4 Allowed 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.704 2.269 . . . . 71.44 112.306 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 29.9 m -83.34 126.84 70.75 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-O 121.605 0.717 . . . . 34.24 111.117 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 165.85 29.59 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.708 2.272 . . . . 65.42 112.325 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 85.3 t -109.41 107.69 23.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.274 -0.421 . . . . 60.35 111.115 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 6.7 p -83.69 110.57 18.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.151 -0.477 . . . . 75.05 110.882 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 11.9 p -121.93 171.5 8.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 73.1 111.15 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 29.9 ttpt -153.52 148.08 26.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.208 -0.451 . . . . 65.41 110.922 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 5.9 tp -142.74 124.06 11.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 63.4 111.098 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 190' ' ' GLU . . . . . 0.422 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 19.5 pt-20 -96.94 116.9 30.0 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 70.22 110.863 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 4.1 m -138.36 158.79 31.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 72.3 111.108 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.406 ' HA ' ' HD2' ' A' ' 193' ' ' PRO . 1.9 p30 -107.85 89.85 5.79 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.581 0.705 . . . . 73.24 110.875 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . 0.406 ' HD2' ' HA ' ' A' ' 192' ' ' ASP . 53.6 Cg_endo -69.79 138.46 37.78 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.721 2.281 . . . . 73.34 112.358 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 12.9 m-85 -124.68 116.66 22.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 72.45 110.865 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 195' ' ' ILE . . . . . 0.412 ' HB ' ' HB3' ' A' ' 168' ' ' ARG . 45.3 mt -106.44 131.28 56.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.199 -0.455 . . . . 64.41 111.109 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . 0.895 HD12 HG22 ' A' ' 167' ' ' VAL . 7.4 tp -117.74 112.33 20.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 74.31 110.889 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -97.87 124.59 42.35 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.145 -0.48 . . . . 72.21 110.855 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 198' ' ' LEU . . . . . 0.409 HD22 ' CD2' ' A' ' 196' ' ' LEU . 0.5 OUTLIER -144.64 119.59 9.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.133 -0.485 . . . . 53.41 110.906 -179.993 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 199' ' ' GLY . . . . . 0.41 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -177.91 -145.83 6.1 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.759 -0.734 . . . . 60.4 112.467 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 200' ' ' ALA . . . . . 0.504 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -127.19 173.8 9.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.803 0.335 . . . . 70.31 111.083 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -140.13 175.82 9.27 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.227 -0.442 . . . . 62.42 110.85 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 202' ' ' TYR . . . . . 0.709 ' C ' HG23 ' A' ' 18' ' ' VAL . 16.2 t80 -146.55 115.65 6.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.095 -0.502 . . . . 70.02 110.915 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.428 ' N ' HG23 ' A' ' 18' ' ' VAL . 15.0 p -77.12 147.66 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.103 -0.499 . . . . 71.01 111.159 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -152.9 143.14 22.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 72.03 110.867 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 12.9 ptmt -104.83 140.29 38.33 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.142 -0.481 . . . . 75.5 110.894 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -53.05 151.52 4.76 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.24 -0.436 . . . . 64.15 110.917 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -85.03 -43.0 14.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 71.12 111.075 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -54.99 125.53 20.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.239 -0.437 . . . . 72.53 111.108 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -99.91 136.38 39.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.237 -0.438 . . . . 74.33 111.066 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -107.55 155.96 19.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.176 -0.465 . . . . 74.22 110.909 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.236 -0.438 . . . . 74.35 110.895 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.1 mmm . . . . . 0 N--CA 1.458 -0.073 0 CA-C-O 120.804 0.335 . . . . 73.24 110.952 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 56.6 m-20 -106.77 55.84 0.66 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 72.35 110.839 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 22.4 mt-10 -144.94 55.97 1.25 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 63.25 110.869 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -143.31 145.3 32.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.139 -0.482 . . . . 73.23 110.801 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 2.2 p90 -141.58 157.6 65.0 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.655 0.74 . . . . 71.45 110.927 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 140.12 41.74 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.622 2.215 . . . . 42.41 112.384 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -115.49 116.96 29.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.199 -0.455 . . . . 60.33 111.057 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 11.2 ptpt -105.61 155.9 18.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.124 -0.489 . . . . 74.41 110.87 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 11.3 m -155.51 148.15 24.11 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.207 -0.451 . . . . 71.0 110.827 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -147.23 159.71 43.32 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.091 -0.504 . . . . 73.13 111.08 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -51.91 -34.87 38.73 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.748 -0.739 . . . . 31.22 112.48 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.2 p90 -157.96 114.35 2.84 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.824 0.345 . . . . 74.33 110.917 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -122.88 167.24 13.8 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.101 -0.499 . . . . 42.23 110.893 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 19.1 pt20 -69.47 120.17 14.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.238 -0.437 . . . . 65.32 110.861 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.41 6.28 38.86 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.781 -0.723 . . . . 73.43 112.543 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -78.43 163.36 25.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.811 0.338 . . . . 72.21 110.878 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 3.7 p-90 -139.96 151.58 45.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.154 -0.475 . . . . 71.1 110.896 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.771 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 2.3 m -144.55 139.36 23.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.226 -0.443 . . . . 63.11 111.107 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.414 ' HB1' ' CZ ' ' A' ' 21' ' ' PHE . . . -99.14 101.78 13.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.124 -0.489 . . . . 63.25 111.146 179.794 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 66.6 m -97.53 121.46 39.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 73.31 110.829 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.414 ' CZ ' ' HB1' ' A' ' 19' ' ' ALA . 18.8 m-85 -118.64 118.29 31.26 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.134 -0.484 . . . . 74.32 110.888 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -148.01 172.84 13.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.102 -0.499 . . . . 75.11 110.845 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -100.64 124.27 46.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.132 -0.486 . . . . 74.31 110.897 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . 0.506 ' HB2' HG21 ' A' ' 56' ' ' THR . 69.5 m -102.28 115.11 29.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.129 -0.487 . . . . 71.0 110.848 -179.732 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -98.84 113.78 26.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.18 -0.464 . . . . 63.4 110.915 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 32.4 t -92.49 146.62 6.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.242 -0.436 . . . . 73.42 111.124 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -135.21 110.52 9.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 72.22 110.937 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.3 p -166.51 150.34 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.136 -0.484 . . . . 75.23 111.193 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 136.27 76.13 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.721 -0.752 . . . . 71.24 112.474 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -89.51 -65.89 0.97 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.832 0.348 . . . . 73.05 110.836 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.501 ' HA ' HG12 ' A' ' 47' ' ' VAL . 14.3 mt-10 -162.87 146.89 11.34 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 72.13 110.878 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.613 HD12 HG13 ' A' ' 189' ' ' ILE . 2.0 tp -109.81 160.73 16.1 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.195 -0.457 . . . . 54.33 110.933 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.51 ' N ' HD11 ' A' ' 189' ' ' ILE . . . 145.64 -142.41 10.64 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.742 -0.742 . . . . 73.22 112.501 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 18.5 m-20 -136.56 169.55 17.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.921 0.391 . . . . 74.24 110.78 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 12.7 mt -136.73 118.85 15.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 61.34 110.926 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 12.7 m120 -145.23 178.6 7.96 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.206 -0.452 . . . . 61.3 110.911 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 44.2 t -76.05 -62.79 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 75.21 111.115 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -157.5 174.13 34.94 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.776 -0.726 . . . . 53.53 112.421 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 137.96 85.99 0.16 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 63.12 112.461 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 61.18 -161.3 25.58 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.73 -0.748 . . . . 45.01 112.454 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -57.92 140.97 50.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.756 0.312 . . . . 41.32 111.081 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -131.98 68.92 80.75 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.608 0.718 . . . . 73.02 110.922 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 -177.4 1.86 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.642 2.228 . . . . 73.32 112.36 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -139.78 118.85 12.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.197 -0.456 . . . . 61.22 110.941 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.564 ' HB1' ' HA ' ' A' ' 84' ' ' GLU . . . -67.81 -178.59 0.98 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.174 -0.466 . . . . 73.24 111.091 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -132.38 125.81 31.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 70.34 110.857 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 82' ' ' GLN . 11.3 p -111.7 137.81 42.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 63.22 111.131 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -147.4 142.05 26.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.084 -0.507 . . . . 43.23 110.895 -179.834 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 39.0 pt -115.72 156.62 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 73.24 111.076 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -84.94 179.02 51.13 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.711 -0.757 . . . . 62.45 112.506 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 79.0 m-20 -133.64 112.95 11.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.836 0.351 . . . . 63.14 110.918 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -145.42 140.58 27.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 75.02 110.831 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 29.8 p -55.68 128.49 35.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 60.22 111.095 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 5.7 t -137.12 150.35 47.93 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.197 -0.456 . . . . 65.12 111.107 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -113.49 152.46 30.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 65.31 110.885 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.506 HG21 ' HB2' ' A' ' 24' ' ' SER . 0.8 OUTLIER -136.51 137.29 40.16 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.188 -0.46 . . . . 52.12 111.153 179.921 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -103.12 132.14 49.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 71.34 110.891 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -130.96 130.2 43.1 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.123 -0.49 . . . . 74.42 110.856 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.98 115.2 48.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 65.02 111.081 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.771 ' HB3' ' CG2' ' A' ' 18' ' ' VAL . . . -101.94 125.61 48.66 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.188 -0.46 . . . . 63.14 111.123 179.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -107.03 117.11 33.21 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.235 -0.439 . . . . 75.04 110.887 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -83.76 95.74 8.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.054 -0.521 . . . . 65.5 110.919 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 9.5 p -92.17 -34.29 6.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 72.43 111.175 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 17.0 m -133.68 160.69 36.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.097 -0.501 . . . . 75.43 110.842 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.6 p -83.48 2.98 34.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.123 -0.489 . . . . 70.31 110.868 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -119.75 -32.27 4.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.13 -0.486 . . . . 75.04 110.93 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.437 HG22 ' CD1' ' A' ' 107' ' ' TYR . 40.5 pt -139.72 153.46 23.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 71.01 111.098 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -146.95 162.92 37.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 65.54 111.088 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.5 m -103.84 151.37 6.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.23 -0.441 . . . . 74.31 111.095 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -141.92 135.75 29.75 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.19 -0.459 . . . . 75.05 110.823 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.493 ' CE2' HD13 ' A' ' 103' ' ' LEU . 7.2 m-85 -122.2 108.18 13.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.13 -0.486 . . . . 71.13 110.88 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.832 ' HB2' HG23 ' A' ' 102' ' ' ILE . 18.1 m-85 -94.77 123.43 38.22 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.118 -0.492 . . . . 75.23 110.833 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.2 p -149.78 154.63 8.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.067 -0.515 . . . . 54.14 111.166 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -162.57 142.23 7.77 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.767 -0.73 . . . . 45.02 112.472 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.9 m -115.17 73.24 3.42 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.617 0.722 . . . . 64.42 111.115 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 161.27 46.56 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.651 2.234 . . . . 64.44 112.357 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -68.71 -169.88 0.19 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.248 -0.433 . . . . 74.42 111.077 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 1.2 tmm_? -78.88 140.67 38.07 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.246 -0.434 . . . . 73.54 110.85 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -128.2 142.27 51.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.201 -0.454 . . . . 53.34 111.077 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 28.9 ttpt -108.11 135.74 48.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.265 -0.425 . . . . 73.35 110.924 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 6.9 p90 -141.97 157.98 44.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 75.42 110.916 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.516 ' O ' HG23 ' A' ' 47' ' ' VAL . 0.5 OUTLIER -96.42 160.78 14.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.151 -0.477 . . . . 72.14 110.896 -179.925 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.518 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -177.87 66.0 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.792 -0.718 . . . . 40.33 112.531 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.564 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.3 tp10 -173.84 -176.8 1.27 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.931 0.396 . . . . 44.31 110.869 -179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.88 -68.87 0.7 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 71.23 110.874 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 5.1 m -83.83 -34.55 24.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.208 -0.451 . . . . 74.31 110.897 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.752 HG22 HG22 ' A' ' 93' ' ' VAL . 5.8 mm -64.55 -33.78 65.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.142 -0.481 . . . . 74.51 111.109 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.3 t -63.05 -45.26 93.06 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.13 -0.486 . . . . 50.41 110.825 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 22.7 t -53.6 -41.72 66.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.124 -0.489 . . . . 72.52 110.88 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.405 HD22 ' HA ' ' A' ' 90' ' ' LEU . 0.3 OUTLIER -59.5 -44.19 93.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 73.41 110.917 179.989 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 110.21 -14.14 30.96 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.762 -0.732 . . . . 61.4 112.505 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 20.2 mtt180 -120.22 93.61 4.11 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.836 0.35 . . . . 75.22 110.813 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.752 HG22 HG22 ' A' ' 87' ' ' ILE . 13.1 t -113.56 -45.82 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 72.52 111.099 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 67.5 m -140.58 144.94 36.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.176 -0.466 . . . . 72.45 110.834 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -142.01 119.56 11.7 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.103 -0.499 . . . . 53.34 110.909 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.471 HG23 ' HB2' ' A' ' 131' ' ' LYS . 7.2 p -175.04 157.92 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 72.33 111.151 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.424 ' N ' HG22 ' A' ' 96' ' ' VAL . 8.2 p-10 -81.17 173.53 12.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.182 -0.463 . . . . 54.34 110.858 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 11.6 m-85 -117.43 130.73 56.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.222 -0.445 . . . . 71.44 110.894 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -117.49 65.81 0.35 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.675 -0.774 . . . . 72.14 112.478 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.75 115.3 4.03 Favored 'Trans proline' 0 N--CA 1.465 -0.187 0 C-N-CA 122.708 2.272 . . . . 72.43 112.384 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.587 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -123.03 100.18 6.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.223 -0.444 . . . . 62.3 111.083 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.832 HG23 ' HB2' ' A' ' 72' ' ' PHE . 2.5 tp -122.06 119.83 59.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.194 -0.457 . . . . 74.52 111.137 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.493 HD13 ' CE2' ' A' ' 71' ' ' PHE . 0.2 OUTLIER -120.65 113.67 20.57 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.199 -0.455 . . . . 71.52 110.897 179.892 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.439 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 4.9 p -142.81 159.48 42.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 55.05 110.858 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.58 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.6 OUTLIER -103.94 149.63 24.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.101 -0.5 . . . . 54.12 110.925 -179.994 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 15.8 mm-40 -101.58 144.95 29.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.468 . . . . 74.53 110.895 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.437 ' CD1' HG22 ' A' ' 67' ' ' ILE . 6.8 t80 -139.94 128.94 23.53 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.185 -0.461 . . . . 62.24 110.933 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 28.1 p80 -115.86 148.98 39.37 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.07 -0.514 . . . . 72.53 110.835 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -77.29 127.11 32.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.195 -0.457 . . . . 73.2 110.915 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 16.2 p-10 -100.42 53.88 0.88 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 63.03 110.825 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.3 p -114.94 -179.01 3.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.247 -0.433 . . . . 72.42 110.866 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 44.9 t80 -97.96 96.46 8.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 74.25 110.886 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -163.58 177.14 9.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 71.21 110.891 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 4.3 ptp180 -58.56 176.87 0.16 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.114 -0.494 . . . . 51.23 110.942 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -70.78 159.76 33.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.247 -0.433 . . . . 71.23 110.884 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 1.4 p90 -173.69 157.56 2.87 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.68 0.752 . . . . 74.22 110.889 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 177.53 5.5 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.625 2.216 . . . . 62.34 112.315 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -110.97 144.36 40.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.187 -0.461 . . . . 74.11 110.875 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 8.0 p -101.16 130.67 50.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.053 -0.521 . . . . 74.54 111.114 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -129.71 165.33 22.26 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.747 -0.739 . . . . 72.53 112.46 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 13.7 p -161.54 149.7 4.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.881 0.372 . . . . 51.45 111.128 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.439 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -174.41 -155.12 11.68 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.748 -0.739 . . . . 54.24 112.485 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.419 HG13 ' O ' ' A' ' 123' ' ' VAL . 7.5 p -109.2 124.83 66.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.878 0.37 . . . . 75.11 111.154 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -110.1 114.3 3.81 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.776 -0.726 . . . . 72.05 112.497 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . 0.587 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 25.5 ptt180 -115.9 124.56 50.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.823 0.344 . . . . 63.25 110.84 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.491 ' O ' HD23 ' A' ' 127' ' ' LEU . 26.1 t -104.68 116.34 48.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.274 -0.421 . . . . 52.15 111.151 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.491 HD23 ' O ' ' A' ' 126' ' ' VAL . 9.9 mt -130.76 171.24 13.34 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 75.32 110.86 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -160.25 169.53 23.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 54.12 110.895 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -102.93 118.78 37.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 62.5 110.883 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -48.93 108.07 0.17 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.056 -0.52 . . . . 50.44 110.877 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.471 ' HB2' HG23 ' A' ' 96' ' ' VAL . 3.6 mmmp? -111.52 -80.84 0.58 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.479 . . . . 74.32 110.875 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 21.9 m -161.52 81.0 0.59 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 64.42 111.135 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 39.2 m-20 -102.84 166.57 10.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.46 . . . . 44.4 110.899 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.64 155.26 0.11 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.705 -0.759 . . . . 61.55 112.503 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.744 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -81.24 3.67 23.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.8 0.333 . . . . 51.13 111.099 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -86.19 -175.33 5.48 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.455 . . . . 62.01 110.911 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 88.6 p -65.59 83.2 0.06 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 61.34 110.87 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 5.4 t 50.31 75.15 0.18 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 61.21 110.869 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -80.04 146.94 31.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 74.43 110.806 -179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . 0.432 ' O ' HG23 ' A' ' 176' ' ' VAL . 2.7 p30 -106.74 161.04 15.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.131 -0.486 . . . . 55.04 110.865 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 57.2 mt -115.73 143.86 24.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.171 -0.468 . . . . 74.2 111.12 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 3.4 mmtp -94.27 104.59 16.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 65.2 110.937 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.471 ' HB2' HD23 ' A' ' 127' ' ' LEU . 0.6 OUTLIER -58.21 -174.86 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.466 . . . . 73.42 110.866 179.897 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -162.28 164.87 27.32 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.233 -0.44 . . . . 75.1 110.906 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 22.6 p-90 -146.6 154.41 41.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.211 -0.45 . . . . 75.42 110.981 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.706 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.23 164.43 0.97 Allowed Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.579 0.704 . . . . 72.03 111.096 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.706 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 54.0 Cg_endo -69.82 127.49 14.62 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.577 2.185 . . . . 53.13 112.364 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.616 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -120.52 167.94 11.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 73.43 111.132 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -123.04 142.13 51.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 74.42 110.872 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 15.5 tt0 -123.17 151.98 41.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.165 -0.471 . . . . 71.4 110.879 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.1 t -151.08 122.8 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 52.52 111.092 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . 0.41 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . -174.68 -174.75 41.64 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.73 -0.748 . . . . 53.33 112.461 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.4 HD23 ' N ' ' A' ' 153' ' ' LEU . 1.9 pt? -135.58 160.43 38.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.776 0.322 . . . . 75.1 110.988 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.3 tpp85 -122.06 118.54 29.0 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.241 -0.436 . . . . 64.23 110.873 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 24.9 t80 -101.35 127.97 47.73 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.204 -0.453 . . . . 73.03 110.897 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -116.73 102.12 9.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.157 -0.474 . . . . 75.2 110.898 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 7.3 tp -97.24 97.01 8.8 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.192 -0.458 . . . . 64.55 110.851 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 51.45 -159.18 2.3 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.608 -0.806 . . . . 70.24 112.516 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 23.2 m-20 -71.71 -29.44 64.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.83 0.348 . . . . 73.5 110.896 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 8.2 p -52.05 172.12 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.155 -0.475 . . . . 71.41 110.909 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 25.4 m0 -49.84 144.2 6.72 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.107 -0.497 . . . . 75.34 110.92 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.44 ' C ' HD12 ' A' ' 163' ' ' LEU . 2.6 mtt -98.91 173.78 6.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.243 -0.435 . . . . 64.4 110.944 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.44 HD12 ' C ' ' A' ' 162' ' ' MET . 8.9 mp -125.68 142.86 51.3 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.268 -0.423 . . . . 63.33 110.876 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -140.15 134.59 31.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 63.22 110.873 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 3.3 t -142.23 122.47 13.87 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.145 -0.479 . . . . 44.23 110.842 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . 0.41 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.4 OUTLIER -150.88 165.08 34.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 53.44 110.92 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.512 HG13 ' HG ' ' A' ' 196' ' ' LEU . 1.5 t -133.51 139.76 48.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.212 -0.449 . . . . 34.05 111.192 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . 0.808 ' HD3' HD13 ' A' ' 195' ' ' ILE . 21.9 ttt180 -111.31 131.38 55.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 72.23 110.87 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' TYR . . . . . 0.471 ' OH ' HG11 ' A' ' 167' ' ' VAL . 94.4 m-85 -134.31 137.0 43.9 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.23 -0.441 . . . . 73.34 110.924 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' ILE . . . . . 0.776 HD13 ' O ' ' A' ' 170' ' ' ILE . 0.0 OUTLIER -179.34 102.92 0.19 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.606 0.717 . . . . 50.42 111.144 179.898 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 139.22 39.71 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.691 2.261 . . . . 71.4 112.368 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . 0.688 ' CZ ' ' HB2' ' A' ' 146' ' ' ALA . 0.1 OUTLIER -165.9 177.26 7.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 75.12 110.816 -179.963 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 8.0 ptmt -128.52 150.61 50.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.053 -0.522 . . . . 71.3 110.873 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 15.3 t -119.43 161.21 20.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.143 -0.48 . . . . 74.15 111.141 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -116.1 172.62 7.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.269 -0.423 . . . . 72.21 110.877 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 140' ' ' ASP . 14.8 p -164.98 140.06 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 73.51 111.084 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.0 t -165.81 177.67 7.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.177 -0.465 . . . . 74.31 111.114 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -154.83 -139.13 2.73 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.696 -0.764 . . . . 72.33 112.499 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -157.57 104.6 2.0 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.811 0.338 . . . . 72.21 111.11 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -139.52 114.4 9.44 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.245 -0.434 . . . . 64.03 110.955 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 46.11 -105.9 0.11 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.741 -0.742 . . . . 75.31 112.514 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -165.64 0.16 Allowed 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.663 2.242 . . . . 74.31 112.376 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.406 HG13 ' HD2' ' A' ' 184' ' ' PRO . 52.7 t -54.47 132.72 63.04 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-O 121.628 0.728 . . . . 62.54 111.184 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . 0.406 ' HD2' HG13 ' A' ' 183' ' ' VAL . 54.0 Cg_endo -69.68 161.17 46.96 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.715 2.277 . . . . 74.4 112.37 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.502 HG12 HG23 ' A' ' 187' ' ' THR . 85.6 t -96.73 108.35 21.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.248 -0.433 . . . . 70.41 111.146 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 62.0 p -98.12 106.52 18.82 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.188 -0.46 . . . . 63.2 110.889 -179.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . 0.502 HG23 HG12 ' A' ' 185' ' ' VAL . 22.2 p -115.74 167.62 10.77 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 72.44 111.122 -179.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 188' ' ' LYS . . . . . 0.483 ' O ' HD13 ' A' ' 189' ' ' ILE . 0.0 OUTLIER -155.29 159.26 39.86 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.203 -0.453 . . . . 63.43 110.976 179.898 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 189' ' ' ILE . . . . . 0.613 HG13 HD12 ' A' ' 32' ' ' LEU . 26.4 mm -142.76 137.67 27.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 71.2 111.07 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -104.78 114.94 29.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 50.02 110.862 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 191' ' ' VAL . . . . . 0.406 HG12 ' N ' ' A' ' 192' ' ' ASP . 2.6 t -137.33 163.09 32.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.148 -0.478 . . . . 71.43 111.177 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.416 ' HA ' ' HD2' ' A' ' 193' ' ' PRO . 0.5 OUTLIER -107.25 90.0 5.26 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.612 0.72 . . . . 72.22 110.883 179.919 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' ' 192' ' ' ASP . 53.8 Cg_endo -69.78 138.04 36.8 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.693 2.262 . . . . 75.11 112.313 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 10.0 m-85 -120.32 119.67 33.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.195 -0.457 . . . . 72.11 110.897 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 195' ' ' ILE . . . . . 0.808 HD13 ' HD3' ' A' ' 168' ' ' ARG . 3.6 mp -112.99 132.45 61.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.464 . . . . 63.42 111.101 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . 0.512 ' HG ' HG13 ' A' ' 167' ' ' VAL . 1.4 tt -125.79 112.16 15.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.444 . . . . 61.0 110.895 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 2.6 p -100.39 127.58 46.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.21 -0.45 . . . . 71.43 110.855 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 198' ' ' LEU . . . . . 0.409 HD23 ' C ' ' A' ' 198' ' ' LEU . 10.5 tt -147.83 126.05 12.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.154 -0.475 . . . . 74.23 110.963 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -179.42 -142.53 5.02 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.719 -0.753 . . . . 62.12 112.47 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 200' ' ' ALA . . . . . 0.415 ' HA ' ' HA ' ' A' ' 163' ' ' LEU . . . -117.99 174.28 6.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.73 0.3 . . . . 32.22 111.098 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 63.7 p -156.37 163.33 39.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.262 -0.426 . . . . 70.33 110.806 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -136.14 130.05 32.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.047 -0.524 . . . . 70.34 110.925 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.409 HG13 ' SD ' ' A' ' 162' ' ' MET . 19.7 m -85.18 147.72 5.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.1 -0.5 . . . . 52.41 111.125 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -141.27 105.0 4.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.181 -0.463 . . . . 74.41 110.889 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 37.0 mttm -72.61 -65.88 0.73 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.068 -0.515 . . . . 74.33 110.913 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 15.3 tp 58.9 56.29 4.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.192 -0.458 . . . . 63.32 110.912 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -67.98 -48.0 67.02 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.164 -0.471 . . . . 42.33 111.134 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -77.72 151.28 34.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.208 -0.451 . . . . 71.32 111.145 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -65.79 -64.07 0.94 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 75.31 111.045 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 4.3 pp -79.27 166.84 21.7 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.19 -0.459 . . . . 71.21 110.907 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 54.15 110.895 179.946 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.458 -0.046 0 CA-C-O 120.829 0.347 . . . . 75.05 110.861 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 4.6 t-20 -140.27 160.05 40.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.239 -0.437 . . . . 73.11 110.917 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 50.7 mt-10 -146.94 146.56 30.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.189 -0.459 . . . . 71.15 110.892 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 90.5 m-20 -95.17 -61.29 1.5 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.135 -0.484 . . . . 72.15 110.893 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 6.9 t80 58.82 72.05 0.89 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.687 0.756 . . . . 64.51 110.898 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.74 -171.57 0.49 Allowed 'Trans proline' 0 C--N 1.341 0.135 0 C-N-CA 122.662 2.241 . . . . 73.14 112.333 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -124.09 155.8 37.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 43.12 111.079 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.65 107.02 0.63 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.28 -0.418 . . . . 64.45 110.899 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 30.1 m -102.8 -36.3 8.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.236 -0.438 . . . . 75.24 110.84 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -52.89 134.3 37.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.131 -0.486 . . . . 71.44 111.113 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -174.28 -97.23 0.11 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.803 -0.713 . . . . 70.51 112.55 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -158.9 119.11 3.17 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.82 0.343 . . . . 72.44 110.942 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 11.0 t30 -167.28 164.31 15.37 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.113 -0.494 . . . . 75.43 110.925 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 -56.78 124.16 17.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.191 -0.459 . . . . 75.14 110.942 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 92.18 6.53 64.74 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.756 -0.735 . . . . 73.45 112.464 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -78.93 151.16 31.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.815 0.341 . . . . 74.31 110.883 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.583 ' CZ2' HG21 ' A' ' 59' ' ' ILE . 0.2 OUTLIER -125.36 139.42 53.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 64.1 110.908 -179.969 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.725 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 4.9 m -145.71 134.67 17.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 55.24 111.18 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -97.8 110.91 23.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 72.23 111.095 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 17.5 t -103.78 117.48 34.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 74.33 110.855 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 30.4 p90 -117.98 124.04 47.21 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 73.34 110.88 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.4 ' HB2' ' C ' ' A' ' 198' ' ' LEU . 4.1 p30 -149.7 171.88 15.98 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.128 -0.487 . . . . 74.32 110.883 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -94.8 122.32 37.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 65.5 110.931 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -93.82 113.53 25.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 34.34 110.845 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 36.7 mttt -93.66 106.97 18.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.197 -0.456 . . . . 72.15 110.877 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.512 HG22 HG23 ' A' ' 28' ' ' VAL . 12.3 p -87.26 130.95 36.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 44.33 111.158 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -121.42 102.69 8.43 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 73.4 110.911 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.512 HG23 HG22 ' A' ' 26' ' ' VAL . 7.9 t -140.16 155.34 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.061 -0.518 . . . . 75.04 111.079 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.487 ' HA2' HG13 ' A' ' 47' ' ' VAL . . . 130.73 62.16 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.762 -0.732 . . . . 61.3 112.467 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -89.87 -66.15 0.95 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.899 0.38 . . . . 72.1 110.969 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 179.18 130.05 0.08 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.088 -0.505 . . . . 71.32 110.849 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.739 HD22 ' HB3' ' A' ' 45' ' ' ALA . 1.8 tp -51.9 170.12 0.06 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.133 -0.485 . . . . 75.23 110.903 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.45 106.46 1.68 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.712 -0.756 . . . . 71.3 112.473 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -51.54 -58.54 6.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.848 0.356 . . . . 71.22 110.932 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 11.0 tp -173.73 161.68 3.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.177 -0.465 . . . . 71.5 110.937 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 34.5 m-80 -97.57 -56.46 2.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.148 -0.478 . . . . 74.22 110.877 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 28.1 m -70.64 -35.13 59.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 71.3 111.162 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 60.34 -164.8 14.26 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.758 -0.735 . . . . 74.03 112.439 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 138.74 -67.59 0.51 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.663 -0.78 . . . . 40.53 112.419 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -97.27 174.78 30.11 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.731 -0.747 . . . . 72.22 112.501 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -68.78 130.37 42.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.821 0.344 . . . . 51.34 111.053 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.401 HD12 ' HA ' ' A' ' 42' ' ' LEU . 8.3 tp -148.73 137.45 11.9 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.66 0.743 . . . . 72.32 110.825 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -172.45 0.58 Allowed 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.65 2.233 . . . . 61.41 112.352 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -136.09 142.47 44.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 72.22 110.855 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.739 ' HB3' HD22 ' A' ' 32' ' ' LEU . . . -117.67 -171.16 2.0 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.482 . . . . 64.15 111.161 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . 0.579 ' O ' HD13 ' A' ' 32' ' ' LEU . 0.4 OUTLIER -121.04 -170.36 2.0 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 74.31 110.807 179.949 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.487 HG13 ' HA2' ' A' ' 29' ' ' GLY . 10.4 p -166.08 135.6 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.157 -0.474 . . . . 71.41 111.167 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -175.05 171.53 3.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.469 . . . . 71.22 110.839 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 2.2 pp -102.43 158.22 4.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.09 -0.505 . . . . 73.13 111.106 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -88.72 -81.73 1.29 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.733 -0.746 . . . . 72.12 112.432 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.7 p30 -151.87 93.38 1.84 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.791 0.329 . . . . 72.42 110.867 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -115.49 65.52 0.69 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 71.11 110.851 179.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.441 ' O ' HG23 ' A' ' 54' ' ' THR . 0.7 OUTLIER -95.31 103.5 15.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.148 -0.478 . . . . 62.23 111.142 -179.887 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.441 HG23 ' O ' ' A' ' 53' ' ' THR . 2.2 p -156.75 163.31 39.4 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.251 -0.432 . . . . 60.42 111.142 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 11.8 mt -88.4 163.23 16.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 75.53 110.927 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -131.42 142.57 50.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 74.5 111.103 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -113.88 131.75 56.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.45 . . . . 52.02 110.864 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.414 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.2 OUTLIER -130.78 143.77 50.97 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.089 -0.505 . . . . 61.54 110.788 -179.938 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.583 HG21 ' CZ2' ' A' ' 17' ' ' TRP . 12.5 mm -108.09 117.68 54.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 73.44 111.12 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.725 ' HB3' ' CG2' ' A' ' 18' ' ' VAL . . . -100.44 132.72 45.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 53.2 111.097 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.452 ' HB3' HG22 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -114.85 116.84 29.22 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.205 -0.452 . . . . 72.44 110.936 -179.861 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -87.0 101.91 13.9 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 74.53 110.969 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 8.1 p -100.57 -34.57 4.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.121 -0.49 . . . . 65.1 111.084 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 20.3 t -132.46 158.78 41.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.171 -0.468 . . . . 63.42 110.894 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.4 m -84.18 2.82 37.95 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 74.55 110.771 -179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -112.33 -31.16 6.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 63.41 110.853 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.403 HG22 ' HA ' ' A' ' 107' ' ' TYR . 25.4 pt -148.78 162.24 5.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.24 -0.437 . . . . 73.15 111.148 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -149.57 170.24 19.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 74.12 111.116 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.452 HG22 ' HB3' ' A' ' 61' ' ' TYR . 10.6 m -112.3 153.57 13.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.203 -0.453 . . . . 74.44 111.203 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -146.15 132.12 19.2 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.191 -0.459 . . . . 73.51 110.841 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.414 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 12.0 t80 -115.01 108.82 17.19 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.253 -0.431 . . . . 71.12 110.889 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -86.19 128.49 34.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 64.35 110.945 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 2.7 p -145.32 144.43 21.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.128 -0.487 . . . . 71.11 111.119 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -159.38 133.76 3.48 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.793 -0.718 . . . . 51.32 112.496 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.476 ' O ' HG13 ' A' ' 75' ' ' VAL . 4.5 p -112.93 75.41 1.96 Allowed Pre-proline 0 C--N 1.33 -0.243 0 CA-C-O 121.659 0.742 . . . . 70.52 111.083 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 162.49 41.87 Favored 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.654 2.236 . . . . 63.04 112.416 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -76.29 -167.93 0.86 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.26 -0.427 . . . . 61.15 111.132 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 35.3 ttp180 -78.02 131.09 37.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.243 -0.435 . . . . 73.42 110.916 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -132.45 151.14 52.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 62.44 111.056 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 22.3 pttm -92.78 135.17 34.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 71.25 110.915 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 68.8 t80 -116.09 137.23 52.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 72.04 110.891 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 -95.92 151.78 19.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 72.51 110.916 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.608 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 174.77 73.6 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.812 -0.709 . . . . 54.34 112.511 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.532 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.3 mm-40 -170.47 -176.44 2.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.912 0.387 . . . . 74.12 110.846 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.19 -70.12 0.62 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 73.24 110.923 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.8 t -85.81 -30.62 22.84 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.212 -0.449 . . . . 74.13 110.788 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.569 HG22 HG22 ' A' ' 93' ' ' VAL . 4.4 mm -68.5 -34.66 66.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 65.55 111.156 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.4 t -61.38 -49.66 76.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.465 . . . . 75.24 110.871 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 22.3 t -51.73 -42.46 62.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 64.24 110.851 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.449 HD22 ' HG2' ' A' ' 92' ' ' ARG . 0.7 OUTLIER -57.66 -45.61 85.3 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.147 -0.479 . . . . 64.11 110.918 179.978 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 111.49 -14.82 27.48 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.772 -0.728 . . . . 63.51 112.547 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.449 ' HG2' HD22 ' A' ' 90' ' ' LEU . 9.6 ptt85 -120.46 95.77 4.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.84 0.353 . . . . 65.04 110.94 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.608 HG21 ' H ' ' A' ' 83' ' ' GLY . 21.9 t -110.5 -46.06 6.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 74.04 111.121 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.409 ' HA ' ' HA ' ' A' ' 133' ' ' ASP . 1.6 p -139.63 153.47 47.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.477 . . . . 74.2 110.834 -179.801 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -135.69 121.96 20.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.142 -0.481 . . . . 72.22 110.896 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.623 HG21 ' O ' ' A' ' 129' ' ' PHE . 7.6 p -174.18 161.39 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.199 -0.455 . . . . 74.23 111.118 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.43 ' N ' HG22 ' A' ' 96' ' ' VAL . 3.3 p30 -80.13 172.72 13.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.188 -0.46 . . . . 75.14 110.873 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -125.31 130.83 52.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.446 . . . . 63.34 110.919 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -118.68 66.75 0.37 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.708 -0.758 . . . . 75.42 112.441 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 124.99 11.63 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.705 2.27 . . . . 73.24 112.319 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.602 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -138.68 106.05 5.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 75.33 111.1 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.658 ' C ' HD23 ' A' ' 103' ' ' LEU . 16.3 mm -118.56 150.48 20.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.25 -0.432 . . . . 74.03 111.105 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.658 HD23 ' C ' ' A' ' 102' ' ' ILE . 0.0 OUTLIER -149.15 109.75 4.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 71.52 110.916 179.869 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.0 p -144.37 171.56 14.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 75.0 110.891 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -120.42 153.06 37.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.465 . . . . 55.33 110.888 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 15.3 pt20 -106.25 139.03 41.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.156 -0.475 . . . . 55.31 110.902 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.403 ' HA ' HG22 ' A' ' 67' ' ' ILE . 30.7 p90 -143.16 148.3 36.32 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 73.04 110.884 -179.822 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 25.0 p-80 -97.5 158.77 15.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 73.33 110.876 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -128.06 125.1 38.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.226 -0.443 . . . . 74.25 110.925 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -52.59 128.64 26.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.099 -0.5 . . . . 70.21 110.913 179.87 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 46.8 m -141.77 172.29 12.89 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 71.02 110.857 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 30.7 t80 -76.57 -38.34 55.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 54.21 110.872 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 61.7 mt-10 -59.63 177.26 0.22 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.138 -0.483 . . . . 75.24 110.954 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 25.9 ttm180 -99.31 -65.55 0.96 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 72.31 110.927 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 26.5 mt -101.49 138.82 37.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 52.23 110.917 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 4.1 p90 -171.49 157.65 4.63 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-O 121.625 0.726 . . . . 72.52 110.921 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 177.55 5.48 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.702 2.268 . . . . 65.2 112.345 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 8.0 m-85 -117.35 157.6 25.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 75.03 110.96 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 72.7 t -106.99 128.38 61.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.063 -0.517 . . . . 73.11 111.109 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -119.27 172.88 14.81 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.714 -0.755 . . . . 72.33 112.53 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.3 p -175.56 153.13 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.848 0.356 . . . . 72.53 111.141 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 178.17 -148.65 8.64 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.823 -0.704 . . . . 60.03 112.511 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.652 HG13 ' HG ' ' A' ' 103' ' ' LEU . 4.9 p -110.39 137.71 41.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.882 0.372 . . . . 64.33 111.145 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . 0.424 ' HA3' HD12 ' A' ' 102' ' ' ILE . . . -127.36 105.87 0.78 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.712 -0.756 . . . . 70.52 112.408 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . 0.602 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 13.0 ptp180 -98.85 130.17 45.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.854 0.359 . . . . 75.44 110.891 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 3.2 m -106.99 109.65 28.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 71.0 111.172 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 1.4 tt -86.47 141.59 29.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 62.1 110.932 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -152.58 129.93 11.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 74.0 110.844 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.623 ' O ' HG21 ' A' ' 96' ' ' VAL . 0.8 OUTLIER -101.56 176.48 5.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.097 -0.501 . . . . 72.1 110.948 -179.973 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -109.19 95.19 5.47 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.218 -0.447 . . . . 73.21 110.85 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.426 ' HB2' HG23 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -89.16 -79.61 0.32 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 71.31 110.858 179.976 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.7 m -163.22 113.22 1.36 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.254 -0.43 . . . . 73.42 111.135 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . 0.43 ' HB3' ' CB ' ' A' ' 139' ' ' PHE . 10.0 t0 -106.27 117.1 33.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.159 -0.473 . . . . 73.13 110.901 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -78.25 -11.15 85.63 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.759 -0.734 . . . . 73.12 112.49 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.455 ' HB2' HG12 ' A' ' 93' ' ' VAL . . . -44.95 -30.31 0.99 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.781 0.324 . . . . 72.21 111.076 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 3.4 tp -160.79 -177.49 6.19 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.227 -0.442 . . . . 75.24 110.916 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 14.9 t -54.28 94.06 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 74.33 110.854 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 68.2 m 49.16 75.49 0.15 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.18 -0.464 . . . . 75.3 110.849 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.43 ' CB ' ' HB3' ' A' ' 133' ' ' ASP . 0.4 OUTLIER -101.58 162.28 13.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 65.43 110.864 -179.958 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -138.53 170.35 16.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.129 -0.487 . . . . 74.45 110.888 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.425 HG22 ' N ' ' A' ' 142' ' ' LYS . 1.9 mp -116.7 160.73 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 52.34 111.13 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . 0.425 ' N ' HG22 ' A' ' 141' ' ' ILE . 3.6 mtmt -122.19 122.36 39.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 74.31 110.899 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -74.31 -172.68 1.49 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.239 -0.437 . . . . 72.04 110.873 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 3.1 mmtm -171.36 -173.46 1.25 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 63.33 110.884 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 52.2 p-90 -154.62 153.23 31.04 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 72.14 110.955 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.757 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -176.44 165.41 1.65 Allowed Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.572 0.701 . . . . 72.44 111.116 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.757 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.1 Cg_endo -69.77 167.06 25.54 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.635 2.224 . . . . 62.33 112.363 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -160.26 154.97 24.07 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.207 -0.451 . . . . 44.34 111.113 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 11.6 m-85 -104.7 129.32 52.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.234 -0.439 . . . . 71.02 110.872 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 6.2 mm-40 -104.72 156.73 17.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.13 -0.486 . . . . 74.15 110.946 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.3 p -155.79 128.91 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 70.55 111.144 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 166.97 -162.82 36.6 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.749 -0.738 . . . . 71.22 112.517 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.424 HD12 ' N ' ' A' ' 154' ' ' ARG . 3.3 pp -155.98 170.47 22.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.824 0.345 . . . . 70.24 110.897 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.424 ' N ' HD12 ' A' ' 153' ' ' LEU . 5.9 tpp85 -117.68 122.3 43.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 71.32 110.867 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -108.56 153.99 22.59 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.185 -0.461 . . . . 71.14 110.964 -179.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 35.7 t0 -121.53 99.26 6.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.482 . . . . 60.32 110.847 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' LEU . . . . . 0.448 HD12 HD12 ' A' ' 163' ' ' LEU . 13.2 mt -97.71 97.53 9.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.28 -0.418 . . . . 74.33 110.936 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 80.65 -147.26 27.91 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.8 -0.714 . . . . 74.12 112.519 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -123.23 -35.49 2.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.866 0.365 . . . . 62.53 110.92 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 1.7 m -51.77 -61.84 2.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 74.5 110.845 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 18.6 p90 -139.58 153.72 47.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.215 -0.448 . . . . 71.23 110.927 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.483 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 11.0 mtt -108.34 176.49 5.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 75.52 110.849 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.448 HD12 HD12 ' A' ' 157' ' ' LEU . 0.9 OUTLIER -116.51 146.31 42.69 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 53.34 110.83 -179.961 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -141.76 134.38 28.39 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.142 -0.481 . . . . 62.43 110.863 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 10.8 t -136.78 124.18 22.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 61.31 110.805 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -144.23 160.72 40.5 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.123 -0.489 . . . . 62.11 110.883 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 58.1 t -150.0 126.73 2.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 64.5 111.156 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . 0.564 ' HD2' HD12 ' A' ' 195' ' ' ILE . 0.4 OUTLIER -104.58 133.58 49.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.198 -0.456 . . . . 72.51 110.834 -179.986 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 19.6 t80 -136.74 132.07 34.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 64.53 110.914 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' ILE . . . . . 0.423 HG21 ' O ' ' A' ' 147' ' ' PRO . 5.0 tp 178.65 132.89 0.23 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.628 0.727 . . . . 61.44 111.144 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.78 112.77 3.17 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.649 2.233 . . . . 72.33 112.374 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . 0.418 ' HZ ' HG23 ' A' ' 174' ' ' THR . 0.1 OUTLIER -122.83 151.45 41.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.259 -0.428 . . . . 73.24 110.859 -179.953 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 20.1 pttt -123.85 134.56 53.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 71.21 110.881 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . 0.426 HG22 ' H ' ' A' ' 175' ' ' ASP . 0.2 OUTLIER -101.2 171.21 7.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.228 -0.442 . . . . 64.14 111.133 179.985 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . 0.426 ' H ' HG22 ' A' ' 174' ' ' THR . 0.2 OUTLIER -123.51 161.2 25.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.197 -0.456 . . . . 71.22 110.911 179.869 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 3.4 t -151.07 143.05 16.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.173 -0.467 . . . . 62.11 111.107 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.4 t -166.98 -178.15 4.09 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.18 -0.464 . . . . 52.13 111.114 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -119.74 -158.38 10.58 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.763 -0.732 . . . . 71.1 112.56 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 6.6 t -128.63 -172.28 2.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.858 0.361 . . . . 71.33 111.152 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 2.0 mp -65.58 140.19 58.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 75.13 110.945 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 117.81 -82.16 0.33 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.692 -0.766 . . . . 71.51 112.47 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.72 -161.94 0.08 OUTLIER 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.68 2.253 . . . . 65.03 112.38 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 5.1 m -107.45 86.1 2.57 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.675 0.75 . . . . 53.34 111.173 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.66 151.32 69.59 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.684 2.256 . . . . 64.12 112.317 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 45.2 t -139.17 112.4 6.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.151 -0.477 . . . . 72.44 111.083 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.02 104.75 5.72 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.476 . . . . 54.4 110.849 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 29.4 p -124.14 174.04 7.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 65.12 111.123 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 5.2 ptmt -150.3 145.76 26.36 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.226 -0.443 . . . . 65.35 110.883 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 189' ' ' ILE . . . . . 0.546 HG21 HD12 ' A' ' 32' ' ' LEU . 6.3 pt -127.27 111.24 24.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.273 -0.421 . . . . 61.25 111.149 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -92.0 113.48 25.76 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.186 -0.461 . . . . 63.12 110.913 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 191' ' ' VAL . . . . . 0.445 HG21 ' CG1' ' A' ' 28' ' ' VAL . 12.1 m -136.77 167.31 24.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 72.13 111.096 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -107.25 88.54 3.98 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.553 0.692 . . . . 73.3 110.86 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 132.5 23.48 Favored 'Trans proline' 0 C--O 1.233 0.242 0 C-N-CA 122.685 2.257 . . . . 74.03 112.363 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -110.05 113.98 27.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.282 -0.417 . . . . 75.23 110.848 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 195' ' ' ILE . . . . . 0.564 HD12 ' HD2' ' A' ' 168' ' ' ARG . 71.5 mt -105.86 119.94 55.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.158 -0.474 . . . . 52.45 111.159 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 9.7 mp -116.03 108.66 16.5 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.195 -0.457 . . . . 62.12 110.92 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 53.9 p -99.21 114.04 26.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.244 -0.434 . . . . 71.33 110.862 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 198' ' ' LEU . . . . . 0.4 ' C ' ' HB2' ' A' ' 22' ' ' ASN . 0.4 OUTLIER -134.14 122.2 22.52 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.186 -0.461 . . . . 74.43 110.92 -179.978 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -175.63 -140.58 3.46 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.774 -0.727 . . . . 64.04 112.497 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 200' ' ' ALA . . . . . 0.483 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -126.65 174.24 8.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.826 0.346 . . . . 45.24 111.078 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 73.7 p -148.11 166.23 28.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.212 -0.449 . . . . 63.44 110.832 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -133.6 136.94 45.19 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.08 -0.509 . . . . 74.42 110.874 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.555 ' HA ' HG12 ' A' ' 18' ' ' VAL . 25.1 m -91.11 149.7 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.095 -0.502 . . . . 73.21 111.137 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -149.84 114.92 5.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 64.43 110.834 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.33 168.03 6.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 73.12 110.927 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -133.98 111.19 10.21 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.237 -0.438 . . . . 73.42 110.925 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -143.97 159.83 41.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 61.21 111.086 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -116.79 163.74 15.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 72.13 111.085 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -68.61 144.32 54.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.178 -0.464 . . . . 75.31 111.165 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 13.6 tp -87.07 149.27 24.83 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.248 -0.433 . . . . 74.54 110.912 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 42.0 mp0 . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 74.22 110.878 179.952 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.3 mmm . . . . . 0 C--O 1.23 0.05 0 CA-C-O 120.735 0.302 . . . . 75.22 110.833 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 6.2 m-80 55.19 36.22 26.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.266 -0.425 . . . . 75.32 110.876 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -58.85 124.08 18.62 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 74.54 110.865 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 20.0 p-10 -127.11 149.42 49.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.146 -0.479 . . . . 61.13 110.891 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 7.7 m-85 -117.31 160.4 37.77 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-O 121.677 0.751 . . . . 73.43 110.885 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.65 171.41 14.39 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.767 2.312 . . . . 74.52 112.392 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.22 -42.21 3.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.299 -0.41 . . . . 74.44 111.084 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -146.77 141.08 26.35 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.265 -0.425 . . . . 65.13 110.906 179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 73.3 p -116.36 50.8 1.02 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.2 -0.455 . . . . 72.03 110.872 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.38 -175.15 2.71 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.077 -0.511 . . . . 71.22 111.117 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.99 -64.11 3.08 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.765 -0.731 . . . . 72.13 112.519 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 14.1 p90 -151.89 115.7 4.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.836 0.351 . . . . 75.05 110.99 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 62.4 t30 -151.29 157.35 42.42 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.109 -0.496 . . . . 71.41 110.871 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -52.29 121.1 6.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 64.12 110.903 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 99.36 6.08 55.46 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.801 -0.714 . . . . 75.12 112.511 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.455 ' OD2' HG13 ' A' ' 18' ' ' VAL . 0.7 OUTLIER -77.33 150.9 35.15 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.853 0.359 . . . . 72.31 110.835 -179.92 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 23.8 m-90 -117.75 138.37 52.08 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.21 -0.45 . . . . 70.35 110.923 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.629 HG23 ' HB3' ' A' ' 60' ' ' ALA . 11.5 m -141.56 134.7 29.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.25 -0.432 . . . . 73.41 111.108 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.56 ' HB1' ' CZ ' ' A' ' 21' ' ' PHE . . . -99.66 112.45 24.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.447 . . . . 73.03 111.085 179.846 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -99.21 109.37 22.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 71.23 110.81 -179.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.56 ' CZ ' ' HB1' ' A' ' 19' ' ' ALA . 12.7 m-85 -107.64 116.51 32.08 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 74.24 110.889 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.415 ' HB2' ' C ' ' A' ' 198' ' ' LEU . 1.4 p-10 -154.12 172.66 17.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 53.32 110.967 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 16.0 p90 -103.57 134.96 46.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.249 -0.432 . . . . 72.15 110.835 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 2.8 m -105.0 107.88 19.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.144 -0.48 . . . . 73.52 110.851 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.633 ' O ' HD12 ' A' ' 196' ' ' LEU . 31.8 tttp -87.71 109.37 19.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.11 -0.495 . . . . 74.54 110.844 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 9.7 p -92.65 130.93 41.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 75.44 111.168 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -119.42 100.59 7.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 74.54 110.932 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.43 HG23 ' CG1' ' A' ' 191' ' ' VAL . 7.4 p -149.34 145.31 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.093 -0.503 . . . . 73.52 111.114 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 148.84 67.32 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.735 -0.745 . . . . 72.24 112.518 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 8.3 tt0 -89.18 -65.84 0.98 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.832 0.349 . . . . 62.31 110.928 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -170.61 169.25 7.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.125 -0.488 . . . . 73.32 110.92 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.718 HD12 HG21 ' A' ' 189' ' ' ILE . 11.3 tp -84.59 161.55 20.12 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.167 -0.47 . . . . 65.42 110.905 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.11 -33.1 36.91 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.763 -0.732 . . . . 64.41 112.51 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 46.1 m-20 54.19 37.22 26.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.866 0.365 . . . . 73.33 110.859 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 60.4 tp -67.06 127.77 33.85 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.194 -0.457 . . . . 61.32 110.891 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 4.7 p-10 -111.67 103.15 11.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.14 -0.482 . . . . 72.44 110.86 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 11.2 p -75.61 -34.48 29.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.172 -0.467 . . . . 75.03 111.154 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -169.56 114.12 0.54 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.732 -0.747 . . . . 61.53 112.467 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 170.14 -177.28 43.53 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.741 -0.742 . . . . 75.44 112.524 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -103.56 -119.35 4.6 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.723 -0.751 . . . . 52.32 112.49 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.473 ' C ' HD22 ' A' ' 42' ' ' LEU . . . -90.85 106.22 18.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.805 0.335 . . . . 71.53 111.143 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.473 HD22 ' C ' ' A' ' 41' ' ' ALA . 4.6 mm? -119.18 159.32 45.66 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.582 0.706 . . . . 62.45 110.895 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -172.11 0.55 Allowed 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.712 2.275 . . . . 71.34 112.32 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 2.7 p30 -128.06 145.58 50.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.247 -0.433 . . . . 71.12 110.92 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.457 ' HB1' ' HA ' ' A' ' 84' ' ' GLU . . . -92.07 167.89 11.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.465 . . . . 75.43 111.084 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -137.61 134.7 35.84 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.29 -0.414 . . . . 55.33 110.872 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 73.6 t -104.94 142.61 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 44.54 111.149 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 m -155.19 152.9 29.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 73.32 110.882 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 38.3 pt -136.79 157.71 36.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.158 -0.474 . . . . 73.5 111.138 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -88.78 -90.33 1.15 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.745 -0.741 . . . . 60.24 112.499 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 9.2 m120 57.57 57.27 4.41 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.795 0.331 . . . . 64.31 110.883 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.529 ' O ' HG23 ' A' ' 53' ' ' THR . 0.7 OUTLIER -55.61 -57.86 10.2 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 74.34 110.915 179.918 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.529 HG23 ' O ' ' A' ' 52' ' ' ASP . 0.7 OUTLIER -162.85 138.18 6.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 71.35 111.177 -179.953 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.524 HG23 ' O ' ' A' ' 53' ' ' THR . 0.7 OUTLIER -161.89 146.65 12.89 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.227 -0.442 . . . . 73.23 111.132 -179.942 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 88.9 mt -90.06 157.65 17.69 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.455 . . . . 74.5 110.828 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.36 144.32 33.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.13 -0.486 . . . . 74.34 111.129 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 15.4 m-85 -102.37 132.53 48.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 71.33 110.935 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.495 ' C ' HD13 ' A' ' 59' ' ' ILE . 3.6 m-20 -128.43 139.43 52.36 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.145 -0.48 . . . . 72.24 110.923 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.495 HD13 ' C ' ' A' ' 58' ' ' ASP . 3.4 mm -110.07 114.92 48.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.196 -0.457 . . . . 74.44 111.123 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.629 ' HB3' HG23 ' A' ' 18' ' ' VAL . . . -116.15 149.53 38.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.116 -0.493 . . . . 64.55 111.145 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.485 ' CE2' HG22 ' A' ' 59' ' ' ILE . 14.6 m-85 -129.33 137.59 51.08 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.289 -0.414 . . . . 73.34 110.946 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -98.33 102.28 13.98 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.158 -0.474 . . . . 73.03 110.867 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.7 m -99.35 -34.06 4.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.472 . . . . 75.04 111.088 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 58.4 m -135.51 158.77 43.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 74.04 110.917 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 3.9 t -83.99 3.39 34.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 74.52 110.861 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -114.06 -30.56 6.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.149 -0.478 . . . . 63.31 110.849 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -140.89 165.23 20.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.252 -0.431 . . . . 65.12 111.124 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -155.18 168.83 25.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.133 -0.485 . . . . 65.32 111.116 179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.433 HG22 ' HB2' ' A' ' 61' ' ' TYR . 4.2 m -111.66 147.67 15.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 63.1 111.125 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -149.93 128.53 12.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.189 -0.46 . . . . 61.23 110.849 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -121.5 132.91 54.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 71.31 110.882 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.612 ' CD1' HD11 ' A' ' 102' ' ' ILE . 13.1 m-30 -95.02 134.85 37.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.131 -0.486 . . . . 62.32 110.926 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 63.3 t -144.41 136.81 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.107 -0.497 . . . . 64.51 111.086 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -155.29 140.55 7.43 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.743 -0.742 . . . . 63.15 112.439 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.8 t -124.38 66.87 45.5 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.621 0.724 . . . . 71.14 111.083 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 154.91 67.45 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.656 2.237 . . . . 73.3 112.374 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -68.14 -167.63 0.09 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 50.43 111.09 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 9.8 ttm180 -77.46 129.0 35.16 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.203 -0.453 . . . . 73.54 110.859 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . 0.554 ' HB3' ' CZ ' ' A' ' 81' ' ' PHE . . . -120.72 142.41 49.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.449 . . . . 62.23 111.072 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 21.0 ttpp -91.64 134.99 34.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.165 -0.471 . . . . 72.12 110.9 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . 0.554 ' CZ ' ' HB3' ' A' ' 79' ' ' ALA . 22.1 m-85 -131.98 152.01 51.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.221 -0.445 . . . . 70.43 110.92 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -99.93 156.1 17.33 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 73.23 110.897 -179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.585 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 179.86 68.16 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.737 -0.744 . . . . 55.15 112.487 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.457 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.5 tp10 -170.53 -176.44 2.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.935 0.398 . . . . 74.41 110.94 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.81 -70.17 0.61 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 74.11 110.847 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.8 t -85.25 -31.24 23.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 73.12 110.828 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.616 HG22 HG22 ' A' ' 93' ' ' VAL . 4.8 mm -67.75 -33.59 62.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.198 -0.456 . . . . 73.11 111.146 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 10.0 t -63.66 -48.06 78.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 74.43 110.87 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 27.1 t -51.92 -42.48 62.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.147 -0.479 . . . . 72.31 110.87 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 82.6 mt -57.73 -48.38 79.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.115 -0.493 . . . . 61.41 110.884 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 115.32 -15.21 18.07 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.758 -0.734 . . . . 73.52 112.446 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 14.4 ttp180 -120.31 92.61 3.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.817 0.342 . . . . 63.41 110.885 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.616 HG22 HG22 ' A' ' 87' ' ' ILE . 25.3 t -108.15 -52.76 6.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.224 -0.444 . . . . 73.52 111.119 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 60.4 m -140.69 146.06 37.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 70.13 110.846 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -131.01 125.86 34.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 72.41 110.859 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.452 HG22 ' N ' ' A' ' 97' ' ' ASP . 13.2 p -174.42 156.79 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 63.03 111.167 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.452 ' N ' HG22 ' A' ' 96' ' ' VAL . 2.8 p-10 -86.39 173.43 9.68 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.187 -0.46 . . . . 70.34 110.83 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -133.48 126.07 30.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 64.31 110.929 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -113.5 72.36 0.23 Allowed Glycine 0 N--CA 1.453 -0.232 0 C-N-CA 120.717 -0.754 . . . . 72.12 112.458 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 114.21 3.62 Favored 'Trans proline' 0 N--CA 1.465 -0.177 0 C-N-CA 122.754 2.303 . . . . 74.13 112.367 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -129.56 104.87 7.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.219 -0.446 . . . . 72.34 111.129 179.858 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.612 HD11 ' CD1' ' A' ' 72' ' ' PHE . 1.2 pp -127.89 151.3 34.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 64.43 111.123 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.439 ' HG ' HG13 ' A' ' 123' ' ' VAL . 0.2 OUTLIER -141.01 111.64 6.95 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.132 -0.485 . . . . 75.31 110.912 179.854 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.408 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 3.6 p -134.24 -174.15 3.47 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.23 -0.441 . . . . 75.22 110.837 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.421 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -134.97 147.98 49.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.091 -0.504 . . . . 45.54 110.931 179.994 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 14.4 pt20 -104.31 134.82 46.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 75.12 110.97 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.518 ' CE1' HG13 ' A' ' 119' ' ' VAL . 12.9 p90 -144.71 159.03 43.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.228 -0.442 . . . . 64.22 110.925 -179.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 9.8 t60 -129.36 149.9 50.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.111 -0.495 . . . . 73.1 110.855 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -90.69 150.01 21.83 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.251 -0.431 . . . . 74.51 110.978 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -55.58 106.86 0.28 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.115 -0.493 . . . . 72.22 110.902 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.0 t -148.43 126.19 11.86 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.275 -0.42 . . . . 63.41 110.86 -179.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 19.3 p90 -121.45 40.96 3.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.115 -0.493 . . . . 73.14 110.871 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 34.1 mt-10 -97.15 -60.73 1.52 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.103 -0.499 . . . . 64.02 110.921 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 46.3 mtt180 -158.74 171.21 20.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.198 -0.455 . . . . 64.45 110.922 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -64.43 132.88 51.31 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.194 -0.457 . . . . 74.11 110.928 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -153.3 160.52 30.84 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.701 0.762 . . . . 74.31 110.913 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.81 177.52 5.53 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.725 2.283 . . . . 65.51 112.338 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -116.69 154.54 30.41 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.204 -0.453 . . . . 74.13 110.946 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.518 HG13 ' CE1' ' A' ' 107' ' ' TYR . 5.4 p -102.57 127.38 56.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.122 -0.49 . . . . 73.25 111.109 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -119.87 167.67 13.56 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.728 -0.749 . . . . 53.23 112.534 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 7.3 p -171.38 154.45 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.826 0.346 . . . . 51.2 111.135 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.408 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . 178.87 -147.02 7.57 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.695 -0.764 . . . . 50.33 112.452 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.462 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.7 p -112.6 132.43 61.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.852 0.358 . . . . 52.51 111.112 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . 0.515 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -123.3 109.6 1.37 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.761 -0.733 . . . . 53.54 112.463 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . 0.666 ' HE ' HD11 ' A' ' 127' ' ' LEU . 10.5 ptm180 -109.41 123.47 49.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.817 0.342 . . . . 55.13 110.892 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.456 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 2.5 p -107.35 119.35 56.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.47 . . . . 73.34 111.152 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.666 HD11 ' HE ' ' A' ' 125' ' ' ARG . 2.7 mp -129.46 153.62 47.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.19 -0.459 . . . . 70.52 110.81 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 7.3 p90 -160.21 169.71 22.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.078 -0.51 . . . . 70.12 110.894 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.406 ' O ' HG23 ' A' ' 96' ' ' VAL . 45.1 m-85 -101.88 117.57 35.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 73.43 110.877 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -53.43 101.38 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.138 -0.483 . . . . 75.15 110.873 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.67 -82.97 0.09 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.234 -0.439 . . . . 61.41 110.865 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.8 m -173.42 128.22 0.43 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 62.21 111.195 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . 0.436 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 5.3 m-20 -114.37 115.3 27.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 73.21 110.878 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -80.82 -2.96 90.47 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.731 -0.747 . . . . 41.42 112.511 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.572 ' HB2' HG12 ' A' ' 93' ' ' VAL . . . -47.13 -29.73 2.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.824 0.345 . . . . 72.41 111.079 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.8 tp -158.93 -177.94 6.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 53.22 110.921 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -52.19 96.49 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.157 -0.474 . . . . 72.4 110.826 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 93.2 p 46.94 74.13 0.16 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 63.03 110.865 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.436 ' HB3' ' HB2' ' A' ' 133' ' ' ASP . 0.5 OUTLIER -95.76 158.85 15.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.127 -0.488 . . . . 71.14 110.905 -179.928 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -141.36 174.95 10.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 73.44 110.829 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.815 HG23 HG12 ' A' ' 176' ' ' VAL . 2.6 mt -131.41 152.68 37.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.155 -0.475 . . . . 64.54 111.118 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . 0.412 ' O ' HG22 ' A' ' 174' ' ' THR . 7.1 mmpt? -122.43 122.11 38.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 71.2 110.928 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.456 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 1.9 p-10 -72.08 -166.52 0.24 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.212 -0.449 . . . . 63.25 110.93 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -173.35 177.27 2.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.239 -0.437 . . . . 71.23 110.875 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' TRP . . . . . 0.404 ' O ' ' HB2' ' A' ' 146' ' ' ALA . 30.9 p90 -146.54 153.51 40.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 72.52 110.912 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.81 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 178.98 168.1 0.61 Allowed Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.618 0.723 . . . . 73.41 111.128 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.81 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.7 Cg_endo -69.79 150.73 68.43 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.68 2.253 . . . . 74.21 112.387 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.541 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -148.11 167.31 25.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.217 -0.447 . . . . 51.12 111.087 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 -118.94 166.21 13.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.205 -0.452 . . . . 73.5 110.883 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 1.3 pt20 -157.9 162.48 38.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.167 -0.47 . . . . 73.22 110.973 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 94.1 t -150.61 124.81 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.222 -0.445 . . . . 75.23 111.113 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . 0.438 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . -171.46 -167.16 31.31 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.769 -0.729 . . . . 44.2 112.541 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.471 HD12 ' CD2' ' A' ' 155' ' ' TYR . 1.1 pt? -145.11 158.54 43.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.834 0.349 . . . . 63.22 110.925 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 3.7 tpp85 -125.33 121.86 35.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 62.14 110.806 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . 0.471 ' CD2' HD12 ' A' ' 153' ' ' LEU . 5.1 m-85 -128.52 173.16 10.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 73.01 110.873 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -121.74 106.83 11.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.1 -0.5 . . . . 65.24 110.883 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' LEU . . . . . 0.4 HD22 ' HA ' ' A' ' 157' ' ' LEU . 0.3 OUTLIER -102.94 97.41 7.54 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.194 -0.457 . . . . 74.03 110.948 -179.992 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 85.75 161.99 35.68 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.677 -0.773 . . . . 65.24 112.537 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -74.26 147.21 42.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.889 0.376 . . . . 72.31 110.889 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 14.2 m 51.9 36.45 18.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.198 -0.455 . . . . 74.22 110.861 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 2.9 t90 -172.69 112.08 0.24 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.153 -0.476 . . . . 71.32 110.933 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 5.3 mtt -110.47 172.74 6.69 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 75.52 110.905 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.4 ' HA ' ' HA ' ' A' ' 200' ' ' ALA . 41.9 mt -129.49 140.3 51.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.253 -0.43 . . . . 60.43 110.903 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -138.41 136.05 35.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 72.0 110.864 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 24.0 p -143.94 122.27 12.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 74.3 110.84 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . 0.438 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.6 OUTLIER -150.77 171.84 16.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.128 -0.487 . . . . 72.44 110.833 179.972 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.497 HG11 ' OH ' ' A' ' 169' ' ' TYR . 0.9 OUTLIER -141.89 120.12 8.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 73.45 111.101 -179.979 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . 0.561 ' HD3' HG22 ' A' ' 170' ' ' ILE . 1.9 tmm_? -93.55 135.65 34.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 63.41 110.845 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' TYR . . . . . 0.497 ' OH ' HG11 ' A' ' 167' ' ' VAL . 21.7 m-85 -134.28 136.27 43.43 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 74.45 110.873 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' ILE . . . . . 0.77 HD12 ' HD2' ' A' ' 171' ' ' PRO . 8.0 tp 178.66 118.89 0.2 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.685 0.755 . . . . 73.04 111.086 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . 0.77 ' HD2' HD12 ' A' ' 170' ' ' ILE . 53.7 Cg_endo -69.75 113.44 3.37 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.633 2.222 . . . . 61.31 112.359 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -117.11 177.34 4.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.216 -0.447 . . . . 74.24 110.846 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 6.8 ptmt -152.32 138.58 18.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.128 -0.487 . . . . 64.23 110.933 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . 0.412 HG22 ' O ' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -102.95 155.1 18.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.258 -0.428 . . . . 75.1 111.15 179.963 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -116.19 102.11 9.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 71.04 110.868 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.815 HG12 HG23 ' A' ' 141' ' ' ILE . 20.3 m -96.89 146.35 7.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 71.04 111.139 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.6 t -166.7 163.29 16.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 70.13 111.132 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -123.35 162.3 17.3 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.798 -0.715 . . . . 61.12 112.488 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.2 106.7 16.23 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.811 0.339 . . . . 62.11 111.17 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.418 HD23 ' HD2' ' A' ' 182' ' ' PRO . 0.1 OUTLIER -140.27 167.21 22.67 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.166 -0.47 . . . . 73.4 110.853 -179.959 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -50.5 -71.65 0.6 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.753 -0.737 . . . . 54.22 112.484 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.418 ' HD2' HD23 ' A' ' 180' ' ' LEU . 53.5 Cg_endo -69.86 -171.91 0.53 Allowed 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.65 2.233 . . . . 73.33 112.322 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.44 HG13 ' O ' ' A' ' 183' ' ' VAL . 3.5 p -57.7 111.66 3.75 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.636 0.732 . . . . 74.42 111.114 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 165.98 29.15 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.658 2.238 . . . . 75.03 112.301 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 87.4 t -95.67 107.17 19.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 64.54 111.16 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 81.0 p -110.02 125.26 52.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 73.1 110.831 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 35.7 p -138.21 159.54 41.77 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.122 -0.49 . . . . 71.23 111.114 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 3.6 pttm -128.87 150.02 50.52 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 74.04 110.94 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 189' ' ' ILE . . . . . 0.718 HG21 HD12 ' A' ' 32' ' ' LEU . 6.3 pt -131.56 108.2 14.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.245 -0.434 . . . . 72.44 111.138 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -98.87 118.34 35.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 62.42 110.86 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 191' ' ' VAL . . . . . 0.435 HG12 ' H ' ' A' ' 192' ' ' ASP . 2.4 t -137.66 164.53 28.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 65.51 111.073 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.435 ' H ' HG12 ' A' ' 191' ' ' VAL . 0.2 OUTLIER -106.96 87.73 3.16 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.604 0.716 . . . . 75.24 110.871 179.929 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.64 131.71 21.99 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.704 2.269 . . . . 75.24 112.311 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -100.17 107.03 18.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 55.55 110.89 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 195' ' ' ILE . . . . . 0.531 HD13 ' NE ' ' A' ' 168' ' ' ARG . 3.9 mp -97.99 125.33 51.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.111 -0.495 . . . . 62.23 111.159 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . 0.633 HD12 ' O ' ' A' ' 25' ' ' LYS . 2.1 mp -119.31 108.12 14.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 61.12 110.977 179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.2 120.52 33.57 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 53.33 110.851 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 198' ' ' LEU . . . . . 0.415 ' C ' ' HB2' ' A' ' 22' ' ' ASN . 1.3 tt -144.74 127.41 16.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.116 -0.493 . . . . 65.14 110.823 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 176.18 -146.98 8.35 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.834 -0.698 . . . . 53.11 112.535 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 200' ' ' ALA . . . . . 0.4 ' HA ' ' HA ' ' A' ' 163' ' ' LEU . . . -118.32 174.14 6.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.788 0.327 . . . . 75.34 111.106 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 8.9 p -151.76 171.77 17.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 63.24 110.884 -179.802 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -145.4 148.1 32.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.147 -0.479 . . . . 54.33 110.912 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.619 ' HA ' HG12 ' A' ' 18' ' ' VAL . 14.5 m -111.76 157.4 12.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.49 . . . . 73.01 111.206 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -173.76 155.25 2.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.211 -0.449 . . . . 74.34 110.912 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 18.2 pttp -133.5 178.32 7.01 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.152 -0.476 . . . . 74.34 110.835 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -67.83 133.86 49.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 72.11 110.963 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -69.55 142.32 53.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 73.34 111.092 179.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -80.71 106.13 12.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.139 -0.482 . . . . 73.13 111.116 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -93.15 -46.05 7.6 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.266 -0.425 . . . . 22.43 111.064 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -111.06 113.94 26.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 72.15 110.924 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.186 -0.461 . . . . 72.44 110.889 179.945 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 14.6 mtm . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.796 0.331 . . . . 64.51 110.897 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -121.83 172.89 7.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 61.32 110.903 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -125.66 144.22 50.69 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.087 -0.506 . . . . 65.31 110.931 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -142.05 163.97 31.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 62.04 110.877 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -114.08 160.48 32.26 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.688 0.756 . . . . 72.1 110.921 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 178.66 4.32 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.674 2.25 . . . . 71.2 112.344 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -149.39 143.61 25.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 75.32 111.119 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 76.5 mttt -135.52 146.18 47.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.207 -0.451 . . . . 64.31 110.912 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 2.2 t -60.53 142.26 55.54 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 73.33 110.895 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -84.37 -45.33 12.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 63.12 111.06 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -53.67 -39.52 61.26 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.766 -0.731 . . . . 70.0 112.467 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 10.7 p90 -144.2 112.66 6.51 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.904 0.383 . . . . 73.23 110.921 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 20.1 t30 -131.08 157.03 44.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.465 . . . . 72.12 110.902 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.2 mt-30 -54.52 119.95 5.97 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.224 -0.444 . . . . 70.24 110.887 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.61 6.47 46.9 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.731 -0.747 . . . . 63.35 112.521 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.16 150.4 40.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.793 0.33 . . . . 70.44 110.802 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.428 ' CZ3' HD21 ' A' ' 206' ' ' LEU . 33.4 m0 -122.24 140.85 52.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.189 -0.459 . . . . 73.41 110.936 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.739 HG13 ' HB3' ' A' ' 60' ' ' ALA . 2.1 p -148.55 122.58 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.171 -0.468 . . . . 72.21 111.151 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -84.81 114.17 21.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 64.22 111.083 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 7.7 p -106.06 109.3 21.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.247 -0.433 . . . . 73.13 110.823 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -113.08 123.58 50.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 74.32 110.852 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.87 168.47 25.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 71.24 110.916 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -96.01 127.82 42.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 75.25 110.882 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.1 p -97.45 109.75 22.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.243 -0.435 . . . . 71.41 110.808 -179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 9.2 tmtt? -88.05 106.63 18.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.077 -0.51 . . . . 74.03 110.904 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 11.1 p -86.29 139.13 17.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.461 . . . . 63.53 111.107 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -135.27 102.46 5.17 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.207 -0.451 . . . . 63.5 110.977 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.548 ' O ' HD13 ' A' ' 49' ' ' ILE . 8.5 p -168.73 153.99 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.16 -0.473 . . . . 75.14 111.142 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 130.11 71.16 0.12 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.779 -0.724 . . . . 72.31 112.505 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -89.73 -66.07 0.96 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.83 0.347 . . . . 75.42 110.916 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -161.93 154.97 20.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 64.41 110.864 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 9.1 tp -69.74 167.46 17.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.086 -0.506 . . . . 73.52 110.896 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -85.65 65.36 3.96 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 72.33 112.487 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -85.29 103.97 14.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.834 0.349 . . . . 71.12 110.864 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 30.5 tp -83.24 -35.92 24.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 53.35 110.877 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -51.81 -36.31 47.42 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 75.22 110.938 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 23.2 t -82.71 128.08 39.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 72.1 111.113 179.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -119.98 54.73 0.64 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.662 -0.78 . . . . 61.44 112.489 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 52.95 34.99 47.1 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.782 -0.723 . . . . 61.04 112.484 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -157.16 -103.22 0.2 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.71 -0.757 . . . . 74.43 112.421 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -69.82 166.32 19.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.84 0.352 . . . . 45.11 111.103 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.2 tp 66.4 137.41 0.05 OUTLIER Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.594 0.711 . . . . 73.13 110.869 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 140.87 43.7 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.741 2.294 . . . . 54.12 112.291 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 9.1 t-20 -93.3 150.46 20.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.194 -0.457 . . . . 71.13 110.911 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -93.87 160.55 14.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 74.11 111.058 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -147.36 140.31 25.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.134 -0.485 . . . . 74.03 110.875 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 29.7 m -104.96 147.81 10.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.209 -0.45 . . . . 55.01 111.107 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.5 t -139.33 124.12 18.58 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.137 -0.483 . . . . 70.34 110.877 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.548 HD13 ' O ' ' A' ' 28' ' ' VAL . 5.3 mp -120.76 105.33 16.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.167 -0.469 . . . . 73.14 111.165 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -135.67 109.99 0.79 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.772 -0.727 . . . . 74.31 112.527 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -147.7 152.19 37.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.853 0.359 . . . . 63.34 110.893 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -52.32 148.93 6.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 63.05 110.817 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 43.9 p -76.55 109.41 10.28 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.172 -0.467 . . . . 74.55 111.135 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.8 p -94.61 176.54 6.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 64.24 111.203 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 1.5 pt? -108.71 155.52 20.63 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.202 -0.454 . . . . 61.04 110.921 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -126.02 141.78 51.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.215 -0.448 . . . . 74.4 111.124 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -103.39 131.88 50.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 74.04 110.944 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.465 ' C ' HD13 ' A' ' 59' ' ' ILE . 2.8 m-20 -131.87 144.39 50.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.129 -0.487 . . . . 63.04 110.914 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.465 HD13 ' C ' ' A' ' 58' ' ' ASP . 5.1 mm -115.2 114.2 45.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 54.04 111.118 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.739 ' HB3' HG13 ' A' ' 18' ' ' VAL . . . -102.87 129.95 49.73 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.15 -0.477 . . . . 72.14 111.06 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.456 ' HB2' HG22 ' A' ' 69' ' ' VAL . 22.7 m-85 -115.62 122.15 44.75 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 71.33 110.962 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -88.96 100.9 13.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 75.31 110.844 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.6 p -96.51 -33.17 4.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.122 -0.49 . . . . 70.01 111.132 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.6 m -132.01 159.17 39.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.15 -0.477 . . . . 71.04 110.828 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -84.03 3.18 35.6 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.105 -0.498 . . . . 62.54 110.788 -179.79 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -116.56 -31.49 5.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.228 -0.442 . . . . 71.34 110.878 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.432 HD12 ' CE1' ' A' ' 107' ' ' TYR . 33.8 pt -144.21 162.19 15.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 70.53 111.142 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -152.7 170.63 19.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 43.33 111.127 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.456 HG22 ' HB2' ' A' ' 61' ' ' TYR . 4.6 m -115.17 152.56 16.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 63.12 111.158 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.4 ' HA ' ' HA ' ' A' ' 60' ' ' ALA . 0.9 OUTLIER -149.96 128.92 12.58 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.185 -0.461 . . . . 74.0 110.82 179.976 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.405 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 6.7 m-85 -105.99 132.13 52.44 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.176 -0.466 . . . . 70.43 110.892 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -105.39 121.83 44.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.152 -0.476 . . . . 73.4 110.906 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.415 HG12 ' N ' ' A' ' 74' ' ' GLY . 5.9 t -145.73 159.24 12.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.129 -0.487 . . . . 73.11 111.08 -179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.415 ' N ' HG12 ' A' ' 73' ' ' VAL . . . -152.64 170.16 31.77 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.65 -0.786 . . . . 72.12 112.425 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.4 t -119.69 64.77 8.88 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.643 0.735 . . . . 74.42 111.148 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 163.36 38.58 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.642 2.228 . . . . 60.34 112.37 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -120.35 -166.96 1.38 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 62.03 111.139 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 33.8 ttp85 -76.86 120.65 22.29 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.266 -0.425 . . . . 61.11 110.821 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . 0.483 ' HB3' ' HE1' ' A' ' 98' ' ' TYR . . . -124.26 150.92 44.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.216 -0.447 . . . . 75.11 111.121 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -101.92 139.66 37.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.188 -0.46 . . . . 73.41 110.864 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . 0.535 ' CE2' HG23 ' A' ' 49' ' ' ILE . 43.7 m-85 -140.87 158.28 44.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 74.35 110.906 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 9.6 mt-30 -99.03 156.83 16.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 71.14 110.889 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.568 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -179.67 71.56 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.803 -0.713 . . . . 63.45 112.525 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -178.37 -177.36 0.56 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.893 0.378 . . . . 61.53 110.864 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.02 -68.95 0.7 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 72.42 110.903 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.8 t -83.24 -35.11 25.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.126 -0.488 . . . . 54.44 110.854 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.916 HG21 ' HB2' ' A' ' 135' ' ' ALA . 6.9 mm -63.54 -33.78 63.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.09 -0.505 . . . . 75.34 111.135 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 55.2 p -62.4 -49.24 76.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.235 -0.438 . . . . 62.2 110.911 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.3 t -51.21 -40.26 58.36 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.143 -0.48 . . . . 64.32 110.811 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 13.4 mt -60.73 -46.33 90.81 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.143 -0.48 . . . . 73.23 110.949 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 112.41 -14.43 25.3 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.714 -0.755 . . . . 34.02 112.481 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 27.8 mtp180 -121.1 96.34 5.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.824 0.345 . . . . 71.44 110.862 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.892 HG22 HG22 ' A' ' 87' ' ' ILE . 39.6 t -113.8 -44.36 4.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.461 . . . . 45.04 111.138 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.5 p -142.62 147.75 36.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 71.14 110.874 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -149.39 118.83 6.89 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.172 -0.467 . . . . 54.42 110.843 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.648 HG23 ' HB2' ' A' ' 131' ' ' LYS . 2.9 p -177.76 166.25 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 73.35 111.155 179.908 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.477 ' H ' HG22 ' A' ' 96' ' ' VAL . 11.8 t70 -90.59 156.58 18.03 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.088 -0.505 . . . . 54.32 110.904 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' TYR . . . . . 0.483 ' HE1' ' HB3' ' A' ' 79' ' ' ALA . 0.1 OUTLIER -113.61 155.03 26.19 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.245 -0.434 . . . . 71.44 110.953 -179.838 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -122.41 70.11 0.42 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.736 -0.745 . . . . 63.13 112.463 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 112.77 3.17 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.738 2.292 . . . . 63.14 112.328 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.483 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -131.97 110.19 10.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.24 -0.437 . . . . 70.32 111.105 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 2.7 mt -129.51 150.01 34.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 74.25 111.103 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 1.2 pp -152.35 115.39 4.65 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.119 -0.491 . . . . 72.4 110.862 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.443 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 4.3 p -138.78 -176.47 4.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.234 -0.439 . . . . 55.3 110.857 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.562 HD12 ' CE1' ' A' ' 107' ' ' TYR . 0.1 OUTLIER -130.37 154.97 47.14 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.167 -0.469 . . . . 74.42 110.943 179.994 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 45.0 mt-30 -102.65 135.89 43.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 62.14 110.979 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.562 ' CE1' HD12 ' A' ' 105' ' ' LEU . 2.0 m-85 -120.54 118.76 31.05 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.263 -0.426 . . . . 70.44 110.868 -179.756 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -110.9 105.53 14.36 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.126 -0.488 . . . . 71.22 110.869 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -85.22 161.82 19.42 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.201 -0.454 . . . . 72.02 110.938 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -55.02 103.96 0.1 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.107 -0.497 . . . . 73.32 110.844 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 27.2 m -93.9 151.87 19.27 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.182 -0.463 . . . . 70.5 110.883 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -65.25 -179.25 0.57 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.161 -0.472 . . . . 71.13 110.905 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -51.66 -36.04 44.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.171 -0.468 . . . . 74.1 110.899 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 41.6 mtt180 -66.6 -179.97 0.94 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 75.43 110.866 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 13.2 tp -93.47 128.92 39.77 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.216 -0.447 . . . . 73.52 110.974 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.7 t80 -135.24 134.66 21.57 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.63 0.729 . . . . 72.44 110.921 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . 0.742 ' HB3' HD12 ' A' ' 153' ' ' LEU . 53.6 Cg_endo -69.82 177.64 5.41 Favored 'Trans proline' 0 N--CA 1.465 -0.175 0 C-N-CA 122.713 2.275 . . . . 52.43 112.363 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -112.7 155.25 24.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.245 -0.434 . . . . 75.42 110.941 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.2 p -106.29 124.21 61.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.099 -0.501 . . . . 74.31 111.154 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -116.77 163.37 12.49 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.737 -0.744 . . . . 31.03 112.52 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.1 p -175.73 150.65 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.842 0.353 . . . . 55.34 111.141 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.443 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -176.98 -150.39 8.31 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.757 -0.735 . . . . 63.44 112.508 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.536 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 12.7 p -108.34 130.48 60.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.85 0.357 . . . . 62.43 111.195 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -124.45 109.94 1.33 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.784 -0.722 . . . . 42.43 112.51 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . 0.483 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 13.8 ptm180 -104.97 131.81 52.01 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.837 0.351 . . . . 75.34 110.847 -179.802 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.413 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 3.6 p -116.49 119.18 61.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.217 -0.447 . . . . 73.15 111.08 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.7 mp -113.52 172.7 6.81 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.126 -0.488 . . . . 72.02 110.917 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.475 ' CD2' HG22 ' A' ' 141' ' ' ILE . 3.3 p90 -131.2 172.55 12.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.443 . . . . 72.03 110.899 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.647 ' HB3' HG22 ' A' ' 96' ' ' VAL . 1.5 t80 -111.71 174.69 5.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 62.34 110.918 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -112.68 112.09 23.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.12 -0.491 . . . . 72.13 110.865 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.648 ' HB2' HG23 ' A' ' 96' ' ' VAL . 63.5 mmtt -146.11 -85.8 0.11 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 72.3 110.887 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 7.4 m -163.11 96.22 0.88 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.254 -0.43 . . . . 74.14 111.133 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -112.29 165.83 11.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 70.13 110.884 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 64.22 153.49 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 74.14 112.471 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.916 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -82.9 1.8 37.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.838 0.351 . . . . 72.42 111.056 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.462 HD12 HD13 ' A' ' 180' ' ' LEU . 2.9 mm? -87.04 -177.24 5.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.446 . . . . 74.13 110.882 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 6.1 m -64.76 88.1 0.06 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 73.34 110.848 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 9.6 m 53.62 75.28 0.27 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.46 . . . . 73.32 110.793 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -90.49 159.2 16.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.108 -0.496 . . . . 72.43 110.845 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -130.85 172.69 11.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.072 -0.513 . . . . 74.24 110.822 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.475 HG22 ' CD2' ' A' ' 128' ' ' PHE . 1.4 tt -117.41 171.61 5.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.128 -0.487 . . . . 52.14 111.136 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -119.59 103.98 9.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 73.43 110.896 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.413 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 0.6 OUTLIER -72.74 -171.55 0.86 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.28 -0.418 . . . . 74.33 110.89 179.867 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -172.44 179.28 2.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.221 -0.445 . . . . 60.25 110.929 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 28.7 p-90 -152.08 154.01 35.08 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.232 -0.44 . . . . 74.12 110.878 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.792 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.81 166.86 0.82 Allowed Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.594 0.711 . . . . 72.4 111.108 179.874 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.792 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.9 Cg_endo -69.71 137.16 34.93 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.687 2.258 . . . . 73.24 112.388 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.566 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -126.91 160.51 30.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.272 -0.422 . . . . 73.53 111.092 179.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -103.54 163.94 11.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 75.04 110.917 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 44.4 tt0 -153.07 149.47 28.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.222 -0.445 . . . . 55.24 110.936 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.2 p -146.05 129.85 10.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 62.5 111.113 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . 0.436 ' C ' HD13 ' A' ' 153' ' ' LEU . . . 172.89 -167.58 40.44 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.718 -0.753 . . . . 44.2 112.528 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.742 HD12 ' HB3' ' A' ' 117' ' ' PRO . 0.0 OUTLIER -148.51 168.42 22.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.803 0.335 . . . . 62.01 110.911 -179.911 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 7.2 tpp85 -116.76 118.84 33.64 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 53.41 110.895 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -101.68 149.92 23.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.137 -0.483 . . . . 75.44 110.928 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -120.64 98.19 5.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.134 -0.485 . . . . 74.45 110.923 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 25.0 tp -95.98 98.13 10.15 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 72.55 110.9 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 72.99 -146.38 38.0 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.675 -0.774 . . . . 52.24 112.458 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 35.3 t-20 -120.47 -33.43 3.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.807 0.336 . . . . 74.02 110.847 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 24.3 p -50.74 -65.5 0.55 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.479 . . . . 72.14 110.866 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 52.4 p-90 -141.02 146.18 36.88 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.144 -0.48 . . . . 72.35 110.938 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.508 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 10.8 mmt -101.67 178.69 4.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 60.2 110.898 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 9.2 mt -120.23 149.51 42.15 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.234 -0.439 . . . . 75.34 110.944 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -142.42 133.42 25.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 72.52 110.894 179.864 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.5 t -137.89 122.39 18.44 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.187 -0.46 . . . . 74.11 110.826 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . 0.435 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.5 OUTLIER -154.2 162.73 40.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.146 -0.479 . . . . 61.52 110.859 179.909 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.454 HG13 ' O ' ' A' ' 195' ' ' ILE . 42.1 t -146.0 125.34 5.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 65.14 111.148 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . 0.417 ' HD3' ' HB ' ' A' ' 195' ' ' ILE . 0.0 OUTLIER -100.92 155.73 17.79 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.259 -0.428 . . . . 72.14 110.871 -179.961 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 26.3 t80 -163.43 143.3 8.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.208 -0.451 . . . . 74.33 110.986 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' ILE . . . . . 0.566 HG21 ' HB2' ' A' ' 148' ' ' ALA . 3.1 tp -179.74 131.51 0.26 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 71.12 111.163 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 116.0 4.35 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.724 2.283 . . . . 72.43 112.272 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . 0.681 ' CZ ' ' HB3' ' A' ' 146' ' ' ALA . 2.1 m-85 -117.47 177.1 4.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 62.14 110.894 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.84 116.93 6.38 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 75.44 110.955 179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.2 t -105.92 161.52 14.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.262 -0.426 . . . . 43.24 111.203 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -127.51 176.8 7.2 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.264 -0.425 . . . . 71.14 110.873 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.615 HG12 ' OG1' ' A' ' 187' ' ' THR . 2.4 p -145.5 141.94 22.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.192 -0.458 . . . . 61.43 111.131 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 2.0 t -166.24 160.17 15.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 74.34 111.139 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -159.3 -157.75 8.73 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.813 -0.708 . . . . 74.44 112.478 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 73.2 p -127.01 96.39 4.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.774 0.321 . . . . 74.41 111.154 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.462 HD13 HD12 ' A' ' 136' ' ' LEU . 9.7 tt -141.33 102.88 4.31 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.253 -0.431 . . . . 64.11 110.95 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 57.68 173.62 0.33 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.822 -0.704 . . . . 63.34 112.449 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.535 ' O ' ' HB ' ' A' ' 183' ' ' VAL . 53.5 Cg_endo -69.71 75.1 1.22 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.698 2.265 . . . . 74.4 112.397 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.535 ' HB ' ' O ' ' A' ' 182' ' ' PRO . 2.4 p 159.57 83.55 0.0 OUTLIER Pre-proline 0 C--N 1.331 -0.232 0 CA-C-O 121.635 0.731 . . . . 75.02 111.121 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 142.22 47.63 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.733 2.289 . . . . 72.21 112.338 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 62.8 t -95.57 105.84 17.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.242 -0.435 . . . . 43.54 111.139 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.72 109.06 20.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.16 -0.473 . . . . 74.22 110.854 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . 0.615 ' OG1' HG12 ' A' ' 176' ' ' VAL . 0.7 OUTLIER -118.3 161.03 20.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 70.3 111.161 -179.976 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 21.9 pttt -136.84 157.28 47.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.435 . . . . 74.22 110.906 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 189' ' ' ILE . . . . . 0.423 ' O ' HG23 ' A' ' 189' ' ' ILE . 5.7 tp -154.79 120.7 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.228 -0.442 . . . . 75.41 111.132 179.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.38 116.05 31.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.144 -0.48 . . . . 64.21 110.893 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 7.6 p -136.18 155.37 34.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.145 -0.48 . . . . 74.43 111.097 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.04 88.69 3.88 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.683 0.754 . . . . 72.41 110.831 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.87 142.56 47.79 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.659 2.24 . . . . 52.25 112.297 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 5.1 t80 -112.65 123.15 49.65 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.14 -0.482 . . . . 70.1 110.895 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 195' ' ' ILE . . . . . 0.454 ' O ' HG13 ' A' ' 167' ' ' VAL . 56.7 mt -116.37 125.02 73.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.168 -0.469 . . . . 73.42 111.1 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . 0.524 ' O ' HD23 ' A' ' 196' ' ' LEU . 7.5 tt -116.39 109.88 17.92 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.122 -0.49 . . . . 71.22 110.982 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -96.96 119.23 35.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.202 -0.454 . . . . 71.45 110.856 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 55.1 tp -140.07 126.8 20.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.113 -0.494 . . . . 71.51 110.9 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -177.32 -141.27 3.99 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.74 -0.743 . . . . 60.22 112.466 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 200' ' ' ALA . . . . . 0.508 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -129.37 173.42 10.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.781 0.324 . . . . 54.34 111.113 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 99.4 p -146.58 170.26 17.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 53.42 110.803 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 202' ' ' TYR . . . . . 0.467 ' C ' HG23 ' A' ' 18' ' ' VAL . 68.6 t80 -139.69 113.01 8.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.099 -0.501 . . . . 74.23 110.938 -179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 12.6 t -77.33 154.24 5.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.043 -0.526 . . . . 73.52 111.123 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 77.6 t80 -160.32 122.21 3.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.166 -0.47 . . . . 63.14 110.888 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 6.6 ptpp? -102.89 162.6 12.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 71.33 110.915 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 206' ' ' LEU . . . . . 0.428 HD21 ' CZ3' ' A' ' 17' ' ' TRP . 59.6 mt -97.95 48.14 1.01 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.213 -0.449 . . . . 74.34 110.902 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -132.61 -45.98 0.89 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.252 -0.431 . . . . 62.13 111.101 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -64.8 135.53 55.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.186 -0.461 . . . . 74.22 111.092 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -156.72 169.13 25.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.234 -0.439 . . . . 65.13 111.117 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 7.4 tp 63.06 39.31 10.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 65.13 110.902 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.261 -0.427 . . . . 74.12 110.861 179.935 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 48.4 mtm . . . . . 0 N--CA 1.457 -0.116 0 CA-C-O 120.774 0.321 . . . . 72.54 110.916 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 63.9 m-20 -103.15 52.88 0.77 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 72.32 110.912 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -141.34 55.33 1.53 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.162 -0.472 . . . . 71.44 110.861 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -103.52 135.19 45.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 74.21 110.916 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 38.3 t80 -121.8 136.72 26.38 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.704 0.764 . . . . 73.12 110.973 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 78.6 0.98 Allowed 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.682 2.255 . . . . 73.04 112.361 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -102.39 174.04 6.09 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.241 -0.436 . . . . 62.44 111.114 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 17.5 mtpp 52.92 36.14 20.99 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 72.05 110.819 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 22.2 m -53.59 131.65 39.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.424 . . . . 63.41 110.886 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.52 135.79 33.77 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.172 -0.467 . . . . 74.53 111.114 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.525 ' CA ' HD12 ' A' ' 206' ' ' LEU . . . -147.41 122.2 1.52 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.721 -0.752 . . . . 62.31 112.493 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -158.46 116.56 2.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.901 0.382 . . . . 65.31 110.915 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 26.1 m120 -152.05 157.76 42.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.131 -0.486 . . . . 73.45 110.822 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.4 pt20 -53.47 127.84 26.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.159 -0.473 . . . . 71.53 110.913 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.97 5.78 52.94 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.761 -0.733 . . . . 54.0 112.534 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -72.53 150.95 42.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.816 0.341 . . . . 73.13 110.848 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.547 ' HE1' HG23 ' A' ' 59' ' ' ILE . 25.1 t90 -116.32 143.96 44.86 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.206 -0.452 . . . . 70.5 111.001 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.9 t -145.57 123.27 4.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.265 -0.425 . . . . 63.1 111.058 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -82.61 109.19 16.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 74.32 111.108 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -95.07 127.75 41.36 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.155 -0.475 . . . . 71.15 110.851 -179.772 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 64.4 t80 -138.63 116.18 11.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.102 -0.499 . . . . 73.11 110.945 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -152.62 173.42 15.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.187 -0.46 . . . . 72.35 110.917 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 14.6 m-85 -102.38 128.41 48.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 73.01 110.856 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . 0.506 ' HB3' HG21 ' A' ' 56' ' ' THR . 24.6 p -96.72 136.66 36.94 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.194 -0.457 . . . . 45.13 110.857 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.79 106.73 12.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.133 -0.485 . . . . 74.44 110.927 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.811 HG12 HD12 ' A' ' 195' ' ' ILE . 27.5 m -78.55 126.68 38.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.435 . . . . 70.41 111.101 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -119.19 106.16 12.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.134 -0.485 . . . . 64.54 110.954 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.9 p -174.07 152.73 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 72.22 111.154 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.72 72.35 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.726 -0.749 . . . . 75.53 112.488 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -89.53 -66.11 0.95 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.813 0.339 . . . . 52.41 110.85 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -171.55 149.07 2.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.127 -0.488 . . . . 72.25 110.882 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.521 HD13 ' HA3' ' A' ' 83' ' ' GLY . 7.2 tt -103.15 143.67 32.31 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.123 -0.489 . . . . 74.11 110.971 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.601 ' H ' HD11 ' A' ' 189' ' ' ILE . . . -64.26 106.59 1.48 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.767 -0.73 . . . . 61.41 112.463 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -95.55 -51.39 4.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.764 0.316 . . . . 73.22 110.854 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.487 HD21 ' HA3' ' A' ' 38' ' ' GLY . 17.7 tp -154.32 145.51 22.85 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.212 -0.449 . . . . 74.3 111.009 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 21.2 p-10 -98.14 -39.5 8.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 73.11 110.865 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 16.2 m -142.54 138.44 28.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.199 -0.455 . . . . 62.25 111.127 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.487 ' HA3' HD21 ' A' ' 35' ' ' LEU . . . 154.84 -136.66 5.27 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.727 -0.749 . . . . 71.14 112.492 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -149.82 -150.66 5.31 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.737 -0.744 . . . . 73.11 112.493 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 108.0 161.21 20.82 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.752 -0.737 . . . . 71.11 112.53 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -78.32 113.16 16.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.813 0.339 . . . . 60.5 111.157 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 16.5 mt 51.84 71.39 1.51 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.622 0.725 . . . . 74.24 110.957 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 81.84 0.79 Allowed 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.649 2.233 . . . . 72.12 112.393 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 10.2 p30 -153.27 127.77 9.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.17 -0.468 . . . . 64.55 110.869 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.518 ' HB1' ' CA ' ' A' ' 84' ' ' GLU . . . -100.18 -178.3 3.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.197 -0.456 . . . . 62.42 111.093 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -143.18 128.44 18.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 71.31 110.874 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 14.4 p -104.77 146.59 11.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 44.11 111.21 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 15.1 t -156.92 137.24 12.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 61.41 110.816 -179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 18.5 tt -112.05 144.69 19.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.133 -0.485 . . . . 74.34 111.115 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -117.45 129.45 8.33 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.699 -0.763 . . . . 71.14 112.505 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.1 t-20 -150.82 128.21 11.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.824 0.345 . . . . 61.13 110.812 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.408 ' O ' ' C ' ' A' ' 53' ' ' THR . 12.8 p-10 -153.79 163.49 39.93 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.107 -0.497 . . . . 72.41 110.897 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.408 ' C ' ' O ' ' A' ' 52' ' ' ASP . 10.0 t 37.45 43.56 0.42 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 71.22 111.143 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.607 ' C ' HD13 ' A' ' 55' ' ' LEU . 0.2 OUTLIER -109.97 170.5 8.04 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.158 -0.474 . . . . 51.02 111.163 -179.998 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.607 HD13 ' C ' ' A' ' 54' ' ' THR . 0.0 OUTLIER -156.06 166.15 34.31 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.26 -0.427 . . . . 75.43 110.915 179.987 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.506 HG21 ' HB3' ' A' ' 24' ' ' SER . 43.8 p -140.39 144.66 36.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.198 -0.455 . . . . 60.22 111.144 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -118.94 132.41 56.08 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.434 . . . . 74.53 110.86 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.41 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -131.87 150.51 52.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 74.21 110.832 -179.969 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.547 HG23 ' HE1' ' A' ' 17' ' ' TRP . 20.0 mm -110.47 114.41 46.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.236 -0.438 . . . . 44.21 111.123 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.438 ' HB2' ' OD2' ' A' ' 70' ' ' ASP . . . -103.36 123.73 47.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.176 -0.465 . . . . 32.45 111.124 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.411 ' O ' ' HB1' ' A' ' 68' ' ' ALA . 0.5 OUTLIER -112.97 119.51 38.18 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 73.14 110.883 -179.81 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -80.1 113.73 18.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.084 -0.507 . . . . 65.32 110.863 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 83.3 t -111.27 -32.69 2.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 70.13 111.222 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -124.09 -172.53 2.56 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.104 -0.498 . . . . 75.3 110.85 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 5.0 p -85.82 -36.25 20.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.121 -0.49 . . . . 71.12 110.832 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -126.31 19.36 7.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 53.24 110.932 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 24.8 mt -148.97 135.77 13.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.111 -0.495 . . . . 75.35 111.122 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.411 ' HB1' ' O ' ' A' ' 61' ' ' TYR . . . -153.32 170.13 21.39 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.172 -0.467 . . . . 71.31 111.076 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.3 m -106.34 151.32 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.265 -0.425 . . . . 55.35 111.083 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.438 ' OD2' ' HB2' ' A' ' 60' ' ' ALA . 0.8 OUTLIER -143.03 138.32 29.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.129 -0.487 . . . . 61.21 110.839 179.883 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.41 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 12.0 m-85 -121.59 109.32 14.64 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 73.13 110.92 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.55 ' CD2' HD13 ' A' ' 102' ' ' ILE . 1.3 t80 -83.83 121.44 27.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.154 -0.475 . . . . 74.05 110.867 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 24.8 t -135.89 146.59 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 75.42 111.1 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -162.31 124.35 1.29 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.678 -0.772 . . . . 62.3 112.497 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 43.7 t -114.91 70.18 2.39 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.638 0.733 . . . . 60.34 111.132 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 162.79 40.72 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.687 2.258 . . . . 75.24 112.331 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -76.32 -170.52 1.49 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.213 -0.449 . . . . 73.55 111.13 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 19.8 ttp180 -77.48 137.2 38.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 72.4 110.916 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -134.28 150.93 51.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.226 -0.443 . . . . 53.53 111.068 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 2.3 ttmp? -100.51 138.31 37.73 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 73.43 110.898 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -128.09 155.31 44.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 72.22 110.894 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.464 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 1.1 pt20 -110.26 153.26 25.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 62.12 110.995 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.612 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 179.93 75.22 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.758 -0.734 . . . . 42.52 112.52 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.518 ' CA ' ' HB1' ' A' ' 45' ' ' ALA . 1.0 OUTLIER -177.25 -176.89 0.68 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.906 0.384 . . . . 71.55 110.86 -179.898 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 3.6 mtpm? -85.67 -69.66 0.65 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 74.04 110.868 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.5 t -84.31 -33.41 23.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.205 -0.452 . . . . 72.05 110.928 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.885 HG22 HG22 ' A' ' 93' ' ' VAL . 6.1 mm -64.62 -34.33 69.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.124 -0.489 . . . . 74.11 111.113 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 78.6 p -63.7 -50.48 69.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.144 -0.48 . . . . 72.43 110.856 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 44.6 t -51.45 -38.06 51.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.146 -0.479 . . . . 62.21 110.863 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 9.3 tp -64.83 -42.66 94.79 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.172 -0.467 . . . . 63.1 110.931 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 106.14 -14.57 44.1 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.755 -0.736 . . . . 74.23 112.491 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 24.3 ttp180 -114.37 94.33 4.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.834 0.349 . . . . 73.12 110.922 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.885 HG22 HG22 ' A' ' 87' ' ' ILE . 85.5 t -112.86 -51.83 5.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 44.13 111.106 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 10.9 p -139.12 143.52 38.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.158 -0.474 . . . . 73.12 110.829 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -130.92 118.22 20.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.136 -0.484 . . . . 64.03 110.917 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.533 HG21 ' CD2' ' A' ' 128' ' ' PHE . 9.8 p -176.08 161.26 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.181 -0.463 . . . . 61.15 111.113 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.435 ' N ' HG22 ' A' ' 96' ' ' VAL . 2.0 p30 -91.07 174.12 7.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.116 -0.493 . . . . 63.33 110.849 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -119.91 134.53 55.21 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.165 -0.471 . . . . 62.33 110.947 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -121.76 66.61 0.46 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.719 -0.753 . . . . 64.22 112.509 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 117.43 5.08 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.617 2.211 . . . . 74.02 112.321 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -132.37 104.24 6.62 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.157 -0.474 . . . . 71.45 111.087 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.602 HG23 ' CA ' ' A' ' 124' ' ' GLY . 5.0 mp -130.03 150.57 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 73.31 111.094 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -143.75 115.39 8.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 72.42 110.899 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.1 p -142.87 159.65 41.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.232 -0.44 . . . . 45.34 110.887 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.622 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.8 OUTLIER -108.12 146.58 32.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.141 -0.481 . . . . 55.54 110.893 -179.963 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -100.97 137.99 38.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 71.04 110.872 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 28.6 p90 -141.63 156.19 45.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.204 -0.453 . . . . 72.53 110.916 -179.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 20.0 m-70 -95.77 130.62 42.64 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.115 -0.493 . . . . 71.33 110.835 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 52.5 t80 -98.5 140.57 32.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 74.43 110.92 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -62.65 125.63 24.61 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.082 -0.508 . . . . 64.51 110.809 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.3 m -150.0 147.39 27.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.47 . . . . 74.31 110.856 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -57.93 -39.42 77.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.136 -0.484 . . . . 74.44 110.914 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 20.9 mm-40 -53.95 172.78 0.07 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.142 -0.481 . . . . 74.43 110.897 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 6.8 tpt85 -117.23 -37.74 3.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.133 -0.485 . . . . 73.13 110.881 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -113.85 110.47 20.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 75.13 110.922 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 21.6 p90 -164.36 155.57 13.58 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.672 0.749 . . . . 75.23 110.919 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . 0.703 ' HA ' HD23 ' A' ' 153' ' ' LEU . 53.8 Cg_endo -69.73 177.74 5.25 Favored 'Trans proline' 0 N--CA 1.465 -0.186 0 C-N-CA 122.69 2.26 . . . . 53.11 112.402 179.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 1.2 p90 -112.05 162.78 15.02 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.261 -0.427 . . . . 63.32 110.941 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 43.9 t -121.41 136.24 58.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.124 -0.489 . . . . 74.24 111.173 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -128.58 179.09 16.81 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.771 -0.728 . . . . 74.22 112.437 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.4 HG22 ' N ' ' A' ' 122' ' ' GLY . 7.6 p -163.44 155.79 2.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.89 0.376 . . . . 65.13 111.125 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.4 ' N ' HG22 ' A' ' 121' ' ' VAL . . . -179.34 -157.41 19.69 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.73 -0.748 . . . . 33.01 112.509 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.4 p -107.28 123.71 62.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.812 0.339 . . . . 75.03 111.173 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . 0.602 ' CA ' HG23 ' A' ' 102' ' ' ILE . . . -115.45 107.66 1.77 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.774 -0.727 . . . . 21.15 112.497 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -106.13 126.82 52.67 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.932 0.396 . . . . 72.42 110.824 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.411 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 2.1 p -105.59 108.92 26.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.152 -0.476 . . . . 71.15 111.144 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 3.1 tp -116.58 170.33 8.66 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.259 -0.428 . . . . 75.42 110.993 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.533 ' CD2' HG21 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -161.7 179.35 8.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.246 -0.433 . . . . 71.4 110.926 179.951 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -117.23 115.47 25.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.469 . . . . 74.41 110.882 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -48.05 110.55 0.34 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 65.41 110.799 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.496 ' HB2' HG23 ' A' ' 96' ' ' VAL . 2.8 mmmt -104.09 -89.05 0.41 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 72.42 110.885 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.3 m -175.78 133.94 0.28 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.23 -0.441 . . . . 74.2 111.152 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . 0.462 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 19.3 m-20 -115.9 127.63 55.15 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.166 -0.47 . . . . 73.22 110.937 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -77.12 -11.09 85.88 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.753 -0.737 . . . . 63.01 112.522 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -45.12 -31.09 1.28 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.872 0.368 . . . . 61.11 111.077 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.5 tp -164.6 -177.18 4.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 54.34 110.938 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.538 ' HB2' HD13 ' A' ' 180' ' ' LEU . 16.5 m -51.42 95.24 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 43.15 110.862 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 93.3 p 47.26 72.03 0.28 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.071 -0.513 . . . . 71.11 110.892 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.462 ' HB3' ' HB2' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -88.97 160.26 17.22 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.131 -0.486 . . . . 54.13 110.84 -179.904 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 69.9 m-20 -147.2 -178.61 6.31 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.112 -0.495 . . . . 63.52 110.844 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.647 HG22 ' HA ' ' A' ' 176' ' ' VAL . 1.1 pt -141.92 174.39 6.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.128 -0.487 . . . . 74.42 111.139 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . 0.403 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 14.7 tptt -123.85 135.58 53.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 70.34 110.877 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.411 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 2.8 p30 -78.5 -173.29 3.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 72.33 110.891 179.862 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 1.4 tttp -166.77 177.24 6.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 72.5 110.901 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' TRP . . . . . 0.433 ' O ' ' HB2' ' A' ' 146' ' ' ALA . 64.7 p-90 -156.95 160.3 38.93 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.227 -0.442 . . . . 73.45 110.928 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.769 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 177.44 166.73 0.51 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.622 0.725 . . . . 75.02 111.068 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.769 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.4 Cg_endo -69.77 129.64 17.93 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.711 2.274 . . . . 74.32 112.279 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.532 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -122.69 170.17 10.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.217 -0.447 . . . . 62.53 111.113 179.821 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 13.2 m-85 -124.18 154.66 39.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.258 -0.428 . . . . 74.45 110.807 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 5.8 tt0 -130.63 151.95 50.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.102 -0.499 . . . . 74.45 110.862 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 6.4 p -153.1 125.85 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 64.24 111.185 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -179.78 -162.63 29.1 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.776 -0.726 . . . . 72.31 112.451 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.764 HD13 ' N ' ' A' ' 154' ' ' ARG . 3.0 tm? -142.6 145.43 33.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.784 0.326 . . . . 64.43 110.857 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.764 ' N ' HD13 ' A' ' 153' ' ' LEU . 3.9 tpp85 -115.37 119.34 35.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 75.32 110.855 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 63.3 t80 -110.59 150.21 29.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.223 -0.444 . . . . 74.35 110.951 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -121.27 123.52 42.39 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.151 -0.477 . . . . 54.34 110.852 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' LEU . . . . . 0.665 HD22 ' HB2' ' A' ' 160' ' ' SER . 1.7 tt -92.29 136.12 33.46 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.157 -0.474 . . . . 75.42 110.898 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . 0.577 ' N ' HD23 ' A' ' 157' ' ' LEU . . . -75.41 137.39 21.77 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.782 -0.723 . . . . 72.21 112.52 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 53.02 37.23 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.892 0.377 . . . . 72.43 110.894 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . 0.665 ' HB2' HD22 ' A' ' 157' ' ' LEU . 2.3 m -172.59 173.95 3.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.154 -0.476 . . . . 44.2 110.82 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 7.0 m0 -62.55 158.76 17.27 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.146 -0.479 . . . . 64.22 110.912 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.46 ' SD ' HG23 ' A' ' 203' ' ' VAL . 0.3 OUTLIER -92.97 171.17 9.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.255 -0.429 . . . . 54.23 110.927 179.924 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 80.7 mt -124.3 145.35 49.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 75.22 110.895 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -143.64 134.47 25.28 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.164 -0.471 . . . . 55.24 110.832 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 78.4 p -145.11 121.54 10.99 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.118 -0.492 . . . . 63.41 110.834 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -153.4 174.0 14.92 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.158 -0.474 . . . . 73.12 110.859 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.437 HG22 HD12 ' A' ' 196' ' ' LEU . 1.5 t -135.68 151.87 30.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.153 -0.476 . . . . 71.41 111.178 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . 0.402 ' HB2' ' HB ' ' A' ' 195' ' ' ILE . 0.1 OUTLIER -117.73 131.49 56.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 75.33 110.901 179.994 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 23.4 m-85 -132.07 134.68 45.78 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.144 -0.48 . . . . 75.42 110.966 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' ILE . . . . . 0.532 HG21 ' HB2' ' A' ' 148' ' ' ALA . 0.0 OUTLIER -179.13 120.49 0.23 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.618 0.723 . . . . 71.24 111.138 179.93 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.77 108.61 2.12 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.635 2.224 . . . . 73.05 112.333 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -116.48 157.11 25.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 74.52 110.834 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.36 118.98 25.18 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.131 -0.486 . . . . 75.14 110.89 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.9 t -95.08 144.64 25.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.21 -0.45 . . . . 73.43 111.092 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . 0.403 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.1 OUTLIER -100.21 150.58 22.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.163 -0.472 . . . . 72.11 110.855 179.916 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.647 ' HA ' HG22 ' A' ' 141' ' ' ILE . 14.7 p -146.46 127.53 6.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.197 -0.456 . . . . 74.42 111.159 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 15.2 t -167.32 172.16 10.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 73.43 111.073 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -145.48 171.77 26.42 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.688 -0.768 . . . . 71.52 112.493 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -115.28 113.03 23.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.885 0.374 . . . . 73.54 111.124 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.538 HD13 ' HB2' ' A' ' 137' ' ' SER . 11.1 tp -140.26 167.16 22.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.157 -0.474 . . . . 71.11 110.905 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -46.47 -68.79 0.98 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 72.54 112.505 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.84 -170.13 0.38 Allowed 'Trans proline' 0 C--O 1.232 0.19 0 C-N-CA 122.681 2.254 . . . . 61.41 112.37 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.416 HG13 ' O ' ' A' ' 183' ' ' VAL . 4.5 p -66.86 116.12 31.95 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.661 0.743 . . . . 63.13 111.172 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 165.11 32.03 Favored 'Trans proline' 0 C--O 1.231 0.158 0 C-N-CA 122.654 2.236 . . . . 62.42 112.387 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 49.6 t -96.73 107.99 20.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.265 -0.425 . . . . 72.12 111.14 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 1.7 p -104.16 118.72 37.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 71.52 110.83 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 23.2 p -145.9 176.12 9.92 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.183 -0.462 . . . . 65.54 111.149 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 188' ' ' LYS . . . . . 0.535 ' O ' HD13 ' A' ' 189' ' ' ILE . 0.2 OUTLIER -154.67 166.66 32.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 75.21 110.878 179.964 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 189' ' ' ILE . . . . . 0.601 HD11 ' H ' ' A' ' 33' ' ' GLY . 47.7 mm -140.23 114.44 6.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 73.11 111.099 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 7.6 tm-20 -103.01 106.74 17.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.136 -0.484 . . . . 65.13 110.93 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 8.7 m -137.03 163.49 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.174 -0.466 . . . . 72.51 111.145 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.3 89.28 4.63 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.61 0.719 . . . . 65.43 110.814 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 137.36 35.11 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.675 2.25 . . . . 63.14 112.385 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -104.26 114.7 29.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.308 -0.405 . . . . 72.51 110.813 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 195' ' ' ILE . . . . . 0.811 HD12 HG12 ' A' ' 26' ' ' VAL . 4.0 mm -101.68 119.2 49.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.109 -0.496 . . . . 74.14 111.116 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . 0.437 HD12 HG22 ' A' ' 167' ' ' VAL . 11.9 tp -104.86 109.49 21.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.241 -0.436 . . . . 62.03 110.902 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -102.46 119.58 39.07 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.163 -0.471 . . . . 54.05 110.833 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 198' ' ' LEU . . . . . 0.463 ' H ' HD23 ' A' ' 198' ' ' LEU . 2.0 pt? -139.13 129.65 25.8 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.164 -0.471 . . . . 72.23 110.963 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 179.88 -144.15 5.89 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.766 -0.73 . . . . 65.22 112.454 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 200' ' ' ALA . . . . . 0.427 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -127.1 173.42 9.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.812 0.339 . . . . 65.5 111.087 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 15.2 m -146.96 169.87 18.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.214 -0.448 . . . . 72.33 110.89 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 1.1 t80 -141.49 131.66 24.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.168 -0.469 . . . . 75.14 110.935 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.46 HG23 ' SD ' ' A' ' 162' ' ' MET . 5.8 t -81.12 158.58 4.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.479 . . . . 41.52 111.089 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 204' ' ' PHE . . . . . 0.411 ' N ' HG12 ' A' ' 203' ' ' VAL . 2.1 m-85 -164.6 147.95 8.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.466 . . . . 72.34 110.915 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 35.8 mtpt 63.87 60.74 1.01 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 70.34 110.895 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 206' ' ' LEU . . . . . 0.525 HD12 ' CA ' ' A' ' 11' ' ' GLY . 1.8 pt? -124.35 -178.85 4.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.221 -0.445 . . . . 74.52 110.923 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -88.39 98.97 11.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 61.15 111.081 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -116.85 123.2 46.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.262 -0.426 . . . . 64.14 111.073 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -158.58 157.92 32.92 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.471 . . . . 71.51 111.073 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . 0.53 ' H ' HD23 ' A' ' 210' ' ' LEU . 1.7 pt? -118.32 160.47 21.58 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.201 -0.454 . . . . 65.55 110.896 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.156 -0.475 . . . . 75.13 110.91 179.879 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.046 0 CA-C-O 120.794 0.331 . . . . 45.5 110.858 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -123.22 115.08 21.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 64.24 110.935 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 25.1 mp0 -127.03 177.66 6.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.227 -0.442 . . . . 71.31 110.808 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 29.1 m120 -93.8 115.17 27.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.077 -0.51 . . . . 72.11 110.875 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.685 ' O ' ' HB3' ' A' ' 209' ' ' ALA . 6.3 t80 -163.02 74.09 1.98 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.659 0.743 . . . . 74.11 110.907 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.83 151.78 68.78 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.72 2.28 . . . . 51.45 112.274 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.406 ' HB3' ' HB1' ' A' ' 209' ' ' ALA . . . -158.65 169.59 24.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.238 -0.437 . . . . 34.14 111.074 179.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.77 175.14 0.06 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.211 -0.45 . . . . 75.23 110.884 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.0 p -103.1 167.46 9.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.229 -0.441 . . . . 43.54 110.831 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -107.83 179.78 4.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.083 -0.508 . . . . 40.41 111.085 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.38 -85.9 1.71 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.698 -0.763 . . . . 70.52 112.513 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 14.1 m-85 -143.81 112.29 6.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.939 0.399 . . . . 74.13 110.894 -179.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -139.01 159.82 41.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.069 -0.514 . . . . 64.44 110.912 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 17.5 pt20 -51.54 120.04 4.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 74.45 110.907 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 101.7 7.91 46.97 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.729 -0.748 . . . . 42.51 112.468 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -79.62 156.23 27.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.81 0.338 . . . . 64.43 110.856 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 41.5 m95 -133.0 143.63 49.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.109 -0.496 . . . . 75.11 110.944 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.757 ' CG2' ' HB3' ' A' ' 60' ' ' ALA . 2.6 m -142.71 137.76 27.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.251 -0.431 . . . . 64.14 111.132 179.877 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -96.62 104.91 16.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 73.24 111.087 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 4.4 m -91.63 130.18 37.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 74.13 110.87 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.704 ' CE2' ' HB3' ' A' ' 200' ' ' ALA . 13.7 p90 -134.78 116.76 15.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.066 -0.515 . . . . 65.4 110.88 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -150.95 172.32 15.88 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.177 -0.465 . . . . 75.33 110.94 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 12.8 p90 -105.16 131.39 52.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 74.21 110.906 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . 0.412 ' HB2' HG22 ' A' ' 195' ' ' ILE . 0.3 OUTLIER -96.58 137.3 35.87 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.149 -0.478 . . . . 44.14 110.837 -179.76 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.7 mmtp -116.19 111.64 20.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.128 -0.487 . . . . 71.31 110.878 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.512 HG22 HD12 ' A' ' 195' ' ' ILE . 25.4 t -75.11 128.32 36.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.237 -0.438 . . . . 72.32 111.097 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 6.9 m-85 -125.96 106.92 9.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 74.33 110.977 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.7 p -171.59 152.92 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.119 -0.491 . . . . 72.21 111.146 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 169.34 64.74 0.04 OUTLIER Glycine 0 N--CA 1.453 -0.197 0 C-N-CA 120.766 -0.731 . . . . 75.43 112.491 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 13.8 tt0 -89.78 -66.3 0.94 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.76 0.314 . . . . 64.13 110.861 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 71.1 tt0 -175.05 154.88 1.88 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 65.42 110.905 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.593 HD13 ' N ' ' A' ' 33' ' ' GLY . 0.3 OUTLIER -110.07 133.91 52.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.136 -0.484 . . . . 71.11 110.958 -179.952 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.593 ' N ' HD13 ' A' ' 32' ' ' LEU . . . -62.44 120.88 23.52 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.746 -0.74 . . . . 42.33 112.49 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -133.42 130.84 39.23 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.838 0.352 . . . . 54.14 110.818 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 5.6 mp -128.55 173.54 10.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.177 -0.465 . . . . 74.24 110.887 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -131.41 148.04 52.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 74.12 110.871 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.6 p -88.78 -34.6 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.469 . . . . 72.31 111.109 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -109.4 151.8 17.19 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.686 -0.769 . . . . 71.03 112.481 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -59.23 126.71 43.2 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.759 -0.734 . . . . 75.05 112.537 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -172.77 -141.24 3.38 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.717 -0.754 . . . . 52.34 112.474 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -84.53 161.47 20.21 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.805 0.336 . . . . 60.44 111.077 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 7.0 mt -127.45 69.02 74.6 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.636 0.731 . . . . 72.22 110.912 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.77 -170.88 0.42 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.677 2.251 . . . . 74.32 112.314 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -131.62 123.12 27.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 44.1 110.839 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.463 ' HB1' ' CA ' ' A' ' 84' ' ' GLU . . . -76.4 178.75 6.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.174 -0.466 . . . . 72.13 111.104 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -143.25 130.41 20.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.453 . . . . 73.31 110.846 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.5 p -104.78 138.56 29.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.185 -0.461 . . . . 74.23 111.089 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -142.85 159.16 42.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.117 -0.492 . . . . 75.22 110.835 -179.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -108.47 132.76 55.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.119 -0.491 . . . . 75.41 111.149 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -131.07 51.81 0.85 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.746 -0.74 . . . . 52.44 112.488 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.4 t-20 -102.81 112.6 25.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.834 0.35 . . . . 75.13 110.919 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.659 ' O ' HG23 ' A' ' 54' ' ' THR . 1.8 t70 -55.03 175.18 0.06 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 75.2 110.859 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 7.5 p -53.16 101.82 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.238 -0.437 . . . . 72.25 111.135 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.659 HG23 ' O ' ' A' ' 52' ' ' ASP . 44.9 p -100.94 176.1 5.39 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 74.12 111.182 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 5.2 mp -129.78 161.51 30.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.269 -0.423 . . . . 63.05 110.924 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.5 143.01 30.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 70.21 111.087 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 57.2 m-85 -123.05 132.41 54.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.248 -0.433 . . . . 75.23 110.862 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.436 ' C ' HD13 ' A' ' 59' ' ' ILE . 14.5 p-10 -134.75 145.21 48.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 65.22 110.825 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.436 HD13 ' C ' ' A' ' 58' ' ' ASP . 5.8 mm -108.95 116.81 52.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.199 -0.455 . . . . 54.25 111.085 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.757 ' HB3' ' CG2' ' A' ' 18' ' ' VAL . . . -101.87 125.2 48.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.185 -0.461 . . . . 63.14 111.07 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.632 ' HB3' HG13 ' A' ' 69' ' ' VAL . 27.1 t80 -110.47 115.59 29.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.22 -0.445 . . . . 62.32 110.91 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -84.14 101.95 12.22 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.092 -0.503 . . . . 72.23 110.89 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.5 p -94.21 -33.15 4.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.151 -0.477 . . . . 75.34 111.041 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.0 m -134.1 164.33 27.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.175 -0.466 . . . . 73.54 110.782 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 7.8 p -86.67 3.14 45.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.083 -0.508 . . . . 54.12 110.885 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -112.43 -32.59 6.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.101 -0.5 . . . . 72.04 110.912 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 21.6 pt -146.44 167.81 6.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.173 -0.467 . . . . 73.42 111.163 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -154.69 169.13 24.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 72.23 111.12 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.632 HG13 ' HB3' ' A' ' 61' ' ' TYR . 1.4 p -111.62 147.2 15.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.3 -0.409 . . . . 65.22 111.19 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -139.78 127.0 21.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 64.32 110.798 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.748 ' CZ ' HD22 ' A' ' 103' ' ' LEU . 0.6 OUTLIER -108.56 110.43 21.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 71.31 110.874 -179.96 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -87.03 129.4 34.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.126 -0.488 . . . . 70.13 110.872 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 9.9 m -149.44 163.42 4.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.118 -0.492 . . . . 65.44 111.134 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 175.01 142.57 4.13 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.757 -0.735 . . . . 62.12 112.477 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.473 ' O ' HG13 ' A' ' 75' ' ' VAL . 3.9 p -118.71 77.78 14.95 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.657 0.741 . . . . 74.43 111.16 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 148.7 65.97 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.63 2.22 . . . . 74.1 112.387 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -67.31 -165.62 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.29 -0.414 . . . . 64.41 111.061 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 43.1 ttp180 -76.66 115.54 16.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 73.21 110.83 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . 0.467 ' HB3' ' CZ ' ' A' ' 81' ' ' PHE . . . -110.3 149.71 29.79 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.212 -0.449 . . . . 20.44 111.145 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.6 tmmm? -103.27 141.23 36.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 74.32 110.825 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . 0.467 ' CZ ' ' HB3' ' A' ' 79' ' ' ALA . 10.3 m-85 -139.47 157.33 46.03 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.136 -0.484 . . . . 61.3 110.86 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 9.3 mt-30 -105.96 156.15 18.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.198 -0.455 . . . . 74.0 110.977 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.59 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 176.26 73.81 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.712 -0.756 . . . . 74.51 112.512 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.463 ' CA ' ' HB1' ' A' ' 45' ' ' ALA . 1.3 tp10 -174.37 -177.21 1.21 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.959 0.409 . . . . 71.41 110.857 -179.831 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 2.3 ptmt -86.76 -69.95 0.64 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.096 -0.502 . . . . 65.25 110.858 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.6 t -84.07 -33.38 24.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.45 . . . . 54.31 110.913 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.841 HG21 ' HB2' ' A' ' 135' ' ' ALA . 4.6 mm -65.39 -34.46 70.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.115 -0.493 . . . . 75.33 111.146 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 63.5 p -61.48 -48.68 80.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.13 -0.486 . . . . 62.42 110.751 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.7 t -52.1 -39.93 60.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 71.21 110.83 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 82.5 mt -60.41 -47.86 84.25 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.163 -0.471 . . . . 74.43 110.941 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 114.93 -14.96 19.22 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.759 -0.734 . . . . 64.02 112.515 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 8.9 mtm180 -121.34 97.15 5.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.899 0.381 . . . . 75.25 110.901 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.628 HG22 HG22 ' A' ' 87' ' ' ILE . 17.0 t -112.97 -41.99 4.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.159 -0.473 . . . . 75.31 111.023 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 13.3 p -141.51 154.2 45.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 61.33 110.872 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 82.9 mt-10 -152.56 118.64 5.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.134 -0.485 . . . . 75.42 110.836 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.734 HG21 ' O ' ' A' ' 129' ' ' PHE . 4.5 p -178.46 164.16 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 72.24 111.165 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.435 ' H ' HG22 ' A' ' 96' ' ' VAL . 4.0 p30 -90.84 133.51 35.16 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.174 -0.466 . . . . 73.51 110.86 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -92.21 146.14 23.95 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 74.33 110.86 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -113.49 70.93 0.23 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.767 -0.73 . . . . 42.11 112.497 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 112.48 3.1 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.714 2.276 . . . . 74.44 112.302 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -136.87 113.76 10.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.239 -0.437 . . . . 63.04 111.171 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.657 HD13 ' HD2' ' A' ' 168' ' ' ARG . 13.5 pt -139.68 153.61 23.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.209 -0.451 . . . . 72.4 111.117 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.748 HD22 ' CZ ' ' A' ' 71' ' ' PHE . 0.5 OUTLIER -142.21 117.05 9.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.204 -0.453 . . . . 71.21 110.898 179.954 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.413 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 5.3 p -142.82 161.26 38.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.227 -0.442 . . . . 71.31 110.885 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.461 ' O ' HD12 ' A' ' 105' ' ' LEU . 4.5 pp -110.08 146.03 36.09 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.168 -0.469 . . . . 73.55 110.955 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 1.7 pp0? -101.13 144.43 30.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 65.32 110.965 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -152.58 159.78 43.24 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.244 -0.435 . . . . 63.01 110.955 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 7.7 p-80 -133.09 147.29 52.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.114 -0.494 . . . . 73.23 110.779 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 6.5 t80 -159.53 167.69 27.97 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.159 -0.473 . . . . 72.54 110.886 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 38.8 t0 58.58 47.41 13.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.105 -0.498 . . . . 62.53 110.946 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 36.0 p -53.91 113.64 1.29 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.171 -0.468 . . . . 74.33 110.856 -179.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 55.4 t80 -112.97 -36.28 5.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.097 -0.501 . . . . 73.4 110.861 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 2.1 tp10 -117.2 155.14 29.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 61.55 110.885 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 55.2 ttp180 -54.3 -45.1 72.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.145 -0.48 . . . . 72.44 110.897 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 13.0 mt -123.66 127.66 48.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.149 -0.478 . . . . 72.41 110.872 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 20.8 p90 -161.2 153.89 17.34 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.624 0.726 . . . . 62.4 110.952 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . 0.684 ' HB3' HD12 ' A' ' 153' ' ' LEU . 54.5 Cg_endo -69.67 178.37 4.58 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.72 2.28 . . . . 74.14 112.359 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 1.6 p90 -127.38 159.07 35.56 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.295 -0.411 . . . . 71.23 110.895 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 48.1 t -113.3 136.5 49.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.107 -0.497 . . . . 63.41 111.1 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -127.24 172.46 18.65 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.759 -0.734 . . . . 71.33 112.515 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.2 p -162.46 151.67 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.877 0.37 . . . . 44.21 111.18 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.413 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -176.65 -156.23 15.1 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.693 -0.765 . . . . 64.15 112.46 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.471 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 5.8 m -107.82 122.04 61.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.921 0.391 . . . . 60.34 111.083 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . 0.539 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -115.9 121.31 5.2 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.699 -0.762 . . . . 50.25 112.523 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -116.51 132.7 56.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.829 0.347 . . . . 73.03 110.862 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.421 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 2.8 m -107.66 108.67 25.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 75.02 111.147 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.523 HD23 ' N ' ' A' ' 128' ' ' PHE . 0.5 OUTLIER -86.86 166.53 15.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 73.23 110.956 179.901 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.523 ' N ' HD23 ' A' ' 127' ' ' LEU . 0.5 OUTLIER -149.24 134.51 18.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 54.3 110.902 179.914 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.734 ' O ' HG21 ' A' ' 96' ' ' VAL . 28.3 t80 -100.34 165.13 11.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.147 -0.479 . . . . 73.34 110.909 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -97.49 120.19 37.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 62.4 110.826 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.69 ' CB ' HG23 ' A' ' 96' ' ' VAL . 4.3 tppp? -141.17 -82.18 0.23 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 71.24 110.838 180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 31.7 m -162.78 83.92 0.52 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.267 -0.424 . . . . 71.24 111.185 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -104.57 165.11 11.28 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.229 -0.441 . . . . 72.31 110.898 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 62.13 154.85 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.725 -0.75 . . . . 54.43 112.463 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.841 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -84.77 1.71 45.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.808 0.337 . . . . 62.1 111.088 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -86.26 -175.75 5.63 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.26 -0.427 . . . . 74.34 110.965 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.4 m -63.55 87.53 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.191 -0.459 . . . . 72.44 110.83 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 38.6 t 51.17 76.63 0.15 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.074 -0.512 . . . . 44.53 110.854 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.715 ' CE1' HG12 ' A' ' 176' ' ' VAL . 1.0 OUTLIER -86.55 148.87 25.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.163 -0.471 . . . . 73.44 110.806 -179.913 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 59.4 m-20 -122.03 -178.76 3.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.045 -0.525 . . . . 75.24 110.898 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.423 ' HA ' ' HA ' ' A' ' 176' ' ' VAL . 0.1 OUTLIER -145.2 160.51 13.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.445 . . . . 63.14 111.124 179.988 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . 0.424 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 3.4 ttmt -105.27 122.42 45.89 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.21 -0.45 . . . . 73.3 110.918 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.421 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 0.8 OUTLIER -63.59 -173.48 0.07 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.241 -0.436 . . . . 74.11 110.859 179.84 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 18.6 tptt -158.45 164.62 36.04 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.191 -0.459 . . . . 74.33 110.913 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 17.6 p90 -155.87 146.48 21.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.167 -0.469 . . . . 63.22 110.889 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.833 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 179.74 168.76 0.68 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.592 0.711 . . . . 62.5 111.138 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.833 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.8 Cg_endo -69.75 125.1 11.76 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.703 2.269 . . . . 60.21 112.364 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.659 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -117.96 171.08 8.32 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.238 -0.437 . . . . 55.32 111.078 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 16.3 m-85 -123.6 138.55 54.53 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.13 -0.486 . . . . 74.32 110.861 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 40.0 tt0 -119.93 159.49 24.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.138 -0.483 . . . . 74.21 110.862 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.4 p -160.7 133.32 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.453 . . . . 71.44 111.154 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . 0.443 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 179.38 -158.67 22.79 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.66 -0.781 . . . . 72.24 112.442 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.684 HD12 ' HB3' ' A' ' 117' ' ' PRO . 0.0 OUTLIER -146.93 166.38 26.93 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.777 0.322 . . . . 74.13 110.94 -179.969 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.417 ' HD3' ' N ' ' A' ' 155' ' ' TYR . 5.6 tpp85 -129.56 117.86 21.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.248 -0.433 . . . . 72.0 110.858 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . 0.417 ' N ' ' HD3' ' A' ' 154' ' ' ARG . 3.4 t80 -104.12 144.32 31.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.234 -0.439 . . . . 74.01 110.85 -179.811 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -120.47 98.26 5.96 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.124 -0.489 . . . . 74.05 110.842 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 78.8 mt -69.53 152.77 44.41 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.204 -0.453 . . . . 75.11 110.898 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -52.8 -33.84 43.59 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.733 -0.746 . . . . 72.15 112.495 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -65.78 178.53 1.03 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.86 0.362 . . . . 75.13 110.932 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 1.2 m -66.08 -35.88 81.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.144 -0.48 . . . . 73.34 110.958 -179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 47.0 p90 -82.76 152.82 25.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.068 -0.515 . . . . 70.23 110.991 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.424 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 2.3 mpt? -123.7 177.44 5.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.28 -0.418 . . . . 63.13 110.819 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.464 HD23 ' N ' ' A' ' 164' ' ' ASN . 1.0 OUTLIER -118.42 144.56 45.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.178 -0.464 . . . . 71.44 110.87 -179.998 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . 0.464 ' N ' HD23 ' A' ' 163' ' ' LEU . 3.1 t-20 -143.63 137.61 28.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.15 -0.477 . . . . 55.05 110.923 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.0 t -144.06 121.44 11.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 72.54 110.803 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . 0.443 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.8 OUTLIER -137.37 159.66 41.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 74.35 110.908 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.545 HG13 ' CD1' ' A' ' 196' ' ' LEU . 50.4 t -132.84 134.44 58.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 72.01 111.15 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . 0.657 ' HD2' HD13 ' A' ' 102' ' ' ILE . 2.1 ttt85 -106.17 137.59 43.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 61.13 110.8 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 23.1 t80 -148.55 132.5 17.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 74.01 110.894 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' ILE . . . . . 0.659 HG21 ' HB2' ' A' ' 148' ' ' ALA . 0.0 OUTLIER -178.71 123.63 0.25 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.705 0.764 . . . . 63.34 111.121 179.93 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 104.16 1.27 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.669 2.246 . . . . 74.21 112.284 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . 0.436 ' HE1' HG23 ' A' ' 174' ' ' THR . 0.3 OUTLIER -117.53 175.03 5.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 73.32 110.935 179.95 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.2 132.88 25.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.249 -0.432 . . . . 70.13 110.951 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . 0.436 HG23 ' HE1' ' A' ' 172' ' ' PHE . 0.0 OUTLIER -111.15 150.85 28.89 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.244 -0.434 . . . . 73.32 111.123 179.989 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . 0.424 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -106.44 158.84 16.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.223 -0.444 . . . . 65.42 110.849 179.922 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.715 HG12 ' CE1' ' A' ' 139' ' ' PHE . 10.3 t -138.61 123.2 21.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.461 . . . . 72.21 111.172 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 15.3 t -166.67 172.57 10.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 74.53 111.149 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 117.72 140.07 6.45 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.755 -0.736 . . . . 62.41 112.443 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . 0.509 HG21 ' HG2' ' A' ' 182' ' ' PRO . 43.5 m -167.77 143.24 3.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.799 0.333 . . . . 75.41 111.08 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 7.9 tp -102.84 89.05 3.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.143 -0.481 . . . . 64.33 110.927 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 131.2 -90.7 0.29 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.742 -0.742 . . . . 74.13 112.489 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.509 ' HG2' HG21 ' A' ' 179' ' ' THR . 53.6 Cg_endo -69.8 -176.92 1.66 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.712 2.275 . . . . 62.41 112.303 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 89.3 t -74.84 120.24 80.62 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-O 121.615 0.722 . . . . 64.52 111.19 179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.79 157.36 60.59 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.71 2.274 . . . . 65.13 112.281 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.4 HG12 ' N ' ' A' ' 186' ' ' SER . 4.2 t -95.96 159.05 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 64.42 111.186 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 186' ' ' SER . . . . . 0.4 ' N ' HG12 ' A' ' 185' ' ' VAL . 6.2 p -130.43 108.55 10.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.974 0.416 . . . . 61.45 110.906 -179.845 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 16.8 p -127.36 167.21 16.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.18 -0.464 . . . . 75.23 111.177 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 4.0 tttt -151.92 142.71 22.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.251 -0.431 . . . . 62.24 110.955 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 6.8 tp -137.5 125.68 32.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 73.51 111.092 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -106.55 112.42 25.42 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.137 -0.483 . . . . 43.2 110.876 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 8.2 m -137.83 158.88 33.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.192 -0.458 . . . . 64.21 111.083 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -108.22 88.78 5.11 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.616 0.722 . . . . 53.25 110.813 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 142.16 46.94 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.619 2.213 . . . . 74.4 112.385 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -113.75 112.21 23.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.245 -0.434 . . . . 74.51 110.901 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 195' ' ' ILE . . . . . 0.512 HD12 HG22 ' A' ' 26' ' ' VAL . 4.6 mm -100.45 124.9 54.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 72.31 111.144 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . 0.545 ' CD1' HG13 ' A' ' 167' ' ' VAL . 0.8 OUTLIER -107.9 109.01 20.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.157 -0.474 . . . . 70.53 110.955 179.875 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -97.28 123.8 41.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.212 -0.449 . . . . 43.43 110.856 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 22.8 tp -142.38 127.59 18.65 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.128 -0.487 . . . . 73.23 110.943 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -179.21 -143.93 5.58 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.751 -0.738 . . . . 33.01 112.509 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 200' ' ' ALA . . . . . 0.704 ' HB3' ' CE2' ' A' ' 21' ' ' PHE . . . -123.93 173.66 8.07 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.815 0.341 . . . . 60.01 111.094 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 19.1 m -154.04 163.55 39.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 63.4 110.825 -179.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -131.47 131.6 43.64 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.217 -0.447 . . . . 74.24 110.897 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.657 HG13 HG12 ' A' ' 18' ' ' VAL . 60.5 t -102.22 146.61 10.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.112 -0.494 . . . . 62.11 111.109 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -160.76 157.49 26.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.099 -0.5 . . . . 63.2 110.838 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 3.9 ptmm? -108.01 -35.88 6.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.128 -0.487 . . . . 62.1 110.863 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 8.0 tp -174.11 164.0 4.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 72.54 110.928 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -65.76 -35.81 81.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.468 . . . . 73.04 111.043 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -128.9 178.25 6.51 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.172 -0.467 . . . . 72.45 111.111 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 209' ' ' ALA . . . . . 0.685 ' HB3' ' O ' ' A' ' 5' ' ' TYR . . . -87.92 -68.15 0.78 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 63.43 111.138 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 11.9 tp 53.56 37.74 26.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 74.01 110.885 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 61.41 110.911 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 40.8 mtt . . . . . 0 C--O 1.23 0.048 0 CA-C-O 120.807 0.337 . . . . 74.31 110.863 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 17.0 p30 -160.55 154.65 23.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 73.54 110.896 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 24.1 tp10 -142.11 138.08 31.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 73.23 110.852 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 50.9 m-20 -142.77 131.83 23.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.163 -0.471 . . . . 75.33 110.921 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 28.8 t80 -174.55 69.51 0.3 Allowed Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 121.685 0.755 . . . . 52.32 110.911 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 133.35 25.42 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.678 2.252 . . . . 73.33 112.329 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -79.63 165.76 22.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.182 -0.463 . . . . 74.35 111.162 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 4.4 ptpp? -129.09 154.03 47.08 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.262 -0.426 . . . . 72.45 110.932 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 75.8 m -103.21 148.05 26.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.224 -0.444 . . . . 62.43 110.884 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.28 179.38 5.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.122 -0.49 . . . . 61.31 111.091 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.66 37.71 3.35 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.709 -0.758 . . . . 65.13 112.397 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 20.0 m-85 -151.07 115.99 5.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.924 0.393 . . . . 64.43 110.931 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 7.6 m120 -146.87 165.49 29.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 74.33 110.925 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 7.3 mp0 -69.01 120.41 14.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.444 . . . . 70.21 110.907 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.35 5.84 36.77 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.711 -0.757 . . . . 72.13 112.507 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -66.74 153.3 43.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.337 . . . . 71.01 110.911 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 17.3 t90 -123.74 125.11 44.15 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.197 -0.456 . . . . 72.34 110.965 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.812 HG23 ' HB3' ' A' ' 60' ' ' ALA . 12.5 m -136.92 135.02 48.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.251 -0.431 . . . . 75.5 111.106 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -93.11 158.01 15.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 65.34 111.135 179.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.0 109.51 5.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.258 -0.428 . . . . 72.21 110.845 -179.745 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 63.8 t80 -111.37 115.66 29.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 72.23 110.865 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -150.69 173.0 14.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 74.43 110.906 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 28.2 p90 -108.43 132.21 54.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.167 -0.47 . . . . 71.52 110.908 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 25.2 p -104.85 142.45 34.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 63.31 110.841 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 25.4 tptt -121.96 122.95 40.53 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.082 -0.508 . . . . 75.51 110.975 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.734 HG12 HD12 ' A' ' 195' ' ' ILE . 20.9 m -89.92 135.29 26.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.281 -0.418 . . . . 62.33 111.154 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -126.68 114.37 17.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.252 -0.431 . . . . 75.01 111.015 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.0 p -174.79 153.55 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 60.32 111.156 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 150.5 67.26 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.775 -0.726 . . . . 63.31 112.517 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -90.16 -66.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.812 0.339 . . . . 73.35 110.958 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.661 ' C ' HG12 ' A' ' 47' ' ' VAL . 25.0 pt-20 -174.91 170.61 3.24 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.128 -0.487 . . . . 53.24 110.887 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.555 HD23 ' CB ' ' A' ' 45' ' ' ALA . 36.4 tp -98.27 150.14 21.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.138 -0.483 . . . . 71.21 110.913 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -85.58 74.16 2.48 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.732 -0.747 . . . . 65.23 112.464 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -102.37 125.3 49.04 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.879 0.371 . . . . 63.23 110.89 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -151.57 160.33 43.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.163 -0.472 . . . . 61.22 110.911 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -159.59 157.78 30.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 62.22 110.881 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 42.0 t -86.06 -68.96 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.192 -0.458 . . . . 64.12 111.126 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -115.92 119.56 4.6 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.699 -0.762 . . . . 60.14 112.494 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 91.67 153.17 29.39 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.719 -0.753 . . . . 75.14 112.506 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 144.3 176.03 17.96 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.706 -0.759 . . . . 51.15 112.408 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -89.4 149.8 22.81 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.791 0.329 . . . . 73.15 111.143 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.492 ' N ' ' HD2' ' A' ' 43' ' ' PRO . 0.6 OUTLIER -55.07 -60.32 8.44 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.623 0.725 . . . . 74.44 110.877 -179.975 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.492 ' HD2' ' N ' ' A' ' 42' ' ' LEU . 53.1 Cg_endo -69.77 146.65 60.8 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.701 2.267 . . . . 72.41 112.278 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 17.3 p30 -98.09 142.89 29.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.219 -0.446 . . . . 52.44 110.922 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.555 ' CB ' HD23 ' A' ' 32' ' ' LEU . . . -53.64 164.29 0.56 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 75.15 111.087 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -142.36 135.65 28.84 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.241 -0.436 . . . . 61.53 110.833 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.661 HG12 ' C ' ' A' ' 31' ' ' GLU . 7.7 p -105.44 142.83 17.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.144 -0.48 . . . . 75.2 111.138 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.0 t -158.14 135.05 9.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 64.14 110.81 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 3.0 pt -89.44 156.38 3.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 71.21 111.104 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.15 -157.12 9.52 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.738 -0.744 . . . . 62.54 112.463 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -152.05 128.21 10.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.858 0.361 . . . . 74.23 110.847 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -163.64 119.35 1.66 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.147 -0.479 . . . . 65.15 110.92 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.494 ' O ' HG23 ' A' ' 54' ' ' THR . 14.9 t -58.7 142.36 50.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 51.11 111.103 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.494 HG23 ' O ' ' A' ' 53' ' ' THR . 0.8 OUTLIER -160.12 164.39 33.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 43.45 111.22 179.966 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.458 ' O ' HD12 ' A' ' 55' ' ' LEU . 0.6 OUTLIER -109.31 163.0 13.78 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.282 -0.417 . . . . 54.25 110.96 179.961 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 9.4 p -142.55 144.0 32.72 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.239 -0.437 . . . . 75.31 111.19 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.423 ' HE2' HD13 ' A' ' 55' ' ' LEU . 48.2 m-85 -113.84 134.81 54.57 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.261 -0.427 . . . . 64.23 110.924 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.463 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -131.15 142.89 50.29 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.109 -0.496 . . . . 74.34 110.847 -179.949 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -109.3 115.28 49.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 75.54 111.116 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.812 ' HB3' HG23 ' A' ' 18' ' ' VAL . . . -104.01 134.94 46.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 54.04 111.091 179.834 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -120.43 123.4 42.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.25 -0.432 . . . . 74.11 110.859 -179.827 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -89.57 101.36 14.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.045 -0.525 . . . . 72.4 110.912 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.5 t -99.48 -38.77 7.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 64.11 111.101 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -125.44 159.01 32.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 64.11 110.829 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 12.2 p -84.35 3.16 37.07 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.104 -0.498 . . . . 60.34 110.862 -179.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -116.63 -33.13 4.96 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.101 -0.499 . . . . 71.2 110.877 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.438 HG21 ' CD1' ' A' ' 107' ' ' TYR . 1.9 pp -139.31 164.07 25.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 72.12 111.121 179.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -150.12 167.89 25.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 64.33 111.117 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 13.5 m -113.31 152.98 14.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 60.35 111.203 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -147.91 147.15 29.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 75.44 110.88 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.463 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 16.7 m-85 -127.34 110.33 12.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.266 -0.424 . . . . 72.54 110.867 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -87.83 122.85 31.98 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.094 -0.503 . . . . 74.4 110.863 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 25.2 t -145.88 149.11 16.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.136 -0.484 . . . . 51.15 111.094 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -152.97 167.59 31.71 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.744 -0.741 . . . . 41.24 112.511 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.6 m -134.55 67.65 71.76 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.59 0.709 . . . . 62.34 111.104 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 163.65 37.47 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.667 2.244 . . . . 64.01 112.363 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -83.85 -170.91 3.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.192 -0.458 . . . . 71.3 111.129 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 20.5 ttm105 -76.55 135.49 39.26 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 61.43 110.823 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -129.7 144.3 51.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.114 -0.494 . . . . 62.54 111.148 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.83 137.49 42.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 62.35 110.915 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 43.6 p90 -129.78 159.09 37.61 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.435 . . . . 74.52 110.865 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.411 ' O ' HG23 ' A' ' 47' ' ' VAL . 26.0 mt-30 -98.29 158.08 15.79 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.117 -0.492 . . . . 74.13 110.878 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.532 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -178.0 60.13 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.666 -0.778 . . . . 74.41 112.479 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.453 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.3 tp10 -167.97 -175.55 2.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.928 0.394 . . . . 63.15 110.85 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.15 -69.27 0.68 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.187 -0.461 . . . . 73.24 110.899 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -84.15 -33.39 24.26 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.203 -0.453 . . . . 64.25 110.817 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.751 HG22 HG22 ' A' ' 93' ' ' VAL . 5.8 mm -64.68 -35.11 73.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 55.25 111.126 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 78.8 p -62.98 -47.89 81.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.472 . . . . 73.12 110.83 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 t -51.29 -37.88 49.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.125 -0.489 . . . . 74.15 110.851 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 9.1 tp -63.34 -39.01 93.36 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.103 -0.499 . . . . 70.43 110.929 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 103.13 -15.41 54.82 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.714 -0.755 . . . . 43.22 112.494 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -120.35 89.43 3.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.873 0.368 . . . . 75.43 110.825 -179.832 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.751 HG22 HG22 ' A' ' 87' ' ' ILE . 32.4 t -105.38 -47.4 9.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.207 -0.451 . . . . 60.23 111.157 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 17.9 t -142.22 144.29 33.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.151 -0.477 . . . . 75.11 110.869 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.4 pm0 -133.65 128.56 35.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.09 -0.504 . . . . 72.1 110.865 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.483 HG22 ' N ' ' A' ' 97' ' ' ASP . 10.1 p -175.88 157.02 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.464 . . . . 71.33 111.135 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.483 ' N ' HG22 ' A' ' 96' ' ' VAL . 1.7 t0 -81.0 172.52 13.63 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 73.12 110.921 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -132.92 130.72 40.0 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.269 -0.423 . . . . 74.01 110.913 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -113.4 70.98 0.23 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.71 -0.757 . . . . 54.12 112.42 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.66 114.43 3.69 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.694 2.263 . . . . 74.51 112.346 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -133.61 107.45 7.98 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.221 -0.445 . . . . 65.43 111.025 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.566 HG22 ' CA ' ' A' ' 124' ' ' GLY . 8.0 pt -131.55 149.69 33.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.247 -0.433 . . . . 55.12 111.117 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.455 ' O ' HD12 ' A' ' 103' ' ' LEU . 1.9 pp -138.28 124.15 19.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.127 -0.488 . . . . 71.23 110.945 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.4 p -144.74 165.88 26.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 73.5 110.818 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.465 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.9 OUTLIER -113.14 155.0 25.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.138 -0.483 . . . . 62.32 110.904 179.982 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 -102.07 132.03 48.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.466 . . . . 62.54 110.844 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.438 ' CD1' HG21 ' A' ' 67' ' ' ILE . 13.0 t80 -120.26 121.91 39.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.24 -0.436 . . . . 72.31 110.902 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -60.84 126.12 26.23 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.137 -0.483 . . . . 74.5 110.852 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -155.92 108.45 2.63 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.218 -0.446 . . . . 74.22 110.938 -179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -65.45 127.29 31.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.046 -0.525 . . . . 64.44 110.845 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 32.6 p -112.58 -69.66 0.85 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.122 -0.49 . . . . 64.33 110.879 -179.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -109.33 174.44 5.87 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.149 -0.478 . . . . 74.52 110.863 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -76.89 -65.12 0.98 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.134 -0.485 . . . . 75.11 110.918 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 18.8 ttt180 -52.26 -65.71 0.51 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.152 -0.477 . . . . 72.11 110.865 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -99.21 121.52 41.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.442 . . . . 72.51 110.896 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 8.8 p90 -118.73 67.88 7.96 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.648 0.737 . . . . 62.02 110.873 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 177.75 5.22 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.76 2.307 . . . . 75.41 112.297 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 9.0 m-85 -115.69 159.27 21.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.148 -0.478 . . . . 71.0 110.878 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 6.8 p -109.69 124.13 66.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.11 -0.495 . . . . 72.11 111.137 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -117.87 163.51 12.83 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.777 -0.725 . . . . 64.31 112.458 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.0 p -163.71 151.35 3.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.901 0.381 . . . . 74.23 111.164 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -179.26 -151.78 10.03 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.689 -0.767 . . . . 61.51 112.446 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.454 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 32.8 m -110.6 152.27 12.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.896 0.379 . . . . 73.14 111.154 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . 0.566 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -139.03 106.24 0.5 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.691 -0.766 . . . . 74.05 112.447 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 7.2 ptp180 -105.82 128.35 53.67 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.862 0.363 . . . . 74.34 110.84 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 60.4 t -113.52 114.62 47.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 73.14 111.136 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.1 tt -122.42 152.27 40.4 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 72.23 110.95 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 11.5 p90 -161.58 162.17 30.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.288 -0.415 . . . . 73.03 110.886 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -101.17 116.86 33.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.142 -0.481 . . . . 72.13 110.912 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -50.74 104.56 0.08 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.156 -0.474 . . . . 72.45 110.861 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.447 ' HB2' ' HA ' ' A' ' 96' ' ' VAL . 0.7 OUTLIER -79.49 -79.35 0.14 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 62.32 110.934 179.963 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 32.0 m -167.01 126.44 1.44 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 73.12 111.147 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . 0.487 ' HB3' ' HB3' ' A' ' 139' ' ' PHE . 26.2 t0 -115.18 114.84 25.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.27 -0.423 . . . . 74.4 110.892 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -79.95 -8.1 87.95 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.758 -0.734 . . . . 73.12 112.488 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.618 ' HB2' HG12 ' A' ' 93' ' ' VAL . . . -46.17 -29.38 1.54 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.831 0.348 . . . . 75.12 111.13 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.419 ' HB3' ' CD1' ' A' ' 139' ' ' PHE . 2.6 tp -157.12 -176.83 6.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.222 -0.445 . . . . 73.11 110.869 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 68.4 m -56.63 92.75 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.114 -0.494 . . . . 75.23 110.815 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 58.1 m 50.78 75.08 0.2 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.139 -0.482 . . . . 63.12 110.812 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.487 ' HB3' ' HB3' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -102.54 160.59 14.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 35.11 110.914 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -139.73 172.54 12.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 74.31 110.94 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.493 HD13 HG13 ' A' ' 176' ' ' VAL . 5.8 mm -114.26 161.8 12.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.219 -0.446 . . . . 74.43 111.147 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 13.5 mttm -124.11 114.82 20.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.178 -0.464 . . . . 60.14 110.923 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -69.64 -175.33 0.84 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.279 -0.419 . . . . 64.31 110.895 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 6.9 tttp -172.84 -173.64 1.0 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.23 -0.441 . . . . 71.51 110.894 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 59.3 p-90 -148.75 160.23 43.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.187 -0.461 . . . . 73.4 110.966 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.691 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 179.87 163.54 0.84 Allowed Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.593 0.711 . . . . 73.24 111.105 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.691 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 54.3 Cg_endo -69.78 169.1 19.74 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.688 2.258 . . . . 74.41 112.306 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.626 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -167.79 157.07 9.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 63.41 111.094 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 6.2 p90 -115.99 138.42 51.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.449 . . . . 71.55 110.898 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.406 ' HA ' ' HA ' ' A' ' 168' ' ' ARG . 25.2 tt0 -116.53 158.88 22.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 71.45 110.864 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.3 p -142.79 129.35 17.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.16 -0.473 . . . . 71.45 111.07 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 166.4 -164.42 37.61 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.749 -0.738 . . . . 61.03 112.456 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -161.22 174.01 14.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.709 0.29 . . . . 74.23 110.992 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 7.8 tpp85 -109.45 121.21 44.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.232 -0.44 . . . . 73.23 110.846 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 47.8 t80 -106.98 147.86 29.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 75.55 110.974 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -110.07 112.63 24.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.127 -0.488 . . . . 73.51 110.845 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 23.9 tp -86.15 158.14 19.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.165 -0.47 . . . . 64.34 110.908 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -58.24 -39.57 92.67 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.731 -0.747 . . . . 35.41 112.466 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -64.26 169.35 4.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.832 0.349 . . . . 72.54 110.855 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 72.6 m -54.35 -47.55 72.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 73.14 110.875 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 18.1 p90 -74.23 145.64 43.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.096 -0.502 . . . . 62.22 110.929 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 1.8 mpt? -100.34 178.79 4.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.256 -0.429 . . . . 50.42 110.904 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 4.5 tp -119.55 141.95 48.79 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 74.42 110.839 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -135.37 136.29 41.35 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.144 -0.48 . . . . 63.0 110.875 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.3 p -133.99 134.03 42.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 75.24 110.912 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -163.81 152.74 13.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 64.21 110.838 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.452 HG13 ' O ' ' A' ' 195' ' ' ILE . 44.3 t -144.8 119.04 3.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 72.44 111.143 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . 0.406 ' HA ' ' HA ' ' A' ' 150' ' ' GLN . 0.4 OUTLIER -93.52 147.08 23.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.196 -0.457 . . . . 73.22 110.868 -179.959 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' TYR . . . . . 0.413 ' O ' ' HB ' ' A' ' 170' ' ' ILE . 20.1 t80 -152.6 140.03 19.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 70.14 110.943 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' ILE . . . . . 0.626 HG21 ' HB2' ' A' ' 148' ' ' ALA . 0.0 OUTLIER 178.64 132.03 0.22 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.594 0.712 . . . . 73.43 111.196 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . 0.509 ' N ' HD13 ' A' ' 170' ' ' ILE . 53.8 Cg_endo -69.75 107.97 1.97 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.691 2.261 . . . . 61.21 112.362 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -124.02 152.63 42.38 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.172 -0.467 . . . . 64.23 110.858 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 10.4 pttm -122.7 132.92 54.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 64.41 110.869 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.6 t -100.16 162.01 13.24 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 72.41 111.131 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -110.63 157.44 19.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 61.53 110.921 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.493 HG13 HD13 ' A' ' 141' ' ' ILE . 2.9 t -150.54 136.5 11.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.983 0.42 . . . . 74.11 111.063 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.0 t -166.83 161.83 15.6 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 72.24 111.154 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -123.78 174.56 16.76 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.769 -0.729 . . . . 63.44 112.5 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . 0.408 ' O ' HG23 ' A' ' 179' ' ' THR . 1.8 t -115.52 98.26 6.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.823 0.345 . . . . 64.25 111.107 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 11.2 tp -128.87 165.95 20.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 61.35 110.868 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -51.46 -69.25 1.19 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.708 -0.758 . . . . 61.22 112.531 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 179.78 3.45 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.666 2.244 . . . . 54.31 112.364 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.445 HG13 ' O ' ' A' ' 183' ' ' VAL . 3.5 p -55.73 111.16 2.81 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.588 0.709 . . . . 74.44 111.196 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 183' ' ' VAL . 53.9 Cg_endo -69.74 166.19 28.41 Favored 'Trans proline' 0 N--CA 1.465 -0.194 0 C-N-CA 122.757 2.305 . . . . 61.34 112.39 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 84.9 t -98.68 126.22 51.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.291 -0.413 . . . . 63.2 111.129 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 1.3 p -112.46 111.67 22.68 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.155 -0.475 . . . . 72.23 110.831 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 61.9 p -116.44 167.57 10.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.083 -0.508 . . . . 75.44 111.165 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 11.5 ptmt -147.16 160.32 42.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.444 . . . . 75.44 110.837 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 189' ' ' ILE . . . . . 0.542 HG22 HG23 ' A' ' 191' ' ' VAL . 26.7 mt -137.69 109.24 6.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 74.22 111.127 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.52 106.0 18.18 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 73.03 110.871 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 191' ' ' VAL . . . . . 0.542 HG23 HG22 ' A' ' 189' ' ' ILE . 2.3 t -137.01 164.66 29.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.085 -0.507 . . . . 75.22 111.136 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.433 ' H ' HG12 ' A' ' 191' ' ' VAL . 0.0 OUTLIER -106.94 89.64 4.6 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-O 121.531 0.681 . . . . 74.45 110.816 -179.998 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 192' ' ' ASP . 53.8 Cg_endo -69.79 135.18 29.75 Favored 'Trans proline' 0 C--N 1.34 0.131 0 C-N-CA 122.758 2.306 . . . . 63.33 112.257 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -103.09 118.16 36.18 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.165 -0.47 . . . . 55.13 110.884 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 195' ' ' ILE . . . . . 0.734 HD12 HG12 ' A' ' 26' ' ' VAL . 24.1 mm -109.26 110.37 31.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 53.44 111.196 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . 0.44 HD12 HD21 ' A' ' 198' ' ' LEU . 0.9 OUTLIER -109.15 108.49 19.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 71.45 110.925 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -105.63 133.52 50.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 70.15 110.881 -179.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 198' ' ' LEU . . . . . 0.44 HD21 HD12 ' A' ' 196' ' ' LEU . 0.1 OUTLIER -153.64 137.74 16.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 72.33 110.916 179.966 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 175.48 -140.15 5.07 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.685 -0.769 . . . . 73.33 112.44 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -117.42 173.32 6.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.814 0.34 . . . . 44.01 111.112 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 4.8 p -155.8 166.29 33.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 74.45 110.833 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -132.04 150.7 52.08 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.076 -0.511 . . . . 73.0 110.931 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.592 HG23 HG12 ' A' ' 18' ' ' VAL . 5.6 p -113.05 143.62 22.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 74.22 111.148 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 4.6 t80 -141.76 107.86 5.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 71.24 110.889 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 63.5 tttt -93.96 126.14 38.99 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.153 -0.476 . . . . 73.34 110.863 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 9.0 mp -82.36 107.47 15.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.251 -0.431 . . . . 75.45 110.949 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -61.86 -48.62 79.71 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.458 . . . . 73.31 111.106 179.79 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -128.18 150.65 49.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 70.3 111.122 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -57.74 119.78 7.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.202 -0.454 . . . . 61.42 111.088 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 19.2 tp -67.91 143.39 55.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.207 -0.451 . . . . 74.13 110.972 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.253 -0.43 . . . . 51.33 110.84 -179.98 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.2 mmt . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.788 0.328 . . . . 55.24 110.909 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -120.06 177.84 4.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.264 -0.426 . . . . 65.44 110.868 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -148.51 159.01 44.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 63.15 110.847 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 11.0 m120 -160.6 157.99 28.23 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 63.1 110.916 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -139.5 145.67 44.83 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.654 0.74 . . . . 73.03 110.927 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.83 163.3 38.85 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.708 2.272 . . . . 74.34 112.328 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -149.38 125.25 10.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.238 -0.437 . . . . 74.03 111.149 179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 25.0 mmtt -138.75 175.5 9.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.283 -0.417 . . . . 73.33 110.894 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 74.1 m -127.06 165.44 19.48 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.2 -0.454 . . . . 73.32 110.832 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -164.79 177.24 8.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.108 -0.496 . . . . 75.14 111.102 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -61.07 -32.95 82.23 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.768 -0.729 . . . . 64.53 112.522 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 9.1 p90 -140.18 110.9 6.81 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.897 0.38 . . . . 73.21 110.938 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -130.2 -177.74 4.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.122 -0.49 . . . . 75.21 110.86 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 11.8 mp0 -57.11 120.74 8.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.133 -0.485 . . . . 74.04 110.901 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 110.6 5.8 27.46 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.734 -0.746 . . . . 72.54 112.481 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -59.69 152.84 21.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.726 0.298 . . . . 74.21 110.922 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.579 ' HE1' HG23 ' A' ' 59' ' ' ILE . 25.0 t90 -121.6 142.36 50.19 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.234 -0.439 . . . . 71.34 110.936 -179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.46 HG22 ' HA ' ' A' ' 203' ' ' VAL . 39.5 t -146.72 116.75 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 72.53 111.091 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -86.61 105.31 16.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.126 -0.488 . . . . 74.14 111.137 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -101.75 112.77 25.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 64.21 110.847 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -110.16 121.2 44.71 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.123 -0.49 . . . . 65.01 110.998 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -152.12 166.68 30.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.435 . . . . 73.4 110.913 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -100.52 130.59 46.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 72.33 110.894 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -97.17 139.09 33.68 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 74.32 110.882 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 68.8 mttt -111.05 106.97 16.2 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.14 -0.482 . . . . 70.35 110.924 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.629 HG12 HD12 ' A' ' 195' ' ' ILE . 23.4 m -79.13 132.9 31.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 72.35 111.112 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 27.9 t80 -126.97 99.25 5.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 74.34 110.945 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 p -166.12 149.77 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 63.32 111.102 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 132.44 78.71 0.15 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.702 -0.761 . . . . 72.05 112.459 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -89.77 -65.93 0.97 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.735 0.302 . . . . 64.22 110.829 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.522 ' O ' HD12 ' A' ' 189' ' ' ILE . 1.6 mt-10 -171.54 174.28 4.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.196 -0.457 . . . . 72.32 110.846 -179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.472 ' HB3' ' HB3' ' A' ' 45' ' ' ALA . 14.9 tp -81.1 155.06 26.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.082 -0.508 . . . . 61.32 110.927 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.95 -32.13 41.11 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.75 -0.738 . . . . 41.4 112.494 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 42.02 38.89 1.17 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.797 0.332 . . . . 74.43 110.856 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 4.9 tp -62.46 -37.03 84.35 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.251 -0.432 . . . . 73.42 110.946 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 22.3 m120 -68.73 126.78 30.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.225 -0.443 . . . . 71.31 110.834 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 13.9 p -90.6 144.89 8.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.105 -0.498 . . . . 73.25 111.111 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -132.15 -172.42 13.05 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.723 -0.751 . . . . 73.35 112.482 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -153.7 125.53 1.77 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.694 -0.765 . . . . 71.54 112.494 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.3 -101.43 1.49 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.793 -0.718 . . . . 64.42 112.498 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -77.96 169.72 17.8 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.852 0.358 . . . . 45.01 111.074 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 15.1 mt 59.47 73.29 0.69 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.56 0.695 . . . . 71.33 110.95 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -176.73 1.58 Allowed 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.706 2.271 . . . . 62.3 112.303 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -57.08 168.88 0.61 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.451 . . . . 61.24 110.898 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.472 ' HB3' ' HB3' ' A' ' 32' ' ' LEU . . . -90.12 -178.37 5.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.158 -0.474 . . . . 72.23 111.1 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 -153.49 125.85 8.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 73.31 110.921 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.471 HG22 ' HA2' ' A' ' 83' ' ' GLY . 92.0 t -109.45 141.3 25.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 74.22 111.11 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 43.0 t -167.94 159.02 11.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 41.14 110.809 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.727 HG22 ' HB3' ' A' ' 81' ' ' PHE . 45.0 pt -126.08 157.85 35.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.102 -0.499 . . . . 73.22 111.147 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.25 -138.94 0.36 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.742 -0.742 . . . . 54.35 112.45 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -154.22 117.11 4.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.884 0.373 . . . . 72.13 110.802 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -151.94 105.83 3.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.069 -0.514 . . . . 72.21 110.874 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 46.9 p -72.7 117.25 14.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 43.14 111.126 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.1 m -117.74 162.49 17.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 62.34 111.159 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -94.16 162.3 13.92 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.212 -0.449 . . . . 74.43 110.934 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.23 140.21 32.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.239 -0.437 . . . . 74.23 111.14 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 12.6 m-85 -103.45 131.99 50.08 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.216 -0.447 . . . . 72.43 110.831 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 53.3 m-20 -130.13 133.3 46.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 73.43 110.896 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.579 HG23 ' HE1' ' A' ' 17' ' ' TRP . 22.1 mm -109.2 113.53 44.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 74.0 111.139 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -103.74 117.78 35.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 62.12 111.021 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -106.75 114.21 28.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.184 -0.462 . . . . 74.55 110.892 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -81.56 97.19 7.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.089 -0.505 . . . . 74.24 110.88 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.0 m -88.05 -34.15 7.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 73.51 111.129 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 69.2 m -136.23 167.47 21.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 72.0 110.899 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 46.8 t -86.94 2.64 48.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 70.53 110.895 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 65.1 m-20 -113.59 -33.86 5.72 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.096 -0.502 . . . . 61.54 110.912 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 2.2 pp -145.52 169.01 7.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 41.22 111.205 179.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -155.7 173.19 17.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.222 -0.444 . . . . 72.44 111.066 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.425 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 11.6 m -111.55 151.03 13.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 73.32 111.112 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -140.28 133.23 29.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 62.42 110.882 179.881 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.756 ' CZ ' HD22 ' A' ' 103' ' ' LEU . 0.5 OUTLIER -113.54 113.91 25.76 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.198 -0.456 . . . . 70.13 110.842 -179.852 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -91.64 119.99 32.01 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 74.53 110.909 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 36.7 t -146.64 149.35 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 63.25 111.144 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -156.51 164.45 32.55 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.697 -0.763 . . . . 70.32 112.473 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 24.6 t -136.55 66.03 56.47 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.614 0.721 . . . . 71.52 111.142 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 162.62 41.36 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.636 2.224 . . . . 71.31 112.353 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -79.28 -168.98 1.68 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.244 -0.435 . . . . 51.11 111.054 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.96 138.52 38.9 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.15 -0.477 . . . . 62.13 110.832 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -128.35 135.65 49.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.445 . . . . 72.11 111.144 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 6.8 ttpm? -107.92 141.63 39.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.223 -0.444 . . . . 75.32 110.857 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . 0.727 ' HB3' HG22 ' A' ' 49' ' ' ILE . 13.6 p90 -142.07 158.47 43.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.153 -0.476 . . . . 73.35 110.89 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.419 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 1.2 pm0 -98.05 158.51 15.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 75.24 110.909 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.605 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -177.44 69.59 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.759 -0.734 . . . . 73.53 112.505 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.434 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.9 mm-40 -178.33 -177.14 0.55 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.824 0.345 . . . . 73.21 110.916 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.23 -67.42 0.82 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.163 -0.472 . . . . 72.34 110.915 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.9 t -83.1 -35.62 25.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.447 . . . . 72.03 110.851 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.929 HG22 HG22 ' A' ' 93' ' ' VAL . 5.7 mm -64.62 -33.65 64.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.122 -0.49 . . . . 72.21 111.131 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.7 t -61.85 -47.95 82.72 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.206 -0.452 . . . . 65.24 110.861 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.9 t -53.23 -39.87 64.12 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.153 -0.476 . . . . 43.2 110.844 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -59.83 -42.48 93.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.119 -0.491 . . . . 61.34 110.927 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 104.93 -13.48 49.48 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.704 -0.76 . . . . 64.31 112.506 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 7.2 ptp180 -120.16 96.9 5.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.856 0.36 . . . . 62.11 110.873 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.929 HG22 HG22 ' A' ' 87' ' ' ILE . 98.6 t -113.55 -55.41 4.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.234 -0.439 . . . . 73.02 111.175 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 5.8 m -140.51 143.39 35.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 40.42 110.841 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -146.7 126.17 13.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.49 . . . . 72.22 110.862 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.452 HG22 ' N ' ' A' ' 97' ' ' ASP . 14.2 p -166.1 156.72 1.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 64.13 111.155 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.452 ' N ' HG22 ' A' ' 96' ' ' VAL . 6.0 p-10 -72.94 172.97 9.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 75.55 110.835 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 3.5 m-85 -115.74 125.39 52.72 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.106 -0.497 . . . . 70.52 110.889 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -119.46 67.04 0.39 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.664 -0.779 . . . . 64.42 112.464 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 112.01 2.96 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.694 2.263 . . . . 62.2 112.33 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.455 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -122.66 95.94 4.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.215 -0.448 . . . . 35.23 111.092 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.669 HG23 ' CA ' ' A' ' 124' ' ' GLY . 5.8 mm -121.7 149.98 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 75.01 111.109 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.756 HD22 ' CZ ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -150.42 111.1 4.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 70.34 110.913 179.936 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.4 p -142.87 167.87 21.05 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.223 -0.444 . . . . 55.0 110.883 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.425 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -113.58 149.52 34.37 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.144 -0.48 . . . . 74.53 110.92 -179.968 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -101.9 149.19 24.46 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 70.11 110.922 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -155.5 149.24 25.29 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.177 -0.465 . . . . 74.52 110.958 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 14.6 t-160 -118.46 134.5 55.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 73.1 110.891 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 21.9 t80 -104.85 144.8 31.28 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.231 -0.441 . . . . 75.14 110.923 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -62.55 120.63 11.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.072 -0.513 . . . . 73.34 110.874 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 31.7 p -130.27 175.68 8.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 61.12 110.838 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -78.17 -51.52 10.09 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.141 -0.481 . . . . 70.04 110.83 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -54.54 138.24 41.23 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.466 . . . . 74.11 110.929 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 10.6 mmp_? -72.08 -50.65 26.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 73.11 110.892 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 11.8 mt -97.73 112.96 24.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.464 . . . . 72.3 110.893 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -156.53 139.81 11.05 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.681 0.753 . . . . 74.01 110.905 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . 0.559 ' HA ' HD13 ' A' ' 153' ' ' LEU . 55.0 Cg_endo -69.67 177.35 5.61 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.695 2.263 . . . . 64.32 112.4 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -110.47 162.84 14.29 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.258 -0.428 . . . . 73.11 110.889 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 92.0 t -128.74 143.81 40.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.065 -0.516 . . . . 41.15 111.14 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -134.96 -175.02 13.65 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.779 -0.724 . . . . 62.03 112.464 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.2 p -169.25 156.1 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.877 0.37 . . . . 74.42 111.129 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 177.78 -152.1 11.48 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.69 -0.767 . . . . 54.5 112.474 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.5 HG23 ' HG ' ' A' ' 103' ' ' LEU . 34.2 m -107.85 130.35 60.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.897 0.38 . . . . 63.1 111.137 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . 0.669 ' CA ' HG23 ' A' ' 102' ' ' ILE . . . -125.5 113.31 1.87 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.74 -0.743 . . . . 64.22 112.495 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . 0.455 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 14.2 ptt180 -114.58 124.4 51.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.846 0.355 . . . . 74.0 110.925 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.417 ' O ' ' HB2' ' A' ' 143' ' ' ASP . 51.5 t -106.09 110.19 30.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 52.42 111.116 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.477 HD23 ' HB2' ' A' ' 143' ' ' ASP . 6.2 mt -126.5 174.5 8.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 54.23 110.83 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.517 ' CE2' HG23 ' A' ' 141' ' ' ILE . 0.1 OUTLIER -159.02 173.17 16.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.149 -0.478 . . . . 64.5 110.877 179.921 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.437 ' O ' HG23 ' A' ' 96' ' ' VAL . 5.9 t80 -101.78 119.11 38.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 74.13 110.924 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -46.41 106.18 0.08 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.131 -0.486 . . . . 74.53 110.914 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 31.7 mmtm -105.21 -79.95 0.55 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.232 -0.44 . . . . 63.11 110.882 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 1.5 m -160.45 85.02 0.71 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.215 -0.448 . . . . 54.55 111.149 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -102.72 166.94 10.21 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.239 -0.437 . . . . 64.32 110.864 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 135' ' ' ALA . . . 83.23 145.49 6.13 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.772 -0.727 . . . . 74.23 112.578 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.507 ' HB2' HG13 ' A' ' 87' ' ' ILE . . . -36.5 -65.32 0.28 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.747 0.308 . . . . 63.5 111.081 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.439 HD23 ' HB1' ' A' ' 135' ' ' ALA . 0.4 OUTLIER -167.38 93.18 0.42 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.24 -0.437 . . . . 64.32 110.911 -179.952 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.655 ' HB2' HD21 ' A' ' 180' ' ' LEU . 1.5 p 167.83 59.82 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.225 -0.443 . . . . 62.21 110.844 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.539 ' C ' ' O ' ' A' ' 137' ' ' SER . 54.1 m 25.97 74.45 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.165 -0.47 . . . . 53.45 110.884 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -106.04 143.23 34.46 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.099 -0.5 . . . . 74.42 110.894 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 -111.62 173.76 6.19 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.157 -0.474 . . . . 64.11 110.794 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.517 HG23 ' CE2' ' A' ' 128' ' ' PHE . 6.8 tt -128.02 126.47 66.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.133 -0.485 . . . . 43.12 111.132 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . 0.411 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 1.3 mtmt -74.58 106.11 6.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 72.35 110.885 179.836 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.477 ' HB2' HD23 ' A' ' 127' ' ' LEU . 0.9 OUTLIER -57.4 -176.11 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.175 -0.466 . . . . 64.43 110.856 179.854 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . 0.554 ' CE ' HG22 ' A' ' 174' ' ' THR . 0.0 OUTLIER -139.92 161.55 37.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 63.34 110.955 179.952 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 43.7 p-90 -155.37 135.73 13.21 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.279 -0.419 . . . . 64.32 110.915 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.735 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 179.94 165.54 0.82 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.568 0.699 . . . . 60.31 111.112 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.735 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 52.7 Cg_endo -69.8 142.33 47.48 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.689 2.26 . . . . 74.22 112.266 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.563 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -133.73 167.52 20.38 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 62.21 111.126 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 58.8 m-85 -117.76 156.61 28.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.257 -0.429 . . . . 73.32 110.863 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -128.06 149.05 50.56 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.161 -0.472 . . . . 70.52 110.925 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 84.7 t -151.14 123.32 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 71.33 111.125 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . 0.441 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 179.53 -159.04 23.37 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.756 -0.735 . . . . 70.32 112.486 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.559 HD13 ' HA ' ' A' ' 117' ' ' PRO . 20.3 tp -150.78 161.0 43.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.83 0.348 . . . . 52.13 110.939 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.4 tpp85 -117.64 118.71 32.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 60.1 110.887 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 10.1 t80 -103.91 142.85 33.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 74.55 110.905 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -121.74 97.51 5.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.153 -0.476 . . . . 75.5 110.835 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 6.1 tp -73.24 158.69 34.7 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 71.04 110.911 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -52.53 -46.24 58.77 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.695 -0.764 . . . . 70.44 112.498 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -58.1 166.51 1.55 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.824 0.345 . . . . 71.34 110.895 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 5.9 m -57.51 -36.73 71.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.141 -0.481 . . . . 61.41 110.871 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 87.5 m95 -79.4 134.7 36.57 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.13 -0.486 . . . . 74.52 110.9 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.491 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 32.8 mtt -108.93 176.79 4.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.44 . . . . 75.23 110.82 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.416 HD13 ' O ' ' A' ' 199' ' ' GLY . 3.2 mm? -115.92 148.77 39.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 63.23 110.914 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -146.89 133.25 19.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.469 . . . . 74.25 110.929 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 66.0 p -139.98 122.23 15.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 75.01 110.89 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . 0.441 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.7 OUTLIER -147.34 155.33 41.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.178 -0.464 . . . . 75.25 110.896 179.921 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.691 HG22 HD23 ' A' ' 196' ' ' LEU . 14.6 t -133.18 134.57 57.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 73.14 111.103 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 7.1 tmm_? -107.5 132.16 53.53 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.129 -0.487 . . . . 74.53 110.9 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 38.0 t80 -132.83 139.52 47.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.461 . . . . 72.32 110.852 -179.802 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' ILE . . . . . 0.563 HG21 ' HB2' ' A' ' 148' ' ' ALA . 1.3 tp -178.1 102.23 0.21 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.622 0.725 . . . . 72.44 111.106 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 128.26 15.75 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.658 2.239 . . . . 72.25 112.419 179.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . 0.41 ' CE2' ' HB2' ' A' ' 146' ' ' ALA . 1.5 t80 -153.17 178.09 10.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 73.32 110.831 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.45 135.45 50.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.15 -0.477 . . . . 63.13 110.886 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . 0.554 HG22 ' CE ' ' A' ' 144' ' ' LYS . 1.0 OUTLIER -102.62 164.97 11.34 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.224 -0.443 . . . . 74.02 111.186 179.965 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . 0.411 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.3 OUTLIER -127.24 167.28 16.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 64.44 110.832 179.98 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 24.7 t -148.37 139.08 17.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.451 . . . . 71.41 111.165 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.3 t -166.85 155.82 10.52 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 73.24 111.138 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -138.87 -162.04 8.98 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.749 -0.739 . . . . 41.43 112.482 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . 0.642 ' O ' HD22 ' A' ' 180' ' ' LEU . 1.9 t -124.28 107.59 11.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.818 0.342 . . . . 74.25 111.168 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.655 HD21 ' HB2' ' A' ' 137' ' ' SER . 4.3 mm? -132.59 166.87 21.12 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.24 -0.436 . . . . 71.12 110.922 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -49.59 -69.65 0.99 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.769 -0.729 . . . . 60.13 112.517 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.75 -171.39 0.47 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.644 2.229 . . . . 72.52 112.401 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.405 HG23 ' HD2' ' A' ' 184' ' ' PRO . 7.4 p -55.97 132.9 73.85 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.662 0.744 . . . . 41.41 111.137 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . 0.405 ' HD2' HG23 ' A' ' 183' ' ' VAL . 54.6 Cg_endo -69.75 150.13 67.9 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 122.666 2.244 . . . . 55.21 112.338 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 55.1 t -96.12 107.57 19.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 55.44 111.102 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 9.8 p -99.88 105.39 17.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.125 -0.489 . . . . 72.4 110.918 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 11.8 p -104.62 161.94 13.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.486 . . . . 53.5 111.096 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.46 152.09 31.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 61.43 110.91 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 189' ' ' ILE . . . . . 0.522 HD12 ' O ' ' A' ' 31' ' ' GLU . 6.4 tt -152.48 130.35 2.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 74.55 111.089 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -100.7 115.03 29.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.461 . . . . 73.43 110.912 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 191' ' ' VAL . . . . . 0.463 HG12 ' H ' ' A' ' 192' ' ' ASP . 1.8 t -137.94 166.61 23.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 65.54 111.086 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.463 ' H ' HG12 ' A' ' 191' ' ' VAL . 1.0 OUTLIER -107.03 90.15 5.13 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.572 0.701 . . . . 63.25 110.836 -179.998 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.69 117.52 5.13 Favored 'Trans proline' 0 C--O 1.233 0.225 0 C-N-CA 122.617 2.211 . . . . 75.21 112.375 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -100.66 121.82 42.28 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.275 -0.421 . . . . 71.34 110.882 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 195' ' ' ILE . . . . . 0.629 HD12 HG12 ' A' ' 26' ' ' VAL . 13.6 mm -112.33 107.26 22.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.469 . . . . 51.12 111.108 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . 0.691 HD23 HG22 ' A' ' 167' ' ' VAL . 2.3 mt -100.4 108.02 19.92 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.108 -0.497 . . . . 72.13 110.938 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.4 m -100.03 127.53 46.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.44 . . . . 70.1 110.882 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 43.9 tp -146.7 132.23 18.73 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.117 -0.492 . . . . 65.24 110.901 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 199' ' ' GLY . . . . . 0.416 ' O ' HD13 ' A' ' 163' ' ' LEU . . . 177.26 -141.64 5.41 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.773 -0.727 . . . . 23.4 112.506 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 200' ' ' ALA . . . . . 0.491 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -124.49 172.57 9.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.721 0.296 . . . . 55.14 111.179 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 37.1 t -149.56 170.48 18.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.301 -0.409 . . . . 72.52 110.893 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 202' ' ' TYR . . . . . 0.449 ' O ' HG13 ' A' ' 18' ' ' VAL . 22.9 t80 -146.5 131.62 18.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.11 -0.495 . . . . 73.24 110.941 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.46 ' HA ' HG22 ' A' ' 18' ' ' VAL . 34.4 m -88.62 160.77 2.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 74.12 111.09 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -169.35 148.96 3.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 70.33 110.885 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.74 176.91 5.0 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.145 -0.48 . . . . 74.41 110.878 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 12.6 tp -90.59 153.42 20.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.434 . . . . 70.15 110.943 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . 61.81 47.85 5.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.251 -0.431 . . . . 63.31 111.096 179.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -128.22 145.92 50.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 55.01 111.107 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -134.59 172.2 13.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.229 -0.441 . . . . 63.41 111.164 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 12.6 mt -88.41 144.73 26.2 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.244 -0.435 . . . . 74.51 110.877 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 . . . . . 0 C--N 1.331 -0.238 0 CA-C-N 116.193 -0.458 . . . . 72.24 110.858 179.942 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 17.2 mtt . . . . . 0 C--O 1.23 0.038 0 CA-C-O 120.822 0.344 . . . . 73.13 110.868 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 44.7 t30 -109.62 59.72 0.6 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.444 . . . . 73.23 110.958 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -121.91 142.19 50.53 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.126 -0.488 . . . . 73.13 110.804 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 40.74 40.98 1.05 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 74.14 110.882 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 20.3 p90 -59.39 153.78 46.88 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.713 0.768 . . . . 72.12 110.878 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 145.53 57.22 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.673 2.249 . . . . 73.43 112.376 179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -140.18 163.02 33.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.286 -0.416 . . . . 52.11 111.105 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 13.2 ttmm -140.63 108.18 5.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 64.32 110.904 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 84.6 p -114.84 50.3 0.98 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.228 -0.442 . . . . 52.31 110.862 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -174.23 157.15 2.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.167 -0.469 . . . . 72.13 111.095 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.06 -93.22 1.85 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.637 -0.792 . . . . 51.53 112.451 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 15.5 p90 -158.64 118.93 3.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.933 0.397 . . . . 65.41 110.891 -179.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -139.21 162.4 35.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.129 -0.487 . . . . 62.14 110.861 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.7 pt20 -53.48 120.2 5.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 70.11 110.865 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.83 5.35 29.3 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.678 -0.772 . . . . 53.44 112.493 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.1 145.58 52.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.835 0.35 . . . . 74.3 110.885 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 27.9 m0 -105.66 137.51 43.39 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.183 -0.462 . . . . 74.43 110.934 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.503 HG11 HH12 ' A' ' 154' ' ' ARG . 10.2 t -144.86 112.53 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.188 -0.46 . . . . 52.25 111.066 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.45 106.0 14.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.178 -0.465 . . . . 63.11 111.074 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 10.2 t -95.89 111.94 23.8 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.463 . . . . 71.52 110.886 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.573 ' HE1' HD13 ' A' ' 55' ' ' LEU . 39.0 t80 -113.14 116.87 30.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 74.24 110.857 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -154.22 168.42 26.61 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 74.42 110.856 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 20.0 p90 -101.25 133.75 45.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 74.53 110.864 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.5 p -109.29 114.09 27.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.107 -0.497 . . . . 71.53 110.825 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 21.3 mmmt -98.37 106.59 18.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.108 -0.496 . . . . 74.22 110.868 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.572 HG23 HG12 ' A' ' 195' ' ' ILE . 12.2 p -85.07 143.12 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 54.5 111.135 179.844 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 13.3 m-85 -122.82 116.06 23.04 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.227 -0.442 . . . . 75.31 110.937 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.1 m -148.61 -170.61 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.134 -0.485 . . . . 73.21 111.077 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.66 66.16 0.84 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.712 -0.756 . . . . 75.31 112.495 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.465 ' HB2' HG13 ' A' ' 191' ' ' VAL . 7.0 tp10 -90.51 -68.19 0.8 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.86 0.362 . . . . 74.35 110.942 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 179.05 121.21 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.125 -0.489 . . . . 73.32 110.897 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.626 HD12 HG22 ' A' ' 47' ' ' VAL . 3.4 mt -83.12 153.05 25.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 63.22 110.953 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 81.32 -132.98 11.6 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.772 -0.728 . . . . 41.14 112.522 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -136.09 162.59 32.49 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.876 0.369 . . . . 64.43 110.813 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 12.4 tp -80.91 -36.97 30.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.141 -0.481 . . . . 75.33 110.921 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -55.84 146.75 20.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 73.35 110.892 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 26.8 m -139.65 172.86 12.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 72.31 111.162 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -114.37 -131.5 5.2 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.738 -0.744 . . . . 64.53 112.439 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -100.22 -171.39 29.68 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.732 -0.747 . . . . 51.31 112.462 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 52.22 -146.58 14.75 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.752 -0.737 . . . . 63.21 112.415 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -100.36 104.17 15.6 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.803 0.335 . . . . 61.35 111.105 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 70.0 mt -151.37 73.83 8.24 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.621 0.724 . . . . 71.44 110.912 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 -177.39 1.84 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.672 2.248 . . . . 55.32 112.367 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 5.5 p-10 -91.92 140.28 29.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.251 -0.431 . . . . 61.23 110.918 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.4 ' HB1' ' HA ' ' A' ' 84' ' ' GLU . . . -65.75 167.89 8.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 43.01 111.118 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -144.9 127.56 16.17 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.245 -0.434 . . . . 72.24 110.874 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.626 HG22 HD12 ' A' ' 32' ' ' LEU . 22.0 t -105.18 138.85 28.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.166 -0.47 . . . . 63.53 111.151 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.0 m -160.34 151.74 19.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 65.4 110.862 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 16.2 tt -138.11 140.09 41.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.199 -0.455 . . . . 75.14 111.178 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -60.37 -170.04 0.51 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.756 -0.735 . . . . 60.4 112.523 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 -66.46 -58.02 6.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.778 0.323 . . . . 53.2 110.899 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 41.69 40.67 1.5 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 74.12 110.848 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.0 t -68.68 141.3 55.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.177 -0.465 . . . . 62.03 111.168 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.4 t -156.09 174.72 14.96 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.249 -0.432 . . . . 71.01 111.152 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.573 HD13 ' HE1' ' A' ' 21' ' ' PHE . 4.6 pp -90.06 159.18 16.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.208 -0.451 . . . . 75.14 110.908 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -131.16 137.13 48.87 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 74.54 111.092 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -104.24 131.96 51.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 74.01 110.879 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -135.59 139.28 43.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.139 -0.482 . . . . 74.31 110.865 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.84 114.04 45.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.249 -0.432 . . . . 72.22 111.13 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.64 ' HB2' ' OD2' ' A' ' 70' ' ' ASP . . . -106.04 127.9 53.49 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.205 -0.452 . . . . 45.43 111.1 179.835 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 28.5 m-85 -113.74 125.27 53.93 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.45 . . . . 73.32 110.963 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -88.66 103.01 15.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.143 -0.481 . . . . 75.33 110.859 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 35.3 m -95.66 -34.4 5.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 74.53 111.136 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -134.25 161.79 33.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.08 -0.509 . . . . 43.02 110.884 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 80.2 p -84.33 3.07 37.4 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 61.34 110.864 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -115.69 -32.47 5.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.468 . . . . 72.45 110.842 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 17.8 pt -142.24 168.69 14.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 75.41 111.153 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -156.78 172.79 18.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.171 -0.468 . . . . 73.31 111.108 179.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.456 HG12 ' HB3' ' A' ' 105' ' ' LEU . 12.0 m -119.04 151.71 21.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 73.32 111.111 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.64 ' OD2' ' HB2' ' A' ' 60' ' ' ALA . 10.5 t70 -148.28 144.61 27.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 74.22 110.893 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -127.46 113.68 16.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.202 -0.454 . . . . 72.2 110.91 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 15.5 m-85 -85.74 130.46 34.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.152 -0.476 . . . . 70.15 110.913 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 16.7 t -146.06 154.44 12.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.141 -0.481 . . . . 60.4 111.071 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -156.79 148.25 17.81 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.723 -0.751 . . . . 71.32 112.47 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.3 m -119.77 64.47 8.9 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.573 0.702 . . . . 74.03 111.111 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.72 164.05 35.94 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.663 2.242 . . . . 72.2 112.318 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -90.83 -167.98 1.96 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.18 -0.464 . . . . 51.24 111.134 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 17.1 ttm105 -77.38 136.48 38.43 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.236 -0.438 . . . . 62.15 110.882 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -133.61 151.09 51.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 62.01 111.128 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 39.9 ttmt -116.19 131.25 57.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.228 -0.442 . . . . 71.3 110.838 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -131.26 159.05 38.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 64.21 110.869 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.443 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 15.7 pt20 -94.06 157.27 16.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.116 -0.493 . . . . 74.34 110.92 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.576 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -176.05 68.4 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.755 -0.736 . . . . 51.22 112.521 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.4 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.5 tp10 -175.04 -176.83 1.0 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.912 0.387 . . . . 73.31 110.878 -179.83 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.7 -69.27 0.67 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.481 . . . . 74.34 110.924 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.9 m -83.67 -34.55 24.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 61.43 110.896 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.931 HG21 ' HB2' ' A' ' 135' ' ' ALA . 6.0 mm -63.73 -33.95 64.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.491 . . . . 73.13 111.131 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 58.2 p -62.32 -44.85 95.55 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.164 -0.471 . . . . 71.41 110.871 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.1 t -57.63 -35.18 70.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.134 -0.484 . . . . 63.1 110.872 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.668 HD12 ' HA ' ' A' ' 87' ' ' ILE . 24.6 mt -65.28 -50.25 66.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.172 -0.467 . . . . 65.43 110.947 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 116.04 -14.35 16.49 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.747 -0.74 . . . . 50.3 112.517 179.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 23.8 ptt180 -117.72 94.22 4.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.81 0.338 . . . . 74.11 110.861 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.898 HG22 HG22 ' A' ' 87' ' ' ILE . 64.5 t -114.5 -56.96 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 63.41 111.128 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 69.3 m -138.01 142.62 40.41 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.175 -0.466 . . . . 71.44 110.879 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -146.42 116.47 7.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.134 -0.484 . . . . 71.31 110.901 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 28.8 m -155.78 175.2 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 62.43 111.18 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -83.36 173.77 11.27 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.186 -0.461 . . . . 72.33 110.872 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -120.05 132.87 55.61 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 70.13 110.849 -179.765 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -132.08 62.06 0.65 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.694 -0.765 . . . . 31.15 112.472 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 113.05 3.24 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.673 2.249 . . . . 64.0 112.394 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.724 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -125.7 108.19 11.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 73.34 111.059 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 3.5 mp -129.17 147.92 33.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.28 -0.418 . . . . 73.14 111.104 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.412 ' HG ' HG13 ' A' ' 123' ' ' VAL . 0.2 OUTLIER -151.97 114.74 4.62 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.155 -0.475 . . . . 75.25 110.939 179.905 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 13.0 p -144.79 166.17 25.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 73.42 110.878 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.456 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -111.02 150.47 29.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.144 -0.48 . . . . 75.43 110.956 179.964 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 18.1 mt-30 -101.61 133.55 46.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.464 . . . . 72.22 110.905 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -122.82 119.37 30.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.164 -0.471 . . . . 54.21 110.839 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 2.4 t60 -78.56 106.72 10.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.092 -0.504 . . . . 54.52 110.838 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 34.0 t80 -79.22 147.43 32.6 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.152 -0.476 . . . . 73.24 110.94 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -74.59 131.59 41.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.086 -0.506 . . . . 63.32 110.912 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 87.9 p -134.58 158.55 43.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.231 -0.441 . . . . 55.13 110.872 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 81.3 t80 -81.47 -46.75 14.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 72.45 110.892 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 33.4 mm-40 -58.01 173.36 0.34 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.086 -0.507 . . . . 72.11 110.956 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.62 ' HG2' HD23 ' A' ' 115' ' ' LEU . 17.9 ptp180 -78.7 -35.93 44.28 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.207 -0.451 . . . . 73.41 110.794 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.62 HD23 ' HG2' ' A' ' 114' ' ' ARG . 1.2 pt? -111.41 142.47 43.62 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.231 -0.441 . . . . 72.4 110.953 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 27.4 t80 -166.71 134.63 2.15 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.669 0.747 . . . . 74.5 110.924 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 177.57 5.46 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.64 2.226 . . . . 64.13 112.37 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 9.7 m-85 -117.99 147.5 43.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 75.23 110.874 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 23.5 t -104.2 124.2 58.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.088 -0.505 . . . . 60.12 111.109 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -120.04 161.79 14.32 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.795 -0.717 . . . . 42.44 112.534 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.8 p -159.93 147.34 6.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.923 0.392 . . . . 65.23 111.091 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -175.54 -155.9 13.66 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.748 -0.739 . . . . 70.32 112.475 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.471 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.2 p -107.28 133.49 51.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.864 0.364 . . . . 51.11 111.085 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -119.74 110.8 1.89 Allowed Glycine 0 N--CA 1.453 -0.227 0 C-N-CA 120.646 -0.788 . . . . 65.22 112.493 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . 0.724 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 11.8 ptm180 -111.78 122.22 47.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.903 0.382 . . . . 70.41 110.912 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.566 HG13 ' HD2' ' A' ' 144' ' ' LYS . 1.4 p -108.12 110.24 31.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.178 -0.465 . . . . 75.41 111.179 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.41 HD12 ' HB3' ' A' ' 143' ' ' ASP . 17.7 tp -116.84 167.19 11.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.116 -0.493 . . . . 71.22 110.931 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -150.94 178.93 8.68 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 73.42 110.885 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -107.36 144.82 33.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.143 -0.48 . . . . 74.02 110.868 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -81.78 95.41 7.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.458 . . . . 51.24 110.885 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 16.5 tppt? -110.37 -75.9 0.61 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.155 -0.475 . . . . 54.41 110.976 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . 0.484 HG23 ' HA ' ' A' ' 138' ' ' SER . 88.0 m -160.85 89.64 0.81 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.236 -0.438 . . . . 61.02 111.127 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . 0.612 ' OD1' HD12 ' A' ' 141' ' ' ILE . 15.8 t70 -102.86 162.72 12.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 75.12 110.863 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 67.4 156.93 0.68 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.774 -0.726 . . . . 71.51 112.473 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.931 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -77.54 1.43 19.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.881 0.372 . . . . 62.21 111.12 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -85.89 -178.16 6.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 64.2 110.922 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 16.6 t -67.71 85.72 0.21 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.131 -0.486 . . . . 72.31 110.914 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.484 ' HA ' HG23 ' A' ' 132' ' ' THR . 3.6 m 50.84 74.84 0.21 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.466 . . . . 74.02 110.887 -179.791 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -84.52 156.08 21.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.118 -0.492 . . . . 64.42 110.914 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -102.7 173.47 6.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.167 -0.469 . . . . 72.41 110.873 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.791 HG13 HG23 ' A' ' 176' ' ' VAL . 0.6 OUTLIER -153.94 144.11 14.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.258 -0.428 . . . . 62.11 111.126 -179.974 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . 0.439 ' HB2' ' HB3' ' A' ' 175' ' ' ASP . 19.8 tptt -91.03 118.02 30.05 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 73.41 110.905 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.41 ' HB3' HD12 ' A' ' 127' ' ' LEU . 0.8 OUTLIER -58.25 -168.74 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.26 -0.427 . . . . 64.03 110.887 179.823 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . 0.566 ' HD2' HG13 ' A' ' 126' ' ' VAL . 0.0 OUTLIER -137.59 154.59 49.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 74.32 110.822 -179.976 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 5.1 t90 -157.32 129.0 6.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 71.1 110.912 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.83 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -173.59 168.96 2.22 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.626 0.727 . . . . 55.43 111.107 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.83 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.7 Cg_endo -69.84 132.86 24.08 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.634 2.223 . . . . 31.22 112.346 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -120.29 166.27 13.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 64.43 111.115 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -123.58 137.11 54.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.29 -0.414 . . . . 73.32 110.891 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -114.35 145.55 41.66 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.111 -0.495 . . . . 74.02 110.891 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 58.5 t -143.42 120.49 5.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 62.44 111.086 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . 0.425 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 175.77 -171.98 45.01 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.713 -0.756 . . . . 73.35 112.481 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.5 pt? -131.17 161.19 32.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.847 0.356 . . . . 75.43 110.901 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.503 HH12 HG11 ' A' ' 18' ' ' VAL . 2.7 tpp85 -129.71 120.01 24.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 61.41 110.941 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 5.6 t80 -103.77 136.05 44.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.217 -0.447 . . . . 73.13 110.95 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -121.43 105.41 10.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.1 -0.5 . . . . 75.24 110.786 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 7.8 mt -94.74 162.88 13.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.162 -0.472 . . . . 55.34 110.926 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -97.94 36.55 3.9 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.783 -0.723 . . . . 63.54 112.534 179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 95.8 m-20 -123.91 35.99 4.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.832 0.349 . . . . 62.44 110.888 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 18.0 p 50.95 38.81 21.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 72.22 110.892 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 8.4 t-105 -165.05 107.13 0.82 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.158 -0.473 . . . . 61.24 110.909 179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.645 ' SD ' HG13 ' A' ' 203' ' ' VAL . 0.0 OUTLIER -99.1 170.54 8.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.205 -0.452 . . . . 53.12 110.885 179.89 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.573 HD22 ' O ' ' A' ' 162' ' ' MET . 4.5 mm? -129.13 145.21 51.35 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.21 -0.45 . . . . 64.24 110.849 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -144.27 133.42 22.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.131 -0.486 . . . . 51.4 110.865 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 50.7 p -145.89 120.7 9.91 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.188 -0.46 . . . . 64.23 110.891 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . 0.425 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.6 OUTLIER -153.3 175.85 12.63 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.089 -0.505 . . . . 75.34 110.897 180.0 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.521 HG22 HD13 ' A' ' 196' ' ' LEU . 21.7 t -138.12 133.34 43.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.457 . . . . 54.41 111.105 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . 0.563 HH21 HG21 ' A' ' 170' ' ' ILE . 2.1 ttt180 -109.16 125.01 51.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.095 -0.502 . . . . 65.24 110.865 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 13.7 p90 -128.99 146.79 50.88 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.172 -0.467 . . . . 72.44 110.929 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' ILE . . . . . 0.587 HD11 ' HB3' ' A' ' 146' ' ' ALA . 5.5 tt -176.8 97.77 0.24 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.557 0.694 . . . . 70.12 111.155 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 170' ' ' ILE . 53.5 Cg_endo -69.82 128.74 16.4 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.691 2.261 . . . . 74.31 112.3 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 11.6 p90 -155.08 178.96 9.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.245 -0.434 . . . . 72.02 110.863 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 13.3 pttp -130.32 140.98 50.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 64.21 110.871 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . 0.416 HG22 HG23 ' A' ' 189' ' ' ILE . 9.0 t -104.27 167.81 9.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 75.43 111.189 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . 0.439 ' HB3' ' HB2' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -119.38 159.72 23.66 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.27 -0.423 . . . . 64.32 110.849 179.908 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.791 HG23 HG13 ' A' ' 141' ' ' ILE . 13.7 p -144.76 135.74 20.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.122 -0.49 . . . . 62.11 111.088 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.8 t -166.36 159.44 14.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 74.03 111.156 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -146.13 -134.15 2.6 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.773 -0.727 . . . . 55.12 112.491 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 98.7 m -159.9 93.77 1.09 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.835 0.35 . . . . 52.04 111.169 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.525 ' H ' HD23 ' A' ' 180' ' ' LEU . 1.6 pt? -142.84 117.14 9.58 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.182 -0.463 . . . . 52.32 110.961 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 55.01 172.16 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.671 -0.776 . . . . 75.14 112.493 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.54 ' O ' ' HB ' ' A' ' 183' ' ' VAL . 54.6 Cg_endo -69.69 71.16 1.5 Allowed 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.699 2.266 . . . . 74.42 112.371 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.54 ' HB ' ' O ' ' A' ' 182' ' ' PRO . 2.5 p 158.13 84.19 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.635 0.731 . . . . 73.13 111.063 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.65 147.84 64.45 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.649 2.233 . . . . 53.35 112.392 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 23.8 t -95.45 106.37 18.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 75.21 111.161 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 83.2 p -110.16 120.22 41.74 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.177 -0.465 . . . . 63.44 110.894 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -140.54 176.37 8.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.125 -0.489 . . . . 72.1 111.082 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.39 162.48 40.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 74.12 110.918 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 189' ' ' ILE . . . . . 0.566 HD12 ' HA ' ' A' ' 32' ' ' LEU . 4.6 tt -146.04 120.91 2.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.256 -0.429 . . . . 74.02 111.121 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -96.67 118.16 32.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.157 -0.474 . . . . 65.43 110.871 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 191' ' ' VAL . . . . . 0.465 HG13 ' HB2' ' A' ' 30' ' ' GLU . 4.4 t -137.52 159.68 34.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 74.01 111.167 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.423 ' N ' HG12 ' A' ' 191' ' ' VAL . 0.4 OUTLIER -107.27 90.42 5.68 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.558 0.694 . . . . 74.41 110.869 179.918 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 138.09 37.05 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.61 2.207 . . . . 61.51 112.368 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 23.4 m-85 -121.96 109.67 14.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.179 -0.464 . . . . 50.22 110.925 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 195' ' ' ILE . . . . . 0.572 HG12 HG23 ' A' ' 26' ' ' VAL . 8.8 mt -105.25 135.03 45.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.157 -0.474 . . . . 53.55 111.171 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . 0.521 HD13 HG22 ' A' ' 167' ' ' VAL . 10.3 tp -120.57 115.43 23.4 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.093 -0.503 . . . . 54.43 110.957 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -99.26 129.25 45.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 61.44 110.907 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 32.8 tp -150.25 129.35 12.68 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.149 -0.478 . . . . 71.21 110.91 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 177.38 -146.67 7.83 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.801 -0.714 . . . . 62.32 112.536 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 200' ' ' ALA . . . . . 0.401 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -124.0 173.23 8.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.757 0.313 . . . . 65.12 111.101 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -138.35 164.78 28.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.452 . . . . 73.03 110.899 -179.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 34.1 m-85 -133.82 129.95 37.23 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.205 -0.452 . . . . 74.24 110.93 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.645 HG13 ' SD ' ' A' ' 162' ' ' MET . 28.0 m -77.36 148.28 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 73.44 111.207 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -152.34 105.96 3.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.278 -0.419 . . . . 75.15 110.886 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 14.2 ptmt -102.69 -179.68 4.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.15 -0.477 . . . . 64.55 110.939 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 206' ' ' LEU . . . . . 0.472 HD12 ' O ' ' A' ' 206' ' ' LEU . 0.8 OUTLIER -110.68 159.82 17.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.285 -0.416 . . . . 73.51 110.877 179.993 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -62.62 -68.34 0.34 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.46 . . . . 62.43 111.109 179.79 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -146.21 140.66 26.74 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.201 -0.454 . . . . 44.42 111.098 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -149.38 150.25 32.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.264 -0.425 . . . . 60.11 111.048 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . 0.527 ' H ' HD23 ' A' ' 210' ' ' LEU . 1.2 pt? -112.17 147.74 35.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 61.03 110.934 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.204 -0.453 . . . . 63.11 110.855 179.933 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.4 ptt? . . . . . 0 C--O 1.229 0.016 0 CA-C-O 120.81 0.338 . . . . 63.24 110.895 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 9.2 p-10 -166.57 160.18 14.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 74.43 110.897 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 24.6 mp0 -150.25 153.77 36.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 44.35 110.863 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -115.62 104.56 11.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.143 -0.48 . . . . 74.11 110.899 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -116.69 160.5 36.26 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-O 121.716 0.769 . . . . 75.15 110.874 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 175.67 7.79 Favored 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.665 2.244 . . . . 75.4 112.37 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -87.25 111.18 20.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.454 . . . . 60.51 111.059 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 16.9 tptt -94.08 -36.57 12.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.25 -0.432 . . . . 75.01 110.89 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.63 ' CB ' HG11 ' A' ' 203' ' ' VAL . 8.4 t 62.84 36.86 12.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.255 -0.429 . . . . 72.31 110.851 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -75.06 -35.25 61.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.148 -0.478 . . . . 71.55 111.109 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -167.38 -145.82 4.65 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.775 -0.726 . . . . 54.34 112.487 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 16.4 p90 -161.67 121.0 2.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.92 0.391 . . . . 75.11 110.93 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -132.02 175.0 9.6 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.096 -0.502 . . . . 71.4 110.921 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.34 134.88 53.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 75.42 110.953 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.73 6.48 76.5 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.758 -0.734 . . . . 52.43 112.487 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -76.89 144.9 38.63 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.837 0.351 . . . . 73.42 110.838 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 13.5 t90 -106.44 150.93 25.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 71.2 110.919 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.581 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 22.1 t -145.59 125.82 6.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.242 -0.435 . . . . 74.2 111.131 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -109.76 112.4 24.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 55.43 111.075 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 201' ' ' SER . 60.2 p -124.42 146.57 48.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 73.22 110.837 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 15.1 p90 -127.19 122.52 34.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.111 -0.495 . . . . 72.11 110.827 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -146.89 158.28 43.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.159 -0.473 . . . . 75.41 110.869 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.803 ' HB3' HD23 ' A' ' 55' ' ' LEU . 29.4 p90 -93.69 133.57 36.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.143 -0.481 . . . . 72.23 110.886 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -98.89 114.57 27.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.47 . . . . 61.52 110.843 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.1 tppt? -92.68 108.24 19.83 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.041 -0.527 . . . . 70.22 110.874 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.455 HG23 ' CD1' ' A' ' 195' ' ' ILE . 14.2 p -87.01 140.69 15.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.236 -0.438 . . . . 72.41 111.057 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 41.3 m-85 -134.36 112.85 11.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.111 -0.495 . . . . 73.2 110.959 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 m -72.65 -176.9 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.092 -0.504 . . . . 74.43 111.182 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -93.84 -125.16 4.06 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.748 -0.739 . . . . 54.43 112.465 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -92.37 -66.39 0.93 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.771 0.32 . . . . 62.43 110.861 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.5 mp0 -150.23 -174.21 4.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.155 -0.475 . . . . 63.32 110.877 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.562 ' HA ' HG23 ' A' ' 189' ' ' ILE . 3.4 pp -86.32 -173.33 4.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 63.5 110.909 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -79.35 65.06 3.69 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.722 -0.751 . . . . 61.1 112.491 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -90.58 51.7 2.05 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.872 0.368 . . . . 63.23 110.866 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.487 ' O ' HD12 ' A' ' 35' ' ' LEU . 1.1 pp -137.94 47.81 2.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 63.44 110.98 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 38.8 t30 -85.86 129.49 34.82 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 55.31 110.919 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.3 p -61.34 131.52 26.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.178 -0.465 . . . . 72.42 111.13 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.85 -141.29 9.57 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.717 -0.754 . . . . 73.44 112.44 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -111.0 75.92 0.22 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.69 -0.767 . . . . 51.34 112.49 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -81.03 -150.9 7.55 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.803 -0.713 . . . . 71.15 112.477 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -118.64 168.29 10.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.884 0.373 . . . . 73.53 110.991 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.492 ' N ' ' HD2' ' A' ' 43' ' ' PRO . 0.7 OUTLIER -59.89 -60.54 10.28 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.624 0.726 . . . . 61.23 110.908 -179.967 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.492 ' HD2' ' N ' ' A' ' 42' ' ' LEU . 54.0 Cg_endo -69.71 170.25 16.94 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.737 2.291 . . . . 63.51 112.347 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -119.19 165.11 14.62 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.247 -0.433 . . . . 65.04 110.905 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.408 ' HB1' HD21 ' A' ' 32' ' ' LEU . . . -73.86 -175.78 2.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.21 -0.45 . . . . 65.13 111.139 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -166.33 125.75 1.58 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 75.43 110.897 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 98.7 t -105.65 131.51 54.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 73.22 111.069 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.5 m -159.4 151.36 20.7 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.138 -0.483 . . . . 75.55 110.803 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 20.0 pt -100.71 157.61 4.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.082 -0.508 . . . . 74.14 111.119 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -72.02 -146.78 0.59 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.737 -0.744 . . . . 72.54 112.508 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -126.1 111.16 14.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.881 0.372 . . . . 73.32 110.88 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -164.01 159.06 20.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.13 -0.487 . . . . 65.24 110.862 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 16.4 p -125.88 123.99 39.88 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 71.43 111.154 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.0 p -137.4 139.33 40.65 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.176 -0.465 . . . . 60.54 111.076 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.803 HD23 ' HB3' ' A' ' 23' ' ' PHE . 2.5 mt -99.11 153.95 18.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.454 . . . . 72.11 110.921 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 6.1 p -123.26 161.38 24.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.289 -0.414 . . . . 73.24 111.172 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -105.56 133.36 50.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 73.12 110.861 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -124.04 130.06 51.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 54.34 110.867 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.4 ' O ' HG22 ' A' ' 59' ' ' ILE . 1.6 mp -107.24 114.0 45.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.478 . . . . 72.43 111.101 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.581 ' HB3' ' HB ' ' A' ' 18' ' ' VAL . . . -104.13 137.88 41.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.454 . . . . 72.22 111.128 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.427 ' HB2' HG13 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -123.28 121.98 37.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.279 -0.418 . . . . 73.42 110.893 -179.835 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -89.01 102.26 14.9 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.111 -0.495 . . . . 65.44 110.892 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.1 m -100.84 -33.4 3.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.105 -0.498 . . . . 72.31 111.125 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.9 t -136.23 158.6 44.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.189 -0.46 . . . . 64.01 110.838 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 47.0 t -83.56 3.21 33.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.102 -0.499 . . . . 75.23 110.848 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 47.6 t30 -115.69 -30.6 6.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 63.32 110.885 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.593 HG22 ' HB2' ' A' ' 107' ' ' TYR . 43.5 pt -138.23 157.48 31.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.132 -0.486 . . . . 75.25 111.127 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -145.33 157.65 44.0 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.154 -0.475 . . . . 71.13 111.046 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.497 ' CG2' HD21 ' A' ' 103' ' ' LEU . 1.4 p -106.96 145.93 13.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.15 -0.477 . . . . 64.2 111.145 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -140.54 128.01 21.36 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.209 -0.45 . . . . 73.45 110.897 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -108.65 110.43 21.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.259 -0.428 . . . . 74.32 110.919 -179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -87.95 115.42 25.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.228 -0.442 . . . . 74.24 110.907 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 8.9 m -139.59 156.76 26.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 72.24 111.109 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -164.55 142.37 7.72 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.75 -0.738 . . . . 73.04 112.501 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.4 t -118.64 66.21 6.91 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.551 0.691 . . . . 55.2 111.145 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 161.89 44.16 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.758 2.305 . . . . 61.02 112.349 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -78.73 -173.21 3.34 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 31.4 111.092 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 18.1 ttp180 -78.27 132.73 37.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 63.1 110.924 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -131.54 150.8 52.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.223 -0.444 . . . . 60.44 111.074 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 7.3 tttt -109.37 134.08 52.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.3 -0.409 . . . . 65.22 110.911 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -134.51 158.66 43.37 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.247 -0.433 . . . . 63.31 110.902 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -91.32 156.18 17.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.112 -0.495 . . . . 75.32 110.857 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.577 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -176.12 65.14 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.803 -0.713 . . . . 75.23 112.513 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -174.29 -174.79 0.91 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.93 0.395 . . . . 63.33 110.882 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -85.5 -70.04 0.62 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.147 -0.478 . . . . 61.12 110.855 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 32.1 t -84.83 -32.18 23.44 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.26 -0.427 . . . . 63.44 110.808 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.946 HG21 ' HB2' ' A' ' 135' ' ' ALA . 5.4 mm -66.58 -34.04 67.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.157 -0.474 . . . . 71.44 111.181 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 t -63.11 -41.21 99.31 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.164 -0.471 . . . . 43.03 110.812 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 61.7 m -60.68 -36.98 80.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.183 -0.462 . . . . 74.03 110.862 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.4 mp -64.14 -50.25 68.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.12 -0.491 . . . . 70.15 110.934 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 116.35 -14.25 15.71 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.754 -0.736 . . . . 63.42 112.482 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 58.4 mtm180 -115.06 89.87 3.2 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.889 0.376 . . . . 73.44 110.809 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.873 HG22 HG22 ' A' ' 87' ' ' ILE . 98.5 t -113.67 -53.25 5.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 70.14 111.137 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 13.3 m -139.28 143.47 37.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 63.42 110.887 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . 0.577 ' O ' HG13 ' A' ' 96' ' ' VAL . 1.7 tt0 -145.19 114.3 6.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.465 . . . . 62.42 110.928 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.577 HG13 ' O ' ' A' ' 95' ' ' GLU . 11.8 m -160.45 -178.17 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 50.22 111.116 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -98.65 149.13 23.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 54.03 110.831 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -93.16 125.66 37.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 75.44 110.957 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -119.42 63.16 0.46 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.749 -0.739 . . . . 62.35 112.501 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.67 122.53 9.24 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.687 2.258 . . . . 64.42 112.392 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.601 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -139.22 97.87 3.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.185 -0.461 . . . . 74.31 111.101 179.838 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . . . . . . . . . 5.3 mp -129.18 117.56 43.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 72.41 111.157 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.662 HD13 ' O ' ' A' ' 103' ' ' LEU . 0.9 OUTLIER -113.71 112.98 24.35 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.228 -0.442 . . . . 60.32 110.948 179.905 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.583 ' N ' HD22 ' A' ' 103' ' ' LEU . 3.5 p -140.51 165.11 28.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.446 . . . . 73.22 110.822 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.428 ' H ' HD23 ' A' ' 105' ' ' LEU . 1.0 OUTLIER -112.76 142.23 45.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.069 -0.514 . . . . 74.11 110.933 179.963 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 16.0 pt20 -101.4 151.5 21.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.166 -0.47 . . . . 75.32 110.92 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.593 ' HB2' HG22 ' A' ' 67' ' ' ILE . 5.1 t80 -149.69 135.8 18.88 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.249 -0.432 . . . . 75.53 110.962 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 10.6 t60 -65.69 105.15 1.18 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.114 -0.494 . . . . 71.54 110.817 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.42 ' HB2' HG12 ' A' ' 119' ' ' VAL . 43.8 t80 -110.17 115.7 30.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.173 -0.467 . . . . 71.22 110.874 -179.823 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -163.98 165.9 22.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.082 -0.508 . . . . 54.52 110.851 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 20.9 m -82.87 -46.32 13.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 65.11 110.853 -179.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 3.1 p90 -138.36 156.96 47.12 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 73.31 110.883 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -52.32 108.61 0.31 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 54.11 110.859 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 4.4 tpt180 -160.18 160.67 33.1 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.096 -0.502 . . . . 62.12 110.89 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -70.08 98.85 1.37 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 74.23 110.917 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 26.0 m-85 -148.41 159.06 39.9 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-O 121.737 0.78 . . . . 74.11 110.903 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.69 176.86 6.15 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.678 2.252 . . . . 70.25 112.353 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -116.47 150.54 37.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.202 -0.454 . . . . 74.11 110.978 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.42 HG12 ' HB2' ' A' ' 109' ' ' TYR . 13.1 p -104.01 133.94 46.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 73.15 111.093 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -132.09 160.2 23.55 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.749 -0.739 . . . . 51.21 112.504 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 7.5 p -156.57 154.73 5.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.874 0.369 . . . . 63.31 111.157 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 178.76 -147.11 7.65 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.777 -0.725 . . . . 65.0 112.489 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 13.8 p -106.57 131.56 56.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.881 0.372 . . . . 72.12 111.093 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -124.29 111.62 1.64 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.749 -0.738 . . . . 43.44 112.508 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . 0.601 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 29.0 ptt180 -114.51 130.13 56.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.774 0.321 . . . . 72.15 110.895 -179.844 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.461 ' O ' ' HB3' ' A' ' 143' ' ' ASP . 3.1 m -111.37 112.66 41.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.237 -0.438 . . . . 71.04 111.091 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 1.3 tp -114.86 171.59 7.56 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.202 -0.454 . . . . 71.4 110.925 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -140.03 178.88 6.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.174 -0.466 . . . . 65.33 110.841 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -117.72 119.4 34.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.144 -0.48 . . . . 73.4 110.906 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -51.89 102.34 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.14 -0.482 . . . . 73.51 110.846 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -129.86 -80.84 0.55 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 72.01 110.889 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 45.8 m -164.54 89.78 0.53 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 74.32 111.168 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -107.59 172.61 6.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.231 -0.44 . . . . 75.11 110.886 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.53 152.89 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.706 -0.759 . . . . 74.04 112.501 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.946 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -79.42 -1.97 39.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.809 0.338 . . . . 64.41 111.04 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -87.2 -177.52 6.01 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.245 -0.434 . . . . 62.34 110.929 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.7 m -66.57 98.12 0.48 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 72.25 110.88 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 89.4 p 46.79 75.17 0.13 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.125 -0.489 . . . . 65.22 110.794 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.64 ' CE2' HG12 ' A' ' 176' ' ' VAL . 1.5 t80 -89.02 148.26 23.84 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.086 -0.506 . . . . 72.1 110.867 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.18 159.76 15.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.139 -0.482 . . . . 70.54 110.818 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -126.9 118.26 50.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 73.33 111.155 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . 0.43 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 1.6 mtpp -69.13 110.84 4.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 72.53 110.843 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.461 ' HB3' ' O ' ' A' ' 126' ' ' VAL . 61.2 m-20 -57.66 -173.44 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 73.4 110.888 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.39 162.53 39.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 64.52 110.906 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 31.1 p-90 -156.47 137.96 14.01 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.217 -0.447 . . . . 63.31 110.896 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.803 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -178.44 167.51 1.01 Allowed Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.603 0.716 . . . . 73.11 111.083 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.803 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.5 Cg_endo -69.79 138.62 38.15 Favored 'Trans proline' 0 N--CA 1.465 -0.171 0 C-N-CA 122.712 2.275 . . . . 70.22 112.31 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.572 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -132.85 165.16 25.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.181 -0.463 . . . . 74.43 111.117 179.856 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -123.27 126.18 46.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.192 -0.458 . . . . 73.23 110.895 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 28.6 tt0 -110.12 155.3 22.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 72.02 110.889 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.575 HG13 HG23 ' A' ' 167' ' ' VAL . 4.6 p -144.58 125.73 8.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 71.51 111.138 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . 0.436 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . -176.36 -167.68 35.43 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.728 -0.749 . . . . 75.0 112.474 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 2.1 pp -143.87 161.03 39.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.765 0.317 . . . . 75.31 110.923 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 7.6 tpp85 -117.21 119.49 35.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 64.41 110.852 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.1 t80 -100.13 139.42 35.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.146 -0.479 . . . . 71.41 110.885 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -111.85 92.4 4.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 74.23 110.876 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 3.0 tt -86.27 97.02 10.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 63.52 110.953 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 58.77 -138.35 49.49 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.704 -0.76 . . . . 74.54 112.536 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -119.74 -30.35 4.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.878 0.37 . . . . 71.41 110.886 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -48.86 -66.72 0.35 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 73.33 110.878 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 23.7 p90 -145.73 150.92 37.15 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.151 -0.477 . . . . 71.41 110.904 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 2.4 mpt? -108.63 177.57 4.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 44.55 110.858 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 3.8 tp -126.12 149.15 49.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.232 -0.44 . . . . 75.33 110.916 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 13.8 t-20 -143.9 131.51 21.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 72.54 110.858 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 2.5 p -141.48 124.41 16.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.179 -0.464 . . . . 52.34 110.871 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . 0.436 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 2.3 p30 -156.11 169.69 23.92 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.138 -0.483 . . . . 74.2 110.878 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.575 HG23 HG13 ' A' ' 151' ' ' VAL . 0.1 OUTLIER -142.4 134.04 25.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.182 -0.463 . . . . 75.04 111.119 179.972 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.61 142.56 33.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 72.3 110.886 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 4.3 t80 -142.0 137.65 31.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 73.34 110.889 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' ILE . . . . . 0.572 HG21 ' HB2' ' A' ' 148' ' ' ALA . 2.9 tp -177.47 102.25 0.22 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.628 0.728 . . . . 75.54 111.08 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 192' ' ' ASP . 53.9 Cg_endo -69.75 125.27 11.95 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.696 2.264 . . . . 42.55 112.364 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 24.7 p90 -150.93 178.04 9.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 74.22 110.9 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . 0.433 ' HA ' ' HA ' ' A' ' 190' ' ' GLU . 9.7 ptpt -130.85 126.52 36.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 74.2 110.879 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 14.6 t -93.59 175.26 6.81 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.236 -0.438 . . . . 73.41 111.143 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . 0.43 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.3 OUTLIER -126.81 163.71 22.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.254 -0.43 . . . . 74.21 110.844 179.906 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.64 HG12 ' CE2' ' A' ' 139' ' ' PHE . 32.7 t -148.84 133.28 9.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.223 -0.444 . . . . 74.01 111.143 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.4 t -165.58 177.69 7.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.216 -0.447 . . . . 75.24 111.173 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 121.68 141.52 6.12 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.72 -0.753 . . . . 42.44 112.485 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.4 m -172.55 141.28 1.12 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.737 0.303 . . . . 73.51 111.195 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 29.9 tp -104.87 89.18 3.08 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.287 -0.415 . . . . 72.25 110.988 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 125.2 -85.73 0.36 Allowed Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.746 -0.74 . . . . 43.11 112.458 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 -170.56 0.4 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.681 2.254 . . . . 71.2 112.36 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 26.6 m -84.47 126.4 69.22 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.576 0.703 . . . . 62.32 111.193 179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 165.59 30.41 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.688 2.259 . . . . 65.5 112.35 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 39.6 t -113.38 107.68 23.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.276 -0.42 . . . . 74.14 111.145 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -81.33 106.72 13.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.161 -0.472 . . . . 72.34 110.835 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 21.0 p -121.38 174.7 6.58 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.108 -0.496 . . . . 55.43 111.104 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 188' ' ' LYS . . . . . 0.486 ' C ' HD12 ' A' ' 189' ' ' ILE . 0.0 OUTLIER -148.55 164.03 35.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.194 -0.457 . . . . 73.52 110.872 179.925 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 189' ' ' ILE . . . . . 0.562 HG23 ' HA ' ' A' ' 32' ' ' LEU . 5.4 mp -144.03 105.8 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 74.24 111.129 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 190' ' ' GLU . . . . . 0.433 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 61.4 tt0 -91.0 102.08 14.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.449 . . . . 73.11 110.869 179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 9.3 m -138.68 164.08 26.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.458 . . . . 61.01 111.156 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.43 ' HA ' ' HA ' ' A' ' 171' ' ' PRO . 6.6 p-10 -110.04 88.65 7.18 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.582 0.706 . . . . 75.3 110.867 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 143.28 50.53 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.704 2.269 . . . . 64.34 112.338 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 5.5 t80 -119.8 123.69 44.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 62.51 110.882 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 195' ' ' ILE . . . . . 0.455 ' CD1' HG23 ' A' ' 26' ' ' VAL . 18.6 mm -109.03 132.06 58.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.147 -0.479 . . . . 62.31 111.171 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 4.6 tp -120.68 108.25 13.78 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.246 -0.433 . . . . 71.31 110.962 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.41 120.14 35.13 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.239 -0.437 . . . . 60.2 110.919 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -139.4 124.29 18.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.468 . . . . 73.42 110.988 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -176.9 -148.54 7.19 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.737 -0.745 . . . . 45.54 112.494 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 200' ' ' ALA . . . . . . . . . . . . . . . -115.82 171.04 8.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.812 0.339 . . . . 40.14 111.108 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 20' ' ' SER . 0.3 OUTLIER -138.49 156.81 47.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.434 . . . . 65.12 110.806 -179.73 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 8.2 t80 -138.07 135.6 35.99 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.132 -0.485 . . . . 75.13 110.958 -179.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.63 HG11 ' CB ' ' A' ' 9' ' ' SER . 14.9 p -77.36 147.46 7.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.08 -0.509 . . . . 64.02 111.179 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -144.57 88.01 1.9 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.16 -0.473 . . . . 73.43 110.872 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 23.1 mtmt -70.46 166.84 19.57 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 70.41 110.902 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 14.5 tp -99.19 -41.21 7.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 60.04 110.872 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -141.95 138.05 31.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.209 -0.451 . . . . 72.25 111.065 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -104.11 -36.26 7.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.23 -0.441 . . . . 63.45 111.122 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -148.63 157.31 43.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.209 -0.45 . . . . 43.12 111.061 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 3.9 tt -151.69 115.46 4.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 75.14 110.922 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 116.127 -0.488 . . . . 65.14 110.898 179.926 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.037 0 CA-C-O 120.81 0.338 . . . . 61.12 110.862 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 20.7 p30 40.47 40.04 0.81 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 70.22 110.917 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -78.03 123.71 27.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 73.52 110.88 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 -134.85 166.35 23.18 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 71.21 110.846 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 8.9 p90 -134.41 157.56 77.14 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.695 0.76 . . . . 74.22 110.868 -179.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 142.62 48.33 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.58 2.186 . . . . 63.22 112.334 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -67.48 113.07 5.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 72.4 111.139 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 21.9 ttpp -77.5 135.03 38.19 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.216 -0.447 . . . . 74.14 110.881 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 4.9 t -138.15 145.73 41.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.262 -0.426 . . . . 61.31 110.891 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.612 ' HB1' ' OD1' ' A' ' 13' ' ' ASN . . . -65.23 -58.18 6.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.066 -0.515 . . . . 72.4 111.195 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.56 -70.68 2.35 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.759 -0.734 . . . . 74.1 112.504 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.2 p90 -156.13 115.62 3.56 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.882 0.372 . . . . 74.23 110.889 -179.799 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.612 ' OD1' ' HB1' ' A' ' 10' ' ' ALA . 17.2 m120 -128.26 158.13 39.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.459 . . . . 71.53 110.904 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -56.22 121.68 10.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.181 -0.463 . . . . 75.33 110.923 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.37 6.22 41.95 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.706 -0.759 . . . . 65.52 112.491 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -61.81 146.12 50.51 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.817 0.341 . . . . 64.43 110.829 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 19.8 t90 -111.47 121.19 44.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.09 -0.504 . . . . 71.3 110.947 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.817 HG22 HG23 ' A' ' 203' ' ' VAL . 57.2 t -123.4 120.17 59.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.242 -0.435 . . . . 64.4 111.121 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.623 ' HB3' ' CD1' ' A' ' 202' ' ' TYR . . . -86.8 112.35 21.63 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 43.41 111.127 179.849 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 11.1 t -109.03 110.0 21.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.236 -0.438 . . . . 61.35 110.874 -179.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.404 ' CZ ' HD12 ' A' ' 55' ' ' LEU . 43.5 t80 -107.64 120.01 41.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.477 . . . . 70.41 110.919 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.445 ' HA ' ' HA3' ' A' ' 199' ' ' GLY . 7.4 p30 -149.86 174.87 12.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.442 . . . . 72.55 110.91 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.648 ' HB3' HD13 ' A' ' 55' ' ' LEU . 19.1 p90 -110.83 132.9 53.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 54.13 110.861 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . 0.445 ' HB3' HG21 ' A' ' 56' ' ' THR . 41.9 p -98.18 146.18 25.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 63.21 110.894 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.4 tmtp? -127.25 106.52 9.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 61.43 110.904 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.8 m -77.31 129.7 37.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.245 -0.434 . . . . 64.31 111.128 179.842 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -126.4 107.78 10.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.126 -0.488 . . . . 74.14 110.956 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.8 p -175.71 153.79 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.485 . . . . 73.32 111.079 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.43 71.68 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.778 -0.725 . . . . 70.34 112.54 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -89.14 -65.87 0.98 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.807 0.337 . . . . 72.31 110.895 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -174.99 152.44 1.49 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.106 -0.497 . . . . 71.34 110.855 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.618 HD23 ' N ' ' A' ' 33' ' ' GLY . 0.8 OUTLIER -96.11 162.32 13.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.163 -0.471 . . . . 73.22 110.909 -179.99 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.618 ' N ' HD23 ' A' ' 32' ' ' LEU . . . -53.67 101.9 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.761 -0.733 . . . . 72.34 112.434 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -64.77 -69.84 0.26 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.909 0.385 . . . . 70.55 110.894 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 4.5 tp -81.03 147.56 30.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.138 -0.483 . . . . 70.1 110.982 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 -128.87 149.54 50.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.182 -0.463 . . . . 65.33 110.864 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 30.6 m -51.53 -35.37 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.206 -0.452 . . . . 61.53 111.094 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -136.87 131.56 5.66 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.768 -0.73 . . . . 52.23 112.518 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 126.64 153.86 8.44 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.753 -0.737 . . . . 61.45 112.475 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -87.13 110.9 3.6 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.681 -0.771 . . . . 64.23 112.469 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -118.84 -179.26 3.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.784 0.326 . . . . 70.41 111.089 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.542 ' N ' ' HD2' ' A' ' 43' ' ' PRO . 0.2 OUTLIER 177.47 -57.6 0.0 OUTLIER Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.571 0.701 . . . . 72.34 110.923 179.999 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.542 ' HD2' ' N ' ' A' ' 42' ' ' LEU . 54.1 Cg_endo -69.78 152.21 69.17 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.668 2.245 . . . . 70.14 112.35 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 6.5 m120 -86.5 139.85 30.49 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.2 -0.454 . . . . 74.13 110.938 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.9 169.33 11.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 61.04 111.084 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 35.8 m-20 -153.64 127.24 8.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.238 -0.437 . . . . 71.03 110.828 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 10.8 p -104.52 137.52 33.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 70.02 111.171 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.0 t -148.45 154.87 40.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.094 -0.503 . . . . 74.1 110.835 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.471 HD13 ' H ' ' A' ' 49' ' ' ILE . 0.2 OUTLIER -119.62 154.67 22.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.087 -0.506 . . . . 70.43 111.1 179.939 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.39 -124.59 0.56 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.751 -0.738 . . . . 75.21 112.444 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 38.9 m-20 -82.41 -35.61 27.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.87 0.367 . . . . 74.32 110.911 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 41.9 40.03 1.44 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 71.41 110.85 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 1.4 p -108.37 113.09 25.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 65.03 111.158 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.5 t -154.35 173.95 15.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.136 -0.484 . . . . 61.24 111.139 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.648 HD13 ' HB3' ' A' ' 23' ' ' PHE . 4.2 mm? -92.55 169.11 10.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.248 -0.433 . . . . 60.22 110.924 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.445 HG21 ' HB3' ' A' ' 24' ' ' SER . 18.6 p -149.36 141.54 24.02 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.172 -0.467 . . . . 75.12 111.113 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -103.27 132.82 49.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 73.12 110.861 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -130.63 130.12 43.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.159 -0.473 . . . . 43.53 110.84 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.41 ' O ' HG22 ' A' ' 59' ' ' ILE . 1.6 mp -108.08 112.94 42.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.196 -0.456 . . . . 74.31 111.077 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -102.76 121.69 42.97 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.206 -0.452 . . . . 75.53 111.076 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -106.85 122.72 46.97 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 73.12 110.93 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -88.89 107.22 18.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.17 -0.468 . . . . 65.14 110.908 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 63.8 t -103.24 -48.13 10.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.157 -0.474 . . . . 70.41 111.097 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 40.2 t -124.38 165.99 16.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 54.22 110.854 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.1 m -87.43 2.71 49.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.087 -0.506 . . . . 73.31 110.837 -179.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -112.99 -33.68 5.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.084 -0.507 . . . . 74.32 110.936 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.405 HG22 ' CD1' ' A' ' 107' ' ' TYR . 31.4 pt -146.12 160.22 11.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.48 . . . . 62.4 111.081 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -146.57 173.4 12.35 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 70.34 111.112 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.483 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 14.4 m -115.16 152.13 16.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.255 -0.429 . . . . 64.32 111.163 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -144.13 144.43 31.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.251 -0.431 . . . . 53.43 110.834 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.445 ' CZ ' HD22 ' A' ' 103' ' ' LEU . 0.5 OUTLIER -120.74 110.14 16.01 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.157 -0.474 . . . . 73.11 110.914 -179.949 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.405 ' HB3' HG23 ' A' ' 102' ' ' ILE . 2.5 t80 -92.6 117.84 30.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 53.12 110.896 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.4 p -150.26 154.61 8.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.161 -0.472 . . . . 65.05 111.117 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -155.56 150.95 22.52 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.691 -0.766 . . . . 73.43 112.452 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 5.8 m -118.2 67.05 6.45 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.587 0.708 . . . . 63.14 111.11 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.69 159.48 53.28 Favored 'Trans proline' 0 N--CA 1.465 -0.16 0 C-N-CA 122.767 2.312 . . . . 65.43 112.35 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -83.39 -167.96 1.91 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.211 -0.45 . . . . 51.45 111.108 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -77.74 127.52 32.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 71.52 110.852 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -123.87 150.62 44.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.245 -0.434 . . . . 74.2 111.166 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 5.4 ttpm? -104.19 144.85 31.04 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.213 -0.449 . . . . 74.14 110.887 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -142.0 155.0 45.43 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.269 -0.423 . . . . 72.3 110.923 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.427 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 0.2 OUTLIER -107.18 151.57 25.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.12 -0.491 . . . . 73.51 110.943 -179.942 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.637 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -175.86 75.86 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.707 -0.759 . . . . 62.43 112.41 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -178.52 -176.33 0.48 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.94 0.4 . . . . 64.23 110.881 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -85.41 -69.71 0.64 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.192 -0.458 . . . . 74.13 110.88 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 75.3 m -84.58 -34.09 23.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.435 . . . . 41.4 110.886 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.943 HG21 ' HB2' ' A' ' 135' ' ' ALA . 5.2 mm -64.06 -34.75 70.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 72.2 111.146 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 78.8 p -62.61 -49.09 76.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.471 . . . . 64.03 110.818 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 41.6 t -51.72 -36.89 48.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.102 -0.499 . . . . 61.14 110.786 -179.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -68.55 -46.39 69.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 61.24 110.881 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.67 -12.76 38.9 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.751 -0.738 . . . . 44.4 112.529 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 21.1 mmt85 -108.87 88.69 2.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.827 0.346 . . . . 74.12 110.875 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.85 HG22 HG22 ' A' ' 87' ' ' ILE . 99.0 t -113.91 -52.87 5.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 43.22 111.044 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.401 ' HA ' ' HA ' ' A' ' 133' ' ' ASP . 8.5 p -139.85 144.5 37.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 73.32 110.924 -179.828 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -149.7 119.53 7.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 72.12 110.896 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.722 HG23 ' HB2' ' A' ' 131' ' ' LYS . 3.8 p -177.65 163.84 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.163 -0.471 . . . . 72.4 111.154 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -76.29 163.66 26.81 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.218 -0.447 . . . . 73.11 110.881 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 2.6 m-85 -114.21 139.55 49.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.184 -0.462 . . . . 73.53 110.881 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -117.92 65.94 0.36 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.754 -0.736 . . . . 44.24 112.428 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 115.34 4.05 Favored 'Trans proline' 0 C--N 1.341 0.134 0 C-N-CA 122.682 2.255 . . . . 73.43 112.313 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -139.08 119.88 14.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 73.24 111.103 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.406 ' HA ' ' HA2' ' A' ' 124' ' ' GLY . 0.0 OUTLIER -155.2 136.2 5.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 62.45 111.104 179.913 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.445 HD22 ' CZ ' ' A' ' 71' ' ' PHE . 0.3 OUTLIER -119.69 124.2 45.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.103 -0.499 . . . . 72.03 110.924 179.942 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.425 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 72.3 m -143.69 159.38 42.58 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.177 -0.465 . . . . 53.23 110.874 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.535 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.6 OUTLIER -106.85 152.05 24.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.118 -0.492 . . . . 64.33 110.851 -179.912 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 75.7 mt-30 -101.69 140.36 36.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 74.52 110.857 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.405 ' CD1' HG22 ' A' ' 67' ' ' ILE . 0.3 OUTLIER -122.65 110.73 15.89 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.12 -0.491 . . . . 74.34 110.953 -179.814 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 -101.36 161.3 13.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.153 -0.476 . . . . 71.43 110.835 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 2.2 t80 -113.78 177.35 4.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.228 -0.442 . . . . 74.55 110.922 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -107.36 126.98 53.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.136 -0.484 . . . . 64.12 110.858 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 179.78 149.8 0.33 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 54.52 110.841 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -95.68 -74.8 0.54 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.147 -0.479 . . . . 74.24 110.887 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -71.35 143.5 50.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.159 -0.473 . . . . 74.44 110.91 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 23.7 ttt180 53.11 62.02 2.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.159 -0.473 . . . . 65.32 110.856 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 29.2 tp -63.94 94.34 0.1 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 72.12 110.904 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -60.45 160.57 17.58 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.642 0.734 . . . . 71.43 110.981 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 176.96 6.06 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.684 2.256 . . . . 74.03 112.309 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 15.7 p90 -111.08 154.12 24.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.474 . . . . 72.22 110.91 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.3 p -113.75 131.43 65.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 75.14 111.153 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -124.14 168.0 16.36 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.626 -0.797 . . . . 72.31 112.475 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 8.4 p -171.99 153.4 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.886 0.374 . . . . 71.11 111.131 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.425 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -178.26 -152.16 10.04 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.732 -0.747 . . . . 60.21 112.459 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.44 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 12.1 p -107.72 134.57 49.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.786 0.326 . . . . 72.42 111.182 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . 0.406 ' HA2' ' HA ' ' A' ' 102' ' ' ILE . . . -121.87 172.52 15.52 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.709 -0.758 . . . . 72.42 112.553 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 12.3 ptm180 -169.69 130.07 1.02 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.816 0.341 . . . . 65.51 110.904 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 4.0 p -110.18 120.46 61.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.196 -0.456 . . . . 75.41 111.131 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 5.7 mp -109.42 149.77 29.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.166 -0.47 . . . . 74.13 110.949 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.553 ' HE2' HG21 ' A' ' 174' ' ' THR . 20.9 m-85 -131.97 152.6 51.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.255 -0.43 . . . . 74.24 110.872 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.683 ' O ' HG21 ' A' ' 96' ' ' VAL . 1.0 OUTLIER -102.61 175.09 5.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.087 -0.506 . . . . 64.14 110.851 -179.882 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.6 p-10 -110.66 95.51 5.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.166 -0.47 . . . . 72.32 110.888 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.722 ' HB2' HG23 ' A' ' 96' ' ' VAL . 9.5 tmtt? -119.35 -68.17 0.93 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 63.31 110.941 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 2.7 m -161.68 63.75 0.25 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.246 -0.434 . . . . 73.42 111.189 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . 0.401 ' HA ' ' HA ' ' A' ' 94' ' ' SER . 4.4 m-20 -93.04 163.76 13.53 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.235 -0.439 . . . . 72.4 110.882 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 64.25 150.92 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.699 -0.763 . . . . 73.23 112.448 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.943 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -79.66 2.26 23.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.861 0.362 . . . . 75.05 111.115 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.606 HD12 HD22 ' A' ' 180' ' ' LEU . 1.4 mm? -86.09 -176.64 6.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.441 . . . . 73.03 110.916 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.699 ' OG ' HD13 ' A' ' 180' ' ' LEU . 89.0 p -64.93 88.91 0.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 54.51 110.867 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 7.6 m 49.88 76.17 0.15 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.147 -0.479 . . . . 70.41 110.853 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -93.66 159.27 15.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.1 -0.5 . . . . 71.22 110.913 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -117.64 170.6 8.64 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.193 -0.458 . . . . 71.54 110.879 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.953 HD13 HG13 ' A' ' 176' ' ' VAL . 30.3 mm -116.09 141.61 32.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 64.3 111.113 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . 0.407 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 0.2 OUTLIER -90.7 106.2 18.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.163 -0.471 . . . . 54.5 110.918 179.854 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -57.23 -176.68 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.225 -0.443 . . . . 73.02 110.868 179.854 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 24.0 tptt -163.73 161.12 23.29 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.141 -0.481 . . . . 71.52 110.858 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 5.8 p90 -132.77 146.69 52.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 73.04 110.911 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.663 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.39 162.77 0.96 Allowed Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.527 0.679 . . . . 64.33 111.167 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.663 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.6 Cg_endo -69.72 166.43 27.57 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.651 2.234 . . . . 52.42 112.354 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.419 ' HA ' ' HB ' ' A' ' 170' ' ' ILE . . . -153.19 151.47 30.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.261 -0.427 . . . . 71.4 111.11 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 32.0 m-85 -111.81 125.05 53.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 74.32 110.898 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -107.48 158.28 17.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.104 -0.498 . . . . 74.24 110.938 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 15.0 p -161.25 134.79 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.234 -0.439 . . . . 72.2 111.128 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . 0.448 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 179.5 -159.21 23.67 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.71 -0.757 . . . . 51.23 112.506 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.86 148.81 39.39 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.872 0.368 . . . . 72.22 110.85 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 3.8 tpp85 -126.97 122.15 33.71 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.142 -0.481 . . . . 73.03 110.868 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . 0.421 ' HB3' HD21 ' A' ' 163' ' ' LEU . 0.8 OUTLIER -125.97 164.27 21.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.216 -0.447 . . . . 65.43 111.014 -179.916 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -122.61 108.74 13.46 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 71.4 110.919 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' LEU . . . . . 0.489 HD23 ' N ' ' A' ' 158' ' ' GLY . 0.4 OUTLIER -50.51 158.79 0.57 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 53.01 110.93 -179.945 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . 0.489 ' N ' HD23 ' A' ' 157' ' ' LEU . . . -50.6 -32.15 23.68 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.775 -0.726 . . . . 44.25 112.482 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -80.76 -168.64 1.84 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.836 0.351 . . . . 74.31 110.901 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 46.9 t -71.04 -35.3 71.91 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.47 . . . . 72.23 110.846 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 3.1 m0 -71.47 153.93 41.87 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.172 -0.467 . . . . 74.5 110.954 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.41 ' C ' HD13 ' A' ' 163' ' ' LEU . 2.3 mpt? -131.9 173.98 10.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 63.34 110.819 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.702 ' N ' HD13 ' A' ' 163' ' ' LEU . 0.0 OUTLIER -140.84 160.59 39.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 71.43 110.922 179.998 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -163.74 156.62 18.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 74.51 110.908 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 12.2 p -148.25 121.9 9.22 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 73.44 110.829 -179.804 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . 0.448 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 15.6 t70 -130.72 160.84 33.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 73.0 110.883 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.513 HG13 ' O ' ' A' ' 195' ' ' ILE . 31.8 t -137.04 132.06 46.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.236 -0.438 . . . . 75.41 111.147 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . 0.587 ' HD2' HD12 ' A' ' 195' ' ' ILE . 0.0 OUTLIER -101.41 139.31 37.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 75.23 110.868 -179.96 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 66.5 t80 -143.97 134.21 24.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.146 -0.479 . . . . 71.35 110.897 -179.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' ILE . . . . . 0.453 HD13 ' N ' ' A' ' 171' ' ' PRO . 0.0 OUTLIER 179.83 131.58 0.25 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.601 0.715 . . . . 64.41 111.217 179.904 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . 0.453 ' N ' HD13 ' A' ' 170' ' ' ILE . 54.3 Cg_endo -69.69 109.27 2.26 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.709 2.273 . . . . 53.42 112.355 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -119.0 176.87 5.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.445 . . . . 72.34 110.865 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.53 147.53 29.16 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.161 -0.472 . . . . 73.34 110.829 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . 0.553 HG21 ' HE2' ' A' ' 128' ' ' PHE . 0.6 OUTLIER -132.36 162.83 30.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.489 . . . . 71.53 111.177 179.94 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . 0.407 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.1 OUTLIER -119.74 170.87 8.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 73.34 110.849 179.93 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.953 HG13 HD13 ' A' ' 141' ' ' ILE . 21.9 t -148.73 133.19 9.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.217 -0.447 . . . . 75.45 111.119 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 14.8 t -166.55 175.03 8.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 40.53 111.169 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -156.62 -137.08 2.25 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.799 -0.715 . . . . 71.43 112.536 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 98.6 m -156.26 113.3 3.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.785 0.326 . . . . 74.43 111.156 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.699 HD13 ' OG ' ' A' ' 137' ' ' SER . 13.8 tp -139.39 167.86 21.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.197 -0.456 . . . . 62.32 110.907 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -40.82 -71.51 0.31 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.715 -0.755 . . . . 43.45 112.479 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -169.15 0.31 Allowed 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.622 2.214 . . . . 73.23 112.347 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.404 HG13 ' HD2' ' A' ' 184' ' ' PRO . 61.4 t -61.21 132.64 92.58 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.634 0.731 . . . . 74.42 111.103 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . 0.404 ' HD2' HG13 ' A' ' 183' ' ' VAL . 53.7 Cg_endo -69.79 163.14 39.42 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.684 2.256 . . . . 73.22 112.336 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 29.7 t -106.62 115.56 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.19 -0.459 . . . . 70.34 111.094 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 19.4 p -110.1 105.84 15.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 60.21 110.814 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 16.2 p -107.74 159.46 16.47 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.115 -0.493 . . . . 65.14 111.138 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 34.8 ttpt -147.17 145.18 29.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 64.31 110.857 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 20.6 pt -146.1 142.05 21.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.127 -0.488 . . . . 62.43 111.1 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -124.14 110.8 15.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 74.23 110.896 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 191' ' ' VAL . . . . . 0.404 HG12 ' N ' ' A' ' 192' ' ' ASP . 5.6 t -137.06 157.99 35.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 75.44 111.08 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.404 ' N ' HG12 ' A' ' 191' ' ' VAL . 2.0 p-10 -108.14 88.39 4.71 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.601 0.715 . . . . 72.44 110.898 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 169.13 19.7 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.716 2.277 . . . . 63.2 112.318 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -126.91 117.2 22.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.465 . . . . 73.12 110.888 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 195' ' ' ILE . . . . . 0.587 HD12 ' HD2' ' A' ' 168' ' ' ARG . 61.8 mt -103.29 104.27 16.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 73.33 111.187 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . 0.441 HD23 ' CG1' ' A' ' 167' ' ' VAL . 5.5 mt -96.12 108.88 21.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.217 -0.447 . . . . 54.13 110.93 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -108.99 127.7 54.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.244 -0.435 . . . . 73.42 110.848 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 198' ' ' LEU . . . . . 0.4 ' C ' ' HB2' ' A' ' 22' ' ' ASN . 10.4 tt -149.95 132.75 15.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.165 -0.471 . . . . 72.12 110.904 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 199' ' ' GLY . . . . . 0.445 ' HA3' ' HA ' ' A' ' 22' ' ' ASN . . . -177.97 -152.12 9.91 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.776 -0.726 . . . . 62.41 112.468 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 200' ' ' ALA . . . . . 0.53 ' HA ' ' HA ' ' A' ' 163' ' ' LEU . . . -110.09 173.1 6.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.822 0.344 . . . . 55.41 111.034 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 40.6 t -159.98 162.66 34.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 62.42 110.852 -179.739 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 202' ' ' TYR . . . . . 0.623 ' CD1' ' HB3' ' A' ' 19' ' ' ALA . 0.2 OUTLIER -146.55 135.27 22.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.14 -0.482 . . . . 74.3 110.917 -179.898 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.817 HG23 HG22 ' A' ' 18' ' ' VAL . 11.2 p -83.63 152.56 3.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.122 -0.49 . . . . 73.44 111.129 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -151.37 132.08 14.03 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 75.21 110.887 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.31 161.31 18.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.125 -0.489 . . . . 75.45 110.885 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -118.51 106.42 12.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.258 -0.428 . . . . 55.4 110.895 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -96.08 -36.48 10.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 74.34 111.114 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -59.11 167.81 1.58 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.178 -0.465 . . . . 62.53 111.09 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -77.15 167.88 21.02 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 62.33 111.084 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -143.86 136.55 27.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 73.05 110.897 -179.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 73.2 110.865 179.951 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.6 mpt? . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.789 0.328 . . . . 63.14 110.893 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -147.82 109.74 4.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 72.41 110.912 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.1 mp0 -133.64 177.44 7.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 61.31 110.879 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -85.49 -51.14 6.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.105 -0.498 . . . . 72.34 110.863 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 1.1 t80 58.07 68.49 1.83 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.709 0.766 . . . . 74.01 110.922 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 163.82 36.9 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.683 2.255 . . . . 65.33 112.377 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -140.82 167.02 23.18 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.256 -0.429 . . . . 72.32 111.154 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . 0.622 ' O ' ' HB2' ' A' ' 207' ' ' ALA . 0.0 OUTLIER -156.24 132.97 10.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 71.11 110.882 -179.984 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 7.2 p -55.53 -35.32 65.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.261 -0.427 . . . . 74.2 110.793 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -51.37 -52.3 46.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 40.23 111.059 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -52.71 153.45 6.62 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.663 -0.78 . . . . 74.14 112.547 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 21.2 p90 -169.53 127.01 0.92 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.999 0.428 . . . . 75.51 110.939 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 6.2 t30 -169.33 -176.79 2.63 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.474 . . . . 71.33 110.955 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 41.6 mt-30 -51.73 130.9 29.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 73.24 110.945 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.9 9.76 31.78 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.779 -0.724 . . . . 72.11 112.456 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -78.71 169.39 18.31 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.803 0.335 . . . . 73.41 110.874 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 10.1 m-90 -114.9 159.85 20.21 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.215 -0.448 . . . . 74.11 110.937 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.639 HG23 ' HB3' ' A' ' 60' ' ' ALA . 15.5 m -153.38 126.96 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 41.32 111.152 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -96.4 114.95 26.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.154 -0.475 . . . . 75.5 111.077 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -111.95 113.7 26.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.175 -0.466 . . . . 62.12 110.91 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.773 ' CZ ' ' HB3' ' A' ' 200' ' ' ALA . 48.9 p90 -106.65 125.66 51.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 72.34 110.873 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -155.55 166.58 33.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.135 -0.484 . . . . 55.32 110.915 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 23.4 p90 -98.86 132.39 44.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.143 -0.48 . . . . 74.44 110.85 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -98.7 122.69 42.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.152 -0.476 . . . . 74.3 110.871 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 29.2 tptt -99.29 106.53 18.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.172 -0.467 . . . . 63.41 110.867 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.4 p -81.2 133.88 28.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.312 -0.404 . . . . 75.33 111.114 179.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -120.5 112.51 19.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.094 -0.503 . . . . 64.23 110.909 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.484 HG23 HG22 ' A' ' 49' ' ' ILE . 4.0 m -153.13 -179.34 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.097 -0.501 . . . . 64.2 111.147 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.63 52.48 0.54 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.682 -0.771 . . . . 71.1 112.477 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 34.0 mt-10 -90.03 -66.75 0.89 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.849 0.357 . . . . 64.03 110.903 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? 177.81 151.94 0.25 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.088 -0.506 . . . . 73.14 110.945 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.474 HD21 ' HB1' ' A' ' 45' ' ' ALA . 0.9 OUTLIER -109.03 163.73 13.05 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.15 -0.477 . . . . 70.54 110.921 -179.982 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 52.37 -102.47 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.737 -0.744 . . . . 75.52 112.452 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 47.6 t0 53.67 42.77 31.77 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.914 0.388 . . . . 73.52 110.865 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.559 HD13 ' N ' ' A' ' 36' ' ' ASN . 0.4 OUTLIER -106.41 128.85 54.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.135 -0.484 . . . . 54.35 110.941 -179.979 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.559 ' N ' HD13 ' A' ' 35' ' ' LEU . 3.2 p-10 -166.32 177.23 6.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 52.0 110.856 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 34.8 m -128.79 140.4 49.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.133 -0.485 . . . . 73.21 111.11 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 68.03 153.02 0.4 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.774 -0.727 . . . . 61.14 112.51 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 73.82 -172.87 50.69 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.756 -0.735 . . . . 74.43 112.554 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -83.64 -145.81 6.64 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.754 -0.736 . . . . 72.54 112.447 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -119.4 142.67 47.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.799 0.333 . . . . 42.12 111.103 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -146.19 70.62 13.18 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 121.567 0.699 . . . . 75.2 110.909 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.89 102.8 1.09 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.714 2.276 . . . . 75.22 112.278 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -79.75 -43.3 22.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 55.44 110.941 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.474 ' HB1' HD21 ' A' ' 32' ' ' LEU . . . -61.87 -179.46 0.2 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 54.21 111.105 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -159.52 125.15 4.22 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.231 -0.441 . . . . 61.01 110.869 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.423 ' HA ' ' HA2' ' A' ' 83' ' ' GLY . 6.5 p -118.14 148.91 20.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.193 -0.458 . . . . 75.35 111.072 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -173.14 174.47 3.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 72.41 110.878 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.775 HD11 ' CE2' ' A' ' 98' ' ' TYR . 19.3 tt -141.57 154.79 20.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.112 -0.494 . . . . 70.11 111.086 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -124.42 167.54 16.72 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.715 -0.755 . . . . 64.21 112.426 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.9 m-80 -162.66 163.91 26.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.821 0.343 . . . . 71.22 110.904 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -120.36 -68.83 0.88 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 62.43 110.827 179.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 72.3 p -91.93 172.87 8.17 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.216 -0.447 . . . . 65.23 111.144 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 40.3 p -148.38 106.52 3.73 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.226 -0.443 . . . . 73.43 111.122 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.406 HD12 ' O ' ' A' ' 55' ' ' LEU . 3.3 pp -160.73 128.74 4.47 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 64.54 110.94 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.459 HG22 ' HA3' ' A' ' 74' ' ' GLY . 0.0 OUTLIER -142.54 155.74 45.05 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.274 -0.421 . . . . 72.35 111.182 179.948 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -114.95 132.46 56.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 70.42 110.893 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.451 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.0 OUTLIER -129.88 134.83 47.76 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.211 -0.449 . . . . 63.24 110.991 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.43 HD13 ' C ' ' A' ' 58' ' ' ASP . 3.0 mm -109.29 115.16 48.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.274 -0.421 . . . . 54.03 111.125 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.639 ' HB3' HG23 ' A' ' 18' ' ' VAL . . . -111.31 151.48 28.33 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.178 -0.464 . . . . 61.1 111.084 179.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.457 ' HB2' HG22 ' A' ' 69' ' ' VAL . 5.3 m-85 -125.74 132.37 52.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 73.04 110.932 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -98.3 95.22 7.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.081 -0.509 . . . . 73.24 110.893 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.5 t -94.35 -31.74 4.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.151 -0.477 . . . . 52.24 111.089 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 29.7 t -136.15 158.07 45.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 72.22 110.831 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 59.8 p -85.07 3.98 36.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 72.41 110.859 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -114.41 -29.47 6.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 72.41 110.84 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.424 HG22 ' CD2' ' A' ' 107' ' ' TYR . 32.5 pt -142.08 158.0 20.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 62.32 111.113 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -148.91 163.27 37.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 62.12 111.115 179.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.457 HG22 ' HB2' ' A' ' 61' ' ' TYR . 6.1 m -112.24 152.14 14.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 71.02 111.155 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.449 ' HA ' ' HA ' ' A' ' 60' ' ' ALA . 1.5 p30 -144.58 143.31 30.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 64.25 110.885 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.451 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -127.19 108.44 10.89 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 71.33 110.851 -179.907 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -86.33 127.26 34.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.12 -0.491 . . . . 60.15 110.819 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 14.6 p -147.3 147.49 17.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 63.11 111.198 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.459 ' HA3' HG22 ' A' ' 56' ' ' THR . . . -161.88 144.18 9.51 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.753 -0.737 . . . . 73.55 112.487 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 44.3 t -119.74 73.18 16.91 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.608 0.718 . . . . 61.43 111.129 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 159.09 54.7 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.669 2.246 . . . . 44.34 112.365 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -74.91 -165.8 0.41 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.251 -0.431 . . . . 72.35 111.181 179.818 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 18.2 ttm105 -77.05 138.22 39.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.283 -0.417 . . . . 61.54 110.833 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . 0.668 ' HB3' ' CE2' ' A' ' 98' ' ' TYR . . . -132.77 148.99 52.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.443 . . . . 52.45 111.128 179.836 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.6 ttpm? -89.12 123.8 33.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.182 -0.463 . . . . 72.41 110.93 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 59.6 t80 -109.13 138.82 44.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 62.45 110.878 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.416 ' O ' HG23 ' A' ' 47' ' ' VAL . 7.6 pt20 -109.17 150.91 27.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 74.43 110.917 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.657 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 174.37 84.88 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.696 -0.764 . . . . 74.31 112.447 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -178.07 -175.68 0.5 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.894 0.378 . . . . 52.44 110.976 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 1.4 ptpt -86.54 -70.13 0.63 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.198 -0.455 . . . . 74.22 110.879 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 8.4 t -85.25 -30.52 23.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.225 -0.443 . . . . 73.35 110.869 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.849 HG22 HG22 ' A' ' 93' ' ' VAL . 4.8 mm -68.81 -35.21 68.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.123 -0.489 . . . . 72.12 111.114 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.1 t -62.68 -47.38 83.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 44.42 110.861 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.1 t -54.67 -39.85 68.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.149 -0.478 . . . . 71.23 110.837 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 13.9 tp -60.55 -44.23 96.37 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.083 -0.508 . . . . 75.13 110.995 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.24 -14.55 39.86 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.743 -0.741 . . . . 74.55 112.501 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 9.8 mtm180 -120.54 96.74 5.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.897 0.38 . . . . 71.12 110.813 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.849 HG22 HG22 ' A' ' 87' ' ' ILE . 99.3 t -107.24 -58.27 3.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 64.05 111.1 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.413 ' HA ' ' HA ' ' A' ' 133' ' ' ASP . 0.9 OUTLIER -140.09 148.73 42.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.154 -0.475 . . . . 64.43 110.902 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 31.6 mt-10 -126.01 124.59 41.03 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.132 -0.485 . . . . 71.21 110.972 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.45 HG22 ' N ' ' A' ' 97' ' ' ASP . 14.8 p -176.05 156.76 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 64.45 111.11 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.45 ' N ' HG22 ' A' ' 96' ' ' VAL . 3.9 p30 -84.27 173.49 10.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 75.34 110.902 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' TYR . . . . . 0.775 ' CE2' HD11 ' A' ' 49' ' ' ILE . 14.4 m-85 -130.48 133.17 46.08 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 74.23 110.933 -179.825 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -114.11 69.63 0.24 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.703 -0.761 . . . . 54.42 112.445 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.82 138.44 37.64 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.694 2.263 . . . . 55.12 112.294 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -155.7 118.08 4.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 60.55 111.115 179.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.649 HG22 ' CA ' ' A' ' 124' ' ' GLY . 30.0 pt -140.15 146.1 25.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 62.24 111.165 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.42 HD22 ' CE1' ' A' ' 71' ' ' PHE . 2.3 pp -132.82 118.99 19.66 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.196 -0.456 . . . . 74.11 110.846 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.421 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 5.6 p -142.93 163.92 31.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.202 -0.454 . . . . 65.11 110.875 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.577 ' O ' HD12 ' A' ' 105' ' ' LEU . 1.1 pp -113.87 151.46 32.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 54.52 110.886 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 31.5 mt-30 -106.49 144.05 33.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 73.55 110.907 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.424 ' CD2' HG22 ' A' ' 67' ' ' ILE . 5.4 t80 -136.02 125.41 24.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 65.53 110.968 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -86.5 123.14 31.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.173 -0.467 . . . . 64.31 110.843 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 5.9 t80 -91.98 138.82 31.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.142 -0.481 . . . . 73.11 110.95 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -51.6 113.06 0.87 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 73.12 110.846 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 35.0 m -62.35 165.67 5.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.166 -0.47 . . . . 71.34 110.835 -179.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 38.2 m-85 -114.51 -67.13 1.02 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.148 -0.478 . . . . 75.02 110.898 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 35.2 mt-10 -102.31 -73.45 0.66 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 71.23 110.854 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 8.2 ttm180 -105.39 179.76 4.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.49 . . . . 72.41 110.903 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 4.0 pp -69.28 146.34 52.35 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 74.01 110.938 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 6.1 m-85 -141.86 160.66 55.02 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-O 121.689 0.757 . . . . 73.4 110.884 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 178.43 4.57 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.633 2.222 . . . . 73.43 112.349 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 4.0 m-85 -110.24 151.95 26.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.462 . . . . 74.35 110.949 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 8.3 p -101.93 133.01 46.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.109 -0.496 . . . . 75.11 111.101 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -131.92 174.67 20.11 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.796 -0.716 . . . . 71.15 112.568 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.505 HG23 ' HA ' ' A' ' 149' ' ' PHE . 9.4 p -175.95 153.54 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.865 0.364 . . . . 73.43 111.106 -179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -176.01 -158.21 19.09 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.76 -0.734 . . . . 54.2 112.543 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.45 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 21.3 m -107.7 150.66 10.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.869 0.366 . . . . 72.03 111.116 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . 0.649 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -130.53 169.07 21.46 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.687 -0.768 . . . . 75.24 112.455 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . 0.432 ' HA ' ' HA ' ' A' ' 145' ' ' TRP . 0.0 OUTLIER -168.55 129.26 1.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.86 0.362 . . . . 71.3 110.923 -179.855 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.468 ' O ' HG13 ' A' ' 126' ' ' VAL . 3.9 p -118.73 112.04 36.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 51.3 111.152 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.457 HD23 ' N ' ' A' ' 128' ' ' PHE . 10.0 tt -122.52 151.23 41.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 73.34 110.883 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.602 ' CE1' HG23 ' A' ' 141' ' ' ILE . 1.3 p90 -160.89 161.94 31.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.187 -0.461 . . . . 72.21 110.833 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 51.5 t80 -101.07 118.59 37.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.49 . . . . 71.53 110.88 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -50.55 102.37 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 65.21 110.845 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -77.52 -80.81 0.1 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.139 -0.482 . . . . 74.35 110.901 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -165.43 112.9 0.96 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.256 -0.429 . . . . 74.34 111.125 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . 0.538 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 1.4 m-20 -103.07 119.36 38.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.144 -0.48 . . . . 71.35 110.923 179.853 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -79.89 -5.82 89.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.806 -0.712 . . . . 53.51 112.445 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -46.81 -28.18 1.46 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.81 0.338 . . . . 73.2 111.113 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -162.86 -178.56 6.2 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.191 -0.458 . . . . 71.52 111.019 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 1.5 m -53.02 93.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.275 -0.42 . . . . 73.1 110.828 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 7.0 m 50.68 71.19 0.44 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.081 -0.509 . . . . 70.22 110.891 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.623 ' CE2' HG12 ' A' ' 176' ' ' VAL . 0.5 OUTLIER -92.98 159.88 15.12 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.135 -0.484 . . . . 72.25 110.838 -179.912 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 94.0 m-20 -134.0 167.41 20.67 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.112 -0.495 . . . . 75.54 110.891 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.602 HG23 ' CE1' ' A' ' 128' ' ' PHE . 17.6 tt -117.97 149.11 20.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.192 -0.458 . . . . 74.04 111.182 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 16.2 mmtt -113.36 124.54 52.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 73.43 110.931 179.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.421 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 0.0 OUTLIER -85.53 -173.32 4.59 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.225 -0.443 . . . . 44.51 110.868 179.915 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -171.54 -175.36 1.58 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 72.51 110.904 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' TRP . . . . . 0.432 ' HA ' ' HA ' ' A' ' 125' ' ' ARG . 22.5 p-90 -143.57 160.49 40.54 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.198 -0.456 . . . . 64.32 110.917 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.679 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 178.86 163.15 0.69 Allowed Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.623 0.725 . . . . 23.01 111.086 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.679 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 54.3 Cg_endo -69.66 170.61 16.06 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.683 2.255 . . . . 70.32 112.375 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.45 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -165.55 153.0 10.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.222 -0.445 . . . . 72.12 111.13 179.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . 0.505 ' HA ' HG23 ' A' ' 121' ' ' VAL . 12.9 m-85 -96.17 161.3 14.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.242 -0.435 . . . . 71.52 110.819 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 27.7 tp60 -135.0 148.59 50.0 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 61.22 110.949 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 10.2 p -151.54 130.84 3.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.17 -0.468 . . . . 74.33 111.161 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . 0.405 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 164.95 -163.21 36.27 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.727 -0.749 . . . . 52.15 112.481 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -148.93 168.26 23.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.788 0.328 . . . . 62.31 110.95 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -133.68 128.51 35.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 64.02 110.88 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -132.66 161.64 33.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.442 . . . . 74.31 110.933 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -121.28 109.58 15.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.147 -0.479 . . . . 73.01 110.904 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 3.6 tp -57.46 160.45 4.12 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.169 -0.469 . . . . 62.24 110.944 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -52.05 -33.24 36.77 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.775 -0.726 . . . . 64.04 112.495 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 4.6 m120 -80.52 173.65 12.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.907 0.384 . . . . 74.14 110.821 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 81.1 p -54.78 -35.74 64.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.113 -0.494 . . . . 75.45 110.815 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 10.3 m0 -69.31 151.68 45.91 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.199 -0.455 . . . . 64.34 110.97 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 38.8 mtt -121.22 174.92 6.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.246 -0.433 . . . . 73.11 110.862 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.435 ' HA ' ' HA ' ' A' ' 200' ' ' ALA . 0.6 OUTLIER -128.65 139.25 52.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.262 -0.427 . . . . 72.0 110.909 179.999 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 12.1 t-20 -139.84 138.33 35.68 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 71.13 110.984 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.7 p -141.61 121.79 13.85 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.214 -0.448 . . . . 73.24 110.892 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . 0.405 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 23.3 m-20 -140.26 167.59 21.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.08 -0.509 . . . . 72.41 110.812 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.528 HG13 ' O ' ' A' ' 195' ' ' ILE . 46.7 t -150.43 129.05 2.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.157 -0.474 . . . . 61.33 111.115 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . 0.552 ' NH1' HG21 ' A' ' 102' ' ' ILE . 0.0 OUTLIER -98.59 137.71 36.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 71.32 110.862 -179.972 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 15.9 t80 -138.22 125.37 21.52 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.162 -0.472 . . . . 62.2 110.929 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' ILE . . . . . 0.468 HG13 ' HD2' ' A' ' 171' ' ' PRO . 4.7 tp 178.9 134.69 0.24 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.599 0.714 . . . . 72.34 111.116 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . 0.468 ' HD2' HG13 ' A' ' 170' ' ' ILE . 54.0 Cg_endo -69.85 111.55 2.86 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.609 2.206 . . . . 64.54 112.386 179.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . 0.535 ' CE2' ' HB3' ' A' ' 146' ' ' ALA . 5.3 t80 -116.1 159.76 21.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.139 -0.482 . . . . 72.35 110.856 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 5.4 ptpt -140.06 144.79 37.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.146 -0.479 . . . . 73.41 110.926 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 9.4 t -117.79 161.9 18.96 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 73.52 111.137 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 21.6 t70 -118.48 158.54 25.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.14 -0.482 . . . . 71.3 110.844 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.623 HG12 ' CE2' ' A' ' 139' ' ' PHE . 4.5 t -147.94 138.26 16.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.203 -0.453 . . . . 72.54 111.082 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 12.3 t -166.92 -179.22 4.59 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.131 -0.486 . . . . 71.11 111.116 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -120.55 -161.66 11.53 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.746 -0.74 . . . . 61.35 112.458 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 6.4 t -119.9 -171.74 2.2 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.84 0.353 . . . . 75.22 111.16 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 4.9 mp -61.36 147.68 43.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 71.34 110.907 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 116.21 -88.0 0.45 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.716 -0.754 . . . . 73.11 112.441 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.403 ' O ' ' HD3' ' A' ' 184' ' ' PRO . 53.9 Cg_endo -69.67 -160.22 0.06 OUTLIER 'Trans proline' 0 N--CA 1.465 -0.181 0 C-N-CA 122.772 2.314 . . . . 72.34 112.331 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 16.4 t -105.99 87.76 2.62 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.66 0.743 . . . . 54.23 111.174 179.818 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . 0.403 ' HD3' ' O ' ' A' ' 182' ' ' PRO . 53.1 Cg_endo -69.87 122.84 9.48 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.671 2.247 . . . . 64.53 112.317 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.418 HG12 HG23 ' A' ' 187' ' ' THR . 26.5 t -103.59 108.17 23.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 71.34 111.111 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -74.13 104.83 5.08 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.137 -0.483 . . . . 74.14 110.82 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . 0.418 HG23 HG12 ' A' ' 185' ' ' VAL . 65.1 p -124.44 168.59 12.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.136 -0.484 . . . . 73.31 111.171 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 3.0 ttpm? -158.97 134.09 8.34 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.207 -0.451 . . . . 41.54 110.944 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -115.75 139.59 41.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.279 -0.419 . . . . 72.33 111.107 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 71.7 tt0 -119.55 114.99 23.1 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.125 -0.489 . . . . 74.22 110.817 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 191' ' ' VAL . . . . . 0.539 HG22 ' H ' ' A' ' 192' ' ' ASP . 1.2 p -137.18 171.28 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 70.41 111.111 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.539 ' H ' HG22 ' A' ' 191' ' ' VAL . 4.2 m-20 -106.93 87.14 2.73 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.594 0.711 . . . . 62.11 110.915 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.65 120.96 7.68 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.742 2.295 . . . . 62.21 112.379 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 194' ' ' PHE . . . . . 0.425 ' CE1' HG11 ' A' ' 167' ' ' VAL . 2.1 t80 -102.09 114.0 27.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.258 -0.428 . . . . 72.4 110.887 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 195' ' ' ILE . . . . . 0.55 HD12 ' HG2' ' A' ' 168' ' ' ARG . 5.6 mt -103.56 127.3 57.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.162 -0.472 . . . . 74.22 111.133 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . 0.41 ' HG ' HG22 ' A' ' 167' ' ' VAL . 1.1 tt -117.14 107.72 14.82 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.182 -0.463 . . . . 64.34 110.89 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 3.2 m -96.38 123.62 40.09 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.24 -0.436 . . . . 65.42 110.847 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 2.5 tt -144.13 129.21 18.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 62.21 110.86 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 178.94 -146.98 7.53 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.75 -0.738 . . . . 73.21 112.478 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 200' ' ' ALA . . . . . 0.773 ' HB3' ' CZ ' ' A' ' 21' ' ' PHE . . . -118.65 174.26 6.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.781 0.324 . . . . 61.35 111.17 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 78.1 p -149.66 175.71 11.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.28 -0.418 . . . . 74.21 110.843 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -157.31 160.9 39.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 73.52 110.895 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.503 ' HA ' HG12 ' A' ' 18' ' ' VAL . 18.2 m -76.76 161.21 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.065 -0.516 . . . . 65.0 111.15 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -155.95 127.59 7.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 71.11 110.865 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 14.3 ttmm 46.77 60.84 3.12 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.119 -0.492 . . . . 73.2 110.924 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 206' ' ' LEU . . . . . 0.472 HD21 ' HB ' ' A' ' 203' ' ' VAL . 4.0 mm? -52.33 -54.26 33.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.456 . . . . 72.43 110.957 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 207' ' ' ALA . . . . . 0.622 ' HB2' ' O ' ' A' ' 8' ' ' LYS . . . -50.46 113.78 0.97 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.151 -0.477 . . . . 64.24 111.019 179.822 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -139.5 126.51 21.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 72.11 111.104 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . 61.37 38.66 16.03 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.22 -0.445 . . . . 63.41 111.161 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 11.2 tp -134.01 126.14 29.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 73.34 110.912 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 84.0 mt-10 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 62.33 110.871 179.892 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.458 -0.075 0 CA-C-O 120.783 0.325 . . . . 61.31 110.826 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 29.9 m120 -110.36 59.48 0.61 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.23 -0.441 . . . . 73.34 110.879 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 71.9 mm-40 -114.75 153.94 29.42 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.245 -0.434 . . . . 73.42 110.892 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -105.1 168.7 8.89 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.182 -0.463 . . . . 70.15 110.863 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 7.7 m-85 -121.96 160.42 47.25 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.676 0.751 . . . . 73.04 110.881 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 -179.77 3.14 Favored 'Trans proline' 0 N--CA 1.465 -0.165 0 C-N-CA 122.705 2.27 . . . . 75.44 112.353 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.28 159.45 17.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.265 -0.425 . . . . 72.2 111.054 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 2.5 mmpt? -111.75 167.96 9.94 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.214 -0.448 . . . . 70.34 110.92 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 17.6 m -65.29 103.6 0.82 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.192 -0.458 . . . . 74.52 110.852 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -115.52 140.2 49.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.069 -0.514 . . . . 52.13 111.121 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -117.33 46.42 1.15 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.793 -0.717 . . . . 51.34 112.529 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 16.2 p90 -157.21 118.01 3.59 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.864 0.364 . . . . 74.21 110.943 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 43.2 t30 -124.05 153.0 42.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.09 -0.505 . . . . 61.24 110.888 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -53.03 119.25 4.46 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.138 -0.483 . . . . 75.43 110.881 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.71 11.57 28.33 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 61.41 112.498 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -82.66 160.51 22.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.766 0.317 . . . . 63.25 110.922 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 12.8 m95 -108.76 159.65 16.6 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.257 -0.429 . . . . 71.43 110.936 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.437 HG13 ' O ' ' A' ' 202' ' ' TYR . 48.1 t -150.5 119.2 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.426 . . . . 45.31 111.139 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -85.0 107.52 17.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.096 -0.502 . . . . 63.13 111.078 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -105.45 112.76 25.98 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 63.11 110.902 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -111.73 125.79 54.36 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.159 -0.473 . . . . 73.11 110.879 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.43 ' O ' HG22 ' A' ' 56' ' ' THR . 4.0 p30 -155.78 172.66 17.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 71.44 110.907 -179.887 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.8 p90 -100.96 132.21 46.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 71.24 110.867 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . 0.591 ' OG ' HG23 ' A' ' 195' ' ' ILE . 0.3 OUTLIER -100.68 120.04 39.48 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.151 -0.477 . . . . 65.34 110.88 -179.797 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 39.1 tttm -93.56 106.82 18.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 63.1 110.849 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.614 ' HA ' HD13 ' A' ' 195' ' ' ILE . 11.3 p -84.12 135.8 24.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 72.4 111.106 179.874 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -125.84 99.42 5.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.154 -0.475 . . . . 74.34 110.855 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.68 HG23 HG11 ' A' ' 191' ' ' VAL . 2.7 p -147.33 142.26 19.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.155 -0.475 . . . . 71.24 111.152 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 142.08 64.57 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.706 -0.759 . . . . 54.11 112.528 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -89.86 -66.16 0.95 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.766 0.317 . . . . 72.35 110.911 -179.863 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -171.41 134.87 0.9 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.122 -0.49 . . . . 61.14 110.873 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 5.1 tt -104.94 152.69 22.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.186 -0.461 . . . . 71.35 110.992 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.24 -45.27 2.81 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.666 -0.778 . . . . 54.13 112.502 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -52.01 140.08 21.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.861 0.362 . . . . 70.35 110.827 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.547 HD13 ' OE1' ' A' ' 190' ' ' GLU . 0.9 OUTLIER 63.13 53.45 2.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.145 -0.48 . . . . 75.1 110.948 -179.944 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 16.0 t30 -90.6 -43.28 10.28 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.144 -0.48 . . . . 74.23 110.901 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.604 ' O ' HG22 ' A' ' 37' ' ' VAL . 13.2 p 39.44 38.69 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.132 -0.485 . . . . 70.33 111.095 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -175.55 112.85 0.42 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.778 -0.725 . . . . 73.24 112.5 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.3 -152.32 43.19 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.756 -0.735 . . . . 74.3 112.481 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -52.42 143.14 22.9 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.767 -0.73 . . . . 65.42 112.497 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -115.14 101.32 8.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.772 0.32 . . . . 62.42 111.141 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.626 HD22 ' OE2' ' A' ' 84' ' ' GLU . 0.4 OUTLIER -119.51 67.5 10.15 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.613 0.72 . . . . 73.33 110.901 -179.946 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.78 -23.37 30.8 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.694 2.262 . . . . 74.35 112.352 179.843 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -85.97 50.61 2.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.224 -0.444 . . . . 74.33 110.874 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -104.15 -170.12 1.73 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 74.21 111.062 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 21.8 m-20 -160.48 125.37 3.79 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 54.4 110.922 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.54 HG13 ' O ' ' A' ' 82' ' ' GLN . 18.5 t -104.4 135.51 41.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.187 -0.46 . . . . 65.31 111.159 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -132.63 137.59 47.06 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 73.13 110.816 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 3.8 tt -101.3 145.03 12.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.094 -0.503 . . . . 73.51 111.094 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -60.24 -168.58 0.38 Allowed Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.746 -0.74 . . . . 63.32 112.462 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -119.05 -37.34 3.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.781 0.324 . . . . 73.14 110.937 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -51.96 150.51 4.21 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.147 -0.479 . . . . 75.15 110.881 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 3.7 p -146.13 178.21 8.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 62.13 111.138 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.6 t -160.14 169.47 23.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.268 -0.424 . . . . 75.14 111.183 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 5.0 mp -91.13 168.38 11.67 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 65.22 110.921 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.43 HG22 ' O ' ' A' ' 22' ' ' ASN . 12.1 t -135.94 149.51 48.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.186 -0.461 . . . . 65.41 111.133 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -102.75 133.05 48.43 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.292 -0.413 . . . . 73.35 110.846 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -125.91 138.62 53.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 53.45 110.84 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -108.53 114.15 45.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 65.42 111.164 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -105.87 121.64 44.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 73.4 111.057 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.785 ' HB3' HG22 ' A' ' 69' ' ' VAL . 7.4 t80 -106.08 117.38 33.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 73.03 110.931 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -92.43 101.83 14.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.124 -0.489 . . . . 60.03 110.892 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.41 HG23 ' OG ' ' A' ' 64' ' ' SER . 32.5 m -98.39 -31.72 3.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.189 -0.46 . . . . 70.22 111.156 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.41 ' OG ' HG23 ' A' ' 63' ' ' VAL . 1.1 m -125.92 -169.51 2.02 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.192 -0.458 . . . . 71.0 110.895 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.5 m -84.18 -38.92 20.02 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 74.1 110.893 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -126.09 25.99 6.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.067 -0.515 . . . . 71.3 110.865 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 3.4 mt -145.16 126.94 8.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.22 -0.446 . . . . 70.04 111.136 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.484 ' HB1' ' O ' ' A' ' 61' ' ' TYR . . . -155.05 168.61 26.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.138 -0.483 . . . . 52.34 111.119 179.843 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.785 HG22 ' HB3' ' A' ' 61' ' ' TYR . 2.5 m -111.76 152.47 13.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 61.12 111.14 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -131.66 129.41 40.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 63.23 110.821 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -114.38 110.15 19.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 73.31 110.87 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -81.82 113.08 19.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 73.14 110.955 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.8 t -124.04 116.46 47.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.167 -0.47 . . . . 74.4 111.03 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -131.87 152.14 20.03 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.71 -0.757 . . . . 74.23 112.48 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 39.4 t -143.38 69.81 17.69 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.575 0.702 . . . . 71.2 111.144 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.79 140.61 42.98 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.666 2.244 . . . . 71.22 112.373 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -66.87 -173.66 0.26 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.188 -0.46 . . . . 72.33 111.075 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 8.9 ttm180 -76.43 129.61 36.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 75.12 110.856 -179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -131.03 151.71 51.12 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.227 -0.442 . . . . 70.21 111.085 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.8 tttp -97.59 123.9 41.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.134 -0.485 . . . . 62.41 110.847 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -111.43 151.68 28.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 71.43 110.907 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.54 ' O ' HG13 ' A' ' 47' ' ' VAL . 18.1 mt-30 -111.71 148.47 33.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.12 -0.491 . . . . 75.31 110.899 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.571 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -178.71 81.41 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.789 -0.719 . . . . 74.51 112.479 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.626 ' OE2' HD22 ' A' ' 42' ' ' LEU . 1.4 mm-40 -176.52 -175.59 0.67 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.95 0.405 . . . . 60.2 110.868 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.17 -69.72 0.65 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.127 -0.488 . . . . 65.0 110.949 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 16.9 p -85.16 -32.05 22.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.237 -0.438 . . . . 72.01 110.853 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.951 HG21 ' HB2' ' A' ' 135' ' ' ALA . 4.6 mm -67.34 -35.13 72.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.094 -0.503 . . . . 74.35 111.111 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.8 t -62.38 -44.85 95.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.219 -0.446 . . . . 52.23 110.79 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 39.1 t -57.43 -37.31 72.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 62.1 110.904 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 98.5 mt -63.56 -50.3 70.02 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.107 -0.497 . . . . 52.32 110.902 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 114.14 -13.22 21.69 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.721 -0.752 . . . . 75.42 112.475 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.61 96.19 5.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.839 0.352 . . . . 74.13 110.821 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.887 HG22 HG22 ' A' ' 87' ' ' ILE . 64.5 t -113.74 -50.84 5.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.253 -0.431 . . . . 64.12 111.108 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 60.5 p -140.11 148.69 42.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 64.42 110.91 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -140.68 118.52 11.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 71.42 110.79 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.526 HG22 ' H ' ' A' ' 97' ' ' ASP . 1.6 p -179.24 170.31 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.171 -0.468 . . . . 71.22 111.089 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.526 ' H ' HG22 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -109.43 160.29 16.32 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.198 -0.455 . . . . 74.21 110.869 179.931 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' TYR . . . . . 0.424 ' HA ' ' HB2' ' A' ' 128' ' ' PHE . 17.7 m-85 -120.35 145.23 47.35 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.226 -0.443 . . . . 75.11 110.948 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -108.67 87.3 0.48 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.775 -0.726 . . . . 72.12 112.412 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.656 ' HA ' HG12 ' A' ' 126' ' ' VAL . 54.2 Cg_endo -69.76 110.43 2.55 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.668 2.245 . . . . 74.41 112.406 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.409 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -128.88 95.57 4.12 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.241 -0.436 . . . . 42.13 111.12 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.617 HG23 ' CA ' ' A' ' 124' ' ' GLY . 5.8 mm -116.64 142.22 31.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.229 -0.441 . . . . 62.24 111.138 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.46 ' HG ' HG13 ' A' ' 123' ' ' VAL . 0.3 OUTLIER -140.13 109.66 6.27 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.188 -0.46 . . . . 74.14 110.934 179.959 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.413 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 4.8 p -138.19 -177.6 4.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 73.13 110.854 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.606 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.7 OUTLIER -128.87 141.89 51.14 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 71.23 110.863 -179.946 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 -101.55 132.72 47.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 65.11 110.992 179.853 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 27.5 t80 -137.1 145.61 44.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.237 -0.438 . . . . 64.21 110.937 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 59.0 t-80 -71.43 153.64 42.12 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.152 -0.476 . . . . 64.44 110.917 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 5.2 t80 -149.98 139.74 21.77 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.201 -0.454 . . . . 75.01 110.928 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -57.74 130.03 44.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.056 -0.52 . . . . 75.11 110.87 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.6 t -138.32 161.17 37.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.457 . . . . 63.22 110.834 -179.768 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 28.2 p90 -129.82 39.76 3.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.115 -0.493 . . . . 70.33 110.878 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -117.08 177.67 4.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.209 -0.45 . . . . 44.12 110.851 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 7.8 tpm_? -56.54 -37.79 71.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 64.54 110.855 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 8.1 tp -114.78 153.01 31.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 74.24 110.868 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -120.87 69.61 17.64 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.655 0.74 . . . . 72.44 110.985 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . 0.684 ' HA ' HD12 ' A' ' 153' ' ' LEU . 53.8 Cg_endo -69.81 176.95 6.13 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.6 2.2 . . . . 71.54 112.31 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.474 ' O ' HG23 ' A' ' 151' ' ' VAL . 26.5 m-85 -111.53 144.24 41.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 71.14 110.924 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 13.2 p -100.7 133.26 44.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.237 -0.438 . . . . 73.24 111.102 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.418 ' HA2' ' O ' ' A' ' 105' ' ' LEU . . . -125.92 159.01 20.32 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.738 -0.744 . . . . 71.34 112.489 179.936 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.1 p -161.6 149.47 4.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.81 0.338 . . . . 75.14 111.15 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.413 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -177.5 -151.3 9.07 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.744 -0.741 . . . . 53.04 112.5 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.531 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.3 p -110.39 126.31 67.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.877 0.37 . . . . 72.21 111.114 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . 0.617 ' CA ' HG23 ' A' ' 102' ' ' ILE . . . -116.06 119.94 4.72 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.769 -0.729 . . . . 60.05 112.503 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . 0.409 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 13.5 ptm180 -120.44 122.88 41.67 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.921 0.391 . . . . 74.13 110.854 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.656 HG12 ' HA ' ' A' ' 100' ' ' PRO . 3.7 m -118.34 118.6 58.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.202 -0.454 . . . . 60.11 111.117 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.423 ' HA ' ' HB3' ' A' ' 143' ' ' ASP . 1.2 pt? -160.02 165.23 32.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.231 -0.441 . . . . 72.53 110.985 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.424 ' HB2' ' HA ' ' A' ' 98' ' ' TYR . 1.0 OUTLIER -165.93 -171.12 1.93 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.236 -0.438 . . . . 74.11 110.897 179.925 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 1.6 t80 -94.13 135.12 35.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.174 -0.466 . . . . 73.3 110.926 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -69.63 148.01 49.9 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.138 -0.483 . . . . 72.43 110.843 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.482 ' CB ' HG23 ' A' ' 96' ' ' VAL . 0.2 OUTLIER -129.55 -69.29 0.69 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 73.05 110.933 179.94 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 33.8 m -159.93 75.12 0.6 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.185 -0.461 . . . . 74.15 111.189 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -97.85 175.5 6.13 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.224 -0.444 . . . . 73.21 110.81 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 62.99 149.55 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.735 -0.745 . . . . 71.03 112.479 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.951 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -76.51 -1.7 28.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.892 0.377 . . . . 43.04 111.187 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -86.5 -177.09 6.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.135 -0.484 . . . . 71.42 110.906 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -64.06 93.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.198 -0.455 . . . . 62.44 110.847 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 89.0 p 46.06 76.26 0.1 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 62.12 110.88 -179.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -82.96 151.16 26.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 71.42 110.794 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . 0.447 ' O ' HG13 ' A' ' 176' ' ' VAL . 1.6 t70 -101.74 165.63 11.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.093 -0.503 . . . . 72.51 110.776 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -127.08 163.0 30.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 64.25 111.168 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . 0.41 ' HB3' ' HB2' ' A' ' 175' ' ' ASP . 0.2 OUTLIER -119.21 108.14 14.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.189 -0.46 . . . . 74.45 110.898 179.847 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.428 ' HB2' ' O ' ' A' ' 126' ' ' VAL . 1.0 OUTLIER -58.84 -172.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.243 -0.435 . . . . 44.22 110.819 179.967 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 15.9 mmtt -149.47 155.28 40.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.45 . . . . 55.33 110.886 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 45.3 p90 -151.67 136.23 16.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.227 -0.442 . . . . 63.53 110.926 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.933 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.28 172.14 0.61 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.583 0.706 . . . . 51.15 111.051 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.933 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 54.3 Cg_endo -69.69 134.09 27.29 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.631 2.221 . . . . 52.51 112.421 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.468 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -130.1 166.47 20.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.262 -0.426 . . . . 64.2 111.126 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -121.55 167.39 12.92 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.183 -0.462 . . . . 71.21 110.951 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -165.85 162.3 18.29 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 71.41 110.923 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.474 HG23 ' O ' ' A' ' 118' ' ' TYR . 10.7 p -153.51 141.32 13.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 73.0 111.147 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -169.4 -171.79 35.41 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.772 -0.728 . . . . 64.24 112.451 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.684 HD12 ' HA ' ' A' ' 117' ' ' PRO . 8.5 tt -149.2 157.08 43.07 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.738 0.304 . . . . 74.35 110.934 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.438 ' N ' HD23 ' A' ' 153' ' ' LEU . 7.1 tpp85 -108.08 117.43 34.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.224 -0.444 . . . . 74.43 110.836 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 4.5 t80 -105.17 145.38 30.66 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.184 -0.462 . . . . 74.24 110.876 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -115.38 105.77 13.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.091 -0.504 . . . . 55.45 110.897 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 11.9 tp -93.93 164.34 13.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.184 -0.462 . . . . 64.25 110.925 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -76.08 68.38 2.31 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.75 -0.738 . . . . 55.53 112.468 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 64.7 m-80 -151.41 175.25 12.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.804 0.335 . . . . 74.3 110.876 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 6.2 m -56.32 -38.55 71.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.209 -0.45 . . . . 65.32 110.85 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 4.6 p90 -111.8 178.26 4.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.167 -0.47 . . . . 73.22 110.905 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.46 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 0.0 OUTLIER -117.08 170.81 8.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 53.41 110.92 179.873 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 5.8 tp -104.09 151.35 23.38 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.246 -0.433 . . . . 71.11 110.886 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 4.0 t-20 -145.07 137.84 26.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.17 -0.468 . . . . 74.1 110.919 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 26.8 p -136.22 122.5 20.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 72.54 110.906 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -140.5 164.62 29.67 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.136 -0.484 . . . . 61.22 110.878 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 94.7 t -150.51 116.61 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.248 -0.433 . . . . 73.4 111.115 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -97.66 146.49 25.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.171 -0.468 . . . . 74.24 110.879 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 62.2 t80 -146.81 143.3 28.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 71.14 110.86 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' ILE . . . . . 0.468 HG21 ' HB2' ' A' ' 148' ' ' ALA . 0.0 OUTLIER -179.0 103.14 0.2 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.66 0.743 . . . . 73.32 111.154 179.918 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 127.32 14.48 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.661 2.241 . . . . 72.24 112.439 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -148.64 178.42 8.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.254 -0.43 . . . . 62.04 110.952 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.82 127.74 37.26 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.187 -0.461 . . . . 74.04 110.892 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 8.8 t -91.88 165.96 12.97 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.291 -0.413 . . . . 63.33 111.123 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . 0.41 ' HB2' ' HB3' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -124.58 167.06 15.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 72.23 110.86 179.884 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.447 HG13 ' O ' ' A' ' 140' ' ' ASP . 45.7 t -152.16 139.78 13.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.13 -0.487 . . . . 72.22 111.163 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 14.5 t -167.27 179.35 5.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 63.01 111.149 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 131.63 143.49 5.21 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.747 -0.739 . . . . 63.34 112.45 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 7.1 t -173.07 179.09 2.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.86 0.362 . . . . 64.21 111.111 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 9.6 tp -139.29 89.14 2.32 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.184 -0.462 . . . . 74.53 111.015 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 118.03 -82.33 0.33 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.784 -0.722 . . . . 62.14 112.47 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -168.87 0.29 Allowed 'Trans proline' 0 C--N 1.343 0.243 0 C-N-CA 122.644 2.23 . . . . 53.25 112.363 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 7.5 p -82.21 125.63 76.43 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.65 0.738 . . . . 72.54 111.117 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 159.43 53.43 Favored 'Trans proline' 0 C--O 1.231 0.157 0 C-N-CA 122.704 2.269 . . . . 73.11 112.368 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 44.6 t -96.8 107.5 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.227 -0.442 . . . . 71.03 111.092 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 13.3 p -89.36 104.98 17.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 63.51 110.861 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 10.8 p -110.22 166.53 10.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.083 -0.508 . . . . 74.13 111.151 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -152.23 146.6 25.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 73.1 110.922 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 18.2 pt -142.51 130.39 20.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 74.21 111.14 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 190' ' ' GLU . . . . . 0.547 ' OE1' HD13 ' A' ' 35' ' ' LEU . 10.3 pt-20 -99.29 118.23 35.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 74.01 110.837 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 191' ' ' VAL . . . . . 0.68 HG11 HG23 ' A' ' 28' ' ' VAL . 8.5 p -137.79 159.99 33.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 72.11 111.143 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.408 ' N ' HG22 ' A' ' 191' ' ' VAL . 0.2 OUTLIER -107.22 90.26 5.46 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.567 0.699 . . . . 74.13 110.927 179.982 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 116.31 4.5 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.683 2.255 . . . . 75.44 112.342 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -100.28 119.65 38.72 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.176 -0.466 . . . . 70.2 110.918 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 195' ' ' ILE . . . . . 0.614 HD13 ' HA ' ' A' ' 26' ' ' VAL . 40.5 mm -108.79 119.48 58.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.123 -0.49 . . . . 63.44 111.094 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 7.3 mp -113.03 107.25 15.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.156 -0.475 . . . . 74.13 110.949 179.863 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . 0.603 ' O ' HD12 ' A' ' 198' ' ' LEU . 0.9 OUTLIER -95.31 124.47 39.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.225 -0.443 . . . . 70.13 110.826 -179.907 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 198' ' ' LEU . . . . . 0.603 HD12 ' O ' ' A' ' 197' ' ' SER . 5.0 mp -146.39 127.92 15.07 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.101 -0.5 . . . . 71.43 110.987 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 177.27 -136.25 3.05 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.655 -0.783 . . . . 64.42 112.442 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 200' ' ' ALA . . . . . 0.46 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -134.06 173.15 11.89 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.85 0.357 . . . . 64.32 111.114 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 2.3 p -144.92 174.83 10.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.434 . . . . 71.53 110.92 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 202' ' ' TYR . . . . . 0.437 ' O ' HG13 ' A' ' 18' ' ' VAL . 12.6 t80 -148.63 138.77 22.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.101 -0.499 . . . . 74.23 110.854 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 11.5 p -77.2 151.23 5.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.077 -0.51 . . . . 73.14 111.117 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 20.1 m-85 -153.13 114.15 4.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.133 -0.485 . . . . 71.14 110.896 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 5.7 ptpt -108.02 -36.54 6.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 71.21 110.879 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 17.1 mt -100.77 151.64 21.44 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.24 -0.436 . . . . 74.52 110.914 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -95.09 117.47 30.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 65.03 111.065 179.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -94.03 -50.44 5.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 75.32 111.154 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -95.43 108.68 20.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 61.33 111.165 179.853 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 23.3 tp -123.29 123.37 40.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 60.43 110.834 -179.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 . . . . . 0 C--N 1.33 -0.239 0 CA-C-N 116.157 -0.474 . . . . 73.35 110.91 179.93 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 81.1 mmm . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.791 0.329 . . . . 74.13 110.916 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -136.29 136.69 39.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.264 -0.426 . . . . 61.04 110.922 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.7 mp0 -141.69 172.61 12.45 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 63.5 110.848 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -108.65 174.26 5.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.12 -0.491 . . . . 55.11 110.864 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -149.63 143.96 17.32 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.714 0.768 . . . . 71.21 110.885 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 -170.67 0.41 Allowed 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.744 2.296 . . . . 74.21 112.342 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -126.21 163.65 22.71 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.258 -0.428 . . . . 60.02 111.084 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 19.9 mmmt -120.32 171.42 8.52 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.205 -0.452 . . . . 75.24 110.962 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 94.9 p -121.49 173.57 7.31 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.262 -0.426 . . . . 53.54 110.828 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -151.78 171.26 17.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 74.45 111.074 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -100.5 33.61 6.22 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.739 -0.743 . . . . 72.11 112.446 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 13.8 p90 -160.33 117.43 2.47 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.906 0.384 . . . . 73.44 110.935 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -162.34 148.96 13.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.476 . . . . 74.4 110.927 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -52.03 127.83 22.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.161 -0.472 . . . . 62.53 110.919 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.94 6.9 68.96 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.72 -0.753 . . . . 60.24 112.421 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -75.54 145.24 41.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.752 0.31 . . . . 74.13 110.884 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 0.6 OUTLIER -127.22 121.56 31.58 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.234 -0.439 . . . . 73.22 110.958 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.783 HG13 ' HB3' ' A' ' 60' ' ' ALA . 2.9 p -131.28 123.55 53.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.252 -0.431 . . . . 74.21 111.115 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -84.41 115.18 22.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.117 -0.492 . . . . 64.33 111.097 179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -104.62 108.8 20.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 62.35 110.9 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -111.97 125.3 53.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 64.3 110.942 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.404 ' HB2' ' C ' ' A' ' 198' ' ' LEU . 5.4 p30 -153.53 174.05 14.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 61.13 110.829 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -98.0 129.45 44.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.113 -0.494 . . . . 74.5 110.814 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -97.22 122.47 40.27 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.148 -0.478 . . . . 72.23 110.836 -179.847 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -102.4 105.76 16.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.089 -0.505 . . . . 73.43 110.902 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 24.5 m -82.71 131.04 34.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.272 -0.422 . . . . 71.04 111.164 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 10.2 m-85 -123.98 99.35 6.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.177 -0.465 . . . . 71.42 110.901 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.2 p -158.46 151.26 7.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.216 -0.447 . . . . 51.02 111.164 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.99 72.32 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.707 -0.759 . . . . 64.01 112.419 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.5 tp10 -89.07 -66.47 0.92 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.853 0.358 . . . . 75.12 110.83 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -176.23 172.5 2.31 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 43.05 110.88 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.56 ' HB3' ' HB3' ' A' ' 45' ' ' ALA . 24.4 tp -104.22 150.77 24.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 55.33 110.884 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.16 105.34 0.19 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.718 -0.753 . . . . 42.44 112.495 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -50.73 -32.77 20.56 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.858 0.361 . . . . 54.42 110.901 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 23.8 tp -50.2 -34.75 23.77 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.114 -0.494 . . . . 71.12 110.9 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 5.5 t30 -51.62 103.78 0.07 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 50.02 110.908 179.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.7 p -58.8 152.23 4.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.441 . . . . 74.42 111.121 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -135.76 -67.39 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.735 -0.745 . . . . 51.41 112.517 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 176.95 120.94 0.65 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.756 -0.735 . . . . 52.34 112.494 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.98 -117.53 8.09 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.74 -0.743 . . . . 61.24 112.47 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -54.62 174.85 0.06 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.803 0.335 . . . . 75.22 111.122 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.6 mt -120.18 67.84 12.9 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.539 0.685 . . . . 75.45 110.89 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.75 -170.66 0.41 Allowed 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.668 2.245 . . . . 65.21 112.337 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -122.79 134.32 54.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 75.12 110.912 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.56 ' HB3' ' HB3' ' A' ' 32' ' ' LEU . . . -88.78 166.32 14.11 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 65.42 111.094 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -137.49 133.96 35.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 71.15 110.833 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.404 HG12 ' CA ' ' A' ' 83' ' ' GLY . 21.8 m -106.73 151.17 8.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 73.42 111.105 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 14.7 t -156.8 151.28 25.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 75.35 110.818 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.468 HD12 ' CD1' ' A' ' 81' ' ' PHE . 38.4 mm -120.93 116.49 50.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.088 -0.506 . . . . 74.04 111.09 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -51.56 157.9 2.84 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.693 -0.765 . . . . 40.41 112.425 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -51.75 103.28 0.06 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.817 0.341 . . . . 72.33 110.954 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.409 ' O ' ' C ' ' A' ' 53' ' ' THR . 1.1 p-10 -58.48 -56.9 16.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 71.14 110.931 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.409 ' C ' ' O ' ' A' ' 52' ' ' ASP . 10.2 t 36.73 44.08 0.32 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.115 -0.493 . . . . 74.13 111.186 -179.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.445 HG22 ' H ' ' A' ' 55' ' ' LEU . 0.2 OUTLIER -107.6 169.17 8.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.198 -0.455 . . . . 64.23 111.096 -179.93 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.602 ' O ' HD12 ' A' ' 55' ' ' LEU . 0.9 OUTLIER -109.49 150.23 28.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.198 -0.455 . . . . 73.14 110.907 -179.981 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.5 t -134.47 144.65 48.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.284 -0.416 . . . . 72.21 111.161 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 42.2 m-85 -102.9 132.57 49.02 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.252 -0.431 . . . . 73.53 110.826 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.547 ' C ' HD12 ' A' ' 59' ' ' ILE . 0.3 OUTLIER -127.31 146.63 50.38 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.148 -0.478 . . . . 74.21 110.91 179.96 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.547 HD12 ' C ' ' A' ' 58' ' ' ASP . 1.5 mp -119.28 113.61 41.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.224 -0.444 . . . . 65.31 111.131 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.783 ' HB3' HG13 ' A' ' 18' ' ' VAL . . . -102.66 117.0 33.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.467 . . . . 74.33 111.09 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 34.7 t80 -108.73 115.76 30.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.156 -0.475 . . . . 74.21 110.96 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -87.23 96.97 10.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.129 -0.487 . . . . 73.55 110.889 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.7 p -86.72 -33.15 6.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.146 -0.479 . . . . 72.42 111.12 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 t -130.67 164.91 23.98 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.184 -0.462 . . . . 62.21 110.892 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.9 t -87.21 3.24 47.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.179 -0.464 . . . . 61.21 110.92 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 61.6 t30 -110.72 -33.45 6.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.109 -0.496 . . . . 52.05 110.865 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.446 HG22 ' HA ' ' A' ' 107' ' ' TYR . 44.4 pt -150.54 172.02 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 72.35 111.12 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -157.16 172.85 17.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.14 -0.482 . . . . 72.14 111.058 179.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 105' ' ' LEU . 10.2 m -112.1 150.97 14.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.223 -0.444 . . . . 72.33 111.129 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -138.11 127.48 24.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 64.24 110.857 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -102.4 147.2 27.01 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.471 . . . . 64.54 110.888 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.4 ' HB3' ' HB ' ' A' ' 102' ' ' ILE . 30.4 t80 -121.25 112.95 19.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.149 -0.478 . . . . 65.54 110.9 -179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 7.5 m -129.47 147.0 33.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 73.21 111.102 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -164.26 128.78 1.87 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.741 -0.742 . . . . 64.52 112.475 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 23.4 t -117.21 68.18 4.89 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.674 0.75 . . . . 53.12 111.155 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 162.67 41.21 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.679 2.253 . . . . 62.35 112.344 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -79.48 -165.67 0.83 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.265 -0.425 . . . . 72.5 111.059 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . 0.404 ' HA ' ' HA ' ' A' ' 97' ' ' ASP . 55.1 ttp85 -76.88 139.28 40.2 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.148 -0.478 . . . . 74.14 110.916 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -133.83 151.88 51.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 52.13 111.088 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 3.0 ttpt -104.48 130.7 52.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.16 -0.473 . . . . 72.41 110.863 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . 0.468 ' CD1' HD12 ' A' ' 49' ' ' ILE . 26.9 m-85 -119.26 157.42 28.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 74.43 110.879 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.433 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -110.84 149.53 30.45 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 73.42 110.926 -179.921 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.644 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -177.14 75.64 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.783 -0.722 . . . . 73.23 112.493 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.532 ' HA ' ' HB1' ' A' ' 45' ' ' ALA . 1.8 tp10 -178.26 -176.37 0.52 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.999 0.428 . . . . 73.15 110.866 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.31 -69.15 0.69 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.174 -0.466 . . . . 65.1 110.92 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.4 t -84.63 -32.88 23.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.254 -0.43 . . . . 73.3 110.855 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.87 HG22 HG22 ' A' ' 93' ' ' VAL . 5.8 mm -65.57 -34.31 69.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 74.54 111.129 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 74.2 p -62.57 -53.81 49.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.475 . . . . 44.23 110.852 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.7 t -51.13 -35.86 37.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.134 -0.485 . . . . 62.21 110.867 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.515 HD13 ' O ' ' A' ' 90' ' ' LEU . 0.3 OUTLIER -63.5 -38.26 90.47 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.139 -0.482 . . . . 62.32 110.96 179.921 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 100.56 -14.37 59.25 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.776 -0.726 . . . . 61.12 112.505 179.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 19.2 ttt-85 -118.63 95.38 4.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.797 0.332 . . . . 74.33 110.941 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.87 HG22 HG22 ' A' ' 87' ' ' ILE . 94.0 t -111.66 -53.81 5.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 62.44 111.184 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 11.5 t -140.26 143.05 35.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 65.12 110.821 -179.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -132.27 115.37 15.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.116 -0.493 . . . . 63.42 110.931 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.582 ' HA ' ' HB2' ' A' ' 131' ' ' LYS . 1.4 m -154.47 171.49 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.107 -0.497 . . . . 75.12 111.146 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.485 ' O ' HG23 ' A' ' 96' ' ' VAL . 1.1 m-20 -86.34 172.1 10.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.202 -0.454 . . . . 64.4 110.895 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -123.25 130.52 52.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.266 -0.424 . . . . 64.32 110.919 -179.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.543 ' HA3' HD12 ' A' ' 127' ' ' LEU . . . -129.12 65.63 0.58 Allowed Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.733 -0.746 . . . . 73.42 112.431 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 112.76 3.16 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.704 2.269 . . . . 62.11 112.381 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -127.43 105.06 8.25 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.167 -0.469 . . . . 73.43 111.054 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.636 HG23 ' CA ' ' A' ' 124' ' ' GLY . 4.8 mp -128.23 151.13 34.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 74.45 111.133 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -145.99 115.7 7.26 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 61.54 110.924 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.8 p -139.62 -175.82 4.34 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.216 -0.447 . . . . 72.02 110.832 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.638 ' O ' HD12 ' A' ' 105' ' ' LEU . 1.5 pp -134.54 147.86 50.38 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.139 -0.482 . . . . 53.32 110.908 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 1.8 pp0? -104.65 139.0 40.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 73.33 110.915 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.446 ' HA ' HG22 ' A' ' 67' ' ' ILE . 14.2 p90 -143.18 142.74 31.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 72.44 110.956 -179.864 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 17.5 t-160 -94.49 138.88 31.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.143 -0.481 . . . . 71.44 110.876 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 4.4 t80 -131.12 107.89 9.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.224 -0.444 . . . . 73.51 110.915 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -173.28 178.07 2.51 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.108 -0.496 . . . . 23.41 110.956 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 57.9 m -110.95 36.22 3.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.274 -0.421 . . . . 53.34 110.819 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 53.57 36.53 23.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.182 -0.463 . . . . 73.54 110.912 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 75.5 mm-40 -84.11 -72.81 0.45 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.151 -0.477 . . . . 74.13 110.877 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 10.9 mmt85 -131.6 171.43 13.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 75.12 110.851 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 10.6 tp -66.61 136.99 56.41 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.193 -0.458 . . . . 70.41 110.934 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 6.3 m-85 -157.32 160.43 30.43 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.714 0.769 . . . . 63.52 110.88 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . 0.704 ' HA ' HD13 ' A' ' 153' ' ' LEU . 54.1 Cg_endo -69.77 177.93 5.09 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.67 2.247 . . . . 74.34 112.333 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 11.2 m-85 -115.98 143.99 44.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.242 -0.436 . . . . 71.4 110.876 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.459 HG13 ' HE1' ' A' ' 149' ' ' PHE . 75.7 t -99.35 132.89 43.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.085 -0.507 . . . . 71.24 111.116 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -125.51 169.43 17.46 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.712 -0.756 . . . . 54.55 112.512 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 7.7 p -175.59 152.53 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.915 0.388 . . . . 63.44 111.125 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -179.78 -151.7 10.13 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.834 -0.698 . . . . 71.35 112.555 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 7.7 p -111.37 127.25 68.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.827 0.346 . . . . 64.11 111.103 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . 0.636 ' CA ' HG23 ' A' ' 102' ' ' ILE . . . -119.77 108.85 1.54 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.79 -0.719 . . . . 71.34 112.513 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 35.7 ptt180 -100.73 123.23 44.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.909 0.385 . . . . 71.44 110.891 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 34.6 t -103.12 110.27 29.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.174 -0.467 . . . . 74.2 111.136 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.543 HD12 ' HA3' ' A' ' 99' ' ' GLY . 2.8 pp -120.3 156.7 30.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.474 . . . . 70.23 110.903 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 9.4 p90 -160.43 166.04 29.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 74.3 110.855 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -102.24 118.03 36.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 74.3 110.899 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -66.11 93.48 0.21 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.129 -0.487 . . . . 60.32 110.89 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.582 ' HB2' ' HA ' ' A' ' 96' ' ' VAL . 0.0 OUTLIER -74.18 -76.39 0.13 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.243 -0.435 . . . . 65.43 110.934 179.984 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 20.2 m -161.97 121.92 2.5 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.214 -0.448 . . . . 74.24 111.055 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . 0.583 ' HB3' ' HB3' ' A' ' 139' ' ' PHE . 27.0 t0 -108.08 114.56 28.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 43.43 110.789 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -75.78 -12.42 83.88 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.691 -0.766 . . . . 64.23 112.469 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -44.37 -29.36 0.67 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.902 0.382 . . . . 51.11 111.083 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -160.29 163.96 32.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.236 -0.438 . . . . 74.14 110.867 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 3.8 m -42.17 97.86 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.136 -0.484 . . . . 72.22 110.922 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 70.7 m 49.81 65.16 1.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 70.0 110.908 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.583 ' HB3' ' HB3' ' A' ' 133' ' ' ASP . 1.2 t80 -94.5 160.85 14.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 73.42 110.868 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -139.96 167.19 22.69 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.124 -0.489 . . . . 53.34 110.848 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.474 ' HA ' HG23 ' A' ' 176' ' ' VAL . 15.4 mt -117.36 151.79 19.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.471 . . . . 74.42 111.151 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 12.3 tppt? -113.18 122.62 48.05 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 75.45 110.913 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -76.81 -173.74 2.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.129 -0.487 . . . . 73.45 110.853 179.85 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -171.75 179.09 2.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 75.21 110.931 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 52.1 p-90 -140.06 161.37 37.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.216 -0.447 . . . . 74.3 110.881 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.757 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.8 165.29 0.87 Allowed Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.59 0.71 . . . . 62.3 111.135 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.757 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 54.5 Cg_endo -69.74 161.92 44.08 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.673 2.248 . . . . 74.42 112.402 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.403 ' HA ' ' CB ' ' A' ' 170' ' ' ILE . . . -151.3 146.01 25.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 71.4 111.142 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . 0.459 ' HE1' HG13 ' A' ' 119' ' ' VAL . 1.4 t80 -103.07 120.24 40.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 52.12 110.896 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 16.7 tt0 -102.94 156.87 17.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 63.04 110.899 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.443 HG13 ' HB ' ' A' ' 167' ' ' VAL . 7.3 p -164.85 123.67 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.264 -0.426 . . . . 72.0 111.146 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -174.73 -159.54 21.19 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.717 -0.754 . . . . 51.23 112.47 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.704 HD13 ' HA ' ' A' ' 117' ' ' PRO . 19.5 tp -151.8 164.78 36.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.784 0.325 . . . . 71.15 110.876 -179.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.4 tpp85 -115.78 120.43 39.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 75.44 110.931 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -104.68 154.79 19.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 74.43 110.933 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -120.24 104.18 9.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.116 -0.493 . . . . 72.11 110.824 179.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' LEU . . . . . 0.636 HD11 HD12 ' A' ' 163' ' ' LEU . 23.6 mt -72.57 153.1 41.45 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.197 -0.456 . . . . 71.0 110.905 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -53.0 -33.44 44.24 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.759 -0.734 . . . . 52.44 112.523 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -71.32 176.18 4.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.819 0.342 . . . . 73.41 110.847 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 73.0 m -60.86 -36.53 79.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.127 -0.488 . . . . 73.24 110.884 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 26.6 m0 -80.92 144.17 32.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 74.01 110.945 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.451 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 2.4 mpt? -106.77 169.56 8.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 74.52 110.876 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.636 HD12 HD11 ' A' ' 157' ' ' LEU . 0.3 OUTLIER -107.24 148.78 28.5 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 53.11 110.916 -179.975 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -143.85 133.28 23.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 75.21 110.857 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 42.1 t -135.41 122.53 21.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 70.22 110.858 -179.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -131.47 153.71 49.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.107 -0.497 . . . . 74.34 110.945 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.621 HG13 ' HE1' ' A' ' 194' ' ' PHE . 78.4 t -133.45 121.49 41.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.27 -0.423 . . . . 60.54 111.089 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . 0.798 ' HD2' HD12 ' A' ' 195' ' ' ILE . 3.9 ttm-85 -103.46 132.41 49.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 64.21 110.876 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -143.01 128.18 18.65 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 75.4 110.942 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' ILE . . . . . 0.459 HG21 ' O ' ' A' ' 147' ' ' PRO . 3.6 tp 177.91 133.78 0.22 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.576 0.703 . . . . 75.33 111.118 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . 0.407 ' HD2' HG13 ' A' ' 170' ' ' ILE . 53.5 Cg_endo -69.74 111.6 2.85 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.676 2.251 . . . . 50.45 112.366 179.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -122.5 153.16 39.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 73.35 110.909 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 14.5 pttm -130.57 153.58 48.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 61.43 110.854 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -123.28 170.74 9.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.126 -0.488 . . . . 73.52 111.094 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -125.03 164.88 19.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 73.04 110.87 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.48 HG22 ' CE1' ' A' ' 139' ' ' PHE . 5.6 p -156.46 142.63 10.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 73.1 111.117 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 10.0 t -166.62 -179.25 4.76 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.215 -0.448 . . . . 62.34 111.12 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -120.49 -161.1 11.36 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.734 -0.746 . . . . 64.32 112.475 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -124.59 -172.09 2.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.786 0.327 . . . . 71.21 111.178 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 7.8 tp -61.86 146.18 50.5 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.218 -0.447 . . . . 75.44 110.912 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 116.52 -86.78 0.42 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.76 -0.733 . . . . 72.52 112.445 179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.83 -160.83 0.07 OUTLIER 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.648 2.232 . . . . 74.53 112.32 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 19.9 t -106.28 87.66 2.73 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.646 0.736 . . . . 74.44 111.118 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 141.54 45.51 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.674 2.249 . . . . 73.33 112.359 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.444 HG12 ' CG2' ' A' ' 187' ' ' THR . 21.6 t -127.17 107.2 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.222 -0.445 . . . . 71.44 111.179 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 1.2 p -74.93 104.43 5.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.199 -0.455 . . . . 74.4 110.865 -179.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . 0.444 ' CG2' HG12 ' A' ' 185' ' ' VAL . 12.1 p -131.6 172.06 12.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.105 -0.498 . . . . 65.1 111.155 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.84 162.62 39.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.265 -0.425 . . . . 75.4 110.914 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 189' ' ' ILE . . . . . 0.484 HD11 ' CD1' ' A' ' 32' ' ' LEU . 56.7 mt -137.85 128.33 37.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 74.21 111.153 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -106.57 113.3 26.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.133 -0.485 . . . . 71.33 110.871 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 191' ' ' VAL . . . . . 0.49 HG12 ' H ' ' A' ' 192' ' ' ASP . 1.3 t -136.96 169.59 19.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.087 -0.506 . . . . 62.41 111.088 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.49 ' H ' HG12 ' A' ' 191' ' ' VAL . 20.5 t70 -107.27 87.14 2.98 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.61 0.719 . . . . 51.43 110.896 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 121.51 8.19 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.631 2.22 . . . . 65.41 112.395 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 194' ' ' PHE . . . . . 0.621 ' HE1' HG13 ' A' ' 167' ' ' VAL . 1.7 t80 -103.12 115.89 31.46 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 52.12 110.881 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 195' ' ' ILE . . . . . 0.798 HD12 ' HD2' ' A' ' 168' ' ' ARG . 9.7 mt -102.9 124.68 57.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 61.54 111.118 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 1.2 tt -112.71 108.54 17.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 74.31 110.897 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.25 115.68 28.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.257 -0.429 . . . . 71.34 110.818 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 198' ' ' LEU . . . . . 0.404 ' C ' ' HB2' ' A' ' 22' ' ' ASN . 5.7 tt -138.21 121.06 16.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.122 -0.49 . . . . 74.13 110.938 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -175.36 -141.44 3.73 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.825 -0.702 . . . . 64.5 112.538 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 200' ' ' ALA . . . . . 0.451 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -128.51 173.82 9.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.781 0.324 . . . . 70.03 111.104 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 26.2 t -146.55 163.51 35.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.458 . . . . 74.22 110.832 -179.749 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 202' ' ' TYR . . . . . 0.551 ' C ' HG23 ' A' ' 18' ' ' VAL . 2.1 t80 -133.9 114.4 13.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.149 -0.478 . . . . 75.31 110.883 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 57.8 t -76.88 145.11 10.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.091 -0.504 . . . . 72.15 111.108 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 -148.08 137.01 21.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.107 -0.497 . . . . 72.35 110.888 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.43 174.74 10.2 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.081 -0.508 . . . . 75.2 110.898 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 10.3 mp -75.88 -62.02 1.73 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.222 -0.444 . . . . 74.41 110.954 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -55.76 134.22 51.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 60.2 111.145 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . 0.563 ' HB1' HD13 ' A' ' 210' ' ' LEU . . . -75.37 -60.42 2.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.449 . . . . 52.03 111.088 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . 62.67 40.34 10.33 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.199 -0.455 . . . . 60.45 111.103 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . 0.563 HD13 ' HB1' ' A' ' 208' ' ' ALA . 6.4 mp -97.84 -45.55 6.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 53.41 110.893 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.205 -0.452 . . . . 62.42 110.908 179.865 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 20.5 mtm . . . . . 0 C--O 1.23 0.053 0 CA-C-O 120.774 0.321 . . . . 73.44 110.895 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 12.1 m-80 54.57 39.29 31.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 70.52 110.921 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 64.9 tt0 -77.53 111.93 13.78 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.18 -0.464 . . . . 65.21 110.804 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -101.17 151.54 21.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.163 -0.471 . . . . 73.04 110.866 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 10.0 p90 -51.8 156.98 2.15 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.738 0.78 . . . . 63.02 110.907 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 178.29 4.71 Favored 'Trans proline' 0 N--CA 1.465 -0.2 0 C-N-CA 122.746 2.297 . . . . 70.31 112.351 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -79.22 131.8 36.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.23 -0.441 . . . . 53.01 111.065 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 12.8 ptmm? -97.23 -36.03 10.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 73.42 110.868 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 2.5 t -52.14 -37.62 55.0 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.234 -0.439 . . . . 74.31 110.851 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -53.24 156.16 2.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.176 -0.465 . . . . 74.41 111.093 179.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -102.6 38.73 3.06 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.731 -0.747 . . . . 73.52 112.512 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 10.5 p90 -163.77 112.13 1.2 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.909 0.385 . . . . 70.02 110.884 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -168.36 169.64 10.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 73.31 110.905 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 15.4 mp0 -57.86 119.84 7.41 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.142 -0.481 . . . . 74.05 110.904 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.87 6.45 40.17 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.808 -0.711 . . . . 52.35 112.533 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -67.11 145.45 55.29 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.778 0.323 . . . . 72.05 110.857 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -125.43 121.68 34.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.203 -0.453 . . . . 52.33 110.894 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.724 HG23 ' HB3' ' A' ' 60' ' ' ALA . 13.5 m -130.69 134.91 61.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 63.23 111.145 179.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.56 ' HB1' ' CZ ' ' A' ' 21' ' ' PHE . . . -94.24 116.81 29.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 45.52 111.162 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 3.0 p -105.94 108.21 19.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 65.42 110.796 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.56 ' CZ ' ' HB1' ' A' ' 19' ' ' ALA . 16.5 m-85 -112.11 121.22 44.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.146 -0.479 . . . . 71.25 110.89 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -152.15 172.46 16.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 73.35 110.885 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -95.89 131.97 41.68 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.153 -0.476 . . . . 73.22 110.819 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -101.01 109.92 21.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.111 -0.495 . . . . 64.03 110.882 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 29.4 mmtt -93.9 106.33 18.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.485 . . . . 74.35 110.89 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.682 HG22 ' CD1' ' A' ' 195' ' ' ILE . 21.8 t -79.62 121.08 32.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.259 -0.428 . . . . 71.1 111.128 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.512 ' CD1' HD13 ' A' ' 196' ' ' LEU . 10.5 m-85 -105.64 99.67 9.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.455 . . . . 75.22 110.948 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.9 HG23 HG11 ' A' ' 191' ' ' VAL . 5.5 p -167.69 141.09 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.123 -0.49 . . . . 74.2 111.16 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.75 72.09 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.753 -0.736 . . . . 54.03 112.44 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 16.6 tt0 -89.93 -66.19 0.95 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.809 0.338 . . . . 72.32 110.85 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 179.4 103.44 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 73.43 110.89 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.688 HD22 ' C ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -57.15 167.25 0.91 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.092 -0.504 . . . . 72.23 110.901 -179.952 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.549 ' N ' HD22 ' A' ' 32' ' ' LEU . . . -80.68 114.69 3.88 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.705 -0.759 . . . . 61.24 112.506 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -51.48 140.53 17.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.804 0.335 . . . . 75.2 110.868 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.615 ' HB2' HG11 ' A' ' 185' ' ' VAL . 2.2 pt? -77.11 -33.28 56.92 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.131 -0.486 . . . . 74.15 110.924 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 32.2 t30 -170.5 156.67 5.57 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.223 -0.444 . . . . 73.31 110.896 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.4 p -98.63 138.86 21.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.223 -0.444 . . . . 31.22 111.202 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -105.67 -98.45 2.55 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.759 -0.734 . . . . 43.32 112.496 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -148.87 144.08 11.73 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.757 -0.735 . . . . 60.52 112.519 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 106.15 146.35 13.8 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.763 -0.732 . . . . 23.41 112.568 -179.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -72.2 99.57 2.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.844 0.354 . . . . 74.44 111.111 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.1 mt -145.24 158.83 50.77 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.534 0.683 . . . . 73.23 110.914 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.84 179.57 3.65 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.663 2.242 . . . . 53.13 112.341 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 -56.88 -68.13 0.25 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 64.33 110.909 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.4 ' HB1' HD11 ' A' ' 32' ' ' LEU . . . -170.96 -172.59 1.16 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.232 -0.44 . . . . 71.44 111.164 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -150.43 125.25 9.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.276 -0.42 . . . . 64.15 110.873 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 82' ' ' GLN . 12.5 p -119.13 134.02 64.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.203 -0.453 . . . . 72.41 111.114 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.9 m -153.45 178.51 9.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 54.52 110.849 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.532 HG22 ' CD1' ' A' ' 81' ' ' PHE . 42.6 pt -134.97 145.88 31.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.094 -0.503 . . . . 72.52 111.173 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -62.33 179.13 4.77 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.768 -0.73 . . . . 62.22 112.518 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.7 m-80 -119.96 107.84 13.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.8 0.333 . . . . 54.1 110.896 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -143.92 148.53 35.51 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 71.4 110.898 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.9 p -61.46 134.26 56.69 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.217 -0.447 . . . . 64.02 111.151 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 15.3 t -143.75 169.68 17.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 41.34 111.133 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -155.9 160.44 40.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 71.24 110.931 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.442 HG22 ' HA3' ' A' ' 74' ' ' GLY . 8.8 p -141.12 142.51 34.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.449 . . . . 60.13 111.162 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -102.44 132.2 48.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 73.35 110.899 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.65 ' O ' HD13 ' A' ' 59' ' ' ILE . 1.3 m-20 -129.14 149.91 50.75 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.142 -0.481 . . . . 70.33 110.863 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.65 HD13 ' O ' ' A' ' 58' ' ' ASP . 8.0 mm -122.39 114.36 42.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.443 . . . . 72.03 111.175 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.724 ' HB3' HG23 ' A' ' 18' ' ' VAL . . . -101.92 130.06 48.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 72.12 111.086 179.831 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.501 ' HB3' HG22 ' A' ' 69' ' ' VAL . 14.9 t80 -118.15 118.35 31.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.233 -0.439 . . . . 74.43 110.936 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -90.52 97.01 10.93 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.156 -0.474 . . . . 72.01 110.897 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.0 p -91.16 -34.91 6.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.206 -0.452 . . . . 73.44 111.129 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.2 t -130.02 159.67 35.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 64.33 110.894 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 93.4 p -84.13 2.76 37.96 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 61.13 110.827 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 41.2 m-80 -112.01 -32.5 6.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 73.34 110.876 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.511 HG22 ' CB ' ' A' ' 107' ' ' TYR . 2.3 pp -149.13 164.78 4.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.474 . . . . 74.44 111.142 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -154.68 169.89 22.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 60.04 111.124 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.501 HG22 ' HB3' ' A' ' 61' ' ' TYR . 6.1 m -110.97 152.93 12.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.445 . . . . 74.14 111.112 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -148.61 124.27 10.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.465 . . . . 54.32 110.875 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.658 ' CZ ' HD22 ' A' ' 103' ' ' LEU . 2.4 t80 -102.72 131.06 49.8 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 64.33 110.917 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.553 ' HE2' ' HG ' ' A' ' 197' ' ' SER . 24.2 m-85 -111.65 118.64 36.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.108 -0.496 . . . . 72.43 110.829 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 11.0 p -142.51 151.79 17.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 42.0 111.116 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.442 ' HA3' HG22 ' A' ' 56' ' ' THR . . . -160.05 160.7 31.85 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.732 . . . . 74.11 112.491 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.477 ' O ' HG13 ' A' ' 75' ' ' VAL . 4.0 p -138.29 77.72 35.08 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.691 0.758 . . . . 72.32 111.129 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 152.26 69.32 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.734 2.289 . . . . 73.35 112.346 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -71.17 -168.38 0.29 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 72.01 111.071 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 19.8 ttp-105 -77.58 127.31 32.28 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 74.23 110.857 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -133.66 140.69 47.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 44.23 111.118 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -89.58 141.73 28.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.443 . . . . 54.23 110.921 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . 0.532 ' CD1' HG22 ' A' ' 49' ' ' ILE . 11.9 m-85 -132.73 147.43 52.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.237 -0.438 . . . . 72.43 110.858 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.583 ' O ' HG23 ' A' ' 47' ' ' VAL . 0.4 OUTLIER -92.82 155.52 17.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 65.41 110.877 -179.92 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.537 ' H ' HG21 ' A' ' 93' ' ' VAL . . . -179.46 72.79 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.759 -0.734 . . . . 61.34 112.517 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -178.9 -174.15 0.34 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.937 0.399 . . . . 70.12 110.846 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 6.0 mtpt -85.82 -70.17 0.61 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.114 -0.494 . . . . 72.33 110.904 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 74.0 m -84.3 -31.1 25.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.259 -0.428 . . . . 72.11 110.899 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.929 HG22 HG22 ' A' ' 93' ' ' VAL . 1.2 mt -68.17 -33.73 62.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.122 -0.49 . . . . 74.45 111.119 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 12.2 t -62.46 -47.26 84.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 74.32 110.842 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 36.9 t -57.69 -35.37 70.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.183 -0.462 . . . . 75.3 110.833 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.541 HD23 ' HG2' ' A' ' 92' ' ' ARG . 4.2 tp -63.64 -48.33 77.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.474 . . . . 71.31 110.988 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 111.37 -13.33 28.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.716 -0.754 . . . . 64.13 112.474 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.541 ' HG2' HD23 ' A' ' 90' ' ' LEU . 0.0 OUTLIER -117.79 87.47 2.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.906 0.384 . . . . 73.44 110.911 -179.837 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.929 HG22 HG22 ' A' ' 87' ' ' ILE . 32.3 t -113.05 -42.05 4.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.195 -0.457 . . . . 75.15 111.14 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 80.4 p -141.0 152.05 44.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.253 -0.43 . . . . 54.34 110.897 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -141.43 116.98 10.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.141 -0.481 . . . . 72.13 110.92 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.746 HG23 ' HB2' ' A' ' 131' ' ' LYS . 2.6 p -178.23 166.42 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 72.3 111.182 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.473 ' H ' HG22 ' A' ' 96' ' ' VAL . 2.5 p30 -95.07 156.48 16.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.146 -0.479 . . . . 72.42 110.855 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -93.98 147.63 22.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.165 -0.471 . . . . 64.24 110.99 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -126.39 60.87 0.64 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.773 -0.727 . . . . 70.52 112.501 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 113.86 3.52 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.644 2.229 . . . . 53.33 112.323 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.43 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -131.47 108.53 9.65 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.167 -0.469 . . . . 52.42 111.079 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.689 HG22 ' CA ' ' A' ' 124' ' ' GLY . 1.2 pp -140.27 153.06 21.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.481 . . . . 73.3 111.085 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.658 HD22 ' CZ ' ' A' ' 71' ' ' PHE . 0.7 OUTLIER -149.62 130.97 14.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.145 -0.48 . . . . 43.31 110.924 179.913 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.2 p -151.34 170.45 19.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.212 -0.449 . . . . 52.0 110.87 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.593 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.7 OUTLIER -113.46 147.01 38.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 74.21 110.908 179.981 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 34.4 mt-30 -101.7 144.78 29.98 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.181 -0.463 . . . . 73.54 110.98 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.511 ' CB ' HG22 ' A' ' 67' ' ' ILE . 46.7 p90 -153.73 150.4 28.49 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.244 -0.435 . . . . 63.34 110.967 -179.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 2.2 p80 -130.7 160.77 33.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.126 -0.488 . . . . 75.1 110.863 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 10.0 t80 -90.38 107.51 19.19 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.181 -0.463 . . . . 74.31 110.914 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 20.0 t0 -68.65 108.61 3.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.485 . . . . 73.02 110.84 179.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 31.2 p -170.1 149.04 3.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 62.42 110.956 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 66.1 m-85 -62.59 105.5 0.65 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.193 -0.458 . . . . 74.4 110.89 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -167.09 161.65 14.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.223 -0.444 . . . . 75.33 110.845 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 21.6 ttt180 -52.16 164.5 0.29 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 74.0 110.876 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 8.6 tp -64.61 123.93 20.57 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.246 -0.434 . . . . 74.23 110.893 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 8.1 m-85 -137.74 160.64 64.06 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.683 0.754 . . . . 75.43 110.919 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . 0.418 ' HA ' HD13 ' A' ' 153' ' ' LEU . 54.3 Cg_endo -69.72 177.38 5.61 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.685 2.257 . . . . 74.54 112.38 179.884 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.433 ' CE1' HD12 ' A' ' 153' ' ' LEU . 3.0 m-85 -115.32 152.4 32.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.191 -0.459 . . . . 74.43 110.864 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 61.6 t -111.0 141.13 27.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.102 -0.499 . . . . 60.44 111.186 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -133.39 175.69 20.04 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.775 -0.726 . . . . 71.15 112.546 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.5 p -168.16 151.97 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.944 0.402 . . . . 61.12 111.058 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -179.54 -149.68 8.57 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.714 -0.755 . . . . 73.12 112.517 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 11.3 p -108.01 146.07 14.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.829 0.347 . . . . 73.24 111.168 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . 0.689 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -140.99 121.03 1.82 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.806 -0.712 . . . . 61.41 112.51 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . 0.43 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 3.1 ptm180 -117.48 128.7 55.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.893 0.378 . . . . 74.54 110.874 -179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 97.8 t -105.94 109.44 27.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.091 -0.504 . . . . 63.44 111.161 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.445 HD23 ' HB2' ' A' ' 143' ' ' ASP . 41.7 mt -118.22 171.99 7.74 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.125 -0.489 . . . . 71.33 110.896 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -148.41 176.39 10.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 72.52 110.949 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.594 ' O ' HG21 ' A' ' 96' ' ' VAL . 2.5 t80 -104.57 171.71 7.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 73.04 110.812 -179.897 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 16.8 t0 -109.72 96.58 6.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.122 -0.49 . . . . 75.44 110.847 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.746 ' HB2' HG23 ' A' ' 96' ' ' VAL . 2.0 mmmp? -118.1 -81.44 0.62 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.466 . . . . 73.02 110.892 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 98.5 m -162.64 85.24 0.55 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.202 -0.454 . . . . 71.12 111.15 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -99.15 161.67 13.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.221 -0.445 . . . . 72.42 110.885 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.46 154.08 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.705 -0.759 . . . . 71.23 112.489 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.533 ' CB ' HD13 ' A' ' 87' ' ' ILE . . . -82.51 3.24 29.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.833 0.349 . . . . 70.2 111.149 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.746 HD12 HD22 ' A' ' 180' ' ' LEU . 2.7 mm? -86.83 -176.14 5.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 71.23 110.937 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 23.1 t -65.0 87.0 0.06 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 75.35 110.849 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 65.5 m 51.93 75.37 0.22 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 74.02 110.878 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -91.03 157.11 17.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.481 . . . . 61.41 110.883 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -138.12 -173.9 3.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.107 -0.497 . . . . 71.2 110.878 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.786 HG22 HG13 ' A' ' 176' ' ' VAL . 5.1 pt -141.0 156.98 22.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.205 -0.452 . . . . 70.23 111.147 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . 0.433 ' HB2' ' HB3' ' A' ' 175' ' ' ASP . 1.8 tttt -96.02 116.39 28.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.159 -0.473 . . . . 72.43 110.941 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.445 ' HB2' HD23 ' A' ' 127' ' ' LEU . 0.9 OUTLIER -63.33 -173.76 0.07 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.241 -0.436 . . . . 71.21 110.866 179.887 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -157.18 169.72 24.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.242 -0.435 . . . . 73.33 110.955 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 28.0 p-90 -156.69 146.71 21.06 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.341 -0.39 . . . . 75.5 110.893 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.722 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 179.95 165.06 0.84 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.549 0.69 . . . . 72.32 111.097 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.722 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.1 Cg_endo -69.82 140.41 42.4 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.677 2.252 . . . . 70.35 112.314 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.651 ' HB1' ' O ' ' A' ' 169' ' ' TYR . . . -135.98 177.82 7.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 74.2 111.096 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -126.63 166.54 17.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.18 -0.464 . . . . 74.44 110.872 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 11.3 tt0 -145.32 155.29 43.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 74.31 110.912 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.1 p -154.92 126.87 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.226 -0.443 . . . . 61.35 111.15 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -177.79 -158.69 21.27 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.677 -0.773 . . . . 53.14 112.43 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.433 HD12 ' CE1' ' A' ' 118' ' ' TYR . 46.7 tp -145.17 157.39 44.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.844 0.354 . . . . 74.42 110.867 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 6.2 tpp85 -120.97 117.71 27.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 72.3 110.85 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 3.0 t80 -95.91 132.21 41.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 74.02 110.928 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -119.23 113.34 20.71 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.162 -0.472 . . . . 71.11 110.879 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' LEU . . . . . 0.46 HD12 ' O ' ' A' ' 161' ' ' TRP . 38.8 mt -88.44 163.02 16.16 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.209 -0.451 . . . . 72.12 110.861 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -99.44 126.91 9.08 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.758 -0.734 . . . . 71.0 112.482 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 65.3 m-20 58.78 37.84 24.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.873 0.368 . . . . 75.21 110.916 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 3.1 m -167.18 178.03 5.86 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.167 -0.47 . . . . 72.42 110.869 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' TRP . . . . . 0.46 ' O ' HD12 ' A' ' 157' ' ' LEU . 5.3 m-90 -64.12 162.09 14.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 71.4 110.936 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.421 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 21.5 mtm -106.64 170.56 7.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.231 -0.44 . . . . 74.51 110.918 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.509 HD23 ' N ' ' A' ' 164' ' ' ASN . 1.2 tt -124.08 148.81 46.81 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.246 -0.434 . . . . 71.54 110.904 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . 0.509 ' N ' HD23 ' A' ' 163' ' ' LEU . 4.8 t-20 -143.94 131.79 21.47 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 73.31 110.887 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 60.5 p -146.56 122.23 10.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.446 . . . . 75.02 110.807 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -157.69 161.22 38.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.053 -0.521 . . . . 73.43 110.89 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 10.9 t -118.58 130.52 73.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 74.5 111.128 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . 0.585 ' CZ ' HD13 ' A' ' 102' ' ' ILE . 0.0 OUTLIER -107.04 122.17 45.93 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.169 -0.468 . . . . 64.4 110.866 -179.958 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' TYR . . . . . 0.651 ' O ' ' HB1' ' A' ' 148' ' ' ALA . 15.3 t80 -108.29 115.56 30.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.184 -0.462 . . . . 73.44 110.927 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' ILE . . . . . 0.563 HG23 ' HG2' ' A' ' 193' ' ' PRO . 9.6 tt -134.45 79.35 54.59 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.558 0.694 . . . . 65.12 111.092 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . 0.424 ' HA ' ' HD2' ' A' ' 193' ' ' PRO . 54.0 Cg_endo -69.72 125.06 11.72 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.587 2.192 . . . . 74.24 112.364 179.835 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 11.8 p90 -162.14 177.58 9.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 74.32 110.891 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 10.1 pttp -122.83 137.69 54.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.126 -0.488 . . . . 62.42 110.844 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.49 156.1 18.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 62.43 111.146 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . 0.433 ' HB3' ' HB2' ' A' ' 142' ' ' LYS . 0.1 OUTLIER -111.81 161.24 16.55 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.259 -0.428 . . . . 71.52 110.915 179.851 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.786 HG13 HG22 ' A' ' 141' ' ' ILE . 4.7 t -138.31 133.01 42.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.229 -0.441 . . . . 75.51 111.17 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 1.7 t -166.36 160.48 15.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 74.03 111.134 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -160.38 -133.48 1.5 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.704 -0.76 . . . . 44.34 112.479 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 52.9 m -153.01 96.65 2.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.817 0.342 . . . . 63.55 111.089 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.746 HD22 HD12 ' A' ' 136' ' ' LEU . 3.7 tp -140.03 114.09 8.97 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.2 -0.455 . . . . 60.24 110.878 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 56.84 175.64 0.29 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.738 -0.744 . . . . 64.11 112.437 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.881 ' O ' HG23 ' A' ' 183' ' ' VAL . 53.8 Cg_endo -69.72 71.36 1.5 Allowed 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.696 2.264 . . . . 61.04 112.322 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.881 HG23 ' O ' ' A' ' 182' ' ' PRO . 1.5 t 153.34 93.95 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.543 0.687 . . . . 72.51 111.044 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 146.0 58.62 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.706 2.27 . . . . 72.13 112.324 179.9 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.615 HG11 ' HB2' ' A' ' 35' ' ' LEU . 82.5 t -96.28 107.74 20.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 72.41 111.129 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -108.66 125.46 51.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 63.13 110.882 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 12.8 p -139.66 174.73 10.21 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.099 -0.501 . . . . 64.44 111.128 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 34.4 ttpt -158.95 145.35 16.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 65.34 110.921 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 8.6 tt -143.15 138.31 26.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.254 -0.43 . . . . 64.54 111.147 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -102.17 119.71 39.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.234 -0.439 . . . . 74.1 110.968 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 191' ' ' VAL . . . . . 0.9 HG11 HG23 ' A' ' 28' ' ' VAL . 4.1 t -136.82 158.25 36.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.163 -0.471 . . . . 73.12 111.168 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.4 ' N ' HG12 ' A' ' 191' ' ' VAL . 0.4 OUTLIER -107.73 89.95 5.76 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.624 0.725 . . . . 74.11 110.933 179.857 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . 0.563 ' HG2' HG23 ' A' ' 170' ' ' ILE . 53.2 Cg_endo -69.8 121.62 8.3 Favored 'Trans proline' 0 C--O 1.232 0.211 0 C-N-CA 122.697 2.265 . . . . 71.22 112.296 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -99.76 107.43 19.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.268 -0.424 . . . . 74.23 110.889 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 195' ' ' ILE . . . . . 0.682 ' CD1' HG22 ' A' ' 26' ' ' VAL . 49.1 mm -87.93 119.39 35.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.138 -0.483 . . . . 60.44 111.148 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . 0.512 HD13 ' CD1' ' A' ' 27' ' ' TYR . 5.4 mp -105.98 108.18 19.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.206 -0.452 . . . . 64.24 110.951 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . 0.553 ' HG ' ' HE2' ' A' ' 72' ' ' PHE . 9.4 m -98.97 112.03 24.26 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.213 -0.448 . . . . 75.13 110.897 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 1.9 tt -136.72 119.88 16.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 64.44 110.899 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -176.16 -145.55 5.61 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.779 -0.724 . . . . 65.51 112.482 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 200' ' ' ALA . . . . . 0.421 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -125.17 173.83 8.49 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.75 0.31 . . . . 65.2 111.186 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 43.7 t -148.89 169.77 19.8 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.26 -0.427 . . . . 63.02 110.835 -179.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -138.8 146.01 40.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.131 -0.486 . . . . 72.52 110.878 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.691 ' HA ' HG12 ' A' ' 18' ' ' VAL . 15.6 m -97.91 144.81 10.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.124 -0.489 . . . . 43.52 111.158 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -148.28 139.75 23.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.48 . . . . 74.43 110.812 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -107.93 -35.5 6.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.09 -0.504 . . . . 71.44 110.892 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 206' ' ' LEU . . . . . 0.458 HD21 ' C ' ' A' ' 208' ' ' ALA . 10.0 tt -62.45 140.18 58.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.222 -0.444 . . . . 74.33 110.969 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -112.64 -38.68 4.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.19 -0.459 . . . . 71.43 111.095 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . 0.458 ' C ' HD21 ' A' ' 206' ' ' LEU . . . -112.95 125.5 54.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.459 . . . . 72.02 111.084 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -109.14 172.22 6.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.262 -0.427 . . . . 70.5 111.17 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -131.04 148.45 52.75 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.279 -0.419 . . . . 44.44 110.957 -179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 15.9 mm-40 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.266 -0.425 . . . . 70.3 110.855 179.967 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 45.8 mtt . . . . . 0 C--O 1.23 0.058 0 CA-C-O 120.74 0.305 . . . . 65.41 110.891 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -111.05 161.41 15.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.25 -0.432 . . . . 74.41 110.934 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -157.15 143.49 18.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.266 -0.425 . . . . 64.44 110.863 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 59.9 m-20 -148.37 172.85 13.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.489 . . . . 62.23 110.867 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 9.6 p90 -118.48 157.61 49.06 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.722 0.773 . . . . 74.22 110.897 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 179.61 3.57 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.697 2.265 . . . . 54.44 112.363 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -110.16 172.47 6.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.259 -0.428 . . . . 72.41 111.109 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 38.5 mmtm -77.92 146.71 35.38 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.194 -0.457 . . . . 73.41 110.857 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 3.6 m -166.49 157.23 12.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.159 -0.473 . . . . 73.33 110.831 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -79.04 135.72 36.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.109 -0.496 . . . . 61.4 111.09 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -87.75 76.37 2.0 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.831 -0.7 . . . . 73.22 112.532 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -113.46 38.22 2.97 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.886 0.374 . . . . 73.24 110.924 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -143.42 150.06 38.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.117 -0.492 . . . . 63.33 110.912 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -51.99 119.44 4.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 65.42 110.964 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 103.28 11.67 33.2 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.675 -0.774 . . . . 53.34 112.514 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -83.28 159.16 21.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.781 0.324 . . . . 70.54 110.887 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 13.3 m95 -107.36 158.34 17.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.247 -0.433 . . . . 73.54 110.902 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.462 HG13 ' O ' ' A' ' 202' ' ' TYR . 42.9 t -150.71 120.78 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.281 -0.418 . . . . 72.51 111.133 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -87.77 110.08 20.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 63.11 111.117 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 6.5 t -107.61 113.3 26.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.214 -0.448 . . . . 74.43 110.894 -179.822 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.677 ' CE1' ' HB3' ' A' ' 200' ' ' ALA . 17.0 p90 -108.41 122.36 46.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 75.1 110.863 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -152.76 167.93 27.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.138 -0.483 . . . . 54.23 110.92 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -102.01 134.89 44.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 70.01 110.929 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -102.69 122.68 44.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 65.32 110.801 -179.763 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 11.3 tptm -96.59 106.61 18.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.054 -0.521 . . . . 64.11 110.83 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 34.3 m -78.86 134.0 28.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.456 . . . . 70.22 111.201 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 17.0 t80 -130.9 99.74 5.01 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.223 -0.444 . . . . 75.42 110.9 -179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.0 p -165.82 152.86 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.118 -0.492 . . . . 75.34 111.127 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 123.59 77.11 0.35 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.739 -0.743 . . . . 71.34 112.48 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 25.6 pt-20 -90.26 -44.11 9.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.837 0.351 . . . . 75.34 110.85 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.683 ' HA ' HG22 ' A' ' 47' ' ' VAL . 0.9 OUTLIER 178.58 170.64 0.81 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 70.32 110.866 -179.937 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.482 HD23 ' CB ' ' A' ' 45' ' ' ALA . 20.8 tp -74.9 161.58 29.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.131 -0.486 . . . . 64.31 110.876 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.93 39.1 2.88 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.709 -0.757 . . . . 51.13 112.496 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . 0.72 ' O ' HD23 ' A' ' 35' ' ' LEU . 3.7 t70 -104.21 155.56 18.63 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.746 0.308 . . . . 72.21 110.953 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.72 HD23 ' O ' ' A' ' 34' ' ' ASP . 9.2 mt -130.6 167.53 18.58 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.219 -0.446 . . . . 70.32 110.905 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 17.7 t30 -91.74 172.48 8.45 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 71.14 110.886 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 61.1 t -90.65 -38.65 11.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 62.43 111.173 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -78.04 98.7 1.48 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.768 -0.73 . . . . 52.5 112.522 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 65.27 169.01 2.22 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.752 -0.737 . . . . 42.02 112.471 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -99.21 85.93 0.69 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.705 -0.76 . . . . 50.01 112.522 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -114.5 -179.61 3.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.836 0.351 . . . . 73.41 111.065 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 21.5 mt -53.26 158.84 2.41 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.575 0.702 . . . . 72.41 110.944 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 152.77 69.37 Favored 'Trans proline' 0 C--N 1.34 0.127 0 C-N-CA 122.7 2.267 . . . . 73.42 112.371 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -102.79 -38.06 7.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.443 . . . . 75.42 110.867 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.482 ' CB ' HD23 ' A' ' 32' ' ' LEU . . . -56.93 179.27 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 74.22 111.071 179.885 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -161.2 128.61 4.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.225 -0.443 . . . . 73.23 110.861 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.683 HG22 ' HA ' ' A' ' 31' ' ' GLU . 22.3 m -104.36 167.39 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 45.3 111.15 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -164.76 174.41 10.72 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.13 -0.486 . . . . 74.24 110.804 -179.806 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 7.9 tt -134.04 149.24 30.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.089 -0.505 . . . . 65.11 111.08 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -139.3 85.5 0.22 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.709 -0.758 . . . . 74.41 112.468 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -147.77 152.5 37.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.814 0.34 . . . . 72.54 110.925 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 46.2 m-20 -104.0 178.09 4.66 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.156 -0.474 . . . . 71.12 110.818 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 2.3 t -55.73 150.22 13.09 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.193 -0.458 . . . . 73.42 111.124 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -151.58 162.72 40.5 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.208 -0.451 . . . . 75.23 111.112 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 20.3 mt -108.28 153.49 23.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.169 -0.469 . . . . 75.11 110.978 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.703 HG21 ' CZ ' ' A' ' 72' ' ' PHE . 0.0 OUTLIER -135.56 147.89 48.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.26 -0.427 . . . . 70.05 111.062 -179.995 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -104.22 131.49 51.48 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.18 -0.464 . . . . 73.45 110.835 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 30.1 m-20 -126.63 138.29 53.42 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.19 -0.459 . . . . 60.55 110.85 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.404 ' O ' HG22 ' A' ' 59' ' ' ILE . 1.6 mp -108.08 113.56 44.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.144 -0.48 . . . . 65.05 111.132 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -106.02 120.39 41.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 74.42 111.161 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.671 ' HB3' HG22 ' A' ' 69' ' ' VAL . 8.1 t80 -105.69 118.53 36.83 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.164 -0.471 . . . . 73.4 110.93 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -93.76 96.64 9.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.088 -0.505 . . . . 72.22 110.895 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.424 HG22 ' CE1' ' A' ' 61' ' ' TYR . 57.4 t -91.23 -35.17 6.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.144 -0.48 . . . . 73.44 111.133 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.6 m -131.87 163.42 28.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.179 -0.464 . . . . 74.13 110.894 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 33.4 m -87.49 3.45 47.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 62.33 110.865 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 7.1 m120 -107.77 -33.08 7.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.112 -0.495 . . . . 55.23 110.895 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.8 pt -150.36 169.9 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 62.34 111.142 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -157.12 167.32 30.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.45 . . . . 52.43 111.105 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.671 HG22 ' HB3' ' A' ' 61' ' ' TYR . 2.7 m -110.54 151.57 12.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.183 -0.462 . . . . 74.33 111.077 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -141.69 137.31 31.65 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.173 -0.467 . . . . 72.23 110.866 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -121.02 110.39 16.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.248 -0.433 . . . . 73.13 110.903 -179.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.703 ' CZ ' HG21 ' A' ' 56' ' ' THR . 41.0 t80 -87.27 125.95 34.53 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 75.34 110.908 -179.883 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 40.4 t -146.42 146.78 18.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.234 -0.439 . . . . 74.5 111.16 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.548 ' HA3' HG22 ' A' ' 56' ' ' THR . . . -147.97 178.89 25.26 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.673 -0.775 . . . . 60.34 112.458 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.6 t -144.26 66.0 13.81 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.583 0.706 . . . . 75.33 111.111 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 138.14 37.22 Favored 'Trans proline' 0 C--N 1.34 0.132 0 C-N-CA 122.714 2.276 . . . . 73.52 112.359 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -67.47 -166.81 0.05 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.213 -0.448 . . . . 35.34 111.161 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 23.1 ttp180 -75.77 123.75 26.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.242 -0.436 . . . . 63.24 110.881 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -110.66 150.93 28.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 71.03 111.166 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.22 119.51 38.85 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 71.52 110.891 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -114.31 144.84 42.59 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.213 -0.449 . . . . 73.24 110.858 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . . . . . . . . . 28.3 mt-30 -104.26 153.22 21.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.453 . . . . 71.12 110.979 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.645 ' HA2' HG12 ' A' ' 47' ' ' VAL . . . -178.84 75.9 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.734 -0.746 . . . . 63.35 112.453 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -177.4 -177.46 0.7 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.899 0.381 . . . . 72.52 110.907 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.17 -68.96 0.7 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.152 -0.476 . . . . 63.24 110.917 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.6 m -84.97 -32.74 22.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.236 -0.438 . . . . 73.11 110.829 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.651 HG22 HG22 ' A' ' 93' ' ' VAL . 5.1 mm -66.52 -34.45 70.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.121 -0.491 . . . . 73.34 111.157 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 28.1 t -63.23 -51.28 66.86 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.177 -0.465 . . . . 73.21 110.831 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 58.5 m -51.46 -36.92 46.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.152 -0.476 . . . . 74.42 110.894 -179.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 35.9 mt -64.71 -42.92 94.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.13 -0.487 . . . . 74.3 110.88 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 107.34 -13.98 39.71 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.831 -0.699 . . . . 74.21 112.534 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.1 mtp-105 -115.91 90.09 3.25 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.84 0.352 . . . . 74.25 110.825 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.651 HG22 HG22 ' A' ' 87' ' ' ILE . 3.9 t -113.79 -43.94 4.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 71.02 111.108 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.3 m -141.18 144.06 34.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 73.1 110.839 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -138.44 118.22 13.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.172 -0.467 . . . . 63.31 110.954 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.438 HG22 ' N ' ' A' ' 97' ' ' ASP . 5.3 p -178.14 164.41 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.485 . . . . 63.42 111.151 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.438 ' N ' HG22 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -100.21 173.0 6.82 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.208 -0.451 . . . . 62.03 110.923 179.908 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' TYR . . . . . 0.434 ' HA ' ' HB2' ' A' ' 128' ' ' PHE . 62.1 m-85 -133.16 141.3 48.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 74.52 110.873 -179.804 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -108.99 82.07 0.3 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.799 -0.715 . . . . 72.14 112.493 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 112.22 3.01 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.681 2.254 . . . . 74.35 112.374 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -124.89 94.98 4.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.259 -0.428 . . . . 71.21 111.168 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.49 HD12 ' CD1' ' A' ' 72' ' ' PHE . 12.2 mt -112.35 145.73 18.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 74.15 111.098 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -149.2 109.43 4.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.17 -0.468 . . . . 61.12 110.943 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.3 p -140.62 166.21 25.36 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 73.4 110.911 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.429 ' HA ' ' HA ' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -114.76 140.41 48.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.146 -0.479 . . . . 74.23 110.925 -179.99 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 6.9 pt20 -102.62 145.41 29.69 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 64.14 110.864 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 10.5 p90 -140.42 145.31 36.85 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.144 -0.48 . . . . 74.43 110.879 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 58.0 t60 -100.23 141.09 33.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.111 -0.495 . . . . 74.5 110.838 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.1 t80 -101.13 142.71 32.18 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.461 . . . . 74.15 110.96 -179.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 33.6 t70 -83.56 132.08 34.94 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.14 -0.482 . . . . 73.15 110.906 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.0 m -153.59 -174.35 4.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.46 . . . . 55.4 110.807 -179.7 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 15.2 t80 -118.43 -29.9 5.35 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.104 -0.498 . . . . 65.52 110.923 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -57.36 -176.04 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.127 -0.488 . . . . 73.01 110.854 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 55.0 mtm180 -58.05 -174.82 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.115 -0.493 . . . . 70.32 110.935 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 10.8 mp -67.14 165.28 16.27 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 70.12 110.918 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . 0.414 ' HB2' ' HD2' ' A' ' 117' ' ' PRO . 6.4 p90 -165.85 159.5 13.11 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.628 0.727 . . . . 74.54 111.004 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . 0.414 ' HD2' ' HB2' ' A' ' 116' ' ' TYR . 53.4 Cg_endo -69.74 178.95 4.04 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.669 2.246 . . . . 74.43 112.335 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -108.82 157.2 18.81 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 72.42 110.878 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 93.4 t -111.4 134.4 53.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.059 -0.519 . . . . 54.33 111.146 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -135.98 168.93 23.81 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.776 -0.726 . . . . 75.04 112.543 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 10.6 p -162.35 152.15 3.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.876 0.37 . . . . 73.05 111.131 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -176.83 -154.32 11.78 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.689 -0.767 . . . . 74.14 112.502 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.476 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 10.2 p -111.13 139.04 36.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.95 0.405 . . . . 60.14 111.086 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -128.72 115.75 2.08 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.777 -0.725 . . . . 62.53 112.546 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 17.3 ptp180 -122.82 116.59 23.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.852 0.358 . . . . 71.11 110.848 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.429 ' O ' HG13 ' A' ' 126' ' ' VAL . 3.6 p -117.22 114.48 45.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.182 -0.463 . . . . 52.32 111.043 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.425 HD21 ' HB3' ' A' ' 145' ' ' TRP . 0.0 OUTLIER -150.55 168.15 25.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 62.33 110.924 179.894 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.434 ' HB2' ' HA ' ' A' ' 98' ' ' TYR . 1.0 OUTLIER -164.36 -172.45 2.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.475 . . . . 65.23 110.899 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -94.44 129.22 41.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.155 -0.475 . . . . 71.31 110.884 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -67.11 124.39 22.94 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.194 -0.457 . . . . 72.33 110.797 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 20.0 mmmt -102.39 -72.48 0.69 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.159 -0.473 . . . . 73.25 110.9 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -151.63 77.13 1.23 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 74.14 111.152 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -94.1 158.68 15.5 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.467 . . . . 71.54 110.905 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 63.02 159.71 0.19 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.728 -0.749 . . . . 61.1 112.544 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.599 ' HB2' HG21 ' A' ' 87' ' ' ILE . . . -78.01 4.93 10.96 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.819 0.342 . . . . 65.14 111.14 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.639 HD12 HD22 ' A' ' 180' ' ' LEU . 2.8 mm? -86.27 -176.68 6.0 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 74.44 110.956 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.6 t -68.33 85.28 0.27 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.194 -0.457 . . . . 71.24 110.889 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 89.5 p 46.22 74.85 0.13 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 71.14 110.953 -179.729 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -86.29 156.5 20.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.149 -0.478 . . . . 74.33 110.837 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -107.62 175.01 5.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.068 -0.515 . . . . 54.24 110.886 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.656 HG22 HG13 ' A' ' 176' ' ' VAL . 24.7 pt -152.2 135.64 7.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.222 -0.445 . . . . 43.11 111.106 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . 0.626 ' O ' HG22 ' A' ' 174' ' ' THR . 0.0 OUTLIER -72.54 116.94 13.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.113 -0.494 . . . . 75.51 110.925 179.861 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -63.63 -158.43 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.452 . . . . 71.03 110.801 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . 0.625 ' NZ ' HG23 ' A' ' 170' ' ' ILE . 3.0 tttt -128.99 147.3 50.85 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.228 -0.442 . . . . 74.44 110.888 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' TRP . . . . . 0.425 ' HB3' HD21 ' A' ' 127' ' ' LEU . 43.2 p90 -158.6 119.01 3.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.156 -0.474 . . . . 70.02 110.897 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.834 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -179.38 168.46 0.8 Allowed Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.566 0.698 . . . . 63.02 111.112 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.834 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.4 Cg_endo -69.78 141.01 44.0 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.661 2.24 . . . . 50.43 112.362 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.6 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -135.27 168.15 19.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 71.01 111.102 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -116.79 139.78 50.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.243 -0.435 . . . . 74.41 110.837 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 -116.76 145.75 43.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.104 -0.498 . . . . 74.31 110.919 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.59 127.18 8.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.455 . . . . 74.02 111.133 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . 0.411 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 176.9 -179.6 47.77 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.724 -0.75 . . . . 55.22 112.531 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.494 ' H ' HD23 ' A' ' 153' ' ' LEU . 2.0 pt? -121.98 158.82 28.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.876 0.369 . . . . 73.31 110.842 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -142.79 128.34 19.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.187 -0.461 . . . . 62.23 110.847 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . 0.539 ' HB3' HD11 ' A' ' 163' ' ' LEU . 0.8 OUTLIER -145.33 179.5 7.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.483 . . . . 75.12 110.974 -179.901 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -114.16 90.76 3.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.179 -0.464 . . . . 62.54 110.839 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 24.4 tp -58.99 97.2 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 70.12 110.939 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 66.52 -136.38 34.03 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.716 -0.754 . . . . 70.22 112.495 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 52.2 t30 -119.49 -30.89 4.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.795 0.331 . . . . 72.44 110.886 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 35.7 m -49.4 -67.12 0.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.464 . . . . 64.14 110.833 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 5.3 p90 -147.54 161.87 40.22 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.152 -0.476 . . . . 62.44 110.886 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.556 ' SD ' HG13 ' A' ' 203' ' ' VAL . 78.7 mtp -93.28 172.13 8.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 61.41 110.888 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.822 HD22 ' C ' ' A' ' 163' ' ' LEU . 0.0 OUTLIER -136.09 152.08 50.49 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.187 -0.46 . . . . 64.5 111.002 179.972 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . 0.409 ' N ' HD22 ' A' ' 163' ' ' LEU . 6.1 t-20 -155.49 146.68 22.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.265 -0.425 . . . . 53.22 110.854 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 10.2 t -152.59 122.27 6.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.213 -0.448 . . . . 73.35 110.937 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . 0.411 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.3 OUTLIER -145.85 177.27 9.05 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.099 -0.501 . . . . 73.34 110.822 -179.982 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.451 HG13 ' O ' ' A' ' 195' ' ' ILE . 16.4 t -147.44 141.34 19.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 63.35 111.135 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . 0.401 ' HG2' HD12 ' A' ' 195' ' ' ILE . 0.0 OUTLIER -108.97 141.99 40.27 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.127 -0.488 . . . . 74.31 110.814 -179.967 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 9.5 t80 -139.86 138.88 36.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.11 -0.495 . . . . 74.34 110.916 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' ILE . . . . . 0.738 HD12 ' HD2' ' A' ' 171' ' ' PRO . 1.9 tp -177.87 110.04 0.22 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.613 0.72 . . . . 71.52 111.069 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . 0.738 ' HD2' HD12 ' A' ' 170' ' ' ILE . 52.9 Cg_endo -69.85 124.78 11.38 Favored 'Trans proline' 0 N--CA 1.464 -0.217 0 C-N-CA 122.685 2.256 . . . . 64.54 112.353 179.888 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . 0.516 ' CE2' ' HB2' ' A' ' 146' ' ' ALA . 2.3 t80 -147.04 177.49 9.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.238 -0.437 . . . . 71.23 110.883 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 22.1 pttm -136.73 137.32 39.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 52.01 110.922 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . 0.626 HG22 ' O ' ' A' ' 142' ' ' LYS . 0.0 OUTLIER -99.51 169.55 9.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 63.24 111.149 -179.974 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . 0.423 ' HB3' ' HB2' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -129.87 161.98 29.58 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.257 -0.429 . . . . 64.33 110.891 179.933 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.656 HG13 HG22 ' A' ' 141' ' ' ILE . 99.1 t -144.46 127.22 11.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.225 -0.443 . . . . 73.25 111.111 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 5.0 t -163.7 166.04 22.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.146 -0.479 . . . . 72.4 111.182 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -167.7 -150.38 6.5 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.785 -0.721 . . . . 63.52 112.507 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . 0.402 ' O ' HG23 ' A' ' 179' ' ' THR . 1.7 t -131.75 96.3 3.92 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.9 0.381 . . . . 64.04 111.081 -179.845 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.639 HD22 HD12 ' A' ' 136' ' ' LEU . 0.5 OUTLIER -141.93 101.84 4.02 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.46 . . . . 41.23 110.904 179.961 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 58.22 172.88 0.36 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.772 -0.728 . . . . 70.33 112.513 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.518 ' O ' ' HB ' ' A' ' 183' ' ' VAL . 53.2 Cg_endo -69.76 75.43 1.21 Allowed 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.698 2.265 . . . . 75.25 112.308 -179.913 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.518 ' HB ' ' O ' ' A' ' 182' ' ' PRO . 2.4 p 160.46 84.0 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.562 0.696 . . . . 51.23 111.149 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 141.73 45.97 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.652 2.235 . . . . 71.43 112.359 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . 0.488 HG12 HG23 ' A' ' 187' ' ' THR . 57.3 t -96.16 105.34 16.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.275 -0.42 . . . . 73.01 111.063 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -104.78 104.88 14.74 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.173 -0.467 . . . . 74.43 110.843 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . 0.488 HG23 HG12 ' A' ' 185' ' ' VAL . 6.1 p -122.33 148.57 44.88 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.132 -0.485 . . . . 73.1 111.107 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.02 155.78 47.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.213 -0.449 . . . . 64.24 110.877 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 189' ' ' ILE . . . . . . . . . . . . . 6.0 pt -144.01 109.91 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.46 . . . . 72.32 111.135 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -90.44 111.51 22.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 71.43 110.921 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 191' ' ' VAL . . . . . . . . . . . . . 2.7 t -137.79 162.27 32.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 74.03 111.108 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -107.23 88.5 3.94 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.662 0.744 . . . . 43.25 110.871 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 138.45 37.83 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.708 2.272 . . . . 42.45 112.354 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -122.21 126.63 48.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.242 -0.435 . . . . 62.24 110.904 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 195' ' ' ILE . . . . . 0.451 ' O ' HG13 ' A' ' 167' ' ' VAL . 21.4 mt -112.44 120.01 61.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.175 -0.466 . . . . 72.42 111.109 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 9.5 tt -104.53 107.93 19.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.446 . . . . 64.53 110.918 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 1.1 t -96.49 123.4 40.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.128 -0.487 . . . . 62.21 110.878 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 27.2 tp -146.36 127.3 14.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 74.25 110.92 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . -179.79 -150.68 9.29 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.711 -0.757 . . . . 42.15 112.496 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 200' ' ' ALA . . . . . 0.677 ' HB3' ' CE1' ' A' ' 21' ' ' PHE . . . -117.8 173.01 6.99 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.852 0.358 . . . . 73.34 111.101 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 2.3 p -149.7 169.48 20.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.466 . . . . 75.55 110.88 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 202' ' ' TYR . . . . . 0.462 ' O ' HG13 ' A' ' 18' ' ' VAL . 23.2 t80 -148.93 142.36 25.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 72.15 110.926 -179.868 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.556 HG13 ' SD ' ' A' ' 162' ' ' MET . 21.5 m -76.95 161.31 4.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.109 -0.496 . . . . 65.42 111.132 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -161.82 116.55 1.95 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 75.03 110.914 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 5.6 ttmm -92.76 147.63 22.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.161 -0.472 . . . . 64.12 110.906 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -143.83 111.94 6.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 73.11 110.882 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -129.4 176.39 8.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.252 -0.431 . . . . 73.24 111.095 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -81.7 -39.26 24.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 52.34 111.15 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -102.5 155.67 18.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 64.41 111.094 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -122.86 154.7 37.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.23 -0.441 . . . . 62.13 110.938 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 . . . . . 0 C--N 1.33 -0.242 0 CA-C-N 116.169 -0.468 . . . . 72.32 110.888 179.975 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.079 0 CA-C-O 120.869 0.366 . . . . 62.54 110.903 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -125.48 149.05 48.6 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.161 -0.472 . . . . 72.32 110.951 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.9 tt0 -129.22 142.53 50.83 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 63.3 110.955 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 20.8 p30 -75.79 175.9 8.28 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.203 -0.453 . . . . 74.4 110.908 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 5.4 p90 -129.1 157.48 75.82 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.627 0.727 . . . . 71.42 110.975 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 89.72 0.52 Allowed 'Trans proline' 0 N--CA 1.466 -0.132 0 C-N-CA 122.718 2.279 . . . . 64.21 112.344 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -80.17 -51.48 8.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.455 . . . . 73.23 111.091 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -55.72 159.92 2.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.471 . . . . 73.43 110.962 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -130.01 147.34 51.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 63.03 110.847 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.2 177.8 5.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.14 -0.482 . . . . 74.44 111.106 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -119.74 42.16 1.81 Allowed Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.634 -0.794 . . . . 74.54 112.476 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 13.3 m-85 -124.99 85.03 2.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.876 0.37 . . . . 75.02 110.892 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -169.55 -173.37 1.64 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.151 -0.477 . . . . 72.5 110.85 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -45.75 125.5 6.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 71.41 110.883 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.85 7.91 21.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.734 -0.746 . . . . 72.54 112.513 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -55.15 166.44 0.55 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.8 0.334 . . . . 71.04 110.865 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.415 ' HB2' ' HB3' ' A' ' 204' ' ' PHE . 10.9 m-90 -109.54 151.33 26.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.131 -0.486 . . . . 74.3 110.883 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.464 HG12 ' HB3' ' A' ' 60' ' ' ALA . 61.6 t -153.24 115.25 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.245 -0.434 . . . . 75.33 111.17 179.848 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.04 140.49 32.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.168 -0.469 . . . . 62.35 111.095 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 16.7 t -136.6 115.09 11.87 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 64.3 110.836 -179.787 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.579 ' CE2' ' HB3' ' A' ' 200' ' ' ALA . 1.9 p90 -123.15 117.11 24.62 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.087 -0.506 . . . . 73.3 110.861 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -152.79 169.58 22.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.13 -0.486 . . . . 72.25 110.882 -179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 21.5 p90 -102.85 135.33 44.72 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.15 -0.477 . . . . 73.22 110.813 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 1.3 p -102.3 137.54 40.42 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.063 -0.517 . . . . 63.25 110.873 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 24.4 ttmt -112.55 108.08 17.04 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.098 -0.501 . . . . 71.53 110.961 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.6 p -76.74 129.65 37.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.186 -0.461 . . . . 52.14 111.145 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -123.39 113.62 19.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 72.14 110.939 -179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.56 HG21 HG11 ' A' ' 191' ' ' VAL . 7.8 p -176.78 146.11 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.099 -0.5 . . . . 62.44 111.108 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.47 68.94 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.673 -0.775 . . . . 72.12 112.468 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -90.23 -66.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.751 0.31 . . . . 72.4 110.911 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 -175.98 167.78 2.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 71.34 110.931 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.619 HD12 HG21 ' A' ' 189' ' ' ILE . 41.4 tp -101.28 156.16 17.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 75.14 110.927 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.25 80.7 0.35 Allowed Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.809 -0.71 . . . . 71.04 112.556 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 11.6 t0 -58.89 140.86 54.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.85 0.357 . . . . 54.45 110.876 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.418 HD23 ' N ' ' A' ' 36' ' ' ASN . 3.4 tt -159.73 122.16 3.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.454 . . . . 70.55 110.932 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.418 ' N ' HD23 ' A' ' 35' ' ' LEU . 2.7 p30 -143.87 167.45 22.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.138 -0.483 . . . . 75.11 110.854 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.3 p -59.38 -36.26 63.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.475 . . . . 62.4 111.14 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.12 -156.89 9.08 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.769 -0.729 . . . . 64.44 112.509 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 135.27 -163.08 24.89 Favored Glycine 0 N--CA 1.453 -0.203 0 C-N-CA 120.728 -0.749 . . . . 74.41 112.456 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -91.44 -94.79 1.31 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.742 -0.742 . . . . 61.33 112.458 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -92.98 171.82 8.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.818 0.342 . . . . 50.42 111.136 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.6 tp -135.94 70.24 64.05 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.63 0.729 . . . . 75.24 110.923 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -170.67 0.4 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.702 2.268 . . . . 64.1 112.362 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 75.4 m-20 -109.65 112.93 25.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.211 -0.45 . . . . 72.05 110.877 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -81.13 -176.32 5.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.217 -0.447 . . . . 62.43 111.068 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -146.41 126.06 13.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.225 -0.443 . . . . 64.43 110.793 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 82' ' ' GLN . 12.0 p -104.79 138.19 30.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 63.15 111.063 -179.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.7 m -154.74 177.95 10.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.152 -0.476 . . . . 71.04 110.857 -179.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -137.16 154.3 30.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.15 -0.477 . . . . 71.54 111.134 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -111.69 62.7 0.29 Allowed Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.682 -0.771 . . . . 55.53 112.441 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 32.5 m120 -87.88 162.94 16.65 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.872 0.368 . . . . 61.11 110.81 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -129.13 163.29 25.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.093 -0.503 . . . . 65.23 110.928 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.5 p -69.14 104.58 2.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 74.35 111.11 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -131.16 168.41 17.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.182 -0.463 . . . . 64.11 111.182 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.561 ' H ' HD23 ' A' ' 55' ' ' LEU . 1.0 OUTLIER -91.07 168.77 11.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 65.13 110.939 179.952 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.98 147.39 38.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.231 -0.441 . . . . 73.22 111.206 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -101.77 151.2 22.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.27 -0.423 . . . . 72.44 110.866 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.406 ' HA ' ' O ' ' A' ' 71' ' ' PHE . 0.9 OUTLIER -149.81 135.48 18.47 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.169 -0.469 . . . . 51.41 110.902 -179.982 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.418 ' O ' HG22 ' A' ' 59' ' ' ILE . 1.6 mp -107.7 112.47 40.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 30.33 111.088 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.464 ' HB3' HG12 ' A' ' 18' ' ' VAL . . . -101.42 129.15 47.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 55.34 111.045 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.512 ' HB3' HG22 ' A' ' 69' ' ' VAL . 0.8 OUTLIER -117.0 128.47 55.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 75.3 110.916 -179.876 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -98.25 98.41 9.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.489 . . . . 74.41 110.881 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.9 p -95.88 -34.1 5.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 53.53 111.108 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 25.1 p -139.6 163.16 33.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.48 . . . . 52.31 110.816 -179.832 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 12.0 p -87.23 3.24 47.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 72.34 110.849 -179.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 20.1 m120 -106.55 -31.18 8.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.135 -0.484 . . . . 73.5 110.911 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 36.9 pt -150.43 165.48 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.122 -0.49 . . . . 74.35 111.091 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -146.8 166.9 25.28 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.104 -0.498 . . . . 70.04 111.061 179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.512 HG22 ' HB3' ' A' ' 61' ' ' TYR . 6.1 m -114.78 151.41 16.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.161 -0.472 . . . . 75.03 111.086 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -144.62 132.28 21.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.135 -0.484 . . . . 72.24 110.822 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.406 ' O ' ' HA ' ' A' ' 58' ' ' ASP . 5.5 m-85 -108.47 118.04 35.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 63.34 110.882 -179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -88.3 121.39 30.64 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.145 -0.48 . . . . 70.1 110.853 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 42.1 t -146.88 146.86 18.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.191 -0.459 . . . . 73.21 111.094 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -151.33 162.22 29.45 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.79 -0.719 . . . . 71.34 112.465 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.495 ' O ' HG13 ' A' ' 75' ' ' VAL . 6.8 p -115.47 70.64 3.17 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.655 0.741 . . . . 75.12 111.173 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 158.96 55.12 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.651 2.234 . . . . 62.03 112.324 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -104.04 -169.81 1.68 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.247 -0.433 . . . . 42.44 111.145 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 50.4 ttp180 -76.35 126.77 31.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.428 . . . . 74.35 110.856 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -121.62 150.3 41.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 61.53 111.141 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 5.5 tttm -84.16 107.81 16.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.252 -0.431 . . . . 65.3 110.966 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 72.0 t80 -84.43 128.29 34.5 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 75.51 110.85 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.441 ' O ' HG23 ' A' ' 47' ' ' VAL . 41.7 mt-30 -103.38 151.61 22.56 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.129 -0.487 . . . . 73.33 110.899 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.551 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 172.68 82.45 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.801 -0.714 . . . . 62.14 112.492 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -176.83 -175.08 0.59 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.879 0.371 . . . . 63.44 110.952 -179.903 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.84 -69.5 0.67 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 61.13 110.916 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.6 t -84.96 -31.61 23.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 75.33 110.913 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.828 HG22 HG22 ' A' ' 93' ' ' VAL . 1.1 mt -68.19 -34.23 65.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.11 -0.496 . . . . 74.15 111.143 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.6 t -63.3 -51.11 67.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.174 -0.467 . . . . 62.42 110.851 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.8 t -52.01 -38.87 58.32 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.081 -0.508 . . . . 64.03 110.873 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 13.6 mt -64.85 -35.34 80.81 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.14 -0.482 . . . . 74.44 110.909 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.15 -13.39 67.02 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.686 -0.768 . . . . 73.5 112.47 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 10.4 ptp180 -115.0 94.93 4.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.812 0.339 . . . . 71.31 110.837 -179.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.828 HG22 HG22 ' A' ' 87' ' ' ILE . 99.9 t -111.66 -57.47 3.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.186 -0.461 . . . . 73.3 111.114 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 18.0 p -140.74 159.21 42.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 74.03 110.848 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -128.85 124.62 35.8 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.101 -0.5 . . . . 72.41 110.863 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.492 HG11 HG21 ' A' ' 141' ' ' ILE . 10.4 p -175.53 159.58 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.103 -0.499 . . . . 54.03 111.125 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.47 ' N ' HG22 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -106.81 173.11 6.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 64.24 110.926 179.863 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' TYR . . . . . 0.492 ' HA ' ' HB2' ' A' ' 128' ' ' PHE . 19.3 m-85 -133.61 144.04 49.01 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.255 -0.429 . . . . 72.54 110.94 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -106.91 87.09 0.49 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.781 -0.724 . . . . 74.03 112.46 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 124.72 11.38 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.697 2.264 . . . . 54.03 112.382 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.508 ' HB3' ' HG2' ' A' ' 125' ' ' ARG . . . -141.25 94.73 2.73 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 72.11 111.109 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.404 ' HA ' ' HA2' ' A' ' 124' ' ' GLY . 3.1 mp -117.35 153.99 19.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.195 -0.457 . . . . 74.41 111.11 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -153.03 108.57 3.28 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.191 -0.459 . . . . 75.12 110.913 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 23.6 p -134.38 166.4 22.92 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 75.24 110.859 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.587 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.8 OUTLIER -119.7 150.89 39.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.147 -0.479 . . . . 71.15 110.943 179.988 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -102.02 138.26 39.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.216 -0.447 . . . . 73.53 110.88 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . . . . . . . . . 33.2 p90 -149.48 146.99 27.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 75.43 110.918 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 17.6 p80 -148.06 127.48 13.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.077 -0.51 . . . . 74.04 110.847 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 88.2 t80 -100.14 128.45 46.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.194 -0.457 . . . . 74.23 110.917 -179.827 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -51.98 107.81 0.23 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 73.24 110.868 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 24.8 p -113.97 -37.58 4.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.151 -0.477 . . . . 72.34 110.913 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -145.42 170.7 15.85 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.157 -0.474 . . . . 73.05 110.884 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 37.1 tp10 -78.22 -43.48 28.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.142 -0.481 . . . . 64.4 110.893 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 44.5 mtp180 -52.18 160.11 0.82 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.168 -0.469 . . . . 70.54 110.901 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 58.5 tp -76.25 149.93 37.08 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.179 -0.464 . . . . 73.3 110.854 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -164.01 157.45 15.76 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.653 0.739 . . . . 53.41 110.935 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.77 177.76 5.27 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.664 2.242 . . . . 74.32 112.353 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -117.46 154.34 31.57 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.235 -0.439 . . . . 64.0 110.958 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 25.2 t -102.78 128.16 55.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.111 -0.495 . . . . 35.54 111.095 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -123.17 169.08 15.37 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.774 -0.726 . . . . 62.22 112.525 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 12.9 p -163.77 149.24 3.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.888 0.375 . . . . 75.41 111.131 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -171.47 -149.21 6.44 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.751 -0.738 . . . . 71.43 112.458 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.573 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 14.9 p -129.4 136.14 60.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.829 0.347 . . . . 74.31 111.146 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . 0.404 ' HA2' ' HA ' ' A' ' 102' ' ' ILE . . . -122.35 118.29 3.6 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.75 -0.738 . . . . 71.25 112.446 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . 0.508 ' HG2' ' HB3' ' A' ' 101' ' ' ALA . 0.0 OUTLIER -121.47 124.72 45.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.827 0.346 . . . . 74.33 110.939 -179.894 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 27.2 t -118.15 119.79 62.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.255 -0.43 . . . . 74.0 111.107 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.2 pp -150.99 156.57 41.43 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 72.44 110.888 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.492 ' HB2' ' HA ' ' A' ' 98' ' ' TYR . 0.6 OUTLIER -167.42 -173.42 2.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 71.24 110.907 179.949 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 1.2 t80 -96.89 142.87 28.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 74.53 110.91 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -78.37 114.58 17.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.451 . . . . 73.31 110.875 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.439 ' H ' HG23 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -76.05 -78.11 0.12 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 63.33 110.91 179.981 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 3.4 m -170.67 120.3 0.56 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.25 -0.432 . . . . 71.24 111.123 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . 0.406 ' HB2' ' CB ' ' A' ' 139' ' ' PHE . 0.8 OUTLIER -105.63 122.98 47.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.48 . . . . 41.44 110.813 179.953 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 135' ' ' ALA . . . -80.63 -22.89 61.17 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.699 -0.762 . . . . 72.24 112.464 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.637 ' HB2' ' CG1' ' A' ' 93' ' ' VAL . . . -36.95 -42.75 0.42 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.872 0.368 . . . . 54.02 111.164 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.508 HD22 ' O ' ' A' ' 135' ' ' ALA . 0.5 OUTLIER -142.44 168.49 19.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 71.14 110.896 179.976 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 90.1 p -48.27 96.75 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.18 -0.464 . . . . 52.31 110.811 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 4.4 m 49.48 73.79 0.23 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.088 -0.505 . . . . 63.35 110.815 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.406 ' CB ' ' HB2' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -100.06 161.63 13.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.074 -0.512 . . . . 74.14 110.934 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -130.03 165.56 21.94 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.185 -0.462 . . . . 74.2 110.916 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.492 HG21 HG11 ' A' ' 96' ' ' VAL . 6.4 tt -103.38 155.25 5.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.249 -0.432 . . . . 74.24 111.113 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 7.2 mmtp -123.33 111.96 17.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 74.52 110.858 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -78.95 -159.84 0.2 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.237 -0.438 . . . . 73.15 110.851 179.79 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -171.14 173.53 4.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 71.13 110.945 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' TRP . . . . . 0.409 ' O ' ' HB2' ' A' ' 146' ' ' ALA . 29.1 p90 -154.75 149.19 26.23 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.219 -0.446 . . . . 73.35 110.864 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.865 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 177.97 169.07 0.51 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.562 0.696 . . . . 55.33 111.086 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.865 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.6 Cg_endo -69.79 144.0 52.49 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.662 2.241 . . . . 75.54 112.344 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.645 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -138.84 167.99 20.79 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 75.11 111.144 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -108.71 161.77 14.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.247 -0.433 . . . . 74.25 110.881 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -140.18 157.18 46.01 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.159 -0.473 . . . . 63.03 110.89 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 7.6 p -154.4 131.03 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 74.42 111.092 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 169.77 -167.61 40.66 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 71.04 112.521 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.54 HD12 ' N ' ' A' ' 154' ' ' ARG . 1.7 pp -152.42 169.13 23.32 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.779 0.323 . . . . 70.54 110.979 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.54 ' N ' HD12 ' A' ' 153' ' ' LEU . 10.1 tpp85 -120.14 125.0 47.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.179 -0.464 . . . . 74.52 110.92 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -123.63 175.09 7.03 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.285 -0.416 . . . . 72.22 110.93 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -122.1 96.66 5.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.1 -0.5 . . . . 73.02 110.891 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' LEU . . . . . 0.409 HD23 ' N ' ' A' ' 158' ' ' GLY . 8.8 tt -102.92 140.26 37.42 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.233 -0.439 . . . . 71.42 110.934 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . 0.409 ' N ' HD23 ' A' ' 157' ' ' LEU . . . 59.29 171.63 0.43 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.745 -0.741 . . . . 72.33 112.444 179.824 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 45.4 t30 -93.07 158.57 15.71 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.907 0.384 . . . . 75.11 110.804 -179.824 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 58.7 m 51.18 32.24 7.75 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.18 -0.464 . . . . 60.23 110.843 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -174.68 149.7 1.26 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.143 -0.48 . . . . 72.24 110.91 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 11.9 mmt -121.18 172.77 7.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 73.55 110.928 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 5.0 tp -126.11 139.56 53.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.288 -0.415 . . . . 73.05 110.948 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -139.34 139.72 37.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.446 . . . . 75.23 110.927 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 69.2 p -139.8 121.8 15.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.445 . . . . 62.2 110.857 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . 0.421 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.5 OUTLIER -141.72 164.55 29.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 62.04 110.869 179.95 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.518 HG13 ' O ' ' A' ' 195' ' ' ILE . 40.1 t -150.16 129.86 3.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.147 -0.479 . . . . 73.1 111.104 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . 0.744 ' HG2' HD12 ' A' ' 195' ' ' ILE . 0.0 OUTLIER -101.08 144.92 29.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.136 -0.483 . . . . 74.11 110.832 -179.911 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -146.02 135.16 22.75 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.184 -0.462 . . . . 65.12 110.966 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' ILE . . . . . 0.645 HG21 ' HB2' ' A' ' 148' ' ' ALA . 4.7 tp 179.9 131.85 0.25 Allowed Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.594 0.711 . . . . 74.02 111.15 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.8 109.74 2.39 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.752 2.301 . . . . 74.35 112.315 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . 0.673 ' CZ ' ' HB3' ' A' ' 146' ' ' ALA . 2.0 m-85 -116.92 178.11 4.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 74.2 110.922 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.01 133.94 18.04 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.178 -0.464 . . . . 75.41 110.84 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . 0.443 HG22 HG13 ' A' ' 189' ' ' ILE . 13.2 t -105.64 154.28 20.65 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.166 -0.47 . . . . 62.31 111.077 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -128.53 161.81 28.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.135 -0.484 . . . . 71.12 110.858 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 20.3 t -146.58 132.42 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 50.41 111.175 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 3.3 t -165.59 160.25 17.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.183 -0.462 . . . . 64.2 111.145 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -136.3 171.37 22.88 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.751 -0.738 . . . . 63.03 112.454 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . 0.409 ' O ' HG23 ' A' ' 179' ' ' THR . 2.1 t -110.84 106.07 15.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.766 0.317 . . . . 71.32 111.173 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.68 HD11 ' CA ' ' A' ' 184' ' ' PRO . 0.4 OUTLIER -129.29 167.95 16.94 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.226 -0.443 . . . . 75.03 110.902 179.908 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -46.53 -66.81 1.6 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.692 -0.766 . . . . 42.54 112.502 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.68 -167.45 0.22 Allowed 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.68 2.253 . . . . 74.44 112.389 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.449 HG13 ' O ' ' A' ' 183' ' ' VAL . 4.4 p -73.95 113.89 27.48 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.677 0.751 . . . . 63.25 111.11 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . 0.68 ' CA ' HD11 ' A' ' 180' ' ' LEU . 54.1 Cg_endo -69.71 165.62 30.29 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.691 2.26 . . . . 61.33 112.353 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 15.0 t -101.32 139.33 22.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.235 -0.439 . . . . 64.12 111.095 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 43.0 p -121.25 105.03 10.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.162 -0.472 . . . . 50.51 110.907 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 22.1 p -105.06 162.07 13.69 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.162 -0.472 . . . . 63.41 111.152 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -159.32 157.38 30.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 72.32 110.884 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 189' ' ' ILE . . . . . 0.619 HG21 HD12 ' A' ' 32' ' ' LEU . 3.5 pt -154.13 130.43 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 51.45 111.139 179.889 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -101.62 118.4 36.86 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 63.31 110.881 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 191' ' ' VAL . . . . . 0.56 HG11 HG21 ' A' ' 28' ' ' VAL . 7.1 p -136.25 160.97 38.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.144 -0.48 . . . . 73.41 111.127 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.415 ' N ' HG22 ' A' ' 191' ' ' VAL . 1.7 p30 -106.91 87.82 3.19 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.613 0.721 . . . . 71.34 110.85 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.69 158.85 55.6 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.703 2.268 . . . . 63.2 112.33 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -136.94 120.87 17.59 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.23 -0.441 . . . . 52.22 110.889 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 195' ' ' ILE . . . . . 0.744 HD12 ' HG2' ' A' ' 168' ' ' ARG . 45.4 mt -105.62 118.5 53.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.445 . . . . 74.13 111.167 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 3.9 mt -106.73 108.33 19.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.156 -0.474 . . . . 45.42 110.924 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 16.6 p -101.03 134.22 44.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 74.54 110.874 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 198' ' ' LEU . . . . . . . . . . . . . 22.0 tp -156.49 129.7 8.03 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.109 -0.496 . . . . 73.33 110.909 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 179.83 -145.59 6.56 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.74 -0.743 . . . . 61.22 112.501 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 200' ' ' ALA . . . . . 0.579 ' HB3' ' CE2' ' A' ' 21' ' ' PHE . . . -116.73 174.53 6.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.755 0.312 . . . . 71.24 111.084 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 71.8 m -155.67 164.85 38.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 65.52 110.887 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 9.7 t80 -134.34 122.63 22.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.141 -0.481 . . . . 74.34 110.887 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 19.7 m -76.9 127.96 37.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.087 -0.506 . . . . 71.12 111.136 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 204' ' ' PHE . . . . . 0.415 ' HB3' ' HB2' ' A' ' 17' ' ' TRP . 1.1 m-85 -112.46 81.35 1.46 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 73.12 110.924 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . 0.545 ' HG3' HD23 ' A' ' 206' ' ' LEU . 55.3 pttt -164.12 -166.89 1.21 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.499 . . . . 62.3 110.838 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 206' ' ' LEU . . . . . 0.545 HD23 ' HG3' ' A' ' 205' ' ' LYS . 1.4 pt? -51.47 170.99 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.221 -0.445 . . . . 71.44 110.928 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -154.05 152.83 30.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.275 -0.42 . . . . 53.34 111.198 179.759 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -77.31 169.9 17.51 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.265 -0.425 . . . . 73.02 111.099 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -155.51 142.01 18.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.182 -0.463 . . . . 53.41 111.072 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . 0.473 ' O ' HD12 ' A' ' 210' ' ' LEU . 0.7 OUTLIER -130.38 158.95 38.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 70.14 110.921 -179.913 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 53.3 mt-10 . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.275 -0.42 . . . . 74.42 110.92 179.875 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.4 mmm . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.817 0.341 . . . . 72.21 110.884 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 49.5 t30 -152.3 146.55 25.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.25 -0.432 . . . . 73.2 110.833 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 18.9 mm-40 -135.45 105.48 6.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.455 . . . . 75.42 110.93 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -104.85 168.25 9.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.131 -0.486 . . . . 64.1 110.892 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -119.6 73.42 16.33 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.685 0.755 . . . . 60.45 110.897 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 90.07 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.673 2.248 . . . . 71.21 112.376 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -101.91 137.94 39.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.255 -0.429 . . . . 70.43 111.174 179.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -71.41 117.64 13.21 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.302 -0.408 . . . . 73.22 110.893 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 7.8 t -98.91 141.43 31.69 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 62.24 110.835 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -106.16 162.52 13.57 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.095 -0.502 . . . . 73.13 111.093 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -170.13 172.38 43.87 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.756 -0.735 . . . . 71.11 112.489 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 15.1 p90 -159.97 120.64 3.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.877 0.37 . . . . 74.42 110.916 -179.78 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -140.86 162.9 34.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 60.21 110.868 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -52.09 120.36 5.33 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.113 -0.494 . . . . 62.13 110.926 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.85 5.52 35.69 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.781 -0.723 . . . . 45.35 112.423 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -66.8 150.16 49.53 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.778 0.323 . . . . 52.13 110.867 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.511 ' HE1' HG23 ' A' ' 59' ' ' ILE . 25.9 t90 -116.6 144.18 44.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.164 -0.471 . . . . 74.2 110.882 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.67 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 12.9 t -141.6 118.83 7.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.268 -0.424 . . . . 72.14 111.13 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -84.76 101.71 12.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.229 -0.441 . . . . 65.23 111.083 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 1.4 t -97.93 142.09 30.09 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 75.01 110.866 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.549 ' HE2' HD13 ' A' ' 55' ' ' LEU . 73.6 t80 -146.52 118.89 8.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.164 -0.471 . . . . 74.45 110.856 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.412 ' O ' HG23 ' A' ' 56' ' ' THR . 3.9 p30 -149.77 174.72 12.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.132 -0.486 . . . . 51.4 110.927 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 13.3 t80 -106.52 128.76 54.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.471 . . . . 75.32 110.914 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -94.21 147.56 23.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.171 -0.468 . . . . 75.13 110.856 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 20.7 tttt -127.49 111.42 13.78 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.135 -0.484 . . . . 71.32 110.891 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 8.1 p -75.63 127.09 37.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 65.35 111.153 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 2.6 t80 -119.46 105.15 10.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.144 -0.48 . . . . 70.24 110.915 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.803 HG11 HG11 ' A' ' 47' ' ' VAL . 6.4 t -78.65 157.76 4.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.083 -0.508 . . . . 54.14 111.154 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.505 ' HA3' HG21 ' A' ' 191' ' ' VAL . . . -76.5 -112.6 0.13 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.693 -0.765 . . . . 53.51 112.528 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 66.6 mt-10 -89.86 -67.08 0.87 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.854 0.359 . . . . 64.31 110.942 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.544 ' HA ' HG12 ' A' ' 47' ' ' VAL . 1.7 pm0 -177.11 -173.79 0.48 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.127 -0.488 . . . . 73.11 110.88 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.823 ' HA ' HG21 ' A' ' 189' ' ' ILE . 1.9 mt -85.0 -177.78 6.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.194 -0.457 . . . . 74.52 110.911 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.29 75.25 0.42 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.771 -0.728 . . . . 65.02 112.481 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -94.69 152.06 18.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.784 0.326 . . . . 73.42 110.858 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 2.3 tt -155.75 95.04 1.62 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 63.32 110.908 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -74.21 141.53 45.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.121 -0.49 . . . . 75.4 110.901 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 19.8 m -95.68 137.22 24.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.17 -0.468 . . . . 71.25 111.18 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 131.6 -82.53 0.31 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.823 -0.703 . . . . 74.41 112.491 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . -173.19 -179.84 44.14 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.737 -0.745 . . . . 43.14 112.474 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.21 148.25 23.89 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.745 -0.741 . . . . 70.4 112.501 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -55.04 142.08 31.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.848 0.356 . . . . 44.23 111.07 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -148.57 67.9 9.75 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.595 0.712 . . . . 73.2 110.937 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.85 -170.18 0.38 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.663 2.242 . . . . 74.45 112.322 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -67.72 118.17 10.62 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 64.33 110.855 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -62.4 -176.7 0.11 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.089 -0.505 . . . . 72.04 111.057 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -157.9 126.01 5.4 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 72.41 110.875 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.803 HG11 HG11 ' A' ' 28' ' ' VAL . 7.2 p -104.39 140.71 21.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 65.02 111.152 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -140.48 164.83 29.1 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 65.13 110.828 -179.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.597 HG22 ' CE2' ' A' ' 81' ' ' PHE . 23.2 pt -112.25 157.17 13.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.101 -0.5 . . . . 73.03 111.178 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.07 142.52 31.87 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.772 -0.728 . . . . 34.1 112.506 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -93.38 110.86 22.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.805 0.336 . . . . 51.31 110.858 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 19.9 t0 -174.07 148.83 1.39 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.46 . . . . 72.23 110.857 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 2.0 m -70.73 130.54 41.99 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 72.04 111.148 -179.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.97 177.54 7.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.171 -0.468 . . . . 62.24 111.143 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.549 HD13 ' HE2' ' A' ' 21' ' ' PHE . 3.1 pp -159.97 165.39 32.11 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.219 -0.446 . . . . 73.14 110.942 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.491 HG21 ' CE2' ' A' ' 72' ' ' PHE . 0.3 OUTLIER -143.3 143.27 31.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 62.43 111.132 -179.993 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -103.18 133.29 48.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.221 -0.445 . . . . 74.45 110.897 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -121.39 136.44 54.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.12 -0.491 . . . . 63.43 110.844 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.511 HG23 ' HE1' ' A' ' 17' ' ' TRP . 27.5 mm -108.51 113.39 43.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.161 -0.472 . . . . 74.4 111.067 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.67 ' HB3' ' HB ' ' A' ' 18' ' ' VAL . . . -102.78 121.19 41.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 72.34 111.1 179.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.435 ' HB3' HG22 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -111.3 115.41 29.28 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.187 -0.461 . . . . 65.51 110.968 -179.835 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -82.54 101.9 11.03 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.108 -0.496 . . . . 71.2 110.83 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 62.0 t -97.1 -35.37 5.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.135 -0.484 . . . . 64.41 111.106 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 27.8 t -134.07 162.09 33.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.487 . . . . 63.01 110.876 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 59.4 p -84.46 2.85 38.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.171 -0.468 . . . . 64.42 110.83 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 28.8 m120 -115.0 -32.98 5.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.085 -0.507 . . . . 75.54 110.912 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.425 HG22 ' CB ' ' A' ' 107' ' ' TYR . 21.7 pt -142.35 165.04 17.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.164 -0.471 . . . . 73.14 111.156 179.849 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -151.55 167.09 29.15 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.222 -0.445 . . . . 63.13 111.118 179.827 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.435 HG22 ' HB3' ' A' ' 61' ' ' TYR . 6.5 m -108.01 151.07 10.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 61.23 111.179 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -139.15 132.48 30.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 62.41 110.877 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -115.83 110.02 18.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.15 -0.477 . . . . 70.05 110.85 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.491 ' CE2' HG21 ' A' ' 56' ' ' THR . 30.9 t80 -91.26 115.94 28.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.14 -0.482 . . . . 74.42 110.888 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.404 HG12 ' N ' ' A' ' 74' ' ' GLY . 11.3 t -142.23 156.17 19.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 72.01 111.082 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.404 ' N ' HG12 ' A' ' 73' ' ' VAL . . . -163.96 148.68 15.11 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.691 -0.766 . . . . 53.0 112.427 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.7 t -119.65 65.35 9.13 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.637 0.732 . . . . 44.21 111.144 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 163.42 38.33 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.688 2.259 . . . . 55.54 112.349 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -89.42 -169.29 2.43 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.237 -0.438 . . . . 70.34 111.08 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.5 ttp180 -77.42 132.52 38.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.258 -0.428 . . . . 74.41 110.921 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . 0.514 ' HB3' ' CZ ' ' A' ' 98' ' ' TYR . . . -133.38 152.84 51.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 64.14 111.048 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 14.6 ttmt -82.12 150.33 27.53 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.172 -0.467 . . . . 54.21 110.938 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . 0.597 ' CE2' HG22 ' A' ' 49' ' ' ILE . 2.5 t80 -138.77 147.69 42.92 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 74.23 110.896 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.511 ' O ' HG23 ' A' ' 47' ' ' VAL . 10.6 mt-30 -113.61 153.31 29.07 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.137 -0.483 . . . . 74.34 110.894 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.541 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 174.96 80.86 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.758 . . . . 62.24 112.423 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -178.26 -178.37 0.63 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.92 0.391 . . . . 74.24 110.962 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.0 -69.42 0.67 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.213 -0.448 . . . . 54.3 110.877 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 5.3 m -85.22 -32.41 22.64 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.23 -0.441 . . . . 63.34 110.829 -179.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.556 HG22 HG22 ' A' ' 93' ' ' VAL . 4.3 mm -66.83 -34.9 72.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 74.33 111.097 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 15.1 t -63.32 -47.84 80.53 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 64.34 110.864 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.2 p -53.14 -38.64 62.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 72.13 110.844 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -63.47 -43.39 97.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.178 -0.464 . . . . 74.15 110.867 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 109.86 -13.55 32.03 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.747 -0.739 . . . . 72.13 112.498 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 41.6 mtt180 -118.81 93.38 4.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.852 0.358 . . . . 73.24 110.916 -179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.556 HG22 HG22 ' A' ' 87' ' ' ILE . 4.0 t -113.57 -35.0 2.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 75.4 111.158 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 19.5 m -156.17 161.29 40.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 62.11 110.779 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . 0.629 ' O ' HG13 ' A' ' 96' ' ' VAL . 44.7 mt-10 -153.86 115.89 4.29 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.118 -0.492 . . . . 65.52 110.875 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.629 HG13 ' O ' ' A' ' 95' ' ' GLU . 2.1 m -161.68 179.53 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.148 -0.478 . . . . 75.03 111.089 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -98.28 147.92 24.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 74.23 110.854 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' TYR . . . . . 0.514 ' CZ ' ' HB3' ' A' ' 79' ' ' ALA . 11.6 m-85 -92.34 139.98 30.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.219 -0.446 . . . . 74.43 110.946 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.402 ' N ' ' CD ' ' A' ' 100' ' ' PRO . . . -127.37 55.07 0.76 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.721 -0.752 . . . . 51.24 112.476 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.402 ' CD ' ' N ' ' A' ' 99' ' ' GLY . 53.6 Cg_endo -69.73 111.69 2.87 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.71 2.273 . . . . 55.22 112.402 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.453 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -136.07 110.08 8.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.265 -0.425 . . . . 73.01 111.107 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.554 HG22 ' CA ' ' A' ' 124' ' ' GLY . 11.0 pt -140.82 140.59 33.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.213 -0.449 . . . . 74.34 111.17 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.567 ' HG ' HG23 ' A' ' 123' ' ' VAL . 0.1 OUTLIER -132.49 120.14 21.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.142 -0.481 . . . . 73.53 110.933 179.904 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 2.4 p -142.14 162.86 34.41 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 61.33 110.878 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -109.23 144.6 37.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.146 -0.479 . . . . 72.54 110.876 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 3.0 pm0 -105.38 148.99 26.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.109 -0.496 . . . . 71.11 110.87 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.612 ' CE2' HG13 ' A' ' 119' ' ' VAL . 32.2 p90 -149.33 148.44 29.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 72.2 110.913 -179.852 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 32.3 t60 -115.46 152.09 33.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.087 -0.506 . . . . 74.41 110.849 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 17.4 t80 -88.55 110.09 20.6 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 73.31 110.908 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 22.3 m-20 -51.18 109.07 0.3 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.074 -0.512 . . . . 61.25 110.841 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.1 m -170.98 146.86 2.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 73.11 110.884 -179.798 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 15.6 p90 -116.99 49.69 1.15 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 71.22 110.94 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -93.51 -55.19 3.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 73.34 110.925 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 67.7 mtt180 -152.68 -179.7 7.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 64.32 110.922 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 25.9 tp -95.82 117.23 30.16 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.245 -0.434 . . . . 71.04 110.931 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 5.4 p90 -147.58 158.85 42.68 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 121.654 0.74 . . . . 73.21 110.893 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 179.09 3.93 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.727 2.284 . . . . 53.15 112.35 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -109.87 164.59 12.44 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.22 -0.445 . . . . 64.34 110.974 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.612 HG13 ' CE2' ' A' ' 107' ' ' TYR . 6.2 p -117.51 139.0 46.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.169 -0.469 . . . . 73.44 111.096 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -139.95 160.5 26.23 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.713 -0.756 . . . . 74.12 112.499 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 4.9 m -152.75 163.88 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.877 0.37 . . . . 64.0 111.18 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 174.98 -145.99 8.19 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.722 -0.751 . . . . 41.42 112.429 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.567 HG23 ' HG ' ' A' ' 103' ' ' LEU . 11.8 m -105.5 148.89 9.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.853 0.358 . . . . 61.5 111.192 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . 0.554 ' CA ' HG22 ' A' ' 102' ' ' ILE . . . -144.25 105.95 0.39 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.697 -0.763 . . . . 55.31 112.467 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . 0.453 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 15.7 ptm180 -99.78 125.07 45.63 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.899 0.38 . . . . 70.33 110.903 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 25.2 t -109.51 114.02 45.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.25 -0.432 . . . . 64.11 111.125 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.575 HD12 ' N ' ' A' ' 128' ' ' PHE . 2.1 pp -124.24 171.12 10.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.465 . . . . 74.2 110.885 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.575 ' N ' HD12 ' A' ' 127' ' ' LEU . 0.6 OUTLIER -141.14 178.55 7.31 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.148 -0.478 . . . . 53.41 110.831 179.953 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -118.15 119.82 35.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.115 -0.493 . . . . 73.02 110.918 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -60.45 103.61 0.26 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.125 -0.489 . . . . 54.41 110.892 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.519 ' H ' HG12 ' A' ' 96' ' ' VAL . 7.9 tppt? -123.69 -71.91 0.7 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.449 . . . . 71.23 110.912 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 23.5 m -166.87 92.68 0.44 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.459 . . . . 61.32 111.136 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -107.73 168.98 8.88 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.178 -0.464 . . . . 53.15 110.871 179.879 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 79.28 151.68 6.39 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.748 -0.739 . . . . 73.14 112.481 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -39.38 -66.85 0.26 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.831 0.348 . . . . 74.15 111.09 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -166.64 92.33 0.45 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 70.44 110.852 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.645 ' OG ' HD13 ' A' ' 180' ' ' LEU . 0.4 OUTLIER 169.01 60.78 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 33.45 110.878 -179.947 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.533 ' C ' ' O ' ' A' ' 137' ' ' SER . 8.7 t 27.21 73.93 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.152 -0.476 . . . . 63.25 110.906 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -107.3 159.15 16.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.144 -0.48 . . . . 73.24 110.854 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -145.19 167.12 23.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.088 -0.506 . . . . 65.03 110.943 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.595 ' HA ' HG23 ' A' ' 176' ' ' VAL . 12.5 tt -116.76 132.5 66.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.209 -0.45 . . . . 62.31 111.131 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . 0.733 ' O ' HG22 ' A' ' 174' ' ' THR . 0.0 OUTLIER -80.72 106.64 12.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 74.01 110.863 179.899 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -82.72 -172.43 4.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.228 -0.442 . . . . 62.41 110.879 179.87 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 5.2 tptt -174.95 -169.73 0.42 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 71.14 110.906 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' TRP . . . . . 0.427 ' O ' ' HB2' ' A' ' 146' ' ' ALA . 66.9 p-90 -144.62 161.01 40.22 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.208 -0.451 . . . . 74.22 110.98 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.724 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . 178.02 165.29 0.59 Allowed Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.567 0.698 . . . . 53.31 111.14 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.724 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.6 Cg_endo -69.74 161.88 44.2 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.705 2.27 . . . . 73.23 112.354 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.644 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -153.79 160.11 42.14 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.249 -0.432 . . . . 63.4 111.064 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -118.91 115.23 23.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.223 -0.444 . . . . 65.25 110.903 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 20.6 tt0 -102.86 164.41 11.64 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.105 -0.498 . . . . 72.14 110.921 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 14.6 p -160.12 137.17 2.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.153 -0.476 . . . . 60.21 111.052 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . 0.408 ' HA3' ' HA ' ' A' ' 166' ' ' ASP . . . 177.55 -162.25 30.02 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.767 -0.73 . . . . 60.41 112.528 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.1 pt? -138.69 160.61 39.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.827 0.346 . . . . 73.43 110.888 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 3.4 tpp85 -132.05 119.74 21.43 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 73.35 110.883 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -105.46 140.96 37.78 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.181 -0.463 . . . . 74.43 110.932 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -120.93 117.55 27.63 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.472 . . . . 73.42 110.864 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 3.9 tp -102.3 164.4 11.7 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 75.34 110.887 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -99.51 53.79 0.99 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.739 -0.744 . . . . 65.53 112.486 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -149.87 35.87 0.69 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.362 . . . . 75.32 110.966 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 51.79 35.4 15.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 72.25 110.8 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 51.2 m95 -154.99 101.43 2.26 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.134 -0.484 . . . . 73.44 110.849 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.435 ' O ' ' HB1' ' A' ' 200' ' ' ALA . 0.0 OUTLIER -97.7 168.25 10.45 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.253 -0.43 . . . . 75.35 110.909 179.855 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 4.0 tp -125.26 144.18 50.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.252 -0.431 . . . . 63.21 110.934 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -142.99 139.98 30.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 70.11 110.84 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 52.8 p -150.95 120.94 7.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 71.13 110.87 -179.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . 0.408 ' HA ' ' HA3' ' A' ' 152' ' ' GLY . 0.6 OUTLIER -149.08 171.13 16.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.167 -0.47 . . . . 55.23 110.881 179.921 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 4.3 t -144.75 135.96 20.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.171 -0.468 . . . . 72.22 111.076 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -102.67 137.34 41.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.183 -0.462 . . . . 74.45 110.872 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' TYR . . . . . . . . . . . . . 35.1 t80 -141.79 139.2 32.7 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.201 -0.454 . . . . 73.45 110.887 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' ILE . . . . . 0.644 HG21 ' HB2' ' A' ' 148' ' ' ALA . 0.0 OUTLIER 178.96 125.93 0.21 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.633 0.73 . . . . 74.35 111.096 179.885 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 107.25 1.82 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.649 2.233 . . . . 74.33 112.337 179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -126.94 170.0 12.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 65.1 110.894 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -136.7 141.4 43.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.114 -0.494 . . . . 75.22 110.875 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . 0.733 HG22 ' O ' ' A' ' 142' ' ' LYS . 0.2 OUTLIER -125.32 169.48 12.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 70.12 111.141 179.958 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -126.64 170.45 12.08 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 52.2 110.888 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . 0.595 HG23 ' HA ' ' A' ' 141' ' ' ILE . 7.6 p -160.14 137.1 2.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.45 . . . . 72.12 111.213 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . 0.558 HG22 ' HD3' ' A' ' 142' ' ' LYS . 12.8 t -166.84 175.6 7.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.245 -0.434 . . . . 72.43 111.169 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . -156.95 -140.99 3.07 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.8 -0.714 . . . . 45.3 112.495 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -157.05 106.17 2.19 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.816 0.341 . . . . 72.33 111.073 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . 0.645 HD13 ' OG ' ' A' ' 137' ' ' SER . 19.4 tp -139.88 117.78 11.75 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.213 -0.449 . . . . 70.01 110.957 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 46.42 -106.07 0.12 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.827 -0.701 . . . . 75.34 112.442 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 -167.87 0.24 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.694 2.263 . . . . 74.31 112.303 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.408 HG13 ' HD2' ' A' ' 184' ' ' PRO . 59.0 t -54.7 133.18 65.14 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.643 0.735 . . . . 71.32 111.163 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . 0.408 ' HD2' HG13 ' A' ' 183' ' ' VAL . 54.0 Cg_endo -69.71 164.02 36.04 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.686 2.258 . . . . 71.23 112.34 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 48.4 t -108.36 108.82 26.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 71.02 111.106 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 85.5 p -99.22 111.3 23.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.075 -0.512 . . . . 63.43 110.827 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 3.1 p -108.53 163.31 13.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 54.03 111.152 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -146.53 148.06 31.78 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.271 -0.422 . . . . 74.51 110.92 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 189' ' ' ILE . . . . . 0.823 HG21 ' HA ' ' A' ' 32' ' ' LEU . 3.6 pt -142.36 136.35 28.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.285 -0.416 . . . . 51.05 111.165 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -112.17 104.23 12.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.208 -0.451 . . . . 40.33 110.882 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 191' ' ' VAL . . . . . 0.505 HG21 ' HA3' ' A' ' 29' ' ' GLY . 4.9 p -136.6 163.18 33.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 74.15 111.156 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.409 ' N ' HG22 ' A' ' 191' ' ' VAL . 1.4 p-10 -106.71 90.68 5.31 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.63 0.729 . . . . 72.45 110.875 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.73 135.99 31.92 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.698 2.265 . . . . 71.4 112.316 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -103.67 124.94 49.77 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.254 -0.43 . . . . 73.41 110.936 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 195' ' ' ILE . . . . . . . . . . . . . 26.4 mm -107.45 103.19 15.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.159 -0.473 . . . . 75.12 111.186 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . . . . . . . . . 20.7 tp -91.47 110.55 21.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 74.32 110.88 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . . . . . . . . . 20.5 p -110.35 123.58 50.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 75.22 110.864 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 198' ' ' LEU . . . . . 0.411 HD23 ' N ' ' A' ' 198' ' ' LEU . 1.0 OUTLIER -141.4 132.65 26.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 75.13 110.944 -179.948 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 179.02 -146.43 7.22 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.823 -0.703 . . . . 75.11 112.544 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 200' ' ' ALA . . . . . 0.435 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -125.52 173.37 8.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.796 0.331 . . . . 72.34 111.168 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -147.53 171.1 16.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.425 . . . . 73.25 110.914 -179.77 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 202' ' ' TYR . . . . . . . . . . . . . 12.6 m-85 -139.33 133.87 31.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.137 -0.483 . . . . 61.51 110.92 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . . . . . . . . . 11.2 p -79.56 147.64 6.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.122 -0.49 . . . . 65.55 111.167 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -146.67 98.07 3.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.212 -0.449 . . . . 63.15 110.865 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 18.1 mtmt -65.91 173.34 3.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.095 -0.502 . . . . 65.25 110.809 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 206' ' ' LEU . . . . . . . . . . . . . 11.1 mp -60.7 109.71 1.11 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 72.02 110.877 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . -105.6 169.09 8.67 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.192 -0.458 . . . . 65.33 111.127 179.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -123.31 132.18 53.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.283 -0.417 . . . . 62.21 111.108 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -162.07 173.24 14.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 62.02 111.07 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . 0.534 ' H ' HD23 ' A' ' 210' ' ' LEU . 1.8 pt? -120.21 163.38 17.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 60.05 110.86 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.136 -0.484 . . . . 64.52 110.944 179.923 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.7 tpt . . . . . 0 C--O 1.23 0.044 0 CA-C-O 120.817 0.342 . . . . 63.02 110.904 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 11.4 t-20 -60.77 148.69 38.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.448 . . . . 74.33 110.885 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.9 tm-20 -139.71 107.84 5.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.154 -0.475 . . . . 73.03 110.879 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 8.2 p30 -53.52 147.24 11.29 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.102 -0.499 . . . . 63.31 110.946 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' TYR . . . . . 0.519 ' N ' ' HD2' ' A' ' 6' ' ' PRO . 0.0 OUTLIER 175.67 -58.53 0.0 OUTLIER Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.698 0.761 . . . . 74.52 110.964 -179.884 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.519 ' HD2' ' N ' ' A' ' 5' ' ' TYR . 53.8 Cg_endo -69.71 161.24 46.67 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.712 2.275 . . . . 62.25 112.339 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.92 119.47 38.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.261 -0.427 . . . . 65.11 111.203 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 8.4 tptt -110.0 61.85 0.6 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.248 -0.433 . . . . 75.3 110.862 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 60.2 p -170.57 170.66 6.72 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.298 -0.41 . . . . 44.41 110.849 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.713 ' HB1' ' CE2' ' A' ' 12' ' ' TYR . . . -91.32 170.54 9.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.137 -0.483 . . . . 50.44 111.127 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -104.38 43.26 1.7 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.749 -0.739 . . . . 73.2 112.543 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.713 ' CE2' ' HB1' ' A' ' 10' ' ' ALA . 14.6 p90 -162.38 120.02 2.1 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.894 0.378 . . . . 63.42 110.877 -179.743 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -166.03 -178.94 4.91 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.11 -0.495 . . . . 63.44 110.877 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -69.4 120.52 15.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.173 -0.467 . . . . 74.35 110.926 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 103.88 6.21 43.42 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.762 -0.732 . . . . 70.13 112.513 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -66.93 150.46 49.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.809 0.337 . . . . 73.23 110.815 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.588 ' CZ2' HD13 ' A' ' 206' ' ' LEU . 4.5 m0 -111.96 142.05 44.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.152 -0.477 . . . . 63.21 110.939 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.632 ' HB ' ' HB3' ' A' ' 60' ' ' ALA . 43.2 t -145.04 118.95 2.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.263 -0.426 . . . . 72.41 111.041 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -83.4 119.96 25.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.098 -0.501 . . . . 64.22 111.031 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 22.0 t -106.65 128.6 54.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 65.45 110.807 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.536 ' CE2' HD21 ' A' ' 55' ' ' LEU . 19.2 t80 -138.19 114.55 10.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.095 -0.502 . . . . 72.3 110.829 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 2.3 p30 -153.5 174.05 14.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 74.42 110.906 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -102.45 129.01 48.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.455 . . . . 64.52 110.915 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.2 p -98.64 148.04 24.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.129 -0.487 . . . . 53.23 110.839 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 39.2 tptt -129.45 106.84 9.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 61.35 110.854 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.2 m -89.68 124.2 42.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.226 -0.443 . . . . 61.34 111.139 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 28.5 t80 -118.93 104.12 10.22 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.166 -0.47 . . . . 75.33 110.933 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.0 p -157.8 150.45 8.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 50.45 111.189 179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 144.77 76.8 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.776 -0.726 . . . . 55.42 112.506 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -89.5 -65.63 1.0 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.758 0.313 . . . . 72.31 110.849 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -169.09 124.76 0.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.447 . . . . 72.11 110.902 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.687 HD13 HG13 ' A' ' 189' ' ' ILE . 0.9 OUTLIER -89.2 152.78 21.41 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.164 -0.471 . . . . 73.21 110.86 -179.95 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.45 -119.11 4.92 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.726 -0.75 . . . . 63.32 112.459 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -160.17 157.54 28.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.818 0.342 . . . . 72.44 110.893 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 30.5 tp -81.57 153.2 26.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.218 -0.447 . . . . 63.51 110.926 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 28.9 m120 -75.19 153.48 38.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.217 -0.447 . . . . 71.15 110.926 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 24.0 t -67.55 -41.83 86.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 51.34 111.127 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -179.98 -150.3 9.1 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.72 -0.753 . . . . 73.22 112.517 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.18 -156.56 43.68 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.756 -0.735 . . . . 25.44 112.425 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -52.13 148.27 11.23 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.682 -0.771 . . . . 64.33 112.477 -179.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.504 ' C ' HD22 ' A' ' 42' ' ' LEU . . . -91.13 108.88 20.17 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.806 0.336 . . . . 63.41 111.134 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.504 HD22 ' C ' ' A' ' 41' ' ' ALA . 4.5 mm? -120.89 159.25 49.74 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.563 0.697 . . . . 75.54 110.885 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.75 97.83 0.66 Allowed 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.645 2.23 . . . . 73.42 112.373 179.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -52.36 171.5 0.05 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.465 . . . . 70.13 110.866 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.553 ' HB3' ' O ' ' A' ' 32' ' ' LEU . . . -51.55 156.54 1.28 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.479 . . . . 41.24 111.042 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 17.8 t0 -146.18 126.57 14.02 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.152 -0.476 . . . . 60.24 110.866 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.633 ' HB ' HD23 ' A' ' 32' ' ' LEU . 7.1 p -105.36 140.56 23.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 62.21 111.135 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -158.8 157.85 32.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.45 . . . . 70.12 110.829 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 9.4 tt -132.4 144.04 38.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.102 -0.499 . . . . 74.45 111.084 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -108.19 97.23 1.1 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.782 -0.723 . . . . 54.22 112.517 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -136.7 119.09 15.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.802 0.334 . . . . 74.1 110.895 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 77.1 m-20 -100.81 -56.5 2.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.206 -0.452 . . . . 74.04 110.914 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 5.1 t -60.78 134.06 56.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.137 -0.483 . . . . 73.21 111.127 -179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.4 p -120.24 121.29 38.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 74.2 111.151 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.536 HD21 ' CE2' ' A' ' 21' ' ' PHE . 0.3 OUTLIER -159.9 123.41 3.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.247 -0.433 . . . . 73.11 110.946 179.978 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.667 HG21 ' CE1' ' A' ' 72' ' ' PHE . 5.4 m -137.74 130.76 30.29 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 64.11 111.143 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -102.93 132.53 49.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 72.41 110.874 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.577 ' O ' HD13 ' A' ' 59' ' ' ILE . 0.7 OUTLIER -131.93 155.95 47.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.119 -0.491 . . . . 63.34 110.872 179.92 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.577 HD13 ' O ' ' A' ' 58' ' ' ASP . 27.4 mm -126.05 115.16 41.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 75.33 111.153 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.632 ' HB3' ' HB ' ' A' ' 18' ' ' VAL . . . -99.9 126.05 45.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 73.14 111.11 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.555 ' HB3' HG22 ' A' ' 69' ' ' VAL . 0.5 OUTLIER -116.72 118.26 32.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.272 -0.422 . . . . 71.14 110.968 -179.857 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -88.42 101.0 13.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.145 -0.479 . . . . 63.52 110.856 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 9.0 p -98.01 -35.17 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.114 -0.494 . . . . 72.32 111.144 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.2 m -136.88 161.31 36.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.138 -0.483 . . . . 75.43 110.871 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 2.8 m -83.74 2.99 35.25 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.171 -0.468 . . . . 72.44 110.827 -179.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -120.16 -33.57 3.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.156 -0.474 . . . . 74.43 110.831 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.572 HG22 ' CD1' ' A' ' 107' ' ' TYR . 2.5 pp -136.06 148.12 27.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.242 -0.435 . . . . 54.11 111.143 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -143.73 167.78 21.46 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.249 -0.432 . . . . 74.02 111.143 179.777 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.555 HG22 ' HB3' ' A' ' 61' ' ' TYR . 4.2 m -114.69 151.21 16.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 64.41 111.134 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -143.89 132.45 22.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.167 -0.469 . . . . 34.12 110.885 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -103.88 142.03 35.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 70.35 110.924 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.667 ' CE1' HG21 ' A' ' 56' ' ' THR . 7.5 t80 -121.4 118.57 29.75 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.187 -0.46 . . . . 73.24 110.871 -179.883 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 44.7 t -147.18 145.75 18.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 71.22 111.114 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -132.96 -30.23 0.49 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.754 -0.736 . . . . 63.15 112.514 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 11.0 m 36.6 62.76 2.97 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.623 0.725 . . . . 71.01 111.124 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 163.57 37.78 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.738 2.292 . . . . 65.15 112.306 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -79.64 -169.82 2.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 74.21 111.037 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.7 ttp180 -77.94 126.43 30.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.472 . . . . 72.42 110.912 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -135.77 151.93 50.61 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 75.33 111.089 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 26.3 ttpp -93.15 143.8 25.9 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 74.51 110.844 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . 0.599 ' HE2' HG12 ' A' ' 96' ' ' VAL . 13.8 p90 -139.39 157.73 45.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 75.31 110.917 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.467 ' HA ' ' HB ' ' A' ' 93' ' ' VAL . 5.2 pt20 -106.85 157.2 17.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 75.12 110.93 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.661 ' H ' HG21 ' A' ' 93' ' ' VAL . . . 178.4 71.05 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.73 -0.748 . . . . 43.23 112.498 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -168.36 -173.48 1.99 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.926 0.393 . . . . 74.33 110.913 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.33 -71.23 0.55 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 65.23 110.932 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 23.1 t -84.89 -30.35 24.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.255 -0.43 . . . . 55.4 110.835 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.82 HG22 HG22 ' A' ' 93' ' ' VAL . 4.7 mm -67.99 -34.26 65.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 52.42 111.13 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 4.0 t -63.02 -44.13 96.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.152 -0.476 . . . . 74.4 110.806 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 73.4 m -55.18 -41.6 72.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.134 -0.485 . . . . 60.55 110.85 -179.821 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -58.86 -49.85 76.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.112 -0.495 . . . . 73.3 110.911 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 116.2 -17.12 14.85 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.829 -0.7 . . . . 62.31 112.534 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 6.8 ttp180 -121.27 95.52 4.72 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.856 0.36 . . . . 70.42 110.864 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.82 HG22 HG22 ' A' ' 87' ' ' ILE . 93.0 t -104.45 -61.09 2.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.136 -0.483 . . . . 71.5 111.073 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.403 ' HA ' ' HA ' ' A' ' 133' ' ' ASP . 1.8 p -139.47 149.52 44.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.24 -0.437 . . . . 64.11 110.921 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -127.74 129.58 47.32 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.146 -0.479 . . . . 55.11 110.906 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.61 HG21 ' O ' ' A' ' 129' ' ' PHE . 6.1 p -173.43 163.27 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 75.51 111.126 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.442 ' N ' HG22 ' A' ' 96' ' ' VAL . 10.3 p-10 -92.58 152.61 19.51 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.2 -0.454 . . . . 73.04 110.851 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -103.41 148.94 25.29 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.225 -0.443 . . . . 72.2 110.868 -179.81 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -139.07 62.23 0.56 Allowed Glycine 0 N--CA 1.453 -0.194 0 C-N-CA 120.751 -0.738 . . . . 65.41 112.547 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 118.43 5.68 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.65 2.233 . . . . 71.41 112.325 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.62 ' HB3' ' HG3' ' A' ' 125' ' ' ARG . . . -122.38 102.57 8.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.233 -0.44 . . . . 75.33 111.138 179.841 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.456 HD12 ' HA3' ' A' ' 124' ' ' GLY . 10.8 mm -117.85 147.73 21.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.243 -0.435 . . . . 61.34 111.152 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -151.49 122.46 7.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 65.13 110.924 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.405 ' HA ' ' HA3' ' A' ' 122' ' ' GLY . 8.6 p -147.17 173.63 12.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 72.51 110.867 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.482 ' O ' HD12 ' A' ' 105' ' ' LEU . 0.8 OUTLIER -122.03 153.84 38.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.13 -0.486 . . . . 73.11 110.938 179.99 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 19.9 mm-40 -102.1 137.15 40.75 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.137 -0.483 . . . . 71.45 110.897 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' TYR . . . . . 0.572 ' CD1' HG22 ' A' ' 67' ' ' ILE . 10.9 t80 -140.91 133.76 29.01 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.184 -0.462 . . . . 73.55 110.933 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 26.9 t60 -79.17 146.76 32.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 64.44 110.879 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 5.1 m-85 -77.92 140.63 39.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.262 -0.427 . . . . 74.04 110.878 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -100.07 53.12 0.9 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.068 -0.514 . . . . 70.34 110.78 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 87.7 p -137.92 -50.41 0.59 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.218 -0.447 . . . . 75.35 110.869 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -95.78 136.51 36.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.128 -0.487 . . . . 74.31 110.873 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 -96.92 -36.38 10.58 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.135 -0.484 . . . . 64.33 110.912 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 10.1 mpt_? -54.27 173.02 0.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 73.33 110.817 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -68.47 107.86 3.06 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.159 -0.473 . . . . 71.33 110.889 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -141.0 160.64 57.42 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.666 0.746 . . . . 74.44 110.9 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 177.52 5.47 Favored 'Trans proline' 0 N--CA 1.465 -0.197 0 C-N-CA 122.71 2.273 . . . . 75.33 112.362 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 14.0 m-85 -117.22 157.78 25.43 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.454 . . . . 72.52 110.932 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 12.5 p -107.24 132.01 55.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.084 -0.507 . . . . 75.1 111.118 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -121.5 161.23 15.65 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.769 -0.729 . . . . 70.23 112.519 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 12.3 p -161.1 150.16 5.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.8 0.333 . . . . 53.21 111.08 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.405 ' HA3' ' HA ' ' A' ' 104' ' ' SER . . . -174.01 -155.37 11.89 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.68 -0.771 . . . . 70.23 112.489 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.447 ' HA ' ' HA ' ' A' ' 147' ' ' PRO . 28.9 m -113.75 134.04 57.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.803 0.335 . . . . 74.15 111.168 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . 0.456 ' HA3' HD12 ' A' ' 102' ' ' ILE . . . -117.27 105.91 1.35 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.734 -0.746 . . . . 44.01 112.531 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . 0.62 ' HG3' ' HB3' ' A' ' 101' ' ' ALA . 28.5 ptt180 -99.45 112.44 24.64 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.901 0.381 . . . . 74.1 110.866 -179.843 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 20.0 t -87.24 110.04 20.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.26 -0.427 . . . . 64.12 111.147 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.521 HD13 ' N ' ' A' ' 128' ' ' PHE . 0.2 OUTLIER -101.03 135.98 41.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 64.1 110.878 179.979 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.521 ' N ' HD13 ' A' ' 127' ' ' LEU . 13.8 m-85 -135.73 148.26 48.76 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.148 -0.478 . . . . 71.23 110.845 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.61 ' O ' HG21 ' A' ' 96' ' ' VAL . 10.2 m-85 -100.75 172.75 6.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.101 -0.5 . . . . 62.04 110.859 -179.896 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -113.53 94.87 5.06 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.178 -0.464 . . . . 61.23 110.9 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.476 ' HB2' HG23 ' A' ' 96' ' ' VAL . 2.6 mmmt -92.62 -86.6 0.24 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.206 -0.452 . . . . 75.43 110.95 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -168.23 111.82 0.61 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.293 -0.412 . . . . 70.31 111.182 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . 0.547 ' HB2' ' HB3' ' A' ' 139' ' ' PHE . 49.8 m-20 -101.1 112.76 25.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.429 . . . . 75.34 110.829 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . -74.91 -9.87 83.61 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.738 -0.744 . . . . 62.31 112.452 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.453 ' HB2' ' CG1' ' A' ' 93' ' ' VAL . . . -45.4 -28.89 0.95 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.721 0.296 . . . . 65.15 111.05 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 5.2 mt -160.28 179.67 8.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.264 -0.425 . . . . 73.4 110.89 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 9.9 m -53.32 92.36 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.172 -0.467 . . . . 73.22 110.848 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 6.9 m 51.38 73.6 0.3 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.092 -0.503 . . . . 54.2 110.868 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.547 ' HB3' ' HB2' ' A' ' 133' ' ' ASP . 0.1 OUTLIER -94.32 158.55 15.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.12 -0.491 . . . . 74.4 110.892 -179.959 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -135.89 167.64 20.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.461 . . . . 75.21 110.822 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 12.3 tt -112.98 151.04 14.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.12 -0.491 . . . . 75.33 111.13 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' LYS . . . . . . . . . . . . . 6.0 tppt? -119.51 112.06 18.89 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 54.43 110.896 179.824 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.41 -173.34 0.29 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.25 -0.432 . . . . 74.02 110.875 179.845 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -170.6 165.2 8.35 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 74.24 110.882 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' TRP . . . . . . . . . . . . . 49.2 p90 -132.47 154.48 49.85 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 73.41 110.927 179.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.726 ' HB1' ' HD2' ' A' ' 147' ' ' PRO . . . -178.5 164.28 1.13 Allowed Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.574 0.702 . . . . 41.1 111.11 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' PRO . . . . . 0.726 ' HD2' ' HB1' ' A' ' 146' ' ' ALA . 53.5 Cg_endo -69.71 169.49 18.73 Favored 'Trans proline' 0 N--CA 1.466 -0.144 0 C-N-CA 122.717 2.278 . . . . 72.24 112.376 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.422 ' HB2' HG21 ' A' ' 170' ' ' ILE . . . -165.37 153.54 11.43 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.246 -0.434 . . . . 34.0 111.086 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' PHE . . . . . . . . . . . . . 6.7 p90 -122.03 139.11 54.1 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.218 -0.446 . . . . 75.42 110.857 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -130.75 174.52 9.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.125 -0.489 . . . . 75.41 110.988 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 10.8 p -158.91 147.12 7.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 51.33 111.093 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 170.97 -158.77 30.51 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.777 -0.725 . . . . 51.44 112.58 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.6 pt? -158.22 168.02 28.19 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.768 0.318 . . . . 71.2 110.928 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.6 tpp85 -117.93 120.64 38.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 74.2 110.954 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' TYR . . . . . . . . . . . . . 2.8 t80 -115.37 169.64 8.99 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.245 -0.434 . . . . 63.31 110.949 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -121.86 99.66 6.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.147 -0.478 . . . . 70.2 110.924 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' LEU . . . . . . . . . . . . . 5.9 tt -102.31 103.7 14.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 74.31 110.87 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . 94.37 -160.71 23.84 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.792 -0.718 . . . . 65.41 112.51 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' ASN . . . . . . . . . . . . . 6.3 p30 -118.7 -36.56 3.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.854 0.359 . . . . 64.33 110.928 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 3.7 p -66.39 -56.04 12.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.113 -0.494 . . . . 73.11 110.866 -179.877 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' TRP . . . . . . . . . . . . . 12.3 p90 -124.91 172.69 9.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.179 -0.464 . . . . 72.43 110.951 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.541 ' CE ' HG13 ' A' ' 203' ' ' VAL . 5.5 ptp -121.84 177.47 5.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.269 -0.423 . . . . 71.14 110.903 179.878 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 8.7 tp -111.94 146.2 38.23 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.21 -0.45 . . . . 63.34 110.915 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -144.44 133.51 22.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 64.4 110.9 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 19.6 t -130.89 125.93 34.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.13 -0.487 . . . . 55.43 110.842 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' ASP . . . . . . . . . . . . . 26.7 m-20 -150.33 142.16 23.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.093 -0.503 . . . . 72.53 110.87 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.747 ' CG2' HD12 ' A' ' 196' ' ' LEU . 40.6 t -139.59 122.62 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 43.3 111.148 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.49 159.99 14.71 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.236 -0.438 . . . . 63.23 110.804 -179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' TYR . . . . . 0.411 ' O ' ' HB ' ' A' ' 170' ' ' ILE . 26.3 t80 -164.56 140.99 6.12 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.159 -0.473 . . . . 73.45 110.919 -179.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' ILE . . . . . 0.446 HG12 ' O ' ' A' ' 147' ' ' PRO . 5.9 tp 177.86 133.15 0.22 Allowed Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.656 0.741 . . . . 72.32 111.109 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.69 104.37 1.3 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.716 2.277 . . . . 65.23 112.304 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -121.78 154.25 37.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.257 -0.429 . . . . 74.23 110.858 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 9.6 ptpp? -122.86 146.69 47.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 63.4 110.884 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' THR . . . . . . . . . . . . . 11.1 t -116.91 166.0 12.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.211 -0.45 . . . . 54.51 111.185 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -122.8 158.19 30.76 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.26 -0.427 . . . . 52.35 110.858 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' VAL . . . . . . . . . . . . . 43.9 t -150.26 132.48 5.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 75.45 111.152 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 13.6 t -168.43 176.78 5.63 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.205 -0.452 . . . . 70.52 111.104 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 178' ' ' GLY . . . . . . . . . . . . . . . 131.99 150.39 6.56 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.725 -0.75 . . . . 32.14 112.525 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 6.1 t -171.21 177.5 3.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.843 0.354 . . . . 74.04 111.161 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 180' ' ' LEU . . . . . . . . . . . . . 5.7 tt -138.07 89.56 2.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 65.13 110.894 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 118.21 -81.23 0.32 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.725 -0.75 . . . . 61.2 112.505 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -170.13 0.37 Allowed 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.709 2.273 . . . . 71.5 112.351 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 30.7 m -82.86 124.32 77.07 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.59 0.71 . . . . 63.15 111.138 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 184' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 155.42 66.08 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.67 2.246 . . . . 73.12 112.344 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 185' ' ' VAL . . . . . . . . . . . . . 68.0 t -103.61 111.44 33.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 75.35 111.098 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 186' ' ' SER . . . . . . . . . . . . . 3.9 p -84.57 135.02 34.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.094 -0.503 . . . . 64.14 110.893 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 187' ' ' THR . . . . . . . . . . . . . 40.4 p -145.48 167.75 22.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.141 -0.481 . . . . 63.22 111.097 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 188' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -158.99 157.31 31.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.451 . . . . 71.2 110.887 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 189' ' ' ILE . . . . . 0.687 HG13 HD13 ' A' ' 32' ' ' LEU . 36.8 mm -146.66 125.6 4.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.193 -0.458 . . . . 74.5 111.13 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 190' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -102.31 114.6 28.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.18 -0.464 . . . . 75.01 110.864 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 191' ' ' VAL . . . . . 0.447 HG23 HG22 ' A' ' 189' ' ' ILE . 2.5 t -136.53 164.32 31.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.126 -0.488 . . . . 54.01 111.1 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 192' ' ' ASP . . . . . 0.434 ' H ' HG12 ' A' ' 191' ' ' VAL . 0.1 OUTLIER -107.23 87.59 3.27 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.651 0.739 . . . . 73.34 110.856 179.89 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.93 133.58 25.59 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.722 2.282 . . . . 74.33 112.249 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 194' ' ' PHE . . . . . . . . . . . . . 23.4 m-85 -100.68 119.33 38.42 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.161 -0.472 . . . . 72.03 110.83 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 195' ' ' ILE . . . . . 0.484 ' O ' HG13 ' A' ' 167' ' ' VAL . 53.4 mt -105.57 110.18 30.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.124 -0.489 . . . . 71.31 111.156 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 196' ' ' LEU . . . . . 0.747 HD12 ' CG2' ' A' ' 167' ' ' VAL . 2.6 tp -110.54 108.84 18.95 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.199 -0.455 . . . . 74.42 110.974 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 197' ' ' SER . . . . . 0.522 ' O ' HD12 ' A' ' 198' ' ' LEU . 0.4 OUTLIER -110.55 129.27 55.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.231 -0.441 . . . . 73.43 110.901 -179.906 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 198' ' ' LEU . . . . . 0.522 HD12 ' O ' ' A' ' 197' ' ' SER . 3.1 mp -150.51 134.45 16.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.115 -0.493 . . . . 72.33 110.937 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 199' ' ' GLY . . . . . . . . . . . . . . . 178.94 -136.95 3.02 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.686 -0.768 . . . . 54.3 112.467 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 200' ' ' ALA . . . . . 0.429 ' HB1' ' O ' ' A' ' 162' ' ' MET . . . -125.02 173.33 8.75 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.835 0.35 . . . . 73.13 111.041 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 201' ' ' SER . . . . . . . . . . . . . 29.5 m -149.09 171.0 17.13 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.16 -0.473 . . . . 60.51 110.841 -179.755 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 202' ' ' TYR . . . . . 0.449 ' O ' HG13 ' A' ' 18' ' ' VAL . 40.5 t80 -142.24 145.45 34.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.501 . . . . 71.44 110.86 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 203' ' ' VAL . . . . . 0.541 HG13 ' CE ' ' A' ' 162' ' ' MET . 33.6 m -93.28 156.83 3.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.04 -0.527 . . . . 72.52 111.108 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 204' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -159.72 110.8 1.98 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.127 -0.488 . . . . 75.54 110.911 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 205' ' ' LYS . . . . . . . . . . . . . 37.1 mtmt -74.92 173.63 10.38 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 73.13 110.914 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 206' ' ' LEU . . . . . 0.588 HD13 ' CZ2' ' A' ' 17' ' ' TRP . 4.5 mm? -53.75 -52.16 61.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.27 -0.423 . . . . 64.42 110.931 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 207' ' ' ALA . . . . . . . . . . . . . . . 56.21 36.12 26.9 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 62.31 111.054 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 208' ' ' ALA . . . . . . . . . . . . . . . -89.91 112.74 24.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.237 -0.438 . . . . 53.45 111.081 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 209' ' ' ALA . . . . . . . . . . . . . . . -144.88 177.0 9.05 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 63.35 111.059 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 8.7 tt -78.15 107.07 10.47 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.234 -0.439 . . . . 75.41 110.913 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 211' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.175 -0.466 . . . . 61.33 110.952 179.892 . . . . . . . . 0 0 . 1 stop_ save_